<SEC-DOCUMENT>0001193125-21-281546.txt : 20210924
<SEC-HEADER>0001193125-21-281546.hdr.sgml : 20210924
<ACCEPTANCE-DATETIME>20210924093034
ACCESSION NUMBER:		0001193125-21-281546
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20210924
DATE AS OF CHANGE:		20210924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioventus Inc.
		CENTRAL INDEX KEY:			0001665988
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				810980861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259392
		FILM NUMBER:		211274507

	BUSINESS ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		(919) 474-6700

	MAIL ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d180330d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(3) <BR>Registration No. 333-259392 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g180330g03a11.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g180330g03b22.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_1"></A>MERGER PROPOSAL&#151;YOUR VOTE IS VERY IMPORTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Bioventus Stockholders and Misonix Stockholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
July&nbsp;29, 2021, Bioventus Inc., which is referred to as &#147;Bioventus,&#148; Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, which is referred to as &#147;Merger Sub I,&#148; Oyster Merger Sub II, LLC, a wholly owned
subsidiary of Bioventus, which is referred to as &#147;Merger Sub II,&#148; and Misonix, Inc., which is referred to as &#147;Misonix,&#148; entered into an Agreement and Plan of Merger, as it may be amended from time to time, which is referred to as
the &#147;merger agreement,&#148; that provides for the acquisition of Misonix by Bioventus. Upon the terms and subject to the conditions of the merger agreement, Bioventus will acquire Misonix through a merger of Merger Sub I with and into Misonix,
with Misonix continuing as the surviving corporation, which is referred to as the &#147;first merger,&#148; followed by a merger of Misonix with and into Merger Sub II, with Merger Sub II continuing as the surviving entity and a wholly owned
subsidiary of Bioventus, which is referred to as the &#147;second merger&#148; and, together with the first merger is referred to as the &#147;mergers.&#148; The combined company created by the mergers will be named Bioventus Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the successful completion of the mergers, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held
by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be
converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Bioventus class A common stock, based on the election of the
holder thereof and subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described below and in the accompanying joint proxy statement/prospectus. Bioventus stockholders will continue to own their
existing shares of Bioventus common stock. The exchange ratio is fixed and will not be adjusted for changes in the market price of either Bioventus class A common stock or Misonix common stock between the date of signing of the merger agreement and
the completion date of the first merger. As such, the market value of the merger consideration payable to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix
stockholders vote on the merger agreement. Upon completion of the mergers, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the
mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Bioventus class A common stock is traded on the Nasdaq Global Select Market, which is referred to as &#147;Nasdaq,&#148; under the symbol
&#147;BVS.&#148; Misonix common stock is traded on Nasdaq under the symbol &#147;MSON.&#148; We encourage you to obtain current quotes for both the Bioventus class A common stock and the Misonix common stock before voting at the special meetings of
stockholders described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of
outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. If the aggregate amount of cash that holders of Misonix common stock elect to receive exceeds the available cash amount, the number of shares of
Misonix common stock as to which the holder elected to receive cash consideration will be reduced on a pro rata basis and each such share will be paid $28.00 per share in cash, and the remainder of such shares of Misonix common stock as to which a
cash election was made will be paid 1.6839 shares of Bioventus class A common stock. In such case, for each share of Misonix common stock as to which the holder elected to receive the stock consideration or made no election, the holder will receive
1.6839 shares of Bioventus common stock. If the aggregate amount of cash that holders of Misonix common stock elect to receive is less than the available cash amount, each share of Misonix common stock as to which the holder elected to receive cash
consideration will receive $28.00 per share in cash. In such case, the remaining excess cash consideration will be first paid at a rate of $28.00 for each share of Misonix common stock as to which the holder made no election (with such cash being
distributed on a pro rata basis based on the number of shares for </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which no election was made if the number of such shares multiplied by $28.00 is less than the remaining cash to be paid), and thereafter (to the extent any excess cash consideration remains) at a
rate of $28.00 per share in cash to the shares of Misonix common stock as to which the holder elected to receive the stock consideration on a pro rata basis based on the amount of cash remaining to be paid, if any. The balance of the shares of
Misonix common stock will receive 1.6839 shares of Bioventus class A common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the value of merger consideration to be received by a specific
holder of Misonix common stock will depend on whether they elect to receive the cash consideration, elect to receive the stock consideration, or make no election, if all Misonix stockholders elect to receive the cash consideration (or if all Misonix
stockholders elect to receive the stock consideration), each holder of Misonix common stock would receive, on an aggregate basis, $10.50 in cash and 1.0524 shares of Bioventus class A common stock for each share of Misonix common stock that they
own. Based on the Bioventus class A common stock price of $ $16.63 per share, which is the average of the daily volume weighted average price per share for the seven consecutive trading day period up to and including July&nbsp;27, 2021, two trading
days prior to the entry by Bioventus and Misonix into the merger agreement, the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders
elect to receive the stock consideration), was $28.00 per share of Misonix common stock. On September&nbsp;1, 2021, the latest practicable trading day before the date of the filing of this joint proxy statement/prospectus, the closing price of
Bioventus class A common stock on Nasdaq was $14.98 per share, resulting in the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders
elect to receive the stock consideration), was $26.27 per share of Misonix common stock. The value of the merger consideration to Misonix stockholders will continue to fluctuate with the value of Bioventus class A common stock until the completion
of the mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix will each hold special meetings of their respective stockholders to vote on the proposals necessary to complete the
mergers. Such special meetings are referred to as the &#147;Bioventus special meeting&#148; and the &#147;Misonix special meeting,&#148; respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
the Bioventus special meeting, Bioventus stockholders will be asked to consider and vote on (i)&nbsp;a proposal to approve the issuance of shares of Bioventus class A common stock to Misonix stockholders in connection with the first merger, which
proposal is referred to as the &#147;Bioventus share issuance proposal,&#148; and (ii)&nbsp;a proposal to adjourn the Bioventus special meeting to solicit additional proxies if there are insufficient votes to approve the Bioventus share issuance
proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Bioventus stockholders. <B>The Bioventus board unanimously recommends that Bioventus stockholders vote &#147;FOR&#148; each of the
proposals to be considered at the Bioventus special meeting.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Misonix special meeting, Misonix stockholders will be asked to consider and vote
on (i)&nbsp;a proposal to adopt the merger agreement, which proposal is referred to as the &#147;Misonix merger proposal,&#148; (ii)&nbsp;a proposal to approve, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis, the
compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement and (iii)&nbsp;a proposal to adjourn the Misonix special meeting to
solicit additional proxies, if necessary or appropriate, if there are insufficient votes to approve the Misonix merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Misonix
stockholders. <B>The Misonix board unanimously recommends that Misonix stockholders vote &#147;FOR&#148; each of the proposals to be considered at the Misonix special meeting.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot complete the mergers unless the Bioventus share issuance proposal is approved by Bioventus stockholders and the Misonix merger proposal is approved
by Misonix stockholders. <B>Your vote on these matters is very important, regardless of the number of shares you own. Whether or not you plan to attend your company&#146;s respective special meeting, please vote by proxy over the internet or
telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to authorize the individuals named on your proxy card to vote your shares
at the applicable special meeting.</B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>The accompanying joint proxy statement/prospectus provides you with important information about the
special meetings, the mergers and each of the proposals. We encourage you to read the entire document carefully, in particular the information under &#147;<A HREF="#toc180330_10">Risk Factors</A>&#148; beginning on page&nbsp;39 for a discussion of
risks relevant to the mergers. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to the successful completion of the mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>/s/ Ken Reali&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ken Reali</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive
Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bioventus Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>/s/ Stavros Vizirgianakis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stavros Vizirgianakis</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief
Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Misonix, Inc.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * * * * </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of the mergers, the adoption of the
merger agreement, the Bioventus class A common stock to be issued in the first merger or any of the other transactions described in the accompanying joint proxy statement/prospectus or determined if the accompanying joint proxy statement/prospectus
is accurate or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying joint proxy statement/prospectus is dated as of,
and is first being mailed to Bioventus and Misonix stockholders on or about, September 24, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g03a11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4721 Emperor Boulevard, Suite 400 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Durham, North Carolina 27703 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(919) <FONT STYLE="white-space:nowrap">474-6700</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_2"></A>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON OCTOBER 26, 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
Stockholders of Bioventus Inc.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice is hereby given that Bioventus Inc., which is referred to as &#147;Bioventus,&#148; will hold a special meeting of
its stockholders, which is referred to as the &#147;Bioventus special meeting,&#148; virtually via live webcast on October&nbsp;26, 2021, beginning at 11:00 a.m., Eastern Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of ongoing developments related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Bioventus special meeting will be held solely
in a virtual meeting format via live webcast. You will be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the &#147;Bioventus special meeting
website.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus special meeting will be held for the purpose of Bioventus stockholders considering and voting on the following proposals:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to approve the issuance of shares of Bioventus class A common stock to the stockholders of Misonix, Inc., which
is referred to as &#147;Misonix,&#148; in connection with the merger contemplated by the Agreement and Plan of Merger, dated July&nbsp;29, 2021, as it may be amended from time to time, which is referred to as the &#147;merger agreement,&#148; by and
among Bioventus, Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus and Misonix, which issuance is referred to as the &#147;share issuance&#148; and which proposal is
referred to as the &#147;Bioventus share issuance proposal&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to approve the adjournment of the Bioventus special meeting, if necessary or appropriate, to solicit additional
proxies if there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely
provided to Bioventus stockholders, which proposal is referred to as the &#147;Bioventus adjournment proposal.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will
transact no other business at the Bioventus special meeting except such business as may properly be brought before the Bioventus special meeting or any adjournment or postponement thereof. The accompanying joint proxy statement/prospectus, including
the merger agreement attached as <U>Annex</U><U></U><U>&nbsp;A</U> thereto, contains further information relating to these matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only holders of
record of Bioventus common stock at the close of business on September 22, 2021, the record date for voting at the Bioventus special meeting, which is referred to as the &#147;Bioventus record date,&#148; are entitled to notice of and to vote at the
Bioventus special meeting and any adjournments or postponements thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board has unanimously determined that the terms of the merger
agreement and the merger are fair to and in the best interests of Bioventus and its stockholders, and has approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance.
<B>Accordingly, the Bioventus board unanimously recommends that Bioventus stockholders vote: </B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; the Bioventus share issuance proposal; and </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; the Bioventus adjournment proposal. </B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important, regardless of the number of shares of Bioventus common stock you own.</B>
The parties cannot complete the merger unless the Bioventus share issuance proposal is approved by Bioventus stockholders. Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the
affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote is important. Whether
or not you plan to virtually attend the Bioventus special meeting, please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the
enclosed postage-paid envelope, in order to authorize the individuals named on your proxy card to vote your shares of Bioventus common stock at the Bioventus special meeting. If you hold your shares through a broker, bank or other nominee in
&#147;street name&#148; (instead of as a registered holder) please follow the instructions on the voting instruction form provided by your bank, broker or nominee to vote your shares. The list of Bioventus stockholders entitled to vote at the
Bioventus special meeting will be available at Bioventus&#146; headquarters during regular business hours for examination by any Bioventus stockholder for any purpose germane to the Bioventus special meeting for a period of at least ten days prior
to the Bioventus special meeting. If you would like to examine the list of Bioventus stockholders of record, please contact Bioventus&#146; Corporate Secretary at tony.dadamio@bioventus.com.com to schedule an appointment or request access. If
Bioventus&#146; headquarters are closed for health and safety reasons related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic during such period, the list of stockholders will be made available for examination electronically upon
request to Bioventus&#146; Corporate Secretary, subject to satisfactory verification of stockholder status. The list of Bioventus stockholders entitled to vote at the Bioventus special meeting will also be available for examination by any Bioventus
stockholder during the Bioventus special meeting via the Bioventus special meeting website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions about the transactions, please
contact Bioventus at (919) <FONT STYLE="white-space:nowrap">474-6700</FONT> or write to Bioventus Inc., Attn: Corporate Secretary, at tony.dadamio@bioventus.com.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By Order of the Board of Directors, </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ William A.
Hawkins III&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>William A. Hawkins III </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairperson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, North Carolina </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September 24, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g03b22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1938 New Highway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Farmingdale, New York 11735 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(631) <FONT STYLE="white-space:nowrap">694-9555</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_3"></A>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON OCTOBER 26, 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
Stockholders of Misonix, Inc.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice is hereby given that Misonix, Inc., which is referred to as &#147;Misonix,&#148; will hold a special meeting of its
stockholders, which is referred to as the &#147;Misonix special meeting,&#148; at Misonix&#146;s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on October 26, 2021, beginning at 10:00 a.m., Eastern Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of Misonix&#146;s precautions regarding the novel coronavirus or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> Misonix is planning for the
possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of
stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix special meeting will be
held for the purpose of Misonix stockholders considering and voting on the following proposals: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to adopt the Agreement and Plan of Merger, dated July&nbsp;29, 2021, as it may be amended from time to time,
which is referred to as the &#147;merger agreement,&#148; by and among Bioventus Inc. (which is referred to as &#147;Bioventus&#148;), Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, Oyster Merger Sub II, LLC, a wholly owned
subsidiary of Bioventus, and Misonix, a copy of which is attached as <U>Annex A</U> to the accompanying joint proxy statement/prospectus and which proposal is referred to as the &#147;Misonix merger proposal&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to approve, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis, the compensation that may
be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement, which proposal is referred to as the &#147;Misonix compensation proposal&#148;; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to approve the adjournment of the Misonix special meeting, if necessary or appropriate, to solicit additional
proxies if there are insufficient votes at the time of the Misonix special meeting to approve the Misonix merger proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to
Misonix stockholders, which proposal is referred to as the &#147;Misonix adjournment proposal.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix will transact no other
business at the Misonix special meeting except such business as may properly be brought before the Misonix special meeting or any adjournment or postponement thereof. The accompanying joint proxy statement/prospectus, including the merger agreement
attached as <U>Annex</U><U></U><U>&nbsp;A</U> thereto, contains further information relating to these matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only holders of record of Misonix common
stock at the close of business on September 22, 2021, the record date for voting at the Misonix special meeting, which is referred to as the &#147;Misonix record date,&#148; are entitled to notice of and to vote at the Misonix special meeting and
any adjournments or postponements thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board has unanimously determined that the terms of the merger agreement and the merger are fair to
and in the best interests of Misonix and its stockholders, and has approved and declared advisable the merger agreement and the transactions contemplated thereby, including the mergers. <B>Accordingly, the Misonix board unanimously recommends that
Misonix stockholders vote: </B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; the Misonix merger proposal; </B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; the Misonix compensation proposal; and </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; the Misonix adjournment proposal. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important, regardless of the number of shares of Misonix common stock you own.</B> The parties cannot complete the merger unless the
Misonix merger proposal is approved by Misonix stockholders. Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the issued and
outstanding shares of Misonix common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote is important. Whether or not you plan to attend the Misonix special meeting, please vote your
shares of Misonix common stock either electronically over the Internet, by telephone, or by completing and returning the accompanying proxy card. Voting instructions are provided in the accompanying joint proxy statement/prospectus and in the Notice
of Internet Availability of Proxy Materials. By submitting your proxy promptly, you will save us the expense of further proxy solicitation. We encourage you to submit your proxy as soon as possible by Internet, by telephone or by signing, dating and
returning the accompanying proxy cards provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions about the transactions, please contact Misonix at misonixproxy@misonix.com or
write to Misonix, Inc., Attn: Secretary, at our principal executive offices at 1938 New Highway, Farmingdale, New York 11735. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions
about how to vote or direct a vote in respect of your shares of Misonix common stock, please contact, MacKenzie Partners, Inc., Misonix&#146;s proxy solicitor, by telephone toll-free at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-322-2885,</FONT></FONT></FONT> Monday through Friday (except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at
proxy@mackenziepartners.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By Order of the Board of Directors, </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph P. Dwyer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Joseph P. Dwyer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Misonix, Inc.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Farmingdale, New York </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:
September 24, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_4"></A>REFERENCES TO ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus incorporates important business and financial information about Bioventus and Misonix from other documents that
Bioventus and Misonix have filed with the SEC and that are not contained in and are instead incorporated by reference in this joint proxy statement/prospectus. For a list of documents incorporated by reference in this joint proxy
statement/prospectus, see &#147;Where You Can Find More Information.&#148; This information is available for you, without charge, to review through the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of this joint proxy statement/prospectus, any of the documents incorporated by reference in this joint proxy statement/prospectus or
other information filed with the SEC by Bioventus or Misonix, without charge, by written or telephonic request directed to the appropriate company at the following contacts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>For Bioventus stockholders:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>For Misonix stockholders:</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bioventus Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">tony.dadamio@bioventus.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(919) <FONT
STYLE="white-space:nowrap">474-6700</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Misonix, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">misonixproxy@misonix.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(631) <FONT
STYLE="white-space:nowrap">694-9555</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In order for you to receive timely delivery of the documents in advance of the special meeting of Bioventus stockholders to
be held on October 26, 2021, which is referred to as the &#147;Bioventus special meeting,&#148; or the special meeting of Misonix stockholders to be held on October 26, 2021, which is referred to as the &#147;Misonix special meeting,&#148; as
applicable, you must request the information no later than October 19, 2021. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you have any questions about the Misonix special meeting, or need
to obtain proxy cards or other information, please contact MacKenzie Partners, Inc., Misonix&#146;s proxy solicitor, by telephone toll-free at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-322-2885,</FONT></FONT></FONT> or for banks and brokers, collect at (212) <FONT STYLE="white-space:nowrap">929-5500,</FONT> Monday through
Friday (except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at proxy@mackenziepartners.com. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g60w51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The contents of the websites of the SEC, Bioventus, Misonix or any other entity are not incorporated in this joint proxy
statement/prospectus.</B> The information about how you can obtain certain documents that are incorporated by reference in this joint proxy statement/prospectus at these websites is being provided only for your convenience. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_5"></A>ABOUT THIS JOINT PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus, which forms part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed with the SEC by
Bioventus, constitutes a prospectus of Bioventus under Section&nbsp;5 of the Securities Act with respect to the shares of Bioventus class A common stock to be issued to Misonix stockholders pursuant to the Agreement and Plan of Merger, dated
July&nbsp;29, 2021, as it may be amended from time to time, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix, which is referred to as the &#147;merger agreement.&#148; This document also constitutes a proxy statement of each of
Bioventus and Misonix under Section&nbsp;14(a) of the Exchange Act. This joint proxy statement/prospectus also constitutes a notice of meeting with respect to each of the Bioventus and Misonix special meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has supplied all information contained or incorporated by reference in this joint proxy statement/prospectus relating to Bioventus, Merger Sub I and
Merger Sub II, and Misonix has supplied all such information relating to Misonix. Bioventus and Misonix have both contributed to such information relating to the mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference in this joint proxy statement/prospectus. Bioventus and Misonix have not
authorized anyone to provide you with information that is different from that contained or incorporated by reference in this joint proxy statement/prospectus. This joint proxy statement/prospectus is dated September 24, 2021, and you should not
assume that the information contained in this joint proxy statement/prospectus is accurate as of any date other than such date unless otherwise specifically provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, you should not assume that the information incorporated by reference in this joint proxy statement/prospectus is accurate as of any date other than
the date of the incorporated document. Neither the mailing of this joint proxy statement/prospectus to Bioventus or Misonix stockholders nor the issuance by Bioventus of shares of Bioventus class A common stock pursuant to the merger agreement will
create any implication to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This joint proxy statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to
buy, any securities, or the solicitation of a proxy, in any jurisdiction to or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or the context otherwise requires, when used in this joint proxy statement/prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus&#148; refers to Bioventus Inc., a Delaware corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus adjournment proposal&#148; refers to the proposal to approve the adjournment of the Bioventus
special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment
to the accompanying joint proxy statement/prospectus is timely provided to Bioventus stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus board&#148; refers to the board of directors of Bioventus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus class A common stock&#148; refers to the Class&nbsp;A common stock, par value $0.001 per share,
of Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus class B common stock&#148; refers to the Class&nbsp;B common stock, par value $0.001 per share,
of Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus common stock&#148; refers Bioventus class A common stock and the Bioventus Class&nbsp;B common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus LLC agreement&#148; refers to the Second Amended and Restated Limited Liability Company Agreement
of Bioventus LLC dated as of February&nbsp;16, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus record date&#148; refers to September 22, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus share issuance proposal&#148; refers to the proposal to approve the issuance of shares of
Bioventus common stock to Misonix stockholders in connection with the mergers; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Bioventus special meeting&#148; refers to the special meeting of Bioventus stockholders to consider and
vote upon the Bioventus share issuance proposal and the Bioventus adjournment proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;BV LLC&#148; refers to Bioventus LLC, a subsidiary of Bioventus Inc.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;cash election consideration&#148; refers to an amount of cash equal to $28.00, without interest, which
reflects the amount of cash that Misonix stockholders will be entitled to receive in the first merger for each share of Misonix common stock held immediately prior to the effective time, if such stockholder elects the cash election consideration and
subject to proration under the terms of the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Code&#148; refers to the Internal Revenue Code of 1986, as amended; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;combined company&#148; refers to Bioventus immediately following the completion of the merger and the other
transactions contemplated by the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;DGCL&#148; refers to the General Corporation Law of the State of Delaware; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;DLLCA&#148; refers to the Limited Liability Company Act of the State of Delaware; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;effective time&#148; refers to the date and time when the first merger becomes effective under the DGCL,
which will be the date and time at which the certificate of merger with respect to the first merger is filed with the Secretary of State of the State of Delaware, or such later date and time as may be mutually agreed to in writing by Bioventus and
Misonix and specified in such certificate of merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;end date&#148; refers to January&nbsp;31, 2022, the date on which, subject to certain limitations in the
merger agreement, the merger agreement may be terminated and the merger abandoned by either Bioventus or Misonix (which date will be automatically extended in certain circumstances related to the receipt of required regulatory approvals or the
absence of restraints under certain competition laws to March&nbsp;31, 2022, pursuant to the terms of the merger agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Exchange Act&#148; refers to the Securities Exchange Act of 1934, as amended; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;first merger&#148; refers to the merger of Merger Sub I with and into Misonix; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;former LLC owners&#148; refers to certain members of BV LLC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;GAAP&#148; refers to U.S. generally accepted accounting principles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;HSR Act&#148; refers to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;J.P Morgan&#148; refers to J.P. Morgan Securities LLC, financial advisor to Misonix in connection with the
proposed mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;LLC interests&#148; refers to single class of common membership interests in BV LLC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;mergers&#148; refers to the first merger and the second merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;merger agreement&#148; refers to the Agreement and Plan of Merger, dated July&nbsp;29, 2021, as it may be
amended from time to time, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;merger consideration&#148; refers to the aggregate cash election consideration and stock election
consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Sub I&#148; refers to Oyster Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary
of Bioventus, formed for the purpose of effecting the first merger as described in this joint proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Sub II&#148; refers to Oyster Merger Sub II, LLC, a Delaware limited liability company and wholly
owned subsidiary of Bioventus, formed for the purpose of effecting the second merger as described in this joint proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix&#148; refers to Misonix, Inc., a Delaware corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix adjournment proposal&#148; refers to the proposal to approve the adjournment of the Misonix special
meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
at the time of the Misonix special meeting to approve the Misonix merger proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely
provided to Misonix stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix board&#148; refers to the board of directors of Misonix; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix common stock&#148; refers to the common stock, par value $0.0001 per share, of Misonix;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix compensation proposal&#148; refers to the proposal to approve, on a
<FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis, the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix merger proposal&#148; refers to the proposal to adopt the merger agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix record date&#148; refers to September 22, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Misonix special meeting&#148; refers to the special meeting of Misonix stockholders to consider and vote
upon the Misonix merger proposal and related matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Nasdaq&#148; refers to the Nasdaq Global Select Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;original LLC owners&#148; refers to the holders of BV LLC membership interests prior to the execution of
the Bioventus LLC agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Perella Weinberg&#148; refers to Perella Weinberg Partners L.P., financial advisor to Bioventus in
connection with the proposed mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;SEC&#148; refers to the U.S. Securities and Exchange Commission; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;second effective time&#148; refers to the date and time when the second merger becomes effective under the
DGCL, which will be the date and time at which the certificate of merger with respect to the second merger is filed with the Secretary of State of the State of Delaware, or such later date and time as may be mutually agreed to in writing by
Bioventus and Misonix and specified in such certificate of merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;second merger&#148; refers to the merger of Misonix with and into Merger Sub II; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Securities Act&#148; refers to the Securities Act of 1933, as amended; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;share issuance&#148; refers to the issuance of shares of Bioventus class A common stock to Misonix
stockholders in connection with the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;stock election consideration&#148; refers to 1.6839 validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Bioventus class A common stock, which figure reflects the number of shares of Bioventus class A common stock that Misonix stockholders will be entitled to receive in the first merger for
each share of Misonix common stock held immediately prior to the effective time if such stockholder elects the stock election consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;stockholders agreement&#148; refers to Stockholders Agreement, dated February&nbsp;16, 2021, by and among
Bioventus Inc., Bioventus LLC and the principal stockholders named therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;TRA&#148; refers to the Tax Receivable Agreement, dated as of February&nbsp;16, 2021, by and among
Bioventus Inc., Bioventus LLC and the continuing LLC owner; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;transaction&#148; refers to the transactions contemplated by the merger agreement including the mergers.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_6">QUESTIONS AND ANSWERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_7">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_8">MARKET PRICE AND DIVIDEND INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_9">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_10">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_11">THE PARTIES TO THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_12">THE BIOVENTUS SPECIAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_13">BIOVENTUS PROPOSAL 1: APPROVAL OF THE SHARE ISSUANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_14">BIOVENTUS PROPOSAL 2: ADJOURNMENT OF THE BIOVENTUS SPECIAL
MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_15">THE MISONIX SPECIAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_16">MISONIX PROPOSAL 1: ADOPTION OF THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_17">MISONIX PROPOSAL 2: ADVISORY <FONT STYLE="white-space:nowrap">NON-BINDING
</FONT> VOTE ON MERGER-RELATED COMPENSATION FOR NAMED EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_18">MISONIX PROPOSAL 3: ADJOURNMENT OF THE MISONIX SPECIAL
MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_19">THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_20">THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_21">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_22">DESCRIPTION OF BIOVENTUS&#146; BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_23">BIOVENTUS&#146; MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
 AND RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_24">BIOVENTUS DIRECTOR AND OFFICER COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_25">SECURITIES AUTHORIZED FOR ISSUANCE UNDER BIOVENTUS&#146; EQUITY COMPENSATION
 PLANS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_26">INTERESTS OF BIOVENTUS DIRECTORS AND EXECUTIVE OFFICERS IN THE
MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_27">INTERESTS OF MISONIX DIRECTORS AND EXECUTIVE OFFICERS IN THE
MERGERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_28">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE FIRST MERGER AND THE
 SECOND MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_29">COMPARISON OF STOCKHOLDERS&#146; RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_30">APPRAISAL RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_31">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_32">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_33">CERTAIN BENEFICIAL OWNERS OF BIOVENTUS COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_34">CERTAIN BENEFICIAL OWNERS OF MISONIX COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_35">STOCKHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_36">HOUSEHOLDING OF PROXY MATERIALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_37">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_38">INDEX TO BIOVENTUS INC. FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_40">Annex A&#151;Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_41">Annex B&#151;Opinion of Perella Weinberg Partners L.P.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">B-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_42">Annex C&#151;Opinion of J.P. Morgan Securities LLC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">C-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc180330_43">Annex D&#151;Appraisal Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">D-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_6"></A>QUESTIONS AND ANSWERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following are brief answers to certain questions that you, as a Bioventus stockholder or Misonix stockholder, may have regarding the mergers and the
other matters being considered at the Bioventus and Misonix special meetings, as applicable. You are urged to carefully read this joint proxy statement/prospectus and the other documents referred to in this joint proxy statement/prospectus in their
entirety because this section may not provide all the information that is important to you regarding these matters. See &#147;Summary&#148; for a summary of important information regarding the merger agreement, the mergers and the related
transactions. Additional important information is contained in the annexes to, and the documents incorporated by reference in, this joint proxy statement/prospectus. You may obtain the information incorporated by reference in this joint proxy
statement/prospectus, without charge, by following the instructions under &#147;Where You Can Find More Information.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why am I receiving this
joint proxy statement/prospectus? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are receiving this joint proxy statement/prospectus because Misonix has agreed to be acquired by Bioventus
through a merger of Merger Sub I with and into Misonix with Misonix continuing as the surviving corporation, and immediately following, a merger of Misonix with and into Merger Sub II, with Merger Sub II continuing as the surviving entity in the
merger and a wholly owned subsidiary of Bioventus. The merger agreement, which governs the terms and conditions of the mergers, is attached as <U>Annex A</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote is required in connection with the mergers. Bioventus and Misonix are sending these materials to their respective stockholders to help them decide
how to vote their shares at the Bioventus special meeting and Misonix special meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What matters am I being asked to vote on? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to complete the mergers, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus stockholders must approve the Bioventus share issuance proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix stockholders must approve the Misonix merger proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus</I>: Bioventus is holding the Bioventus special meeting to obtain approval of the Bioventus share issuance proposal and the Bioventus adjournment
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix</I>: Misonix is holding the Misonix special meeting to obtain approval of the Misonix merger proposal. At the Misonix special
meeting, Misonix stockholders will also be asked to consider and vote on the Misonix compensation proposal and the Misonix adjournment proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your
vote is very important, regardless of the number of shares that you own. The approval of the Bioventus share issuance proposal and the Misonix merger proposal are conditions to the obligations of Bioventus and Misonix to complete the mergers. The
approval of the Bioventus adjournment proposal, the Misonix compensation proposal and the Misonix adjournment proposal are not conditions to the obligations of Bioventus or Misonix to complete the mergers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When and where will each of the special meetings take place? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus</I>: The Bioventus special meeting will be held solely virtually via live webcast on October 26, 2021, beginning at 11:00 a.m., Eastern Time.
Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the &#147;Bioventus special meeting website.&#148; In order to
virtually attend and vote at the Bioventus special meeting, you will need the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number located on your proxy card. Bioventus has retained Broadridge Financial Solutions,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which is referred to as &#147;Broadridge,&#148; to host the live webcast of the Bioventus special meeting. Thirty minutes prior to the Bioventus special meeting, Broadridge may be contacted at
(855) <FONT STYLE="white-space:nowrap">499-0991</FONT> (U.S. toll-free) or (720) <FONT STYLE="white-space:nowrap">378-5962</FONT> (international toll), and will be available to answer any questions regarding how to virtually attend the Bioventus
special meeting or if you encounter any technical difficulty accessing or during the Bioventus special meeting. Technical support phone numbers will also be available via the virtual meeting url 30 minutes prior to the start of the meeting. See
&#147;The Bioventus Special Meeting&#151;Virtually Attending the Bioventus Special Meeting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix</I>: The Misonix special meeting will be
held at Misonix&#146;s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on October 26, 2021, beginning at 10:00 a.m., Eastern Time. As part of Misonix&#146;s precautions regarding the novel coronavirus or <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> Misonix is planning for the possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and
details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if you plan to attend your respective company&#146;s special meeting, Bioventus and Misonix recommend that you vote by proxy in advance as described
below so that your vote will be counted if you later decide not to or become unable to attend the applicable special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold your shares in
&#147;street name,&#148; you may attend and vote at your respective company&#146;s special meeting only if you obtain a specific control number from your bank, broker or other nominee giving you the right to vote such shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Does my vote matter? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes, your vote is very important,
regardless of the number of shares that you own. The mergers cannot be completed unless the Bioventus share issuance proposal is approved by Bioventus stockholders and the Misonix merger proposal is approved by Misonix stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Bioventus Share Issuance Proposal. </I>Assuming a quorum is present at the Bioventus special meeting, approval
of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy
(including due to the failure of a Bioventus stockholder who holds shares of Bioventus common stock in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no
effect on the outcome of the Bioventus share issuance proposal. An abstention, or other failure of any shares of Bioventus common stock virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus
share issuance proposal to vote on the Bioventus share issuance proposal, will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting,
if a Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed
to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Bioventus Adjournment Proposal. </I>Whether or not a quorum is present at the Bioventus special meeting,
approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy
(including due to the failure of an Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of
the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Bioventus adjournment proposal. An abstention or other failure of any shares of Bioventus common stock virtually present or represented by proxy and entitled to vote at the Bioventus special
meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal, will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus adjournment proposal. However, if a Bioventus stockholder who holds shares of
Bioventus common stock in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with
respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Misonix merger proposal</I>. Assuming a quorum is present at the Misonix special meeting, approval of the
Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate &#147;FOR,&#148; &#147;AGAINST&#148; or
&#147;ABSTAIN&#148; on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers&#146; unvoted shares on the Misonix merger proposal or to vote their customers&#146; shares if the customers have not furnished
voting instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in
&#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and
entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Misonix merger proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Misonix compensation proposal</I>. Assuming a quorum is present at the Misonix special meeting, approval of
the Misonix compensation proposal requires the affirmative vote of the holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting.
For the Misonix compensation proposal, a Misonix stockholder may indicate &#147;FOR,&#148; &#147;AGAINST&#148; or &#147;ABSTAIN&#148; on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation
proposal, only those votes cast &#147;FOR&#148; or &#147;AGAINST&#148; are included. Brokerage firms and nominees will not have the authority to vote their customers&#146; unvoted shares on the Misonix compensation proposal or to vote their
customers&#146; shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted only for
purposes of determining whether a quorum is present at the meeting and therefore will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of
the mergers, and the vote with respect to this proposal is advisory only and will not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation
may be paid to Misonix&#146;s named executive officers to the extent payable in accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory
vote, the Misonix compensation proposal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Misonix adjournment proposal.</I> Whether or not a quorum is present at the Misonix special meeting, approval
of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present
or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no
effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Misonix adjournment proposal. However,
if a Misonix stockholder who holds shares of Misonix common stock in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting
power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What will Misonix stockholders receive for their shares of Misonix common stock if the mergers are completed? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the mergers are completed, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of
Misonix, Bioventus, Merger Sub I or Merger Sub II, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be
converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Bioventus class A common stock, based on the election of the
holder thereof and, in each case, subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described under &#147;The Merger Agreement&#151;The Mergers; Merger Consideration&#151;Proration and
Reallocation&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the value of the merger consideration payable to holders of Misonix common stock? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange ratio of 1.6839 shares of Bioventus class A common stock is fixed and will not be adjusted for changes in the market price of either Bioventus
class A common stock or Misonix common stock between the date of signing of the merger agreement and the completion date of the first merger. As such, the market value of the merger consideration payable to Misonix stockholders will fluctuate with
the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the Misonix merger proposal. Upon completion of the mergers, former Misonix stockholders are expected to own approximately 25%
of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Bioventus class A common stock is traded on
the Nasdaq Global Select Market, which is referred to as &#147;Nasdaq,&#148; under the symbol &#147;BVS.&#148; Misonix common stock is traded on Nasdaq under the symbol &#147;MSON.&#148; We encourage you to obtain current quotes for both the
Bioventus class A common stock and the Misonix common stock before voting at the Misonix special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the value of merger consideration to be
received by a specific holder of Misonix common stock will depend on whether they elect to receive the cash consideration, elect to receive the stock consideration, or make no election, if all Misonix stockholders elect to receive the cash
consideration (or if all Misonix stockholders elect to receive the stock consideration), each holder of Misonix common stock would receive, on an aggregate basis, $10.50 in cash and 1.0524 shares of Bioventus class A common stock for each share of
Misonix common stock that they own. Based on the Bioventus class A common stock price of $16.63 per share, which is the average of the daily volume weighted average price per share for the seven consecutive trading day period up to and including
July&nbsp;27, 2021, two trading days prior to the entry by Bioventus and Misonix into the merger agreement, the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash
consideration or all Misonix stockholders elect to receive the stock consideration), was $28.00 per share of Misonix common stock. On September&nbsp;1, 2021, the latest practicable trading day before the date of the filing of this joint proxy
statement/prospectus, the closing price of Bioventus class A common stock on the Nasdaq was $14.98 per share, resulting in the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the
cash consideration or all Misonix stockholders elect to receive the stock consideration), was $26.27 per share of Misonix common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I elect the type of merger consideration I prefer to receive? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not less than 30 days prior to the anticipated closing date of the first merger, letter of election and transmittal will be mailed to each Misonix stockholder
that is a holder of record as of five business days prior to the mailing date. To elect to receive the cash consideration, the stock consideration or a combination of the two, you must indicate on the letter of election and transmittal the number of
shares of Misonix common stock with respect to which you elect to receive the cash consideration, the number of shares of Misonix common stock with respect to which you elect to receive the stock consideration and the number of shares of Misonix
common stock with respect to which you make no election. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing Misonix, stockholders of the expiration of the election period,
which expiration we refer to as the &#147;election deadline.&#148; You must return the letter of election and transmittal in the <FONT STYLE="white-space:nowrap">pre-addressed,</FONT> return envelope provided so that it is received no later than
5:00&nbsp;p.m. (New York City time) on the election deadline for your election to be properly submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold shares of Misonix common stock in
&#147;street name&#148;, you should receive instructions from the bank, brokerage firm or other nominee that is holding your shares advising you of the procedures for making your election. If these instructions are not received, you should contact
the bank, brokerage firm or other nominee holding your shares of Misonix common stock as soon as possible. Election forms must be returned to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are
encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage firm or other nominee holding your shares, as that deadline may be earlier than the election deadline described in this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I make one election for some of my shares of Misonix common stock and another election for the rest? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. The letter of election and transmittal permits you to specify, among the shares of Misonix common stock you hold, (i)&nbsp;the number of shares of Misonix
common stock for which you are electing to receive the cash consideration of $28.00 per share, (ii)&nbsp;the number of shares of Misonix common stock for which you are electing to receive the stock consideration of 1.6839 shares of Bioventus class A
common stock, or (iii)&nbsp;the number of shares of Misonix common stock for which you make no election. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I do not make an election or my
letter of election and transmittal is not received before the election deadline? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you do not submit a properly completed and signed letter of
election and transmittal to the exchange agent by the election deadline (or if you submit a properly completed letter of election and transmittal indicating no election), then you will be deemed to have made no election and will therefore receive
the cash consideration or the stock consideration or a combination of both, depending on the elections made by other Misonix stockholders (as described in the section entitled &#147;The Merger Agreement&#151;The Mergers; Effects of the
Mergers&#151;Proration and Reallocation&#148; of this joint proxy statement/prospectus), except with respect to shares as to which you have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal
rights pursuant to Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete
and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a
letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my election after I submit a letter of election and transmittal? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. You may revoke your election of the form of merger consideration you will receive with respect to all or a portion of your shares of Misonix common stock
by delivering written notice of your revocation to the exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent prior to the election deadline. If you instructed a bank, brokerage firm or other nominee to submit an election for your shares, you must follow its directions for changing those
instructions, as the deadline to revoke your election may be earlier than the election deadline described in this joint proxy statement/prospectus. In addition, any election of merger consideration you make will automatically be revoked if the
merger agreement is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix stockholders will not be entitled to revoke or change their election following the election deadline. For Misonix
stockholders who hold shares in &#147;street name&#148;, the election deadline provided by the bank, brokerage firm or other nominee holding your shares may be earlier than the election deadline described in this joint proxy statement/prospectus. As
a result, if you make an election, you will be unable to revoke your election or sell your shares of Misonix common stock after the applicable election deadline unless the merger agreement is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May I submit a letter of election and transmittal even if I vote against the Misonix merger proposal? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. You should submit a letter of election and transmittal even if you vote against the Misonix merger proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May I transfer my shares of Misonix common stock once I have made an election? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes you may transfer your shares prior to the election deadline, however, for Misonix stockholders who have made an election, any further transfer of shares
made on the stock transfer books of Misonix will be deemed to be a revocation of their election. Furthermore, you will not be able to transfer your shares of Misonix common stock after the election deadline unless the merger agreement is terminated.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What happens if I am eligible to receive a fraction of a share of Bioventus class A common stock as part of the merger consideration? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the aggregate number of shares of Bioventus class A common stock, if any, that you are entitled to receive as merger consideration includes a fraction of a
share of Bioventus class A common stock, you will receive cash in lieu of that fractional share. See the section entitled &#147;The Merger Agreement&#151;Fractional Shares&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What will holders of Misonix equity compensation awards receive in the mergers? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding Misonix stock option held by employees and directors of Misonix who meet the <FONT STYLE="white-space:nowrap">S-8</FONT> definition of
&#147;employee&#148; shall (i)&nbsp;become fully vested immediately upon the effective time and (ii)&nbsp;be assumed by Bioventus and converted automatically into an option to purchase Bioventus Class&nbsp;A Common Stock based on the option exchange
ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will generally remain subject to the same vesting and other terms and conditions
that applied to such awards immediately prior to the effective time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding Misonix stock option held by an individual who does not meet the <FONT
STYLE="white-space:nowrap">S-8</FONT> definition of &#147;employee&#148; will become fully vested and be settled in cash immediately prior to the effective time in an amount equal to the product of (x)&nbsp;the number of shares of Misonix common
stock subject to the applicable option and (y)&nbsp;the excess, if any, of (i)&nbsp;the average of the volume-weighted average trading price per share of Bioventus Class&nbsp;A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the
five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii)&nbsp;the per share exercise price of such option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;The Merger Agreement&#151;Treatment of Misonix Equity Awards&#148; of this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How will the mergers be financed? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus expects to fund the aggregate cash consideration upon completion of the mergers with cash on hand, together with the proceeds of senior secured term
loans in an aggregate principal amount of approximately $262.0 to be incurred initially by Merger Sub I. The receipt of financing by Bioventus is not a condition to completion of the mergers and, accordingly, Bioventus will be required to complete
the mergers (assuming that all of the conditions to its obligations under the merger agreement are satisfied) whether or not debt financing is available at all or on acceptable terms. See the section entitled &#147;Financing of the Mergers&#148; of
this joint proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How does the Bioventus board recommend that I vote at the Bioventus special meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board unanimously recommends that you vote &#147;<B>FOR</B>&#148; the Bioventus share issuance proposal and &#147;<B>FOR</B>&#148; the Bioventus
adjournment proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than with respect to continued service for, employment by and the right to continued indemnification by the combined company,
as of the date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the merger that are different from, or in addition to, the interests of other Bioventus stockholders generally. See
&#147;Interests of Bioventus Directors and Executive Officers in the Merger.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How does the Misonix board recommend that I vote at the Misonix
special meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board unanimously recommends that you vote &#147;<B>FOR</B>&#148; the Misonix merger proposal, &#147;<B>FOR</B>&#148; the
Misonix compensation proposal and &#147;<B>FOR</B>&#148; the Misonix adjournment proposal. For a description of some of the factors considered by the Misonix board in reaching its decision to approve the merger agreement and the transactions
contemplated thereby, including the merger, and additional information on the recommendation of the Misonix board, see &#147;The Merger&#151;Recommendation of the Misonix Board of Directors; Misonix&#146;s Reasons for the Merger.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is entitled to vote at each special meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All holders of record of shares of Bioventus
common stock who held shares at the close of business on September&nbsp;22, 2021 (the Bioventus record date) are entitled to receive notice of, and to vote at, the Bioventus special meeting. Each such holder of Bioventus common stock is entitled to
cast one vote on each matter properly brought before the Bioventus special meeting for each share of Bioventus common stock that such holder owned of record as of the Bioventus record date. Virtual attendance at the Bioventus special meeting via the
Bioventus special meeting website is not required to vote. See below and &#147;The Bioventus Special Meeting&#151;Methods of Voting&#148; for instructions on how to vote without virtually attending the Bioventus special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All holders of record of shares of Misonix
common stock who held shares at the close of business on September&nbsp;22, 2021 (the Misonix record date) are entitled to receive notice of, and to vote at, the Misonix special meeting. Each such holder of Misonix common stock is entitled to cast
one vote on each matter properly brought before the Misonix special meeting for each share of Misonix common stock that such holder owned of record as of the Misonix record date. Physical attendance at the Misonix special meeting is not required to
vote. See below and &#147;The Misonix Special Meeting&#151;Methods of Voting&#148; for instructions on how to vote without attending the Misonix special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is a proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proxy is a stockholder&#146;s legal designation of another person to vote shares owned by such stockholder on their behalf. The document used to designate a
proxy to vote your shares of Bioventus or Misonix common stock, as applicable, is referred to as a &#147;proxy card.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have at
each special meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Bioventus
stockholder is entitled to one vote for each share of Bioventus common stock held of record as of the close of business on the Bioventus record date. As of the close of business on the Bioventus record date, there were 56,849,338 shares of Bioventus
common stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Misonix
stockholder is entitled to one vote for each share of Misonix common stock held of record as of the close of business on the Misonix record date. As of the close of business on the Misonix record date, there were 17,425,045 shares of Misonix common
stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What constitutes a quorum for each special meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum is the minimum number of shares
required to be represented, either through virtual attendance or through representation by proxy, to hold a valid meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority of
in voting power of the stock issued and outstanding and entitled to vote at the meeting, must be present in person, or by remote communication, if applicable, or represented by proxy to constitute a quorum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority in voting power of the
shares of stock issued and outstanding and entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Where
will the Bioventus common stock that I receive in the merger be publicly traded? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Bioventus class A common stock to be issued to Misonix
stockholders in the merger will be listed for trading on Nasdaq under the symbol &#147;BVS.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What happens if the merger is not completed?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Bioventus share issuance proposal is not approved by Bioventus stockholders, if the Misonix merger proposal is not approved by Misonix
stockholders or if the mergers are not completed for any other reason, Misonix stockholders will not receive the merger consideration or any other consideration in connection with the mergers, and their shares of Misonix common stock will remain
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the mergers are not completed, Misonix will remain an independent public company, the Misonix common stock will continue to be listed and
traded on Nasdaq under the symbol &#147;MSON&#148; and Bioventus will not complete the share issuance contemplated by the merger agreement, regardless of whether the Bioventus share issuance proposal has been approved by Bioventus stockholders. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the merger agreement, Bioventus and Misonix will each be required to pay a termination fee of
$20,661,000 to the other party if the merger agreement is terminated in certain circumstances, including if the respective party&#146;s board changes its recommendation in connection with the mergers and the other party terminates the merger
agreement. Additionally, Misonix may terminate the merger agreement if it enters into an alternative acquisition agreement with respect to a superior proposal and pays Bioventus the termination fee. See &#147;The Merger Agreement&#151;Termination
Fee.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I vote my shares at my respective special meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares held directly in your name as a
Bioventus stockholder of record may be virtually voted at the Bioventus special meeting via the Bioventus special meeting website. You will need the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number included on your proxy card in order
to access and vote via the Bioventus special meeting website as described under &#147;The Bioventus Special Meeting&#151;Virtually Attending the Bioventus Special Meeting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares held in &#147;street name&#148; may be virtually voted at the Bioventus special meeting via the Bioventus special meeting website only if you obtain a
specific control number and follow the instructions provided by your bank, broker or other nominee. See &#147;The Bioventus Special Meeting&#151;Virtually Attending the Bioventus Special Meeting.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may vote by attending the Misonix special
meeting and voting in person or by submitting a proxy. The method of voting by proxy differs (i)&nbsp;depending on whether you are viewing this proxy statement on the Internet or submitting a paper copy and (ii)&nbsp;for shares of Misonix common
stock held as a record holder and shares held in &#147;street name.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold your shares of Misonix common stock as a record holder and you are
viewing this joint proxy statement/prospectus on the Internet, you may submit a proxy over the Internet by following the instructions on the proxy card that was included with this joint proxy statement/prospectus. If you hold your shares of Misonix
common stock as a record holder and you are reviewing a paper copy of this joint proxy statement/prospectus, you may submit a proxy over the Internet or by telephone by following the instructions on the proxy card, or by completing, dating and
signing the proxy card that was included with this joint proxy statement/prospectus and promptly returning it in the <FONT STYLE="white-space:nowrap">pre-addressed,</FONT> postage-paid envelope provided to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Street name&#148; holders generally cannot submit a proxy or vote their shares directly and must instead instruct the broker, bank, trust or other
nominee how to vote their shares using the methods described below. If you hold your shares of Misonix common stock in street name, you will receive a notice from your broker, bank, trust or other nominee that includes instructions on how to vote
your shares. Your broker, bank, trust or other nominee may allow you to deliver your voting instructions over the Internet and may also permit you to submit your voting instructions by telephone. In addition, you may request paper copies of this
proxy statement and accompanying proxy card from your broker by following the instructions on the notice provided by your broker, bank, trust or other nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information on virtually attending the special meetings, see &#147;The Bioventus Special Meeting&#148; and &#147;The Misonix Special
Meeting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I vote my shares without attending my company&#146;s special meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether you hold your shares directly as a stockholder of record of Bioventus or Misonix or beneficially in &#147;street name,&#148; you may direct your vote
by proxy without attending the Bioventus or Misonix special meeting, as applicable. If you are a stockholder of record, you can vote by proxy over the internet, by telephone or by mail by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following the instructions provided in the enclosed proxy card. If you hold shares beneficially in &#147;street name,&#148; you should follow the voting instructions provided by your bank, broker
or other nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information on voting procedures, see &#147;The Bioventus Special Meeting&#148; and &#147;The Misonix Special
Meeting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is a &#147;broker <FONT STYLE="white-space:nowrap">non-vote&#148;?</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Nasdaq rules, banks, brokers and other nominees may use their discretion to vote &#147;uninstructed&#148; shares (i.e., shares of record held by banks,
brokers or other nominees, but with respect to which the beneficial owner of such shares has not provided instructions on how to vote on a particular proposal) with respect to matters that are considered to be &#147;routine,&#148; but not with
respect to <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. All of the proposals currently expected to be brought before the Bioventus and Misonix special meetings are
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;broker
<FONT STYLE="white-space:nowrap">non-vote&#148;</FONT> occurs on an item when (i)&nbsp;a bank, broker or other nominee has discretionary authority to vote on one or more proposals to be voted on at a meeting of stockholders, but is not permitted to
vote on other proposals without instructions from the beneficial owner of the shares, and (ii)&nbsp;the beneficial owner fails to provide the bank, broker or other nominee with such instructions. Because all of the proposals currently expected to be
voted on at the Bioventus and Misonix special meetings are <FONT STYLE="white-space:nowrap">non-routine</FONT> matters under Nasdaq rules for which brokers do not have discretionary authority to vote, Bioventus and Misonix do not expect there to be
any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> at the Bioventus or Misonix special meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Are there any Misonix stockholders already
committed to vote in favor of the Misonix merger proposal and Misonix compensation proposal? Are there any Bioventus stockholders already committed to vote in favor of the Bioventus share issuance proposal? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus:</I> Yes. Subsequent to the execution of the merger agreement, Misonix entered into a voting agreement (the &#147;Bioventus support
agreement&#148;) with EW Healthcare Partners Acquisition Fund, L.P., White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith&nbsp;&amp; Nephew, Inc., Smith&nbsp;&amp; Nephew USD Ltd and
<FONT STYLE="white-space:nowrap">AMP-CF</FONT> Holdings, LLC (together, the &#147;Bioventus supporting stockholders&#148;), pursuant to which such stockholders have agreed, among other things, to vote the shares of Bioventus common stock that they
beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the
record date for the Bioventus special meeting, such stockholders beneficially own approximately 67.4% of the outstanding shares of Bioventus common stock. Therefore, the Bioventus supporting stockholders hold a sufficient number of shares of
Bioventus common stock in order to approve the Bioventus share issuance proposal. On July&nbsp;29, 2021, in connection with execution of the merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with
Bioventus (each a &#147;lock up agreement&#148;) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or 180 days, subject to the terms of the lock up agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix: </I>Yes. Subsequent to the execution of the merger agreement, Bioventus entered into a voting agreement (the &#147;Misonix support
agreement&#148;) with each of Stavros G. Vizirgianakis, 1315 Capital, LLC, SV Life Sciences Fund VI Strategic Partners, L.P. and SV Life Sciences Fund VI, L.P. (together, the &#147;Misonix supporting stockholders&#148;), pursuant to which such
stockholders have agreed, among other things, to vote the shares of Misonix common stock that they own at the time such vote is taken in favor of the Misonix merger proposal and Misonix compensation proposal and against approval of any proposal made
in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Misonix special meeting, the Misonix supporting stockholders beneficially own approximately 28.8% of the outstanding
shares of Misonix common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What stockholder vote is required for the approval of each proposal at the Bioventus special meeting?
What will happen if I fail to vote or abstain from voting on each proposal at the Bioventus special meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus Proposal 1: Bioventus Share
Issuance Proposal </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the
affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder
who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or
other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote
&#147;<B>AGAINST</B>&#148; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if a Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee
provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting
instructions will have no effect on the Bioventus share issuance proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus Proposal 2: Bioventus Adjournment Proposal </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the
holders of a majority in voting power of the votes cast on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of a Bioventus stockholder who holds shares in
&#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any
shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal will have the same effect as a vote &#147;AGAINST&#148; the
Bioventus adjournment proposal. However, if a Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus
adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What stockholder vote is required for the approval of each proposal at the Misonix special meeting? What will happen if I fail to vote or abstain from
voting on each proposal at the Misonix special meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Proposal 1: Misonix Merger Proposal </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority
of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate &#147;FOR,&#148; &#147;AGAINST&#148; or &#147;ABSTAIN&#148; on the proxy card. Brokerage firms and nominees will not have
the authority to vote their customers&#146; unvoted shares on the Misonix merger proposal or to vote their customers&#146; shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special
meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions
to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the
Misonix merger proposal, will each have the same effect as a vote <B>&#147;AGAINST&#148;</B> the Misonix merger proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Proposal 2: Misonix Compensation Proposal </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the holders of a
majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate
&#147;FOR,&#148; &#147;AGAINST&#148; or &#147;ABSTAIN&#148; on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast &#147;FOR&#148; or &#147;AGAINST&#148; are
included. Brokerage firms and nominees will not have the authority to vote their customers&#146; unvoted shares on the Misonix compensation proposal or to vote their customers&#146; shares if the customers have not furnished voting instructions
within a specified period of time prior to the Misonix special meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted only for purposes of determining whether a quorum is present at the meeting and therefore
will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will
not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix&#146;s named executive officers to the extent payable in
accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote, the Misonix compensation proposal.<I> </I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Proposal 3: Misonix Adjournment Proposal </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether
or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy
at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting
instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at
the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Misonix adjournment proposal. However, if a Misonix stockholder who holds
shares of Misonix common stock in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld
with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why am I being asked to consider and vote on a proposal to approve, by <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote, the
merger-related compensation for named executive officers (the Misonix compensation proposal)? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under SEC rules, Misonix is required to seek a <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory vote of its stockholders relating to the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the merger (also known as
&#147;golden parachute&#148; compensation). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What happens if Misonix stockholders do not approve, by
<FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote, the merger-related compensation for Misonix named executive officers (the Misonix compensation proposal)? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the vote on the proposal to approve the Misonix compensation proposal is advisory in nature, the outcome of the vote will not be binding upon Misonix
or the combined company. Accordingly, the merger-related compensation, which is described under &#147;Interests of Misonix Directors and Executive Officers in the Merger,&#148; may be paid to Misonix named executive officers even if Misonix
stockholders do not approve the Misonix compensation proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I hold shares of both Bioventus and Misonix common stock? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are both a Bioventus stockholder and a Misonix stockholder, you will receive two separate packages of proxy materials. A vote cast as a Bioventus
stockholder will not count as a vote cast as a Misonix stockholder, and a vote cast as a Misonix stockholder will not count as a vote cast as a Bioventus stockholder. <B>Therefore, please follow the instructions received with each set of materials
you receive in order to submit separate proxies for your shares of Bioventus common stock and your shares of Misonix common stock.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the
difference between holding shares as a stockholder of record and as a beneficial owner of shares held in &#147;street name&#148;? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares of
Bioventus or Misonix common stock are registered directly in your name with the transfer agent of Bioventus and Misonix, respectively, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have
the right to vote directly at the applicable special meeting. You may also grant a proxy directly to Bioventus or Misonix, as applicable, or to a third party to vote your shares at the applicable special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares of Bioventus or Misonix common stock are held by a bank, broker or other nominee, you are considered the beneficial owner of shares held in
&#147;street name.&#148; Your bank, broker or other nominee will send you, as the beneficial owner, a package describing the procedures for voting your shares. You should follow the instructions provided by them to vote your shares. In order to
attend and vote at the Bioventus special meeting via the Bioventus special meeting website or the Misonix special meeting in person, you will need to obtain a specific control number and follow the other procedures provided by your bank, broker or
other nominee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If my shares of Bioventus or Misonix common stock are held in &#147;street name&#148; by my bank, broker or other nominee, will my
bank, broker or other nominee automatically vote those shares for me? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No. Your bank, broker or other nominee will only be permitted to vote your
shares of Bioventus or Misonix common stock, as applicable, if you instruct your bank, broker or other nominee how to vote. You should follow the procedures provided by your bank, broker or other nominee regarding the voting of your shares. Under
Nasdaq rules, banks, brokers and other nominees who hold shares of Bioventus or Misonix common stock in &#147;street name&#148; for their customers have authority to vote on &#147;routine&#148; proposals when they have not received instructions from
beneficial owners. However, banks, brokers and other nominees are prohibited from exercising their voting discretion with respect to <FONT STYLE="white-space:nowrap">non-routine</FONT> matters, which include all the proposals currently scheduled to
be considered and voted on at the Bioventus and Misonix special meetings. As a result, absent specific instructions from the beneficial owner of such shares, banks, brokers and other nominees are not empowered to vote such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Bioventus stockholders, the effect of not instructing your bank, broker or other nominee how you wish to vote your shares of Bioventus common stock will
have no effect on the Bioventus share issuance proposal or the Bioventus adjournment proposal (assuming a quorum is present at the Bioventus special meeting). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix stockholders, the effect of not instructing your bank, broker or other nominee how you wish to vote your shares of Misonix common stock will be
the same as a vote &#147;<B>AGAINST</B>&#148; the Misonix merger proposal, but will have no effect on the Misonix compensation proposal (assuming a quorum is present at the Misonix special meeting) or the Misonix adjournment proposal. In addition,
if a Misonix stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix compensation proposal or the Misonix adjournment
proposal, it will have the same effect as a vote &#147;<B>AGAINST</B>&#148; such proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What should I do if I receive more than one set of voting materials for the same special meeting?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold shares of Bioventus or Misonix common stock in &#147;street name&#148; and also directly in your name as a stockholder of record or
otherwise, or if you hold shares of Bioventus or Misonix common stock in more than one brokerage account, you may receive more than one set of voting materials relating to the same special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Record Holders</I>. For shares held directly, please vote by proxy over the internet or telephone using the instructions included with the accompanying
proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to ensure that all of your shares of Bioventus or Misonix common stock are voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shares in &#147;street name.&#148; </I>For shares held in &#147;street name&#148; through a bank, broker or other nominee, you should follow the procedures
provided by your bank, broker or other nominee to submit a proxy or vote your shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If a stockholder gives a proxy, how are the shares of Bioventus
or Misonix common stock voted? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regardless of the method you choose to vote, the individuals named on the enclosed proxy card will vote your shares of
Bioventus or Misonix common stock, as applicable, in the way that you indicate. For each item before the Bioventus or Misonix special meeting, as applicable, you may specify whether your shares of Bioventus or Misonix common stock, as applicable,
should be voted for or against, or abstain from voting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How will my shares of Bioventus common stock be voted if I return a blank proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you sign, date and return your proxy and do not indicate how you want your shares of Bioventus common stock to be voted, then your shares of Bioventus
common stock will be voted in accordance with the recommendation of the Bioventus board: &#147;<B>FOR</B>&#148; the Bioventus share issuance proposal and &#147;<B>FOR</B>&#148; the Bioventus adjournment proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How will my shares of Misonix common stock be voted if I return a blank proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you sign, date and return your proxy and do not indicate how you want your shares of Misonix common stock to be voted, then your shares of Misonix common
stock will be voted in accordance with the recommendation of the Misonix board: &#147;<B>FOR</B>&#148; the Misonix merger proposal, &#147;<B>FOR</B>&#148; the Misonix compensation proposal and &#147;<B>FOR</B>&#148; the Misonix adjournment proposal.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote after I have submitted my proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Bioventus or Misonix&#146;s stockholder giving a proxy has the right to revoke the proxy and change their vote before the proxy is voted at the applicable
special meeting by doing any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsequently submitting a new proxy (including over the internet or telephone) for the applicable special meeting
that is received by the deadline specified on the accompanying proxy card; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">giving timely written notice of your revocation to Bioventus&#146; or Misonix&#146;s Corporate Secretary, as
applicable; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attending and voting at the applicable special meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Execution or revocation of a proxy will not in any way affect your right to attend and vote at the
applicable special meeting, whether in person or, in the case of the Bioventus special meeting, via the special meeting website. Written notices of revocation and other communications relating to the revocation of proxies should be addressed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>If you are an Bioventus stockholder:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>If you are a Misonix stockholder:</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bioventus Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4721 Emperor Boulevard, Suite 400</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Durham, North Carolina 27703</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">tony.dadamio@bioventus.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(919) <FONT
STYLE="white-space:nowrap">474-6700</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bioventus Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Misonix, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1938 New Highway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Farmingdale, NY
11735</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">misonixproxy@misonix.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(631)
694-9555</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Misonix, Inc.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;The Bioventus Special Meeting&#151;Revocability of Proxies&#148; and &#147;The Misonix Special
Meeting&#151;Revocability of Proxies.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If I hold my shares in &#147;street name,&#148; can I change my voting instructions after I have submitted
voting instructions to my bank, broker or other nominee? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in the name of a bank, broker or other nominee and you previously
provided voting instructions to your bank, broker or other nominee, you should follow the instructions provided by your bank, broker or other nominee to revoke or change your voting instructions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Where can I find the voting results of the special meetings? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preliminary voting results for each special meeting are expected to be announced at that special meeting. In addition, within four business days following
certification of the final voting results, each of Bioventus and Misonix will file the final voting results of its respective special meeting (or, if the final voting results have not yet been certified, the preliminary results) with the SEC on a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Do Misonix stockholders have dissenters&#146; or appraisal rights? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the closing of the mergers, Misonix stockholders who do not vote in favor of the Misonix merger proposal and otherwise comply with the procedures
and satisfy the conditions set forth in Section&nbsp;262 of the DGCL are entitled to appraisal rights under Section&nbsp;262 of the DGCL. For more information regarding appraisal rights, see the section entitled &#147;Appraisal Rights,&#148; In
addition, a copy of Section&nbsp;262 of the DGCL is attached as <U>Annex D</U> to this joint proxy statement/prospectus. Failure to strictly comply with Section&nbsp;262 of the DGCL may result in your waiver of, or inability to, exercise appraisal
rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Are there any risks that I should consider in deciding whether to vote for the approval of the Bioventus share issuance proposal or the
Misonix merger proposal? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. You should read and carefully consider the risk factors set forth under &#147;Risk Factors.&#148; You also should read
and carefully consider the risk factors relating to Bioventus and Misonix that are contained in the documents that are incorporated by reference in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What happens if I sell my shares of Bioventus or Misonix common stock after the respective record date but before the respective special meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus record date is earlier than the date of the Bioventus special meeting, and the Misonix record date is earlier than the date of the Misonix
special meeting. If you sell or otherwise transfer your shares of Bioventus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or Misonix common stock after the applicable record date but before the applicable special meeting, you will, unless special arrangements are made, retain your right to vote at the applicable
special meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who will solicit and pay the cost of soliciting proxies? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix has engaged the services of MacKenzie Partners to assist in the distribution of the proxies. Misonix estimates that it will pay a fee of approximately
$18,500 plus reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses to MacKenzie Partners for this service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix also may be required to reimburse banks, brokers and other custodians, nominees and fiduciaries or their respective agents for their
expenses in forwarding proxy materials to beneficial owners of Bioventus Misonix common stock, respectively. Bioventus and Misonix directors, officers and employees also may solicit proxies by telephone, by electronic means or in person. They will
not be paid any additional amounts for soliciting proxies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When are the mergers expected to be completed? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of the closing conditions described under &#147;The Merger Agreement&#151;Conditions to the Completion of the
Merger,&#148; including approval of the Bioventus share issuance proposal by Bioventus stockholders and approval of the Misonix merger proposal by Misonix stockholders, the mergers are currently expected to be completed by the end of the 2021
calendar year. However, neither Bioventus nor Misonix can predict the actual date on which the mergers will be completed, or if the mergers will be completed at all, because completion of the mergers is subject to conditions and factors beyond the
control of both companies, including the receipt of certain required regulatory approvals. Bioventus and Misonix hope to complete the merger as soon as reasonably practicable. Also see &#147;The Mergers&#151;Regulatory Approvals.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What respective equity stakes will Bioventus and Misonix stockholders hold in the combined company immediately following the merger? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of shares of Bioventus and Misonix common stock outstanding on September&nbsp;1, 2021, the latest practicable date prior to the date of
this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger
are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the merger will
depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If I am a Misonix
stockholder, how will I receive the merger consideration to which I am entitled? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your receipt of the merger consideration will depend on whether your
shares of Misonix common stock are represented by stock certificates (&#147;Misonix stock certificates&#148;) or if you hold book-entry shares (&#147;Misonix book-entry shares&#148;). Not less than 30 days prior to the anticipated closing date of
the first merger, the exchange agent will mail to each holder of record of Misonix common stock a letter of election and transmittal. You are encouraged to complete and return your letter of election and transmittal in accordance with the
instructions therein as soon as reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix stock certificates, no later than three business days after the consummation of the
mergers, the exchange agent will mail to each holder of record of Misonix stock certificates (a)&nbsp;a notice advising such holder of the effectiveness of the mergers, and (b)&nbsp;a letter of transmittal and (c)&nbsp;instructions for surrendering
Misonix stock certificates to the exchange agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon surrender of a Misonix stock certificate and a duly executed letter of election and transmittal (or
letter of transmittal if an election is not submitted) to the exchange agent in compliance with the instructions for surrender, the exchange agent will mail to each holder of record, as promptly as reasonably practicable thereafter: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a statement reflecting the number of whole shares of Bioventus class A common stock, if any, that such holder is
entitled to receive in <FONT STYLE="white-space:nowrap">non-certificated</FONT> book-entry form in the name of such record holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer
instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&nbsp;any applicable cash election consideration, (b)&nbsp;any cash in lieu
of fractional shares of Bioventus class A common stock plus (c)&nbsp;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to the merger agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix book-entry shares that are not held through DTC, upon the later of the consummation of the mergers and the holder&#146;s delivery to the exchange
agent of a duly executed letter of election and transmittal (or letter of transmittal, if an election is not submitted), the exchange agent will pay and deliver to each such holder of record of any such Misonix book-entry shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable stock election consideration, if any, that such holder is entitled to receive in <FONT
STYLE="white-space:nowrap">non-certificated</FONT> book-entry form in the name of such record holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer
instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&nbsp;any applicable cash election consideration, (b)&nbsp;any cash in lieu
of fractional shares of Bioventus class A common stock plus (c)&nbsp;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly
cancel each such <FONT STYLE="white-space:nowrap">non-DTC</FONT> book-entry share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix share certificates and Misonix
book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your
transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the
consummation of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix book-entry shares that are held through DTC, no later than three business days after the consummation of the
mergers, the exchange agent will transmit to DTC or its nominees, upon surrender of shares held of record by DTC or its nominees in accordance with DTC&#146;s customary surrender procedures: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable stock election consideration, if any, that such holder is entitled to receive in <FONT
STYLE="white-space:nowrap">non-certificated</FONT> book-entry form in the name of such record holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer
instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&nbsp;any applicable cash election consideration, (b)&nbsp;any cash in lieu
of fractional shares of Bioventus Class&nbsp;A Common Stock plus (c)&nbsp;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly
cancel each such DTC book-entry share. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What should I do now? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this joint proxy statement/prospectus carefully and in its entirety, including the annexes. Then, you may vote by proxy over the internet or
telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, so that your shares will be voted in accordance with your instructions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find more information about Bioventus and Misonix? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can find more information about Bioventus and Misonix from various sources described under &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Whom do I call if I have questions about the special meetings or the merger? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have questions about the special meetings or the merger, or desire additional copies of this joint proxy statement/prospectus or additional proxies, you
may contact the applicable company contacts below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>If you are an Bioventus stockholder:</I></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bioventus Inc.,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Corporate Secretary</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4721
Emperor Boulevard, Suite 100,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Durham, North Carolina 27703</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">tony.dadamio@bioventus.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(919) <FONT
STYLE="white-space:nowrap">474-6700</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>If you are a Misonix stockholder:</I></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Misonix, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Secretary</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1938 New
Highway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Farmingdale, NY 11735</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">misonixproxy@misonix.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(631) <FONT
STYLE="white-space:nowrap">694-9555</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_7"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For your convenience, provided below is a brief summary of certain information contained in this joint proxy statement/prospectus. This summary highlights
selected information from this joint proxy statement/ prospectus and does not contain all of the information that may be important to you as a Bioventus or Misonix stockholder. To understand the merger fully and for a more complete description of
the terms of the merger, you should read carefully this entire joint proxy statement/prospectus, its annexes and the other documents to which you are referred. Items in this summary include a page reference directing you to a more complete
description of those items. You may obtain the information incorporated by reference in this joint proxy statement/prospectus, without charge, by following the instructions under &#147;Where You Can Find More Information.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Parties to the Merger </B>(Page&nbsp;117) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a global leader of
innovations for active healing. Through a combination of internal product development, product/business acquisition, and distribution agreements, it will bring to market products which address a growing need for clinically effective, cost efficient,
minimally invasive medical treatments, that engage and enhance the body&#146;s natural healing processes. Bioventus&#146; principal place of business is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is
(919) <FONT STYLE="white-space:nowrap">474-6700.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix designs, manufactures and markets minimally invasive surgical ultrasonic medical devices. These products are used for precise bone sculpting, removal
of soft and hard tumors, and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. Misonix also exclusively markets, sells and distributes skin allografts and wound
care products used to support healing of wounds, and which complement Misonix&#146;s ultrasonic medical devices. Misonix&#146;s principal place of business is 1938 New Highway, Farmingdale, New York, and its telephone number is (631) <FONT
STYLE="white-space:nowrap">694-9555.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oyster Merger Sub I, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub I was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any
nature other than as set forth in the merger agreement. By operation of the merger, Merger Sub I will be merged with and into Misonix, with Misonix continuing as the surviving corporation. Merger Sub&#146;s principal executive offices are located at
4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <FONT STYLE="white-space:nowrap">474-6700.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oyster Merger Sub II, LLC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub II was
formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, following the first
merger, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (renamed as Misonix LLC) and a wholly owned subsidiary of Bioventus. Merger Sub&#146;s principal executive offices are located at 4721
Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <FONT STYLE="white-space:nowrap">474-6700.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Mergers and the Merger Agreement </B>(Pages&nbsp;137 and 198) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms and conditions of the merger are contained in the merger agreement, a copy of
which is attached as <U>Annex A</U> hereto. Bioventus and Misonix encourage you to read the merger agreement carefully and in its entirety, as it is the legal document that governs the merger. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, subject to the terms and conditions of the merger agreement, Merger Sub
I will be merged with and into Misonix, with Misonix continuing as the surviving corporation and subsequently, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity in the second merger and as a
wholly owned subsidiary of Bioventus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Consideration </B>(Page&nbsp;137) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the mergers are completed, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of
Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the
right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Bioventus class A common stock, based on the election of the holder thereof and, in
each case, subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described under &#147;The Merger Agreement&#151;The Merger Consideration&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proration and Reallocation</B> (Page&nbsp;137) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate
amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. In order to deliver this aggregate cash
amount, the merger agreement provides for pro rata adjustments to, and reallocation of, the cash and stock elections made by Misonix stockholders, as well as the allocation of consideration to be paid with respect to shares of Misonix common stock
as to which no election regarding the form of merger consideration to be paid to them, is received prior to the election deadline. Such no election shares will be exchanged for the cash consideration, the stock consideration or a combination of
both. Additionally, depending on the elections made by other Misonix stockholders, each Misonix stockholder who elects to receive Bioventus class A common stock for their shares in the mergers, referred to as &#147;stock election shares&#148; may
receive a portion of their consideration in cash, and each Misonix stockholder who elects to receive cash for their shares in the mergers, referred to as &#147;cash election shares&#148; may receive a portion of their consideration in Bioventus
class A common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration, which is the amount equal to the aggregate number of cash election shares multiplied by $28.00,
exceeds the available cash amount, then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all stock election shares and all no election shares will be exchanged for 1.6839 shares of Bioventus class A
common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a portion of the cash election shares of each Misonix stockholder will be exchanged for $28.00 in cash as
follows: cash election shares exchanged for $28.00 in cash = </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of such stockholder&#146;s cash election shares)
* (maximum cash amount) </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">elected cash consideration </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration is less than the available cash amount, which difference we refer to as the shortfall amount, then: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all cash election shares will be exchanged for the cash consideration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all stock election shares and no election shares will be treated in the following manner: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the shortfall amount is less than or equal to the product of the aggregate number of no election shares and
$28.00, which we refer to as the &#147;no election value&#148;, then (1)&nbsp;all stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock, and (2)&nbsp;a portion of the
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
no election shares of each Misonix stockholder, calculated as follows, will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#146;s no election shares, if
any, will be exchanged for 1.6839 shares of Bioventus class A common stock): </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">no election shares exchanged for cash
consideration = </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of no election shares of such stockholder) * (shortfall amount) </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(no election value) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the shortfall amount is more than the no election value, then (1)&nbsp;all no election shares will be
exchanged for $28.00 in cash and (2)&nbsp;a portion of the stock election shares of each stockholder will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#146;s stock election shares will be exchanged for
1.6839 shares of Bioventus class A common stock): </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">stock election shares exchanged for cash consideration = </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of stock election shares of such stockholder) * (shortfall amount &#150; no election value) </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(aggregate number of stock election shares) * $28.00 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration equals the available cash amount, then: (1)&nbsp;all cash election shares will be converted into the right to receive $28.00
in cash and (2)&nbsp;all stock election shares and all no election shares will be converted into the right to receive 1.6839 shares of Bioventus class A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;The Merger Agreement&#151;Proration&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election Procedures </B>(Page&nbsp;138)<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange
agent will mail to Misonix stockholders of record not less than 30 days prior to the anticipated closing date of the first merger a letter of election and transmittal. The letter of election and transmittal enables Misonix stockholders to choose to
make a cash election, a stock election or no election with respect to each share of Misonix common stock eligible to receive the merger consideration. Misonix intends to issue a press release at least five business days prior to the expiration of
the election period informing Misonix stockholders of the expiration of the election period, which expiration we refer to as the &#147;election deadline&#148;, to make their election and return their completed letters of election and transmittal. If
a Misonix stockholder holds shares of Misonix common stock through a bank, brokerage firm or other nominee, such bank, brokerage firm, or other nominee, as applicable, will provide such stockholder with instructions on how to make an election.
Election forms must be returned to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage
firm or other nominee holding your shares, as that deadline may be earlier than the election deadline described in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any election will have been properly made only if the exchange agent has actually received a properly completed letter of election and transmittal by the
election deadline. Any election form may be revoked or changed by written notice received by the exchange agent prior to the election deadline. If an election form is revoked, the shares of Misonix common stock as to which such election previously
applied will be no election shares unless an election is subsequently submitted by the Misonix stockholder prior to the election deadline. For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should
complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not
return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. See &#147;The Merger Agreement&#151;Election
Procedures&#148;. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Misonix Equity Awards </B>(Page&nbsp;204) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding Misonix stock option held by employees and directors of Misonix who meet the <FONT STYLE="white-space:nowrap">S-8</FONT> definition of
&#147;employee&#148; shall (i)&nbsp;become fully vested immediately upon the effective time and (ii)&nbsp;be assumed by Bioventus and converted automatically into an option to purchase Bioventus class A common stock based on the option exchange
ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will generally remain subject to the same vesting and other terms and conditions
that applied to such awards immediately prior to the effective time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each outstanding Misonix stock option held by an individual who does not meet the <FONT
STYLE="white-space:nowrap">S-8</FONT> definition of &#147;employee&#148; will become fully vested and be settled in cash immediately prior to the effective time in an amount equal to the product of (x)&nbsp;the number of shares of Misonix common
stock subject to the applicable option and (y)&nbsp;the excess, if any, of (i)&nbsp;the average of the volume-weighted average trading prices per share of Bioventus Class&nbsp;A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the
five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii)&nbsp;the per share exercise price of such option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;The Merger Agreement&#151;Treatment of Misonix Equity Awards&#148; of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Bioventus Board of Directors; Bioventus&#146; Reasons for the Merger </B>(Page&nbsp;155)<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board unanimously recommends that you vote &#147;<B>FOR</B>&#148; the Bioventus share issuance proposal and &#147;<B>FOR</B>&#148; the Bioventus
adjournment proposal. For a description of some of the factors considered by the Bioventus board in reaching its decision to approve the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, and
additional information on the recommendation of the Bioventus board, see &#147;The Mergers&#151;Recommendation of the Bioventus Board of Directors; Bioventus&#146; Reasons for the Merger.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Misonix Board of Directors; Misonix&#146;s Reasons for the Merger </B>(Page&nbsp;158)<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board unanimously recommends that you vote &#147;<B>FOR</B>&#148; the Misonix merger proposal, &#147;<B>FOR</B>&#148; the Misonix compensation
proposal and &#147;<B>FOR</B>&#148; the Misonix adjournment proposal. For a description of some of the factors considered by the Misonix board in reaching its decision to approve the merger agreement and the transactions contemplated thereby,
including the merger, and additional information on the recommendation of the Misonix board, see &#147;The Mergers&#151;Recommendation of the Misonix Board of Directors; Misonix&#146;s Reasons for the Merger.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinions of Bioventus&#146; Financial Advisor </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion
of Perella Weinberg </I>(Page&nbsp;165; <U>Annex B</U>)<I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bioventus retained Perella Weinberg Partners LP, or Perella Weinberg, to
act as its financial advisor in connection with the mergers. Bioventus selected Perella Weinberg based on its qualifications, expertise and reputation and its knowledge of the business and affairs of Bioventus, Misonix and the industries in which
Bioventus and Misonix conduct their respective businesses. Perella Weinberg and its affiliates, as part of their investment banking business, are continually engaged in performing financial analyses with respect to businesses and their securities in
connection with mergers and acquisitions, leveraged buyouts and other transactions as well as for corporate and other purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;28, 2021, Perella Weinberg rendered its oral opinion, subsequently confirmed in writing, to the Bioventus board that, as of such date and based upon and subject to the various assumptions made, procedures
</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
followed, matters considered and qualifications and limitations set forth therein, the merger consideration to be paid by Bioventus pursuant to the merger agreement, consisting of, at the option
of the holders of Misonix common stock issued and outstanding immediately prior to the effective time of the first merger, (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by
Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law), and subject to certain limitations and proration procedures set forth in the
merger agreement (as to which Perella Weinberg expressed no opinion), (i) $28.00 in cash per share of Misonix common stock, or the cash election consideration, or (ii) 1.6839 shares of Bioventus common stock per share of Misonix common stock, or the
stock election consideration was, as of the date of the opinion, fair, from a financial point of view, to Bioventus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The full text of Perella
Weinberg&#146;s written opinion, dated July&nbsp;29, 2021 which sets forth, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by Perella Weinberg, is
attached hereto as <U>Annex</U><U></U><U>&nbsp;B</U> and is incorporated by reference herein. Perella Weinberg&#146;s opinion was not intended to be and does not constitute a recommendation to any holder of Bioventus common stock or any other person
as to how such person should vote or otherwise act with respect to the mergers or any other matter. Perella Weinberg&#146;s opinion does not in any manner address the prices at which Misonix common stock or Bioventus common stock will trade at any
time. In addition, Perella Weinberg expressed no opinion as to the fairness of the mergers to the holders of any class of securities, creditors or other constituents of Bioventus or Misonix or as to the underlying decision by any person to engage in
the mergers or as to the relative merits of the mergers compared to alternative transactions or business strategies. Perella Weinberg provided its opinion for the information and assistance of the Bioventus board in connection with, and for the
purposes of its evaluation of, the mergers. This summary is qualified in its entirety by reference to the full text of the opinion. Opinion of Misonix&#146;s Financial Advisor. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion of JP Morgan Securities </I>(Page 176; <U>Annex C</U>)<I> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan rendered an oral opinion to the Misonix board on July 28, 2021 (subsequently confirmed in writing on July 29, 2021) to the effect that, as of such
date and based on and subject to the assumptions made, procedures followed, matters considered and other limitations on the review undertaken by J.P.&nbsp;Morgan in preparing its opinion, the merger consideration to be paid to the holders of Misonix
common stock in the merger was fair, from a financial point of view, to such holders, as more fully described in the section entitled &#147;Opinion of Misonix&#146;s Financial Advisor&#148; of this joint proxy statement/prospectus. The full text of
the written opinion of J.P. Morgan, dated July&nbsp;29, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P.&nbsp;Morgan in preparing its opinion,
is attached as Annex C to this joint proxy statement/prospectus&nbsp;and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Bioventus Special Meeting
</B>(Page&nbsp;119) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of ongoing developments related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Bioventus special
meeting will be held solely in a virtual meeting format via live webcast on October&nbsp;26, 2021, beginning at 11:00 a.m., Eastern Time. Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting
the Bioventus special meeting website at www.virtualshareholdermeeting.com/BVS2021SM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purposes of the Bioventus special meeting are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bioventus Proposal 1</B><I>: Approval of the Share Issuance.</I> To consider and vote on the Bioventus share
issuance proposal; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bioventus Proposal 2</B><I>: Adjournment of the Bioventus Special Meeting. </I>To consider and vote on the
Bioventus adjournment proposal. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Completion of the mergers is conditioned on the approval of the Bioventus share issuance proposal (Bioventus
Proposal 1) by Bioventus stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only holders of record of shares of Bioventus common stock outstanding as of the close of business on
September&nbsp;22, 2021 (the Bioventus record date) are entitled to notice of, and to vote at, the Bioventus special meeting or any adjournment or postponement thereof. Bioventus stockholders may cast one vote for each share of Bioventus common
stock that they own of record as of the Bioventus record date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of Bioventus stockholders is necessary to hold the Bioventus special meeting. A
quorum will exist at the Bioventus special meeting if holders of record of shares of Bioventus common stock representing a majority in voting power of the stock issued and outstanding and entitled to vote at the meeting, is present in person, or by
remote communication, if applicable, or represented by proxy. All shares of Bioventus common stock represented by a valid proxy and all abstentions will be counted as present for purposes of establishing a quorum. All of the proposals for
consideration at the Bioventus special meeting are considered <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules, and, therefore, brokers are not permitted to vote on any of the matters to be considered at the
Bioventus special meeting unless they have received instructions from the beneficial owners. As a result, no &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;</FONT> are expected at the Bioventus special meeting, and shares held in
&#147;street name&#148; will not be counted as present for the purpose of determining the existence of a quorum unless the Bioventus stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals
brought before the Bioventus special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance
proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at
the Bioventus special meeting on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#147;street name&#148;
through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or other failure of any shares virtually present
or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus
share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if an Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or
more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the
Bioventus share issuance proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal
requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the
Bioventus special meeting on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#147;street name&#148; through a
bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any shares virtually present or
represented by proxy and entitled to vote on the Bioventus adjournment proposal to vote at the Bioventus special meeting on the Bioventus adjournment proposal will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus adjournment
proposal. However, if an Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting
power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Misonix Special Meeting </B>(Page&nbsp;128) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Misonix special meeting is to consider and vote on each of the following proposals, each of which is further described in this joint proxy
statement/prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 1</B><I>: Adoption of the Merger Agreement.</I> To consider and vote on the Misonix merger
proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 2</B>: <I>Approval, on an Advisory <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Basis,
of Certain Merger-Related Compensatory Arrangements with Misonix&#146;s Named Executive Officers.</I> To consider and vote on the Misonix compensation proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 3</B>: <I>Adjournment of the Misonix Special Meeting.</I> To consider and vote on the Misonix
adjournment proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Completion of the mergers is conditioned on the approval of the Misonix merger proposal (Misonix Proposal 1) by
Misonix stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only holders of record of shares of Misonix common stock outstanding as of the close of business on September&nbsp;22, 2021 (the
Misonix record date) are entitled to notice of, and to vote at, the Misonix special meeting or any adjournment or postponement thereof. Misonix stockholders may cast one vote for each share of Misonix common stock that they own of record as of the
Misonix record date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of Misonix stockholders is necessary to conduct the Misonix special meeting. The presence of the holders of a majority of
the outstanding shares of Misonix common stock entitled to vote at the Misonix special meeting will constitute a quorum. Shares of Misonix common stock represented at the Misonix special meeting in person or by a properly authorized and submitted
proxy (submitted by mail, by telephone or over the Internet), entitled to vote, but not voted, including shares for which a Misonix stockholder directs an &#147;abstention&#148; from voting, will be counted for purposes of determining a quorum.
However, because all of the proposals for consideration at the Misonix special meeting are considered <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules, shares held in &#147;street name&#148; will not be
counted as present for the purpose of determining the existence of a quorum unless the Misonix stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals at the Misonix special meeting. If a
quorum is not present, Misonix expects that the Misonix special meeting will be adjourned or postponed until the holders of the number of shares of Misonix common stock required to constitute a quorum attend. At any subsequent reconvening of the
Misonix special meeting, all proxies will be voted in the same manner as the proxies would have been voted at the original convening of the Misonix special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the
subsequent meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix special meeting will be held at Misonix&#146;s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on
October 26, 2021, beginning at 10:00 a.m., Eastern Time. As part of Misonix&#146;s precautions regarding the novel coronavirus or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> Misonix is planning for the possibility that the meeting may be held
solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on
our website at www.misonix.com and filed with the SEC as proxy material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present at the Misonix special meeting, approval of the
Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate &#147;FOR,&#148; &#147;AGAINST&#148; or
&#147;ABSTAIN&#148; on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers&#146; unvoted shares on the Misonix merger proposal or to vote their customers&#146; shares if the customers have not furnished
voting </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who
holds shares of Misonix common stock in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock
present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote <B>&#147;AGAINST&#148;</B> the Misonix merger
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the
holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate
&#147;FOR,&#148; &#147;AGAINST&#148; or &#147;ABSTAIN&#148; on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast &#147;FOR&#148; or &#147;AGAINST&#148; are
included. Brokerage firms and nominees will not have the authority to vote their customers&#146; unvoted shares on the Misonix compensation proposal or to vote their customers&#146; shares if the customers have not furnished voting instructions
within a specified period of time prior to the Misonix special meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted only for purposes of determining whether a quorum is present at the meeting and therefore
will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will
not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix&#146;s named executive officers to the extent payable in
accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote, the Misonix compensation proposal.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders
of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder
who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other
failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote
&#147;<B>AGAINST</B>&#148; the Misonix adjournment proposal. However, if a Misonix stockholder who holds shares of Misonix common stock in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more
other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment
proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Support Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the
execution of the merger agreement, Misonix entered into a voting agreement (the &#147;Bioventus support agreement&#148;) with EW Healthcare Partners Acquisition Fund, L.P., White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund,
L.P.), Smith&nbsp;&amp; Nephew, Inc., Smith&nbsp;&amp; Nephew USD Ltd and <FONT STYLE="white-space:nowrap">AMP-CF</FONT> Holdings, LLC (together, the &#147;Bioventus supporting stockholders&#148;), pursuant to which such stockholders have agreed,
among other things, to vote the shares of Bioventus common stock that they beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal made in opposition to, in competition with,
or inconsistent with, the merger agreement or the transaction. As of the record date for the Bioventus special meeting, such stockholders beneficially own approximately 67.4% of the outstanding shares of Bioventus common stock. Therefore, the
Bioventus supporting </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders hold a sufficient number of shares of Bioventus common stock in order to approve the Bioventus share issuance proposal. On July&nbsp;29, 2021, in connection with execution of the
merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with Bioventus (each a &#147;lock up agreement&#148;) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or 180
days, subject to the terms of the lock up agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the execution of the merger agreement, Bioventus entered into a voting agreement (the
&#147;Misonix support agreement&#148;) with each of Stavros G. Vizirgianakis, 1315 Capital, LLC, SV Life Sciences Fund&nbsp;VI Strategic Partners, L.P. and SV Life Sciences Fund&nbsp;VI, L.P. (together, the &#147;Misonix supporting
stockholders&#148;), pursuant to which such stockholders have agreed, among other things, to vote the shares of Misonix common stock that they own at the time such vote is taken in favor of the Misonix merger proposal and Misonix compensation
proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Misonix special meeting, the Misonix supporting stockholders
beneficially own approximately 28.8% of the outstanding shares of Misonix common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of Bioventus Directors and Executive Officers in the
Mergers </B>(Page&nbsp;337)<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than with respect to continued service for, employment by and the right to continued indemnification by the
combined company, as of the date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the mergers that are different from, or in addition to, the interests of other Bioventus stockholders
generally. See &#147;Interests of Bioventus Directors and Executive Officers in the Mergers.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of Misonix Directors and Executive
Officers in the Merger </B>(Page&nbsp;338) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the recommendations of the Misonix board, Misonix stockholders should be aware that Misonix
directors and executive officers have interests in the mergers, including financial interests, which may be different from, or in addition to, the interests of other Misonix stockholders generally. The Misonix board was aware of and considered these
interests, among other matters, when it determined that the mergers are fair to and in the best interests of Misonix and its stockholders, approving and declaring advisable the merger agreement and the transactions contemplated thereby, and
recommending that Misonix stockholders approve the Misonix mergers. These interests are discussed in more detail under &#147;Interests of Misonix Directors and Executive Officers in the Mergers.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For an estimate of the value of the benefits and financial interests that the Misonix named executive officers may become eligible to receive as a result of
their interests in the mergers, assuming, among other things, that the merger was completed on August&nbsp;31, 2021 and each such named executive officer experienced a qualifying termination of employment immediately thereafter, see &#147;Interests
of Misonix Directors and Executive Officers in the Mergers&#151;Quantification of Payments and Benefits to Misonix Named Executive Officers&#151;Golden Parachute Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governance of the Combined Company </B>(Page&nbsp;205)<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board, the opportunity to join the Bioventus board as of
the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No other governance changes are planned in connection with the mergers. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Organizational Documents and Directors and Officers of the Surviving Corporation </B>(Page&nbsp;205) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the effective time, Misonix&#146;s certificate of incorporation as in effect immediately prior to the effective time and Misonix&#146;s bylaws as in effect
immediately prior to the effective time will continue to be the certificate of incorporation and the bylaws of the surviving company of the first merger. At the second effective time, the certificate of formation and the limited liability company
agreement of Merger Sub II in effect immediately prior to the second effective time, will continue to be the certificate of formation and the limited liability company agreement of Merger Sub II, as the surviving entity of the second merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Beneficial Owners of Bioventus Common Stock </B>(Page&nbsp;369) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the close of business on September&nbsp;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Bioventus directors
and executive officers and their affiliates, as a group, owned and were entitled to vote less than 1% of the shares of Bioventus common stock outstanding on such date. Although none of them has entered into any agreement obligating them to do so,
Bioventus currently expects that all Bioventus directors and executive officers will vote their shares &#147;<B>FOR</B>&#148; the Bioventus share issuance proposal and &#147;<B>FOR</B>&#148; the Bioventus adjournment proposal. For more information
regarding the security ownership of Bioventus directors and executive officers, see &#147;Certain Beneficial Owners of Bioventus Common Stock&#151;Security Ownership of Bioventus Directors and Executive Officers.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Beneficial Owners of Misonix Common Stock </B>(Page&nbsp;372) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the close of business on September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/ prospectus, Misonix directors and
executive officers and their affiliates, as a group, owned and were entitled to vote approximately 31.62% of the shares of Misonix common stock outstanding on such date. On July&nbsp;29, 2021, Stavros Vizirgianakis, Misonix&#146;s Chief Executive
Officer and Director, entered into a Voting and Support Agreement with Bioventus and the stockholders named therein, pursuant to which he agreed to, among other things, vote his shares of Misonix common stock in favor of the adoption of the Misonix
merger proposal. Although no Misonix director or executive officer other than Mr. Vizirgianakis has entered into any agreement obligating them to vote their shares of Misonix common stock in favor of the proposals at the special meeting, Misonix
currently expects that all Misonix directors and executive officers will vote their shares of Misonix common stock &#147;FOR&#148; the Misonix merger proposal, &#147;FOR&#148; the Misonix compensation proposal and &#147;FOR&#148; the Misonix
adjournment proposal. See &#147;Interests of Misonix Directors and Executive Officers in the Merger&#148; and the arrangements described in Misonix&#146;s Annual Report on Form 10-K, which is incorporated by reference in this joint proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Approvals </B>(Page&nbsp;195) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus, Merger Sub I, Merger Sub II and Misonix have each agreed to cooperate with each other and to use (and to cause their subsidiaries to use) reasonable
best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary to cause the conditions to the closing to be satisfied as promptly as reasonably practicable (and in any event no later than the end date)
and to consummate and make effective the transactions contemplated by the merger agreement, including to obtain all required regulatory approvals as promptly as practicable, subject to certain limits. See &#147;The Mergers&#151;Regulatory
Approvals.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Bioventus and Misonix to consummate the mergers are subject to, among other conditions, the termination or expiration
of any waiting period (or any extension thereof) applicable to the transactions contemplated by the merger agreement under the HSR Act. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of the Combined Company</B> (Page&nbsp;196) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of shares of Bioventus and Misonix common stock outstanding as of September&nbsp;1, 2021, the latest practicable date prior to the date of
this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger
are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the merger will
depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights
</B>(Page&nbsp;361) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;262 of the DGCL, Misonix stockholders who do not vote in favor of Misonix merger proposal and who comply with
the applicable requirements of Section&nbsp;262 of the DGCL have the right to seek appraisal of such shares by the Delaware Court of Chancery and to receive payment in cash of the fair value of those shares. It is possible that the fair value as
determined by the Delaware Court of Chancery may be more or less than, or the same as, the per share value of the merger consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix
stockholders who wish to preserve their appraisal rights must make a demand for appraisal prior to the time the Misonix stockholder vote is taken on the Misonix merger proposal. In addition to submitting a demand for appraisal, such Misonix
stockholders must continuously hold such shares through the effective time, must not vote in favor of the Misonix merger proposal, must not surrender their shares in exchange for the merger consideration, and must otherwise follow the procedures
prescribed by Section&nbsp;262 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are encouraged to read Section&nbsp;262 of the DGCL carefully and in their entirety. Due to the
complexity of the procedures for exercising your appraisal rights, Misonix stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel. Failure to strictly comply with these provisions will result in
the loss of appraisal rights. See the section entitled &#147;Appraisal Rights&#148; of this joint proxy statement/prospectus for additional information and the text of Section&nbsp;262 of the DGCL reproduced in its entirety as <U>Annex D</U> to this
proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus stockholders are not entitled to appraisal rights in connection with the mergers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to the Completion of the Mergers </B>(Page&nbsp;222) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of each of Bioventus and Misonix to complete the mergers are subject to the satisfaction or waiver, as of the closing, of each of the following
conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy
statement/prospectus forms a part must have become effective in accordance with the provisions of the Securities Act, no stop order may have been issued by the SEC and remain in effect with respect to the Form
<FONT STYLE="white-space:nowrap">S-4</FONT> and no proceedings for that purpose may have been commenced or threatened in writing by the SEC and not withdrawn; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by Misonix stockholders of the Misonix merger proposal must have been obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by Bioventus stockholders of the Bioventus share issuance proposal must have been obtained;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any waiting period (or any agreed upon extension of any waiting period or commitment not to consummate the
mergers for any period of time) applicable to the consummation of the mergers under the HSR Act must have expired or been terminated by the relevant governmental entity, and there must be no pending agreement between Bioventus and any governmental
entity not to close; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares of Bioventus class A common stock to be issued pursuant to the first merger, including the shares of
Bioventus class A common stock to be issued upon the exercise of converted Misonix stock </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
options and upon vesting of converted Misonix RSUs, must have been approved for listing (subject to notice of issuance) on Nasdaq; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no law or order preventing, enjoining or making illegal the consummation of the mergers may have been entered,
issued or adopted by any court of competent jurisdiction or other governmental entity of competent jurisdiction and remain in effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each party&#146;s obligation to complete the mergers is subject to, among other things, the accuracy of certain representations and warranties of
the other party and the compliance by such other party with certain of its covenants, in each case, subject to the materiality standards set forth in the merger agreement, and the absence of the occurrence of any material adverse effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Bioventus nor Misonix can be certain when, or if, the conditions to the mergers will be satisfied or waived, or that the mergers will be completed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;The Merger Agreement&#151;Conditions to the Completion of the Mergers.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Solicitation of Acquisition Proposals </B>(Page&nbsp;211)<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As more fully described under &#147;The Merger Agreement&#151;No Solicitation of Acquisition Proposals,&#148; subject to the exceptions summarized below,
Bioventus and Misonix have each agreed that they will not (a)&nbsp;solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding, or the submission or announcement by any person (other
than, in the case of Misonix, Bioventus or in the case of Bioventus, Misonix, or its respective affiliates and representatives) of, any proposal or offer that constitutes, or would reasonably be expected to lead to, an acquisition proposal (as
defined under &#147;The Merger Agreement&#151;No Solicitation of Acquisition Proposals&#148;) (with certain exceptions related to each board of directors informing itself of an acquisition proposal), (b) furnish any information regarding such party
or its subsidiaries (other than to the other party and its subsidiaries) or afford access to such party&#146;s or its subsidiaries&#146; representatives, books, records or property, in each case in connection with, or for the purpose of soliciting,
initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to an acquisition proposal, (c)&nbsp;engage in, enter into, continue or otherwise participate in any
discussions or negotiations with any person (other than, in the case of Bioventus, Misonix, or in the case of Misonix, Bioventus, or its respective representatives) with respect to any acquisition proposal or any inquiry, proposal or offer that
would reasonably be expected to lead to an acquisition proposal (with certain exceptions related to each board of directors informing itself of an acquisition proposal), (d)&nbsp;approve, adopt, recommend, agree to or enter into, or publicly propose
to approve, adopt, recommend, agree to or enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment or agreement in principle with respect to any acquisition proposal or (e)&nbsp;resolve or agree to do
any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the restrictions described above, if at any time prior to obtaining approval of the Misonix merger proposal, in the
case of Misonix, or the Bioventus share issuance proposal, in the case of Bioventus, Bioventus or Misonix, as applicable, receives a bona fide, written acquisition proposal after the date of the merger agreement that did not result from a breach of
the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions in the merger agreement and that the Bioventus board or the Misonix board, as applicable, determines in good faith (after consultation with its outside legal counsel and
financial advisor) that such acquisition proposal constitutes or would reasonably be expected to lead to a superior proposal (as defined under &#147;The Merger Agreement&#151;No Solicitation of Acquisition Proposals&#148;), Bioventus or Misonix, as
applicable, may (a)&nbsp;engage in discussions or negotiations with the party making such acquisition proposal and (b)&nbsp;following the receipt from such party making the acquisition proposal, (or there is then in effect with such party) an
executed confidentiality agreement with nondisclosure provisions at least as restrictive of such third party as the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement with Bioventus or Misonix, as applicable, furnish information to
such party with respect to Bioventus or Misonix, as applicable, in either case, subject to certain conditions and obligations in the merger agreement. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix have also agreed to notify the other (a)&nbsp;promptly following (and in any event,
within 48 hours of the receipt of) any acquisition proposal or any inquiry or request for information with respect to an acquisition proposal or that is reasonably likely to lead to an acquisition proposal and (b)&nbsp;to keep the other party
reasonably informed on a current basis (and in any event, within 48 hours) as to the status of any acquisition proposal, including informing the other party of any material change to such acquisition proposal&#146;s terms, the status of any
negotiations, and any change in its intentions. See &#147;The Merger Agreement&#151;No Solicitation of Acquisition Proposals.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Change of
Recommendation </B>(Page&nbsp;214) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement provides that, among other restrictions and subject to certain exceptions, neither the Bioventus
board nor the Misonix board may (a)&nbsp;withhold, withdraw, modify, amend or qualify (or publicly propose to do so), in a manner adverse the other party, the Bioventus board&#146;s recommendation to Bioventus stockholders to approve the share
issuance or the Misonix board&#146;s recommendation to Misonix stockholders to adopt the merger agreement, as applicable, or (b)&nbsp;approve, recommend or declare advisable (or publicly propose to do so) any acquisition proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the restrictions described above, at any time prior to obtaining the approval by Bioventus stockholders of the Bioventus share issuance
proposal or by Misonix stockholders of the Misonix merger proposal, as the case may be, the Bioventus board or the Misonix board, as applicable, may make a change of recommendation and/or terminate the merger agreement to concurrently enter into a
definitive agreement with respect to an acquisition proposal if it determines in good faith (after consultation with its outside legal counsel and financial advisor) that such acquisition proposal is a superior proposal and that failure to take such
action with respect to such acquisition proposal would reasonably be expected to be inconsistent with the such board of directors&#146; fiduciary duties to such party and its stockholders under applicable laws (and subject to compliance with certain
obligations set forth in the merger agreement, including providing the other party with prior notice and the opportunity to negotiate for a period to make such acquisition proposal no longer a superior proposal and payment of a the applicable
termination fee in connection with any such termination of the merger agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Bioventus board or the Misonix board, as the case may
be, is permitted under certain circumstances, prior to obtaining stockholder approval of the Bioventus share issuance proposal, in the case of Bioventus, or the Misonix merger proposal, in the case of Misonix, and subject to compliance with certain
obligations set forth in the merger agreement (including providing the other party with prior notice and the opportunity to negotiate during such notice period to amend the terms of the merger agreement) to make a change of recommendation in
response to an intervening event (unrelated to an acquisition proposal) if the Bioventus board or the Misonix board, as applicable, determines in good faith (after consultation with its outside legal counsel and financial advisor) that the failure
to do so would be reasonably likely to be inconsistent with its fiduciary duties. See &#147;The Merger Agreement&#151;No Change of Recommendation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination of the Merger Agreement </B>(Page&nbsp;225) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
merger agreement may be terminated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by mutual written consent of Bioventus and Misonix at any time prior to the effective time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix, if the merger has not been consummated at or prior to the end date, provided,
that the end date will be automatically extended in the event the only closing condition not satisfied or waived is the condition related to antitrust laws (however, a party may not terminate the merger agreement if such party&#146;s material breach
of any of its obligations under the merger agreement materially contributed to the failure of the closing to have occurred by the end date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix at any time prior to the effective time if a relevant legal restraint permanently
preventing, enjoining or making illegal the consummation of the mergers shall have </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
become final and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> provided, that the party seeking to terminate the merger agreement must have used reasonable best efforts to prevent the
entry of and to remove such relevant legal restraint in accordance with the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Bioventus at any time prior to Misonix obtaining its required stockholder approval, if the Misonix board has
made a change in recommendation or Misonix has willfully breached in any material respect the covenants applicable to it regarding <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> special meetings and changes in recommendation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Misonix at any time prior to Bioventus obtaining its required stockholder approval, if (a)&nbsp;the Bioventus
board has made a change in recommendation, (b)&nbsp;Bioventus has willfully breached in any material respect the covenants applicable to it regarding <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> special meetings and changes in
recommendation or (c)&nbsp;if Bioventus has materially breached its representations and warranties regarding financing and solvency under the merger agreement or its covenants regarding financing and financing cooperation under the merger agreement,
and (i)&nbsp;any such breach is not cured by the earlier of the end date or prior to the twentieth business day after Misonix gives written notice of such breach to Bioventus, (ii)&nbsp;all of the conditions, the satisfaction or waiver of which
would be necessary to trigger the obligation of Bioventus to consummate the mergers (not including the condition related to the certificate to be provided by Misonix), have been satisfied and continue to be satisfied (other than those conditions
that by their nature cannot be satisfied other than at the closing), (iii) Misonix has committed to Bioventus that Misonix is ready, willing and able to consummate the transactions contemplated by the merger agreement, and (iv)&nbsp;Bioventus,
Merger Sub I or Merger Sub II fails to consummate the transactions contemplated by the merger agreement by the earlier of the end date or within two business days following the written notice delivered by Misonix to Bioventus following the
expiration of the cure period specified above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Misonix, if prior to obtaining its required stockholder approval, (a)&nbsp;the Misonix board has authorized
Misonix to enter into a definitive agreement relating to a superior proposal in material compliance with the merger agreement and (b)&nbsp;substantially concurrently with the termination of the merger agreement, Misonix enters into the definitive
agreement relating to a superior proposal and pays Bioventus the applicable termination fee pursuant to the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix, if the approval by Misonix stockholders of the Misonix merger proposal has not
been obtained after a vote on approval of such proposal has been taken at the Misonix special meeting (including any postponement or adjournment thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix, if the approval by Bioventus stockholders of the Bioventus share issuance
proposal has not been obtained after a vote on approval of such proposal has been taken at the Bioventus special meeting (including any postponement or adjournment thereof); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Bioventus (a)&nbsp;if any of Misonix&#146;s representations and warranties contained in the merger agreement
are inaccurate such that the conditions to closing would not be satisfied or (b)&nbsp;if Misonix has breached any covenant in the merger agreement and such breach would result in the failure of a condition to closing, provided, that if an inaccuracy
in any of Misonix&#146;s representations and warranties or a breach of a covenant of Misonix is curable by Misonix by the end date and Misonix is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Bioventus
may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of thirty business days commencing on the date that Misonix receives written
notice of such inaccuracy or breach from Bioventus; provided, further, that Bioventus shall not have the right to terminate the merger agreement pursuant to this paragraph if Bioventus is then in breach of any of its representations, warranties or
agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing; or </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Misonix if: (a)&nbsp;any of Bioventus&#146;, Merger Sub I&#146;s or Merger Sub II&#146;s representations and
warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied; or (b)&nbsp;any of Bioventus&#146; covenants contained in the merger agreement will have been breached such that the conditions
to closing would not be satisfied; provided, however, that for purposes of clauses (a)&nbsp;and (b) above, if an inaccuracy in any of Bioventus&#146;, Merger Sub I&#146;s or Merger Sub II&#146;s representations and warranties or a breach of a
covenant of Bioventus is curable by Bioventus by the end date and Bioventus is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Misonix may not terminate the merger agreement under this paragraph on account
of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of thirty business days commencing on the date that Bioventus receives written notice of such inaccuracy or breach from Misonix; provided, further, that
Misonix shall not have the right to terminate the merger agreement pursuant to this paragraph if Misonix is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the
failure of a condition to closing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;The Merger Agreement&#151;Termination of the Merger Agreement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination </B><B>Fees</B> (Page&nbsp;226) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and
Misonix have each agreed to pay a termination fee of $20,661,000 in cash (the &#147;termination fee&#148;) to the other party, if the merger agreement is terminated in certain circumstances involving a change of recommendation, breach of certain
covenants of such party or termination of the merger agreement to enter into a superior proposal, in each case by the party obligated to pay the fee. Bioventus and Misonix are also required to pay the applicable termination fee if the party
obligated to pay the termination fee enters into or consummates a superior proposal following certain terminations of the merger agreement, including a termination due to such party&#146;s failure to obtain the required stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A termination fee will be payable by a party only once and not in duplication even though the termination fee may be payable by such party pursuant to
multiple circumstances. Furthermore, except in the case of fraud or intentional and material breach of the merger agreement, if a party receives a termination fee, then the termination fee will be the recipient&#146;s sole and exclusive remedy
against the other party, its affiliates and its and their respective representatives in connection with the merger agreement. See &#147;The Merger Agreement&#151;Termination Fees.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment </B>(Page&nbsp;196) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus prepares
its financial statements in accordance with GAAP. The mergers will be accounted for using the acquisition method of accounting under the provisions of Accounting Standards Codification (&#147;ASC&#148;) 805, Business Combinations, with Bioventus
representing the accounting acquirer under this guidance. Bioventus will record assets acquired, including identifiable intangible assets, and liabilities assumed from Misonix at their respective fair values at the date of completion of the mergers.
Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial condition and results
of operations of Bioventus after completion of the mergers will reflect Misonix after completion of the mergers, but will not be restated retroactively to reflect the historical financial condition or results of operations of Misonix. The earnings
of Bioventus following completion of the mergers will reflect acquisition accounting adjustments, including the effect of changes in the carrying value for assets and liabilities on depreciation expense and amortization expense. Indefinite-lived
intangible assets, including goodwill, will not be amortized but will be tested for impairment at least annually, and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the
future, Bioventus determines that tangible or intangible assets (including goodwill) are impaired, Bioventus would record an impairment charge at that time. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences of the Mergers </B>(Page&nbsp;343)<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, the first merger and the second merger, taken together, are
intended to qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. Assuming the mergers so qualify, a U.S. holder (as defined under &#147;Material U.S. Federal Income Tax Consequences of the First Merger and
Second Merger&#148;) of Misonix common stock generally will not recognize any gain or loss for U.S. federal income tax purposes upon the exchange of Misonix common stock for Bioventus class A common stock in the mergers, except with respect to cash
received by Misonix stockholders in lieu of fractional shares of Bioventus common stock, but a U.S. holder of Misonix common stock generally will recognize any gain for U.S. federal income tax purposes upon the exchange of Misonix common stock for
cash consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Material U.S. Federal Income Tax Consequences of the First Merger and the Second Merger&#148; for a more complete
description of certain U.S. federal income tax consequences of the mergers. You are urged to consult your own tax advisor as to the specific tax consequences to you of the mergers in light of your particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Stockholders&#146; Rights </B>(Page&nbsp;351) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the merger, Misonix stockholders receiving shares of Bioventus common stock will become Bioventus stockholders. The rights of Bioventus
stockholders will be governed by the DGCL and the Bioventus charter and bylaws in effect at the effective time. As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different.
However, there are certain differences in the rights of Bioventus stockholders under the Bioventus charter and bylaws and of Misonix stockholders under the Misonix charter and bylaws. See &#147;Comparison of Stockholders&#146; Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing of Bioventus Common Stock; Delisting and Deregistration of Misonix Common Stock </B>(Page&nbsp;197)<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is a condition to the merger that the shares of Bioventus common stock to be issued to Misonix stockholders in the merger be approved for listing on Nasdaq,
subject to official notice of issuance. If the transaction is completed, Misonix common stock will be delisted from Nasdaq and deregistered under the Exchange Act, following which Misonix will no longer be required to file periodic reports with the
SEC with respect to Misonix common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix has agreed to cooperate with Bioventus prior to the closing to cause the Misonix common stock to be
delisted from Nasdaq and be deregistered under the Exchange Act as soon as practicable after the effective time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B>(Page&nbsp;39) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In evaluating the merger agreement, the merger and the share issuance, you should carefully read this joint proxy statement/prospectus and give special
consideration to the factors discussed under &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020, BV LLC made a $15.0&nbsp;million equity investment in CartiHeal (2009)&nbsp;Ltd. (&#147;CartiHeal&#148;), a privately-held company
headquartered in Israel and developer of the proprietary <FONT STYLE="white-space:nowrap">Agili-C</FONT> implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. Concurrent with the July&nbsp;15, 2020 investment, BV
LLC entered into an Option and Equity Purchase Agreement with CartiHeal and its shareholders, which provides BV LLC with an exclusive option to acquire 100% of CartiHeal&#146;s shares, or the Call Option, and provides CartiHeal with a put option
that would require BV LLC to purchase 100% of CartiHeal&#146;s shares under certain conditions, or the Put Option. The Call Option is exercisable by BV LLC at any time. The Put Option is </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <FONT STYLE="white-space:nowrap">Agili-C</FONT>
device with a label consistent in all respects with pivotal clinical trial success. If not previously exercised, the Call Option and the Put Option terminate 45 days following FDA approval of <FONT STYLE="white-space:nowrap">Agili-C</FONT> (subject
to final review by BV LLC of updated disclosures by CartiHeal). Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, consideration for the acquisition of all of the shares of CartiHeal pursuant to the
Option and Equity Purchase Agreement would be $350.0&nbsp;million in cash, subject to customary adjustments, all of which would be payable at closing, with an additional $150.0&nbsp;million payable upon achievement of certain sales milestones
related to <FONT STYLE="white-space:nowrap">Agili-C.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;27, 2021, the Bioventus board, after its review of the statistical report for
CartiHeal&#146;s pivotal clinical trial and determination that the results of the statistical report indicated a Pivotal Clinical Trial Success (as contemplated by the Option and Equity Purchase Agreement), approved BV LLC&#146;s continued pursuit
of a potential acquisition of CartiHeal. BV LLC thereafter deposited $50.0&nbsp;million in escrow in accordance with the terms of the Option and Equity Purchase Agreement. Should the Put Option or Call Option be exercised and the acquisition of
CartiHeal consummated, the escrowed funds will be applied towards the consideration payable by BV LLC pursuant to the Option and Equity Purchase Agreement. The closing of the transaction is subject to, among other things (including customary closing
conditions), the valid exercise of the Call Option or the Put Option. CartiHeal plans to submit the clinical module of their PMA later this year, and the decision from the FDA is expected in the second half of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Litigation Relating to the Merger </B>(Page 197)<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
September 15, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Stein v. Misonix, Inc., et al., Case No. 2:21-cv-05127 (E.D.N.Y) (the &#147;Stein
Complaint&#148;). The Stein Complaint names Misonix and members of its board of directors as defendants. On September 16, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Southern District of
New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.) (the &#147;Ciccotelli Complaint&#148;). The Ciccotelli Complaint names Misonix, members of its board of directors, Bioventus, Merger Sub I, and Merger Sub II
as defendants. Both complaints assert claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on
September 8, 2021, regarding Misonix&#146;s and Bioventus&#146; projections and J.P. Morgan&#146;s financial analysis. The complaints seek, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger, (ii)
rescission in the event that the merger is consummated, and (iii) an award of costs, including attorneys&#146; and experts&#146; fees. More information can be found under &#147;The Merger&#151;Litigation Relating to the Merger.&#148; </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_8"></A>MARKET PRICE AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Class&nbsp;A Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus class A
common stock is currently listed on The Nasdaq Global Select Market under the symbol &#147;BVS.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing price of Bioventus class A common stock
on July&nbsp;28, 2021, the trading day immediately prior to the public announcement of the Merger on July&nbsp;29, 2021, as reported on The Nasdaq Global Select Market, was $17.15 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the market price of Bioventus class A common stock is subject to fluctuation, the market value of the shares of Bioventus class A common stock that
Misonix stockholders who elect the stock election consideration will be entitled to receive in the first merger may increase or decrease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September
22, 2021, the record date for the Bioventus special meeting, there were approximately 8 holders of record of Bioventus class A common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has never declared or paid any cash dividends on Bioventus class A common stock and does not anticipate paying cash dividends on Bioventus
class A common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the mergers will be at the discretion of the combined company&#146;s then-current board of directors and will
depend upon a number of factors, including the combined company&#146;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of
directors deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_9"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy statement/prospectus forms a part, the
documents that Bioventus and Misonix refer you to in the registration statement and oral statements made or to be made by Bioventus and Misonix include certain &#147;forward-looking statements&#148; within the meaning of, and subject to the safe
harbor created by, Section&nbsp;27A of the Securities Act, Section&nbsp;21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995, which are referred to as the &#147;safe harbor provisions.&#148; Statements contained or
incorporated by reference in the registration statement of which this joint proxy statement/prospectus forms a part that are not historical facts are forward-looking statements, including statements about the beliefs and expectations of Bioventus
and Misonix management relating to the merger and future financial condition and performance. Words such as &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;intends,&#148;
&#147;estimate,&#148; &#147;forecast,&#148; &#147;project,&#148; &#147;should,&#148; &#147;may,&#148; &#147;will,&#148; &#147;would&#148; or the negative thereof and similar expressions are intended to identify such forward-looking statements that
are intended to be covered by the safe harbor provisions. Investors are cautioned that any forward-looking statements are subject to known and unknown risks and uncertainties, many of which are beyond the control of both companies, and which may
cause actual results and future trends to differ materially from those matters expressed in, or implied or projected by, such forward-looking statements, which speak only as of the date of this joint proxy statement/prospectus. Although these
forward-looking statements are based on assumptions that Bioventus and Misonix management, as applicable, believe to be reasonable, they can give no assurance that these expectations will prove to be correct. Investors are cautioned not to place
undue reliance on these forward-looking statements. Among the risks and uncertainties that could cause actual results to differ from those described in forward-looking statements are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any change, event, series of events or circumstances that could give rise to the termination of
the merger agreement, including a termination of the merger agreement under circumstances that could require Bioventus to pay a termination fee to Misonix or require Misonix to pay a termination fee to Bioventus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties related to the timing of the receipt of required regulatory approvals for the merger and the
possibility that Bioventus and Misonix may be required to accept conditions that could reduce or eliminate the anticipated benefits of the merger as a condition to obtaining regulatory approvals or that the required regulatory approvals might not be
obtained at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price of Bioventus and Misonix common stock could change before the completion of the merger, including as a
result of uncertainty as to the long-term value of the common stock of the combined company or as a result of broader stock market movements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the parties are unable to complete the merger due to the failure of Bioventus stockholders
to approve the share issuance or of Misonix stockholders to adopt the merger agreement, or the failure to satisfy any of the other conditions to the completion of the merger, or unexpected delays in satisfying any conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in closing, or the failure to close, the merger for any reason, could negatively impact Bioventus, Misonix
or the combined company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks that the pendency or completion of the merger and the other transactions contemplated by the merger
agreement disrupt current plans and operations, which may adversely impact Bioventus&#146;s or Misonix&#146;s respective businesses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties or delays in integrating the businesses of Bioventus and Misonix following completion of the merger
or fully realizing the anticipated synergies or other benefits expected from the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain restrictions during the pendency of the proposed merger that may impact the ability of Bioventus or
Misonix to pursue certain business opportunities or strategic transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk of legal proceedings that have been or may be instituted against Bioventus, Misonix, their directors
and/or others relating to the merger; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks related to the diversion of the attention and time of Bioventus or Misonix management from ongoing business
concerns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the proposed merger or any announcement relating to the proposed merger could have an adverse
effect on the ability of Bioventus or Misonix to retain and hire key personnel or maintain relationships with customers, suppliers, distributors, vendors, strategic partners or other third parties, including regulators and other governmental
authorities or agencies, or on Bioventus&#146;s or Misonix&#146;s respective operating results and businesses generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potentially significant amount of any costs, fees, expenses, impairments or charges related to the merger;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential dilution of Bioventus and Misonix stockholders&#146; ownership percentage of the combined company
as compared to their ownership percentage of Bioventus or Misonix, as applicable, prior to the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business, economic, political and other conditions in the countries in which Bioventus or Misonix operate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">events beyond the control of Bioventus and Misonix, such as acts of terrorism or the continuation or worsening of
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and changes in applicable law, including changes in Bioventus&#146;s or Misonix&#146;s estimates of their expected tax rate based on current tax law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential dilution of the combined company&#146;s earnings per share as a result of the merger;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus and Misonix directors and executive officers having interests in the merger that are different from, or
in addition to, the interests of Bioventus and Misonix stockholders generally; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the combined company&#146;s results of operations, cash flows and financial position after
the merger may differ materially from the unaudited pro forma condensed combined financial information contained in this proxy statement/prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further discussion of these and other risks, contingencies and uncertainties applicable to Bioventus and Misonix, their respective businesses and the
proposed merger, see &#147;Risk Factors&#148; in this joint proxy statement/prospectus and in similarly titled sections in Bioventus&#146;s and Misonix&#146;s other filings with the SEC that are incorporated by reference herein. See &#147;Where You
Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All subsequent written or oral forward-looking statements attributable to Bioventus, Misonix or any person acting on
either of their behalf are expressly qualified in their entirety by these cautionary statements. Neither Bioventus nor Misonix is under any obligation to update, alter or otherwise revise any forward-looking statements, whether written or oral, that
may be made from time to time, whether as a result of new information, future events or otherwise, and each expressly disclaims any obligation to do so, except as may be required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_10"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In considering how to vote on the proposals to be considered and voted on at the Bioventus and Misonix special meetings, you are urged to carefully
consider all of the information contained or incorporated by reference in this joint proxy statement/prospectus. See &#147;Where You Can Find More Information.&#148; You should also read and consider the risks associated with each of the businesses
of Bioventus and Misonix because those risks will affect the combined company. The risks associated with the business of Bioventus are presented below and the risks associated with the business of Misonix can be found in Misonix Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2021, as such risks may be updated or supplemented in Misonix&#146;s subsequently filed Quarterly Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (excluding any information and exhibits furnished under Item&nbsp;2.02 or 7.01 thereof), each of which is incorporated by
reference in this joint proxy statement/prospectus. In addition, you are urged to carefully consider the following material risks relating to the merger and the businesses of Bioventus, Misonix and the combined company. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factor Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Relating to the Mergers
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because the exchange ratio is fixed and will not be adjusted in the event of any change in the price of either
Bioventus or Misonix common stock, the value of the consideration that Misonix stockholders will receive in the first merger is uncertain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The market price of Bioventus common stock will continue to fluctuate after the mergers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The mergers may not be completed and the merger agreement may be terminated in accordance with its terms.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The termination of the merger agreement could negatively impact Bioventus or Misonix and the trading prices of
the Bioventus or Misonix common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Relating to the Combined Company </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combining the businesses of Bioventus and Misonix may be more difficult, costly or time-consuming than expected
and the combined company may fail to realize the anticipated benefits of the merger, which may adversely affect the combined company&#146;s business results and negatively affect the value of the combined company&#146;s common stock.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The failure to successfully integrate the businesses and operations of Bioventus and Misonix in the expected time
frame may adversely affect the combined company&#146;s future results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The combined company may not be able to retain customers, suppliers or distributors, or customers, suppliers or
distributors may seek to modify contractual relationships with the combined company, which could have an adverse effect on the combined company&#146;s business and operations. Third parties may terminate or alter existing contracts or relationships
with Bioventus or Misonix. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The combined company may be exposed to increased litigation, which could have an adverse effect on the combined
company&#146;s business and operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Bioventus and Misonix unaudited prospective financial information is inherently subject to uncertainties, the
unaudited pro forma condensed combined financial information included in this document is preliminary and the combined company&#146;s actual financial position and results of operations after the transaction may differ materially from these
estimates and the unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus. The unaudited pro forma condensed combined financial information does not reflect the effect of any divestitures that
may be required in connection with the transaction. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Relating to Bioventus </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; business may continue to experience adverse impacts as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus is highly dependent on a limited number of products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; long-term growth depends on its ability to develop, acquire and commercialize new products, line
extensions or expanded indications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus may be unable to successfully commercialize newly developed or acquired products or therapies in the
United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; products and operations are subject to extensive governmental regulation, and its failure to
comply with applicable requirements could cause its business to suffer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus may be subject to enforcement action if it engages in improper claims submission practices and
resulting audits or denials of Bioventus&#146; claims by government agencies could reduce Bioventus&#146; net sales or profits. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain
required regulatory clearances and approvals could prevent Bioventus from commercializing its products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Protection of Bioventus&#146; intellectual property rights may be difficult and costly, and Bioventus&#146;
inability to protect its intellectual property could adversely affect its competitive position. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus depends on certain technologies that are licensed to it. Bioventus does not control the intellectual
property rights covering these technologies and any loss of Bioventus&#146; rights to these technologies or the rights licensed to Bioventus could prevent Bioventus from selling Bioventus&#146; products, which could adversely impact its business,
results of operations and financial condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the past, Bioventus identified material weaknesses in its internal control over financial reporting. If
Bioventus experiences additional material weaknesses in the future or otherwise fails to maintain an effective system of internal controls, Bioventus may not be able to accurately or timely requirements applicable to public companies, which may
adversely affect investor confidence in Bioventus, and, as a result, the market price of Bioventus class A common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus is a &#147;controlled company&#148; within the meaning of Nasdaq listing standards and, as a result,
will qualify for, and intend to rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that are subject to such requirements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; principal asset is Bioventus&#146; interest in BV LLC, and, accordingly, Bioventus depends on
distributions from BV LLC to pay Bioventus&#146; taxes and expenses, including payments under the Tax Receivable Agreement. BV LLC&#146;s ability to make such distributions may be subject to various limitations and restrictions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The TRA with Smith&nbsp;&amp; Nephew, Inc. (&#147;the continuing LLC owner&#148;) requires Bioventus to make cash
payments to it in respect of certain tax benefits to which Bioventus is or may become entitled, and Bioventus expects that the payments it will be required to make could be significant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Taking advantage of the reduced disclosure requirements applicable to &#147;emerging growth companies&#148; may
make Bioventus class A common stock less attractive to investors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because the exchange ratio is fixed and will not be adjusted in the event of any change in the price of either Bioventus or Misonix common stock, the
value of the consideration that Misonix stockholders will receive in the first merger is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the first merger, each
issued and outstanding share of Misonix common stock (other than treasury shares and shares held by Bioventus, Merger Sub&nbsp;I or Merger Sub&nbsp;II and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal
and prefected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Bioventus class A common stock, based on the election of the holder thereof and subject to proration in accordance with the terms of the merger agreement. Bioventus stockholders will
continue to own their existing shares of Bioventus common stock. The exchange ratio for the stock election consideration is fixed in the merger agreement and will not be adjusted for changes in the market price of either Bioventus or Misonix common
stock prior to the completion of the mergers. The market prices of Bioventus and Misonix common stock have fluctuated prior to and after the date of the announcement of the merger agreement and will continue to fluctuate from the date of this joint
proxy statement/prospectus to the dates of the Bioventus and Misonix special meetings, and through the date the mergers are consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the
exchange ratio is fixed, the market value of the stock election consideration to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the
mergers. Similarly, Bioventus stockholders will not know or be able to determine at the time of the Bioventus special meeting the market value of the shares of Bioventus common stock to be issued to those Misonix stockholders receiving the stock
election consideration pursuant to the merger agreement compared to the market value of the shares of Misonix common stock that are being exchanged in the first merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock price changes may result from a variety of factors, including, among others, general market and economic conditions, changes in Bioventus&#146; or
Misonix&#146;s respective businesses, operations and prospects, the uncertainty as to the extent of the duration, scope and impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, market assessments of the likelihood that the
mergers will be completed, interest rates, general market, industry and economic conditions and other factors generally affecting the respective prices of Bioventus and Misonix common stock, federal, state and local legislation, governmental
regulation and legal developments in the industry segments in which Bioventus and Misonix operate, and the timing of the mergers and receipt of required regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of these factors are beyond the control of Bioventus and Misonix, and neither Bioventus nor Misonix is permitted to terminate the merger agreement solely
due to a decline in the market price of the common stock of the other party. You are urged to obtain current market quotations for Bioventus and Misonix common stock in determining whether to vote in favor of the Bioventus share issuance proposal,
in the case of Bioventus stockholders, or the Misonix merger proposal, in the case of Misonix stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of Bioventus common
stock will continue to fluctuate after the mergers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the first merger, Misonix stockholders who receive the stock election
consideration will become holders of Bioventus common stock. The market price of the common stock of the combined company will continue to fluctuate, potentially significantly, following completion of the mergers, including for the reasons described
above. As a result, former Misonix stockholders could lose some or all of the value of their investment in Bioventus common stock. In addition, any significant price or volume fluctuations in the stock market generally could have a material adverse
effect on the market for, or liquidity of, the Bioventus common stock received in the first merger, regardless of the combined company&#146;s actual operating performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The mergers may not be completed and the merger agreement may be terminated in accordance with its terms. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mergers are subject to a number of conditions that must be satisfied, including the approval by Bioventus stockholders of the Bioventus share issuance
proposal and approval by Misonix stockholders of the Misonix </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger proposal, or waived (to the extent permitted), in each case prior to the completion of the mergers. These conditions are described under &#147;The Merger Agreement&#151;Conditions to the
Completion of the Mergers.&#148; These conditions to the completion of the mergers, some of which are beyond the control of Bioventus and Misonix, may not be satisfied or waived in a timely manner or at all, and, accordingly, the merger may be
delayed or not completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, either Bioventus or Misonix may terminate the merger agreement under certain circumstances, including, among
other reasons, if the mergers are not completed by the end date. Under the merger agreement, Bioventus and Misonix will each be required to pay a termination fee of $20,661,000 to the other party if the merger agreement is terminated in certain
circumstances, including if the respective party&#146;s board changes its recommendation in connection with the mergers. Additionally, Misonix may terminate the merger agreement if it enters into an alternative acquisition agreement with respect to
a superior proposal and pays Bioventus the termination fee. See &#147;The Merger Agreement&#151;Termination of the Merger Agreement&#148; and &#147;The Merger Agreement&#151;Termination Fee&#148; for a more complete discussion of the circumstances
under which the merger agreement could be terminated and when a termination fee may be payable by Bioventus or Misonix. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The termination of the
merger agreement could negatively impact Bioventus or Misonix and the trading prices of the Bioventus or Misonix common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the mergers are
not completed for any reason, including because Bioventus stockholders fail to approve the Bioventus share issuance proposal or because Misonix stockholders fail to approve the Misonix merger proposal, the ongoing businesses of Bioventus and Misonix
may be adversely affected and, without realizing any of the expected benefits of having completed the mergers, Bioventus and Misonix would be subject to a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each company may experience negative reactions from the financial markets, including negative impacts on its
stock price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each company may experience negative reactions from its customers, suppliers, distributors and employees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each company will be required to pay its respective costs relating to the mergers, such as financial advisory,
legal, financing and accounting costs and associated fees and expenses, whether or not the mergers are completed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger agreement places certain restrictions on the conduct of each company&#146;s business prior to
completion of the mergers and such restrictions, the waiver of which is subject to the consent of the other company (not to be unreasonably withheld, conditioned or delayed), which may have prevented Bioventus and Misonix from taking actions during
the pendency of the mergers that would have been beneficial (see &#147;The Merger Agreement&#151;Conduct of Business Prior to Completion of the Mergers&#148; for a description of the restrictive covenants applicable to Bioventus and Misonix); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">matters relating to the mergers (including integration planning) will require substantial commitments of time and
resources by Bioventus and Misonix management, which could otherwise have been devoted to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations or to other opportunities that may have been beneficial
to Bioventus or Misonix, as applicable, as an independent company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price for shares of Bioventus common stock may be
affected by factors different from, or in addition to, those that historically have affected or currently affect the market prices of shares of Bioventus or Misonix common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the first merger, Bioventus stockholders and the Misonix stockholders who receive the stock election consideration will both hold shares
of common stock in the combined company. Bioventus&#146; businesses differ from those of Misonix, and Misonix&#146;s businesses differ from those of Bioventus, and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordingly, the results of operations of the combined company will be affected by some factors that are different from those currently or historically affecting the results of operations of
Bioventus and Misonix. The results of operations of the combined company may also be affected by factors different from those that currently affect or have historically affected either Bioventus or Misonix. For a discussion of the businesses of each
of Bioventus and Misonix and some important factors to consider in connection with those businesses, see &#147;The Parties to the Mergers&#148; and the other information contained or incorporated in this joint proxy statement/prospectus. See
&#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of shares of Misonix common stock outstanding as of September&nbsp;1, 2021, the
latest practicable date prior to the date of this joint proxy statement/prospectus, it is expected that Bioventus will issue approximately 18,322,984 million shares of Bioventus common stock in the first merger. Former Misonix stockholders may
decide not to hold the shares of Bioventus common stock that they will receive in the first merger, and Bioventus stockholders may decide to reduce their investment in Bioventus as a result of the changes to Bioventus&#146; investment profile as a
result of the transaction. Such sales of Bioventus common stock could have the effect of depressing the market price for Bioventus common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The shares of common stock of the combined company to be received by Misonix stockholders as a result of the first merger will have rights different
from the shares of Misonix common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the transaction, Misonix stockholders will no longer be stockholders of Misonix, but
will instead become stockholders of Bioventus. As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different. However, there are certain differences in the rights of Bioventus
stockholders under Bioventus&#146; amended and restated certificate of incorporation, which is referred to as the &#147;Bioventus charter,&#148; and Bioventus&#146; amended and restated bylaws, which are referred to as the &#147;Bioventus
bylaws,&#148; and of Misonix stockholders under Misonix&#146;s amended and restated certificate of incorporation, which is referred to as the &#147;Misonix charter,&#148; and Misonix&#146;s amended and restated bylaws, which are referred to as the
&#147;Misonix bylaws.&#148; See &#147;Comparison of Stockholders&#146; Rights&#148; for a discussion of these rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After the transaction,
Misonix stockholders will have a significantly lower ownership and voting interest in Bioventus than they currently have in Misonix and will exercise less influence over management and policies of the combined company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of shares of Bioventus and Misonix common stock outstanding on September&nbsp;1, 2021, the latest practicable date prior to the date of
this joint proxy statement/prospectus, upon completion of the first merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the
first merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Consequently, former Misonix stockholders will have less influence over the management and policies of the combined company than they currently
have over the management and policies of Misonix. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Until the completion of the transaction or the termination of the merger agreement in accordance
with its terms, Bioventus and Misonix are each prohibited from entering into certain transactions and taking certain actions that might otherwise be beneficial to Bioventus, Misonix and/or their respective stockholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and after the date of the merger agreement and prior to completion of the transaction, the merger agreement restricts Bioventus and Misonix from taking
specified actions without the consent of the other party and requires that the business of each company and its respective subsidiaries be conducted in the ordinary course in all material respects. These restrictions may prevent Bioventus or
Misonix, as applicable, from taking actions during the pendency of the transaction that would have been beneficial. Adverse effects arising from these restrictions during the pendency of the transaction could be exacerbated by any delays in
consummation of the transaction or termination of the merger agreement. See &#147;The Merger Agreement&#151;Conduct of Business Prior to Completion of the Mergers.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining required approvals and satisfying closing conditions may prevent or delay completion of the
transaction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction is subject to a number of conditions to closing as specified in the merger agreement. These closing conditions
include, among others, the effectiveness of the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy statement/prospectus forms a part registering the Bioventus common stock issuable pursuant to the
merger agreement and the absence of any stop order or proceedings by the SEC with respect thereto, the expiration or earlier termination of any applicable waiting period (or any extension thereof), and the receipt of required approvals, under U.S.
antitrust laws, approval for listing on Nasdaq of the shares of Bioventus common stock to be issued pursuant to the merger agreement, and the absence of governmental restraints or prohibitions preventing the consummation of the transaction. To the
extent required, foreign investment filings will also be made, though these are not closing conditions. The obligation of each of Bioventus and Misonix to consummate the transaction is also conditioned on, among other things, the truth and accuracy
of the representations and warranties made by the other party on the date of the merger agreement and on the closing date (subject to certain materiality and material adverse effect qualifiers), and the performance by the other party in all material
respects of its obligations under the merger agreement. No assurance can be given that the required stockholder, governmental and regulatory consents and approvals will be obtained or that the required conditions to closing will be satisfied, and,
if all required consents and approvals are obtained and the required conditions are satisfied, no assurance can be given as to the terms, conditions and timing of such consents and approvals. Any delay in completing the transaction could cause the
combined company not to realize, or to be delayed in realizing, some or all of the benefits that Bioventus and Misonix expect to achieve if the transaction is successfully completed within its expected time frame. For a more complete summary of the
conditions that must be satisfied or waived prior to completion of the transaction, see &#147;The Merger Agreement&#151;Conditions to the Completion of the Mergers.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus and Misonix must obtain certain regulatory approvals and clearances to consummate the transaction, which, if delayed, not granted or granted
with burdensome or unacceptable conditions, could prevent, substantially delay or impair consummation of the transaction, result in additional expenditures of money and resources or reduce the anticipated benefits of the transaction. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The completion of the transaction is subject to the termination or expiration of any applicable waiting period (or extension thereof) under the HSR Act, which
occurred as of 11:59 p.m., Eastern Time, on September&nbsp;13, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the HSR Act, the transaction may not be completed until Notification and
Report Forms have been filed with the U.S. Federal Trade Commission, which is referred to as the &#147;FTC,&#148; and the U.S. Department of Justice, which is referred to as the &#147;DOJ,&#148; and the applicable waiting period (or any extension
thereof) has expired or been terminated. A transaction requiring notification under the HSR Act may not be completed until the expiration of the applicable <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period following the parties&#146;
filing of their respective HSR notifications or the early termination of that waiting period, at the earliest. Each of Bioventus and Misonix filed an HSR notification with the FTC and the DOJ on August&nbsp;12, 2021. Effective as of 11:59 p.m.,
Eastern Time, on September 13, 2021, the waiting period under the HSR Act expired with respect to the transactions contemplated by the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time before or after consummation of the transaction, notwithstanding the expiration or termination of the applicable waiting period under the HSR Act,
the DOJ or the FTC, or any state, could take such action under competition laws as it deems necessary or desirable in the public interest, including seeking to enjoin the completion of the transaction, seeking divestiture of substantial assets of
the parties or requiring the parties to license, or hold separate, assets or to terminate existing relationships and contractual rights. Under certain circumstances, private parties may also seek to take legal action against the transaction under
competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no assurance that Bioventus and Misonix will obtain all required regulatory clearances or approvals on a timely basis, or at
all. Failure to obtain the necessary clearances in any of these jurisdictions could substantially delay or prevent the consummation of the transaction, which could negatively impact both Bioventus and Misonix. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to attract, motivate and retain executives and other key employees could diminish the
anticipated benefits of the transaction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of the transaction will depend in part on the combined company&#146;s ability to retain the
talents and dedication of the professionals currently employed by Bioventus and Misonix. It is possible that these employees may decide not to remain with Bioventus or Misonix, as applicable, while the transaction is pending, or with the combined
company. If key employees terminate their employment, or if an insufficient number of employees are retained to maintain effective operations, the combined company&#146;s business activities may be adversely affected and management&#146;s attention
may be diverted from successfully integrating Bioventus and Misonix to hiring suitable replacements, all of which may cause the combined company&#146;s business to suffer. In addition, Bioventus and Misonix may not be able to locate suitable
replacements for any key employees that leave either company or offer employment to potential replacements on reasonable terms. In addition, there could be disruptions to or distractions for the workforce and management, including disruptions
associated with integrating employees into the combined company. No assurance can be given that the combined company will be able to attract or retain key employees of Bioventus and Misonix to the same extent that those companies have been able to
attract or retain their own employees in the past. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The transaction, and uncertainty regarding the transaction, may cause customers, suppliers,
distributors or strategic partners to delay or defer decisions concerning Bioventus or Misonix and adversely affect each company&#146;s ability to effectively manage its respective business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction will happen only if the stated conditions are met, including the approval of the Bioventus share issuance proposal, the approval of the Misonix
merger proposal and the receipt of required regulatory approvals, among other conditions. Many of the conditions are beyond the control of Bioventus and Misonix, and both parties also have certain rights to terminate the merger agreement.
Accordingly, there may be uncertainty regarding the completion of the transaction. This uncertainty may cause customers, suppliers, distributors, vendors, strategic partners or others that deal with Bioventus or Misonix to delay or defer entering
into contracts with Bioventus or Misonix or making other decisions concerning Bioventus or Misonix or seek to change or cancel existing business relationships with Bioventus or Misonix, which could negatively affect their respective businesses. Any
delay or deferral of those decisions or changes in existing agreements could have an adverse impact on the respective businesses of Bioventus and Misonix, regardless of whether the transaction is ultimately completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the merger agreement restricts Bioventus, Misonix and their respective subsidiaries from taking certain actions during the pendency of the
transaction without the consent of the other parties. These restrictions may prevent Bioventus and Misonix from pursuing attractive business opportunities or strategic transactions that may arise prior to the completion of the transaction. See
&#147;The Merger Agreement&#151;Conduct of Business Prior to Completion of the Mergers&#148; for a description of the restrictive covenants to which each of Bioventus and Misonix is subject. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The opinions rendered to Bioventus and Misonix from their respective financial advisors will not reflect changes in circumstances between the dates of
such opinions and the completion of the transaction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg delivered its oral opinion to the Bioventus board on July&nbsp;28, 2021,
which opinion was subsequently confirmed in a written opinion dated as of July&nbsp;29, 2021, to the effect that as of such date and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken and
other matters considered in connection with the preparation of the opinion, the merger consideration to be paid by Bioventus pursuant to the merger agreement was fair, from a financial point of view, to Bioventus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan rendered its oral opinion to the Misonix board on July&nbsp;28, 2021, which opinion was subsequently confirmed in writing dated as of
July&nbsp;29, 2021, to the effect that, as of such date and based on and subject to the assumptions made, procedures followed, matters considered and other limitations on the review undertaken by J.P. Morgan in preparing its opinion, the merger
consideration to be paid to the holders of Misonix common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock in the merger was fair, from a financial point of view, to such holders, as more fully described in the section entitled &#147;Opinion of Misonix&#146;s Financial Advisor&#148;. The full
text of the written opinion of J.P. Morgan, dated July&nbsp;29, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan in preparing its
opinion, is attached as Annex C to this joint proxy statement/prospectus and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Bioventus nor Misonix has
obtained, nor will either of them obtain, an updated opinion from Perella Weinberg or J.P. Morgan, as applicable, regarding the fairness, from a financial point of view, of the merger consideration or exchange ratio, including as of the date of this
joint proxy statement/prospectus or of the special meetings, or prior to the completion of the transaction. Each of the respective opinions of Perella Weinberg and J.P. Morgan was necessarily based on general financial, economic, monetary, market
and other conditions and circumstances as in effect on, and the information made available to Perella Weinberg and J.P. Morgan as applicable, only as of the dates of the respective opinions of Perella Weinberg and J.P. Morgan, and such opinions do
not address the fairness of the merger consideration, from a financial point of view, at the time the transaction is completed. Changes in the operations and prospects of Bioventus or Misonix, general financial, economic, monetary, market and other
conditions, circumstances and factors that may be beyond the control of Bioventus and Misonix, and on which each of the respective opinions of Perella Weinberg and J.P. Morgan was based, may alter the value of Bioventus or Misonix or the prices of
shares of Bioventus or Misonix common stock by the time the mergers are completed. The opinions of Perella Weinberg and J.P. Morgan do not speak as of any date other than the respective dates of such opinions. The recommendation of the Bioventus
board that Bioventus stockholders vote &#147;<B>FOR</B>&#148; the Bioventus share issuance proposal and &#147;<B>FOR</B>&#148; the Bioventus adjournment proposal and the recommendation of the Misonix board that Misonix stockholders vote
&#147;<B>FOR</B>&#148; the Misonix merger proposal, &#147;<B>FOR</B>&#148; the Misonix compensation proposal and &#147;<B>FOR</B>&#148; the Misonix adjournment proposal are each made as of the date of this joint proxy statement/prospectus. For a
description of the opinions that Bioventus and Misonix received from their respective financial advisors, see &#147;The Merger&#151;Opinion of Bioventus&#146; Financial Advisor&#148; and &#147;The Merger&#151;Opinion of Misonix&#146;s Financial
Advisor.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Whether or not the transaction is completed, the announcement and pendency of the mergers could cause disruptions in the businesses
of Bioventus and Misonix, which could have an adverse effect on their respective businesses and financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the transaction
is completed, the announcement and pendency of the mergers could cause disruptions in the businesses of Bioventus and Misonix, including by diverting the attention of Bioventus and Misonix management toward the completion of the transaction. In
addition, Bioventus and Misonix have each diverted significant management resources in an effort to complete the transaction and are each subject to restrictions contained in the merger agreement on the conduct of their respective businesses. If the
transaction is not completed, Bioventus and Misonix will have incurred significant costs, including the diversion of management resources, for which they will have received little or no benefit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix directors and executive officers have interests and arrangements that may be different from, or in addition to, those of Misonix stockholders
generally. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering the recommendations of the Misonix board on how to vote on the proposals described in this joint proxy
statement/prospectus, Misonix stockholders should be aware that Misonix directors and executive officers have interests in the transaction that are different from, or in addition to, those of Misonix stockholders generally. These interests include
the continued service of certain Misonix directors as directors of the combined company, the treatment in the mergers of outstanding equity, equity-based and incentive awards, severance arrangements, other compensation and benefit arrangements, and
the right to continued indemnification of former Misonix directors and officers by the combined company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix stockholders should be aware of these interests when they consider the recommendations of the
Misonix board that they vote to approve the Misonix merger proposal. The Misonix board was aware of and considered these interests when it determined that the transaction was fair to and in the best interests of Misonix and its stockholders,
approved and declared advisable the merger agreement, and recommended that Misonix stockholders adopt the merger agreement. The interests of Misonix directors and executive officers are described in more detail under &#147;Interests of Misonix
Directors and Executive Officers in the Mergers.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus or Misonix may waive one or more of the closing conditions without <FONT
STYLE="white-space:nowrap">re-soliciting</FONT> stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent permitted by law, Bioventus or Misonix may determine to waive,
in whole or part, one or more of the conditions to their respective obligations to consummate the mergers. Bioventus and Misonix currently expect to evaluate the materiality of any waiver and its effect on Bioventus or Misonix stockholders, as
applicable, in light of the facts and circumstances at the time to determine whether any amendment of this joint proxy statement/prospectus or any <FONT STYLE="white-space:nowrap">re-solicitation</FONT> of proxies is required in light of such
waiver. Any determination as to whether to waive any condition to the transaction, and as to whether to <FONT STYLE="white-space:nowrap">re-solicit</FONT> stockholder approval and/or amend this joint proxy statement/prospectus as a result of such
waiver, will be made by Bioventus or Misonix, as applicable, at the time of such waiver based on the facts and circumstances as they exist at that time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The merger agreement contains provisions that could discourage a potential competing acquirer that might be willing to pay more to acquire or merge with
either Bioventus or Misonix. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement contains &#147;no shop&#148; provisions that restrict the ability of Bioventus and Misonix to,
among other things (each as described under &#147;The Merger Agreement&#151;No Solicitation of Acquisition Proposals&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit, initiate, knowingly encourage, knowingly induce, knowingly assist, or knowingly facilitate any inquiries
regarding, or the submission or announcement by any person of, any proposal or offer that constitutes, or would reasonably be expected to lead to, an acquisition proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">furnish any information regarding Bioventus, Misonix or their respective subsidiaries in connection with, for the
purpose of soliciting, initiating, encouraging or facilitating, or in response to, an acquisition proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in or otherwise participate in any discussions or negotiations with any person with respect to any
acquisition proposal or any inquiry, proposal or offer that would reasonably be expected to lead to an acquisition proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve, adopt, recommend, agree to, or enter into, or propose to approve, adopt, recommend, agree to, or enter
into, any letter of intent or similar document, agreement, commitment, or agreement in principle with respect to any acquisition proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, there are only limited exceptions to the requirement under the merger agreement that neither the Bioventus nor Misonix boards of directors
withdraw, modify, amend or qualify the Bioventus recommendation or the Misonix recommendation, as applicable (each as defined under &#147;The Merger Agreement&#151;Representations and Warranties&#148;). Although the Bioventus or Misonix board is
permitted to effect a change of recommendation, after complying with certain procedures set forth in the merger agreement, in response to a superior proposal or to an intervening event (if the applicable board of directors determines in good faith
after consultation with its outside legal counsel and its financial advisor that a failure to do so would be reasonably likely to be inconsistent with its fiduciary duties under applicable law), such change of recommendation by the Misonix board
would entitle Bioventus to terminate the merger agreement and collect a termination fee from Misonix. See &#147;The Merger Agreement&#151;Termination of the Merger Agreement&#148; and &#147;The Merger Agreement&#151;Termination Fees.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions could discourage a potential competing acquirer from considering or proposing an
acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the exchange ratio in the first merger, or might result in a potential competing acquirer proposing to pay a lower per share price than it
might otherwise have proposed to pay because of the added expense of the termination fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The transaction will involve substantial costs.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix have incurred and expect to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs associated with combining the
operations of the two companies, as well as transaction fees and other costs related to the transaction. As of the date of this joint proxy statement/prospectus, Bioventus and Misonix estimate that their aggregate costs associated with the
transaction and related transactions will be approximately $18.0&nbsp;million and $10.4&nbsp;million, respectively. These costs include filing and registration fees with the SEC, printing and mailing costs associated with this joint
proxy/registration statement, and legal, accounting, investment banking, consulting, public relations and proxy solicitation fees. These costs do not include severance and retention payments that may be made to certain Misonix employees and costs
that will be incurred in connection with the integration of Bioventus&#146; and Misonix&#146;s businesses. Some of these costs are payable by Bioventus or Misonix regardless of whether the transaction is completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined company will also incur restructuring and integration costs in connection with the mergers. The costs related to restructuring will be expensed
as a cost of the ongoing results of operations of either Bioventus or the combined company. There are processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the mergers and the integration of
Misonix&#146;s business. Although Bioventus expects that the elimination of duplicative costs, strategic benefits, and additional income, as well as the realization of other efficiencies related to the integration of the businesses, may offset
incremental transaction, merger-related and restructuring costs over time, any net benefit may not be achieved in the near term or at all. Many of these costs will be borne by Bioventus even if the mergers are not completed. While Bioventus has
assumed that certain expenses would be incurred in connection with the transaction, there are many factors beyond Bioventus&#146; control that could affect the total amount or the timing of the integration and implementation expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus stockholders will not be entitled to appraisal rights in the transaction, though Misonix stockholders will be entitled to appraisal rights in
the transaction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Appraisal rights are statutory rights that, if applicable under law, enable stockholders of a corporation to dissent from an
extraordinary transaction, such as a merger, and to demand that such corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the consideration offered to such stockholders in connection
with the extraordinary transaction. Under the DGCL, stockholders generally do not have appraisal rights if the shares of stock they hold are either listed on a national securities exchange or held of record by more than 2,000 holders.
Notwithstanding the foregoing, appraisal rights are available if stockholders are required by the terms of the merger agreement to accept for their shares anything other than (a)&nbsp;shares of stock of the surviving corporation, (b)&nbsp;shares of
stock of another corporation that will either be listed on a national securities exchange or held of record by more than 2,000 holders, (c)&nbsp;cash in lieu of fractional shares or (d)&nbsp;any combination of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the mergers are of Merger Sub with and into Misonix and then Misonix with and into Merger Sub II and holders of Bioventus common stock will continue
to hold their shares following completion of the mergers, holders of Bioventus common stock are not entitled to appraisal rights in connection with the mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;262 of the DGCL, Misonix stockholders who do not vote in favor of Misonix merger proposal and who comply with the applicable
requirements of Section&nbsp;262 of the DGCL have the right to seek appraisal of such shares by the Delaware Court of Chancery and to receive payment in cash of the fair value of those shares. It is possible that the fair value as determined by the
Delaware Court of Chancery may be more or less than, or the same as, the per share value of the merger consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix stockholders who wish to preserve their appraisal rights must make a demand for appraisal prior to
the time the Misonix stockholder vote is taken on the Misonix merger proposal. In addition to submitting a demand for appraisal, such Misonix stockholders must continuously hold such shares through the effective time, must not vote in favor of the
Misonix merger proposal, must not surrender their shares in exchange for the merger consideration, and must otherwise follow the procedures prescribed by Section&nbsp;262 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix stockholders are encouraged to read Section&nbsp;262 of the DGCL carefully and in their entirety. Due to the complexity of the procedures for
exercising your appraisal rights, Misonix stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel. Failure to strictly comply with these provisions will result in the loss of appraisal rights. See
the section entitled &#147;Appraisal Rights&#148; of this joint proxy statement/prospectus for additional information and the text of Section&nbsp;262 of the DGCL reproduced in its entirety as <U>Annex D</U> to this proxy statement/prospectus. See
&#147;Appraisal Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lawsuits filed against Bioventus and/or Misonix may delay or prevent the transaction from being completed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus, Misonix and members of the Bioventus and Misonix boards of directors may in the future be parties, among others, to various claims and
litigation related to the merger agreement and the merger, including putative shareholder class actions. See &#147;The Mergers&#151;Litigation Relating to the Mergers.&#148; Among other remedies, the plaintiffs in such matters are seeking to enjoin
the transaction. The results of complex legal proceedings are difficult to predict, and could prevent or delay the merger from being completed in a timely manner, and could result in substantial costs to Bioventus and Misonix, including, but not
limited to, costs associated with the indemnification of their respective directors and officers. The existence of litigation relating to the merger could also impact the likelihood of obtaining the required approvals from either Bioventus or
Misonix stockholders. Moreover, the pending litigation and any future additional litigation could be time consuming and expensive, could divert the attention of Bioventus and Misonix management away from their regular businesses and, if any one of
these lawsuits is adversely resolved against either Bioventus or Misonix, could have a material adverse effect on Bioventus&#146; or Misonix&#146;s respective financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the conditions to the completion of the mergers is that no relevant legal restraint (as defined in the merger agreement) will be in effect. As such,
any relevant legal restraint may delay or prevent the mergers from becoming effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Combined Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Combining the businesses of Bioventus and Misonix may be more difficult, costly or time-consuming than expected and the combined company may fail to
realize the anticipated benefits of the merger, which may adversely affect the combined company&#146;s business results and negatively affect the value of the combined company&#146;s common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of the mergers will depend on, among other things, the ability of Bioventus and Misonix to combine their businesses in a manner that facilitates
growth opportunities and realizes expected cost savings. Bioventus and Misonix have entered into the merger agreement because each believes that the transaction is fair to and in the best interests of their respective stockholders and that combining
the businesses of Bioventus and Misonix will produce benefits and cost savings. See &#147;The Mergers&#151;Recommendation of the Bioventus Board of Directors; Bioventus&#146; Reasons for the Mergers&#148; and &#147;The Mergers&#151;Recommendation of
the Misonix Board of Directors; Misonix&#146;s Reasons for the Mergers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, Bioventus and Misonix must successfully combine their respective
businesses in a manner that permits these benefits to be realized. In addition, the combined company must achieve the anticipated growth and cost savings without adversely affecting current revenues and investments in future growth. If the combined
company is not able to successfully achieve these objectives, the anticipated benefits of the transaction may not be realized fully, or at all, or may take longer to realize than expected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An inability to realize the full extent of the anticipated benefits of the transaction, as well as any
delays encountered in the integration process, could have an adverse effect upon the revenues, level of expenses and operating results of the combined company, which may adversely affect the value of the common stock of the combined company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the actual integration may result in additional and unforeseen expenses, and the anticipated benefits of the integration plan may not be
realized. Actual growth and cost savings, if achieved, may be lower than what Bioventus and Misonix expect and may take longer to achieve than anticipated. If Bioventus and Misonix are not able to adequately address integration challenges, they may
be unable to successfully integrate their operations or realize the anticipated benefits of the integration of the two companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The failure to
successfully integrate the businesses and operations of Bioventus and Misonix in the expected time frame may adversely affect the combined company&#146;s future results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix have operated and, until the completion of the transaction, will continue to operate independently. There can be no assurances that their
businesses can be integrated successfully. It is possible that the integration process could result in the loss of key Bioventus or Misonix employees, the loss of customers, the disruption of either company&#146;s or both companies&#146; ongoing
businesses, inconsistencies in standards, controls, procedures and policies, unexpected integration issues, higher than expected integration costs and an overall post-completion integration process that takes longer than originally anticipated.
Specifically, the following issues, among others, must be addressed in integrating the operations of Bioventus and Misonix in order to realize the anticipated benefits of the transaction so the combined company performs as expected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">combining the companies&#146; operations and corporate functions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">combining the businesses of Bioventus and Misonix and meeting the capital requirements of the combined company,
in a manner that permits the combined company to achieve any cost savings or other synergies anticipated to result from the mergers, the failure of which would result in the anticipated benefits of the transaction not being realized in the time
frame currently anticipated or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrating personnel from the two companies, especially in the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
environment which has required many employees to work remotely; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrating the companies&#146; technologies and technologies licensed from third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrating and unifying the offerings and services available to customers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and eliminating redundant and underperforming functions and assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">harmonizing the companies&#146; operating practices, employee development and compensation programs, internal
controls and other policies, procedures and processes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining existing agreements with customers, suppliers, distributors and vendors, avoiding delays in entering
into new agreements with prospective customers, suppliers, distributors and vendors, and leveraging relationships with such third parties for the benefit of the combined company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing possible differences in business backgrounds, corporate cultures and management philosophies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consolidating the companies&#146; administrative and information technology infrastructure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating distribution and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the movement of certain positions to different locations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating geographically dispersed organizations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effecting actions that may be required in connection with obtaining regulatory or other governmental approvals.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, at times the attention of certain members of either company&#146;s or both companies&#146;
management and resources may be focused on completion of the transaction and the integration of the businesses of the two companies and diverted from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business
operations or other opportunities that may have been beneficial to such company, which may disrupt each company&#146;s ongoing business and the business of the combined company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company may not be able to retain customers, suppliers or distributors, or customers, suppliers or distributors may seek to modify
contractual relationships with the combined company, which could have an adverse effect on the combined company&#146;s business and operations. Third parties may terminate or alter existing contracts or relationships with Bioventus or Misonix.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the transaction, the combined company may experience impacts on relationships with customers, suppliers and distributors that may
harm the combined company&#146;s business and results of operations. Certain customers, suppliers or distributors may seek to terminate or modify contractual obligations following the transaction whether or not contractual rights are triggered as a
result of the transaction. There can be no guarantee that customers, suppliers and distributors will remain with or continue to have a relationship with the combined company or do so on the same or similar contractual terms following the
transaction. If any customers, suppliers or distributors seek to terminate or modify contractual obligations or discontinue the relationship with the combined company, then the combined company&#146;s business and results of operations may be
harmed. Furthermore, the combined company will not have long-term arrangements with many of its significant suppliers. If the combined company&#146;s suppliers were to seek to terminate or modify an arrangement with the combined company, then the
combined company may be unable to procure necessary supplies from other suppliers in a timely and efficient manner and on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix also have contracts with vendors, landlords, licensors and other business partners which may require Bioventus or Misonix, as
applicable, to obtain consent from these other parties in connection with the transaction, or which may otherwise contain limitations applicable to such contracts following the transaction. If these consents cannot be obtained, the combined company
may suffer a loss of potential future revenue, incur costs and lose rights that may be material to the combined company&#146;s business. In addition, third parties with whom Bioventus or Misonix currently have relationships may terminate or
otherwise reduce the scope of their relationship with either party in anticipation of the transaction. Any such disruptions could limit the combined company&#146;s ability to achieve the anticipated benefits of the transaction. The adverse effect of
any such disruptions could also be exacerbated by a delay in the completion of the transaction or by a termination of the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
combined company may be exposed to increased litigation, which could have an adverse effect on the combined company&#146;s business and operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined company may be exposed to increased litigation from stockholders, customers, suppliers, distributors, consumers and other third parties due to the
combination of Bioventus&#146; and Misonix&#146;s businesses following the mergers. Such litigation may have an adverse impact on the combined company&#146;s business and results of operations or may cause disruptions to the combined company&#146;s
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Bioventus and Misonix unaudited prospective financial information is inherently subject to
uncertainties, the unaudited pro forma condensed combined financial information included in this document is preliminary and the combined company&#146;s actual financial position and results of operations after the transaction may differ materially
from these estimates and the unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus. The unaudited pro forma condensed combined financial information does not reflect the effect of any
divestitures that may be required in connection with the transaction. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information included in
this joint proxy statement/prospectus is presented for illustrative purposes only, contains a variety of adjustments, assumptions and preliminary estimates and is not necessarily indicative of what the combined company&#146;s actual financial
position or results of operations would have been had the transaction been completed on the dates indicated. The combined company&#146;s actual results and financial position after the transaction may differ materially and adversely from the
unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus. The unaudited pro forma condensed combined financial information does not reflect the effect of any divestitures that may be required in
connection with the transaction. See &#147;Unaudited Pro Forma Condensed Combined Financial Statements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While presented with numeric specificity,
the Bioventus and Misonix unaudited pro forma condensed combined financial information provided in this joint proxy statement/prospectus is based on numerous variables and assumptions (including, but not limited to, those related to industry
performance and competition, general business, the semiconductor and related industries, and economic, market and financial conditions and additional matters specific to Bioventus&#146; or Misonix&#146;s business, as applicable) that are inherently
subjective and uncertain and are beyond the control of the respective management teams of Bioventus and Misonix. As a result, actual results may differ materially from the unaudited pro forma condensed combined financial information. Important
factors that may affect actual results and cause these unaudited projected financial forecasts to not be achieved include, but are not limited to, risks and uncertainties relating to Bioventus&#146; or Misonix&#146;s business, as applicable
(including each company&#146;s ability to achieve strategic goals, objectives and targets over applicable periods), industry performance, general business and economic conditions. See &#147;The Merger&#151;Bioventus Unaudited Financial
Projections,&#148; &#147;The Merger&#151;Misonix Unaudited Financial Projections&#148; and &#147;The Merger&#151;Certain Estimated Synergies.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company&#146;s debt may limit its financial flexibility. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix continue to review the treatment of their existing indebtedness. Bioventus and Misonix may seek to repay, refinance, repurchase, redeem,
exchange or otherwise terminate their existing indebtedness prior to, in connection with or following the completion of the mergers. If either Bioventus or Misonix seeks to refinance its existing indebtedness, there can be no guarantee that it will
be able to execute the refinancing on favorable terms or at all. Alternatively, Bioventus and Misonix may seek to leave all or a portion of their existing indebtedness outstanding as the primary obligation of the combined company or to incur
additional indebtedness or refinancing indebtedness prior to, in connection with or following the completion of the mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; or
Misonix&#146;s substantial indebtedness could have adverse effects on such company&#146;s and/or the combined company&#146;s financial condition and results of operations, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing its vulnerability to changing economic, regulatory and industry conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limiting its ability to compete and its flexibility in planning for, or reacting to, changes in its business and
the industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limiting its ability to pay dividends to its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limiting its ability to borrow additional funds; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing its interest expense and requiring it to dedicate a substantial portion of its cash flow from
operations to payments on its debt, thereby reducing funds available for working capital, capital expenditures, acquisitions, and share repurchases, dividends and other purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The companies&#146; ability to arrange any additional financing for the purposes described above or otherwise will depend on, among other factors, the
companies&#146; respective financial positions and performance, as well as prevailing market conditions and other factors beyond their control. The level and quality of the combined company&#146;s earnings, operations, business and management, among
other things, will impact the determination of the combined company&#146;s credit ratings. A decrease in the ratings assigned to the combined company by the ratings agencies may negatively impact the combined company&#146;s access to the debt
capital markets and increase the combined company&#146;s cost of borrowing. There can be no assurance that the combined company will be able to obtain financing on acceptable terms or at all. In addition, there can be no assurance that the combined
company will be able to maintain the current creditworthiness or prospective credit ratings of Bioventus or Misonix, and any actual or anticipated changes or downgrades in such credit ratings may have a negative impact on the liquidity, capital
position or access to capital markets of the combined company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the existing indebtedness of Bioventus and/or Misonix remains outstanding, or if
either company refinances its existing indebtedness, covenants contained in the agreements governing such indebtedness will impose restrictions on the combined company and certain of its subsidiaries that may affect their ability to operate their
businesses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements that govern the indebtedness of Bioventus and Misonix, in addition to any refinanced indebtedness, may contain various
affirmative and negative covenants. Such covenants may, subject to certain significant exceptions, restrict the ability of the combined company and certain of its subsidiaries to, among other things, incur liens, incur debt, engage in mergers,
consolidations and acquisitions, transfer assets outside the ordinary course of business, make loans or other investments, pay dividends, repurchase equity interests, make other payments with respect to equity interests, repay or repurchase
subordinated debt and engage in affiliate transactions. In addition, the agreements governing the existing indebtedness of Bioventus and Misonix contain financial covenants that would require the combined company to maintain certain financial ratios
under certain circumstances. The ability of the combined company and its subsidiaries to comply with these provisions may be affected by events beyond their control. Failure to comply with these covenants could result in an event of default, which,
if not cured or waived, could accelerate the combined company&#146;s repayment obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Declaration, payment and amounts of dividends, if any,
distributed to stockholders of the combined company will be uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has not historically paid cash dividends on its capital stock.
Whether any dividends are declared or paid to stockholders of the combined company, and the amounts of any such dividends that are declared or paid, are uncertain and depend on a number of factors. If dividends are paid to stockholders of the
combined company, they may not be of the same amount as paid by Misonix to its stockholders prior to the mergers. The Bioventus board will have the discretion to determine the dividend policy of the combined company, including the amount and timing
of dividends, if any, that the combined company may declare from time to time, which may be impacted by any of the following factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the combined company may not have enough cash to pay such dividends or to repurchase shares due to its cash
requirements, capital spending plans, cash flow or financial position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decisions on whether, when and in which amounts to make any future distributions will remain at all times
entirely at the discretion of the Bioventus board, which could change its dividend practices at any time and for any reason; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the combined company&#146;s desire to maintain or improve the credit ratings on its debt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of dividends that the combined company may distribute to its stockholders is subject to restrictions
under Delaware law and is limited by restricted payment and leverage covenants in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
combined company&#146;s credit facilities and indentures and, potentially, the terms of any future indebtedness that the combined company may incur; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain limitations on the amount of dividends subsidiaries of the combined company can distribute to the
combined company, as imposed by state law, regulators or agreements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders should be aware that they have no contractual or
other legal right to dividends that have not been declared. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company is subject to risks arising from the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outbreak <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19,</FONT> which the World Health
Organization declared a pandemic in March 2020, has spread across the globe and disrupted the global economy. Governmental actions to reduce the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> have negatively impacted the macroeconomic
environment in many ways, while the pandemic itself has significantly increased economic uncertainty and abruptly reduced economic activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The extent
to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will impact the combined company is highly uncertain and is difficult to predict. The pandemic&#146;s effects and their extent will depend on various factors, including, but not
limited to, the duration, scope and impact of the pandemic, restrictions on business and social distancing guidelines that may be requested or mandated by governmental authorities and how quickly and to what extent normal economic and operating
conditions can resume. Relevant adverse consequences of the pandemic could include reduced liquidity, increased volatility of the combined company&#146;s stock price, operational disruption or failure due to spread of disease within the combined
company or due to restrictions on business and social distancing guidelines imposed or requested by governmental authorities, unavailability of raw materials, disruption in the supply chain and increased cybersecurity and fraud risks due to
increased online and remote activity, as well as the adverse consequences of a macroeconomic slowdown, recession or depression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even after <FONT
STYLE="white-space:nowrap">the&nbsp;COVID-19</FONT> pandemic has subsided, the combined company may continue to experience adverse impacts to its business as a result of the&nbsp;global economic impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including reduced availability of credit, adverse impacts on liquidity and the negative financial effects from any recession or depression that may occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any impairment of the combined company&#146;s tangible, definite-lived intangible or indefinite-lived intangible assets, including goodwill, may
adversely impact the combined company&#146;s financial position and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mergers will be accounted for using the acquisition
method of accounting under the provisions of ASC 805, Business Combinations, with Bioventus representing the accounting acquirer under this guidance. Bioventus will record assets acquired, including identifiable intangible assets, and liabilities
assumed from Misonix at their respective fair values at the date of completion of the mergers. Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill. In connection with the mergers, the
combined company is expected to record significant goodwill and other intangible assets on its consolidated balance sheet. See &#147;Unaudited Pro Forma Condensed Combined Financial Statements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indefinite-lived intangible assets, including goodwill, will be tested for impairment at least annually, and all tangible and intangible assets including
goodwill will be tested for impairment when certain indicators are present. If, in the future, the combined company determines that tangible or intangible assets, including goodwill, are impaired, the combined company would record an impairment
charge at that time. Impairment testing of goodwill and intangible assets requires significant use of judgment and assumptions, particularly as it relates to the determination of fair value. A decrease in the long-term economic outlook and future
cash flows of the combined company&#146;s business could significantly impact asset values and potentially result in the impairment of intangible assets, including goodwill, which may have a material adverse impact on the combined company&#146;s
financial position and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Bioventus charter designates, to the fullest extent permitted by law, the Court of Chancery of the
State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) as the exclusive forums for substantially all disputes
between Bioventus and its stockholders, which will restrict the ability of stockholders of the combined company to choose the judicial forum for disputes with the combined company or its directors, officers or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus charter provides that, unless Bioventus consents in writing to the selection of an alternative forum, the Court of Chancery of the State of
Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the sole and
exclusive forum for the following types of actions, suits or proceedings: (i)&nbsp;any derivative action, suit or proceeding brought on behalf of Bioventus; (ii)&nbsp;any action, suit or proceeding asserting a claim of breach of a fiduciary duty
owed by any current or former Bioventus director, officer, employee or stockholder to Bioventus or its stockholders; (iii)&nbsp;any action, suit or proceeding asserting a claim arising pursuant to any provision of the DGCL, the Bioventus charter,
the Bioventus bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&nbsp;any action, suit or proceeding asserting a claim governed by the internal affairs doctrine. Nothing in the Bioventus
charter or the Bioventus bylaws would preclude stockholders that assert claims under the Exchange Act from bringing such claims in federal court to the extent the Exchange Act confers exclusive federal jurisdiction over such claims, subject to
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all Securities Act actions.
Accordingly, both state and federal courts have jurisdiction to entertain such claims. The Bioventus charter provides that the U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under
the Securities Act. However, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forum selection provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the
combined company or its directors, officers or other employees, which may discourage such lawsuits. While Delaware courts have determined that such forum selection provisions are facially valid, a stockholder may nevertheless seek to bring such a
claim arising under the Securities Act against the combined company and its directors, officers or other employees in a venue other than in the U.S. federal district courts. In such instance, the combined company would expect to vigorously assert
the validity and enforceability of these forum selection provisions. This may require further significant additional costs associated with resolving the dispute in other jurisdictions, and there can be no assurance that the forum selection
provisions will be enforced by a court in those other jurisdictions, any of which could seriously harm the combined company&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Relating to Bioventus&#146; Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; business may continue to experience adverse impacts as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic spread around the
world and in the U.S. and, more recently, new variants of the virus have emerged, some of which have shown to be more contagious. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had widespread, rapidly evolving and unpredictable
impacts on global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to minimize the spread of the virus and ongoing effects of the pandemic, including social
distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of business, work from home, supply chain logistical changes and other measures, which have caused global business disruptions
and significant volatility in U.S. and international debt and equity markets. Bioventus&#146; business, results of operations and financial condition have been, and may continue to be, materially impacted due to the decrease in patient visits and
elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;</FONT></FONT> orders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Bioventus&#146; business will
depend on many factors, including, but not limited to, the duration and severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability and effectiveness of vaccines to combat
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on Bioventus&#146; partners, patients and communities in which Bioventus operates, all
of which continue to be uncertain. For example, there has been a decrease in patient visits to hospitals due to risk and fear of exposure to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> as well as decreases in, or temporary moratoriums on,
elective procedures, which may be <FONT STYLE="white-space:nowrap">re-imposed</FONT> in the future. In addition to lower sales, Bioventus has experienced decreased costs as a result of the pandemic including declines in travel and lower compensation
related expenses. Bioventus has also implemented other various cost reduction initiatives and measures to safeguard liquidity, refer to &#147;Bioventus&#146; Management&#146;s Discussion and Analysis&#148; for further details on the impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> on Bioventus&#146; business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> disruptions
continue to adversely impact Bioventus&#146; business, results of operations and financial condition, it may also have the effect of heightening many of the other risks described in &#147;Risk Factors&#148; including risks relating to
Bioventus&#146; ability to successfully commercialize new developed or acquired products or therapies, consolidation in the healthcare industry, disruptions in the supply or manufacturing of Bioventus&#146; products or their components, intensified
pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of Bioventus&#146; numerous contractual relationships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is highly dependent on a limited number of products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; pain treatment and joint preservation products accounted for 53%, 54% and 49% of Bioventus&#146; total revenue for the years ended
December&nbsp;31, 2020, 2019 and 2018, respectively. Bioventus expects that sales of such products will continue to account for a substantial portion of its revenue, and therefore, its ability to execute its growth strategy and maintain
profitability will depend upon the continued demand for these products. In addition, Bioventus&#146; supply and distribution agreements for Durolane, <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> and SUPARTZ FX are subject to renewal and their
terms end in December 2115, February 2026 and December 2028, respectively. If the supply and distribution agreements for any of Bioventus&#146; HA viscosupplementation therapies were terminated, its revenue would be impaired. If Bioventus&#146; pain
treatment and joint preservation products fail to maintain their market acceptance for any reason, its business, results of operations and financial condition may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; long-term growth depends on its ability to develop, acquire and commercialize new products, line extensions or expanded indications.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; industry is highly competitive and subject to rapid change and technological advancements. Therefore, it is important to
Bioventus&#146; business that it continues to introduce new products and/or enhance its existing product offerings through line extensions or expanded indications. Developing, acquiring and commercializing products is expensive, time-consuming and
could divert management&#146;s attention away from Bioventus&#146; existing business. Even if Bioventus is successful in developing additional products, the success of any new product offering or enhancements to existing products will depend on
several factors, including its ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">properly identify and anticipate the needs of healthcare professionals and patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and introduce new products, line extensions and expanded indications in a timely manner;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distinguish Bioventus&#146; products from those of its competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoid infringing upon the intellectual property rights of third-parties and maintain necessary intellectual
property licenses from third-parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical
trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain clearance or approval, if required, from the FDA and other regulatory agencies, for such new products,
line extensions and expanded indications, and maintain full compliance with FDA and other regulatory requirements applicable to new devices or products or modifications of existing devices or products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide adequate training to potential users of Bioventus&#146; products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive adequate coverage and reimbursement for Bioventus&#146; products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain an effective and dedicated sales and marketing team. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus is unsuccessful in developing, acquiring and commercializing new products or enhancing its existing product offerings through line extensions and
expanded indications, Bioventus&#146; ability to increase its net sales may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Bioventus&#146; research and development efforts
may require a substantial investment of time and resources before Bioventus is adequately able to determine the commercial viability of a new product, technology, material or other innovation. Such efforts may not result in the development of a
viable product. In addition, even if Bioventus is able to successfully develop new active healing products, line extensions and expanded indications, these products may not produce sales in excess of the costs of development and they may be rendered
obsolete by changing customer preferences or the introduction by Bioventus&#146; competitors of products embodying new technologies or features. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may be unable to successfully commercialize newly developed or acquired products or therapies in the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commercial success of newly acquired or developed products, such as MOTYS, in the United States will depend upon the awareness and acceptance of such
products among the medical community, including physicians and patients. Market acceptance will depend on a number of factors, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the perceived advantages and disadvantages of such products over existing therapies and other competitive
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to secure and maintain adequate coverage, including obtaining a unique reimbursement code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which physicians prescribe the Company&#146;s products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support of the Company&#146;s new products and competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity concerning the Company&#146;s new products, Bioventus&#146; existing products or competing products and
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing and cost effectiveness of such new therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of Bioventus&#146; sales and marketing strategies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of third-party reimbursement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; efforts to educate the medical community about the benefits of newly acquired or developed products may require significant resources and
Bioventus may never be successful. If such newly acquired or developed products do not achieve an adequate level of acceptance by patients and physicians in the United States, its business, results of operations and financial condition may be
adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand for Bioventus&#146; existing portfolio of products and any new products, line extensions or
expanded indications depends on the continued and future acceptance of its products by physicians, patients, third-party payers and others in the medical community. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus cannot be certain that its existing portfolio of products and any new products, line extensions or expanded indications that it develops will achieve
or maintain market acceptance. With respect to Bioventus&#146; pain treatment and joint preservation products, third-party payers may be reluctant to continue to cover Bioventus&#146; HA viscosupplementation therapies at their current prices.
Further, new injectable therapies or oral medications may become available that help manage pain in a more convenient and/or cost effective manner than Bioventus&#146; HA viscosupplementation therapies. With respect to Bioventus&#146; BGS products,
new allograft, DBMs, synthetics, growth factors, or other enhancements to Bioventus&#146; existing implants may never achieve broad market acceptance, which can be affected by a lack of clinical acceptance of BGSs and technologies, introduction of
competitive treatment options which render BGSs and technologies too expensive or obsolete and difficulty training surgeons in the use of BGSs and technologies. Media reports or other negative publicity concerning both methods of tissue recovery
from donors and actual or potential disease transmission from donated tissue may limit widespread acceptance by the medical community of Bioventus&#146; allografts, growth factor and DBMs, whether directed at these products generally or
Bioventus&#146; products specifically. Unfavorable reports of improper or illegal tissue recovery practices by any participant in the industry, both in the United States and internationally, as well as incidents of improperly processed tissue
leading to transmission of disease, may broadly affect the rate of future tissue donation and market acceptance of allograft based technologies by the medical community. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Bioventus believes that even if the medical community generally accepts its existing portfolio of products and any new products, line extensions
or expanded indications, acceptance and recommendations by influential members of the medical community will be important to their broad commercial success. If the medical community does not broadly accept its products, Bioventus may not remain
competitive in the market, which could adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; commercial
success depends on its ability to differentiate the HA viscosupplementation therapies that it owns or distributes from alternative therapies for the treatment of OA. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; ability to achieve commercial success will, at least in part, depend on its ability to differentiate the HA viscosupplementation therapies that
Bioventus owns or distributes in such a way that physicians and patients will select them. The HA viscosupplementation therapies that Bioventus owns or distributes could face competition from steroid injections, other HA viscosupplementation
therapies, combination HA viscosupplementation/steroid therapies and alternate therapies for the treatment of OA, including those currently in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus expects that the HA viscosupplementation therapies that it owns or distributes will continue to be used primarily after oral analgesics and steroid
injections no longer provide adequate pain relief. In addition, the five and three injection HA viscosupplementation therapies that Bioventus distributes face competition from single injection therapies. Bioventus expects the three injection market
to decline by a projected 3.1% CAGR and the five injection market to decline by a projected 13.6% CAGR from 2019 to 2024. Due to the convenience associated with the single injection treatments, it is expected that these products will continue to
capture increasing market share of the HA viscosupplementation therapies market, which may adversely affect its business, results of operations and financial condition to the extent physicians and patients do not select Durolane, its single
injection HA viscosupplementation therapy. There are also a number of combination HA viscosupplementation/steroid therapies currently in development. The American Association of Orthopedic Surgeons (AAOS), since the release of their May 2013
clinical practice guidelines, does not recommend the use of HA for patients with symptomatic knee OA. The evidence for the AAOS recommendation is based on two or more high quality studies with consistent findings for recommending for or against the
intervention. The AAOS recommendation states that practitioners should follow a strong recommendation, such as this one, unless a clear </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and compelling rationale for an alternative approach is present. In May 2018, the Journal of the AAOS ranked the nonsteroidal anti-inflammatory drug naproxen the most effective in individual knee
OA treatment for improving both pain and function. To the extent that any additional therapies receive approval or alternative therapies receive positive support from the AAOS or other physician associations, they could reduce the market share
represented by HA viscosupplementation therapies for OA treatment and adversely affect Bioventus&#146; commercial success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus is unable to
differentiate the HA viscosupplementation therapies it owns or distributes from other therapies, physicians and patients may not be willing to use them or be willing to switch from existing therapies with which they are familiar. Once physicians
incorporate a particular treatment into their practice, they may not alter their practice absent compelling clinical evidence of safety and/or effectiveness and/or significant pricing reimbursement advantages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The proposed down-classification of <FONT STYLE="white-space:nowrap">non-invasive</FONT> bone growth stimulators, including Bioventus&#146; Exogen
system, by the FDA could increase future competition for bone growth stimulators and otherwise adversely affect the Company&#146;s sales of Exogen. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;17, 2020, FDA published a Federal Register notice announcing its proposal to reclassify <FONT STYLE="white-space:nowrap">non-invasive</FONT>
bone growth stimulators, such as Exogen, from Class&nbsp;III medical devices to Class&nbsp;II with special controls. Class&nbsp;III devices are subject to the most stringent regulatory pathway for approval for medical devices requiring, among other
things, rigorous clinical studies and <FONT STYLE="white-space:nowrap">pre-approval</FONT> manufacturing review. Class&nbsp;II devices may be cleared for marketing by the FDA under the 510(k) pathway if they are determined to be substantially
equivalent to a legally marketed predicate device. The 510(k) clearance process does not always require clinical testing, and is generally less onerous than the premarket approval process applicable to Class&nbsp;III devices. On September <FONT
STYLE="white-space:nowrap">8-9,</FONT> 2020, the Orthopaedic and Rehabilitation Devices Panel of the FDA Medical Devices Advisory Committee met and discussed FDA&#146;s proposal. The Panel, whose authority is
<FONT STYLE="white-space:nowrap">non-binding</FONT> but nonetheless considered by FDA, ultimately voted in favor of FDA&#146;s proposal to down-classify <FONT STYLE="white-space:nowrap">non-invasive</FONT> bone growth stimulators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has proposed that any final order would become effective 30 days after publication. While FDA has not yet finalized its proposal to down-classify <FONT
STYLE="white-space:nowrap">non-invasive</FONT> bone growth stimulators, should such down-classification occur now or in the future, Bioventus may face additional competition from new market entrants who would be able to pursue marketing
authorization through the 510(k) clearance pathway instead of the more onerous and burdensome PMA approval process. Class&nbsp;II devices that qualify as durable medical equipment under the Medicare program may also be eligible for inclusion in
Medicare&#146;s competitive bidding program for durable medical equipment, prosthetics, orthotics and supplies. As a result of down-classification, Exogen could face additional competition or Bioventus could receive lower reimbursement amounts for
Exogen, all of which could adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus is unable to achieve and
maintain adequate levels of coverage and/or reimbursement for its products, the procedures using its products, or any future products it may seek to commercialize, the commercial success of these products may be severely hindered. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; products are purchased by healthcare providers and customers who typically bill third-party payers, such as government programs, including
Medicare and Medicaid, or private insurance plans and healthcare networks, to cover all or a portion of the costs and fees associated with its products. Patients may also be billed for deductibles or
<FONT STYLE="white-space:nowrap">co-payments</FONT> in accordance with third-party payer policies. These third-party payers and insurers may deny reimbursement if they determine that a device or product provided to a patient or used in a procedure
does not meet applicable payment criteria or if the policyholder&#146;s healthcare insurance benefits are limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by law, the CMS, which
administers the Medicare program, has continued efforts to implement a competitive bidding program for selected durable medical equipment, prosthetic and orthotic supplies items paid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for by the Medicare program. In this program, Medicare rates are based on bid amounts for certain products in designated geographic areas, rather than the Medicare fee schedule amount. Bone
growth stimulation products like Bioventus&#146; Exogen system are currently exempt from this competitive bidding process, but may be eligible for inclusion if the FDA&#146;s proposed down-classification order becomes effective. Bioventus cannot
predict which products from any of its businesses may ultimately be affected or whether or when the competitive bidding process may be extended to its businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Limits put on reimbursement by third-party payers, whether foreign or domestic, governmental or commercial, could make it more difficult to buy
Bioventus&#146; products and substantially reduce, or possibly eliminate, patient access to its products. The healthcare industry in the United States has experienced a trend toward cost containment as government and private insurers seek to control
rising healthcare costs by imposing lower payment rates and negotiating reduced contract rates with providers and suppliers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no uniform policy
of coverage and reimbursement for Bioventus&#146; products or procedures using Bioventus&#146; products among third-party payers in the United States, and coverage and reimbursement for Bioventus&#146; products and procedures using Bioventus&#146;
products can differ significantly from payer to payer. Further, these payers regularly review new and existing technologies for possible coverage and can, without notice, deny or reverse coverage for new or existing products and treatments.
Third-party payers may not consider Bioventus&#146; products to be medically necessary or cost-effective for certain indications or <FONT STYLE="white-space:nowrap">off-label</FONT> uses or for all uses, and as a result, may not provide coverage for
the products. For example, Blue Cross Blue Shield Association&#146;s Evidence Street platform issued a report in April 2018 questioning the efficacy of Bioventus&#146; Exogen system, which resulted in several non-coverage policies being issued by
member organizations. Additionally, to the extent that third party payers decide that they are no longer willing to provide reimbursement for physician prescribed <FONT STYLE="white-space:nowrap">off-label</FONT> uses of Exogen, sales may be
negatively impacted. See <B><I></I></B>&#147;Risk Factors&#151;Risks Relating to Government Regulation.&#148; Bioventus may be subject to enforcement action if it engages in improper marketing or promotion of Bioventus&#146; products, and the misuse
or <FONT STYLE="white-space:nowrap">off-label</FONT> use of Bioventus&#146; products may harm its image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory
bodies if Bioventus is deemed to have engaged in the promotion of these uses, any of which could be costly to Bioventus&#146; business.<B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus may also be required to conduct expensive clinical studies to justify coverage and reimbursement and/or the level of reimbursement relative to other
therapies. In addition, should governmental authorities continue to enact legislation or adopt regulations that affect third-party coverage and reimbursement, access to Bioventus&#146; products and coverage by private or public insurers may be
reduced. If third-party payers or insurers that currently cover or reimburse Bioventus&#146; products or the procedures in which they are used limit their coverage or reimbursement in the future, or if other third-party payers or insurers issue
similar policies, this could impact Bioventus&#146; ability to sell its products, force Bioventus to lower the price it charges for Bioventus&#146; products, and adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; ability to market and sell its products could be harmed by future actions by CMS, other government agencies or private payers to diminish
payments to healthcare providers and suppliers. For example, the CMS, in its ongoing implementation of the Medicare program, periodically reviews medical study literature to determine how the literature addresses certain procedures and therapies in
the Medicare population. The impact that these assessments could have on Medicare or third-party payer coverage determinations for Bioventus&#146; products is currently unknown, but Bioventus cannot provide assurances that the resulting actions will
not restrict Medicare or other insurance coverage for its products. In addition, there can be no assurance that Bioventus or Bioventus&#146; distributors will not experience significant coverage or reimbursement impediments in the future related to
these or other programs and policies of CMS. Specifically, drug pricing reform legislation and executive orders, which could negatively affect the reimbursement rates paid for HA viscosupplements, have been issued by the White House and proposed and
enacted by Congress. For example, the Consolidated Appropriations Act, 2021(CAA), was signed into law on December&nbsp;27, 2020, and will expand price reporting obligations for manufacturers of certain products reimbursed under Medicare Part B
beginning, January&nbsp;1, 2022. CMS could utilize the new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pricing information to adjust Medicare payment for these products, which may include HA viscosupplements. Bioventus cannot predict how this law will be implemented by CMS, or the extent to which
this law, or other proposals that may be enacted in the future, may impact the Medicare payment available for its HA viscosupplements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Private payers may
adopt coverage decisions and payment amounts determined by CMS as guidelines in setting their coverage and reimbursement policies. In addition, for some governmental programs, such as Medicaid, coverage and reimbursement differs from state to state.
Medicaid payments to physicians, facilities and other providers are often lower than payments by other third-party payers and some state Medicaid programs may not pay an adequate amount for the procedures performed with Bioventus&#146; products, if
any payment is made at all. If CMS, other government agencies or private payers lower their reimbursement rates, or if any of the proposed drug pricing executive orders or legislative reforms are enacted, the commercial success of Bioventus&#146;
products may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; business may be adversely affected if consolidation in the healthcare industry leads to demand
for price concessions or if a GPO, third-party payers or other similar entities exclude Bioventus from being a supplier. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare costs have
risen significantly over the past decade, which has resulted in or led to numerous cost reform initiatives by legislators, regulators and third-party payers. Cost reform has triggered a consolidation trend in the healthcare industry to aggregate
purchasing power, which may increase requests for pricing concessions or risk vendor exclusion. For example, <FONT STYLE="white-space:nowrap">non-clinical</FONT> staff at hospitals are increasingly involved in the evaluation of products and product
purchasing decisions. In order for Bioventus to sell its products, Bioventus must convince such staff as well as physicians and hospitals that its products are attractive alternatives to competing products for use in surgical procedures.
Additionally, GPOs, independent delivery networks and large single accounts may continue to use their market power to consolidate purchasing decisions for physicians. Third-party payers may also continue to use their market power to reduce the
reimbursement for Bioventus&#146; products by increasing the rebates Bioventus is required to pay them when its products are covered, which may negatively impact its results. Bioventus expects that market demand, government regulation, third-party
coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among Bioventus&#146; customers, which may exert further downward
pressure on the prices of its products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus chooses to acquire or invest in new businesses, products or technologies, it may be unable to
complete these acquisitions or to successfully integrate them in a cost-effective and <FONT STYLE="white-space:nowrap">non-disruptive</FONT> manner. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; success depends on its ability to enhance and broaden its product offerings in response to changing customer demands, competitive pressures and
advances in technologies. Bioventus continues to search for viable acquisition candidates or strategic alliances that would expand its market sector and/or global presence, as well as additional products appropriate for current distribution
channels. Accordingly, Bioventus may in the future pursue the acquisition of, or joint ventures relating to, new businesses, products or technologies instead of developing them internally. For example, BV LLC entered into an Option and Equity
Purchase Agreement with CartiHeal providing, among other things, (i)&nbsp;BV LLC with an exclusive option to acquire 100% of CartiHeal&#146;s shares, or the Call Option, and (ii)&nbsp;CartiHeal with a put option that would require BV LLC to purchase
100% of CartiHeal&#146;s shares, or the Put Option, in each case pursuant to the terms and subject to the conditions set forth in the Option and Equity Purchase Agreement and as described above. See &#147;Description of Bioventus&#146;
Business&#151;Development and Clinical Pipeline&#151;Treatment of Cartilage for Osteochondral defects&#151;CartiHeal (developer of <FONT STYLE="white-space:nowrap">Agili-C)</FONT> investment and option and equity purchase agreement.&#148; Other
risks involving potential future and completed acquisitions and strategic investments include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with conducting due diligence; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">problems integrating the purchased technologies, products or business operations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to achieve the anticipated synergies and overpaying for acquisitions or unanticipated costs associated
with acquisitions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">invalid net sales assumptions for potential acquisitions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issues maintaining uniform standards, procedures, controls and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s attention from Bioventus&#146; core business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse effects on existing business relationships with suppliers, distributors and customers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with entering new markets in which Bioventus has limited or no experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential loss of key employees of acquired businesses; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased legal, accounting and compliance costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus competes with other companies for these opportunities, and it may be unable to consummate such acquisitions or joint ventures on commercially
reasonable terms, or at all. In addition, acquired businesses may have ongoing or potential liabilities, legal claims (including tort and/or personal injury claims) or adverse operating issues that Bioventus fails to discover through due diligence
prior to the acquisition. Even if Bioventus is aware of such liabilities, claims or issues, it may not be able to accurately estimate the magnitude of the related liabilities and damages. In particular, to the extent that prior owners of any
acquired businesses or properties failed to comply with or otherwise violated applicable laws or regulations, failed to fulfill their contractual obligations to their customers, or failed to satisfy legal obligations to employees or third parties,
we, as the successor, may be financially responsible for these violations and failures and may suffer reputational harm or otherwise be adversely affected. Acquisitions also frequently result in the recording of goodwill and other intangible assets
which are subject to potential impairment in the future that could harm Bioventus&#146; financial results. If Bioventus were to issue additional equity in connection with such acquisitions, this may dilute its stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pricing pressure from Bioventus&#146; competitors or hospitals may affect its ability to sell its products at prices necessary to support its current
business strategies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medical device companies, healthcare systems and GPOs have intensified competitive pricing pressure as a result of industry
trends and new technologies. Purchasing decisions are gradually shifting to hospitals, IDNs and other hospital groups, with surgeons and other physicians increasingly acting only as &#147;employees.&#148; Changes in the purchasing behavior of
hospitals or the amount third-party payers are willing to reimburse Bioventus&#146; customers for procedures using its products, including those as a result of healthcare reform initiatives, could create additional pricing pressure on Bioventus. In
addition to these competitive forces, Bioventus continues to see pricing pressure as hospitals introduce new pricing structures into their contracts and agreements, including fixed price formulas, capitated pricing and episodic or bundled payments
intended to contain healthcare costs. If such trends continue to drive down the prices Bioventus is able to charge for its products, its profit margins will shrink, adversely affecting its business, results of operations and financial condition.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus fails to successfully enter into purchasing contracts for its BGS products or engage in contract bidding processes internationally,
Bioventus may not be able to receive access to certain hospital facilities and its sales may decrease. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the hospital
facilities where physicians treat patients with Bioventus&#146; BGS products typically require Bioventus to enter into purchasing contracts. The process of securing a satisfactory contract can be lengthy and time-consuming and require extensive
negotiations and management time. In certain international jurisdictions, from time to time, certain institutions require Bioventus to engage in a contract bidding process in the event that such institutions are considering making purchase
commitments that exceed specified cost thresholds, which vary by jurisdiction. These processes are only open at certain periods of time, and Bioventus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be successful in the bidding process. If Bioventus does not receive access to hospital facilities through these contracting processes or otherwise, or if Bioventus is unable to secure
contracts or tender successful bids, its sales may stagnate or decrease and its operating results may be harmed. Furthermore, Bioventus may expend significant effort in these time-consuming processes and still may not obtain a purchase contract from
such hospitals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governments outside the United States may not provide coverage or reimbursement of Bioventus&#146; products, which may adversely
affect its business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acceptance of Bioventus&#146; products in international markets may depend, in
part, upon the availability of coverage and reimbursement within prevailing healthcare payment systems. Reimbursement and healthcare payment systems in international markets vary significantly by country, and include both government-sponsored
healthcare and private insurance. Bioventus&#146; products may not obtain international coverage and reimbursement approvals in a timely manner, if at all, which may require consumers desiring Bioventus&#146; products to purchase them directly.
Third-party coverage and reimbursement for Bioventus&#146; products or any of its products in development for which it may receive regulatory approval may not be available or adequate in international markets, which could adversely affect its
business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; future growth depends on physician awareness of the distinctive
characteristics, benefits, safety, clinical efficacy and cost-effectiveness of its products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus focuses its sales, marketing and training
efforts on physicians, surgeons and other health care professionals. The acceptance of Bioventus&#146; products depends in part on its ability to educate physicians as to the distinctive characteristics, benefits, safety, clinical efficacy and
cost-effectiveness of Bioventus&#146; products compared to alternative products, procedures and therapies. If physicians, surgeons or other healthcare professionals are not properly trained, they may misuse or ineffectively use Bioventus&#146;
products, which may result in unsatisfactory patient outcomes, patient injury, negative publicity or lawsuits against Bioventus. In addition, a failure to educate physicians, surgeons or other healthcare professionals regarding Bioventus&#146;
products may impair its ability to achieve market acceptance of its products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus competes and may compete in the future against other
companies, some of which have longer operating histories, more established products or greater resources than Bioventus does, which may prevent Bioventus from achieving increased market penetration or improved operating results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The medical device industry is characterized by intense competition, subject to rapid change and significantly affected by market activities of industry
participants, new product introductions and other technological advancements. Bioventus believes that its competitors have historically dedicated and will continue to dedicate significant resources to promote their products or to develop new
products. Bioventus has competitors in the United States and internationally, including major medical device and pharmaceutical companies, biotechnology companies and universities and other research institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These companies and other industry participants may develop alternative treatments, products or procedures that compete directly or indirectly with
Bioventus&#146; products. If alternative treatments are, or are perceived to be, superior to Bioventus&#146; products, sales of Bioventus&#146; products could be adversely affected and its results of operations could suffer. Bioventus&#146;
competitors may also develop and patent processes or products earlier than Bioventus can or obtain regulatory clearance or approvals for competing products more rapidly than it can, which could impair Bioventus&#146; ability to develop and
commercialize similar processes or products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of Bioventus&#146; current and potential competitors are major medical device and pharmaceutical
companies that have substantially greater financial, technical and marketing resources than Bioventus does, and they may succeed in developing products that would render Bioventus&#146; products obsolete or noncompetitive. It is also possible that
Bioventus&#146; competition will be able to leverage their large market share to set prices at a level below that which is profitable for Bioventus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of Bioventus&#146; competitors enjoy several competitive advantages over Bioventus, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater financial, human and other resources for product research and development, sales and marketing and
litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly greater name recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">control of intellectual property and more expansive portfolios of intellectual property rights, which could
impact future products under development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater experience in obtaining and maintaining regulatory clearances or approvals for products and product
enhancements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established relationships with hospitals and other healthcare providers, physicians, suppliers, customers and
third-party payers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional lines of products, and the ability to bundle products to offer greater incentives to gain a
competitive advantage; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more established sales, marketing and worldwide distribution networks. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potential introduction by competitors of products that compete with Bioventus&#146; existing or planned products may also make it difficult to market or
sell its products. In addition, the entry of multiple new products and competitors may lead some of Bioventus&#146; competitors to employ pricing strategies that could adversely affect the pricing of its products and pricing in the market generally.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, Bioventus&#146; ability to compete successfully will depend on its ability to develop proprietary products that reach the market in a timely
manner, receive adequate coverage and reimbursement from third-party payers, and are safer, less invasive and more effective than alternatives available for similar purposes. If Bioventus is unable to do so, its sales or margins could decrease,
which would adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The reclassification of Bioventus&#146; HA products from
medical devices to drugs in the United States by the FDA could negatively impact its ability to market these products and may require that Bioventus conduct costly additional clinical studies to support current or future indications for use of those
products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2018, the FDA published notice in the Federal Register announcing its intention to reconsider the appropriate
classification of HA intra-articular products intended for the treatment of pain in OA of the knee. Although HA products intended for this use have previously been regulated as medical devices, in its notice the FDA stated that current published
scientific literature supports that HA products achieve their primary intended purpose of treatment of pain in OA of the knee through biological action in the body which would require such products being classified as drugs. The FDA has encouraged
organizations intending to submit applications for changes in indications for use, formulation, or route of administration of their HA products to obtain from the FDA an informal or formal classification and jurisdiction determination as a drug or
device through a <FONT STYLE="white-space:nowrap">pre-request</FONT> for designation or request for designation, respectively, prior to submission of such application. However, the FDA to date has taken no action to reclassify HA products from
medical devices to drugs, or indicated what the potential ramifications would be for currently marketed HA products if a reclassification were to occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus currently markets three HA products: Durolane, <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> and SUPARTZ FX. If the reclassification of HA
products were to occur, the FDA may not allow Bioventus to continue to market these products without submitting additional clinical trial data, obtaining approval of a NDA for these products, or without otherwise complying with new conditions or
limitations on how those products are marketed. Clinical testing can take years to complete, can be expensive and carries uncertain outcomes, and there is no guarantee that would be able to successfully obtain and maintain any required regulatory
approvals. These new regulatory obligations could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result in increased regulation of Durolane, <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> and SUPARTZ FX and would subject these products to a new set of regulatory requirements to which they
have not been previously subject. These changes could ultimately increase Bioventus&#146; costs and adversely impact its business, results of operations and financial condition if they were to be implemented. See &#147;Risk Factors&#151;Risks
Relating to Bioventus&#146; Business.&#148; If Bioventus is unable to achieve and maintain adequate levels of coverage and/or reimbursement for Bioventus&#146; products, the procedures using Bioventus&#146; products, or any future products Bioventus
may seek to commercialize, the commercial success of these products may be severely hindered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; ability to maintain its competitive
position depends on its ability to attract, retain and motivate its senior management team and highly qualified personnel, and Bioventus&#146; failure to do so could adversely affect its business, results of operations and financial condition.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus believes that its continued success depends to a significant extent upon the skill, experience and performance of members of its senior
management team, who have been critical to the management of Bioventus&#146; operations and implementation of its strategy, as well as Bioventus&#146; ability to continue to attract, retain and motivate additional executive officers, and other key
employees and consultants, such as those individuals who are engaged in Bioventus&#146; research and development efforts. The replacement of any of Bioventus&#146; key personnel likely would involve significant time and costs and may significantly
delay or prevent the achievement of Bioventus&#146; business objectives and could therefore adversely affect its business, results of operations and financial condition. In addition, Bioventus does not carry any &#147;key person&#148; insurance
policies that could offset potential loss of service under applicable circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competition for experienced employees in the medical device industry
can be intense. To attract, retain and motivate qualified employees, Bioventus may utilize equity-based incentive awards such as employee stock options. If the value of such equity incentive awards does not appreciate as measured by the performance
of the price of Bioventus class A common stock and ceases to be viewed as a valuable benefit, Bioventus&#146; ability to attract, retain and motivate its employees could be adversely impacted, which could adversely affect its business, results of
operations and financial condition and/or require Bioventus to increase the amount Bioventus expends on cash and other forms of compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Since
inception, Bioventus&#146; history of operations has included periods of net losses, and Bioventus may not be able to sustain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
the years ended December&nbsp;31, 2020, 2019 and 2018, Bioventus had net income from continuing operations of $14.7&nbsp;million, $8.1&nbsp;million and $4.4&nbsp;million, respectively. Bioventus had an accumulated deficit of $144.5&nbsp;million and
$141.7&nbsp;million as of December&nbsp;31, 2020 and 2019, respectively. Bioventus&#146; ability to generate sufficient net sales from its existing products or from any of its products in development or products that Bioventus acquires, in order to
sustain profitability, is uncertain, and, since inception, Bioventus&#146; history of operations has previously included periods of net loss. Bioventus expects that its operating expenses will continue to increase as Bioventus continues to develop,
enhance and commercialize new products and incur additional operational costs associated with being a public company. Furthermore, Bioventus may not be able to sustain or increase profitability on an ongoing basis. If Bioventus does not achieve
sustained profitability, it will be more difficult for Bioventus to finance its business and accomplish its strategic objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus
fails to properly manage its anticipated growth, its business could suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has been growing steadily in recent periods, prior to the
impact of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Bioventus intends to continue to grow and may experience periods of rapid growth and expansion, which could place a significant additional strain on Bioventus&#146; limited personnel,
information technology systems and other resources. In particular, Bioventus&#146; sales force and distributor network requires significant management, training, financial and other supporting resources. Any failure by Bioventus to manage its growth
effectively could have an adverse effect on Bioventus&#146; ability to achieve its development and commercialization goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To achieve its revenue goals, Bioventus must also successfully increase supply of its products to meet
expected customer demand. In the future, Bioventus may experience difficulties with yields, quality control, component supply and shortages of qualified personnel, among other problems. These problems could result in delays in product availability
and increases in expenses. Any such delay or increased expense could adversely affect Bioventus&#146; ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future growth will
also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth will place a strain on Bioventus&#146; administrative and
operational infrastructure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to manage its operations and growth Bioventus will need to continue to improve its operational and management
controls, reporting and information technology systems and financial internal control procedures. If Bioventus is unable to manage its growth effectively, it may be difficult for Bioventus to execute its business strategy and its operating results
and business could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may not be able to strengthen Bioventus&#146; brand and the brands associated with Bioventus&#146; products.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus believes that strengthening the Bioventus brand and the brands associated with Bioventus&#146; products is critical to achieving
widespread acceptance of its products, particularly because of the rapidly developing nature of the market for active healing products. Promoting and positioning Bioventus&#146; brand will depend largely on the success of its marketing efforts and
the reliability of its products. Historically, Bioventus&#146; efforts to build its brand have involved marketing expenses, and it is likely that Bioventus&#146; future marketing efforts will require it to incur additional expenses. These brand
promotion activities may not yield increased sales and, even if they do, any sales increases may not offset the expenses Bioventus incurs to promote its brand and its products. If Bioventus fails to successfully promote and maintain its brand, or if
Bioventus incurs substantial expenses in an unsuccessful attempt to promote and maintain its brand and the brands of its products, Bioventus&#146; products may not be accepted by healthcare providers, which would cause Bioventus&#146; sales to
decrease and would adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus faces the risk of product liability
claims that could be expensive, divert management&#146;s attention and harm its reputation and business. Bioventus may not be able to maintain adequate product liability insurance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; business exposes Bioventus to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of its
products. This risk exists even if a product is cleared or approved for commercial sale by the FDA and manufactured in facilities regulated by the FDA or an applicable foreign regulatory authority. Bioventus&#146; products are designed to affect,
and any future products will be designed to affect, important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with Bioventus&#146; products or Bioventus&#146; products in development could result
in patient injury or death. The medical device industry has historically been subject to extensive litigation over product liability claims, and Bioventus cannot assure you that it will not face product liability claims. Bioventus may be subject to
product liability claims if its products or products in development cause, or merely appear to have caused, patient injury or death, even if such injury or death was as a result of supplies or components that are produced by third-party suppliers.
Product liability claims may be brought against Bioventus by consumers, healthcare providers or others selling or otherwise coming into contact with Bioventus&#146; products, among others. If Bioventus cannot successfully defend Bioventus against
product liability claims, Bioventus will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distraction of management&#146;s attention from Bioventus&#146; primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize existing or new products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for Bioventus&#146; products or, if cleared or approved, products in development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage to Bioventus&#146; business reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls or withdrawals from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to patients or other claimants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of net sales. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Bioventus has attempted and may continue to attempt to manage Bioventus&#146; product liability exposure by proactively recalling or withdrawing from
the market any defective products, any recall or market withdrawal of Bioventus&#146; products may delay the supply of those products to its customers and may impact its reputation. For example, Bioventus has in the past instituted a voluntary
recall for certain of its products. Bioventus cannot assure you that it will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of
preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by Bioventus&#146; competitors to harm its reputation for product safety or be perceived by patients as a safety
risk when considering the use of Bioventus&#146; products, either of which could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, although Bioventus has product liability and clinical study liability insurance that Bioventus believes is appropriate, this insurance is subject
to deductibles and coverage limitations. Bioventus&#146; current product liability insurance may not continue to be available to it on acceptable terms, if at all, and, if available, coverage may not be adequate to protect Bioventus against any
future product liability claims. If Bioventus is unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, Bioventus could be exposed to significant liabilities. A
product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fluctuations in the demand for Bioventus&#146; products or its inability to forecast demand accurately may influence the ability of Bioventus&#146;
suppliers to meet its delivery needs or result in excess product inventory. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is required by some of its contracts with suppliers of its
products to forecast future product demand or meet minimum purchase requirements. Bioventus&#146; supply agreement for Durolane is subject to a minimum order volume for each order and purchase amounts are based in part on forecasts. Bioventus is
also subject to certain annual minimum purchase requirements for <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> and SUPARTZ FX and purchase amounts are based on rolling annual forecasts. Bioventus&#146; forecasts are based on multiple assumptions
of product and market demand, which may cause Bioventus&#146; estimates to be inaccurate. If Bioventus underestimates demand, it may not have adequate supplies and could have reduced control over pricing, availability and delivery schedules with
Bioventus&#146; suppliers, which could prevent Bioventus from meeting increased customer or consumer demand and harm Bioventus&#146; business. However, if Bioventus overestimates its demand, it may have underutilized assets and may experience
reduced margins. If Bioventus does not accurately align its supplies with demand and/or fail to meet contractual minimum purchase requirements, its business, results of operations and financial condition may be adversely affected. For example, if
Bioventus fails to order the minimum order quantity of SUPARTZ FX from SKK Bioventus is obligated to pay SKK a specified fee equal to the number of units needed to meet the minimum order quantity multiplied by a specified percentage of the purchase
price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may face issues with respect to the supply of Bioventus&#146; products or their components, including increased costs, disruptions
of supply, shortages, contamination or mislabeling. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is dependent on a limited number of suppliers for Bioventus&#146; products and
components used in the manufacturing process of its products. Bioventus&#146; top three suppliers provide Bioventus with products and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
components that constituted 53%, 54% and 49% of total net sales for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively. Durolane, <FONT STYLE="white-space:nowrap">GELSYN-3</FONT>
and SUPARTZ FX are supplied by single-source third-party manufacturers. Bioventus&#146; Exogen system undergoes final assembly with components procured from various suppliers, including a transducer, which is a key component that is supplied by a
single source supplier. Bioventus may not be able to renew or enter into new contracts with its existing suppliers following the expiration of such contracts on commercially reasonable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the success of Bioventus&#146; bone graft substitutions product portfolio, depends on its suppliers continuing to have access to donated human
cadaveric tissue, as well as the maintenance of high standards in their processing methodology. The supply of such donors can fluctuate over time. Bioventus cannot be certain that its current suppliers who rely on allograft bone tissue, plus any
additional sources that its suppliers identify in the future, will be sufficient to meet its product needs. Bioventus&#146; dependence on a limited number of third-party suppliers and the challenges that they may face in obtaining adequate supplies
of allograft bone tissue involve several risks, including limited control over pricing, availability, quality and delivery schedules. Bioventus may be unable to find an alternative supplier in a reasonable time period or on commercially reasonable
terms, if at all, which would adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of Bioventus&#146; products or the
components used in its products are alleged or proven to include quality or product defects, including as a result of improper methods of tissue recovery from donors and disease transmission from donated tissue or illegal harvesting, Bioventus may
need to find alternate supplies, delay production of its products, discard or otherwise dispose of its products, or engage in a product recall, all of which may adversely affect its business, results of operations and financial condition. If
Bioventus&#146; products or the components in its products are affected by adverse prices or quality or other concerns, Bioventus may not be able to identify alternate sources of components or other supplies that meet its quality controls and
standards to sustain its sales volumes or on commercially reasonable terms, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus relies on a limited number of third-party
manufacturers to manufacture certain of Bioventus&#146; products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party manufacturers generally manufacture Durolane, <FONT
STYLE="white-space:nowrap">GELSYN-3,</FONT> SUPARTZ FX, Exogen components and Bioventus&#146; bone graft substitutions product portfolio. Bioventus has developed <FONT STYLE="white-space:nowrap">in-house</FONT> assembly capabilities for its Exogen
system. Bioventus and its third-party manufacturers are required to comply with the QSR which is a set of FDA regulations that establishes cGMP requirements for medical devices and covers the methods and documentation of the design, testing,
production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of such devices. Moreover, certain of Bioventus&#146; products may be <FONT STYLE="white-space:nowrap">re-classified</FONT> as drugs, and Bioventus is
planning to seek approval of a product pursuant to the BLA pathway. In each case, such products would be required to comply with the cGMP requirements that apply to drugs and biologics, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are a limited number of suppliers and third-party manufacturers that operate under FDA&#146;s QSR requirements and that have the necessary expertise and
capacity to manufacture Bioventus&#146; products or components for its products. As a result, it may be difficult for Bioventus to locate manufacturers for its anticipated future needs, and its anticipated growth could strain the ability of its
current suppliers and third-party manufacturers to deliver products, materials and components to Bioventus. Upon expiration of Bioventus&#146; existing agreements with these third-party manufacturers, Bioventus may not be able to renegotiate the
terms of its agreements with these third-party manufacturers on a commercially reasonable basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus or its third-party manufacturers
fail to maintain facilities in accordance with the FDA&#146;s QSR, the noncomplying party could lose the ability to manufacture Bioventus&#146; products on a commercial scale. Loss of this manufacturing capability would limit Bioventus&#146; ability
to sell its products, including Durolane, <FONT STYLE="white-space:nowrap">GELSYN-3,</FONT> SUPARTZ FX and Bioventus&#146; bone graft substitutions product portfolio, which are manufactured by single-source third-party manufacturers. See
&#147;Description of Bioventus&#146; Business&#151;Manufacturing and supply.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing of Bioventus&#146; products may not be easily transferable to other sites in the event
that any of its third-party manufacturers experience breakdown, failure or substandard performance of equipment, disruption of supply or shortages of, or quality issues with, components of Bioventus&#146; products and other supplies, labor problems,
power outages, adverse weather conditions, natural disasters, global pandemics, such as <FONT STYLE="white-space:nowrap">COVID-19,</FONT> or the need to comply with environmental and other directives of governmental agencies. From time to time, a
third-party manufacturer may experience financial difficulties, bankruptcy or other business disruptions, which could disrupt Bioventus&#146; supply of finished goods or require that Bioventus incur additional expense by providing financial
accommodations to the third-party manufacturer or taking other steps to seek to minimize or avoid supply disruption, such as establishing a new third-party manufacturing arrangement with another provider. The loss of any of these third-party
manufacturers or the failure for any reason of any of these third-party manufacturers to fulfill their obligations under their agreements with Bioventus, including a failure to meet Bioventus&#146; quality controls and standards, may result in
disruptions to Bioventus&#146; supply of finished goods. Bioventus may be unable to locate an additional or alternate third-party manufacturing arrangement that meets Bioventus&#146; quality controls and standards in a timely manner or on
commercially reasonable terms, if at all. If this occurs, its business, results of operations and financial condition will be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus&#146; facilities are damaged or become inoperable, Bioventus will be unable to continue to research, develop and manufacture its products
and, as a result, its business, results of operations and financial condition may be adversely affected until Bioventus is able to secure a new facility. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus does not have redundant facilities for the final assembly of its Exogen system. Bioventus&#146; other facilities and equipment would be costly to
replace and could require substantial lead-time to repair or replace. Bioventus&#146; facilities may be harmed or rendered inoperable by natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters, including, but not limited to, tornadoes,
flooding, fire and power outages. Such disasters may render it difficult or impossible to manufacture and commercialize Bioventus&#146; products and conduct its research and development activities for new products, line extensions and expanded
indications. The inability to perform those activities, combined with Bioventus&#146; limited inventory of supplies, components and finished product, may result in the inability to continue manufacturing or supplying Bioventus&#146; products during
such periods and the loss of customers or harm to Bioventus&#146; reputation. Although Bioventus possesses insurance for damage to its facilities and the disruption of its business, this insurance may not be sufficient to cover all of
Bioventus&#146; potential losses and this insurance may not continue to be available to Bioventus on acceptable terms, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus
fails to maintain its numerous contractual relationships, its business, results of operations and financial condition could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is party to numerous contracts in the normal course of its business, including its supply and distribution agreements for Durolane, which has a
current term expiring in December 2115, <FONT STYLE="white-space:nowrap">GELSYN-3,</FONT> which has a current term expiring in February 2026, and SUPARTZ FX, which has a current term expiring in December 2028. Bioventus has contractual relationships
with suppliers, distributors and agents, as well as service providers. In the aggregate, these contractual relationships are necessary for Bioventus to operate its business. From time to time, Bioventus amends, terminates or negotiates its
contracts. Bioventus may also periodically be subject to, or make claims of breach of contract, or threaten legal action relating to Bioventus&#146; contracts. These actions may result in litigation. At any one time, Bioventus has a number of
negotiations under way for new or amended commercial agreements. Bioventus devotes substantial time, effort and expense to the administration and negotiation of contracts involved in Bioventus&#146; business. However, these contracts may not
continue in effect past their current term or Bioventus may not be able to negotiate satisfactory contracts in the future with current or new business partners, which may adversely affect its business, results of operations and financial condition.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus is unable to manage, train, maintain and grow its direct sales team and network of
independent distributors, Bioventus may not be able to generate anticipated sales or it may be subject to regulatory or enforcement action. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; operating results are directly dependent upon the sales and marketing efforts of not only its direct sales team, but also its independent
distributors. If Bioventus&#146; direct sales team or independent distributors fail to adequately promote, market and sell its products, its sales could significantly decrease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus faces significant challenges and risks in managing its geographically dispersed distribution network and retaining the individuals who make up that
network. If any members of Bioventus&#146; direct sales team were to leave Bioventus, or if any of its independent distributors were to cease to do business with Bioventus, Bioventus&#146; sales could be adversely affected. In such a situation,
Bioventus may need to seek alternative independent distributors or increase its reliance on its direct sales team, which may not prevent Bioventus&#146; sales from being adversely affected. If a member of Bioventus&#146; direct sales team or
independent distributor were to depart and be retained by one of its competitors, Bioventus may be unable to prevent them from helping competitors solicit business from its existing customers, which could further adversely affect Bioventus&#146;
sales. Because of the competition for their services, Bioventus may be unable to recruit or retain additional qualified independent distributors or to hire additional direct sales team members to work with Bioventus on favorable or commercially
reasonable terms, if at all. Failure to hire or retain qualified members of its direct sales team or independent distributors would prevent Bioventus from maintaining or expanding its business and generating sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus launches new products or increase its marketing efforts with respect to existing products, it will need to expand the reach of Bioventus&#146;
marketing and sales networks. Bioventus&#146; future success will depend largely on its ability to continue to hire, train, retain and motivate skilled members of its direct sales team and independent distributors with significant technical
knowledge in active healing products. New hires require training and take time to achieve full productivity. If Bioventus fails to train new hires adequately, or if Bioventus experiences high turnover in its sales force in the future, Bioventus
cannot be certain that new hires will become as productive as may be necessary to maintain or increase its sales. Further, if Bioventus is unable to adequately train new hires and/or members of Bioventus&#146; direct sales team, if new hires and/or
members of Bioventus&#146; direct sales team engage in practices such as the promotion of unapproved or <FONT STYLE="white-space:nowrap">off-label</FONT> uses of its devices or if new hires and/or members of its direct sales team assist with the
reimbursement process in a manner that results in false or fraudulent claims for reimbursement being submitted to government or private payers, Bioventus may be subject to investigations or regulatory or enforcement actions by governmental
authorities or third party payers for reasons such as the promotion of unapproved or <FONT STYLE="white-space:nowrap">off-label</FONT> uses of Bioventus&#146; devices, inappropriate actions and involvement in the reimbursement process, or
inappropriate completion of reimbursement forms. See &#147;Risk Factors&#151;Risks Relating to Government Regulation.&#148; Bioventus may be subject to enforcement action if it engages in improper claims submission practices and resulting audits or
denials of Bioventus&#146; claims by government agencies could reduce Bioventus&#146; net sales or profits.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus is unable to expand its
sales and marketing capabilities domestically and internationally, it may not be able to effectively commercialize Bioventus&#146; products, which would adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Actual or attempted breaches of security, unauthorized disclosure of information, denial of service attacks or the perception that personal and/or other
sensitive or confidential information in Bioventus&#146; possession or control is not secure, could result in a material loss of business, substantial legal liability or significant harm to Bioventus&#146; reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus receives, collects, processes, use and stores a large amount of information, including personally identifiable, protected health and other sensitive
and confidential information. This data is often accessed by Bioventus through transmissions over public and private networks, including the Internet. The secure transmission of such information over the Internet and other mechanisms is essential to
maintain confidence in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bioventus&#146; Information Technology (IT) systems. Despite the privacy and security measures Bioventus has in place to ensure compliance with applicable laws, regulations and contractual
requirements, Bioventus&#146; facilities and systems, and those of Bioventus&#146; third-party vendors and service providers, are vulnerable to privacy and security incidents including, but not limited to, computer hacking, breaches, acts of
vandalism or theft, computer viruses and other malware, including ransomware or other forms of cyber-attack, misplaced or lost data, programming and/or human errors or other similar events. A party, whether internal or external, that is able to
circumvent Bioventus&#146; security systems could, among other things, misappropriate or misuse sensitive or confidential information, user information or other proprietary information, or cause significant interruptions in Bioventus&#146;
operations. Internal or external parties have and will continue to attempt to circumvent Bioventus&#146; security systems, and Bioventus expects that it may in the future experience external attacks on its network, such as, reconnaissance probes,
denial of service attempts, malicious software attacks and phishing attacks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the techniques used to circumvent security systems can be highly
sophisticated and change frequently, often are not recognized until launched against a target and may originate from less regulated and remote areas around the world, Bioventus may be unable to proactively address all possible techniques or
implement adequate preventive measures for all situations. Recent, well-publicized attacks on prominent companies have resulted in the theft of significant amounts of sensitive and personal information and demonstrate the sophistication of the
perpetrators and magnitude of the threat posed to companies across the nation, including the health care industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If someone is able to circumvent or
breach Bioventus&#146; security systems, they could steal any information located therein or cause interruptions to its operations. Security breaches or attempts thereof could also damage Bioventus&#146; reputation and expose Bioventus to a risk of
monetary loss and/or litigation, fines and sanctions. Bioventus also faces risks associated with security breaches affecting third parties that conduct business with Bioventus or its customers and others who interact with its data. While Bioventus
maintains insurance that covers certain security and privacy breaches, it may not carry appropriate insurance or maintain sufficient coverage to compensate for all potential liability. Additionally, the costs incurred to remediate any data security
or privacy incident could be substantial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus cannot assure you that its third-party service providers with access to Bioventus&#146; or its
customers&#146;, suppliers&#146;, trial patients&#146;, and employees&#146; personally identifiable and other sensitive or confidential information in relation to which Bioventus is responsible will not breach contractual obligations imposed by
Bioventus, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on Bioventus&#146; business including putting Bioventus in breach of its obligations under privacy laws and regulations
and/or which could in turn adversely affect its business, results of operations and financial condition. While Bioventus attempts to address the associated risks by performing security assessments and detailed due diligence, it cannot assure you
that these contractual measures and Bioventus&#146; own privacy and security-related safeguards will protect it from the risks associated with the third-party processing, storage and transmission of such information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure of a key information technology and communication system, process or site could adversely affect its business, results of operations and
financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus relies extensively on information technology and communication systems and software and hardware products,
including those of external providers, to conduct business. These systems and software and hardware impact, among other things, ordering and managing components of Bioventus&#146; products from suppliers, shipping products to customers on a timely
basis, processing transactions, coordinating its sales activities across all of its products, summarizing and reporting results of operations, complying with regulatory, legal or tax requirements, data security and other processes necessary to
manage its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite any precautions Bioventus may take, Bioventus&#146; systems and software and hardware could be exposed to damage or
interruption from circumstances beyond its control, such as fire, natural disasters, systems failures, power outages, cyber-attacks, terrorism, energy loss, telecommunications failure, security breaches and attempts
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof, computer viruses and similar disruptions affecting the global Internet. Although Bioventus has taken steps to prevent system failures and have
<FONT STYLE="white-space:nowrap">back-up</FONT> systems and procedures to prevent or reduce disruptions, such steps may not prevent an interruption of services and Bioventus&#146; disaster recovery planning may not be adequate or account for all
contingencies. Additionally, Bioventus&#146; insurance may not adequately compensate Bioventus for all losses or failures that may occur. If Bioventus&#146; systems or software and hardware are damaged or cease to function properly and
Bioventus&#146; business continuity plans do not effectively compensate on a timely basis, Bioventus may suffer interruptions in Bioventus&#146; operations, which could adversely affect its business, results of operations and financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will need to improve and upgrade Bioventus&#146; systems and infrastructure as Bioventus&#146; operations grow in scale in order to maintain
the reliability and integrity of Bioventus&#146; systems and infrastructure. The expansion of Bioventus&#146; systems and infrastructure will require Bioventus to commit substantial financial, operational and technical resources before the volume of
Bioventus&#146; business increases, with no assurance that the volume of business will increase. Any service outages or delays due to the installation of any new or upgraded technology (and customer issues therewith), or the impact on the
reliability of Bioventus&#146; data from any new or upgraded technology could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; business subjects Bioventus to economic, political, regulatory and other risks associated with international sales and operations that
could adversely affect its business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since Bioventus sells Bioventus&#146; products in many
different jurisdictions outside the United States, Bioventus&#146; business is subject to risks associated with conducting business internationally. Bioventus anticipates that net sales from international operations will continue to represent a
portion of Bioventus&#146; total net sales. In addition, a number of Bioventus&#146; third-party manufacturing facilities and suppliers of Bioventus&#146; products are located outside the United States. Accordingly, Bioventus&#146; future results
could be harmed by a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customers in some foreign countries potentially having longer payment cycles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disadvantages of competing against companies from countries that are not subject to U.S. laws and regulations,
including the U.S. Foreign Corrupt Practices Act (FCPA), regulations of the U.S. Office of Foreign Assets Controls, and U.S. anti-money laundering regulations, as well as exposure of Bioventus&#146; foreign operations to liability under these
regulatory regimes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">training of third-parties on Bioventus&#146; products and the procedures in which they are used;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for and greater difficulty enforcing Bioventus&#146; intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements, export licensing requirements or other
restrictive actions by foreign governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in staffing and managing widespread operations, including compliance with tax, employment, immigration
and labor laws for employees living or traveling abroad; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign taxes, including withholding of payroll taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">international regulators and third-party payers requiring additional clinical studies prior to approving or
allowing reimbursement for Bioventus&#146; products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payer reimbursement regimes, government payers or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting material supply or manufacturing capabilities abroad;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, global pandemics or
natural disasters including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, further expansion into new international markets may
require significant resources and the efforts and attention of Bioventus&#146; management and other personnel, which may divert resources from its existing business operations. As Bioventus expands its business internationally, Bioventus&#146;
success will depend, in large part, on its ability to anticipate and effectively manage these and other risks associated with its operations outside of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is exposed to foreign currency risks, which may adversely affect its business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">External events such as the withdrawal by the United Kingdom from the EU, global pandemics, the ongoing uncertainty regarding actual and potential shifts in
U.S. and foreign trade, economic and other policies and the passage of U.S. taxation reform legislation each have caused, and may continue to cause, significant volatility in currency exchange rates. Because some of Bioventus&#146; revenue,
expenses, assets and liabilities are denominated in foreign currencies, Bioventus is subject to exchange rate and currency risks. In preparing Bioventus&#146; financial statements, which are presented in U.S. dollars, Bioventus must convert all <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> dollar financial results to U.S. dollars at varying exchange rates. This may ultimately result in currency gain or loss, the outcome of which Bioventus cannot predict. Furthermore, to the extent that
Bioventus incurs expenses or earn revenue in currencies other than in U.S. dollars, any change in the values of those foreign currencies relative to the U.S. dollar could cause Bioventus&#146; profits to decrease or its products to be less
competitive against those of its competitors. To the extent that Bioventus&#146; current assets denominated in foreign currency are greater or less than its current liabilities denominated in foreign currencies, Bioventus faces potential foreign
exchange exposure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To minimize such exposures, Bioventus has entered, and may in the future enter, into derivative instruments related to forecasted
foreign currency transactions or currency hedges from time to time. Losses from changes in the value of the Euro or other foreign currencies relative to the U.S. dollar could adversely affect its business, results of operations and financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is subject to differing tax rates in several jurisdictions in which Bioventus operates, which may adversely affect its
business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will be subject to taxes in the United States and certain foreign
jurisdictions. Due to economic and political conditions, tax rates in various jurisdictions, including the United States, may be subject to change. Bioventus&#146; future effective tax rates could be affected by changes in the mix of earnings in
countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities and changes in tax laws or their interpretation. In addition, Bioventus may be subject to income tax audits by various tax jurisdictions.
Although Bioventus believes its income tax liabilities are reasonably estimated and accounted for in accordance with applicable laws and principles, an adverse resolution by one or more taxing authorities could have a material impact on the results
of Bioventus&#146; operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International tariffs applied to goods traded between the United States and China may adversely affect its business,
results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International tariffs, including tariffs applied to goods traded between the United States and
China, may adversely affect its business, results of operations and financial condition. Since the beginning of 2018, there has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been increasing rhetoric, in some cases coupled with legislative or executive action, from several U.S. and foreign leaders regarding the possibility of instituting tariffs against foreign
imports of certain materials. More specifically, in March and April of 2018, the U.S. and China applied tariffs to certain of each other&#146;s exports. The institution of trade tariffs both globally and between the U.S. and China specifically
carries the risk of adversely affecting overall economic condition, which could have a negative impact on Bioventus as imposition of tariffs could cause an increase in the cost of Bioventus&#146; products and the components for Bioventus&#146;
products, specifically with respect to Bioventus&#146; Exogen system, which may adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The 2019 Credit Agreement contains financial and operating restrictions that may limit Bioventus&#146; access to credit. If Bioventus fails to comply
with financial or other covenants in the 2019 Credit Agreement, it may be required to repay indebtedness to its existing lenders, which may harm Bioventus&#146; liquidity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2019, Bioventus entered into a $250.0&nbsp;million credit and guaranty agreement, or the 2019 Credit Agreement, with Wells Fargo Bank
National Association, as administrative agent and collateral agent, and a syndicate of other entities as lenders. As of December&nbsp;31, 2020, Bioventus had outstanding indebtedness of $190.0&nbsp;million under its term loan (leaving
$49.9&nbsp;million available under Bioventus&#146; revolving credit facility after giving effect to $0.1&nbsp;million in an outstanding letter of credit). Bioventus is subject to certain covenants under the 2019 Credit Agreement, including, but not
limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a minimum interest coverage ratio and a maximum debt leverage ratio requirement as defined in Bioventus&#146;
credit agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the declaration or payment of certain distributions on or in respect of Bioventus&#146; equity
interests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on acquisitions, investments and certain other payments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on the incurrence of new indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on the incurrence of new liens on property or assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on transfers, sales and other dispositions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on entering into transactions with affiliates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on making any material change in any of Bioventus&#146; business objectives that could reasonably be
expected to have a material adverse effect on the repayment of Bioventus&#146; credit agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such indebtedness could have
significant consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring a substantial portion of Bioventus&#146; cash flows to be dedicated to debt service payments instead of
funding growth, working capital, capital expenditures, investments or other cash requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing Bioventus&#146; flexibility to adjust to changing business conditions or obtain additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposing Bioventus to the risk of increased interest rates as certain of Bioventus&#146; borrowings, including
borrowings under Bioventus&#146; term loan, are at variable rates, making it more difficult for Bioventus to make payments on Bioventus&#146; indebtedness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricting Bioventus from making strategic acquisitions or causing Bioventus to make <FONT
STYLE="white-space:nowrap">non-strategic</FONT> divestitures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting Bioventus to restrictive covenants that may limit Bioventus&#146; flexibility in operating
Bioventus&#146; business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limiting Bioventus&#146; ability to obtain additional financing for working capital, capital expenditures, debt
service requirements and general corporate or other purposes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Bioventus may not be able to comply with these financial covenants described above in the
future. In the absence of a waiver from Bioventus&#146; lenders, any failure by Bioventus to comply with these covenants in the future may result in the declaration of an event of default, which could adversely affect Bioventus&#146; business,
results of operations and financial position. See <I>&#147;</I>Bioventus&#146; Management&#146;s Discussion and Analysis&#151;Indebtedness.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uncertainty relating to the LIBOR calculation process and potential phasing out of LIBOR in the future may adversely affect Bioventus&#146; financing
costs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, the 2019 Credit Agreement utilizes the London Interbank Offered Rate (LIBOR), or various alternative methods set forth in the
2019 Credit Agreement to calculate interest on any borrowings. National and international regulators and law enforcement agencies have conducted investigations into a number of rates or indices known as &#147;reference rates.&#148; Actions by such
regulators and law enforcement agencies may result in changes to the manner in which certain reference rates are determined, their discontinuance or the establishment of alternative reference rates. In particular, on July&nbsp;27, 2017, the Chief
Executive of the United Kingdom Financial Conduct Authority (FCA), which regulates LIBOR, announced that the FCA will no longer persuade or compel banks to submit rates for the calculation of LIBOR after 2021 or, in certain cases, 2023, pursuant to
an updated announcement in November 2020. Such announcements indicate that the continuation of LIBOR on the current basis cannot and will not be guaranteed after such dates, as applicable, and it appears highly likely that LIBOR will be discontinued
or modified by 2021 or, in certain cases 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this time, it is not possible to predict the effect that these developments, any discontinuance,
modification or other reforms to LIBOR or any other reference rate, or the establishment of alternative reference rates may have on LIBOR, other benchmarks or LIBOR-based debt instruments. Uncertainty as to the nature of such potential
discontinuance, modification, alternative reference rates or other reforms could cause the interest rates calculated for the 2019 Credit Agreement to be materially different than expected, which could have a material adverse effect on
Bioventus&#146; financing costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to the high degree of uncertainty regarding the implementation and impact of the CARES Act and other
legislation related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> there can be no assurance as to the total amount of financial assistance Bioventus will receive or that Bioventus will be able to comply with the applicable terms and
conditions for retaining such assistance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was signed into
law, which is aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and generally supporting the U.S. economy. The CARES Act, among
other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest
deduction limitations. The CARES Act and similar legislation intended to provide assistance related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic also authorized $175.0&nbsp;billion in funding to be distributed by HHS to eligible
health care providers. This funding, known as the Provider Relief Fund, is designated to fund eligible healthcare providers&#146; healthcare-related expenses or lost revenues attributable to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> On
December&nbsp;27, 2020, the Consolidated Appropriations Act, 2021 was signed into law, which adds $3.0&nbsp;billion to the Provider Relief Fund. Payments from the Provider Relief Fund are subject to certain eligibility criteria, as well as reporting
and auditing requirements, but do not need to be repaid to the U.S. government if recipients comply with the applicable terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In reliance
on the CARES Act, Bioventus deferred its employer social security payroll tax payments from May 2020 until the remainder of the 2020 calendar year of which, 50% is deferred until December&nbsp;31, 2021, with the remaining 50% deferred until
December&nbsp;31, 2022. The Company has deferred $1.9&nbsp;million of payroll tax payments as of December&nbsp;31, 2020, half of which has been recorded in accrued liabilities and the remainder in other long-term liabilities on the condensed
consolidated balance sheet. Bioventus is in the process of analyzing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other provision of the CARES Act to determine the financial impact on Bioventus&#146; condensed consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, Bioventus received, without request, a $1.2&nbsp;million payment from the Provider Relief Fund from HHS. Bioventus determined that it complied
with the conditions to be able to keep and use the funds as reimbursement for health care related expenses and lost revenue attributable to the public health emergency resulting from <FONT STYLE="white-space:nowrap">COVID-19</FONT> and submitted to
HHS the required attestation to agree to the applicable terms and conditions of the Provider Relief Fund Phase I General Distribution. In July 2020, Bioventus applied for and received a second Provider Relief Fund payment totaling $2.9&nbsp;million,
which is subject to the same conditions as the initial payment. The payments were recorded as other income on the condensed consolidated statement of operations and comprehensive income (loss) for year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the high degree of uncertainty regarding the implementation of the CARES Act, the Consolidated Appropriations Act, 2021 and other stimulus legislation,
there can be no assurance that the terms and conditions of the Provider Relief Fund or other relief programs will not change or be interpreted in ways that affect Bioventus&#146; ability to comply with such terms and conditions in the future, which
could affect Bioventus&#146; ability to retain such assistance. Bioventus will continue to monitor its compliance with the terms and conditions of the Provider Relief Fund, including demonstrating that the distributions received have been used for
healthcare-related expenses or lost revenue attributable to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> If Bioventus is unable to comply with current or future terms and conditions, Bioventus&#146; ability to retain some or all of the
distributions received may be impacted, and Bioventus may be subject to actions including payment recoupment, audits and inquiries by governmental authorities, and criminal, civil or administrative penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; future capital needs are uncertain and Bioventus may need to raise additional funds in the future, and such funds may not be available
on acceptable terms or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus believes that its current cash and cash equivalents, in combination with the borrowing availability under
Bioventus&#146; credit facility and its expected cash from operations, will be sufficient to meet Bioventus&#146; projected operating requirements for the foreseeable future. However, Bioventus may seek additional funds from public and private stock
offerings, borrowings under Bioventus&#146; existing or new credit facilities or other sources in order to fund future initiatives related to the expansion of Bioventus&#146; business, which financing may not be available on acceptable or
commercially reasonable terms, if at all. For example, pursuant to the Option and Equity Purchase Agreement with CartiHeal and its shareholders, CartiHeal has a put option that, if validly exercised, would require BV LLC to purchase 100% of
CartiHeal&#146;s shares for $350.0&nbsp;million following pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <FONT STYLE="white-space:nowrap">Agili-C</FONT> device with a label consistent in
all respects with pivotal clinical trial success, pursuant to the terms and subject to the conditions of the Option and Equity Purchase Agreement. See <I>&#147;</I>Bioventus&#146; Management&#146;s Discussion and Analysis&#151;Strategic
transactions&#151;CartiHeal (developer of <FONT STYLE="white-space:nowrap">Agili-C)</FONT> investment and option and equity purchase agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, if Bioventus issues equity or debt securities to raise additional capital, its existing stockholders may experience dilution, and the new equity
or debt securities may have rights, preferences and privileges senior to those of Bioventus&#146; existing stockholders. In addition, if Bioventus raises additional capital through collaboration, licensing or other similar arrangements, it may be
necessary to relinquish valuable rights to Bioventus&#146; products, potential products or proprietary technologies, or grant licenses on terms that are not favorable to Bioventus. If Bioventus cannot raise capital on acceptable terms, it may not be
able to develop or enhance Bioventus&#146; products, execute Bioventus&#146; business plan, take advantage of future opportunities, or respond to competitive pressures, changes in Bioventus&#146; supplier relationships, or unanticipated customer
requirements. Any of these events could adversely affect its business, results of operations and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk factors listed below describe the risks Bioventus faces related to government regulation. The companies who manufacture or produce certain of the
products Bioventus distributes face similar risks with respect to government regulation relating to such products. If such suppliers are unable to comply with government regulations, they may not be able to continue to supply Bioventus with
products, which could adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; products and operations are
subject to extensive governmental regulation, and its failure to comply with applicable requirements could cause its business to suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
healthcare industry, and in particular the medical device industry, are regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies and authorities. The FDA and other U.S. and
foreign governmental agencies and authorities regulate and oversee, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design, development and manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">testing, labeling, content and language of instructions for use and storage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product safety; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing, sales and distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">premarket clearance and approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conformity assessment procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">record-keeping procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advertising and promotion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls and other field safety corrective actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">postmarket surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to
recur, could lead to death or serious injury; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">postmarket studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product import and export. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulations to which Bioventus is subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions
on Bioventus&#146; ability to carry on or expand its operations, higher than anticipated costs or lower than anticipated sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply
with applicable regulations could jeopardize Bioventus&#146; ability to sell its products and result in enforcement actions such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administrative or judicially imposed sanctions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated expenditures to address or defend such actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions, consent decrees or the imposition of civil penalties or fines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall or seizure of Bioventus&#146; products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">total or partial suspension of production or distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to grant pending or future clearances or approvals for Bioventus&#146; products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal or suspension of regulatory clearances or approvals; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">untitled letters or warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of Bioventus&#146; products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution of Bioventus or Bioventus&#146; employees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and harm Bioventus&#146; reputation, business, results of
operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, governmental authorities outside the United States have become increasingly stringent in their regulation
of medical devices, and Bioventus&#146; products may become subject to more rigorous regulation by non U.S. governmental authorities in the future. U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government regulations may be imposed in the
future that adversely affect its business, results of operations and financial condition. The European Commission has harmonized national regulations for the control of medical devices through European Medical Device Directives with which
manufacturers must comply. Under these new regulations, manufacturing plants must have received a full Quality Assurance Certification from a &#147;Notified Body&#148; in order to be able to sell products within the member states of the EU. This
certification allows manufacturers to stamp the products of certified plants with a &#147;CE&#148; mark. Products covered by European Commission regulations that do not bear the CE mark cannot be sold or distributed within the EU. Bioventus has
received certification for all of Bioventus&#146; manufacturing facilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may be subject to enforcement action if it engages in
improper claims submission practices and resulting audits or denials of Bioventus&#146; claims by government agencies could reduce Bioventus&#146; net sales or profits. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its Exogen system, Bioventus submits claims directly to, and receive payments directly from, the Medicare and Medicaid programs and private
payers. Therefore, Bioventus is subject to extensive government regulation, including detailed requirements for submitting claims under appropriate codes and maintaining certain documentation, including evidence that all medical necessity
requirements are met to support Bioventus&#146; claims. Billing for Bioventus&#146; Exogen system is complex, time-consuming and expensive, particularly for items and services provided to government healthcare program beneficiaries, such as Medicare
and Medicaid. Reimbursement claims may be adversely affected by improper completion of the CMN required in connection with Medicare claims for the Exogen system and Bioventus may be subject to investigations by governmental authorities or third
party payers and required to prove the validity of the claims or the authenticity of the signatures on the CMNs under investigation. Reimbursement claims may also be adversely affected by the promotion of Bioventus&#146; devices for unapproved or <FONT
STYLE="white-space:nowrap">off-label</FONT> uses or assistance with the reimbursement process that could result in false or fraudulent claims for reimbursement being submitted to government or private payers. Depending on the billing arrangement and
applicable law, Bioventus bills various payers, all of which may have different prior authorization, patient qualification and medical necessity requirements, as well as patients for any applicable <FONT STYLE="white-space:nowrap">co-payments</FONT>
or <FONT STYLE="white-space:nowrap">co-insurance</FONT> amounts. In addition, Bioventus may also face increased risk in Bioventus&#146; collection efforts, including potential write-offs of doubtful accounts and long collection cycles, any of which
could adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is also required to implement compliance procedures and
oversight, train and monitor Bioventus&#146; employees, appeal coverage and payment denials, and perform internal audits periodically to assess compliance with applicable laws and regulations as well as internal compliance policies and procedures.
Bioventus is required to report and return any overpayments received from government payers within 60 days of identification and exercise of reasonable diligence to investigate credible information regarding potential overpayments. Failure to
identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. See <I>&#147;</I>Risk Factors&#151;Risks Relating to Government Regulation.<B><I>&#148; </I></B>Bioventus is subject to federal,
state and foreign laws and regulations relating to Bioventus&#146; healthcare business, and could face substantial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
penalties if Bioventus is determined not to have fully complied with such laws, which would adversely affect its business, results of operations and financial condition.<B><I> </I></B>Moreover,
Medicare contractors and Medicaid agencies periodically conduct <FONT STYLE="white-space:nowrap">pre-</FONT> and post-payment reviews and other audits of claims and are under increasing pressure to more closely scrutinize healthcare claims and
supporting documentation. Bioventus may be subject to prepayment and post-payment reviews, as well as audits of claims in the future. Private payers may from time to time conduct similar reviews and audits. Any third-party payer reviews and audits
of Bioventus&#146; claims could result in material delays in payment, material recoupments, overpayments, claim denials, fines, revocations of billing privileges, bars on <FONT STYLE="white-space:nowrap">re-enrollment</FONT> in federal or state
healthcare programs, cancellation of Bioventus&#146; agreements or damage to Bioventus&#146; reputation, any of which would reduce its net sales and profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, in July of 2018 Bioventus became aware of allegations that certain of Bioventus&#146; sales personnel may have been completing Section B of the
CMN required in connection with Medicare claims for the Exogen system, which, under federal law, must be completed by the physician and/or physician staff. Together with Bioventus&#146; outside counsel, Ropes&nbsp;&amp; Gray LLP, Bioventus initiated
an investigation into these allegations, and Bioventus determined that the CMN forms for a portion of Medicare claims for the Exogen system were in fact improperly completed by Bioventus&#146; sales representatives, some of which also failed to meet
CMS coverage requirements. As a result of its findings, Bioventus made a self-disclosure on November&nbsp;30, 2018 to the OIG, under the Provider Self-Disclosure Protocol. Bioventus&#146; self-disclosure disclosed the extent of its findings relating
to the inappropriate completion of CMN forms by its sales personnel and offered to make repayment for such claims which failed to meet CMS coverage requirements and which Bioventus submitted to the Medicare program between October&nbsp;1, 2012 and
September&nbsp;30, 2018, the statutory period applicable to such conduct. The total value of impacted claims was $30.1&nbsp;million in the aggregate. In October 2019, Bioventus&#146; outside counsel received a letter from the Office of the United
States Attorney in the Middle District of North Carolina (USAO), stating that the USAO would be working with the OIG to resolve Bioventus&#146; self-disclosure. After settlement discussions with the USAO and OIG, on January&nbsp;25, 2021 Bioventus
reached a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which Bioventus&#146; sales representatives completed Section B of the CMN forms. On
February&nbsp;22, 2021, Bioventus finalized all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with Bioventus&#146; previous agreement in principle and which included releases from
associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type. Under the agreement, Bioventus resolved the potential liability related to Bioventus&#146; self-disclosure for
$3.6&nbsp;million, of which $2.4&nbsp;million had already been paid through Bioventus&#146; 2019 return of overpayments described previously, leaving a net payment to be made of $1.2&nbsp;million. Bioventus made payment of the $1.2&nbsp;million net
settlement amount due under the agreement on February&nbsp;23, 2021. The settlement amount noted above was recorded in the consolidated financial statements for the year ended December&nbsp;31, 2020. In connection with this settlement, Bioventus was
not subjected to any <FONT STYLE="white-space:nowrap">non-monetary</FONT> penalties, such as monitoring agreements or requirements to conduct audits and submit reports to the HHS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and
approvals could prevent Bioventus from commercializing its products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before Bioventus can market or sell a new medical device or other product or
a new use of or a claim for or significant modification to an existing medical device in the United States, Bioventus must obtain either clearance from the FDA under 510(k) pathway or approval of a PMA, unless an exemption applies. In the United
States, Bioventus has obtained 510(k) premarket clearance from the FDA to market products such as Signafuse Bioactive Bone Graft Putty, Interface Bioactive Bone Graft and Signafuse Mineralized Collagen Scaffold. Bioventus&#146; pain treatment and
joint preservation products, including Durolane, <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> and SUPARTZ FX, and its Exogen system, have obtained PMA approval. In the 510(k) clearance process, before a device may be marketed, the FDA must
determine that a proposed device is &#147;substantially equivalent&#148; to a legally-marketed &#147;predicate&#148; device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed
prior to May&nbsp;28, 1976 (preamendments device), a device that was originally on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. market pursuant to an approved PMA application and later downclassified, or a 510(k)-exempt device. To be &#147;substantially equivalent,&#148; the proposed device must have the same
intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate
device. Clinical data are sometimes required to support substantial equivalence. In the PMA process, the FDA must determine that a proposed product is safe and effective for Bioventus&#146; intended use based, in part, on extensive data, including,
but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for products that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable
devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Modifications to products that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to
products cleared through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#146;s 510(k) clearance process usually takes from three to twelve months,
but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from six to 18 months, or even longer, from the time the application is filed with the FDA. In addition, a
PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, Bioventus cannot assure you that any particular device will be approved or cleared by the FDA. Any delay or failure to obtain necessary
regulatory approvals could harm Bioventus&#146; business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any modification to one of Bioventus&#146; 510(k) cleared products that would constitute a
major change in its intended use, or any change that could significantly affect the safety or effectiveness of the device would require Bioventus to obtain a new 510(k) marketing clearance and may even, in some circumstances, require the submission
of a PMA application, if the change raises complex or novel scientific issues or the product has a new intended use. The FDA requires every manufacturer to make the determination regarding the need for a new 510(k) submission in the first instance,
but the FDA may review any manufacturer&#146;s decision. Bioventus may make changes to its 510(k)-cleared products in the future that it may determine do not require a new 510(k) clearance or PMA approval. If the FDA disagrees with Bioventus&#146;
decision not to seek a new 510(k) or PMA approval for changes or modifications to existing devices and requires new clearances or approvals, Bioventus may be required to recall and stop marketing its products as modified, which could require
Bioventus to redesign its products, conduct clinical trials to support any modifications, and pay significant regulatory fines or penalties. If there is any delay or failure in obtaining required clearances or approvals or if the FDA requires
Bioventus to go through a lengthier, more rigorous examination for future products or modifications to existing products than Bioventus had expected, its ability to introduce new or enhanced products in a timely manner would be adversely affected,
which in turn would result in delayed or no realization of revenue from such product enhancements or new products and could also result in substantial additional costs which could decrease Bioventus&#146; profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus may not be able to demonstrate to the FDA&#146;s satisfaction that the product or modification is
substantially equivalent to the proposed predicate device or safe and effective for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data from Bioventus&#146; preclinical studies and clinical trials may be insufficient to support clearance or
approval, where required; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing process or facilities Bioventus uses may not meet applicable requirements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or
take other actions, which may prevent or delay approval or clearance of Bioventus&#146; future products under development or impact its ability to modify its currently cleared or approved products on a timely basis. Even after clearance or approval
for Bioventus&#146; products is obtained, Bioventus and the products are subject to extensive postmarket regulation by the FDA, including with respect to advertising, marketing, labeling, manufacturing, distribution, import, export, and clinical
evaluation. For example, as a condition of approving a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PMA application, the FDA may require some form of post-approval study or post-market surveillance, whereby the applicant conducts a <FONT STYLE="white-space:nowrap">follow-up</FONT> study or
follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device.
The product labeling must be updated and submitted in a PMA supplement once results, including any adverse event data from the post-approval study, become available. Failure to conduct post-approval studies in compliance with applicable regulations
or to timely complete required post-approval studies or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm Bioventus&#146; business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is also required to timely file various reports with regulatory agencies. If these reports are not timely filed, regulators may impose sanctions and
sales of Bioventus&#146; products may suffer, and Bioventus may be subject to product liability or regulatory enforcement actions, all of which could harm Bioventus&#146; business. In addition, if Bioventus initiates a correction or removal for one
of its devices, issue a safety alert, or undertake a field action or recall to reduce a risk to health posed by the device, Bioventus may be required to submit a report to the FDA, and in many cases, to other regulatory agencies. Such reports could
lead to increased scrutiny by the FDA, other international regulatory agencies and Bioventus&#146; customers regarding the quality and safety of its devices and to negative publicity, including FDA alerts, press releases, or administrative or
judicial actions. Furthermore, the submission of these reports has been and could be used by competitors against Bioventus in competitive situations and cause customers to delay purchase decisions or cancel orders, which would harm Bioventus&#146;
reputation and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and state authorities have broad enforcement powers. Bioventus&#146; failure to comply with applicable regulatory
requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of
Bioventus&#146; products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions, partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer notifications or repair, replacement or refunds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing Bioventus&#146; requests for 510(k) clearance or PMA approvals or foreign regulatory approvals of new
products, new intended uses or modifications to existing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawals of current 510(k) clearances or PMAs or foreign regulatory approvals, resulting in prohibitions on
sales of Bioventus&#146; products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales and adversely affect its business, results of
operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA&#146;s and other regulatory authorities&#146; policies may change and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of Bioventus&#146; product candidates. If Bioventus is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or
if it is not able to maintain regulatory compliance as a result of a changing regulatory landscape, Bioventus may lose any marketing approvals or clearances that Bioventus has already obtained or fail to obtain new marketing approvals or clearances,
and Bioventus may not be able to achieve or sustain profitability, which would adversely affect Bioventus&#146; business, prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus also cannot predict the likelihood, nature or extent of government regulation that may arise from
future legislation or administrative or executive action, either in the United States or abroad. The results of the 2020 Presidential election may impact Bioventus&#146; business and industry. Moreover, the Trump administration took several
executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing
statutes through rule making, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these executive actions, including the Executive Orders, will be implemented, or whether they will be
rescinded or replaced under the Biden administration. The policies and priorities of an incoming administration are unknown and could materially impact the regulatory framework governing Bioventus&#146; products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Once obtained, Bioventus cannot guarantee that FDA or international product approvals will not be withdrawn or rescinded or that relevant regulatory
authorities will not require other corrective action, and any withdrawal, rescission or corrective action could materially affect Bioventus&#146; business and financial results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once obtained, marketing approval can be withdrawn by the FDA or comparable foreign regulatory authorities for a number of reasons, including the failure to
comply with ongoing regulatory requirements or the occurrence of unforeseen problems following initial approval. Regulatory authorities could also limit or prevent the manufacture or distribution of Bioventus&#146; products. Any regulatory
limitations on the use of Bioventus&#146; products or any withdrawal, suspension or rescission of approval by the FDA or a comparable foreign regulatory authority could have a material adverse effect on its business, financial condition, and results
of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislative or regulatory reforms, including those currently under consideration by FDA, could make it more difficult or costly for
Bioventus to obtain regulatory clearance or approval of any future products and to manufacture, market and distribute its products after clearance or approval is obtained, which could adversely affect its competitive position and materially affect
Bioventus&#146; business and financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted and introduced in Congress that could significantly
change the statutory provisions governing the regulatory clearance or approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA may change its clearance and approval policies, adopt additional
regulations or revise existing regulations, propose new reclassification orders, or take other actions, which may prevent or delay approval or clearance of Bioventus&#146; future products under development or impact Bioventus&#146; ability to market
or modify its currently cleared products on a timely basis. FDA and foreign regulations depend heavily on administrative interpretation, and Bioventus cannot assure you that future interpretations made by the FDA or other regulatory bodies, with
possible retroactive effect, will not adversely affect Bioventus. Additionally, any changes, whether in interpretation or substance, in existing regulations or policies, or any future adoption of new regulations or policies by relevant regulatory
bodies, could prevent or delay approval of Bioventus&#146; products. In the event Bioventus&#146; future, or current, products, including HA generally, are classified, or <FONT STYLE="white-space:nowrap">re-classified,</FONT> as human drugs,
combination products, or biologics by the FDA or an applicable international regulatory body, the applicable review process related to such products is typically substantially longer and substantially more expensive than the review process to which
they are currently subject as medical devices. In 2018, FDA publicly indicated its intent to consider HA products for certain indications as drugs and has indicated that sponsors of HA products who submit PMAs or PMA supplements for changes in
indications for use, formulation or route of administration should obtain an informal or formal classification and jurisdictional determination through a <FONT STYLE="white-space:nowrap">pre-request</FONT> for determination or request for
determination prior to submission. There exists uncertainty with respect to the final interpretation, implementation, and consequences of this development, and this or any other potential regulatory changes in approach or interpretation similar in
substance to those mentioned in this paragraph and affecting Bioventus&#146; products could materially impact its competitive position, business, and financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements
for clinical data and a longer review period, or could make it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take
to modernize the premarket notification pathway under Section&nbsp;510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates.
These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial
equivalence to predicate devices that are more than 10 years old. The FDA also announced that it intended to finalize guidance to establish a premarket review pathway for &#147;manufacturers of certain well-understood device types&#148; as an
alternative to the 510(k) clearance pathway and that such premarket review pathway would allow manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for
manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the FDA
solicited public feedback on its plans to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates, including whether the FDA should publish a list of devices that have been cleared on the basis of
demonstrated substantial equivalence to predicate devices that are more than 10 years old. The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older
devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the
extent to which any proposals, if adopted, could impose additional regulatory requirements on Bioventus that could delay its ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict Bioventus&#146; ability to maintain
its current clearances, or otherwise create competition that may negatively affect its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More recently, in September 2019, the FDA finalized the
aforementioned guidance to describe an optional &#147;safety and performance based&#148; premarket review pathway for manufacturers of &#147;certain, well-understood device types&#148; to demonstrate substantial equivalence under the 510(k)
clearance pathway, by demonstrating that such device meets objective safety and performance criteria established by the FDA, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate
devices in the clearance process. The FDA intends to maintain a list device types appropriate for the &#147;safety and performance based pathway&#148; and develop product-specific guidance documents that identify the performance criteria for each
such device type, as well as the testing methods recommended in the guidance, where feasible. The FDA may establish performance criteria for classes of devices for which Bioventus or Bioventus&#146; competitors seek or currently has received
clearance, and it is unclear the extent to which such performance standards, if established, could impact its ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect Bioventus&#146; business and its
products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance or approval for, manufacture,
market or distribute Bioventus&#146; products. Bioventus cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on Bioventus&#146; business in the future.
Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of Bioventus&#146; products; or additional record keeping.
Additionally, the implementation of the new EU MDR set to take full effect on May&nbsp;26, 2021 after a <FONT STYLE="white-space:nowrap">one-year</FONT> postponement due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, is expected
to change several aspects of the existing regulatory framework in Europe. Specifically, the EU MDR will require changes in the clinical evidence required for medical devices, post-market clinical <FONT STYLE="white-space:nowrap">follow-up</FONT>
evidence, annual reporting of safety information for Class&nbsp;III products, and <FONT STYLE="white-space:nowrap">bi-annual</FONT> reporting for Class&nbsp;II products, Unique Device Identification (UDI) for all products, submission of core data
elements to a European UDI database prior to placement of a device on the market, reclassification of medical devices, and multiple other labeling changes. While Bioventus will be able to continue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing its currently <FONT STYLE="white-space:nowrap">CE-marked</FONT> products in the EEA after the EU MDR enters into full effect and until the associated CE mark certificates expire,
acquiring approvals for new products or renewing Bioventus&#146; existing CE mark certificates once these expire could be more challenging and costly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; HCT/P products are subject to extensive government regulation and Bioventus&#146; failure to comply with these requirements could cause
its business to suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, Bioventus sells human tissue-derived BGSs, such as PureBone and OsteoAMP, which are referred to by
the FDA as human cells, tissues and cellular or tissue-based products, or HCT/Ps. In the U.S., Bioventus is marketing its HCT/Ps pursuant to Section&nbsp;361 of the PHSA and 21 CFR Part 1271 of FDA&#146;s regulations. Bioventus does not manufacture
these HCT/P products, but serve as a distributor for them. <FONT STYLE="white-space:nowrap">So-called</FONT> Section&nbsp;361 HCT/Ps are not currently subject to the FDA requirements to obtain marketing authorizations as long as they meet certain
criteria provided in FDA&#146;s regulations. HCT/Ps regulated as &#147;361 HCT/Ps&#148; are currently subject to requirements relating to registering facilities and listing products with the FDA, screening and testing for tissue donor eligibility,
cGTP, when processing, storing, labeling and distributing HCT/Ps, including required labeling information, stringent record keeping and adverse event reporting. If Bioventus or Bioventus&#146; suppliers fail to comply with these requirements,
Bioventus could be subject to FDA enforcement action, including, for example, warning letters, fines, injunctions, product recalls or seizures, and, in the most serious cases, criminal penalties. To be regulated as Section&nbsp;361 HCT/Ps, these
products must meet FDA&#146;s criteria to be considered &#147;minimally manipulated&#148; and intended for &#147;homologous use,&#148; among other requirements. HCT/Ps that do not meet the criteria to be considered Section&nbsp;361 HCT/Ps are
subject to the FDA&#146;s regulatory requirements applicable to medical devices, biologics or drugs. Device, biologic or drug HCT/Ps must comply both with the requirements exclusively applicable to Section&nbsp;361 HCT/Ps and, in addition, with
other requirements, including requirements for marketing authorization. For example, Section&nbsp;361 HCT/Ps do not require 510(k) clearance, PMA approval, approval of a BLA, or other premarket authorization from FDA before marketing. Except as
described below with regard to MOTYS, Bioventus believes its HCT/Ps are regulated solely under Section&nbsp;361 of the PHSA, and therefore, Bioventus has not sought or obtained 510(k) clearance, PMA approval, or licensure through a BLA for such
HCT/Ps. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA could disagree with Bioventus&#146; determination that these human tissue products are Section&nbsp;361 HCT/Ps and could determine that
these products are biologics requiring a BLA or medical devices requiring 510(k) clearance or PMA approval, and could require that Bioventus cease marketing such products and/or recall them pending appropriate clearance, approval or licensure from
the FDA. For example, the FDA&#146;s CDRH issued Bioventus a letter in March 2016 in which it asserted that OsteoAMP meets the definition of a medical device, and requested that Bioventus provide CDRH with information in support of its position that
OsteoAMP does not require 510(k) clearance or PMA approval. Bioventus provided CDRH with the requested information in support of this position in May 2016 and Bioventus has received no further inquiries to date. Bioventus believes that CDRH&#146;s
assertion is unfounded and inconsistent with a 2011 letter from the FDA concluding that OsteoAMP meets the criteria for regulation solely as a Section&nbsp;361 HCT/P. However, if the FDA were to disagree, and if Bioventus is otherwise unsuccessful
in asserting its position, the FDA may then require that Bioventus obtains 510(k) clearance or PMA approval and that it ceases marketing OsteoAMP and/or recall OsteoAMP unless and until Bioventus receives clearance or approval. If Bioventus has to
cease marketing and/or has to recall any of Bioventus&#146; BGSs products, including OsteoAmp, Bioventus&#146; net sales would decrease, which would adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCT/Ps that do not meet the criteria of Section&nbsp;361 are regulated under Section&nbsp;351 of the PHSA. Unlike Section&nbsp;361 HCT/Ps, HCT/Ps regulated as
&#147;351&#148; HCT/Ps are subject to premarket review and approval by the FDA. In November 2017, the FDA released a guidance document entitled &#147;Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue&#151;Based Products:
Minimal Manipulation and Homologous Use&#151;Guidance for Industry and Food and Drug Administration Staff.&#148; The guidance outlined the FDA&#146;s position that all lyophilized amniotic products are more than minimally manipulated and would
therefore require a BLA to be lawfully marketed in the United States. The guidance also indicated that the FDA would exercise enforcement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discretion, using a risk-based approach, with respect to the IND application and <FONT STYLE="white-space:nowrap">pre-market</FONT> approval requirements for certain HCT/Ps for a period of 36
months from the issuance date of the guidance to allow manufacturers to pursue its IND application. Under this approach, FDA indicated that high-risk products and uses could be subject to immediate enforcement action; at that time FDA has not
clearly stated what must happen by the end of its enforcement discretion period in order to avoid enforcement (i.e., whether a BLA must be approved by that time, or merely submitted). In July 2020, the FDA extended its period of enforcement
discretion to May&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the expiration of the enforcement discretionary period and FDA&#146;s decision not to further extend it,
Bioventus discontinued it limited marketing of MOTYS on May&nbsp;31, 2021, which had commenced as Bioventus pursued marketing authorization under a BLA for the product, to avoid being subject to enforcement on the grounds that Bioventus was
marketing a product at the same time Bioventus is investigating that product pursuant to an IND, in violation of FDA&#146;s prohibition on the preapproval promotion of an investigational product. In addition, Bioventus expects the cost to
manufacture Bioventus&#146; products will be higher than its other HCT/Ps because of the costs to comply with the more stringent requirements that apply to products regulated as biologics for which a BLA is required (and not just as Section&nbsp;361
HCT/Ps). These requirements include satisfying cGMP manufacturing standards and performing ongoing product testing. If Bioventus does receive BLA approval for this product, changes such as adding new indications, manufacturing changes and additional
labeling claims, will be subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA may in the future modify the scope of
its enforcement discretion with respect to Section&nbsp;361 HCT/Ps or change its position on which current or future products qualify as Section&nbsp;361 HCT/Ps, or determine that some or all of Bioventus&#146; HCT/P products should not have been
marketed under the FDA&#146;s policy of enforcement discretion. Any regulatory changes could have adverse consequences for Bioventus and make it more difficult or expensive for Bioventus to conduct its business by requiring <FONT
STYLE="white-space:nowrap">pre-market</FONT> clearance or approval and compliance with additional post-market regulatory requirements with respect to those products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical studies of Bioventus&#146; future products do not produce results necessary to support regulatory clearance or approval in the United States
or elsewhere, Bioventus will be unable to expand the indications for or commercialize these products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will likely need to conduct
additional clinical studies in the future to support new indications for Bioventus&#146; products or for clearances or approvals of new product lines, or for the approval of the use of Bioventus&#146; products in some foreign countries. Clinical
testing can take many years, can be expensive and carries uncertain outcomes. The initiation and completion of any of these studies may be prevented, delayed, or halted for numerous reasons. Conducting successful clinical studies requires the
enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and <FONT STYLE="white-space:nowrap">follow-up</FONT> depends on
many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical
trial investigators and support staff, proximity of patients to clinical sites, patient ability to meet the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged
from enrolling in Bioventus&#146; clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or <FONT STYLE="white-space:nowrap">follow-up</FONT> to assess the safety and effectiveness of Bioventus&#146;
products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in Bioventus&#146; clinical trials if they choose to participate
in contemporaneous clinical trials of competitive products. In addition, patients participating in clinical trials may die before completion of the trial or suffer adverse medical events unrelated to investigational products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, in late 2017 Bioventus began enrollment for the B.O.N.E.S. clinical study, a uniquely designed trial to further broaden the label of
Bioventus&#146; Exogen system to include a fuller range of bones that may be treated as fresh fractures in predisposed patients at risk of nonunion. The B.O.N.E.S clinical study design includes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospective inclusion of 3,000 Exogen-treated patients presenting certain risk factors observed over the course of 12 months. In April 2021, Bioventus received a letter from the FDA identifying
certain deficiencies in the PMA supplement for Exogen that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and endpoints from the B.O.N.E.S. study, and requests for <FONT
STYLE="white-space:nowrap">re-analyses</FONT> of certain data and provision of other information to support the findings. Bioventus continues to evaluate the FDA&#146;s comments and are initiating discussions with them to address their concerns.
See<I> </I>&#147;Description of Bioventus&#146; Business&#151;Development and Clinical Pipeline&#151;Exogen clinical data&#151;Ongoing Bioventus-sponsored clinical studies (B.O.N.E.S.).&#148; If Bioventus is unable to successfully complete
enrollment and conclude the B.O.N.E.S. study, or the data generated from the study does not support these new indications, future demand for Bioventus&#146; Exogen system may be affected. In October 2020, Bioventus received FDA confirmation
indicating its authorization of its IND, which will allow Bioventus to conduct a clinical trial to support a BLA submission for MOTYS, as well as an additional clinical trial based on a registry of patients who received MOTYS during Bioventus&#146;
limited commercial sale of the product, which has since been discontinued, or during the trial. If Bioventus is unable to complete enrollment of these trials or if these trials do not support Bioventus&#146; desired clinical indications for use or
show clinical efficacy of the MOTYS product, Bioventus may not obtain approval of the BLA and may not be able to continue to sell MOTYS or obtain coverage or reimbursement for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical failure can occur at any stage of testing. Bioventus&#146; clinical studies may produce negative or inconclusive results, and Bioventus may decide,
or regulators may require Bioventus, to conduct additional clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies in addition to those Bioventus has planned. In addition, failure to adequately demonstrate the safety and efficacy
of any of Bioventus&#146; devices would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that device or indication for use. Even if Bioventus&#146; future products are cleared in the United States,
commercialization of Bioventus&#146; products in foreign countries would require approval by regulatory authorities in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods
different from, and greater than, those in the United States, including additional preclinical studies or clinical trials. Any of these occurrences could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from Bioventus&#146; clinical trials that Bioventus announces
or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, Bioventus may publish interim, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> or preliminary data from its clinical trials.
Interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> or preliminary data from clinical trials that Bioventus may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues
and more patient data become available. Preliminary, <FONT STYLE="white-space:nowrap">&#147;top-line,&#148;</FONT> or interim data also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data Bioventus previously published. As a result, interim, <FONT STYLE="white-space:nowrap">&#147;top-line,&#148;</FONT> and preliminary data should be viewed with caution until the final data are available. Differences between
preliminary, interim, or <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> data and final data could significantly harm Bioventus&#146; business prospects and may cause the trading price of its common stock to fluctuate significantly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with Bioventus&#146; assumptions, estimates, calculations, conclusions or
analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and Bioventus&#146; business in
general. In addition, the information Bioventus chooses to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Bioventus determines is the
material or otherwise appropriate information to include in its disclosure, and any information it determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise
regarding a particular product candidate or Bioventus&#146; business. If the interim, <FONT STYLE="white-space:nowrap">&#147;top-line,&#148;</FONT> or preliminary data that Bioventus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, its ability to obtain approval for and commercialize its product
candidates, its business, operating results, prospects or financial condition may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may be subject to enforcement action if it
engages in improper marketing or promotion of Bioventus&#146; products, and the misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of Bioventus&#146; products may harm its image in the marketplace, result in injuries that lead to
product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if Bioventus is deemed to have engaged in the promotion of these uses, any of which could be costly to Bioventus&#146; business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The medical devices that Bioventus currently markets have been cleared or approved by the FDA and other foreign regulatory bodies for specific treatments.
However, Bioventus cannot prevent a physician from using its products outside of such cleared or approved indications for use, known as <FONT STYLE="white-space:nowrap">off-label</FONT> uses, when in the physician&#146;s independent professional
medical judgment, he or she deems it appropriate, and Bioventus does not analyze the ordering practices of physicians with respect to <FONT STYLE="white-space:nowrap">off-label</FONT> uses. In cases where prescriptions of Bioventus&#146; Exogen
system are written for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, Bioventus could be subject to regulatory or enforcement actions if it was determined to have engaged in promotion of Bioventus&#146; products for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, or otherwise determined to have made false or misleading statements about its products. There may be increased risk of injury to patients if physicians attempt to use Bioventus&#146; products <FONT
STYLE="white-space:nowrap">off-label.</FONT> Furthermore, the use of Bioventus&#146; products for indications other than those cleared or approved by the FDA or any foreign regulatory body may not effectively treat such conditions, which could harm
Bioventus&#146; reputation in the marketplace among physicians and patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, physicians may misuse Bioventus&#146; products or use improper
techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If Bioventus&#146; products are misused or used with improper technique, Bioventus may become subject to costly litigation by
its customers or their patients. Product liability claims could divert management&#146;s attention from Bioventus&#146; core business, be expensive to defend and result in sizeable damage awards against Bioventus that may not be covered by
insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Bioventus&#146; promotional materials and training methods must comply with FDA and other applicable laws and regulations, including
the prohibition of the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> use. If the FDA or any foreign regulatory body determines that Bioventus&#146; promotional materials or training constitute promotion of an <FONT
STYLE="white-space:nowrap">off-label</FONT> use, the FDA could request that Bioventus modify Bioventus&#146; training, promotional materials or subject Bioventus to regulatory or enforcement actions, including the issuance of an untitled letter, a
warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider Bioventus&#146; business activities to constitute promotion of
an <FONT STYLE="white-space:nowrap">off-label</FONT> use, which could result in significant penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Such enforcement actions may include, but are not
limited to, criminal, civil and administrative penalties, treble damages, fines, disgorgement, exclusion from participation in government healthcare programs, additional reporting requirements and oversight if Bioventus becomes subject to a
corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the curtailment or restructuring of Bioventus&#146; operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; products may cause or contribute to adverse medical events that Bioventus is required to report to the FDA, and if Bioventus fails to do
so, it would be subject to sanctions that could materially harm its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of Bioventus&#146; marketed products are subject to MDR
obligations, which require that Bioventus report to the FDA any incident in which its products may have caused or contributed to a death or serious injury, or in which Bioventus&#146; products malfunctioned and, if the malfunction were to recur, it
could likely cause or contribute to a death or serious injury. The timing of Bioventus&#146; obligation to report under the MDR regulations is triggered by the date Bioventus becomes aware of the adverse event as well as the nature of the event.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bioventus may fail to report adverse events of which it becomes aware within the prescribed timeframe. Bioventus may also fail to recognize that it has become aware of a reportable adverse event,
especially if it is not reported to Bioventus as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of Bioventus&#146; products. If Bioventus fails to comply with Bioventus&#146; reporting obligations,
the FDA could take action including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of Bioventus&#146; device clearances, seizure of Bioventus&#146; products, or
delay in clearance of future products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus and Bioventus&#146; third-party manufacturers and suppliers are subject to various governmental
regulations related to the manufacturing of Bioventus&#146; products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; products and the manufacturing processes, reporting
requirements, post-approval clinical data and promotional activities for such products, will be subject to continued regulatory review, oversight and periodic inspection by the FDA and other domestic and foreign regulatory bodies. In particular, the
methods used in, and the facilities used for, the manufacture of the products that Bioventus owns and distributes that are regulated as medical devices must comply with the FDA&#146;s QSR, which covers the procedures and documentation of the design,
testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces the QSR through periodic announced or unannounced inspections of manufacturing facilities, and both
Bioventus and Bioventus&#146; third-party manufacturers and suppliers are subject to such inspections. Similarly, the devices Bioventus distributes on behalf of third-party manufacturers that are regulated as Section&nbsp;361 HCT/Ps must be
manufactured in compliance with cGTP requirements and other related requirements. Moreover, should any of Bioventus&#146; HA products be <FONT STYLE="white-space:nowrap">re-classified</FONT> as drugs, such products would be required to comply with a
different set of manufacturing requirements under FDA&#146;s cGMP requirements for drugs. Similarly, if Bioventus is successful in obtaining BLA approval for MOTYS, that product will need to comply with the cGMP requirements for biologics, instead
of the cGTP requirements that will apply to the product upon Bioventus&#146; planned launch of the product as a Section&nbsp;361 HCT/P. The need to comply with different manufacturing requirements may require Bioventus to seek new suppliers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with Bioventus&#146; products or the manufacturing
processes of Bioventus&#146; third-party manufacturers and suppliers, including any failure to take satisfactory corrective action in response to an adverse regulatory inspection, can result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administrative or judicially imposed sanctions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil penalties or fines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall or seizure of Bioventus&#146; products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">total or partial suspension of production or distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to grant pending or future clearances or approvals for Bioventus&#146; products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal or suspension of regulatory clearances or approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">untitled letters or warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of Bioventus&#146; products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution of Bioventus or Bioventus&#146; employees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these actions could prevent or delay Bioventus from marketing, distributing or selling Bioventus&#146; products and would likely harm its business.
Furthermore, Bioventus&#146; suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in Bioventus&#146; failure to produce its products on a timely basis and in the
required quantities, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; products may be subject to product recalls. A recall of Bioventus&#146; products,
either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with its products, could adversely affect Bioventus. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies
or defects in their design or manufacture. The FDA&#146;s authority to require a recall for medical devices must be based on a finding that there is reasonable probability that the device would cause serious injury or death. Bioventus may also
decide to voluntarily recall Bioventus&#146; products if certain deficiencies are found. Bioventus has in the past instituted a voluntary recall for certain of Bioventus&#146; products, and Bioventus is currently undertaking a voluntary
Class&nbsp;II recall of certain vials of ultrasound gel that Bioventus provide with Bioventus&#146; Exogen system due to particulates, which were microbial in nature, found in the gel. The gel is manufactured by a third-party supplier, and Bioventus
has discontinued the use of that suppliers&#146; gel and has replaced that gel with that of another manufacturer. Bioventus has identified the affected lots and has notified patients to discard gel bottles from those lots. A government-mandated or
voluntary recall could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of Bioventus&#146; products would divert
managerial and financial resources and could adversely affect Bioventus&#146; reputation and business, which could impair Bioventus&#146; ability to produce Bioventus&#146; products in a cost-effective and timely manner in order to meet
Bioventus&#146; customers&#146; demands. Bioventus may also be subject to liability claims, be required to bear other costs, or take other actions that could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. Bioventus may initiate voluntary
recalls or corrections for Bioventus&#146; products in the future that Bioventus determines do not require notification of the FDA. If the FDA disagrees with Bioventus&#146; determinations, they could require Bioventus to report those actions as
recalls and Bioventus may be subject to enforcement action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As Bioventus conducts clinical studies designed to generate long-term data on some of
Bioventus&#146; existing products, the data Bioventus generates may not be consistent with its existing data and may demonstrate less favorable safety or efficacy. Data Bioventus generates may ultimately not be favorable, or could even hurt the
commercial prospects for its products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is currently collecting and plans to continue collecting long-term clinical data regarding the
quality, safety and effectiveness of some of Bioventus&#146; existing products. The clinical data collected and generated as part of these studies will further strengthen Bioventus&#146; clinical evaluation concerning safety and performance of these
products. Bioventus believes that this additional data will help with the marketing of its products by providing surgeons and physicians with additional confidence in their long-term safety and efficacy. If the results of these clinical studies are
negative, these results could reduce demand for Bioventus&#146; products and significantly reduce its ability to achieve expected net sales. Bioventus does not expect to undertake such studies for all of its products and will only do so in the
future where Bioventus anticipates the benefits will outweigh the costs and risks. For these reasons, surgeons and physicians could be less likely to purchase Bioventus&#146; products than competing products for which longer-term clinical data are
available. Also, Bioventus may not choose or be able to generate the comparative data that some of its competitors have or are generating and it may be subject to greater regulatory and product liability risks. If Bioventus is unable to or unwilling
to collect sufficient long-term clinical data supporting the quality, safety and effectiveness of Bioventus&#146; existing products, its business, results of operations and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may rely on third parties to conduct Bioventus&#146; clinical studies and to assist it with preclinical development and if they fail to
perform as contractually required or expected, Bioventus may not be able to obtain regulatory clearance or approval to commercialize its products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has relied upon and may continue to rely upon third parties, such as contract research organizations, medical institutions, clinical investigators
and contract laboratories to assist in conducting Bioventus&#146; clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies, which must be conducted in accordance with applicable regulations, including GCP and its preclinical development activities. Bioventus relies on these parties for execution of its
studies, and control only certain aspects of their activities. Nevertheless, Bioventus is responsible for ensuring that each of its clinical studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific
standards, and Bioventus&#146; reliance on these third parties does not relieve Bioventus of its regulatory responsibilities. GCPs are regulations and guidelines enforced by the FDA and other regulatory authorities for products in clinical
development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, trial sites, and CROs. Bioventus cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of Bioventus&#146; clinical trials comply with GCP regulations. In addition, Bioventus&#146; clinical trials must be conducted with product produced under applicable manufacturing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If these third parties fail to successfully carry out their contractual duties, comply with applicable regulatory obligations, including GCP requirements, or
meet expected deadlines, or if these third parties must be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to clinical protocols or applicable regulatory requirements or for other reasons,
Bioventus&#146; <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development activities or clinical studies may be extended, delayed, suspended or terminated. Under these circumstances Bioventus may not be able to obtain regulatory clearance or
approval for, or successfully commercialize, Bioventus&#146; products on a timely basis, if at all, and its business, results of operations and financial condition may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of its relationships with these third parties terminate, Bioventus may not be able to enter into arrangements with alternative third parties or to do
so on commercially reasonable terms. In addition, Bioventus&#146; third parties are not its employees, and except for remedies available to Bioventus under its agreements with them, Bioventus cannot control whether or not they devote sufficient time
and resources to its <FONT STYLE="white-space:nowrap">on-going</FONT> clinical, nonclinical and preclinical programs. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is
a natural transition period when a new contract research organization (CRO) or other third party vendor commences work. As a result, delays occur, which can materially impact Bioventus&#146; ability to meet its desired development timelines. Though
Bioventus carefully manages its relationships with Bioventus&#146; third party vendors including CROs, there can be no assurance that Bioventus will not encounter similar challenges or delays in the future or that these delays or challenges will not
have a material adverse impact on Bioventus&#146; business, financial condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare regulatory reform may affect
Bioventus&#146; ability to sell its products profitably and could adversely affect its business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the United States and in certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the regulatory and healthcare systems in ways that could prevent or delay marketing approval of Bioventus&#146;
products in development, restrict or regulate post-approval activities of its products and impact its ability to sell its products profitably. In the United States in recent years, new legislation has been proposed and adopted at the federal and
state level that is effecting major changes in the healthcare system. In addition, new regulations and interpretations of existing healthcare statutes and regulations are frequently adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2010, the Affordable Care Act was signed into law. While the goal of healthcare reform is to expand coverage to more individuals, it also involves
increased government price controls, additional regulatory mandates and other measures designed to constrain medical costs. The Affordable Care Act substantially changes the way healthcare is financed by both governmental and private insurers,
encourages improvements in the quality of healthcare items and services and significantly impacts the medical device industry. Among other things, the Affordable Care Act: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extended manufacturers&#146; Medicaid rebate liability to individuals enrolled in Medicaid managed care
organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded eligibility criteria for Medicaid programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative
clinical effectiveness research in an effort to coordinate and develop such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals,
physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the former
Trump administration to repeal or replace certain aspects of the ACA, and Bioventus expects such challenges and amendments to continue. For example, the Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&nbsp;1, 2019,
the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it
was repealed as part of the U.S. Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate
was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March&nbsp;2, 2020, the United States Supreme Court granted the petitions for
writs of certiorari to review this case, and the Court held oral argument on November&nbsp;10, 2020. The case is expected to be decided in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> It is unclear how this decision and other efforts to
challenge, repeal or replace the Affordable Care Act will impact the Affordable Care Act or Bioventus&#146; business. Bioventus expects there will be additional challenges and amendments to the Affordable Care Act in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of the 2020 U.S. presidential and congressional elections have created regulatory uncertainty, including with respect to the U.S.
government&#146;s role, in the U.S. healthcare industry. As a result of such elections, there are renewed and reinvigorated calls for health insurance reform, which could cause significant uncertainty in the U.S. healthcare market, could increase
Bioventus&#146; costs, decrease its revenues or inhibit its ability to sell its products. Bioventus cannot predict with certainty what impact any U.S. federal and state health reforms will have on Bioventus, but such changes could impose new and/or
more stringent regulatory requirements on Bioventus&#146; activities or result in reduced reimbursement for its products, any of which could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, third-party payers regularly update payments to physicians and hospitals where Bioventus&#146; products are used. For example, the Medicare
Access and CHIP Reauthorization Act of 2015 (MACRA) ended the use of the Sustainable Growth Rate Formula, and provided for a 0.5% annual increase in payment rates under the Medicare Physician Fee Schedule through 2019, but no annual update from 2020
through 2025. MACRA also introduced a merit based incentive bonus program for Medicare physicians beginning in 2019. At this time, it is unclear how the introduction of the merit based incentive program will impact overall physician reimbursement
under the Medicare program. In addition, the Budget Control Act of 2011 imposed reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013. Subsequent legislative amendments related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic suspended this Medicare sequestration payment reduction from May&nbsp;1, 2020 through March&nbsp;31, 2021, but extended sequestration through 2030. In January 2013, President Obama signed into law
the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers, and increased the statute of limitations period for the government to recover overpayments to providers from three
to five years. These and other payment updates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could directly impact the demand for Bioventus&#146; products or any products Bioventus may develop in the future, if cleared or approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus expects that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in additional
reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that Bioventus receives for any cleared or approved products. Furthermore, Bioventus
believes that many individuals who have obtained insurance coverage through the health insurance exchanges which arose as a result of the Affordable Care Act have done so with policies that have significantly higher deductibles than policies they
may have obtained prior to its enactment. Because the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of undergoing certain procedures for patients who have not met their deductible for a given
year would be significantly higher than they historically would have been, these patients may be discouraged from undergoing certain procedures due to the cost. Any reluctance on the part of patients to undergo procedures utilizing Bioventus&#146;
products due to cost could impact its ability to expand sales of its products and could adversely impact its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is subject to federal, state and foreign laws and regulations relating to Bioventus&#146; healthcare business, and could face substantial
penalties if Bioventus is determined not to have fully complied with such laws, which would adversely affect its business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both in Bioventus&#146; capacity as a pharmaceutical and medical device manufacturer and/or as a supplier of covered items and services to federal health care
program beneficiaries, with respect to which items and services Bioventus submits claims for reimbursement from such programs, Bioventus is subject to healthcare fraud and abuse regulation and enforcement by federal, state and foreign governments,
which could adversely impact its business, results of operations and financial condition. Healthcare fraud and abuse and health information privacy and security laws potentially applicable to Bioventus&#146; operations include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which applies to Bioventus&#146; marketing practices, educational programs,
pricing and discounting policies and relationships with healthcare providers, by prohibiting, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or providing remuneration intended to induce or
reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare or Medicaid programs. A person or entity does
not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation. Violations are also subject to civil monetary penalties up to $100,000 for each violation, plus up to three times the remuneration
involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations of the federal Anti-Kickback Statute may also result civil and criminal penalties, including criminal fines of up to $100,000 and
imprisonment of up to ten years, or exclusion from Medicare, Medicaid or other governmental programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the &#147;Stark Law,&#148; which prohibits a physician from referring Medicare or Medicaid patients to an entity
providing &#147;designated health services,&#148; which includes durable medical equipment, if the physician or immediate family member of the physician, has an ownership or investment interest in or compensation arrangement with such entity that
does not comply with the requirements of a Stark exception; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the False Claims Act, which impose civil and criminal
penalties through governmental, civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are
false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or
transmit money or property to the federal government. Suits filed under the False Claims Act, can be brought by any individual on behalf of the government, known as &#145;&#145;qui tam&#146;&#146; actions, and such individuals, commonly
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
known as &#145;&#145;whistleblowers,&#146;&#146; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased
significantly in recent years, causing greater numbers of pharmaceutical, medical device and other healthcare companies to have to defend a False Claims Act action. When an entity is determined to have violated the False Claims Act, the government
may impose civil fines and penalties ranging from $11,665 to $23,331 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. The government may assert that a
claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or
transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner, or supplier of services reimbursable
by Medicare or a state healthcare program, unless an exception applies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA and its implementing regulations, which created federal criminal laws that prohibit, among other things,
executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge
of the statute or specific intent to violate it to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by HITECH, and its implementing regulations, which also imposes certain regulatory and
contractual requirements regarding the privacy, security and transmission of protected health information, or PHI; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the government information related to certain payments or other &#147;transfers
of value&#148; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and, beginning in 2022, physician assistants, nurse practitioners, and other practitioners, and requires
applicable manufacturers to report annually to the government ownership and investment interests held by the providers described above and their immediate family members and payments or other &#147;transfers of value&#148; to such provider owners.
Failure to submit required information may result in civil monetary penalties of $11,766 per failure up to an aggregate of $176,495 per year (or up to an aggregate of $1.177&nbsp;million per year for &#147;knowing failures&#148;), for all payments,
transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require Bioventus to calculate and report complex pricing metrics
in an accurate and timely manner to government programs, and where the failure to report such prices may expose Bioventus to potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state and foreign law equivalents of each of the above federal laws and regulations, such as anti-kickback,
self-referral, <FONT STYLE="white-space:nowrap">fee-splitting</FONT> and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical and device
companies to comply with the industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise that restrict payments that may be made to healthcare providers; state laws that
require drug and device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state and foreign
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
laws governing the privacy and security of certain health information, such as GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals
located in the EU (including health data), many of which differ from each other in significant ways and some of which may be more stringent than HIPAA or HITECH. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk of Bioventus being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the
regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Bioventus is unable to predict what additional federal, state or foreign legislation or regulatory initiatives may be enacted in the future
regarding Bioventus&#146; business or the healthcare industry in general, or what effect such legislation or regulations may have on Bioventus. Federal, state or foreign governments may impose additional restrictions or adopt interpretations of
existing laws that could adversely affect Bioventus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors
available under such laws, it is possible that some of Bioventus&#146; business activities, including certain sales and marketing practices and financial arrangements with physicians and other healthcare providers, some of whom recommend, use,
prescribe or purchase Bioventus&#146; products, and other customers, could be subject to challenge under one or more of such laws. Any action against Bioventus for violation of these laws, even if Bioventus successfully defends against it, could
cause Bioventus to incur significant legal expenses and divert its management&#146;s attention from the operation of its business. If Bioventus&#146; operations are found to be in violation of any of the laws described above or any other
governmental regulations that apply to Bioventus, Bioventus may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from governmental healthcare programs, disgorgement, contractual damages, reputational harm,
diminished profits and future earnings, and the curtailment or restructuring of Bioventus&#146; operations, any of which could adversely impact its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is subject to governmental regulation and other legal obligations, particularly related to privacy, data protection and information security,
and Bioventus is subject to consumer protection laws that regulate its marketing practices and prohibit unfair or deceptive acts or practices. Bioventus&#146; actual or perceived failure to comply with such obligations could harm its business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is subject to diverse laws and regulations relating to data privacy and security, including, in the United States, HIPAA and, in the EU,
EEA, Regulation 2016/679, known as the GDPR. New privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened. Complying with these numerous, complex and often changing regulations is
expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or
consumer information, whether by Bioventus, one of Bioventus&#146; business associates or another third-party, could adversely affect its business, results of operations and financial condition, including but not limited to: investigation costs,
material fines and penalties; compensatory, special, punitive, and statutory damages; litigation; reputational damage; consent orders regarding Bioventus&#146; privacy and security practices; requirements that Bioventus provide notices, credit
monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against Bioventus&#146; licenses to do business; and injunctive relief. Furthermore, these rules are constantly changing. For
example, the CCPA took effect on January&nbsp;1, 2020. The CCPA establishes a new privacy framework for covered businesses and provides new and enhanced data privacy rights to California residents, such as affording consumers the right to access and
delete their information and to opt out of certain sharing and sales of personal information. The CCPA imposes severe statutory damages as well as a private right of action for certain data breaches that result in the loss of personal information.
This private right of action is expected to increase the likelihood of, and risks associated with, data breach litigation. It remains unclear how various provisions of the CCPA will be interpreted and enforced. The CCPA contains an exemption for
medical information governed by the CMIA and for PHI collected by a covered entity or business associate governed by the privacy, security and breach notification rules established pursuant to HIPAA, but the precise application and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scope of this exemption is not yet clear, and the law may still apply to certain aspects of Bioventus&#146; business. The CCPA may lead other states to pass comparable legislation, with
potentially greater penalties, and more rigorous compliance requirements relevant to Bioventus&#146; business, and that may not include exemptions for businesses subject to HIPAA. The effects of the CCPA, and other similar state or federal laws, are
potentially significant and may require Bioventus to modify its data processing practices and policies and to incur substantial costs and potential liability in an effort to comply with such legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The privacy laws in the EU have been significantly reformed. On May&nbsp;25, 2018, the GDPR entered into force and became directly applicable in all EU member
states. The GDPR implements more stringent operational requirements than its predecessor legislation. For example, the GDPR requires Bioventus to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which
Bioventus can process personal data, makes it harder for Bioventus to obtain valid consent for processing, requires the appointment of data protection officers when sensitive personal data, such as health data, is processed on a large scale,
provides more robust rights for data subjects, introduces mandatory data breach notification through the EU, imposes additional obligations on Bioventus when contracting with service providers and requires Bioventus to adopt appropriate privacy
governance including policies, procedures, training and data audit. If Bioventus does not comply with its obligations under the GDPR, Bioventus could be exposed to fines of up to the greater of &#128;20&nbsp;million or up to 4% of its total global
annual revenue in the event of a significant breach. In addition, Bioventus may be the subject of litigation and/or adverse publicity, which could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the effectiveness of the GDPR, the <FONT STYLE="white-space:nowrap">US-EU</FONT> Safe Harbor framework provided a method which permitted the transfer
of personal data to the United States under European privacy law; in 2015 it was declared invalid and replaced with the <FONT STYLE="white-space:nowrap">US-EU</FONT> Privacy Shield framework, or Privacy Shield. On July&nbsp;16, 2020, the Court of
Justice of the European Union, or CJEU, invalidated Privacy Shield. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer
mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances; this has created increasing uncertainty. This recent development will require Bioventus to
review and amend the legal mechanisms by which Bioventus makes and/or receive personal data transfers to/in the U.S. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard
contractual clauses cannot be used, and/or start taking enforcement action, Bioventus could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if Bioventus is otherwise unable to transfer personal data between and
among countries and regions in which Bioventus operates, it could affect the manner in which Bioventus provides its services, the geographical location or segregation of Bioventus&#146; relevant systems and operations, and could adversely affect
Bioventus&#146; financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally starting on January&nbsp;1, 2021 (following the United Kingdom&#146;s departure from the EU), Bioventus
will have to comply with the GDPR and the UK GDPR (i.e. the GDPR as implemented into UK law) if Bioventus offers services to UK users, monitor their behavior or are established in the United Kingdom. Failure to comply with the UK GDPR can result in
fines up to the greater of &pound;17&nbsp;million (approximately $20 million), or 4% of global revenue. However, the relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains
unclear. For example, it is unclear what the role of the Information Commissioner&#146;s Office will be following the end of the transitional period. In addition, it is likely that documentation will need to be put in place between UK entities and
entities in European member states to ensure adequate safeguards are in place for data transfers, which may result in increased costs with respect to transfers of personal data between the European Union and the UK, which would increase
Bioventus&#146; expenses. Bioventus may find it necessary or advantageous to join industry bodies or self-regulatory organizations that impose stricter compliance requirements than those set out in applicable laws, including the GDPR. Bioventus may
also be bound by contractual restrictions that prevent Bioventus from participating in data processing activities that would otherwise be permissible under applicable laws, including the GDPR. Such strategic choices may impact Bioventus&#146;
ability to use and exploit data, and may have an adverse impact on Bioventus&#146; business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with the FCPA and laws associated with Bioventus&#146; activities outside the United
States could adversely affect its business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is subject to the FCPA and other anti-bribery
legislation around the world. The FCPA generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments, offers or promises to foreign officials for the purpose of obtaining or retaining
business or other advantages. In addition, the FCPA imposes recordkeeping and internal controls requirements on publicly traded corporations and their foreign affiliates, which are intended to, among other things, prevent the diversion of corporate
funds to the payment of bribes and other improper payments, and to prevent the establishment of &#147;off books&#148; slush funds from which such improper payments can be made. As Bioventus conducts its business in jurisdictions outside of the
United States, Bioventus faces significant risks if it fails to comply with the FCPA and other laws that prohibit improper payments, offers or promises of payment to foreign governments and their officials and political parties by Bioventus and
other business entities for the purpose of obtaining or retaining business or other advantages. In many foreign countries, particularly in countries with developing economies, it may be a local custom that businesses operating in such countries
engage in business practices that are prohibited by the FCPA or other laws and regulations. Although Bioventus has implemented a company policy requiring its employees and consultants to comply with the FCPA and similar laws, such policy may not be
effective at preventing all potential FCPA or other violations. Although Bioventus&#146; agreements with its international distributors clearly state Bioventus&#146; expectations for its distributors&#146; compliance with U.S. laws, including the
FCPA, and provide Bioventus with various remedies upon any <FONT STYLE="white-space:nowrap">non-compliance,</FONT> including the ability to terminate the agreement, Bioventus also cannot guarantee its distributors&#146; compliance with U.S. laws,
including the FCPA. Therefore, there can be no assurance that Bioventus&#146; employees and agents, or those companies to which Bioventus outsources certain of its business operations, have not and will not take actions that violate its policies or
applicable laws, for which Bioventus may be ultimately held responsible. Any violation of the FCPA and related policies could result in severe criminal or civil sanctions, which could adversely affect its business, results of operations and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, Bioventus is subject to the export controls and economic embargo rules and regulations of the United States, including,
but not limited to, the Export Administration Regulations and trade sanctions against embargoed countries, which are administered by the Office of Foreign Assets Control within the Department of the Treasury, as well as the laws and regulations
administered by the Department of Commerce. These regulations limit Bioventus&#146; ability to market, sell, distribute or otherwise transfer its products or technology to prohibited countries or persons. A determination that Bioventus has failed to
comply, whether knowingly or inadvertently, may result in substantial penalties, including fines, enforcement actions, civil and/or criminal sanctions, the disgorgement of profits, the imposition of a court-appointed monitor, as well as the denial
of export privileges, and may adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus fails to meet Medicare
accreditation and surety bond requirements or DMEPOS supplier standards, it could adversely affect its business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; Exogen system is classified by CMS and third-party payers as durable medical equipment. Suppliers of Medicare durable medical equipment,
prosthetics, orthotics and supplies (DMEPOS) must be accredited by an approved accreditation organization as meeting DMEPOS quality standards adopted by CMS and are required to meet surety bond requirements. In addition, Medicare DMEPOS suppliers
must comply with Medicare supplier standards in order to obtain and retain billing privileges, including meeting all applicable federal and state licensure and regulatory requirements. CMS periodically expands or otherwise clarifies the Medicare
DMEPOS supplier standards, and states periodically change licensure requirements, including licensure rules imposing more stringent requirements on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT> DMEPOS
suppliers. Bioventus believes it is currently in compliance with these requirements. If Bioventus fails to maintain Bioventus&#146; Medicare accreditation status and/or do not comply with Medicare surety bond or supplier standard requirements or
state licensure requirements in the future, or if these requirements are changed or expanded, it could adversely affect its business, results of operations and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; operations involve the use of hazardous and toxic materials, and Bioventus must comply
with environmental, health and safety laws and regulations, which can be expensive, and could adversely affect its business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is subject to a variety of federal, state, local and foreign laws and regulations relating to the protection of the environment or of human health
and safety, including laws pertaining to the use, handling, storage, disposal and human exposure to hazardous and toxic materials. Liability under environmental laws can be imposed on a joint and several basis (which could result in an entity paying
more than its fair share) and without regard to comparative fault, and environmental laws are likely to become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could
adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; employees, independent distributors, independent
contractors, suppliers and other third parties may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could expose Bioventus to liability and hurt its reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is exposed to the risk that Bioventus&#146; employees, independent distributors, independent contractors, suppliers and others may engage in
fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to Bioventus that violates: (1)&nbsp;FDA laws and regulations, including
those laws that require the reporting of true, complete and accurate information to the FDA, (2)&nbsp;manufacturing standards, (3)&nbsp;healthcare fraud and abuse laws, or (4)&nbsp;laws that require the true, complete and accurate reporting of
financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in Bioventus&#146; preclinical studies or clinical
trials or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to Bioventus&#146; reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the
precautions Bioventus takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting it from governmental investigations or other actions or lawsuits stemming from a failure to be
in compliance with such laws or regulations. Additionally, Bioventus is subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any such actions are instituted against Bioventus, and Bioventus is not successful in defending Bioventus or asserting its rights, those actions could have
a significant impact on Bioventus&#146; business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in
Medicare, Medicaid and other federal healthcare programs, reputational harm, diminished profits and future earnings, and curtailment of Bioventus&#146; operations, any of which could adversely affect its business, results of operations and financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Intellectual Property Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk factors listed below describe the risks Bioventus faces related to intellectual property matters. The companies who own certain of the products
Bioventus distributes face similar risks with respect to intellectual property relating to such products. If such suppliers are unable to protect their intellectual property rights, they may not be able to continue to supply Bioventus with products,
which could adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Protection of Bioventus&#146; intellectual property
rights may be difficult and costly, and Bioventus&#146; inability to protect its intellectual property could adversely affect its competitive position. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; success depends on its ability to protect its proprietary rights to the technologies and inventions used in, or embodied by, Bioventus&#146;
products. To protect Bioventus&#146; proprietary technology, Bioventus relies on patent protection, as well as a combination of copyright, trade secret and trademark laws, as well as nondisclosure, confidentiality and other contractual restrictions
in Bioventus&#146; consulting and employment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements. These legal means afford only limited protection, however, and may not adequately protect Bioventus&#146; rights or permit Bioventus to gain or keep any competitive advantage.
Bioventus&#146; existing confidentiality and/or invention assignment agreements with employees, contractors, and others who participate in IP development activities could be breached, or Bioventus may not enter into sufficient and adequate
agreements with those individuals in the first instance, and it may not have adequate remedies for such breaches. Furthermore, Bioventus may be subject to, and forced to defend against, third-party claims of ownership to its intellectual property.
If Bioventus fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or rights to use, valuable intellectual property. Such an outcome could
adversely affect its business, results of operations and financial condition. Even if Bioventus is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of applying for patent protection is
time-consuming and expensive and Bioventus cannot assure you that all of Bioventus&#146; patent applications will issue as patents or that, if issued, they will issue in a form that will be advantageous to Bioventus. The rights granted to Bioventus
under its patents, including prospective rights sought in Bioventus&#146; pending patent applications, may not be meaningful or provide Bioventus with any commercial advantage, and they could be opposed, contested, narrowed, or circumvented by
Bioventus&#146; competitors or declared invalid or unenforceable in judicial or administrative proceedings. Bioventus may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It
is also possible that Bioventus will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection. As a result, some of Bioventus&#146; products are not, and in the future may not be,
protected by patents. Bioventus generally applies for patents in those countries where it intends to make, has made, use, offer for sale, or sell products and where it assesses the risk of infringement to justify the cost of seeking patent
protection. However, Bioventus does not seek protection in all countries where it sells products and Bioventus may not accurately predict all the countries where patent protection would ultimately be desirable. If Bioventus fails to timely file a
patent application in any such country or major market, it may be precluded from doing so at a later date. Competitors may use Bioventus&#146; technologies in jurisdictions where Bioventus has not obtained patent protection to develop their own
products and, further, may export otherwise infringing products to territories in which Bioventus has patent protection but where such protection may not be sufficient to terminate infringing activities. Furthermore, Bioventus may not have the right
to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to Bioventus by third-parties. Therefore, these patents and applications may not be prosecuted or enforced in a manner
consistent with the best interests of Bioventus&#146; business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights Bioventus has licensed may be reduced or eliminated, which could also adversely affect its
business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus owns numerous issued patents and pending patent applications relating to its
technology and products. The rights granted to Bioventus under these patents, including prospective rights sought in Bioventus&#146; pending patent applications, could be opposed, contested or circumvented by its competitors or declared invalid or
unenforceable in judicial or administrative proceedings. If any of Bioventus&#146; patents are challenged, invalidated or legally circumvented by third-parties, and if Bioventus does not own other enforceable patents protecting its products,
competitors could market products and use processes that are substantially similar to, or superior to, those of Bioventus&#146;, and Bioventus&#146; business will suffer. In addition, the patents Bioventus owns may not be of sufficient scope or
strength to provide it with any meaningful protection or commercial advantage, and competitors may be able to design around Bioventus&#146; patents or develop products that provide outcomes comparable to those of Bioventus&#146; without infringing
on Bioventus&#146; intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if Bioventus&#146; patents are determined by the U.S. Patent and Trademark Office (USPTO) foreign
patent office, or a court to be valid and enforceable, they may not be drafted or interpreted sufficiently broadly to prevent others from marketing products and services similar to Bioventus&#146; or designing around Bioventus&#146;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents. For example, third parties may be able to develop products that are similar to Bioventus&#146; but that are not covered by the claims of Bioventus&#146; patents. Third parties may assert
that Bioventus or its licensors were not the first to make the inventions covered by Bioventus&#146; issued patents or pending patent applications. The claims of Bioventus&#146; issued patents or patent applications when issued may not cover
Bioventus&#146; commercial technology or the future products and services that it develops. Bioventus may not have freedom to operate unimpeded by the patent rights of others. Third parties may have dominating, blocking or other patents relevant to
Bioventus&#146; technology of which Bioventus is not aware. In addition, because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after the filing of certain priority documents (or,
in some cases, are not published until they issue as patents) and because publications in the scientific literature often lag behind actual discoveries, Bioventus cannot be certain that others have not filed patent applications for Bioventus&#146;
technology or its contemplated technology. Any such patent applications may have priority over Bioventus&#146; patent applications or issued patents, which could require Bioventus to obtain rights from third parties to issued patents or pending
patent applications covering such technologies to allow it to commercialize its technology. If another party has filed a U.S. patent application on inventions similar to Bioventus&#146;, depending on when the timing of the filing date falls under
certain patent laws, Bioventus may have to participate in a priority contest (such as an interference proceeding) declared by the USPTO to determine priority of invention in the United States. There may be prior public disclosures of which Bioventus
is not aware that could invalidate its patents or a portion of the claims of its patents. Further, Bioventus may not develop additional proprietary technologies and, even if Bioventus does, they may not be patentable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution,
enforcement, and defense of Bioventus&#146; patents and applications. Bioventus may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, inter partes review,
post-grant review or other patent office proceedings or litigation, in the United States or elsewhere, challenging Bioventus&#146; patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or
invalidate, Bioventus&#146; patent rights, allow third-parties to commercialize Bioventus&#146; technology or products and compete directly with Bioventus, without payment to Bioventus, or result in its inability to manufacture or commercialize
products without infringing third-party patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the USPTO and various foreign governmental patent agencies require compliance with a
number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime
of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent
or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application
include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. If Bioventus fails to
maintain the patents and patent applications covering Bioventus&#146; products or procedures, it may not be able to stop a competitor from marketing products that are the same as or similar to its products, which would adversely affect its business,
results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on Bioventus&#146; products in all countries throughout the
world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign
countries may not protect Bioventus&#146; intellectual property rights to the same extent as laws in the United States. Consequently, Bioventus may not be able to prevent third parties from practicing its inventions in all countries outside the
United States. Competitors may use Bioventus&#146; technologies in jurisdictions where Bioventus has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which
Bioventus has patent protection that may not be sufficient to terminate infringing activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to differences between foreign and U.S. patent laws, Bioventus&#146; patented intellectual property
rights may not receive the same degree of protection in every jurisdiction in which Bioventus obtains patents. Furthermore, Bioventus does not have patent rights in certain foreign countries in which a market may exist in the future. Bioventus may
need to expend additional resources to protect or defend its intellectual property rights in these countries, and the inability to protect or defend the same could impair Bioventus&#146; brand or adversely affect the growth of Bioventus&#146;
business internationally. For example, Bioventus may not be able to stop a competitor from marketing and selling in foreign countries products that are the same as or similar to Bioventus&#146; products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan, and the protection patents affords is limited. In the United States, if all maintenance fees are timely paid, the natural
expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Even if patents covering Bioventus&#146; products are obtained, once the patent life has expired for patents
covering a product, Bioventus may be open to competition from competitive products and services. As a result, Bioventus&#146; patent portfolio may not provide it with sufficient rights to exclude others from commercializing product candidates
similar or identical to Bioventus&#146;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trademarks </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus relies on its trademarks as one means to distinguish Bioventus&#146; products from the products of its competitors, and have registered or applied to
register many of these trademarks. However, Bioventus may not be able to successfully secure trademark registrations for all such applications. Third-parties may oppose Bioventus&#146; trademark applications, or otherwise challenge Bioventus&#146;
use of both registered and unregistered trademarks. In the event that Bioventus&#146; trademarks are successfully challenged, Bioventus could be forced to rebrand its products, which could result in loss of brand recognition and could require
Bioventus to devote resources to advertising and marketing new brands. Bioventus&#146; competitors may infringe Bioventus&#146; trademarks and Bioventus may not have adequate resources to enforce its trademarks. Over the long term, if Bioventus is
unable to establish name recognition based on its trademarks, then Bioventus may not be able to compete effectively and its business, results of operations and financial condition may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus may not be able to prevent the unauthorized disclosure or use of its technical knowledge or other trade secrets by consultants, vendors, former
employees or current employees, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures of Bioventus&#146; intellectual property is difficult, and Bioventus does
not know whether the steps it has taken to protect Bioventus&#146; intellectual property will be effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, Bioventus&#146; competitors may
independently develop equivalent knowledge, methods and <FONT STYLE="white-space:nowrap">know-how.</FONT> For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly
available on a routine basis, including information that Bioventus may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all.
Bioventus&#146; competitors could use any of the information Bioventus may be required to disclose by the FDA to develop independently technology similar to those of Bioventus&#146;. Competitors could purchase Bioventus&#146; products and attempt to
replicate some or all of the competitive advantages Bioventus derives from Bioventus&#146; development efforts, willfully infringe Bioventus&#146; intellectual property rights, design around Bioventus&#146; protected technology or develop their own
competitive technologies that fall outside of Bioventus&#146; intellectual property rights. If Bioventus&#146; intellectual property is not adequately protected so as to protect Bioventus&#146; market against competitors&#146; products and methods,
its competitive position could be adversely affected, as could its business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus was to enforce a
claim that a third-party had illegally obtained, misappropriated or was using Bioventus&#146; trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less
willing to protect trade secrets. If any of the technology or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information that Bioventus protects as trade secrets were to be independently developed by a competitor, Bioventus would have no right to prevent them from using that technology or information to
compete with Bioventus. Misappropriation or unauthorized disclosure of Bioventus&#146; trade secrets could impair Bioventus&#146; competitive position and may adversely affect its business, results of operations and financial condition.
Additionally, if the steps taken to maintain Bioventus&#146; trade secrets are deemed inadequate, Bioventus may have insufficient recourse against third parties for misappropriating the trade secret. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus depends on certain technologies that are licensed to it. Bioventus does not control the intellectual property rights covering these
technologies and any loss of Bioventus&#146; rights to these technologies or the rights licensed to Bioventus could prevent Bioventus from selling Bioventus&#146; products, which could adversely impact its business, results of operations and
financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a party to license agreements under which Bioventus is granted rights to intellectual property that is important
to Bioventus&#146; business, and Bioventus may need to enter into additional license agreements in the future. Bioventus relies on these licenses in order to be able to use and sell various proprietary technologies that are material to
Bioventus&#146; business, as well as technologies which Bioventus intends to use in its future commercial activities. Bioventus&#146; rights to use these technologies and the inventions claimed in the licensed patents are subject to the continuation
of and Bioventus&#146; compliance with the terms of those licenses. Bioventus&#146; existing license agreements impose, and Bioventus expects that future license agreements will impose on Bioventus, various diligence obligations, payment of
milestones or royalties and other obligations. If Bioventus fails to comply with Bioventus&#146; obligations under these agreements, or Bioventus is subject to a bankruptcy, the licensor may have the right to terminate the license, in which case
Bioventus would not be able to market products covered by the license, which would adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Bioventus has done previously, Bioventus may need to obtain licenses from third parties to advance Bioventus&#146; research or allow commercialization of
Bioventus&#146; products and technologies. Bioventus may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if Bioventus is able to obtain a license, it may be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving Bioventus&#146; competitors access to the same technologies licensed to Bioventus. In the event that Bioventus is not able to acquire a license, Bioventus may be required to
expend significant time and resources to develop or license replacement technology. If Bioventus is unable to do so, Bioventus may be unable to develop or commercialize the affected products and technologies, which could materially harm
Bioventus&#146; business. In addition, the third parties owning such intellectual property rights could seek either an injunction prohibiting Bioventus&#146; sales, or, with respect to Bioventus&#146; sales, an obligation on Bioventus&#146; part to
pay royalties or other forms of compensation and damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, Bioventus may not have the right to control the prosecution, maintenance, or
filing of the patents that are licensed to Bioventus, or the enforcement of these patents against infringement by third parties. Some of Bioventus&#146; patents and patent applications were not filed by Bioventus, but were either acquired by
Bioventus or are licensed from third parties. Thus, these patents and patent applications were not drafted by Bioventus or Bioventus&#146; attorneys, and Bioventus did not control or have any input into the prosecution of these patents and patent
applications prior to Bioventus&#146; acquisition of, or Bioventus&#146; entry into a license with respect to, such patents and patent applications. Bioventus cannot be certain that the drafting or prosecution of the patents and patent applications
licensed to Bioventus will result or has resulted in valid and enforceable patents. Further, Bioventus does not always retain complete control over Bioventus&#146; ability to enforce Bioventus&#146; licensed patent rights against third-party
infringement. In those cases, Bioventus cannot be certain that Bioventus&#146; licensor will elect to enforce these patents to the extent that Bioventus would choose to do so, or in a way that will ensure that Bioventus retains the rights Bioventus
currently has under Bioventus&#146; license. If Bioventus&#146; licensor fails to properly enforce the patents subject to Bioventus&#146; license in the event of third-party infringement, Bioventus&#146; ability to retain Bioventus&#146; competitive
advantage with respect to Bioventus&#146; products may be materially and adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property is an important part of Bioventus&#146; business and involves complex
legal, business and scientific issues. Disputes may arise between Bioventus and Bioventus&#146; licensors regarding intellectual property that is subject to a license agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which Bioventus&#146; technology and processes infringe on intellectual property of the
licensor that is not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; right to sublicense patent and other rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; diligence obligations with respect to the use of the licensed technology in relation to
Bioventus&#146; development and commercialization of its products and technologies, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by Bioventus&#146; licensors and Bioventus and Bioventus&#146; partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
Bioventus may become the owner of intellectual property that was obtained through assignments which may be subject to <FONT STYLE="white-space:nowrap">re-assignment</FONT> back to the original assignor upon Bioventus&#146; failure to prosecute or
maintain such intellectual property, upon Bioventus&#146; breach of the agreement pursuant to which such intellectual property was assigned, or upon Bioventus&#146; bankruptcy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that Bioventus has licensed prevent or impair Bioventus&#146; ability to maintain its current licensing arrangements on
acceptable terms, or if intellectual property is <FONT STYLE="white-space:nowrap">re-assigned</FONT> back to the original assignor, Bioventus may be unable to successfully develop and commercialize the affected products and technologies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the
scope of Bioventus&#146; rights to the relevant intellectual property or technology. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions in Bioventus&#146; intellectual property
agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of Bioventus&#146; rights to the relevant intellectual property or technology, or affect
financial or other obligations under the relevant agreement, either of which could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, while it is Bioventus&#146; policy to require its employees and contractors who may be involved in the conception or development of intellectual
property to execute agreements assigning such intellectual property to it, Bioventus may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that Bioventus regards as its own.
Bioventus&#146; assignment agreements may not be self-executing or may be breached, and Bioventus may be forced to bring claims against third parties, or defend claims they may bring against Bioventus, to determine the ownership of what Bioventus
regards as its intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may in the future be a party to patent and other intellectual property litigation and
administrative proceedings that could be costly and could interfere with Bioventus&#146; ability to successfully market Bioventus&#146; products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The medical device industry has been characterized by frequent and extensive intellectual property litigation and is highly competitive. Bioventus&#146;
competitors or other patent holders may assert that Bioventus&#146; products and/or the methods employed in Bioventus&#146; products are covered by their patents or that Bioventus is infringing, misappropriating, or misusing their trademark,
copyright, trade secret, and/or other proprietary rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus&#146; products or methods are found to infringe, Bioventus could be prevented from
manufacturing or marketing Bioventus&#146; products. In the event that Bioventus becomes involved in such a dispute, Bioventus may incur significant costs and expenses and may need to devote resources to resolving any claims, which would reduce the
cash Bioventus has available for operations and may be distracting to management and other employees, including those involved in the development of intellectual property. Bioventus does not know whether Bioventus&#146; competitors or potential
competitors have applied for, will apply for, or will obtain patents that will prevent, limit or interfere with Bioventus&#146; ability to make, use, sell, import or export Bioventus&#146; products. Because patent applications can take many years to
issue, third parties may have currently pending patent applications which may later result in issued patents that Bioventus&#146; products and technologies may infringe, or which such third parties claim are infringed by the use of Bioventus&#146;
products or technologies. There is no guarantee that patents will not issue in the future from currently pending applications that may be infringed by Bioventus&#146; technology or products. In addition, identification of third-party patent rights
that may be relevant to Bioventus&#146; technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and difficulty in assessing the meaning of patent claims. Moreover, as the
medical device industry expands and more patents are issued in this area, the risk increases that Bioventus may be subject to claims of infringement of the patent rights of third parties. Bioventus cannot assure you that Bioventus will prevail in
such actions, or that other actions alleging misappropriation or misuse by Bioventus of third-party trade secrets or infringement by Bioventus of third-party patents, copyrights, trademarks or other rights or challenging the validity of
Bioventus&#146; patents, copyrights, trademarks or other rights will not be asserted against Bioventus. Competing products may also be sold in other countries in which Bioventus&#146; patent coverage might not exist or be as strong. If Bioventus
loses a foreign patent lawsuit alleging Bioventus&#146; infringement of a competitor&#146;s patents, Bioventus could be prevented from marketing Bioventus&#146; products in one or more foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus may also initiate litigation against third-parties to enforce Bioventus&#146; patent and proprietary rights or to determine the scope,
enforceability or validity of the proprietary rights of others. Bioventus&#146; intellectual property has not been tested in litigation. If Bioventus initiates litigation to protect Bioventus&#146; rights, Bioventus runs the risk of having
Bioventus&#146; patents and other proprietary rights invalidated, canceled or narrowed, which could undermine Bioventus&#146; competitive position. Further, if the scope of protection provided by Bioventus&#146; patents or patent applications or
other proprietary rights is threatened or reduced as a result of litigation, it could discourage third parties from entering into collaborations with Bioventus that are important to the commercialization of Bioventus&#146; products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or
others who are involved in developing Bioventus&#146; product. Furthermore, if a license to necessary technology is terminated, the licensor may initiate litigation claiming that Bioventus&#146; processes or products infringe or misappropriate its
patent or other intellectual property rights and/or that Bioventus breached Bioventus&#146; obligations under the license agreement, and Bioventus and Bioventus&#146; collaborators would need to defend against such proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and
attention of managerial and technical personnel, which could materially adversely affect its business, results of operations and financial condition. Any such claim could also force use to do one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur substantial monetary liability for infringement or other violations of intellectual property rights, which
Bioventus may have to pay if a court decides that the product, service, or technology at issue infringes or violates the third-party&#146;s rights, and if the court finds that the infringement was willful, Bioventus could be ordered to pay treble
damages and the third-party&#146;s attorneys&#146; fees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay substantial damages to Bioventus&#146; customers or end users to discontinue use or replace infringing
technology with <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the product or
technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such product, service, or technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain from the owner of the infringed intellectual property right a license, which may require Bioventus to pay
substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign Bioventus&#146; products, services, and technology so they do not infringe or violate the
third-party&#146;s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into cross-licenses with Bioventus&#146; competitors, which could weaken Bioventus&#146; overall
intellectual property position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lose the opportunity to license Bioventus&#146; technology to others or to collect royalty payments based upon
successful protection and assertion of Bioventus&#146; intellectual property against others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">find alternative suppliers for <FONT STYLE="white-space:nowrap">non-infringing</FONT> products and technologies,
which could be costly and create significant delay; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relinquish rights associated with one or more of Bioventus&#146; patent claims, if Bioventus&#146; claims are
held invalid or otherwise unenforceable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of Bioventus&#146; competitors may be able to sustain the costs of complex intellectual
property litigation more effectively than Bioventus can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective
customers, cause product shipment delays, divert the time, attention and resources of management, or prohibit Bioventus from manufacturing, marketing or otherwise commercializing Bioventus&#146; products, services and technology. Any uncertainties
resulting from the initiation and continuation of any litigation could adversely affect Bioventus&#146; ability to raise additional funds or otherwise adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of
Bioventus&#146; confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other
interim proceedings or developments. If these results are perceived to be negative, the price of Bioventus class A common stock could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain of Bioventus&#146; agreements with suppliers, distributors, customers and other entities with whom Bioventus does business may require
Bioventus to defend or indemnify these parties to the extent they become involved in infringement claims relating to Bioventus&#146; technologies or products, or rights licensed to them by Bioventus. Bioventus could also voluntarily agree to defend
or indemnify third parties in instances where Bioventus is not obligated to do so if Bioventus determines it would be important to Bioventus&#146; business relationships. If Bioventus is required or agree to defend or indemnify any of these third
parties in connection with any infringement claims, Bioventus could incur significant costs and expenses that could adversely affect Bioventus&#146; business, results of operation and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may be subject to damages resulting from claims that Bioventus or Bioventus&#146; employees have wrongfully used or disclosed alleged trade
secrets of Bioventus&#146; competitors or former employers or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements with Bioventus&#146; competitors or former
employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus could in the future be subject to claims that Bioventus or Bioventus&#146; employees have inadvertently or otherwise used or
disclosed alleged trade secrets or other proprietary information of former employers or competitors. In addition, Bioventus may in the future be subject to claims that Bioventus caused an employee to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach the terms of his or her <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement. Litigation may be necessary to defend
against these claims. Even if Bioventus is successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If Bioventus&#146; defense to those claims fails, in addition to paying
monetary damages, a court could prohibit Bioventus from using technologies or features that are essential to Bioventus&#146; products, if such technologies or features are found to incorporate or be derived from the trade secrets or other
proprietary information of the competitors or former employers. An inability to incorporate technologies or features that are important or essential to Bioventus&#146; products could adversely affect its business, results of operations and financial
condition, and may prevent Bioventus from selling Bioventus&#146; products. In addition, Bioventus may lose valuable intellectual property rights or personnel. Any litigation or the threat thereof may adversely affect Bioventus&#146; ability to hire
employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent Bioventus&#146; ability to commercialize Bioventus&#146; products, which could adversely affect its business, results
of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidates that Bioventus develops as biologics subject to the BLA pathway may be subject to
competition sooner than anticipated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus expects to submit a BLA to allow for the marketing of MOTYS. See &#147;Risk
Factors&#150;&#150;Risks Relating to Government Regulation.&#148; Bioventus&#146; HCT/P products are subject to extensive government regulation and Bioventus&#146; failure to comply with these requirements could cause its business to suffer. These
products could be subject to significant additional regulatory requirements. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of
biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on
its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and
implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when processes intended to implement BPCIA may be fully adopted by the FDA, any of these processes could have a
material adverse effect on the future commercial prospects for Bioventus&#146; biological products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus believes that any of the product candidates
Bioventus develops that is approved in the United States as a biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be
shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than
anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT>
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the approval of a
biologic product biosimilar to one of Bioventus&#146; products could have a material adverse impact on Bioventus&#146; business as it may be significantly less costly to bring to market and may be priced significantly lower than Bioventus&#146;
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to Bioventus&#146; business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once granted, patents may remain open to invalidity challenges including opposition, interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT>
post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant.
In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the degree of future protection afforded by Bioventus&#146; intellectual property rights is
uncertain because even granted intellectual property rights have limitations, and may not adequately protect Bioventus&#146; business, provide a barrier to entry against Bioventus&#146; competitors or potential competitors or permit Bioventus to
maintain Bioventus&#146; competitive advantage. Moreover, if a third-party has intellectual property rights that cover the practice of Bioventus&#146; technology, Bioventus may not be able to fully exercise or extract value from Bioventus&#146;
intellectual property rights. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to develop and/or practice technology that is similar to Bioventus&#146; technology or aspects
of Bioventus&#146; technology, but that are not covered by the claims of the patents that Bioventus owns or controls, assuming such patents have issued or do issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus or Bioventus&#146; licensors or any future strategic partners might not have been the first to conceive
or reduce to practice the inventions covered by the issued patent or pending patent application that Bioventus owns or has exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus or Bioventus&#146; licensors or any future strategic partners might not have been the first to file
patent applications covering certain of Bioventus&#146; inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of Bioventus&#146;
technologies without infringing Bioventus&#146; intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; pending patent applications may not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that Bioventus owns or exclusively licenses may not provide Bioventus with any competitive
advantage, or may be held invalid or unenforceable, as a result of legal challenges by Bioventus&#146; competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; competitors might conduct research and development activities in countries where Bioventus does
not have patent rights and then use the information learned from such activities to develop competitive products for sale in Bioventus&#146; major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties performing manufacturing or testing for Bioventus using Bioventus&#146; products or technologies
could use the intellectual property of others without obtaining a proper license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">parties may assert an ownership interest in Bioventus&#146; intellectual property and, if successful, such
disputes may preclude Bioventus from exercising exclusive rights over that intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus may not develop or <FONT STYLE="white-space:nowrap">in-license</FONT> additional proprietary
technologies that are patentable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may adversely affect Bioventus&#146; business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Bioventus&#146; Organizational Structure and the Tax Receivable Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; principal asset is Bioventus&#146; interest in BV LLC, and, accordingly, Bioventus depends on distributions from BV LLC to pay
Bioventus&#146; taxes and expenses, including payments under the Tax Receivable Agreement. BV LLC&#146;s ability to make such distributions may be subject to various limitations and restrictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a holding company and has no material assets other than Bioventus&#146; ownership of LLC interests of BV LLC. As such, Bioventus has no
independent means of generating net sales or cash flow, and Bioventus&#146; ability to pay Bioventus&#146; taxes and operating expenses or declare and pay dividends in the future, if any, will be dependent upon the financial results and cash flows
of BV LLC and its subsidiaries and distributions Bioventus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receives from BV LLC. There can be no assurance that BV LLC and its subsidiaries will generate sufficient cash flow to distribute funds to Bioventus or that applicable state law and contractual
restrictions, including negative covenants in Bioventus&#146; debt instruments, will permit such distributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BV LLC is treated as a partnership for
U.S. federal income tax purposes and, as such, generally will not be subject to any entity-level U.S. federal income tax. Instead, taxable income will be allocated to holders of LLC interests, including Bioventus. Accordingly, Bioventus will incur
income taxes on Bioventus&#146; allocable share of any net taxable income of BV LLC. Under the terms of the Bioventus LLC agreement, BV LLC will be obligated to make tax distributions to holders of LLC interests, including Bioventus, subject to any
limitations or restrictions in Bioventus&#146; debt arrangements. In addition to tax expenses, Bioventus will also incur expenses related to Bioventus&#146; operations, including payments under the Tax Receivable Agreement (TRA), which Bioventus
expects could be significant. See &#147;Description of Bioventus&#146; Business&#151;Tax Receivable Agreement.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus intends, as its managing
member, to cause BV LLC to make cash distributions to the owners of LLC interests, including Bioventus, in an amount sufficient to (i)&nbsp;fund their or Bioventus&#146; tax obligations in respect of allocations of taxable income from BV LLC and
(ii)&nbsp;cover Bioventus&#146; operating expenses, including payments under the TRA. However, BV LLC&#146;s ability to make such distributions may be subject to various limitations and restrictions, such as restrictions on distributions that would
either violate any contract or agreement to which BV LLC is then a party, including debt agreements, or any applicable law, or that would have the effect of rendering BV LLC insolvent. If Bioventus does not have sufficient funds to pay taxes or
other liabilities or to fund Bioventus&#146; operations, Bioventus may have to borrow funds, which could materially adversely affect Bioventus&#146; liquidity and financial condition and subject Bioventus to various restrictions imposed by any such
lenders. To the extent that Bioventus is unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a
material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA. See &#147;Description of Bioventus&#146; Business&#151;Tax Receivable Agreement&#148;. In addition, if BV LLC does not have sufficient funds
to make distributions, Bioventus&#146; ability to declare and pay cash dividends will also be restricted or impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The TRA with the continuing
LLC owner requires Bioventus to make cash payments to it in respect of certain tax benefits to which Bioventus is or may become entitled, and Bioventus expects that the payments it will be required to make could be significant. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a party to a TRA with the continuing LLC owner. Under the TRA, Bioventus is required to make cash payments to the continuing LLC owner equal to
85% of the tax benefits, if any, that Bioventus actually realizes, or in certain circumstances are deemed to realize, as a result of (1)&nbsp;increases in the tax basis of assets of BV LLC resulting from (a)&nbsp;any future redemptions or exchanges
of LLC interests described under<I> </I>&#147;Description of Bioventus&#146; Business&#151;Bioventus LLC Agreement&#151;LLC Interest Redemption Right,&#148; and (b)&nbsp;certain distributions (or deemed distributions) by BV LLC and (2)&nbsp;certain
other tax benefits arising from payments under the TRA. Bioventus expects the amount of the cash payments that it will be required to make under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary
depending upon a number of factors, including the timing of redemptions or exchanges by the continuing LLC owner, the amount of gain recognized by the continuing LLC owner, the amount and timing of the taxable income Bioventus generates in the
future, and the federal tax rates then applicable. Any payments made by Bioventus to the continuing LLC owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to Bioventus. To the extent
that Bioventus is unable to make timely payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid by Bioventus. Furthermore, Bioventus&#146; obligation to make payments under the TRA could make it
a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits that are the subject of the TRA. Payments under the TRA are not conditioned on the continuing LLC owner&#146;s
continued ownership of LLC interests or Bioventus class A common stock. For more information, see &#147;Description of Bioventus&#146; Business&#151;Tax Receivable Agreement.&#148; The actual amounts Bioventus will be required to pay under the TRA
will depend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on, among other things, the timing of subsequent redemptions or exchanges of LLC interests by the continuing LLC owner, the price of Bioventus&#146; shares of Class&nbsp;A common stock at the
time of each such redemption or exchange, and the amounts and timing of Bioventus&#146; future taxable income, and may be significantly different from the amounts described in the preceding sentence. Additionally, in certain cases such payments may
be accelerated or significantly exceed the actual benefits Bioventus realize. In certain cases, payments under the TRA to the continuing LLC owners may be accelerated or significantly exceed the actual benefits Bioventus realizes in respect of tax
attributes subject to the TRA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; organizational structure, including the TRA, confers certain tax benefits upon the continuing LLC
owner that may not benefit Class&nbsp;A common stockholders to the same extent as they will benefit the continuing LLC owner. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146;
organizational structure, including the TRA, confers certain tax benefits upon the continuing LLC owner that may not benefit the holders of Bioventus class A common stock to the same extent as they will benefit the continuing LLC owner. Bioventus
entered into the TRA with BV LLC and the continuing LLC owner that provides for Bioventus&#146; payment to the continuing LLC owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes (or in some circumstances are deemed
to realize) as a result of (i)&nbsp;increases in the tax basis of assets of BV LLC resulting from (a)&nbsp;any future redemptions or exchanges of LLC interests described under &#147;Description of Bioventus&#146; Business&#151;Bioventus LLC
agreement&#151;LLC Interest Redemption Right&#148;, and (b)&nbsp;certain distributions (or deemed distributions) by BV LLC and (ii)&nbsp;certain other tax benefits arising from payments under the TRA. Although Bioventus will retain 15% of such tax
benefits, this and other aspects of Bioventus&#146; organizational structure may adversely impact the future trading market for the Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In certain cases, payments under the TRA to the continuing LLC owner may be accelerated or significantly exceed the actual benefits Bioventus realizes
in respect of the tax attributes subject to the TRA. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TRA provides that if (i)&nbsp;Bioventus materially breaches any of Bioventus&#146;
material obligations under the TRA, (ii)&nbsp;certain mergers, asset sales, other forms of business combinations or other changes of control were to occur on or before December&nbsp;31, 2021 or (iii)&nbsp;Bioventus elects an early termination of the
TRA, then Bioventus&#146; obligations or Bioventus&#146; successor&#146;s obligations under the TRA to make payments thereunder would be based on certain assumptions, including an assumption that Bioventus would have sufficient taxable income to
fully utilize all potential future tax benefits that are subject to the TRA (or, in the case of certain mergers, asset sales, other forms of business combinations or other changes of control occurring after December&nbsp;31, 2021, that Bioventus
would have taxable income at least equal to Bioventus&#146; times the highest taxable income in any of the Bioventus&#146; fiscal quarters ending prior to the closing date of such transaction (increased by 10% for each taxable year beginning with
the second taxable year following such closing date)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the foregoing, (i)&nbsp;Bioventus could be required to make payments under the TRA
that are greater than the specified percentage of the actual benefits Bioventus ultimately realizes in respect of the tax benefits that are subject to the TRA and (ii)&nbsp;if Bioventus materially breaches any of its material obligations under the
TRA or if Bioventus elected to terminate the TRA early, it would be required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the TRA, which payment may be made significantly
in advance of the actual realization, if any, of such future tax benefits. In these situations, Bioventus&#146; obligations under the TRA could have a substantial negative impact on its liquidity and could have the effect of delaying, deferring or
preventing certain mergers, asset sales, other forms of business combinations or other changes of control. There can be no assurance that Bioventus will be able to fund or finance its obligations under the TRA. Bioventus may elect to completely
terminate the TRA early only with the written approval of a majority of its directors other than any directors that have been appointed or designated by the continuing LLC owner or any of such person&#146;s affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may make payments to the continuing LLC owner under the TRA that exceed the tax benefits
actually realized by it in the event that any tax benefits are disallowed by a taxing authority. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments under the TRA are based on the tax
reporting positions that Bioventus determines, and the Internal Revenue Service (IRS) or another tax authority may challenge all or part of the tax basis increases, as well as other related tax positions Bioventus takes, and a court could sustain
such challenge. Pursuant to the TRA, the continuing LLC owner is required to reimburse Bioventus for any cash payments previously made to it under the TRA in the event that any tax benefits actually realized by Bioventus and for which payment has
been made under the TRA are subsequently challenged by a taxing authority and are ultimately disallowed. In addition, but without duplication of any amounts previously reimbursed by the continuing LLC owner, any excess cash payments made by
Bioventus to the continuing LLC owner will be netted against any future cash payments that Bioventus might otherwise be required to make to the continuing LLC owner under the terms of the TRA. However, Bioventus might not determine that it has
effectively made an excess cash payment to the continuing LLC owner for a number of years following the initial time of such payment. Moreover, there can be no assurance that any excess cash payments for which the continuing LLC owner has a
reimbursement obligation under the TRA will be repaid to Bioventus. As a result, payments could be made under the TRA in excess of the tax savings that Bioventus realizes in respect of the tax attributes with respect to the continuing LLC owner that
are the subject of the TRA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of Bioventus&#146; income
or other tax returns could adversely affect its results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is subject to taxes by the U.S. federal,
state, local and foreign tax authorities, and Bioventus&#146; tax liabilities will be affected by the allocation of expenses to differing jurisdictions. Bioventus&#146; future effective tax rates could be subject to volatility or adversely affected
by a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the valuation of Bioventus&#146; deferred tax assets and liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expected timing and amount of the release of any tax valuation allowances; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax effects of equity-based compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in tax laws, regulations or interpretations thereof; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future earnings being lower than anticipated in countries where Bioventus has lower statutory tax rates and
higher than anticipated earnings in countries where it has higher statutory tax rates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Bioventus may be subject to audits
of its income, sales and other transaction taxes by U.S. federal, state, local and foreign taxing authorities. Outcomes from these audits could adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Bioventus was deemed to be an investment company under the Investment Company Act of 1940, as amended, or the 1940 Act, as a result of
Bioventus&#146; ownership of BV LLC, applicable restrictions could make it impractical for Bioventus to continue its business as contemplated and could adversely affect its business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Sections 3(a)(1)(A) and (C)&nbsp;of the 1940 Act, a company generally will be deemed to be an &#147;investment company&#148; for purposes of the 1940 Act
if (i)&nbsp;it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (ii)&nbsp;it engages, or proposes to engage, in the business of investing,
reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an
unconsolidated basis. Bioventus does not believe that it is an &#147;investment company,&#148; as such term is defined in either of those sections of the 1940 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the sole managing member of BV LLC, Bioventus controls and operates BV LLC. On that basis, Bioventus believes that its interest in BV LLC is not an
&#147;investment security&#148; as that term is used in the 1940 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
However, if Bioventus was to cease participation in the management of BV LLC, Bioventus&#146; interest in BV LLC could be deemed an &#147;investment security&#148; for purposes of the 1940 Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and BV LLC intend to conduct Bioventus&#146; operations so that it will not be deemed an investment company. However, if Bioventus was to be
deemed an investment company, restrictions imposed by the 1940 Act, including limitations on its capital structure and its ability to transact with affiliates, could make it impractical for Bioventus to continue its business as contemplated and
could adversely affect its business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is controlled by the original LLC owners, whose
interests may differ from those of Bioventus&#146; public stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;22, 2021, the original LLC owners control approximately
83.8% of the combined voting power of Bioventus&#146; common stock through their ownership of both Bioventus class A common stock and Bioventus class B common stock. The original LLC owners will, for the foreseeable future, have the ability to
substantially influence Bioventus through their ownership position over corporate management and affairs, and will be able to control virtually all matters requiring stockholder approval. The original LLC owners are able to, subject to applicable
law, and the voting arrangements described in the stockholders agreement, elect a majority of the members of Bioventus&#146; Board control actions to be taken by Bioventus and Bioventus board, including amendments to Bioventus&#146; certificate of
incorporation and bylaws and approval of significant corporate transactions, including mergers and sales of substantially all of Bioventus&#146; assets. The directors so elected will have the authority, subject to the terms of Bioventus&#146;
indebtedness and applicable rules and regulations, to issue additional stock, implement stock repurchase programs, declare dividends and make other decisions. It is possible that the interests of the original LLC owners may in some circumstances
conflict with Bioventus&#146; interests and the interests of its other stockholders, including you. For example, the continuing LLC owner may have different tax positions from Bioventus, especially in light of the TRA that could influence
Bioventus&#146; decisions regarding whether and when to dispose of assets, whether and when to incur new or refinance existing indebtedness, and whether and when Bioventus should terminate the TRA and accelerate its obligations thereunder. In
addition, the determination of future tax reporting positions and the structuring of future transactions may take into consideration the continuing LLC owner&#146;s tax or other considerations, which may differ from the considerations of Bioventus
or Bioventus&#146; other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Ownership of Bioventus&#146; Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In the past, Bioventus identified material weaknesses in its internal control over financial reporting. If Bioventus experiences additional material
weaknesses in the future or otherwise fails to maintain an effective system of internal controls, Bioventus may not be able to accurately or timely requirements applicable to public companies, which may adversely affect investor confidence in
Bioventus, and, as a result, the market price of Bioventus class A common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that Bioventus has adequate internal financial and
accounting controls and procedures in place so that it can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Bioventus&#146; internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A material weakness is a deficiency, or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility
that a material misstatement of Bioventus&#146; financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the audit of
Bioventus&#146; consolidated financial statements as of and for the year ended December&nbsp;31, 2020, Bioventus determined that it no longer has a material weakness associated with the proper </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processing of Exogen reimbursement claims in accordance with regulations and contractual terms. Bioventus implemented measures designed to improve its internal control over financial reporting to
remediate such material weakness. These efforts included: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the augmentation, reorganization and training of Bioventus&#146; prescription to cash staff, which includes its
direct sales team, order management personnel, patient financial services personnel and reimbursement services and accounts receivable personnel, regarding key aspects of regulations and requirements and how to deal with inconsistencies within
patient medical records; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementation of monthly sales order testing on sampling basis by Bioventus&#146; Compliance department
including a review of medical necessity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a cross functional governance committee, reporting to an executive steering committee to review
and approve Bioventus&#146; Exogen Medicare policy and oversee future Exogen policy and process interpretations and changes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementation of a checklist to be completed for each Medicare order to ensure compliance with Bioventus&#146;
policy for Medicare claims and then further automating this checklist. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus cannot assure you that the measures Bioventus has
taken to date, and actions Bioventus may take in the future, will be sufficient to prevent or avoid potential future material weaknesses. If Bioventus identifies any additional material weaknesses, the accuracy and timing of its financial reporting
may be adversely affected, Bioventus may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in
its financial reporting, and the market price of its Class&nbsp;A common stock may decline as a result. Bioventus could also become subject to investigations by the SEC or other regulatory authorities, which could require additional financial and
management resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to establish and maintain effective internal controls in accordance with Section&nbsp;404 of the Sarbanes-Oxley Act
could adversely affect Bioventus&#146; business and stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is required to comply with the SEC&#146;s rules implementing Sections
302 and 404 of the Sarbanes-Oxley Act, which require management to certify financial and other information in its quarterly and annual reports and provide an annual management report on the effectiveness of internal controls over financial
reporting. Though Bioventus will be required to disclose changes made in its internal controls and procedures on a quarterly basis, Bioventus will not be required to make Bioventus&#146; first annual assessment of its internal control over financial
reporting pursuant to Section&nbsp;404 until the year following its first annual report required to be filed with the SEC. However, as an emerging growth company, Bioventus&#146; independent registered public accounting firm will not be required to
formally attest to the effectiveness of its internal control over financial reporting pursuant to Section&nbsp;404 until the later of the year following its first annual report required to be filed with the SEC or the date it is no longer an
emerging growth company. At such time, Bioventus&#146; independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which Bioventus&#146; controls are documented, designed or
operating. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To comply with the requirements of being a public company, Bioventus has undertaken various actions, and may need to take additional actions,
such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Testing and maintaining internal controls can divert Bioventus&#146; management&#146;s attention from other matters that are
important to the operation of Bioventus&#146; business. Additionally, when evaluating Bioventus&#146; internal controls over financial reporting, Bioventus may identify material weaknesses that Bioventus may not be able to remediate in time to meet
the applicable deadline imposed upon Bioventus for compliance with the requirements of Section&nbsp;404. If Bioventus identifies any material weaknesses in Bioventus&#146; internal controls over financial reporting or are unable to comply with the
requirements of Section&nbsp;404 in a timely manner or assert that Bioventus&#146; internal controls over financial reporting is effective, or if Bioventus&#146; independent registered public accounting firm is unable to express an opinion as to the
effectiveness of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bioventus&#146; internal controls over financial reporting once Bioventus is no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of
Bioventus&#146; financial reports and the market price of Bioventus class A common stock could be adversely affected, and Bioventus could become subject to investigations by the stock exchange on which Bioventus&#146; securities are listed, the SEC
or other regulatory authorities, which could require additional financial and management resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is a &#147;controlled company&#148;
within the meaning of Nasdaq listing standards and, as a result, will qualify for, and intend to rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that
are subject to such requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The former LLC owners and continuing LLC owner (&#147;Voting Group&#148;), which holds Bioventus class A common
stock and Bioventus class B common stock representing approximately 83.8% of the combined voting power of Bioventus&#146; common stock, entered into a stockholders agreement filed as exhibit 10.4 hereto. For a period of time, the parties to the
stockholders agreement will agree to vote their shares of Bioventus class A common stock and Bioventus class B common stock in favor of the election of the nominees of certain members of the Voting Group to Bioventus&#146; Board upon their
nomination by the nominating and corporate governance committee of Bioventus&#146; Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the stockholders agreement and the aggregate voting
power over Bioventus class A common stock and Bioventus class B common stock held by the parties to the stockholders agreement, Bioventus is considered a &#147;controlled company&#148; for the purposes of Nasdaq. As such, Bioventus is exempt from
certain corporate governance requirements of Nasdaq, including (1)&nbsp;the requirement that a majority of the Board consist of independent directors, (2)&nbsp;the requirement that Bioventus has a nominating and corporate governance committee that
is composed entirely of independent directors and (3)&nbsp;the requirement that Bioventus has a compensation committee that is composed entirely of independent directors. Bioventus intends to rely on some or all of these exemptions. As a result,
Bioventus does not have a majority of independent directors and Bioventus&#146; compensation and nominating and corporate governance committees do not consist entirely of independent directors. Accordingly, you will not have the same protections
afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taking advantage of the reduced
disclosure requirements applicable to &#147;emerging growth companies&#148; may make Bioventus class A common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JOBS Act provides that, so long as a company qualifies as an &#147;emerging growth company,&#148; it will, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be exempt from the provisions of Section&nbsp;404(b) of the Sarbanes-Oxley Act requiring that its independent
registered public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be exempt from the &#147;say on pay&#148; and &#147;say on golden parachute&#148; advisory vote requirements of
the Dodd-Frank Wall Street Reform and Customer Protection Act, or the Dodd-Frank Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be exempt from certain disclosure requirements of the Dodd-Frank Act relating to compensation of its executive
officers and be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Exchange Act; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be permitted to provide a reduced level of disclosure concerning executive compensation and be exempt from any
rules that have been adopted by the Public Company Accounting Oversight Board requiring a supplement to the auditor&#146;s report on the financial statements or that may be adopted requiring mandatory audit firm rotations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is an &#147;emerging growth company,&#148; as defined in the JOBS Act, and Bioventus could be an emerging growth company for up to five years
following its IPO. For as long as Bioventus continues to be an emerging </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
growth company, Bioventus may choose to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. Bioventus has irrevocably elected
not to take advantage of the extension of time to comply with new or revised financial accounting standards available under Section&nbsp;107(b) of the JOBS Act. Bioventus has also taken advantage of certain reduced reporting burdens in this joint
proxy statement/prospectus. Bioventus could be an emerging growth company for up to five years after its IPO and will continue to be an emerging growth company unless Bioventus&#146; total annual gross revenues are $1.07&nbsp;billion or more,
Bioventus has issued more than $1&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in the past three years or Bioventus becomes a &#147;large accelerated filer&#148; as defined in the Exchange Act. If Bioventus remains an
&#147;emerging growth company&#148;, Bioventus may take advantage of other exemptions, including the exemptions from the advisory vote requirements and executive compensation disclosures under the Dodd-Frank Act and the exemption from the provisions
of Section&nbsp;404(b) of the Sarbanes-Oxley Act. Bioventus cannot predict if investors will find its Bioventus class A common stock less attractive if Bioventus elects to rely on these exemptions, or if taking advantage of these exemptions would
result in less active trading or more volatility in the price of Bioventus class A common stock. Also, as a result of Bioventus&#146; intention to take advantage of some or all of the reduced regulatory and reporting requirements that will be
available to Bioventus as long as Bioventus qualifies as an &#147;emerging growth company,&#148; Bioventus&#146; financial statements may not be comparable to those of companies that fully comply with regulatory and reporting requirements upon the
public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus does not currently expect to pay any cash dividends. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus does not anticipate declaring or paying any cash dividends to holders of its Bioventus class A common stock in the foreseeable future. Bioventus
currently intends to retain future earnings, if any, to finance its growth. Any determination to pay cash dividends in the future will be at the sole discretion of Bioventus&#146; Board, subject to limitations under applicable law and may be
discontinued at any time. In addition, Bioventus&#146; ability to pay cash dividends is currently restricted by the terms of Bioventus&#146; 2019 Credit Agreement. Therefore, you are not likely to receive any dividends on your Bioventus class A
common stock for the foreseeable future, and the success of an investment in Bioventus class A common stock will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of Bioventus
class A common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that Bioventus class A common stock will appreciate in value or even maintain the price at
which Bioventus&#146; stockholders have purchased Bioventus class A common stock. Investors seeking cash dividends should not purchase Bioventus class A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Bioventus&#146; operations are currently conducted entirely through BV LLC and its subsidiaries and Bioventus&#146; ability to generate cash to
meet its debt service obligations or to make future dividend payments, if any, is highly dependent on the earnings and the receipt of funds from BV LLC and its subsidiaries via dividends or intercompany loans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; amended and restated certificate of incorporation, to the extent permitted by applicable law, contains provisions renouncing
Bioventus&#146; interest and expectation to participate in certain corporate opportunities identified or presented to certain of its original LLC owners. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the original LLC owners are in the business of making or advising on investments in companies and these Original LLC owners may hold, and may, from
time to time in the future, acquire interests in or provide advice to businesses that directly or indirectly compete with certain portions of Bioventus&#146; business or the business of Bioventus&#146; suppliers. Bioventus&#146; amended and restated
certificate of incorporation provides that, to the fullest extent permitted by law, none of the original LLC owners or any director who is not employed by Bioventus or his or her affiliates will have any duty to refrain from engaging in a corporate
opportunity in the same or similar lines of business as Bioventus. The original LLC owners may also pursue acquisitions that may be complementary to Bioventus&#146; business, and, as a result, those acquisition opportunities may not be available to
Bioventus. As a result, these arrangements could adversely affect Bioventus&#146; business, results of operations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial condition or prospects if attractive business opportunities are allocated to any of the original LLC owners instead of to Bioventus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus may issue shares of preferred stock in the future, which could make it difficult for another company to acquire Bioventus or could otherwise
adversely affect holders of Bioventus class A common stock, which could depress the price of Bioventus class A common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146;
amended and restated certificate of incorporation will authorize Bioventus to issue one or more series of preferred stock. Bioventus&#146; Board will have the authority to determine the preferences, limitations and relative rights of the shares of
preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by Bioventus&#146; stockholders. Bioventus&#146; preferred stock could be issued with voting, liquidation,
dividend and other rights superior to the rights of Bioventus class A common stock. The potential issuance of preferred stock may delay or prevent a change in control of Bioventus, discourage bids for Bioventus class A common stock at a premium to
the market price, and materially and adversely affect the market price and the voting and other rights of the holders of Bioventus class A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in Bioventus&#146; governing documents and under Delaware law could make an acquisition of its company more difficult, limit
attempts by Bioventus&#146; stockholders to replace or remove Bioventus&#146; current management, and depress the market price of Bioventus&#146; common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could have the effect
of rendering more difficult, delaying or preventing an acquisition deemed undesirable by Bioventus&#146; Board and include the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorizing the issuance of &#147;blank check&#148; preferred stock that could be issued by Bioventus&#146; Board
to increase the number of outstanding shares and thwart a takeover attempt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing a classified Board so that not all members of Bioventus&#146; Board are elected at one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the removal of directors only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibiting the use of cumulative voting for the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limiting the ability of stockholders to call special meetings or amend Bioventus&#146; bylaws;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring all stockholder actions to be taken at a meeting of Bioventus&#146; stockholders; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing advance notice and duration of ownership requirements for nominations for election to the Board or
for proposing matters that can be acted upon by stockholders at stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, alone or together, could delay
or prevent hostile takeovers and changes in control or changes in Bioventus&#146; management. As a Delaware corporation, Bioventus is also subject to provisions of Delaware law, including Section&nbsp;203 of the DGCL, which prevents interested
stockholders, such as certain stockholders holding more than 15% of Bioventus&#146; outstanding common stock from engaging in certain business combinations unless (i)&nbsp;prior to the time such stockholder became an interested stockholder, the
board approved the transaction that resulted in such stockholder becoming an interested stockholder, (ii)&nbsp;upon consummation of the transaction that resulted in such stockholder becoming an interested stockholder, the interested stockholder
owned 85% of the common stock or (iii)&nbsp;following board approval, the business combination receives the approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of Bioventus&#146; outstanding common stock not held
by such interested stockholder. Because Bioventus has &#147;opted out&#148; of Section&nbsp;203 of the DGCL in its amended and restated certificate of incorporation, the statute will not apply to business combinations involving Bioventus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any provision of Bioventus&#146; amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of
delaying, preventing or deterring a change in control could limit the opportunity for Bioventus&#146; stockholders to receive a premium for their shares of Bioventus&#146; common stock and could also affect the price that some investors are willing
to pay for Bioventus&#146; common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; amended and restated certificate of incorporation provides that the Court of Chancery
of the State of Delaware will be the sole and exclusive forum for substantially all disputes between Bioventus and Bioventus&#146; stockholders, which could limit Bioventus&#146; stockholders&#146; ability to obtain a favorable judicial forum for
disputes with Bioventus or Bioventus&#146; directors, officers or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; amended and restated certificate of incorporation
provides that, unless Bioventus consents to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for: (a)&nbsp;any derivative action, suit or proceeding brought on its behalf;
(b)&nbsp;any action, suit or proceeding asserting a claim of breach of fiduciary duty owed by any of Bioventus&#146; directors, officers or stockholders to Bioventus or to Bioventus&#146; stockholders; (c)&nbsp;any action, suit or proceeding arising
pursuant to any provision of the DGCL, Bioventus&#146; amended and restated certificate of incorporation or amended bylaws (as either may be amended from time to time); or, (d)&nbsp;any action, suit or proceeding asserting a claim governed by the
internal affairs doctrine; provided that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The choice of forum
provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with Bioventus or Bioventus&#146; directors, officers or other employees, which may discourage such lawsuits against Bioventus
and Bioventus&#146; directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in Bioventus&#146; amended and restated certificate of incorporation to be inapplicable or unenforceable in
an action, Bioventus may incur additional costs associated with resolving such action in other jurisdictions, which could harm its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Proposed Acquisition of Misonix </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus is subject to various risks related to the proposed acquisition of Misonix. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has entered into a merger agreement with Misonix pursuant to which Bioventus has agreed to acquire Misonix. The risks, contingencies and other
uncertainties that could result in the failure of the proposed acquisition to be completed or, if completed, that could have a material adverse effect on Bioventus&#146; business, financial condition or results of operations following the proposed
acquisition, and any anticipated benefits of the proposed acquisition, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to obtain necessary stockholder approvals for the share issuance and the adoption of the merger
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to satisfy required closing conditions or complete the proposed acquisition in a timely manner or at
all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of the announcement of the proposed acquisition on each company&#146;s ability to retain and hire key
personnel, maintain business relationships, and on operating results and the businesses generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of Misonix to pursue alternatives to the proposed acquisition with us pursuant to the merger
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the diversion of Bioventus&#146; management&#146;s attention from its core business as Bioventus works to take
all steps necessary to close the transaction and integrate Misonix&#146;s business into Bioventus&#146;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of additional equity in connection with the acquisition may dilute Bioventus&#146; stockholders and
the uncertainties related to the potential impact of the proposed acquisition on Bioventus&#146; stock price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to achieve the anticipated synergies and Bioventus&#146; incurrence of significant transaction
related costs in connection with the proposed acquisition that are, and will be, incurred regardless of whether the proposed acquisition is completed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any event giving rise to the right to terminate the merger agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus&#146; future results following the proposed acquisition will suffer if Bioventus does not
effectively manage the expanded operations or successfully integrate the businesses of Misonix. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; future success will depend, in
part, upon its ability to manage the expanded business, including challenges related to the management and monitoring of new operations and associated increased costs and complexity associated with the acquisition of Misonix and other acquisitions.
If Bioventus is not able to successfully complete integrations in an efficient and effective manner, the anticipated benefits of these acquisitions may not be realized fully, or at all, or may take longer to realize than expected, and the value of
Bioventus&#146; common stock may be affected adversely. An inability to realize the full extent of the anticipated benefits of the proposed acquisitions, as well as any delays encountered in the integration processes, could have an adverse effect
upon on Bioventus&#146; business, financial condition or results of operations. In addition, the actual integrations may result in additional and unforeseen expenses, including increased legal, accounting and compliance costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to complete the proposed acquisition may negatively impact Bioventus&#146; share price, the future business and Bioventus&#146; financial
results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the proposed acquisition is not completed on a timely basis, Bioventus&#146; and Misonix ongoing businesses may be adversely affected.
If the proposed acquisition is not completed at all, Bioventus will be subject to a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being required to pay costs and expenses relating to the transactions, such as legal, accounting, financial
advisory and printing fees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and resources committed by Bioventus&#146; management to matters relating to the proposed acquisition could
otherwise have been devoted to pursuing other beneficial opportunities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the proposed acquisition is not completed, the price of
Bioventus&#146; common stock may decline to the extent that the current market price reflects a market assumption that the proposed acquisition will be completed and that the related benefits will be realized, or a market perception that the
proposed acquisition was not completed due to an adverse change in Bioventus&#146; business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Risk Factors of Misonix </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix&#146;s business is and will be subject to the risks described above. In addition, Misonix is, and will continue to be, subject to the risks described
in its Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the fiscal year ended June&nbsp;30, 2021, as such risks may be updated or supplemented in Misonix&#146;s subsequently filed Quarterly Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> each of which are filed with the SEC and incorporated by reference in this joint proxy statement/prospectus. See
&#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_11"></A>THE PARTIES TO THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>4721 Emperor Boulevard, Suite 400
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Durham, North Carolina 27703 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(919) <FONT
STYLE="white-space:nowrap">474-6700</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a global leader of innovations for active healing. Through a combination of internal product
development, product/business acquisition, and distribution agreements, it will bring to market products which address a growing need for clinically effective, cost efficient, minimally invasive medical treatments, that engage and enhance the
body&#146;s natural healing processes. Bioventus&#146; principal place of business is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <FONT STYLE="white-space:nowrap">474-6700.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a Delaware corporation and Bioventus common stock is listed on Nasdaq under the ticker symbol &#147;BVS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about Bioventus, visit Bioventus&#146; website at www.bioventus.com. The information contained on or accessible through Bioventus&#146;
website (other than the documents incorporated by reference herein) does not constitute a part of this joint proxy statement/prospectus or any other report or document on file with or furnished to the SEC. Additional information about Bioventus is
included in the documents incorporated by reference in this joint proxy statement/prospectus. See &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1938 New Highway </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Farmingdale, New York </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(631) <FONT
STYLE="white-space:nowrap">694-9555</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix designs, manufactures and markets minimally invasive surgical ultrasonic medical devices. These
products are used for precise bone sculpting, removal of soft and hard tumors, and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. Misonix also exclusively
markets, sells and distributes skin allografts and wound care products used to support healing of wounds, and which complement Misonix&#146;s ultrasonic medical devices Misonix&#146;s principal place of business is 1938 New Highway, Farmingdale, New
York, and its telephone number is (631) <FONT STYLE="white-space:nowrap">694-9555.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix is a Delaware corporation and Misonix common stock is
listed on Nasdaq under the ticker symbol &#147;MSON.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about Misonix, visit Misonix&#146;s website at www.Misonix.com. The
information contained on or accessible through Misonix&#146;s website (other than the documents incorporated by reference herein) does not constitute a part of this joint proxy statement/prospectus or any other report or document on file with or
furnished to the SEC. Additional information about Misonix is included in the documents incorporated by reference in this joint proxy statement/prospectus. See &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oyster Merger Sub I, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>4721 Emperor Boulevard,
Suite 100 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Durham, North Carolina 27703 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(919) <FONT
STYLE="white-space:nowrap">474-6700</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub I was formed by Bioventus solely in contemplation of the merger, has not conducted any business
and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, Merger Sub I will be merged with and into Misonix, with Misonix continuing as the surviving corporation. Merger
Sub I&#146;s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <FONT STYLE="white-space:nowrap">474-67002485.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oyster Merger Sub II, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>4721 Emperor Boulevard, Suite 100 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Durham, North
Carolina 27703 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(919) <FONT STYLE="white-space:nowrap">474-6700</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merger Sub II was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of
any nature other than as set forth in the merger agreement. By operation of the merger, following the first merger, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (renamed as Misonix LLC)
and a wholly owned subsidiary of Bioventus. Merger Sub II&#146;s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919)
<FONT STYLE="white-space:nowrap">474-6700.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_12"></A>THE BIOVENTUS SPECIAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is being provided to Bioventus stockholders in connection with the solicitation of proxies by the Bioventus board for
use at the Bioventus special meeting and at any adjournments or postponements thereof. Bioventus stockholders are encouraged to read this entire document carefully, including its annexes and the documents incorporated by reference herein, for more
detailed information regarding the merger agreement and the transactions contemplated thereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date, Time and Place of the Bioventus Special Meeting
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus special meeting is scheduled to be held virtually via live webcast on October 26, 2021, beginning at 11:00 a.m., Eastern Time, unless
postponed to a later date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of ongoing developments related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Bioventus has
elected to hold the Bioventus special meeting solely by means of remote communication via live webcast. Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting
www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the &#147;Bioventus special meeting website.&#148; Bioventus stockholders will need the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number found on their proxy card in
order to access the Bioventus special meeting website and to access the list of Bioventus stockholders entitled to vote at the Bioventus special meeting during the time of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has retained Broadridge to host the live webcast of the Bioventus special meeting. Thirty minutes prior to the Bioventus special meeting, Broadridge
may be contacted at (855) <FONT STYLE="white-space:nowrap">499-0991</FONT> (U.S. toll-free) or (720) <FONT STYLE="white-space:nowrap">378-5962</FONT> (international toll), and will be available to answer any questions regarding how to virtually
attend the Bioventus special meeting or if you encounter any technical difficulty accessing or during the Bioventus special meeting. Technical support phone numbers will also be available via the virtual meeting url 30 minutes prior to the start of
the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Matters to Be Considered at the Bioventus Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Bioventus special meeting is to consider and vote on each of the following proposals, each of which is further described in this joint proxy
statement/prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bioventus Proposal 1:</B> <I>Approval of the Share Issuance</I>. To consider and vote on the Bioventus share
issuance proposal; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bioventus Proposal 2:</B> <I>Adjournment of the Bioventus Special Meeting</I>. To consider and vote on the
Bioventus adjournment proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Bioventus Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board unanimously recommends that Bioventus stockholders vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bioventus Proposal 1:</B> &#147;<B>FOR</B>&#148; the Bioventus share issuance proposal; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bioventus Proposal 2:</B> &#147;<B>FOR</B>&#148; the Bioventus adjournment proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After careful consideration, the Bioventus board unanimously: (i)&nbsp;determined that the terms of the merger agreement and the merger are fair to and in the
best interests of Bioventus and its stockholders; (ii)&nbsp;approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, each on the terms and subject to the conditions
set forth in the merger agreement; and (iii)&nbsp;recommended that Bioventus stockholders approve of the Bioventus share issuance proposal. See &#147;The Mergers&#151;Recommendation of the Bioventus Board of Directors; Bioventus&#146;s Reasons for
the Merger.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date for the Bioventus Special Meeting and Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date to determine Bioventus stockholders who are entitled to receive notice of and to vote at the Bioventus special meeting or any adjournments or
postponements thereof is September 22, 2021. As of the close of business on the Bioventus record date, there were 56,849,338 shares of Bioventus common stock issued and outstanding and entitled to vote at the Bioventus special meeting. Each
Bioventus stockholder is entitled to one vote for each share of Bioventus common stock such holder owned of record at the close of business on the Bioventus record date with respect to each matter properly brought before the Bioventus special
meeting. Only Bioventus stockholders of record at the close of business on the Bioventus record date are entitled to receive notice of and to vote at the Bioventus special meeting and any and all adjournments or postponements thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum; Abstentions and Broker <FONT STYLE="white-space:nowrap">Non-Votes</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of Bioventus stockholders is necessary to conduct the Bioventus special meeting. The presence, virtually via the Bioventus special meeting website or
by proxy, of the holders of a majority in voting power of the stock issued and outstanding and entitled to vote at the Bioventus special meeting will constitute a quorum. Shares of Bioventus common stock represented at the Bioventus special meeting
by virtual attendance via the Bioventus special meeting website or by proxy and entitled to vote, but not voted, including shares for which an Bioventus stockholder directs an &#147;abstention&#148; from voting, will be counted for purposes of
determining a quorum. However, because all of the proposals for consideration at the Bioventus special meeting are considered <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules (as described below), shares
held in &#147;street name&#148; will not be counted as present for the purpose of determining the existence of a quorum unless the Bioventus stockholder provides their bank, broker or other nominee with voting instructions for at least one of the
proposals at the Bioventus special meeting. If a quorum is not present, the Bioventus special meeting will be adjourned or postponed until the holders of the number of shares of Bioventus common stock required to constitute a quorum attend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Nasdaq rules, banks, brokers or other nominees who hold shares in &#147;street name&#148; on behalf of the beneficial owner of such shares have the
authority to vote such shares in their discretion on certain &#147;routine&#148; proposals when they have not received voting instructions from the beneficial owners. However, banks, brokers or other nominees are not allowed to exercise their voting
discretion with respect to matters that under Nasdaq rules are <FONT STYLE="white-space:nowrap">&#147;non-routine.&#148;</FONT> This can result in a &#147;broker <FONT STYLE="white-space:nowrap">non-vote,&#148;</FONT> which occurs on an item when
(i)&nbsp;a bank, broker or other nominee has discretionary authority to vote on one or more &#147;routine&#148; proposals to be voted on at a meeting of stockholders, but is not permitted to vote on other
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> proposals without instructions from the beneficial owner of the shares, and (ii)&nbsp;the beneficial owner fails to provide the bank, broker or other nominee with voting instructions on
a <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matter. All of the proposals before the Bioventus special meeting are considered <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules, and banks,
brokers or other nominees will not have discretionary authority to vote on any matter before the Bioventus special meeting. As a result, Bioventus does not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> at the Bioventus special
meeting and if you hold your shares of Bioventus common stock in &#147;street name,&#148; your shares will not be represented and will not be voted on any matter unless you affirmatively instruct your bank, broker or other nominee how to vote your
shares in accordance with the voting instructions provided by your bank, broker or other nominee. It is therefore critical that you cast your vote by instructing your bank, broker or other nominee on how to vote. <B>Brokers will not be able to vote
on any of the proposals before the Bioventus special meeting unless they have received voting instructions from the beneficial owners.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Votes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the Bioventus adjournment proposal, the vote required to approve each of the proposals listed below assumes the presence of a quorum at the
Bioventus special meeting. As described above, Bioventus does not expect there to be any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> at the Bioventus special meeting. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Proposal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Required Vote</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effects of Certain Actions</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Proposal&nbsp;1:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus
share issuance proposal</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Assuming a quorum is present at the Bioventus special meeting, approval requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to
such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal
will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if an Bioventus stockholder who holds shares in &#147;street name&#148;
through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal
and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Proposal 2:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus
adjournment proposal</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus
adjournment proposal.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in
&#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">An abstention or other failure of any shares virtually present or represented by proxy
and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus adjournment proposal. However, if an Bioventus stockholder who holds shares in
&#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus
adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Support Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the execution of the merger agreement, Misonix entered into the Bioventus support agreement with the Bioventus supporting stockholders, pursuant
to which such stockholders have agreed, among other things, to vote the shares of Bioventus common stock that they beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal
made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Bioventus special meeting, such stockholders beneficially own approximately 67.4% of the outstanding shares of
Bioventus common stock. Therefore, the Bioventus supporting stockholders hold a sufficient number of shares of Bioventus common stock in order to approve the Bioventus share issuance proposal. On July&nbsp;29, 2021, in connection with execution of
the merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with Bioventus (each a &#147;lock up agreement&#148;) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or
180 days, subject to the terms of the lock up agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote of Bioventus Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Bioventus directors and executive
officers, and their affiliates, as a group, owned and were entitled to vote less than 1% of the total outstanding shares of Bioventus common stock. Although none of them has entered into any agreement obligating them to do so, Bioventus currently
expects that all Bioventus directors and executive officers will vote their shares &#147;<B>FOR</B>&#148; the Bioventus share issuance proposal and &#147;<B>FOR</B>&#148; the Bioventus adjournment proposal. See &#147;Interests of Bioventus Directors
and Executive Officers in the Merger&#148; and &#147;Bioventus Executive Officer and Director Compensation&#148; in this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Methods of Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registered Stockholders
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are an Bioventus stockholder of record, you may vote at the Bioventus special meeting by proxy over the Internet or telephone or by mail,
or by virtually attending and voting at the Bioventus special meeting via the Bioventus special meeting website, as described below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By Internet</B>: By following the instructions provided on your proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By Telephone</B>: By following the instructions provided on your proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By Mail</B>: If you have received a paper copy of the proxy materials by mail, you may complete and return by
mail the enclosed proxy card in the postage-paid envelope. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Virtually via the Bioventus Special Meeting Website</B>: By visiting the Bioventus special meeting website,
you can virtually attend and vote at the Bioventus special meeting. Bioventus stockholders who plan to virtually attend the Bioventus special meeting will need the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number included on their
proxy card in order to access the Bioventus special meeting website. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless revoked, all duly executed proxies representing shares of
Bioventus common stock entitled to vote at the Bioventus special meeting will be voted at the Bioventus special meeting and, where a choice has been specified on the proxy card, will be voted in accordance with such specification. If you submit an
executed proxy without providing instructions for any proposal, then the Bioventus officers identified on the proxy will vote your shares consistent with the recommendation of the Bioventus board on such proposal. If you are an Bioventus stockholder
of record, proxies submitted over the internet or by telephone as described above must be received by 11:59 p.m, Eastern Time, on October 25, 2021. To reduce administrative costs and help the environment by conserving natural resources, Bioventus
asks that you submit a proxy to vote your shares through the internet or by telephone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By executing and delivering a proxy in connection with the
Bioventus special meeting, you designate certain Bioventus officers identified therein as your proxies at the Bioventus special meeting. If you deliver an executed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proxy, but do not specify a choice for any proposal properly brought before the Bioventus special meeting, such proxies will vote your shares of Bioventus common stock on such uninstructed
proposal in accordance with the recommendation of the Bioventus board. Bioventus does not expect that any matter other than the proposals listed above will be brought before the Bioventus special meeting, and the Bioventus bylaws provide that the
only business that may be conducted at the Bioventus special meeting are those proposals brought before the Bioventus special meeting by or at the direction of the Bioventus board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Beneficial (Street Name) Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold
your shares of Bioventus common stock through a bank, broker or other nominee in &#147;street name&#148; instead of as a registered holder, you must follow the voting instructions provided by your bank, broker or other nominee in order to vote your
shares. Your voting instructions must be received by your bank, broker or other nominee prior to the deadline set forth in the information from your bank, broker or other nominee on how to submit voting instructions. If you do not provide voting
instructions to your bank, broker or other nominee for a proposal, your shares of Bioventus common stock will not be voted on that proposal because your bank, broker or other nominee does not have discretionary authority to vote on any of the
proposals to be voted on at the Bioventus special meeting. See &#147;&#151;Quorum; Abstentions and Broker <FONT STYLE="white-space:nowrap">Non-Votes.&#148;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold your shares of Bioventus common stock through a bank, broker or other nominee in &#147;street name&#148; (instead of as a registered holder), you
must obtain a specific control number from your bank, broker or other nominee in order to virtually attend and vote at the Bioventus special meeting via the Bioventus special meeting website. See &#147;&#151;Virtually Attending the Bioventus Special
Meeting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revocability of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
Bioventus stockholder giving a proxy has the right to revoke it at any time before the proxy is voted at the Bioventus special meeting. If you are an Bioventus stockholder of record, you may revoke your proxy by any one of the following actions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by sending a signed written notice of revocation to Bioventus&#146;s Corporate Secretary, provided such notice is
received no later than October 25, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by voting again over the internet or telephone as instructed on your proxy card before the closing of the voting
facilities at 11:59 p.m, Eastern Time, on October 25, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by submitting a properly signed and dated proxy card with a later date that is received by Bioventus no later
than the close of business on October 25, 2021; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by virtually attending the Bioventus special meeting via the Bioventus special meeting website and requesting
that your proxy be revoked, or virtually voting via the Bioventus special meeting website as described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only your last submitted
proxy will be considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Execution or revocation of a proxy will not in any way affect an Bioventus stockholder&#146;s right to virtually attend and
vote at the Bioventus special meeting via the Bioventus special meeting website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Written notices of revocation and other communications relating to the
revocation of proxies should be addressed to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bioventus Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tony.dadamio@bioventus.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4721
Emperor Boulevard, Suite 400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Durham, North Carolina 27703 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares of Bioventus common stock are held in &#147;street name&#148; and you previously provided
voting instructions to your broker, bank or other nominee, you should follow the instructions provided by your broker, bank or other nominee to revoke or change your voting instructions. You may also change your vote by obtaining your specific
control number and instructions from your bank, broker or other nominee and voting your shares at the Bioventus special meeting via the Bioventus special meeting website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Solicitation Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is soliciting proxies
to provide an opportunity to all Bioventus stockholders to vote on agenda items, whether or not such Bioventus stockholders are able to virtually attend the Bioventus special meeting or any adjournment or postponement thereof. Bioventus will bear
the entire cost of soliciting proxies from Bioventus stockholders. In addition to the solicitation of proxies by mail, Bioventus will request that banks, brokers and other nominee record holders send proxies and proxy material to the beneficial
owners of Bioventus common stock and secure their voting instructions, if necessary. Bioventus may be required to reimburse those banks, brokers and other nominees on request for their reasonable expenses in taking those actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxies may be solicited on behalf of Bioventus or by Bioventus directors, officers and other employees in person or by mail, telephone, facsimile, messenger,
the internet or other means of communication, including electronic communication. Bioventus directors, officers and employees will not be paid any additional amounts for their services or solicitation in this regard. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Virtually Attending the Bioventus Special Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you
wish to virtually attend the Bioventus special meeting via the Bioventus special meeting website, you must (i)&nbsp;be a Bioventus stockholder of record at the close of business on September 22, 2021 (the Bioventus record date), (ii) hold your
shares of Bioventus common stock beneficially in the name of a broker, bank or other nominee as of the Bioventus record date or (iii)&nbsp;hold a valid proxy for the Bioventus special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To enter the Bioventus special meeting website and virtually attend the Bioventus special meeting, you will need the
<FONT STYLE="white-space:nowrap">16-digit</FONT> control number located on your proxy card. If you hold your shares of Bioventus common stock in street name beneficially through a broker, bank or other nominee and you wish to virtually attend the
Bioventus special meeting via the Bioventus special meeting website, you will need to obtain your specific control number and further instructions from your bank, broker or other nominee. The <FONT STYLE="white-space:nowrap">16-digit</FONT> control
number is also needed to access the list of Bioventus stockholders entitled to vote at the Bioventus special meeting during the time of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
you plan to virtually attend and vote at the Bioventus special meeting via the Bioventus special meeting website, Bioventus still encourages you to vote in advance by the internet, telephone or (if you received a paper copy of the proxy materials)
by mail so that your vote will be counted even if you later decide not to virtually attend the Bioventus special meeting via the Bioventus special meeting website. Voting your proxy by the internet, telephone or mail will not limit your right to
virtually attend and vote at the Bioventus special meeting via the Bioventus special meeting website if you later decide to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Householding
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or
more stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; provides cost savings for companies.
Bioventus has previously adopted householding for Bioventus stockholders of record. As a result, Bioventus stockholders with the same address and last name may receive only one copy of this joint proxy statement/prospectus. Registered Bioventus
stockholders (those who hold shares of Bioventus common stock directly in their name with Bioventus&#146;s transfer agent) may opt out of householding and receive a separate joint proxy statement/prospectus or other proxy materials by sending a
written request to Bioventus at the address below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some brokers household proxy materials, delivering a single proxy statement or notice to multiple Bioventus
stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until
you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, or if your household is receiving multiple copies of
these documents and you wish to request that future deliveries be limited to a single copy, please notify your broker. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will promptly deliver a
copy of this joint proxy statement/prospectus to any Bioventus stockholder who only received one copy of these materials due to householding upon request in writing to: Bioventus Inc., Attn: Corporate Secretary, tony.dadamio@bioventus.com, 4721
Emperor Boulevard, Suite 100, Durham, North Carolina 27703 or by calling (919) <FONT STYLE="white-space:nowrap">474-6700.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tabulation of Votes
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board will appoint an independent inspector of election for the Bioventus special meeting. The inspector of election will, among other
matters, determine the number of shares of Bioventus common stock virtually present or represented by proxy at the Bioventus special meeting to confirm the existence of a quorum, determine the validity of all proxies and ballots and certify the
results of voting on all proposals submitted to Bioventus stockholders at the Bioventus special meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adjournments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a quorum is present at the Bioventus special meeting but there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus
share issuance proposal, then Bioventus stockholders may be asked to vote on the Bioventus adjournment proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any subsequent reconvening of the
Bioventus special meeting at which a quorum is present, any business may be transacted that might have been transacted at the original meeting, and all proxies will be voted in the same manner as they would have been voted at the original convening
of the Bioventus special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the time the proxy is voted at the reconvened meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS STOCKHOLDERS SHOULD CAREFULLY READ THIS JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY FOR MORE DETAILED INFORMATION CONCERNING
THE MERGER AGREEMENT AND THE MERGER. IN PARTICULAR, BIOVENTUS STOCKHOLDERS ARE DIRECTED TO THE MERGER AGREEMENT, WHICH IS ATTACHED AS <U>ANNEX</U><U></U><U>&nbsp;A</U> HERETO. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_13"></A>BIOVENTUS PROPOSAL 1: APPROVAL OF THE SHARE ISSUANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is being furnished to you as an Bioventus stockholder in connection with the solicitation of proxies by the Bioventus
board for use at the Bioventus special meeting. At the Bioventus special meeting, Bioventus is asking Bioventus stockholders to consider and vote upon a proposal to approve the issuance of shares of Bioventus common stock to Misonix stockholders in
connection with the merger. Based on the number of shares of Misonix common stock outstanding as of September&nbsp;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Bioventus expects to issue
approximately 18,322,984 million shares of Bioventus common stock to Misonix stockholders in connection with the merger. The actual number of shares of Bioventus common stock to be issued in connection with the merger will be determined at the
effective time based on the exchange ratio of 1.6839 shares of Bioventus common stock for each share of Misonix common stock and the number of shares of Misonix common stock outstanding at such time. Based on the number of shares of Bioventus common
stock and Misonix common stock outstanding as of September&nbsp;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own
approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board, after careful consideration, unanimously determined that the terms of the merger agreement and the merger are fair to and in the best
interests of Bioventus and its stockholders, and approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Bioventus board unanimously recommends that Bioventus stockholders vote &#147;FOR&#148; the Bioventus share issuance proposal. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders
of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share
issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting
instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the
Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus share issuance proposal. However, assuming a quorum is
present at the Bioventus special meeting, if an Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share
issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF YOU ARE AN BIOVENTUS STOCKHOLDER, THE BIOVENTUS BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE BIOVENTUS
SHARE ISSUANCE PROPOSAL </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(BIOVENTUS PROPOSAL&nbsp;1) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_14"></A>BIOVENTUS PROPOSAL 2: ADJOURNMENT OF THE BIOVENTUS SPECIAL
MEETING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus special meeting may be adjourned to another time and place if necessary or appropriate to permit the solicitation of additional
proxies if there are insufficient votes to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Bioventus stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is asking Bioventus stockholders to authorize the holder of any proxy solicited by the Bioventus board to vote in favor of any adjournment of the
Bioventus special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to this joint proxy
statement/prospectus is timely provided to Bioventus stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Bioventus board unanimously recommends that Bioventus stockholders vote
&#147;FOR&#148; the Bioventus adjournment proposal. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus
adjournment proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled
to vote at the Bioventus special meeting on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#147;street
name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any shares virtually
present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Bioventus
adjournment proposal. However, if an Bioventus stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment
proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF YOU ARE AN BIOVENTUS STOCKHOLDER, THE BIOVENTUS BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE BIOVENTUS
ADJOURNMENT PROPOSAL </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(BIOVENTUS PROPOSAL&nbsp;2) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_15"></A>THE MISONIX SPECIAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is being provided to Misonix stockholders in connection with the solicitation of proxies by the Misonix board for use at
the Misonix special meeting and at any adjournments or postponements thereof. Misonix stockholders are encouraged to read this entire document carefully, including its annexes and the documents incorporated by reference herein, for more detailed
information regarding the merger agreement and the transactions contemplated thereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date, Time and Place of the Misonix Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix special meeting is scheduled to be held at 10:00 a.m., Eastern Time on October 26, 2021, at the Misonix corporate offices, located at 1938 New
Highway, Farmingdale, NY 11735. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix currently intends to hold the special meeting in person. However, as part of its precautions regarding the novel
coronavirus or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> Misonix is planning for the possibility that the special meeting may be held solely by means of remote communications. If Misonix takes this step, it will announce the decision to do
so in advance, and details on how to participate will be posted on its website at www.misonix.com and filed with the SEC as proxy material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Matters to
Be Considered at the Misonix Special Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Misonix special meeting is to consider and vote on each of the following proposals,
each of which is further described in this joint proxy statement/prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 1</B><I>: Adoption of the Merger Agreement.</I> To consider and vote on the Misonix merger
proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 2</B>: <I>Approval, on an Advisory <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Basis,
of Certain Merger-Related Compensatory Arrangements with Misonix&#146;s Named Executive Officers.</I> To consider and vote on the Misonix compensation proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 3</B>: <I>Adjournment of the Misonix Special Meeting.</I> To consider and vote on the Misonix
adjournment proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Misonix Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board unanimously recommends that Misonix stockholders vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 1: &#147;FOR&#148;</B> the Misonix merger proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 2: &#147;FOR&#148;</B> the Misonix compensation proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Misonix Proposal 3: &#147;FOR&#148;</B> the Misonix adjournment proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After careful consideration, the Misonix board unanimously: (i)&nbsp;determined that the terms of the merger agreement and the transactions contemplated
thereby are fair to and in the best interests of Misonix and its stockholders; (ii)&nbsp;declared advisable, approved and authorized in all respects the merger agreement, the performance of Misonix of its obligations thereunder and the consummation
of the transactions contemplated thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&nbsp;recommended that Misonix stockholders adopt the merger agreement. See &#147;The Merger&#151;Recommendation of the
Misonix Board of Directors; Misonix&#146;s Reasons for the Merger.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date for the Misonix Special Meeting and Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date to determine Misonix stockholders who are entitled to receive notice of and to vote at the Misonix special meeting or any adjournments or
postponements thereof is September 22, 2021. As of the close of business on the Misonix record date, there were 17,425,045 shares of Misonix common stock issued and outstanding and entitled to vote at the Misonix special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Misonix stockholder is entitled to one vote for each share of Misonix common stock such holder owned of
record at the close of business on the Misonix record date with respect to each matter properly brought before the Misonix special meeting. Only Misonix stockholders of record at the close of business on the Misonix record date are entitled to
receive notice of and to vote at the Misonix special meeting and any and all adjournments or postponements thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum; Abstentions and Broker <FONT
STYLE="white-space:nowrap">Non-Votes</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of Misonix stockholders is necessary to conduct the Misonix special meeting. The presence of the
holders of a majority of the outstanding shares of Misonix common stock entitled to vote at the Misonix special meeting will constitute a quorum. Shares of Misonix common stock represented at the Misonix special meeting in person or by a properly
authorized and submitted proxy (submitted by mail, by telephone or over the Internet), entitled to vote, but not voted, including shares for which a Misonix stockholder directs an &#147;abstention&#148; from voting, will be counted for purposes of
determining a quorum. However, because all of the proposals for consideration at the Misonix special meeting are considered <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters under Nasdaq rules (as described below), shares held
in &#147;street name&#148; will not be counted as present for the purpose of determining the existence of a quorum unless the Misonix stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals
at the Misonix special meeting. If a quorum is not present, Misonix expects that the Misonix special meeting will be adjourned or postponed until the holders of the number of shares of Misonix common stock required to constitute a quorum attend. At
any subsequent reconvening of the Misonix special meeting, all proxies will be voted in the same manner as the proxies would have been voted at the original convening of the Misonix special meeting, except for any proxies that have been effectively
revoked or withdrawn prior to the subsequent meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the listing requirements of Nasdaq rules, banks, brokers or other nominees who hold shares in
&#147;street name&#148; on behalf of the beneficial owner of such shares have the authority to vote such shares in their discretion on certain &#147;routine&#148; proposals when they have not received voting instructions from the beneficial owners.
However, banks, brokers or other nominees are not allowed to exercise their voting discretion with respect to matters that under Nasdaq rules are <FONT STYLE="white-space:nowrap">&#147;non-routine.&#148;</FONT> This can result in a &#147;broker <FONT
STYLE="white-space:nowrap">non-vote,&#148;</FONT> which occurs on an item when (i)&nbsp;a bank, broker or other nominee has discretionary authority to vote on one or more &#147;routine&#148; proposals to be voted on at a meeting of stockholders, but
is not permitted to vote on other <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> proposals without instructions from the beneficial owner of the shares, and (ii)&nbsp;the beneficial owner fails to provide the bank, broker or other
nominee with voting instructions on a <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matter. All of the proposals before the Misonix special meeting are considered <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT>
matters under Nasdaq rules, and banks, brokers or other nominees will not have discretionary authority to vote on any matter before the Misonix special meeting. As a result, Misonix does not expect any broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> at the Misonix special meeting and if you hold your shares of Misonix common stock in &#147;street name,&#148; your shares will not be represented and will not be voted on any matter unless you
affirmatively instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instructions provided by your bank, broker or other nominee. It is therefore critical that you cast your vote by instructing your bank,
broker or other nominee on how to vote. <B>Brokers will not be able to vote on any of the proposals before the Misonix special meeting unless they have received voting instructions from the beneficial owners. </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Votes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vote required to approve each of the proposals is listed below. As described above, Misonix does not expect there to be any broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> at the Misonix special meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Proposal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Required Vote</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effects of Certain Actions</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix Proposal 1:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Misonix merger
proposal</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approval requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Misonix common stock.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An abstention or other failure to vote on the Misonix merger proposal will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Misonix merger proposal.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix Proposal 2:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Misonix
compensation proposal</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approval requires the affirmative vote of the holders of a majority of the votes cast at the Misonix special meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An abstention or other failure to vote on the Misonix compensation proposal will not have an effect on the Misonix compensation proposal, assuming a quorum is present.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix Proposal&nbsp;3:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Misonix
adjournment proposal</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approval requires the affirmative vote of the holders of a majority of the votes cast at the Misonix special meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An abstention or other failure to vote on the Misonix adjournment proposal will not have an effect on the Misonix adjournment proposal.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote of Misonix Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Misonix directors and executive officers, and
their affiliates, as a group, owned and were entitled to vote 31.62% of the total outstanding shares of Misonix common stock. On July&nbsp;29, 2021, Stavros Vizirgianakis, Misonix&#146;s Chief Executive Officer and Director, entered into a Voting
and Support Agreement with Bioventus and the stockholders named therein, pursuant to which he agreed to, among other things, vote his shares of Misonix common stock in favor of the adoption of the Misonix merger proposal. Although no Misonix
director or executive officer other than Mr.&nbsp;Vizirgianakis has entered into any agreement obligating them to vote their shares of Misonix common stock in favor of the proposals at the special meeting, Misonix currently expects that all Misonix
directors and executive officers will vote their shares of Misonix common stock &#147;<B>FOR</B>&#148; the Misonix merger proposal, &#147;<B>FOR</B>&#148; the Misonix compensation proposal and &#147;<B>FOR</B>&#148; the Misonix adjournment proposal.
See &#147;Interests of Misonix Directors and Executive Officers in the Merger&#148; and the arrangements described in Misonix&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which is incorporated by reference in this joint
proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Methods of Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registered Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a Misonix
stockholder of record, you may vote at the Misonix special meeting by proxy through the Internet, by telephone or by mail, or by attending and voting at the Misonix special meeting, as described below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By Internet</B>: By following the instructions provided on your proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By Telephone</B>: By following the instructions provided on your proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By Mail</B>: If you have received a paper copy of the proxy materials by mail, you may complete and return by
mail the enclosed proxy card in the postage-paid envelope. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>In person at the Misonix Special Meeting</B>: By attending the Misonix special meeting and voting in person.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless revoked, all duly executed proxies representing shares of Misonix common stock entitled to vote at
the Misonix special meeting will be voted at the Misonix special meeting and, where a choice has been specified on the proxy card, will be voted in accordance with such specification. If you submit an executed proxy without providing instructions
for any proposal, then the Misonix officers identified on the proxy will vote your shares consistent with the recommendation of the Misonix board on such proposal. If you are a Misonix stockholder of record, proxies submitted over the Internet or by
telephone as described above must be received by 11:59&nbsp;p.m., Eastern Time, on October 25, 2021. To reduce administrative costs and help the environment by conserving natural resources, Misonix asks that you submit a proxy to vote your shares
through the Internet or by telephone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By executing and delivering a proxy in connection with the Misonix special meeting, you designate certain Misonix
officers identified therein as your proxies at the Misonix special meeting. If you deliver an executed proxy, but do not specify a choice for any proposal properly brought before the Misonix special meeting, such proxies will vote your shares of
Misonix common stock on such uninstructed proposal in accordance with the recommendation of the Misonix board. Misonix does not expect that any matter other than the proposals listed above will be brought before the Misonix special meeting, and the
Misonix bylaws provide that the only business that may be conducted at the Misonix special meeting are those proposals brought before the Misonix special meeting by or at the direction of the Misonix board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Beneficial (Street Name) Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold
your shares of Misonix common stock through a bank, broker or other nominee in &#147;street name&#148; instead of as a registered holder, you must follow the voting instructions provided by your bank, broker or other nominee in order to vote your
shares. Your voting instructions must be received by your bank, broker or other nominee prior to the deadline set forth in the information from your bank, broker or other nominee on how to submit voting instructions. If you do not provide voting
instructions to your bank, broker or other nominee for a proposal, your shares of Misonix common stock will not be voted on that proposal because your bank, broker or other nominee does not have discretionary authority to vote on any of the
proposals to be voted on at the Misonix special meeting. See &#147;&#151;Quorum; Abstentions and Broker <FONT STYLE="white-space:nowrap">Non-Votes.&#148;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares of Misonix common stock are held of record by a broker, bank, trust or other nominee, and you decide to attend and vote at the Misonix special
meeting, your vote in person at the Misonix special meeting will not be effective unless you present a legal proxy, issued in your name from the record holder (your broker, bank, trust or other nominee). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revocability of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Misonix stockholder giving a
proxy has the right to revoke it at any time before the proxy is voted at the Misonix special meeting. If you are a Misonix stockholder of record, you may revoke your proxy by any of the following actions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by sending a signed written notice of revocation to Misonix&#146;s Secretary, provided such notice is received no
later than October 25, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by voting again over the internet or via telephone as instructed on your proxy card before the closing of the
voting facilities at 11:59 p.m., Eastern Time, on October 25, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by submitting a properly signed and dated proxy card with a later date that is received by Misonix no later than
the close of business on October 25, 2021; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by attending the Misonix special meeting in person and requesting that your proxy be revoked.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only your last submitted proxy will be considered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Execution or revocation of a proxy will not in any way affect a Misonix stockholder&#146;s right to attend and vote at the Misonix special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Written notices of revocation and other communications relating to the revocation of proxies should be
addressed to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Misonix, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1938 New Highway
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Farmingdale, NY 11735 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares of
Misonix common stock are held in &#147;street name&#148; and you previously provided voting instructions to your broker, bank or other nominee, you should follow the instructions provided by your broker, bank or other nominee to revoke or change
your voting instructions. If your shares of Misonix common stock are held in street name and you decide to attend and vote at the Misonix special meeting, your vote in person at the Misonix special meeting will not be effective unless you present a
legal proxy, issued in your name from the record holder (your broker, bank, trust or other nominee). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Solicitation Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix is soliciting proxies to provide an opportunity to all Misonix stockholders to vote on agenda items, whether or not such Misonix stockholders are able
to attend the Misonix special meeting or any adjournment or </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">postponement thereof. Misonix will bear the entire cost of soliciting proxies from Misonix
stockholders, provided that Bioventus has agreed to pay for the printing and mailing costs associated with this joint proxy statement/prospectus. In addition to the solicitation of proxies by mail, Misonix will request that banks, brokers and other
nominee record holders send proxies and proxy material to the beneficial owners of Misonix common stock and secure their voting instructions, if necessary. Misonix may be required to reimburse those banks, brokers and other nominees on request for
their reasonable expenses in taking those actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix has also retained MacKenzie Partners to assist in soliciting proxies and in communicating with
Misonix stockholders and estimates that it will pay them a fee of approximately $18,500, plus reimbursement for certain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses. Misonix also has
agreed to indemnify MacKenzie Partners against various liabilities and expenses that relate to or arise out of its solicitation of proxies (subject to certain exceptions). Proxies may be solicited on behalf of Misonix or Misonix directors, officers
and other employees in person or by mail, telephone, facsimile, messenger, the Internet or other means of communication, including electronic communication. Misonix directors, officers and employees will not be paid any additional amounts for their
services or solicitation in this regard. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Householding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or more
stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; provides cost savings for companies. Misonix
has previously adopted householding for Misonix stockholders of record. As a result, Misonix stockholders with the same address and last name may receive only one copy of this joint proxy statement /prospectus. Registered Misonix stockholders (those
who hold shares of Misonix common stock directly in their name with Misonix&#146;s transfer agent) may opt out of householding and receive a separate joint proxy statement/prospectus or other proxy materials by sending a written request to Misonix
at the address below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some brokers also household proxy materials, delivering a single proxy statement or notice to multiple Misonix stockholders sharing
an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified
otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">if your household is receiving multiple copies of these documents and you wish to request that future
deliveries be limited to a single copy, please notify your broker. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix will promptly deliver a copy of this joint proxy statement/prospectus to any
Misonix stockholder who received only one copy of these materials due to householding upon request in writing to: Misonix, Inc., Attn: Secretary, 1938 New Highway, Farmingdale, NY 11735. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tabulation of Votes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board will appoint an
independent inspector of election for the Misonix special meeting. The inspector of election will, among other matters, determine the number of shares of Misonix common stock represented at the Misonix special meeting to confirm the existence of a
quorum, determine the validity of all proxies and ballots and certify the results of voting on all proposals submitted to Misonix stockholders at the Misonix special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adjournments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a quorum is present at the Misonix
special meeting but there are insufficient votes at the time of the Misonix special meeting to approve the Misonix merger proposal, then Misonix stockholders may be asked to vote on the Misonix adjournment proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any subsequent reconvening of the Misonix special meeting at which a quorum is present, any business may be transacted that might have been transacted at
the original meeting and all proxies will be voted in the same manner as they would have been voted at the original convening of the Misonix special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the time
the proxy is voted at the reconvened meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assistance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you need assistance voting or completing your proxy card, or if you have questions regarding the Misonix special meeting, please contact Mackenzie Partners,
Misonix&#146;s proxy solicitor for the Misonix special meeting, by telephone toll-free at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-322-2885,</FONT></FONT></FONT> Monday through Friday
(except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at proxy@mackenziepartners.com. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g10c33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISONIX STOCKHOLDERS SHOULD CAREFULLY READ THIS JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY FOR MORE
DETAILED INFORMATION CONCERNING THE MERGER AGREEMENT AND THE MERGER. IN PARTICULAR, MISONIX STOCKHOLDERS ARE DIRECTED TO THE MERGER AGREEMENT, WHICH IS ATTACHED AS <U>ANNEX A</U> HERETO. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_16"></A>MISONIX PROPOSAL 1: ADOPTION OF THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This joint proxy statement/prospectus is being furnished to you as a Misonix stockholder in connection with the solicitation of proxies by the Misonix board
for use at the Misonix special meeting. At the Misonix special meeting, Misonix is asking Misonix stockholders to consider and vote upon a proposal to adopt the merger agreement to enable Misonix to consummate the mergers and effect the other
transactions in accordance with the terms of the merger agreement. You should read carefully and in its entirety this joint proxy statement/prospectus, including the annexes attached hereto and the documents incorporated by reference, for more
detailed information concerning the Misonix merger proposal and the transactions contemplated thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger and a summary of the terms of the
merger agreement are described in more detail under &#147;The Merger&#148; and &#147;The Merger Agreement,&#148; and Misonix stockholders are encouraged to read the full text of the merger agreement, which is attached as
<U>Annex</U><U></U><U>&nbsp;A</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board, after careful consideration, unanimously determined that the mergers are fair to and in the
best interests of Misonix and its stockholders, and approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Misonix board accordingly unanimously recommends that Misonix stockholders vote &#147;FOR&#148; the Misonix merger proposal. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Misonix common
stock. Accordingly, an abstention or other failure to vote on the Misonix merger proposal will have the same effect as a vote &#147;<B>AGAINST</B>&#148; the Misonix merger proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is a condition to the completion of the merger that Misonix stockholders approve the Misonix merger proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF YOU ARE A MISONIX STOCKHOLDER, THE MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE MISONIX MERGER PROPOSAL
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(MISONIX PROPOSAL 1) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_17"></A>MISONIX PROPOSAL 2: ADVISORY
<FONT STYLE="white-space:nowrap">NON-BINDING</FONT> VOTE ON MERGER-RELATED COMPENSATION FOR NAMED EXECUTIVE OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;14A of
the Exchange Act and Rule <FONT STYLE="white-space:nowrap">14a-21(c)</FONT> thereunder, Misonix is required to submit to a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory stockholder vote certain compensation that may be paid or become
payable to Misonix named executive officers that is based on or otherwise relates to the merger as disclosed under &#147;Interests of Misonix Directors and Executive Officers in the Merger&#151;Quantification of Payments and Benefits to Misonix
Named Executive Officers&#151;Golden Parachute Compensation.&#148; The Misonix compensation proposal gives Misonix stockholders the opportunity to express their views on the merger-related compensation of Misonix named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, Misonix is asking Misonix stockholders to vote &#147;<B>FOR</B>&#148; the adoption of the following resolution, on a <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory basis: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the compensation that may be paid or become payable to Misonix named
executive officers that is based on or otherwise relates to the merger, as disclosed pursuant to Item&nbsp;402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the heading &#147;Interests of Misonix Directors and Executive Officers
in the Merger&#151;Quantification of Payments and Benefits to Misonix Named Executive Officers&#151;Golden Parachute Compensation,&#148; including the associated narrative discussion and the agreements, plans, arrangements or understandings pursuant
to which such compensation may be paid or become payable, are hereby APPROVED.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vote on the Misonix compensation proposal is a vote separate and
apart from the vote to adopt the merger agreement. Accordingly, if you are a Misonix stockholder, you may vote to approve the Misonix merger proposal and vote not to approve the Misonix compensation proposal, and vice versa. The vote on the Misonix
compensation proposal is advisory and <FONT STYLE="white-space:nowrap">non-binding.</FONT> As a result, if the mergers are completed, the merger-related compensation may be paid to Misonix named executive officers to the extent payable in accordance
with the terms of the compensation agreements and arrangements, even if Misonix stockholders do not approve the Misonix compensation proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Misonix board unanimously recommends that Misonix stockholders vote &#147;FOR&#148; the Misonix compensation proposal. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming a quorum is present,
approval of the Misonix compensation proposal requires the affirmative vote of a majority of the votes cast and entitled to vote at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the
failure of a Misonix stockholder who holds shares in &#147;street name&#148; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix compensation
proposal, assuming a quorum is present. In addition, an abstention or other failure of any shares present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix compensation proposal to vote on the Misonix
compensation proposal will have no effect on the outcome of the Misonix compensation proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF YOU ARE A MISONIX STOCKHOLDER, THE
MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE MISONIX COMPENSATION PROPOSAL </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(MISONIX PROPOSAL 2) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_18"></A>MISONIX PROPOSAL 3: ADJOURNMENT OF THE MISONIX SPECIAL MEETING
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix special meeting may be adjourned to another time and place if necessary or appropriate in order to permit the solicitation of additional
proxies if there are insufficient votes to approve the Misonix merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Misonix stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix is asking Misonix stockholders to authorize the holder of any proxy solicited by the Misonix board to vote in favor of any adjournment of the Misonix
special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Misonix merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely
provided to Misonix stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Misonix board unanimously recommends that Misonix stockholders approve the proposal to adjourn the Misonix
special meeting, if necessary or appropriate. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of the Misonix adjournment proposal requires the affirmative vote of a majority of the votes
cast and entitled to vote at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#147;street name&#148; through a bank, broker or other
nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. Additionally, an abstention or other failure of any shares present or represented by proxy and
entitled to vote at the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal will have will have no effect on the outcome of the Misonix adjournment proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IF YOU ARE A MISONIX STOCKHOLDER, THE MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE MISONIX ADJOURNMENT PROPOSAL
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(MISONIX PROPOSAL 3) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_19"></A>THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a description of material aspects of the merger. While Bioventus and Misonix believe that the following description covers the material
terms of the merger, the description may not contain all of the information that is important to you. You are encouraged to read carefully this entire joint proxy statement/prospectus, including the text of the merger agreement attached as
<U>Annex</U><U></U><U>&nbsp;A</U> hereto, for a more complete understanding of the merger. In addition, important business and financial information about each of Bioventus and Misonix is contained or incorporated by reference in this joint proxy
statement/prospectus. See &#147;Where You Can Find More Information.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus, Merger Sub I, Merger Sub II and Misonix have entered into the merger agreement, which provides for the merger of Merger Sub I with and into Misonix
with Misonix surviving, and subsequently, the merger of Misonix with and into Merger Sub II. As a result of the mergers, the separate existences of Merger Sub I and Misonix will cease and Merger Sub II will continue its existence under the DGCL as
the surviving entity and as a wholly owned subsidiary of Bioventus. The surviving entity will be named &#147;Misonix, LLC.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Consideration
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the effective time, each share of Misonix common stock (other than shares held in treasury by Misonix or held directly by Bioventus, Merger Sub I
or Merger Sub II (which shares will be cancelled) and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) that was
issued and outstanding immediately prior to the effective time will be converted into, based on each such Misonix stockholders&#146; election and subject to proration in accordance with the terms of the merger agreement, the right to receive (a)
1.6839 shares of Bioventus class A common stock as well as cash (without interest and less any applicable withholding taxes) in lieu of any fractional shares of Bioventus class A common stock or (b)&nbsp;an amount of cash equal to $28.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange ratio is fixed, which means that it will not change between now and the date of the merger, regardless of whether the market price of Bioventus
or Misonix common stock changes. Therefore, the value of the merger consideration will depend on the market price of Bioventus common stock at the effective time. The market price of Bioventus common stock has fluctuated since the date of the
announcement of the merger agreement and is expected to continue to fluctuate from the date of this joint proxy statement/prospectus to the dates of the respective Bioventus and Misonix special meetings, through the date the merger is completed and
thereafter. The market price of Bioventus common stock, when received by Misonix stockholders who have elected the stock election consideration in connection with the first merger, could be greater than, less than or the same as the market price of
Bioventus class A common stock on the date of this joint proxy statement/prospectus or at the time of the Misonix special meeting. Accordingly, you should obtain current market quotations for Bioventus and Misonix common stock before deciding how to
vote on any of the proposals described in this joint proxy statement/prospectus. Bioventus common stock is traded on Nasdaq under the symbol &#147;BVS&#148; and Misonix common stock is traded on Nasdaq under the symbol &#147;MSON.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proration and Reallocation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate amount of cash
payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock as of 5:00 p.m. New York City time on the election deadline. In order to deliver this aggregate cash amount, the
merger agreement provides for pro rata adjustments to, and reallocation of, the cash and stock elections made by Misonix stockholders, as well as the allocation of consideration to be paid with respect to shares of Misonix common stock as to which
no election regarding the form of merger consideration to be paid to them, is received prior to the election deadline. Such no election shares will be exchanged for the cash consideration, the stock consideration or a combination of both.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, depending on the elections made by other Misonix stockholders, each Misonix stockholder who elects to receive Bioventus class A common stock for their shares in the mergers,
referred to as &#147;stock election shares&#148; may receive a portion of their consideration in cash, and each Misonix stockholder who elects to receive cash for their shares in the mergers, referred to as &#147;cash election shares&#148; may
receive a portion of their consideration in Bioventus class A common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration, which is the amount equal to the aggregate
number of cash election shares multiplied by $28.00, exceeds the available cash amount, then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all stock election shares and all no election shares will be exchanged for 1.6839 shares of Bioventus class A
common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a portion of the cash election shares of each Misonix stockholder will be exchanged for $28.00 in cash as
follows: cash election shares exchanged for $28.00 in cash = </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of such stockholder&#146;s cash election shares)
* (maximum cash amount) </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">elected cash consideration </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration is less than the available cash amount, which difference we refer to as the shortfall amount, then: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all cash election shares will be exchanged for the cash consideration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all stock election shares and no election shares will be treated in the following manner: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the shortfall amount is less than or equal to the product of the aggregate number of no election shares and
$28.00, which we refer to as the &#147;no election value&#148;, then (1)&nbsp;all stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock, and (2)&nbsp;a portion of the no election shares of each Misonix
stockholder, calculated as follows, will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#146;s no election shares, if any, will be exchanged for 1.6839 shares of Bioventus class A common stock):
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">no election shares exchanged for cash consideration = </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of no election shares of such stockholder) * (shortfall amount) </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(no election value) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the shortfall amount is more than the no election value, then (1)&nbsp;all no election shares will be
exchanged for $28.00 in cash and (2)&nbsp;a portion of the stock election shares of each stockholder will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#146;s stock election shares will be exchanged for
1.6839 shares of Bioventus class A common stock): </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">stock election shares exchanged for cash consideration = </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of stock election shares of such stockholder) * (shortfall amount &#150; no election value) </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(aggregate number of stock election shares) * $28.00 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration equals the available cash amount, then: (1)&nbsp;all cash election shares will be converted into the right to receive $28.00
in cash and (2)&nbsp;all stock election shares and all no election shares will be converted into the right to receive 1.6839 shares of Bioventus class A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange agent will mail to
Misonix stockholders of record not less than 30 days prior to the anticipated closing date of the first merger a letter of election and transmittal. The letter of election and transmittal enables Misonix stockholders to choose to make a cash
election, a stock election or no election with respect to each share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Misonix common stock eligible to receive the merger consideration. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing
Misonix stockholders of the expiration of the election period, which expiration we refer to as the &#147;election deadline&#148;, to make their election and return their completed letters of election and transmittal. If a Misonix stockholder holds
shares of Misonix common stock through a bank, brokerage firm or other nominee, such bank, brokerage firm, or other nominee, as applicable, will provide such stockholder with instructions on how to make an election. Election forms must be returned
to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage firm or other nominee holding your
shares, as that deadline may be earlier than the election deadline described in this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any election will have been
properly made only if the exchange agent has actually received a properly completed letters of election and transmittal by the election deadline. Any election form may be revoked or changed by written notice received by the exchange agent prior to
the election deadline. If an election form is revoked, the shares of Misonix common stock as to which such election previously applied will be no election shares unless an election is subsequently submitted by the Misonix stockholder prior to the
election deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the
letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election
and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background of the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Bioventus&#146; and
Misonix&#146;s board of directors and senior management team regularly reviews their respective company&#146;s performance, future growth prospects and overall strategic direction and considers potential opportunities to strengthen their respective
businesses and enhance stockholder value. These reviews have included consideration of whether the continued execution of each company&#146;s strategy or possible strategic opportunities, joint ventures or combination with third parties offered the
best avenue to maximize stockholder value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October of 2020, the Executive Chairman of a publicly traded medical device company
(&#147;Company&nbsp;A&#148;) contacted Stavros Vizirgianakis, Chief Executive Officer of Misonix regarding a potential collaboration arrangement involving both Misonix&#146;s surgical products and existing products of Company&nbsp;A, which
collaboration arrangement would be material to Misonix. Through October and November of 2020, management of Company&nbsp;A and Misonix conducted visits at the other&#146;s headquarters for workshops on their respective products and discussions on
areas of potential collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;6, 2020, Mr.&nbsp;Vizirgianakis held an introductory meeting with the Chief Executive Officer of a
medical device company (&#147;Company&nbsp;B&#148;) at the invitation of Company&nbsp;B&#146;s financial advisor. Mr.&nbsp;Vizirgianakis and the Chief Executive Officer of Company&nbsp;B discussed the operations of their respective companies and
areas of potential collaboration or synergies between the companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;10, 2020, representatives of Company&nbsp;A provided Misonix
management with an initial draft of a non-binding term sheet reflecting terms that would potentially govern the collaboration arrangement. In late December 2020, representatives of Company&nbsp;A sent Misonix management Company&nbsp;A&#146;s
financial analysis of the potential collaboration arrangement based on terms that had been proposed by Company&nbsp;A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;23, 2020, the
Misonix board held a meeting at which members of management and a representative of Jones Day, Misonix&#146;s outside legal advisor, were present to discuss the financial analysis prepared by Company&nbsp;A. At the conclusion of the meeting, the
Misonix board authorized Misonix management to continue the collaboration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discussions with Company&nbsp;A and to continue to negotiate for improved financial terms to the collaboration arrangement. Later in the day on December&nbsp;23, 2020, Mr.&nbsp;Vizirgianakis
spoke with a representative of Company&nbsp;A to convey proposed revisions to the financial terms of the collaboration arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From December of 2020
through May of 2021, Company&nbsp;A and Misonix exchanged revised drafts of the non-binding term sheet reflecting terms that would potentially govern the collaboration arrangement and engaged in discussions in an effort to align on
mutually-agreeable terms. Throughout the negotiations, Company&nbsp;A continued to propose profit-sharing, intellectual property licensing and other economic terms that representatives of Misonix did not deem acceptable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January of 2021, the Vice President of Corporate Development of another publicly traded medical device company (&#147;Company&nbsp;C&#148;) contacted
Mr.&nbsp;Vizirgianakis about potential collaboration between Company&nbsp;C and Misonix. Mr.&nbsp;Vizirgianakis and the representative of Company&nbsp;C discussed their respective company&#146;s products at a high level, but the individuals made no
specific plans for next steps in the collaboration discussions at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2021, the Chief Executive Officer of Company&nbsp;B
contacted Mr.&nbsp;Vizirgianakis regarding Company&nbsp;B&#146;s interest in a potential acquisition of Misonix. To facilitate information-sharing in connection with a potential acquisition, Company&nbsp;B proposed a draft mutual non-disclosure
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2021, the Misonix board held a meeting, at which members of management and a representative of Jones Day were present, to
discuss Company B&#146;s interest in a potential acquisition of Misonix. A representative of Jones Day discussed the potential issues that the Misonix board would need to consider, including their fiduciary duties, in connection with a potential
acquisition. The Misonix board authorized management to provide Company&nbsp;B with additional information to facilitate a proposal from Company&nbsp;B, subject to a non-disclosure agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In late January of 2021, Bioventus management contacted Perella Weinberg Partners L.P. (&#147;Perella Weinberg&#148;) to assist in the potential acquisition
of Misonix as Bioventus&#146; financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;2, 2021, the Misonix board held a meeting at which members of management and a
representative of Jones Day were present. During the course of this meeting, Mr.&nbsp;Vizirgianakis provided the Misonix board with an update on the discussion of a potential collaboration arrangement with Company&nbsp;A and the potential
acquisition of Misonix by Company&nbsp;B. The Misonix board considered the advisability of engaging an investment bank to serve as Misonix&#146;s financial advisor in connection with the potential acquisition of Misonix by Company&nbsp;B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;4, 2021, Company&nbsp;B and Misonix signed a mutual non-disclosure agreement, which included a mutual 12-month standstill restriction on each
party making proposals to acquire the other party that are not supported by the target company&#146;s board (but which standstill would fall away upon Misonix entering into a definitive acquisition agreement with a third party). Shortly after
entering into the mutual non-disclosure agreement, Misonix provided certain limited financial and operational information and documentation to representatives of Company&nbsp;B in response to Company&nbsp;B&#146;s initial due diligence requests.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2021, Mr.&nbsp;Vizirgianakis and Joseph Dwyer, Chief Financial Officer of Misonix, held a meeting with senior management team of
Company&nbsp;B and representatives of Company&nbsp;B&#146;s financial advisor, at the request of Company&nbsp;B to facilitate an acquisition proposal. Messrs.&nbsp;Vizirgianakis and Dwyer delivered to representatives of Company&nbsp;B a presentation
on Misonix, including an overview of its business, history and strategy. The representatives of Company&nbsp;B similarly delivered to Messrs.&nbsp;Vizirgianakis and Dwyer a presentation on Company&nbsp;B, including its history, strategy and
potential synergies and strategic plans for the combined company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;8, 2021, Mr.&nbsp;Dwyer held a call with representatives of Company&nbsp;B&#146;s financial
advisor to discuss the data room being prepared by Misonix to share requested documentation and information, as well as timing and next steps for further discussions between representatives of Misonix and Company&nbsp;B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early February, 2021, Messrs. Vizirgianakis and Dwyer contacted representatives of J.P. Morgan, who had assisted Misonix in connection with its acquisition
of Solsys Medical, LLC in September 2019, to obtain support in connection any offer that may be presented by Company&nbsp;A, in connection with a collaboration arrangement, or by Company&nbsp;B, in connection with an acquisition. In late February
and early March 2021, representatives of J.P. Morgan assisted Misonix management by reviewing financial projections and synergy analyses prepared by Misonix management in connection with a potential acquisition of Misonix by Company&nbsp;B, and by
recommending a process to progress negotiations with Company&nbsp;A and Company&nbsp;B. On March&nbsp;2, 2021, J.P. Morgan provided Misonix management with a market overview of Misonix&#146;s and Company&nbsp;B&#146;s current market valuation.
Representatives of Misonix shared with representatives of Company&nbsp;B preliminary financial projections that were substantially similar to the Misonix preliminary unaudited projections (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2021, members of Misonix&#146;s management again met with members of Company&nbsp;B&#146;s management, with representatives of
Company&nbsp;B&#146;s financial advisor and J.P. Morgan in attendance. Representatives of each company gave an additional presentation on their company, including its history, product lines, organizational charts and product roadmaps. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;2, 2021, Ken Reali, Chief Executive Officer of Bioventus, contacted Mr.&nbsp;Vizirgianakis by telephone expressing Mr.&nbsp;Reali&#146;s
interest in holding a meeting with senior executives of Bioventus and Misonix to discuss potential collaboration between the two companies. The specific nature of the transaction, or the possibility that it would be a proposed acquisition of
Misonix, was not discussed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;5, 2021 and March&nbsp;19, 2021, Mr.&nbsp;Vizirgianakis and Mr.&nbsp;Reali held follow-up calls during which
Messrs.&nbsp;Vizirgianakis and Reali continued to discuss the potential for collaboration between their respective companies and Bioventus&#146; strategic plans. Mr.&nbsp;Reali and Mr.&nbsp;Vizirgianakis agreed to meet in person with other members
of management of their respective companies on April&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2021, the Chief Executive Officer of Company&nbsp;B contacted
Mr.&nbsp;Vizirgianakis to convey that Company&nbsp;B was still interested in an acquisition of Misonix and that their representatives were working to prepare a long-term financial model to share with Misonix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2021, the Chief Executive Officer of Company&nbsp;B contacted Mr.&nbsp;Vizirgianakis to indicate that Company&nbsp;B&#146;s long-term
financial model would be forthcoming to Misonix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;22, 2021, representatives of Company&nbsp;B&#146;s financial advisor sent representatives
of J.P. Morgan a summarized five-year version of Company&nbsp;B&#146;s financial model, which representatives of J.P. Morgan forwarded to Misonix management. On March&nbsp;23, 2021, representatives of Company&nbsp;B&#146;s financial advisor sent
representatives of J.P. Morgan supplemental detail on the revenue breakout in Company&nbsp;B&#146;s five-year financial model, which representatives of J.P. Morgan also forwarded to Misonix management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2021, representatives of J.P. Morgan, at the direction of Misonix management, sent Misonix&#146;s synergy analysis to representatives of
Company B&#146;s financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;26, 2021, the Chief Executive Officer of Company&nbsp;B contacted Mr.&nbsp;Vizirgianakis to convey
that, after review of the preliminary financial projections Misonix provided, Company&nbsp;B remained interested in an acquisition of Misonix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;29, 2021, members of Misonix&#146;s management met with members of Company&nbsp;B&#146;s management, with representatives of Company&nbsp;B&#146;s financial advisor and J.P. Morgan in attendance. At the meeting, the parties reviewed
Misonix&#146;s synergy analysis and discussed each party&#146;s financial projections. Company&nbsp;B also shared a copy of its revenue synergy analysis and allowed Misonix management the opportunity to ask questions about this analysis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2021, Mr.&nbsp;Dwyer contacted the Chief Financial Officer of Company&nbsp;B to inquire
whether members of Company&nbsp;B&#146;s management had further questions about Misonix&#146;s synergy analysis or its preliminary financial projections. The Chief Executive Officer of Company&nbsp;B indicated that Company&nbsp;B would likely submit
a further list of questions and a possible supplemental due diligence request list in the near future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;1, 2021, Bioventus entered into a
non-disclosure agreement with Misonix to facilitate Misonix&#146;s sharing of information at the proposed meeting. Later in the day, Mr.&nbsp;Vizirgianakis and Mr.&nbsp;Dwyer met with Mr.&nbsp;Reali and Chris Yamamoto, Senior Vice President of
Business Development and Strategy of Bioventus. At the meeting, the companies&#146; respective representatives discussed potential ways in which the companies could collaborate together or if there were potential benefits to the parties of
Bioventus&#146; acquisition of Misonix. At the conclusion of these meetings, the representatives of Bioventus indicated they would contact Misonix in late May or early June 2021 to continue the discussions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on April&nbsp;1, 2021, the Chief Executive Officer of Company&nbsp;B contacted Mr.&nbsp;Vizirgianakis to preview that an offer for the acquisition of
Misonix would be forthcoming on or around April&nbsp;4, 2021. On April&nbsp;3, 2021, representatives of Company&nbsp;B&#146;s financial advisor contacted representatives of J.P. Morgan to convey a similar message. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2021, a representative of Company&nbsp;B&#146;s financial advisor contacted Mr.&nbsp;Vizirgianakis to deliver a verbal to offer acquire
Misonix for $21.00 in cash per outstanding share of Misonix common stock. Misonix common stock was priced at $19.73 per share as of the close of trading on April&nbsp;1, 2021. Mr.&nbsp;Vizirgianakis engaged in internal deliberation and discussion
with members of the Misonix board, where board members and Misonix senior management concluded that Company&nbsp;B&#146;s offer did not provide sufficient value to Misonix stockholders, given their understanding of the value of Misonix&#146;s
business and its prospects. Misonix&#146;s senior management informed representatives of Company&nbsp;B that Company&nbsp;B&#146;s offer was inadequate and terminated discussions with Company&nbsp;B at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2021, the Misonix board held a meeting at which members of management and a representative of Jones Day were present. During the course of this
meeting, Mr.&nbsp;Vizirgianakis provided the Misonix board with a further update on the discussion of a potential collaboration arrangement with Company&nbsp;A, including that the parties had not been able to reach agreement on terms that would be
mutually acceptable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early May 2021, Mr.&nbsp;Vizirgianakis was contacted by the Vice President of Corporate Development at Company&nbsp;C to continue
discussions from earlier in the year regarding a potential collaboration arrangement involving Misonix&#146;s surgical products. At that point, discussions with Company&nbsp;A had not progressed beyond the term sheet stage and it appeared that
Company&nbsp;A and Misonix may not be able to reach mutually-acceptable terms regarding the potential collaboration arrangement between the parties. In a follow-up discussion in mid-May, 2021, representatives of Company&nbsp;C indicated that
Company&nbsp;C was still interested in a potential collaboration arrangement with Misonix and proposed a meeting between the companies&#146; respective representatives. To facilitate the sharing of information between Misonix and Company C, the
parties entered into a mutual confidentiality agreement on May&nbsp;25, 2021 and representatives of the companies met in person later that day. At this meeting, representatives of Misonix provided a demonstration of some of Misonix&#146;s surgical
products in a laboratory environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the May&nbsp;25, 2021 meeting, a representative of Company&nbsp;C contacted Mr.&nbsp;Vizirgianakis to
schedule a follow-up meeting for June&nbsp;18, 2021 to discuss further a potential collaboration arrangement between Misonix and Company&nbsp;C. On June&nbsp;4, 2021, Company&nbsp;C provided a proposed non-binding term sheet for the potential
collaboration, which included, among other things, opportunities for the companies to combine specified products and jointly develop future products. The term sheet also included a proposal that Company&nbsp;C would be granted exclusive rights to
distribute Misonix&#146;s existing spine and cranial products and future products co-developed by the parties in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2021, as a result of the Misonix and Bioventus discussions focusing on an acquisition of
Misonix instead of a collaboration, and to facilitate Misonix sharing more sensitive information regarding its business, Misonix and Bioventus entered into a revised non-disclosure agreement, which added an 18-month standstill restriction on
Bioventus making proposals to acquire Misonix that were not supported by the Misonix board (but which standstill would fall away upon Misonix entering into a definitive acquisition agreement), as well as restrictions on Bioventus&#146; ability to
solicit Misonix employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;3, 2021, Messrs. Reali and Yamamoto and Greg Anglum, Senior Vice President and Chief Financial Officer of
Bioventus, held a meeting with Messrs. Vizirgianakis and Dwyer to discuss a potential acquisition of Misonix by Bioventus. At this meeting, the representatives from Misonix and Bioventus discussed their view of public Wall Street analyst projections
for each of their respective companies&#146; future financial performance. The parties also discussed potential revenue and expense synergies between Bioventus and Misonix if the parties were to consummate an acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;7, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr.&nbsp;Vizirgianakis
provided an update to the Misonix board on recent discussions with Bioventus, as well as discussions with Company&nbsp;A and Company&nbsp;C. The Misonix board provided their views and input on potential ways to coordinate and structure the
opportunities and thereafter instructed Messrs.&nbsp;Vizirgianakis and Dwyer to continue discussions with each of the potential counterparties with respect to the strategic opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2021, representatives of Company&nbsp;C provided Misonix management with a non-binding discussion outline with Company&nbsp;C&#146;s proposed
terms for a collaboration arrangement between Company&nbsp;C and Misonix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2021, the Bioventus board held a meeting at which members of
Bioventus management and representatives of Perella Weinberg, Bioventus&#146; financial advisor, attended. Mr.&nbsp;Yamamoto reviewed the potential acquisition of Misonix and presented the materials provided to the Bioventus board in advance of the
meeting, which included a summary of an initial meeting held on June&nbsp;3, 2021 with Messrs.&nbsp;Vizirgianakis and Dwyer, an overview of the strategic merits of the potential combination and a financial overview of Misonix. The materials also
included preliminary valuations of potential transaction scenarios and potential bid tactic considerations, which Mr.&nbsp;Yamamoto presented together with representatives of Perella Weinberg. After considering the potential challenges in
consummating the transaction and integrating the combined companies, the Bioventus board authorized Bioventus management to proceed with delivering a non-binding indication of interest to Misonix at an initial offer price of $26.00 per share of
Misonix common stock in a mix of cash and shares of Bioventus class A common stock. The Bioventus board also agreed to form a special committee of the Bioventus board to oversee the potential transaction with Misonix. The special committee consisted
of Messrs.&nbsp;Phil Cowdy, William Hawkins, Ken Reali and Martin Sutter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2021, Mr.&nbsp;Reali contacted Mr.&nbsp;Vizirgianakis by
telephone to indicate that Bioventus intended to submit a formal non-binding indication of interest to Misonix to consummate an acquisition. Misonix received Bioventus&#146; written indication of interest later that day, which Mr. Vizirgianakis
circulated to the Misonix board for initial review. The indication of interest proposed that Bioventus would acquire Misonix for $26.00 per share of Misonix common stock, consisting of $7.80 in cash and 0.988 shares of Bioventus class&nbsp;A common
stock. The indication of interest further stated that Bioventus&#146; willingness to advance discussions was conditioned on Misonix negotiating with Bioventus on an exclusive basis for a period of six weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;15, 2021, Mr.&nbsp;Vizirgianakis met with the Executive Chairman of Company&nbsp;A. Mr.&nbsp;Vizirgianakis informed the Executive Chairman of
Company&nbsp;A that Misonix&#146;s circumstances had since changed and that the parties would need to transition discussions from a collaboration arrangement to an acquisition of Misonix. If not, Misonix was not in a position to continue forward
with the collaboration discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;16, 2021, Mr.&nbsp;Vizirgianakis and representatives of J.P. Morgan, at the direction of
Misonix, each contacted representatives of Company&nbsp;C to inform Company&nbsp;C that Misonix had received an expression of interest for an acquisition of Misonix and to inquire whether Company&nbsp;C would consider an acquisition. The Vice
President of Corporate Development at Company&nbsp;C indicated that Company C would be interested in discussing an acquisition of Misonix and requested that J.P. Morgan have Misonix prepare a forecast and presentation for Company&nbsp;C. As a result
of this message, Misonix and Company&nbsp;C canceled the planned June&nbsp;18, 2021 follow-up meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on June&nbsp;16, 2021, Mr.&nbsp;Vizirgianakis
contacted Mr.&nbsp;Reali and confirmed that Misonix was still considering the Bioventus indication of interest and would be discussing the offer with the Misonix board on June&nbsp;21, 2021. Later in the day, Mr.&nbsp;Dwyer contacted
Mr.&nbsp;Yamamoto to discuss the potential revenue and cost synergies that could be achieved by Bioventus&#146; acquisition of Misonix. Mr.&nbsp;Yamamoto also provided Mr.&nbsp;Dwyer with the data underlying Bioventus&#146; public Wall Street
analyst projections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;16, 2021, the Misonix board acted by written consent to approve the engagement of J.P. Morgan as its financial advisor.
The Misonix board selected J.P. Morgan on the basis of its qualifications, expertise and reputation, as well as its knowledge and understanding of Misonix&#146;s business, industry and affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;17, 2021, Misonix executed an engagement letter pursuant to which it formally retained J.P. Morgan its exclusive financial advisor in connection
with a potential sale of Misonix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on June&nbsp;17, 2021, a representative of Company&nbsp;A contacted Mr.&nbsp;Vizirgianakis to confirm
Company&nbsp;A&#146;s interest in shifting from a collaboration arrangement to a potential acquisition of Misonix. The representative of Company&nbsp;A requested that Mr.&nbsp;Vizirgianakis prepare a presentation and meet with Company&nbsp;A&#146;s
executive team the week of June&nbsp;21, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2021, representatives of Bioventus provided Misonix management with public Wall Street
analyst </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">financial projections for Bioventus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on
June&nbsp;18, 2021, Mr.&nbsp;Reali provided Messrs. Vizirgianakis and Dwyer with a presentation regarding Bioventus&#146; business, how Misonix&#146;s business could be combined with Bioventus&#146; business and public Wall Street analyst financial
projections for Bioventus. Mr.&nbsp;Reali asked that he be given an opportunity to make the presentation to the Misonix board. Misonix management forwarded this presentation to the Misonix board in advance of Mr.&nbsp;Reali&#146;s and
Mr.&nbsp;Yamamoto&#146;s in-person presentation to the Misonix board, which ultimately occurred on June&nbsp;30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;21, 2021, the Misonix
board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. At the meeting, representatives of Jones Day discussed with the Misonix board their fiduciary duties in the context of the proposed transaction with
Bioventus and other legal matters. Representatives of Misonix management discussed with the Misonix board an assessment of Misonix&#146;s current market position, including an analysis of its share price and an overview of its current market
valuation, and Misonix&#146;s future prospects as a stand-alone enterprise. During this discussion, representatives of Misonix management presented the public Wall Street analyst financial projections for Misonix&#146;s business that had been shared
with Bioventus at the June&nbsp;3, 2021 meeting. Representatives of J.P. Morgan provided the Misonix board with a preliminary financial analysis of the Bioventus indication of interest and of potential ranges for a value of Misonix based on
Misonix&#146;s financial projections. Mr.&nbsp;Vizirgianakis updated the Misonix board on the status of recent discussions with Company&nbsp;A and Company&nbsp;C, including that collaboration discussions with Company&nbsp;C that had been scheduled
for June&nbsp;18, 2021 were postponed in light of the indication of interest received from Bioventus, but Mr.&nbsp;Vizirgianakis noted that Company&nbsp;C may be interested in an acquisition of Misonix and was awaiting feedback from Misonix in terms
of next steps. Following extensive discussion regarding the proposed form of merger consideration in Bioventus&#146; offer, the value of Bioventus&#146; offer, Bioventus&#146; request for exclusivity, the ongoing discussions with potential other
counterparties, and the potential benefits and potential risks of each of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the foregoing, the Misonix board instructed J.P. Morgan to determine if Company&nbsp;A and Company&nbsp;C would be interested in further discussion regarding an acquisition of Misonix, and to
advise Bioventus that Misonix was interested in engaging in further discussions regarding a transaction, but would not agree to exclusivity at the current value offered. The Misonix board also confirmed its willingness to receive a presentation from
Mr.&nbsp;Reali regarding Bioventus&#146; proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2021, Mr.&nbsp;Vizirgianakis contacted Mr.&nbsp;Reali to inform him that the Misonix
board was not prepared to grant Bioventus with exclusivity and that Bioventus needed to improve the value of its offer in order for exclusivity to be seriously considered. Mr.&nbsp;Vizirgianakis confirmed that Misonix was otherwise amenable to
engaging in further discussions regarding a transaction. Mr.&nbsp;Vizirgianakis also invited Mr.&nbsp;Reali to present to the Misonix board at a mutually agreeable time, pursuant to Mr.&nbsp;Reali&#146;s request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2021, as a result of the parties transitioning to more detailed discussion of an acquisition of Misonix, Misonix and Company&nbsp;A entered
into a revised mutual non-disclosure agreement, which added an 18-month standstill restriction on Company&nbsp;A making proposals to acquire Misonix that were not supported by the Misonix board (but which standstill would fall away upon Misonix
entering into a definitive acquisition agreement with a third party), as well as restrictions on Company&nbsp;A&#146;s ability to solicit Misonix employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2021, Mr.&nbsp;Vizirgianakis met with representatives of Company&nbsp;A where Mr.&nbsp;Vizirgianakis presented Misonix&#146;s background and
business strategy. At the conclusion of the meeting, the representatives of Company&nbsp;A indicated that they would consider an acquisition of Misonix, but were skeptical whether Misonix&#146;s wound care business line would be a logical fit with
Company&nbsp;A&#146;s product lines. As a result, Misonix&#146;s management believed it was unlikely that Company&nbsp;A would present a competitive acquisition offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on June&nbsp;29, 2021, Company C presented J.P. Morgan with an indication of interest to acquire Misonix for $27.43 per share of Misonix common stock,
to be paid in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2021, the Misonix board held a meeting, with management, representatives of Jones Day, representatives of J.P.
Morgan, and Messrs.&nbsp;Reali and Yamamoto from Bioventus attending. Messrs.&nbsp;Reali and Yamamoto gave the Misonix board a presentation on Bioventus, including its history, strategy and the potential synergies and strategic plans for the
combined company. Messrs.&nbsp;Reali and Yamamoto stressed Bioventus&#146; desire to sign a merger agreement and announce before Bioventus&#146; scheduled August&nbsp;10, 2021 earnings release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later in the day on June&nbsp;30, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. At the
meeting, Mr.&nbsp;Vizirgianakis reported on his meeting with Company&nbsp;A on the previous day. Representatives of J.P. Morgan discussed the proposal received on the previous day from Company&nbsp;C with the Misonix board and relayed that
Company&nbsp;C would require additional due diligence, including a workshop with Company&nbsp;C&#146;s own doctors, on Misonix&#146;s surgical products in the area of neurosurgery, which Company C requested to schedule for the week of July&nbsp;19,
2021. The Misonix board confirmed that, based on the presentation by Messrs.&nbsp;Reali and Yamamoto earlier in the day, it was apparent Bioventus had undertaken thoughtful analysis, there was general alignment on the potential synergies that could
be realized from a potential acquisition by Bioventus, and Bioventus had proposed a well-articulated plan for integration. The Misonix board also considered the potential risks associated with engaging in a transaction with Bioventus and the
different risks presented by Company&nbsp;C&#146;s proposed all-cash consideration and Bioventus&#146; proposed part-cash and part-stock consideration. The Misonix board also discussed the recent decline in Bioventus&#146; stock price and the
current value implied by the proposed exchange ratio. The Misonix board discussed with J.P. Morgan potential options to preserve value for Misonix stockholders in connection with the Bioventus offer, including a &#147;collar&#148; on the exchange
ratio of Bioventus class&nbsp;A common stock exchanged for Misonix stock and a contingent value right. The Misonix board discussed at length the options currently available and the potential benefits and risks of each of the options, including the
risk that Bioventus would be unwilling to allow for a time delay that would be sufficient for Company&nbsp;C to complete further due diligence and lab tests. The Misonix board directed management and the representatives of J.P. Morgan to convey
their positive disposition to Bioventus&#146; presentation, indicate that Misonix would need to undertake due diligence on Bioventus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
given the stock portion of the consideration, and indicate that exclusivity was not appropriate at the current offer price. The Misonix board also directed representatives of J.P. Morgan to
engage with Company&nbsp;C on value and to ask Company&nbsp;C to accelerate the timing of its due diligence efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2021, at the
direction of Misonix, representatives of J.P. Morgan contacted a representative of Company C to request that Company C improve the value of its offer. The representative of Company&nbsp;C responded that Company&nbsp;C&#146;s offer would remain at
$27.43 per share of Misonix common stock until completion of Company&nbsp;C&#146;s due diligence, including lab tests of Misonix&#146;s neurosurgery products. The representative of Company C followed up with a further call to representatives of J.P.
Morgan to indicate that the necessary lab tests for neurosurgery products could be scheduled the week of July&nbsp;19, 2021, but that Company&nbsp;C would also require an additional week after completion of the lab tests to validate its views on the
results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;2, 2021, the special committee of the Bioventus board held a meeting, which members of Bioventus management and representatives of
Perella Weinberg attended. During the meeting the status of the potential transaction with Misonix was reviewed along with the due diligence process and potential timeline to closing. Mr.&nbsp;Reali updated the special committee based on his
conversation with Misonix management regarding Bioventus&#146; initial offer price. Mr.&nbsp;Reali reported that Mr.&nbsp;Vizirgianakis had indicated that the initial offer was inadequate to establish exclusivity between the companies. The special
committee discussed alternative merger consideration proposals and agreed to increase its offer to $27.50 per share of Misonix common stock in a mix of cash and shares of Bioventus class A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;2, 2021, Bioventus submitted a revised proposal, increasing its offer to what it characterized as $27.50 per share of Misonix common stock based
on the 30-day volume weighted average share price of the Bioventus class&nbsp;A common stock of $17.80 as of the close of trading on July&nbsp;1, 2021. The consideration proposed comprised 0.983&nbsp;shares of Bioventus class A common stock and
$10.00 in cash for each share of Misonix common stock. Bioventus indicated its revised proposal was conditioned upon Misonix committing to negotiate exclusively with Bioventus and signing the merger agreement no later than July&nbsp;30, 2021.
However, on July&nbsp;1, 2021, Goldman Sachs issued a report downgrading the Bioventus class&nbsp;A common stock. As a result, the closing price and the seven day volume weighted average share price of the Bioventus class&nbsp;A common stock on
July&nbsp;2, 2021 was $16.51 and $17.84, respectively. Based on these values, the value of the merger consideration proposed by Bioventus was $26.23 and $27.54, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;2, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Representatives of J.P.
Morgan provided the Misonix board with an update on the discussions with Company&nbsp;C, including the fact that successful lab performance of Misonix&#146;s neurosurgery products would be critical to Company&nbsp;C&#146;s value determination. The
representatives of J.P. Morgan highlighted the timing difficulties raised by Company&nbsp;C&#146;s request for lab trials, but also noted that Company C may be able to provide a significant increase in value if it deemed the lab trials of
Misonix&#146;s neurosurgery products to be successful. Mr.&nbsp;Vizirgianakis provided the Misonix board with an update on the discussions with Bioventus, including the revised proposal received earlier in the day. The Misonix board discussed the
current value Bioventus proposed to pay, the status of discussions with Company&nbsp;C and Company&nbsp;A and the risks and benefits of a number of possible next steps with each of the potential counterparties. Members of the Misonix board placed
particular emphasis on the recent decline in Bioventus&#146; stock price, which had caused the value offered by Bioventus to be lower than the per share value offered by Company C, and the need for price protection to the Misonix stockholders as the
Misonix board considered its options. The Misonix board also considered the risk that if the results of the lab trials of neurosurgery products with Company&nbsp;C were not positive, there was a high degree of risk to execution with Company&nbsp;C
as well as risk to potential upside. The Misonix board determined that Bioventus&#146; revised proposal was not sufficient to warrant exclusivity at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July&nbsp;2, 2021, as directed by the Misonix board, Mr.&nbsp;Vizirgianakis contacted Mr.&nbsp;Reali to inform him that the Misonix board considered
the value presented in Bioventus&#146; revised proposal to be insufficient and that the Misonix board needed price protection in the event of a potential further decline in Bioventus&#146; stock price
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
between signing a merger agreement and closing the transaction. At the conclusion of the discussion, Mr.&nbsp;Reali proposed that the parties work towards signing a merger agreement an announcing
the transaction by July&nbsp;29, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;5, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P.
Morgan attending. After receiving a summary of the current terms proposed in Bioventus&#146; offer and Company&nbsp;C&#146;s indication of interest, discussion focused on the fact that the current value implied by the Bioventus&#146; offer was less
than Company&nbsp;C&#146;s indication of interest given the decline in Bioventus&#146; stock price after the proposal was made. The Misonix board also noted that the downgrade by Goldman Sachs of the Bioventus class A common stock on July&nbsp;1,
2021 further underscored the importance of downside price protection for Misonix stockholders. The representatives of Jones Day discussed with the Misonix board the operation and use of collars on exchange ratios in mergers with stock consideration
as a mechanism for increasing price certainty. The Misonix board directed J.P. Morgan to engage with Bioventus to seek price protection, to commit to commencing reverse due diligence, and to decline to provide Bioventus with exclusivity. The Misonix
board also directed Jones Day to inform Bioventus&#146; outside legal counsel, Latham&nbsp;&amp; Watkins LLP (&#147;Latham&#148;) that the Misonix board would require price protection in connection with a transaction involving the use of Bioventus
class A common stock as consideration. The Misonix board further instructed Jones Day to explore with Latham the feasibility of a transaction in which Misonix&#146;s stockholders could make an election between cash and stock consideration. The
Misonix board also discussed the binary nature of the decision that Company&nbsp;C would potentially make following the lab trials of neurosurgery products, and the importance of timing and maintaining optionality. The Misonix board engaged in an
extensive discussion of the options available to Misonix, including remaining a standalone business, whether a sale of Misonix was advisable now or in the near future and the potential benefits and risks of the options considered. The Misonix board
encouraged Misonix management to continue engagement with Company&nbsp;C and Company&nbsp;A. The Misonix board considered whether it would be appropriate to contact any of a number of potential additional third parties (other than Company&nbsp;C and
Company&nbsp;A) to gauge their interest in an acquisition of Misonix. After discussing the business of each party, their competitive position relative to Misonix, prior contacts between such parties and Misonix, the Misonix board&#146;s perception
of the parties&#146; resources and recent transactions that some of the parties had engaged in, the Misonix board determined not to proceed with additional contacts at that time. At the conclusion of the meeting, the Misonix board discussed with
management and representatives of J.P. Morgan and Jones Day a preliminary timeline for signing a merger agreement with an acquiror and announcing the transaction by July&nbsp;29, 2021 (as proposed by Bioventus) and the steps necessary to achieve
this goal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July&nbsp;5, 2021, Mr.&nbsp;Vizirgianakis contacted a representative of Company&nbsp;C to confirm Company&nbsp;C&#146;s interest in
pursuing an acquisition of Misonix, advise Company&nbsp;C that the timing of Misonix&#146;s discussions with another party had accelerated, and request that Company C accelerate its due diligence efforts. Company&nbsp;C&#146;s representative
indicated that Company C had a high degree of interest in pursuing a transaction with Misonix, but noted that Company&nbsp;C would want to understand Misonix&#146;s soft tissue opportunities as well as conduct lab tests on Misonix&#146;s
neurosurgery products, which lab tests were not scheduled to take place until the week of July&nbsp;19. Company&nbsp;C&#146;s representative confirmed that Company&nbsp;C would plan to sell Misonix&#146;s wound business within a year, making that
element of Misonix&#146;s business difficult to accurately value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After receiving Bioventus&#146; revised offer of July&nbsp;2, 2021, Misonix and
Bioventus began mutual due diligence in earnest, particularly over the weeks of July&nbsp;5, July&nbsp;12 and July&nbsp;19, 2021, with a number of videoconference meetings and telephone calls attended by members of Misonix senior management,
representatives of Misonix&#146;s outside advisors, members of Bioventus senior management and representatives of Bioventus&#146; outside advisors, as applicable, on various business, financial, tax, accounting and legal matters. Concurrently with
mutual due diligence between Misonix and Bioventus, Company C conducted its due diligence on Misonix, involving a number of videoconference meetings and telephone calls attended by members of Misonix senior management, representatives of
Misonix&#146;s outside advisors, members of Company&nbsp;C&#146;s senior management and representatives of Company&nbsp;C&#146;s outside advisors, as applicable, on various business, financial, tax, accounting and legal matters. As discussed below,
Company C also conducted lab tests of Misonix&#146;s neurosurgery products during the week of July&nbsp;19, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2021, Mr.&nbsp;Vizirgianakis contacted Mr.&nbsp;Reali to discuss the Misonix board&#146;s
rationale for not providing exclusivity to Bioventus at that time, including that the current value implied by Bioventus&#146; offer was insufficient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July&nbsp;6, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Representatives of
J.P. Morgan confirmed to the Misonix board that they had not received a response from Company C following their prior discussions over the past few days. Mr. Vizirgianakis provided the Misonix board an update on the response he received from the
representative of Company C on the prior day&#146;s telephone call. The Misonix board also confirmed, after discussing the volatility of Bioventus&#146; stock price and the need to undertake due diligence on Bioventus, that it would still be unable
to commit to exclusive negotiations with Bioventus. The Misonix board directed management and representatives of J.P. Morgan and Jones Day to continue engagement with each of the potential counterparties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 7, 2021, representatives of J.P. Morgan, at the direction of Misonix, contacted representatives of Company A telephonically to confirm Company
A&#146;s continued interest in an acquisition of Misonix. Company A&#146;s representatives indicated that they were still interested in a transaction, but would need to wait until technical developments in Misonix&#146;s discectomy and neurological
products had reached a more advanced stage before committing to an acquisition, which in Company A&#146;s estimation would not likely occur for a period of six to nine months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on July 7, 2021, representatives of Jones Day, at the direction of Misonix, contacted representatives of Latham to advise them that the Misonix board had
not yet agreed to Bioventus&#146; proposed price, that the Misonix board wanted assurance as to the value of the equity consideration that Bioventus proposed to pay in the transaction (including a collar on any decline in Bioventus&#146; stock price
between signing and closing), and that the Misonix board would be interested in a transaction in which Misonix stockholders could make an election between cash consideration and Bioventus class A common stock consideration, subject to a maximum
amount of cash that Bioventus would be required to pay in the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on July 7, 2021, representatives of Bioventus provided Misonix, J.P.
Morgan and Jones Day with a proposed transaction timeline necessary to meet the proposed July 29, 2021 deadline for signing a merger agreement and announcing the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 8, 2021, Messrs. Reali and Yamamoto provided Messrs. Vizirgianakis, Dwyer and the senior management of Misonix a corporate presentation on Bioventus,
including the company&#146;s history, its strategy and potential synergies and strategic plans for the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July 8, 2021, the
Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr. Vizirgianakis and representatives of Jones Day and J.P. Morgan provided the Misonix board with an update on the status of discussions with
Bioventus, Latham and Company C and the proposed timeline for entering into a definitive acquisition agreement by the end of July. Representatives of J.P. Morgan informed the Misonix board of Company A&#146;s decision to delay its engagement in the
sale process to await more advanced technical developments in Misonix&#146;s discectomy and neurological products, such that it was not a currently viable aquiror of Misonix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 9, 2021, the Bioventus and Misonix management teams, along with their respective outside legal counsel and financial advisors held a conference call
to review the timeline proposed by Bioventus to reach a signed merger agreement by July 29, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 13, 2021, as a result of the parties
transitioning to a more detailed discussion of an acquisition of Misonix and in advance of a Misonix management presentation, Misonix and Company C amended and restated their confidential disclosure agreement, which added a 12-month standstill
restriction on Company C (but which standstill would fall away upon Misonix entering into a definitive acquisition agreement with a third party) as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
well as a limited non-solicitation of Misonix employees. Thereafter, the Misonix management team, including Messrs. Vizirgianakis and Dwyer, provided a presentation to Company C and its
representatives and advisors. The presentation provided Company C with a detailed summary of Misonix&#146;s business, product portfolio and new product pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July 13, 2021, representatives of Latham delivered an initial draft merger agreement to representatives of Jones Day. The draft included the
following key terms: (a) a fixed exchange ratio of 0.983 shares of Bioventus class A common stock and $10.00 in cash for each share of Misonix common stock; (b) a requirement that both parties use reasonable best efforts to obtain antitrust
approvals, but with Bioventus excused from having to agree to any divestures or limitations on its post-closing business in order to obtain such approvals; (c) a mutual &#147;force the vote&#148; that would require each of Misonix and Bioventus to
hold special meetings of their stockholders to consider the company&#146;s respective transactions, even if the Misonix board or Bioventus board had changed its recommendation to stockholders with respect to the respective transactions as a result
of an intervening event or as a result of a superior proposal; (d) a fiduciary termination fee payable by Misonix to Bioventus equal to 4.5% of Misonix&#146;s equity value in the event of a termination of the merger agreement under various
circumstances, including a change in recommendation by the Misonix board or a failure to obtain Misonix stockholder adoption of the merger agreement after the announcement of a superior proposal relating to Misonix; and (e) a fiduciary termination
fee payable by Bioventus to Misonix equal to 4.5% of Misonix&#146;s equity value in the event of a termination of the merger agreement under various circumstances, including a change in recommendation by the Bioventus board or a failure to obtain
Bioventus stockholder approval of the stock issuance after the announcement of a superior proposal relating to Bioventus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 18, 2021,
representatives of Jones Day delivered a revised draft merger agreement to representatives of Latham. The draft included the following key terms: (a) an indication that the price proposed by Bioventus had not been accepted by Misonix and was subject
to further negotiation; (b) (i) the option for Misonix stockholders to elect to receive all cash or all shares of Bioventus class A common stock in exchange for each share of Misonix common stock, subject to proration and with the aggregate cash
consideration fixed and (ii) a &#147;collar&#148; on the exchange ratio to fix the value of the stock consideration if the 14-day volume weighted average of Bioventus&#146; share price fell between the signing of the merger agreement and the
completion of the transactions; (c) (i) agreement to use reasonable best efforts to obtain antitrust approvals, with Bioventus obligated to agree to divestures or limitations on its post-closing business unless those remedies, individually or in the
aggregate, would have a material adverse effect on Misonix or Bioventus and (ii) an obligation for each party to refrain from conducting acquisitions or divestitures prior to completion of the mergers, to the extent they could reasonably be expected
to hinder or delay completion of the mergers; (d) no &#147;force the vote&#148; provision and a right of Misonix to terminate the merger agreement and pay to Bioventus a termination fee equal to 2.0% of Misonix&#146;s equity value in the event
Misonix accepts a superior proposal; (e) a termination fee payable by Bioventus to Misonix equal to 2.0% of Misonix&#146;s equity value in the event of a termination of the merger agreement by Misonix upon a Bioventus financing failure, in addition
to other damages that Miosnix may recover if such failure resulted from a willful and material breach of Bioventus&#146; covenants in the merger agreement; and (f) reducing the termination fee payable in all other circumstances to 2.0% of
Misonix&#146;s equity value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 19, 2021, representatives of Latham delivered initial drafts of the form of voting and support agreements for both
Bioventus stockholders and Misonix stockholders to representatives of Jones Day. The terms and conditions of the voting and support agreements were largely identical, except that the voting and support agreement to be executed by Bioventus
stockholders provided that such stockholders would be required to vote only a portion of their Bioventus common stock in favor of the Bioventus stock issuance. This portion was equal to the number of shares that constituted the same percentage of
outstanding Bioventus common stock as the percentage of outstanding Misonix common stock held by Misonix stockholders executing their respective voting and support agreements. Latham&#146;s draft of the form of voting and support agreement for
Misonix stockholders also indicated, by footnote, Bioventus&#146; request that each of the significant Misonix stockholders would also sign a separate lock-up agreement whereby such Misonix stockholders would agree to restrictions on the
post-closing sale of their shares of Bioventus class A common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on July 19, 2021, the Bioventus board held a meeting at which members of Bioventus management and
representatives of Latham were present. Messrs. Reali and Yamamoto provided the Bioventus board with an update on the potential acquisition of Misonix and then representatives of Latham provided an overview of the Bioventus board&#146;s fiduciary
duties related to the potential acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July 19, 2021, representatives of Jones Day delivered an initial draft merger agreement to
representatives of Company C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 20, 2021, representatives of Company C met with Misonix&#146;s management. Misonix management delivered
presentations detailing Misonix&#146;s operations, including product development, research and development, manufacturing, supply chain, marketing and business development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 21, 2021, Bioventus&#146; executed an engagement letter pursuant to which it formally retained Perella Weinberg its exclusive financial advisor in
connection with a potential acquisition of Misonix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on July 21, 2021, representatives of Jones Day and of Latham held a conference call to discuss
the open issues in the revised draft of the merger agreement circulated by representatives of Jones Day. Representatives of Latham conveyed Bioventus&#146; objection to any collar on the exchange ratio for the Bioventus class A common stock
consideration, preferring instead an exchange ratio fixed at the time of signing the merger agreement using a 30-day volume weighted average price for Bioventus class A common stock. The representatives of Latham indicated, however, that Bioventus
would agree to modify the exchange ratio such that the implied value of the merger consideration (using a volume weighted average share price of Bioventus class A common stock over a period to be determined) would, as of the signing of the merger
agreement, be equal to $27.50 per share of Misonix common stock. Representatives of both Jones Day and Latham agreed that Misonix&#146;s request for a collar on the exchange ratio would remain an open discussion point for the parties.
Representatives of Latham then confirmed that Bioventus was agreeable to (a) allowing Misonix stockholders to elect cash or stock consideration (subject to a fixed amount of aggregate cash), (b) Bioventus&#146; significant stockholders signing a
voting and support agreement binding all of their outstanding Bioventus shares, (c) a reverse termination fee payable by Bioventus in the event of a financing failure and (d) a restriction on Bioventus conducting certain other acquisitions during
the pre-closing period. Representatives of Latham then explained Bioventus&#146; continued objection to providing Misonix with the ability to terminate the merger agreement to accept a superior proposal, instead favoring the requirement for Misonix
to proceed with a stockholder vote. Representatives of both Jones Day and Latham agreed that Misonix&#146;s ability to terminate the merger agreement to accept a superior proposal, as well as the amount of the termination fee, would remain open
discussion points for the parties. Representatives of Jones Day informed Latham that the significant stockholders of Misonix signing the voting and support agreement would not be willing to also execute separate lock-up agreements requested by
Bioventus. The representatives of Jones Day and Latham concluded by discussing the efforts standard for obtaining HSR clearance as well as the appropriate scope of the representations and warranties to be given by Bioventus in the merger agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July 21, 2021, representatives of J.P. Morgan, at the direction of Misonix, spoke with representatives of Perella Weinberg and Mr. Vizirgianakis
spoke with Mr. Reali. During these discussions, Mr. Reali and the representatives of Perella Weinberg each separately confirmed that Bioventus would agree to modify the exchange ratio such that the implied value of the merger consideration as of the
signing of the merger agreement would be equal to $27.50 per share of Misonix common stock, based on the 15- or 30-day volume weighted average price of the Bioventus class A common stock ending on the date of the signing of the merger agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 22, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr. Vizirgianakis and the
representatives of J.P. Morgan informed the Misonix board that Company C&#146;s lab tests of Misonix&#146;s neurosurgery products was nearing completion and that Misonix could expect feedback on the test results and a potential revised acquisition
proposal from Company C early in the week of July 26, 2021. The Misonix board considered this timing in connection with the accelerated timeline of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the ongoing negotiations with Bioventus. The Misonix board also considered the fact that Company C&#146;s board of directors may not be in a position to approve any transaction between Misonix
and Company C until late August. The representatives of Jones Day and J.P. Morgan and Mr. Vizirgianakis provided the Misonix board with an update of the discussions with Bioventus, particularly Bioventus&#146; continued resistance to the Misonix
board&#146;s request for a collar on the exchange ratio to provide downside protection to Misonix stockholders, but that Bioventus was prepared to set the exchange ratio so as to ensure that the offer price represented a value of $27.50 as of the
signing date based on a volume weighted average of Bioventus&#146; stock price over a period of 15 or 30 days preceding the signing of the merger agreement. Representatives of Jones Day thereafter provided the Misonix board with an update on
negotiations with Latham and Bioventus&#146; objection to Misonix&#146;s proposal that the Misonix board be permitted to cause Misonix to terminate the merger agreement to accept a superior proposal. The Misonix board discussed the implications of
that objection, in particular, that this restriction would likely have a significant chilling effect on the willingness of any other party to make a superior proposal after the merger agreement had been signed. As a result, the Misonix board
instructed representatives of Jones Day to continue to seek an ability for Misonix to terminate the merger agreement to accept a superior proposal. The representatives of Jones Day reviewed additional material issues discussed with Latham, including
the cash/stock election mechanics, antitrust provisions, scope of Bioventus&#146; representations and warranties proposed in Misonix&#146;s comments to the proposed merger agreement, the scope of proposed stockholder and support agreements for
certain stockholders of Bioventus and Misonix, and Bioventus&#146; request for significant stockholders to execute post-closing lock-up agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later
on July 22, 2021, representatives of Latham delivered to Jones Day a revised draft of the merger agreement. The draft included the following key terms that remained under negotiation between the parties: (a) the ability of Misonix stockholders to
elect to receive either $27.50 in cash or a fixed number of shares of Bioventus class A common stock having a value equal to $27.50 based on the 30-day volume weighted average share price ending on the date of the signing of the merger agreement, in
each case, subject to proration; (b) agreement of the parties to use their reasonable best efforts to obtain antitrust approvals, with Bioventus obligated to agree to divestures or limitations on Misonix&#146;s or Bioventus&#146; post-closing
business unless those remedies, individually or in the aggregate, would materially reduce the reasonably anticipated benefits of the merger to Bioventus or impact Bioventus or Misonix in a manner or amount that is material relative to the value of
Misonix; (c) a mutual &#147;force the vote&#148; in the event the boards of directors of Misonix or Bioventus were to change its recommendation to stockholders with respect to the transaction as a result of either an intervening event or as a result
of a superior proposal; (d) no termination fee payable upon a Bioventus financing failure; and (e) increasing the termination fee payable in all circumstances to 4.25% of Misonix&#146;s equity value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 23, 2021, representatives of Jones Day delivered a revised drafts of the forms of voting and support agreements to representatives of Latham. The
revised draft of the voting and support agreement to be executed by Bioventus stockholders removed the limitation on the number of shares of Bioventus class A common stock applicable to the voting restrictions and also removed the footnote proposal
that Misonix&#146;s significant stockholders also execute separate lock-up agreements restricting the post-closing sale of their shares of Bioventus class A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 24, 2021, representatives of Jones Day and Latham discussed the open issues in the revised draft of the merger agreement previously circulated by
representatives of Latham. Representatives of Jones Day confirmed that Misonix&#146;s request for a collar on the exchange ratio, Misonix&#146;s ability to terminate the merger agreement to accept a superior proposal, the amount of the termination
fee, and Bioventus&#146; request for significant Misonix stockholders to execute separate post-closing lock-up agreements were the remaining key outstanding issues for the parties. Over the course of July 24, 2021 through to the parties&#146;
execution of the merger agreement on July 29, 2021, representatives of Jones Day and Latham exchanged revised drafts of the merger agreement, along with the disclosure schedules and other ancillary exhibits thereto, and the voting and support
agreements until those documents were agreed by the parties to be in final form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 26, 2021, Messrs. Vizirgianakis and Dwyer met with Messrs. Reali, Yamamoto and Anglum from Bioventus
and with representatives of Perella Weinberg, with Messrs. Vizirgianakis and Anglum attending via telephone. The parties discussed anticipated timing for reaching agreement on the merger agreement and voting agreements, and the parties&#146;
communications that they would propose to issue if the parties could favorably conclude their discussions on the merger agreement. The parties acknowledged that material issues remained outstanding, including Misonix&#146;s request for a collar on
the exchange ratio and an ability to terminate the merger agreement to accept a superior proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July 26, 2021, the Misonix board held a
meeting, with management and representatives of Jones Day and J.P. Morgan attending. Representatives of J.P. Morgan reported that Company C had held its internal strategic development committee meeting to consider Company C&#146;s due diligence
conducted on Misonix, including the lab tests of Misonix&#146;s neurosurgery products. While the lab results were reported as being positive, Company C had developed an internal concern that owning Misonix&#146;s TheraSkin product (a biologically
active human skin allograft) could create unacceptable liability for Company C. The representatives of J.P. Morgan reported that this view was based on Company C&#146;s anecdotal experience with an allograft previously owned by Company C that had
resulted in significant litigation for Company C. As a result, Company C indicated that it would not be prepared to acquire all of Misonix at this time. The representatives of J.P. Morgan noted that Company C had instead inquired whether Misonix
would be interested in completing a sale of assets relating to its surgical business, while retaining its wound care business. Mr. Vizirgianakis then reported that he had received a similar call from his primary contact at Company C and, although
Mr. Vizirgianakis had distinguished Misonix&#146;s Theraskin product from the product of concern to Company C, his contact at Company C made clear that significant internal discussion over an extended period of time would be required for Company C
to change its view and, in the contact&#146;s view, there was a high degree of risk that a change in view would not be possible. During the Misonix board meeting, a representative from J.P. Morgan received a call from Company C. Upon returning to
the meeting, he reported that Company C had not changed its view and was not making an offer at that time, but had indicated that, if Company C were to change its view and if Company C received further requisite internal approvals, which would not
be available in the near term, Company C might be able to offer an asset purchase transaction that valued Misonix&#146;s surgical business up to as much as $30.00 per share of Misonix common stock. The Misonix board engaged in a lengthy discussion
of the feasibility of a potential transaction with Company C under the structure proposed by Company C. During this discussion, the Misonix board discussed with representatives of J.P. Morgan and Jones Day (a) potential structures for a sale of
Misonix&#146;s surgical business to Company C, including a direct sale of assets or a potential spin-off of Misonix&#146;s wound care business to Misonix&#146;s stockholders and sale of the remaining portion of Misonix to Company C, (b) the
potential benefits and risks associated with such structures, the perceived tax implications of such structures, and the value that could be obtained for Misonix stockholders if such transactions were successfully structured, negotiated and
completed based on the preliminary value indicated by Company C, (c) the further internal approvals that Company C would need to obtain to complete a transaction, the potential timing of such approvals and the risk that such approvals would not be
obtained, (d) the fact that an asset sale would require the identification of assets to be sold, the negotiation of representations and warranties relating to an asset sale, indemnification arrangements customary for an asset sale and other terms
that were very different than those reflected in the proposed definitive merger agreement that Misonix had provided to Company C, and (e) the fact that none of these terms had been discussed with Company C and the resultant risk that such terms may
not be acceptable to Misonix when or if ultimately proposed by Company C. The Misonix board and management also concluded that the recent indication regarding Misonix&#146;s surgical business (provided by Company C during the course of the meeting)
was highly speculative, not based on a full analysis of Misonix by Company C, and therefore unlikely to ultimately materialize. The Misonix board then considered this new proposal in connection with the status of negotiations with Bioventus. A
representative of Jones Day informed the Misonix board that Bioventus continued to resist any collar on the exchange ratio or any arrangement that would provide Misonix stockholders protection against a potential decline in Bioventus&#146; stock
price between the announcement and closing of a transaction (but that Bioventus would increase its proposed exchange ratio to provide value at signing equal to $27.50 per share of Misonix common stock), that Bioventus continued to require that
Misonix not have the ability to terminate a merger agreement to accept a superior proposal and that Bioventus continued to seek a termination fee equal to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
4.25% of Misonix&#146;s equity value. The representative of Jones Day indicated that if these issues could be resolved, it was likely that Misonix&#146;s and Bioventus&#146; respective management
and advisors could prepare the necessary documentation and communication materials to sign a definitive agreement within the next few days. At the conclusion of this discussion, the Misonix board determined that (i) pursuing a transaction with
Company C would require complex structuring, (ii) a transaction with Company C would require the negotiation of terms that had not yet been proposed by Company C and may be unacceptable to Misonix, (iii) Company C may not receive the internal
approvals it would need to pursue a transaction with Misonix in a timely manner or at all, and (iv) if Misonix delayed entering into a transaction with Bioventus to pursue a transaction with Company C, there was a significant likelihood that
Bioventus would no longer be willing to enter into a transaction with Misonix if the transaction with Company C did not materialize. At the conclusion of this discussion, the Misonix board determined that Misonix should terminate discussions with
Company C and continue discussions of a potential transaction with Bioventus. The Misonix board instructed representatives of J.P. Morgan and Jones Day to convey to Bioventus that the Misonix board would support a transaction with Bioventus if
(i)&nbsp;Bioventus increased the value of the merger consideration in its offer, (ii)&nbsp;Bioventus would allow Misonix to terminate the merger agreement to accept a superior proposal and (iii)&nbsp;the termination fee payable under the
circumstances set forth in the proposed merger agreement was lowered to 3.5% of Misonix&#146;s equity value. The Misonix board further indicated that, on this basis, it would be willing to forego its request that Bioventus provide a collar to
protect against a decline in value of the merger consideration as a result of a decrease in Bioventus&#146; stock price between the signing of the merger agreement and completion of the transaction. The Misonix board made this determination based on
its consideration, among other factors, of its perception of the short- and long-term value of the Bioventus class A common stock (including the view of Misonix&#146;s management based on the Bioventus public Wall Street analyst financial
projections that were previously provided) and that the anticipated mergers could likely be completed prior to the end of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 27, 2021, as
directed by the Misonix board, representatives of J.P. Morgan and Jones Day contacted representatives of Perella Weinberg and Latham, respectively, to present the proposal approved by the Misonix board during its meeting of July 26, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July&nbsp;27, 2021, Mr.&nbsp;Reali contacted Mr.&nbsp;Vizirgianakis by telephone in response to the Misonix board&#146;s proposal, as delivered by
representatives of J.P. Morgan and Jones Day, on behalf of Misonix, earlier in the day. Mr.&nbsp;Reali informed Mr.&nbsp;Vizirgianakis that, in exchange for Misonix agreeing to forego a collar on the exchange ratio on the Bioventus class A common
stock consideration, (a)&nbsp;Bioventus would agree to increase cash portion of its offer to $10.50 to provide aggregate value, at signing of the merger agreement, of $28.00 per share of Misonix common stock, (b)&nbsp;Bioventus and Misonix would
need to agree on the appropriate exchange ratio to use to reflect this value, (c)&nbsp;Bioventus would allow Misonix to terminate the merger agreement to accept a superior proposal, and (d)&nbsp;Bioventus would not agree to a termination fee payable
under the circumstances set forth in the proposed draft merger agreement of less than 4.0% of Misonix&#146;s equity value. Mr.&nbsp;Reali emphasized that $28.00 per share of Misonix common stock was the highest price that Bioventus would be willing
to pay for Misonix. Mr.&nbsp;Vizirgianakis agreed to take this revised proposal to the Misonix board at its meeting later in the day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on
July&nbsp;27, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr.&nbsp;Vizirgianakis provided an update on recent discussions with Mr.&nbsp;Reali and the terms of Bioventus&#146;
revised proposal. After discussing this proposal, the Misonix board determined that it would still be willing to forego its request that Bioventus provide a collar to protect against a decline in value of the merger consideration. The
representatives of Jones Day then discussed with the Misonix board their fiduciary duties in the context of the proposed transaction with Bioventus and reviewed the material terms of the transaction and the present draft of the merger agreement with
the Misonix board. Thereafter, the Misonix board engaged in extensive discussion of the various terms and conditions, including open negotiation points, the status of discussions regarding the voting and support agreements and Bioventus&#146;
continued request for significant stockholders of Misonix to enter into lock-up agreements pursuant to which they would agree to refrain from selling their shares of Bioventus class A common stock for a period of time following completion of the
mergers. The representatives of J.P. Morgan reviewed with the Misonix board the mechanics of the merger consideration and various metrics for analyzing the value implied by the Bioventus class A common stock consideration and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the implied value of the cash consideration to be paid in the mergers, but also noted for the Misonix board that the period for calculating the value weighted average price of Bioventus
class&nbsp;A common stock had not yet been agreed with Bioventus. As part of the presentation, the representative of J.P. Morgan reviewed the increases in value offered by Bioventus as a result of Misonix&#146;s negotiations with Bioventus during
the process thus far. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July&nbsp;27 and early July&nbsp;28, 2021, representatives of J.P. Morgan and Perella Weinberg conducted a series of calls
to discuss the period for calculating the value weighted average price of Bioventus class&nbsp;A common stock. Following the discussions, representatives of Perella Weinberg, at the direction of the Bioventus board, confirmed that Bioventus would
agree to calculate the exchange ratio for Bioventus class&nbsp;A common stock based on the seven-day volume weighted average share price of the Bioventus class A common stock ended on July&nbsp;27, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;28, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. At this meeting,
representatives of J.P. Morgan presented their financial analyses of the merger consideration, including both the cash component and the Bioventus class&nbsp;A common stock component of the merger consideration. The representatives of J.P. Morgan
also informed the Misonix board that Bioventus agreed to calculate the exchange ratio for Bioventus class A common stock based on the seven-day volume weighted average share price of the Bioventus class A common stock ended on July&nbsp;27, 2021.
The representatives of Jones Day then discussed with the Misonix board their fiduciary duties in the context of the proposed transaction with Bioventus and presented the final material terms of the transaction and the current draft of the merger
agreement. J.P. Morgan then delivered to the Misonix board an oral opinion, which was subsequently confirmed by delivery of a written opinion dated July 29, 2021, to the effect that, as of that date and based on and subject to the considerations set
forth in the written opinion, the merger consideration to be paid to holders of Misonix common stock in the proposed transaction was fair, from a financial point of view, to such holders, as more fully described below under &#147;&#151;Opinion of
Misonix&#146;s Financial Advisor&#148;. After discussions, including as to the matters described below under &#147;&#151;Recommendation of the Misonix board of Directors; Misonix&#146;s Reasons for the Merger,&#148; the Misonix board unanimously:
(i)&nbsp;determined that the merger and the other transactions contemplated by the merger agreement are fair to, and in the best interests of, Misonix and its stockholders; (ii)&nbsp;declared advisable, approved and authorized in all respects the
merger agreement, the performance of Misonix of its obligations thereunder and the consummation of the transactions contemplated thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&nbsp;recommended that
Misonix stockholders adopt the merger agreement. Simultaneously, the Misonix board approved and authorized in all respects the voting and support agreement between Misonix and certain significant stockholders of Bioventus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;28, 2021, the Bioventus board held a meeting at which Bioventus management and representatives of Latham and Perella Weinberg were present. At
this meeting, representatives of Perella Weinberg presented their financial analyses of the merger consideration and the principal terms of the potential transaction. Representatives of Latham then discussed that the definitive agreement had been
fully negotiated, presented the final material terms of the transaction and discussed with the Bioventus board their fiduciary duties in connection with the proposed transaction. Perella Weinberg then delivered to the Bioventus board an oral
opinion, which was subsequently confirmed by delivery of a written opinion dated July 29, 2021, that as of that date and based upon and subject to the various assumptions made, procedures followed, matters considered and qualifications and
limitations set forth in the written opinion, the merger consideration to be paid by Bioventus was fair, from a financial point of view, to Bioventus, as more fully described under &#147;Opinion of Bioventus&#146; Financial Advisor.&#148; After
discussions, including as to the matters described below under &#147;&#151;Recommendation of the Bioventus Board of Directors; Bioventus&#146; Reasons for the Merger,&#148; the Bioventus board unanimously: (i)&nbsp;determined that the terms of the
merger agreement, the mergers and the other transactions contemplated by the merger agreement, are fair to and in the best interests of Bioventus and its stockholders; (ii)&nbsp;approved and declared advisable the merger agreement and the
transactions contemplated thereby, including the mergers and the share issuance, each on the terms and subject to the conditions set forth in the merger agreement; and (iii) recommended that Bioventus stockholders approve the Bioventus share
issuance proposal. Simultaneously, the Bioventus board approved and authorized in all respects the voting and support agreement between Bioventus and certain significant stockholders of Misonix. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the course of the evening of July&nbsp;28, 2021, representatives of Jones Day and Latham finalized
the merger agreement, the voting and support agreements and the other ancillary documents contemplated thereby. During this period, representatives of Latham confirmed that Bioventus would not require the significant stockholders of Misonix to
execute lock-up agreements in connection with the transactions. On July&nbsp;29, 2021, representatives of Latham finalized and executed the debt commitment letter and related fee letter with legal counsel for Wells Fargo Securities, LLC and Wells
Fargo Bank, National Association, regarding Bioventus&#146; transaction financing to facilitate Bioventus&#146; entry into the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on
July&nbsp;29, 2021, following the final completion of the execution version of the merger agreement and the execution of the debt commitment letter and related fee letter, the Misonix board, upon reviewing the execution version of the merger
agreement and all ancillary documents contemplated thereby, executed a unanimous written consent that unanimously: (i)&nbsp;determined that the merger and the other transactions contemplated by the merger agreement are fair to, and in the best
interests of, Misonix and its stockholders; (ii)&nbsp;declared advisable, approved and authorized in all respects the merger agreement, the performance of Misonix of its obligations thereunder and the consummation of the transactions contemplated
thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&nbsp;recommended that Misonix stockholders adopt the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on July&nbsp;29, 2021, following the approval of the merger agreement and the merger by the Bioventus board and the Misonix board, Bioventus and Misonix
executed the merger agreement, and on the afternoon of July&nbsp;29, 2021, immediately following the close of trading, issued a joint press release announcing that they had entered into the merger agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Bioventus Board of Directors; Bioventus&#146; Reasons for the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At a special meeting held on July&nbsp;28, 2021, the Bioventus board unanimously: (i)&nbsp;determined that the terms of the merger agreement, the mergers and
the other transactions contemplated by the merger agreement, are fair to and in the best interests of Bioventus and its stockholders; (ii)&nbsp;approved and declared advisable the merger agreement and the transactions contemplated thereby, including
the mergers and the share issuance, each on the terms and subject to the conditions set forth in the merger agreement; and (iii)&nbsp;recommended that Bioventus stockholders approve the Bioventus share issuance proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACCORDINGLY, THE BIOVENTUS BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT BIOVENTUS STOCKHOLDERS VOTE &#147;FOR&#148; THE BIOVENTUS SHARE
ISSUANCE PROPOSAL AND &#147;FOR&#148; THE BIOVENTUS ADJOURNMENT PROPOSAL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described under &#147;&#151;Background of the Merger,&#148; in
evaluating the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, the Bioventus board held a number of meetings and consulted with Bioventus senior management and its outside legal and financial
advisors. In reaching its decision to approve the merger agreement and to recommend that Bioventus stockholders vote to approve the Bioventus share issuance proposal, the Bioventus board considered a number of factors, including, but not limited to
the following (which are not necessarily presented in order of their relative importance to the Bioventus board): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Benefits of the Acquisition.</I> The Bioventus board believe that the acquisition of Misonix enhances
Bioventus&#146; leadership position in the medical device industry. Combining Bioventus&#146; and Misonix&#146;s complementary technologies and markets is expected, taking into account publicly available information about other industry participants
and management&#146;s best view as to industry-related information that is not publicly available, to create an industry leading portfolio of clinically proven and cost-effective medical devices. In this regard, the Bioventus board noted:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; and Misonix&#146;s complementary focus on innovative medical device technologies, and that the
combined company will be able to offer a broad range of safe, effective and clinically proven medical devices; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the combined company will have greater research and development resources, engineering expertise and
technology, which will allow Bioventus to better serve customers and accelerate innovation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the combined company&#146;s complementary product offerings and engineering and technical strengths will be
aligned with important growth trends, such as cost effective and hardware agnostic products used in spinal surgeries and the movement of a patient from the hospital to the ASC to the physician office for the treatment of wounds;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the cultures of Bioventus and Misonix are strongly aligned, including shared values and commitment to
innovation, execution and results orientation, and that this culture, along with Bioventus&#146; commitment to excellence, will accelerate high performance growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the combined company will have increased financial strength and flexibility, with an
estimated $400&nbsp;million in combined revenue in the twelve month period prior to signing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the merger would immediately diversify Bioventus&#146; revenue streams and be accretive to Bioventus&#146;
revenue growth rate, without taking into account expected synergies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the merger will create synergies of approximately $20&nbsp;million by the end of the 2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> full year subsequent to closing, driven primarily by lower operating expenses and cost of goods sold; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the combined company will be well-capitalized with a stronger balance sheet.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Exchange Ratio and Merger Consideration</I>. The Bioventus board considered the relative favorability of the
exchange ratio relative to the exchange ratios historically implied by the relative trading prices of Bioventus and Misonix common stock over various periods and relative to the current assessment of the valuation of each company and of the
synergies and other benefits of the merger, in addition to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, the maximum cash amount payable by Bioventus will be an amount equal to $10.50 multiplied by the
number of outstanding shares of Misonix common stock shortly prior to the completion of the transaction, which as of September&nbsp;1, 2021, the latest practicable date before the filing of this merger, would be $183.0&nbsp;million;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, upon completion of the merger, Bioventus stockholders and former Misonix stockholders will own
approximately 75% and 25%, respectively, of the combined company (based on fully diluted shares outstanding of the combined company); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the oral opinion of Perella Weinberg, rendered to the Bioventus board on July&nbsp;28, 2021, subsequently
confirmed in a written opinion dated July&nbsp;29, 2021, to the effect that, as of July&nbsp;29, 2021, and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered by
Perella Weinberg in connection with the preparation of its opinion, the merger consideration to be paid by Bioventus pursuant to the merger agreement was fair, from a financial point of view, to Bioventus (which opinion is more fully described below
under &#147;&#151;Opinion of Bioventus&#146; Financial Advisor&#151;Opinion of Perella Weinberg&#148; and is attached as <U>Annex B</U> hereto); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Factors Considered by the Bioventus Board of Directors</I>. In addition to considering the factors
described above, the Bioventus board considered the following additional factors that weighed in favor of the mergers: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">historical information concerning Bioventus&#146; and Misonix&#146;s respective businesses, financial condition,
results of operations, earnings, trading prices, technology positions, managements, competitive positions and prospects on stand-alone and forecasted combined bases; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current and prospective business environment in which Bioventus and Misonix operate, including international,
national and local economic conditions and the competitive and regulatory environment, and the likely effect of these factors on Bioventus and the combined company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Terms of the Merger Agreement</I>. The Bioventus board considered that the terms of the merger agreement,
taken as a whole, including the parties&#146; representations, warranties and covenants, and the circumstances under which the merger agreement may be terminated, in its belief, are reasonable. The Bioventus board also reviewed and considered the
conditions to the completion of the merger, and concluded that while the completion of the merger is subject to regulatory approval, such approval is likely to be satisfied on a timely basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board weighed these advantages and opportunities against a number of potentially negative factors in its deliberations concerning the merger
agreement and the mergers, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that, because the exchange ratio under the merger agreement would not be adjusted for changes in the
market price of Bioventus or Misonix common stock, the then-current trading price of the shares of Bioventus class A common stock to be issued to holders of shares of Misonix common stock upon the consummation of the merger could be significantly
higher than the trading price prevailing at the time the merger agreement was entered into; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the opinion of Perella Weinberg as to the fairness, from a financial point of view, of the merger
consideration to be paid by Bioventus pursuant to the merger agreement, to Bioventus speaks only as of the date of such opinion and did not and will not take into account events occurring or information that has become available after such date,
including any changes in the operations and prospects of Bioventus or Misonix, general economic, monetary, market and other conditions and other factors that may be beyond the control of Bioventus and Misonix and on which the fairness opinions were
based, any of which may be material; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that Misonix&#146;s financial performance may not meet Bioventus&#146; expectations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the merger may not be completed or may be delayed despite the parties&#146; efforts, including the
possibility that conditions to the parties&#146; obligations to complete the merger may not be satisfied, and the potential resulting disruptions to Bioventus&#146; and Misonix&#146;s businesses; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential length of the regulatory approval process and the possibility that governmental authorities might
seek to require certain actions of Bioventus or Misonix or impose certain terms, conditions or limitations on Bioventus&#146; or Misonix&#146;s businesses in connection with granting approval of the merger or might otherwise seek to prevent or delay
the merger; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential challenges and difficulties in integrating the operations of Bioventus and Misonix and the risk
that anticipated cost savings and operational efficiencies between the two companies, or other anticipated cost benefits of the merger, might not be realized or might take longer to realize than expected; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the difficulties and challenges inherent in completing the merger and integrating the businesses, operations and
workforce of Misonix with those of Bioventus and the possibility of encountering difficulties in achieving expected revenue growth and other <FONT STYLE="white-space:nowrap">non-cost</FONT> synergies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible diversion of management attention for an extended period of time during the pendency of the merger
and, following closing, the integration of the two companies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the substantial costs to be incurred in connection with the merger, including those incurred regardless of
whether the merger is consummated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Bioventus would be required to pay to Misonix a termination fee of $ $20,661,000 in the event the merger
agreement were to be terminated in certain circumstances if the Bioventus board changes its recommendation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that Misonix stockholders may not approve the adoption of the merger agreement at the Misonix special
meeting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of the Misonix board, subject to certain conditions, to change its recommendation supporting the
merger in response to a superior proposal or an intervening event other than a superior proposal, if the Misonix board determines that failure to take such action would reasonably be expected to be inconsistent with the Misonix board&#146;s
fiduciary duties to its stockholders under applicable laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of the Misonix board, subject to certain conditions, to terminate the merger agreement in order to
enter into a definitive agreement providing for a superior proposal; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks of the type and nature described under entitled &#147;Risk Factors&#148; and &#147;Cautionary Statement
Regarding Forward-Looking Statements.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board considered all of these factors as a whole and, on balance, concluded
that the potential benefits of the merger outweighed the risks and uncertainties of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Bioventus board was aware of and
considered that Bioventus directors and executive officers would have the right to continued service for, employment by and the right to continued indemnification by the combined company. See &#147;Interests of Bioventus&#146; Directors and
Executive Officers in the Merger.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of the information and factors that the Bioventus board considered is not intended to be
exhaustive, but rather is meant to include the material factors that the Bioventus board considered. The Bioventus board collectively reached the conclusion to approve the merger agreement, the merger and the other transactions contemplated by the
merger agreement in light of the various factors described above and other factors that the members of the Bioventus board believed were appropriate. In view of the complexity and wide variety of factors, both positive and negative, that the
Bioventus board considered in connection with its evaluation of the merger, the Bioventus board did not find it practical, and did not attempt, to quantify, rank or otherwise assign relative or specific weights or values to any of the factors it
considered in reaching its decision and did not undertake to make any specific determination as to whether any particular factor, or any aspect of any particular factor, was favorable or unfavorable to the ultimate determination of the Bioventus
board. In considering the factors discussed above, individual directors may have given different weights to different factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description
of Bioventus&#146; consideration of the factors supporting the merger is forward-looking in nature. This information should be read in light of the factors discussed under &#147;Cautionary Statement Regarding Forward-Looking Statements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Misonix Board of Directors; Misonix&#146;s Reasons for the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At a meeting held on July&nbsp;29, 2021, the Misonix board unanimously: (i)&nbsp;determined that the terms of the merger agreement and the transactions
contemplated thereby are fair to, and in the best interests of, Misonix and its stockholders; (ii)&nbsp;declared advisable, approved and authorized in all respects the merger agreement, the performance by Misonix of its obligations thereunder and
the consummation of the transactions contemplated thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&nbsp;recommended that Misonix stockholders adopt the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACCORDINGLY, THE MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT MISONIX STOCKHOLDERS VOTE &#147;FOR&#148; THE MISONIX MERGER PROPOSAL,
&#147;FOR&#148; THE MISONIX COMPENSATION PROPOSAL AND &#147;FOR&#148; THE MISONIX ADJOURNMENT PROPOSAL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described under &#147;&#151;Background of
the Mergers,&#148; in evaluating the merger agreement and the transactions contemplated thereby, including the mergers, the Misonix board met numerous times to consider a potential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction with Bioventus and consulted with Misonix&#146;s senior management, its outside legal counsel and its financial advisor. In reaching its decision to approve the merger agreement and
to recommend that Misonix stockholders vote to adopt the merger agreement, the Misonix board considered a number of factors, including, but not limited to the following (which are not necessarily presented in order of their relative importance to
the Misonix board): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the merger agreement provides for Misonix stockholders to receive, subject to the election
described above and subject to proration, 1.6839 shares of Bioventus class A common stock or $28.00 in cash for each share of Misonix common stock held (the &#147;merger consideration&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger consideration offers strong value for shares of Misonix common stock, based on a consideration of
factors including: Misonix&#146;s current and anticipated business and operations, historical results of operations, financial and market position, strategic business plans and prospects of Misonix on a standalone basis, value of Misonix as an
independent entity based on the Misonix board and management&#146;s experience and knowledge of the industry, opportunities and risks and uncertainties in executing Misonix&#146;s strategic plans, and current and historical trading prices of Misonix
common stock, including that the merger consideration, calculated as of July&nbsp;27, 2021 (the day prior to the Misonix board&#146;s consideration of the transaction) and based on the volume weighted average price of Bioventus&#146; class&nbsp;A
common stock price for the seven-day period ending on July&nbsp;27, 2021 of $16.63, values Misonix at approximately $518 million in equity value, which is a level at which Misonix has never traded and may not be able to trade at in the near term,
over an extended period of time, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Misonix board&#146;s belief that the increased merger consideration that Misonix was able to obtain as a
result of negotiations with Bioventus was the highest price per share that Bioventus was willing to pay; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the premium of the merger consideration to the market trading price of Misonix common stock compared to
comparable transactions, with the implied value of the merger consideration calculated as of July&nbsp;27, 2021 (the day prior to the Misonix board of director&#146;s consideration of the transaction) and based on the volume weighted average price
of Bioventus&#146;s class A common stock price for the <FONT STYLE="white-space:nowrap">seven-day</FONT> period ending on July&nbsp;27, 2021 of $16.63, representing premiums of approximately: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20% over Misonix common stock&#146;s closing price of $23.30 on the Nasdaq on July&nbsp;27, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">23% over Misonix common stock&#146;s volume weighted average price of $22.68 on the Nasdaq for the <FONT
STYLE="white-space:nowrap">30-day</FONT> period ended July&nbsp;27, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">29% over Misonix common stock&#146;s volume weighted average price of $21.65 on the Nasdaq for the <FONT
STYLE="white-space:nowrap">60-day</FONT> period ended July&nbsp;27, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">34% over Misonix common stock&#146;s volume weighted average price of $20.92 on the Nasdaq for the <FONT
STYLE="white-space:nowrap">90-day</FONT> period ended July&nbsp;27, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cash/stock election feature of the merger consideration, which offers Misonix stockholders the opportunity to
participate post-closing in the potential growth and success of the combined company through the stock component of the merger consideration or to realize immediate and certain value for their investment through the cash component of the merger
consideration, subject to a proration adjustment mechanism; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strategic considerations of the mergers, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Misonix&#146;s stockholders would, to the extent they receive Bioventus class A common stock, benefit from
being stockholders in a more risk-diversified business than Misonix currently maintains; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the opportunity to combine the complementary strengths of Misonix and Bioventus to broaden distribution access,
expand complementary product and service offerings, increase the scale and breadth of each of Misonix&#146;s and Bioventus&#146;s distribution and sales capabilities as compared to remaining independent companies, and improve operating efficiency of
the combined company&#146;s </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
businesses, which are expected to position the combined company to be a strong player across a range of care settings and specialties, including pain treatments, restorative therapies, surgical
solutions and sports medicine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the strengths and increased size of the combined company would potentially cause Bioventus class A common
stock to be afforded a higher valuation in the market that would benefit Misonix&#146;s stockholders, to the extent they elect to receive Bioventus class A common stock as merger consideration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the combined company would have a greater market capitalization and increased trading liquidity as compared to
Misonix&#146;s historical market capitalization and trading liquidity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Bioventus believes that the transaction will be accretive to its adjusted EBITDA in the first full year
after completion of the mergers and accretive to its adjusted EBITDA margins by the second full year after completion of the mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assessment of the Misonix board and Misonix senior management of Bioventus&#146;s business, prospects and
strategic plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive guidance from Bioventus regarding its anticipated future operating performance, and analysis of
potential cost synergies that could cause Bioventus class A common stock to appreciate after the transactions close, which increase in price would benefit Misonix stockholders who become Bioventus stockholders in the mergers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the significant cash portion of the merger consideration would limit the impact of any decline in the
trading price of Bioventus class A common stock on the aggregate value of the merger consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Misonix board&#146;s expectation that the transaction will result in Misonix stockholders being able to
participate in approximately $20&nbsp;million of estimated <FONT STYLE="white-space:nowrap">run-rate</FONT> cost synergies expected within two years of the completion of the mergers resulting from, among other things reduction of duplicative
corporate costs and including public company expenses and general support, systems and infrastructure costs, as well as significant revenue synergies across the combined business through enhanced scale and cross-selling opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that two members of the Misonix board would be appointed to the Bioventus board and would be able to contribute
to the future strategy and growth of the combined company&#146;s business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that the above-described or other factors cause the price of Bioventus class A common stock to
appreciate over the period until the transaction closes, the value of the merger consideration would increase fractionally in equal proportion to the benefit of all Misonix stockholders to the extent they receive Bioventus class A common stock; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the mixed stock and cash consideration would enable Misonix stockholders to have a significant ownership position
in the combined company (expected to be approximately 25% of the combined company) and participate in the value and opportunities of the combined company after the mergers, including synergies and expected future growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the view of the Misonix board that the merger agreement was the product of arm&#146;s length negotiations and
contained customary terms and conditions for similar transactions, and its consideration of a number of other factors pertaining to the merger agreement, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right of the Misonix board to terminate the merger agreement if the requisite stockholder vote for Misonix or
Bioventus were not obtained, in each case after a vote on such approval was taken; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited scope of the closing conditions and the absence of a closing condition relating to Bioventus&#146;s
ability to finance its payment of the cash portion of the merger consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the end date under the merger agreement upon which either party, subject to specified exceptions, can terminate
the merger agreement, should provide sufficient time to consummate the mergers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s ability to specifically enforce Bioventus&#146;s obligations under the merger agreement, including
Bioventus&#146;s obligation to consummate the mergers or to seek damages in the event of a willful and material breach of the merger agreement by Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the mergers are intended to qualify as a reorganization for U.S. federal income tax purposes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the merger agreement provides Misonix with sufficient operating flexibility between the signing of the
merger agreement and the completion of the mergers to conduct its business in the ordinary course consistent with past practice; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the unanimous approval of the merger agreement by the Misonix board, which consists of a majority of independent
directors who are not affiliated with Bioventus and are not employees of Misonix or any of its subsidiaries, and which retained and received advice from Misonix&#146;s outside financial and legal advisors in evaluating, negotiating and recommending
the terms of the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that based on a review of the terms of the merger agreement with Misonix&#146;s outside legal advisors, and
assuming the mergers are attractive to Misonix stockholders, there is a high likelihood of completing the mergers, particularly in light of the terms of the merger agreement and the conditions to completing the mergers (see the sections of this
joint proxy statement/prospectus captioned &#147;&#151;Conditions to Completion of the Mergers&#148; and &#147;&#151;Regulatory Approvals&#148;). In making its determination, the Misonix board considered a number of factors, including:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus is obliged to use reasonable best efforts to (1)&nbsp;complete the mergers and obtain the necessary
approvals and clearances required to complete the mergers as promptly as reasonably practical, and (2)&nbsp;resolve impediments or objections, if any, asserted by any governmental authority with respect to the mergers under antitrust laws (including
divestitures or behavioral remedies), except for such remedies that would reasonably be expected to have a material adverse effect on the results of operations of Misonix or a material adverse effect on the results of operations of Bioventus, where,
for purposes of determining whether an effect is or would be materially adverse to the results of operations of Bioventus, Bioventus will be deemed to be the same size (in operations and from a financial point of view) as Misonix;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the voting and support agreement entered into in favor of Misonix by EW Healthcare Partners Acquisition Fund,
L.P., White Pine Medical, LLC, Smith&nbsp;&amp; Nephew, Inc., Smith&nbsp;&amp; Nephew USD Ltd and AMP-CF Holdings, LLC as to approximately 67.4% of Bioventus shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus may not terminate the merger agreement to take a superior proposal or in response to an intervening
event; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the mergers are expected to qualify as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the Code, as amended, and the rules and regulations promulgated thereunder, generally resulting in the mergers being <FONT STYLE="white-space:nowrap">tax-free</FONT> to Misonix stockholders to the extent they receive Bioventus
class A common stock pursuant to the mergers and taxable to holders of Misonix stockholders to the extent they receive cash consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the oral opinion that J.P. Morgan, Misonix&#146;s financial advisor gave to the Misonix board on July&nbsp;28,
2021, subsequently confirmed in writing by delivery of J.P. Morgan&#146;s written opinion addressed to the Misonix board dated July&nbsp;29, 2021, that, as of such date and based upon and subject to the assumptions made, procedures followed, matters
considered, and qualifications and limitations undertaken by J.P. Morgan in preparing its opinion, the consideration to be paid to the Misonix stockholders pursuant to the merger agreement, was fair, from a financial point of view, to such holders,
as more fully described in the section entitled &#147;&#151;Opinion of Misonix&#146;s Financial Advisor, J.P. Morgan&#148; of this joint proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the Misonix board determined that entering into the merger agreement with Bioventus presents the best
opportunity to maximize value for the Misonix stockholders, based on consultation with senior </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
management and Misonix&#146;s financial and legal advisors and an evaluation of alternative transactions (including maintaining the status quo). In making its determination, the Misonix board
considered a number of factors, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Misonix board&#146;s assessment of Misonix&#146;s business and operations, historical results of operations,
financial prospects and conditions, and the determination that continued operation of Misonix on a standalone basis was not likely to produce, on a risk-adjusted basis, more value for Misonix stockholders than the merger consideration offered by
Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential to create meaningful business opportunities and favorable market valuation effects for Bioventus as
a result of combining with Misonix, from which Misonix stockholders would have the opportunity to benefit (in proportion for all Misonix stockholders to the extent reflected in the price performance of Bioventus class A common stock prior to the
closing, and thereafter fully reflected in the value of the merger consideration received in the form of Bioventus class A common stock that is retained by Misonix stockholders post-closing); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the merger consideration proposed by Bioventus included a fixed-share component, the value of which
would be subject to market fluctuations from the announcement of any transaction until the closing of such transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that a delay in executing a definitive merger agreement might lead to an increased risk of leaks
and market rumors prior to execution, which might harm Misonix in the event that an agreement was not reached; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Misonix board&#146;s assessment at the time of such determination of the relative certainty of being able to
expeditiously execute a definitive merger agreement with Bioventus and the relative uncertainty of being able to execute a definitive merger agreement with Company C on a similar timeline or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk of delaying the execution of a definitive merger agreement, including that potential market volatility
associated with COVID or otherwise, might have a negative effect on the value of Misonix common stock and the perceived value of its business in the marketplace, and might affect Company C&#146;s willingness to pursue a transaction; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that Company C was no longer interested in pursuing an acquisition of Misonix, or that a
transaction with Company C would be complicated, tax inefficient and may not be accomplished on favorable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the determination of the Misonix board that negotiating a potential transaction with Bioventus was most likely to
result in the best transaction reasonably available for Misonix stockholders based on: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s process of reviewing strategic alternatives, including discussions with other potential bidders as
part of its market check and discussions of reasons not to pursue other bidders, was appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">among the prospective bidders, Bioventus was best positioned to provide the highest value of consideration to
Misonix stockholders in light of Bioventus&#146;s strategic interest and priorities and the expected business opportunities and favorable market valuation effects for Bioventus arising from the mergers (benefitting all Misonix stockholders to the
extent reflected in the price performance of Bioventus class A common stock prior to the closing of the merger and thereafter benefitting those Misonix stockholders who receive all or a portion of the merger consideration in Bioventus class A common
stock that they continue to hold post-closing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger agreement provides the Misonix board the right to terminate the merger agreement to accept a superior
proposal if the Misonix board determines that failure to do so would reasonably be expected to be inconsistent with its fiduciary duties; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the course of discussions and negotiations between Misonix and Bioventus resulted in improvement in the value of
the consideration to be received by Misonix stockholders and the terms of the merger agreement, as compared with the initial proposal made by Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, while Misonix&#146;s business continues to present opportunities for growth, it has also become
subject to increasing competitive pressures, a changing competitive landscape, and continuing as a standalone company will subject Misonix&#146;s stockholders to 100% of Misonix&#146;s execution risk. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course of its evaluation of the merger agreement and the mergers, the Misonix board also considered a variety of risks, uncertainties and other
potentially negative factors, including the following (which are not necessarily presented in order of relative importance): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Misonix is required to use its reasonable best efforts to call, hold and initially schedule a stockholder
meeting within 45 days after the effectiveness of Bioventus&#146;s registration statement in connection with the mergers (to the extent not a violation of law); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Bioventus can terminate the merger agreement if the Misonix stockholder meeting is convened, a vote on the
merger agreement is taken and the requisite approval of the Misonix stockholders is not obtained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that Bioventus can terminate the merger agreement if the Misonix board changes its recommendation that
stockholders approve the Misonix merger proposal, in which case Misonix will be obligated to pay the termination fee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that a third party may be willing to enter into a strategic combination with Misonix on terms
more favorable than the mergers and the potential that the no shop covenants and termination fees payable by Misonix under the merger agreement might deter alternative bidders that might have been willing to submit a superior proposal to Misonix,
including the requirement that, if Misonix terminates the merger agreement under certain circumstances, Misonix may be required to pay Bioventus a termination fee of $20.7&nbsp;million, or approximately 4% of transaction value, although the Misonix
board believes that the termination fee is reasonable in amount, is customary and consistent with fees and provisions in comparable transactions and would not be preclusive of other offers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that following receipt of the Misonix stockholder approval, the Misonix board would be unable to change its
recommendation in response to a superior proposal or an intervening event or to terminate the merger agreement to accept a superior proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the merger consideration in part consists of a fixed exchange ratio of shares of Bioventus class A
common stock per share of Misonix common stock, the merger agreement does not provide for either any adjustment of such exchange ratio if the trading price of Bioventus class A common stock decreases or a value-based termination right to Misonix,
and the value of the stock portion of the merger consideration at the closing will not be known at the time Misonix stockholders vote on the Merger Proposal, meaning that Misonix stockholders could be adversely affected to an unpredictable extent
and the implied value of the merger consideration could decline if there is a decrease in the trading price of Bioventus class A common stock prior to the closing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the right of Misonix stockholders to elect to receive the cash portion of the merger consideration
or the stock portion of the merger consideration is subject to proration such that the amount of cash to be received by Misonix stockholders in the mergers will, in the aggregate, be equal to $10.50 per share of Misonix common stock outstanding as
of 5:00 p.m. New York City time on the election deadline, 2021, meaning that on an aggregate basis the merger consideration payable by Bioventus will be equal to $10.50 and 1.0524 shares of Bioventus class A common stock per share of Misonix common
stock outstanding as of 5:00 p.m. New York City time on the election deadline, 2021 and Misonix stockholders will in the aggregate be fully exposed to fluctuations in price of Bioventus class A common stock prior to the completion of the mergers;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of the merger consideration being paid in cash would prevent Misonix stockholders from realizing the
benefit of any increase in the trading price of Bioventus class A common stock during the pendency of the mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the significant costs involved in connection with entering into the merger agreement and the transactions
contemplated thereby, and the substantial time and effort of management required to complete the transactions contemplated by the merger agreement, which may disrupt Misonix&#146;s business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the consummation of the mergers requires receipt of regulatory approvals and the risk that, notwithstanding
Bioventus&#146;s obligations with respect to obtaining regulatory approvals as set forth in the merger agreement, governmental entities may delay or fail to grant the required regulatory approvals or impose unfavorable terms or conditions on such
approvals or that remedies implemented by Bioventus or Misonix to obtain regulatory approvals may adversely affect the business and financial results of the combined company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restrictions in the merger agreement on the conduct of Misonix&#146;s business during the period prior to
consummation of the mergers, including that Misonix is required to conduct its business in the ordinary course, subject to specific limitations, which could delay or prevent Misonix from undertaking business opportunities or strategic transactions
that may arise and that, absent the merger agreement, Misonix might have pursued; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that certain of Misonix&#146;s directors and executive officers may have interests in the mergers that may be
different from, or in addition to, those of Misonix&#146;s stockholders generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the mergers might not be consummated, which may cause Misonix to be required to pay its own
expenses associated with the merger agreement and the transactions contemplated thereby; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the mergers might not be consummated, and the possible adverse effect of termination of the
merger agreement on Misonix&#146;s business or the trading price of Misonix common stock </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks that, even though the Misonix stockholder approval has been obtained, other conditions to the
parties&#146; obligations to complete the mergers may not be satisfied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of the public announcement of the merger agreement, including Misonix&#146;s ability to attract and
retain key personnel and to maintain client and distribution partner relations during the pendency of the transactions contemplated by the merger agreement, as well as the potential for litigation in connection with the mergers and the associated
costs, burden and inconvenience involved in defending those proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that Bioventus may not be able to obtain sufficient financing to pay the cash portion of the merger
consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that anticipated cost savings and operational efficiencies between the two companies, or other
anticipated benefits of the mergers, including potential revenue synergies across the combined business, might not be realized or might take longer to realize than expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges inherent in the combination of two businesses of the size, scope and complexity of Misonix and
Bioventus, including the potential for unforeseen difficulties in integrating operations, systems and employees and the potential impact of such difficulties on employees and relationships with existing and prospective customers, distribution
partners, suppliers and other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that Misonix may lose members of management and other key personnel following announcement of the
transaction and may not be able to effectively replace such persons, which could adversely affect Misonix&#146;s business during the period prior to consummation of the mergers or, if the mergers are not consummated, during the period prior to and
after the termination of the merger agreement, as Misonix&#146;s operations are largely dependent on the skill and experience of its management and key personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for the portion of the merger consideration paid in Bioventus class A common stock and retained by Misonix
stockholders following the closing of the transaction, the risk that Bioventus fails to provide holders of Bioventus class A common stock with acceptable returns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that execution of Misonix&#146;s standalone business plan or other strategic alternatives
available to Misonix may have provided greater value to Misonix stockholders than the mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the uncertainty as to whether soliciting potential purchasers of Misonix other than Bioventus would yield greater
value to Misonix and its stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that a combination with Company C or another party may have provided greater value to Misonix
stockholders than the mergers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks of the type and nature described under the sections entitled &#147;Risk Factors&#148; and &#147;Cautionary
Note Regarding Forward-Looking Statements.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board believed that, overall, the potential benefits of the mergers to
Misonix stockholders outweighed the risks and uncertainties of the mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of factors considered by the Misonix board in
reaching its conclusions and recommendation includes the principal factors considered by the Misonix board, but is not intended to be exhaustive and may not include all of the factors considered by the Misonix board, but includes the material
factors considered by the Misonix board. In light of the variety of factors considered in connection with its evaluation of the mergers, the Misonix board did not find it practicable to, and did not, quantify or otherwise assign relative or specific
weights to the specific factors considered in reaching its determinations and recommendations. Rather, the Misonix board viewed its decisions as being based on the totality of the factors and information it considered. Moreover, each member of the
Misonix board applied his or her own personal business judgment to the process and may have given different weight to different factors. The Misonix board based its recommendation on the totality of the information presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion of Bioventus&#146; Financial Advisor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of Perella Weinberg </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bioventus retained Perella Weinberg to act as its financial advisor in connection with the mergers. Bioventus selected Perella Weinberg based
on its qualifications, expertise and reputation and its knowledge of the business and affairs of Bioventus, Misonix and the industries in which Bioventus and Misonix conduct their respective businesses. Perella Weinberg and its affiliates, as part
of their investment banking business, are continually engaged in performing financial analyses with respect to businesses and their securities in connection with mergers and acquisitions, leveraged buyouts and other transactions as well as for
corporate and other purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;28, 2021, Perella Weinberg rendered its oral opinion, subsequently confirmed in writing, to
the Bioventus board that, as of such date and based upon and subject to the various assumptions made, procedures followed, matters considered and qualifications and limitations set forth therein, the per share merger consideration to be paid by
Bioventus to the holders of shares of common stock of Misonix pursuant to the merger agreement was, as of the date of the opinion, fair, from a financial point of view, to Bioventus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The full text of Perella Weinberg&#146;s written opinion, dated July&nbsp;29, 2021 which sets forth, among other things, the assumptions
made, procedures followed, matters considered and qualifications and limitations on the review undertaken by Perella Weinberg, is attached hereto as <U>Annex</U><U></U><U>&nbsp;B</U> and is incorporated by reference herein. Perella Weinberg&#146;s
opinion was not intended to be and does not constitute a recommendation to any holder of Bioventus common stock or any other person as to how such person should vote or otherwise act with respect to the mergers or any other matter. Perella
Weinberg&#146;s opinion </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
does not in any manner address the prices at which Misonix common stock or Bioventus common stock will trade at any time. In addition, Perella Weinberg expressed no opinion as to the fairness of
the mergers to the holders of any class of securities, creditors or other constituents of Bioventus or Misonix or as to the underlying decision by any person to engage in the mergers or as to the relative merits of the mergers compared to
alternative transactions or business strategies. Perella Weinberg provided its opinion for the information and assistance of the Bioventus board in connection with, and for the purposes of its evaluation of, the mergers. This summary is qualified in
its entirety by reference to the full text of the opinion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, Perella Weinberg, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain publicly available financial statements and other publicly available business and financial
information with respect to Misonix and Bioventus, including equity research analyst reports; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain publicly available financial forecasts relating to the business and financial prospects of
Misonix, derived from a consensus of selected equity research analysts that were identified by Misonix&#146;s management and discussed with Perella Weinberg by Misonix for use in Perella Weinberg&#146;s analysis, as adjusted by Bioventus management,
and which forecasts were extrapolated by the management of Bioventus for certain fiscal years (the &#147;Adjusted and Extrapolated Misonix Street Forecasts&#148;) and approved for Perella Weinberg&#146;s use by Bioventus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain publicly available financial forecasts relating to the business and financial prospects of
Bioventus, derived from a consensus of selected equity research analysts that were identified by Bioventus&#146;s management, as adjusted by the management of Bioventus (the &#147;Adjusted Bioventus Street Forecasts&#148;), and approved for Perella
Weinberg&#146;s use by Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain internal financial statements, analyses and/or other financial and operating data relating to
the business of Misonix and Bioventus, prepared by the management of Misonix and the management of Bioventus, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussed the past and current business, operations, financial condition and prospects of Misonix with
representatives of Misonix and Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussed the past and current business, operations, financial condition and prospects of Bioventus with
representatives of Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussed with members of the senior managements of Misonix and Bioventus their assessment of the strategic
rationale for, and the potential benefits of, the mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain estimates as to the amount and timing of certain cost savings anticipated by the management of
Bioventus to result from the consummation of the mergers (the &#147;Cost Savings&#148;), as prepared by the management of Bioventus and approved for Perella Weinberg&#146;s use by Bioventus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compared the financial performance of Misonix and Bioventus with that of certain publicly-traded companies which
Perella Weinberg believed to be generally relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compared the financial terms of the mergers with the publicly available financial terms of certain other
transactions which Perella Weinberg believed to be generally relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed the historical trading prices for Misonix common stock and Bioventus common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participated in discussions among representatives of Misonix and Bioventus and their respective advisors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed a draft of the merger agreement dated July&nbsp;28, 2021; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducted such other financial studies, analyses and investigations, and considered such other factors, as
Perella Weinberg deemed appropriate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of its opinion, Perella Weinberg assumed and relied upon, without independent
verification, the accuracy and completeness of the financial and other information supplied or otherwise made available to it (including information that was available from generally recognized public sources) for purposes of its opinion and further
relied upon the assurances of the management of Bioventus that such information did not contain any material omissions or misstatements of material fact. At Bioventus&#146;s direction, Perella Weinberg relied on the Adjusted and Extrapolated Misonix
Street Forecasts, the Cost Savings and the Adjusted Bioventus Street Forecasts. With respect to the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings, Perella Weinberg assumed, with Bioventus&#146;s consent, that they had been
reasonably prepared on bases reflecting the best then available estimates and good faith judgments of the management of Bioventus as to the matters covered thereby and Perella Weinberg expressed no view as to the assumptions on which they were
based. In that regard, Perella Weinberg was advised by Bioventus, and assumed, with Bioventus&#146;s consent, that the Adjusted and Extrapolated Misonix Street Forecasts and Cost Savings were a reasonable basis upon which to evaluate the future
financial performance of Misonix and Perella Weinberg used the Adjusted and Extrapolated Misonix Street Forecasts and Cost Savings in its analysis. Perella Weinberg further assumed, with Bioventus&#146;s consent, that the Adjusted Bioventus Street
Forecasts represented the best then available estimates as to the matters covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, Perella Weinberg
did not make and was not provided with any independent valuation or appraisal of the assets or liabilities (including any contingent, derivative or <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> assets and liabilities) of Misonix or
Bioventus, nor any of their respective subsidiaries. Perella Weinberg did not assume any obligation to conduct, nor did it conduct, any physical inspection of the properties or facilities of Misonix or Bioventus. In addition, Perella Weinberg did
not evaluate the solvency of any party to the merger agreement, or the impact of the mergers thereon, including under any applicable laws relating to bankruptcy, insolvency or similar matters. Perella Weinberg also assumed that the final executed
merger agreement would not differ from the draft merger agreement reviewed by it in any respect material to its analysis, and that the mergers would be consummated in accordance with the terms set forth in the merger agreement, without modification,
waiver or delay in any respect material to its analysis. In addition, Perella Weinberg assumed that in connection with the receipt of all the necessary approvals for the mergers, no delays, limitations, conditions or restrictions would be imposed
that could have an adverse effect on Misonix, Bioventus or the contemplated benefits of the mergers, in each case, in any way material to its analysis. Perella Weinberg relied as to all legal matters relevant to rendering its opinion upon the advice
of counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg&#146;s opinion addressed only the fairness from a financial point of view, as of the date thereof, of the
Merger Consideration to be paid by Bioventus pursuant to the merger agreement. Perella Weinberg was not asked to, and it did not, offer any opinion as to any other term of the merger agreement or any other related document, the form, structure or
financing of the mergers or the likely timeframe in which the mergers will be consummated. Perella Weinberg expressed no opinion with respect to the allocation of the cash election consideration and stock election consideration among the holders of
Misonix common stock. In addition, Perella Weinberg expressed no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any party to the mergers, or any class of such persons,
relative to the merger consideration or otherwise. Perella Weinberg expressed no opinion as to the fairness of the mergers to the holders of any other class of securities, creditors or other constituencies of Bioventus or Misonix or as to the
underlying decision by any person to engage in the mergers or as to the relative merits of the mergers compared to any alternative transactions or business strategies. Nor did Perella Weinberg express any opinion as to any tax or other consequences
that may result from the transactions contemplated by the merger agreement or any related document, nor did its opinion address any legal, tax, regulatory or accounting matters, as to which it understood Bioventus had received such advice as it
deemed necessary from qualified professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg&#146;s opinion was necessarily based on financial, economic, market and
other conditions as in effect on, and the information made available to it as of, the date of its opinion. Subsequent developments may affect Perella Weinberg&#146;s opinion and the assumptions used in preparing such opinion, and Perella Weinberg
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
does not have any obligation to update, revise, or reaffirm its opinion. The issuance of Perella Weinberg&#146;s opinion was approved by a fairness opinion committee of Perella Weinberg. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Material Financial Analyses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material financial analyses performed by Perella Weinberg and reviewed with the Bioventus board in connection
with Perella Weinberg&#146;s opinion and does not purport to be a complete description of the financial analyses performed by Perella Weinberg. The order of analyses described below does not represent the relative importance or weight given to those
analyses by Perella Weinberg.<B> Some of the</B><B></B><B> summaries of the financial analyses include information presented in tabular format. In order to</B> <B>fully</B><B></B><B> understand Perella Weinberg&#146;s financial analyses, the tables
must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data below without considering the full narrative description of the financial analyses,
including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of Perella Weinberg&#146;s financial analyses. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus &#150; Selected Publicly
Traded Companies Analysis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg reviewed and compared certain financial information for Bioventus with corresponding
financial information, ratios and public market multiples for the following publicly held companies in the medical technology and devices industry, or the Selected Bioventus Publicly Traded Companies. Although none of the following Selected
Bioventus Publicly Traded Companies is identical to Bioventus, Perella Weinberg selected these companies because they had publicly traded equity securities and were deemed to be similar to Bioventus in one or more respects, including operating in
the medical technology and devices industry. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Selected Bioventus Publicly Traded Companies</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alphatec Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anika Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Axogen, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONMED Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globus Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integra LifeSciences Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NuVasive, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organogenesis Holdings Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orthofix Medical Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SeaSpine Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgalign Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vericel Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the Selected Bioventus Publicly Traded Companies and Bioventus, Perella Weinberg calculated and
compared financial information and various financial market multiples and ratios. For each of the Selected Bioventus Publicly Traded Companies, Perella Weinberg based its calculations on company filings for historical information and median
consensus third-party research estimates. For Bioventus, Perella Weinberg based its calculations on Bioventus filings and on the Adjusted Bioventus Street Forecasts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Bioventus and each of the Selected Bioventus Publicly Traded Companies for which relevant data was available, Perella Weinberg
reviewed enterprise value, or EV (calculated as equity value including all outstanding restricted stock units and stock options (whether vested or unvested), and with respect to stock options, using the treasury stock method, plus debt and net <FONT
STYLE="white-space:nowrap">non-operating</FONT> liabilities, less cash and cash equivalents), as of July&nbsp;27, 2021, the day before Perella Weinberg rendered its oral opinion to the Bioventus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board, as a multiple of 2021 and 2022 estimated revenue and as a multiple of 2021 and 2022 estimated adjusted EBITDA (calculated as earnings before interest, tax, depreciation and amortization).
The results of these analyses are summarized in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>EV/2021E and 2022E Revenue and EBITDA Multiples</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/2021E<BR>revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/2022E<BR>revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/2021E<BR>Adj.<BR>EBITDA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/2022E<BR>Adj.<BR>EBITDA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selected Bioventus Publicly Traded Companies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alphatec Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anika Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Axogen, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONMED Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globus Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integra LifeSciences Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NuVasive, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organogenesis Holdings Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orthofix Medical Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SeaSpine Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgalign Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vericel Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Median</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Multiple excluded from Perella Weinberg&#146;s analysis because the relevant EBITDA value was negative and
considered not meaningful, &#147;NM&#148;. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Multiple excluded from Perella Weinberg&#146;s analysis because the figure was greater than 50.0x and
considered not meaningful, &#147;NM&#148;. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the multiples of enterprise value to estimated 2021 and 2022
revenue described above, Perella Weinberg&#146;s analyses of the various Selected Bioventus Publicly Traded Companies and on professional judgments made by Perella Weinberg, Perella Weinberg applied ranges of multiples of 3.75x to 6.00x to
Bioventus&#146;s estimated 2021 revenue and a range of multiples of 3.25x to 5.25x to Bioventus&#146;s estimated 2022 revenue to derive ranges of estimated implied values per share of Bioventus common stock of approximately $24.36 to $42.03 per
share (the &#147;Bioventus 2021 Revenue Implied Value Range&#148;) and approximately $23.61 to $41.12 per share (the &#147;Bioventus 2022 Revenue Implied Value Range&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the multiples of enterprise value to estimated 2021 and 2022 EBITDA described above, Perella Weinberg&#146;s analyses of the various
Selected Bioventus Publicly Traded Companies and on professional judgments made by Perella Weinberg, Perella Weinberg applied a range of multiples of 24.0x to 29.0x to Bioventus&#146;s estimated 2021 EBITDA and a range of multiples of 21.0x to 24.0x
to Bioventus&#146;s estimated 2022 EBITDA to derive ranges of estimated implied values per share of Bioventus common stock of approximately $29.83 to $38.62 per share and approximately $30.66 to $37.48 per share, respectively. Perella Weinberg
compared these ranges to the closing per share price of Bioventus common stock of $16.81 on July&nbsp;27, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg
calculated an implied offer value per share of Misonix common stock by (i)&nbsp;multiplying each of the Bioventus 2021 Revenue Implied Value Range and the Bioventus 2022 Revenue Implied Value Range by 1.0524 and (ii)&nbsp;adding $10.50, representing
the aggregate consideration to be paid for each share of Misonix common stock, to derive ranges of estimated implied offer values per share of Misonix common stock of approximately $36.14 to $54.74 per share (the &#147;Bioventus 2021 Revenue Implied
Offer Value Range&#148;) and approximately $35.35 and $53.78 per share (the &#147;Bioventus 2022 Revenue Implied Offer Value Range&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Selected Bioventus Publicly Traded Companies were used for comparison purposes, no business of any Selected Bioventus Publicly
Traded Company was either identical or directly comparable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bioventus&#146;s business. Accordingly, Perella Weinberg&#146;s comparison of the Selected Bioventus Publicly Traded Companies to Bioventus and analysis of the results of such comparisons was not
purely mathematical, but instead necessarily involved complex considerations and judgments concerning differences in financial and operating characteristics and other factors that could affect the relative values of the Selected Bioventus Publicly
Traded Companies and Bioventus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus &#150; Discounted Cash Flow Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg conducted a discounted cash flow analysis for Bioventus based on company filings and the Adjusted Bioventus Street Forecasts
to derive a range of implied enterprise values for Bioventus by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">calculating the present value as of July&nbsp;27, 2021 of the estimated standalone unlevered free cash flows
(calculated as adjusted operating income after taxes, plus depreciation, minus capital expenditures, and adjusting for changes in net working capital) that Bioventus could generate for the second half of calendar year 2021 and the complete calendar
years 2022 through 2025 using discount rates ranging from 7.75% to 8.75% based on estimates of the weighted average cost of capital of Bioventus derived using the CAPM, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding the present value as of July&nbsp;27, 2021 of the terminal value of Bioventus at the end of calendar year
2025 using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 7.75% to 8.75%. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg estimated the range of perpetuity growth rates utilizing its professional judgment and experience, taking into account market
expectations regarding long-term real growth of gross domestic product and inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg used discount rates ranging from
of 7.75% to 8.75% derived by the application of the CAPM, which takes into account certain company-specific metrics, including Bioventus&#146;s target capital structure, the cost of long-term debt and forecasted tax rate, and Bioventus&#146;s
unlevered beta as estimated with reference to the Bioventus Selected Publicly Traded Companies&#146; predicted betas, as well as certain financial metrics for the United States financial markets generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From the range of implied enterprise values, Perella Weinberg derived a range of implied equity values for Bioventus. To calculate the implied
equity value from the implied enterprise value, Perella Weinberg added cash and cash equivalents and subtracted debt and net <FONT STYLE="white-space:nowrap">non-operating</FONT> liabilities. Perella Weinberg calculated implied equity value per
share by dividing the implied equity value by fully diluted shares (derived by using the treasury stock method based on values implied using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 7.75% to 8.75%).
This analysis resulted in a range of implied values per share of Bioventus common stock of approximately $22.52 to $33.99 per share (the &#147;Bioventus DCF Implied Value Range&#148;). Perella Weinberg compared this range to the closing price per
share of Bioventus common stock of $16.81 on July&nbsp;27, 2021. Perella Weinberg calculated an implied offer value per share of Misonix common stock by (i)&nbsp;multiplying the Bioventus DCF Implied Value Range by 1.0524 and (ii)&nbsp;adding
$10.50, representing the consideration to be paid for each share of Misonix common stock, in the aggregate, to derive a range of estimated implied offer values per share of approximately $34.20 to $46.27 per share (the &#147;Bioventus DCF Implied
Offer Value Range&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix
&#150; Selected Publicly Traded Companies Analysis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg reviewed and compared certain financial information for
Misonix with corresponding financial information, ratios and public market multiples for the following publicly traded companies in the medical technology and devices industry, or the Selected Misonix Publicly Traded Companies, and Bioventus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Although none of the Selected Misonix Publicly Traded Companies is identical to Misonix, Perella Weinberg selected these companies because they had publicly traded equity securities and were
deemed to be similar to Misonix in one or more respects, including operating in the medical technology and devices industry. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Selected Misonix Publicly Traded Companies</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alphatec Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anika Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Apyx Medical Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Axogen, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONMED Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globus Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integra LifeSciences Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MiMedx Group, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NuVasive, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organogenesis Holdings Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PolarityTE, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vericel Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the Selected Misonix Publicly Traded Companies and Bioventus, Perella Weinberg calculated and
compared financial information and various financial market multiples and ratios based on company filings and median consensus third-party research estimates. For Misonix, Perella Weinberg based its calculations on company filings and the Adjusted
and Extrapolated Misonix Street Forecasts. For Bioventus, Perella Weinberg based its calculations on company filings and the Adjusted Bioventus Street Forecasts. Perella Weinberg calculated the Misonix implied equity value as $518&nbsp;million based
on Bioventus&#146;s <FONT STYLE="white-space:nowrap">seven-day</FONT> VWAP of $16.6284 as of July&nbsp;27, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to each of
the Selected Misonix Publicly Traded Companies and Bioventus, Perella Weinberg calculated the multiple of enterprise value, or EV, as of July&nbsp;27, 2021, to estimated 2021 and 2022 revenue. Perella Weinberg calculated the same multiples for
Misonix based upon Misonix&#146;s closing price of $23.20 as of July&nbsp;27, 2021. The results of these analyses are summarized in the following tables: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>EV/2021E and 2022E Revenue Multiples</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Misonix Publicly Traded Companies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alphatec Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anika Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Apyx Medical Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Axogen, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONMED Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globus Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integra LifeSciences Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MiMedx Group, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NuVasive, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organogenesis Holdings Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PolarityTE, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vericel Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Median</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Misonix</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the multiples of enterprise value to estimated 2021 revenue and estimated 2022 revenue described
above, Perella Weinberg&#146;s analyses of the Selected Misonix Publicly Traded Companies and on professional judgments made by Perella Weinberg, Perella Weinberg applied ranges of multiples of 4.50x to 9.00x to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Misonix&#146;s estimated 2021 revenue and a range of 4.50x to 7.50x to Misonix&#146;s estimated 2022 revenue to derive ranges of implied per share equity values for Misonix of approximately
$19.14 to $40.45 per share and approximately $22.31 to $39.50 per share, respectively. Perella Weinberg compared these ranges to the closing per share price of Misonix common stock of $23.30 on July&nbsp;27, 2021, the Merger Consideration of $28.00
per share of Misonix common stock and the Bioventus 2021 Revenue Implied Offer Value Range and the Bioventus 2022 Revenue Implied Offer Value Range of approximately $36.14 to $54.74 per share and approximately $35.35 to $53.78 per share,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Selected Misonix Publicly Traded Companies were used for comparison purposes, no business of any Selected
Misonix Publicly Traded Company was either identical or directly comparable to Misonix&#146;s business. Accordingly, Perella Weinberg&#146;s comparison of the Selected Misonix Publicly Traded Companies to Misonix and analysis of the results of such
comparisons was not purely mathematical, but instead necessarily involved complex considerations and judgments concerning differences in financial and operating characteristics and other factors that could affect the relative values of the Selected
Misonix Publicly Traded Companies and Misonix. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix &#150;Discounted Cash Flow Analysis (Standalone) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg conducted a discounted cash flow analysis for Misonix based on the Adjusted and Extrapolated Misonix Street Forecasts to
derive a range of implied enterprise values for Misonix by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">calculating the present value as of July&nbsp;27, 2021 of the estimated standalone unlevered free cash flows
(calculated as adjusted operating income after taxes, plus depreciation, minus capital expenditures, and adjusting for changes in net working capital) that Misonix could generate for the second half of calendar year 2021 and the complete calendar
years 2022 through 2031, as included in the Adjusted and Extrapolated Misonix Street Forecasts, using discount rates ranging from 8.5% to 9.5% based on estimates of the weighted average cost of capital of Misonix derived using the capital asset
pricing model, or CAPM, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding the present value as of July&nbsp;27, 2021 of the terminal value of Misonix at the end of calendar year
2031 using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg estimated the range of perpetuity growth rates utilizing its professional judgment and experience, taking into account market
expectations regarding long-term real growth of gross domestic product and inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg used discount rates ranging from
8.5% to 9.5% derived by the application of the CAPM, which takes into account certain company-specific metrics, including Misonix&#146;s target capital structure, the cost of long-term debt and forecasted tax rate, and Misonix&#146;s unlevered beta
as estimated with reference to the Misonix Selected Publicly Traded Companies&#146; predicted betas and on professional judgments made by Perella Weinberg, as well as certain financial metrics for the United States financial markets generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From the range of implied enterprise value, Perella Weinberg derived a range of implied equity values for Misonix. To calculate the implied
equity value from the implied enterprise value, Perella Weinberg added cash and cash equivalents and subtracted debt. Perella Weinberg calculated implied equity value per share by dividing the implied equity value by fully diluted shares (derived by
using the treasury stock method based on values implied by using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%). This analysis resulted in a range of implied value per share of Misonix common
stock of approximately $26.55 to $38.54 per share. Perella Weinberg compared this range to the closing per share price of Misonix common stock of $23.30 on July&nbsp;27, 2021, the Merger Consideration of $28.00 per share, and the Bioventus DCF
Implied Offer Value Range of approximately $34.20 to $46.27 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix&#151;Discounted Cash Flow Analysis (Including Cost Savings) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg conducted a discounted cash flow analysis for Misonix based on the Adjusted and Extrapolated Misonix Street Forecasts and the
Cost Savings to derive a range of implied enterprise values for Misonix by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">calculating the present value as of July&nbsp;27, 2021 of the estimated unlevered free cash flows (calculated as
adjusted operating income after taxes, plus depreciation, minus capital expenditures, and adjusting for changes in net working capital) that Misonix could generate for the second half of the calendar year 2021 and the complete calendar years 2022
through 2031, as included in the Adjusted and Extrapolated Misonix Street Forecasts, using discount rates ranging from 8.5% to 9.5% based on estimates of the weighted average cost of capital of Misonix derived using the capital asset pricing model,
or CAPM, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding the present value as of July&nbsp;27, 2021 of the terminal value of Misonix at the end of calendar year
2031 using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding the present value as of July&nbsp;27, 2021 of the cost savings and related cash flows.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg estimated the range of perpetuity growth rates utilizing its professional judgment and experience,
taking into account market expectations regarding long-term real growth of gross domestic product and inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg used
discount rates ranging from 8.5% to 9.5% derived by the application of the CAPM, which takes into account certain company-specific metrics, including Misonix&#146;s target capital structure, the cost of long-term debt and forecasted tax rate, and
Misonix&#146;s unlevered beta as estimated with reference to the Misonix Selected Publicly Traded Companies&#146; predicted Barra betas and on professional judgments made by Perella Weinberg, as well as certain financial metrics for the United
States financial markets generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From the range of implied enterprise values, Perella Weinberg derived a range of implied equity
values for Misonix. To calculate the implied equity value from the implied enterprise value, Perella Weinberg added cash and cash equivalents and subtracted debt. Perella Weinberg calculated implied equity value per share by dividing the implied
equity value by fully diluted shares (derived by using the treasury stock method based on values implied by using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%). This analysis resulted in a
range of implied value per share of Misonix common stock of approximately $42.28 to $60.62 per share. Perella Weinberg compared these range to the closing per share price of Misonix common stock of $23.30 on July&nbsp;27, 2021 and the Merger
Consideration of $28.00 per share, and the Bioventus DCF Implied Offer Value Range of approximately $34.20 to $46.27 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Transactions
Analysis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using publicly available information, Perella Weinberg reviewed the financial terms of nineteen selected precedent
transactions, or the Selected Transactions, involving companies that operated in, or were exposed to, the medical technology and devices industry. Perella Weinberg selected these transactions in the exercise of its professional judgment and
experience because Perella Weinberg deemed them to be most similar in size, scope and impact on the industry to Misonix or otherwise relevant to the mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the Selected Transactions, Perella Weinberg calculated and compared the resulting enterprise value in the transaction as
(i)&nbsp;a multiple of revenue over the last twelve months, referred to as LTM Revenue, publicly reported prior to or at the announcement of the transaction, referred to as EV/LTM Revenue and (ii)&nbsp;a multiple of revenue over the next twelve
months, referred to as NTM Revenue, publicly reported prior to or at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
announcement of the transaction, referred to as EV/NTM Revenue. The following table lists the Selected Transactions and summarizes the observed EV/LTM Revenue and EV/NTM Revenue multiples: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Announcement Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquiror</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/LTM<BR>Revenue<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EV/NTM<BR>Revenue<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">March 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lumenis&nbsp;Ltd.&nbsp;(Surgical&nbsp;Business)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston&nbsp;Scientific&nbsp;Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.4x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">January 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Preventice Solutions, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston Scientific Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7.8x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">January 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Cantel Medical</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Steris plc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.3x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.9x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">December 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">BioTelemetry, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Koninklijke Philips N.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.2x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.3x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">December 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ACell, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Integra&nbsp;LifeSciences&nbsp;Holdings<BR>Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.0x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">October 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Key Surgical</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Steris plc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.0x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">July 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Medicrea International</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Medtronic plc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7.6x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7.3x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">January 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Arthrosurface, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Anika Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.4x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">November 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Wright Medical Group N.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stryker Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.8x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.5x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">July 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Hu-Friedy</FONT> Manufacturing Co., LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cantel Medical</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.6x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">May 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vertiflex, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston Scientific Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">18.0x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9.4x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">March 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">MyoScience, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pacira Pharmaceuticals Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">40.3x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">December 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Buffalo Filter LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CONMED Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8.3x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7.6x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">August 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Cartiva, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wright Medical Group N.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">18.0x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12.4x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">December 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entellus Medical, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stryker Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8.2x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.3x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">October 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jotec GmbH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CryoLife, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.4x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">June 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Novadaq Technologies Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stryker Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7.8x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.0x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">February 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ZELTIQ Aesthetics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Allergan plc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.8x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.9x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">February 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sage Products LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stryker Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.5x</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Mean</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9.5x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.4x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Median</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.8x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.9x</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTM calculated using expected 2021 revenues. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes the approximately 22% of Preventice Solutions already owned by Boston Scientific
Corporation; LTM calculated using 2020 revenues. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes $300&nbsp;million upfront and a $100&nbsp;million earnout; LTM revenue calculated as
of March&nbsp;31, 2020, the latest date for which filings were available. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes approximately $40&nbsp;million of tax benefit; NTM calculated using expected 2020
revenues. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes $60&nbsp;million upfront and a $40&nbsp;million earnout; LTM calculated using
expected 2019 revenues. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes $50&nbsp;million of milestone payments and $100&nbsp;million of tax benefits.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes $465&nbsp;million upfront and a $100&nbsp;million earnout; LTM revenue uses 2018
revenues; NTM Revenue calculated using expected 2019 revenues. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes $120&nbsp;million upfront and a $100&nbsp;million earnout. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transaction value includes $500&nbsp;million of tax asset. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the multiples of enterprise value to LTM Revenue described above, Perella Weinberg&#146;s analyses of the various Selected
Transactions and on professional judgments made by Perella Weinberg, Perella Weinberg applied a range of multiples of 4.50x to 8.50x to Misonix&#146;s revenue for the last twelve months as of June&nbsp;30, 2021 to derive a range of implied equity
values per share of Misonix of approximately $17.75 to $35.20. Perella Weinberg compared these ranges to the closing per share price of Misonix common stock of $23.30 on July&nbsp;27, 2021 and the Merger Consideration of $28.00 per share. Based on
the multiples of enterprise value to NTM Revenue described above, Perella Weinberg&#146;s analyses of the various Selected Transactions and on professional judgments made by Perella Weinberg, Perella Weinberg applied a range of multiples of 4.00x to
6.50x to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Misonix&#146;s NTM Revenue as of June&nbsp;30, 2021 in the Adjusted and Extrapolated Misonix Street Forecasts to derive a range of implied equity values per share of Misonix of approximately
$18.51 to $31.53. Perella Weinberg compared these ranges to the closing per share price of Misonix common stock of $23.30 on July&nbsp;27, 2021 and the Merger Consideration of $28.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Selected Transactions were used for comparison purposes, none of the Selected Transactions nor the companies involved in them was
either identical or directly comparable to the transaction, Misonix or Bioventus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg observed additional information that was not considered part of Perella Weinberg&#146;s financial analysis with respect to its
opinion, but which was noted as reference data for the Bioventus board, including the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Historical Stock Trading.</I> Perella
Weinberg reviewed the closing prices of Bioventus and Misonix common stock on the&nbsp;Nasdaq for the 52 weeks ended on July&nbsp;27, 2021. Perella Weinberg observed that during such period, the closing&nbsp;trading price per share of Bioventus
common stock ranged from $10.74 to $19.94 per share, as compared to the&nbsp;closing per share price of Bioventus common stock of $16.81 on July&nbsp;27, 2021, and the closing trading price per share of Misonix common stock ranged from $11.04 to
$24.42 per share, as compared to the closing per share price of Misonix common stock of $23.30 on July&nbsp;27, 2021 and the cash election consideration of $28.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Research Analyst Price Targets</I>. Perella Weinberg reviewed and analyzed recent publicly available&nbsp;third-party&nbsp;research
analyst price targets for the Bioventus and Misonix common stock.&nbsp;Based on this review,&nbsp;Perella Weinberg&nbsp;noted that the range of recent equity analyst price targets for the shares of Bioventus common stock ranged from a low of $19.00
to a high of $23.00 per share, as compared to the closing per share price of&nbsp;Bioventus common stock of $16.81 on July&nbsp;27, 2021, and the recent equity analyst price targets for the shares of Misonix common stock, $23.00 per share, as
compared to the closing price per share of&nbsp;Misonix common stock of $23.30 on July&nbsp;27, 2021 and the cash election consideration of $28.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The public market trading price targets published by equity research analysts do not necessarily reflect current market trading prices for
Bioventus common stock or Misonix common stock. Further, these estimates are subject to uncertainties, including the future financial performance of Bioventus and Misonix and future financial market conditions. However, these estimates provided
general reference points which enabled Perella Weinberg to compare such estimates with the closing price per share on July&nbsp;27, 2021 of Bioventus common stock and Misonix common stock of $16.81 and $23.30, respectively, and the cash election
consideration of $28.00 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Miscellaneous </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description.
Selecting portions of the analyses or of the summary set forth herein, without considering the analyses or the summary as a whole could create an incomplete view of the processes underlying Perella Weinberg&#146;s opinion. In arriving at its
fairness determination, Perella Weinberg considered the results of all of its analyses and did not attribute any particular weight to any factor or analysis considered. Rather, Perella Weinberg made its determination as to fairness on the basis of
its experience and professional judgment after considering the results of all of its analyses. No company or transaction used in the analyses described herein as a comparison is directly comparable to Misonix, Bioventus or the mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg prepared the analyses described herein for purposes of providing its opinion to the Bioventus board as to the fairness, from a financial
point of view, as of the date of such opinion, of the Merger Consideration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Bioventus. These analyses do not purport to be appraisals or necessarily reflect the prices at which businesses or securities actually may be sold. Perella Weinberg&#146;s analyses were based
in part upon the Adjusted and Extrapolated Misonix Street Forecasts, the Cost Savings and the Adjusted Bioventus Street Forecasts, which are not necessarily indicative of actual future results, and which may be significantly more or less favorable
than suggested by Perella Weinberg&#146;s analyses. Because these analyses are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties to the merger agreement or their respective advisors,
none of Bioventus, Perella Weinberg or any other person assumes responsibility if future results are materially different from those forecasted by Bioventus management or third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, the opinion of Perella Weinberg to the Bioventus board was one of many factors taken into consideration by the Bioventus
board in making its determination to approve the merger. Also, as discussed above, Perella Weinberg&#146;s opinion was not intended to be and does not constitute a recommendation to any holder of Bioventus common stock or any other person as to how
such person should vote or otherwise act with respect to the merger or any other matter and does not in any manner address the prices at which Misonix common stock or Bioventus common stock will trade at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg has acted as financial advisor to Bioventus in connection with the mergers and pursuant to the terms of the engagement letter
between Perella Weinberg and Bioventus, dated July&nbsp;21, 2021, Bioventus agreed to pay Perella Weinberg $1.5&nbsp;million upon the delivery of Perella Weinberg&#146;s opinion (which amount would have become payable if Perella Weinberg had
determined that it was not able to deliver its opinion), and has agreed to pay Perella Weinberg an additional fee of $3.5&nbsp;million upon the closing of the mergers.&nbsp;In addition, Bioventus agreed to reimburse Perella Weinberg for certain
reasonable expenses, including attorneys&#146; fees and disbursements, and to indemnify Perella Weinberg and related persons for certain liabilities that may arise out of its engagement by Bioventus and the rendering of its opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except in connection with Perella Weinberg&#146;s engagement as financial advisor to Bioventus in connection with the mergers, during the two
year period prior to the date hereof, no material relationship existed between Perella Weinberg and its affiliates, on the one hand, and Bioventus, Misonix or any of their respective affiliates, on the other hand, pursuant to which Perella Weinberg
or its affiliates have received or anticipate receiving compensation. However, Perella Weinberg and its affiliates in the future may provide investment banking and other financial services to Bioventus and/or Misonix and their respective affiliates
and in the future may receive compensation for the rendering of these services. In the ordinary course of its business activities, Perella Weinberg or its affiliates may at any time hold long or short positions, and may trade or otherwise effect
transactions, for its account or the accounts of clients, in debt, equity or other securities (or related derivative securities) or financial instruments (including bank loans or other obligations) of Bioventus, Misonix or their respective
affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion of Misonix&#146;s Financial Advisor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion of JP Morgan Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to an
engagement letter, Misonix retained J.P. Morgan as its financial advisor in connection with a potential transaction involving a change of control of Misonix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the meeting of the Misonix board on July&nbsp;28, 2021, J.P. Morgan rendered its oral opinion to the Misonix board that, as of such date and based upon and
subject to the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P.&nbsp;Morgan in preparing its opinion, the merger consideration to be paid to the holders of Misonix common stock in the first
merger was fair, from a financial point of view, to such holders. J.P. Morgan confirmed its July&nbsp;28, 2021 oral opinion by delivering its written opinion to the Misonix board, dated July&nbsp;29, 2021, that, as of such date, the merger
consideration to be paid to the holders of Misonix common stock in the first merger was fair, from a financial point of view, to such holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full text of the written opinion of J.P. Morgan dated July&nbsp;29, 2021, which sets forth, among other
things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan, is attached as <U>Annex C</U> to this joint proxy statement/prospectus and is incorporated herein by reference. <B>The
summary of the opinion of J.P. Morgan set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of such opinion. </B>Misonix stockholders are urged to read the opinion in its entirety. J.P.
Morgan&#146;s written opinion was addressed to the Misonix board (in its capacity as such) in connection with and for the purposes of its evaluation of the proposed first merger, was directed only to the merger consideration to be paid to the
holders of Misonix common stock in the proposed first merger and did not address any other aspect of the proposed first merger. J.P. Morgan expressed no opinion as to the fairness of the merger consideration to the holders of any other class of
securities, creditors or other constituencies of Misonix or as to the underlying decision by Misonix to engage in the proposed transactions. The issuance of J.P. Morgan&#146;s opinion was approved by a fairness committee of J.P. Morgan. The summary
of the opinion of J.P. Morgan set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of such opinion. The opinion does not constitute a recommendation to any stockholder of Misonix as to how
such stockholder should vote with respect to the Misonix merger proposal or any other matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, J.P. Morgan, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed the merger agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain publicly available business and financial information concerning Misonix and Bioventus and the
industries in which they operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compared the proposed financial terms of the merger with the publicly available financial terms of certain
transactions involving companies J.P. Morgan deemed relevant and the consideration paid for such companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compared the financial and operating performance of Misonix and Bioventus with publicly available information
concerning certain other companies J.P. Morgan deemed relevant and reviewed the current and historical market prices of Misonix common stock and Bioventus class A common stock and certain publicly traded securities of such other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed certain internal financial analyses and forecasts prepared by or at the direction of the management of
Misonix relating to Misonix&#146;s and Bioventus&#146; respective businesses, as well as the estimated amount and timing of the cost synergies expected by the management of Misonix to result from the proposed first merger; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performed such other financial studies and analyses and considered such other information as J.P. Morgan deemed
appropriate for the purposes of its opinion. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, J.P. Morgan held discussions with certain members of the management of
Misonix and Bioventus with respect to certain aspects of the proposed first merger, and the past and current business operations of Misonix and Bioventus, the financial condition and future prospects and operations of Misonix and Bioventus, the
effects of the first merger on the financial condition and future prospects of Misonix and Bioventus, and certain other matters J.P. Morgan believed necessary or appropriate to its inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving its opinion, J.P. Morgan relied upon and assumed the accuracy and completeness of all information that was publicly available or was furnished to or
discussed with J.P. Morgan by Misonix and Bioventus or otherwise reviewed by or for J.P. Morgan. J.P. Morgan did not independently verify any such information or its accuracy or completeness and, pursuant to its engagement letter with Misonix, J.P.
Morgan did not assume any obligation to undertake any such independent verification. J.P. Morgan did not conduct and was not provided with any valuation or appraisal of any assets or liabilities, nor did J.P. Morgan evaluate the solvency of Misonix
or Bioventus under any state or federal laws relating to bankruptcy, insolvency or similar matters. In relying on financial analyses and forecasts provided to J.P. Morgan or derived therefrom, including the Misonix projected cost synergies, J.P.
Morgan assumed that they were reasonably prepared based on assumptions reflecting the best </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently available estimates and judgments by Misonix management as to the expected future results of operations and financial condition of Misonix and Bioventus to which such analyses or
forecasts relate. J.P. Morgan expressed no view as to such analyses or forecasts (including the Misonix projected cost synergies) or the assumptions on which they were based and J.P. Morgan expressed no opinion with respect to any other financial
projections relating to Misonix or Bioventus provided to J.P. Morgan by Misonix or Bioventus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan also assumed that the proposed first merger and
the other transactions contemplated by the merger agreement will be consummated as described in the merger agreement and this joint proxy statement/prospectus. J.P. Morgan also assumed that the representations and warranties made by Misonix,
Bioventus, Merger Sub&nbsp;I, and Merger Sub&nbsp;II in the merger agreement and the related agreements were and will be true and correct in all respects material to its analysis. J.P. Morgan is not a legal, regulatory or tax expert and J.P. Morgan
relied on the assessments made by advisors to Misonix with respect to such issues. J.P. Morgan further assumed that all material governmental, regulatory or other consents and approvals necessary for the consummation of the first merger will be
obtained without any adverse effect on Misonix or Bioventus or on the contemplated benefits of the proposed first merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The projections furnished to
J.P. Morgan were prepared by Misonix&#146;s management as discussed more fully under<I>&nbsp;&#147;Misonix Management&#146;s Unaudited Prospective Financial Information&#148;</I>, of this joint proxy statement/prospectus.&nbsp;Misonix does not
publicly disclose internal management projections of the type provided to J.P. Morgan in connection with J.P. Morgan&#146;s analysis of the proposed first merger, and such projections were not prepared with a view toward public disclosure. These
projections were based on numerous variables and assumptions that are inherently uncertain and may be beyond the control of the Misonix&#146;s management, including, without limitation, factors related to general economic and competitive conditions
and prevailing interest rates. Accordingly, actual results could vary significantly from those set forth in such projections. For more information regarding the use of projections and other forward-looking statements, please refer to the section
entitled &#147;<I>Misonix Management&#146;s Unaudited Prospective Financial Information</I>&#148; of this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P.
Morgan&#146;s opinion was necessarily based on economic, market and other conditions as in effect on, and the information made available to J.P. Morgan as of, the date of such opinion. J.P. Morgan&#146;s opinion noted that subsequent developments
may affect J.P. Morgan&#146;s opinion, and that J.P. Morgan does not have any obligation to update, revise, or reaffirm such opinion. J.P. Morgan&#146;s opinion is limited to the fairness, from a financial point of view, of the merger consideration
to be paid to the holders of Misonix common stock in the proposed first merger, and J.P. Morgan has expressed no opinion as to the fairness of any consideration to be paid in connection with the proposed first merger to the holders of any other
class of securities, creditors or other constituencies of Misonix or as to the underlying decision by Misonix to engage in the proposed first merger. Furthermore, J.P. Morgan expressed no opinion with respect to the amount or nature of any
compensation to any officers, directors, or employees of any party to the proposed first merger, or any class of such persons relative to the merger consideration to be paid to the holders of Misonix common stock in the proposed first merger or with
respect to the fairness of any such compensation. J.P. Morgan expressed no opinion as to the price at which the Misonix common stock or the Bioventus class A common stock will trade at any future time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the merger agreement, including the merger consideration, were determined through arm&#146;s length negotiations between Misonix and Bioventus,
and the decision to enter into the merger agreement was solely that of the Misonix board and the Bioventus board. J.P. Morgan&#146;s opinion and financial analyses were only one of the many factors considered by the Misonix board in its evaluation
of the proposed first merger and should not be viewed as determinative of the views of the Misonix board or management with respect to the proposed first merger or the merger consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with customary investment banking practice, J.P. Morgan employed generally accepted valuation methodology in rendering its oral opinion to the
Misonix board on July&nbsp;28, 2021 (subsequently confirmed in writing on July&nbsp;29, 2021) and in the financial analysis presented to the Misonix board on July&nbsp;28, 2021 in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with the rendering of such opinion. The following is a summary of the material financial analyses utilized by J.P. Morgan in connection with rendering its opinion to the Misonix board
and does not purport to be a complete description of the analyses or data presented by J.P. Morgan. Some of the summaries of the financial analyses include information presented in tabular format. The tables are not intended to stand alone, and in
order to more fully understand the financial analyses used by J.P. Morgan, the tables must be read together with the full text of each summary. Considering the data set forth below without considering the full narrative description of the financial
analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of J.P. Morgan&#146;s analyses. In conducting its analyses, at the direction of Misonix&#146;s management, J.P. Morgan used
data included in, or calculated using, the Misonix Projections which are included in<I> </I>the section entitled<I>&nbsp;&#147;Misonix Management&#146;s Unaudited Prospective Financial Information</I>&#148;. At the direction of Misonix&#146;s
management and in accordance with the instructions of Misonix&#146;s management, J.P. Morgan used the Misonix Projections as the underlying data for certain of J.P. Morgan&#146;s analyses as discussed in this summary of J.P. Morgan&#146;s opinion.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Misonix Financial Analyses </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Public Trading Multiples Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, J.P. Morgan compared selected financial data of Misonix with similar data for selected publicly traded companies engaged
in businesses that J.P. Morgan judged to be sufficiently analogous to Misonix (or aspects thereof) based on J.P. Morgan&#146;s experience and its familiarity with the industries in which Misonix operates. The companies selected by J.P. Morgan were:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ConvaTec Group plc; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Integra LifeSciences Holdings Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ConMed Corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NuVasive, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avanos Medical, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AxoGen, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Orthofix Medical Inc.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SurModics, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vapotherm, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anika Therapeutics, Inc.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intersect ENT, Inc.; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sientra, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These companies were selected, among other reasons, because they are publicly traded companies with operations and businesses that, for the purposes of
J.P.&nbsp;Morgan&#146;s analysis, may be considered similar to those of Misonix. However, certain of these companies may have characteristics that are materially different from those of Misonix. The analyses necessarily involve complex
considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect the selected companies differently than they would affect Misonix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, J.P. Morgan calculated the firm value, which we refer to as the &#147;FV,&#148; for each of the selected companies
(calculated as equity value, plus or minus, as applicable, net debt or net cash) as of July&nbsp;27, 2021, as a multiple of the analyst consensus estimates of calendar year 2021 and 2022 revenues for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the applicable company (which we refer to as the &#147;FV/2021E Revenue Multiple&#148; and &#147;FV/2022E Revenue Multiple,&#148; respectively). The results of this analysis are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Value</B><br><B>($ in<BR>millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Firm<BR>Value</B><br><B>($ in<BR>millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/<BR>2021E<BR>Revenue<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/<BR>2022E<BR>Revenue<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ConvaTec Group plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integra LifeSciences Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ConMed Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NuVasive, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avanos Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AxoGen, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orthofix Medical Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SurModics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vapotherm, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anika Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intersect ENT, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sientra, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the results of this analysis and J.P. Morgan&#146;s experience and professional judgment, J.P. Morgan selected a
multiple reference range of 2.6x to 7.1x for FV/2021E Revenue and a multiple reference range of 2.5x to 6.3x for FV/2022E Revenue. J.P. Morgan then applied such reference ranges to Misonix&#146;s revenue forecasts for the fiscal years ended
June&nbsp;30, 2021 and 2022 (as applicable) that were included in the Misonix Projections. The analysis indicated the following ranges of implied equity value per share for the Misonix common stock (rounded to the nearest $0.10): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied&nbsp;Equity&nbsp;Value<BR>Per Share of<BR>Misonix common<BR>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FV/2021E Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FV/2022E Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan compared the foregoing ranges of implied equity value per share for the Misonix common stock to the implied per
share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&nbsp;27, 2021. The implied per share equity value of the merger consideration of $28.00 as used throughout this summary of J.P.
Morgan&#146;s opinion was calculated based on the sum of (A)&nbsp;a cash portion of merger consideration equal to $10.50 per share, and (B)&nbsp;a stock portion of merger consideration equal to 1.0524 shares of Bioventus common stock, valued at the <FONT
STYLE="white-space:nowrap">seven-day</FONT> volume-weighted average price per share of Bioventus class A common stock of $16.63 on July&nbsp;27, 2021. J.P. Morgan used this calculation for the implied value of the merger consideration throughout the
Misonix Financial Analysis because regardless of whether Misonix stockholders elect to receive the cash merger consideration of $28.00 per share or the stock merger consideration of 1.6839 shares of Bioventus class A common stock for each share of
their Misonix common stock, the aggregate cash paid by Bioventus in the first merger will be fixed at an amount equal to $10.50 multiplied by the number of shares of Misonix common stock outstanding on the election deadline and the cash and stock
elections of the Misonix stockholders will be prorated such that this amount of cash is payable by Bioventus in the first merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Transaction Multiples Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, J.P. Morgan reviewed selected transactions involving businesses which J.P. Morgan judged to be analogous to
Misonix&#146;s business (or aspects thereof) based on J.P. Morgan&#146;s experience and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
familiarity with the industries in which Misonix operates. The following transactions were selected by J.P. Morgan as relevant to the evaluation of the proposed first merger: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acquiror</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Announcement Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BioTelemetry, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royal Philips</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;18, 2020</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wright Medical Group N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stryker Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 04, 2019</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buffalo Filter LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conmed Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;13, 2018</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">K2M Group Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stryker Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;30, 2018</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Spectranetics Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royal Philips</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;28, 2017</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vascular Solutions, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teleflex Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 02, 2016</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LDR Holding Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zimmer Biomet Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 07, 2016</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AngioScore Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Spectranetics Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;27, 2014</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Given Imaging Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Covidien plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 08, 2013</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conceptus, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bayer Healthcare LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;29, 2013</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the selected transactions reviewed was identical to the proposed first merger. However, the selected transactions were
chosen because certain aspects of the transactions, for purposes of J.P.&nbsp;Morgan&#146;s analysis, may be considered similar to the proposed first merger. The analyses necessarily involve complex considerations and judgments concerning
differences in financial and operational characteristics of the companies involved and other factors that could affect the transactions differently than they would affect the proposed first merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, J.P. Morgan calculated, for each selected transaction, the multiple of the target company&#146;s FV implied in the
relevant transaction to the target company&#146;s revenue for the twelve-month period after the announcement, which we refer to as the &#147;NTM,&#148; of the applicable transaction, which we refer to as the &#147;FV/NTM Revenue Multiple.&#148; The
results of this analysis are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acquiror</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Company<BR>FV Implied in<BR>the Transaction</B><br><B>($ in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/NTM<BR>Revenue<BR>Multiple<BR>of Target<BR>Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BioTelemetry, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royal Philips</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wright Medical Group N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stryker Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buffalo Filter LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conmed Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">K2M Group Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stryker Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Spectranetics Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royal Philips</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vascular Solutions, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teleflex Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LDR Holding Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zimmer Biomet Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AngioScore Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Spectranetics Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Given Imaging Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Covidien plc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conceptus, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bayer Healthcare LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the above analysis, J.P. Morgan selected a FV/NTM Revenue Multiple reference range for Misonix of 3.7x to 7.5x. J.P.
Morgan then applied such reference range to Misonix projected revenue for the twelve-month period ending December&nbsp;31, 2021. The analysis indicated a range of implied equity values per share of Misonix common stock (rounded to the nearest
$0.10), of $16.10 to $31.80, which J.P. Morgan compared to the implied per share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&nbsp;27, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Excluding synergies: </I>Using the Misonix Projections, J.P. Morgan conducted a discounted cash flow analysis for the purpose of determining the fully
diluted equity value per share of Misonix common stock (excluding cost synergies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A discounted cash flow analysis is a valuation methodology used to
derive a valuation of a company by calculating the present value of the company&#146;s estimated future cash flows. A company&#146;s &#147;estimated future cash flows&#148; are its projected unlevered free cash flows, and &#147;present value&#148;
refers to the value today or as of an assumed date of the future cash flows or amounts and is obtained by discounting the estimated future cash flows or amounts by a discount rate that takes into account macroeconomic assumptions and estimates of
risk, the opportunity cost of capital, capital structure, income taxes, expected returns and other appropriate factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan calculated the
unlevered free cash flow that Misonix is expected to generate from July&nbsp;1, 2021 through June&nbsp;30, 2026 using the Misonix Projections. J.P. Morgan also calculated a range of terminal values for Misonix at the end of this period by applying
perpetual growth rates ranging from 3.0% to 4.0%, based on guidance provided by Misonix&#146;s management, to estimates of the unlevered free cash flow of Misonix (excluding cost synergies) during fiscal year ending June&nbsp;30, 2026, as provided
in the Misonix Projections. J.P. Morgan then discounted the unlevered free cash flow estimates (excluding cost synergies) and the range of terminal values to present value as of June&nbsp;30, 2021 using discount rates ranging from 10.25% to 12.25%,
which range was chosen by J.P. Morgan using its professional judgment and experience based upon its analysis of a weighted average cost of capital of Misonix ranging from 10.25% to 12.25%. The present value of the unlevered free cash flow estimates
and the range of terminal values were then adjusted by subtracting Misonix&#146;s net debt as of June&nbsp;30, 2021. This analysis indicated a range of implied equity values for Misonix (excluding cost synergies), which J.P.&nbsp;Morgan divided by
the number of outstanding shares of Misonix common stock, calculated on a fully-diluted basis (determined using the treasury stock method), to derive a range of implied equity values per share of Misonix common stock (rounded to the nearest $0.10)
of $18.50 to $28.60, which J.P. Morgan compared to the implied per share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&nbsp;27, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Including synergies: </I>J.P. Morgan also conducted a discounted cash flow analysis for the purpose of determining the fully diluted equity value per share
of Misonix common stock including cost synergies using the Misonix Projections. J.P. Morgan calculated the unlevered free cash flow that the Misonix projected cost synergies were expected to generate from July&nbsp;1, 2021 through December&nbsp;31,
2025 as set forth in the Misonix Projections. J.P. Morgan calculated a range of terminal values for Misonix projected cost synergies at the end of this period by applying perpetual growth rates ranging from 0.0% to 1.0%, based on guidance provided
by Misonix&#146;s management, to estimates of the unlevered free cash flow of the Misonix projected cost synergies during the year ending December&nbsp;31, 2025, as provided in the Misonix Projections. J.P. Morgan then discounted the unlevered free
cash flow estimates of the Misonix projected cost synergies and the range of terminal values to present value as of June&nbsp;30, 2021 using discount rates ranging from 10.1% to 12.1%, which range was chosen by J.P. Morgan using its professional
judgment and experience based upon its analysis of a weighted average cost of capital of Misonix and Bioventus of 10.1% to 12.1%. This analysis indicated a range of implied equity values for Misonix projected cost synergies. J.P. Morgan then
adjusted the range of implied equity values for Misonix excluding cost synergies, as calculated pursuant to J.P. Morgan&#146;s discounted cash flow analysis described above, by adding 50% of the implied equity value of the Misonix projected cost
synergies applying 0.0% perpetual growth rate and 11.1% discount rate. J.P. Morgan selected a 0.0% perpetual growth rate based on guidance provided by the Misonix&#146;s management, and an 11.1% discount rate was selected by J.P. Morgan using its
professional judgment and experience based upon its analysis of the weighted average cost of capital of Misonix and Bioventus of 10.1% to 12.1%. This analysis indicated the range of implied equity values for Misonix including cost synergies, which
J.P.&nbsp;Morgan divided by the number of outstanding shares of Misonix common stock, calculated on a fully-diluted basis (determined using the treasury stock method), to derive a range of implied equity values per share of Misonix common stock
(rounded to the nearest $0.10) of $23.50 to $33.60, which J.P. Morgan compared to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the implied per share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&nbsp;27, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Bioventus Financial Analyses </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected
Public Trading Multiples Analysis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, J.P. Morgan compared selected financial data of Bioventus with similar data
for selected publicly traded companies engaged in businesses that J.P. Morgan judged to be sufficiently analogous to Bioventus (or aspects thereof) based on J.P. Morgan&#146;s experience and its familiarity with the industries in which Bioventus
operates. The companies selected by J.P. Morgan were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Globus Medical, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Integra LifeSciences Holdings Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ICU Medical, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ConMed Corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Merit Medical Systems, Inc.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NuVasive, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Medacta Group SA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avanos Medical, Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Orthofix Medical Inc.; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anika Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These companies were selected, among other reasons, because they are publicly traded companies with operations and businesses that, for the purposes of
J.P.&nbsp;Morgan&#146;s analysis, may be considered similar to those of Bioventus. However, certain of these companies may have characteristics that are materially different from those of Bioventus. The analyses necessarily involve complex
considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect the selected companies differently than they would affect Bioventus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using publicly available information, J.P. Morgan calculated the FV for each of the selected companies as of
July 27, 2021 as a multiple of the analyst consensus estimates of (i)&nbsp;calendar year 2021 revenues for the applicable company (which we refer to as the &#147;FV/2021E Revenue<I> </I>Multiple&#148;), (ii) calendar year 2022 revenues for the
applicable company (which we refer to as the &#147;FV/2022E Revenue Multiple&#148;), (iii) calendar year 2021 earnings before interest, taxes, depreciation and amortization but after taking into account stock-based compensation expense, which we
refer to as &#147;Adjusted EBITDA,&#148; for the applicable company (which we refer to as the &#147;FV/2021E EBITDA Multiple&#148;), and (iv)&nbsp;calendar year 2022 Adjusted EBITDA, for the applicable company (which we refer to as the
&#147;FV/2022E EBITDA Multiple&#148;). The results of this analysis are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Value</B><br><B>($ in<BR>millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Firm<BR>Value</B><br><B>($ in<BR>millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/<BR>2021E<BR>Revenue<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/<BR>2022E<BR>Revenue<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/<BR>2021E<BR>EBITDA<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FV/<BR>2021E<BR>EBITDA<BR>Multiple</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globus Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integra LifeSciences Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICU Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ConMed Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merit Medical Systems, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NuVasive, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medacta Group SA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avanos Medical, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orthofix Medical Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.5x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anika Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.6x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.1x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the results of this analysis and J.P. Morgan&#146;s experience and professional judgment, J.P. Morgan selected a
multiple reference range of 1.5x to 4.9x for FV/2021E Revenue, a multiple reference range of 1.5x to 4.6x for FV/2022E Revenue, a multiple reference range of 12.5x to 35.0x for FV/2021E EBITDA, and a multiple reference range of 11.1x to 24.1x for
FV/2022E EBITDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan then applied such reference ranges to the revenue projections for the calendar years 2021 and 2022 (as applicable) included
in Adjusted Bioventus Street Forecasts (based on the Bioventus financial projections). The analysis indicated the following ranges of implied equity value per share for the Bioventus common stock (rounded to the nearest $0.10), which J.P. Morgan
compared to <FONT STYLE="white-space:nowrap">seven-day</FONT> volume-weighted average price per share of Bioventus common stock of $16.63 on July&nbsp;27, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied Equity<BR>Value<BR>Per Share of<BR>Bioventus<BR>common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FV/ 2021E Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FV/2022E Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FV/2021E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FV/2022E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Discounted Cash Flow Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using the Adjusted Bioventus Street Forecasts, J.P. Morgan conducted a discounted cash flow analysis for the purpose of determining the fully diluted equity
value per share of Bioventus class A common stock (excluding cost synergies). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan calculated the unlevered free cash flow that Bioventus is expected to generate from July&nbsp;1,
2021 through December&nbsp;31, 2025 using the Adjusted Bioventus Street Forecasts (as set forth in the section entitled <I>&#147;Bioventus Management&#146;s Unaudited Prospective Financial Information</I>&#148;, which were discussed with, and
approved by Misonix&#146;s management for use by J.P. Morgan in connection with its financial analyses). J.P.&nbsp;Morgan also calculated a range of terminal values for Bioventus at the end of this period by applying perpetual growth rates ranging
from 2.5% to 3.5%, based on guidance provided by Misonix&#146;s management, to estimates of the unlevered free cash flow of Bioventus (excluding cost synergies) during year ending December&nbsp;31, 2025, as provided in the Bioventus Projections.
J.P. Morgan then discounted the unlevered free cash flow estimates (excluding cost synergies) and the range of terminal values to present value as of June&nbsp;30, 2021 using discount rates ranging from 10.0% to 12.0%, which range was chosen by J.P.
Morgan using its professional judgment and experience based upon its analysis of a weighted average cost of capital of Bioventus ranging from 10.0% to 12.0%. The present value of the unlevered free cash flow estimates and the range of terminal
values were then adjusted by subtracting Bioventus&#146; net debt and <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests (which deduction was based upon Bioventus&#146; balance sheet filed May&nbsp;13, 2021) as of June&nbsp;30, 2021.
This analysis indicated a range of implied equity values for Bioventus (excluding cost synergies), which J.P.&nbsp;Morgan divided by the number of outstanding shares of Bioventus common stock, calculated on a fully-diluted basis (determined using
the treasury stock method), to derive a range of implied equity values per share of Bioventus class A common stock (rounded to the nearest $0.10) of $17.10 to $25.70, which J.P. Morgan compared to <FONT STYLE="white-space:nowrap">seven-day</FONT>
volume-weighted average price per share of Bioventus class A common stock of $16.63 on July&nbsp;27, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other Analyses </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Relative Implied Exchange Ratio Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan compared the results for Misonix to the results for Bioventus with respect to the analyses referenced in the table below, assuming that Bioventus
would pay 100% stock consideration in the proposed first merger. For each comparison, J.P. Morgan compared the highest equity value per share of Misonix common stock to the lowest equity value per share of Bioventus class A common stock to derive
the range of exchange ratios implied by each pair of estimates. J.P. Morgan also compared the lowest equity value per share of Misonix common stock to the highest equity value per share of Bioventus class A common stock to derive the range of
exchange ratios implied by each pair of estimates. The analysis indicated the following ranges of implied exchange ratios, which J.P. Morgan compared to the exchange ratio of 1.6839 shares of Bioventus common stock for a share of Misonix common
stock, based on merger consideration of $28.00 per share of Misonix common stock, calculated as of July&nbsp;27, 2021, assuming 100% stock consideration in the proposed first merger. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Implied Exchange<BR>Ratio</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading Multiples &#150; Misonix FV/2021E Revenue / Bioventus FV/2021E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2611x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0828x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading Multiples &#150; Misonix FV/2022E Revenue / Bioventus FV/2022E EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4535x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5298x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounted Cash Flow<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7198x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6725x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excluding cost synergies. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Intrinsic Value Creation Analysis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P.
Morgan conducted an illustrative implied intrinsic value creation analysis, based on the Misonix Projections and the Bioventus Projections that compared the implied equity value of Misonix common stock derived from a discounted cash flow valuation
on a standalone basis to the implied equity value attributable to the existing holders of Misonix common stock in the pro forma combined company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan determined the implied total equity value attributable to the existing holders of Misonix common
stock in the pro forma combined company, which is referred to in this section entitled &#147;Intrinsic Value Creation Analysis&#148; as the implied value to holders of Misonix common stock, by calculating the sum of (i) (A)&nbsp;(1) the sum of the
implied equity values of the Misonix common stock and the Bioventus class A common stock using the midpoint values determined pursuant to J.P. Morgan&#146;s discounted cash flow analyses (without cost synergies) for each company described above,
plus (2)&nbsp;the estimated midpoint present value of the Misonix projected cost synergies pursuant to J.P. Morgan&#146;s discounted cash flow analysis for the cost synergies described above, minus (3)&nbsp;the aggregate amount of cash consideration
to be paid to holders of Misonix common stock based on $10.50 per share of cash consideration, multiplied by (B)&nbsp;the equity ownership percentage of the pro forma combined company attributable to the existing holders of Misonix common stock
pursuant to the proposed first merger, and (ii)&nbsp;the aggregate amount of cash consideration to be paid to holders of Misonix common stock based on $10.50 per share of cash consideration. The analysis indicated that, on an illustrative basis, the
merger created hypothetical incremental implied value of 47% to holders of Misonix common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Miscellaneous </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of certain material financial analyses does not purport to be a complete description of the analyses or data presented by J.P. Morgan.
The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. J.P. Morgan believes that the foregoing summary and its analyses must be considered as a whole and that
selecting portions of the foregoing summary and these analyses, without considering all of its analyses as a whole, could create an incomplete view of the processes underlying the analyses and its opinion. As a result, the ranges of valuations
resulting from any particular analysis or combination of analyses described above were merely utilized to create points of reference for analytical purposes and should not be taken to be the view of J.P. Morgan with respect to the actual value of
Misonix or Bioventus. The order of analyses described does not represent the relative importance or weight given to those analyses by J.P. Morgan. In arriving at its opinion, J.P. Morgan did not attribute any particular weight to any analyses or
factors considered by it and did not form an opinion as to whether any individual analysis or factor (positive or negative), considered in isolation, supported or failed to support its opinion. Rather, J.P. Morgan considered the totality of the
factors and analyses performed in determining its opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Analyses based upon forecasts of future results are inherently uncertain, as they are subject
to numerous factors or events beyond the control of the parties and their advisors. Accordingly, forecasts and analyses used or made by J.P. Morgan are not necessarily indicative of actual future results, which may be significantly more or less
favorable than suggested by those analyses. Moreover, J.P. Morgan&#146;s analyses are not and do not purport to be appraisals or otherwise reflective of the prices at which businesses actually could be acquired or sold. None of the selected
companies reviewed as described in the above summary is identical to Misonix or Bioventus, and none of the selected transactions reviewed was identical to the merger. However, the companies selected were chosen because they are publicly traded
companies with operations and businesses that, for purposes of J.P. Morgan&#146;s analysis and based on its experience and professional judgment, may be considered similar to those of Misonix and Bioventus. The transactions selected were similarly
chosen because their participants, size and other factors, for purposes of J.P. Morgan&#146;s analysis and based on its experience and professional judgment, may be considered similar to the merger. The analyses necessarily involve complex
considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect the companies compared to Misonix and Bioventus and the transactions compared to the
proposed first merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a part of its investment banking business, J.P. Morgan and its affiliates are continually engaged in the valuation of
businesses and their securities in connection with mergers and acquisitions, investments for passive and control purposes, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements, and valuations for
corporate and other purposes. J.P. Morgan was selected to advise Misonix with respect to the merger on the basis of, among other things, such experience and its qualifications and reputation in connection with such matters and its familiarity with
Misonix, Bioventus and the industries in which they operate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of J.P. Morgan&#146;s engagement letter with Misonix, for services rendered in
connection with the merger, Misonix has agreed to pay J.P. Morgan a transaction fee of approximately $8&nbsp;million, of which $1&nbsp;million was payable by Misonix to J.P. Morgan in connection with J.P. Morgan&#146;s delivery of its opinion, and
the balance of which becomes payable upon the closing of the merger. In addition, Misonix has agreed to reimburse J.P. Morgan for its expenses incurred in connection with its services, including the fees and disbursements of counsel, and will
indemnify J.P. Morgan against certain liabilities arising out of J.P. Morgan&#146;s engagement. During the two years preceding the date of J.P. Morgan&#146;s opinion, J.P. Morgan and its affiliates have had commercial or investment banking
relationships with Misonix, Bioventus and Bioventus LLC, an affiliate of Bioventus, for which J.P. Morgan and such affiliates have received customary compensation. Such services during such period have included acting as financial advisor to Misonix
in connection with its acquisition of Solsys Medical in September 2019, joint lead arranger and joint bookrunner on Bioventus LLC&#146;s term loan and revolving line of credit in December 2019 and active bookrunner and stabilization agent on
Bioventus&#146;s IPO in February 2021. In addition, J.P. Morgan and its affiliates hold, on a proprietary basis, less than 1% of the outstanding common stock of each of Misonix and Bioventus. During the
<FONT STYLE="white-space:nowrap">two-year</FONT> period preceding delivery of its written opinion ended on July&nbsp;29, 2021, the aggregate fees recognized by J.P. Morgan from Misonix were approximately $2&nbsp;million and from Bioventus and its
affiliate, Bioventus LLC, were approximately $3.25&nbsp;million. In the ordinary course of their businesses, J.P. Morgan and its affiliates may actively trade the debt and equity securities or financial instruments (including derivatives, bank loans
or other obligations) of Misonix or Bioventus for their own accounts or for the accounts of customers and, accordingly, they may at any time hold long or short positions in such securities or other financial instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Unaudited Financial Projections </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the
annual guidance for fiscal year 2021, Bioventus does not normally publicly disclose long-term projections as to future revenues, earnings or other results due to, among other reasons, the uncertainty, unpredictability and subjectivity of the
underlying assumptions and estimates. In connection with the merger, Bioventus management used certain publicly available financial forecasts relating to the business and financial prospects of Bioventus, derived from a consensus of selected equity
research analysts concerning Bioventus for its 2021 through 2025 fiscal years, which Bioventus management adjusted for Bioventus&#146; revised guidance for the 2021 fiscal year and the assumed growth rate for the 2023 through 2025 fiscal years, as
well as assumed rates of depreciation, stock-based compensation, tax, capital expenditures and change in net working capital. These projections are referred to as the &#147;Adjusted Bioventus Street Forecasts.&#148; Also in connection with the
merger, Bioventus used certain publicly available financial forecasts relating to the business and financial prospects of Misonix, derived from a consensus of selected equity research analysts concerning Misonix for fiscal years 2021 and 2022, which
Bioventus management extrapolated for fiscal years 2023 through 2031 and adjusted for several different factors including assumed rates of depreciation and stock-based compensation and to calendarize to a December
<FONT STYLE="white-space:nowrap">year-end.</FONT> These adjusted projections for the years ending December 2021 through December 2031 are referred to as the &#147;Adjusted and Extrapolated Misonix Street Forecasts.&#148; The Adjusted Bioventus
Street Forecasts and the Adjusted and Extrapolated Misonix Street Forecasts were prepared for internal use only and were provided to the Bioventus board for the purposes of considering, analyzing and evaluating the merger. The Adjusted Bioventus
Street Forecasts and Adjusted and Extrapolated Misonix Street Forecasts were also provided to Bioventus&#146; financial advisor, Perella Weinberg, in connection with rendering its fairness opinion to the Bioventus board and in performing the related
analyses. The Adjusted Bioventus Street Forecasts were also provided to Misonix&#146;s financial advisor, JP Morgan Securities. The Adjusted Bioventus Street Forecasts and the Adjusted and Extrapolated Misonix Street Forecasts, were prepared
treating each of Bioventus and Misonix on a stand-alone basis, without giving effect to the transaction, including the impact of negotiating or executing the merger agreement, the expenses that may be incurred in connection with consummating the
mergers, the potential synergies that may be achieved by the combined company as a result of the transaction, the effect of any business or strategic decision or action that has been or will be taken as a result of the merger agreement having been
executed, or the effect of any business or strategic decisions or actions which would likely have been taken if the merger agreement had not been executed but which were instead altered, accelerated, postponed or not taken in anticipation of the
mergers. In connection with the transaction, Bioventus management also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
independently prepared certain estimates as to the amount and timing of certain cost savings anticipated by the management of Bioventus to result following the closing, which are referred to as
the &#147;Cost Savings&#148; and are summarized under &#147;&#151;Certain Cost Savings.&#148; These Cost Savings are not reflected in the financial projections prepared by Bioventus or by Misonix. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of the Adjusted Bioventus Street Forecasts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents certain publicly available financial forecasts relating to the business and financial prospects of Bioventus, derived from a
consensus of selected equity research analysts concerning Bioventus for its 2021 through 2025 fiscal years, which Bioventus management adjusted for Bioventus&#146; revised guidance for the 2021 fiscal year and the assumed growth rate for the 2023
through 2025 fiscal years, as well as assumed rates of depreciation, stock-based compensation, tax, capital expenditures and change in networking capital. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY21E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY22E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY23E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY24E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FY25E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered free cash flow<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBITDA, a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, refers to earnings
before interest, tax, depreciation and amortization, excluding the impact of stock-based compensation expense and other cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> items that Bioventus does not consider in its evaluation of ongoing
operating performance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered free cash flow, a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, refers to
Adjusted EBITDA less stock-based compensation, which is treated as a cash expense, less taxes, change in net working capital and capital expenditures. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of the Adjusted and Extrapolated Misonix Street Forecasts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as described under &#147;&#151;Misonix Unaudited Financial Projections,&#148; Bioventus management identified certain publicly available financial
forecasts relating to the business and financial prospects of Misonix, derived from a consensus of selected equity research analysts concerning Misonix for fiscal years 2021 and 2022, which Bioventus management extrapolated for fiscal years 2023
through 2031 and adjusted for several different factors including assumed rates of depreciation and stock-based compensation and to calendarize to a December <FONT STYLE="white-space:nowrap">year-end.</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered free cash flow<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ending December</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2027E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2028E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2029E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2030E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2031E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered free cash flow<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBITDA, a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, refers to earnings
before interest, tax, depreciation and amortization, excluding the impact of stock-based compensation expense and other cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> items that Bioventus does not consider in its evaluation of ongoing
operating performance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered free cash flow, a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, refers to
Adjusted EBITDA less stock-based compensation, which is treated as a cash expense, less taxes, change in net working capital and capital expenditures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Important Information about the Adjusted Bioventus Street Forecasts and the Adjusted and Extrapolated
Misonix Street Forecasts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term forecasts or projections as to future performance, revenues, earnings or other results are subject to risks,
due to, among other reasons, the inherent difficulty of accurately predicting financial performance for future periods and the uncertainty of the underlying assumptions and estimates. However, the Adjusted Bioventus Street Forecasts and Adjusted and
Extrapolated Misonix Street Forecasts<B><I> </I></B>are being included in this joint proxy statement/prospectus to give stockholders access to certain <FONT STYLE="white-space:nowrap">non-public</FONT> information provided to the Bioventus board and
Bioventus&#146; financial advisor and to Misonix&#146;s financial advisor<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>for purposes of considering and evaluating the transaction. The inclusion of the Adjusted Bioventus Street Forecasts or
the Adjusted and Extrapolated Misonix Street Forecasts should not be regarded as an indication that the Bioventus board, Bioventus, the Misonix board, Misonix, Perella Weinberg, J.P. Morgan Securities or any other recipient of this information
considered, or now considers, it to be an assurance of the achievement of future results or an accurate prediction of future results, and they should not be relied on as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying Adjusted Bioventus Street Forecasts, Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings were not prepared with a view
toward public disclosure or with a view toward compliance with the published guidelines established by the SEC or the American Institute of Certified Public Accountants for preparation or presentation of prospective financial information, or GAAP,
but, in the view of Bioventus management, were reasonably prepared on bases reflecting the best available estimates and good faith judgments at the time of preparation, and presented as of the time of preparation, to the best of management&#146;s
knowledge and belief, the expected course of action and the expected future financial performance of Bioventus or Misonix, as applicable. However, this information is not fact and should not be relied upon as being necessarily indicative of future
results, and readers of this joint proxy statement/prospectus are cautioned not to place undue reliance on the Adjusted Bioventus Street Forecasts, Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings. Although Bioventus management
believes there is a reasonable basis for such projections and the Cost Savings, Bioventus cautions stockholders that future results could be materially different from the Adjusted Bioventus Street Forecasts and the Cost Savings. This summary of the
Adjusted Bioventus Street Forecasts and the Cost Savings is not being included in this joint proxy statement/prospectus to influence any decision on whether to vote for the Bioventus share issuance proposal or the Misonix merger proposal, but rather
because the Adjusted Bioventus Street Forecasts and the Cost Savings were shared between Bioventus and Misonix and provided to Bioventus&#146; and Misonix&#146;s respective boards of directors and financial advisors for purposes of considering and
evaluating the merger and the merger agreement. Bioventus&#146; independent registered public accounting firm, Grant Thornton LLP nor any other independent accountant, has not audited, reviewed, examined, compiled or applied agreed-upon procedures
with respect to the Adjusted Bioventus Street Forecasts and, accordingly, does not express an opinion or any other form of assurance with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings are subject to estimates and assumptions
in many respects and, as a result, subject to interpretation. While presented with numerical specificity, the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings are based upon a variety
of estimates and assumptions that are inherently uncertain, though considered reasonable by Bioventus management as of the date of their preparation. These estimates and assumptions may prove to be inaccurate for any number of reasons, including
general economic conditions, industry capital spending and unit production trends, competition and the risks discussed under &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; and &#147;Risk Factors.&#148; See also &#147;Where You
Can Find More Information.&#148; The Adjusted Bioventus Street Forecasts, Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings also reflect assumptions as to certain business decisions that are subject to change. Because the
Adjusted Bioventus Street Forecasts and Adjusted and Extrapolated Misonix Street Forecasts were developed for Bioventus on a stand-alone basis without giving effect to the merger, they do not reflect any divestitures or other restrictions that may
be imposed in connection with the receipt of any necessary governmental or regulatory approvals, any synergies that may be realized as a result of the merger or any changes to Bioventus&#146; operations or strategy that may be implemented after
completion of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger. There can be no assurance that the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings will be realized, and actual results may
differ materially from those shown. Generally, the further out the period to which Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings relate, the less predictable and more unreliable the
information becomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adjusted Bioventus Street Forecasts and the Adjusted and Extrapolated Misonix Street Forecasts<B><I> </I></B>contain certain <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures that Bioventus believes are helpful in understanding its past financial performance and future results. Bioventus management regularly uses a variety of financial measures that are not in
accordance with GAAP for forecasting, budgeting and measuring financial performance. The <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures.
While Bioventus believes these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures provide meaningful information to help investors understand the operating results and to analyze Bioventus&#146; financial and business trends on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis, there are limitations associated with the use of these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. These <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures are not prepared in accordance with GAAP, are not reported by all of Bioventus&#146; competitors and may not be directly comparable to similarly titled measures of Bioventus&#146;
competitors due to potential differences in the exact method of calculation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Bioventus nor Misonix has provided reconciliations of the <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> financial measures included in these projections to the comparable GAAP measure due to no reasonably accessible or reliable comparable GAAP measures for these measures and the inherent difficulty in
forecasting and quantifying the measures that are necessary for such reconciliation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of Bioventus, Misonix, the combined company or their respective
affiliates, advisors, officers, directors or other representatives can provide any assurance that actual results will not differ from the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts<B><I> </I></B>or
the Cost Savings, and none of them undertakes any obligation to update, or otherwise revise or reconcile, the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings to reflect circumstances
existing after the date the Adjusted Bioventus Street Forecasts or the Cost Savings were generated or to reflect the occurrence of future events even in the event that any or all of the assumptions underlying Adjusted Bioventus Street Forecasts, the
Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings, as applicable, are shown to be in error. Except as required by applicable laws, Bioventus does not intend to make publicly available any update or other revision to the Adjusted
Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings, even in the event that any or all of the assumptions are shown to be in error. None of Bioventus or its affiliates, advisors, officers, directors
or other representatives has made or makes any representation to any Bioventus stockholder or other person regarding Bioventus&#146; ultimate performance compared to the information contained in the Adjusted Bioventus Street Forecasts, the Adjusted
and Extrapolated Misonix Street Forecasts or the Cost Savings or that forecasted results will be achieved. Bioventus has made no representation to Misonix, in the merger agreement or otherwise, concerning the Adjusted Bioventus Street Forecasts, the
Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has not obtained, and does not intend to obtain, updated, revised or
reaffirmed opinions from Perella Weinberg, and Bioventus has not updated, revised or reaffirmed, and does not intend to update, revise or reaffirm, any of the projections or assumptions that it provided to Perella Weinberg and upon which Perella
Weinberg based its opinion. The opinion of Perella Weinberg does not speak as to the time when the merger will be completed or to any other date other than the date of each opinion. See &#147;&#151;Opinion of Bioventus&#146; Financial Advisor.&#148;
Further, the projections that Bioventus provided to Perella Weinberg were not necessarily indicative of the results that Bioventus will achieve for any period ending after the date of the opinion. However, as of the date of this joint proxy
statement/prospectus and except as otherwise publicly disclosed, Bioventus is not aware of, and does not anticipate to occur before the Bioventus special meeting, any material change or anticipated material change in its operations or performance,
or to the projections or assumptions upon which Perella Weinberg based its opinion, since the date of such opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix Unaudited Financial Projections </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than its quarterly financial guidance and business outlook, which may be updated from time to time, Misonix does not as a matter of course make other
public projections as to future revenues, earnings or other results available. In particular, Misonix does not as a matter of course make public long-term projections or forecasts as to its future revenues, earnings or other results due to the
uncertainty of the underlying assumptions and estimates. However, in connection with its evaluation of the potential strategic transactions, including the merger, Misonix management compiled certain unaudited prospective forecasted financial
information, which is referred to as the &#147;Misonix unaudited projections,&#148; and provided the projections to the Misonix board of directors in connection with their consideration of the transactions contemplated by the merger agreement, and
J.P. Morgan in connection with their preparation of financial analysis and fairness opinion. The Misonix unaudited projections were not provided to Bioventus in connection with its evaluation of a potential transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying prospective financial information was not prepared with a view toward public disclosure or with a view toward complying with the guidelines
established by the American Institute of Certified Public Accountants with respect to prospective financial information, but, in the view of the Company&#146;s management, was prepared on a reasonable basis, reflects the best currently available
estimates and judgments, and presents, to the best of management&#146;s knowledge and belief, the expected course of action and the expected future financial performance of the Company. However, this information is not fact and should not be relied
upon as being necessarily indicative of future results, and readers of this joint proxy statement/prospectus are cautioned not to place undue reliance on the prospective financial information. A summary of this information is presented below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix unaudited projections were prepared treating Misonix on a standalone basis, without giving effect to the merger, including any impact of the
negotiation or execution of the merger, the expenses that may be incurred in connection with the merger or the consummation thereof, the potential synergies that may be achieved by the combined company as a result of the merger, the effect of any
business or strategic decision or action that has been or will be taken as a result of the merger agreement having been executed or in anticipation of the merger, or the effect of any business or strategic decisions or actions which would likely
have been taken if the merger agreement had not been executed but which were instead altered, accelerated, postponed or not taken in anticipation of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Misonix management believes there is a reasonable basis for the Misonix unaudited projections, Misonix cautions stockholders that future results
could be materially different from the unaudited projections. This summary of the material portions of the Misonix unaudited projections is not being included in this joint proxy statement/prospectus to influence any decision whether to vote for the
Misonix merger proposal, but because the Misonix unaudited projections were provided to Misonix&#146;s financial advisor and the Misonix board of directors for purposes of considering and evaluating the merger. The prospective financial information
of Misonix included in this joint proxy statement/prospectus has been prepared by, and is the responsibility of, Misonix management. Neither Misonix&#146;s independent auditors, nor any other independent accountants, have compiled, examined, or
performed any procedures with respect to the prospective financial information contained herein, nor have they expressed any opinion or any other form of assurance on such information or its achievability, and assume no responsibility for, and
disclaim any association with, the prospective financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix unaudited projections are subject to estimates and assumptions in many
respects and, as a result, subject to interpretation. While presented with numerical specificity, the Misonix unaudited projections are based upon a variety of estimates and assumptions that are inherently uncertain, though considered reasonable by
Misonix&#146;s management as of the date of their preparation. These estimates and assumptions may prove to be inaccurate for any number of reasons, including, among others, Misonix&#146;s future results, general economic conditions, including the
effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and the risks discussed under &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; and &#147;Risk Factors.&#148; Also see &#147;Where You Can Find More
Information.&#148; Since the unaudited projections cover multiple years, such information by its nature becomes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significantly less certain with each successive year. The Misonix unaudited projections also reflect assumptions as to certain business decisions that are subject to change. Because the Misonix
unaudited projections were developed for Misonix on a standalone basis without giving effect to the merger, they do not reflect any restrictions that may be imposed in connection with the receipt of any necessary governmental or regulatory
approvals, any synergies that may be realized as a result of the merger or any changes to Misonix&#146;s operations or strategy that may be implemented after completion of the merger. There can be no assurance that the Misonix projections will be
realized, and actual results may differ materially from those shown. Generally, the further out the period to which the Misonix projections relate, the less predictable and more unreliable the information becomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of Misonix, Bioventus, the combined company or their respective affiliates, advisors, officers, directors or other representatives can provide any
assurance that actual results will not differ from the Misonix unaudited projections, and none of them undertakes any obligation to update, or otherwise revise or reconcile, the Misonix unaudited projections to reflect circumstances existing after
the date the Misonix unaudited projections were generated or to reflect the occurrence of future events, even in the event that any or all of the assumptions underlying the Misonix unaudited projections are shown to be in error. Except as required
by applicable securities laws, Misonix does not intend to make publicly available any update or other revision to the Misonix unaudited projections, even in the event that any or all assumptions are shown to be in error. None of Misonix or its
affiliates, advisors, officers, directors or other representatives has made or makes any representation to any Misonix stockholder or other person regarding Misonix&#146;s ultimate performance compared to the information contained in the Misonix
unaudited projections or that forecasted results will be achieved. Misonix has not provided the Misonix unaudited projections to Bioventus or made any representation to Bioventus, in the merger agreement or otherwise, concerning the Misonix
unaudited projections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix has not obtained, and does not intend to obtain, updated, revised or reaffirmed opinions from J.P. Morgan, and Misonix has
not updated, revised or reaffirmed, and does not intend to update, revise or reaffirm, any of the projections or assumptions that it provided to J.P. Morgan and upon which J.P. Morgan based their opinion. The opinion of J.P. Morgan does not speak as
to the time when the merger will be completed or to any other date other than the date of the opinion. See &#147;&#151;Opinion of Misonix&#146;s Financial Advisor.&#148; Further, the projections that Misonix provided to J.P. Morgan were not
necessarily indicative of the results that Misonix will achieve for any period ending after the date of the opinion. However, as of the date of this joint proxy statement/prospectus and except as otherwise publicly disclosed, Misonix is not aware
of, and does not anticipate to occur before the Misonix special meeting, any material change or anticipated material change in its operations or performance, or to the projections or assumptions upon which J.P. Morgan based their opinion, since the
date of such opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Misonix Financial Projections </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Preliminary Unaudited Projections </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table presents certain unaudited prospective financial information of Misonix prepared by Misonix management for Misonix&#146;s fiscal years ending 2022 through 2026, which we refer to as the Misonix preliminary unaudited projections, and which
information was provided to the Misonix board of directors and J.P. Morgan as preliminary estimates that were subject to further refinement. The Misonix preliminary unaudited projections were not provided to Bioventus in connection with its
evaluation of a potential transaction. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended, June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">234.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA (1)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBIT (2)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Operating Profit after Tax (3)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow (4)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure which is calculated as
earnings before interest expense, taxes, depreciation&nbsp;&amp; amortization and further adjusted to exclude <FONT STYLE="white-space:nowrap">non-cash</FONT> items and certain other adjustments like stock based compensation expense.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBIT is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure which is calculated as
Adjusted EBITDA further adjusted to exclude stock based compensation expense and depreciation&nbsp;&amp; amortization. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Net Operating Profit after Tax (&#147;NOPAT&#148;) is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
financial measure, which is calculated as Adjusted EBIT less estimated tax expense, which assumes a marginal tax rate of 23% and accounts for Misonix&#146;s net operating loss balance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered Free Cash Flow is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, which is
calculated as a NOPAT plus depreciation&nbsp;&amp; amortization, less capital expenditures and change in net working capital. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See below under the heading <FONT STYLE="white-space:nowrap">&#147;Non-GAAP</FONT> Financial Measures&#148; for
a reconciliation of the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure to its related GAAP financial measure </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Revised Unaudited Projections </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table presents certain unaudited prospective financial information of Misonix prepared by Misonix management for Misonix&#146;s fiscal years ending 2022 through 2026, which we refer to as the Misonix revised unaudited projections, and, together with
the Misonix preliminary unaudited projections, the Misonix unaudited projections, and which information was provided to the Misonix board of directors and J.P. Morgan. The Misonix revised unaudited projections were updated based on a number of
developments, including, among other things, management&#146;s general course of review, continuing developments in Misonix&#146;s business and recent developments on the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.
Misonix management instructed J.P. Morgan to use and rely upon the prospective information as a basis for its analysis in rendering its opinion described in the section of this proxy statement/prospectus entitled &#147;The Merger&#151;Opinion of
Misonix&#146;s Financial Advisor,&#148; with such adjustments as are discussed in such section. The Misonix revised unaudited projections were not provided to Bioventus in connection with its evaluation of a potential transaction. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended, June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA (1)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBIT (2)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Operating Profit after Tax (3)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unlevered Free Cash Flow (4)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure which is calculated as
earnings before interest expense, taxes, depreciation&nbsp;&amp; amortization and further adjusted to exclude <FONT STYLE="white-space:nowrap">non-cash</FONT> items and certain other adjustments like stock based compensation expense.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjusted EBIT is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure which is calculated as
Adjusted EBITDA further adjusted to exclude stock based compensation expense and depreciation&nbsp;&amp; amortization. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Net Operating Profit after Tax (&#147;NOPAT&#148;) is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
financial measure, which is calculated as Adjusted EBIT less estimated tax expense, which assumes a marginal tax rate of 23% and accounts for Misonix&#146;s net operating loss balance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unlevered Free Cash Flow is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, which is
calculated as a NOPAT plus depreciation&nbsp;&amp; amortization, less capital expenditures and change in net working capital. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See below under the heading <FONT STYLE="white-space:nowrap">&#147;Non-GAAP</FONT> Financial Measures&#148; for
a reconciliation of the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure to its related GAAP financial measure </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix unaudited projections contain certain
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures that Misonix believes are helpful in understanding its past financial performance and future results. Misonix management regularly uses a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
variety of financial measures that are not in accordance with GAAP for forecasting, budgeting and measuring financial performance. The <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial
measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures. While Misonix believes that these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures provide meaningful information to help
investors understand the operating results and to analyze Misonix&#146;s financial and business trends on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis, there are limitations associated with
the use of these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures. These <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures are not prepared in accordance with GAAP, are not reported by all of Misonix&#146;s
competitors and may not be directly comparable to similarly titled measures of Misonix&#146;s competitors due to potential differences in the exact method of calculation. A reconciliation of certain <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
financial measures to its respective comparable GAAP measure is provided below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Preliminary Unaudited Projections </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended, June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">234.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(73.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (Loss) from Operations (GAAP)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bad Debt Expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBIT <FONT STYLE="white-space:nowrap">(Non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income / (Loss) from Operations (GAAP)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bad Debt Expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBIT <FONT STYLE="white-space:nowrap">(Non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation&nbsp;&amp; Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Based Compensation Expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBITDA <FONT STYLE="white-space:nowrap">(Non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Revised Unaudited Projections </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended, June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2026E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(70.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(86.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(134.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (Loss) from Operations (GAAP)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Royalty Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBIT <FONT STYLE="white-space:nowrap">(Non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income / (Loss) from Operations (GAAP)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Royalty Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBIT <FONT STYLE="white-space:nowrap">(Non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation&nbsp;&amp; Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Based Compensation Expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBITDA <FONT STYLE="white-space:nowrap">(Non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Cost Savings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From April through June 2021, Bioventus and Misonix management independently prepared certain estimates as to the amount and timing of certain cost savings
anticipated by the management of Bioventus to result in connection with the proposed transaction. Bioventus and Misonix management agreed that the Cost Savings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include approximately $20&nbsp;million of cost synergies estimated to be potentially realizable by the second full year subsequent to closing, which are referred to as the &#147;Cost
Savings.&#148; The Cost Savings were provided to the Bioventus and Misonix boards of directors and to their respective financial advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cost
Savings assumed that the expected benefits of the merger would be realized, including that no restrictions, terms or other conditions would be imposed in connection with the receipt of any necessary governmental, regulatory or other approvals or
consents in connection with the consummation of the mergers. See &#147;&#151;Bioventus Unaudited Financial Projections&#148; and &#147;&#151;Misonix Unaudited Financial Projections&#148; for further information regarding the uncertainties underlying
the Cost Savings, as well as under &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; and &#147;Risk Factors&#148; for further information regarding the uncertainties and factors associated with realizing the synergies in
connection with the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Closing and Effective Time of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the merger will take place on a date to be designated jointly by Bioventus and Misonix, which date will be no later than the second business day
after the satisfaction or waiver (to the extent permitted) of the last of the conditions to closing (described under &#147;The Merger Agreement&#151;Conditions to the Completion of the Merger&#148;) to be satisfied or waived (other than such
conditions that by their nature are to be satisfied at the closing, but subject to the satisfaction or waiver of each of such conditions at the closing), unless another date is agreed to in writing by Bioventus and Misonix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the closing, the parties to the merger agreement will cause a certificate of merger relating to the first merger, and then a certificate of merger relating
to the second merger, to be executed and filed with the Secretary of State of the State of Delaware and make all other filings or recordings required by the DGCL and the DLLCA in connection with effecting the merger. The first merger and second
merger will become effective at the time when the respective certificate of merger is filed with the Secretary of State of the State of Delaware or at such later time as may be agreed to in writing by Bioventus and Misonix and specified in the
applicable certificate of merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix currently expect the transaction to close by the end of the 2021 calendar year and are working to
complete the transaction on this timeline and prior to the end date of January&nbsp;31, 2022 (which is subject to extension in certain circumstances related to the receipt of required regulatory approvals and the absence of restraints under certain
competition laws to March&nbsp;31, 2022 pursuant to the terms of the merger agreement). However, it is possible that factors outside the control of the parties to the merger agreement could result in the merger being completed at a different time,
or not at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Approvals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
merger agreement, Bioventus, Merger Sub I, Merger Sub II and Misonix have each agreed to cooperate with each other and to use (and to cause their respective subsidiaries to use) reasonable best efforts to take, or cause to be taken, all actions and
to do, or cause to be done, all things necessary to cause the conditions to the closing to be satisfied as promptly as reasonably practicable (and in any event no later than the end date) and to consummate the transactions, including preparing and
filing promptly and fully all documentation to effect all necessary filings to consummate the transaction including under the HSR Act. Bioventus and Misonix have agreed to use their respective reasonable best efforts to respond as promptly as
reasonably practicable to any inquiries or requests for additional information or documentary material received from and Bioventus has agreed to use its reasonable best efforts to remove each and every impediment under antitrust laws to enable the
consummation of the transactions, subject to the below limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any administrative or judicial action or proceeding including any proceeding by a
private party, is instituted (or threatened to be instituted) challenging the transactions contemplated by the merger agreement as violative of any antitrust law, each of Bioventus and Misonix will use reasonable best efforts to contest and resist
any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation
of the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, Bioventus will not be required to do any of the following in order to obtain antitrust approval or
otherwise to consummate the merger: (a)&nbsp;sell, divest, exclusively license, hold separate, or otherwise dispose of, or (b)&nbsp;grant any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, accept any operational restrictions or take
or commit to any actions which restrictions or actions would limit Bioventus&#146; or any of its affiliates&#146; freedom of action, in each case with respect to assets, licenses, product lines, operations or businesses of Bioventus, Misonix or
either&#146;s respective subsidiaries that, individually or in the aggregate, would reasonably be expected to have a materially adverse effect on (A)&nbsp;the results of operation of Misonix and its subsidiaries (taken as a whole) or
(B)&nbsp;results of operations of Bioventus and its subsidiaries (taken as a whole), <I>provided that, </I>in each case, Bioventus and its subsidiaries, taken as a whole, shall be deemed to be the same size (in operations and from a financial point
of view) as Misonix and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary, without the prior written consent of Bioventus,
neither Misonix nor any of its subsidiaries will grant or offer to grant any accommodation or concession (financial or otherwise) to any third party in connection with seeking or obtaining its consent to the transactions contemplated by the merger
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#151;Risks Relating to the Mergers.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of the Combined Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of
shares of Bioventus and Misonix common stock outstanding on September&nbsp;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the mergers, former Misonix stockholders are expected to
own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership
interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the mergers will depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the
merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors of the Combined Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has agreed to offer to at least two members of the Misonix board appointment to the Bioventus board as of the effective time, with such directors to
hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Securities Law Consequences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming the
effectiveness of the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy statement/prospectus forms a part, the shares of Bioventus class A common stock issued in the mergers will not be subject to
any restrictions on transfer arising under the Securities Act or the Exchange Act, except for shares of Bioventus class A common stock issued to any Misonix stockholder who may be deemed an &#147;affiliate&#148; of Bioventus after the completion of
the mergers. This joint proxy statement/prospectus does not cover resales of shares of Bioventus class A common stock received by any person upon the completion of the mergers, and no person is authorized to make any use of this joint proxy
statement/prospectus, or the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy statement/prospectus forms a part, in connection with any resale of shares of Bioventus common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus prepares its financial
statements in accordance with GAAP. The mergers will be accounted for using the acquisition method of accounting under the provisions of Accounting Standards Codification (&#147;ASC&#148;) 805, Business Combinations, with Bioventus representing the
accounting acquirer under this guidance. Bioventus will record assets acquired, including identifiable intangible assets, and liabilities assumed from Misonix at their respective fair values at the date of completion of the mergers. Any excess of
the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial condition and results of operations of Bioventus after completion of the mergers will reflect
Misonix after completion of the mergers, but will not be restated retroactively to reflect the historical financial condition or results of operations of Misonix. The earnings of Bioventus following completion of the mergers will reflect acquisition
accounting adjustments, including the effect of changes in the carrying value for assets and liabilities on depreciation expense and amortization expense. Indefinite-lived intangible assets, including goodwill, will not be amortized but will be
tested for impairment at least annually, and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the future, Bioventus determines that tangible or intangible assets
(including goodwill) are impaired, Bioventus would record an impairment charge at that time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing date, Bioventus will select its transfer agent or, after consultation with Misonix, another reputable bank or trust company reasonably
satisfactory to both parties to act as exchange agent with respect to the mergers. At or prior to the effective time, Bioventus will deposit with the exchange agent (a)&nbsp;certificates or evidence of book-entry shares representing the shares of
Bioventus class A common stock issuable pursuant to the merger agreement and (b)&nbsp;cash sufficient to make payments (i)&nbsp;in lieu of fractional shares in accordance with the merger agreement with respect to the stock election consideration and
(ii)&nbsp;in respect of the cash election consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information can be found under &#147;The Merger Agreement&#151;Exchange of Shares.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing of Bioventus Common Stock; Delisting and Deregistration of Misonix Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is a condition of the mergers that the shares of Bioventus class A common stock to be issued to Misonix stockholders in the merger be approved for listing
on Nasdaq, subject to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the mergers are completed, Misonix common stock will be delisted from Nasdaq and deregistered under
the Exchange Act, and Misonix will no longer be required to file periodic reports with the SEC with respect to Misonix common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix has agreed
to cooperate with Bioventus and use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable laws and Nasdaq rules and
policies to enable the delisting by the combined company of the shares of Misonix common stock from Nasdaq and the deregistration of the shares of Misonix common stock under the Exchange Act as promptly as practicable after the effective time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Litigation Relating to the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 15, 2021,
a purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Stein v. Misonix, Inc., et al., Case No. 2:21-cv-05127 (E.D.N.Y) (the &#147;Stein Complaint&#148;). The Stein
Complaint names Misonix and members of its board of directors as defendants. On September 16, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned
Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.) (the &#147;Ciccotelli Complaint&#148;). The Ciccotelli Complaint names Misonix, members of its board of directors, Bioventus, Merger Sub I, and Merger Sub II as defendants. Both
complaints assert claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021,
regarding Misonix&#146;s and Bioventus&#146; projections and J.P. Morgan&#146;s financial analysis. The complaints seek, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger, (ii) rescission in the event
that the merger is consummated, and (iii) an award of costs, including attorneys&#146; and experts&#146; fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and/or Misonix stockholders may
file additional lawsuits challenging the merger, which may name Bioventus, Misonix, members of the Bioventus or Misonix boards of directors and/or others as defendants. No assurance can be made as to the outcome of such lawsuits or the complaint,
including the amount of costs associated with defending, or any other liabilities that may be incurred in connection with the litigation of, such claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_20"></A>THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description sets forth the principal terms of the merger agreement, which is attached as <U>Annex</U><U></U><U>&nbsp;A</U> hereto and
incorporated by reference in this joint proxy statement/prospectus. The rights and obligations of the parties are governed by the express terms and conditions of the merger agreement and not by this description, which is summary by nature. This
description does not purport to be complete and is qualified in its entirety by reference to the complete text of the merger agreement. You are encouraged to read the merger agreement carefully and in its entirety, as well as this joint proxy
statement/prospectus and the documents incorporated by reference herein, before making any decisions regarding any of the proposals described in this joint proxy statement/prospectus. This section is intended to provide you with information
regarding the terms of the merger agreement. Accordingly, the representations, warranties, covenants and other agreements in the merger agreement should not be read alone, and you should read the information provided elsewhere in this joint proxy
statement/prospectus and in the public filings Bioventus and Misonix make with the SEC. See &#147;Where You Can Find More Information.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Explanatory Note Regarding the Merger Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
merger agreement and this summary of its terms have been included to provide you with information regarding the terms of the merger agreement. Bioventus and Misonix are responsible for considering whether additional disclosure of material
information is required to make the statements in this joint proxy statement/prospectus not misleading. Factual disclosures about Bioventus and Misonix contained in this joint proxy statement/prospectus and in the public filings Bioventus and
Misonix make with the SEC may supplement, update or modify the factual disclosures about Bioventus and Misonix contained in the merger agreement and described in this summary. The representations, warranties and covenants made in the merger
agreement by Bioventus, Merger Sub I, Merger Sub II and Misonix are qualified and subject to important limitations agreed to by the parties to the merger agreement in connection with negotiating the terms of the merger agreement. In particular, in
your review of the representations and warranties contained in the merger agreement and described in this summary, it is important to bear in mind that the representations and warranties were made solely for the benefit of the parties to the merger
agreement, and were negotiated with the principal purpose of allocating risk between the parties to the merger agreement, rather than establishing matters as facts. The representations and warranties may also be subject to a contractual standard of
materiality that may be different from that generally relevant to stockholders or applicable to reports and documents filed with the SEC, and in some cases are qualified by confidential disclosures that were made by each party to the other, which
disclosures are not reflected in the merger agreement or otherwise publicly disclosed. The representations and warranties in the merger agreement will not survive the completion of the mergers. Moreover, information concerning the subject matter of
the representations and warranties, which do not purport to be accurate as of the date of this joint proxy statement/prospectus, may have changed since the date of the merger agreement. If specific material facts exist that contradict the
representations, warranties and covenants contained in the merger agreement, Bioventus and Misonix have disclosed those material facts in this joint proxy statement/prospectus. If subsequent information concerning the subject matter of the
representations, warranties and covenants contained in the merger agreement has not been reflected in this joint proxy statement/prospectus, each of Bioventus and Misonix will make publicly available any material information necessary to provide
stockholders a materially complete understanding of the provisions of the merger agreement. For the foregoing reasons, the representations, warranties and covenants or any descriptions of those provisions should not be read alone, but instead should
be read together with the information provided elsewhere in this joint proxy statement/prospectus and in the public filings Bioventus and Misonix make with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information about Bioventus and Misonix can be found elsewhere in this joint proxy statement/prospectus and in the public filings Bioventus and
Misonix make with the SEC. See &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Structure of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>First</U>, on the closing date, at the effective time, Merger Sub I will be merged with and into Misonix in accordance with the DGCL and on the terms and
subject to the conditions set forth in the merger agreement, whereupon the separate existence of Merger Sub I will cease and Misonix will be the surviving corporation of the first merger and a wholly owned subsidiary of Bioventus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Second</U>, on the closing date following the first merger, at the effective time of the second merger (the &#147;Second Effective Time&#148;), Misonix
will be merged with and into Merger Sub II in accordance with the DGCL and the DLLCA, whereupon the separate existence of Misonix will cease and Merger Sub II will be the surviving limited liability company (the &#147;Surviving Company&#148;).</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Second Effective Time, all of the property, rights, powers, privileges and franchises of Misonix, Merger Sub I and Merger Sub II will vest in the
Surviving Company as the surviving limited liability company, and all of the debts, obligations, liabilities, restrictions and duties of Misonix, Merger Sub I and Merger Sub II will become debts, obligations, liabilities, restrictions and duties of
the Surviving Company as the surviving limited liability company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Completion and Effectiveness of the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the mergers will take place on a date to be designated jointly by Bioventus and Misonix, which date will be no later than the second business
day after the satisfaction or waiver (to the extent permitted) of the last of the conditions to closing (described under &#147;&#151;Conditions to the Completion of the Mergers&#148;) to be satisfied or waived (other than such conditions that by
their nature are to be satisfied at the closing, but subject to the satisfaction or waiver of each of such conditions at the closing), unless another date is agreed to in writing by Bioventus and Misonix. The date on which the closing occurs is
referred to as the &#147;closing date.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the closing, the parties to the merger agreement will cause separate certificates of merger relating to
each merger to be executed and filed with the Secretary of State of the State of Delaware and make all other filings or recordings required by the DGCL in connection with each merger (and, in connection with the second merger, required by the
DLLCA). Each merger will become effective at the time when the respective certificate of merger is filed with the Secretary of State of the State of Delaware or at such later time as may be agreed to in writing by Bioventus and Misonix and specified
in the applicable certificate of merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the effective time, automatically, by virtue of the first merger and without any further action on the part of Misonix, Misonix stockholders, Bioventus or
Merger Sub I: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all shares of Misonix common stock that are held in treasury by Misonix or are held directly by any direct or
indirect subsidiary of Misonix, Bioventus or Merger Sub I immediately prior to the effective time will be cancelled and will cease to exist and no consideration will be paid or payable in respect thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as described in the preceding bullet, each share of Misonix common stock that is issued and outstanding
immediately prior to the effective time will be converted into the right to receive, at the election of the holder of such share, either (a)&nbsp;an amount of cash equal to $28, without interest (the &#147;Cash Election Consideration&#148;), or (b)
1.6839 validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Bioventus class A common stock (the &#147;Stock Election Consideration&#148;), based on the election of the holder thereof and subject to
automatic proration and adjustment in accordance with the terms of the merger agreement as described below under &#147;The Merger Agreement&#151;The Mergers; Merger Consideration&#151;Proration and Reallocation&#148;; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each share of common stock, par value $0.0001 per share, of Merger Sub I that is issued and outstanding
immediately prior to the effective time will be converted into one validly issued, fully paid </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of common stock, par value $0.0001 per share, of Misonix as the surviving corporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Second Effective Time, automatically, by virtue of the second merger and without any further action on the part of Misonix, Misonix stockholders,
Bioventus, Merger Sub II or Merger Sub I: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each share of common stock, par value $0.0001 per share, of Misonix that is issued and outstanding immediately
prior to the Second Effective Time will be cancelled and will cease to exist. Each limited liability company interest of Merger Sub II issued and outstanding immediately prior to the Second Effective Time will remain outstanding as a limited
liability interest of the surviving limited liability company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Fractional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional shares of Bioventus class A common stock will be issued in connection with the mergers. Each Misonix stockholder who would otherwise have been
entitled to receive in the mergers a fractional share of Bioventus class A common stock pursuant to the merger agreement will, in lieu of such fractional share and upon surrender of such holder&#146;s certificates representing shares of Misonix
common stock or book-entry positions representing <FONT STYLE="white-space:nowrap">non-certificated</FONT> shares of Misonix common stock, in each case outstanding as of immediately prior to the effective time, be paid in cash the dollar amount
(rounded to the nearest whole cent), without interest and subject to any required tax withholding, determined by multiplying such fraction by the average of the volume-weighted average trading price per share of Bioventus class A common stock on
Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time (the &#147;Average Company Stock Price&#148;). No such
holder will be entitled to dividends, voting rights or any other rights in respect of any fractional share of Bioventus class A common stock that would otherwise have been issuable as part of the merger consideration. The payment of cash in lieu of
fractional share interests merely represents a mechanical <FONT STYLE="white-space:nowrap">rounding-off</FONT> of the fractions in the exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate amount of cash payable by
Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. In order to deliver this aggregate cash amount, the merger agreement
provides for pro rata adjustments to, and reallocation of, the cash and stock elections made by Misonix stockholders, as well as the allocation of consideration to be paid with respect to shares of Misonix common stock as to which no election
regarding the form of merger consideration to be paid to them, is received prior to the election deadline. Such no election shares will be exchanged for the cash consideration, the stock consideration or a combination of both. Additionally,
depending on the elections made by other Misonix stockholders, each Misonix stockholder who elects to receive Bioventus class A common stock for their shares in the mergers, referred to as &#147;stock election shares&#148; may receive a portion of
their consideration in cash, and each Misonix stockholder who elects to receive cash for their shares in the mergers, referred to as &#147;cash election shares&#148; may receive a portion of their consideration in Bioventus class A common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration, which is the amount equal to the aggregate number of cash election shares multiplied by $28.00, exceeds the available
cash amount, then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all stock election shares and all no election shares will be exchanged for 1.6839 shares of Bioventus class A
common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a portion of the cash election shares of each Misonix stockholder will be exchanged for $28.00 in cash as
follows: cash election shares exchanged for $28.00 in cash = </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of such stockholder&#146;s cash election shares)
* (maximum cash amount) </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">elected cash consideration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration is less than the available cash amount, which difference we refer to as
the shortfall amount, then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all cash election shares will be exchanged for the cash consideration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all stock election shares and no election shares will be treated in the following manner: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the shortfall amount is less than or equal to the product of the aggregate number of no election shares and
$28.00, which we refer to as the no election value, then (1)&nbsp;all stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock, and (2)&nbsp;a portion of the no election shares of each Misonix stockholder,
calculated as follows, will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#146;s no election shares, if any, will be exchanged for 1.6839 shares of Bioventus class A common stock): </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">no election shares exchanged for cash consideration = </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of no election shares of such stockholder) * (shortfall amount) </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(no election value) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the shortfall amount is more than the no election value, then (1)&nbsp;all no election shares will be
exchanged for $28.00 in cash and (2)&nbsp;a portion of the stock election shares of each stockholder will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#146;s stock election shares will be exchanged for
1.6839 shares of Bioventus class A common stock): </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">stock election shares exchanged for cash consideration = </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>(number of stock election shares of such stockholder) * (shortfall amount &#150; no election value) </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(aggregate number of stock election shares) * $28.00 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the elected cash consideration equals the available cash amount, then: (1)&nbsp;all cash election shares will be converted into the right to receive $28.00
in cash and (2)&nbsp;all stock election shares and all no election shares will be converted into the right to receive 1.6839 shares of Bioventus class A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange agent will mail to
Misonix stockholders of record not less than 30 days prior to the anticipated closing date of the first merger a letter of election and transmittal. The letter of election and transmittal enables Misonix stockholders to choose to make a cash
election, a stock election or no election with respect to each share of Misonix common stock eligible to receive the merger consideration. Misonix intends to issue a press release at least five business days prior to the expiration of the election
period informing Misonix stockholders of the expiration of the election period, which expiration we refer to as the &#147;election deadline&#148;. Misonix stockholders have until 5:00 p.m., New York City time, on the election deadline, to make their
election and return their completed letter of election and transmittal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any election will have been properly made only if the exchange agent has actually
received a properly completed letter of election and transmittal by the election deadline. Any election form may be revoked or changed by written notice received by the exchange agent prior to the election deadline. If an election form is revoked,
the shares of Misonix common stock as to which such election previously applied will be no election shares unless an election is subsequently submitted by the Misonix stockholder prior to the election deadline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange Agent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing date, Bioventus must select its transfer agent or, after consultation with Misonix, another reputable bank or trust company reasonably
satisfactory to both parties to act as exchange agent with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the mergers. At or prior to the effective time, Bioventus must deposit with the exchange agent (a)&nbsp;certificates or evidence of book-entry shares representing the shares of Bioventus class A
common stock issuable pursuant to the merger agreement and (b)&nbsp;cash sufficient to make payments (i)&nbsp;in lieu of fractional shares in accordance with the merger agreement with respect to the stock election consideration and (ii)&nbsp;in
respect of the cash election consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange of Misonix Stock Certificates and Misonix Book-Entry Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not less than 30 days prior to the anticipated closing date of the first merger, the exchange agent will mail to each holder of record of Misonix common stock
a letter of election and transmittal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to certificates representing shares of Misonix common stock, which are referred to collectively as
&#147;Misonix stock certificates&#148;, as promptly as reasonably practicable after the effective time, and in any event within three business days, the exchange agent must mail to each holder of record of each such Misonix stock certificate
(a)&nbsp;a notice advising such holder of the effectiveness of the mergers, and (b)&nbsp;a letter of transmittal and (c)&nbsp;instructions for surrendering Misonix stock certificates to the exchange agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon surrender of a Misonix stock certificate and a duly executed letter of election and transmittal (or letter of transmittal, if an election is not
submitted) to the exchange agent in compliance with the instructions for surrender, the exchange agent must mail to each holder of record, as promptly as reasonably practicable following the effectiveness of the mergers: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a statement reflecting the number of whole shares of Bioventus class A common stock, if any, that such holder is
entitled to receive pursuant to the merger agreement in <FONT STYLE="white-space:nowrap">non-certificated</FONT> book-entry form in the name of such record holder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer
instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&nbsp;any applicable Cash Election Consideration, (b)&nbsp;any cash in lieu
of fractional shares of Bioventus class A common stock plus (c)&nbsp;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to the merger agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to book-entry positions representing <FONT STYLE="white-space:nowrap">non-certificated</FONT> shares of Misonix common stock, which are referred
to as &#147;Misonix book-entry shares&#148;, that are not held through DTC, upon the later of the consummation of the mergers and the holder&#146;s delivery to the exchange agent of a duly executed letter of election and transmittal (or letter of
transmittal, if an election is not submitted), the exchange agent will pay and deliver to each such holder of record of any such Misonix book-entry shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable Stock Election Consideration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer
instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&nbsp;any applicable Cash Election Consideration, (b)&nbsp;any cash in lieu
of fractional shares of Bioventus class A common stock plus (c)&nbsp;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly
cancel each such <FONT STYLE="white-space:nowrap">non-DTC</FONT> book-entry share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix share certificates and Misonix
book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your
transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the
consummation of the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to Misonix book-entry shares that are held through DTC, Bioventus and Misonix must cooperate to
establish procedures with the exchange agent and DTC to ensure that the exchange agent will transmit to DTC or its nominees as soon as practicable after the effective time, but in any event within three business days thereafter, upon surrender of
shares held of record by DTC or its nominees in accordance with DTC&#146;s customary surrender procedures: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable Stock Election Consideration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer
instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&nbsp;any applicable Cash Election Consideration, (b)&nbsp;any cash in lieu
of fractional shares of Bioventus Class&nbsp;A Common Stock plus (c)&nbsp;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly
cancel each such <FONT STYLE="white-space:nowrap">non-DTC</FONT> book-entry share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a transfer of ownership of shares of
Misonix common stock that is not registered in Misonix&#146;s transfer records, the exchange agent may deliver the merger consideration, any cash in lieu of fractional shares of Bioventus common stock, and any unpaid cash dividends and any other
dividends or other distributions, to such transferee if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of Misonix book-entry shares, written instructions authorizing the transfer of the Misonix book-entry
shares are presented to the exchange agent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of Misonix stock certificates, the Misonix stock certificates formerly representing such shares of
Misonix common stock are surrendered to the exchange agent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such Misonix stock certificates or Misonix book-entry shares are presented to the exchange agent accompanied by
all documents required to evidence and effect such transfer and to evidence that any applicable transfer taxes have been paid or are not applicable, in each case, in form and substance reasonably satisfactory to Bioventus and the exchange agent.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lost, Stolen or Destroyed Certificates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that any Misonix stock certificate has been lost, stolen or destroyed and has not been replaced by Misonix or its transfer agent prior to the
election deadline, then, upon the making of an affidavit of that fact by the person claiming such Misonix stock certificate to be lost, stolen or destroyed and the posting by such person of a bond in a reasonable and customary amount and upon such
terms as may reasonably be required as indemnity against any claim that may be made against it with respect to such Misonix stock certificate, the exchange agent will issue in exchange for such lost, stolen or destroyed Misonix stock certificate,
the merger consideration, any cash in lieu of fractional shares of Bioventus class A common stock, and any unpaid cash dividends and any other dividends or other distributions, in each case, payable or issuable pursuant to the merger agreement, as
if such lost, stolen or destroyed Misonix stock certificate had been surrendered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Distributions with Respect to Unexchanged Shares of
Misonix Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No dividends or other distributions declared or made with respect to shares of Bioventus class A common stock with a record
date after the effective time will be paid or otherwise delivered to the holder of any unsurrendered Misonix stock certificate or Misonix book-entry shares with respect to the shares of Bioventus class A common stock that such holder has the right
to receive pursuant to the mergers until the later to occur of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the holder surrenders such Misonix stock certificate or Misonix book-entry shares in accordance
with the merger agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment date for such dividend or distribution with respect to shares of Bioventus class A common stock (at
which time such holder will be entitled, subject to the effect of applicable abandoned property, escheat or similar laws, to receive all such dividends and distributions, without interest). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights of Misonix Stockholders Following the Effective Time and Transfers Following the Effective Time
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the effective time, all shares of Misonix common stock outstanding immediately prior to the effective time will automatically be cancelled and
retired and will cease to exist, and all holders of Misonix stock certificates and of Misonix book-entry shares will cease to have any rights as Misonix stockholders, except the right to receive the merger consideration, any cash in lieu of
fractional shares of Bioventus class A common stock, and any dividends or other distributions that such holder has the right to receive pursuant to the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of Bioventus, Misonix, Merger Sub I, Merger Sub II nor the Surviving Company as the surviving limited liability company will be liable to any holder or
former holder of shares of Misonix common stock or to any other person with respect to any portion of the merger consideration delivered to any public official pursuant to any applicable abandoned property law, escheat law or other similar law. If
any Misonix stock certificate or Misonix book-entry share has not been surrendered prior to the date on which any portion of the merger consideration and any dividends or distributions, in each case, that a holder of such Misonix stock certificate
or Misonix book-entry share has the right to receive pursuant to the merger agreement in respect of such Misonix stock certificate or Misonix book-entry share would otherwise escheat to or become property of any governmental entity, any such shares,
cash, dividends or distributions in respect of such Misonix stock certificate or Misonix book-entry share will, to the extent permitted by applicable law, become the property of Bioventus, free and clear of all claims or interests of any person
previously entitled thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withholding Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus, the exchange agent, Merger Sub I, Merger Sub II and Misonix, Misonix as the surviving corporation of the first merger and Surviving Company as the
surviving entity of the second merger will each be entitled to deduct and withhold any amounts required to be deducted or withheld pursuant to applicable tax laws from the amounts that would otherwise be payable under the terms of the merger
agreement. Any such amounts that are deducted or withheld and, if required, paid over to the appropriate governmental authorities will be treated as having been paid to the person in respect of which such deduction or withholding was made. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Misonix Equity Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix
Restricted Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the effective time, each outstanding award of Misonix restricted stock that is held by a Misonix employee immediately
prior to the effective time, will accelerate in full (to the extent not otherwise previously vested in accordance with their terms) as of immediately prior to the effective time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the effective time, any
outstanding Misonix Option held by an &#147;employee&#148; of Bioventus (within the meaning of Form <FONT STYLE="white-space:nowrap">S-8)</FONT> (the &#147;Assumed Misonix Options&#148;) will be automatically converted into an option to acquire a
number of shares of Bioventus class A common stock determined based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside from the foregoing adjustments, Assumed Misonix Options, if any, will generally remain subject to the same vesting and other terms and conditions that
applied to such awards immediately prior to the effective time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Misonix Option that is not an Assumed Misonix Option and that is outstanding and
unexercised will be accelerated in full (to the extent not otherwise previously vested in accordance with their terms) and be settled in cash immediately prior to the effective time in an amount equal to the product of (x)&nbsp;the number of shares
of Misonix common stock subject to such Misonix Option, and (y)&nbsp;the excess, if any, of (i)&nbsp;the average of the volume-weighted average trading price per share of Bioventus class A common stock on Nasdaq (as reported by Bloomberg L.P.) on
each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii)&nbsp;the per share exercise price of such Misonix Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Misonix&#146;s Employee Stock Purchase Plan, which is referred to as the &#147;ESPP&#148;, Misonix is subject to the following requirements under the
merger agreement: (a)&nbsp;no new offering periods under the ESPP may commence during the period from the date of the merger agreement through the closing date, (b)&nbsp;there may be no increase in the amount of payroll deductions permitted to be
made by the participants in accordance with payroll deduction elections that are in effect as of the date of the merger agreement and (c)&nbsp;no individuals may commence participation in the ESPP during the period from the date of the merger
agreement through the closing date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governance of the Combined Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board to the Bioventus board as of the effective time,
with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No other governance changes are planned in connection with the mergers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Organizational Documents and Directors and Officers of the Surviving Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the requirements described under &#147;&#151;Indemnification; Directors&#146; and Officers&#146; Insurance,&#148;: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the effective time, the certificate of incorporation of Misonix, as in effect immediately prior to the
effective time, will continue to be the certificate of incorporation of the surviving corporation of the first merger until, subject to the terms of the merger agreement, thereafter changed or amended as provided therein or by applicable laws;
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">at the Second Effective Time, the certificate of formation of Merger Sub II, as in effect immediately prior to the
Second Effective Time, will continue to be the certificate of formation of the Surviving Company as the surviving limited liability company of the second merger until, subject to the terms of the merger agreement, thereafter changed or amended as
provided therein or by applicable laws; and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the parties will take all requisite actions so that the limited liability company agreement of Merger Sub II will
continue to be the limited liability company agreement of the Surviving Company until, subject to the terms of the merger agreement, thereafter changed or amended as provided therein or by applicable laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the effective time, the directors and officers of Merger Sub I immediately prior to the effective time will become the initial directors and officers of
Misonix as the surviving corporation of the first merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Second Effective Time, the officers of Merger Sub II immediately prior to the Second
Effective Time will become the initial officers of the Surviving Company as the surviving limited liability company of the second merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Representations and Warranties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement
contains customary and, in certain cases, reciprocal, representations and warranties by Bioventus, Merger Sub I, Merger Sub II and Misonix that are subject, in some cases, to specified exceptions and qualifications contained in confidential
disclosure letters and qualified by certain information filed by the parties with the SEC, excluding, in each case, any disclosures set forth in any risk factor section or &#147;forward-looking statements&#148; sections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reciprocal representations and warranties relate to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">organization, good standing and qualification to do business and subsidiaries&#146; organization, good standing
and qualification to do business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capitalization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate authority and approval relating to the execution, delivery and performance of the merger agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any violation of organizational documents, any conflict with or violation of applicable laws, any
violation of or default under contracts, or any lien on the properties, rights or assets of a party or its subsidiaries as a result of the execution and delivery of the merger agreement and completion of the mergers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proper filing of reports, schedules, forms, documents and financial statements required by the SEC and
compliance with certain provisions of the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maintenance of internal controls and procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of undisclosed liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of certain material changes or events in the respective businesses of each of Bioventus and Misonix;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with applicable laws and the holding of necessary permits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigations, litigations and proceedings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with anti-corruption laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product defects and warranties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with healthcare laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any need for action by governmental authorities in order to complete the mergers, except as may be
required by the Securities Act, the Exchange Act, the DGCL, the HSR Act or other applicable competition laws, applicable state securities takeover and &#147;blue sky&#148; laws or Nasdaq rules and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inapplicability of state anti-takeover statutes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">opinions of financial advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker&#146;s and finder&#146;s fees; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information provided by a party for inclusion in the Form <FONT STYLE="white-space:nowrap">S-4</FONT> (including
the joint proxy statement/prospectus). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement also contains additional representations and warranties by Misonix relating
to, among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s required stockholder approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property and information technology, including with respect to the enforceability of intellectual
property, third-party intellectual property infringement claims, licensing arrangements, the protection of trade secrets, security breaches and compliance with privacy and security laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personal property owned and leased and real property leased by Misonix; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s significant contracts and agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee benefit plans and employment and labor practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with environmental laws and regulations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of ownership (as defined in Section&nbsp;203(c) of the DGCL) of shares of Bioventus common stock by
Misonix and its subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement also contains additional representations and warranties by Bioventus relating to,
among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of Bioventus&#146;s, merger sub I&#146;s and merger sub II&#146;s required stockholder approvals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property and information technology, including with respect to the enforceability of intellectual
property and third-party intellectual property infringement claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee benefit plans and employment and labor practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of beneficial ownership of shares of Misonix common stock by Bioventus and its subsidiaries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">debt financing related to merger sub I and merger sub II; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data privacy and security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">top customers, suppliers and distributors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ownership or membership (as the case may be) and operation of merger sub I and merger sub II.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representations and warranties will not survive the mergers. Many of the representations and warranties contained in the merger
agreement are qualified by a &#147;materiality&#148; standard or by a &#147;material adverse effect&#148; standard. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Adverse Effect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A material adverse effect, with respect to Bioventus or Misonix, as applicable, means any fact, circumstance, condition, event, change, development,
occurrence, result, effect, action or omission that, individually or in the aggregate, (i)&nbsp;prevents, materially impairs, materially impedes or materially delays the consummation of the mergers and the other transactions contemplated by the
merger agreement on a timely basis and in any event on or before the end date or (ii)&nbsp;results in a material adverse effect on the business, condition (financial or otherwise) or results of operations of the party and its subsidiaries, taken as
a whole, excluding with respect to clause (ii)&nbsp;any fact, circumstance, condition, event, change, development, occurrence, result, effect, action or omission that results from or arises out of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, political, business, financial or market conditions affecting the industry in which the party
and its subsidiaries operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pandemic (including the continuation or worsening of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic), epidemic, plague, or other outbreak of illness or public health event, hurricane, flood, tornado, earthquake or other natural disaster or act of God or changes resulting from weather conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in applicable laws or the interpretation thereof (including any measures related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in GAAP or any other applicable accounting standards or the interpretation thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">geopolitical conditions, including trade and national security policies and export controls and executive orders
relating thereto, any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a failure by the party or any of its subsidiaries to meet any internal or external projections or forecasts or
any decline in stock price (excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves constitute or be taken into account in determining whether there has been or would be a material adverse
effect); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public announcement or pendency of the mergers and the other transactions contemplated by the merger
agreement, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, business partners or employees&nbsp;(with certain limitations); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action expressly required to be taken by the party pursuant to the terms of the merger agreement or at the
express written direction or consent of the other party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claims, suits, actions or proceedings arising from allegations of breach of fiduciary duty or violation of
applicable law or otherwise relating to the merger agreement or the transactions contemplated thereby; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach, violation or <FONT STYLE="white-space:nowrap">non-performance</FONT> of any provision of the merger
agreement by the party or any of its affiliates; provided, further, that any effect relating to or arising out of or resulting from any change or event referred to in the first five bullets above may constitute, and be taken into account in
determining the occurrence of, a material adverse event if and only to the extent that such change or event has a disproportionate impact on the party and its subsidiaries as compared to other participants that operate in the industry in which the
party and its subsidiaries operate. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conduct of Business Prior to the Completion of the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix have agreed that, except as may be required by applicable laws, as expressly required by the merger agreement, as set forth in their
respective disclosure schedules, or unless the other party approves in writing (such approval not to be unreasonably withheld, conditioned or delayed), Bioventus and Misonix, as applicable, must, and must cause each of its subsidiaries to, use
commercially reasonable efforts to conduct its business in the ordinary course of business. Misonix has also agreed that, except as may be required by applicable laws, as expressly permitted or required by the merger agreement, as set forth in
Misonix&#146;s disclosure schedule, or unless Bioventus approves in writing (in the case of the fourth through twelfth bullets, and in the thirteenth bullet, below, such approval not to be unreasonably withheld, conditioned or delayed), Misonix must
not, and must not permit its subsidiaries to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend its or its subsidiaries&#146; organizational documents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of Misonix&#146;s
capital stock or other equity interests of Misonix or any of its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside, make or pay any dividend or other distribution (whether payable in cash, stock or property)
on any shares of its capital stock or the capital stock or equity interest of any subsidiary of Misonix, other than dividends or distributions only to the extent paid by any wholly owned subsidiary of Misonix to Misonix or another wholly owned
subsidiary of Misonix. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or assets,
formation of a joint venture or otherwise)&nbsp;(a) any other entity, (b)&nbsp;any equity interest in any other entity (other than investments in equity securities that constitute short term investments that are accounted for as cash equivalents),
(c)&nbsp;any business or division or another entity, or (d)&nbsp;any material assets, except (i)&nbsp;acquisitions by Misonix from any of its wholly owned subsidiaries or among any of its wholly owned subsidiaries; (ii)&nbsp;the purchase of
equipment, supplies and inventory in the ordinary course of business; and (iii)&nbsp;inbound licenses of intellectual property in the ordinary course of business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except in connection with any transaction between Misonix and any of its subsidiaries or among any of its
subsidiaries, sell, assign, transfer, lease or license to any third party, or incur any lien on any of its material tangible property or tangible assets (except for certain permitted encumbrances), or otherwise dispose of (by merger, consolidation,
operation of law, division or otherwise), any of Misonix&#146;s intellectual property or material tangible assets, other than (a)&nbsp;sales of inventory, goods or services in the ordinary course of business in a manner consistent with past practice
or of obsolete equipment or assets in the ordinary course of business consistent with past practice, (b)&nbsp;pursuant to written contracts </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
or commitments existing as of the date of the merger agreement, (c)&nbsp;as security for any borrowings permitted by the merger agreement, or (d)&nbsp;licenses granted to customers or other third
parties in the ordinary course of business consistent with past practice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur (other than draws on existing revolving loans), redeem, repurchase, prepay (other than prepayments of
revolving loans), defease or cancel or guarantee any indebtedness for borrowed money, issue or sell any debt securities or rights to acquire any debt securities (directly, contingently or otherwise) or make any loans or capital contributions, except
for indebtedness among Misonix and its wholly owned subsidiaries (and guarantees by Misonix or its subsidiaries in respect thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)&nbsp;adopt, terminate or amend any Misonix employee benefit plan (except to the extent permitted in this
paragraph below), (b)&nbsp;increase, or accelerate the vesting or payment of, the compensation or benefits of any member of the board of directors of Misonix, (c)&nbsp;grant any rights to severance, retention, change in control or termination pay to
any member of the Misonix board, any current or former employee of Misonix or its subsidiaries, (d)&nbsp;hire or promote any employee at or to the level of Vice President or above, or (e)&nbsp;terminate the employment of any employee of Misonix or
its subsidiaries whose annual base salary exceeds $100,000 (other than for cause), except, in each case, for (i)&nbsp;amendments to Misonix employee benefit plans determined by it in good faith to be required to comply with applicable laws,
(ii)&nbsp;hiring any person for employment (including by means of internal promotion) to fill any currently existing Vice President or higher position that becomes vacant after the date of the merger agreement, and, notwithstanding anything to the
contrary in the merger agreement, provide such person with compensation and benefits for such position consistent with past practice, (iii)&nbsp;hiring any person for employment in accordance with Misonix&#146;s present hiring plan made available to
Bioventus or otherwise hiring an individual below the level of Vice President in the ordinary course of business in a manner consistent with past practice, (iv)&nbsp;increases in compensation or benefits required pursuant to any Misonix employee
benfit plan in effect on the date of the merger agreement, (v)&nbsp;increases to total target cash opportunities (i.e.,&nbsp;annual base salary or wage rates and target annual cash bonus opportunities) in amounts that are in the ordinary course of
business in a manner consistent with past practice,&nbsp;and (vi)&nbsp;any other actions set forth in Misonix&#146;s disclosure schedule; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except in the ordinary course of business, amend or terminate (except for terminations pursuant to the expiration
of the existing term of any material contract or lease) certain material contracts or material property leases or waive, release or assign any materials rights under any material contracts or material property leases; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make (except for elections made in the ordinary course of business), change or revoke any tax election, change
any tax accounting period or method of tax accounting, amend any material tax return if such amendment would reasonably be expected to result in a material tax liability, settle or compromise any material liability for taxes or any tax audit, claim,
or other proceeding relating to a material amount of taxes, enter into any agreement with a governmental entity relating to taxes if such agreement would reasonably be expected to result in a material tax liability, request any tax ruling from any
governmental entity, surrender any right to claim a material refund of taxes, or, other than in the ordinary course of business, agree to an extension or waiver of the statute of limitations with respect to a material amount of taxes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other than consignment of Misonix products in the ordinary course of business, make any capital expenditure that
is not contemplated by the capital expenditure budget set forth in Misonix&#146;s disclosure schedule, unless such expenditures by Misonix and its subsidiaries do not, in the aggregate, exceed such budget by more than $200,000;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settle or compromise any litigation, claim, suit, action or proceeding, except for (a)&nbsp;the payment,
discharge or satisfaction, in the ordinary course of business in a manner consistent with past practice, of liabilities reflected or reserved against in the most recent balance sheet of Misonix, or (b)&nbsp;those that do not (i)&nbsp;impose any
injunctive relief on Misonix or any of its subsidiaries, (ii)&nbsp;involve the payment of money greater than $250,000 in excess of existing insurance coverage, and (c)&nbsp;do not include an admission of liability or fault on the part of Misonix or
any of its subsidiaries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">materially reduce insurance coverage or fail to renew material existing insurance policies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) amend any permits in a manner that adversely impacts Misonix&#146;s ability to conduct its business in any
material respect or terminate or allow to lapse any material permits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except in connection with any transaction between Misonix and any of its wholly owned subsidiaries or among any
of its wholly owned subsidiaries, issue, sell, grant or otherwise permit to become outstanding any additional shares of its capital stock or other equity interests, any securities convertible into or exchangeable for any such shares, or any options,
warrants or rights to acquire any such shares, other than (a)&nbsp;shares of Misonix common stock issuable upon exercise of Misonix outstanding stock options or the vesting of Misonix RSUs, or (b)&nbsp;pursuant to the ESPP and (to the extent not
already covered), Misonix&#146;s equity incentive plans, in the ordinary course of business consistent with past practice and in accordance with the merger agreement&#146;s terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly or indirectly repurchase, redeem or otherwise acquire any shares of Misonix&#146;s or any of its
subsidiaries&#146; capital stock or equity interests, or any other securities or obligations convertible (currently or after the passage of time or the occurrence of certain events) into or exchangeable for any shares of Misonix&#146;s or any of its
subsidiaries&#146; capital stock or equity interests, except (a)&nbsp;shares of Misonix common stock repurchased from employees or consultants or former employees or consultants pursuant to the exercise of repurchase rights existing prior to the
date of the merger agreement, or (b)&nbsp;shares of Misonix common stock accepted as payment for the exercise price of options to purchase Misonix common stock pursuant to Misonix&#146;s stock incentive plan or for withholding taxes incurred in
connection with the exercise, vesting or settlement of Misonix stock options or Misonix RSUs, as applicable, in accordance with the terms of the applicable award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change any methods of financial accounting or accounting practices in any material respect other than as required
by changes in GAAP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any contract or agreement that would constitute a material contract or material property lease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as expressly required by applicable law or Misonix&#146;s organizational documents, convene (a)&nbsp;any
special meeting of Misonix stockholders, other than the Misonix special meeting to be held in connection with the transactions contemplated by the merger agreement, or (b)&nbsp;any other meeting of Misonix stockholders to consider a proposal that
would reasonably be expected to impair, prevent or delay the transactions contemplated by the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any agreement, understanding or arrangement with respect to the voting of any of Misonix&#146;s
capital stock or other equity interests (including any voting trust), other than with respect to awards under Misonix&#146;s equity plans otherwise permitted under the merger agreement or in connection with the granting of revocable proxies in
connection with any meeting of Misonix stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt a plan of (a)&nbsp;complete or partial liquidation of Misonix or any of its subsidiaries or
(b)&nbsp;dissolution, merger, consolidation, division, restructuring, recapitalization or other reorganization, other than, in the case of clause (b), transactions between Misonix&#146;s wholly owned subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to make any issuance, renewal, maintenance and other payments that become due with respect to any of
Misonix&#146;s material registered intellectual property or otherwise abandon, cancel or permit to lapse any material Misonix&#146;s material registered intellectual property, other than in its reasonable business judgment or in the ordinary course
of business consistent with past practice, or authorize the disclosure to any third party of any material trade secret in a way that results in loss of trade secret protection, other than in the ordinary course of business consistent with past
practice; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize, approve, enter or commit to do any of the foregoing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has also agreed that, except as may be required by applicable laws, as expressly permitted or
required by the merger agreement, as set forth in Bioventus&#146;s disclosure schedule, or unless Misonix approves in writing (such approval not to be unreasonably withheld, conditioned or delayed), Bioventus will not, and will not permit its
subsidiaries to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend its, merger sub I&#146;s or merger sub II&#146;s organizational documents in a manner that would be adverse
in any material respect to the holders of Misonix common stock (after giving effect to the mergers); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of Bioventus&#146;s
capital stock or other equity interests, except for any such transaction involving only wholly owned subsidiaries of Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside, make or pay any dividend or other distribution (whether payable in cash, stock or property)
on any shares of its capital stock, except dividends or distributions may be paid by any wholly owned subsidiary of Bioventus to Bioventus or to another wholly owned subsidiary of Bioventus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or assets,
formation of a joint venture or otherwise)&nbsp;(a) any other entity, (b)&nbsp;any equity interest in any other entity (other than investments in equity securities that constitute short term investments that are accounted for as cash equivalents),
(c)&nbsp;any business or division or another entity; (d)&nbsp;any assets material to Misonix and subsidiaries of Misonix, taken as a whole, except in each case, (i)&nbsp;acquisitions by Bioventus from any of its wholly owned subsidiaries or among
any of its wholly owned subsidiaries, (ii)&nbsp;the purchase of equipment, supplies and inventory in the ordinary course of business, (iii)&nbsp;inbound licenses of intellectual property in the ordinary course of business, or (iv)&nbsp;acquisitions
that in each case would not reasonably be expected to (1)&nbsp;result in the holders of Misonix common stock having different rights and privileges than holders of Bioventus class A common stock following the consummation of the mergers,
(2)&nbsp;materially delay, materially imped or prevent the consummation of the transactions contemplated by the merger agreement or (3)&nbsp;result in the failure of any of the conditions to closing set forth in the merger agreement to be satisfied
prior to the end date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidate (completely or partially), dissolve or adopt a plan or resolution providing for any of the foregoing,
in each case, with respect to Bioventus, merger sub I or merger sub II; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize, approve, enter or commit to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Solicitation of Acquisition Proposals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as
expressly permitted by the merger agreement and described under &#147;&#151;No Change of Recommendation&#151;Permitted Change of Recommendation&#151;Superior Proposal&#148; and &#147;&#151;No Change of Recommendation&#151;Permitted Change of
Recommendation&#151;Intervening Event,&#148; Bioventus and Misonix have agreed that neither Bioventus nor Misonix, nor any of their respective subsidiaries, will, and that they must cause their and their respective subsidiaries&#146; representatives
not, directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries
regarding, or the submission or announcement by any person (other than, in the case of Misonix, Bioventus or in the case of Bioventus, Misonix, or its respective affiliates and representatives) of, any proposal or offer that constitutes, or would
reasonably be expected to lead to, an acquisition proposal (as defined below) (provided, however, that Bioventus or Misonix, as applicable, receiving such acquisition proposal, and its representatives, may refer the person making such proposal or
offer to the provisions of the merger agreement and make inquiries of a person making an acquisition proposal involving such party (and its representatives) to solely clarify the terms of such acquisition proposal for the purpose of the Bioventus
board or the Misonix board, as applicable, informing itself about such acquisition proposal); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">furnish any information regarding Bioventus or Misonix, as applicable, receiving such acquisition proposal, or of
its subsidiaries (other than to the other party and its subsidiaries), or afford access to such party&#146;s or its subsidiaries&#146; representatives, books, records or property, in each case, in connection with or for the purpose of soliciting,
initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to an acquisition proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in, enter into, continue or otherwise participate in any discussions or negotiations with any person
(other than, in the case of Bioventus, Misonix, or in the case of Misonix, Bioventus, or its respective representatives) with respect to any acquisition proposal or any inquiry, proposal or offer that would reasonably be expected to lead to an
acquisition proposal (provided, however, that each party and its representatives may refer the person making such proposal or offer to the provisions of the merger agreement and make inquiries of a person making such acquisition proposal to solely
clarify the terms of such acquisition proposal for the purpose of the Bioventus board or the Misonix board, as applicable, informing itself about such acquisition proposal); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve, adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or
enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment, or agreement in principle with respect to any acquisition proposal; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resolve or agree to do any of the foregoing; provided, however, that, notwithstanding anything to the contrary
contained in the merger agreement, prior to obtaining the applicable required stockholder approval, Bioventus and Misonix, as applicable, and its respective representatives may engage or otherwise participate in discussions or negotiations with, and
provide information to, any person (including its representatives and financing sources and their representatives) that has made a bona fide written acquisition proposal after the date of the merger agreement that did not result from any breach of
the foregoing restrictions by Bioventus or Misonix, their subsidiaries, or any of their representatives, if: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) prior
to taking any such action, the Bioventus board or the Misonix board, as applicable, receiving such acquisition proposal determines in good faith, after consultation with its outside legal counsel and financial advisor, that such acquisition proposal
either constitutes a superior proposal (as defined below) or would reasonably be expected to lead to a superior proposal; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) prior
to providing any information regarding Bioventus or Misonix or any of their respective subsidiaries, as applicable, to such third party in response to such acquisition proposal, Bioventus or Misonix, as applicable, receives from such third party (or
there is then in effect with such third party) an executed confidentiality agreement with nondisclosure provisions at least as restrictive of such third party as the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement with Bioventus or
Misonix, as applicable, and that does not prohibit compliance of Bioventus or Misonix, as applicable, with the merger agreement&#146;s <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to or substantially concurrently with providing any <FONT STYLE="white-space:nowrap">non-public</FONT> information to such third party, Bioventus or
Misonix, as applicable, must make such <FONT STYLE="white-space:nowrap">non-public</FONT> information available to the other party (to the extent such <FONT STYLE="white-space:nowrap">non-public</FONT> information has not been previously made
available by such party to the other party). Bioventus or Misonix, as applicable, must promptly (and in any event within 48 hours) inform the other party if such party furnishes <FONT STYLE="white-space:nowrap">non-public</FONT> information and/or
enters into discussions or negotiations as provided for in the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions of the merger agreement and must keep the other party reasonably informed, on a current basis (and, in any event,
within 48 hours), of the status and material terms of any acquisition proposal (including any material changes to the material terms thereof) and the status of any material discussions and negotiations with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus or Misonix, as applicable, receives an acquisition proposal (or notice from any person that it intends to make an acquisition proposal) or any
inquiry or request for information with respect to an acquisition proposal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or that is reasonably likely to lead to an acquisition proposal, then Bioventus or Misonix, as applicable, must promptly (and in no event later than 48 hours after its receipt of such acquisition
proposal or request) notify the other party in writing of such acquisition proposal or request (which notification must include the identity of the person making or submitting such request or acquisition proposal and an unredacted copy of any such
written request or proposal (or, if not in writing, the material terms and conditions thereof)), together with copies of any proposed agreements relevant to such transaction, and Bioventus or Misonix, as applicable, must thereafter keep the other
party reasonably informed, on a current basis (and, in any event, within 48 hours), of the status of such acquisition proposal, including informing such other party of any material change to the terms of such acquisition proposal, and the status of
any negotiations, including any change in its intentions as previously notified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly following the execution and delivery of the merger agreement
(and in any event within 24 hours after the execution and delivery of the merger agreement), Bioventus or Misonix, as applicable, must, and must cause each of its subsidiaries and must instruct their respective representatives to, promptly cease and
cause to be terminated any existing solicitation of, or discussions or negotiations with, any person (other than the other party and its representatives) relating to any acquisition proposal made prior to the date of the merger agreement and any
access any such persons may have to any physical or electronic data room relating to any potential acquisition proposal. Bioventus or Misonix, as applicable, must not, and must cause its affiliates not to, release any third party from, or waive,
amend or modify any provision of, or grant permission under, or fail to enforce, any standstill provision in any agreement to which Bioventus or Misonix, or any of their respective affiliates, as applicable, is a party, unless the failure to take
such action would reasonably be expected to be inconsistent with the Bioventus or Misonix board&#146;s (as applicable) fiduciary duties to Bioventus or Misonix (as applicable) and its stockholders under applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any violation of the restrictions contained in the <FONT STYLE="white-space:nowrap">non-solicitatoin</FONT> provisions of the merger agreement by any of the
subsidiaries or any representatives of Bioventus or Misonix, as applicable, or any of its respective subsidiaries will be deemed to be a breach of the <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions in the merger agreement by
such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An &#147;acquisition proposal&#148; means any offer, indication of interest or proposal (other than an offer or proposal made or submitted by
or on behalf of, in the case of Bioventus, Misonix or any of its affiliates, or in the case of Misonix, Bioventus or any of its affiliates) contemplating or otherwise relating to an acquisition transaction (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An &#147;acquisition transaction&#148; means any transaction or series of related transactions (other than the mergers) involving: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger, consolidation, amalgamation, business combination, joint venture, reorganization or other similar
transaction involving Bioventus or Misonix, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction (i)&nbsp;in which any person or &#147;group&#148; (as defined in the Exchange Act) of persons
acquires beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of Bioventus or Misonix, as applicable; or
(ii)&nbsp;in which Bioventus or Misonix, as applicable, or any of its subsidiaries issues securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of
Bioventus or Misonix, as applicable (after giving effect to such transaction);; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, exchange, transfer, acquisition or disposition of 20% or more of the consolidated assets (including
equity securities of respective subsidiaries) Bioventus and its subsidiaries, or of Misonix and its subsidiaries, as applicable, taken as a whole, or of any business or businesses (or the assets of any business or businesses, including equity
securities of any subsidiary of Bioventus or Misonix, as applicable) that constitute or account for 20% or more of the consolidated net revenues or net income of Bioventus and its subsidiaries, or of Misonix and its subsidiaries, as applicable,
taken as a whole; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any tender offer or exchange offer that if consummated would result in any person or &#147;group&#148; (as
defined in the Exchange Act) of persons acquiring beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for such securities) representing 20% or more of the voting power of Bioventus or Misonix,
as applicable; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing types of transactions if the sum of the percentage of the voting power of
Bioventus or Misonix, as applicable, or of the consolidated net revenues, net income or assets of Bioventus and its subsidiaries or of Misonix and its subsidiaries, as applicable, taken as a whole, involved is 20% or more. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;superior proposal&#148; means any bona fide, unsolicited written acquisition proposal made to Bioventus or Misonix, as applicable, after the date of
the merger agreement that: (a)&nbsp;if consummated, would result in any person or &#147;group&#148; (as defined in the Exchange Act) of persons (other than the other party) directly or indirectly becoming the beneficial owner of (i)&nbsp;any
business or businesses that constitute or account for 50% or more of the net revenues, net income or assets of the other party, or (ii) 50% or more of the outstanding total voting power of the equity securities of the other party; and (b)&nbsp;the
other party&#146;s board of directors determines in good faith, after consultation with its outside legal counsel and financial advisor, is reasonably capable of being consummated on the terms proposed and which, taking into account such factors as
the Bioventus board or the Misonix board, as applicable, reasonably considers in good faith to be appropriate and relevant, including the financial, legal, timing, likelihood of consummation, confidentiality, regulatory, financing and other aspects
of such acquisition proposal would be more favorable to the holders of shares of common stock of Bioventus or Misonix, as applicable, from a financial point of view than the transactions contemplated by the merger agreement (after giving effect to
any revisions to the terms of the merger agreement that is accepted by the other party would be legal binding on Bioventus or Misonix, as applicable, in response to such acquisition proposal pursuant to the merger agreement). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Change of Recommendation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix have
agreed that, except as otherwise set forth in the merger agreement, neither the Bioventus board nor the Misonix board, nor any respective committee thereof, will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withhold, withdraw, modify, amend or qualify (or publicly propose to do so), in a manner adverse to Bioventus,
Merger Sub I and Merger Sub II, on the one hand, or to Misonix, on the other hand, the Misonix board&#146;s required recommendation to Misonix stockholders to adopt the merger agreement, which is referred to as the &#147;Misonix
recommendation&#148;, or the Bioventus board&#146;s required recommendation to Bioventus stockholders to approve the share issuance, which is referred to as the &#147;Bioventus recommendation&#148;, as applicable or fail to include the Misonix
recommendation or Bioventus recommendation, as applicable, in the joint proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve, recommend or declare advisable (or publicly propose to do so) any acquisition proposal;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to publicly announce, within ten business days after a tender offer or exchange offer relating to the equity
securities of Bioventus or Misonix, as applicable, have been commenced by any third party (and in no event later than one business day prior to the date of the Misonix special meeting or the Bioventus special meeting, as applicable, as either may be
postponed or adjourned pursuant to this merger agreement), a statement disclosing that the Misonix board or the Bioventus board, as applicable, recommends rejection of such tender or exchange offer (for the avoidance of doubt, the taking of no
position or a neutral position in respect of the acceptance of any such tender offer or exchange offer as of the end of such period will constitute a failure to publicly announce that such board of directors recommends rejection of such tender or
exchange offer); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if requested by the other party, fail to issue, within ten business days after an acquisition proposal is
publicly announced (and in no event later than one business day prior to the date of the Misonix special meeting or the Bioventus special meeting, as applicable, as it may be postponed or adjourned pursuant
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
to the merger agreement), a press release reaffirming the Misonix recommendation or the Bioventus recommendation, as applicable, provided, further, that in no event will Misonix or Bioventus, as
applicable, or its board of directors, be obligated to publicly reaffirm the Misonix recommendation or the Bioventus recommendation, as applicable, on more than one occasion with respect to each such publicly announced acquisition proposal or on
more than one occasion with respect to each publicly announced material modification thereof (any action described in the foregoing being referred to as a &#147;change in recommendation&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause or permit Bioventus or Misonix, as the case may be, to enter into any contract, letter of intent,
memorandum of understanding, agreement in principle or other arrangement or understanding (other than a confidentiality agreement entered into in compliance with the merger agreement) contemplating or relating to an acquisition transaction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any action to make the provisions of any anti-takeover or similar statute or regulation inapplicable to any
acquisition proposal or counterparty thereto; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly propose to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Permitted Change of Recommendation&#151;Superior Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, Misonix, at any time prior to its stockholders voting on the Misonix merger proposal, and Bioventus, at any time prior to its stockholders voting on
the Bioventus share issuance proposal, may make a change of recommendation related to an acquisition proposal and authorize termination of the merger agreement if and only if Bioventus or Misonix, as applicable, receives from a third party a bona
fide written acquisition proposal that has not been withdrawn and that did not result from a breach of the merger agreement&#146;s <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions, if, prior to making such change of recommendation
and/or authorizing termination of the merger agreement to concurrently enter into a definitive agreement with respect to such acquisition proposal: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recipient&#146;s board of directors determines in good faith, after consultation with its outside legal
counsel and financial advisor, that such acquisition proposal constitutes a superior proposal and that failure to take such action would reasonably be expected to be inconsistent with the recipient&#146;s board of directors&#146; fiduciary duties to
its stockholders under applicable laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recipient delivers to the other party a written notice at least four business days in advance stating that
the recipient&#146;s board of directors intends to make a change of recommendation, which notice must include the identity of the person making such acquisition proposal and a copy of such proposal and a draft of the definitive agreement to be
entered into in connection therewith (or, if not in writing, the material terms and conditions thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during such four business day period, if requested by the other party, the recipient engages in good faith
negotiations with the other party regarding a possible amendment of the merger agreement so that the acquisition proposal that is the subject of the notice regarding a superior proposal ceases to be a superior proposal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the expiration of the negotiation period described above and in a manner that would be binding upon
Misonix, on the one hand, and Bioventus, Merger Sub I and Merger Sub II on the other, as applicable, if accepted by the other party, the Misonix board or the Bioventus board, as applicable, determines in good faith, after consultation with its
outside legal counsel and financial advisor, after taking into account any amendments to the merger agreement that the other party has committed in writing to make as a result of the negotiations contemplated above, that such acquisition proposal
continues to constitute a superior proposal, provided, that if there is any change to any of the financial terms or any other material terms of such acquisition proposal, the acquisition proposal&#146;s recipient will, in each case, be required to
deliver to the other party an additional notice consistent with that described above and a new negotiation period consistent with that described above will commence (except that the original four business day notice period referred to above must
instead be equal to the longer of (i) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
11:59 p.m. New York City time on the second business day immediately following the receiving party&#146;s receipt of such notice, and (ii)&nbsp;the period remaining under the original four
business day notice period above), during which time Misonix or Bioventus, as applicable, will be required to comply with the requirements of the merger agreement anew with respect to such additional notice (but substituting the time periods therein
with the foregoing two business day period). The actions of the applicable board of directors making a determination that an acquisition proposal constitutes a superior proposal and its authorizing and providing the notices to the other party
required by the merger agreement will not in and of itself, constitute a change in recommendation or a violation of the merger agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Permitted Change of Recommendation&#151;Intervening Event </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Misonix, at any time prior to its stockholders voting on the Misonix merger proposal, and Bioventus, at any time prior to its stockholders voting
on the Bioventus share issuance proposal, may make a change of recommendation if an intervening event (as defined below) arises and prior to making such change of recommendation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Misonix board or the Bioventus board, as applicable, determines in good faith, after consultation with its
outside legal counsel and financial advisor, that, in light of such intervening event, a failure to effect a change of recommendation would reasonably be expected to be inconsistent with such board of directors&#146; fiduciary duties to Misonix or
Bioventus, as applicable, and its stockholders under applicable laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">less than four business days prior to the making of such change in recommendation, Misonix or Bioventus, as
applicable, receives a written notice from the other party confirming that the applicable board of directors intends to effect such change in recommendation, specifying the reasons therefor in reasonable detail; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during such four business day period, if requested by the other party, the party experiencing the intervening
event engages in good faith negotiations with the other party to amend the merger agreement in such a way that obviates the need for the applicable board of directors to effect a change of recommendation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the expiration of such four business day period, the board of directors of the party experiencing the
intervening event determines in good faith, after consultation with its outside legal counsel and financial advisor and after taking into account any amendments to the merger agreement that the other party has committed in writing to make a result
of such negotiations contemplated by the clause above and in a manner that would be binding on such other party if accepted by the party experiencing the intervening event, that in light of such intervening event, a failure to effect a change of
recommendation would reasonably be expected to be inconsistent with such board of directors&#146; fiduciary duties to its stockholders under applicable laws, even if such changes committed to in writing were to be given effect.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actions of the applicable board of directors making a determination that an intervening event has occurred and the applicable
party&#146;s authorizing and providing the notices to the other party required by the merger agreement will not in and of itself constitute a change in recommendation or a violation of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An &#147;intervening event&#148; means any state of fact, event, change, effect, circumstance, occurrence or development, or combination thereof, that arises
following the date of the merger agreement that (a)&nbsp;was neither known to nor reasonably foreseeable by the Misonix board or the Bioventus board, as applicable, as of the date of the merger agreement (or, if known to or reasonably foreseeable by
such board of directors, the consequences of which were neither known to nor reasonably foreseeable by such board of directors as of the date of the merger agreement) and (b)&nbsp;is material to Bioventus and any of its subsidiaries or Misonix and
any of its subsidiaries, as applicable, taken as a whole, and (c)&nbsp;is not related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an acquisition proposal or a superior proposal or any inquiry or communications relating thereto, any matter
relating thereto or consequences thereof; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in each case in and of itself, any changes in the market price or trading volume of the Bioventus class A common
stock or Misonix common stock, as applicable, or the fact that Bioventus or Misonix, as applicable, meets, fails to meet or exceeds any internal or published projections, forecasts or estimates of its revenue, earnings or other financial performance
or results of operations for any period (except that any underlying cause of any of the foregoing may be taken into account unless excluded pursuant the other bullet points); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any event, condition or circumstance related to Bioventus and any of its subsidiaries or Misonix and any of its
subsidiaries, as applicable. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix must take all actions necessary under applicable laws and each party&#146;s organizational documents to, in consultation with the other
party as promptly as reasonably practicable after the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy statement/prospectus forms a part is declared effective by the SEC (and in any event within 45
days thereafter to the extent legally permitted), to, in the case of Bioventus, convene the Bioventus special meeting to vote on the Bioventus share issuance proposal, in the case of Misonix, convene the Misonix special meeting to vote on (a)&nbsp;a
proposal to adopt the merger agreement, (b)&nbsp;a proposal for a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote of Misonix stockholders to approve certain compensation that may become payable to Misonix&#146;s named executive
officers in connection with the completion of the mergers, and (c)&nbsp;an adjournment proposal. Except as described above with respect to a change in recommendation, Bioventus and Misonix must use reasonable best efforts to solicit proxies in favor
of their respective proposals and will not submit any other proposal to its stockholders in connection with the applicable special meeting without the prior written consent of the other party. Each of Misonix and Bioventus, in consultation with the
other party, must set a record date for determining the persons entitled to notice of, and to vote at, the applicable special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and
Misonix may not postpone or adjourn the Bioventus special meeting and the Misonix special meeting, as applicable, unless the other party provides its prior written consent, other than: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent reasonably necessary to ensure that any supplement or amendment to this joint proxy
statement/prospectus which the Bioventus board or the Misonix board, as applicable, has determined in good faith, after consultation with the other party and its outside counsel, is required by applicable law is disclosed to Bioventus or Misonix
stockholders, as applicable, and promptly disseminated to such stockholders within a reasonable amount of time (as determined by such board of directors in good faith after consultation with its outside counsel) prior to the applicable special
meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if required by applicable law or a request from the SEC or its staff; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, as of the time for which the Bioventus special meeting or the Misonix special meeting, as applicable, is
scheduled, there are insufficient shares of Bioventus class A common stock or Misonix common stock, as applicable, represented (either in person or by proxy) to constitute a quorum necessary to conduct the business to be conducted at such special
meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Bioventus or Misonix may, and if the other party so requests at any time, must, postpone or adjourn the Bioventus
special meeting or the Misonix special meeting, as applicable, in order to solicit additional proxies in favor of the Bioventus share issuance proposal or Misonix merger proposal, as applicable, if on the date for which such special meeting is
scheduled, there would be insufficient votes to obtain approval of such proposal, whether or not a quorum is present. In such case, except where the Bioventus board or the Misonix board, as applicable, has made a change in recommendation, Bioventus
or Misonix, as applicable, must use reasonable best efforts during any such postponement or adjournment to solicit and obtain such proxies in favor of such proposal as soon as reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, without Bioventus&#146; or Misonix&#146;s consent, as applicable, or except as may be required by applicable laws or a request from the SEC or its
staff, no single adjournment or postponement may be for more than ten </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business days, and, subject to certain exceptions, all such adjournments and postponements together may not postpone the Bioventus or Misonix special meeting, as applicable, for more than twenty
business days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix must also use reasonable best efforts to initially hold their respective special meetings on the same date or, if
notwithstanding such efforts, the other party&#146;s special meeting is held on a date prior, as promptly as reasonably practicable following the date of the other party&#146;s special meeting. Upon request of Bioventus or Misonix (which may not
exceed one request per day), the other party must, during the ten business days prior to the date of such other party&#146;s special meeting, advise the requesting party as to the aggregate number of shares of such other party&#146;s common stock
entitled to vote at such other party&#146;s special meeting for which proxies have been received by such other party with respect to the required stockholder approval of such other party and the number of such proxies authorizing the holder thereof
to vote in favor of the required stockholder approval of such other party.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Approvals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the merger agreement, Bioventus, Merger Sub I, Merger Sub II and Misonix have each agreed to cooperate with each other and use (and cause any of their
respective subsidiaries to use) reasonable best efforts to take, or cause to be taken, all actions, and do, or cause to be done, all things, necessary to cause the conditions to the closing to be satisfied as promptly as reasonably practicable (and
in any event no later than the end date) and to consummate the mergers, including to obtain (and to cooperate with each other in obtaining) the regulatory approvals described above as promptly as reasonably practicable (and in any event no later
than the end date), subject to the limitations described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, Bioventus will not be required to do any of the following in order to obtain any
regulatory approval or otherwise to consummate the mergers: (a)&nbsp;sell, divest, exclusively license, hold separate, or otherwise dispose of, or (b)&nbsp;grant any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, accept any
operational restrictions or take or commit to any actions which restrictions or actions would limit Bioventus&#146; or any of its affiliates&#146; freedom of action, in each case with respect to assets, licenses, product lines, operations or
businesses of Bioventus, Misonix or either&#146;s respective subsidiaries that, individually or in the aggregate, would reasonably be expected to have (i)&nbsp;an effect that results in a material adverse effect on the results of operations of
Misonix and its subsidiaries, taken as a whole, or (ii)&nbsp;an effect that results in a material adverse effect on the results of operations of Bioventus and its subsidiaries (taken as a whole), but for purposes of determining whether an effect is
or would be materially adverse to the results of operations of Bioventus and its subsidiaries, taken as a whole, Bioventus and its subsidiaries, taken as a whole, will be deemed to be the same size (in operations and from a financial point of view)
as Misonix and its subsidiaries, taken as a whole. Notwithstanding anything to the contrary contained in the merger agreement, without the prior written consent of Bioventus, neither Misonix nor any of its subsidiaries or affiliates may grant or
offer to grant any accommodation or concession (financial or otherwise) to any third party in connection with seeking or obtaining its consent to the transactions contemplated by the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In furtherance and not in limitation of the covenants of the parties contained in the provisions regarding regulatory approvals in the merger agreement, if
any administrative or judicial action or proceeding, including any proceeding by a private party, is instituted (or threatened to be instituted) challenging any transaction contemplated by the merger agreement as violative of any antitrust law, each
of Bioventus and Misonix must use reasonable best efforts to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction or other order, whether temporary, preliminary or
permanent, that is in effect and that prohibits, prevents or restricts consummation of the transactions contemplated by the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Access
to Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain limitations, prior to the effective time, each of Bioventus and Misonix must afford the other party and its
representatives reasonable access, during normal business hours upon prior notice, to Bioventus&#146; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Misonix&#146;s, as applicable, and its subsidiaries&#146; personnel, properties, contracts, filings with governmental entities, books and records and, during such period, must furnish promptly to
the other party all available information concerning Bioventus&#146; or Misonix&#146;s, as applicable, business as the other party may reasonably request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consents of Merger Sub I and Merger Sub II; Vote of Bioventus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period from the date of the merger agreement through the earlier of the effective time or the date of termination of the merger agreement, Merger
Sub I and Merger Sub II must not engage in any activities of any nature except as provided in or contemplated by the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus must
ensure that each of Merger Sub I and Merger Sub II duly performs, satisfies and discharges on a timely basis each of the covenants, obligations and liabilities of such entity under the merger agreement, and Bioventus will be jointly and severally
liable with each of Merger Sub I and Merger Sub II for the due and timely performance and satisfaction of each such covenant, obligation and liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following the execution of the merger agreement, Bioventus must execute and deliver, in accordance with the DGCL and DLLCA, as applicable, and in
its capacity as the sole stockholder of Merger Sub I and sole member of Merger Sub II, a written consent adopting the merger agreement on behalf of Merger Sub I and Merger Sub II respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Publicity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix must consult with one
another prior to issuing, and provide each other with the opportunity to review and comment upon, any public announcement, statement or other disclosure with respect to the merger agreement or the mergers and may not issue any such public
announcement or statement prior to such consultation, except as may be required by applicable law or by Nasdaq rules and regulations (in which event Bioventus or Misonix, as applicable, must endeavor, on a basis reasonable under the circumstances,
to provide a meaningful opportunity to the other party to review and comment upon such public announcement in advance, and must give due consideration to all reasonable additions, deletions or changes suggested thereto). Notwithstanding the
foregoing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of Bioventus and Misonix may make public announcements concerning the merger agreement or the merger that
consist solely of information previously disclosed in previous public announcements, statements or other disclosures made by Bioventus and/or Misonix in compliance with the publicity provisions of the merger agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of Bioventus and Misonix may make any public statements in response to questions by the press, analysts,
investors or those participating in investor calls or industry conferences, so long as such public statements consist solely of information previously disclosed in previous press releases, public disclosures or public statements made by Bioventus
and/or Misonix in compliance with the publicity provisions of the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix need not consult with Bioventus in connection with any public announcement or statement to be made with
respect to any acquisition proposal; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus and Misonix need not consult with the other party in connection with any public announcement or,
statement to be made with respect to any change of recommendation. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefits Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For twelve months following the effective time, Bioventus will provide, or will cause to be provided, to (i)&nbsp;each employee of Misonix and its subsidiaries
who continues employment with Bioventus or its subsidiaries with (a)&nbsp;an annual base salary or base wage rate that is, and (b)&nbsp;a target annual cash opportunity that, taken together with the annual base salary or base wage rate provided to
such employee is, in each case, no less favorable than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided to each such employee immediately prior to the effective time and (ii)&nbsp;each such employee with employee welfare and retirement benefits (excluding any benefits under any defined
benefit pension plan or post-retirement medical plan) that are substantially comparable or more favorable in the aggregate to those provided to such continuing employee by Misonix and its subsidiaries immediately prior to the effective time to at
least&nbsp;those provided to similarly situated employees of Bioventus, except to the extent such recognition would result in the duplication of benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will provide service credit to continuing Misonix employees for purposes of determining eligibility to participate, vesting and accrual and level of
benefits with respect to Bioventus benefit plans. For its welfare benefit plans, Bioventus will use commercially reasonable efforts to (a)&nbsp;waive limitations on preexisting conditions, exclusions and waiting periods for continuing Misonix
employees, other than as are already in effect and have not been satisfied or waived prior to the effective time, and (b)&nbsp;credit annual deductibles, <FONT STYLE="white-space:nowrap">co-payments</FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> maximums paid under Misonix benefit plans during the applicable plan year, except to the extent such recognition would result in the duplication of benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If requested by Bioventus not less than ten business days before the closing date, the Misonix board (or the appropriate committee thereof) must adopt
resolutions and take such corporate action as is reasonably necessary to terminate Misonix&#146;s 401(k) plan, effective as of the day prior to the closing date. In the event that Bioventus requests that Misonix&#146;s 401(k) plan be terminated,
(i)&nbsp;Misonix must provide Bioventus with evidence that such plan has been terminated (the form and substance of which will be subject to reasonable prior review and comment by Bioventus) not later than the day preceding the closing date and
(ii)&nbsp;following the Second Effective Time and as soon as reasonably practicable following receipt of a favorable determination letter from the IRS on the termination of Misonix&#146;s 401(k) plan, to the extent that Bioventus requests that
Misonix seek such determination letter, the assets thereof will be distributed to the participants, and Bioventus must permit such continuing employees who are then actively employed to make rollover contributions of &#147;eligible rollover
distributions&#148; (within the meaning of Section&nbsp;401(a)(31) of the Code, inclusive of loans) to Bioventus&#146; 401(k) plan, in the form of cash, in an amount equal to the full account balance (including any promissory notes) distributed to
such Misonix continuing employees from Misonix&#146;s 401(k) plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Tax Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus, Merger Sub I, Merger Sub II and Misonix intend to report and, except to the extent otherwise required pursuant to a &#147;determination&#148; within
the meaning of Section&nbsp;1313(a) of the Code, will report, for U.S., state and other relevant tax purposes, the mergers as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, which is referred to as the
&#147;intended tax treatment.&#148; Each of Bioventus, Merger Sub I, Merger Sub II and Misonix will use reasonable best efforts to cause the merger to qualify, and will not take any action or cause any action to be taken which action would
reasonably be expected to prevent the mergers from qualifying, for the intended tax treatment. The merger agreement is intended to constitute a &#147;plan of reorganization&#148; for purposes of Treasury Regulations Sections <FONT
STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a),</FONT> to which each of Bioventus and Misonix are parties under Section&nbsp;368(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Bioventus, Merger Sub I, Merger Sub II and Misonix will use commercially reasonable efforts to obtain from Jones Day or other nationally recognized
tax counsel reasonably acceptable to Misonix any opinions and disclosures required to be filed with the SEC in connection with the registration of the applicable Form <FONT STYLE="white-space:nowrap">S-4,</FONT> including the appropriate officers of
Bioventus, Merger Sub I, Merger Sub II and Misonix executing and delivering to the tax opinion counsel certificates setting forth certain representations and assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix must use commercially reasonable efforts to cooperate with Bioventus and its affiliates to cause any subsidiary of Misonix that is treated as a
corporation for U.S. federal income tax purposes to merge into Misonix LLC (as the surviving limited liability company of the second merger), which merger will be effective after the Second Effective Time and occur, at Bioventus&#146; sole
discretion, on the closing date after the closing or after the closing date. However, no officer or employee of Misonix or its subsidiaries will be obligated to execute </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
documents prior to the closing for purposes of effecting any such merger, and Misonix and its subsidiaries may not be obligated to make or have be effective any tax elections or tax filings in
connection therewith prior to the closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification; Directors&#146; and Officers&#146; Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For at least six years following the Second Effective Time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus and Misonix as the surviving limited liability company must indemnify and hold harmless, and provide
advancement of expenses to, all current or former directors and officers of Misonix or any of its subsidiaries, any person who becomes a director or officer of Misonix or any of its subsidiaries prior to the effective time and any current or former
director of officer of Misonix or any of its subsidiaries who is, was or at any time prior to the effective time does serve as a director, officer, member, trustee or fiduciary of another corporation, partnership joint venture, trust, pension plan
or employee benefit plan at the request of or for the benefit of Misonix or any of its subsidiaries (which individuals are referred to as the &#147;indemnified parties&#148;) to the fullest extent permitted by applicable laws; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix as the surviving limited liability company must maintain in effect the provisions in the organizational
documents of Misonix and each of its subsidiaries and other agreements of Misonix or any of its subsidiaries with any indemnified party, in each case, regarding exculpation, elimination or limitation of liability, indemnification of officers, and
directors or other fiduciaries and advancement of expenses that are in existence on the date of the merger agreement (including acts or omissions in connection with the approval of the merger agreement and the consummation of the mergers and the
related transactions) and set forth in Misonix&#146;s disclosure schedule, and no such provision may be amended, modified or repealed in any manner that would adversely affect the rights or protections thereunder of any such indemnified party in
respect of acts or omissions occurring or alleged to have occurred at or prior to the effective time without the consent of such indemnified party. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, for at least six years following the Second Effective Time, Bioventus and Misonix as the surviving limited liability company must maintain in
effect Misonix&#146;s existing directors&#146; and officers&#146; liability insurance policy (or a comparable replacement policy), which is referred to as the &#147;D&amp;O Policy&#148;, for claims arising from facts or events that occurred at or
prior to the effective time (including with respect to the approval of the merger agreement and the consummation of the mergers) and covering each of Misonix&#146;s current directors and officers on terms with respect to coverage and amounts that
are no less favorable than those terms in effect on the date of the merger agreement. However, in no event will Bioventus or Misonix as the surviving limited liability company be required to expend in any one year an amount in excess of 300% of the
current annual premium paid by Misonix for such insurance, and if the premium for such insurance exceeds such 300% allowance, then Bioventus and Misonix must purchase a policy with the greatest comparable coverage available not exceeding such
allowance. However, in lieu of the foregoing obligation, Misonix may, or if Misonix is unable to, Bioventus may on its behalf, purchase, prior to the effective time, a <FONT STYLE="white-space:nowrap">six-</FONT> year &#147;tail&#148; prepaid policy
on the D&amp;O Policy with an annual cost not exceeding such 300% of the current annual premium paid by Misonix for such insurance. Each of the indemnified parties or other persons who are beneficiaries under the D&amp;O Policy or such
&#147;tail&#148; policy (and, after the death of any of the foregoing persons, such person&#146;s heirs and representatives) are intended to be third party beneficiaries of the merger agreement&#146;s indemnification provisions, with full rights of
enforcement as if a party thereto. Notwithstanding anything in the merger agreement to the contrary, if any indemnified party notifies Bioventus on or prior to the sixth anniversary of the effective time of a matter in respect of which such person
may seek indemnification pursuant to the provisions regarding the D&amp;O Policy in the merger agreement, the provisions of the merger agreement that require Bioventus and Misonix (as the surviving limited liability company) to indemnify and advance
expenses must continue in effect with respect to such matter until the final disposition of all claims, actions, investigations, suits and proceedings relating thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing of the Mergers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the date of the merger
agreement, Misonix must, and must cause its subsidiaries and their respective representatives to, provide such cooperation as is reasonably requested by Bioventus, is reasonably and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
customarily necessary in connection with the contemplated debt financing in connection with the mergers (for which Bioventus has, prior to the date of the merger agreement, provided to Misonix an
accurate and complete copy of the relevant executed debt commitment letter) and is customarily provided for issuers in financings of the type contemplated by such debt commitment letter, pursuant to which, upon the terms and subject only to the
conditions therein, the debt financing sources party thereto have agreed to lend the amounts set forth therein. Subject to customary limitations and exceptions, such cooperation includes using commercially reasonable efforts to, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">furnish to Bioventus certain customary financial information with respect to the Misonix and its subsidiaries as
is necessary for Bioventus to prepare the customary bank information memoranda, lender presentations, rating agency presentations and other similar customary documents, and to assist Bioventus in the preparation thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide Bioventus with requested information that is required in connection with the financing by U.S. regulatory
authorities under applicable &#147;know-your-customer&#148; and anti-money laundering rules and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver, or cause the applicable Company Subsidiary to deliver, necessary prepayment and/or termination notices
in accordance with the terms of each of existing credit facilities of Misonix and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execute and deliver credit agreements and to reasonably facilitate the pledging of collateral and the provision
of guarantees in respect of the financing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause members of the senior management of Misonix and its representatives and advisors to participate in
meetings, conference calls, roadshows and presentations with prospective lenders and investors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the date of the merger agreement,
Bioventus shall use its reasonable best efforts to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain the effect of the debt commitment letter; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiate definitive financing agreements on the terms set forth in the debt commitment letter; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfy the conditions in the debt commitment letter on a timely basis and consummate the financing contemplated
thereby. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the financing contemplated by the debt commitment letter becomes unavailable, Bioventus shall as promptly as practicable
following the occurrence thereof use its reasonable best efforts to obtain substitute financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Additional Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement also contains additional covenants, including, among others, covenants relating to coordination with respect to litigation relating to the
mergers, the listing of Bioventus class A common stock and the delisting of shares of Misonix common stock from Nasdaq and the deregistration of Misonix under the Exchange Act (which are described under &#147;The Merger&#151;Listing of Bioventus
Common Stock; Delisting and Deregistration of Misonix Common Stock&#148;), reporting requirements under Section&nbsp;16 of the Exchange Act, resignations of Misonix directors, termination of Misonix&#146;s credit facilities and handling of any
applicable antitakeover or similar statutes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to the Completion of the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of each of Bioventus and Misonix to complete the mergers are subject to the satisfaction or waiver, as of the closing, of each of the following
conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy
statement/prospectus forms a part must have become effective in accordance with the provisions of the Securities Act, no stop order may have been issued by the SEC and remain in effect with respect to the Form
<FONT STYLE="white-space:nowrap">S-4</FONT> and no proceedings for that purpose may have been commenced or threatened in writing by the SEC and not withdrawn; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by Misonix stockholders of the Misonix merger proposal must have been obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by Bioventus stockholders of the Bioventus share issuance proposal must have been obtained;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any waiting period (or any agreed upon extension of any waiting period or commitment not to consummate the
mergers for any period of time) applicable to the consummation of the mergers under the HSR Act must have expired or been terminated by the relevant governmental entity, and there must be no pending agreement between Bioventus and any governmental
entity not to close; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares of Bioventus class A common stock to be issued pursuant to the first merger, including the shares of
Bioventus class A common stock to be issued upon the exercise of converted Misonix stock options and upon vesting of converted Misonix RSUs, must have been approved for listing (subject to notice of issuance) on Nasdaq; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no law or order preventing, enjoining or making illegal the consummation of the mergers may have been entered,
issued or adopted by any court of competent jurisdiction or other governmental entity of competent jurisdiction and remain in effect (any such law or order is referred to as a &#147;relevant legal restraint&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligation of Bioventus to complete the mergers is subject to the satisfaction or waiver, by Bioventus as of the closing, of each of the following
conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s representations and warranties regarding the numbers of its issued, reserved for issuance and/or
outstanding capital stock or other equity interests must have been true and accurate, other than de minimis inaccuracies, at and as of the date of the merger agreement, and must be true and accurate, other than de minimis inaccuracies, at and as of
the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be
true and accurate, other than de minimis inaccuracies, as of such particular date or period of time); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s representations and warranties regarding (a)&nbsp;Misonix&#146;s organization and good standing,
(b)&nbsp;capitalization (other than regarding its capital stock as described in the preceding bullet), (c) corporate authority and approval, (d)&nbsp;Misonix&#146;s required stockholder approval,
<FONT STYLE="white-space:nowrap">(e)&nbsp;non-violation</FONT> of Misonix&#146;s or its subsidiaries&#146; organizational documents, (f)&nbsp;takeover statutes and (g)&nbsp;any broker, finder or investment banker fees must have been true and
accurate in all material respects at and as of the date of the merger agreement and must be true and accurate in all material respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation
and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be so true and accurate in all material respects as of such particular date or period of time), without
giving effect to any materiality or material adverse effect qualifications contained therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s remaining representations and warranties must have been true and accurate in all respects at and
as of the date of the merger agreement and must be true and accurate in all respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular
date or period of time, in which case such representation and warranty will only be required to be so true and accurate as of such particular date or period of time), except as, individually or in the aggregate has not constituted or resulted in or
would not reasonably be expected to constitute or result in, a material adverse effect, without giving effect to any materiality or material adverse effect qualifications contained therein (provided, that if there has been, from the date of the most
recent company balance sheet provided by Misonix to Bioventus pursuant to the merger agreement through the date of the merger agreement, any fact, event, change, effect, circumstance, occurrence or development that, individually or in the aggregate,
has had or would reasonably be expected to have a material adverse effect to Misonix, such fact, event, change, effect circumstance, occurrence or development will be given effect); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s covenants required to be complied with or performed at or prior to the closing must have been
complied with and performed in all material respects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since the date of the merger agreement, there must not have occurred any effects that, individually or in the
aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a material adverse effect for Misonix; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus must have received a certificate, dated as of the closing date and executed by the Chief Executive
Officer or Chief Financial Officer of Misonix, confirming that the conditions described in the preceding five bullets have been satisfied. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligation of Misonix to complete the mergers are subject to the satisfaction or waiver, by Misonix as of the closing, of each of the following
conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; representations and warranties regarding the numbers of its issued, reserved for issuance and/or
outstanding capital stock or other equity interests must have been true and accurate, other than de minimis inaccuracies, at and as of the date of the merger agreement and must be true and accurate, other than de minimis inaccuracies, at and as of
the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be
true and accurate, other than de minimis inaccuracies, as of such particular date or period of time); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; representations and warranties regarding (a)&nbsp;Bioventus&#146;, Merger Sub I&#146;s and Merger
Sub II&#146;s organization and good standing, (b)&nbsp;capitalization (other than regarding its capital stock as described in the preceding bullet), (c) corporate authority and approval, (d)&nbsp;Bioventus&#146; required stockholder approval, <FONT
STYLE="white-space:nowrap">(e)&nbsp;non-violation</FONT> of Bioventus&#146; or its subsidiaries&#146; organizational documents and (e)&nbsp;any broker, finder or investment banker fees must have been true and accurate in all material respects at and
as of the date of the merger agreement and will only be required to be true and accurate in all material respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty
expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be so true and accurate in all material respects as of such particular date or period of time), without giving effect
to any materiality or material adverse effect qualifications contained therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; remaining representations and warranties must have been true and accurate in all respects at and
as of the date of the merger agreement and will only be required to be true and accurate in all respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks
as of a particular date or period of time, in which case such representation and warranty must be so true and accurate in all respects as of such particular date or period of time), except as, individually or in the aggregate, has not constituted or
resulted in or would not reasonably be expected to constitute or result in, a material adverse effect, without giving effect to any materiality or material adverse effect qualifications contained therein (provided, that if there has been, from the
date of the most recent company balance sheet provided by Bioventus to Misonix pursuant to the merger agreement through the date of the merger agreement, any fact, event, change, effect, circumstance, occurrence or development that, individually or
in the aggregate, has had or would reasonably be expected to have a material adverse effect to Misonix, such fact, event, change, effect circumstance, occurrence or development will be given effect); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; covenants required to be complied with or performed at or prior to the effective time must have
been complied with and performed in all material respects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since the date of the merger agreement, there must not have occurred any effects that, individually or in the
aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a material adverse effect for Bioventus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix must have received a certificate, dated as of the closing date and executed by the Chief Executive
Officer or Chief Financial Officer of Bioventus, confirming that the conditions described in the preceding five bullets have been satisfied; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix must have received an opinion from Jones Day or other nationally recognized tax counsel reasonably
acceptable to Misonix, dated as of the closing date, to the effect that the mergers qualify for a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code at a level of comfort at least equivalent to the corresponding tax
opinion provided by such tax opinion counsel in the registration statement contained in Form <FONT STYLE="white-space:nowrap">S-4.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination of the Merger Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement
may be terminated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by mutual written consent of Bioventus and Misonix at any time prior to the effective time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix, if the merger has not been consummated at or prior to 11:59 p.m. New York City
time on January&nbsp;31, 2022, which is referred to as the &#147;end date&#148; (however, if all of the conditions to closing have been satisfied or waived or are capable of being satisfied at the relevant time other than any conditions to closing
that cannot be satisfied or waived due to a relevant legal restraint involving antitrust laws, the end date will be automatically extended to 11:59 p.m. on March&nbsp;31, 2022), provided, that a party will not be permitted to terminate the merger
agreement pursuant to this provision if the material breach by such party (or any affiliate of such party) of any of such party&#146;s obligation under the merger agreement will have materially contributed to the failure of the closing to have
occurred on or before the end date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix at any time prior to the effective time if a relevant legal restraint permanently
preventing, enjoining or making illegal the consummation of the mergers will have become final and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> provided, that the party seeking to terminate the merger agreement will have used reasonable
best efforts to prevent the entry of and to remove such relevant legal restraint in accordance with the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Bioventus at any time prior to Misonix obtaining its required stockholder approval, if the Misonix board has
made a change in recommendation or Misonix has willfully breached in any material respect the covenants applicable to it regarding <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> special meetings and changes in recommendation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Misonix at any time prior to Bioventus obtaining its required stockholder approval, if (a)&nbsp;the Bioventus
board has made a change in recommendation, (b)&nbsp;Bioventus has willfully breached in any material respect the covenants applicable to it regarding <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> special meetings and changes in
recommendation or (c)&nbsp;if Bioventus has materially breached its representations and warranties regarding financing and solvency under the merger agreement or its covenants regarding financing and financing cooperation under the merger agreement
(collectively referred to as the &#147;financing requirements&#148;) and (i)&nbsp;any such breach of the financing requirements is not cured by the earlier of the end date or prior to the twentieth business day after Misonix gives written notice of
such breach to Bioventus, (ii)&nbsp;all of the conditions, the satisfaction or waiver of which would be necessary to trigger the obligation of Bioventus to consummate the mergers (not including the condition related to the certificate to be provided
by Misonix), have been satisfied and continue to be satisfied (other than those conditions that by their nature cannot be satisfied other than at the closing), (iii) Misonix has irrevocably committed in a written notice delivered to Bioventus
following the expiration of the cure period specified above that Misonix is ready, willing and able to consummate the transactions contemplated by the merger agreement; provided, however, that, with respect to such conditions and Misonix&#146;s
readiness, willingness and ability to consummate the transactions contemplated by the merger agreement, any such condition will be deemed satisfied if the failure of such condition resulted primarily from (1)&nbsp;any action or inaction by
Bioventus, Merger Sub I or Merger Sub II, or (2)&nbsp;Bioventus&#146; breach of the financing requirements, and (iv)&nbsp;Bioventus, Merger Sub I or Merger Sub II fails to consummate the transactions contemplated by the merger agreement by the
earlier of the end date or within two business days following the written notice delivered by Misonix to Bioventus following the expiration of the cure period specified above; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Misonix, if prior to obtaining its required stockholder approval, (a)&nbsp;the Misonix board will have
authorized Misonix to enter into a definitive agreement relating to a superior proposal in material compliance with the merger agreement and (b)&nbsp;substantially concurrently with the termination of the merger agreement, Misonix enters into the
definitive agreement relating to a superior proposal and pays Bioventus the applicable termination fee pursuant to the merger agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix, if the approval by Misonix stockholders of the Misonix merger proposal has not
been obtained after a vote on approval of such proposal has been taken at the Misonix special meeting (including any postponement or adjournment thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either Bioventus or Misonix, if the approval by Bioventus stockholders of the Bioventus share issuance
proposal has not been obtained after a vote on approval of such proposal has been taken at the Bioventus special meeting (including any postponement or adjournment thereof); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Bioventus (i)&nbsp;if any of Misonix&#146;s representations and warranties contained in the merger agreement
are inaccurate such that the conditions to closing would not be satisfied or (ii)&nbsp;if Misonix has breached any covenant in the merger agreement and such breach (a)&nbsp;would result in the failure of a condition to closing, provided, that if an
inaccuracy in any of Misonix&#146;s representations and warranties or a breach of a covenant of Misonix is curable by Misonix by the end date and Misonix is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then
Bioventus may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach remains uncured for a period of thirty business days commencing on the date that Misonix receives written
notice of such inaccuracy or breach from Bioventus; provided, further, that Bioventus will not have the right to terminate the merger agreement pursuant to this paragraph if Bioventus is then in breach of any of its representations, warranties or
agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Misonix if: (i)&nbsp;any of Bioventus&#146;, Merger Sub I&#146;s or Merger Sub II&#146;s representations and
warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied; or (ii)&nbsp;any of Bioventus&#146; covenants contained in the merger agreement will have been breached such that the conditions
to closing would not be satisfied; provided, however, that for purposes of clauses (i)&nbsp;and (ii) above, if an inaccuracy in any of Bioventus&#146;, Merger Sub I&#146;s or Merger Sub II&#146;s representations and warranties or a breach of a
covenant of Bioventus is curable by Bioventus by the end date and Bioventus is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Misonix may not terminate the merger agreement under this paragraph on account
of such inaccuracy or breach unless such inaccuracy or breach remains uncured for a period of thirty business days commencing on the date that Bioventus receives written notice of such inaccuracy or breach from Misonix; provided, further, that
Misonix will not have the right to terminate the merger agreement pursuant to this paragraph if Misonix is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the
failure of a condition to closing. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Misonix Termination Fee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix will be obligated
to pay to Bioventus a termination fee of $20,661,000 in cash if the merger agreement is terminated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) by Misonix if prior to obtaining its required stockholder approval, (i)&nbsp;the Misonix board has authorized
Misonix to enter into a definitive agreement relating to a superior proposal and (ii)&nbsp;substantially concurrently with the termination of the merger agreement, Misonix enters into the definitive agreement relating to a superior proposal,
(b)&nbsp;by Bioventus at any time prior to Misonix obtaining its required stockholder approval, if the Misonix board has made a change in recommendation or Misonix has willfully breached in any material respect any covenant applicable to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
it regarding <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> special meetings and changes in recommendation, or (c)&nbsp;by either Bioventus or Misonix (x)&nbsp;if the merger has not
been consummated on or prior 11:59 p.m. New York City time on the end date and at the end date all of the conditions to Misonix&#146;s obligations to consummate the transactions other than receipt of its required stockholder approval have been
satisfied, or are capable of satisfaction had the closing occurred on the end date, or (y)&nbsp;due to the failure of Misonix to obtain approval by Misonix stockholders of the Misonix merger proposal, in each of the previous cases under
(c)&nbsp;above, at a time when Bioventus would have been entitled to terminate the merger agreement pursuant to (b)&nbsp;above; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) by either Bioventus or Misonix, if the approval by Misonix stockholders of the Misonix merger proposal has
not been obtained after a vote on approval of such proposal has been taken at the Misonix special meeting, (b)&nbsp;by Bioventus (i)&nbsp;if any of Misonix&#146;s representations and warranties contained in the merger agreement are inaccurate such
that the conditions to closing would not be satisfied or (ii)&nbsp;if Misonix has breached any covenant in the merger agreement and such breach would result in the failure of a condition to closing, or (c)&nbsp;by either Bioventus or Misonix, if the
merger has not been consummated on or prior 11:59 p.m. New York City time on the end date and at the end date all of the conditions to Misonix&#146;s obligations to consummate the transactions other than receipt of its required stockholder approval
have been satisfied, or are capable of satisfaction had the closing occurred on the end date, at a time when the merger agreement could have been terminated pursuant to (a)&nbsp;or (b) above, and: (x)&nbsp;at or prior to the Misonix special meeting
(in the case of a termination pursuant to (a)&nbsp;above), or at or prior to the time of the applicable breach by Misonix (in the case of a termination pursuant to (b)&nbsp;above), any person must have publicly announced an intention to make an
acquisition proposal involving Misonix, or such an acquisition proposal must have been publicly disclosed, publicly announced, commenced, submitted or made and must not have been publicly withdrawn without qualification at least five business days
prior to the date of the Misonix special meeting, in the case of a termination pursuant to (a)&nbsp;above, or the time of such breach, in the case of a termination pursuant to (b)&nbsp;above; and (ii)&nbsp;on or prior to the date that is twelve
months following the termination of the merger agreement, either (A)&nbsp;an acquisition transaction involving Misonix is consummated or (B)&nbsp;a definitive agreement relating to such an acquisition transaction is entered into by Misonix and the
transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this clause (B), each reference to 20% in the definition of &#147;acquisition transaction&#148; above will be deemed to be a reference to 50%).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The termination fee will be payable by Misonix only once and not in duplication even if the termination fee may be payable by Misonix
pursuant to more than one of the circumstances described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus Termination Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will be obligated to pay to Misonix a termination fee of $20,661,000 in cash if the merger agreement is terminated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) by Misonix at any time prior to Bioventus obtaining its required stockholder approval, if (i)&nbsp;the
Bioventus board has made a change in recommendation, (ii)&nbsp;Bioventus has willfully breached in any material respect the covenants applicable to it regarding <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> special meetings and changes
in recommendation or (iii)&nbsp;if Bioventus has materially breached the financing requirements, (b)&nbsp;by either Bioventus or Misonix (x)&nbsp;if the merger has not been consummated on or prior to close of business on the end date or (y)&nbsp;if
the approval by Bioventus stockholders of the Bioventus share issuance proposal has not been obtained after a vote on approval of such proposal has been taken at the Bioventus special meeting, in each of the previous cases under (b)&nbsp;above, at a
time when Misonix would have been entitled to terminate the merger agreement pursuant to (a)&nbsp;above; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) by either Bioventus or Misonix, if the approval by Bioventus stockholders of the Bioventus share issuance
proposal has not been obtained after a vote on approval of such proposal has been taken at the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Bioventus special meeting, (b)&nbsp;by Misonix if: (i)&nbsp;any of Bioventus&#146;, Merger Sub I&#146;s or Merger Sub II&#146;s representations and warranties contained in the merger agreement
are inaccurate such that the conditions to closing would not be satisfied; or (ii)&nbsp;any of Bioventus&#146; covenants contained in the merger agreement will have been breached such that the conditions to closing would not be satisfied or
(c)&nbsp;by either Bioventus or Misonix, if the merger has not been consummated on or prior 11:59 p.m. New York City time on the end date, at a time when the merger agreement could have been terminated pursuant to (a)&nbsp;or (b) above, and:
(x)&nbsp;at or prior to the Bioventus special meeting (in the case of a termination pursuant to (a)&nbsp;above), or at or prior to the time of the applicable breach by Bioventus (in the case of a termination pursuant to (b)&nbsp;above), any person
must have publicly announced an intention to make an acquisition proposal involving Bioventus, or such an acquisition proposal must have been publicly disclosed, publicly announced, commenced, submitted or made and may not have been publicly
withdrawn without qualification at least five business days prior to date of the Bioventus special meeting, in the case of a termination pursuant to (a)&nbsp;above, or the time of such breach, in the case of a termination pursuant to (b)&nbsp;above,
and (y)&nbsp;on or prior to the date that is twelve months following the termination of the merger agreement, either (A)&nbsp;an acquisition transaction involving Bioventus is consummated or (B)&nbsp;a definitive agreement relating to such an
acquisition transaction is entered into by Bioventus and the transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this clause (B), each reference to 20% in the definition of &#147;acquisition
transaction&#148; above will be deemed to be a reference to 50%). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A termination fee will be payable by Bioventus only once and not in
duplication even if the termination fee may be payable by Bioventus pursuant to more than one of the circumstances described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Termination Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except in the case of
fraud or in the case of intentional and material breach of the merger agreement, if a party receives a termination fee, then the receipt of the termination fee will be the receiving party&#146;s sole and exclusive remedy against the paying party,
its affiliates and its and their respective representatives in connection with the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement may be amended at any time prior to the effective time by an instrument in writing signed on behalf of each of the parties to the merger
agreement, except that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Bioventus share issuance proposal is approved, no amendment may be made which by applicable law or Nasdaq
regulation requires further approval of Bioventus stockholders without the further approval of such Bioventus stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Misonix merger proposal is approved, no amendment may be made which by applicable law or Nasdaq regulation
requires further approval of Misonix stockholders without the further approval of such Misonix stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise
provided in the merger agreement, any failure of any of the parties to comply with any obligation, covenant, agreement or condition therein may be waived by the party or parties entitled to the benefits thereof only by a written instrument signed by
the party granting such waiver. Any such waiver will not be applicable or have any effect except in the specific instance in which it is given. No failure on the part of any party to exercise any power, right, privilege or remedy under the merger
agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under the merger agreement, will operate as a waiver of such power, right, privilege or remedy. No single or partial exercise of any such power,
right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assignment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement is not assignable by any party to the merger agreement, in whole or in part, by operation of law or otherwise, without the express prior
written consent of the other parties thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third-Party Beneficiaries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus, Merger Sub I, Merger Sub II and Misonix have agreed that their respective representations and warranties set forth in the merger agreement are
solely for the benefit of the other parties thereto, in accordance with and subject to the merger agreement&#146;s terms. The merger agreement is not intended to, and does not, confer upon any person other than Bioventus, Merger Sub I, Merger Sub II
and Misonix and their respective successors, legal representatives and permitted assigns any rights or remedies, express or implied, thereunder, including the right to rely upon the representations and warranties set forth in the merger agreement,
except with respect to certain provisions (i)&nbsp;after the Second Effective Time, relating to payment of the merger consideration, any cash in lieu of fractional shares of Bioventus class A common stock, and any dividends or other distributions,
which provisions inure to the benefit of, and are enforceable by, holders of Misonix common stock and Misonix equity awards as of immediately prior to the effective time to the extent necessary to receive the consideration and amount due to such
persons thereunder, (ii)&nbsp;regarding indemnification of directors and officers of Misonix and (iii)&nbsp;intended for the benefit of certain entities that are debt financing sources in connection with the mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representations and warranties in the merger agreement are the product of negotiations among the parties. Any inaccuracies in such representations and
warranties are subject to waiver by the parties in accordance with the merger agreement without notice or liability to any other person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jurisdiction;
Specific Performance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Bioventus, Merger Sub I, Merger Sub II and Misonix has consented to the exclusive personal jurisdiction of the Delaware
Court of Chancery (or if the Delaware Court of Chancery does not have jurisdiction, any federal court within the State of Delaware) in any legal actions or proceedings relating to the merger agreement or any of the transactions contemplated thereby.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Bioventus, Merger Sub I, Merger Sub II and Misonix has also agreed that irreparable damage would occur in the event that any of the provisions of
the merger agreement were not performed or were threatened to be not performed, or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. Accordingly, and in addition to any other remedy that
each may be entitled to, Bioventus, Merger Sub I, Merger Sub II and Misonix have agreed that each will be entitled to an injunction or injunctions to prevent breaches of the merger agreement and to enforce specifically the terms and provisions of
the merger agreement (except that Misonix, its subsidiaries and respective representatives will not be able to seek specific performance in relation to the proposed debt financing in connection with the mergers). Each of Bioventus, Merger Sub I,
Merger Sub II and Misonix has also irrevocably waived any requirement for the securing or posting of any bond in connection with such injunctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_21"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 29, 2021, Bioventus, Misonix, Merger Sub I and Merger Sub II, entered into a merger agreement. The mergers contemplated by the merger
agreement will be implemented through the merger of Merger Sub I with and into Misonix, with Misonix becoming a wholly owned subsidiary of Bioventus, the first merger. Misonix will then merge with and into Merger Sub II with Merger Sub II as the
surviving limited liability company and will be Bioventus&#146; wholly owned subsidiary, the second merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2021, Bioventus closed
an Initial Public Offering (IPO) and the net proceeds were used to purchase membership interests from BV LLC. Bioventus is the sole managing member and owns 72.2% of BV LLC. Bioventus has a majority economic interest, the sole voting interest in,
and controls the management of BV LLC. As a result, Bioventus consolidates the financial results of BV LLC and reports a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest representing the 27.8% interest not held by Bioventus.
Bioventus&#146; amended and restated certificate of incorporation and the Bioventus LLC agreement requires that Bioventus and BV LLC at all times maintain a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT>
ratio between the number of shares of Class&nbsp;A common stock issued by Bioventus and the number LLC interests owned by Bioventus. As a result, after the second merger Bioventus will contribute the Merger Sub II assets to BV LLC resulting in
Bioventus owning 79.0% of BV LLC and a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest of 21.0%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma
condensed combined financial statements have been prepared to illustrate the estimated effects of the Bioventus IPO, the mergers and the financing required to complete the mergers (together, the Pro Forma Transactions). The unaudited pro forma
condensed combined statements of operations for the fiscal year ended December&nbsp;31, 2020 and for six months ended July&nbsp;3, 2021 combines the historical consolidated statements of operations of Bioventus and Misonix, giving effect to the Pro
Forma Transactions assuming they took place on January&nbsp;1, 2020. The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheets of Bioventus and Misonix as of July&nbsp;3, 2021 and June&nbsp;30,
2021, respectively, giving effect to the Pro Forma Transactions assuming they took place on July&nbsp;3, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma balance sheet data and pro
forma statement of operation data have been prepared utilizing period ends that differ by more than 93 days, as permitted by Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> Because Bioventus&#146; fiscal year end is December&nbsp;31 and
Misonix&#146;s fiscal year end is June&nbsp;30, the pro forma balance sheet data utilizes Misonix&#146;s audited consolidated balance sheet as of June&nbsp;30, 2021. The pro forma statement of operations data for the fiscal year ended
December&nbsp;31, 2020 were determined by adding Misonix&#146;s audited consolidated statement of operations for the fiscal year ended June&nbsp;30, 2020, subtracting Misonix&#146;s unaudited condensed consolidated statement of operations for the
six months ended December&nbsp;31, 2019 and adding Misonix&#146;s unaudited condensed consolidated statement of operations for the six months ended June&nbsp;30, 2021. The consolidated statement of operations of Misonix for the six months ended
July&nbsp;3, 2021 were determined by adding Misonix&#146;s audited consolidated statement of operations for the fiscal year ended June&nbsp;30, 2021 and subtracting Misonix&#146;s unaudited condensed consolidated statement of operations for the six
months ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are based on, and should be read in conjunction with
the historical audited consolidated financial statements of each of Bioventus and Misonix as of and for the year ended December&nbsp;31, 2020 and June&nbsp;30, 2021, respectively, as well as the Bioventus unaudited consolidated condensed financial
statements for the three and six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020 which are included in this joint proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the consolidated financial position or results of operations that would have been realized had the
mergers occurred as of the dates indicated, nor is it meant to be indicative of any future consolidated financial position or future results of operations that Bioventus will experience. The unaudited pro forma condensed combined financial
statements combine the historical consolidated statements of Bioventus and Misonix for the period on a pro forma basis along with the Pro Forma Transactions, summarized below. The pro forma adjustments included in the accompanying unaudited pro
forma condensed combined financial statements are based on currently available data and assumptions that management of Bioventus believes are reasonable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited pro forma condensed combined balance sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>As of July&nbsp;3, 2021 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Dollar amounts in thousands)
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Bioventus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Misonix</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Merger<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Financing<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>Interest<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 7)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 8)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,065</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,046</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(244,204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,248</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,155</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,029</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,350</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,379</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,020</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,752</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,662</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,434</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,943</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,087</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,060</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,267</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(238,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,273</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,058</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,960</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,253</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,213</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,135</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,235</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,041</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,411</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257,848</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,530</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424,470</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702,848</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,669</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,289</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,958</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Investments and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,483</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,967</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646,636</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,860</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,840</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,600</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,257,936</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,881</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,368</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,246</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,185</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,097</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(f</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,528</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(g</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,338</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,338</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current portion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,220</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,220</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,964</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,770</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(h</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,535</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,186</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,692</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,338</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,864</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Long-term debt, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,084</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,346</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(g</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,569</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334,653</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,410</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,388</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(n</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,871</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Contingent consideration, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,421</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,421</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,171</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,720</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">427,272</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,660</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,690</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,907</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">735,529</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(i</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Class&nbsp;B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,199</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,983</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,056</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(i</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(106,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">351,454</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,078</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(j</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; equity attributable to Bioventus</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,557</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,200</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,150</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(106,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337,816</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,784</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184,591</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,364</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,200</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,150</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">522,407</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646,636</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,860</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,840</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,600</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,257,936</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See Notes to the Unaudited Pro Forma Condensed Combined Financial Information. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited pro forma condensed combined statement of operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the year ended December&nbsp;31, 2020 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Dollar
amounts in thousands, except unit/share and per unit/share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>BV LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Misonix</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Offering<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Merger<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Financing<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>Interest<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 7)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 8)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,608</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388,769</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cost of sales (including depreciation and amortization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,642</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,967</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,939</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">(d</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">(k</P></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">)&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">)&nbsp;</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,548</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233,519</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,641</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253,221</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,078</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,395</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,044</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,512</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(k<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">(m</P></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,307</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">282,336</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,202</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,276</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(k</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,596</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,439</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,198</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,858</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,237</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Interest expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,751</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,563</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(l</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,418</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,525</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,323</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,554</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,418</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,088</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,914</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(n</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(f</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,087</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,776</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income (loss) attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,087</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accumulated unpaid preferred distribution</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income allocated to participating shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income attributable to Bioventus common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income (loss) per unit/share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.89</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(Note&nbsp;9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Weighted-average units/shares used to compute net income (loss) per unit/share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,044,744</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(Note&nbsp;9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,125,824</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See Notes to the Unaudited Pro Forma Condensed Combined Financial Information. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited pro forma condensed combined statement of operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the six months ended July&nbsp;3, 2021 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Dollar
amounts in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Bioventus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical<BR>Misonix</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Offering<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Merger<BR>adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Financing<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>Interest<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;7)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 8)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,032</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229,626</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cost of sales (including depreciation and amortization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,013</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"></P></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">(k</P></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,857</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,769</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,642</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(k</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,288</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(k</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,390</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,236</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,182</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Impairment of variable interest entity assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,674</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest (income) expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,731</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(l</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,818</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,429</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,580</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(n</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(f</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,871</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss) attributable to stock holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(Note&nbsp;9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,802,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,226,190</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(Note 9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,125,824</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bioventus per share information for the six months ended July&nbsp;3, 2021 represents loss per share of
Class&nbsp;A common stock and weighted-average shares of Class&nbsp;A common stock outstanding from February&nbsp;16, 2021 through July&nbsp;3, 2021, the period following Bioventus Inc.&#146;s IPO and related transactions described in the Bioventus
2020 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See Notes to the Unaudited Pro Forma Condensed Combined
Financial Information.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the unaudited pro forma condensed combined consolidated financial statements
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except unit, share, per unit and per share data) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of the mergers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger agreement
includes two mergers. After the first merger, each share of Misonix common stock issued and outstanding (Misonix Shares) immediately prior to the second merger will be converted into the right to receive $28.00 per share (Cash Election Shares) or
1.6839 shares of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Bioventus Class&nbsp;A common stock. If the settlement of the Cash Election Shares exceeds the maximum amount of cash consideration per share of $10.50 or
$182.8&nbsp;million, then a portion of the Cash Election Shares will be settled in Bioventus Class&nbsp;A common stock (Bioventus Shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
mergers, Bioventus will assume each outstanding and unexercised option held by a Misonix employee to purchase shares of Misonix common stock (Assumed Options), which will be converted into and exchangeable for options to Bioventus Shares according
to the option exchange ratio as defined in the merger agreement (Exchange Ratio). In the mergers, each outstanding option to purchase Misonix Shares will be cancelled and terminated without any payment. No fractional shares will be issued in
connection with the mergers and Bioventus will pay cash in lieu of any such fractional shares. For option holders which are not a Misonix employee, Bioventus will settle each outstanding and unexercised option to purchase Misonix Shares in cash.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma
condensed combined financial information has been prepared in accordance with Article 11, as amended by SEC Final Rule Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786,</FONT> Amendments to Financial Disclosures About Acquired and Disposed
Businesses. In accordance with Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786,</FONT> the unaudited condensed combined pro forma balance sheet and statements of operations reflect transaction accounting adjustments irrespective of
whether or not such adjustments is deemed to be recurring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information was prepared using the
acquisition method of accounting in accordance with Accounting Standards Codification (ASC) 805, Business Combinations, with Bioventus as the accounting acquirer. Under the acquisition method of accounting, the Misonix identifiable assets acquired,
and liabilities assumed are recognized and measured as of the acquisition date at fair value, defined in ASC 820, Fair Value Measurement, and added to those of Bioventus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial statements of Bioventus issued after the completion of the mergers may be different than the estimated values included in this unaudited pro forma
condensed combined financial information. The financial statements of Bioventus issued after the completion of the mergers will not be retroactively restated to reflect the historical financial position or results of operations of Misonix. In
addition, ASC 805 establishes that the consideration transferred be measured at the closing date of the mergers at the then-current share prices, which will likely result in a purchase price that is different from the amount assumed in these
unaudited pro forma condensed combined financial statements (see Note 4 Estimated preliminary merger consideration and preliminary purchase price allocation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC 805, acquisition-related transaction costs (such as advisory, legal, valuation, other professional fees) are included in the unaudited pro forma
condensed combined statement of operations. Such costs will be expensed in the historical consolidated statement of operations in the period incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 820 defines the term &#147;fair value&#148; and sets forth the valuation requirements for any asset or liability measured at fair value, expands related
disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as &#147;the price that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants at the measurement date.&#148; This is an exit price concept for the valuation of the asset or liability. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">addition, market participants are assumed to be buyers and sellers unrelated to the company in the principal
(or the most advantageous) market for the asset or liability. Fair value measurements for an asset assume the highest and best use by these market participants. As a result of these standards, Bioventus may be required to record assets which are not
intended to be used or sold and/or to value assets at fair value measures that do not reflect the intended use of those assets. Many of these fair value measurements can be highly subjective and it is also possible that others, applying reasonable
judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The allocation of the merger
consideration for the mergers depends upon certain estimates and assumptions, all of which are preliminary. The allocation of the merger consideration has been made for the purpose of developing the unaudited pro forma condensed combined financial
information. The final determination of fair values of assets acquired and liabilities assumed relating to the mergers could differ materially from the preliminary allocation of purchase consideration. The final valuation will be based on the actual
net tangible and intangible assets of Misonix existing immediately after the mergers. The final valuation may materially change the allocation of the merger consideration, which could materially affect the fair values assigned to the assets and
liabilities and could result in a material change to the unaudited pro forma condensed combined financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma adjustments
represent Bioventus management&#146;s best estimates and are based upon currently-available information and certain assumptions that Bioventus management believes are reasonable under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma information is not necessarily indicative of what the combined company&#146;s financial position or results of operations would have
been had the mergers been completed on the dates indicated. In addition, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the combined company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no material transactions between Bioventus and Misonix during the periods presented in the unaudited pro forma condensed combined financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Accounting policies and reclassification adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies used in the preparation of this unaudited pro forma condensed combined financial information are those set out in Bioventus&#146;
consolidated financial statements as of and for the year ended December&nbsp;31, 2020. Based on Bioventus management&#146;s assessment to date, the accounting policies of Misonix are similar in all material respects to Bioventus&#146; accounting
policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the mergers, Bioventus management will perform a comprehensive review of Misonix&#146;s accounting policies. The combined
company may, as a result, identify additional differences between the accounting policies of the two companies which, when conformed, could have a material impact on the combined consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the acquisition method of accounting, the identifiable assets acquired, and liabilities assumed of Misonix are recognized and measured as of the
acquisition date at fair value and added to those of Bioventus. The determination of fair value used in the transaction accounting adjustments presented herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix&#146;s fiscal year end is June&nbsp;30 while Bioventus&#146; is December 31. Bioventus management
utilized Misonix financials as filed with the SEC to prepare financial information for the six months ended July&nbsp;3, 2021 and the twelve months ended December&nbsp;31, 2020. In addition, certain reclassifications have been made to amounts in the
historical consolidated financial information of Misonix to conform to the Bioventus&#146; financial statement presentation, including reclassifying the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical&nbsp;as&nbsp;of<BR>June&nbsp;30,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reclassifications</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,267</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,267</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,253</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,253</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,235</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,235</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,740</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,530</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,289</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,289</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,860</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,860</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,185</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,185</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,185</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,449</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,770</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,770</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,692</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,692</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,346</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,346</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">763</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">786</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">763</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,660</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,660</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,200</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,200</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,860</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,860</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Twelve months ended December&nbsp;31, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>year&nbsp;ended<BR>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six<BR>months ended<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six<BR>months ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reclassifications</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>twelve moths<BR>ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,484</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,868</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,992</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,608</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,774</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,182</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,375</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,967</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,710</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,686</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,617</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,641</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,395</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,395</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,233</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,001</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,393</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,954</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,357</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,371</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,916</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,219</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,276</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,198</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,198</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,620</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">869</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,563</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,523</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">846</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,554</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six months ended July&nbsp;3, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR><BR><BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>For the<BR>year&nbsp;ended<BR>June&nbsp;30,<BR>2021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR><BR>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR><BR><BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>For the six<BR>months ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR><BR>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Reclassifications</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR><BR><BR><BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>For the<BR>six&nbsp;months<BR>ended<BR>July&nbsp;3,<BR>2021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR>&nbsp;<BR><BR>&nbsp;<BR>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,024</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,992</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,032</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,388</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,375</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,013</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,636</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,617</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,019</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,642</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,642</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,087</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,393</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,555</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,371</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,029</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,219</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,236</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,236</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,620</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,731</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,429</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Estimated preliminary merger consideration and preliminary purchase price allocation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of the merger consideration expected to be transferred on the closing date is calculated as follows based on the Misonix Shares and
Bioventus closing stock price on August&nbsp;26, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash election consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,410,045</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.50</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,805</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock election consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,322,984</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.39</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281,991</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">464,796</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated cash to settle Misonix debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,994</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,306</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total estimated preliminary merger consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517,509</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger consideration of $464.8&nbsp;million will be subject to change based on the Misonix Shares at the first merger, the
cash versus stock election by holders of the Misonix Shares as well as changes in the Bioventus closing stock price. Assuming the Misonix Shares remain at 17,410,045 and the cash cap of $10.50 per Misonix Shares is met the cash election
consideration would remain unchanged. The value of the stock election consideration will change based on fluctuations in the market price of Bioventus common shares since the right to receive 1.6839 shares of Bioventus Shares for each Misonix Share
is fixed. A 10% fluctuation in market price of Bioventus Shares would have the following potential effect on stock election consideration: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;election<BR>consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As presented</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.39</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">281,991</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10% increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.93</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">310,190</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10% decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.85</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">253,792</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total estimated preliminary merger consideration includes the value of the Assumed Options. The actual value of which will
be subject to change based on the final Exchange Ratio which is dependent upon the underlying market price of both the Bioventus and Misonix Shares. The options were valued at $8.51 per option using a Black-Scholes valuation model with the
assumptions shown in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.86</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price of stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected term of the options is estimated using the remaining time until expiration and estimated timing of exercise.
Expected volatility is based on the historical volatility of Bioventus&#146; peers common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term
of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming the option Exchange Ratio remains unchanged, a 10% fluctuation in market price of Bioventus Shares would have the following
potential effect on the value of the Assumed Options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assumed&nbsp;Options<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As presented</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.39</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,306</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10% increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.93</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,662</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10% decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.85</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,079</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following sets forth a preliminary allocation of the total estimated preliminary merger consideration to
the identifiable tangible and intangible Misonix assets acquired and liabilities assumed based on Misonix&#146;s consolidated balance sheet as of June&nbsp;30, 2021, with the excess recorded to goodwill: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,350</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,414</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,253</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,276</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">445,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644,858</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,768</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,461</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities assumed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,349</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517,509</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Goodwill represents the excess of merger consideration over the fair value of the underlying net assets
acquired. In accordance with ASC 350, Goodwill and Other Intangible Assets, goodwill will not be amortized but rather subject to annual impairment test, absent any indicators of impairment. Goodwill is attributable to planned growth in new markets
and synergies expected to be achieved from the combined operations of Bioventus and Misonix. Goodwill recorded in the mergers is not expected to be deductible for tax purposes. Bioventus management is still in the process of valuing any identifiable
intangible assets, to which the valuation may impact the final goodwill amount. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Offering adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2021, Bioventus closed an IPO. The unaudited pro forma condensed combined financial statements reflect the following adjustments related
to the IPO: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the IPO Bioventus granted new equity-based compensation awards to certain employees and
directors and launched its employee stock purchase plan. Accordingly this results in additional estimated equity compensation expense. In addition, during the six months ended July&nbsp;3, 2021, in advance of the IPO, Bioventus recognized a change
in fair value of accrued equity-based compensation resulting in a recovery of equity compensation expense. Adjustments to the statement of operations represents the following: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months<BR>Ended<BR>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,044</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of equity awards granted prior to IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,654</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,044</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,454</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of equity awards granted prior to IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,741</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,865</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the IPO an original LLC owner owned an Equity Participation Right Unit (EPR Unit). The EPR Unit was
redeemed in connection with the IPO, at which time the EPR ceased to exist and all entitlements ended. Accordingly interest expense related to the EPR unit of $0.6&nbsp;million was removed for the year ended December&nbsp;31, 2020. During the six
months ended July&nbsp;3, 2021, in advance of the IPO, Bioventus recognized a change in fair value of the EPR resulting in interest income totaling $2.8&nbsp;million which was also removed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax expense was adjusted to record the income tax impacts of the offering adjustments using an estimated
statutory tax rate of 25.1%. This rate does not reflect the combined company&#146;s effective tax rate, which includes other items and may be significantly different than the rates assumed for purposes of preparing these statements.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Merger adjustments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
unaudited pro forma condensed combined financial statements reflect the following adjustments related to the mergers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to cash represents the following: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash election consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(182,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated cash to settle Misonix debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for transaction costs expected to be incurred through the consummation of the
transactions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(244,204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fees directly related to this filing totaling $2.2&nbsp;million are estimated to be incurred by Bioventus and
are recorded against APIC. $9.5&nbsp;million in transaction costs are estimated to be incurred by Misonix and $7.7&nbsp;million incurred by Bioventus which are included in the pro forma condensed combined statement of operations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to acquired inventory, which consists primarily of raw materials and finished goods, at its
preliminary fair value. The preliminary fair value considers replacement cost for raw materials and for finished goods, the estimated selling price adjusted for costs of the selling effort and a reasonable profit allowance for the selling effort.
Bioventus will recognize the increased value of inventory in cost of goods sold as the inventory is sold, which for purposes of these unaudited pro forma condensed combined financial statements is assumed to occur within the first year after the
mergers. The cost of goods sold associated with the increased inventory value totaling $5.7&nbsp;million is included in the unaudited pro forma condensed combined statements of operations for the twelve months ended December&nbsp;31, 2020.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to eliminate Misonix&#146;s historical goodwill of $108.2&nbsp;million and to recognize goodwill
related to the proposed Combination of $155.3&nbsp;million. Goodwill is calculated as the difference between the estimated purchase price and the fair value of identifiable tangible and intangible assets acquired net of liabilities assumed. The
adjustment is preliminary and subject to change based upon final determination of the fair value of assets acquired and liabilities assumed and finalization of the purchase price. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to acquired intangible assets, consisting of intellectual property at its preliminary fair value,
and the required increase to historical Misonix amortization expense to the balances below. The estimated fair value was determined using an income approach, a valuation technique that estimates the fair value of an asset based on market participant
expectations of the cash flows that an asset would generate over its remaining useful life. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortization Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>July&nbsp;3, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired intangible assets<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cost of sales</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,250</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The adjustment to amortization expense was determined using the straight line method over the estimated useful
life of 20 years. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These preliminary estimates of fair value and estimated useful lives will likely differ from final amounts Bioventus
will calculate after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying unaudited pro forma condensed combined financial statements. With other assumptions held constant, a 10% change to the
fair value of acquired finite lived intangible assets would result in an increase or decrease to amortization expense of $1.9&nbsp;million annually and $1.0&nbsp;million for a six month period. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to eliminate $0.1&nbsp;million of historical deferred financing fee assets associated with
Misonix&#146;s historical revolving credit facility. The <FONT STYLE="white-space:nowrap">write-off</FONT> of the deferred financing fee is recorded against accumulated deficit solely for the purposes of this presentation. As there is no continuing
impact of the <FONT STYLE="white-space:nowrap">write-off</FONT> on the combined company&#146;s results, the debt deferred financing fee is not included in the unaudited pro forma condensed combined statements of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to accrue for severance and change of control payments totaling $1.7&nbsp;million for the certain
Misonix employees partially offset by $0.4&nbsp;million of accrued interest and $0.2&nbsp;million of accrued exit fees associated with Misonix&#146;s historical debt obligations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to extinguish Misonix&#146;s outstanding debt obligations of $40.6&nbsp;million. The cash to be paid
for the extinguishment of Misonix&#146;s outstanding debt obligations totaled $42.0&nbsp;million as described in Note 4. The difference between the cash to be paid and the carrying amount represents the loss on debt extinguishment from the
prepayment penalties of $0.8&nbsp;million, $0.4&nbsp;million in accrued interest and $0.2&nbsp;million of accrued exit fees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to remove Misonix&#146;s outstanding loan under the Paycheck Protection Program of $5.2&nbsp;million
as it is expected to be forgiven. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to remove Misonix historical common stock and APIC, issuance of stock election consideration, as
well as Assumed Options: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>APIC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elimination of historical balance<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(188,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of stock election
consideration<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281,972</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed Options<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registration expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,056</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the elimination of Misonix&#146;s APIC balance at June&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the additional APIC value of the shares issued in connection with the mergers. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the fair value of the Assumed Options. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustments to eliminate Misonix&#146;s historical accumulated deficit balance and Bioventus transaction fees
totaling $7.7&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to share-based compensation expense for the acceleration of Misonix&#146;s unvested stock
compensation awards and awards granted to the two additional board members. These increases were partially offset by the removal of historical Misonix share-based compensation expense for each of the unaudited pro forma condensed combined statements
of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to eliminate the historical interest expense associated with Misonix&#146;s historical debt
obligations for each of the unaudited pro forma condensed combined statements of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to add Misonix and Bioventus transaction costs totaling $17.2&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The mergers will qualify as a reorganization within the meaning of Section&nbsp;368(a) of the Code. Deferred
tax liability was adjusted to reflect the estimated deferred tax impacts related to acquisition accounting adjustments primarily as a result of the <FONT STYLE="white-space:nowrap">step-up</FONT> in fair value of intangible assets and inventory. The
incremental deferred tax impacts were calculated based on the tax effect of the estimated <FONT STYLE="white-space:nowrap">step-up</FONT> in book basis of the net assets of Misonix using an estimated statutory tax rate of 25.1%. Tax expense was
adjusted to record the income tax impacts of the merger adjustments using the same rate. This rate does not reflect the combined company&#146;s effective tax rate, which includes other items and may be significantly different than the rates assumed
for purposes of preparing these statements. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Financing adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance the mergers, Bioventus intends to consummate the following transactions: (i)&nbsp;borrowing of $262.0&nbsp;million in incremental term
loans as allowed in the existing Bioventus credit agreement and (ii)&nbsp;pay $80.0&nbsp;million on the outstanding historical term loans under the existing Bioventus credit agreement (Debt Transactions). The unaudited pro forma condensed combined
financial statements reflect the following adjustments related to the financing, the proceeds of which were used in part to fund the mergers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to cash represents the following as of July&nbsp;3, 2021: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts borrowed under the Term Loan Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment on Bioventus outstanding historical term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for fees related to the Term Loan Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,752</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,248</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to debt represents the following: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current portion of long-term debt:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record current portion of the Term Loan
Facility<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,338</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Long-term debt, less current portion:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record noncurrent portion of the Term Loan
Facility<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249,663</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment on Bioventus outstanding historical term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing fees related to the Term Loan Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total adjustment to long-term debt, less current portion</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,569</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Term Loan Facility, Bioventus is required to repay the amounts borrowed under the
Term Loan Facility and the existing debt after the $80.0&nbsp;million payment in quarterly installments of 1.875% of the total principal amount through December&nbsp;31, 2022 and quarterly installments of 2.5% of the total principal amount through
the maturity date, at which time the remaining principal balance will be due. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to record the new deferred financing fee asset of $0.3&nbsp;million associated with the Term Loan
Facility and allocated to the revolver. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to record the financing fees not eligible for deferral totaling $1.3&nbsp;million associated with
the Term Loan Facility. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adjustment to interest expense consists of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months<BR>ended<BR>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eliminate historical Bioventus interest expense on long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense on long-term debt subsequent to the Debt Transactions<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,010</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in amortization of the original issue discount and certain deferred financing fees<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,418</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Comprised of interest expense related to on long-term debt subsequent to the Debt Transactions. The weighted
average cash interest rate, calculated including the effects of quarterly principal payment, is approximately 1.83%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the original issue discount (OID) as well as certain fees paid to third parties for their services
in arranging and structuring the financing. The OID and deferred financing fees are amortized using the straight line method which approximates the effective interest method </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A 0.125% change in the estimated interest rates on the variable rate indebtedness of $364.5&nbsp;million at the closing of the Debt
Transactions, would result in an increase or decrease in the pro forma interest expense of approximately $0.5&nbsp;million for a twelve month period and $0.2&nbsp;million for a six month period. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax expense was adjusted to record the income tax impacts of the offering adjustments using an estimated
statutory tax rate of 25.1%. This rate does not reflect the combined company&#146;s effective tax rate, which includes other items and may be significantly different than the rates assumed for purposes of preparing these statements.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Noncontrolling interest adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the Bioventus 2020 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> following the completion of the IPO and and other
transactions on February&nbsp;16, 2021, Bioventus owned 72.2% of BV LLC with a noncontrolling interest of 27.8%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus LLC Agreement requires
that Bioventus, at all times, maintain a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Bioventus Class&nbsp;A common stock issued and LLC interests owned by
Bioventus. As a result, the issuance of Bioventus Class&nbsp;A common stock in connection with the mergers will decrease the noncontrolling interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
computation of the noncontrolling interest before and after the mergers are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BV LLC interest held by Bioventus Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,062,652</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,385,636</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BV LLC noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,849,389</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,172,373</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma noncontrolling interest as of July&nbsp;3, 2021 is computed as follows by adjustment:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BV&nbsp;LLC&nbsp;noncontrolling<BR>interest after mergers</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro forma<BR>noncontrolling<BR>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Bioventus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,807</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in Misonix</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517,509</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bioventus transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing fees expensed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">508,495</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">21.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">106,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184,591</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma net loss (income) attributable to noncontrolling interest for the twelve months ended
December&nbsp;31, 2020 is computed as follows by adjustment: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BV LLC<BR>noncontrolling<BR>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;forma&nbsp;loss&nbsp;(income)<BR>attributable to<BR>noncontrolling interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical BV LLC loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical BV LLC net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Misonix net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,461</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,086</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,775</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma net loss (income) attributable to noncontrolling interest for the six months ended July&nbsp;3,
2021 is computed as follows by adjustment: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BV LLC<BR>noncontrolling<BR>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;forma&nbsp;loss&nbsp;(income)<BR>attributable to<BR>noncontrolling interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Bioventus loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,062</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical BV LLC net income prior to IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,977</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,469</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Misonix net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,728</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,809</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,871</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Combined company earnings per share information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted pro forma loss per share of the combined company&#146;s Class&nbsp;A common stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months<BR>ended<BR>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator for basic and diluted earnings per share calculation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,776</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,871</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss attributable to the combined company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for basic and diluted earnings per share calculation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average Bioventus&#146; outstanding common stock<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,802,840</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,802,840</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock issued in connection with the mergers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,322,984</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,322,984</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares (basic and diluted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,125,824</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,125,824</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Weighted-average shares of Bioventus Class&nbsp;A common stock outstanding, basic and diluted as of
July&nbsp;3, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Bioventus Class&nbsp;B common stock do not share in the losses of the Company and are therefore not
participating securities. As such, separate presentation of basic and diluted losses per share of Class&nbsp;B common stock under the <FONT STYLE="white-space:nowrap">two-class</FONT> method has not been presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potential shares of Bioventus common stock that were excluded from the computation of diluted net loss per share attributable to combined company common
stockholders for the periods presented, because including them would have been anti-dilutive, are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BV LLC noncontrolling interest <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,398,979</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">951,911</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares of Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,698</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,172,325</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Class&nbsp;A Shares reserved for future issuance upon redemption or exchange of LLC interests not held by
Bioventus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_22"></A>DESCRIPTION OF BIOVENTUS&#146; BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial public offering and organizational transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2021, Bioventus closed an initial public offering (IPO) of 9,200,000 shares of its Class&nbsp;A common stock at a public offering price of
$13.00 per share, which included 1,200,000 shares issued pursuant to the underwriters&#146; over-allotment option. Bioventus received $111.2&nbsp;million in proceeds, net of underwriting discounts and commissions, which Bioventus used to purchase
newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of its Class&nbsp;A common stock of $13.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a
holding company with no direct operations and its principal asset is the equity interest in BV LLC. In connection with the IPO, Bioventus completed a series of organizational transactions including, without limitation, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited liability company agreement of BV LLC was amended and restated (Bioventus LLC agreement) to, among
other things, (i)&nbsp;provide for a new single class of common membership interests in BV LLC (LLC interests), (ii) exchange all of the then existing membership interests of the holders of BV LLC membership interests (original LLC owners) for LLC
interests and (iii)&nbsp;appoint Bioventus Inc. as the sole managing member of BV LLC; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>the acquisition, by merger, of certain members of BV LLC (former LLC owners), for which Bioventus issued
31,838,589 shares of Class&nbsp;A common stock as merger consideration (Merger). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to <I>Note 4 Subsequent events</I> in the
&#147;Notes to the Audited Consolidated Financial Statements&#148; included in this joint proxy statement/prospectus for more information about the above-mentioned transactions as well as the other transactions completed in connection with the IPO
(Transactions). Following the completion of the Transactions, Bioventus owned 72.2% of BV LLC. Smith&nbsp;&amp; Nephew, Inc. (continuing LLC owner) owned the remaining 27.8% of BV LLC. Bioventus has a majority economic interest, the sole voting
interest in, and control the management of, BV LLC. As a result, Bioventus will consolidate the financial results of BV LLC and will report a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest representing the LLC interests held by the
continuing LLC owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus
is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#146;s natural healing process. Bioventus&#146; devices are
most often used to delay or replace the need for an elective surgical procedure and are focused on reaching patients early on in their treatment paradigm. The Company is headquartered in Durham, North Carolina. Bioventus has administrative
facilities in the United States (U.S.), Canada, and the Netherlands, and a manufacturing facility in the U.S. Bioventus directly distributes products in the U.S., Canada, United Kingdom (U.K.), Germany and the Netherlands. In several of these and
other markets, Bioventus also distributes its products through independent distributors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus believes its
<FONT STYLE="white-space:nowrap">non-invasive</FONT> medical device and biologic products play a critical role in supporting the body&#146;s own healing mechanisms to heal or eliminate the pain caused by orthopedic conditions and problems, which
Bioventus defines as its active healing products. These products address an estimated $6.0&nbsp;billion market opportunity across pain treatment and joint preservation, spinal fusion surgery and bone fractures, each of which is experiencing growth
through multiple industry tailwinds, including an aging population, increased participation in sports and active lifestyles and a rise in obesity rates. Bioventus&#146; devices are most often used to delay or replace the need for an elective
surgical procedure and are focused on reaching patients early on in their treatment paradigm. Bioventus&#146; products are widely reimbursed by both public and private health insurers and are sold in the physician&#146;s office or clinic, in
ambulatory surgical centers (ASCs), and in the hospital setting in the U.S. and across 37 countries. Bioventus manages its business by its two reporting segments, U.S. and International which accounted for 91% and 9%, respectively, of its total net
sales during the fiscal year ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2020. Financial information regarding its reportable business segments and certain geographic information is included in &#147;Bioventus&#146;<I> </I>Management&#146;s
Discussion and Analysis&#148;<I> </I>of this joint proxy statement/prospectus. See also <I>Note 15. Segments</I> in the &#147;Notes to the Audited Consolidated Financial Statements&#148; included in this joint proxy statement/prospectus for further
information regarding its business segments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; existing portfolio of products is grouped into three verticals based on its targeted
customer focus. These verticals were updated and renamed after completing the acquisition of Bioness as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pain Treatments and Joint Preservation</B>. Bioventus is the largest pure play orthopedics-focused company in
the pain treatment and joint preservation market. Bioventus has been the fastest growing hyaluronic acid (HA) participant over the last three years, driving its share to number two by revenue in the U.S. market. Bioventus offers the only complete
portfolio of HA viscosupplementation therapies, including single, three and five injection regimens, for patients experiencing pain related to OA in the knee. Bioventus&#146; HA products are all approved by the U.S. Food and Drug Administration
(FDA) through premarket approvals (PMAs), and include: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Durolane, a single injection therapy, was launched in the United States in 2018 and is also marketed outside
the United States in more than 30 countries including Europe through a CE mark, which is an abbreviation for Conformit&eacute; Europ&eacute;enne or European Conformity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">GELSYN-3,</FONT> a three injection therapy, was launched in the United States
in 2016; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SUPARTZ FX, a five injection therapy, was launched in the United States in 2001; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">STIMROUTER, a peripheral nerve stimulation product offered through Bioness. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Bone Graft Substitutes.</B> Bioventus is the fastest growing participant in the bone graft substitutes (BGSs)
market and offer a broad portfolio of products including human tissue allografts and synthetics. Bioventus&#146; BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion
rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient&#146;s own bone, which is associated with additional cost and morbidity. Bioventus&#146; products include an allograft-derived bone graft with
growth factors (OsteoAMP), a demineralized bone matrix (DBM) (Exponent), a cancellous bone in different preparations (PureBone), bioactive synthetics (Signafuse and Interface), a collagen ceramic matrix (OsteoMatrix) and two bone marrow isolation
systems (CellXtract and Extractor). Bioventus&#146; products have received either 510(k) clearance from the FDA or are marketed pursuant to Section&nbsp;361 of the Public Health Service Act (PHSA) as Section&nbsp;361 HCT/Ps. HCT/Ps regulated solely
under Section&nbsp;361 are human cells, tissues and cellular and tissue-based products that do not require marketing authorization to be marketed in the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Restorative Therapies.</B> This vertical consists of products from Bioventus&#146; previous &#147;minimally
invasive fracture treatments&#148; vertical and Bioness&#146; advanced rehabilitation products. Bioventus&#146; Exogen system was the number one prescribed device in the bone growth stimulatory market in 2018 (the latest period for which data is
available). It has had marketing authorization via a PMA through the FDA for over 25 years. Bioventus is the only company to utilize advanced, pulsed ultrasound technology for bone growth in delayed and nonunion fractures in all fracture locations
except spine, as well as in fresh fractures of the tibia and radius. Bioventus&#146; Exogen system offers significant advantages over electrical based long bone stimulation systems, including a documented mechanism of action, shorter treatment times
and superior nonunion heal rates. The system is also sold internationally under a CE mark for nonunions and fresh fractures and is the market-leading bone healing treatment in the delayed union and nonunion market in Japan. Bioness&#146; advanced
rehabilitation products include the L300 GO, which is a device that applies electrical stimulation to a patient&#146;s leg to restore a patient&#146;s normal walking gait and the Bioness Integrated Therapy System for Balance or &#147;BITS&#148;,
which uses proprietary hardware and software programs to track movements, allowing clinicians to assess and tract patient balance throughout the restorative treatment continuum. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the measures imposed to contain the spread
of the virus disrupted its business beginning in early March 2020 as healthcare systems across the U.S. were forced to limit patient visits and elective surgical procedures. The effects of the pandemic began to decrease in late April 2020 and
Bioventus saw a very strong recovery for its products at the end of the second quarter as restrictions on orthopedic procedures were lifted across the United States and patients also returned to orthopedic offices. Refer to the information under<I>
</I>&#147;Risk Factors&#148; and &#147;Bioventus&#146;<I> </I>Management&#146;s Discussion and Analysis&#148;<I> </I>for more information regarding the impact and related risks of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus&#146; growth strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus
intends to pursue the following strategies to build a market-leading and customer-focused company centered on the pain treatment and joint preservation, BGSs and restorative therapies, and to continue to grow its net sales and Adjusted EBITDA: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to expand market share in HA viscosupplementation</B>. Bioventus intends to increase sales of its HA
viscosupplementation therapies and extend its market leadership in this category by building on its unique positioning as the only company to offer a one, three and five injection treatment regimen and by expanding payer coverage, which Bioventus
has done successfully, increasing the number of lives under contract from 6&nbsp;million to 48&nbsp;million between 2017 and 2020. This increase in lives, along with its differentiated portfolio and dedicated direct sales team, has allowed Bioventus
to achieve significant market share gains over the last several years and positioned Bioventus as the largest pure play orthopedic-focused company in the U.S. HA viscosupplementation market with a market share of approximately 17% as of
September&nbsp;26, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Introduce new pain treatment and joint preservation products.</B> To expand its offering beyond HA
viscosupplementation therapies and build a comprehensive portfolio for the pain treatment and joint preservation, Bioventus is planning to commercially launch a range of new therapies over the next several years, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Agili-C.</FONT></B> An <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> aragonite implant designed for implantation into osteochondral defects in the knee. The <FONT STYLE="white-space:nowrap">Agili-C</FONT> implant received breakthrough device designation by the
FDA in the fourth quarter of 2020. Bioventus has an option to acquire 100% of CartiHeal&#146;s shares pursuant to the terms and subject to the conditions set forth in the Option and Equity Purchase Agreement and as described above. See
&#147;Description of Bioventus&#146; Business&#151;Development and Clinical Pipeline&#151;Treatment of Cartilage for Osteochondral defects&#151;CartiHeal (developer of <FONT STYLE="white-space:nowrap">Agili-C)</FONT> investment and option and equity
purchase agreement.&#148; CartiHeal submitted the <FONT STYLE="white-space:nowrap">non-clinical</FONT> module of the PMA in January 2021 and expects to submit the final, clinical module of a Modular PMA in the fourth quarter of 2021 seeking FDA
approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MOTYS.</B> A placental tissue injectable biologic for knee OA, for which on October&nbsp;29, 2020, Bioventus
received FDA confirmation indicating its authorization of its investigational new drug application (IND), and a clinical trial for MOTYS has commenced in the first quarter of 2021. In parallel, Bioventus plans to pursue a required BLA premarket
approval for this product, which Bioventus expects would expand insurance payment alternatives over time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROcuff.</B> A <FONT STYLE="white-space:nowrap">bio-inductive</FONT> collagen implant for regeneration of
tendon tissue in the rotator cuff. Bioventus expects to file a request for 510(k) clearance in either the second or third quarter of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Further develop and commercialize its BGS portfolio.</B> Bioventus intends to grow its presence in the BGS
market and expand its reach into the operating room in both ASCs and hospitals. In the near-term, Bioventus plans to maintain and selectively expand its profitable product lines by adding to its U.S. distributor base in an effort to reach
significantly underpenetrated markets. Over time, Bioventus intends to launch product line enhancements and invest in the development of next-generation BGS therapies to continue to grow its market share. Consistent with this strategy, Bioventus
recently launched the Signafuse Bioactive Strip and OsteoAmp Flowable products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand indications for use for its Exogen system</B>. Bioventus is focused on generating incremental clinical
data and peer-reviewed publications to expand its indications and continue to grow its market leading share. Bioventus is currently underway with the B.O.N.E.S. clinical studies, which are aimed at generating data to support label expansion in
additional bone types and expanded reimbursement for the treatment of fresh fractures in patients at risk of nonunion due to certain comorbidities, such as diabetes or obesity. Bioventus commenced patient enrollment to study three specific bones in
2017 and began a rolling release of data in late 2020. Depending on the results from its studies, Bioventus plans to submit a total of three PMA supplements to the FDA, the first of which was submitted in December 2020 seeking approval for the
adjunctive treatment of acute and delayed metatarsal fractures to reduce the risk of <FONT STYLE="white-space:nowrap">non-union.</FONT> Bioventus plans to submit the second PMA supplement in the second quarter of 2022 and the third PMA supplement in
the second half of 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Invest in research and development.</B> Bioventus is focused on internal research and development to broaden
its portfolio of therapies for pain treatment and joint preservation, expand its Exogen system product label and undertake clinical research to support commercialization of its next-generation of BGS products. Bioventus sees significant opportunity
to develop innovative and clinically differentiated products internally with its qualified research and development team. Bioventus relies on a team of 40 highly trained individuals to develop new products, conduct clinical investigations and help
educate health care providers using its products. Bioventus&#146; research and development team is comprised of 13 members holding PhDs and 18 members with more than 20 years of experience in the medical device industry. Bioventus collaborates with
academic centers of excellence, leading contract research organizations and other industrial groups to complement and expedite execution of its research and development programs and minimize fixed costs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue business development opportunities.</B> Consistent with its track record of pursuing investments.
partnerships and acquisitions including those with respect to MOTYS, PROcuff and CartiHeal, Bioventus intends to continue to pursue business development opportunities that leverage its significant customer presence across orthopedics, broaden its
portfolio and increase its global footprint. Bioventus will continue to search for clinically differentiated and cost-effective products and technologies that also balance its portfolio in terms of risk and time to market. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically grow its international markets.</B> Bioventus intends to focus its international business on
markets where its existing portfolio can maintain profitable growth over time, either through direct or distributor based channels. For example, Bioventus launched OsteoAMP in Canada in 2020, where Durolane and Exogen had a market leading presence
in 2016. Bioventus plans to selectively expand to new markets with Durolane, Exogen and its BGSs and intend to pursue further opportunities in the Asia Pacific markets. In particular, China represents an attractive and exciting market given its
large and aging population as well as its rising middle class. Bioventus has added management in China and will be creating a legal entity as Bioventus seeks approval from the China Food and Drug Administration for Durolane, which Bioventus believes
will be facilitated by the successful completion of its Chinese randomized controlled trial (RCT). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cartiheal </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;27, 2021, the Bioventus
board, after its review of the statistical report for CartiHeal&#146;s pivotal clinical trial and determination that the results of the statistical report indicated a Pivotal Clinical Trial Success (as contemplated by the Option and Equity Purchase
Agreement), approved BV LLC and its affiliates&#146; continued pursuit of a potential acquisition of CartiHeal. The report was delivered in connection with the Option and Equity Purchase Agreement entered into on July&nbsp;15, 2020, by and among BV
LLC and CartiHeal (2009)&nbsp;Ltd., a privately-held company headquartered in Israel and the developer of the proprietary <FONT STYLE="white-space:nowrap">Agili-C</FONT><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> implant for the
treatment of joint surface lesions in traumatic and osteoarthritic joint, and its shareholders. The agreement provides BV LLC with an exclusive option to acquire 100% of CartiHeal&#146;s shares under certain conditions, or the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#146;s shares under certain conditions, or the Put Option. The Put Option is only
exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <FONT STYLE="white-space:nowrap">Agili-C</FONT> device with a label consistent in all respects with pivotal
clinical trial success. BV LLC and its affiliates thereafter deposited $50.0&nbsp;million in escrow in accordance with the terms of the Option and Equity Purchase Agreement. The closing of the transaction is subject to, among other things (including
customary closing conditions), the valid exercise of the Call Option or the Put Option, the latter of which cannot be exercised unless and until premarket approval (PMA) by the Food and Drug Administration (FDA) is received with respect to the <FONT
STYLE="white-space:nowrap">Agili-C</FONT> implant, which was granted Breakthrough Device Designation by the FDA last year. CartiHeal plans to submit the clinical module of their PMA later this year, and the decision from the FDA is expected in the
second half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioness </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;30, 2021, Bioventus completed the acquisition of Bioness, a global leader in neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation (&#147;PNS&#148;) therapy and premium rehabilitation
solutions, for $45&nbsp;million in <FONT STYLE="white-space:nowrap">up-front</FONT> consideration, with up to $65&nbsp;million of contingent consideration related to the achievement of certain key milestones. The acquisition includes the entire
portfolio of Bioness products as well as its research and development pipeline. Under the merger agreement, Bioness has become a wholly-owned indirect subsidiary of Bioventus, and all Bioness employees have become employees of Bioventus. The <FONT
STYLE="white-space:nowrap">up-front</FONT> consideration was funded exclusively through the use of cash on hand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus&#146; products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus offers a diverse portfolio of active healing products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint
reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery, in the physician&#146;s office or clinic, ASCs or in the hospital setting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; portfolio of products is grouped into three verticals based on clinical use: (i)&nbsp;pain treatment and joint preservation, (ii)&nbsp;BGSs
and (iii)&nbsp;restorative therapies (formerly, minimally invasive fracture treatments). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pain treatments and joint preservation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Knee OA is a degenerative condition that is chronic in nature and is characterized by gradual breakdown and destruction of the cartilage in the knee. This
condition develops over years and is often found in patients who exhibit joint malalignment, have had a joint injury, or are overweight. The disease can involve joint inflammation and results in symptoms that include redness, warmth, swelling,
stiffness, tenderness, limited range of motion and pain. As the condition advances, the knee joint gradually loses cartilage tissue and the cartilage layer attached to the bone deteriorates to the point where eventually the bone becomes exposed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has the only complete one, three and five injection portfolio in the HA viscosupplementation market in the United States with Durolane, <FONT
STYLE="white-space:nowrap">GELSYN-3</FONT> and SUPARTZ FX. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Regulatory&nbsp;pathway</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Region&nbsp;where&nbsp;marketed<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g09d44.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Single injection HA</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">viscosupplementation therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;PMA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Device&nbsp;approval by Health Canada</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;CE mark and
other&nbsp;registrations<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;United&nbsp;States</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Canada</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Europe</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Regulatory&nbsp;pathway</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Region&nbsp;where&nbsp;marketed<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g09f66.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Three injection HA</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">viscosupplementation therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;PMA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;United&nbsp;States</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g09f66.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Five injection HA</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">viscosupplementation therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;PMA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;United&nbsp;States</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bioventus maintains exclusive distribution agreements with respect to Durolane,
<FONT STYLE="white-space:nowrap">GELSYN-3</FONT> and SUPARTZ FX in the United States. Bioventus maintains exclusive distribution agreements and own certain assets with respect to Durolane outside the United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Durolane is also approved for marketing in Argentina, Australia, Brazil, Columbia, India, Indonesia, Jordan,
Malaysia, Mexico, New Zealand, Russia, Switzerland, Taiwan, Turkey and the United Arab Emirates (UAE). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Single Injection Therapy
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durolane is a sterile, transparent and viscoelastic gel that is a single injection therapy that is indicated for the symptomatic treatment of OA in
the knee in the United States. Durolane is also indicated for the hip, ankle and shoulder, as well as for treatment of other small orthopedic joints outside the United States. Durolane contains high levels of HA and is injected directly into the
joints affected by OA to relieve pain and restore lubrication and cushioning. This may improve joint function and help to potentially avoid or delay knee replacement surgery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Physicians administer Durolane to the affected knee joint in a single injection and it has been observed to provide a benefit for pain reduction in patients
with OA in the knee for up to 26 weeks. Durolane&#146;s injection schedule results in economic advantages and greater patient convenience and compliance compared to other HA viscosupplementation therapies which require weekly injections over a
period of three to five weeks. For example, Bioventus believes that changes in physician visiting patterns, as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, have led to increased preference for single injection
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durolane is highly purified and based upon a natural and patented <FONT STYLE="white-space:nowrap">non-animal</FONT> stabilized HA (NASHA),
expanding use to patients who are allergic to animal derived solutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of major <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
single injection HA viscosupplementation therapies </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Product</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B></B><I>Manufacturer
or</I><B></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B></B><I>distributor</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Source and process</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Active ingredient /</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>treatment dosage</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Duration</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g180330g09d44.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Bioventus</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA&nbsp;of&nbsp;the&nbsp;knee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Non-animalstabilized</FONT> HA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>NASHA / (60 mg)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Synvisc-One</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Sanofi S.A.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Animal sourced Hylan A and Hylan B polymers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Hylan <FONT STYLE="white-space:nowrap">G-F</FONT> 20 / (48&nbsp;mg)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Monovisc</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>DePuy Orthopaedics,
Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Non-animal</FONT> cross-linked sourced HA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>2.2% sodium hyaluronate / (88 mg)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Gel-One</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Zimmer Biomet Holdings, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Animal sourced HA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>1.0% sodium hyaluronate /(30 mg)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Three months</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Durolane clinical data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durolane&#146;s proprietary stabilizing technology substantially extends the amount of time it remains in the joint. Multiple studies have been conducted to
determine Durolane&#146;s half-life, which is the amount of time needed for 50% of the injected material to be broken down and excreted from the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
one study, Durolane&#146;s half-life in the joint was studied in a rabbit model. Results showed the Durolane remained in the joint with an observable half-life of 32 days, substantially longer than the half-lives of Synvisc and unmodified HA, as
determined in comparable studies, which were 1.5 days and less than 1 day, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The long half-life of Durolane was also observed in the 2002
Lindqvist et al. human study where six healthy volunteers were given a single injection of Durolane that contained a radioactive isotope that could be traced, allowing scientists to measure Durolane&#146;s elimination from the body over time. The
results showed a <FONT STYLE="white-space:nowrap">30-day</FONT> half-life, indicative of the expected long residence time in the joint due to Durolane&#146;s proprietary stabilizing technology and preclinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In terms of efficacy, Durolane has been directly compared against the main intra-articular therapeutic options available for managing osteoarthritic pain:
SUPARTZ FX, a five injection product, Synvisc One, a single injection product and methylprednisolone acetate, an intra-articular corticosteroid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a
multi-center randomized, blinded, controlled trial of 349 patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mild-to-moderate</FONT></FONT> knee OA, Durolane was compared with SUPARTZ FX. This 2015 Zhang et al. study
concluded that one injection of Durolane was <FONT STYLE="white-space:nowrap">non-inferior</FONT> to five weekly injections of SUPARTZ FX in terms of pain, stiffness, physical function and global self-assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In an independent, investigator-initiated randomized, controlled study involving 213 patients with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mild-to-moderate</FONT></FONT> knee OA, Durolane was further compared to <FONT STYLE="white-space:nowrap">Synvisc-One.</FONT> After following up with the patients over a span of 12 months following the treatment, the
results from this 2013 McGrath et al. study showed that Durolane produced significantly more durable pain relief effects than <FONT STYLE="white-space:nowrap">Synvisc-One,</FONT> while also providing longer-lasting improvements in range of motion
and a reduction in the use of pain medication for study participants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Greater Reduction in Knee Pain versus <FONT STYLE="white-space:nowrap">Synvisc-One</FONT> </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g11g62.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*<I>p</I>&lt;0.000 compared to
Synvisc</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#<I>p</I>&lt;0.000&nbsp;compared&nbsp;to
DUROLANE&nbsp;baseline</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*<I>p</I>=0.008&nbsp;compared&nbsp;to&nbsp;Synvisc&nbsp;
baseline</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(n=168) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mean values +/- standard deviation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a separate
prospective, multi-center, randomized, active-controlled, double-blind, <FONT STYLE="white-space:nowrap">non-inferiority</FONT> clinical trial with 442 enrolled patients with knee OA, it was observed that single injection Durolane was well tolerated
and <FONT STYLE="white-space:nowrap">non-inferior</FONT> compared to the corticosteroid methylprednisolone acetate at twelve weeks. Methylprednisolone acetate is a steroid injectable formulation used to treat pain and swelling that occurs with OA
and other joint disorders. The effect size for pain, physical function and stiffness scores favored Durolane over methylprednisolone acetate from twelve to 26 weeks. The benefit of Durolane was maintained through 26 weeks, while that of
methylprednisolone acetate declined during the same period. An additional injection of Durolane at 26 weeks conferred improvements through 52 weeks without increased sensitivity or risk of complications compared to the initial injection. One subset
of 31 patients treated with Durolane remained pain free after six months from the first injection and did not elect to receive a second injection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2020, over 2&nbsp;million injections of the Durolane formulation have been safely administered globally since its international launch in 2006. Bioventus launched Durolane in the United States in March 2018 and have owned certain
Durolane assets outside of the United States relating to trademark, product registrations and clinical data since November 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Three Injection Therapy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GELSYN-3</FONT> is an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> sterile, buffered solution of highly purified
sodium hyaluronate that is administered as a three injection HA viscosupplementation therapy. It is indicated for the treatment of pain due to knee OA in patients who have failed to respond adequately to conservative
<FONT STYLE="white-space:nowrap">non-pharmacologic</FONT> therapy and simple analgesics. The solution treats knee OA by providing temporary replacement for the diseased synovial fluid and restoring lubricity of bearing joint surfaces. Physicians
administer <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> to the affected knee joint once a week for three consecutive weeks. <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> provides relief of knee pain and may help delay the need for total knee
replacement surgery. <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> is derived from bacterial fermentation, is highly purified and does not involve the use of animal products, thereby reducing the potential risk of an immune response following
injection. Bioventus currently markets <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> in the United States. As of December&nbsp;31, 2020, approximately 900,000 injections of the <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> HA formulation have
been safely administered in the United&nbsp;States since its launch in 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GELSYN-3</FONT> clinical data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety and efficacy of <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> was assessed in a prospective, multicenter, randomized, controlled, double-blind, <FONT
STYLE="white-space:nowrap">non-inferiority</FONT> pivotal study that enrolled 381 adult patients with knee OA. Patients were randomized to receive three weekly injections of <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> or three weekly injections
of Synvisc 3, a three injection regimen commercialized in the United States by Sanofi S.A., with <FONT STYLE="white-space:nowrap">follow-up</FONT> visits scheduled up to 26&nbsp;weeks. <FONT STYLE="white-space:nowrap">GELSYN-3</FONT> was observed to
be <FONT STYLE="white-space:nowrap">non-inferior</FONT> to Synvisc 3 at the <FONT STYLE="white-space:nowrap">26-week</FONT> time point. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Five Injection
Therapy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SUPARTZ FX is an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> sterile and viscoelastic solution of HA that is administered as a five
injection HA viscosupplementation therapy. It is indicated for the treatment of pain in patients with knee OA who failed to adequately respond to conservative nonpharmacological therapy and simple analgesics. The solution treats knee OA by providing
temporary replacement for the diseased synovial fluid and restoring the lubricity of the bearing joint surfaces. Physicians administer SUPARTZ FX to the affected knee joint once a week for five consecutive weeks. SUPARTZ FX may also delay the need
for total knee replacement. SUPARTZ FX is derived from HA extracted from certified and veterinary inspected chicken combs. Risks can include general knee pain, warmth and redness or pain at the injection site. Bioventus currently markets SUPARTZ FX
in the United States. As of December&nbsp;31, 2020, over 410&nbsp;million injections of the SUPARTZ FX HA formulation have been safely administered globally since its launch in 1987. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SUPARTZ FX clinical data </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a double blind, randomized,
multi center, parallel group study conducted by Day et al. in 2004 of the effectiveness and tolerance of intra-articular SUPARTZ FX compared to control (saline) treatment for knee OA, it was observed that SUPARTZ FX reduced knee pain in patients
during the post-injection period by about 50% from the baseline. Of 240 patients randomized for inclusion in the study, 223 patients were evaluable for the modified intention to treat analysis and the statistically significant difference from the
control was apparent after the series of injections was complete. Intra-articular SUPARTZ FX therapy was shown to be more effective than saline in mild to moderate knee OA for the <FONT STYLE="white-space:nowrap">13-week</FONT> post injection period
of the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety and efficacy of SUPARTZ FX was observed by Strand et al. in an integrated analysis. This integrated analysis included five
separate double-blind, randomized, saline-controlled trials, and included a total of 1,155 patients comparing five weekly injections of SUPARTZ FX versus a saline placebo. The pooled results from this study showed that SUPARTZ FX produced
statistically significantly greater reduction from baseline in total Lequesne scores, a measure of overall function including pain. The incidence of adverse events were observed to be minimal and similar in both treatment arms. Furthermore, none of
the reported adverse events were observed to be deemed treatment-related suggesting that SUPARTZ FX was safe and well-tolerated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of <FONT STYLE="white-space:nowrap">FDA-approved</FONT> multi-injection HA
viscosupplementation therapies </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Product</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B></B><I>Manufacturer&nbsp;or&nbsp;distributor</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Source and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>process</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Active ingredient /</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>total treatment</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>dosage</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>injections</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per
course</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Duration</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt"><B><I></I></B>


<IMG SRC="g180330g13h77.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA&nbsp;of&nbsp;the&nbsp;knee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Fermented, bacterial derived HA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">0.84% sodium hyaluronate</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(50.4 mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Three</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six&nbsp;months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g180330g13i88.jpg" ALT="LOGO">
<B><I></I></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Naturally derived, purified HA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.0% sodium hyaluronate</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(75/125 mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Three&nbsp;to&nbsp;Five</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Synvisc</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Sanofi
S.A.</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Hylan polymers, purified HA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">0.8% Hylan <FONT STYLE="white-space:nowrap">G-F</FONT></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">20 (48 mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Three</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Euflexx</B>a</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ferring</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Pharmaceuticals Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Fermented, bacterial derived HA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.0% sodium hyaluronate</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(60 mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Three</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hyalgan</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fidia
Farmaceutici</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>S.p.A.</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Naturally derived, purified HA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.0% sodium hyaluronate</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(60 mg/100 mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Three to Five</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Genvisc-850</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>OrthogenRx, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>OA of the knee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Fermented, bacterial derived HA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.0% sodium hyaluronate</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(75/125 mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Three to Five</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Six months</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Development and Clinical Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amniotic tissue products for the treatment of OA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and development agreement for MOTYS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;29, 2019, Bioventus entered into a Development Agreement with Musculoskeletal Transplant Foundation, Inc. (MTF) to develop an injectable placental tissue product, MOTYS, for use in the pain treatment and joint preservation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of the product is subject to the FDA&#146;s BLA <FONT STYLE="white-space:nowrap">pre-market</FONT> approval process.
Once approved as a biologic, MOTYS will be eligible for health insurance reimbursement and hence gain access a broader patient population. Bioventus is planning to conduct randomized clinical trials to ultimately support the submission to the FDA of
a BLA for the use of MOTYS in the pain treatment and joint preservation vertical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on its preclinical evidence, Bioventus believes the MOTYS
formulation holds potential for mitigating pain while protecting damaged cartilage and promoting anti-catabolic and <FONT STYLE="white-space:nowrap">pro-anabolic</FONT> events that could ultimately result in delayed disease progression in OA.
Bioventus has completed extensive in vitro and in vivo studies comparing the effect of MOTYS to the clinical standard of care (steroid injections). MOTYS provided <FONT STYLE="white-space:nowrap">non-inferior</FONT> pain relief effects to a steroid,
but was superior in its effect on cartilage protection and in promotion of new tissue formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2020, Bioventus received FDA confirmation
indicating its authorization of its IND and plan to initiate clinical studies by year end. Amniotic products have been extensively and safely used in clinical practice, and FDA has granted Regenerative Medicine Advanced Therapy (RMAT), designation
to other amniotic tissue products being investigated for use in OA, which enables an expedited development pathway as well as eligibility for increased and earlier interactions with FDA. Bioventus intends to submit a request for RMAT designation for
MOTYS in 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Implantable for the treatment of rotator cuff injuries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Development collaboration agreement for PROcuff </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
August&nbsp;23, 2019, Bioventus entered into an exclusive Collaboration Agreement with Harbor Medtech Inc. (Harbor) to develop and license the rights to commercialize a woven-suture-collagen composite implant product, PROcuff, for the regeneration
of tendon tissue. Concurrently with the execution of the agreement, Bioventus purchased $1.0&nbsp;million of shares of Harbor. As a result of Harbor&#146;s achievement of certain milestones, on October&nbsp;5, 2020, Bioventus purchased
$1.0&nbsp;million of additional shares of Harbor. The sole use of proceeds from these investments is for the development of the woven-suture-collagen composite implant product and Bioventus has the right to purchase the product from Harbor once it
is cleared for marketing by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus terminated the collaboration agreement with Harbor on June 8, 2021 and determined that the termination was
a triggering event requiring an impairment assessment of Harbor&#146;s long lived assets. The assessment resulted in an impairment of $5,674, representing Harbor&#146;s long-lived asset balance, which was recorded within impairment of variable
entity assets in the consolidated condensed statements of operations and comprehensive (loss) income, of which $5,176 is attributable to the non-controlling interest. Bioventus stopped consolidating Harbor upon the termination of the collaboration
agreement, as Bioventus ceased being the primary beneficiary because it no longer had the power to direct Harbor&#146;s significant activities. Bioventus also assessed its Harbor investment post deconsolidation, which resulted in a $1,369
impairment, representing the remaining investment balance in Harbor and was recorded within other expense in the consolidated condensed statements of operations and comprehensive (loss) income. Bioventus continues to have license rights to certain
technology obtained from Harbor and is continuing product development initiated under the Collaboration Agreement. See Note 3. Business combinations and investments within the Notes to the Unaudited Condensed Consolidated Financial Statements
included in this joint proxy statement/prospectus for further details concerning the impairment and deconsolidation of Harbor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of
Cartilage for Osteochondral defects </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CartiHeal (developer of <FONT STYLE="white-space:nowrap">Agili-C)</FONT> investment and option and equity
purchase agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020, BV LLC made a $15.0&nbsp;million equity investment in CartiHeal (2009)&nbsp;Ltd. (CartiHeal), a
privately-held company headquartered in Israel and developer of the proprietary <FONT STYLE="white-space:nowrap">Agili-C</FONT> implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus believes <FONT STYLE="white-space:nowrap">Agili-C</FONT> is the only product in clinical development in the United States as an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> scaffold implant that is designed to regenerate hyaline cartilage and subchondral bone simultaneously. The associated surgical procedure is similar to
osteochondral allograft implantation, but is a single-step process and is easier, faster and more cost-effective. Bioventus believes this is the first cartilage repair technology to be tested in trials designed for regulatory approval in the United
States in <FONT STYLE="white-space:nowrap">non-OA</FONT> and OA patients, potentially unlocking applications for millions of patients with knee OA and cartilage defects. Bioventus also believes <FONT STYLE="white-space:nowrap">Agili-C</FONT> will
enable the treatment of cartilage lesions in a significant population of OA patients, including those younger, active patients for whom available treatment options are limited. The FDA&#146;s grant of breakthrough device designation in the fourth
quarter of 2020 for the treatment of an International Cartilage Repair Society (ICRS) grade III or above knee-joint surface lesions(s), with a total treatable area of <FONT STYLE="white-space:nowrap">1-7cm2,</FONT> without severe osteoarthritis
(Kellgren-Lawrence grade <FONT STYLE="white-space:nowrap">0-3)</FONT> is a promising development, as such designation may help patients receive more timely access to <FONT STYLE="white-space:nowrap">Agili-C</FONT> by expediting its development,
assessment and review by the FDA. On January&nbsp;12, 2021, the Centers for Medicare and Medicaid Services (CMS) issued a final rule under which a breakthrough device designation by the FDA also provides a streamlined pathway to national Medicare
coverage for a period of four years, beginning as early as the FDA approval for the product. On March&nbsp;12, 2021, CMS delayed by 60 days the effective date of the final rule on Medicare coverage for innovative technology, which was previously
slated to become effective March&nbsp;15, 2021. The agency also provided a <FONT STYLE="white-space:nowrap">30-day</FONT> public comment period, which ends April&nbsp;16, 2021. Bioventus believes <FONT STYLE="white-space:nowrap">Agili-C</FONT> also
has the potential for broader indications for use in other joints, providing entrance into the global market for cartilage repair products designed to delay or eliminate the need for knee replacements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical studies <FONT STYLE="white-space:nowrap">Agili-C</FONT> was associated with osteochondral
regeneration, good lateral integration and hyaline cartilage formation in critical size defects at 20 months when implanted in a goat, with the implant being fully resorbed between six to 20 months. The
<FONT STYLE="white-space:nowrap">Agili-C</FONT> implant has been implanted in more than 190 patients outside the United States with follow up of more than four years and is CE marked. The implant is currently being evaluated in a pivotal study
pursuant to an IDE filed with the FDA. The trial&#146;s objective is to demonstrate the superiority of the <FONT STYLE="white-space:nowrap">Agili-C</FONT> implant over the surgical standard of care (microfracture and debridement) for the treatment
of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. The study&#146;s protocol design, which is based on feedback from multiple <FONT STYLE="white-space:nowrap">pre-IDE</FONT> interactions with
the FDA, involves broad inclusionary criteria, such as defect size, age, and etiology, multiple controls, including microfracture and debridement, and multiple <FONT STYLE="white-space:nowrap">pre-planned</FONT> secondary endpoints. The study has an
adaptive design, which allows for a maximum of 500 planned patients, includes multiple interim analyses to estimate sample size needs and includes European Union (EU), Israeli and U.S. sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BV LLC&#146;s CartiHeal investment follows the recently completed enrollment and reporting of interim results in CartiHeal&#146;s IDE multinational pivotal
study for <FONT STYLE="white-space:nowrap">Agili-C.</FONT> This investment is expected to enable CartiHeal to complete the study, including all patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> and submit a PMA to the FDA. Under the equity
purchase agreement, CartiHeal can secure an additional $5.0&nbsp;million from us, if needed, for IDE study completion. BV LLC previously made an initial $2.5&nbsp;million investment in CartiHeal in January 2018 and a subsequent investment of
$0.2&nbsp;million in January 2020 as part of prior CartiHeal financing rounds. Any additional investment Bioventus makes will be subject to customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the July&nbsp;15, 2020 investment, BV LLC entered into an Option and Equity Purchase Agreement with CartiHeal and its shareholders, which
provides BV LLC with an exclusive option to acquire 100% of CartiHeal&#146;s shares, or the Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#146;s shares under certain conditions, or the
Put Option. The Call Option is exercisable by BV LLC at any time after the closing of the investment. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA
approval of the <FONT STYLE="white-space:nowrap">Agili-C</FONT> device with a label consistent in all respects with pivotal clinical trial success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
not previously exercised, the Call Option and the Put Option terminate 45 days following the FDA approval of <FONT STYLE="white-space:nowrap">Agili-C</FONT> (subject to final review by BV LLC of updated disclosures by CartiHeal). Should the Put
Option or Call Option be exercised and the acquisition of CartiHeal consummated, consideration for the acquisition of all of the shares of CartiHeal pursuant to the Option and Equity Purchase Agreement would be $350.0&nbsp;million in cash, subject
to customary adjustments, all of which would be payable at closing, with an additional $150.0&nbsp;million payable upon achievement of certain sales milestones related to <FONT STYLE="white-space:nowrap">Agili-C.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Recent Developments&#151;CartiHeal.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bone
Graft Substitutes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BGSs in spinal fusion and other procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bone grafting is a surgical procedure used to fuse spinal vertebrae, replace missing bones, fix bones that are damaged from trauma or problem joints, or to
facilitate growing bones around an implanted device, such as a total knee replacement. The bones used in a bone graft can come from a particular patient&#146;s own body, referred to as an autograft, or from a donor, referred to as an allograft, or
can be entirely <FONT STYLE="white-space:nowrap">man-made,</FONT> referred to as a synthetic. Most bone grafts are expected to be reabsorbed and replaced as the natural bone heals over a few months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; BGS product portfolio is comprised of clinically efficacious and cost effective bone graft solutions to meet a broad range of patient needs
and procedures. Bioventus&#146; products are designed to improve bone fusion rates following spinal and other orthopedic surgeries, including trauma and reconstructive foot and ankle procedures. These products include an allograft-derived bone graft
with growth factors (OsteoAMP), a DBM </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(Exponent), cancellous bone in different preparations (PureBone), bioactive synthetics (Signafuse and Interface), a collagen ceramic matrix (OsteoMatrix) and two bone marrow isolation systems
(CellXtract and Extractor). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Bioventus builds the body of clinical evidence supporting its products, Bioventus continues to look for and execute on
opportunities to innovate in its BGS portfolio. To meet growing market demand and evolving surgical techniques, Bioventus continues to develop product extensions and adjust formulations. For example, Bioventus launched OsteoAMP Select in 2019 and
OsteoAMP Flowable in 2021. Bioventus designed OsteoAMP Flowable to be moldable and easy to use, with a convenient, ready to use syringe. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indications</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Regulatory</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>pathway / year</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>launched</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Allograft</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g16j01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orthopedic, neurosurgical and reconstructive bone grafting procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An allogeneic bone graft that is available in multiple formats (fibers, putty, sponge and granules) that is processed with bone marrow cells to maintain the wide array of growth factors present in native bone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#149;Section&nbsp;361 HCT/P /</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2009</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g16k02.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Posterolateral spine procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Derived from human allograft bone tissue and is combined with a migration-resistant resorbable carrier and formulated into a putty</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#149;510(k) / 2012</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g16l03.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orthopedic, neurosurgical and reconstructive bone grafting procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">100% cancellous bone with compressible, elastic and sponge-like attributes, offered in filler, block and strip options, as well as mineralized chips</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#149;Section&nbsp;361</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HCT/P /</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2012</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B><I>Synthetic</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g16m04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Standalone posterolateral spine, extremities and pelvis, as well as a bone graft extender in the posterolateral spine</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioactive synthetic bone graft substitute comprised of a mixture of calcium phosphate granules and bioglass granules</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">suspended in a resorbable polymer carrier that facilitates handling and delivery of the granule components to fill spaces of missing bone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#149;510(k)&nbsp;/&nbsp;2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g17n05.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Posterolateral spine when mixed with autograft, extremities and pelvis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bioactive synthetic bone graft in the form of irregular granules of bioglass to repair bone defects</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#149;510(k) / 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g180330g17o06.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Posterolateral spine, extremities and pelvis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Next-generation mineralized <FONT STYLE="white-space:nowrap">two-phase</FONT> calcium phosphate bone void filler comprised of a collagen scaffold designed for optimized intra-operative handling and biologic responsiveness at the
defect site</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#149;510(k) / 2010</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center">


<IMG SRC="g180330g16m04.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Posterolateral spine, extremities and pelvis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Next-generation mineralized bone void filler comprised of bioglass and biphasic mineral granules embedded in a collagen scaffold designed for optimized intra-operative handling and biologic responsiveness at the defect site.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#149;510(k)&nbsp;/&nbsp;2020</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restorative Therapies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bone fractures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fractures, also known as broken bones,
occur when there is a high force or impact put on a bone, most commonly from trauma resulting from sports injuries, car accidents, falls or from osteoporosis, which is bone weakening due to aging. Immediately following a fracture, patients are
treated to realign the fractured bone ends. If possible or required, the affected limb is immobilized using plaster or a splint. In some cases, fractures require surgical fixation with devices such as screws, plates, rods and frames. <FONT
STYLE="white-space:nowrap">X-rays,</FONT> CT and MRI imaging are utilized to verify alignment of the bone and to assess progress towards healing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
fracture is considered a fresh fracture during the first 14 days after the fracture occurs. After a fracture is treated, new bone tissue begins to form and bridge the gap. With modern treatment methods, most fractures heal spontaneously over the
course of several months following injury. However, some fractures fail to heal even when they receive the best surgical or <FONT STYLE="white-space:nowrap">non-surgical</FONT> treatments. This condition may be diagnosed as a nonunion fracture.
Nonunions may occur due to mechanical instability of the fracture site, due to inadequate immobilization, poor blood supply, gaps in bone to bone contact, or a number of comorbidities experienced by the patient. In clinical literature, it is
estimated that five to ten percent of all fractures fail to heal, often in high impact fractures or in patients that have compromised health from old age, obesity, cardiovascular disorders, arthritis, diabetes or smoking. A nonunion is considered to
be established when the fracture site shows no visibly progressive signs of healing. Nonunions have a negative impact on quality of life with symptoms, such as reduced mobility, swelling, pain, tenderness, deformity and difficulty bearing weight.
Patients with nonunions may undergo surgery when certain conditions occur, such as an unstable or misaligned fracture, or a larger inter-fragment gap. Some nonunions can be treated <FONT STYLE="white-space:nowrap">non-surgically</FONT> using bone
stimulation devices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long bone stimulation systems </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus offers its Exogen ultrasound bone healing system for the <FONT STYLE="white-space:nowrap">non-invasive</FONT> treatment of established nonunion
fractures and certain fresh fractures. Bioventus&#146; Exogen system was the number one prescribed device in the long bone growth stimulatory market in 2018. It has been sold commercially for over 25 years and is the only <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> device on the market for the accelerated healing of fresh, closed posteriorly displaced distal fractures of the radius and fresh, closed or grade I open long bone fractures. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Regulatory pathway</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Region where</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>marketed<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g180330g18p07.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ultrasound bone healing system for nonunion fractures and fresh fractures to the tibia and radius(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;PMA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Device approval by Health Canada</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;CE mark and other
registrations<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;United States</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Canada</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Europe</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Japan</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bioventus&#146; Exogen system is indicated in the United States for the
<FONT STYLE="white-space:nowrap">non-invasive</FONT> treatment of established nonunions, excluding skull and vertebra, and for accelerating the time to a healed fracture for fresh, closed,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
posteriorly displaced distal radius fractures and fresh, closed or Grade I open long bone fractures in skeletally mature individuals when these fractures are orthopedically managed by closed
reduction and cast immobilization. Bioventus own its Exogen system and market it both in and outside the United States. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exogen is also approved for marketing in Australia, Japan, New Zealand, Saudi Arabia, Turkey and the UAE.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; Exogen system is used to administer treatment in a location of convenience, including at home or work, once daily, for
20 minutes, or as prescribed by the patient&#146;s physician, for accelerating bone healing. This therapy provides a cost-effective treatment alternative to surgical intervention for nonunions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; Exogen system consists of the portable device, a charger, a gel bottle and strap. The device features a transducer at the end of a coiled
cord, a color screen, a power button and a <FONT STYLE="white-space:nowrap">mini-USB</FONT> charging port to allow for recharging the battery. The transducer sends specifically-programmed <FONT STYLE="white-space:nowrap">low-intensity</FONT> pulsed
ultrasound to the fracture site through the skin and soft tissue, with little or no sensation felt by the patient during the treatment. The gel facilitates ultrasound signal transmission through the patient&#146;s skin. Bioventus&#146; Exogen system
provides an easy to use interface that tracks treatment use and promotes compliance. In a clinical study of its Exogen system, Bioventus observed a 91% patient compliance with the treatment regimen, based on median total time of device usage. An
additional support tool for the patient is Exogen Connects, a free smartphone app that provides daily automated treatment reminders and helpful healing information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; Exogen system utilizes <FONT STYLE="white-space:nowrap">low-intensity</FONT> pulsed ultrasound technology to stimulate the body&#146;s natural
bone healing process. The ultrasound output intensity of the device is comparable to diagnostic ultrasound intensity levels used in obstetrical sonogram procedures for fetal monitoring and is typically only one to five percent of the output
intensity of conventional therapeutic ultrasound devices used for physical therapy. Some patients report experiencing a tingling sensation at the treatment site. The depth and breadth of the Exogen ultrasound signal enables it to treat superficial
and deep indicated fractures. Exogen ultrasound is osteoinductive, which means it stimulates cells to differentiate into osteoblasts, or cells that make new bone. The growth of this new bone helps bridge the gap at the fracture site. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of U.S. long bone stimulation devices </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Product</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>Manufacturer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Daily&nbsp;treatment</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>times</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Technology</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indications</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g180330g18p07.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Bioventus</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">20 minutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Low-intensity</FONT> pulsed ultrasound</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Nonunions and select fresh fractures<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CMF OL1000</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>DJO Global,
Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">30 minutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Combined magnetic field</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Nonunions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Physio-Stim</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Orthofix International
B.V.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3 hours</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Pulsed electromagnetic field</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Nonunions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EBI Bone Healing System</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Zimmer Biomet
Holdings, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10 hours</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Pulsed electromagnetic field</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Nonunions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OsteoGen</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Zimmer Biomet Holdings,
Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">24 hours</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Direct electrical current (implanted)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Nonunions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orthopak 2 Bone Growth Stimulator</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Zimmer Biomet Holdings, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">24 hours</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Capacitive coupling</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Nonunions</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Heal rates for fresh fracture as compared to placebo. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bioventus&#146; Exogen system is indicated in the United States for the
<FONT STYLE="white-space:nowrap">non-invasive</FONT> treatment of established nonunions excluding skull and vertebra and for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh,
closed or Grade I open long bone fractures in skeletally mature individuals when these fractures are orthopedically managed by closed reduction and cast immobilization. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exogen clinical data </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a meta-analysis published
by Leighton et al. in 2017 studied heal rates of many different fracture nonunions treated with its Exogen system. A total of 13 eligible studies were identified which reported success of treatment with its Exogen system in 1,441 nonunions. Overall,
that analysis estimated that 82% of nonunions of at least three months in age treated with its Exogen system successfully healed. Because healing of established nonunion is not expected without treatment, these findings are compelling.
Bioventus&#146; Exogen system may be most useful in patients for whom surgery is high risk. With an observed overall average nonunion heal rate of at least 80% after treatment with its Exogen system, the study authors concluded that treatment with
its Exogen system was comparable to surgical treatment for nonunion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional published evidence supports the efficacy of its Exogen system in treating
fracture nonunions. Established fracture nonunions rarely heal without corrective surgery, though nonunion revision surgery is expensive, invasive and the expected heal rate averages approximately 86%. In a study that looked at patient data
collected over a four-year period, Zura et al. found that was that the Exogen system enhanced the heal rate among chronic nonunions and even healed fractures that had been nonunion for more than 10 years, without further surgical intervention. Heal
rate was 86.2% among patients with fractures that had not healed for at least one year, 82.7% among 98 patients with chronic nonunion of greater than five years duration, and furthermore 12 patients healed after chronic nonunion of greater than 10
years. Therefore, its Exogen system offers a heal rate comparable to surgery, with fewer associated risks and morbidities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developmental and
clinical pipeline </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ongoing Bioventus-sponsored clinical studies (B.O.N.E.S.) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While currently indicated for the treatment of both established nonunions, excluding skull and vertebrae, and certain types of conservatively managed acute
fractures of the tibia and radius, its Exogen system&#146;s use in fracture care management has grown over its 20 year clinical history in both the United States and internationally. The use of its Exogen system for the management of fresh fractures
has been the subject of numerous published peer reviewed research articles. The current prescription data indicate that the product&#146;s use in routine practice of fresh fracture management is based on clinician&#146;s determination of medical
necessity, in an effort to mitigate risk of progression to fracture nonunion in <FONT STYLE="white-space:nowrap">at-risk</FONT> patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to
quantify the effectiveness of its Exogen system in mitigating the risk of progression to fracture nonunion, and in an effort to obtain regulatory approval for expanded indications, Bioventus is seeking to supplement the body of clinical knowledge in
an innovative population-based clinical development program, B.O.N.E.S., which stands for Bioventus Observational <FONT STYLE="white-space:nowrap">Non-interventional</FONT> Exogen Studies. With enrollment started in late 2017, the B.O.N.E.S.
clinical study design includes the parallel conduct of three independent study protocols which, taken together, are designed to prospectively include more than 3,000 Exogen-treated patients presenting with certain risk factors to be observed over
the course of 9 to 12 months. Bioventus&#146; Exogen system treated patients will be propensity matched to one or more untreated controls extracted from a real-world health claims database provided by Truven Healthcare Analytics, generating a total
sample size of at least 6,000 patients. The program involves the concurrent execution of three studies on <FONT STYLE="white-space:nowrap">pre-specified</FONT> anatomical locations, such as the tibia, scaphoid and fifth metatarsal, with the
objective of determining if the use of its Exogen system mitigates risk of fracture nonunion in predisposed patients. Depending on the results from its studies, Bioventus plans to submit a total of three PMA supplements to the FDA, the first of
which was submitted in December 2020 seeking approval for the adjunctive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment of acute and delayed metatarsal fractures to reduce the risk of <FONT STYLE="white-space:nowrap">non-union.</FONT> Bioventus plans to submit the second PMA supplement in the second
quarter of 2022 and the third PMA supplement in either the third or fourth quarter of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2021, Bioventus received a letter from the FDA
identifying certain deficiencies in the PMA supplement that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and endpoints from the B.O.N.E.S. study, and requests for
re-analyses of certain data and provision of other information to support the findings. Bioventus continues to evaluate the FDA&#146;s comments and is initiating discussions with them to address their concerns. Bioventus can give no assurance that
it will be able to resolve the deficiencies identified by the FDA in a timely manner, or at all. Consequently, the FDA&#146;s decision on the PMA supplement may be delayed beyond the time originally anticipated by Bioventus. Moreover, if
Bioventus&#146; responses do not satisfy the FDA&#146;s concerns, the FDA may not approve Bioventus&#146; PMA supplement seeking to expand the indications for use of EXOGEN as proposed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; expansive direct
sales and distribution channel across its product portfolio provides Bioventus with broad and differentiated customer reach, and allows Bioventus to serve physicians spanning the orthopedic continuum, including sports medicine, total joint
reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Bioventus&#146; products are widely reimbursed by both public and private health insurers and are sold in the physician&#146;s office or
clinic, ASCs, and in the hospital setting in the United States and across 37 countries. Bioventus&#146; sales team and distributors work directly with its physician customers on a frequent basis, providing Bioventus with a significant opportunity to
introduce new products and upsell from its current portfolio. Bioventus believes its sales organization will provide Bioventus with an opportunity to efficiently roll out its deep pipeline and participate in business development opportunities going
forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; pain treatment and joint preservation products and its restorative therapies products are sold by a direct sales team of
approximately 240 in the United States and approximately 45 internationally as of December&nbsp;31, 2020. This direct team is complimented by approximately 20 account representatives who work with its sales team to provide account access through
IDNs, GPOs and payer contracting. Bioventus&#146; direct sales organization, totaling approximately 305 globally, is supplemented by approximately 35 sales managers. Bioventus&#146; sales leaders have considerable experience, with an average of five
years of experience. Bioventus&#146; BGS products are sold by approximately 170 independent distributors in the United States, each with their own independent sales force, supported by its 15 member regionalized sales support team as of
December&nbsp;31, 2020. Bioventus markets its BGSs primarily to orthopedic spine surgeons and neurosurgeons for use in the operating room in both the hospital and ASC setting. Bioventus believes that its broad customer reach has and will continue to
enable strong and durable growth in each of its verticals and provides a significant foundation for future product launches. Bioventus supports its sales organization with extensive training to help them excel, and Bioventus has a performance
culture built on serving its core orthopedic patient customers and delivering its products to a variety of physicians and care settings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and
clinical operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus sees significant opportunity to develop innovative and clinically differentiated products internally with its
experienced research and development team. Bioventus is focused on internal research and development to broaden its portfolio of therapies to manage pain and joint preservation, expand its Exogen system product label and undertake clinical research
to support commercialization of its next-generation of BGS products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, Bioventus expects its research and development expense to increase to
the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits as a percentage of net sales as Bioventus introduces new products, extend existing product lines and expand indications. Bioventus&#146; research and development activities are focused on
product development in BGSs, treatments for OA and soft tissue surgery. Bioventus&#146; clinical research is focused on running the B.O.N.E.S. and MOTYS clinical programs, as well as continuing to build its body of clinical evidence to demonstrate
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efficacy and value of its products through collaborations with prominent academic investigators. Bioventus collaborates with academic centers of excellence, leading contract research
organizations and other industrial groups to complement and expedite execution of its research and development programs and minimize fixed costs. Research and development expense, including spending on its clinical evidence development efforts,
totaled $11.2&nbsp;million, $11.1&nbsp;million and $8.1&nbsp;million for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The medical device industry is highly
competitive, subject to change and significantly affected by activities of industry participants. The multi-injection HA viscosupplementation therapies that Bioventus owns or distributes compete against Ferring Pharmaceutical Inc.&#146;s Euflexxa,
Fidia Farmaceutici S.p.A.&#146;s Hyalgan, DePuy Orthopaedics, Inc. (Johnson&nbsp;&amp; Johnson&#146;s) Orthovisc, Sanofi S.A.&#146;s Synvisc and OrthogenRx Inc.&#146;s GenVisc 850. These products have faced significant competition from single
injection therapies, such as Sanofi S.A.&#146;s <FONT STYLE="white-space:nowrap">Synvisc-One,</FONT> Zimmer Biomet Holdings, Inc.&#146;s <FONT STYLE="white-space:nowrap">Gel-One</FONT> and DePuy Orthopaedics, Inc. (Johnson&nbsp;&amp; Johnson&#146;s)
Monovisc. Bioventus&#146; BGS product portfolio competes with products from Medtronic, DePuy Orthopaedics, Inc. (Johnson&nbsp;&amp; Johnson), Stryker Corporation, NuVasive, Inc., SeaSpine, Inc., Orthofix Medical Inc., Zimmer Biomet Holdings, Inc.
and Globus Medical Inc. Bioventus&#146; Exogen system competes with products marketed by Orthofix Medical Inc., Zimmer Biomet Holdings, Inc. and DJO Global Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time, these or other market participants may develop alternative treatments, products or procedures that compete directly or indirectly with its
products. They may also develop and patent processes or products earlier than Bioventus can or obtain regulatory clearance or approvals for competing products more rapidly than Bioventus can. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus strives to protect and
enhance the proprietary technologies, inventions and improvements that Bioventus believes are important to its business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties.
Bioventus&#146; policy is to seek to protect its proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to its proprietary technology,
inventions and improvements that are important to the development and implementation of its business. Bioventus also relies on trademarks, trade secrets and careful monitoring of and contractual obligations with respect to its proprietary
information to protect aspects of its business that are not amenable to, or that Bioventus does not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; success will depend on its ability to obtain and maintain patent and other proprietary protection for commercially important technology,
inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to its business, defend and enforce its patents, maintain its licenses to use intellectual property owned by third parties and operate without infringing the valid and
enforceable patents and other proprietary rights of third parties. For important factors related to its proprietary technology, inventions and improvements, please see &#147;Risk Factors&#151;Risks Relating to Intellectual Property Matters.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus owns numerous patents
and/or patent applications which relate to its material products, including patents and/or patent applications with respect to its Exogen system, OsteoAMP and MOTYS. Although in the aggregate its intellectual property is of material importance to
its business, Bioventus does not believe that any single patent is of material importance to its product portfolio. As of November&nbsp;13, 2020, Bioventus owned four issued U.S. patents and two pending U.S. patent applications relating to its
material products. Bioventus also owned nine issued foreign patents and 11 pending foreign patent applications directed to its material products. Bioventus&#146; patents and patent applications as of November&nbsp;30, 2020 directed to its material
products are summarized below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus owned three issued U.S. patents and one issued foreign patent in Australia directed to its Exogen
system. The U.S. patents are expected to expire between 2025 and 2029, and the foreign patent is expected to expire in 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus owned one issued
U.S. patent, one pending U.S. patent application, eight issued foreign patents, and ten pending foreign patent applications directed to its OsteoAMP product, including foreign patents and patent applications in Europe, Asia, Canada and Australia.
The issued U.S. patent is expected to expire in 2029. The issued foreign patents are expected to expire in 2029. The pending patent applications, if issued, are expected to expire in 2029, without accounting for potential patent term extensions and
adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus also owns one pending U.S. patent application and one pending Patent Cooperation Treaty application directed to MOTYS. Patents
issuing from these applications, if any, are expected to expire in 2040, without accounting for potential patent term extensions and adjustments. Bioventus&#146; patents and pending patent applications directed to its material products (excluding
those patents associated with the Bioness products) are detailed in the below table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Product</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">AU</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2009324417</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2009324417</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">AU</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2014259553</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November&nbsp;14,<BR>2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2014259553</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Product</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">AU</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2016213839</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August&nbsp;11,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2016213839</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">CA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2746668</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2746668</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">CN</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200980155596.X</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">200980155596.X</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">CN</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">201410413348.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August&nbsp;20,<BR>2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">201410413348.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Product</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">EP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">HK</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15105678.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;16, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">HK1205007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">IN</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2567/KOLNP/<BR>2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;4,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">KR</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">10-2011-7016270</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;2, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">10-1713346</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">15/016072</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10383974</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Issued</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16/459778</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;4,<BR>2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">GB</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">FR</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">DE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">IT</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Product</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">CH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">BE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">ES</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">PT</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9832666.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,<BR>2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to methods of making osteoinductive implants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">OsteoAMP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">09/925,193</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August&nbsp;9,<BR>2001</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7429248</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Granted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to applying ultrasound to tissue using a modal converter having a plurality of angled sides.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Exogen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">AU</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2006203281</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August&nbsp;1,<BR>2006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2006203281</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Granted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August<BR>2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to treating a neuropathy disease with ultrasound using a specific frequency and pulse rate for the signal</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Exogen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11/462271</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">August&nbsp;3,<BR>2006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8048006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Granted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to treating a neuropathy disease with ultrasound using a specific frequency and pulse rate for the signal</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Exogen</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent&nbsp;Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application</B><br><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Product</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12/296,333</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;7, 2007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8226582</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Granted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June 2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to applying ultrasound to tissue using a modal converter having an oblique angle and speed of sound similar to human tissue</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Exogen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17/097,350</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November&nbsp;13,<BR>2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November<BR>2040</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to placental tissue particulates compositions, methods of treating musculoskeletal or orthopedic conditions, methods of treating pain associated with osteoarthritis, kits and methods of making the
compositions</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">MOTYS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">PCT</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">PCT/US20/60393</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November&nbsp;13,<BR>2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pending</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">November<BR>2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Directed to placental tissue particulates compositions, for use in treating musculoskeletal or orthopedic conditions, methods of treating pain associated with osteoarthritis, kits and methods of making the
compositions</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">MOTYS</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus owns registered trademarks for Bioventus, Cellxtract, Durolane, Exogen, Exponent, <FONT STYLE="white-space:nowrap">Gelsyn-3,</FONT> OsteoAMP,
Osteofuse, Prohesion, PureBone, SAFHS, and Signafuse in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade secrets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus may rely on trade secret law to protect some of its technology, including the processing of tissue for OsteoAMP. Trade secrets, however, can be
difficult to protect. Bioventus seeks to protect its proprietary technology and manufacturing process, in part, by confidentiality and invention assignment agreements with employees, under which they are bound to assign to Bioventus inventions that
are made during the term of their employment and relate to its business, unless there is an exception. These agreements further prohibit its employees from using, disclosing, or bringing onto the premises any proprietary information belonging to any
third-party. In addition, its consultants, scientific advisors and contractors are required to sign agreements under which they must assign to Bioventus any inventions that relate to its business. These agreements also prohibit these third-parties
from incorporating into any inventions the proprietary rights of third-parties without informing Bioventus. It is its policy to require all employees to document potential inventions and other intellectual property in laboratory notebooks and to
disclose inventions to patent counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus also seeks to preserve the integrity and confidentiality of its data and trade secrets by taking
commercially reasonable efforts to maintain the physical security of its premises and physical and electronic security of its information technology systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Bioventus has confidence in these individuals, organizations and systems, its security measures may be breached, or may otherwise prove inadequate to
protect the integrity and confidentiality of its data and trade secrets. Further, its agreements may be breached (or not obtained in the first place) and Bioventus may not have adequate remedies for any breach. In addition, its trade secrets may
otherwise become known or be independently discovered by competitors. To the extent that its consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or
resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patents, trademarks, and trade secrets, Bioventus also relies
on assignment and license agreements, pursuant to which Bioventus may license rights under patents held by third parties, and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, to protect its proprietary intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus obtains assignments or licenses of varying durations for certain of its products from third parties. Bioventus typically acquires rights under such
assignments or licenses in exchange for <FONT STYLE="white-space:nowrap">lump-sum</FONT> payments or arrangements under which Bioventus pays a percentage of sales to the licensor. However, while assignments or licenses to Bioventus generally are
irrevocable, no assurance can be given that these arrangements will continue to be made available to Bioventus on terms that are acceptable to us, or at all. The terms of its license and assignment agreements vary in length from a specified number
of years to the life of product patents or the economic life of the product. These agreements generally provide for royalty payments and termination rights in the event of a material breach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and supply </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; HA
viscosupplementation therapies and certain of its surgical products are manufactured exclusively by single-source third-party manufacturers, pursuant to multi-year supply agreements. Bioventus works closely with each of its manufacturing partners
and provide them with a forecast, which enables them to better capacity plan and sequence their production efficiently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Durolane, Bioventus is
subject to minimum order volumes for each order and purchase amounts are also based in part on forecasts. For <FONT STYLE="white-space:nowrap">GELSYN-3,</FONT> Bioventus will be subject to certain annual minimum purchase requirements and purchase
amounts based on rolling forecasts. For SUPARTZ FX, Bioventus is subject to certain annual minimum purchase requirements based on a percentage of its SUPARTZ FX annual forecast. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Durolane, in December 2016, Bioventus entered into an amended and restated supply agreement, or the <FONT STYLE="white-space:nowrap">Q-Med</FONT> Supply
Agreement, with <FONT STYLE="white-space:nowrap">Q-Med</FONT> AB, or <FONT STYLE="white-space:nowrap">Q-Med.</FONT> Under the <FONT STYLE="white-space:nowrap">Q-Med</FONT> Supply Agreement, <FONT STYLE="white-space:nowrap">Q-Med</FONT> supplies
Durolane products exclusively to Bioventus for sale in the United States for use in the in the prevention or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment of pain due to OA on a purchase order basis, based on the amounts of Durolane Bioventus requires as set forth in rolling forecasts and Bioventus is subject to certain semi-annual
minimum purchase requirements based on a percentage of its Durolane forecast. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus assembles, inspects, tests and packages its Exogen system at its
facility in Cordova, Tennessee with components supplied by third-party suppliers. Bioventus&#146; Exogen system includes a transducer which is a key component that is supplied by a single-source supplier. Bioventus performs inspections of these
components before use in its manufacturing operations. Bioventus believes its manufacturing operations are in compliance with regulations mandated by the FDA. Bioventus is an <FONT STYLE="white-space:nowrap">FDA-registered</FONT> medical device
manufacturer. Bioventus&#146; manufacturing facilities and processes are subject to periodic inspections and audits by various federal, state and foreign regulatory agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MTF will exclusively manufacture and supply MOTYS under current Good Tissue Practices (cGTPs) to Bioventus to allow for its limited commercialization that
began in the fourth quarter of 2020 under the tissue regulations while Bioventus pursues a BLA for the product. MTF is responsible for obtaining and storing all materials, including all tissue materials, required for the manufacture, testing,
handling, packaging, labeling, release and delivery of the product to Bioventus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus intends to maintain sufficient supplies of the products and
components from these single-source suppliers in the event that one or more of these suppliers were to encounter certain interruptions in supply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government regulation of
medical devices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; medical devices are subject to regulation by numerous government agencies, including the FDA and comparable
foreign agencies. The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design, development and manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">testing, labeling, content and language of instructions for use and storage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product safety; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing, sales and distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">premarket clearance and approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">record keeping procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advertising and promotion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls and field safety corrective actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">postmarket surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to
recur, could lead to death or serious injury; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">postmarket approval studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product import and export. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulations to which Bioventus is subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions
on its ability to carry on or expand its operations, higher than anticipated costs or lower than anticipated sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA premarket clearance and approval requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each medical device Bioventus seeks to commercially distribute in the United States must first receive 510(k) clearance or approval of a PMA application from
the FDA, unless specifically exempt. The FDA classifies all medical devices into one of three classes. Devices deemed to pose lower risk are categorized as either Class&nbsp;I or Class&nbsp;II. Class&nbsp;II devices require the manufacturer to
submit to the FDA a 510(k) <FONT STYLE="white-space:nowrap">pre-market</FONT> notification requesting clearance of the device for commercial distribution in the United States. Class&nbsp;I devices are exempted from this requirement. Devices deemed
by the FDA to pose the greatest risk, such as life sustaining, life-supporting, selected implantable devices, or devices deemed not substantially equivalent to a previously 510(k) cleared device, are categorized as Class&nbsp;III, generally
requiring submission and approval of a PMA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>510(k) clearance process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain 510(k) clearance, Bioventus must submit a premarket notification to the FDA demonstrating the proposed device to be substantially equivalent to a
predicate device. A predicate is a previously cleared 510(k) device, a device that was in commercial distribution before May&nbsp;28, 1976 for which the FDA has not yet called for the submission of PMA applications, or is a device that has been
reclassified from Class&nbsp;III to either Class&nbsp;II or I. The standard review process for 510(k)s is between 30 days to 3 months, dependent upon the type of 510(k) filing submitted. Although many 510(k) premarket notifications are cleared
without clinical data, in some cases, the FDA may require clinical data to support substantial equivalence. In reviewing a premarket notification, the FDA may request additional information, including clinical data, which may significantly prolong
the review process and clearance is never assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a device receives 510(k) clearance, any subsequent modification of the device that could
significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require submission and approval of a PMA application in cases where new indications are sought
for which there is no predicate. <FONT STYLE="white-space:nowrap">Non-significant</FONT> changes are handled via internal documentation by the Company. Each manufacturer must judge the significance of modifications based on algorithms within FDA
510(k) guidance documents. FDA may review any such decision and may disagree with a manufacturer&#146;s determination. If the FDA disagrees with a manufacturer&#146;s determination, the FDA may require the manufacturer to cease marketing and/or
recall the modified device until 510(k) clearance or PMA approval is obtained. Bioventus has modified aspects of some of its devices since receiving initial regulatory clearance. Bioventus concluded that some of those modifications did not
significantly affect the safety or efficacy of the device and therefore, that new 510(k) clearances were not required. Bioventus has also obtained new 510(k) clearances from the FDA for other modifications to its devices. In the future, Bioventus
may make additional modifications to its products after they have received FDA clearance or approval and in appropriate circumstances, determine that new clearance or approval is unnecessary. However, the FDA may disagree with its determination and
if the FDA requires Bioventus to seek 510(k) clearance or submit new PMA applications for any modifications to a previously cleared product, Bioventus may be required to cease marketing or recall the modified device until Bioventus obtains the
required clearance or approval. Under these circumstances, Bioventus may also be subject to significant regulatory fines or other penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus
has obtained 510(k) premarket clearance from the FDA for Signafuse Bioactive Bone Graft Putty, Interface Bioactive Bone Graft, Osteomatrix +, and Signafuse Mineralized Collagen Scaffold. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Premarket approval process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A PMA application must
be submitted if the medical device is in Class&nbsp;III (although the FDA has the discretion to continue to allow certain <FONT STYLE="white-space:nowrap">pre-amendment</FONT> Class&nbsp;III devices to use the 510(k) process) or cannot be cleared
through the 510(k) process. A PMA application must be supported by, among other things, extensive technical, preclinical, clinical trials, manufacturing and labeling data to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of
the device. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a PMA application is submitted and filed, the FDA begins an
<FONT STYLE="white-space:nowrap">in-depth</FONT> review of the submitted information. The standard review of such application is six months. During this review period, the FDA may request additional information or clarification of information
already provided. This can extend the overall review process and typically PMAs take between one to three years in total for approval. Also during the review period, an advisory panel of experts from outside the FDA will usually be convened for a
new type of device to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility to ensure compliance with Quality System Regulation (QSR), which impose elaborate design development, testing, control, documentation and other quality assurance procedures in the design and manufacturing process. The FDA may
approve a PMA application with post-approval conditions intended to ensure the safety and effectiveness of the device including, among other things, restrictions on labeling, promotion, sale and distribution and collection of long-term <FONT
STYLE="white-space:nowrap">follow-up</FONT> data from patients in the clinical study that supported approval. Failure to comply with the conditions of approval can result in materially adverse enforcement action, including the loss or withdrawal of
the approval. PMA supplements are required for significant modifications to the manufacturing process, labeling of the product and design of a device that is approved through the PMA process. PMA supplements requires submission of information needed
to support any changes from the device covered by the original PMA and typically do not require clinical data or the convening of an advisory panel. <FONT STYLE="white-space:nowrap">Non-significant</FONT> changes must be reported to the FDA through
an annual report filing with the FDA. In review of this joint proxy statement/prospectus, FDA may disagree with a manufacturer&#146;s determination of the level of significance of the change. If the FDA disagrees with a manufacturer&#146;s
determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until PMA supplement approval is obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durolane, <FONT STYLE="white-space:nowrap">GELSYN-3,</FONT> SUPARTZ FX and its Exogen bone healing system have each been approved through the PMA process.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A clinical trial is
typically required to support a PMA and is sometimes required for a 510(k) premarket notification. In the United States, authorization to conduct a clinical trial generally requires submission of an application for an IDE to the FDA. The IDE
application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the investigational protocol is scientifically sound. The IDE application must be
approved in advance by the FDA for a specified number of patients, unless the product is deemed a <FONT STYLE="white-space:nowrap">non-significant</FONT> risk device and eligible for abbreviated IDE requirements. Clinical trials for a significant
risk device may begin once the IDE application is approved by the FDA as well as the appropriate institutional review boards (IRBs), at the clinical trial sites and the informed consent of the patients participating in the clinical trial is
obtained. After a trial begins, the FDA may place it on hold or terminate it if, among other reasons, it concludes that the clinical subjects are exposed to an unacceptable health risk. Any trials Bioventus conducts must be conducted in accordance
with FDA regulations as well as other federal regulations and state laws concerning human subject protection and privacy. Moreover, the results of a clinical trial may not be sufficient to obtain clearance or approval of the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pervasive and continuing FDA regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a
medical device is placed on the market, numerous FDA regulatory requirements apply, including, but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">QSRs, which requires manufacturers to follow design, testing, control, documentation and other quality assurance
procedures during the manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establishment Registration, which requires establishments involved in the production and distribution of medical
devices, intended for commercial distribution in the United States, to register with the FDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Medical Device Listing, which requires manufacturers to list the devices they have in commercial distribution
with the FDA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Labeling regulations, which prohibit &#147;misbranded&#148; devices from entering the market, as well as prohibit
the promotion of products for unapproved or <FONT STYLE="white-space:nowrap">off-label</FONT> uses and impose other restrictions on labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Postmarket surveillance, including Medical Device Reporting (MDR) requirements which requires manufacturers to
report to the FDA if their device may have caused or contributed to a death or serious injury, or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Corrections and Removal Reporting regulations, which require that manufacturers report to the FDA field
corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the United States Federal Food, Drug, and Cosmetic Act (FDCA) that may present a risk to health.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA enforces these requirements by inspection and market surveillance. Failure to comply with applicable regulatory requirements
may result in enforcement action by the FDA, which may include one or more of the following sanctions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">untitled letters or warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, injunctions and civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandatory recall or seizure of its products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administrative detention or banning of its products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions, partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing its request for 510(k) clearances or PMA approvals for new product versions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revocation of 510(k) clearances or PMA approvals previously granted; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution and penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. regulation of HCT/Ps </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146;
products, including OsteoAMP and PureBone, are regulated as human cells, tissues and cellular and tissue-based products, or HCT/Ps. Section&nbsp;361 of the PHSA authorizes the FDA to issue regulations to prevent the introduction, transmission or
spread of communicable disease. HCT/Ps regulated as &#147;Section&nbsp;361&#148; HCT/Ps are subject to requirements relating to registering facilities and listing products with the FDA, screening and testing for tissue donor eligibility, cGTP, when
processing, storing, labeling and distributing HCT/Ps, including required labeling information, stringent record keeping and adverse event reporting, among other applicable requirements and laws. Specifically, cGTPs are requirements that govern the
methods used in, and the facilities and controls used for, the manufacture of HCT/Ps in a way that prevents the introduction, transmission, or spread of communicable diseases. Section&nbsp;361 HCT/Ps do not require 510(k) clearance, PMA approval,
BLAs, or other premarket authorization from the FDA before marketing. However, to be regulated as a Section&nbsp;361 HCT/P, the product must, among other things, be &#147;minimally manipulated,&#148; which for structural tissue products means that
the manufacturing processes do not alter the original relevant characteristics of the tissue relating to the tissue&#146;s utility for reconstruction, repair, or replacement and for cells or nonstructural tissue products, means that the
manufacturing processes do not alter the relevant biological characteristics of cells or tissues. A Section&nbsp;361 HCT/P must also be intended for &#147;homologous use,&#148; which refers to use in the repair, reconstruction, replacement, or
supplementation of a recipient&#146;s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus believes its OsteoAMP product is properly regulated as a Section&nbsp;361 HCT/P and therefore have not sought or obtained 510(k) clearance, PMA
approval, or licensure through a BLA. However, the FDA&#146;s Center for Devices and Radiological Health (CDRH) issued Bioventus a letter in March 2016 in which it asserted that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OsteoAMP meets the definition of a medical device and requested that Bioventus provides CDRH with information in support of its position that OsteoAMP does not require 510(k) clearance or PMA
approval. Bioventus provided CDRH with the requested information in support of this position in May 2016 and Bioventus has received no further inquiries to date. Bioventus believes that CDRH&#146;s assertion is unfounded and inconsistent with a 2011
letter from the FDA concluding that OsteoAMP meets the criteria for regulation solely as a Section&nbsp;361 HCT/P. However, if the FDA were to disagree and if Bioventus is otherwise unsuccessful in asserting its position, the FDA may then require
that Bioventus obtains 510(k) clearance or PMA approval and that Bioventus ceases marketing OsteoAMP and/or recall OsteoAMP unless and until Bioventus receives clearance or approval. Bioventus estimates that if Bioventus were to cease marketing
OsteoAmp and/or recall OsteoAmp that its net sales would decrease, which would adversely affect its results of operations. See <I>&#147;</I>Risk Factors&#151;Risks relating to government regulation&#151;&#148; Bioventus&#146; HCT/P products are
subject to extensive government regulation and its failure to comply with these requirements could cause its business to suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCT/Ps that do not meet
the criteria of Section&nbsp;361 are regulated under Section&nbsp;351 of the PHSA. Unlike 361 HCT/Ps, HCT/Ps regulated as &#147;351&#148; HCT/Ps are subject to premarket review and/or approval by the FDA, as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2017, the FDA released a guidance document entitled &#147;Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue&#151;Based
Products: Minimal Manipulation and Homologous Use&#151;Guidance for Industry and Food and Drug Administration Staff.&#148; The guidance outlined the FDA&#146;s position that all lyophilized amniotic products are more than minimally manipulated and
would therefore require a BLA to be lawfully marketed in the United States. The guidance also indicated that the FDA would exercise enforcement discretion, using a risk-based approach, with respect to the IND application and <FONT
STYLE="white-space:nowrap">pre-market</FONT> approval requirements for certain HCT/Ps for a period of 36 months from the issuance date of the guidance to allow manufacturers to pursue its IND application. Under this approach, FDA indicated that
high-risk products and uses could be subject to immediate enforcement action. In July 2020, the FDA extended its period of enforcement discretion to May&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including the seizure or recall
of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. regulation of drugs and biologics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus
expects that MOTYS will be regulated by the FDA as a biological product, or biologic. Bioventus planned to market MOTYS while it pursued a BLA for the product, but withdrew those plans and discontinued its limited marketing of MOTYS upon the
expiration of the FDA&#146;s enforcement discretion period for certain HCT/Ps. Biologics are regulated under both the FDCA and the PHSA and other federal, state, local and foreign statutes and regulations. Bioventus, along with third-party
contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which Bioventus wishes to conduct studies or seek approval or licensure of its
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process required by the FDA before product candidates may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable
regulations, including the FDA&#146;s Good Laboratory Practice (GLP), regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND which must become effective before clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before
the trial is commenced; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety and effectiveness of
the proposed drug candidate and the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of an New Drug Application (NDA) or BLA after completion of all pivotal
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a NDA or BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP requirements, and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s safety and effectiveness,
and of selected clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of a NDA or BLA to permit commercial marketing of the product for particular indications
for use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and Clinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate, Bioventus must submit an IND to the FDA. An IND is a request for authorization from the
FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols clinical trials. The IND also includes results of animal and <I>in vitro</I>
studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls (CMC), information, and any available human data or literature to support the use of the
investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> period,
raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin.
Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the
investigational product to human subjects under the supervision of qualified investigators in accordance with good clinical practices (GCPs), which include the requirement that all research subjects provide their informed consent for their
participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate
submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial
must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical
trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of
qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study
and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and
clinical trials and clinical study results to public registries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of regulatory approval, human clinical trials are typically conducted in three sequential
phases that may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1</I>. The investigational product is initially introduced into patients with the target disease or
condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence
on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2</I>. The investigational product is administered to a limited patient population to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3</I>. The investigational product is administered to an expanded patient population to further evaluate
dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
ratio of the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or
companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to approval of the
NDA or BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product
in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity,
strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate
does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive
monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time on various grounds, including a finding that the
research participant or participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the
IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to patients. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public
registries. Sponsors of clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products may be required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA or BLA Submission and Review </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a NDA or BLA requesting approval
to market the product for one or more indications. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with
detailed information relating to the product&#146;s CMCs and proposed labeling, among other things. The submission of a NDA or BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. The FDA has
60 days from the applicant&#146;s submission of a NDA or BLA to either issue a refusal to file letter or accept the NDA or BLA for filing, indicating that it is sufficiently complete to permit substantive review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a NDA or BLA has been accepted for filing, the FDA&#146;s goal is to review standard applications within ten months after it accepts the application for
filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significantly extended by FDA requests for additional information or clarification. The FDA reviews a NDA or BLA to determine, among other things, whether a product is safe and effective, or
safe, pure, and potent, for its intended use, and whether the facility in which it is manufactured, processed, packed or held meets standards designed to assure and preserve the product&#146;s identity, safety, strength, quality, potency and purity.
The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before
approving a NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the
deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or
its drug substance will be manufactured, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete
Response letter will describe all of the deficiencies that the FDA has identified in the NDA or BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete
Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the NDA
or BLA in condition for approval, including requests for additional information or clarification, including the potential requirement for additional clinical studies. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria
are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for
which such product may be marketed. For example, the FDA may approve the NDA or BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or
potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such
as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once
approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require
one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing
studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
products manufactured or distributed by Bioventus pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences,
periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and
approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Manufacturers and their subcontractors are required to register their establishments
with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Bioventus and its third-party manufacturers. Changes to the manufacturing process are
strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements
upon Bioventus and any third-party manufacturers that Bioventus may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other
aspects of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory
requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a
Risk Evaluation and Mitigation Strategy (REMS) program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. A company can make only those claims relating to safety
and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA
approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things,
adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those
tested by Bioventus and approved by the FDA, but physicians may not submit claims for reimbursement that are false or fraudulent. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may
believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however,
restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International regulation of medical devices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales
of medical devices outside the United States are subject to foreign government regulations, which vary substantially from country to country. In order to market its products in other countries, Bioventus must obtain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approvals and comply with extensive safety and quality regulations in other countries. The time required to obtain approval by a foreign country may be longer or shorter than that
required for FDA approval and the requirements may differ significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EU regulation of medical devices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EU has adopted legislation, in the form of directives to be implemented in each Member State, concerning the regulation of medical devices within the EU.
The directives include, among others, the Medical Device Directive (Council Directive 93/42/EEC) that establishes certain requirements, such as the essential requirements, with which medical devices must comply before they can be commercialized in
the European Economic Area (EEA) (which is comprised of the Member States of the EU plus Norway, Liechtenstein and Iceland). Under the EU Medical Device Directive, medical devices are classified into four Classes, I, IIa, IIb and III, with
Class&nbsp;I being the lowest risk and Class&nbsp;III being the highest risk. Under the Medical Device Directive, a competent authority is nominated by the government of each Member State to monitor and ensure compliance with the Directive. To
demonstrate compliance of their medical devices with the essential requirements, manufacturers must undergo a conformity assessment evaluation, which varies according to the type of medical device and its classification. Except for certain types of
low risk medical devices (Class I <FONT STYLE="white-space:nowrap">non-sterile,</FONT> <FONT STYLE="white-space:nowrap">non-measuring</FONT> devices), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the
conformity of its products with the essential requirements of the Medical Devices Directive, a conformity assessment evaluation requires the intervention of an organization accredited by a Member State of the EEA to conduct conformity assessments, a
<FONT STYLE="white-space:nowrap">so-called</FONT> Notified Body. The Notified Body would typically audit and examine the quality system for the manufacture, design and final inspection of the medical devices, along with conducting a technical review
of data supporting the device&#146;s safety and efficacy, before issuing a certification demonstrating compliance with the essential requirements. Both the quality system and the product are reviewed and certified. The Company is subject to annual
surveillance audits by the Notified Body and must undergo <FONT STYLE="white-space:nowrap">re-certification</FONT> every 5 years. During these audits, (minor or major) <FONT STYLE="white-space:nowrap">non-conformities</FONT> to the essential
requirement may be issued to the Company. The Company could potentially lose marketing authorization if these <FONT STYLE="white-space:nowrap">non-conformities</FONT> are not remediated with the Notified Body. Significant modifications to the
quality system or product changes for Class&nbsp;III devices must be submitted to the Notified Body for review prior to implementation. <FONT STYLE="white-space:nowrap">Non-significant</FONT> changes are subject to review during the annual
surveillance audits. Medical devices that comply with the essential requirements are entitled to bear the CE mark. Medical devices properly bearing the CE mark may be commercially distributed throughout the EEA. Bioventus has received CE
certification from the British Standards Institute, a United Kingdom Notified Body, for conformity with the EU Medical Device Directive allowing Bioventus to place the CE mark on Durolane (Class III) and its Exogen bone healing system (Class IIa).
Additional PMAs in individual EEA countries are sometimes required prior to marketing of a product. Failure to maintain the CE mark would preclude Bioventus from selling its products in the EEA, as could failure to comply with the specific
requirements of the Member States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2017, the European Parliament passed the Medical Devices Regulation, which repeals and replaces the
EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA Member States, the regulations would be directly applicable without the need for adoption of EEA Member State laws implementing them in all
EEA Member States and are intended to eliminate current differences in the regulation of medical devices among EEA Member States. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and
sustainable regulatory framework across the EEA for medical devices and <I>in vitro</I> diagnostic devices and ensure a high level of safety and health while supporting innovation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Medical Devices Regulation was meant to become applicable three years after publication (in May 2020).
However, on April&nbsp;23, 2020, to take the pressure off EEA national authorities, notified bodies, manufacturers and other actors so they can focus fully on urgent priorities related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, the European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the Medical Devices Regulation by one year (to May 2021). Once applicable, the new regulations will among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish explicit provisions on manufacturers&#146; responsibilities for the
<FONT STYLE="white-space:nowrap">follow-up</FONT> on the quality, performance and safety of devices placed on the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improve the traceability of medical devices throughout the supply chain to the
<FONT STYLE="white-space:nowrap">end-user</FONT> or patient through a unique identification number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">set up a central database to provide patients, healthcare professionals and the public with comprehensive
information on products available in the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an
additional check by experts before they are placed on the market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These new rules and procedures may result in increased regulatory
oversight of its devices and this may, in turn, increase the costs, time and requirements that Bioventus needs to meet in order to maintain or place such devices on the EEA market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the advertising and promotion of its products in the EEA is subject to the laws of individual EEA Member States implementing the EU Medical Devices
Directive, Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, as well as other EEA Member State laws governing the advertising and promotion of medical devices. These laws
may limit or restrict the advertising and promotion of its products to the general public and may impose limitations on its promotional activities with healthcare professionals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other countries&#146; regulation of medical devices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many other countries have specific requirements for classification, registration and post marketing surveillance that are independent of the countries already
listed. Bioventus obtains what Bioventus believes are the appropriate clearances for Durolane and its Exogen bone healing system and conduct its business in accordance with the applicable laws of each country. This landscape is constantly changing
and Bioventus could be found in violation if Bioventus interprets the laws incorrectly or fail to keep pace with changes. In the event of either of these occurrences, Bioventus could be instructed to recall products, cease distribution and/or be
subject to civil or criminal penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-kickback, false claims and other healthcare laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on the marketing of pharmaceutical, biological and medical device products, Bioventus is also subject to healthcare regulation
and enforcement by the federal government and the states and foreign governments and authorities in the locations in which Bioventus conducts its business. These other agencies include, without limitation, CMS, other divisions of the U.S. Department
of Health and Human Services (HHS), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, as well as state and local governments. Such agencies enforce a variety of laws which include, without
limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security and physician payment transparency laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting or receiving
any remuneration (including any kickback, bribe or rebate), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or
service reimbursable, in whole or in part, by Medicare, Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value, including cash, improper discounts and free or
reduced price items and services. Among other things, the Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical, biotechnology and medical device manufacturers on the one hand and prescribers, purchasers and
formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve
remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the
requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#146;s intent requirement to mean that if
any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil monetary penalties up to $100,000 for each violation, plus up to three times the remuneration involved, and may result in criminal fines
of up to $100,000 and imprisonment of up to ten years, or exclusion from Medicare, Medicaid or other governmental programs. Further, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute also constitutes
a false or fraudulent claim for purposes of the federal civil False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Federal law also includes a provision commonly known as the &#147;Stark
Law,&#148; which prohibits a physician from referring Medicare or Medicaid patients to an entity providing &#147;designated health services,&#148; which includes durable medical equipment, if the physician or immediate family member of the
physician, has an ownership or investment interest or compensation arrangement with such entity that does not comply with the requirements of a Stark exception. Violation of the Stark Law could result in denial of payment, disgorgement of
reimbursements received under a <FONT STYLE="white-space:nowrap">non-compliant</FONT> arrangement, civil penalties, and exclusion from Medicare, Medicaid or other governmental programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal false claims and civil monetary penalties laws, including the civil False Claims Act, prohibit, among other things, any person or entity from
knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent
claim to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private
individual in the name of the U.S. government. Violations of the False Claims Act can result in very significant monetary penalties and treble damages. The federal government is using the False Claims Act and the accompanying threat of significant
liability, in its investigation and prosecution of pharmaceutical, biotechnology and medical device companies throughout the country. Manufacturers can be held liable under these laws if they are deemed to &#147;cause&#148; the submission of false
or fraudulent claims by for example, in connection with the promotion of products for unapproved or <FONT STYLE="white-space:nowrap">off-label</FONT> uses and other sales and marketing practices. The government has obtained multi-million and
multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. When an entity is determined to have violated the federal civil False Claims Act, the government may
impose civil fines and penalties ranging from $11,181 to $22,363 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. In addition, companies found liable
under the False Claims Act have been forced to implement extensive corrective action plans, and have often become subject to consent decrees or corporate integrity agreements, severely restricting the manner in which they conduct their business and
imposing ongoing reporting and disclosure obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal civil monetary penalties statute imposes penalties against any person or entity that, among
other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Given the
significant size of actual and potential settlements, it is expected that governmental authorities will continue to devote substantial resources to investigating healthcare providers&#146; and manufacturers&#146; compliance with applicable fraud and
abuse laws. For drugs that are covered under Medicare Part B, the manufacturer must report average sales price (ASP), to CMS on a quarterly basis. Failure to report this information in a timely and accurate manner can lead to substantial civil and
criminal penalties and to liability under the False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July of 2018 Bioventus became aware of allegations that certain of its sales personnel
may have been completing Section B of the Certificate for Medical Necessity form (CMN) required in connection with Medicare claims for the Exogen system, which, under federal law, must be completed by the physician and/or physician staff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with its outside counsel, Bioventus initiated an investigation into these allegations, and Bioventus determined that the CMN forms for a portion of
Medicare claims for the Exogen system were in fact improperly completed by its sales representatives, some of which also failed to meet CMS coverage requirements. As a result of its findings Bioventus made a self-disclosure on November&nbsp;30, 2018
to the Office of Inspector General of the HHS (OIG), under the Provider Self-Disclosure Protocol. Bioventus&#146; self-disclosure disclosed the extent of its findings relative to the inappropriate completion of CMN forms by its sales personnel and
offered to make repayment for such claims which failed to meet CMS coverage requirements and which Bioventus submitted to the Medicare program between October&nbsp;1, 2012 and September&nbsp;30, 2018, the statutory period applicable to such conduct.
The total value of impacted claims was $30.1&nbsp;million in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2019, its outside counsel received a letter from the Office of the
United States Attorney in the Middle District of North Carolina (USAO) stating that the USAO would be working with the OIG to resolve its self-disclosure. After settlement discussions with the USAO and OIG, on January&nbsp;25, 2021 Bioventus reached
an agreement in principle with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which its sales representatives completed Section B of the CMN forms. On February&nbsp;22,
2021, Bioventus finalized all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with its previous agreement in principle and which included releases from associated False Claims Act
liability and further Civil Monetary Penalties that are customary in self-disclosures of this type. Under the agreement, Bioventus resolved the potential liability related to its self-disclosure for $3.6&nbsp;million, of which $2.4&nbsp;million had
already been paid through its 2019 return of overpayments described previously, leaving a net payment to be made of $1.2&nbsp;million. Bioventus made payment of the $1.2&nbsp;million net settlement amount due under the agreement on February&nbsp;23,
2021. The settlement amount noted above was recorded in the consolidated financial statements for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2019,
separate from the self-disclosure described above, as a result of its internal auditing of Exogen Medicare claims, Bioventus made repayments to its Medicare Administrative Contractors (MACs) for overpayments identified during such auditing totaling
$7.5&nbsp;million for the period October&nbsp;1, 2012 through December&nbsp;31, 2018. This amount reflected certain Medicare claims for Exogen for which Bioventus lacked adequate documentation of medical necessity consistent with Medicare coverage
requirements. Similarly, in July of 2020, Bioventus made repayments to the MACs of $1.5&nbsp;million after completing its internal auditing of Exogen Medicare claims for the period beginning January&nbsp;1, 2019 through December&nbsp;31, 2019.
Bioventus maintains a reserve for reimbursement claims related to its Exogen system that may have been processed for payment without adequate medical records support. Bioventus&#146; reserve is estimated using an extrapolation of an error rate from
a statistical sample, which represents its best estimate as of the date of the financial statements, but because of the uncertainty inherent in such estimates, the ultimate repayment amounts may be materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#151;Risks Relating to Government Regulation.&#148; Bioventus may be subject to enforcement action if Bioventus engages in improper
claims submission practices and resulting audits or denials of its claims by government agencies could reduce its net sales or profits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Health Insurance Portability and Accountability Act of 1996, as amended by Health Information
Technology for Economic and Clinical Health Act (HITECH), and the regulations that implement both laws, collectively known as HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a
healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or
services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payer, in addition to items
and services reimbursed under Medicaid and other state programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any
remuneration, including waivers of <FONT STYLE="white-space:nowrap">co-payments</FONT> and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#146;s selection of a particular
provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $20,866 for each wrongful act. Moreover, in certain cases, providers who routinely waive <FONT
STYLE="white-space:nowrap">co-payments</FONT> and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can impose additional penalties associated with the
wrongful act. One of the statutory exceptions to the prohibition is <FONT STYLE="white-space:nowrap">non-routine,</FONT> unadvertised waivers of <FONT STYLE="white-space:nowrap">co-payments</FONT> or deductible amounts based on individualized
determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition
applies only to federal healthcare program beneficiaries, the routine waivers of <FONT STYLE="white-space:nowrap">co-payments</FONT> and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to,
among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent its patient assistance programs are found to be inconsistent with applicable
laws, Bioventus may be required to restructure or discontinue such programs, or be subject to other significant penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, there has been a
recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act, or
collectively, the Affordable Care Act, imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#147;transfers of value&#148; provided to
physicians and teaching hospitals, and, beginning in 2022, physician assistants, nurse practitioners and other practitioners, as well as ownership and investment interests held by such providers and their immediate family members. Failure to submit
timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $176,495 per year and up to an aggregate of
$1.177&nbsp;million per year for &#147;knowing failures.&#148; Covered manufacturers must submit reports by the 90th day of each calendar year. In addition, certain states require implementation of compliance programs and compliance with the
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, make periodic public disclosures on sales, marketing, pricing, clinical trials
and other activities and/or require tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These laws impact the kinds of financial arrangements Bioventus may have with hospitals, physicians or other potential purchasers of its products. They
particularly impact how Bioventus structures its sales offerings, including discount practices, customer support, education and training programs, physician consulting, research grants and other arrangements. If its operations are found to be in
violation of any of the health regulatory laws </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
described above or any other laws or regulations that apply to us, Bioventus may be subject to penalties, including, without limitation, potentially significant criminal, civil and/or
administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, imprisonment, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the
curtailment or restructuring of its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of its sale or distribution of products in a foreign country, Bioventus may be subject to
similar foreign laws and regulations, which may include, for instance, applicable post marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or
other transfers of value to healthcare professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus participates in state government-managed Medicaid programs as well as certain other
qualifying federal and state government programs where discounts and mandatory rebates are provided to participating state and local government entities. In connection with several of these government programs, Bioventus is required to report prices
to various government agencies. Pricing calculations vary among programs. The calculations are complex and are often subject to interpretation by the reporting entities, government agencies and the courts. Bioventus&#146; methodologies for
calculating these prices could be challenged under false claims laws or other laws. Bioventus could make a mistake in calculating reported prices and required discounts, which could result in retroactive liability to government agencies. Government
agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. If Bioventus makes these mistakes or if governmental agencies make
these changes, Bioventus could face, in addition to prosecution under federal and state false claims laws, substantial liability and civil monetary penalties, exclusion of its products from reimbursement under government programs, criminal fines or
imprisonment, or prosecutors may impose a Corporate Integrity Agreement, Deferred Prosecution Agreement, or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Medicare
Prescription Drug, Improvement and Modernization Act of 2003 (MMA), requires that manufacturers report data to CMS on pricing of covered drugs reimbursed under Medicare Part B. These are generally drugs and biologicals, such as injectable products,
that are administered &#147;incident to&#148; a physician service and in general are not self-administered. Effective January&nbsp;1, 2005, ASP became the basis for reimbursement to physicians and suppliers for drugs and biologicals covered under
Medicare Part B, replacing the average wholesale price (AWP), provided and published by pricing services. In general, Bioventus must comply with all reporting requirements for any drug that is separately reimbursable under Medicare. The SUPARTZ FX
product is reimbursed under Medicare Part B and, as a result, Bioventus provides ASP data on this product to CMS on a quarterly basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Privacy and
data protection laws in the United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA and its implementing regulations, contain substantial restrictions and requirements with respect
to the use and disclosure of certain protected health information (PHI). These restrictions and requirements are set forth in the HIPAA Privacy, Security and Breach Notification Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some of its operations, such those involving the acceptance of payments, Bioventus is a &#147;covered entity&#148; under HIPAA and therefore required to
comply with the Privacy, Security and Breach Notification Rules and is subject to significant civil and criminal penalties for failure to do so. Bioventus also provides services to customers that are covered entities themselves and Bioventus is
required to provide satisfactory written assurances to these customers through written &#147;business associate&#148; agreements that Bioventus will provide its services in accordance with HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Final Rule published by HHS Office for Civil Rights (OCR) in January 2013 and effective March&nbsp;23, 2013, modified the HIPAA Privacy, Security, Breach
Notification and Enforcement Rules, including revisions/additions made by the HITECH Act. The rule expanded the privacy and security requirements for business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associates that create, receive, maintain or transmit PHI for or on behalf of covered entities, increased penalties for noncompliance and strengthened requirements for reporting of breaches of
unsecured PHI, among other changes. The rule also made business associates and their subcontractors directly liable for civil monetary penalties for impermissible uses and disclosures of PHI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Bioventus was to be found to have breached its obligations under HIPAA, Bioventus could be subject to enforcement actions by the OCR and state health
regulators and lawsuits, including class action law suits, by private plaintiffs. In addition, OCR performs compliance audits in order to proactively enforce the HIPAA privacy and security standards. OCR has become an increasingly active regulator
and has signaled its intention to continue this trend. OCR has the discretion to impose penalties without being required to attempt to resolve violations through informal means; further OCR may require companies to enter into resolution agreements
and corrective action plans which impose ongoing compliance requirements. OCR enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In
addition to enforcement by OCR, state attorneys general are authorized to bring civil actions under either HIPAA or relevant state laws seeking either injunctions or damages in response to violations that threaten the privacy of state residents.
Although Bioventus has implemented and maintained policies, processes and a compliance program infrastructure to assist Bioventus in complying with these laws and regulations and its contractual obligations, Bioventus cannot provide assurance
regarding how these laws and regulations will be interpreted, enforced or applied to its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to HIPAA, Bioventus must adhere to state
patient confidentiality laws that are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, including those that are more stringent than HIPAA requirements. Numerous other state, federal and foreign laws, including consumer protection
laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy
and security of medical records or medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, all states have passed laws regulating the actions that a business
must take if it experiences a data breach, such as prompt disclosure to affected customers. Generally, these laws are limited to electronic data and make some exemptions for smaller breaches. Congress has also been considering similar federal
legislation relating to data breaches. The Federal Trade Commission (FTC) and states&#146; Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act.
In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security
requirements for personal information. For example, the California Consumer Privacy Act (CCPA) took effect on January&nbsp;1, 2020. The CCPA establishes a new privacy framework for covered businesses and provides new and enhanced data privacy rights
to California residents, such as affording consumers the right to access and delete their information and to opt out of certain sharing and sales of personal information. The CCPA imposes severe statutory damages as well as a private right of action
for certain data breaches that result in the loss of personal information. This private right of action is expected to increase the likelihood of, and risks associated with, data breach litigation. It remains unclear how various provisions of the
CCPA will be interpreted and enforced. The CCPA contains an exemption for medical information governed by the California Confidentiality of Medical Information Act (CMIA) and for PHI collected by a covered entity or business associate governed by
the privacy, security and breach notification rules established pursuant to HIPAA and HITECH, but the precise application and scope of this exemption is not yet clear, and the law may still apply to certain aspects of its business. Additionally, a
new privacy law, the California Privacy Rights Act (CPRA), was approved by California voters in the November&nbsp;3, 2020 election. The CPRA generally takes effect on January&nbsp;1, 2023 and significantly modifies the CCPA, including by expanding
consumers&#146; rights with respect to certain personal information, restricting use of sensitive personal information, which includes health information, and creating a new state agency to oversee implementation and enforcement efforts, potentially
resulting in further uncertainty and requiring Bioventus to incur additional costs and expenses in an effort to comply. The CCPA and CPRA may lead other states to pass comparable legislation, with potentially greater penalties, and more rigorous
compliance requirements relevant to its business, and that may not include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemptions for businesses subject to HIPAA. The effects of the CCPA, and other similar state or federal laws, are potentially significant and may require Bioventus to modify its data processing
practices and policies and to incur substantial costs and potential liability in an effort to comply with such legislation. As with HIPAA, any laws regulating the collection, dissemination, use, access to, confidentiality and security of personal
information may apply directly to its business or indirectly by contract when Bioventus provides services to other companies. Bioventus intends to continue to comprehensively protect all consumer data and to comply with all applicable laws regarding
the protection of this data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Privacy and data protection laws in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is subject to European laws relating to its and its suppliers&#146;, partners&#146; and subcontractors&#146; collection, control, processing and
other use of personal data, such as data relating to an identifiable living individual, whether that individual can be identified directly or indirectly. Bioventus and its suppliers, partners and subcontractors process personal data including in
relation to its employees, employees of customers, trial patients, health care professions and employees of suppliers including health and medical information. The data privacy regime in the EU includes the General Data Protection Regulation (GDPR),
the <FONT STYLE="white-space:nowrap">E-Privacy</FONT> Directive (2002/58/EC) and national laws implementing or supplementing each of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GDPR
requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws and the data may then only be processed in a manner consistent with those purposes. The personal data collected and
processed must be adequate, relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the EEA unless certain steps are taken to ensure an adequate level of
protection and must not be retained for longer than necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain organizational steps to ensure that they have adequate
records, policies, security, training and governance frameworks in place to ensure the protection of data subject rights, including as required to respond to complaints and requests from data subjects. In addition, to the extent a company processes,
controls or otherwise uses &#145;special category&#146; personal data (including patients&#146; health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the
manner in which a company is legally permitted to process that data. Finally, GDPR provides a broad right for EU Member States to create supplemental national laws. Such laws and they are increasingly adopting different approaches to the role of the
parties in clinical trials. Such laws, for example may relate to the processing of health, genetic and biometric data, which could further limit its ability to use and share such data or could cause its costs to increase and harm its business and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2021, Bioventus is also subject to the GDPR and also the UK GDPR, which, together with the amended UK Data
Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#128;20&nbsp;million (&pound;17.9 million) or 4% of global turnover. The relationship between the United Kingdom
and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United
Kingdom will be regulated in the long term. Currently there is a four to <FONT STYLE="white-space:nowrap">six-month</FONT> grace period agreed in the EU and UK Trade and Cooperation Agreement, ending 30&nbsp;June 2021 at the latest, whilst the
parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional
measures. These changes will lead to additional costs and increase its overall risk exposure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the United Kingdom&#146;s withdrawal from the
European Union means that the United Kingdom will become a &#147;third country&#148; for the purposes of data transfers from the European Union to the United Kingdom following the expiration of the four to
<FONT STYLE="white-space:nowrap">six-month</FONT> personal data transfer grace period (from January&nbsp;1, 2021) set out in the EU and UK Trade and Cooperation Agreement, unless a relevant adequacy decision is adopted in favor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the United Kingdom (which would allow data transfers without additional measures). These changes may require Bioventus to find alternative solutions for the compliant transfer of personal data
into the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is also subject to evolving European laws on data export and electronic marketing. The rules on data export will apply
when Bioventus transfers personal data to group companies or third parties outside of the EEA. For example, in 2015, the Court of Justice of the European Union (CJEU) ruled that the <FONT STYLE="white-space:nowrap">U.S.-EU</FONT> Safe Harbor
framework, one compliance method by which companies could transfer personal data regarding citizens of the EU to the United States, was invalid and could no longer be relied upon. European and U.S. negotiators agreed in February 2016 to a new
framework, the <FONT STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield framework, which replaced the Safe Harbor framework, however, on July&nbsp;16, 2020 the CJEU also invalidated the Privacy Shield framework as a method to transfer personal
data from the EEA to US. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the
Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances; this has created uncertainty. These changes will require Bioventus to review and amend the legal mechanisms by which Bioventus makes
and/ or receive personal data transfers to/ in the U.S. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking
enforcement action, Bioventus could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if Bioventus is otherwise unable to transfer personal data between and among countries and regions in which Bioventus operates,
it could affect the manner in which Bioventus provides its services, the geographical location or segregation of its relevant systems and operations, and could adversely affect its financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is also subject to evolving EU and UK privacy laws on cookies and <FONT STYLE="white-space:nowrap">e-marketing.</FONT> In the European Union and the
United Kingdom, regulators are increasingly focusing on compliance with requirements in the online behavioral advertising ecosystem, and current national laws that implement the ePrivacy Directive are highly likely to be replaced by an EU regulation
known as the ePrivacy Regulation which will significantly increase fines for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> In the European Union and the United Kingdom, informed consent is required for the placement of a cookie or similar
technologies on a user&#146;s device and for direct electronic marketing. The GDPR also imposes conditions on obtaining valid consent, such as a prohibition on <FONT STYLE="white-space:nowrap">pre-checked</FONT> consents and a requirement to ensure
separate consents are sought for each type of cookie or similar technology. While the text of the ePrivacy Regulation is still under development, a recent European court decision and regulators&#146; recent guidance are driving increased attention
to cookies and tracking technologies. If regulators start to enforce the strict approach in recent guidance, this could lead to substantial costs, require significant systems changes, limit the effectiveness of its marketing activities, divert the
attention of its technology personnel, adversely affect its margins, increase costs and subject Bioventus to additional liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is subject
to the supervision of local data protection authorities in those jurisdictions where Bioventus is established or collecting data from EU residents. Bioventus depends on a number of third parties in relation to its provision of its services, a number
of which process personal data on its behalf. With each such provider Bioventus enters into contractual arrangements to ensure that they only process personal data according to its instructions, and that they have sufficient technical and
organizational security measures in place. Where Bioventus transfers personal data outside the EEA, Bioventus does so in compliance with the relevant data export requirements. As previously described, following the CJEU&#146;s decision to invalidate
Privacy Shield, Bioventus is now required to review and amend the legal mechanisms by which Bioventus makes and/or receive personal data transfers to/in the U.S. As supervisory authorities issue further guidance on personal data export mechanisms,
including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, Bioventus could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if Bioventus is otherwise
unable to transfer personal data between and among countries and regions in which Bioventus operates, it could affect the manner in which Bioventus provides its services, the geographical location or segregation of its relevant systems and
operations, and could adversely affect its financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus takes its data protection obligations seriously, as any improper, unlawful or accidental
disclosure, loss, alteration or access to, personal data, particularly sensitive personal data, such as special category, could adversely affect its business and/or its reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus may find it necessary or desirable to join self-regulatory bodies or other privacy-related organizations, particularly relating to biopharmacy
and/or scientific research that require compliance with certain rules pertaining to privacy and data security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are costs and administrative burdens
associated with compliance with GDPR and the resultant changes in the EU and EEA Member States&#146; national laws and the introduction of the <FONT STYLE="white-space:nowrap">e-Privacy</FONT> Regulation once it takes effect. Any failure or
perceived failure to comply with global privacy laws carries with it the risk of significant penalties and sanctions. These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose
additional operational requirements on its business, and could affect the manner in which Bioventus uses and transmits patient information and could increase its cost of doing business. Claims of violations of privacy rights or contractual breaches,
even if Bioventus is not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm its business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant
uncertainty exists as to the coverage and reimbursement status of any pharmaceutical, biological or medical device product. In the United States and markets in other countries, patients who are prescribed treatments or undergo procedures for their
conditions and the providers performing the services generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Patients are unlikely to use its products unless coverage is provided and reimbursement is
adequate to cover a significant portion of the cost of its products or related procedures. Sales of any products will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers
include government authorities, managed care organizations, private health insurers and other organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process for determining whether a
third-party payer will provide coverage for a product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payer will pay for the product once coverage is approved.
Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication, or place
products at certain formulary levels that result in lower reimbursement levels and higher cost-sharing obligation imposed on patients. A decision by a third-party payer not to cover any of its products or product candidates could reduce physician
utilization of such products and adversely affect its business, results of operations and financial condition. Moreover, a third-party payer&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be
approved. Adequate third-party reimbursement may not be available to enable Bioventus to maintain price levels sufficient to realize an appropriate return on its investment in product development. Additionally, coverage and reimbursement for
products can differ significantly from payer to payer. One third-party payer&#146;s decision to cover a particular medical product or service does not ensure that other payers will also provide coverage for the medical product or service, or will
provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will often require Bioventus to provide scientific and clinical support for the use of its products to each payer separately and can be a
time-consuming process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical
products and services, in addition to their safety and efficacy. Third-party payers may not consider its products to be medically necessary or cost-effective for certain indications or for all uses, and as a result, may not provide coverage for its
products. In order to obtain and maintain coverage and reimbursement for its products and product candidates, Bioventus may need to conduct expensive clinical trials in order to demonstrate the medical necessity and cost-effectiveness of such
products, in addition to the costs required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain regulatory approvals. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product as a benefit under their
plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Any changes in coverage and reimbursement that further restrict coverage of its products or lower reimbursement for procedures
using its devices could materially affect its business. See the information under &#147;Risk Factors&#151;Risks Relating to Bioventus&#146; Business.&#148; If Bioventus is unable to achieve and maintain adequate levels of coverage and/or
reimbursement for its products, the procedures using its products, or any future products Bioventus may seek to commercialize, the commercial success of these products may be severely hindered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside of the United States, the pricing of medical devices and prescription pharmaceuticals is subject to governmental control in many countries. For
example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional
studies that compare the cost-effectiveness of a particular therapy to currently available therapies or so called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their
own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of medical devices and pharmaceutical products could continue as countries
attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. There can be no assurance that any country that has price controls or reimbursement limitations for medical
devices or pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of its products, if approved in those countries. See the information under &#147;Risk Factors&#151;Risks Relating to Bioventus&#146;
Business.&#148; Governments outside the United States may not provide coverage or reimbursement of its products, which may adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exogen reimbursement and order fulfillment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; Exogen system is classified as durable medical equipment, meaning the product is used by the patient in the home and that the patient and/or
insurance company, rather than the physician, is billed for the product. Bioventus bills third-party payers, such as private insurance or Medicare, on behalf of its patients and bill the patient for their
<FONT STYLE="white-space:nowrap">co-payment</FONT> obligations and deductibles. An internal team and external consultants assist with billing and processing orders for its Exogen system and has been trained in verifying <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> benefits, obtaining prior authorization and billing and collecting payments from payers. Bioventus also has a separate dedicated team of employees that provides
customer support services for its Exogen system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has strong and established payer relationships, including the largest private payers in the
United States. Based on its estimates, Bioventus is contracted as a provider with payers covering over 200&nbsp;million lives. These contracts allow patients to access its Exogen system at a competitive rate and copay comparable to other suppliers
and easing its administrative burden in processing at both authorization and when billing. Bioventus&#146; Exogen system is reimbursed under Healthcare Common Procedure Coding System (HCPCS) code E0760. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current and future legislative
proposals to further reform healthcare or reduce healthcare costs may limit coverage for the procedures associated with the use of its products, or result in lower reimbursement for those procedures. The cost containment measures that payers and
providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce its revenues from the sale of its products. By way of example, the Affordable Care Act substantially changed healthcare
financing and delivery by both governmental and private insurers and significantly impacted the pharmaceutical and medical device industries. The Affordable Care Act imposed, among other things, a new federal excise tax on the sale of certain
medical devices, provided incentives to programs that increase the federal government&#146;s comparative effectiveness research and implemented payment system reforms including a national pilot program on payment
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Since its
enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, including the permanent repeal of the federal excise tax on the sale of certain medical devices effective January&nbsp;1, 2020. Bioventus
expects there will be additional challenges and amendments to the Affordable Care Act in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been
proposed and adopted in the United States since the Affordable Care Act was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2%
per fiscal year, which went into effect on April&nbsp;1, 2013. Subsequent legislative amendments related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic suspended this Medicare sequestration payment reduction from May&nbsp;1, 2020
through March&nbsp;31, 2021, but extended sequestration through 2030. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several types of providers,
including hospitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes due to healthcare legislation and regulatory initiatives. For example, CMS
may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in
several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare and review the relationship between
pricing and manufacturer patient programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers
will be included in their prescription drug and other healthcare programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, similar political, economic and regulatory developments have
occurred or are being contemplated. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or Member State level may result in significant additional requirements or obstacles that may increase
operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National
governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU
Member States have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus expects that
additional foreign, state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced
demand for its products or additional pricing pressure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Bioventus had approximately 700 employees, none of whom were covered by collective bargaining agreements. Most of these employees
are located in the United States with approximately 90 located outside the United States. Bioventus believes that its relations with its employees are generally good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus values its employees and regularly benchmark total rewards Bioventus provides, such as short and long term compensation, 401(k) contributions,
health, welfare and quality of life benefits, paid time off and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personal leave, against its industry peers to ensure Bioventus remains competitive and attractive to potential new hires. Bioventus seeks to create a workplace environment that fosters personal
and business successes by offering training and development programs, which further assist its current employees in meeting and exceeding its established standards of performance. Additionally, through its Diversity, Equity and Inclusion Counsel,
its employees work directly with its executive management team to address any internal concerns and continuously improve the ways in which Bioventus serves its employees and customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Receivable Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus expects to obtain an
increase in its share of the tax basis of the assets of BV LLC when the continuing LLC owner receives shares of Bioventus class A common stock or, if Bioventus and the continuing LLC owner agree, cash in connection with an exercise of the continuing
LLC owner&#146;s right to have its LLC interests redeemed by BV LLC or, at Bioventus&#146; election, directly exchanged (such basis increases, together with the basis increases resulting from certain distributions (or deemed distributions) from BV
LLC, the &#147;basis adjustments&#148;). Bioventus intends to treat such redemptions or exchanges of LLC interests as the direct purchase of LLC interests by Bioventus from the continuing LLC owner for U.S. federal income and other applicable tax
purposes, regardless of whether such LLC interests are surrendered by the continuing LLC owner to BV LLC for redemption or sold to Bioventus upon the exercise of our election to acquire such LLC interests directly. A basis adjustment may have the
effect of reducing the amounts that Bioventus would otherwise pay in the future to various tax authorities. The basis adjustments may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis
is allocated to those capital assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus entered into the TRA with the continuing LLC owner. The TRA provides for Bioventus&#146; payment to the
continuing LLC owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes, or in some circumstances are deemed to realize, as a result of any basis adjustments and certain other tax benefits arising from payments under the
TRA. BV LLC has in effect an election under Section&nbsp;754 of the Code effective for each taxable year in which a redemption or exchange (including deemed exchange) of LLC interests for shares of our Class&nbsp;A common stock or cash occurs. These
TRA payments are not conditioned upon any continued ownership interest in either BV LLC or Bioventus by the continuing LLC owner. The rights of the continuing LLC owner under the TRA are assignable to transferees of its LLC interests (other than
Bioventus as transferee pursuant to subsequent redemptions or exchanges of the transferred LLC interests). Bioventus expects to benefit from the remaining 15% of tax benefits, if any, that it may actually realize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actual basis adjustments, as well as any amounts paid to the continuing LLC owner under the TRA, will vary depending on a number of factors, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>the timing of any subsequent redemptions or exchanges&#151;</I>for instance, the increase in any tax
deductions will vary depending on the fair value, which may fluctuate over time, of the depreciable or amortizable assets of BV LLC at the time of each redemption or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>the price of shares of our Class</I><I></I><I>&nbsp;A common stock at the time of redemptions or
exchanges</I>&#151;the basis adjustments, as well as any related increase in any tax deductions, is directly related to the price of shares of our Class&nbsp;A common stock at the time of each redemption or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>the extent to which such redemptions or exchanges are taxable&#151;</I>if a redemption or exchange is not
taxable for any reason, increased tax deductions will not be available; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>the amount and timing of our income&#151;</I>the TRA generally requires Bioventus to pay 85% of the tax
benefits as and when those benefits are treated as realized under the terms of the TRA. Except as discussed below in cases of (i)&nbsp;a material breach of a material obligation under the TRA, (ii)&nbsp;a change of control or (iii)&nbsp;an early
termination of the TRA, if Bioventus does not have taxable income, it will generally not be required to make payments under the TRA for that taxable year because no tax benefits will have been realized. However, any tax benefits that do not result
in realized tax benefits in a given taxable year may generate tax attributes that may be utilized to generate tax benefits in future taxable years. The utilization of any such tax attributes will result in payments under the TRA.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the TRA, cash savings in income tax will be computed by comparing Bioventus&#146; actual
income tax liability to the amount of such taxes that it would have been required to pay had there been no basis adjustments and had the TRA not been entered into. The TRA generally applies to each of Bioventus&#146; taxable years, beginning with
the first taxable year ending after the consummation of the offering. There is no maximum term for the TRA; however, the TRA may be terminated by Bioventus pursuant to an early termination procedure that requires Bioventus to pay the continuing LLC
owner an agreed upon amount equal to the estimated present value of the remaining payments to be made under the agreement (calculated based on certain assumptions, including regarding tax rates and utilization of the basis adjustments). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The payment obligations under the TRA are Bioventus&#146; obligation and not BV LLC&#146;s. Although the actual timing and amount of any payments that may be
made under the TRA will vary, Bioventus expects that the payments that we may be required to make to the continuing LLC owner could be significant. Any payments made by Bioventus to the continuing LLC owner under the TRA generally reduces the amount
of overall cash flow that might have otherwise been available to Bioventus or to BV LLC and, to the extent that Bioventus is unable to make payments under the TRA for any reason, the unpaid amounts generally are deferred and accrue interest until
paid by Bioventus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Decisions made by Bioventus in the course of running Bioventus&#146; business, such as with respect to mergers, asset sales, other
forms of business combinations or other changes in control, may influence the timing and amount of payments that are received by the continuing LLC owner under the TRA. For example, the earlier disposition of assets following a transaction that
results in a basis adjustment generally accelerate payments under the TRA and increase the present value of such payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TRA provides that if
(i)&nbsp;Bioventus materially breaches any of its material obligations under the TRA, (ii)&nbsp;certain mergers, asset sales, other forms of business combination, or other changes of control were to occur, on or before December&nbsp;31, 2021 or
(iii)&nbsp;Bioventus elects an early termination of the TRA, then its obligations, or its successor&#146;s obligations, under the TRA would be based on certain assumptions, including an assumption that it would have sufficient taxable income to
fully utilize all potential future tax benefits that are subject to the TRA. The TRA also provides that in the case of certain mergers, asset sales, other forms of business combination or other changes of control occurring on or after
December&nbsp;31, 2021, payments under the TRA would be based on certain assumptions, including an assumption that in each taxable year ending on or after the change of control, Bioventus would have taxable income equal to the greater of
(A)&nbsp;actual taxable income for such taxable year and (B)&nbsp;the product of (x)&nbsp;four and (y)&nbsp;the highest taxable income in any of the four fiscal quarters ended prior to the change in control (increased by 10% for each taxable year
beginning with the second taxable year following the change in control), in each case, as adjusted to take into account our actual percentage ownership in BV LLC for the taxable year for which the tax benefit payment is being determined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the foregoing, (i)&nbsp;we could be required to make cash payments to the continuing LLC owner that are greater than the specified percentage
of the actual benefits Bioventus ultimately realizes in respect of the tax benefits that are subject to the TRA, and (ii)&nbsp;if Bioventus materially breach any of its material obligations under the TRA or if it elected to terminate the TRA early,
it would be required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the TRA, which payment may be made significantly in advance of the actual realization, if any, of such
future tax benefits. In these situations, Bioventus&#146; obligations under the TRA could have a material adverse effect on our liquidity and could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of
business combination, or other changes of control. There can be no assurance that Bioventus will be able to finance its obligations under the TRA. Bioventus anticipates funding ordinary course payments under the TRA from distributions from BV LLC
out of distributable cash, to the extent permitted by its agreements governing its indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments under the TRA are based on the tax reporting
positions that Bioventus determines. Pursuant to the TRA, the continuing LLC owner is required to reimburse Bioventus for cash payments previously made to it pursuant to the TRA if any tax benefits actually realized by Bioventus are subsequently
challenged by a taxing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authority and ultimately disallowed. In addition, but without duplication of any amounts previously reimbursed by the continuing LLC owner, any excess cash payments made by us to the continuing
LLC owner will be netted against any future cash payments that we might otherwise be required to make under the terms of the TRA. However, a challenge to any tax benefits actually realized by Bioventus may not arise for a number of years following
the initial time of such payment and Bioventus might not determine that it has effectively made an excess cash payment to the continuing LLC owner for a number of years following the initial time of such payment. Moreover, there can be no assurance
that any excess cash payments for which the continuing LLC owner has a reimbursement obligation under the TRA will be repaid to Bioventus. As a result, it is possible that Bioventus could make cash payments under the TRA that are substantially
greater than its actual cash tax savings. The applicable U.S. federal income tax rules are complex and factual in nature, and Bioventus cannot assure you that the IRS or a court will not disagree with its tax reporting positions. Bioventus has full
responsibility for, and sole discretion over, all of its and BV LLC&#146;s tax matters, including the filing and amendment of all tax returns and claims for refund and defense of all tax contests, subject to certain participation and approval rights
held by the continuing LLC owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments are generally due under the TRA within a specified period of time following the filing of Bioventus&#146; tax
return for the taxable year with respect to which the payment obligation arises, although interest on such payments begin to accrue at a rate of LIBOR plus 100 basis points from the due date, without extensions, of such tax return and ending on the
date that such payments are required to be made under the terms of the TRA. Any late payments that may be made under the TRA continue to accrue interest at LIBOR plus 500 basis points from the due date of such payments under the TRA until such
payments are made, including any late payments that Bioventus may subsequently make because Bioventus did not have enough available cash to satisfy its payment obligations at the time at which they originally arose, including as a result of
restrictions on payments to its equity owners in the agreements governing our indebtedness. To date, there have been no payments to the continuing LLC owner made by Bioventus pursuant to this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus LLC Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus operates its business
through BV LLC and its subsidiaries. Bioventus and the continuing LLC owner entered into the Bioventus LLC agreement, which sets forth terms for the operations of BV LLC, and the rights and obligations of the holders of LLC interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appointment as Manager </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Bioventus LLC
agreement, Bioventus is a member and the sole manager of BV LLC. As the sole manager, Bioventus is able to control all of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business affairs and
decision-making of BV LLC. As such, Bioventus, through our officers and directors, are responsible for all operational and administrative decisions of BV LLC and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of BV LLC&#146;s business. Pursuant to the terms of the Bioventus LLC agreement, Bioventus cannot, under any circumstances, be removed as the sole
manager of BV LLC except by Bioventus&#146; election. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is not entitled to compensation for its services as manager. Bioventus is entitled to reimbursement or capital contribution credit by BV LLC for fees
and expenses incurred on behalf of BV LLC, including all expenses associated with Bioventus&#146; IPO and maintaining its corporate existence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recapitalization. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus LLC agreement
recapitalizes the units that were held prior to the IPO in BV LLC into a new single class of common membership units, which Bioventus refers to as the &#147;LLC interests.&#148; Each LLC interest entitles the holder to a pro rata share of the net
profits and net losses and distributions of BV LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus LLC agreement requires &#147;tax distributions&#148; to be made by BV LLC to its members, as that term is defined in the agreement. Tax
distributions will be made to members on a pro rata basis, including Bioventus, in an amount sufficient to allow the members, including Bioventus, to pay taxes owed in respect of income allocated by BV LLC and to allow Bioventus to meet its
obligations under the TRA (as described above under the heading &#147;Tax Receivable Agreement&#148; above). For tax distributions made in the fiscal year ending December&nbsp;31, 2021 (the 2021 fiscal year), the tax rate that Bioventus expect to
use for purposes of determining tax distributions from BV LLC to its members will equal the combined federal, state, and local statutory tax rate applicable to it for the 2021 fiscal year, taking into account the deductibility of state and local
taxes for federal purposes. For each subsequent fiscal year, the tax rate applicable to Bioventus for the 2021 fiscal year will apply with respect to tax distributions made during such fiscal year unless the Bioventus board determines otherwise. The
tax rate used to determine tax distributions will apply regardless of the actual final tax liability of any such member. Tax distributions will also be made only to the extent all distributions from BV LLC for the relevant period were otherwise
insufficient to enable each member to cover its tax liabilities as calculated in the manner described above. The Bioventus LLC agreement allows for distributions to be made by BV LLC to its members on a pro rata basis out of &#147;distributable
cash,&#148; as that term is defined in the agreement. We expect BV LLC may make distributions out of distributable cash periodically to the extent permitted by our agreements governing Bioventus&#146; indebtedness and necessary to enable us to cover
our operating expenses and other obligations, including Bioventus&#146; tax liability and obligations under the TRA, as well as to make dividend payments, if any, to the holders of Bioventus class A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>LLC Interest Redemption Right </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus LLC
agreement provides a redemption right to the continuing LLC owner which entitles it to have its LLC interests redeemed, at its election, for newly-issued shares of Bioventus class A common stock on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis or a cash payment equal to a volume weighted average market price of one share of Bioventus class A common stock for each LLC interest redeemed (subject to customary adjustments, including
for stock splits, stock dividends and reclassifications). If the continuing LLC owner elects to receive a cash payment, Bioventus may elect to settle such redemption with Bioventus class A common stock in lieu of a cash payment, provided that if it
elects to do so, the continuing LLC owner has the option to rescind its redemption request within a specified time period. Upon the exercise of the redemption right, the redeeming member will surrender its LLC interests to BV LLC for cancellation.
The Bioventus LLC agreement requires that Bioventus contribute cash or shares of Bioventus class A common stock to BV LLC in exchange for an amount of newly-issued LLC interests in BV LLC that will be issued to us equal to the number of LLC
interests redeemed from the continuing LLC owner. BV LLC will then distribute the cash or shares of Bioventus class A common stock to the continuing LLC owner to complete the redemption. In the event of such a redemption election by the continuing
LLC owner, Bioventus may effect a direct exchange of cash or Bioventus class A common stock for such LLC interests in lieu of such a redemption. Whether by redemption or exchange, we are obligated to ensure that at all times the number of LLC
interests that Bioventus owns equals the number of shares of Bioventus class A common stock issued by Bioventus (subject to certain exceptions for treasury shares and shares underlying certain convertible or exchangeable securities). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus LLC agreement provides for
indemnification of the manager, members and officers of BV LLC and their respective subsidiaries or affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; website is located at www.bioventus.com. Information on its website or connected to its website is not incorporated by references into this
joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_23"></A>BIOVENTUS&#146; MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of Bioventus&#146; financial condition and results of
operations should be read in conjunction with the disclosure under &#147;Risk Factors&#148; and Bioventus&#146; consolidated financial statements and the related notes to those statements included elsewhere in this joint proxy statement/prospectus.
In addition to historical consolidated financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the
convenience of presentation. Bioventus&#146; actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#147;Risk Factors&#148; and &#147;Cautionary
Statement Regarding Forward-Looking Statements&#148; in this joint proxy statement/prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive summary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive
treatments that engage and enhance the body&#146;s natural healing process. Bioventus operates its business through two reportable segments, U.S. and International, and Bioventus&#146; portfolio of products is grouped into three verticals: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pain Treatments and Joint Preservation includes the legacy osteoarthritis (OA) joint pain treatment and joint
preservation products, plus the Peripheral Nerve Stimulation (PNS) products sold previously by Bioness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bone Graft Substitutes (BGS) is comprised of human tissue allograft and synthetic products used primarily in
spine surgery; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restorative Therapies includes the legacy minimally invasive fracture treatments, plus the rehabilitation
products sold previously by Bioness. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; U.S. segment offers its full existing portfolio of products. This includes its
pain treatment and joint preservation products, which address the entire market for HA viscosupplementation with offerings for single, three and five injection therapies: (i)&nbsp;Durolane, a single injection therapy, which Bioventus launched in the
United States in the first half of 2018 and also market outside the United States in more than 30 countries; <FONT STYLE="white-space:nowrap">(ii)&nbsp;GELSYN-3,</FONT> a three injection therapy, which Bioventus has marketed in the United States
since the second half of 2016; and (iii)&nbsp;SUPARTZ FX, a five injection therapy, which Bioventus has marketed in the United States since May 2012. Bioventus&#146; U.S. segment also offers its BGS products, which are targeted at improving bone
fusion rates following spinal fusion and other orthopedic surgeries. These products include allograft-derived bone graft with growth factors (OsteoAMP), a DBM (Exponent), cancellous bone in different preparations (PureBone), bioactive synthetics
(Signafuse and Interface), a collagen ceramic matrix (OsteoMatrix) and two bone marrow isolation systems (CellXtract and Extractor). Further, its U.S. segment offers its Exogen system, which Bioventus believes offers significant advantages over
electrical based long bone stimulation systems, including documented mechanism of action, shorter treatment times and superior nonunion heal rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; International segment offers Durolane, or single injection therapy, OsteoAMP, its allograft-derived bone graft with growth factors, and its
Exogen system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth total net sales, net income from continuing operations, Adjusted EBITDA and
pro forma net income (loss) per unit attributable to common unit holders - basic and diluted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,141</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,443</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,188</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per unit attributable to common unit holders - basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.89</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See below under<I> Components of Bioventus&#146; results of operations-Adjusted EBITDA</I> for a definition of
Adjusted EBITDA and <I>Results from continuing operations</I> for a reconciliation of net income from continuing operations to Adjusted EBITDA. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See below for a computation of pro forma net income per unit attributable to common unit holders - basic and
diluted after the recapitalization described below which was in conjunction with Bioventus&#146; IPO. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2021,
Bioventus&#146; limited liability company agreement was amended and restated to, among other things, (i)&nbsp;provide for a new single class of common membership interests in the Company (LLC Interests) and (ii)&nbsp;exchange all of the existing
membership interests for LLC Interests. For purposes of calculating pro forma earnings per unit, Bioventus has adjusted the number of outstanding membership units retroactively to give effect to the amendment and resulting recapitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pro forma basic net income per unit is computed by dividing net income by the pro forma weighted-average number of units outstanding during the period. Pro
forma diluted net income per unit is computed by dividing net income by the pro forma weighted-average number of units outstanding adjusted to give effect to potentially dilutive securities. As a result of the recapitalization and the New LLC Owner
assuming the obligations of the Company&#146;s Phantom Plan awards there are no dilutive securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a reconciliation of
the numerators and denominators used to compute pro forma basic and diluted net income per unit for the years ended December&nbsp;31 as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income from continuing operations attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,666</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,851</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income per unit attributable to common unit holders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average units used in computing basic and diluted net income per common
unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,825,325</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,825,325</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has pursued and continue to pursue business development opportunities that leverage its significant customer presence across orthopedics, broaden its
portfolio and increase its global footprint. Below is a summary of some of Bioventus&#146; recent transactions: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and development
agreement for MOTYS </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2019, Bioventus entered into a collaboration and development agreement (Development Agreement), with
Musculoskeletal Transplant Foundation, Inc., or MTF, to develop an injectable placental tissue product, MOTYS, for use in the pain treatment and joint preservation. The development and commercialization of the product is anticipated to take place in
two stages. In consideration for achieving its development milestones, Bioventus paid MTF $1.5&nbsp;million and are obligated to pay additional payments totaling $0.8&nbsp;million if certain further milestones are achieved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development collaboration agreement for PROcuff </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2019, Bioventus entered into an exclusive Collaboration Agreement with Harbor, to develop and license the rights to commercialize a
woven-suture-collagen composite implant product. Concurrently with the execution of the agreement, Bioventus purchased $1.0&nbsp;million of shares of Harbor. As a result of Harbor&#146;s achievement of certain milestones, on October&nbsp;5, 2020,
Bioventus purchased $1.0&nbsp;million of additional shares of Harbor. Furthermore, Bioventus is obligated to make two additional <FONT STYLE="white-space:nowrap">one-time</FONT> payments totaling $6.0&nbsp;million in aggregate upon Harbor&#146;s
achievement of (i)&nbsp;receiving regulatory approval and (ii)&nbsp;achieving a certain net sales target. The sole use of proceeds from these investments is for the development of the implant product that is the subject of its agreement. Bioventus
intends to negotiate and enter into a definitive supply agreement with Harbor if and when the product is cleared for marketing by the FDA at a price per unit not to exceed an agreed upon maximum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the foregoing transactions have had a significant impact on Bioventus&#146; financial results of operations for the periods in which they occurred,
and they have affected the comparability of these statements for the corresponding comparative periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outlook </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus plans to continue to expand its business and to increase its net sales and profitability by executing on the following strategies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to expand market share in HA viscosupplementation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">introduce new pain treatment and joint preservation products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop and commercialize Bioventus&#146; BGS portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand indications for use for Bioventus&#146; Exogen system; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">invest in research and development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue business development opportunities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">opportunistically grow Bioventus&#146; international markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus expects to face challenges as Bioventus executes on its business strategy. Bioventus&#146; industry is highly competitive, subject to rapid change
and significantly affected by market activities of industry participants, new product introductions and other technological advancements. Bioventus believes its experienced management team positions Bioventus for success in facing these and other
challenges. However, there are several factors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affecting Bioventus&#146; business that are beyond its control, such as its ability to successfully introduce new products and line extensions, expand labels, continue to obtain reimbursement for
its products at acceptable rates and receive necessary governmental approvals. In addition, Bioventus expects that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change
the healthcare industry worldwide, resulting in further business consolidations and alliances among its customers, which may exert further downward pressure on the prices of its products. For information about additional factors that may affect its
outlook, see<I> </I>&#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; sections of this joint proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Misonix Acquisition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;29, 2021, Bioventus entered into the Misonix Merger Agreement to acquire Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic
medical devices and regenerative products that enhance clinical outcomes, in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-and-stock</FONT></FONT> transaction. The Transaction is expected to close in the fourth quarter of
2021 and is subject to regulatory approvals, the approval of Bioventus&#146; stockholders, Misonix stockholder approval and customary closing conditions. Misonix is a provider of minimally invasive therapeutic ultrasonic technologies and
regenerative medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix stockholders will receive aggregate consideration that values Misonix at approximately $518.0&nbsp;million on a fully
diluted basis, based on the Company&#146;s <FONT STYLE="white-space:nowrap">7-day</FONT> weighted average stock price of $16.6284 per share as of July&nbsp;27, 2021. The Transaction involves both cash and stock consideration based on the election of
the Misonix stockholder. Each share of Misonix Common Stock issued and outstanding immediately prior to the Transaction, will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Class&nbsp;A common stock of the Company, $0.001 par value per share, based on the election of the holder. The maximum cash amount payable by the Company will be an amount equal to $10.50
multiplied by the number of outstanding shares of Misonix Common Stock shortly prior to the completion of the Transaction. The Company expects to fund the cash portion of the acquisition with cash on hand and through committed financing provided by
Wells Fargo Bank, National Association (Wells Fargo Bank). The number of shares held by Misonix stockholders electing to receive cash will be reduced on a pro rata basis if the cash elected to be received exceeds the maximum cash amount payable and
will be paid with stock consideration of 1.6839 of shares of the Company&#146;s Class&nbsp;A common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioness Acquisition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2021, Bioventus completed the acquisition of Bioness, a global leader in neuromodulation and advanced rehabilitation medical devices through
its innovative PNS therapy and premium advanced rehabilitation solutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioness acquisition gives Bioventus access into two large and growing
markets: PNS and the advanced rehabilitation market, and Bioventus estimates their medical devices address total global market opportunities approaching $8&nbsp;billion per year. Bioventus believes both of these markets offer attractive growth
opportunities driven by demographic trends and the need for safe, effective, treatment options for the many patients suffering from post-surgical pain, stroke, multiple sclerosis, traumatic brain injury, spinal cord injury and cerebral palsy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioness advanced rehabilitation solutions have a broad portfolio of offerings, including proprietary electrical stimulation exoskeletal devices for both the
upper and lower extremities, robotic gait and fall safety systems, and high-tech, interactive software learning and recovery assessment platforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These
products play an essential role in helping patients regain mobility due to stroke, traumatic brain injury, multiple sclerosis and osteoarthritis, and are used by physical or occupational therapists in a clinical setting or by the patient at home,
with the guidance of a clinician through telemedicine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioness PNS Systems help patients suffering from pain after surgery on an extremity, which affects over
16&nbsp;million patients each year globally, and addresses the growing need to reduce opioid usage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement pursuant to which
Bioventus acquired Bioness (the Bioness Merger Agreement), Bioventus paid $48.9&nbsp;million at the closing of the transaction and agreed to pay up to an additional $43.0&nbsp;million of discounted contingent consideration related to the achievement
of certain key milestones. The acquisition includes the entire portfolio of Bioness products as well as its research and development pipeline. The <FONT STYLE="white-space:nowrap">up-front</FONT> consideration was funded exclusively through the use
of cash on hand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CartiHeal </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020,
BV LLC entered into an Option and Equity Purchase Agreement with CartiHeal (2009)&nbsp;Ltd., a privately-held company headquartered in Israel and the developer of the proprietary <FONT STYLE="white-space:nowrap">Agili-C</FONT><SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> implant for the treatment of joint surface lesions in traumatic and osteoarthritic joint, and its shareholders. The agreement provides BV LLC with an exclusive option to acquire 100% of
CartiHeal&#146;s shares under certain conditions, or the Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#146;s shares under certain conditions, or the Put Option. The Put Option is only
exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <FONT STYLE="white-space:nowrap">Agili-C</FONT> device with a label consistent in all respects with pivotal
clinical trial success. The pivotal clinical trial&#146;s objective is to demonstrate the superiority of the <FONT STYLE="white-space:nowrap">Agili-C</FONT> implant over the surgical standard of care, including microfracture and debridement, for the
treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. The investment follows the recently completed enrollment and outcome of interim analysis in CartiHeal&#146;s IDE multinational
pivotal study for <FONT STYLE="white-space:nowrap">Agili-C.</FONT> This new round of funding is expected to enable CartiHeal to complete all patient <FONT STYLE="white-space:nowrap">follow-up</FONT> in the
<FONT STYLE="white-space:nowrap">Agili-C</FONT> study and submit an application for PMA to the FDA. Under the terms of BV LLC&#146;s investment in CartiHeal, CartiHeal can secure an additional $5.0&nbsp;million equity investment from BV LLC, if
needed, for IDE study completion. BV LLC previously made an initial $2.5&nbsp;million investment in CartiHeal in January 2018 and a subsequent investment of $0.2&nbsp;million in January 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;2, 2021, pursuant to the Option and Equity Purchase Agreement, CartiHeal provided BV LLC with a statistical report containing the results of
the pivotal clinical trial. On August&nbsp;27, 2021, the Bioventus board, after its review of the statistical report for CartiHeal&#146;s pivotal clinical trial and determination that the results of the statistical report indicated a Pivotal
Clinical Trial Success (as contemplated by the Option and Equity Purchase Agreement), approved BV LLC&#146;s continued pursuit of a potential acquisition of CartiHeal. BV LLC thereafter deposited $50.0&nbsp;million in escrow in accordance with the
terms of the Option and Equity Purchase Agreement. The closing of the transaction is subject to, among other things (including customary closing conditions), the valid exercise of the Call Option or the Put Option, the latter of which cannot be
exercised unless and until premarket approval (PMA) by the Food and Drug Administration (FDA) is received with respect to the <FONT STYLE="white-space:nowrap">Agili-C</FONT> implant, which was granted Breakthrough Device Designation by the FDA last
year. CartiHeal plans to submit the clinical module of their PMA later this year, and the decision from the FDA is expected in the second half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, the consideration for the acquisition of all of the shares of
CartiHeal, excluding those Bioventus owns, would be $350&nbsp;million payable in cash, subject to customary adjustments, all of which would be payable at closing, with an additional $150.0&nbsp;million payable upon achievement of certain sales
milestones related to <FONT STYLE="white-space:nowrap">Agili-C.</FONT> Should the closing occur, the $50&nbsp;million escrowed by BV LLC will be applied towards the consideration payable by BV LLC pursuant to the Option and Equity Purchase
Agreement. CartiHeal has announced that it expects to submit its PMA application to the FDA later this year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BONES Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus submitted a supplemental PMA to the FDA in December 2020 seeking approval of an expanded indication for EXOGEN, specifically, for the adjunctive
treatment of acute and delayed metatarsal fractures to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduce the risk of <FONT STYLE="white-space:nowrap">non-union.</FONT> This PMA supplement was based on and supported by clinical data in metatarsal fractures from the ongoing B.O.N.E.S. study. In
April 2021, Bioventus received a letter from the FDA identifying certain deficiencies in the PMA supplement that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and
endpoints from the B.O.N.E.S. study, and requests for <FONT STYLE="white-space:nowrap">re-analyses</FONT> of certain data and provision of other information to support the findings. Bioventus continues to evaluate the FDA&#146;s comments and are
initiating discussions with them to address their concerns. Bioventus can give no assurance that Bioventus will be able to resolve the deficiencies identified by the FDA in a timely manner, or at all. Consequently, the FDA&#146;s decision on the PMA
supplement may be delayed beyond the time originally anticipated. Moreover, if Bioventus&#146; responses do not satisfy the FDA&#146;s concerns, the FDA may not approve Bioventus&#146; PMA supplement seeking to expand the indications for Bioventus
of EXOGEN as proposed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic spread around the world and in the United States. New variants of the virus have
emerged, some of which have shown to be more contagious. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business
practices. Federal and state governments have implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on
public gatherings, mandatory closure or reduced capacity of businesses, work from home, supply chain logistical changes and other measures, which caused global business disruptions and significant volatility in U.S. and international debt and equity
markets. Bioventus&#146; business, results of operations and financial condition have been and may continue to be, materially impacted by fluctuations in patient visits and elective procedures and any future temporary cessations of elective
procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;</FONT></FONT> orders or advisories,
facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Bioventus&#146; business will depend on many factors, including, but not limited to, the duration
and severity of the pandemic, the spread of new variants of the virus, new and ongoing measures taken in response to the pandemic, the availability, adoption and effectiveness of vaccines, the impact on economic activity from the pandemic and
actions taken in response and the resulting impact it has on Bioventus&#146; partners, patients and communities in which Bioventus operates, all of which continue to be uncertain. As of the date of this joint proxy statement/prospectus, the extent
to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially impact the Company&#146;s financial conditions, liquidity or results of operations is uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent <FONT STYLE="white-space:nowrap">COVID-19</FONT> disruptions continue to adversely impact Bioventus&#146; business, results of operations and
financial condition, it may also have the effect of heightening risks relating to Bioventus&#146; ability to successfully commercialize newly developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing
pressure as a result of changes in the purchasing behavior of hospitals and maintenance of Bioventus&#146; numerous contractual relationships. For additional information on the risks Bioventus may face as a result of
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> refer to &#147;Risk Factors&#151;Risks Relating to Bioventus&#146; Business&#151;Bioventus&#146; business may continue to experience adverse impacts as a result of the COVID-19 pandemic.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of its results of operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net sales
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus generates net sales from a portfolio of active healing products that serve physicians spanning the orthopedic continuum, including
sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Bioventus reports sales net of contractual allowances, rebates and returns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus sells its pain treatment and joint preservation products and restorative therapies through its direct sales team, who manage and maintain the sales
relationship with healthcare providers, distribution centers or specialty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmacies. In certain international markets, Bioventus also sells to independent distributors on prearranged business terms, who manage or maintain the sales relationship with their physician
customers. Refer to <I>Note</I><I></I><I>&nbsp;2. Summary of significant accounting policies</I> in the &#147;Notes to the Audited Consolidated Financial Statements&#148;<I> </I>included in this joint proxy statement/prospectus for further
information. Bioventus recognizes revenue at the point in time when control is transferred to the customer, typically, in the case of its pain treatment and joint preservation products, when these products are shipped to the customer and, in the
case of its Exogen system, when the patient has accepted the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; BGSs are primarily sold in the U.S. market through independent
distributors. Bioventus generally consigns its BGS products to hospitals so its neurosurgeon and orthopedic spine surgeon customers can use them in procedures. Bioventus recognizes revenue based upon consumption in a surgical procedure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of sales </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; cost of sales
primarily consist of costs of products purchased from its third-party suppliers, direct labor and allocated overhead associated with the assembly of its Exogen system, excess and obsolete inventory charges, shipping, inspection and related costs
incurred in making its products available for sale or use. In addition, cost of sales includes depreciation related to production as well as amortization of product-related intellectual property and distribution rights associated with commercialized
products. Bioventus&#146; pain treatment and joint preservation products and BGS products are manufactured by or obtained from third-party suppliers primarily located in Japan, Switzerland, Sweden and the United States. Bioventus receives the
components for its Exogen system from suppliers and assemble each system <FONT STYLE="white-space:nowrap">in-house</FONT> at its Cordova, Tennessee facility. In the future, Bioventus expects its cost of sales to increase due to increased sales
volume. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gross profit and gross margin </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross
profit consists of net sales less cost of sales. Bioventus calculates gross margin as gross profit divided by net sales. Bioventus&#146; gross margin has been and will continue to be affected by a variety of factors, including costs of products
purchased from its third-party suppliers, manufacturing costs, product mix and implementation over time of cost-reduction strategies. Bioventus expects net sales and product mix to vary quarter by quarter and therefore its gross profit will likely
fluctuate from quarter to quarter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, general and administrative expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense primarily consists of salaries, benefits and other related costs, including equity-based compensation, for
personnel employed in sales, marketing, finance, legal, compliance, administrative, information technology, medical education and training, quality and human resource departments. Selling, general and administrative expense also includes third-party
marketing, supply chain and distribution, product recall costs, information technology, legal, human resources, insurance and facilities expenses, selling, general and administrative expenses also include commissions, generally based on a percentage
of sales, to its direct sales team and independent distributors. Bioventus expects its selling, general and administrative expenses will increase with the continued expansion of its sales organization and commercialization of its current and
pipeline products. Bioventus plans to hire more personnel to support the growth of its business. In addition, as a public company, Bioventus will be implementing additional procedures and processes to address the standards and requirements
applicable to public companies. Bioventus expects to incur additional annual selling, general and administrative expenses related to these additional procedures and processes including, among other things, equity-based compensation, increased
liability insurance for its directors and officers, director fees, reporting requirements of the SEC, transfer agent fees, hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses.
Bioventus also expects a change in the timing over which compensation expense is recognized as a result of the termination of the Phantom Plan and the receipt by participants of shares of Class&nbsp;A common stock upon settlement of their awards,
which settlement is expected to take place twelve months after the date of such termination. However, over time, as Bioventus grows its net sales, Bioventus expects selling, general and administrative expenses to decline as a percentage of net
sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense primarily consists of employee compensation, equity compensation and related expenses, as well as contract research
organization service expenses related to clinical trials. Bioventus expenses internal research and development costs as incurred and research and development costs incurred by third parties as they perform contracted work. Bioventus&#146; research
and development expenses may vary substantially from period to period based on the timing of research and development activities. Bioventus is focused on internal research and development to broaden its product portfolio across all verticals, expand
its Exogen system product label and undertake clinical research to support commercialization of all of its products. As a result, Bioventus expects its research and development expenses to increase to the
<FONT STYLE="white-space:nowrap">mid-single</FONT> digits as a percentage of net sales as it introduces new products, extends existing product lines and expands indications. Bioventus sees significant opportunity to develop innovative and clinically
differentiated products <FONT STYLE="white-space:nowrap">in-house</FONT> with its experienced research and development team. Bioventus is currently funding its B.O.N.E.S. clinical study, which began enrollment in 2018 and is aimed at broadening the
label of its Exogen system to include a broader range of bones that may be treated as fresh fractures in predisposed patients at risk of nonunion. In addition, Bioventus is planning preclinical and animal model studies for MOTYS and PROcuff.
Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restructuring costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restructuring costs primarily
consist of employee severance, legal, consulting and temporary labor expenses. During the periods presented, restructuring costs were associated with headcount reductions in its international business to improve operating efficiency. Key assumptions
in determining the restructuring costs include headcount reductions, as well as terms and negotiated payments to terminate certain contractual obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Depreciation and amortization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation
expense primarily consists of depreciation of computer equipment and software as well as leasehold improvements, furniture, fixtures, machinery and equipment. Amortization expense primarily consists of amortization expense related to customer
relationships and other intangible assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense primarily consists of interest on its indebtedness, which currently consists of its term loan and revolving credit facility, which was
incurred pursuant to the 2019 Credit Agreement. Bioventus has entered into interest rate swaps to limit its exposure to changes in the variable interest rate on its term loan. Interest expense includes any fair value gain or losses on these swaps.
Interest expense also includes the revaluation for the liability related to its Equity Participation Right, or EPR, Unit. The EPR Unit&#146;s entitlement is 0.55% of available distributions arising from a distribution event as defined in the
Bioventus LLC Agreement and was settled in cash as part of its IPO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other (income) expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other (income) expense primarily consists of foreign currency transaction and remeasurement gains and losses on transactions denominated in currencies other
than its functional currency. Bioventus&#146; foreign currency transaction and remeasurement gains and losses are primarily related to foreign currency denominated cash, liabilities and intercompany receivables and payables. Other (income) expense
may also include certain nonrecurring items. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income tax expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BV LLC is a partnership for U.S. federal tax purposes. Accordingly, the members include the profits and losses of BV LLC in their income tax returns. Certain
wholly-owned subsidiaries of BV LLC are taxable entities for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal and state and international income taxes, including certain taxes
applicable to BV LLC and U.S. federal income taxes for one of its subsidiaries that is treated as a corporation for U.S. federal tax purposes. Certain income and expense items in income tax returns are not reported in the same year as financial
statements. Bioventus reports the income tax effects of these differences as deferred income taxes. Valuation allowances recognized reduce the related deferred tax assets to an amount which will, more likely than not, be realized. Bioventus
recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is subject to U.S. federal, state
and local income taxes at the prevailing corporate tax rates with respect to its taxable income. In addition to tax expenses, Bioventus is obligated to make payments under the TRA, which could be significant. The TRA, obligates Bioventus to pay to
the Continuing LLC Owner 85% of the amount of any realized tax benefits, (or in some circumstances are deemed to realize) resulting from (i)&nbsp;increases in the tax basis of assets of BV LLC as a result of (a)&nbsp;any future redemptions or
exchanges of LLC Interests described under &#147;Description of Bioventus&#146; Business&#151;Bioventus LLC agreement&#151;LLC Interest Redemption Right&#148;, and (b)&nbsp;certain distributions (or deemed distributions) by BV LLC and
(ii)&nbsp;certain other tax benefits arising from its making payments under the TRA. For more information, see &#147;Description of Bioventus&#146; Business&#151;Tax Receivable Agreement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures - Adjusted EBITDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus presents Adjusted EBITDA, a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure because Bioventus believes it is a useful indicator of
its operating performance. Bioventus&#146; management uses Adjusted EBITDA principally as a measure of its operating performance and believes that Adjusted EBITDA is useful to its investors because it is frequently used by securities analysts,
investors and other interested parties frequently use it in their evaluation of the operating performance of companies in industries similar to Bioventus&#146;. Bioventus&#146; management also uses Adjusted EBITDA for planning purposes, including
the preparation of its annual operating budget and financial projections. Bioventus defines Adjusted EBITDA as net income (loss) from continuing operations before depreciation and amortization, provision of income taxes and interest expense,
adjusted for the impact of certain cash, <FONT STYLE="white-space:nowrap">non-cash</FONT> and other items that Bioventus does not consider in its evaluation of ongoing operating performance. These items include equity compensation, change in fair
value of contingent consideration, <FONT STYLE="white-space:nowrap">COVID-19</FONT> benefits, succession and transition charges, loss on impairment of intangible assets, losses associated with debt refinancing, restructuring costs, foreign currency
impact and other <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs. The allocation of
corporate overhead costs is determined based on various methods but is primarily based on a ratio of net sales by segment to total consolidated net sales. See table within Results from continuing operations for a reconciliation of net income from
continuing operations to Adjusted EBITDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interim Periods </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reports quarterly interim periods on a <FONT STYLE="white-space:nowrap">13-week</FONT> basis within a standard calendar year. Each annual reporting
period begins on January&nbsp;1 and ends on December 31. Each quarter ends on the Saturday closest to calendar <FONT STYLE="white-space:nowrap">quarter-end,</FONT> with the exception of the fourth quarter, which ends on December 31. The <FONT
STYLE="white-space:nowrap">13-week</FONT> quarterly periods ended on March&nbsp;28, June&nbsp;27 and September&nbsp;26 for the year ended December&nbsp;31, 2020. As a result, the fourth and first quarters may vary in length depending on the calendar
year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth components of Bioventus&#146; condensed consolidated statements of operations as a percentage of net sales for the periods
presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales (including depreciation and amortization)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of variable interest entity assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of net (loss) income to Adjusted EBITDA for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net (loss) income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,748</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,506</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization<SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation<SUP STYLE="font-size:85%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> benefits, net<SUP
STYLE="font-size:85%; vertical-align:top">(c)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Succession and transition charges<SUP STYLE="font-size:85%; vertical-align:top">(d)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency impact<SUP STYLE="font-size:85%; vertical-align:top">(e)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition and integration costs<SUP STYLE="font-size:85%; vertical-align:top">(f)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory <FONT STYLE="white-space:nowrap">step-up</FONT> costs<SUP
STYLE="font-size:85%; vertical-align:top">(g)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity loss in unconsolidated
investments<SUP STYLE="font-size:85%; vertical-align:top">(h)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent
consideration<SUP STYLE="font-size:85%; vertical-align:top">(i)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairments related to variable interest
entity<SUP STYLE="font-size:85%; vertical-align:top">(j)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs<SUP
STYLE="font-size:85%; vertical-align:top">(k)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBITDA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30,957</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>21,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes for the six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020, respectively, depreciation and
amortization of $10,854 and $10,599 in cost of sales, and $3,777 and $3,638 presented in the consolidated statements of operations and comprehensive (loss) income with the balance in research and development. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(b)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The six months ended July&nbsp;3, 2021 primarily includes equity-based compensation expense (income) resulting
from awards granted under the Company&#146;s current equity based compensation plan (2021 Plan) and compensation costs. The six months ended July&nbsp;3, 2021 also includes the change in fair market value of accrued equity-based compensation related
to the BV LLC Phantom Profits Interest Plan (Phantom Plan) due to expected pricing with Bioventus&#146; IPO. Equity compensation expenses for the six months ended June&nbsp;27, 2020 represents compensation from the Company&#146;s management
incentive plan and Phantom Plan as well as the change in fair market value of accrued equity-based compensation related to the plans due to the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Bioventus&#146; business.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(c)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents income resulting from the CARES Act offset by additional cleaning and disinfecting expenses and
contract termination fees for canceled events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(d)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Primarily represents costs related to the CEO transition. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(e)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Foreign currency impact represents realized and unrealized gains and losses from fluctuations in foreign
currency and is included within other expense (income) in the consolidated statements of operations and comprehensive (loss) income. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(f)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents costs incurred to acquire and integrate Bioness. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(g)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amortization of the inventory <FONT STYLE="white-space:nowrap">step-up</FONT> associated with the Bioness
acquisition. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(h)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents CartiHeal equity investment losses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(i)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents change in fair value of contingent consideration resulting from the Bioness Acquisition.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(j)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents loss on impairment of Harbor&#146;s long-lived assets and the Company&#146;s investment in Harbor.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(k)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs primarily includes charges associated with
strategic transactions, such as potential acquisitions and public company preparation costs, primarily accounting and legal fees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus presents Adjusted EBITDA, a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure, because Bioventus believes it is a useful indicator
of Bioventus&#146; operating performance. Bioventus&#146; management uses Adjusted EBITDA principally as a measure of Bioventus&#146; operating performance and believes that Adjusted EBITDA is useful to Bioventus&#146; investors because it is
frequently used by securities analysts, investors and other interested parties frequently use it in their evaluation of the operating performance of companies in industries similar to Bioventus&#146;. Bioventus&#146; management also uses Adjusted
EBITDA for planning purposes, including the preparation of Bioventus&#146; annual operating budget and financial projections. Bioventus defines Adjusted EBITDA as net (loss) income before depreciation and amortization, provision of income taxes and
interest expense, adjusted for the impact of certain cash, <FONT STYLE="white-space:nowrap">non-cash</FONT> and other items that Bioventus does not consider in Bioventus&#146; evaluation of ongoing operating performance. These items include equity
compensation, change in fair value of contingent consideration, Bioness acquisition costs, succession and transition charges, loss on impairment of intangible assets, losses associated with debt refinancing, foreign currency impact and other <FONT
STYLE="white-space:nowrap">non-recurring</FONT> costs. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs. The allocation of corporate overhead
costs is determined based on various methods but is primarily based on a ratio of net sales by segment to total consolidated net sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net sales
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">(in thousands, except for percentage)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six months ended July&nbsp;3, 2021 compared to June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Net sales increased
$48.1&nbsp;million, or 38.4%. The changes in net sales by vertical are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;&nbsp;&nbsp;Pain Treatments and Joint Preservation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.3&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;&nbsp;&nbsp;Bone Graft Substitutes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.7 million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;&nbsp;&nbsp;Restorative Therapies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.1 million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue increased primarily due to volume growth as revenue in 2020 was negatively affected by the economic impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The Bioness acquisition contributed $9.4&nbsp;million in additional sales primarily within the Pain Treatments and Joint Preservation vertical. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>International </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net sales increased $6.8&nbsp;million, or
59.4%, primarily due to sales volume growth as revenue in 2020 was negatively affected by the economic impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The Bioness acquisition contributed $2.5&nbsp;million in additional
sales, a majority of which was reported within Bioventus&#146; Pain Treatments and Joint Preservation vertical. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gross profit and gross margin </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">(in thousands, except for percentage)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Gross margin</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six months ended July&nbsp;3, 2021 compared to June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross profit increased $33.4&nbsp;million, or 37.1%,
primarily due to the increase in net sales. Gross margin remained consistent with the prior year comparable period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>International </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross profit increased $4.9&nbsp;million, or 64.3%, primarily due to the increase in net sales. Gross margin increased slightly due to product mix. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, general and administrative expense </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><U></U></B><U>(in thousands, except for percentage)<B></B></U><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six months ended July&nbsp;3, 2021 compared to June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased $22.9&nbsp;million, or 28.4%, primarily due to the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Bioventus&#146; business in 2020 as well as the Bioness Acquisition. The increases were primarily in the following areas: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;Compensation related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.0&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.30em; text-indent:-1.30em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;Equity compensation excluding change in the fair value discussed further
below</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.6&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;Consulting expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;Corporate and employee health insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149; &nbsp;&nbsp;Legal and accounting expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These increases were partially offset by a higher change in fair value of Bioventus&#146; accrued equity-based compensation
resulting in an increased net recovery of expense compared to the prior year of $15.6&nbsp;million. The change in fair value for 2021 was due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual
offering price. The change in fair value for 2020 was due to the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Bioventus&#146; business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><U></U></B><U>(in thousands, except for percentage)<B></B></U><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six months ended July&nbsp;3, 2021 compared to June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense increased by $1.0&nbsp;million, or 22.0%, partially due to Bioventus&#146; cost reduction efforts implemented during 2020 as a
result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as well as the Bioness acquisition. In addition, compensation related expenses increased $1.0&nbsp;million and equity compensation, excluding the change in fair value discussed
below, increased $0.9&nbsp;million. These increases were partially offset by a higher change in fair value of Bioventus&#146; accrued equity-based compensation resulting in an increased net recovery of expense totaling $1.8&nbsp;million. The change
in fair value during 2021 was due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price. The change in fair value during 2020 was due to the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Bioventus&#146; business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in fair value of contingent consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $0.6&nbsp;million change in fair value of Bioness Acquisition contingent consideration during the six months ended July&nbsp;3, 2021 resulted from the
change in present value of discounted cash flows due to the passage of time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Depreciation and amortization </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><U></U></B><U>(in thousands, except for percentage)<B></B></U><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization remained consistent with the six months ended June&nbsp;27, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of variable interest entity assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company terminated the Harbor Collaboration Agreement on June&nbsp;8, 2021 which resulted in a $5.7&nbsp;million impairment on Harbor&#146;s long-lived asset balances, of which $5.2&nbsp;million was recorded in loss attributable to noncontrolling
interest. Refer to <I>Note 3. Business combinations and investments</I> within the &#147;Notes to the Unaudited Condensed Consolidated Financial Statements&#148; of the Bioventus financial statements included in this joint proxy statement/prospectus
for further details concerning the impairment and deconsolidation of Harbor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other (income) expense </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NM = Not meaningful </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six
months ended July&nbsp;3, 2021 compared to June&nbsp;27, 2020 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest (income) expense changed $6.4&nbsp;million. In conjunction with Bioventus&#146;
IPO, Bioventus settled Bioventus&#146; equity participation right (EPR) liability resulting in interest income of $2.8&nbsp;million. In addition, the change in the fair value of Bioventus&#146; interest rate swap resulted in interest income of
$1.3&nbsp;million during 2021 compared to interest expense of $2.0&nbsp;million in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense increased $3.3&nbsp;million primarily due to the impairment of Bioventus&#146; Harbor
investment of $1.4&nbsp;million and $0.9&nbsp;million in net losses related to Bioventus&#146; equity investment in CartiHeal. In addition, Bioventus had other income in 2020 resulting from a $1.2&nbsp;million Provider Relief Fund payment under the
CARES Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income tax expense </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax expense increased for the six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020 primarily due to the increase
in Bioventus&#146; effective tax rate related to the change in structure resulting from Bioventus&#146; IPO and associated Up C partnership structure as well as the impact of <FONT STYLE="white-space:nowrap">non-deductible</FONT> stock option
expense during 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Noncontrolling interest </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Continuing LLC Owner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harbor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the IPO and Transactions, Bioventus is the sole managing member of BV LLC in which Bioventus owns 72.2%.
Bioventus has a majority economic interest, the sole voting interest in, and control the management of BV LLC. As a result, Bioventus consolidates the financial results of BV LLC and report a <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest representing the 27.8% which is owned by the Continuing LLC Owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus stopped consolidating Harbor upon the termination of the
Collaboration Agreement, as Bioventus ceased being the primary beneficiary because Bioventus no longer had the power to direct Harbor&#146;s significant activities. Prior to the deconsolidation, Bioventus&#146; partial ownership and exclusive
Collaboration Agreement with Harbor resulted in loss attributable to noncontrolling interest through June&nbsp;8, 2021. The $5.0&nbsp;million increase for the six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020 is primarily due to the
$5.7&nbsp;million impairment on Harbor&#146;s long-lived asset balances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Adjusted EBITDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA for each of Bioventus&#146; reportable segments is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><U></U></B><U>(in thousands, except for percentage)<B></B></U><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six months ended July&nbsp;3, 2021 compared to June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA increased $6.0&nbsp;million or 28.3%
primarily due a $33.4&nbsp;million increase in gross profit resulting from the increase in sales. This increase was partially offset by the increase in compensation related charges of $21.3&nbsp;million previously discussed as well as higher public
company costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>International </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA increased $3.8&nbsp;million primarily due to a $4.9&nbsp;million increase in gross profit resulting from the increase in sales. This increase
was partially offset by the increase in compensation related charges of $1.1&nbsp;million previously discussed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2020
compared to the Year ended December&nbsp;31, 2019 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth components of our condensed consolidated statements of operations
from continuing operations as a percentage of net sales for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales (including depreciation and amortization)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of net income from continuing operations to Adjusted EBITDA for the periods
presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,113</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization(a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,643</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,316</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,576</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,751</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,579</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation(b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,103</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,844</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> benefits, net(c)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Succession and transition charges(d)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs(e)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency impact(f)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity loss in unconsolidated investments(g)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs(h)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,633</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,177</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,443</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,188</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes for the years ended December&nbsp;31, 2020 and 2019 depreciation and amortization of
$21.2&nbsp;million and $22.4&nbsp;million in cost of sales and also includes $7.4&nbsp;million and $7.9&nbsp;million, respectively, presented in the consolidated statements of operations and comprehensive income (loss), with the balance in research
and development. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents compensation as well as the change in fair market value resulting from two equity-based compensation
plans, the MIP and the Phantom Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents income resulting from the CARES Act offset by additional cleaning and disinfecting expenses and
contract termination fees for canceled events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Primarily represents costs related to the CEO transition. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents costs related to a shift from direct to an indirect distribution model in our International business
to improve performance. Various international subsidiaries were dissolved and or merged into other BV LLC entities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Foreign currency impact represents realized and unrealized gains and losses from fluctuations in foreign
currency and is included within other (income) loss in the consolidated statements of operations and comprehensive income (loss). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents our share in the losses of CartiHeal for the year ended December&nbsp;31, 2020.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other <FONT STYLE="white-space:nowrap">non-recurring</FONT> items in 2020 includes settlement and legal costs
of $1.9&nbsp;million with the OIG. The remaining activities in 2020 and the balance in 2019 are primarily comprised of charges associated with potential strategic transactions, such as potential acquisitions and preparing to become a public company,
primarily accounting and legal fees. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net sales </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293,697</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305,072</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,464</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,069</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,141</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net sales decreased
$11.4&nbsp;million, or 3.7%, for year ended December&nbsp;31, 2020, compared to the year ended December&nbsp;31, 2019. The changes in net sales by vertical (as named during the 2020 fiscal year) are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Minimally invasive fracture treatment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.5)&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;OA joint pain treatment and joint restoration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">($</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3) million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;Bone graft substitutes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.4&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minimally invasive fracture treatment decreased primarily due to sales volume declines resulting from the disruption caused by
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. OA joint pain and joint preservation decreased primarily due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as well as more treatments being sold under contracts with
major insurers at lower prices, partially offset by sales volume growth. These decreases were also offset by sales volume growth within our BGS vertical. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>International </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net sales decreased $7.6&nbsp;million, or
21.7%, for the year ended December&nbsp;31, 2020, compared to the year ended December&nbsp;31, 2019, primarily due to a decline in order volumes due to the disruption caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gross profit and gross margin </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gross profit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214,572</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,957</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,947</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,249</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.9</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233,519</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249,206</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6.3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gross margin</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross profit
decreased $10.4&nbsp;million, or 4.6%, for the year ended December&nbsp;31, 2020, compared to the year ended December&nbsp;31, 2019, primarily due to the decline in net sales above described. Manufacturing variances created by maintaining consistent
production levels in a period of low demand coupled with idle time attributed to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic caused a slight decrease of 0.6% in gross margin during 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>International </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross profit decreased $5.3&nbsp;million,
or 21.9%, for the year ended December&nbsp;31, 2020, compared to the year ended December&nbsp;31, 2019, primarily due to the decrease in sales from the disruption caused by <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, general and administrative expense </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,078</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,475</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense declined $5.4&nbsp;million, or 2.7%, for the year ended December&nbsp;31, 2020,
compared to the year ended December&nbsp;31, 2019, primarily due to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8195;&#8202;COVID-19</FONT> related decreases, including
declines in travel and meetings from doing business virtually, lower compensation related expenses as well as various cost-reduction initiatives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.3&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Lower legal and accounting expenses, which were higher in 2019 due to the OIG
matter discussed in <I>Note 12. Commitment and contingencies</I> within the &#147;Notes to the Audited Consolidated Financial Statements&#148; included in this joint proxy statement/prospectus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.8&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These items were partially offset by the following increases: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Succession and transition charges associated with the transition to our new
Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.6&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Costs and services related to strategic transactions, product recall expenses
and other <FONT STYLE="white-space:nowrap">non-recurring</FONT> charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1&nbsp;million</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expense </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,202</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,055</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense increased $0.1&nbsp;million, or 1.3%, for the year ended December&nbsp;31, 2020, compared to
the year ended December&nbsp;31, 2019, primarily due to costs relating to the development agreement for MOTYS being almost entirely offset by cost reduction initiatives undertaken as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Depreciation and amortization </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,439</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,908</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.9</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization during the year ended December&nbsp;31, 2020 remained consistent with the year ended
December&nbsp;31, 2019, as it slightly decreased $0.5&nbsp;million, or 5.9%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other expense (income) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,751</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,579</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54.8</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense decreased $11.8&nbsp;million, or 54.8%, for the year ended December&nbsp;31, 2020, compared to the year ended
December&nbsp;31, 2019, primarily due to decreased debt interest resulting from refinancing our debt in December 2019 as well as the decline in interest rates. This decrease was partially offset with an increase of $1.6&nbsp;million primarily
resulting from the decline in value of our interest rate swap. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income during year ended December&nbsp;31, 2020 was primarily the result of
receiving Provider Relief Fund payments of approximately $4.1&nbsp;million in the aggregate pursuant to the CARES Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income tax expense
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands, except for percentage)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,576</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.8</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax expense decreased $0.4&nbsp;million, or 24.4%, for the year ended December&nbsp;31, 2020, compared to the year
ended December&nbsp;31, 2019, primarily due to the change in income from continuing operations before income taxes. Our change in effective tax rate is the result of BV LLC&#146;s pass-through structure for U.S. income tax purposes, while being
treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Adjusted EBITDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA for each of our reportable segments is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,252</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,673</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,191</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,515</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57.5</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA
decreased $2.4&nbsp;million, or 3.4%, during the comparable time periods. The decline was the result of decreased gross profit, excluding depreciation and amortization in cost of sales, due to the decrease in sales primarily resulting from the
economic impact of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which also led to lower expenses resulting from doing business virtually, lower compensation related expenses, as well as various other cost-reduction initiatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>International </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA decreased $4.3&nbsp;million, or 57.5%, during the comparable time periods. The decline was the result of decreased gross profit, excluding
depreciation and amortization in cost of sales, resulting from the decrease in sales primarily due to the economic impact of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which was partially offset by lower expenses resulting from doing business
virtually, reduced compensation related expenses and various other cost-reduction initiatives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; principal liquidity needs
have historically been for acquisitions, working capital, research and development, clinical trials, and capital expenditures. Bioventus expects these needs to continue as Bioventus develops and commercializes new products and further its expansion
into international markets. Bioventus believes that its existing cash and cash equivalents, borrowing capacity under its revolving credit facility, cash flow from operations, and net proceeds from its IPO will be enough to meet its anticipated cash
requirements for at least the next twelve months. Bioventus may require additional liquidity as Bioventus continues to execute its business strategy. Negative impacts to its liquidity would include a decline in sales of its products, including
declines due to changes in its customers&#146; ability to obtain third-party coverage and reimbursement for procedures that utilize its products, increased pricing pressures resulting from intensifying competition and cost increases, as well as
general economic and industry factors. Bioventus anticipates that to the extent that Bioventus requires additional liquidity, Bioventus will obtain funding through the incurrence of other indebtedness, additional equity financings or a combination
of these potential sources of liquidity. In addition, Bioventus may raise additional funds to finance future cash needs through receivables or royalty financings or corporate collaboration and licensing arrangements. If Bioventus raises additional
funds by issuing equity securities or convertible debt, its stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or
restricting its ability to take specific actions, such as incurring additional debt, or making capital expenditures. If Bioventus raises additional funds through collaboration and licensing arrangements with third parties, it may be necessary to
relinquish valuable rights to its products, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to us. The covenants under its credit agreement limit its ability to obtain additional debt financing.
Bioventus cannot be certain that additional funding will be available on acceptable terms, or at all. Any failure to raise capital in the future could have a negative impact on its financial condition and its ability to pursue its business
strategies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial public offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;16, 2021, in connection with its IPO, Bioventus issued and sold 9,200,000 shares of its Class&nbsp;A common stock at a price to the public of $13.00 per share, resulting in gross proceeds to Bioventus of approximately
$119.6&nbsp;million, before deducting the underwriting discount, commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is a holding
company and have no material assets other than its ownership of LLC Interests and no independent means of generating revenue. The limited liability company agreement of BV LLC provides for the payment of certain distributions to the Continuing LLC
Owner and Bioventus in amounts sufficient to cover the income taxes imposed on such members with respect to the allocation of taxable income from BV LLC as well as to cover its obligations under the Tax Receivable Agreement (TRA). Additionally, in
the event Bioventus declares any cash dividend, Bioventus intends to cause BV LLC to make distributions to us, in an amount sufficient to cover such cash dividends declared by us. Deterioration in the financial condition, earnings, or cash flow of
BV LLC and its subsidiaries for any reason could limit or impair their ability to pay such distributions. In addition, the terms of its financing arrangements, including the 2019 Credit Agreement, contain covenants that may restrict BV LLC and its
subsidiaries from paying such distributions, subject to certain exceptions. Further, BV LLC is generally prohibited under Delaware law from making a distribution to a member to the extent that, at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the time of the distribution, after giving effect to the distribution, liabilities of BV LLC (with certain exceptions), as applicable, exceed the fair value of its assets. Subsidiaries of BV LLC
are generally subject to similar legal limitations on their ability to make distributions to BV LLC. If Bioventus does not have sufficient funds to pay taxes or other liabilities or to fund its operations, Bioventus may have to borrow funds, which
could materially adversely affect its liquidity and financial condition and subject Bioventus to various restrictions imposed by any such lenders. To the extent that Bioventus is unable to make payments under the TRA for any reason, such payments
generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the TRA, Bioventus is required to make cash payments to the Continuing LLC Owner equal to 85% of the tax benefits, if any, that
Bioventus actually realizes (or in certain circumstances are deemed to realize), as a result of (1)&nbsp;increases in the tax basis of assets of BV LLC resulting from (a)&nbsp;any future redemptions or exchanges of LLC Interests described under<I>
</I>&#147;Description of Bioventus&#146; Business&#151;Bioventus LLC agreement&#151;LLC Interest Redemption Right,&#148; and (b)&nbsp;certain distributions (or deemed distributions) by BV LLC and (2)&nbsp;certain other tax benefits arising from
payments under the TRA. Bioventus expects the amount of the cash payments required to be made under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including the
timing of redemptions or exchanges by the Continuing LLC Owner, the amount of gain recognized by the Continuing LLC Owner, the amount and timing of the taxable income Bioventus generates in the future, and the federal tax rates then applicable. Any
payments made by Bioventus to the Continuing LLC Owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to Bioventus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash as of July&nbsp;3, 2021 totaled $138.1&nbsp;million compared to $86.8&nbsp;million as of December&nbsp;31, 2020.
The increase in cash was primarily due to the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26,224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(102.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from investing activities - continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NM = Not Meaningful </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash from operating
activities decreased $26.2&nbsp;million, primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensation and annual incentive plan payments increased $14.9&nbsp;million during 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completed and potential acquisition expenses increased in 2021 as well as other nonrecurring costs of
$8.3&nbsp;million; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Larger net settlements in 2021 with the sole MIP awardee of $4.3&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tax payments increased $5.9&nbsp;million during 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Larger directors and officers annual insurance premiums in 2021 for $4.6&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Settlement of Bioventus&#146; EPR liability for $3.3&nbsp;million occurred in 2021 and; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Higher inventory purchases during 2021 of $2.9&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above uses of cash were partially offset by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $21.4&nbsp;million in net collections during 2021, primarily due to the economic impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> during 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash flows used in investing activities increased $48.1&nbsp;million, primarily due to the $45.8&nbsp;million acquisition of Bioness as well as
$1.6&nbsp;million in capital expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash flows provided by financing activities increased $64.0&nbsp;million, primarily due to the $107.8&nbsp;million in net proceeds from the issuance of
Class&nbsp;A common stock sold during Bioventus&#146; IPO and a $9.9&nbsp;million decrease in net partner distributions. These increases were partially offset with no draws on Bioventus&#146; revolving credit facility compared to prior year draw of
$49.0&nbsp;million and a $5.0&nbsp;million increase in debt payments due to the timing of Bioventus&#146; quarter ends and the scheduled escalation in quarterly principal payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Credit Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no material changes to
Bioventus&#146; outstanding indebtedness or the terms of and available borrowing capacity under its credit facilities as disclosed in its 2020 <FONT STYLE="white-space:nowrap">10-K.</FONT> Bioventus was in compliance with all required financial
covenants as of July&nbsp;3, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Misonix Transaction, the Company entered into a debt commitment letter with Wells Fargo Bank,
effective July&nbsp;29, 2021. Wells Fargo Bank has committed to provide a senior secured term loan facility (Term Loan Facility) in the aggregate principal amount of up to $262.0&nbsp;million plus, at the Company&#146;s election, an amount
sufficient to fund any original issue discount or upfront fees, subject to customary closing conditions. The Term Loan Facility stipulates a prepayment of $80.0&nbsp;million on the existing Term Loan under the 2019 Credit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds of the Term Loan Facility would be available through a single draw on the closing date of the Transaction and shall be used (i)&nbsp;to finance
the Transaction; (ii)&nbsp;pay related fees, premiums and expenses and (iii)&nbsp;for working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions. The Term Loan Facility would have a
three year term that would bear interest at either the base rate as prescribed in the Term Loan under the 2019 Credit Agreement or the Eurodollar rate, and, in each case, plus an applicable margin. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information regarding Commitments and
Contingencies, refer to <I>Note 9. Commitments and contingencies</I> and <I>Note 3. Business combinations and</I> <I>investments </I>to the<I> &#147;</I>Notes to the Unaudited Condensed Consolidated Financial statements&#148;<I> </I>of the Bioventus
financial statements included in this joint proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, as of December&nbsp;31, 2020, totaled $86.8&nbsp;million compared to
$64.5&nbsp;million at December&nbsp;31, 2019. Changes in cash are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for percentage)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated statement of cash flow data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,199</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,545</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,654</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(87.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,319</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,746</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities from continuing operations increased $29.7&nbsp;million during the year ended December&nbsp;31, 2020 compared to year
ended December&nbsp;31, 2019 due to collections on accounts receivables staying strong while selling, general and administrative expenses declined, partially offset by the timing of rebate payments. We experienced lower travel expense payments
resulting from the near halting of all travel due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, a reduction in compensation related expenses due to the decline in sales and increased cash savings from cost cutting measures. We
also received stimulus payments from government entities while we purchased less inventory due to the decline in sales. In addition, our interest expense was significantly lower during the year ended December&nbsp;31, 2020 due to the December 2019
refinancing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash flows
used in investing activities increased $12.8&nbsp;million during the year ended December&nbsp;31, 2020 compared to year ended December&nbsp;31, 2019 primarily due to $16.6&nbsp;million in payments for the 2020 CartiHeal investments and an increase
of $1.8&nbsp;million in capital expenditures due to software and technology upgrades. These investing cash outflows were partially offset by the absence of payments for distribution rights in 2020 compared to $6.0&nbsp;million for the purchases of
distribution rights during 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash flows used in financing activities increased $18.6&nbsp;million during the year ended December&nbsp;31, 2020 compared to the year ended December&nbsp;31,
2019 primarily due to a $10.7&nbsp;million increase in distribution to members as well as the $6.1&nbsp;million increase in debt payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indebtedness </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2019, Bioventus entered
into the 2019 Credit Agreement. The 2019 Credit Agreement is comprised of its $200.0&nbsp;million term loan and its $50.0&nbsp;million revolving credit facility. All obligations under the 2019 Credit Agreement are guaranteed by certain of its wholly
owned domestic subsidiaries and secured by substantially all its and the guarantors&#146; assets. The term loan and revolving credit facility mature on December&nbsp;6, 2024. The 2019 Credit Agreement contains various restrictive covenants,
including a quarterly covenant not to exceed a consolidated leverage ratio of 3.50 to 1.00 and an interest coverage ratio of 3.00:1.00 for the prior four consecutive quarters. The leverage and interest coverage ratios are based on Consolidated
EBITDA as defined in the 2019 Credit Agreement, which includes several differences from Adjusted EBITDA as calculated in this joint proxy statement/prospectus. Consolidated EBITDA as defined in the 2019 Credit Agreement permits, among other things,
the exclusion of (1)&nbsp;certain extraordinary, unusual and/or <FONT STYLE="white-space:nowrap">non-recurring</FONT> expenses, some of which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are subject to an aggregate cap, including but not limited to severance, acquisitions, dispositions, debt refinancing/amendment and <FONT STYLE="white-space:nowrap">IPO-related,</FONT>
(2)&nbsp;foreign currency gains/losses recognized in the statement of operations and (3)&nbsp;franchise, excise and property taxes recognized in the statement of operations. The restrictive covenants include limitations on (1)&nbsp;the declaration
or payment of certain distributions on or in respect of its equity interests, (2)&nbsp;restrictions on acquisitions, investments and certain other payments, (3)&nbsp;limitations on the incurrence of new indebtedness, (4)&nbsp;limitations on
transfers, sales and other dispositions and (5)&nbsp;limitations on making changes to its business and organizational documents. As of December&nbsp;31, 2020, Bioventus complied with all covenants under the 2019 Credit Agreement and there was
$190.0&nbsp;million of outstanding borrowings under the term loan. Bioventus has one nominal outstanding letter of credit. In March 2020, as a precautionary measure and in order to increase its cash position and preserve financial flexibility in
view of the uncertainty resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Bioventus drew down $49.0&nbsp;million on its revolving credit facility. On September&nbsp;24, 2020, Bioventus repaid all borrowings outstanding
under its revolving credit facility. Bioventus&#146; revolving credit facility had $50.0&nbsp;million in borrowing capacity as of December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus does not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus acquired leases as
part of the Bioness Acquisition, which resulted in increases to contractual lease commitments previously disclosed in Bioventus&#146; 2020 <FONT STYLE="white-space:nowrap">10-K</FONT> of $489, $808, $775, $776 and $638 for the years ended
December&nbsp;31, 2021, 2022, 2023, 2024 and 2025, respectively. In addition, see above under &#147;Recent Developments &#151;Misonix Acquisition&#148; for a description of contractual obligations under the Merger Agreement that are subject to
regulatory approvals, stockholder approvals and other customary closing conditions. Other than the foregoing, there have been no material changes to Bioventus&#146; contractual obligations s disclosed in Bioventus&#146; 2020 <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; contractual obligations as of December&nbsp;31, 2020 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Contractual Obligations (in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>thousands)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less</B><br><B>than 1</B><br><B>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3</FONT></B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5</FONT></B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More</B><br><B>than</B><br><B>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on long-term debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,606</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,073</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,139</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,818</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,955</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,232</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,921</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,068</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,655</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,920</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,920</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,495</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,221</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,948</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,291</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,921</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293,381</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above does not include certain obligations as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commitments under its multi-year exclusive supply agreements for its OA products except for those amounts that
are contractually committed as of December&nbsp;31, 2020. Bioventus&#146; purchase obligations under these supply agreements are generally based upon its forecasted requirements, subject in some cases to a contractual minimum per annum;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commitments under the Development Agreement with MTF, the Option and Equity Purchase Agreement with CartiHeal and
its shareholders and the Collaboration Agreement with Harbor, for which the relevant contingent events requiring a payment under the respective agreements have not yet occurred; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future milestone payments pursuant to the Development Agreement with MTF, the Option and Equity Purchase
Agreement with CartiHeal and its shareholders, the Collaboration Agreement with Harbor and the amended and restated license agreement, or the <FONT STYLE="white-space:nowrap">Q-Med</FONT> License Agreement, with
<FONT STYLE="white-space:nowrap">Q-Med</FONT> and NSH, as the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
payment obligations under these agreements are contingent upon future events and Bioventus is unable to estimate the timing or likelihood of achieving these milestones or generating future
product sales. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent accounting pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to <I>Note 2. Summary of significant accounting policies </I>in the &#147;Notes to the Audited Consolidated Financial Statements&#148; and <I>Note 1.
Organization</I> in the &#147;Notes to the Unaudited Condensed Consolidated Financial Statements&#148;<I> </I>included in this joint proxy statement/prospectus for further information regarding recently adopted and proposed accounting
pronouncements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal control over financial reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently, as a newly public company, its management is not required to perform an annual
assessment of the effectiveness of its internal control over financial reporting. This requirement will first apply to its second Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> Bioventus&#146; independent public registered
accounting firm will first be required to attest to the effectiveness of its internal control over financial reporting for its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the first year Bioventus is no longer either an
&#147;emerging growth company&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-accelerated</FONT> filer,&#148; as such terms are defined by Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical accounting policies and estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preparation of the consolidated financial statements requires Bioventus to make assumptions, estimates and judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of
the consolidated financial statements, and the reported amounts of sales and expenses during the reporting periods. Certain of its more critical accounting policies require the application of significant judgment by management in selecting the
appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. On an ongoing basis, Bioventus evaluates its judgments, including those related to inventories,
recoverability of long-lived assets and the fair value of its common stock. Bioventus uses historical experience and other assumptions as the basis for its judgments in making these estimates. Because future events and their effects cannot be
determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in its consolidated financial statements as they occur. Refer to <I>Note 1. Organization and basis of
presentation of financial information</I> in the &#147;Notes to the Audited Consolidated Financial Statements&#148; included in this joint proxy statement/prospectus<I> </I>for a further description of its significant accounting policies, however,
Bioventus believes that the following accounting policies and estimates that are considered critical to its business in order to obtain a full understanding and to evaluate its reported financial results. The critical accounting policies addressed
below reflect its most significant judgments and estimates used in the preparation of its consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue recognition
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale of products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus derives revenue
primarily from the sale of its pain treatment and joint preservation products, BGSs and restorative therapies. Bioventus sells these products directly to healthcare institutions, patients, distributors and dealers. Bioventus also enters into
arrangements with pharmacy and health benefit managers that provide for privately negotiated rebates, chargebacks and discounts with respect to the purchase of its products. Bioventus recognizes revenue at a point in time upon transfer of control of
the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. Bioventus excludes from revenues taxes collected from customers and remitted to governmental authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates
of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements and certain distribution and administration fees offered in its customer contracts and other indirect
customer contracts relating to the sale of its products. Bioventus establishes reserves for the estimated variable consideration based on the amounts earned or eligible for claim on the related sales. Where appropriate, these estimates take into
consideration a range of possible outcomes, which are probability-weighted for relevant factors such as its historical experience, current contractual requirements, specific known market events and trends, industry data and forecasted customer
buying and payment patterns.&nbsp;The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a
future period.&nbsp;Bioventus regularly reviews all reserves and update them at the end of each reporting period as needed. There were no adjustments arising from the change in estimates of variable consideration for the years ended
December&nbsp;31, 2020 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pain treatment and joint preservation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from customers such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is
transferred to the customer, typically upon shipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributor chargebacks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has preexisting contracts with established rates with many of the distributors&#146; customers that require the distributors to sell its product at
their established rate. Bioventus offers chargebacks to distributors who supply these customers with its products. Bioventus reduces revenue at the time of sale for the estimated future chargebacks. Bioventus records chargeback reserves as a
reduction of accounts receivable and bases the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discounts and rebates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus offers retrospective
discounts and rebates linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. Bioventus reduces revenue and records the reserve as a reduction to accounts receivable for the estimated discount
and rebate at the most likely amount the customer will earn, based on historical buying trends and forecasted purchases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bone graft substitutes
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of its BGS product sales are through consignment inventory with hospitals, where ownership remains with Bioventus until the hospital
performs a surgery and consumes the consigned inventory. Bioventus recognizes the revenue when the surgery has been performed. The customer does not have control of the product until the customer consumes it, as Bioventus is able to require the
return or transfer of the product to a third-party. An unconditional obligation to pay for the product does not exist until the customer consumes it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restorative Therapies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus recognizes revenue from
third-party payers, such as governmental agencies, insurance companies or managed care providers, when Bioventus transfers control of the Exogen system to the patient, typically when the patient has accepted the product or upon delivery. Bioventus
records this revenue at the contracted rate, net of contractual allowances at the time of sale, or an estimated price based on historical data and other available information for <FONT STYLE="white-space:nowrap">non-contracted</FONT> payers.
Bioventus records contractual allowances based on probability weighting historical data and collections. Bioventus recognizes revenue from patients <FONT STYLE="white-space:nowrap">(self-pay</FONT> and insured patients with coinsurance and
deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent differences between amounts billed and the amounts Bioventus expects to collect from patients,
which considers historical collection experience and current market conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or
investigations are considered variable consideration and are included in the determination of the estimated transaction price using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the
payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits,
reviews and investigations. Bioventus is not aware of any claims, disputes or unsettled matters with any payer that would materially affect revenues for which Bioventus has not been adequately provided. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product returns </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus estimates the amount of
returns and reduce revenue in the period the related product revenue is recognized. Bioventus records a liability for expected returns based on probability weighted historical data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts receivable, net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable, net
are amounts billed and currently due from customers. Bioventus records the amounts due net of allowance for doubtful accounts. Bioventus maintains allowances for credit losses to provide for receivables Bioventus does not expect to collect.
Bioventus bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable. Collection of the consideration that Bioventus expects to receive
typically occurs within 30 to 90 days of billing. Bioventus applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, Bioventus enters into
payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract assets consist of
unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed. Contract assets are included in prepaid and other current assets on the consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract liabilities consist
of customer advance payments or deposits and deferred revenue. Occasionally for certain international customers, Bioventus requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract
liabilities are included in accrued liabilities on the consolidated balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shipping and handling </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other
distribution costs are included in cost of sales. Bioventus has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and are included in cost of sales.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus applies the
practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that Bioventus otherwise would have recognized is one year or less. These incremental costs include
its sales incentive programs for the internal sales force and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense on the consolidated statements
of operations and comprehensive income (loss). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these
estimates, including those related to contractual allowances and sales incentives, allowances for doubtful accounts, inventory reserves, goodwill and intangible assets impairment, useful lives of long lived assets, noncontrolling interest, fair
value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus records certain assets and
liabilities at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use
of unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three
levels of inputs used to measure fair value are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Quoted prices in active markets for identical assets or
liabilities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Observable inputs other than quoted prices included within Level&nbsp;1, such as quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow
methodologies and similar techniques that use significant unobservable inputs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business combinations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus records identifiable assets acquired, liabilities assumed and any noncontrolling interest in an acquiree resulting from a business combination at
their estimated fair values on the date of the acquisition. Bioventus generally has third-party valuations completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating various assumptions. Goodwill
represents the excess of the purchase price over the estimated fair value of the net assets acquired, including the amount assigned to identifiable intangible assets. The most significant estimates and assumptions inherent in a discounted cash flow
analysis include the amount and timing of projected future cash flows, discount rate used to measure the risks inherent in the future cash flows, assessment of the asset&#146;s life cycle, and competitive and other trends impacting the asset,
including consideration of technical, legal, regulatory, economic and other factors. Each of these factors and assumptions can significantly affect the value of the intangible asset. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, or IPR&amp;D, is the
fair value of projects for which the related products have not received regulatory approval and have no alternative future use and is capitalized as an indefinite-lived intangible asset. Due to inherent uncertainty related to research and
development, actual results could differ materially from the assumptions used in the discounted cash flow model. Additionally, there are risks including, but not limited to, delay or failure to receive regulatory requirements to conduct clinical
trials, required market clearances, or patent issuance, and that the research and development project does not result in a successful commercial product. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of
regulatory approval of the related technology or product, the indefinite-lived intangible asset is accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the research and
development project is abandoned, the indefinite-lived asset is charged to expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus recognizes contingent consideration liabilities resulting
from business combinations at estimated fair value on the acquisition date. Contingent consideration liabilities are revalued subsequent to the acquisition date with changes in fair value recognized in earnings. Contingent payments related to
acquisitions consist of development, regulatory and commercial milestone payments, and are valued using discounted cash flow techniques. Significant estimates and assumptions required for these valuations include the probability of achieving
regulatory approval under specified time frames, product sales projections under various scenarios and discount rates used to calculate the present value of the estimated payments. Changes in the fair value of contingent consideration liabilities
result from changes in these estimates and assumptions. Significant judgment is employed in determining the appropriateness of the estimates and assumptions as of the acquisition date and in post-acquisition periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus initially
values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used
to estimate the fair value of contingent consideration include revenue and the probability of achieving the specific targets. After the initial valuation, the Company will use its best estimate to measure contingent consideration at each subsequent
reporting period. Gains and losses are recorded with selling, general and administrative expenses within the consolidated statements of operations and comprehensive (loss) income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus evaluates goodwill and other
indefinite-lived intangible assets for impairment annually during the fourth quarter, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Bioventus&#146; reporting units are U.S. and International and
Bioventus analyzes each reporting unit separately in its goodwill impairment evaluation. Bioventus used independent third-party valuation specialists in 2020 and 2019 using
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> October data in each year to assist management in performing the annual review of goodwill for impairment. Bioventus also utilized valuation specialists in
April 2020 as Bioventus believed <FONT STYLE="white-space:nowrap">COVID-19</FONT> represented a triggering event that might indicate impairment. The specialists assist management in the determination of fair value of reporting units based upon
inputs and assumptions provided by management, which management uses for its impairment assessment. Bioventus analyzes all other indefinite-lived intangible assets qualitatively to determine if it is more likely than not for an impairment to exist.
If Bioventus meets the criteria, Bioventus performs a quantitative analysis to determine if an impairment exists. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146; goodwill impairment process includes applying a quantitative impairment analysis where the fair value of the reporting unit and compare it to
its carrying value (including goodwill). Bioventus determines the fair value of U.S. and International reporting units based primarily on an income approach, which incorporates the use of a discounted free cash flow analysis. The discounted free
cash flow analyses is based on significant judgments, including the current operating budgets, estimated long-term growth projections and future forecasts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for each reporting unit. Bioventus discounts future cash flows based on a market comparable weighted average cost of capital rate for each reporting unit. The discount rates used in the
discounted free cash flow analyses reflect the risks inherent in the expected future cash flows generated by the respective intangible assets. Market risk, industry risk and a small company premium has an impact on the discount rate. The value of
each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price Bioventus estimates it would receive in a sale of the reporting unit in an orderly transaction between market participants
at the measurement date. Significant judgments inherent in this analysis include estimating the amount and timing of future cash flows and the selection of appropriate discount rates, royalty rate and long-term growth rate assumptions. Changes in
these estimates and assumptions could materially affect the determination of fair value for each reporting unit and for some of the reporting units and could result in an impairment charge, which could be material to its financial position and
results of operations. There has been no impairment of its goodwill related to its U.S. and International reporting units since its formation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, the Company
operated two equity-based compensation plans, the MIP and the Phantom Plans, which allows its employees to share its future profit without granting any additional voting rights. Awards granted under the MIP and certain Phantom Plan awards granted in
2015 and thereafter, or the 2015 Phantom Plan Units, are liability-classified. Those Phantom Plan awards granted from inception in 2012 and until the grant of the 2015 Phantom Plan Units, or the 2012 Phantom Plan Units, are equity-classified, as
they do not contain a put option or other features requiring them to be liability-classified. Equity compensation includes compensation expense for all equity awards made to employees that are part of continuing operations and are based on estimated
fair values as of the grant date for the 2012 Phantom Plan Units and period end fair value for the MIP units and 2015 Phantom Plan Units. Bioventus recognizes expense for performance-based awards when it expects them to be earned. Bioventus
recognizes timed-based awards over the requisite service period, which is generally the vesting period of the award. Bioventus recognizes forfeitures as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus used independent third-party valuation specialists in 2020 and 2019 using
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> October data in each year to assist management in performing the annual valuation of MIP and 2015 Phantom Plan Units. Bioventus also utilized valuation
specialists in April 2020 as it believed <FONT STYLE="white-space:nowrap">COVID-19</FONT> represented a triggering event that might indicate impairment. The specialists assist management in the determination of fair value of awards granted using the
Monte Carlo option pricing model. The subjective assumptions and the application of judgment in determining the fair value of the awards represent management&#146;s best estimates. If factors change and different assumptions are used, its equity
compensation expense could be materially different in the future. The most significant assumptions and judgments are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected volatility&#151;Bioventus determines the expected price volatility based on the historical volatilities
of its peer group, as Bioventus does not have a sufficient trading history for its units. Industry peers consist of several public companies in the medical device industry similar to Bioventus in size, stage of life cycle and financial leverage.
Bioventus intends to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or unless
circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Time to liquidity event&#151;The amount of time that the awards are expected to be outstanding.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk-free interest rate&#151;Bioventus based the risk-free rate on U.S. Government Constant Maturity Treasury
rates for a term corresponding to the Time to Liquidity Event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected dividend yield&#151;Bioventus used a dividend rate of zero as it has not previously issued dividends and
do not anticipate paying dividends in the foreseeable future. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions utilized to determine the fair value of the awards are indicated in the following table:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to exit event (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of the fair value of awards also requires an estimate of its equity value, based on inputs from management and
reporting unit valuation reports prepared by the specialists during the annual goodwill impairment process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus determined the value of its equity
utilizing methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Practice Aid, &#147;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&#148;. In the absence of a
public trading market, its Board of Managers determines a reasonable estimate of the grant date fair value of its equity awards based on input from management and the annual valuation reports prepared by the specialists. In addition, Bioventus
exercised judgment in evaluating and assessing the foregoing based on several factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the nature and history of its business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bioventus&#146; historical operating and financial results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market value of companies that are engaged in a similar business to Bioventus&#146;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of its common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the overall inherent risks associated with its business at the time awards were approved; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the overall equity market conditions and general economic trends. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was approximately $9.7&nbsp;million of unrecognized compensation expense to be recognized over a weighted-average period
of 1.3 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BV LLC is
currently a partnership for U.S. federal income tax purposes. As a partnership, taxable income or loss is generally included in the income tax returns of its members. Bioventus also has a subsidiary that operates as a
<FONT STYLE="white-space:nowrap">C-corporation</FONT> that is subject to income tax requirements and international operations that are subject to foreign income tax requirements. Additionally, BV LLC is liable for various other state and local
taxes. As a corporation, Bioventus will be subject to U.S. federal, state and local income taxes. Bioventus recognizes the effect of income tax positions only if these positions are more likely than not to be sustained. Bioventus reflects changes in
recognition or measurement in the period in which the change in judgment occurs. Upon the redemption or exchange of BV LLC Units for shares of Class&nbsp;A common stock or cash, Bioventus will determine if it is likely to realize the resulting tax
benefits. If it is, Bioventus will record (i)&nbsp;a deferred tax asset based on the <FONT STYLE="white-space:nowrap">step-up</FONT> in basis resulting from the exchange and the then effective income tax rate, (ii)&nbsp;a payable to related party in
respect of the corresponding 85% payment under the TRA and (iii)&nbsp;a tax benefit based on the net difference between (i)&nbsp;and (ii). As Bioventus realizes cash tax savings, it will reduce the deferred tax asset and the payments made under the
TRA will reduce the payable to related party. Further, Bioventus will evaluate the likelihood that it will realize the benefit represented by the deferred tax asset and, to the extent that Bioventus estimates it is more likely than not that it will
not realize the benefit, Bioventus will reduce the carrying amount of the deferred tax asset with a valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long-lived assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset&#146;s estimated useful life, or the
lease term if related to leased property, as follows in years: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Machinery and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus amortizes finite-lived identifiable intangible assets using the straight-line method over their estimated remaining
weighted average useful lives as follows in years: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Useful&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developed technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus capitalizes costs incurred from third-party vendors for software design, configuration, coding and testing and
amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. Bioventus does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary
project phase costs, planning, oversight, process <FONT STYLE="white-space:nowrap">re-engineering</FONT> costs, training costs or data conversion costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying values of property, equipment and finite lived intangible assets are reviewed for recoverability if the facts and circumstances suggest that a
potential impairment may have occurred. If this review indicates that carrying values may not be recoverable, Bioventus will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value.
There were no events, facts or circumstances for the years ended December&nbsp;31, 2020 and 2019 that resulted in any impairment charges to its property, equipment or finite lived intangible assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus qualifies as an &#147;emerging growth
company&#148; pursuant to the provisions of the JOBS Act. For as long as Bioventus is an &#147;emerging growth company,&#148; Bioventus may take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies that are not &#147;emerging growth companies,&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, reduced disclosure obligations relating to the presentation of financial statements in the &#147;Management&#146;s discussion and analysis of financial condition and
results of operations&#148; section and exemptions from the requirements of holding advisory <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes on executive compensation and shareholder
advisory votes on golden parachute compensation. Bioventus has availed itself of the reduced reporting obligations and executive compensation disclosure in this joint proxy statement/prospectus and expects to continue to avail itself of the reduced
reporting obligations available to emerging growth companies in future filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, an emerging growth company can delay its adoption of certain
accounting standards until those standards would otherwise apply to private companies. However, Bioventus is choosing to &#147;opt out&#148; of such extended transition period, and as a result, Bioventus plans to comply with any new or revised
accounting standards on the relevant dates on which <FONT STYLE="white-space:nowrap">non-</FONT> emerging growth companies must adopt such standards. Section&nbsp;107 of the JOBS Act provides that its decision to opt out of the extended transition
period for complying with new or revised accounting standards is irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will continue to qualify as an emerging growth company until the earliest of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The last day of its fiscal year following the fifth anniversary of the date of its IPO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The last day of its fiscal year in which have annual gross revenues of $1.07&nbsp;billion or more;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The date on which Bioventus has, during the previous three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The date on which Bioventus is deemed to be a &#147;large accelerated filer&#148;, which will occur at such time
as Bioventus (1)&nbsp;has an aggregate worldwide market value of common equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700&nbsp;million or more as of the last business day of its most recently completed second
quarter, (2)&nbsp;have been required to file annual and quarterly reports under the Exchange Act for a period of at least 12 months and (3)&nbsp;have filed at least one annual report pursuant to the Exchange Act. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_24"></A>BIOVENTUS DIRECTOR AND OFFICER COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section discusses the
material components of the executive compensation program for our executive officers who are named in the &#147;2020 Summary compensation table&#148; below. In 2020, our &#147;named executive officers&#148; and their positions were as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kenneth M. Reali, Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gregory O. Anglum, Senior Vice President&nbsp;&amp; Chief Financial Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">John E. Nosenzo, Senior Vice President&nbsp;&amp; Chief Commercial Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthony D&#146;Adamio, Senior Vice President&nbsp;&amp; General Counsel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Alessandra Pavesio, Senior Vice President&nbsp;&amp; Chief Science Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthony P. Bihl III, former Chief Executive Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Reali became Chief Executive Officer and a member of the BV LLC board of managers, effective as of April&nbsp;13, 2020, in connection with
Mr.&nbsp;Bihl&#146;s retirement on April&nbsp;19, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of our named executive officers for the year ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kenneth M. Reali</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">428,135</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,282</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,111,191</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,631</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426,634</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277,719</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,291,592</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Gregory O. Anglum</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,044</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,793</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178,471</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,392</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">584,700</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Senior Vice President&nbsp;&amp; Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,479</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,386</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">539,884</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">John E. Nosenzo</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">504,893</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,778</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357,646</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,959</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">907,277</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Senior Vice President&nbsp;&amp; Chief Commercial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">490,219</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295,322</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,584</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">808,125</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Anthony D&#146;Adamio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396,597</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,062</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,674</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,959</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">618,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Senior Vice President&nbsp;&amp; General Counsel</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">391,106</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,016</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,584</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563,706</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Alessandra Pavesio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408,657</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,267</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,652</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,375</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">634,951</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Senior Vice President&nbsp;&amp; Chief Science Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">398,165</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,693</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579,858</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Anthony P Bihl III</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,750</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214,111</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,639,984</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,090,845</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Former Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">684,979</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552,910</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,561</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,261,450</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect annual base salary earned with respect to 2019 and 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect discretionary &#147;make whole&#148; bonuses paid to all employees who earned performance-based
cash incentives under the 2020 Annual Incentive Plan in amounts equal to the additional cash incentives that would have otherwise been paid under such plan had salaries not been reduced in connection with the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as described below under &#147;&#151;2020 Salaries&#148;. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount reflects a discretionary &#147;make whole&#148; bonus paid to Mr.&nbsp;Nosenzo in respect of his
performance-based cash incentive under the 2020 Executive Annual Incentive Plan &#150; Chief Commercial Officer in an amount equal to (i)&nbsp;the additional cash incentive that he would have otherwise been paid under such plan had his salary not
been reduced in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as described below under &#147;&#151;2020 Salaries&#148; and (ii)&nbsp;in recognition of his sales efforts during the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the additional cash incentive that he would have been paid had he been a participant in the 2020 Executive Annual Incentive Plan &#150; Non Commercial. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount reflects (i)&nbsp;a $3,167 discretionary &#147;make whole&#148; bonus paid to Ms.&nbsp;Pavesio in
respect of her performance-based cash incentive under the 2020 Executive Annual Incentive Plan &#150; Non Commercial in an amount equal to the additional cash incentive that she would have otherwise been paid under such plan had her salary not been
reduced in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, as described below under &#147;&#151;2020 Salaries&#148;, and (ii) $100 bonus paid to Ms.&nbsp;Pavesio in connection with a CEO determination to pay $100
discretionary bonuses to all employees with five through nine years of service. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the annual performance-based cash incentives earned by our named executive officers in 2019 and
2020 based on achievement of corporate and personal performance objectives as set forth in the 2019 and 2020 Executive Annual Incentive Plan &#150; Non Commercial or the 2019 and 2020 Executive Annual Incentive Plan &#150; Chief Commercial Officer,
as applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2020 amounts reflect (i) $8,550, $8,550, $8,550, $8,550, $8,550, and $8,550 in matching 401(k) contributions
made by us to the 401(k) accounts of Messrs. Reali, Anglum, Nosenzo, D&#146;Adamio, Ms.&nbsp;Pavesio and Mr.&nbsp;Bihl, respectively, (ii)&nbsp;additional fixed <FONT STYLE="white-space:nowrap">non-elective</FONT> contributions of $1,064, $12,402,
$12,825, $12,825, $12,825, and $12,825 made by us to the 401(k) accounts of Messrs. Reali, Anglum, Nosenzo, D&#146;Adamio, Ms.&nbsp;Pavesio and Mr.&nbsp;Bihl, respectively, (iii)&nbsp;reimbursement of cellular telephone expenses to Messrs. Reali,
Anglum, Nosenzo, and D&#146;Adamio equal to $1,056, $1440, $1,584 and $1,584, respectively, (iv)&nbsp;relocation allowance of $250,000 and tax gross up of $17,048 to Mr.&nbsp;Reali, (v)&nbsp;payments to Mr.&nbsp;Bihl of a $4,966 benefit stipend and
$63,700 tax stipend in connection with his status as a partner and associated receipt of a guaranteed payment instead of a salary, and (vi)&nbsp;payments made to Mr.&nbsp;Bihl in connection with his retirement in an aggregate amount of $3,549,943 to
reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">COVID-19-related</FONT></FONT> decrease in the repurchase value of his equity interests. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2019 amounts reflect (i) $2,561 benefit stipend to Mr.&nbsp;Bihl (ii) $8,400, $8,400, $8,400, $8,400 and $8,400
in matching 401(k) contributions made by us to the 401(k) accounts of Messrs. Anglum, Nosenzo, D&#146;Adamio, Ms.&nbsp;Pavesio and Mr.&nbsp;Bihl, respectively, (iii)&nbsp;additional fixed <FONT STYLE="white-space:nowrap">non-elective</FONT>
contributions of $12,600, $12,600, $12,600, $12,600 and $12,600 made by us to the 401(k) accounts of Messrs. Anglum, Nosenzo, D&#146;Adamio, Ms.&nbsp;Pavesio and Mr.&nbsp;Bihl, respectively, and (iv)&nbsp;reimbursement of cellular telephone expenses
to Messrs. Anglum, Nosenzo, and D&#146;Adamio equal to $1,386, $1,584 and $1,584, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount reflects the aggregate grant date fair value of phantom profits interests granted to Mr.&nbsp;Reali
during the year ended December&nbsp;31, 2020 computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. Refer to <I>Note 9. Equity-based compensation</I> within <I>Part II, Item 8. Financial Statements and Supplementary
Data</I> for a discussion of the relevant assumptions used in calculating this amount. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount reflects the aggregate grant date fair value of options granted to Mr.&nbsp;Reali during the year ended
December&nbsp;31, 2020 computed using a Black-Scholes calculation in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment
Letters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of employment for Messrs. Reali, Anglum, Nosenzo, D&#146;Adamio and Ms.&nbsp;Pavesio in effect as of December&nbsp;31, 2020 are
documented in their employment letters dated March&nbsp;12, 2020, August&nbsp;2, 2017, November&nbsp;18, 2016, July&nbsp;11, 2017 and June&nbsp;13, 2013, respectively, with Mr.&nbsp;Reali&#146;s employment letter subsequently amended as of
April&nbsp;24, 2020. The terms of Mr.&nbsp;Bihl&#146;s prior employment are documented in his offer letter dated November&nbsp;4, 2013 as amended on October&nbsp;17, 2019 to reflect his status as a partner. Pursuant to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their respective employment letters, Mr.&nbsp;Bihl was hired to serve as the Chief Executive Officer, Mr.&nbsp;Reali was hired to serve as the Chief Executive Officer following
Mr.&nbsp;Bihl&#146;s retirement, Mr.&nbsp;Anglum was promoted on August&nbsp;7, 2017 to serve as the Chief Financial Officer (after serving as the interim Chief Financial Officer effective May&nbsp;1, 2017), Mr.&nbsp;Nosenzo was hired to serve as
Chief Commercial Officer, Mr.&nbsp;D&#146;Adamio was hired to serve as Senior Vice President and General Counsel and Ms.&nbsp;Pavesio was hired to serve as Chief Science Officer. Mr.&nbsp;Bihl also served as a member of the BV LLC board of managers
until his retirement on April&nbsp;19, 2020 and Mr.&nbsp;Reali now serves as a member of the BV LLC board of managers. In connection with our IPO, we entered into new employment agreements with Messrs. Reali, Anglum, Nosenzo, D&#146;Adamio, and
Ms.&nbsp;Pavesio (as further described below under &#147;&#151;Severance&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Salaries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The named executive officers were entitled to receive a base salary in 2020 to compensate them for services rendered to us. The base salary payable to each
named executive officer is intended to provide a fixed component of compensation reflecting the named executive officer&#146;s skill set, experience, role and responsibilities. The annual base salaries payable to Messrs. Reali, Anglum, Nosenzo,
D&#146;Adamio and Ms.&nbsp;Pavesio as of December&nbsp;31, 2020, were $615,000, $389,881, $518,451, $405,794 and $419,630 respectively, all of which reflect merit increases which were effective March&nbsp;29, 2020 for the named executive officers
other than Mr.&nbsp;Reali. In connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we implemented a 20% reduction in base salary for each of our employees with a base salary of $100,000 or greater, including each of our
named executive officers, effective May&nbsp;31, 2020 and ending June&nbsp;27, 2020, which reductions are reflected in the actual salary paid in the summary compensation table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the consummation of our IPO, we increased the salaries of Messrs. Reali, Anglum, D&#146;Adamio and Ms.&nbsp;Pavesio to $700,000, $430,000,
$420,000 and $430,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Incentive Bonuses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to their services in 2020, Messrs. Reali, Anglum, D&#146;Adamio, Ms.&nbsp;Pavesio and Mr.&nbsp;Bihl were eligible to earn an annual
performance-based cash bonus pursuant to the 2020 Executive Annual Incentive Plan &#150; Non Commercial, or the Non Commercial AIP (with Mr.&nbsp;Bihl&#146;s bonus <FONT STYLE="white-space:nowrap">pro-rated</FONT> for the portion of the year for
which he provided service prior to his retirement date), and Mr.&nbsp;Nosenzo was eligible to earn an annual performance-based cash bonus pursuant to the 2020 Executive Annual Incentive Plan &#150; Chief Commercial Officer, or the Commercial AIP.
Bonuses earned by our named executive officers under both the Non Commercial AIP and Commercial AIP were based upon weighted minimum, target and maximum achievement of both business and personal performance measures. The Non Commercial AIP and the
Commercial AIP objective business measures in 2020 were (1)&nbsp;Global Revenue, (2)&nbsp;Adjusted Global EBITDA and (3)&nbsp;multiple osteoarthritis treatment achievements, including submission of an IND application to FDA for &#147;Biologic&#148;
placental tissue product in the third quarter of 2020, the launch of a GTP placental tissue product in the fourth quarter of 2020 and the achievement of $100,000 in 2020 revenue with respect to such placental tissue product. The personal performance
standards were based on the named executive officers&#146; performance ratings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Reali&#146;s and Mr.&nbsp;Bihl&#146;s target incentive for 2020
was 100% of their respective eligible earnings (as defined under the applicable AIP); Mr.&nbsp;Nosenzo&#146;s was 75% of his eligible earnings; and Messrs. Anglum, D&#146;Adamio and Ms.&nbsp;Pavesio&#146;s was 50% of their respective eligible
earnings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Objective business measures and personal performance were weighted as 80% and 20%, respectively, of the annual bonuses under the Non Commercial
AIP and the Commercial AIP. Possible payouts for the objective business measures under the Non Commercial AIP and the Commercial AIP ranged from 50% for minimum achievement, 100% for target achievement, to 200% for maximum achievement, which amounts
shall correspond to 95%, 100%, and 105% achievement of the applicable objective business measure target, respectively. The personal performance component of the award amount ranged from a 50% for minimum achievement, 100% for target achievement, to
200% for maximum achievement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 2020, the achievement percentage for the objective business measures for each of our NEOs was determined
to be 93.6% (with Mr.&nbsp;Bihl&#146;s <FONT STYLE="white-space:nowrap">pro-rated</FONT> award calculated at actual achievement for the objective business measures). The achievement percentage for the personal performance component was determined to
be 125% for each of Messrs. Reali, D&#146;Adamio, Nosenzo, and Ms.&nbsp;Pavesio and 100% for Mr.&nbsp;Anglum (with Mr.&nbsp;Bihl&#146;s <FONT STYLE="white-space:nowrap">pro-rated</FONT> award calculated at target achievement (100%) for the personal
performance component). In addition to the awards calculated under the applicable AIP for each of our NEOs, each of our employees who participated in an AIP, including our NEOs, received a discretionary &#147;make whole&#148; bonus with respect to
each employee&#146;s performance-based cash incentive under the applicable AIP in an amount equal to the additional cash incentive each employee would have otherwise received had salaries not been reduced in connection with the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In recognition of his sales efforts during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Mr.&nbsp;Nosenzo also received an additional discretionary &#147;make whole&#148; bonus
with respect to his performance-based cash incentive under the Commercial AIP in an amount equal to the additional cash incentive he would have received had he been a participant in the Non Commercial AIP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to our IPO, we
maintained the BV LLC profits interest plan, which we called the Management Incentive Plan (MIP), pursuant to which we granted 333,330 profits interest units of BV LLC (Profits Interest Units), to Mr.&nbsp;Bihl on December&nbsp;2, 2013. In
connection with Mr.&nbsp;Bihl&#146;s retirement, we redeemed all of his Profits Interest Units as described below under &#147;&#151;Severance.&#148; In connection with our IPO the MIP was terminated and no further awards will be made under the MIP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to our IPO, we also maintained the Bioventus Phantom Profits Interest Plan, which was renamed the Bioventus Stock Plan on June&nbsp;1, 2020, and
which we called the Phantom Plan, pursuant to which we granted time-vesting phantom plan units (Time Phantom Units) and performance-vesting phantom plan units (Performance Phantom Units). The Time Phantom Units generally vested ratably over five
years (20% on the first anniversary of the date of grant and 5% quarterly thereafter) and entitled the holder to a cash payment, in an amount determined by reference to the value of our Profits Interest Units, with respect to any vested Time Phantom
Units upon the earlier of a termination from service or certain distribution events with respect to the Company&#146;s profits interest units. In the event of a qualifying distribution event prior to a termination, all Time Phantom Units fully vest.
Generally, Performance Phantom Units were scheduled to vest on June&nbsp;1, 2021, subject to the achievement of 2020 corporate revenue goals, but could also become vested in whole or in part in the board of managers&#146; discretion in the event
such revenue goals were not satisfied. In connection with our IPO, on February&nbsp;11, 2021, we terminated the Phantom Plan and there will be no further awards made under the Phantom Plan. We will settle all awards thereunder 12 months following
the termination. In connection with the Phantom Plan termination, Bioventus Inc. assumed the obligations of BV LLC and Phantom Plan awards will be paid in the form of shares of Class&nbsp;A common stock (or, in the case of former employees whose
employment terminated prior to the offering and who hold vested Phantom Plan awards as of 12 months following the termination of the Phantom Plan, in the form of cash). The number of shares of Class&nbsp;A common stock received by each participant,
including our named executive officers, were determined by dividing (A)&nbsp;the value of the participant&#146;s vested Phantom Units (after giving effect to any accelerations in vesting in connection with our IPO, as described below) as of
February&nbsp;11, 2021 by (B)&nbsp;the $13.00 IPO price of our Class&nbsp;A common stock (with any terminated employees holding vested Phantom Plan awards receiving the cash value of such shares determined as of the date of the IPO). It is
anticipated that, to the extent that a Time Phantom Unit is not otherwise vested as of the date the Phantom Plan is terminated, settlement with respect to such Time Phantom Unit will be subject to the holder&#146;s continued employment with us
through the applicable vesting date or the twelve month anniversary of plan termination, if earlier. As a result of the $13.00 IPO price of our Class&nbsp;A common stock, the Performance Phantom Units had no value as the IPO date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our named executive officers holds Phantom Plan awards in BV LLC as set forth below in &#147;&#151;Outstanding Equity Awards at Fiscal-Year End.&#148;
On June&nbsp;25, 2020, in connection with the commencement of his employment with us, Mr.&nbsp;Reali was granted 417,804 Phantom Units. In addition, on July&nbsp;30, 2020, Mr.&nbsp;Reali </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was granted an option to purchase up to 5,935 equity interests of BV LLC at a per unit price of $42.12 at any time prior to July&nbsp;30, 2021 (or the termination of his service, if earlier), but
Mr.&nbsp;Reali forfeited this option prior to our IPO. No other named executive officers received a grant of equity or phantom equity awards in 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Equity-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
our IPO, our Board adopted the 2021 Incentive Award Plan (2021 Incentive Plan), in order to facilitate the grant of cash and equity incentives to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, employees (including our named
executive officers) and consultants and employees and consultants of our subsidiaries and to enable our Company and our subsidiaries to obtain and retain the services of these individuals, which is essential to our long-term success. In connection
with our IPO, we granted the following under the 2021 Incentive Plan to certain of our employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, including the named executive officers: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">options to purchase 4,561,500 shares of Class&nbsp;A common stock that vest between two and four years from
February&nbsp;11, 2021 and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted stock unit (RSU) awards for 293,170 and 67,500 to employees and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, respectively, of shares of Class&nbsp;A common stock released between one and four years from February&nbsp;11, 2021 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our IPO, our Board also adopted the 2021 Employee Stock Purchase Plan (ESPP). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Severance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The employment letters in effect as of
December&nbsp;31, 2020 for each of our named executive officers provide for severance payments upon termination of employment by us at any time without cause (other than as a result of death or disability) or a termination by the named executive
officer for good reason (as defined below)<I> </I>during the two year period following the date of a change in control (as defined in the respective employment letter)<I>.</I> In the event of a termination by us without cause, each of our named
executive officers would be entitled to receive (1)&nbsp;twelve months&#146; base salary, payable in a lump sum within 60 days following termination of employment, (2) 100% of their respective target annual cash incentive, payable in a lump sum
within 60 days following termination of employment, and (3)&nbsp;payment of COBRA premiums for the first twelve months of coverage following termination of employment. In the event of a termination by Messrs. Anglum, Nosenzo, D&#146;Adamio and
Ms.&nbsp;Pavesio for good reason during the <FONT STYLE="white-space:nowrap">two-year</FONT> period following a change in control, Messrs. Anglum, Nosenzo, D&#146;Adamio and Ms.&nbsp;Pavesio would be entitled to receive the same severance payments
and benefits as in the case of termination by us without cause. In the event of a termination by Mr.&nbsp;Reali for good reason during the <FONT STYLE="white-space:nowrap">two-year</FONT> period following a change in control, under his employment
letter Mr.&nbsp;Reali is entitled to receive enhanced severance equal to 18 months of each of his base salary and his target annual cash incentive, each payable in a lump sum on or about 60 days following termination of employment, as well as
payment of COBRA premiums for the first 18 months of coverage following termination of employment. The severance payments are conditioned upon execution and delivery of a release and compliance with confidentiality and restrictive covenant
obligations as set forth in a separate proprietary information agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his retirement on April&nbsp;19, 2020, Mr.&nbsp;Bihl was not
entitled to receive any severance or other benefits under his employment letter. Subsequent to his retirement, we entered into an agreement with Mr.&nbsp;Bihl on June&nbsp;12, 2020, pursuant to which he received (i)&nbsp;a payment on June&nbsp;16,
2020 of $9.25&nbsp;million, which represented a $918,953 payment in full for amounts due to Mr.&nbsp;Bihl under the Phantom Plan, a $6,328,629 payment for the redemption of 150,252 of his Profits Interest Units under the MIP, and an additional cash
payment of $2,006,796 to reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">COVID-19-related</FONT></FONT> decrease in value of his Phantom Plan award and the redeemed portion of his MIP award and (ii)&nbsp;a payment on
February&nbsp;8, 2021 of $12.3&nbsp;million, which represented a $10,802,387 payment for the redemption of the remaining 183,078 of his Profits Interest Units under the MIP, and an additional cash payment of $1,543,147 to reflect the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">COVID-19-related</FONT></FONT> decrease in value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our IPO, we entered into new employment agreements with each of Messrs. Reali, Anglum,
Nosenzo, D&#146;Adamio, and Ms.&nbsp;Pavesio that became effective February&nbsp;11, 2021 and superseded their previous severance arrangements. Under these new employment agreements, it is anticipated that, upon a termination without cause or
resignation by the named executive officer with good reason, each of our named executive officers are entitled to (i)&nbsp;twelve months&#146; base salary (eighteen months in the case of Mr.&nbsp;Reali), payable in equal installments over the twelve
month period (eighteen month period in the case of Mr.&nbsp;Reali) following such termination, (ii) 100% of target annual cash incentive (150% in the case of Mr.&nbsp;Reali), payable in equal installments over the twelve month period (eighteen month
period in the case of Mr.&nbsp;Reali) following such termination, and (iii)&nbsp;payment of COBRA premiums for the first twelve months of coverage following termination of employment (eighteen months in the case of Mr.&nbsp;Reali). Additionally,
upon a termination without cause or resignation by the named executive officer with good reason within the 24 month period following a change in control, each of our named executive officers are entitled to (i)&nbsp;eighteen months&#146; base salary
(twenty-four months in the case of Mr.&nbsp;Reali), payable in a lump sum within 60 days following such termination, (ii) 150% of target annual cash incentive (200% in the case of Mr.&nbsp;Reali), payable in a lump sum within 60 days following such
termination, (iii)&nbsp;a lump sum payment equal to eighteen months (twenty-four months in the case of Mr.&nbsp;Reali) of COBRA premiums within 60 days following such termination, and (iv)&nbsp;full vesting acceleration of all equity awards. These
severance payments will be conditioned upon execution and delivery of a release and compliance with the restrictive covenants described below in &#147;&#151;Restrictive Covenants.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restrictive Covenants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2020 our named executive officers were subject to certain post-employment restrictive covenants, including twelve-month <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> obligations,
as set forth in proprietary information agreements entered into with each named executive officer. Further, the employment letters for each of our named executive officers provide for mutual <FONT STYLE="white-space:nowrap">non-disparagement</FONT>
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our IPO, we entered into new post-employment restrictive covenants with our named executive officers, effective as of the
date of tour IPO, including twelve-month (and eighteen months in the case of Mr.&nbsp;Reali) noncompetition and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> obligations (increased to eighteen-months (and twenty-four months in the case of
Mr.&nbsp;Reali) in the event a named executive officer receives change in control severance, as described above) and perpetual confidentiality and <FONT STYLE="white-space:nowrap">non-disparagement</FONT> obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Plans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BV LLC currently maintains a
401(k) retirement savings plan, or the 401(k) plan, in which all BV LLC employees, including our named executive officers, who satisfy certain eligibility requirements may participate. The Internal Revenue Code allows eligible employees to defer a
portion of their compensation, within prescribed limits, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis through contributions to the 401(k) plan. Under the terms of the 401(k) plan, we currently make
<FONT STYLE="white-space:nowrap">(a)&nbsp;non-discretionary</FONT> matching contributions equal to 50% of the employee&#146;s contributions, up to a maximum of 6% of the employee&#146;s eligible compensation and (b)&nbsp;a <FONT
STYLE="white-space:nowrap">non-elective</FONT> contribution equal to 4.5% of the employee&#146;s compensation for the plan year. Due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> crisis, we suspended the 4.5%
<FONT STYLE="white-space:nowrap">non-elective</FONT> contribution effective May&nbsp;3, 2020, but have reinstated such benefit effective December&nbsp;26, 2020. Further, our board of managers has discretion under the 401(k) plan to provide for
(i)&nbsp;annual discretionary matching contributions based on eligible compensation contributed by each employee and (ii)&nbsp;discretionary <FONT STYLE="white-space:nowrap">non-elective</FONT> contributions in an amount determined by the board at
year end, subject to continued employment through year end. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though the 401(k) plan adds to the overall desirability of our executive
compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. We anticipate that our employees will continue to be eligible to participate in a 401(k) plan
maintained by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our full-time employees and working partners, including our named executive officers, are eligible to participate in health and welfare plans maintained
by BV LLC, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical, dental and vision benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical flexible spending accounts and health savings account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short-term and long-term disability insurance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">basic life and accidental death&nbsp;&amp; dismemberment insurance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">group accident, critical illness and hospital indemnity plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers participate in these plans on the same basis as other eligible employees. We do not maintain any supplemental health and welfare
plans for our named executive officers. We reimburse our named executive officers for the full cost of their personal cellular phones. We believe the benefits described above are necessary and appropriate to provide a competitive compensation
package to our named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;280G </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The employment letters for Messrs. Reali, Anglum and D&#146;Adamio in effect as of December&nbsp;31, 2020 and the new employment agreements we entered into
with our named executive officers in connection with our IPO provide that, in the case of their receipt of any payments in connection with a change in control (as defined in the employment letter or agreement), or that would otherwise be considered
an &#147;excess parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, such payments will be reduced to the maximum amount that does not trigger the excise tax imposed by Section&nbsp;4999 of the Code if the named executive
officer would be better off on a net <FONT STYLE="white-space:nowrap">after-tax</FONT> basis with such reduction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retention Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2020, we initiated a retention plan with Mr.&nbsp;Nosenzo for an aggregate amount of $520,000 less applicable taxes. Payments of $260,000
will be paid on each of May&nbsp;4, 2021 and May&nbsp;4, 2022, subject to Mr.&nbsp;Nosenzo&#146;s continued service through each such date; provided that if Mr.&nbsp;Nosenzo&#146;s employment is terminated for a reason that would qualify
Mr.&nbsp;Nosenzo for severance benefits under his offer letter (x)&nbsp;before the May&nbsp;4, 2021 payment date he will receive $260,000 in a single lump sum within 60 days following termination of employment and (y)&nbsp;after the May&nbsp;4, 2021
payment date but before the May&nbsp;4, 2022 payment date he will receive $260,000 in a lump sum within 60 days following the termination date. Any such payments are in addition to any severance benefits under Mr.&nbsp;Nosenzo&#146;s offer letter.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the number of option awards and profits interest units (including the number of profits interest units underlying Phantom Units)
for our named executive officers as of December&nbsp;31, 2020. For additional information about the outstanding equity awards granted to our named executive officers, please see the section titled &#147;&#151;Equity-based compensation&#148; above.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;profits<BR>interest units<BR>(including profits<BR>interest units<BR>underlying&nbsp;phantom<BR>units<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP> that have not<BR>vested<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP> (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;of<BR>profits interest&nbsp;units<BR>(including profits<BR>interest
units<BR>underlying&nbsp;phantom<BR>units) that have not<BR>vested ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth Reali</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt">4/13/2020</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">417,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,716,840</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt">7/30/2020</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">5,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-size:10pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42.12</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">7/30/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory O. Anglum</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">04/04/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,300</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">05/01/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,257,420</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/17/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580,600</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John E. Nosenzo</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">02/06/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,250</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,378,750</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/17/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725,750</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony D&#146;Adamio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8/14/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617,680</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/17/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,450</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alessandra Pavesio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/17/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580,600</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Phantom Units do not have an expiration date; provided that any Phantom Units granted on September&nbsp;17,
2018 that do not vest as a result of achieving 2020 revenue targets on June&nbsp;1, 2021 will expire. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column shows the number of profits interest units held by Mr.&nbsp;Bihl and the number of Phantom Units
held by our other named executive officers that have not vested. Phantom Units generally represent the right to receive cash amounts from us based on the distributions that would be made to an equivalent number of profits interests with an
equivalent benchmark amount. The benchmark amounts represent the cumulative distributions that must be made by us pursuant to the Bioventus LLC Agreement before a grantee is entitled to receive any distributions or payments in respect of such
grantee&#146;s units. The benchmark amount for Mr.&nbsp;Anglum&#146;s 2016 grant of Phantom Units is $472,003,000, for Messrs. Nosenzo, Anglum, and D&#146;Adamio&#146;s 2017 grant is $510,000,000, for Messrs. Anglum, Nosenzo and D&#146;Adamio&#146;s
and Ms.&nbsp;Pavesio&#146;s 2018 grant of Phantom Units is $703,691,178, and for Mr.&nbsp;Reali&#146;s 2020 grant of Phantom Units on June&nbsp;25, 2020 is $840,849,878. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Market value is determined based on an independent valuation report on the fair market value of the Company.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Reali was granted 417,804 Phantom Units on June&nbsp;25, 2020; 20% of such grant will vest on
April&nbsp;13, 2021 and 5% will vest each quarter thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Reali was granted 5,935 options to purchase equity interests of BV LLC on July&nbsp;30, 2020, all of
which were fully vested and exercisable at the time of grant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Anglum was granted 20,000 Phantom Units on April&nbsp;4, 2016 and 95,000 Phantom Units on May&nbsp;1,
2017; 20% of each grant vested on the first anniversary of the grant date and 5% vests each quarter thereafter. Mr.&nbsp;Anglum was also granted 20,000 Phantom Units on September&nbsp;17, 2018; these units will vest on June&nbsp;1, 2021 at 100% if
2020 revenue is greater than or equal to $391.8&nbsp;million and at 75% if 2020 revenue is greater than or equal to $336.0&nbsp;million. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Nosenzo was granted 125,000 Phantom Units on February&nbsp;6, 2017; 20% of these Phantom Units vested
on February&nbsp;6, 2018 and 5% vests each quarter thereafter. Mr.&nbsp;Nosenzo was also granted 25,000 Phantom Units on September&nbsp;17, 2018; these units will vest on June&nbsp;1, 2021 at 100% if 2020 revenue is greater than or equal to
$391.8&nbsp;million and at 75% if 2020 revenue is greater than or equal to $336.0&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;D&#146;Adamio was granted 40,000 Phantom Units on August&nbsp;14, 2017; 20% of such grant vested on
the first anniversary of the grant date and 5% vests each quarter thereafter. Mr.&nbsp;D&#146;Adamio was also granted 15,000 Phantom Units on September&nbsp;17, 2018; these units will vest on June&nbsp;1, 2021 at 100% if 2020 revenue is greater than
or equal to $391.8&nbsp;million and at 75% if 2020 revenue is greater than or equal to $336.0&nbsp;million. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Pavesio was granted 20,000 Phantom Units on September&nbsp;17, 2018; these units will vest on
June&nbsp;1, 2021 at 100% if 2020 revenue is greater than or equal to $391.8&nbsp;million and at 75% if 2020 revenue is greater than or equal to $336.0&nbsp;million. Ms.&nbsp;Pavesio was also granted 83,333 Phantom Units on July&nbsp;22, 2013,
15,000 Phantom Units on June&nbsp;1, 2015, and 11,392 Phantom Units on April&nbsp;21, 2016, all of which were fully vested as of December&nbsp;31, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth
information concerning the compensation of the current members of the BV LLC board of managers for the year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William A. Hawkins<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt">2020</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan M. Stalnecker<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guy P. Nohra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martin P. Sutter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bradley J. Cannon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Parker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip G. Cowdy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guido J. Neels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Hawkins received an annual retainer of $40,000 for his service as a member of the board and an
additional annual retainer fee of $50,000 for his service as chairman of the board. Ms.&nbsp;Stalnecker received an annual retainer fee of $50,000 for her service as a member of the board and an additional annual retainer fee of $10,000 for her
service on the Audit and Risk Committee of the board. No other members of our board received any cash compensation in 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No members of our board received equity compensation awards in 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2020, Mr.&nbsp;Hawkins held 50,000 Phantom Units, 95% of which were vested and 5% of
which were unvested, and Ms.&nbsp;Stalnecker held 50,000 Phantom Units, 40% of which were vested and 60% of which were unvested, respectively. The benchmark amount for Mr.&nbsp;Hawkins&#146;s grant of Phantom Units is $472,003,000 and the benchmark
amount for Ms.&nbsp;Stalnecker&#146;s grant of Phantom Units is $703,691,178. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our December&nbsp;11, 2015 offer to
Mr.&nbsp;Hawkins to join the BV LLC board of managers as its chairman, we agreed, pursuant to an offer letter, effective January&nbsp;1, 2016, to (1)&nbsp;pay Mr.&nbsp;Hawkins an annual retainer fee of $40,000 for his service as a member of the
board and $50,000 for his service as chairman of the board, each payable in quarterly installments in arrears and <FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial period of service and (2)&nbsp;award Mr.&nbsp;Hawkins a <FONT
STYLE="white-space:nowrap">one-time</FONT> grant of 50,000 Phantom Units under the Phantom Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective November&nbsp;28, 2018, pursuant to an offer
letter with Ms.&nbsp;Stalnecker providing for her appointment as a member of our board and chair of the Audit and Risk Committee, we agreed to (1)&nbsp;pay Ms.&nbsp;Stalnecker an annual retainer fee of $50,000 for her service as a member of the
board and $10,000 for her participation in the Audit and Risk Committee, each payable in quarterly installments in arrears and <FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial period of service and (2)&nbsp;award Ms.&nbsp;Stalnecker
50,000 Phantom Units under the Phantom Plan. Ms.&nbsp;Stalnecker received a prorated payment of $9,167 for her time on the board and one of the Audit and Risk Committee in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, which became effective February&nbsp;11, 2021, provides that each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director receives an annual cash retainer of $55,000. In addition, (i)&nbsp;the Chairperson of the Board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall receive an additional annual retainer of $50,000, (ii) the Lead Director of the Board shall receive an additional annual retainer of $30,000, (iii) the Chairpersons of the Audit and Risk
Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Compliance, Ethics and Culture Committee shall receive additional annual retainers of $20,000, $15,000, $10,000 and $10,000, respectively, and <FONT
STYLE="white-space:nowrap">(iv)&nbsp;non-Chairperson</FONT> members of the Audit and Risk Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Compliance, Ethics and Culture Committee shall receive additional annual
retainers of $10,000, $7,500, $5,000 and $5,000, respectively. In addition, each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director receives an annual RSU award with a grant date value of $152,000, with all such annual RSU awards
(other than those received in respect of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial year of service, as described below) vesting on the first anniversary of the grant date of the award (or immediately prior to the
date of the annual shareholder meeting immediately following the date of grant, if sooner), subject to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director continuing in service through such date. RSU awards for each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial year of service shall vest in three equal installments, with the first installment vesting on the first anniversary of the grant date of such initial award (or immediately prior
to the date of the annual shareholder meeting immediately following the date of grant, if sooner) and the second and third installments vesting on the first and second anniversaries of such first vesting date, subject to such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director continuing in service through each such date (and any such nonemployee director who commences service on a date other than the date of the annual shareholder meeting receives a <FONT
STYLE="white-space:nowrap">pro-rata</FONT> restricted stock unit award for such initial year of service). In addition, on February&nbsp;11, 2021, in connection with our IPO, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director received
a RSU award with a grant date value of $152,000 that vests on the first anniversary of the grant date of the award. Each RSU award awarded under the policy accelerates and vests in full upon a change in control (as defined in the 2021 Incentive
Plan). In addition, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director is reimbursed for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in connection with his or her services.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_25"></A>SECURITIES AUTHORIZED FOR ISSUANCE UNDER BIOVENTUS&#146; EQUITY
COMPENSATION PLANS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was no public market for Bioventus&#146; common stock and there were no equity compensation
plans approved by security holders under which Bioventus&#146; equity securities were authorized for issuance. The following table provides, as of March&nbsp;22, 2021, equity compensation plan information for all plans under which equity securities
are authorized for issuance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities&nbsp;to&nbsp;be<BR>issued upon<BR>exercise of<BR>outstanding<BR>options&nbsp;and&nbsp;rights<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average&nbsp;exercise<BR>price of<BR>outstanding<BR>options and<BR>rights<BR>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>remaining&nbsp;available&nbsp;for<BR>future issuance under<BR>equity&nbsp;compensation&nbsp;plans<BR>(excluding
securities<BR>reflected under column<BR>(a))<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B><br><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,922,170&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.00&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,212,626</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of the Bioventus Inc. 2021 Incentive Award Plan (2021 Plan) and the Bioventus Inc. 2021 Employee Stock
Purchase Plan (2021 ESPP). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 4,561,500 outstanding options to purchase shares of Bioventus class A common stock and 360,670
outstanding restricted stock units under the 2021 Plan. There were no agreements outstanding to purchase shares of Bioventus class A common stock under the 2021 ESPP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The weighted average exercise price in column (b)&nbsp;does not take into account outstanding restricted stock
units, which do not have an exercise price. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 2,670,306 shares of Bioventus class A common stock available for future issuance under the 2021 Plan
and 542,320 shares of Bioventus class A common stock available for future issuance under the 2021 ESPP. The number of shares of Bioventus class A common stock reserved for issuance under the 2021 Plan will automatically increase on January&nbsp;1 of
each calendar year from January&nbsp;1, 2022 through January&nbsp;1, 2031, by that number of shares of Bioventus class A common stock equal to the lesser of (i) 4.5% of the shares of all of the classes of Bioventus class A common stock outstanding
on the last day of the immediately preceding fiscal year and (ii)&nbsp;such smaller number of shares of Bioventus class A common stock as determined by the board of directors. The number of shares of Bioventus class A common stock reserved for
issuance under the 2021 ESPP will automatically increase on January&nbsp;1 of each calendar year from January&nbsp;1, 2022 through January&nbsp;1, 2031, by that number of shares of Bioventus class A common stock equal to the lesser of (A) 1% of the
shares of all of Bioventus class A common stock outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;such smaller number of shares of Bioventus class A common stock as determined by the board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to Bioventus&#146; IPO, BV LLC maintained the Phantom Plan, pursuant to which Bioventus granted units in order to foster and
promote its long-term success by helping attract and maintain a superior management team and to motivate superior performance by employees selected to participate in the Phantom Plan. As of December&nbsp;31, 2020, there were 1,651,709 units
outstanding. In connection with its IPO, Bioventus terminated the Phantom Plan and Bioventus Inc. assumed the obligations of BV LLC. Vested Phantom Plan awards granted to employees that were active employees on February&nbsp;11, 2021 will be paid in
the form of shares of Bioventus class A common stock after the one year anniversary. The number of shares of Bioventus class A common stock were determined by dividing (i)&nbsp;the value of the participant&#146;s vested Phantom Units (after giving
effect to any accelerations in vesting in connection with Bioventus&#146; IPO) as of February&nbsp;11, 2021 by (ii)&nbsp;the $13.00 IPO price of Bioventus class A common stock. Upon the one year anniversary of Bioventus&#146; IPO 798,422 shares of
Bioventus class A common stock will be issued in settlement of the outstanding units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_26"></A>INTERESTS OF BIOVENTUS DIRECTORS AND EXECUTIVE OFFICERS IN THE
MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than with respect to continued service for, employment by and the right to continued indemnification by the combined company, as of the
date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the merger that are different from, or in addition to, the interests of other Bioventus stockholders generally. The Bioventus board
was aware of and considered these factors, among other matters, in reaching its determination that the terms of the merger agreement and the merger are fair to and in the best interests of Bioventus and its stockholders, approving and declaring
advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, and recommending that Bioventus stockholders approve the Bioventus share proposal issuance. See &#147;The Mergers&#151;Background
of the Merger&#148; and &#147;The Mergers&#151;Recommendation of the Bioventus Board of Directors; Bioventus&#146;s Reasons for the Merger.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146;s &#147;executive
officers&#148; since the beginning of Bioventus&#146;s last fiscal year are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kenneth M. Reali, Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gregory O. Anglum, Senior Vice President&nbsp;&amp; Chief Financial Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">John E. Nosenzo, Senior Vice President&nbsp;&amp; Chief Commercial Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthony D&#146;Adamio, Senior Vice President&nbsp;&amp; General Counsel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Alessandra Pavesio, Senior Vice President&nbsp;&amp; Chief Science Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthony P. Bihl III, former Chief Executive Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Katrina Church, Senior Vice President and Chief Compliance Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus&#146;s directors since the beginning
of Bioventus&#146;s last fiscal year are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">William A Hawkins III; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Philip G. Cowdy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Guido J. Neels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Guy P. Nohra; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David J. Parker; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Susan M. Stalnecker; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Martin P. Sutter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mary Kay Ladone; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kenneth Reali. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governance of the Combined Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has agreed
to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board to the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification
of his or her respective successor or his or her death, resignation, disqualification or proper removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No other governance changes are planned in
connection with the mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;The Mergers Agreement&#151;Governance of the Combined Company.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_27"></A>INTERESTS OF MISONIX DIRECTORS AND EXECUTIVE OFFICERS IN THE
MERGERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the recommendations of the Misonix board, Misonix stockholders should be aware that Misonix directors and executive officers
may have interests in the mergers, including financial interests, which may be different from, or in addition to, the interests of Misonix stockholders generally. These interests are described in more detail below and, with respect to Misonix&#146;s
named executive officers, are quantified under &#147;Quantification of Payments and Benefits to Misonix Named Executive Officers.&#148; The Misonix board was aware of and considered these interests, among other matters, in reaching its determination
that the mergers are fair to and in the best interests of Misonix and its stockholders, approving and declaring advisable the Agreement and Plan of Merger and the transactions contemplated thereby, and recommending that Misonix stockholders approve
the Misonix mergers. See &#147;The Mergers&#151;Background of the Mergers&#148; and &#147;The Mergers&#151;Recommendation of the Misonix Board of Directors; Misonix&#146;s Reasons for the Mergers.&#148; The closing of the mergers are expected to
constitute a &#147;change of control&#148; (or similar phrase) for purposes of each of the compensation plans and agreements, if applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive
Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix&#146;s &#147;named executive officers&#148; are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stavros G. Vizirgianakis, Chief Executive Officer and director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Joseph P. Dwyer, Chief Financial Officer, Treasurer and Secretary; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert S. Ludecker, Senior Vice President of Global Sales and Marketing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix&#146;s &#147;executive officers&#148; are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sharon W. Klugewicz, Chief Operating Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jay Waggoner, Senior Vice President of Sales - Wound. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Ownership </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix&#146;s directors and executive
officers will receive the same merger consideration as other Misonix stockholders for each share of Misonix common stock that they own at the effective time. For information regarding beneficial ownership of Misonix common stock by each of Misonix
current directors, named executive officers and all directors and executive officers as a group, see the section entitled &#147;Certain Beneficial Owners of Misonix Common Stock.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Misonix Equity Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the effective time, each outstanding Misonix stock option held by individuals who meet the <FONT STYLE="white-space:nowrap">S-8</FONT> definition
of &#147;employees&#148; of Misonix, including executive officers and directors of Misonix, shall (i)&nbsp;become fully vested immediately upon the effective time and (ii)&nbsp;be assumed by Bioventus and converted automatically into an option to
purchase Bioventus class A common stock based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will
generally remain subject to the same vesting and other terms and conditions that applied to such awards immediately prior to the effective time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
executive officers and directors who do not meet the <FONT STYLE="white-space:nowrap">S-8</FONT> definition of &#147;employee&#148; as of the effective time, each of their outstanding Misonix stock options will become fully vested and be settled in
cash immediately prior to the effective time in an amount equal to the product of (x)&nbsp;the number of shares of Misonix common stock subject to the applicable option and (y)&nbsp;the excess, if any, of (i)&nbsp;the average of the volume-weighted
average </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trading price per share of Bioventus Class&nbsp;A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day
that is three trading days prior to the date of the effective time over (ii)&nbsp;the per share exercise price of such option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number and value of
outstanding Misonix stock options and held by each named executive officer, other executive officer, and director of Misonix based on holdings as of August&nbsp;27, 2021 is set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Underlying&nbsp;Unexercised<BR>Options<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Exercise Price of<BR>Options</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Unexercised<BR>Options<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stavros G. Vizirgianakis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,006,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph P. Dwyer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,325,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Ludecker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,437,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Other Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sharon W. Klugewicz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">576,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Waggoner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">528,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul LaViolette</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Koby</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas M. Patton</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,174,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Beyer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT>
value of the Misonix stock options based on the closing price per share of Misonix common stock of $26.02 on August&nbsp;27, 2021, as reported by Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of immediately prior to the effective time, all Misonix restricted stock shall accelerate in full and become fully vested (and, once vested, will
be treated in the same manner as other shares of Misonix common stock in the mergers). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Vizirgianakis holds 159,800 shares of restricted stock
with an aggregate value of $4,157,996 as of August&nbsp;27, 2021. None of the other named executive officers, executive officers or directors of Misonix held restricted stock as of such date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Misonix&#146;s ESPP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix adopted an ESPP
in 2021; however, no offering periods under the Misonix ESPP had commenced prior to the execution of the merger agreement. Therefore, no offering periods under the Misonix ESPP are currently active and none will be commenced prior to the closing
date. The Misonix ESPP shall terminate immediately prior to the effective time, contingent upon the occurrence of the closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governance of the
Combined Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board to the Bioventus board as
of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;The Mergers&#151;Board of Directors of the Combined Company.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification; Directors&#146; and Officers&#146; Insurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the merger agreement, certain directors and officers of Misonix and its subsidiaries will be entitled to certain ongoing
indemnification and coverage under directors&#146; and officers&#146; liability and fiduciary liability insurance policies following the mergers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New
Compensation Arrangements with Bioventus </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Misonix executive officers and directors who become officers, directors or employees or who otherwise are
retained to provide services to Bioventus or the surviving corporation may enter into new individualized compensation arrangements and may participate in cash or equity incentive or other benefit plans maintained by Bioventus. As of the date of this
proxy statement/prospectus, no compensation arrangements between such persons and Bioventus and/or its affiliates have been established. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix
Compensation Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vizirgianakis Employment Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2016, Misonix entered into an Employment Agreement (the &#147;Vizirgianakis Agreement&#148;) with Stavros G. Vizirgianakis pursuant to
which Mr.&nbsp;Vizirgianakis serves as Misonix&#146;s full time Chief Executive Officer. Mr.&nbsp;Vizirgianakis also serves as a member of the board of directors of Misonix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Vizirgianakis Agreement, Mr.&nbsp;Vizirgianakis&#146; employment is automatically renewed and extended for consecutive one year renewal terms
on each September&nbsp;13, unless either party sends to the other party a notice of nonrenewal at least 90 days prior to the expiration of any then-current renewal term. Mr.&nbsp;Vizirgianakis receives an annual base salary of not less $360,000 per
annum, subject to review by the board of directors of Misonix at least annually for increase but not for decrease. Mr.&nbsp;Vizirgianakis is also eligible to receive annual bonuses in the discretion of Misonix&#146;s board of directors. If Misonix
terminates Mr.&nbsp;Vizirgianakis&#146; employment without cause (as defined in the Vizirgianakis Agreement), Misonix provides a notice of <FONT STYLE="white-space:nowrap">non-renewal,</FONT> or Mr.&nbsp;Vizirgianakis terminates his employment for
good reason (as defined in the Vizirgianakis Agreement), Mr.&nbsp;Vizirgianakis will be entitled to receive (i)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to 1.5 times the annual base salary as is in
effect immediately prior to the date of such termination, and (ii)&nbsp;continuation of all employee benefits and fringe benefits to which he was entitled under the Vizirgianakis Agreement immediately prior to such termination of employment for a
period of 18 months following the termination of employment. The Vizirgianakis Agreement also contains <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenants from
Mr.&nbsp;Vizirgianakis during the term of employment and for a period of 18 months thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the execution of the Vizirgianakis
Agreement in 2016, Mr.&nbsp;Vizirgianakis received grants of an aggregate of 400,000 shares of restricted stock pursuant to Misonix&#146;s 2014 Employee Equity Incentive as follows: (i)&nbsp;a grant of 134,000 shares vesting in five equal
installments on September&nbsp;1, 2017, 2018, 2019, 2020 and 2021; (ii) a performance grant of 133,000 shares, the performance targets for which have already been satisfied; and (iii)&nbsp;a performance grant of 133,000 shares which vests if both of
the following conditions are satisfied simultaneously: (A)&nbsp;at any time prior to the fifth anniversary of the grant date, the most recent publicly reported trailing four fiscal quarter revenue of Misonix (exclusive of the impact of any
acquisitions after the grant date) is at least $48,000,000 and (B)&nbsp;the closing price of Misonix common stock is at least $13.00 per share (subject to adjustment for stock splits, stock dividends and the like) for 10 consecutive trading days.
Any unvested performance grants will vest on a change of control if the applicable share price threshold is met in such transaction (which share price threshold is expected to be met upon the closing). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dwyer Employment Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;21, 2017,
Misonix entered into an Employment Agreement (the &#147;Dwyer Agreement&#148;) with Joseph P. Dwyer pursuant to which Mr.&nbsp;Dwyer serves as Misonix&#146;s full time Chief Financial Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Dwyer Agreement, Mr.&nbsp;Dwyer&#146;s employment is automatically renewed and extended for
consecutive one year renewal terms on each August&nbsp;21, unless either party sends to the other party a notice of <FONT STYLE="white-space:nowrap">non-renewal</FONT> at least 90 days prior to the expiration of the then-current renewal term.
Mr.&nbsp;Dwyer receives an annual base salary of not less than $275,000 per annum, subject to review by the Misonix board at least annually for increase but not for decrease. Mr.&nbsp;Dwyer is also eligible to receive annual bonuses in the
discretion of the Misonix board. If Misonix terminates Mr.&nbsp;Dwyer&#146;s employment without cause (as defined in the Dwyer Agreement), Misonix provides a notice of <FONT STYLE="white-space:nowrap">non-renewal,</FONT> or Mr.&nbsp;Dwyer terminates
his employment for good reason (as defined in the Dwyer Agreement), Mr.&nbsp;Dwyer will be entitled to receive (i)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to 100% of his annual base salary and
(ii)&nbsp;continuation of all employee benefits and fringe benefits to which he was entitled under the Dwyer Agreement immediately prior to such termination of employment for a period of 12 months following the termination of employment. The Dwyer
Agreement also contains <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenants from Mr.&nbsp;Dwyer during the term of employment and for a period of 12 months thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the execution of the Dwyer Agreement in 2017, Mr.&nbsp;Dwyer received a grant of a <FONT STYLE="white-space:nowrap">ten-year</FONT> stock
option to purchase 100,000 shares (the &#147;Dwyer Stock Option Award&#148;) of Misonix common stock, under the Misonix, Inc. 2017 Equity Incentive Plan. The Dwyer Stock Option Award has an exercise price of $10.20 per share, which equals the fair
market value on the date of grant as defined in the plan and vests and becomes exercisable in four equal annual installments from the date of grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ludecker Letter Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;15, 2016,
Misonix entered into a letter agreement (the &#147;Ludecker Agreement&#148;) with Robert S. Ludecker, pursuant to which Mr.&nbsp;Ludecker serves as Misonix&#146;s Senior Vice President of Global Sales and Marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Ludecker Agreement, if Mr.&nbsp;Ludecker&#146;s employment is terminated involuntarily or Mr.&nbsp;Ludecker terminates his employment for good
reason (as described in the Ludecker Agreement) following a change in control of Misonix, then he will be entitled to receive a lump sum cash payment equal to 12 months of annual base salary within 60 days after the change in control takes place and
his employment terminates. The Ludecker Agreement also contains <FONT STYLE="white-space:nowrap">non-disparagement</FONT> covenants from Mr.&nbsp;Ludecker following his termination of employment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Control Severance Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of
July&nbsp;28, 2021, Misonix adopted a Change in Control Severance Plan, which provides for severance benefits for certain eligible employees in the event of a termination of employment with Misonix either (x)&nbsp;by Misonix or its successor other
than for cause, death or disability or (y)&nbsp;by the participant for good reason, in each case that occurs within one year following a change in control (as defined therein). Subject to satisfaction of the requirements of the Change in Control
Severance Plan (including the participant&#146;s timely execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a general release of claims), the participant shall be entitled to receive a severance amount, which will be paid in cash
within 60 days following such qualifying termination and shall equal (i) 3 months or 6 months (depending on the participant&#146;s employee designation) of the participant&#146;s monthly salary and (ii) 3 months or 6 months (depending on the
participant&#146;s employee designation) of the COBRA premium for health, dental and vision benefits in effect for the participant (and his or her spouse and dependents) immediately prior to such qualifying termination. Any amounts payable under the
Change in Control Severance Plan shall be reduced by the amount of severance of termination payments (if any) payable by Misonix to the participant under any employment contract or other arrangement related to his or her employment with Misonix.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">341 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantification of Payments and Benefits to Misonix Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following information, table and the related footnotes present information about the compensation payable to Misonix named executive officers in connection
with the mergers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Golden Parachute Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The narrative and tables that follow are estimates based on multiple assumptions that may or may not actually occur. They describe potential payments and
benefits to the named executive officers under their existing agreements, including payments and benefits that would be due to them in connection with the occurrence of a change of control, assuming the closing date occurred on August&nbsp;27, 2021
and that each named executive officer experienced a qualifying termination of employment on such closing date. The equity award values are calculated based on the average closing market price of Misonix common stock over the <FONT
STYLE="white-space:nowrap">five-day</FONT> period ending on August&nbsp;27, 2021, or $26.22. The actual amounts, if any, to be received by a named executive officer may differ from the amounts set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Cash<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Equity<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Perquisites/<BR>benefits<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stavros G. Vizirgianakis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,145,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,543,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,722,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph P. Dwyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">556,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,089,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,668,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Ludecker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">404,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">527,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">932,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the base salary severance payment due to such named executive officer upon a qualifying
termination of employment pursuant to his existing employment arrangement (as described above under &#147;Misonix Compensation Arrangements&#148;) and the target bonus amount payable under Misonix&#146;s fiscal year 2022 short-term incentive plan
upon a change in control of Misonix. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the potential value of full acceleration of: (a)&nbsp;for Mr.&nbsp;Vizirgianakis, all unvested
options and restricted stock (which assumes that any stock price conditions and revenue targets, where applicable, have been met); and (b)&nbsp;for Mr.&nbsp;Dwyer and Mr.&nbsp;Ludecker, all unvested options, in each case upon a change in control of
the Misonix (as defined in the applicable award agreements and equity plans) regardless of whether the executive&#146;s employment is terminated. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts include benefits continuation payments upon a qualifying termination of employment pursuant to his
existing employment arrangement (as described above under &#147;Misonix Compensation Arrangements&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">342 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_28"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE FIRST
MERGER AND THE SECOND MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section is a general discussion of certain material U.S. federal income tax consequences that may
be relevant to U.S. holders and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (each as defined below) of shares of Misonix common stock of (i)&nbsp;exchanging their Misonix common stock for Bioventus class A common stock in the mergers
and (ii)&nbsp;holding and disposing of Bioventus class A common stock received by U.S. holders and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders in the mergers. The following discussion is based on the Code, applicable Treasury
Regulations thereunder, administrative interpretations and published rulings of the IRS and court decisions, each as in effect as of the date of this proxy statement/prospectus, and all of which are subject to change and differing interpretations,
possibly with retroactive effect. Any such change or differing interpretation could affect the accuracy of the statements set forth in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is for general information purposes only and it is not a complete description of all tax considerations that may be relevant
to holders of Misonix common stock and it is not a substitute for tax advice. This discussion addresses only holders of (i)&nbsp;Misonix common stock as of immediately before the first merger, and (ii)&nbsp;Bioventus class A common stock received in
the first merger, in each case, who hold their shares of each as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment), and does not address all aspects of U.S. federal income taxation that may
be relevant to particular holders in light of their individual circumstances or to holders that are subject to special rules under the U.S. federal income tax laws, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pass-through entities or investors in pass-through entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension funds, individual retirement and other <FONT STYLE="white-space:nowrap">tax-deferred</FONT> accounts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold Misonix common stock or Bioventus class A common stock, as applicable, as part of a straddle,
hedge, short sale, constructive sale or conversion transaction or other integrated or risk reduction transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who purchased or sell their shares of Misonix common stock or Bioventus class A common stock, as
applicable, as part of a wash sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own (directly, indirectly, or by attribution), or at any time during the five year period ending on
the closing date owned, 5% or more (by vote or value) of Misonix common stock or Bioventus class A common stock, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain U.S. expatriates or U.S. holders that have a functional currency other than the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons required to accelerate the recognition of any item of gross income as a result of such income being
recognized on an &#147;applicable financial statement;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who exercise dissenters&#146; rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and &#147;personal
holding companies&#148;; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">343 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders who acquired their shares of Misonix common stock or Bioventus class A common stock, as applicable,
through the exercise of an employee stock option or otherwise as compensation or through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the discussion does not address any tax consequences arising under the unearned income Medicare contribution tax, any alternative
minimum tax or any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the mergers. This discussion also does not address any <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences of the mergers or
(except as expressly discussed below) any reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a U.S. holder is a beneficial owner of
(i)&nbsp;Misonix common stock at the time of the first merger and (ii)&nbsp;Bioventus class A common stock received in the first merger, in each case, that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or any other entity treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States or any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (1)&nbsp;that is subject to the primary supervision of a court within the United States and all the
substantial decisions of which are controlled by one or more United States persons or (2)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a United States person; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate that is subject to U.S. federal income tax on its income regardless of its source.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a beneficial owner of
(i)&nbsp;Misonix common stock at the time of the first merger and (ii)&nbsp;Bioventus class A common stock received in the first merger, in each case, that is neither a U.S. holder nor a partnership (or any entity or arrangement treated as a
partnership) for U.S. federal income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (including for this purpose any entity or arrangement treated as a
partnership for U.S. federal income tax purposes) holds shares of Misonix common stock or Bioventus class A common stock, as may be applicable, the tax treatment of a partner generally will depend on the status of the partner and the activities of
the partnership. If you are a partner of a partnership holding shares of Misonix common stock or Bioventus class A common stock, you should consult your tax advisor regarding the tax consequences of the mergers and of the ownership and disposition
of Bioventus class A common stock received in the mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE FOLLOWING DISCUSSION DOES NOT PURPORT TO BE A COMPLETE ANALYSIS OR
DISCUSSION OF ALL OF THE POTENTIAL TAX CONSEQUENCES OF THE MERGERS. ALL STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS AS TO THE SPECIFIC TAX CONSEQUENCES TO THEM OF THE MERGERS, INCLUDING TAX RETURN REPORTING REQUIREMENTS AND THE APPLICABILITY AND
EFFECT OF THE ALTERNATIVE MINIMUM TAX AND ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> AND OTHER TAX LAWS IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. HOLDERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences of
the First Merger and the Second Merger to U.S. Holders of Shares of Misonix Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Treatment of the first merger and the
second merger, taken together, as a Reorganization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that, for U.S. federal income tax purposes, the first merger and the
second merger, taken together, qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. It is a condition to Misonix&#146;s obligation to complete the mergers that Misonix receive a tax opinion from Jones Day,
dated as of the Closing Date, to the effect that, on the basis of facts, representations and assumptions set forth or referred to in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">344 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such opinion, the first merger and the second merger, taken together, qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. If Jones Day is unwilling or
unable to provide such tax opinion, another nationally recognized tax counsel reasonably acceptable to Misonix, may deliver the tax opinion. Such tax opinion will be based on certain assumptions, representations and warranties and covenants,
including those contained in the merger agreement and in tax representation letters provided by Misonix and Bioventus (on behalf of itself, Merger Sub I and Merger Sub II). If any of these assumptions, representations and warranties or covenants
underlying the tax opinion described above is or becomes incorrect, incomplete, inaccurate or is violated, the validity of, and the conclusions reached in, such tax opinion may be affected or jeopardized, and the U.S. federal income tax consequences
of the first merger and the second merger could differ materially from those discussed below. In addition, the opinion will be subject to certain qualifications and limitations as set forth therein. Moreover, an opinion of counsel is not binding on
the IRS or any court. Neither Bioventus nor Misonix intends to request a ruling from the IRS regarding the U.S. federal income tax consequences of the first merger and the second merger. Accordingly, even if Misonix receives a tax opinion that
concludes that the first merger and the second merger, taken together, qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, no assurance can be given that the IRS will not challenge the conclusions reflected
in the opinion or that a court would not sustain such a challenge. If the first merger and the second merger, taken together, do not qualify as a reorganization for U.S. federal income tax purposes, the surrender of Misonix common stock by U.S.
holders in exchange for the merger consideration pursuant to the first merger will be treated as a fully taxable exchange with respect to both Bioventus class A common stock and the cash portion of the merger consideration. U.S. holders are urged to
consult their tax advisors regarding the U.S. federal income tax consequences of the mergers to them, including in the event that the first merger and the second merger, taken together, do not qualify as a reorganization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Exchange of Shares of Misonix Common Stock for the Merger Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below relating to the receipt of cash in lieu of fractional shares, provided that the first merger and the second
merger, taken together, qualify as a reorganization, a U.S. holder who surrenders shares of Misonix common stock in exchange for the merger consideration pursuant to the first merger will recognize gain (but not loss) equal to the lesser of:
(i)&nbsp;the cash consideration (excluding cash received in lieu of fractional Misonix common stock, if any) received by such U.S. holder, and (ii)&nbsp;the excess, if any, of (a)&nbsp;the sum of the cash consideration (excluding cash received in
lieu of fractional Misonix common stock, if any) plus the fair market value of the Bioventus class A common stock (including any fractional Bioventus class A common stock deemed received) received by such U.S. holder in the first merger, over
(b)&nbsp;such U.S. holder&#146;s tax basis in its shares of Misonix common stock surrendered. Any recognized gain generally will be long-term capital gain if the U.S. holder&#146;s holding period with respect to the shares of Misonix common stock
surrendered is more than one year. Long-term capital gain of <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders currently is eligible for preferential U.S. federal income tax rates. In the event a holder elects, and receives, solely
cash pursuant to the first merger, such holder can recognize loss realized in the mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder of shares of Misonix common
stock generally will have an aggregate adjusted tax basis in the Bioventus class A common stock received in the first merger, including any fractional Bioventus class A common stock for which cash is received, equal to such holder&#146;s aggregate
adjusted tax basis in its shares of Misonix common stock surrendered in the first merger, increased by the amount of gain, if any, recognized (not including any gain recognized with respect to any cash received in lieu of fractional Bioventus class
A common stock) in the first merger, and reduced by the amount of cash received (excluding any cash received in lieu of fractional Bioventus class A common stock). The holding period for Bioventus class A common stock received in the first merger,
including any fractional Bioventus class A common stock for which cash is received, will include the holding period for the shares of Misonix common stock surrendered in exchange for such Bioventus class A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a U.S. holder who holds shares of Misonix common stock with differing tax bases and/or holding periods, which generally occurs
when blocks of shares are purchased at different times or for different </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">345 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prices, the preceding rules must be applied separately to each identifiable block of shares of Misonix common stock, and such U.S. holder may not offset a loss realized on one block of the shares
against gain recognized on another block of the shares. There are complex rules that may apply if a holder elects to receive cash election consideration for some of its shares of Misonix common stock and stock election consideration for other of its
shares of Misonix stock. Holders are urged to consult with their own tax advisor about the applicability of the tax basis rules to them and the tax implications of differing elections. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cash Received in Lieu of Fractional Shares of Bioventus Class&nbsp;A Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder who receives cash in lieu of a fraction of a share of Bioventus class A common stock as part of the consideration in the first
merger generally will be treated as having received the fractional share pursuant to the first merger and then as having sold to Bioventus that fraction of a share of Bioventus class A common stock for cash in a redemption transaction. As a result,
a U.S. holder of shares of Misonix common stock generally will recognize gain or loss measured by the difference between the amount of cash received in lieu of a fractional share of Bioventus class A common stock in the first merger and the portion
of the U.S. holder&#146;s tax basis in the shares of Misonix common stock allocated to the fractional share of Bioventus class A common stock. Gain or loss recognized with respect to cash received in lieu of any fractional share of Bioventus class A
common stock generally will be capital gain or loss, and generally will be long-term capital gain or loss if, as of the effective time of the first merger, the holding period for the shares of Misonix common stock surrendered in exchange for the
fractional share of Bioventus class A common stock is greater than one year. Long-term capital gain of <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders currently is eligible for preferential U.S. federal income tax rates. The
deductibility of capital losses is subject to limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some circumstances, cash received in lieu of fractional shares of Bioventus
class A common stock could be treated as having the effect of a distribution of a dividend under the tests set forth in Section&nbsp;302 of the Code, in which case such U.S. holder could have dividend income up to the amount of the cash
consideration received. Because the possibility of dividend treatment depends primarily upon the particular circumstances of a U.S. holder, including the application of certain constructive ownership rules, U.S. holders should consult their tax
advisors regarding the potential tax consequences of the receipt of cash in lieu of fractional shares of Bioventus class A common stock to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Reporting Requirements in Connection with the First Merger and the Second Merger </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder of Misonix common stock who receives Bioventus class A common stock in the first merger will be required to retain records
pertaining to the mergers. Each U.S. holder of Misonix common stock who is required to file a U.S. federal income tax return and who is a &#147;significant holder&#148; that receives Bioventus class A common stock in the first merger will be
required to file a statement with such U.S. federal income tax return in accordance with Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-3</FONT> setting forth information regarding the parties to the mergers, the date of
the mergers and such U.S. holder&#146;s adjusted tax basis and fair market value of the Misonix common stock surrendered. A &#147;significant holder&#148; is a holder of Misonix common stock (i)&nbsp;who, immediately before the first merger, owned
at least 5% of the outstanding stock of Misonix, or (ii)&nbsp;whose tax basis in the Misonix common stock for U.S. federal income tax purposes was at least $1&nbsp;million immediately before the first merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences to U.S. Holders of Holding and Disposing of Bioventus class A common stock Received in the first merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Distributions on Bioventus Class&nbsp;A common stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The gross amount of any distribution on Bioventus class A common stock made from Bioventus&#146;s current or accumulated earnings and profits
(as determined for U.S. federal income tax purposes) generally will be taxable to a U.S. holder as dividend income on the date such distribution is actually or constructively received. <FONT STYLE="white-space:nowrap">Non-corporate</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">346 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. holders may be eligible for a reduced rate of taxation on dividends provided that certain holding period requirements and other conditions are satisfied. For corporate U.S. holders,
dividends (a)&nbsp;may be eligible for a dividends received deduction and (b)&nbsp;may be subject to the &#147;extraordinary dividend&#148; provisions of the Code, subject in each case to certain requirements and limitations. To the extent that the
amount of a distribution exceeds Bioventus&#146;s current and accumulated earnings and profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a
<FONT STYLE="white-space:nowrap">non-taxable&nbsp;return</FONT> of capital to the extent of the U.S. holder&#146;s tax basis in its Bioventus class A common stock, and thereafter as capital gain recognized on a sale or exchange, which gain would be
taxable as described below in the section titled &#147;<I>U.S. Holders</I> &#151; <I>Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus class A common stock</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus Class&nbsp;A Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder generally will recognize gain or loss on any sale, exchange, redemption or other taxable disposition of Bioventus class A common
stock in an amount equal to the difference between (i)&nbsp;the amount realized on the disposition and (ii)&nbsp;such U.S. holder&#146;s adjusted tax basis in such shares. Any gain or loss recognized by a U.S. holder on a taxable disposition of
Bioventus class A common stock generally will be capital gain or loss and will be long-term&nbsp;capital gain or loss if such U.S. holder&#146;s holding period in such shares exceeds one year at the time of the disposition. Preferential tax rates
may apply to long-term&nbsp;capital gains of <FONT STYLE="white-space:nowrap">non-corporate&nbsp;U.S.</FONT> holders. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. holder on the sale or exchange
of Bioventus class A common stock generally will be treated as U.S. source gain or loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences of the First Merger and the Second Merger to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of
Shares of Misonix common stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Treatment of the First Merger and the Second Merger, taken together, as a Reorganization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that, for U.S. federal income tax purposes, the first merger and the second merger, taken together, qualify as a
&#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, subject to the limitations and assumptions described above in the section titled &#147;U.S. HOLDERS &#151; <I>Treatment of the First Merger and the Second Merger,
taken together, as a Reorganization</I>.&#148; Accordingly, the U.S. federal income tax consequences described in the section titled &#147;U.S. HOLDERS &#151; <I>Treatment of the First Merger and the Second Merger, taken together, as a
Reorganization</I>&#148; generally will be applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
discussion on backup withholding and FATCA below, any gain recognized by <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders pursuant to the first merger will not be subject to U.S. federal income tax, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the conduct of a trade or business by such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States (or, under certain income tax treaties, is attributable to a U.S. permanent establishment or fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder), in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be subject to U.S. federal income tax on that gain on a net income basis in the same manner as if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder were a U.S. person as defined under the Code, and a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be subject to the branch profits tax at a 30% rate (or lower rate as may be
specified by an applicable income tax treaty); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present in the United States
for 183 days or more in the taxable year in which the first merger occurs and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax on the amount by which its capital
gains allocable to U.S. sources, including gain from the taxable sale or exchange of Misonix common stock pursuant to the first merger, exceeds any capital losses allocable to U.S. sources, except as otherwise required by an applicable income tax
treaty. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">347 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors
regarding the U.S. federal income tax consequences of the mergers to them, including in the event that the first merger and the second merger, taken together, do not qualify as a reorganization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cash Received in Lieu of a Fractional Shares of Bioventus Class&nbsp;A Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion on backup withholding and FATCA below, the U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders on the receipt of cash in lieu of fractional shares of Bioventus class A common stock pursuant to the first merger will be the same as described above in the section titled &#147;U.S. HOLDERS
&#151; <I>Cash Received In Lieu of a Fractional Shares of Bioventus Class</I><I></I><I>&nbsp;A Common Stock</I>.&#148; However, any gain or loss recognized by <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders on their receipt of cash in lieu
of fractional shares of Bioventus class A common stock in the first merger will be subject to U.S. federal income tax only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such gain is effectively connected with the conduct of a trade or business by such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States (or, under certain income tax treaties, is attributable to a U.S. permanent establishment or fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder), in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be subject to U.S. federal income tax on that gain on a net income basis in the same manner as if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder were a U.S. person as defined under the Code, and a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be subject to the branch profits tax at a 30% rate (or lower rate as may be
specified by an applicable income tax treaty), or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present in the United States
for 183 days or more in the taxable year in which the first merger occurs and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax on the amount by which its capital
gains allocable to U.S. sources, including gain from the taxable sale or exchange of a fractional share of Bioventus class A common stock pursuant to the first merger, exceed any capital losses allocable to U.S. sources, except as otherwise required
by an applicable income tax treaty. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if any gain from the deemed sale of a fractional share of Bioventus
class A common stock in exchange for cash is recharacterized as a dividend as described in the section titled &#147;U.S. HOLDERS &#151; <I>Cash Received In Lieu of a Fractional Share of Bioventus Class</I><I></I><I>&nbsp;A Common Stock</I>,&#148;
such dividend generally will be subject to U.S. withholding tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty), unless such dividend is effectively connected with a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax
Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Holding and Disposing of Bioventus class A common stock Received in the First Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Distributions on Bioventus Class&nbsp;A Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above in the section titled &#147;U.S. HOLDERS&#151;U.S. Federal Income Tax Consequences to U.S. Holders of Holding and Disposing
of Bioventus class A common stock received in the first merger&#151;<I>Distributions on Bioventus Class</I><I></I><I>&nbsp;A Common Stock</I>,&#148; the gross amount of any distribution on Bioventus class A common stock made from Bioventus
Inc.&#146;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) generally will be treated as dividend income on the date such distribution is actually or constructively received. Amounts not treated as
dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against and reduce, but not below zero, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s adjusted tax basis in the Bioventus
class A common stock. Any excess will be treated as gain realized on the sale or other disposition of Bioventus class A common stock and will be treated as described under the section titled <FONT STYLE="white-space:nowrap">&#147;NON-U.S.</FONT>
HOLDERS &#151; <I>Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus Class</I><I></I><I>&nbsp;A Common Stock</I>&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends on Bioventus class A common stock paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders generally will be subject to
United&nbsp;States withholding tax at a gross rate of 30%, subject to any exemption or lower rate specified by an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">348 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable income tax treaty, except to the extent that the dividends are &#147;effectively connected dividends,&#148; as described below. Bioventus may withhold up to 30% of the gross amount of
the entire distribution even if greater than the amount constituting a dividend, as described above, to the extent provided for in applicable Treasury regulations. If tax is withheld on the amount of a distribution in excess of the amount
constituting a dividend, then a refund of any such excess amounts may be obtained if a claim for refund is timely filed with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds Bioventus class A common stock in connection with the conduct of a trade or business in the United States, and dividends paid on Bioventus class A common stock are effectively connected
with such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. trade or business (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base maintained by the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be exempt from the aforementioned U.S. federal withholding tax. To claim the exemption, the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish to us or the applicable withholding agent a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that claims a reduction or exemption from withholding because of an applicable
income tax treaty generally will be required to satisfy applicable certification (generally, IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as
applicable) and other requirements prior to the distribution date. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not timely provide Bioventus or the applicable paying agent with the required certification may obtain a refund of
any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that hold Bioventus class A common stock through a financial institution or other agent acting on
their behalf will be required to provide appropriate documentation to such agent, who then will be required to provide certification to Bioventus or the applicable paying agent. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult
their tax advisors regarding their entitlement to benefits under a relevant income tax treaty or applicability of other exemptions from withholding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus Class&nbsp;A Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion on backup withholding and FATCA below, any gain or loss realized by a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on the taxable disposition of its Bioventus class A common stock will be treated in the same manner as any gain required to be recognized by <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders pursuant to the mergers as discussed above in the section titled &#147;U.S. Federal Income Tax Consequences of the First Merger and the Second Merger to Non-U.S. Holders of Shares of Misonix common stock&#151;<I>Treatment of the First Merger
and the Second Merger, taken together, as a Reorganization.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BACKUP WITHHOLDING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of cash and/or shares received by a U.S. holder or a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the mergers or as a
result of distributions paid by or the disposition of Bioventus class A common stock may be subject to information reporting and backup withholding at the applicable rate (currently 24%). To avoid backup withholding, a U.S. Holder that does not
otherwise establish an exemption should timely provide an IRS Form <FONT STYLE="white-space:nowrap">W-9,</FONT> certifying under penalties of perjury that such U.S. holder is a &#147;United States person&#148; (within the meaning of the Code), that
the taxpayer identification number provided is correct and that such U.S. holder is not subject to backup withholding. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally may establish an exemption from backup withholding by
certifying its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person status under penalties of perjury on a properly completed applicable IRS Form <FONT STYLE="white-space:nowrap">W-8.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding does not constitute an additional tax, and any amounts withheld from payments to a holder under the backup withholding
rules will be allowed as a refund or credit against the holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections&nbsp;1471 through 1474 of
the Code and the Treasury regulations and administrative guidance promulgated thereunder (commonly referred to as FATCA) generally impose withholding at a rate of 30% in certain circumstances on certain &#147;withholdable payments&#148; in respect
of securities which are held by or through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">349 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain foreign financial institutions (including investment funds), unless any such institution (i)&nbsp;enters into, and complies with, an agreement with the IRS to report, on an annual basis,
information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities that are wholly or partially owned by U.S. persons
and to withhold on certain payments, or (ii)&nbsp;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information
with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. For this purpose, withholdable payments generally include U.S.-source payments otherwise subject to
nonresident withholding tax (<I>e.g.</I>, a U.S. source dividend) and also include the entire gross proceeds from the sale or other disposition of stock of U.S. corporations, even if the payment would otherwise not be subject to U.S. nonresident
withholding tax (<I>e.g.</I>, because it is capital gain). The IRS issued proposed Treasury Regulations that would eliminate the application of this regime with respect to payments of gross proceeds from dispositions of stock (but not dividends).
Pursuant to these proposed Treasury Regulations, Bioventus and any other withholding agent may (but are not required to) rely on this proposed change to FATCA withholding until final regulations are issued or until such proposed regulations are
rescinded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the entity through which shares of the Misonix common stock or Bioventus class A common stock are held will
affect the determination of whether such FATCA withholding is required. Similarly, if the applicable withholding agent does not rely on the proposed Treasury Regulations, &#147;withholdable payments&#148; in respect of Misonix common stock or
Bioventus class A common stock held by a stockholder that is a <FONT STYLE="white-space:nowrap">non-financial</FONT> <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity that does not qualify under certain exceptions will generally be subject to
withholding at a rate of 30%, unless such entity either (i)&nbsp;certifies to the applicable withholding agent that such entity does not have any &#147;substantial United States owners&#148; or (ii)&nbsp;provides certain information regarding the
entity&#146;s &#147;substantial United States owners&#148;, which will in turn be provided to the U.S. Department of Treasury. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible
implications of FATCA on the mergers and their holding of Misonix common stock or Bioventus class A common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bioventus will not pay
any additional amounts to any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders or U.S. holders in respect of any amounts withheld, including pursuant to FATCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE PRECEDING DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. EACH STOCKHOLDER SHOULD CONSULT
ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES OF THE MERGERS AND OF HOLDING AND DISPOSING OF PARENT CLASS A COMMON STOCK, INCLUDING THE CONSEQUENCES
OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">350 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_29"></A>COMPARISON OF STOCKHOLDERS&#146; RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix are Delaware corporations and the rights of Bioventus and Misonix stockholders are governed by the DGCL.&nbsp;Misonix stockholders&#146;
rights are also governed by the Misonix charter and bylaws.&nbsp;If the transaction is completed, the rights of Misonix stockholders who become Bioventus stockholders will be governed by the Bioventus charter and bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different. However, there are
certain differences in the rights of Bioventus stockholders under the Bioventus charter and bylaws and of Misonix stockholders under the Misonix charter and bylaws, as summarized in the table below. This summary does not purport to be a complete
statement of all the differences, or a complete description of the specific provisions referred to.&nbsp;Further, the identification of specific differences is not intended to indicate that other equally or more significant differences do not
exist.&nbsp;Bioventus and Misonix stockholders should carefully read the relevant provisions of the Bioventus charter, the Bioventus bylaws, the Misonix charter, the Misonix bylaws and the DGCL.&nbsp;Copies of the documents referred to in this
summary may be obtained as described under &#147;Where You Can Find More Information.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Authorized and Outstanding Capital Stock</I></B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is authorized to issue 310,000,000 shares of stock, consisting of 250,000,000 shares of Bioventus class A common stock, par value
$0.001 per share, 50,000,000 shares of Bioventus class B common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">As of the close of business on the Bioventus record date, there were 56,849,338 shares of Bioventus common stock and no shares of serial preferred stock issued
and outstanding.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix is authorized to issue is 47,000,000 shares, consisting of 45,000,000 shares of common stock, par value of $0.0001 per share, and
2,000,000 shares of preferred stock, par value of $0.0001 per share.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">As of the
close of business on the Misonix record date, there were 17,425,045 shares of Misonix common stock and no shares of preferred stock issued and outstanding.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Rights of Preferred Stock</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus is authorized to issue preferred stock in one or more series, each of such series to have such terms as stated or expressed in the
Bioventus charter and in the resolution or resolutions providing for the creation and issuance of such series adopted by the Bioventus board.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to certain limitations, the Bioventus board may issue the preferred stock in one or more series, and in connection with the creation of any such
series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designation relating thereto in accordance with the DGCL to determine and fix the number of shares of such series and
such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof,
dividend rights,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Misonix board is authorized, subject to limitations prescribed by law and the provisions of the Misonix charter, to provide for the creation and issuance from time to time in one or more series of any number of shares of
preferred stock and, by filing a certificate pursuant to the DGCL, to establish the number of shares to be included in each such series, and to fix the designation, relative rights, preferences, qualifications and limitations of the shares of each
such series.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">351 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Rights of Preferred Stock</I></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">conversion rights, redemption privileges and liquidation preferences, and to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series as shall be stated and
expressed in such resolutions, all to the fullest extent now or hereafter permitted by the DGCL.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Voting Rights</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as may be otherwise provided in the Bioventus charter, and subject to the rights, powers and preferences of the holders any series of
preferred stock, each stockholder of Bioventus common stock shall be entitled to one (1)&nbsp;vote for each share of common stock held of record by such stockholder as of the record date for determining stockholders entitled to vote on such
matter.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by the Bioventus charter, at all duly called
or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except as otherwise provided by the Bioventus charter, the Bioventus bylaws, the
rules or regulations of any stock exchange applicable to Bioventus, or applicable law or pursuant to any regulation applicable to Bioventus or its securities, each other matter presented to the stockholders at a duly called or convened meeting at
which a quorum is present shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast (excluding abstentions and broker <FONT STYLE="white-space:nowrap">non-votes)</FONT> on such matter.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any series of preferred stock, each stockholder of Misonix common stock is entitled to one
(1)&nbsp;vote on each matter submitted to a vote at a meeting of stockholders for each share of common stock held of record by such holder as of the record date for the meeting.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by the Misonix charter, at all duly called or convened
meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except where a larger vote is required by the Misonix bylaws, the Misonix charter, a
certificate of designation relating to Misonix preferred stock, or by law each other matter at any meeting of stockholders in which a quorum is present shall be decided by the affirmative vote of a majority of the votes properly cast on the matter
(excluding abstentions and broker <FONT STYLE="white-space:nowrap">non-votes).</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Distributions and Dividends</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board, subject to any restrictions under applicable law (including the DGCL) and the Bioventuscharter, may declare and pay
dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of Bioventus capital stock.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Bioventus board may set apart out of any of the funds of Bioventus available for dividends a reserve or reserves for any proper purpose and may abolish any
such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of Bioventus, and meeting contingencies.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL provides that, the directors of a corporation may, subject to any restrictions contained in its certificate of incorporation, declare and pay dividends upon the shares of its capital stock either (i)&nbsp;out of surplus or
(ii)&nbsp;in the case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Subject to the rights of any other class or series of stock, the holders of shares of Misonix
common stock shall be entitled to receive, if and when declared by the Misonix board, out of the assets of the Misonix legally available therefor such dividends as may be declared from time to time by the Misonix
board.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">352 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Quorum</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Bioventus bylaws provide that, unless otherwise provided by law, or the Bioventus charter or bylaws, the holders of a majority in voting power of the stock issued and outstanding and entitled to vote at the meeting, present in
person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Misonix bylaws provide that, unless otherwise provided by law or in a certificate of designation relating to Misonix preferred stock, the holders of a majority in voting power of the shares of stock issued and outstanding and
entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum at a meeting of stockholders for the transaction of business thereat.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Record Date</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus board may fix a record date for purposes of, among other things, determining the rights of stockholders to notice of or to vote
at any stockholder meeting and determining the identity of stockholders entitled to receive payment of any dividend or other distribution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of determining stockholders entitled to vote at a stockholder meeting, the record date cannot be more than 60 nor less than ten days before the
date of the meeting. In order that Bioventus may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment or any rights or the stockholders entitled to exercise any rights in respect of any change,
conversion or exchange of capital stock, for the purposes of any other lawful action (other than stockholder action by written consent), the record date cannot be more than 60 days before such action.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The record date for determining stockholders entitled to express written consent to
corporate action without a meeting may also be fixed by the Bioventus board, which record date shall not precede, or be more than ten days after, the resolution adopted by the Bioventus board fixing the record date.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Misonix board may fix a record date for purposes of determining the rights of stockholders to notice of or to vote at any stockholder
meeting and determining the identity of stockholders entitled to receive payment of any dividend or other distribution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In the case of determining stockholders entitled to vote at a stockholder meeting, the record date will not precede the date upon which the Board resolution
fixing the same is adopted and will not be more than 60 nor less than 10 calendar days before the date of such meeting. In the case of any other lawful action, the record date cannot be more than 60 days before such action.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Number of Directors</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Bioventus bylaws and Bioventus Charter provide that the total authorized number of directors shall be determined from time to time by resolution of the majority of the Bioventus board. No decrease in the number of directors
shall shorten the term of any incumbent director. There are currently nine Bioventus directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Misonix charter provides that the total authorized number of directors will be fixed exclusively by resolution of a majority of the entire Misonix board. There are currently five Misonix
directors.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">353 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Election of Directors</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the certain rights of the holders of preferred stock (if issued) to elect directors, the directors of Bioventus shall be divided
into three classes, designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. The directors in these three classes serve for rotational terms.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Bioventus bylaws, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a
plurality of the votes cast shall be sufficient to elect a director.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bioventus
charter expressly provides that the election of directors need not be by written ballot unless the Bioventus bylaws so provide.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Bioventus has agreed to offer at least two members of the Misonix board to the Bioventus board as of the effective time, with such directors to hold office
until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. See &#147;Summary&#151;Governance of the Combined
Company.&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors of Misonix are not divided into classes.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Misonix bylaws, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a
plurality of the votes cast shall be sufficient to elect a director.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Cumulative Voting</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bioventus stockholders do not have cumulative voting rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Misonix stockholders do not have cumulative voting rights.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Removal of Directors</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the special rights of the holders of one or more outstanding series of preferred stock (if issued) to elect directors and subject to the Bioventus stockholders agreement, the Bioventus board or any individual director may
be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of all of the then outstanding shares of voting stock of
Bioventus entitled to vote at an election of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, directors may be removed, with cause, by the holders of a majority of the shares of capital stock of Misonix entitled to vote generally in the election of directors, voting together as a single class.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Director Nominations by Stockholders</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Bioventus bylaws provide that stockholders seeking to nominate persons for election to the Bioventus board must (i)&nbsp;be present at the annual or special meeting, (ii)&nbsp;be the record owner of shares of Bioventus both at
the time of giving the required notice and at the time of the meeting (iii)&nbsp;be entitled to vote at the meeting and (iv)&nbsp;comply with the notice provisions set forth in the</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Misonix bylaws provide that, subject to the rights, if any, of any series of preferred stock of Misonix to nominate or elect directors under circumstances specified in a certificate of designation, director nominations may only
be made at an annual meeting of stockholders and only (i)&nbsp;by or at the direction of the Misonix board or (ii)&nbsp;by a</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">354 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Director Nominations by Stockholders</I></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus bylaws. These notice requirements generally require that, among other things, the stockholder deliver a notice of any such
nomination for election of a director at the annual meeting, to the offices of Bioventus not less than 90 days nor more than 120 days prior to the anniversary of the date of the preceding year&#146;s annual meeting (which date of the preceding
year&#146;s annual meeting, for the first annual meeting, shall be deemed to be May&nbsp;14, 2021). For the notice to be timely for the nomination of a director at a special meeting, the stockholder must deliver notice to the Bioventus offices no
earlier than 120 days nor any later than 90 days prior to such special meeting.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, a stockholder (or a group of up to 20 stockholders) who complies with or meets, as applicable, the procedural, informational and stockholder
eligibility requirements set forth in the proxy access provision of the Bioventus bylaws may also nominate a candidate to the Bioventus board at a meeting of stockholders pursuant to such provisions, in which case any such nominees nominated
pursuant to such provisions shall be included by Bioventus in its proxy statement or form of proxy and ballot.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">To nominate a candidate pursuant to such proxy access bylaw, the stockholder must meet certain requirements and, among other things, submit certain information
to Bioventus&#146; Secretary, as prescribed by the Bioventus bylaws, no less than 120 days prior to the first anniversary of the date of Bioventus&#146; proxy materials released to stockholders in connection with the preceding year&#146;s annual
meeting.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">stockholder who (A)&nbsp;has properly complied with the provisions of the Misonix bylaws, (B)&nbsp;was a stockholder of record at the time of
giving the required notice of such nomination and is a stockholder of record at the time of the annual meeting, (C)&nbsp;is entitled to vote at the annual meeting and (D)&nbsp;has nominated a number of nomineeds that does not exceed the number of
directors that will be elected at the annual meeting. A stockholder&#146;s notice of a director nomination must contain the following information: (i)&nbsp;all of the information regarding the nominating person that is required by Section&nbsp;10 of
the Misonix bylaws for proposing persons; and (ii)&nbsp;the following information regarding the nominee: (A)&nbsp;all of the information regarding the nominee that is required by Section&nbsp;10 of the Misonix bylaws for proposing persons;
(B)&nbsp;all information that would be required to be disclosed in a proxy statement or other filing pursuant to Section&nbsp;14(a) of the Exchange Act to be made in connection with a general solicitation of proxies for an election of directors;
(C)&nbsp;a description of all compensation and other material monetary agreements during the past three years, or any material relationships, between the nominating person and his or her affiliates and associates, on the one hand, and the proposed
nominee and his or her affiliates or associates, on the other hand; (D)&nbsp;a completed questionnaire with respect to the identity, background and qualifications of the proposed nominee; and (E)&nbsp;a representation that the nominee (1)&nbsp;is
qualified and intends to serve the entire term if elected; (2)&nbsp;is not and will not become party to any arrangement that has not been disclosed to the Misonix as to how the nominee will vote or act on any issues or questions or any such
arrangement that could limit the nominee&#146;s ability to comply with the nominee&#146;s fiduciary duties; (3)&nbsp;is not and will not become a party to any agreement that has not been disclosed with any person other than the Misonix with respect
to any form of compensation in connection with service as a director; and (4)&nbsp;if elected, will be in compliance and will comply with all policies of Misonix.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A stockholder is not entitled to have its nominees included in Misonix&#146;s proxy statement solely as a result of such stockholder&#146;s compliance with the
foregoing provisions. If the nominating stockholder does not appear at the annual meeting to present its nominee in person, the nomination will be disregarded.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">355 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Stockholder Proposals</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Business may be properly brought before an annual meeting by any stockholder present in person who (A)(1) is a stockholder of record both at
the time of giving notice and at the time of the meeting, (2)&nbsp;is entitled to vote at the meeting, and (3)&nbsp;complies with the notice requirements set forth in the Bioventus bylaws; or (B)&nbsp;properly made such proposal in accordance with
rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act, as amended, and the rules and regulations thereunder.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">To be timely, a stockholder&#146;s notice must generally be delivered to Bioventus&#146; Secretary no less than 90 days and no more than 120 days prior to the
anniversary of the date of immediately precedent annual meeting of stockholders.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Business may be properly brought before an annual meeting by any Misonix stockholder so long as the individual or entity is a Misonix stockholder of record both at the time the written notice provided for in the Misonix bylaws is
delivered and at the time of the meeting, provided such stockholder has also complied with all applicable requirements of Sections 10 and 12 of the Misonix bylaws. The Misonix stockholder must also be entitled to vote at the meeting and comply with
the notice requirements set forth in the Misonix bylaws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Stockholder Action by Written Consent</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Any action required or permitted to be taken by the Bioventus stockholders at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in
writing, setting forth the action so taken, are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of stock of
Bioventus entitled to vote thereon were present and voted and delivered to Bioventus in accordance with the DGCL; provided, however, that no action by stockholders may be taken by written consent in lieu of a meeting of stockholders unless such
written consent and the taking of the action specified therein have been previously approved by the affirmative vote of the majority of the Bioventus board.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Misonix charter provides that any action required or permitted to be taken by the Misonix stockholders may be taken either at a duly called annual or special meeting of stockholders or without a meeting by written
consent.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Special Stockholder Meetings</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the special rights of the holders of one or more series of preferred stock (if issued), special meetings of the stockholders may be called only by the chairperson of the Bioventus board, the Chief Executive Officer, the
President, the Secretary or a majority of the total number of authorized directors. The only matters to be brought before a special meeting are those specified in the meeting notice. Stockholders are not permitted to propose business (other than the
election of directors) to be brought before a special meeting of stockholders.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Special meetings of Misonix stockholders may be called only by (i)&nbsp;a majority of the total number of directors that Misonix would have if there were no vacancies on the Misonix board or (ii)&nbsp;stockholders holding 50% of the
voting power of the shares of Misonix stock generally entitled to vote generally in the election of directors.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">356 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Notice of Stockholder Meetings</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Unless otherwise provided, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with the notice provisions of Bioventus&#146;s bylaws not less than ten nor more than 60 days before the date of the
meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in
person and vote at such meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting), and, in the case of a special
meeting, the purpose or purposes for which the meeting is called.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unless otherwise provided, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with the notice provisions of Misonix&#146;s bylaws not less than ten nor more than 60 days before the date of the
meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in
person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Adjournment of Stockholder Meetings</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No notice need be given of any adjourned meeting if the place, date and time of the meeting, and the means of remote communications, if any,
by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which the adjournment is taken; provided that notice must be given to any stockholder entitled to vote
at the adjourned meeting if the adjournment is longer than 30 days or if a new record date is fixed for the adjourned meeting.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">At any adjourned meeting, Bioventus may transact any business which might have been transacted at the original meeting.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No notice need be given of any adjourned meeting if the place, date and time of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at
such adjourned meeting, are announced at the meeting at which the adjournment is taken; provided that notice must be given to any stockholder entitled to vote at the adjourned meeting if the adjournment is longer than 30 days or if a new record date
is fixed for the adjourned meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Limitation of Personal Liability of Directors</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Bioventus charter provides that no Bioventus director will be personally liable to Bioventus or its stockholders for monetary damages for breach of his or her fiduciary duty as a director, except to the extent such exemption
from liability or limitation thereof is not permitted under the DGCL as the same exists or hereafter may be amended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Misonix charter provides that, to the full extent permitted by the DGCL and other applicable law, no Misonix director shall be personally liable to Misonix or any of its stockholders for or with respect to any breach of a
fiduciary duty or other act or omission as a director of Misonix.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Indemnification of Directors and Officers</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bioventus shall indemnify and hold harmless, to the fullest extent permitted by the DGCL, any current or former director or officer who was or is made or is threatened to be made a party or is otherwise involved in</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Misonix shall indemnify and hold harmless, to the fullest extent permitted by the DGCL, any current or former director or officer who was or is made or is threatened to be made a party to or is
otherwise</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">357 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Indemnification of Directors and Officers</I></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">any action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that the person was a director or officer of Bioventus or, while serving as a director or officer of Bioventus, is or was
serving at the request of Bioventus as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or <FONT STYLE="white-space:nowrap">non-profit</FONT> entity, against all liability and loss
suffered and expenses (including attorneys&#146; fees, judgments, fines ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred by such person in connection with any such proceeding.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">subject to or involved in any claim, demand, action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director or an officer of Misonix or is or was
serving at the request of Misonix as a director or officer, of another company or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan, whether the basis of such proceeding is alleged
action in an official capacity as a director or officer or in any other capacity while serving as a director, officer, employee or agent, against all expense, liability and loss (including attorneys&#146; fees, judgments, fines, ERISA excise taxes
or penalties and amounts paid in settlement) reasonably incurred or suffered.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Rights Upon Liquidation</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pursuant to the Bioventus charter, after payment of the debts and other liabilities of Bioventus, and the distribution of all preferential amounts to be distributed to stockholders in the event of liquidation of Bioventus, holders
of outstanding Bioventus class A common stock are entitled to receive all of Bioventus&#146; remaining assets available for distribution ratably in proportion to the number of shares held by each stockholder.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Misonix charter, the rights of any series of preferred stock of Misonix upon the voluntary or involuntary dissolution of, or upon any distribution of the assets of, Misonix, shall be determined by the Misonix board
upon authorizing such shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Stockholder Rights Plan</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The DGCL does not include a statutory provision expressly validating stockholder rights plans. However, such plans have generally been upheld by the decisions of courts applying Delaware law. Bioventus currently has a stockholder
rights plan in place.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL does not include a statutory provision expressly validating stockholder rights plans. However, such plans have generally been upheld by the decisions of courts applying Delaware law. Misonix does not currently has a
stockholder rights plan in place.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Certain Business Combinations</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;203 of the DGCL generally prohibits a Delaware corporation from engaging in a business combination with an &#147;interested stockholder&#148; that acquires more than 15% but less than 85% of the corporation&#146;s
outstanding voting stock for three years following the time that person becomes an &#147;interested stockholder&#148; (generally defined as a holder who (i)&nbsp;together with its affiliates and associates, owns or (ii)&nbsp;is an affiliate or
associate of the corporation and,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;203 of the DGCL generally prohibits a Delaware corporation from engaging in a business combination with an &#147;interested stockholder&#148; that acquires more than 15% but less than 85% of the corporation&#146;s
outstanding voting stock for three years following the time that person becomes an &#147;interested stockholder&#148; (generally defined as a holder who (i)&nbsp;together with its affiliates and associates, owns or (ii)&nbsp;is an affiliate or
associate of</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">358 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Certain Business Combinations</I></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">together with that person&#146;s affiliates and associates, has owned at any time within the previous three years, at least 15% of the
corporation&#146;s outstanding shares), unless prior to the date the person becomes an interested stockholder, the corporation&#146;s board of directors approves either the business combination or the transaction which resulted in the stockholder
becoming an interested stockholder or the business combination is approved by the corporation&#146;s board of directors and by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the corporation&#146;s outstanding
voting stock that is not owned by the interested stockholder at a meeting of stockholders (and not by written consent) or other specified exceptions are met. The DGCL allows a corporation&#146;s certificate of incorporation to contain a provision
expressly electing not to be governed by Section&nbsp;203, but the Bioventus charter has not opted out of Section&nbsp;203.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Although the DGCL permits a Delaware corporation&#146;s certificate of incorporation to provide for a greater vote for a merger, consolidation or sale of
substantially all the assets of a corporation than the vote described above, the Bioventus charter does not require a greater vote.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the corporation and, together with that person&#146;s affiliates and associates, has owned at any time within the previous three years, at
least 15% of the corporation&#146;s outstanding shares), unless prior to the date the person becomes an interested stockholder, the corporation&#146;s board of directors approves either the business combination or the transaction which resulted in
the stockholder becoming an interested stockholder or the business combination is approved by the corporation&#146;s board of directors and by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
corporation&#146;s outstanding voting stock that is not owned by the interested stockholder at a meeting of stockholders (and not by written consent) or other specified exceptions are met. The DGCL allows a corporation&#146;s certificate of
incorporation to contain a provision expressly electing not to be governed by Section&nbsp;203, but the Misonix charter has not opted out of Section&nbsp;203.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Although the DGCL permits a Delaware corporation&#146;s certificate of incorporation to provide for a greater vote for a merger, consolidation or sale of
substantially all the assets of a corporation than the vote described above, the Misonix charter does not require a greater vote.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Exclusive Forum</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Bioventus charter provides that, unless Bioventus consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is, to the fullest extent permitted by law, the sole and exclusive
forum for the following types of actions or proceedings: (i)&nbsp;any derivative action, suit, or proceeding brought on behalf of Bioventus; (ii)&nbsp;any action, suit, or proceeding asserting a claim of breach of a fiduciary duty owed by any
current or former Bioventus director, officer, other employee or stockholder to Bioventus or its stockholders; (iii)&nbsp;any action, suit, or proceeding asserting a claim arising pursuant to any provision of the DGCL, the Bioventus charter or the
Bioventus bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The Bioventus bylaws also provide that, unless
Bioventus consents in writing to the selection of an alternate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Misonix charter provide that, unless Misonix consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (a)&nbsp;any derivative action
or proceeding brought on behalf of Misonix; (b)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee of Misonix to Misonix or the Misonix&#146;s stockholders;
(c)&nbsp;any action or proceeding asserting a claim against Misonix or any current or former director or officer or other employee of Misonix arising out of or pursuant to any provision of the DGCL, the Misonix charter or Misonix bylaws (including
any right, obligation, or remedy thereunder); (d) any action or proceeding to interpret, apply, enforce or determine the validity of the Misonix charter or Misonix bylaws (including any right, obligation, or remedy thereunder); (e)
any</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">359 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bioventus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Misonix</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><I>Exclusive Forum</I></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">forum, the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Nothing in the Bioventus charter or the Bioventus bylaws would
preclude stockholders that assert claims under the Exchange Act from bringing such claims in federal court to the extent the Exchange Act confers exclusive federal jurisdiction over such claims, subject to applicable law.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (f)&nbsp;any action asserting a claim against Misonix or any director or officer or other employee of Misonix
governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. Nothing in the Misonix charter would
preclude stockholders that assert claims under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">360 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_30"></A>APPRAISAL RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the mergers are completed and you are the
holder of one or more shares of Misonix common stock, you do not vote in favor of the Misonix merger proposal, you properly demand appraisal of your shares of Misonix common stock, you do not withdraw such demand or waive or lose your right to
appraisal and otherwise comply with the requirements for perfecting and preserving your appraisal rights under Section&nbsp;262 of the DGCL, you will be entitled to appraisal rights under Delaware law and to have your shares appraised by the
Delaware Court of Chancery and receive the &#147;fair value&#148; in cash of such shares (exclusive of any element of value arising from the accomplishment or expectation of the mergers) as of completion of the mergers in place of the merger
consideration, as determined by the Delaware Court of Chancery. Any such Misonix stockholder awarded &#147;fair value&#148; for their shares by the court would receive payment of that fair value in cash, together with interest, if any, in lieu of
the right to receive the merger consideration. <B>Failure to strictly comply with the procedures specified in Section</B><B></B><B>&nbsp;262 of the DGCL in a timely and proper manner will result in the loss of your appraisal rights under the
DGCL.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only a holder of record of Misonix common stock issued and outstanding at the time a demand for appraisal is made may assert appraisal rights
for the shares of stock registered in that holder&#146;s name. A person having a beneficial interest in shares of Misonix common stock held of record in the name of another person, such as your bank, broker or other nominee, must act promptly to
cause the record holder to follow the steps summarized in this joint proxy statement/prospectus in a timely manner to perfect appraisal rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following discussion is not intended to be a full summary of the law pertaining to appraisal rights under the DGCL and is qualified in its entirety by the full text of Section&nbsp;262 of the DGCL that is attached to this joint proxy
statement/prospectus as Annex D. All references in Section&nbsp;262 of the DGCL to a &#147;stockholder&#148; are to the record holder of the shares of Misonix common stock. The following discussion does not constitute any legal or other advice, nor
does it constitute a recommendation that you exercise your rights to seek appraisal under Section&nbsp;262 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;262 of the
DGCL, when a merger is submitted for approval at a meeting of stockholders as in the case of the Misonix merger proposal, the constituent corporation, in this case Misonix, not less than 20 days prior to the meeting, must notify each of its
stockholders who was a stockholder on the record date for notice of such meeting and who is entitled to exercise appraisal rights, that appraisal rights are available and include in the notice a copy of Section&nbsp;262 of the DGCL. <B>THIS PROXY
STATEMENT/PROSPECTUS CONSTITUTES THE NOTICE TO THE MISONIX STOCKHOLDERS OF THE AVAILABILITY OF APPRAISAL RIGHTS IN CONNECTION WITH THE MERGERS, AND THE COPY OF THE FULL TEXT OF SECTION 262 OF THE DGCL IS ATTACHED TO THIS PROXY STATEMENT/PROSPECTUS
AS </B><B><U>ANNEX D</U></B>. A holder of Misonix common stock who wishes to exercise appraisal rights or who wishes to preserve the right to do so should review the following discussion and <U>Annex D</U> carefully and should consult with their
legal advisor. Failure to strictly comply with the procedures of Section&nbsp;262 of the DGCL in a timely and proper manner will result in the loss of appraisal rights. A stockholder who loses their appraisal rights will be entitled to receive the
Misonix merger consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>How to Exercise and Perfect Your Appraisal Rights. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix stockholders wishing to exercise the rights to seek an appraisal of their shares must do ALL of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you must not vote in favor of the Misonix merger proposal. Because a proxy that is signed and submitted but does
not otherwise contain voting instructions will, unless revoked, be voted in favor of Misonix merger proposal, if you vote by proxy and wish to exercise your appraisal rights, you must provide instructions in any such proxy to vote against the
Misonix merger proposal or abstain from voting your shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">361 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you must deliver to Misonix a written demand for appraisal of your shares before the vote on the Misonix merger
proposal at the Misonix special meeting. This written demand for appraisal must be in addition to any proxy or vote abstaining from or voting against the Misonix merger agreement proposal. All demands for appraisal must be made by, or on behalf of,
the record holder of shares, fully and correctly, as the record holder&#146;s name appears, with respect to shares evidenced by certificates, on your stock certificate, or, with respect to shares held in &#147;street name&#148; through a bank,
brokerage firm or other nominee, on the stock ledger. Your written demand must reasonably inform Misonix of your identity and your intention to demand appraisal of your shares of common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you must hold the shares on the date of making the demand and must continuously hold such shares from the date of
making the demand through the effective time. You will lose your appraisal rights if you transfer the shares for which you are seeking appraisal before the effective time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you or the Surviving Company must file a petition in the Delaware Court of Chancery requesting a determination of
the fair value of the shares of Misonix common stock within 120 days after the effective time. The Surviving Company is under no obligation to file any such petition in the Delaware Court of Chancery and has no intention of doing so. Accordingly, it
is the obligation of the Misonix stockholders to initiate all necessary action to perfect their appraisal rights in respect of shares of Misonix common stock within the time prescribed in Section&nbsp;262 of the DGCL. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you fail to comply with any of these conditions and the mergers are completed, you will be entitled to receive the merger consideration for your shares of
Misonix common stock as provided for in the merger agreement, but you will have no appraisal rights with respect to your shares of Misonix common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting, in person or by proxy, against, abstaining from voting on or failing to vote on the Misonix merger proposal will not constitute a written demand for
appraisal as required by Section&nbsp;262 of the DGCL. The written demand for appraisal must be in addition to and separate from any proxy or vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
demand for appraisal must be executed by or on behalf of the stockholder of record, fully and correctly, as the stockholder&#146;s name appears on the stock certificates (or in the stock ledger). The demand for appraisal must reasonably inform
Misonix of the identity of the stockholder and that the stockholder intends to demand appraisal of their Misonix common stock. <B>Beneficial owners who do not also hold their shares of Misonix common stock of record may not directly make appraisal
demands to Misonix. The beneficial holder must, in such cases, have the owner of record, such as a bank, brokerage firm or other nominee, submit the required demand in respect of those shares of common stock. </B>A record owner, such as a bank,
brokerage firm or other nominee, who holds shares of Misonix common stock as a nominee for others, may exercise his, her or its right of appraisal with respect to the shares of Misonix common stock held for one or more beneficial owners, while not
exercising this right for other beneficial owners. In that case, the written demand should state the number of shares of Misonix common stock as to which appraisal is sought. Where no number of shares of Misonix common stock is expressly mentioned,
the demand will be presumed to cover all shares of Misonix common stock held in the name of the record owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IF YOU HOLD YOUR SHARES IN BANK OR
BROKERAGE ACCOUNTS OR OTHER NOMINEE FORMS, AND YOU WISH TO EXERCISE APPRAISAL RIGHTS, YOU SHOULD CONSULT WITH YOUR BANK, BROKERAGE FIRM OR OTHER NOMINEE, AS APPLICABLE, TO DETERMINE THE APPROPRIATE PROCEDURES FOR THE BANK, BROKERAGE FIRM OR OTHER
NOMINEE TO MAKE A DEMAND FOR APPRAISAL OF THOSE SHARES. IF YOU HAVE A BENEFICIAL INTEREST IN SHARES HELD OF RECORD IN THE NAME OF ANOTHER PERSON, SUCH AS A BANK, BROKERAGE FIRM OR OTHER NOMINEE, YOU MUST ACT PROMPTLY TO CAUSE THE RECORD HOLDER TO
FOLLOW PROPERLY AND IN A TIMELY MANNER THE STEPS NECESSARY TO PERFECT YOUR APPRAISAL RIGHTS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">362 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you own shares of Misonix common stock jointly with one or more other persons, as in a joint tenancy or
tenancy in common, demand for appraisal must be executed by or on behalf of you and all other joint owners. An authorized agent, including an agent for two or more joint owners, may execute the demand for appraisal on behalf of a stockholder of
record; however, the agent must identify the record owner and expressly disclose the fact that, in exercising the demand, such person is acting as agent for the record owner. If you hold shares of Misonix common stock through a broker who in turn
holds the shares through a central securities depository nominee such as Cede&nbsp;&amp; Co., a demand for appraisal of such shares must be made by or on behalf of the depository nominee and must identify the depository nominee as record holder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you elect to exercise appraisal rights under Section&nbsp;262 of the DGCL, you must mail or deliver a written demand to: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Misonix, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1938 New
Highway, Farmingdale, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Farmingdale, New York 11735 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attention: Secretary </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bioventus&#146;
Actions after Completion of the Mergers. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Misonix merger is completed, the Surviving Company will give written notice that the mergers have
become effective within 10 days after the effective time to you if you did not vote in favor of the Misonix merger proposal and you made a written demand for appraisal of any of your shares in accordance with Section&nbsp;262 of the DGCL. At any
time within 60 days after the effective time, if you have demanded an appraisal but have not commenced an appraisal proceeding or joined such a proceeding as a named party, you have the right to withdraw the demand and to accept the merger
consideration that was payable in respect of shares for which no election to receive cash or stock was made pursuant to the terms of the merger agreement for your shares of Misonix common stock for which you have made a written demand for appraisal.
Any attempt to withdraw a demand made more than 60 days after the effective time will require the written approval of the Surviving Company. Within 120 days after the effective time, but not later, either you, provided you have complied with the
requirements of Section&nbsp;262 of the DGCL, or the Surviving Company may commence an appraisal proceeding by filing a petition in the Delaware Court of Chancery, with a copy served on the Surviving Company in the case of a petition filed by you,
demanding a determination of the fair value of the shares of Misonix common stock held by all stockholders entitled to appraisal. The Surviving Company is under no obligation to file an appraisal petition and has no intention of doing so in the
event there are stockholders entitled to appraisal. Accordingly, if you desire to have any of your shares appraised, it is your obligation to initiate any petitions necessary for the perfection of their appraisal rights within the time period and in
the manner prescribed in Section&nbsp;262 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have not commenced an appraisal proceeding or joined such a proceeding as a named party you
may withdraw a demand for appraisal and accept the merger consideration by delivering a written withdrawal of the demand for appraisal to the Surviving Company, except that any attempt to withdraw made more than 60 days after the effective time will
require written approval of the Surviving Company, and no appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the Delaware Court of Chancery. Such approval may be conditioned on the
terms the Delaware Court of Chancery deems just, provided, however, that this provision will not affect the right of any stockholder who has not commenced an appraisal proceeding or joined such proceeding as a named party to withdraw such
stockholder&#146;s demand for appraisal and to accept the terms offered in the mergers within 60 days after the effective time. If the Surviving Company does not approve your request to withdraw a demand for appraisal when the approval is required
or, except if you withdraw your right to appraisal in accordance with the proviso in the immediately preceding sentence, if the Delaware Court of Chancery does not approve the dismissal of an appraisal proceeding, you would be entitled to receive
only the appraised value determined in any such appraisal proceeding. This value </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">363 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could be greater than, less than or the same as the value of the merger consideration. If you fail to perfect, successfully withdraw or otherwise waive or lose your right to appraisal, your
shares will be converted into the right to receive the merger consideration, without interest thereon, less any withholding taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 120 days after
the effective time, provided you have complied with the provisions of Section&nbsp;262 of the DGCL, you will be entitled to receive from the Surviving Company, upon written request, a statement setting forth the aggregate number of shares not voted
in favor of the Misonix merger proposal and with respect to which Misonix has received demands for appraisal, and the aggregate number of holders of those shares. The Surviving Company must mail this statement to you within the later of 10 days of
receipt of the request or 10 days after expiration of the period for delivery of demands for appraisal. If you are the beneficial owner of shares of stock held in a voting trust or by a nominee on your behalf you may, in your own name, file an
appraisal petition or request from the Surviving Company the statement described in this paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a petition for appraisal is duly filed by you or
another holder of Misonix common stock who has properly exercised his or her appraisal rights in accordance with the provisions of Section&nbsp;262 of the DGCL, you or such other holder (as applicable) must deliver a copy of the petition to the
Surviving Company and the Surviving Company will then be obligated, within 20 days after receiving service of a copy of the petition, to provide the Register in Chancery with a duly verified list containing the names and addresses of all holders who
have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the Surviving Company. Upon the filing of any such petition, the Delaware Court of Chancery may order the Register in
Chancery to give notice of the time and place fixed for the hearing on the petition by registered or certified mail to the Surviving Company and to the stockholders shown on such duly verified list at the addresses therein stated. Such notice will
also be published at least one week before the day of the hearing in a newspaper of general circulation published in the City of Wilmington, Delaware, or in another publication determined by the Delaware Court of Chancery. The costs of these notices
are borne by the Surviving Company. The Delaware Court of Chancery is empowered to conduct a hearing upon the petition to determine which stockholders are entitled to appraisal rights and may require the stockholders demanding appraisal who hold
certificated shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings and the Delaware Court of Chancery may dismiss any stockholder who fails to comply with this
direction from the proceedings. If immediately before a transaction such as the mergers the shares of the class or series of stock of the constituent corporation as to which appraisal rights are available were listed on a national securities
exchange, the Delaware Court of Chancery shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding
shares of the class or series eligible for appraisal, (2)&nbsp;the value of the consideration provided in the merger for such total number of shares exceeds $1&nbsp;million or (3)&nbsp;the merger was approved pursuant to Section&nbsp;253 or 267 of
the DGCL. Misonix common stock is listed on the Nasdaq Global Select Market and therefore this provision will be applicable in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where
proceedings are not dismissed or the demand for appraisal is not successfully withdrawn, the appraisal proceeding will be conducted as to the shares of Misonix common stock owned by such stockholders, in accordance with the rules of the Delaware
Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding, the Delaware Court of Chancery will determine the fair value of the shares of Misonix common stock at the effective time held by dissenting
stockholders, exclusive of any element of value arising from the accomplishment or expectation of the Misonix merger, together with interest, if any, to be paid upon the amount determined to be the fair value. Unless the Delaware Court of Chancery
in its discretion determines otherwise for good cause shown, and except as otherwise provided in Section&nbsp;262 of the DGCL, interest from the effective time through the date of payment of the judgment will be compounded quarterly and will accrue
at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective time and the date of payment of the judgment. At any time before the entry of judgment in the
proceedings, the Surviving Company may pay to each Misonix stockholder entitled to appraisal an amount in cash, in which case interest shall accrue after such payment only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid
and the fair value of the shares as determined by the Delaware Court of Chancery, and (2)&nbsp;interest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">364 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
theretofore accrued, unless paid at that time. Upon application by the Surviving Company or by any holder of Misonix common stock entitled to participate in the appraisal proceeding, the Delaware
Court of Chancery may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any Misonix stockholder whose name appears on the verified list and who has submitted such
stockholder&#146;s stock certificates, if any, to the Register in Chancery, if such is required, may participate fully in all proceedings until it is finally determined that such stockholder is not entitled to appraisal rights under Section&nbsp;262
of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the fair value, the Delaware Court of Chancery is required to take into account all relevant factors. In <I>Weinberger v.
UOP, Inc.</I>, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#147;proof of value by any techniques or methods which are generally considered acceptable
in the financial community and otherwise admissible in court&#148; should be considered and that &#147;[f]air price obviously requires consideration of all relevant factors involving the value of a company.&#148; The Delaware Supreme Court has
stated that, in making this determination of fair value, the court must consider market value, asset value, dividends, earnings prospects, the nature of the enterprise and any other factors which could be ascertained as of the date of the merger
which throw any light on future prospects of the merged corporation. Section&nbsp;262 of the DGCL provides that fair value is to be &#147;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#148; In
<I>Cede</I><I></I><I>&nbsp;&amp; Co. v. Technicolor, Inc.</I>, the Delaware Supreme Court stated that such exclusion is a &#147;narrow exclusion [that] does not encompass known elements of value,&#148; but which rather applies only to the
speculative elements of value arising from such accomplishment or expectation. In <I>Weinberger</I>, the Delaware Supreme Court construed Section&nbsp;262 of the DGCL to mean that &#147;elements of future value, including the nature of the
enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#148; In addition, Delaware courts have decided that the statutory appraisal remedy, depending on factual
circumstances, may or may not be a dissenter&#146;s exclusive remedy. An opinion of an investment banking firm as to the fairness from a financial point of view of the consideration payable in a merger is not an opinion as to, and does not in any
manner address, fair value under Section&nbsp;262 of the DGCL. You should be aware that the fair value of their shares as determined under Section&nbsp;262 of the DGCL could be greater than, the same as, or less than the value of the merger
consideration. We do not anticipate offering more than the merger consideration to any stockholder exercising appraisal rights and reserve the right to assert, in any appraisal proceeding, that, for purposes of Section&nbsp;262 of the DGCL, the
&#147;fair value&#148; of a share of Misonix common stock is less than the merger consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a petition for appraisal is not timely filed, then
you will lose the right to an appraisal, and will instead receive the merger consideration that was payable in respect of shares for which no election to receive cash or stock was made pursuant to the terms of described in the merger agreement,
without interest thereon, less any withholding taxes, upon following the applicable exchange procedures described in the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Delaware
Court of Chancery may determine the costs of the appraisal proceeding and may allocate those costs to the parties as the Delaware Court of Chancery determines to be equitable under the circumstances. However, costs do not include attorneys and
expert witness fees. Each dissenting stockholder is responsible for its own attorneys and expert witnesses expenses, although, upon application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by
any stockholder in connection with the appraisal proceeding, including reasonable attorneys&#146; fees and the fees and expenses of experts utilized in the appraisal proceeding, to be charged pro rata against the value of all shares entitled to
appraisal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have duly demanded an appraisal in compliance with Section&nbsp;262 of the DGCL you may not, after the effective time, vote the shares
of Misonix common stock for any purpose or receive any dividends or other distributions on those shares, except dividends or other distributions payable to holders of record of Misonix shares as of a record date which is prior to the effective time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to follow the steps required by Section&nbsp;262 of the DGCL for perfecting appraisal rights will result in the loss of appraisal rights. In that
event, you will be entitled to receive the merger consideration for your shares in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">365 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with the merger agreement. In view of the complexity of the provisions of Section&nbsp;262 of the DGCL, if you are a Misonix stockholder and are considering exercising your appraisal
rights under the DGCL, you should consult your own legal advisor. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE PROCESS OF DEMANDING AND EXERCISING APPRAISAL RIGHTS REQUIRES
STRICT COMPLIANCE WITH TECHNICAL PREREQUISITES. IF YOU WISH TO EXERCISE YOUR APPRAISAL RIGHTS, YOU SHOULD CONSULT WITH YOUR OWN LEGAL COUNSEL IN CONNECTION WITH COMPLIANCE UNDER SECTION 262 OF THE DGCL. TO THE EXTENT THERE ARE ANY INCONSISTENCIES
BETWEEN THE FOREGOING SUMMARY AND SECTION 262 OF THE DGCL, THE DGCL WILL GOVERN. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">366 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_31"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legality of the shares of Bioventus class A common stock offered hereby will be passed upon for Bioventus by Latham&nbsp;&amp; Watkins LLP. Certain U.S.
federal income tax consequences relating to the first merger and second merger will be passed upon for Misonix by Jones Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">367 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_32"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statement of Bioventus Inc. as
of December&nbsp;31, 2019 and December&nbsp;31, 2020 and the consolidated financial statements of Bioventus LLC as of and for the years ended December&nbsp;31, 2019 and December&nbsp;31, 2020 included in this joint proxy statement/prospectus and
elsewhere in the registration statement have been so included in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Bioventus LLC for the year end December&nbsp;31, 2018 included in this joint proxy statement/prospectus have been so included in
reliance on the report (which contains an emphasis of matter paragraph relating to Bioventus LLC&#146;s identification of noncompliance with certain U.S. Federal statutes and regulations to which Bioventus LLC is subject and the Bioventus LLC&#146;s
voluntary self-disclosure to the U.S. Department of Health and Human Services Office of Inspector General. As a result of the noncompliance, Bioventus LLC may be subject to civil monetary penalties, as well as repayment obligations related to
previously reimbursed claims and fines as described in Notes 2 and 12 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of
Misonix, Inc., and the related financial statement schedules, incorporated in this joint proxy statement/prospectus by reference from Misonix, Inc.&#146;s Annual Report on Form 10-K have been audited by Deloitte &amp; Touche LLP, an independent
registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such financial statements and financial statement schedules have been so incorporated in reliance upon the report of such firm given upon their
authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">368 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_33"></A>CERTAIN BENEFICIAL OWNERS OF BIOVENTUS COMMON STOCK</B><B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information as to the beneficial ownership of Bioventus class A common stock and Bioventus class B common stock, and of
September&nbsp;1, 2021 (except as noted in the footnotes below), the latest practicable date prior to the date of this joint proxy statement/prospectus, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by Bioventus to beneficially own more than 5% of Bioventus
class A common stock or Bioventus class B common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each named executive officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of Bioventus&#146; directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in &#147;Description of Bioventus&#146; Business&#151;Bioventus LLC Agreement,&#148; the continuing LLC owner is entitled to have its LLC
interests (as defined below) redeemed for Bioventus class A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, if Bioventus and the continuing LLC owner agree, a cash payment
equal to the market value of the applicable number of shares of Bioventus class A common stock. In addition, at Bioventus&#146; election, Bioventus may effect a direct exchange of such Bioventus class A common stock or such cash (if mutually agreed)
for such LLC interests in lieu of such a redemption. In connection with its IPO, Bioventus issued to the continuing LLC owner one share of Bioventus class B common stock for each LLC interest it owns. As a result, the number of shares of Bioventus
class B common stock listed in the table below correlates to the number of LLC interests the continuing LLC owner owns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares beneficially
owned by each stockholder is determined under rules issued by the SEC and includes voting or investment power with respect to securities. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or
shared voting power or investment power. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options, or other rights, including the
redemption right described above, held by such person that are currently exercisable or will become exercisable within 60 days of March&nbsp;22, 2021, are considered outstanding, although these shares are not considered outstanding for purposes of
computing the percentage ownership of any other person. Unless otherwise indicated, the address of each of the individuals and entities named below is c/o Bioventus Inc., 4721 Emperor Boulevard, Suite 100, Durham, NC 27703. Each of the stockholders
listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Class&nbsp;A<BR>Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Class&nbsp;B<BR>Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Combined<BR>Voting&nbsp;Power<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EW Healthcare Partners <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,021,324</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Smith&nbsp;&amp; Nephew <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,229,991</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spindletop Healthcare Capital
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,906,395</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampersand Capital<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,255,332</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pantheon Global <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Opportunities Fund L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,821,283</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alta Partners VIII, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,604,264</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integrated Core Strategies (US)
LLC<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,432,581</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">369 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Class&nbsp;A<BR>Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Class&nbsp;B<BR>Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Combined<BR>Voting&nbsp;Power<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth M. Reali</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory O. Anglum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John E. Nosenzo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony D&#146;Adamio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alessandra Pavesio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William A. Hawkins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip G. Cowdy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guido J. Neels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guy P. Nohra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Parker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martin P. Sutter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan M. Stalnecker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Kay Ladone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (13&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the voting power of each owner based on the voting power held through both the owner&#146;s
Bioventus class A common stock and Bioventus class B common stock. Represents percentage of voting power of the Bioventus class A common stock and Bioventus class B common stock voting together as a single class. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 12,096,702 shares held by EW Healthcare Partners Acquisition Fund, L.P., which Bioventus refers to
as the &#147;Essex Stockholder,&#148; and 924,622 shares held by White Pine Medical, LLC, a subsidiary of the Essex Stockholder, which Bioventus refers to as &#147;White Pine.&#148; EW Healthcare Partners Acquisition Fund GP, L.P., a Delaware
limited partnership, is the general partner of the Essex Stockholder and is referred to as the &#147;Partnership,&#148; and EW Healthcare Partners Acquisition Fund UGP, LLC, a Delaware limited liability company, is the general partner of the
Partnership and is referred to as the &#147;General Partner.&#148; Martin P. Sutter, Petri Vainio, Ronald W. Eastman, and Scott Barry are the managers of the General Partner, and each is referred to as a &#147;Manager&#148; and collectively as the
&#147;Managers.&#148; The Partnership is deemed to have sole voting and dispositive power with respect to the shares held by the Essex Stockholder and White Pine. The Managers are deemed to have shared voting and dispositive power with respect to
the shares held by the Essex Stockholder and White Pine by unanimous consent and through the Partnership. Each Manager disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The address of the Essex
Stockholder and White Pine is 21 Waterway Avenue, Suite 225, The Woodlands, Texas 77380. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the shares of Bioventus class A common stock held by Smith &amp; Nephew USD Limited, and the shares
of Bioventus class B common stock held by Smith&nbsp;&amp; Nephew, Inc., a wholly owned indirect U.S. subsidiary of Smith&nbsp;&amp; Nephew plc. The address of Smith&nbsp;&amp; Nephew (Europe) B.V. is Bloemlaan 2, 2132 NP Hoofddorp, Netherlands. The
address of Smith&nbsp;&amp; Nephew, Inc. is 7135 Goodlett Farms, Cordova, Tennessee 38106. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares held by Spindletop Healthcare Capital L.P. Evan Melrose, MD is the Manager of the General
Partner of the General Partner of Spindletop Healthcare Capital L.P. and may be deemed to have shared voting and dispositive power with respect to the shares held by Spindletop Healthcare Capital L.P. The address of Spindletop Healthcare Capital
L.P. is 3571 Far West Blvd., PMB #108, Austin, Texas 78731. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares held by <FONT STYLE="white-space:nowrap">AMP-CF</FONT> Holdings, LLC, which Bioventus refers
to as the &#147;Ampersand Capital Stockholder.&#148; Herbert H. Hooper, the Managing Member of the General Partner of the General Partner of each of the members and managers of the Ampersand Capital Stockholder, may be deemed to have voting and
dispositive power with respect to shares held by the Ampersand Capital Stockholder. The address of the Ampersand Capital Stockholder is in care of Ampersand Capital Partners, 55 William Street, Suite 240, Wellesley, Massachusetts 02481.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">370 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares held by Pantheon Global <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Opportunities
Fund L.P. David Braman, Susan Long McAndrews and Lily Wong are directors of Pantheon Global <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Opportunities GP Limited, the general partner of Pantheon Global
<FONT STYLE="white-space:nowrap">Co-Investment</FONT> Opportunities Fund, L.P. and make the investment and voting decisions with respect to shares held by of Pantheon Global <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Opportunities Fund,
L.P. The address of Pantheon Global <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Opportunities Fund L.P. is 600&nbsp;Montgomery Street, 23rd Floor, San Francisco, CA 94111. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares held by Alta Partners VIII, L.P. Alta Partners Management VIII, LLC is the general partner of
Alta Partners VIII, L.P. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of Alta Partners Management VIII, LLC and exercise shared voting and investment powers with respect to the shares owned by Alta Partners VIII, L.P. Each of
the reporting persons disclaims beneficial ownership of such shares, except to the extent of their proportionate pecuniary interest therein, if any. The principal business address of Alta Partners VIII, L.P. is One Embarcadero Center, 37th Floor San
Francisco, CA&nbsp;94111. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the Schedule 13G filed with the SEC by Integrated Core Strategies (US), LLC (Integrated Core
Strategies) et al, reporting ownership of these shares of Bioventus class A common stock as of March&nbsp;16, 2021. As reported in said Schedule 13G, Integrated Core Strategies reports shared voting and dispositive power with respect to 2,033,399
shares of Bioventus class A common stock, ICS Opportunities II LLC (ICS Opportunities II) reports shared voting and dispositive power with respect to 75,287 shares of Bioventus class A common stock, ICS Opportunities, Ltd. (ICS Opportunities)
reports shared voting and dispositive power with respect to 310,116 shares of Bioventus class A common stock, Integrated Assets, Ltd. (Integrated Assets) reports shared voting and dispositive power with respect to 13,779 shares of Bioventus class A
common stock, Millennium International Management LP (Millennium International Management) reports shared voting and dispositive power with respect to 399,182 shares of Bioventus class A common stock, Millennium Management LLC (Millennium
Management) reports shared voting and dispositive power with respect to 2,432,581 shares of Bioventus class A common stock, Millennium Group Management LLC (Millennium Group Management) reports shared voting and dispositive power with respect to
2,432,581 shares of Bioventus class A common stock, and Israel A. Englander reports shared voting and dispositive power with respect to 2,432,581 shares of Bioventus class A common stock. Millennium International Management is the investment manager
to ICS Opportunities II, ICS Opportunities and Integrated Assets (collective, the ICS Entities) and is deemed to have beneficial ownership of their respective securities. Millennium Management is the general partner of the managing member of
Integrated Core Strategies and the general partner of the 100% owner of the ICS Funds is deemed to have beneficial ownership of the securities owned by each of Integrated Core Strategies and the ICS Entities (collectively, the Integrated Entities).
Millennium Group Management is the managing member of Millennium Management and general partner of Millennium International Management and is deemed to have beneficial ownership of the securities owned by the Integrated Entities. The managing member
of Millennium Group Management is a trust of which Mr.&nbsp;Englander, a United States citizen, currently serves as the sole voting trustee, and therefor Mr.&nbsp;Englander is deemed to have beneficial ownership of securities owned by the Integrated
Entities. The address of Mr.&nbsp;Englander and each of the foregoing entities is 399 Park Avenue, New York, New York 10022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">371 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_34"></A>CERTAIN BENEFICIAL OWNERS OF MISONIX COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Misonix&#146;s knowledge, the following table sets forth certain information regarding the beneficial ownership of Misonix common stock as of
September&nbsp;1, 2021 (except as noted in the footnotes below), the latest practicable date prior to the date of this joint proxy statement/prospectus, by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each named executive officer of Misonix; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each member of the Misonix board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the members of the Misonix board and Misonix current executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known by Misonix to beneficially own more than 5% of the outstanding shares of Misonix common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix has determined beneficial ownership in accordance with the rules of the SEC. Except as noted in the footnotes below, Misonix
believes, based on the information furnished to Misonix, that the persons and entities named in the tables below have sole voting and investment power with respect to all shares of Misonix common stock that they beneficially own. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address
<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B><br><B>Stock</B><br><B>Beneficially</B><br><B>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B><br><B>Of&nbsp;Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stavros G. Vizirgianakis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,783,641</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.02</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1315 Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,714,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SV Health Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,714,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Ludecker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,828</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph P. Dwyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159,531</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas M. Patton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,750</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Koby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul LaViolette</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. Beyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and Directors as a group (Eight&nbsp;people)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,705,784</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise noted, the business address of each of the named individuals in this table is c/o Misonix,
Inc., 1938 New Highway, Farmingdale, NY 11735. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 124,563 shares which Mr.&nbsp;Vizirgianakis has the right to acquire upon exercise of stock options
which are exercisable within 60 days. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 252,328 shares which Mr.&nbsp;Ludecker has the right to acquire upon exercise of stock options which
are exercisable within 60 days. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 154,831 shares which Mr.&nbsp;Dwyer has the right to acquire upon exercise of stock options which are
exercisable within 60 days. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 63,750 shares which Mr.&nbsp;Patton has the right to acquire upon exercise of stock options which are
exercisable within 60 days. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not reflect any securities owned by 1315 Capital. Mr.&nbsp;Koby is a member of 1315 Capital Management,
LLC. Under the Amended and Restated Limited Liability Company Agreement of 1315 Capital Management, LLC, Mr.&nbsp;Koby is deemed to hold securities for the benefit of 1315 Capital who is deemed to have voting and dispositive power with respect the
securities. Mr.&nbsp;Koby disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not reflect any securities owned by SV Health Investors. Mr.&nbsp;LaViolette is a member of SV Health
Investors. Under the Limited Liability Company Agreement of SV Health Investors, Mr.&nbsp;LaViolette is </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">372 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
deemed to hold securities for the benefit of 1315 Capital who is deemed to have voting and dispositive power with respect the securities. Mr.&nbsp;LaViolette disclaims beneficial ownership of the
securities except to the extent of his pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 395,936 shares which such persons have the right to acquire upon exercise of stock options which are
exercisable within 60 days. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">373 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_35"></A>STOCKHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus will hold an annual meeting of
stockholders in 2022, which is referred to as the &#147;Bioventus 2022 annual meeting,&#148; regardless of whether the merger has been completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
stockholder proposals intended to be presented at the Bioventus 2022 annual meeting and considered for inclusion in Bioventus&#146; proxy materials must have been received by Bioventus on or before January&nbsp;14, 2022. Such proposals must have
been submitted in writing to: Bioventus Inc., Attn: Corporate Secretary, 4721 Emperor Boulevard, Suite 400, Durham, North Carolina 27703. Such proposals must also meet the other requirements and procedures prescribed by Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act relating to stockholder proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Bioventus bylaws, nominees for director
submitted by stockholders must be received by Bioventus between January&nbsp;14, 2022 and February&nbsp;13, 2022. Such proposals must also meet the requirements set forth in the Bioventus bylaws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Misonix </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix will hold an annual meeting of
stockholders in 2021, which is referred to as the &#147;Misonix 2021 annual meeting,&#148; only if the mergers have not already been completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
stockholder proposals intended to be presented at the Misonix 2021 annual meeting and considered for inclusion in Misonix&#146;s proxy materials must have been received by Misonix no later than the close of business on January&nbsp;14, 2022. Such
proposals must have been submitted in writing to: Misonix, Inc., Attn: Secretary, 1938 New Highway, Farmingdale, New York 11735. Such proposals must also meet the other requirements and procedures prescribed by Rule
<FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act relating to stockholder proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our bylaws require that a proposal
to be submitted by a stockholder for a vote of the Company&#146;s stockholders at our annual meeting of stockholders, whether or not also submitted for inclusion in the Company&#146;s proxy materials, must be preceded by adequate notice to the
Secretary of the Company. To be adequate, the notice must set forth certain information specified in our bylaws about the stockholder and the proposal. Our bylaws are available in our SEC filings which can be accessed on our website at
www.misonix.com under the &#147;Investors Relations&#148; tab and will be provided to any stockholder upon written request to Misonix, Inc., 1938 New Highway, Farmingdale, New York 11735, Attn: Secretary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">374 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_36"></A>HOUSEHOLDING OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or more
stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; provides cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix have each previously adopted householding for stockholders of record. As a result, stockholders with the same address and last name may
receive only one copy of this joint proxy statement/prospectus from Bioventus or Misonix, as applicable. Registered Bioventus or Misonix stockholders (those who hold shares directly in their name with Bioventus&#146;s or Misonix&#146;s transfer
agent) may opt out of householding and receive a separate joint proxy statement/prospectus or other proxy materials by sending a written request to Bioventus or Misonix, as applicable, at the address below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some brokers also household proxy materials, delivering a single proxy statement or notice to multiple stockholders sharing an address unless contrary
instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke
your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, or if your household is receiving multiple copies of these documents and you wish to request that
future deliveries be limited to a single copy, please notify your broker. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Requests for additional copies of this joint proxy statement/prospectus should
be directed to, as applicable: Bioventus Inc., Attn: Corporate Secretary, tony.dadamio@bioventus.com, (919) <FONT STYLE="white-space:nowrap">474-6700;</FONT> or Misonix, Inc., Attn: Secretary, misonixproxy@misonix.com, (631) <FONT
STYLE="white-space:nowrap">694-9555.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">375 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_37"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus and Misonix file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that
contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including both Bioventus and Misonix, which you can access at www.sec.gov. In addition, you may obtain free copies of
the documents Bioventus and Misonix file with the SEC, including the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of which this joint proxy statement/prospectus forms a part, by going to Bioventus&#146; and
Misonix&#146;s websites at www.bioventus.com and www.misonix.com, respectively. The websites of Bioventus and Misonix are provided as inactive textual references only. The information contained on or accessible through the websites of Bioventus and
Misonix (other than the documents listed below that are incorporated by reference herein) does not constitute a part of this joint proxy statement/prospectus, and is not incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained or incorporated by reference in this joint proxy statement/prospectus regarding the contents of any contract or other document are not
necessarily complete, and each such statement is qualified in its entirety by reference to the full text of that contract or other document filed as an exhibit with the SEC. The SEC allows Misonix to &#147;incorporate by reference&#148; in this
joint proxy statement/prospectus documents that Misonix files with the SEC, including certain information required to be included in the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> of which this joint proxy
statement/prospectus forms a part. This means that Misonix can disclose important information to you by referring you to those documents. The information incorporated by reference herein is considered to be a part of this joint proxy
statement/prospectus, and later information Misonix file with the SEC will update and supersede that information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix incorporates by reference into
this joint proxy statement/prospectus the information or documents listed below that Misonix has filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-10986):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
June&nbsp;30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/880432/000149315221021878/form10-k.htm">September&nbsp;2, 2021</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Misonix&#146;s current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/880432/000119312521229212/d158299d8k.htm">July&nbsp;29,
 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/880432/000149315221019555/form8-k.htm">August&nbsp;12, 2021</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of Misonix common stock set forth in Misonix&#146;s registration statement on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;1-10986)</FONT> filed with the SEC on January&nbsp;22, 1992 under Section&nbsp;12 of the Exchange Act and all amendments or reports filed by Misonix for
the purpose of updating that description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix also incorporate by reference any future filings (other than current reports
furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the
contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the date of the Misonix special meeting. Misonix will not, however, incorporate by reference in this joint proxy statement/prospectus any
documents or portions thereof that are not deemed &#147;filed&#148; with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of Misonix&#146;s current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> unless,
and except to the extent, specified in such current reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix hereby undertakes to provide without charge to each Misonix stockholder as of the
record date, upon written or oral request of any such person, a copy of any and all of the information that has been or may be incorporated by reference in this joint proxy statement/prospectus. Requests for such copies should be directed to our
secretary, at the following address or by calling the following telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Misonix, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1938 New
Highway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Farmingdale, NY 11735 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (631) <FONT STYLE="white-space:nowrap">694-9555</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">376 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc180330_38"></A>INDEX TO BIOVENTUS INC. FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Explanatory Note: With respect to the following financial statements and notes to the financial statements, mentions of &#147;the Company,&#148;
&#147;we,&#148; &#147;our,&#148; and &#147;us&#148; refer to Bioventus Inc. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_2">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_3">Balance Sheets as of December&nbsp;31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_4">Notes to Balance Sheets as of December&nbsp;31, 2020 and
2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Bioventus LLC</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_6">Reports of Independent Registered Public Accounting Firms</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_7">Consolidated Statements of Operations and Comprehensive Income (Loss) for the
 Years Ended December&nbsp;31, 2020, 2019 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_8">Consolidated Balance Sheets as of December&nbsp;31, 2020 and
2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_9">Consolidated Statements of Changes in Members&#146; Equity for the Years Ended
December&nbsp;31, 2020, 2019 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_10">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2020, 2019 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_11">Notes to the Audited Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Financial Statements:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_14">Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income
 for the three and six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_15">Consolidated Condensed Balance Sheets as of July&nbsp;
3, 2021 and December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_16">Consolidated Condensed Statements of Changes in Stockholders&#146; and Members&#146;
 Equity for the three and six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_17">Consolidated Condensed Statements of Cash Flows for the six months ended July&nbsp;3,
 2021 and June&nbsp;27, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#findex180330_18">Notes to the Unaudited Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g180330g33q08.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt"><B>GRANT THORNTON LLP</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><A NAME="findex180330_2"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">4140 ParkLake Ave., Suite 130</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Raleigh, NC 27612-3723</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">D +1 919 881 2700</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">F +1 919 881 2795</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Board of Directors and Shareholders </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Bioventus Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman"><B>Opinion on
the financial statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of Bioventus Inc. (a Delaware corporation) (the
&#147;Company&#148;) as of December&nbsp;31, 2020 and 2019 and the related notes (collectively referred to as the &#147;financial statement&#148;). In our opinion, the financial statement presents fairly, in all material respects, the financial
position of the Company as of December&nbsp;31, 2020 and 2019, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman"><B>Basis for opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">This
financial statement is the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statement based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal
control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks
of material misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statement. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement. We believe that our audits provide a
reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">March&nbsp;26, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="findex180330_3"></A>Balance sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31, 2020 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value - 10 shares authorized, issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="findex180330_4"></A>Notes to balance sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation on December&nbsp;22, 2015 for the purpose of facilitating an initial public
offering (IPO) and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The notes to these financial statements should be read in conjunction with notes to BV LLC&#146;s financial statements.
As of December&nbsp;31, 2020, the Company had not engaged in any business activities except in connection with its formation. On February&nbsp;16, 2021, the Company closed an IPO of 9,200,000 shares of Class&nbsp;A common stock at a public offering
price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#146; over-allotment option. The Company received $111,228 in proceeds, net of underwriting discounts and commissions of $8,372, which was used to
purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $13.00. In addition to the underwriting discounts and commission the Company incurred offering expenses totaling $4,310. Subsequent to the IPO
and related transactions that occurred in connection with the IPO (the Transactions) as described in Note 4, the Company is the sole managing member of BV LLC and owns 72.2% of BV LLC. The Company has a majority economic interest, the sole voting
interest in, and controls the management of BV LLC. As a result, subsequent to the IPO, the Company will consolidate the financial results of BV LLC and will report a non-controlling interest representing the 27.8% interest not held by the Company.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of significant accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of accounting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The balance sheets have been prepared
in accordance with accounting principles generally accepted in the United States of America. Separate statements of income, comprehensive income, changes in stockholder&#146;s equity, and cash flows have not been presented in the financial
statements as there has been no activity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Stockholder&#146;s equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporation had 10 outstanding shares at a nominal value as of December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Subsequent event </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and BV LLC completed the following Transactions regarding the IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&nbsp;provide for a new single class of common membership interests in BV
LLC (LLC Interests), (ii)&nbsp;exchange all of the existing membership interests in BV LLC for new LLC Interests and (iii)&nbsp;appoint Bioventus Inc. as the sole managing member of BV LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company amended and restated its certificate of incorporation to, among other things, provide for the (i)&nbsp;authorization of 250,000,000 shares of
Class&nbsp;A common stock with a par value of $0.001 per share; (ii)&nbsp;authorization of 50,000,000 shares of Class B common stock with a par value of $0.001 per share; (iii)&nbsp;authorization of 10,000,000 shares of undesignated preferred stock
that may be issued from time to time by the Company&#146;s Board of Directors (BOD) in one or more series; and (iv)&nbsp;establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;A and Class B common stock are entitled to one vote per share and, except as otherwise
required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the
liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests held by the only member of BV LLC that remained a
member (Continuing LLC Owner) and the number of shares of Class B common stock held by the Continuing LLC Owner. Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will
be canceled on a one-for-one basis if the Company, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
amended and restated certificate of incorporation and the Bioventus LLC Agreement requires that the Company and BV LLC at all times maintain a one-to-one ratio between the number of shares of Class&nbsp;A common stock issued by the Company and the
number of LLC Interests owned by the Company, as well as a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company acquired, by merger, ten entities that were members of BV LLC (Former LLC Owners), for which the Company issued 31,838,589 shares of Class&nbsp;A
common stock as merger consideration (Merger). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class B common stock. Upon consummation of the Merger, the Company canceled the
31,838,589 shares of Class B common stock and recognized the 31,838.589 of LLC Interests at carrying value, as the Merger is considered to be a transaction between entities under common control. Following the Merger and IPO, the Company now holds
41,038,589 LLC Interests, representing a 72.2% ownership interest in BV LLC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Receivable Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing
LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or
increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16,
2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes as
a result of (i)&nbsp;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&nbsp;certain other tax benefits related to our making payments under
the TRA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February
2021, in connection with the IPO, the BV LLC Phantom Profits Interest Plan (Phantom Plan) terminated and the Company assumed the obligations of settling the vested awards. The awards will be settled 12 months following the Phantom Plan termination.
Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled in cash totaling $10,875. Vested awardees that were active BV LLC employees at the IPO will receive 798,422 shares of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2021, in connection with the IPO, the Company began operating two equity-based compensation plans. These are the Bioventus Inc. 2021 Incentive
Award Plan (2021 Plan) and the Bioventus Inc. 2021 Employee Stock Purchase Plan (ESPP). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for
which the Company competes. The 2021 Plan provides for the grant of stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and
cash awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the IPO, 7,592,476 shares of Class&nbsp;A common stock were authorized for issuance. The number of shares available for
issuance will be increased by an annual increase on January&nbsp;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&nbsp;4.5% of the shares of our Class&nbsp;A common stock outstanding on the final
day of the immediately preceding calendar year and (ii)&nbsp;a smaller number of shares as determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the
IPO, 4,561,500 stock options were granted to certain employees with an exercise price of $13.00 per share and vest equally over two or four years as indicated in each option agreement. Additionally, the Company granted 360,670 RSUs to the directors
and certain employees which vest equally over one or four years as indicated in each RSU agreement and entitles the recipient to the same number of shares of Class&nbsp;A common stock. 2,670,306 shares of Class&nbsp;A common stock remain available
for issuance under the 2021 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ESPP </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP
allows for the Company to grant options to employees to purchase shares of the Company&#146;s Class&nbsp;A common stock through payroll deductions of up to 15% of their eligible compensation as defined in the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the IPO, 542,320 shares of Class&nbsp;A common stock were authorized for issuance. The number of shares available for issuance will be
increased by an annual increase on January&nbsp;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&nbsp;1% of the shares of our Class&nbsp;A common stock outstanding on the final day of the
immediately preceding calendar year and (ii)&nbsp;a smaller number of shares as determined by our board of directors. There have been no grants under the ESPP as of March&nbsp;22, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g180330g33q08.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt"><B>GRANT THORNTON LLP</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><A NAME="findex180330_6"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">4140 ParkLake Ave., Suite 130</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Raleigh, NC 27612-3723</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">D +1 919 881 2700</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">F +1 919 881 2795</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Board of Directors and Shareholders </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Bioventus Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman"><B>Opinion on
the financial statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Bioventus LLC (a Delaware limited liability
company) and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2020 and 2019, the related consolidated statements of operations and comprehensive income (loss), changes in members&#146; equity, and cash flows for the years then ended
and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020 and 2019,
and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman"><B>Basis for opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable
basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:25%; font-size:10pt; font-family:Times New Roman">March&nbsp;26, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Managers and Members of Bioventus LLC </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the consolidated statements of operations and comprehensive income (loss), of changes in members&#146; equity and of cash flows of Bioventus LLC and its subsidiaries (the &#147;Company&#148;) for the year ended December&nbsp;31, 2018,
including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the results of operations and cash flows of
the Company for the year ended December&nbsp;31, 2018 in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB and in
accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement of the consolidated
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable
basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emphasis of Matter </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
discussed in Notes 2 and 12 to the consolidated financial statements, the Company has identified noncompliance with certain U.S. Federal statutes and regulations to which the Company is subject and made a voluntary self-disclosure to the U.S.
Department of Health and Human Services Office of Inspector General. As a result of the noncompliance, the Company may be subject to civil monetary penalties, as well as repayment obligations related to previously reimbursed claims and fines.
Management&#146;s evaluation of the impact of these material contingencies is also discussed in Note 12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;16, 2019, except for the
effects of disclosing net loss per unit information discussed in Note 13 and the effects of discontinued operations discussed in Note 16 to the consolidated financial statements, as to which the date is October&nbsp;6, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We served as the Company&#146;s auditor from 2012 to 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="findex180330_7"></A>Consolidated statements of operations and comprehensive income (loss) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Years ended December&nbsp;31, 2020, 2019 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except unit and per unit data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,141</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319,177</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales (including depreciation and amortization of $21,169, $22,399 and $20,614,
respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,642</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,935</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,168</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233,519</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249,206</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235,009</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,078</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,475</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,672</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,202</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,055</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,095</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,373</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,439</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,908</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,615</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on impairment of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,237</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,193</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,504</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,751</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,579</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,171</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,323</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,504</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,397</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,914</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,107</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,576</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,664</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,113</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,650</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,298</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,851</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss), net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in prior service cost and unrecognized (loss) gain for defined benefit plan
adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,126</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,072</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,483</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,451</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income from continuing operations attributable to unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,666</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated and unpaid preferred distributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income allocated to participating shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from continuing operations attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,156</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,650</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(659</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,988</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per unit attributable to common unit holders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.89</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.89</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average units used in computing basic and diluted net income (loss) per common
unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="findex180330_8"></A>Consolidated balance sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31, 2020 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,839</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,520</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,283</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,128</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,120</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,326</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,552</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,059</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,794</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183,033</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,879</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,489</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,800</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,800</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,650</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,510</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,961</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,267</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,382</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,308</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494,466</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472,407</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Members&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,422</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,440</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,187</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,827</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,054</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,547</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,926</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,201</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,589</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,015</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,378</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,965</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued equity-based compensation, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,249</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,255</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,362</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,874</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,728</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,681</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,306</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">326,790</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members&#146; equity (preferred unit liquidation preference of $210,576 and $204,443 at
December&nbsp;31, 2020 and 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,173</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,147</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,607</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(144,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(141,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity attributable to unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,241</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,982</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,919</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,635</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total members&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,160</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,617</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and members&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494,466</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472,407</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="findex180330_9"></A>Consolidated statements of changes in members&#146; equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Years ended December&nbsp;31, 2020, 2019 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Members&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income&nbsp;(Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Noncontrolling<BR>Interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Members&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,114</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165,457</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profits interest compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit plan adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,153</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(139,821</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,267</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profits interest forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,188</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,188</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,851</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,298</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit plan adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,147</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(141,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,635</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,617</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profits interest forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit plan adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,126</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,126</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,173</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,607</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(144,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,919</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,160</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="findex180330_10"></A>Consolidated statements of cash flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Years ended December&nbsp;31, 2020, 2019 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,298</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,650</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,113</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash provided by operating activities from continuing
operations:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,643</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,316</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,238</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss on impairment of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of contingent consideration in excess of amount established in purchase accounting</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Provision for expected credit losses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,242</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,538</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Profits interest plan, liability-classified and other equity awards compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,103</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,844</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,325</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of Equity Participation Rights unit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of interest rate swap</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,599</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization of debt discount and capitalized loan fees, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss on debt retirement and modification</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,352</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,256</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,510</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,646</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,148</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other current assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash provided by operating activities from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,199</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,545</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,310</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in operating activities of discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,799</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,713</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,187</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Investment and acquisition of distribution rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisition of VIE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in investing activities from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash provided by (used in) investing activities from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Borrowing on revolver</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment on revolver</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the issuance of long-term debt, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,134</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments on long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(199,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Distribution to members</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,319</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,746</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,670</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,520</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,774</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,104</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,839</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,520</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,774</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,577</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,486</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,450</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,273</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash investing and financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued liabilities for distribution rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Debt conversion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable for purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued member distribution</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="findex180330_11"></A>Notes to consolidated financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except unit, share, per unit and per share data) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and basis of presentation of financial information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus LLC and its subsidiaries (the
Company, we, us or our), is a limited liability company formed under the laws of the state of Delaware on November&nbsp;23, 2011 and operates as a partnership. The Company commenced operations in May 2012 in Durham, North Carolina, USA, which is its
headquarters. Bioventus is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately 700&nbsp;employees. The Company is focused on developing and commercializing clinically
differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#146;s natural healing processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus Inc. was
formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of the Company. Bioventus Inc. acquired, by merger, ten entities that were members of
the Company (Former LLC Owners) and upon consummation of the merger, owned 31,838,589 Common LLC Interests (as defined below). On February&nbsp;16, 2021, Bioventus Inc. (New LLC Owner) closed an IPO of 9,200,000 shares of Class&nbsp;A common stock
at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#146; over-allotment option. The New LLC Owner received $111,228 in proceeds, net of underwriting discounts and commissions which was
used to make a capital contribution to the Company in exchange for 9,200,000 newly-issued membership interests (Common LLC Interests) from the Company at a price per interest equal to the IPO price of $13.00. Subsequent to the IPO and related
transactions that occurred in connection with the IPO (Transactions), the New LLC Owner is the sole managing member of the Company. Following the completion of the IPO and Transactions, the New LLC Owner owns 72.2% of the Company. The New LLC Owner
has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, subsequent to the IPO, the New LLC Owner will consolidate the financial results of the Company and will report a non-controlling
interest representing the interests owned by the only member of BV LLC that remained a member (Continuing LLC Owner). Refer to <I>Note 17. Subsequent Events</I> for further details regarding the IPO and related transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interim periods </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reports quarterly interim
periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January&nbsp;1 and ends on December&nbsp;31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth
quarter, which ends on December&nbsp;31. The 13-week quarterly periods ended on March&nbsp;28,&nbsp;June&nbsp;27 and September&nbsp;26 for the year ended December&nbsp;31, 2020. As a result, the fourth and first quarters may vary in length depending
on the calendar year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principles of consolidation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.
GAAP). The consolidated financial statements include the Company, its subsidiaries and investments in which the Company has control. Amounts pertaining to the non-controlling ownership interests held by third parties in the operating results and
financial position of the Company&#146;s controlled subsidiaries are reported as non-controlling interests. All intercompany balances and transactions have been eliminated in consolidation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reclassifications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain prior period amounts have been reclassified to conform to the current period presentation. These changes had no effect on previously reported total
revenues, net income (loss), other comprehensive income (loss), members&#146; equity or cash flows. Unless otherwise noted, all financial information in the consolidated financial statement footnotes reflect the Company&#146;s results from
continuing operations. Discontinued operations are discussed further in <I>Note 16. Discontinued operations</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company identifies a business as an operating segment if: (i)&nbsp;it engages in business activities from which it may earn revenues and incur expenses;
(ii)&nbsp;its operating results are regularly reviewed by the Chief Operating Decision Maker (CODM), to make decisions about resources to be allocated to the segment and assess its performance; and (iii)&nbsp;it has available discrete financial
information. The Company&#146;s CODM is its Chief Executive Officer. The CODM reviews financial information at the operating segment level to allocate resources and to assess the operating results and financial performance for each operating
segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s two reportable segments are U.S. and International. U.S. and International products are primarily sold to physicians spanning
the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery, as well as directly to their patients. Refer to <I>Note 14. Net sales</I>
and <I>Note 15. Segments</I> for further information regarding our business segments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in accordance with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management
evaluates these estimates, including those related to contractual allowances and sales incentives, allowances for doubtful accounts, inventory reserves, goodwill and intangible assets impairment, useful lives of long lived assets, noncontrolling
interest, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to
be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COVID-19 pandemic impact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the COVID-19
pandemic spread around the world and in the U.S. and, more recently, new variants of the virus have emerged, some of which have shown to be more contagious. The COVID-19 pandemic has had widespread, rapidly evolving and unpredictable impacts on
global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social
distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of business, work from home, supply chain logistical changes and other measures, which have caused global business disruptions
and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted due to the decrease in patient visits and elective
procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended &#147;shelter-in-place&#148; orders or advisories, facility closures or
other reasons related to the pandemic. Furthermore, the long-term impact of COVID-19 on our business will depend on many factors, including, but not limited to, the duration and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability and effectiveness of vaccines to combat COVID-19, the impact on economic activity from the
pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. For example, there has been a decrease in patient visits to hospitals due to
risk and fear of exposure to COVID-19, as well as decreases in, or temporary moratoriums on, elective procedures, which may be re-imposed in the future. In addition to lower sales, we have experienced decreased costs as a result of the pandemic
including declines in travel and lower compensation related expenses. We have also implemented other various cost reduction initiatives and measures to safeguard liquidity. As of the date of issuance of these consolidated financial statements, the
extent to which COVID-19 could materially impact the Company&#146;s financial conditions, liquidity or results of operations is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent
COVID-19 disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize new developed or acquired products
or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at providing emergency
assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits,
deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. The CARES Act allowed the Company to defer $1,889 in employer
social security payroll tax payments from May 2020 through December&nbsp;31, 2020. A total of 50% is deferred until December&nbsp;31, 2021 and has been recorded in accrued liabilities, with the remaining balance deferred until December&nbsp;31, 2022
which has been recorded in other long-term liabilities both on the consolidated balance sheet. Refer to <I>Note 10. Income Taxes</I> for further information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $1,247 Provider Relief
Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from
COVID-19. A second Provider Relief Fund Payment totaling $2,854 was received in July 2020. The payments were recorded as other income on the consolidated statement of operations and comprehensive income (loss) for the year ended December&nbsp;31,
2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of significant accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent accounting pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected
to comply with non-accelerated public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are specific to non-accelerated public company filers, which
are generally earlier than when emerging growth companies are required to adopt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting Pronouncements Recently Adopted </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FASB issued Accounting Standards Update 2016-13, Financial Instruments-Credit Losses (ASU 2016-13), in June 2016 that significantly changes accounting for
credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized
cost and replaces the incurred loss impairment methodology in prior GAAP with a methodology that considers a broad range of information for the estimation of credit losses. The Company adopted ASU 2016-13 on January&nbsp;1, 2020 prospectively and
the adoption did not have a material impact on the Company&#146;s consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued Accounting Standards Update 2018-15, Intangibles-Goodwill and
Other-Internal-Use Software (ASU 2018-15), addressing a customer&#146;s accounting for implementation costs incurred in a cloud-computing arrangement (CCA) that is considered a service contract. Under ASU 2018-15, implementation costs for a CCA
should be evaluated for capitalization using the same approach as implementation costs associated with internal-use software. The capitalized implementation costs should be expensed over the term of the hosting arrangement, which includes any
reasonably certain renewal periods. Capitalized implementation costs should be assessed for impairment like long-lived assets. The Company adopted ASU 2018-15 on January&nbsp;1, 2020 prospectively and it had no material impact on the Company&#146;s
consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (ASU 2018-13), modifying
the disclosure requirements on fair value measurements and eliminates the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and
the valuation processes for Level 3 fair value measurements. ASU 2018-13 modifies certain disclosures related to investments measured at net asset value and clarifies that companies are to disclose uncertainties in measurements as of the reporting
date. ASU 2018-13 requires additional disclosure related to changes in unrealized gains and losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements as well as the range and weighted average, or other
quantitative information that would be a more reasonable and rational method, of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 on January&nbsp;1, 2020 and it did not have a material
impact on the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>New Accounting Pronouncements Not Yet Adopted </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (ASU 2019-12), which amended the accounting for income taxes. ASU 2019-12
eliminates certain exceptions to the guidance for income taxes related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside
basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is
effective for annual and interim periods beginning after December&nbsp;15, 2020. Early adoption is permitted in interim or annual periods for which financial statements have not been made available for issuance. Entities that elect to early adopt
the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Certain amendments are to be applied prospectively while others are retrospective. The Company adopted ASU
2019-12 on January&nbsp;1, 2021 and the Company has assessed it will not have a material impact on its consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Variable
Interest Entity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing
whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of entity, the value of the licensed assets to the entity, the value of the entity&#146;s total assets
and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that variable interest entity (VIE), based on a number of
factors, including: (i)&nbsp;which party has the power to direct the activities that most significantly affect the VIE&#146;s economic performance, (ii)&nbsp;the parties&#146; contractual rights and responsibilities pursuant to the collaboration
agreement, and (iii)&nbsp;which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of
the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statement of the VIE into the Company&#146;s consolidated financial statements. On a quarterly basis, the Company evaluates whether
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the
period the determination is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities recorded as a result of consolidating financial results of the VIE into the Company&#146;s
consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company&#146;s general assets or liabilities for which creditors have recourse to the Company&#146;s general assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Noncontrolling Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records
noncontrolling interest related to the consolidated VIEs on its consolidated balance sheet. The Company records loss attributable to noncontrolling interest on its consolidated statements of operations, which reflects the VIE&#146;s net loss for the
reporting period, adjusted for changes in the noncontrolling interest holders claim to net assets, including contingent milestone and royalty payments, which are evaluated each reporting period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deconsolidation and discontinued operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the
occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the
subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i)&nbsp;the aggregate of (a)&nbsp;the fair value of any consideration received, (b)&nbsp;the fair value
of any retained noncontrolling investment in the former subsidiary and (c)&nbsp;the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii)&nbsp;the carrying amount of the former subsidiary&#146;s assets and
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial
statements on the deconsolidation date. This assessment is based on if the deconsolidation represents a strategic shift that has or will have a major effect on the Company&#146;s operations or financial results. If the Company determines that a
deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one-year period following such date, it will present the former subsidiary as a discontinued operation for all periods
presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of foreign currency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets
and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at rates of exchange in effect at the close of their month end. Equity accounts are translated at their historical rates.
Revenues and expenses are translated at the exchange rate on the transaction date. Translation gains and losses are accumulated within accumulated other comprehensive income (loss) as a separate component of members&#146; equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign currency transaction gains and losses are included in other expense on the consolidated statements of operations and comprehensive income (loss).
There were gains of $117 for the year ended December&nbsp;31, 2020, nominal losses for the year ended December&nbsp;31, 2019, and losses of $234 for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive income
(loss) consists of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S.&nbsp;GAAP are recorded as an element of members&#146; equity and are excluded
from net income (loss). The Company&#146;s other comprehensive income (loss) consists of a defined benefit plan adjustment and foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents consist of highly liquid investments with an original maturity of three months or less at date of purchase. The Company&#146;s cash is
primarily held in financial institutions in the United States and the Netherlands. The Company maintains cash balances in the United States in excess of the federally insured limits. The Company did not have restricted cash as of December&nbsp;31,
2020 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Derivatives </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses
derivative instruments to manage exposures to interest rates. Derivatives are recorded on the balance sheet at fair value at each balance sheet date and the Company does not designate whether the derivative instrument is an effective hedge. Changes
in the fair values of derivative instruments are recognized in the consolidated statements of operations and comprehensive income (loss). The Company has entered, and may in the future enter, into derivative contracts related to its debt. Refer to
<I>Note 5. Financial instruments</I> for further details regarding the Company&#146;s derivatives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair value </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records certain assets and liabilities at fair value. Refer to <I>Note 7. Fair value measurements</I> for details regarding assets and liabilities
measured at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market
participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of
unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three
levels of inputs used to measure fair value are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2&#151;Observable inputs other than quoted prices included within Level&nbsp;1, such as quoted prices
for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market data. This includes certain
pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue
recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale of Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company derives
revenue primarily from the sale of its (i)&nbsp;osteoarthritic, or OA, joint pain treatment and joint preservation products, which are hyaluronic acid, or HA, viscosupplementation therapies, (ii)&nbsp;Bone Graft Substitutes (BGS) products and
(iii)&nbsp;a Minimally Invasive Fracture Treatment product. The Company sells product directly to healthcare institutions, patients, distributors and dealers. The Company also enters arrangements with pharmacy and health benefit managers that
provide for negotiated rebates, chargebacks and discounts with respect to the purchase of the Company&#146;s products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue at
a point in time upon transfer of control of the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. The Company excludes taxes collected from customers and remitted to
governmental authorities from revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates
of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements, and certain distribution and administration fees offered in our customer contracts and other indirect
customer contracts relating to the sale of our products. The Company establishes reserves for the estimated variable consideration based on the amounts earned or eligible to be claimed on the related sales. Where appropriate, these estimates take
into consideration a range of possible outcomes, which are probability-weighted for relevant factors such as the Company&#146;s historical experience, current contractual requirements, specific known market events and trends, industry data and
forecasted customer buying and payment patterns. The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not
occur in a future period. The Company regularly reviews all reserves and updates them at the end of each reporting period as needed. There were no adjustments arising from the change in estimates of variable consideration that were significant for
the years ended December&nbsp;31, 2020, 2019 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OA Joint Pain Treatment and Joint Preservation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from customers, such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is
transferred to the customer, typically upon shipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributor chargebacks </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has preexisting contracts with established rates with many of the distributors&#146; customers who require the distributors to sell our product at
their established rate. The Company offers chargebacks to distributors who supply these customers with our products. The Company reduces revenue at the time of sale for the estimated future chargebacks. The Company records chargeback reserves as a
reduction of accounts receivable and base the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Discounts and gross-to-net deductions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company offers
retrospective discounts and gross-to-net deductions linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. The Company reduces revenue and records the reserve as a reduction to accounts
receivable for the estimated discount and rebate at the expected amount the customer will earn, based on historical buying trends and forecasted purchases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bone Graft Substitute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most of the Company&#146;s
BGS product sales are through consignment inventory with hospitals, where ownership remains with the Company until the hospital or ambulatory surgical center (ASC) performs a surgery and consumes the consigned inventory. The Company recognizes
revenue when the surgery has been performed. Control of the product is not transferred until the customer consumes it, as the Company is able to require the return or transfer of the product to a third-party. An unconditional obligation to pay for
the product does not exist until the customer consumes it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Minimally Invasive Fracture Treatment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when the Company
transfers control to the patient, typically when the patient has accepted the product or upon delivery. The Company records this revenue at the contracted rate, net of contractual allowances and estimated third-party payer settlements at the time of
sale, or an estimated price based on historical data and other available information for non-contracted payers. The Company estimates the contractual allowances using the portfolio approach and based on probability weighting historical data and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collections history within those portfolios. The portfolios determined using the portfolio approach consist of the following customer groups: government payers, commercial payers, and patients.
The Company recognizes revenue from patients (self-pay and insured patients with coinsurance and deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent
differences between amounts billed and the amounts the Company expects to collect from patients, which considers historical collection experience and current market conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are
included in the determination of the estimated transaction price using the expected amount method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement
activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved.
Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. The Company is not aware of
any claims, disputes or unsettled matters with any payer that would materially affect revenues for which the Company has not adequately provided for or disclosed in the accompanying consolidated financial statements. Refer to <I>Note 12. Commitments
and contingencies</I> for further information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product returns </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates the amount of returns and reduces revenue in the period the related product revenue is recognized. The Company records a liability for
expected returns based on probability-weighted historical data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts receivable, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for doubtful accounts. The
Company maintains an estimated allowance for doubtful accounts to provide for receivables the Company does not expect to collect. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age
of outstanding receivables and other information as applicable. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with
payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing
component is not deemed significant to the contract. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract assets consist of unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed.
Contract assets totaling $81 and $261 as of December&nbsp;31, 2020 and 2019, are included in prepaid and other current assets on the consolidated balance sheets, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract liabilities consist
of customer advance payments and deferred revenue. Occasionally for certain international customers, the Company requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract liabilities were
nominal as of December&nbsp;31, 2020 and 2019 and are included in accrued liabilities on the consolidated balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shipping and handling
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as
well as other distribution costs are included in cost of sales. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and these are included in cost of
sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies
the practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less. These incremental costs
include the Company&#146;s sales incentive programs for the internal sales force and third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense
on the consolidated statements of operations and comprehensive income (loss). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company values its inventory at the lower of cost or net realizable value and adjusts for the value of inventory that is estimated to be excess, obsolete
or otherwise unmarketable. Cost is determined using the first-in, first-out (FIFO) method. Elements of cost in inventory include raw materials, direct labor, manufacturing overhead and inbound freight. The Company records allowances for excess and
obsolete inventory based on historical and estimated future demand and market conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting for acquisitions requires the Company to recognize separately from goodwill assets acquired and the liabilities assumed at their acquisition date
fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While best estimates and assumptions are
used to accurately value assets acquired and liabilities assumed at the acquisition date, as well as contingent consideration where applicable, estimates are inherently uncertain and subject to refinement. During the measurement period, which may be
up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values
of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations and comprehensive income (loss). Subsequent changes in the estimated fair value of contingent
consideration are recognized in earnings in the period of change. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-lived assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are
stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense are recognized using the straight-line method over the estimated useful life of each asset, or the shorter of the lease term or useful life if
related to leasehold improvements. The useful lives in years are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Machinery and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and intangible assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finite-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated
useful lives in years are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Useful&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developed technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill is not amortized but is evaluated for impairment annually or more frequently if events or changes in circumstances
indicate that goodwill might be impaired. The Company reviews goodwill for impairment by applying a quantitative impairment analysis where the fair value of the reporting unit is compared with the carrying value, including goodwill. The Company
determines the fair value of each reporting unit based on an income approach. The value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a
sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company performs its annual goodwill impairment test on October&nbsp;31st. If the fair value of the reporting unit is less than its
carrying value, the Company will recognize the difference as an impairment loss, which is limited to the amount of goodwill allocated to the reporting units. There were no goodwill impairment charges for the years ended December&nbsp;31, 2020, 2019
and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Software development costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company capitalizes internal and external costs incurred to develop internal-use software during the application development stage for software design, configuration, coding and testing upon placing the asset in service and then amortizes these
costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. The Company does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary project phase costs,
training costs or data conversion costs. Capitalized software costs totaled $17,653 and $14,119 as of December&nbsp;31, 2020 and 2019 and the related accumulated amortization totaled $13,264 and $12,184, respectively. Amortization expense was
$1,184, $1,138 and $1,204 for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying values of property, equipment, intangible
assets as well as other long-lived and indefinite lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable
the Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. If quoted market prices are not available, the Company estimates fair value using an undiscounted value of
estimated future cash flows. During 2018, the Company determined that it would no longer sell a specific BGS product and as a result, an intangible asset related to this product was fully written off and the Company recognized impairment charges of
$489 for the year ended December&nbsp;31, 2018, which is included in the consolidated statements of operations and comprehensive income (loss). Upon retirement or sale of property and equipment, the cost of assets disposed of and the related
accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is included in income from operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were
no events, facts or circumstances for the years ended December&nbsp;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#146;s property, equipment, intangible or other long-lived assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquired in-process research and development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of in-process research and development (IPR&amp;D) assets acquired in a business combination are capitalized and accounted for as
indefinite-lived intangible assets and are not amortized until development is completed and the product is available for sale. Once the product is available for sale, the asset is transferred to developed technology and amortized over its estimated
useful life. Impairment tests for IPR&amp;D assets occur at least annually in December, or more frequently if events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than the
carrying amount, an impairment loss is recognized for the difference. There were no events, facts or circumstances for the years ended December&nbsp;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#146;s IPR&amp;D.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Offering Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred offering costs,
consisting of legal, accounting, filing and other fees related to the initial public offering, are capitalized. The deferred offering costs will be offset against proceeds from the initial public offering upon the effectiveness of the initial public
offering. In the event the initial public offering is terminated, all capitalized deferred offering costs would be expensed. Deferred offering costs capitalized totaled $2,187 as of December&nbsp;31, 2020 and there were there were no deferred
offering costs capitalized as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support
customer receivables. Credit losses are provided for through allowances and have historically been materially within management&#146;s estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&nbsp;31 as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplier A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplier B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplier C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts payable to these significant suppliers at December&nbsp;31 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplier A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,983</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,586</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplier B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplier C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain products provide the Company with a significant percentage of total sales for the years ended December&nbsp;31 as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restructuring costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has restructured portions of its operations and future restructuring activities are possible. Identifying and calculating the cost to exit these
operations requires certain assumptions to be made, the most significant of which are anticipated future liabilities. Although estimates have been reasonably accurate in the past, significant judgment is required, and these estimates and assumptions
may change as additional information becomes available and facts or circumstances change. Restructuring costs are recorded at estimated fair value. Key assumptions in determining the restructuring costs include negotiated terms and payments to
terminate contractual obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Profits interest compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures profits interest compensation cost at the grant date based on the fair value of the award and recognizes this cost as compensation expense
over the required or estimated service period for awards expected to vest. Certain awards are liability-classified, which require they be remeasured at each reporting date. Compensation expense is included in Selling, general and administrative
expense and Research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employees who were granted the awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advertising costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Advertising costs include costs
incurred to promote the Company&#146;s business and are expensed as incurred. Advertising costs were $2,769, $2,351 and $2,916 for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and development expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expense consist primarily of employee compensation and related expenses as well as contract research organization services. Internal research and development costs are expensed as incurred. Research and development costs incurred by
third parties are expensed as the contracted work is performed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaborative agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances
created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and we account for these alliances as a collaborative arrangement by reporting costs incurred
from transactions within research and development expense in our consolidated statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies when a loss is known or considered
probable and the amount may be reasonably estimated. If the reasonable estimate of known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is
reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Legal fees expected to be incurred in connection with a loss contingency are not included in the estimated loss
contingency. The Company accrues for any legal costs as they are incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their
income tax returns. The Company has been required to make tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributions to its members in an amount equal to 40% of the members&#146; taxable income attributable to their ownership. The tax rate applied for purposes of this distribution may be changed
only by approval of the Company&#146;s Board of Managers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain wholly owned subsidiaries of the Company are taxable entities for U.S. or foreign tax
purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the
same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes a tax benefit from any uncertain tax positions only if they are more likely than not to be sustained upon examination based on the
technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon
ultimate settlement of the position. Components of the reserve, if relevant, are classified as a current or noncurrent liability in the consolidated balance sheet based on when the Company expects each of the items to be settled. Interest and
penalties related to unrecognized tax benefits are recognized as a component of income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net income (loss) per common unit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic income (loss) per common unit is determined by dividing the net income (loss) allocable to common unit holders by the weighted average number of common
units outstanding during the periods presented. Diluted loss per common unit is computed by dividing the net income (loss) allocable to common unit holders on an &#147;if converted&#148; basis by the weighted average number of actual common units
outstanding and, when dilutive, the unit equivalents that would arise from the assumed conversion of convertible instruments, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subsequent
Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has considered the effects of subsequent events through March&nbsp;26, 2021, the date the Company&#146;s consolidated financial
statements were issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Balance sheet information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounts receivable, net </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable, net of
allowances, consisted of the following as of December&nbsp;31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,273</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,274</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Allowance for credit losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,283</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,128</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to
make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic
conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific
identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#146;s customers or its collection
experience deteriorates. The Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#146;s reserves have been adequate to cover credit losses.
The Company&#146;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions,
disruption associated with the COVID-19 pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit
losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all other historical, current and future information that is reasonably available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in credit losses were as follows for the years ended December&nbsp;31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for credit losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write-offs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,787</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,949</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recoveries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inventory </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory
consisted of the following as of December&nbsp;31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,665</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,349</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,323</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,509</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,988</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,858</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excess and obsolete reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,120</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,326</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in excess and obsolete reserves for inventory were as follows for the years ended December&nbsp;31: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write-offs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following as of December&nbsp;31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,547</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,854</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,126</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,918</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,474</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,451</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Machinery and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,234</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,138</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets not yet placed in service</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">819</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,200</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,731</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,879</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,489</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense was $2,106, $2,579 and $3,439 for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goodwill and intangible assets, net </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no
changes to goodwill during the years ended December&nbsp;31, 2020 and 2019. Following is a summary of goodwill by reportable segment: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>U.S.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>International</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Consolidated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020 and 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,040</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,760</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,800</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets consisted of the following as of December&nbsp;31: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,422</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,422</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,700</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,700</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,700</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,700</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,095</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developed technology and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,999</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,649</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total carrying amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">397,266</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396,566</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developed technology and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(206,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(179,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net before currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190,491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,057</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,159</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,650</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,510</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company filed a 510(k) in 2019 and began commercializing a next-generation surgical product in the third quarter of 2020.
As a result, $9,650 of IPR&amp;D was reclassified to developed technology and will be amortized over 10 years. On December&nbsp;22, 2020, the Company entered into an amended and restated distribution agreement with the sole supplier of the
Company&#146;s five injection OA product.&nbsp;This agreement provided non-exclusive U.S. market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution rights until December&nbsp;31, 2028. The amended and restated distribution agreement created a $1,000 distribution right that will be amortized over 8 years, which was capitalized as
an intangible asset and included in accrued liabilities on the consolidated balance sheets as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization expense related to
intangible assets was $27,565, $26,252 and $26,622 for the years ended December&nbsp;31, 2020, 2019 and 2018 of which $7,455, $6,416 and $7,766 are included in ending inventory at December&nbsp;31, 2020, 2019 and 2018, respectively. Estimated
amortization expense for the years ended December&nbsp;31, 2021 through 2025 is expected to be $28,262, $23,910, $22,297, $22,297 and $21,259, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accrued liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued liabilities consisted of the
following at December&nbsp;31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross-to-net deductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,656</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,622</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus and commission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,188</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserve for estimated overpayments from third-party payers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,790</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,801</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,875</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,231</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income and other taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,434</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,555</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,244</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,418</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,187</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,827</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Business combinations and investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>VIE </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2019, the Company purchased
285,714 shares of Harbor&#146;s Series C Preferred Stock or 3.1% of fully diluted shares for $1,000. The Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to be
commercialized by the Company and supplied by Harbor. As a result of these transactions, the Company determined that it had a variable interest in Harbor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the Harbor investment as a business combination using the acquisition method of accounting whereby the total purchase price was
allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The results of Harbor operations have been included in the accompanying consolidated financial statements subsequent to acquisition date.
The Company did not disclose post-acquisition or pro forma losses attributable to Harbor as they did not have a material effect on the Company&#146;s consolidated statements of operations and comprehensive income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the fair values of the assets acquired and liabilities assumed at the
acquisition date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,430</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property (10-year useful life)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,834</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of net assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,188</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bioventus purchase price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Harbor&#146;s noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,188</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020 two convertible promissory notes to Harbor shareholders totaling $500 were converted into 142,858 of
Harbor Series C Preferred Stock and warrants for 428,572 shares of the Harbor common stock exercisable at a price of $1.167 per share with a 5-year exercise period expiring March&nbsp;27, 2025. Promissory notes of $320 owed to a certain Harbor
shareholder were converted into 92,500 of Harbor Series C Preferred Stock at $3.50 per share in November 2020. On October&nbsp;5, 2020, the Company purchased an additional 285,714 shares of Harbor&#146;s Series C Preferred Stock for $1,000. The
Company continues to conclude that it is the primary beneficiary since it controls the significant activities of Harbor through the collaboration agreement. The noncontrolling interest related to Harbor was 91.2% as of December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Harbor intellectual property and IPR&amp;D was determined using the income approach through an excess earnings analysis, with projected
earnings discounted at a rate of 16.5%. The $1,445 of IPR&amp;D consists of research and development progress toward developing a product for orthopedic uses. The fair value of the noncontrolling interest was calculated as estimated fair value of
net assets acquired less the Company&#146;s purchase price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harbor assets that can only be used to settle Harbor obligations and Harbor liabilities for
which creditors do not have recourse to the general credit of the Company are as follows for the years ended December&nbsp;31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,127</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,635</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,122</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,863</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,599</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,004</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,395</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,029</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,940</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nearly all the liabilities assumed are payable to Harbor shareholders. As of December&nbsp;31, 2019, other current liabilities
primarily consisted of $1,845 in promissory notes to various Harbor shareholders and were scheduled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to mature on August&nbsp;31, 2020. These promissory notes were refinanced with additional borrowings in August 2020 and total $1,811 as of December&nbsp;31, 2020. The Harbor promissory notes
carry an 8% interest rate and are due on August&nbsp;31, 2021 with payments due monthly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Method </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investments in which the Company can exercise significance influence, but do not control, are recorded under the equity method of accounting and are included
in investments and other assets on the consolidated balance sheets. The Company&#146;s share of net earnings or losses is included in other (income) loss within the consolidated statements of operations and comprehensive income (loss) on a quarter
lag. The Company evaluates investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired. Impairment losses are recorded within earnings within the current period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2018, the Company purchased 337,397 shares of CartiHeal, a privately held entity, Series F Convertible Preferred Stock or 2.8% of fully
diluted shares for $2,500 in cash. The investment does not have a readily determinable fair value. On January&nbsp;22, 2020, the Company made an additional investment in CartiHeal, through a Simple Agreement for Future Equity (SAFE) by paying cash
of $152. On July&nbsp;15, 2020, CartiHeal completed an equity financing that the Company participated in and as a result, the Company received 12,825 in Series G-1 Preferred Shares and the SAFE terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on July&nbsp;15, 2020, the Company entered into an Option and Equity Purchase Agreement with CartiHeal. Under the terms of the agreement, the
Company purchased 1,014,267 shares of CartiHeal Series G Preferred Shares for $15,000. As a result, the Company&#146;s equity ownership in CartiHeal increased to 10.03% of its fully diluted shares. The CartiHeal investment, included capitalized
transaction costs of $1,427 and the $152 investment in January 2020, totaling $16,579 was recorded as an equity method investment beginning in July 2020, as the Company can exercise significant influence over CartiHeal but does not have control. It
is included within investments and other assets on the consolidated balance sheet. The CartiHeal investment carrying value is $18,689 as of December&nbsp;31, 2020, after recording net losses of $467 incurred during 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will, if needed, purchase an additional 338,089 of CartiHeal Series G Preferred Shares for $5,000, for the completion of a certain study. The
Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within 45 days following notice of the U.S. Food and Drug Administration (FDA) approval for a CartiHeal product currently in
development. In addition, upon the same FDA approval, CartiHeal may exercise an option within 45 days that requires the Company to complete the acquisition of the remaining equity in CartiHeal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Financial instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Credit Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2019, the Company entered into a $250,000 credit and guaranty agreement (2019 Credit Agreement) with Wells Fargo Bank National
Association (Wells), as well as a syndicate of other banks, or Lenders. The 2019 Credit Agreement is comprised of a $200,000 term loan (Term Loan), with an original issue discount (OID) of $666, and a $50,000 revolving facility (Revolver). All
obligations under the 2019 Credit Agreement are guaranteed by the Company and certain of the Company&#146;s wholly owned subsidiaries. Substantially all the assets of the Company collateralize the obligations under the 2019 Credit Agreement. The
Term Loan and Revolver mature on December&nbsp;6, 2024 (Maturity). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Term Loan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, $188,378 was outstanding on the Term Loan, net of original issue discount of $524 and deferred financing costs of $1,098. As of
December&nbsp;31, 2020, the Term Loan interest rate including a margin of 2.25% was 2.40%. Scheduled quarterly principal payments are as follows with the final payment of $125,000 at Maturity: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quarterly<BR>payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023 and 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may voluntarily prepay the Term Loan without premium or penalty upon prior notice. The Company may be required to
make additional principal payments on the Term Loan dependent upon the generation of certain cash flow events as defined in the 2019 Credit Agreement. These additional prepayments will be applied to the scheduled installments of principal in direct
order of maturity of the Base Rate (BR) portions of the Term Loan first and then the Eurodollar portions of the Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of
the Term Loan as of December&nbsp;31, 2020 was $189,534. The fair value of these obligations was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by
observable market data for similar obligations and are classified as Level 2 instruments within the fair value hierarchy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revolver </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Revolver is a five-year revolving credit facility of $50,000 which includes revolving and swingline loans as well as letters of credit (LOC) and, inclusive
of all, cannot exceed $50,000 at any one time. LOCs are available in an amount not to exceed $7,500. Revolving loans are due at the earlier of termination or Maturity. Swingline loans are available as BR interest rate option loans only and must be
outstanding for at least five days. Swingline loans are due the fifteenth or last day of a calendar month or Maturity whichever is earlier. The Company had increased its cash position by borrowing $49,000 on its Revolver as a precautionary measure
to preserve financial flexibility in view of the current uncertainty resulting from the COVID-19 pandemic during the first quarter of 2020. The $49,000 was repaid during the third quarter of 2020. As of December&nbsp;31, 2020, there was one nominal
LOC outstanding leaving approximately $49,912 available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Term Loan and Revolver permits the Company to elect either Eurodollar or BR interest rate options for the entire amount or certain portions of the loans
and have interest rates equal to a formula driven base interest rate plus a margin, tied to a leverage ratio. The leverage ratio is the ratio of debt to consolidated EBITDA as defined in the 2019 Credit Agreement, or Bank EBITDA, for four
consecutive quarters at the end of each period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BR portions of the Term Loan have interest due the last day of each calendar quarter-end. Eurodollar
portions of the Term Loan have one, two, three or six-month interest reset periods and interest is due on the last day of each three-month period or the last day of the loan term if less than three months. In advance of the last day of the current
Eurodollar Loan, the Company may select a new loan type so long as it does not extend beyond Maturity. The outstanding Term Loan has been a Eurodollar Loan since inception and is an auto-renewing one-month loan for setting an interest rate. In
addition, the Term Loan has an interest due date concurrent with any scheduled principal repayment or prepayment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest is calculated based on a
360-day year except for BR loans where the base interest is the Wells Prime Rate, in which case it is calculated based on a calendar-day year. The base interest rate for all BR loans is equal to the highest of (a)&nbsp;the Wells Prime Rate,
(b)&nbsp;the greater of the Federal Funds Effective Rate or Overnight Bank </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Funding Rate plus 1/2% and (c)&nbsp;the Eurodollar Rate for a USD deposit with a maturity of one month plus 1.0%. The base interest rate for all Eurodollar Loans is equal to the rate determined
for such day in accordance with the following formula with the Term Loan having a floor of 0%: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LIBOR </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1&#151;Eurocurrency Reserve Requirements </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pricing
grids are used to determine the loan margins based on the type of loan and the leverage ratio. The initial Eurodollar and BR loans had a margin of 2.25% and 1.25%, respectively. Loan margin is adjusted after the quarterly financial statements are
delivered to the lenders in accordance with the pricing grid below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Leverage ratio</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Eurodollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 2.50 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&lt; 0.75 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Revolver includes a commitment fee at 0.25% of the average daily amount of the available revolving commitment, assuming
any swingline loans outstanding are $0. There were no swingline loans outstanding as of December&nbsp;31, 2020. The fee is payable quarterly in arrears on the last day of the calendar quarters and at Maturity. The commitment fee rate is adjusted
after the quarterly financial statements are delivered to lenders based on the pricing grid below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Leverage ratio</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Commitment<BR>fee&nbsp;rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 2.50 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&lt; 0.75 to 1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fees are charged on all outstanding LOCs at an annual rate equal to the margin in effect on Eurodollar revolving loans. A
fronting fee of 0.125%&nbsp;per year on the undrawn and unexpired amount of each LOC is payable as well. The fees are payable quarterly in arrears on the last day of the calendar quarters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company&#146;s effective weighted average interest rate on all outstanding debt, including the commitment fee and interest
rate swap, was 2.72%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2019 Credit
Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of the Company&#146;s equity
interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of Company assets, as well as limitations on making changes to
the Company&#146;s business and organizational documents. Financial covenant requirements include a maximum debt leverage ratio as well as an interest coverage ratio not less than 3.00 to 1.00 as defined in the 2019 Credit Agreement. As of
December&nbsp;31, 2020, the Company complied with the financial covenants in the 2019 Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Lender may provide an additional Term or
Revolving Loan by executing and delivering notice specifying the terms, if doing so would not cause certain undesired events to occur as defined in the 2019 Credit Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or extend repayment beyond Maturity. The aggregate amount of all additional borrowings may not exceed the greater of $100,000 and the trailing four quarters Bank EBITDA without the consent of the
Lenders holding more than 50% of the total outstanding debt under the 2019 Credit Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During December 2019, the Company paid financing costs totaling $2,117 in order to refinance our prior term loan facility, that was repaid in full (Prior
Credit Agreement). The Company recorded $269 directly to selling, general and administrative expense and the remaining $1,848 was capitalized to the consolidated balance sheet. One lender participating in the Prior Credit Agreement became a lender
in the 2019 Credit Agreement and, as a result, $2,985 related to the Prior Credit Agreement was written off and recorded as interest expense. The $269 recorded in selling, general and administrative expense and the $2,985 recorded in interest
expense total the $3,252 of loss on debt retirement and modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total capitalized deferred fees for the Term Loan of $1,398 and Revolver of $653
are being amortized to interest expense on a straight-line basis over each of the respective lives, which approximates the effective interest method. The Company recorded $543, $711 and $745 in interest expense associated with these deferred costs
for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contractual maturities of long-term debt as of December&nbsp;31, 2020, were as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 15,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025 and thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Original issue discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,378</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,378</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its
long-term debt. On March&nbsp;26, 2020, the Company entered an interest rate swap agreement with one of its Lenders, which expires in December 2024. The interest rate swap was not designated as a hedge. The Company has no other active derivatives
and the swap is carried at fair value on the balance sheet. Refer to <I>Note&nbsp;7. Fair value measurements</I> for further details regarding the Company&#146;s interest rate swap. There were no outstanding derivatives as of December&nbsp;31, 2019.
Interest expense of $1,599 was recorded within the consolidated statements of operations and comprehensive income (loss) related to the change in fair value of the swap for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notional value of the swap totaled $100,000 or 52.6%, of the Term Loan outstanding principal at December&nbsp;31, 2020. The swap locked in the variable
portion of the interest rate on the $100,000 notional at 0.64%, with a stated fixed rate of 2.25%. The effective interest rate of the swap was 2.89% as of December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Members&#146; equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members&#146; equity consisted of the following at December&nbsp;31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,373</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,373</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profits interest and other equity awards (Refer to<I> Note 9. Equity-based
compensation</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,800</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,774</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,173</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,147</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The authorized number of common and preferred units were unlimited. On May&nbsp;4, 2012, 4,900,000 common units and 5,100,000
preferred units (2012 Preferred Units) were issued. During November 2015, the Company obtained a $50,000 capital contribution from its existing members and 1,490,000 in preferred units were issued (2015 Preferred Units). The common and preferred
members have stated rights and privileges, which include, but are not limited to: (1)&nbsp;voting and Company governance, (2)&nbsp;the transfer of membership interests and (3)&nbsp;dissolution and liquidation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each preferred unit carried a priority payout (Liquidation Preference), as defined in the Company&#146;s limited liability company agreement in effect at
December&nbsp;31, 2020. The initial Liquidation Preference for the 2012 and 2015 Preferred Units were $23.14 and $33.57, respectively. The preferred units accrued a distribution right at a rate of 3%&nbsp;per annum and was added annually to the
Liquidation Preference. On February&nbsp;11, 2021, the common and preferred units, including the preferred distribution rights, were converted into Common LLC Interests as discussed in <I>Note 1. Organization and basis of presentation of financial
information</I> and no further distribution rights accrued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Continuing LLC Owner owned the only Equity Participation Right Unit (EPR Unit). The EPR
Unit was junior to the common units and its only entitlement was 0.55% of available distributions arising from the closing of a sale of units representing a percentage interest of more than 66.66%, or the sale of all or substantially all of the
assets of the Company, provided such event constitutes a change of control (Distribution Event) as described in <I>Note 7. Fair value measurements.</I> In February 2021, the EPR Unit was redeemed in exchange for $3,327 in connection with the IPO at
which time the EPR ceased to exist and all entitlements ended. Refer to <I>Note 17. Subsequent events</I> for further details regarding the impact of the IPO on members&#146; equity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Fair value measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020,
there were no assets measured at fair value and there were no liabilities measured at fair value using Level&nbsp;1 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level
3 inputs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest rate swap</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management incentive plan and liability-classified awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,303</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,303</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,802</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Participation Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,101</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,101</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,457</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,006</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,404</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,259</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate swap </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not
certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#146;s consolidated balance sheets within accrued liabilities. Changes in
fair value are recognized as interest expense within the consolidated statements of operations and comprehensive income (loss). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management
incentive plan and liability-classified awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, the Company had operated two-equity-based compensation plans, the Management
Incentive Plan (MIP) and the Phantom Profits Interest Plan (Phantom Plan). The estimated fair value reflects assumptions made by management as of December&nbsp;31, 2020, including the impact of COVID-19 on significant unobservable assumptions, such
as the expected timing and volume of elective procedures and the impact of these procedures on future revenues which impact the equity value. However, the actual amount ultimately paid could be higher or lower than the fair value. The Company has
classified $11,054 as accrued equity-based compensation and $29,249 as accrued equity-based compensation, less current portion as of December&nbsp;31, 2020. Any changes in fair value are recorded as an operating expense and included within selling,
general administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant
unobservable inputs or Level 3: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,063</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial estimate (vesting)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,464</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,290</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,802</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial estimate (vesting)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,734</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,641</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,303</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2020, the sole MIP awardee exercised the right to force a cash settlement for 150,252 of the 333,330 vested units
resulting in a payment of $6,329. The remaining 183,078 units were settled for $10,802 in February 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EPR Unit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, after which the EPR ceased to exist and all entitlements ended, the Continuing LLC owners owned the only EPR Unit and its only entitlement
was 0.55% of available distributions arising from a Distribution Event. The estimated fair value reflects assumptions made by management as of December&nbsp;31, 2020, including potential payment scenarios discounted at rates reflective of the risks
associated with the expected future cash flows. The fair value of the EPR Unit was recorded in the Company&#146;s consolidated balance sheets as other long-term liabilities. The revaluation for the EPR liability is recognized in interest expense on
the consolidated statements of operations and comprehensive income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair
value using significant unobservable inputs Level 3: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,892</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,457</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,101</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of the Plans and EPR Unit using a Monte Carlo simulation. This fair value measurement is
based on significant inputs that are unobservable in the market, and thus represents a Level 3 measurement. The key assumptions used in applying the valuation model include the Company&#146;s equity value, the expected timing until a liquidity
event, applicable discount rates applied, and equity volatility. In addition, for the EPR Unit, the estimated accrued preferred distribution at the liquidity event date totaling $43,854 as of December&nbsp;31, 2020 as it is senior in order of
payment. Significant changes in these assumptions could result in a significantly higher or lower fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a range of key
assumptions used within the valuation of the awards as of December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Valuation technique</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Unobservable inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Range</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted Average</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option pricing approach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Time to liquidity event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Risk free rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.10%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">0.10%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Equality volatility</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">35.13%&nbsp;-&nbsp;101.25%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">50.0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Equity value</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">$1,065,000&nbsp;-&nbsp;$1,240,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">$1,145,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lack of marketability discount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.0%</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Restructuring costs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restructuring costs are not allocated to the Company&#146;s reportable segments as they are not part of the segment performance measures regularly reviewed by
management. These charges are included in restructuring expenses in the consolidated statement of operations and comprehensive income (loss). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
fourth quarter of 2020 and 2018, the Company adopted restructuring plans to improve the performance of International operations, principally through headcount reduction and closing offices in certain countries as the Company shifts to an indirect
distribution model in these countries. The plans were completed in 2020 and 2019, respectively, and the Company recorded total pre-tax charges of $563, $575 and $1,373 primarily related to severance for the years ended December&nbsp;31, 2020, 2019
and 2018, respectively. The Company&#146;s costs totaled $563 for the 2020 plan and $1,948 for the 2018 plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s restructuring charges and payments for all plans are comprised of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Employee<BR>severance&nbsp;and<BR>temporary<BR>labor&nbsp;costs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>charges</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">997</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,203</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments made</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments made</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Equity-based compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-based compensation plans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
operated two equity-based compensation plans, the MIP and the Phantom Plan (the Plans) prior to the IPO. The awards granted under both plans represented a non-managing, non-voting interest in the Company designed for grantees to share in the future
appreciation of the value of the Company. Awards granted under the MIP Plan and the 2015 Phantom Units are liability-classified and the 2012 Phantom Units are equity-classified. On February&nbsp;11, 2021, in conjunction with the IPO, the Plans were
terminated and there were no further awards, under the Plans. As a result, the New LLC Owner assumed the obligations of the Company&#146;s Phantom Plan awards on February&nbsp;10, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The awards granted under the MIP fully vested at December&nbsp;2, 2017. There were no MIP awards granted for the years ended December&nbsp;31, 2020, 2019 and
2018. In June 2020, the sole MIP awardee exercised the right to force a cash settlement for 150,252 of the 333,330 vested units resulting in a payment of $6,329. As of December&nbsp;31, 2020 and 2019, respectively, there were 183,078 and 333,330
vested awards outstanding both with a grant date fair value of $4.89. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Profits interest compensation of $10,103, $10,844 and $14,325 for all plans, was
recognized for the years ended December&nbsp;31, 2020, 2019 and 2018 respectively. The expense is included in selling, general and administrative expense and research and development expense on the consolidated statement of operations and
comprehensive income (loss) based upon the classification of the employee. As of December&nbsp;31, 2020, there was approximately $9,741 of unrecognized compensation expense to be recognized over a weighted-average period of 1.3 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the award activity of the Phantom Plan for the year ended December&nbsp;31, 2020 is as follows (number of awards in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012 Phantom Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015 Phantom Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B></B><B><I><U>(awards in thousands)</U></I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;average<BR><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;average<BR><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.72</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.29</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Converted to cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.45</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.98</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.72</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,422</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.41</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Awards vested at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.72</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.15</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no 2012 Phantom Unit awards granted in 2019. The weighted average grant date fair value per Other
Phantom Unit awards granted in the year ended December&nbsp;31, 2019 was $15.31. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012 Phantom Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015 Phantom Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B></B><B><I><U>(awards in thousands)</U></I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;average<BR><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;average<BR><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvested at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.01</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">667</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.71</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested during 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.01</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.81</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvested at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.62</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total fair value of 2012 Phantom Unit awards vested in the year ended December&nbsp;31, 2020 was nominal. The total fair
value of Other Phantom Unit awards vested in the year ended December&nbsp;31, 2020 was $4,703. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Defined contribution plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has various defined contribution plans or plans that share profit which are offered in Canada, Germany, the Netherlands and the United Kingdom.
These plans are required by local laws or regulations in some cases. Contributions are primarily discretionary, except in some countries where contributions are contractually required. These plans cover substantially all eligible employees in the
countries where the plans are offered either voluntarily or statutorily. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the U.S., the Company provides a 401(k) defined contribution plan (U.S. Plan)
that covers substantially all U.S. employees that meet minimum age requirements. The Company matches 50% of the employees&#146; contribution up to 6% of the employees&#146; wages. The Company also contributes 4.5% of the employees&#146; wages to the
U.S. Plan. The 4.5% Company contribution was suspended in May 2020 due to the COVID-19 crisis and reinstated in late December 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended
December&nbsp;31, 2020, 2019 and 2018, Company contributions totaled $3,379, $5,401 and $5,462 respectively, for all global plans. The expense is included in cost of sales, selling, general and administrative expense and research and development
expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income taxes
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of net income from continuing operations before taxes for the years ended December&nbsp;31 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxable subsidiaries:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,679</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,925</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,967</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,646</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,532</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other domestic subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,221</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,043</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,575</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,914</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,107</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">815</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in tax rates - deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,576</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,664</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The differences between the effective income tax rate and the federal statutory income tax rates for the years ended
December&nbsp;31 by taxable and other subsidiaries are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. statutory federal corporate income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LLC flow-through structure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State and local income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.5</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision to return adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s effective tax rate differs from statutory rates primarily due to Bioventus LLC&#146;s pass-through
structure for U.S. income tax purposes while being treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. In addition, certain states assess income taxes on pass-through structures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the
year in which the differences are expected to reverse. The components of the deferred taxes were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,874</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,530</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credit carryforwards and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,570</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,920</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,577</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,497</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired intangible</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,939</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,371</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,362</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,874</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses the need for a valuation allowance against our deferred tax assets. A valuation allowance of $2,822, has
been applied to all of Harbor&#146;s deferred tax assets. The Company also has a valuation allowance of $171 representing the entire balance of deferred tax assets relating to our international operations. These valuation allowances were recorded as
the Company believes it is more-likely-than-not that it will receive future benefit. At December&nbsp;31, 2020, the Company had federal and state net operating loss carryforwards related to Harbor of $25,537 expiring at various dates from 2021
through 2037 and approximately $2,141 with no expiration date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its tax positions in accordance with the recognition and measurement provisions of
ASC&nbsp;740-10 (&#147;FIN 48&#148;) and in accordance with that guidance, has determined that a reserve for any significant uncertain tax positions is not needed as of December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section&nbsp;382 of the U.S.
Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, provides, in general, that if an &#147;ownership change&#148; occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be
available to offset taxable income in each taxable year after the ownership change only up to the &#147;Section&nbsp;382 Limitation&#148; for each year. The Company&#146;s ability to use its loss carryforwards will be limited in the event of an
ownership change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, Dutch income taxes were imposed on a negotiated percentage of sales. The Company has an
agreement with the Dutch taxing authorities where the Company&#146;s Netherlands subsidiary will incur but not have to pay income taxes in years when the subsidiary is operating at a loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minimal tax related interest and penalties were incurred for the years ended December&nbsp;31, 2020 and 2019. The Company is subject to audit by various
taxing jurisdictions for the years 2015 through 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Related-party transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made cash tax distributions of $19,886, $9,137 and $7,846 to its members in an amount equal to approximately 40% of the members&#146; estimated
taxable income for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively. At December&nbsp;31, 2020 and December&nbsp;31, 2019, there were tax distributions payable to tax authorities on the members&#146; behalf totaling $541 and $473,
respectively, and nominal tax distributions payable to the members. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Commitments and contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases its office facilities as
well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under finance leases. The remaining lease terms range from 3 months to 8 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease cost were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,610</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,529</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,998</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,887</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*Includes</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">variable lease cost and sublease income, which are immaterial. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental cash flow information and non-cash activity related to leases were as follow: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,567</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,343</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right-of-use assets obtained in exchange for operating lease obligations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,497</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,016</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current and noncurrent operating and finance lease liabilities are included in other current liabilities and
other long-term liabilities, respectively, on the consolidated balance sheet. Other balance sheet information related to leases are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities&#151;current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities&#151;noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining operating lease term in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate for operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maturities of lease liabilities as of December&nbsp;31, 2020 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,714</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,645</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,460</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,476</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,569</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,281</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,145</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,068</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OIG&#146;s Provider Self-Disclosure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company identified non-compliance with certain U.S. federal statutes and requirements governing the Medicare program in 2018 related to improper completion
of Certificate for Medical Necessity (CMN) forms and in November 2018 made a voluntary self-disclosure to the Office of Inspector General of the U.S. Department of Health and Human Services (OIG) pursuant to the OIG&#146;s Provider Self-Disclosure
Protocol related to this matter. After settlement discussions with the Office of the United States Attorney in the Middle District of North Carolina (USAO) and OIG, on January&nbsp;15, 2021, the Company reached a settlement agreement with the USAO
and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which the Company&#146;s sales representatives completed Section B of the CMN form. On February&nbsp;22, 2021, the Company finalized
all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with the previous agreement in principle and which included releases from associated False Claims Act liability and further Civil
Monetary Penalties that are customary in self-disclosures of this type and resolved the potential liability related to the Company&#146;s self-disclosure for $3,600, of which $2,400 had previously been paid. The remaining $1,200 net settlement
amount due under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&nbsp;31, 2020 and paid on February&nbsp;23, 2021. Refer to <I>Note 17. Subsequent events</I> for further details regarding the
resolution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reserve for estimated overpayments from all third-party payers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a reserve for reimbursement claims related to its Minimally Invasive Fracture Treatment product that may have been processed for payment
by the Company without adequate medical records support. The Company held a reserve of $2,790 and $6,801 at December&nbsp;31, 2020 and 2019, respectively for these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amounts. The Company refunded Medicare $1,519 and $7,458 during the years ended December&nbsp;31, 2020 and 2019, respectively, related to known and estimated overpayments for medical necessity
included in this reserve for periods through December&nbsp;31, 2019. Certain of these overpayments were identified as potential overpayments in the Company&#146;s OIG self-disclosure in November 2018. The Company&#146;s reserve was estimated using
extrapolation of an error rate from a statistical sample, which represents the Company&#146;s best estimate as of the date of the financial statements, but because of the uncertainty inherent in such estimates, the ultimate resolution may be
materially different. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product recall </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2020, we voluntarily recalled our ultrasound gel, an accessory to the Minimally Invasive Fracture Treatment product. We have incurred, and expect to incur in the future, costs associated with this recall. Based on the information that has
been received, we have estimated the probable loss related to this recall globally to be approximately $1,684. We have recorded reserves representing the probable loss within accrued liabilities on the consolidated balance sheet. The final outcome
of this recall is dependent on many factors that are difficult to predict. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2019, the Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to
be commercialized by the Company and supplied by Harbor. As part of the agreement a third-party license was assigned to us and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in
2023. The Company is obligated to pay up to $6,000 upon achieving certain milestones. Unless earlier terminated, the agreement will remain in effect until the earlier of 8 years or until the payment of certain milestones are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2019, the Company and Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development
agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF. The first phase has been completed. Additional fees for the subsequent phases will be determined as the development work
progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection OA product with the supplier of the Company&#146;s single injection OA
product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $10,021, $7,622 and $3,082 for the years ended
December&nbsp;31, 2020, 2019 and 2018 respectively, and are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of a supply agreement entered on February&nbsp;9, 2016 for the Company&#146;s three injection OA product, the Company is subject to annual minimum
purchase requirements for ten years. After the initial ten years, the agreement will automatically renew for an additional five years unless terminated by the Company or the seller in accordance with the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of a supply agreement for the Company&#146;s five injection OA product, that was amended and restated on December&nbsp;22, 2020, the Company is
subject to annual minimum purchase requirements for eight years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an exclusive license agreement for bioactive bone graft putty. The
Company is required to pay a royalty on all commercial sales revenue from the license products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These
royalties are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company causes LOCs to be issued to provide credit support for guarantees,
contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of December&nbsp;31, 2020 and
2019, the Company had one LOC outstanding for a nominal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently maintains insurance for risks associated with the operation of its
business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and
omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#147;claims made&#148; basis for expenses in excess of
$150 per member per year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental
proceedings and investigations that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local
governmental agencies in the U.S. and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#146;s standard practice is to cooperate with regulators and
investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#146;s complete control and may not be known for extended periods of time. Other than the matters discussed above, management of the Company, after
consultation with legal counsel, does not believe there are any unrecorded matters that will have a material adverse effect upon the Company&#146;s financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Net income (loss) per unit </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
presents the computation of basic and diluted net income (loss) per unit for the years ended December&nbsp;31 as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,113</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,666</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income from continuing operations attributable to unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,666</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated and unpaid preferred distributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income allocated to participating shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from continuing operations attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,156</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,650</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(659</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,988</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per unit attributable to common unit holders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.89</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common unit holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.89</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The computation of diluted earnings per unit for the years ended December&nbsp;31, 2020, 2019 and 2018 excludes the effect of
the 6,590 potential common units that would be issued upon the conversion of preferred units. The effect of these units would be antidilutive due to the impact of the accumulated and unpaid preferred distributions as well as the Company being in a
net loss position for the years ended December&nbsp;31, 2019 and 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Net Sales </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the location from which the sale originated. The
following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) for the years ended December&nbsp;31 as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Primary geographic markets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293,697</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305,072</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">282,895</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,464</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,069</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,282</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,141</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319,177</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Vertical:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OA joint pain treatment and joint preservation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171,178</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,082</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,576</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minimally invasive fracture treatment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,624</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,504</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,032</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bone graft substitutes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,359</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,555</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,569</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,141</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319,177</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Segments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Segment
information by asset is not disclosed as it is not reviewed by the CODM or used to allocate resources or to assess the operating results and financial performance. We believe EBITDA, adjusted for additional non-operational factors disclosed in the
table below, or Adjusted EBITDA, is a key measure for internal reporting. Adjusted EBITDA should not be considered in isolation or as a substitute for consolidated net income (loss) attributable to the Company, the most closely analogous U.S. GAAP
measure. Adjusted EBITDA is not defined in the same manner by all companies and may not be comparable to other similarly titled measures of other companies unless the definition is the same. The following table presents segment adjusted EBITDA
reconciled to income from continuing operations before income taxes for the years ended December&nbsp;31 as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment adjusted EBITDA from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,252</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,673</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,480</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,191</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,515</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,691</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COVID-19 benefits, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,123</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Succession and transition charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency impact</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity loss in unconsolidated investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-recurring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from continuing operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,914</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,689</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,107</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Discontinued operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, the Company, under the direction and authority of the Company&#146;s Board of Managers, committed to shut down the bone morphogenetic protein
(BMP) research and development program, which had been reported as its own segment in previous years. Substantially all operations, including project close </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
documentation, contract termination, vacating the facility and ultimately the termination of the employees, ceased by March 2019 and as a result the BMP research and development program met the
criteria for discontinued operations. The Company sold the remaining $172 held for sale asset and paid the remaining $400 accrued liability from the BMP research and development program during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the statement of operations and comprehensive income (loss) from discontinued operations for the years ended December&nbsp;31:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,773</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,127</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,638</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from discontinued operations, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,650</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Subsequent events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2021, the Company made a
convertible debt investment of $1,500 in a medical device company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recapitalization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2021, the following Transactions occurred. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company amended and restated its limited liability company agreement (New LLC Agreement) to, among other
things, (i)&nbsp;provide for the new single class of common membership interests in the Company as discussed in <I>Note 1. Organization and basis of presentation for financial information</I>; (ii)&nbsp;exchange all of the then existing membership
interests of the common and preferred unit holders (Original LLC Owners) for Common LLC Interests and (ii)&nbsp;appoint the New LLC Owner as the sole managing member of the Company. The amendment resulted in the Company&#146;s common and preferred
units, including the preferred distribution rights, being converted into 47,625,326 Common LLC Interests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The New LLC Owner amended and restated its certificate of incorporation to, among other things, (i)&nbsp;provide
for Class&nbsp;A common stock and Class B common stock, each share of which entitles its holders to one vote per share on all matters presented to the New LLC Owner&#146;s stockholders and (ii)&nbsp;issue 15,786,737 shares of Class B common stock to
the Continuing LLC Owner, on a one-to-one basis with the number of LLC Interests it owns. While the Class B common stock holds voting rights it holds no economic interest in the New LLC Owner. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The New LLC Owner acquired, by merger, the Former LLC Owners and upon consummation of the merger, owned
31,838,589 Common LLC Interests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The New LLC Owner closed an IPO of 9,200,000 shares of Class&nbsp;A common stock at a public offering price of
$13.00 per share. The New LLC Owner received $111,228 in proceeds, net of underwriting discounts and commissions, which was used to make a capital contribution to the Company in exchange for 9,200,000 Common LLC Interests of the Company at a price
per interest equal to the IPO price of $13.00. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Transactions, the New LLC Owner owns 41,038,589 Common LLC Interests
or 72.2% of the Company and the Continuing LLC Owner owns 15,786,737 or 27.8%. The New LLC Owner has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, the New LLC Owner will
consolidate the financial results of the Company and will report a non-controlling interest representing the interests owned by the Continuing LLC Owner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New LLC Agreement requires that the Company, at all times, maintain (i)&nbsp;a one-to-one ratio between
the number of shares of Class&nbsp;A common stock issued by the New LLC Owner and the number of Common LLC Interests owned by the New LLC Owner and (ii)&nbsp;a one-to-one ratio between the number of shares of Class B common stock owned by the
Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2021, the Company finalized all terms
related to a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which our sales representatives completed Section B of the CMN forms. The Company
entered into a formal settlement agreement with the USAO and OIG which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type and resolved the potential
liability related to the Company&#146;s self-disclosure in this matter for $3,600, of which $2,400 has already been paid through the Company&#146;s 2019 return of overpayments described previously. The remaining $1,200 net settlement amount due
under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&nbsp;31, 2020 and was paid on February&nbsp;23, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="findex180330_14"></A>Consolidated condensed statements of operations and comprehensive (loss) income </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Three and six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Amounts in thousands, except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,816</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,594</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,662</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales (including depreciation and amortization of $5,618, $5,292, $10,854 and $10,599
respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,503</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,668</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,725</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,077</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,313</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,349</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,869</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,585</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,050</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,533</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,736</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,809</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,836</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,596</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,783</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,742</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,852</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,813</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,777</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of variable interest entity assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,674</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,674</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,258</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,396</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,681</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,834</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,215</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,645</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,497</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">869</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,961</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,066</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,389</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,435</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,714</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,748</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,506</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,654</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,062</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to Bioventus Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,810</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,178</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,748</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,506</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss), net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,767</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,889</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,250</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,648</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,882</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income attributable to Bioventus Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,771</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,922</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share of Class&nbsp;A common stock, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of Class&nbsp;A common stock outstanding, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,805,347</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,802,840</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per share information for the six months ended July&nbsp;3, 2021 represents loss per share of Class&nbsp;A
common stock and weighted-average shares of Class&nbsp;A common stock outstanding from February&nbsp;16, 2021 through July&nbsp;3, 2021, the period following Bioventus Inc.&#146;s initial public offering and related transactions described in <I>Note
1. Organization</I> and <I>Note 7. Earnings per share </I>within the<I> Notes to the Unaudited Condensed Consolidated Financial Statements.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="findex180330_15"></A>Consolidated condensed balance sheets as of July&nbsp;3, 2021 (Unaudited) and December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Amounts in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,065</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,839</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,029</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,283</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,020</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,120</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,943</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,552</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,060</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,794</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,960</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,879</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,135</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,800</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257,848</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,650</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,669</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,961</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,483</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,382</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646,636</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494,466</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; and Members&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,881</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,422</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,246</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,187</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,054</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,220</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,964</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,926</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,186</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,589</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,084</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,378</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued equity-based compensation, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,249</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,410</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,362</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,421</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,171</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,728</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">427,272</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,306</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; and Members&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,160</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.001 par value 250,000,000 shares authorized, 41,062,652 shares
issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares
issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,199</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity attributable to Bioventus Inc. and members&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,557</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,160</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; and members&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,364</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,160</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; and members&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646,636</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494,466</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="findex180330_16"></A>Consolidated condensed statements of changes in stockholders&#146; and members&#146; equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Three and six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Amounts in thousands, except share data) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Unaudited)
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Three Months Ended July&nbsp;3, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT> -<BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>other</B><br><B>comprehensive</B><br><B>income</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-</B><br><B>controlling</B><br><B>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>and</B><br><B>members&#146;</B><br><B>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance at Balance at April&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,038,589</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,923</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,892</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,282</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,063</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Distribution of Continuing LLC Owner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,319</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deconsolidation of variable interest entity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,746</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,746</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Equity based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,355</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,498</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,853</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance at July&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,062,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,199</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,364</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Three Months Ended June&nbsp;27, 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Members&#146;</B><br><B>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at Balance at March&nbsp;28, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,590</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;27, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,791</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Six Months Ended July&nbsp;3, 2021 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A&nbsp;Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B&nbsp;Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Members&#146;</B><br><B>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT> -<BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>other</B><br><B>comprehensive</B><br><B>income</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-</B><br><B>controlling</B><br><B>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>and</B><br><B>members&#146;</B><br><B>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,160</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,160</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Refund from members</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other equity forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income prior to&nbsp;Organizational Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,977</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,977</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Translation adjustment prior to Organizational Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effect of Organizational Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(168,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,838,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,623</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Initial public offering, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,441</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,450</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,063</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Distribution to Continuing LLC Owner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net&nbsp;loss subsequent to&nbsp;Organizational Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deconsolidation of variable interest entity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,746</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,746</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity based compensation subsequent to Organizational Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,821</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,015</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,836</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Translation adjustment subsequent to Organizational Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at July&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,062,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,199</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,364</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six Months Ended June&nbsp;27, 2020 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Members&#146;</B><br><B>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,617</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profits interest forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,506</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;27, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,791</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="findex180330_17"></A>Consolidated condensed statements of cash flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Amounts in thousands) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,748</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,506</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash provided by (used in) operating activities from
continuing operations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,663</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,513</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Recovery) provision for expected credit losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-based compensation from 2021 Stock Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,797</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profits interest plan, liability-classified and other equity awards compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of interest rate swap</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,001</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Equity Participation Rights unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairments related to variable interest entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,043</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,631</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,913</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,917</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,587</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,011</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,511</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of Bioness, Inc, net of cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from investing activities - discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class&nbsp;A common stock sold in initial public offering, net of
underwriting discounts and offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,777</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class&nbsp;A and B common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowing on revolver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments on long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refunds (distributions) - members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">813</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,409</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,425</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,229</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,720</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,839</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,520</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,068</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,240</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash investing and financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued member distributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable for purchase of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bioventus Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="findex180330_18"></A>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Amounts in thousands, except unit, share, per unit and per share data) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other
related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The Company is headquartered in Durham, North Carolina. BV LLC, is a limited liability company formed under the laws of the state of Delaware on
November&nbsp;23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. BV LLC is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately 900
employees. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#146;s natural healing processes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2021, the
Company closed an IPO of 9,200,000 shares of Class&nbsp;A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#146; over-allotment option. The Company received $111,228 in
proceeds, net of underwriting discounts and commissions of $8,372, which was used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $13.00. The Company also incurred offering expenses
totaling $4,778 in addition to the underwriting discounts and commissions. Offering expenses of $1,327 were paid in 2020 and $3,451 were paid in 2021. Subsequent to the IPO and related transactions that occurred in connection with the IPO (the
Transactions), the Company is the sole managing member of BV LLC and owns 72.2% of BV LLC. The Company has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, the Company consolidates the
financial results of BV LLC and reports a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest representing the 27.8% interest not held by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IPO Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and BV LLC completed the
following Transactions in connection with the IPO. BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&nbsp;provide for a new single class of common membership interests in BV LLC (LLC Interests), (ii) exchange all
of the existing membership interests in BV LLC for new LLC Interests and (iii)&nbsp;appoint Bioventus Inc. as the sole managing member of BV LLC. The Company amended and restated its certificate of incorporation to, among other things, provide for
the (i)&nbsp;authorization of 250,000,000 shares of Class&nbsp;A common stock with a par value of $0.001 per share; (ii)&nbsp;authorization of 50,000,000 shares of Class&nbsp;B common stock with a par value of $0.001 per share;
(iii)&nbsp;authorization of 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company&#146;s Board of Directors (BOD) in one or more series; and (iv)&nbsp;establishment of a classified BOD, divided into
three classes, each of whose members will serve for staggered three-year terms. Holders of Class&nbsp;A / Class&nbsp;B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all
matters on which stockholders generally are entitled to vote. Holders of Class&nbsp;B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the
Company. Shares of Class&nbsp;B common stock may only be issued to the extent necessary to maintain the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of LLC Interests held by the
only member of BV LLC that remained a member following the Transactions (Continuing LLC Owner) and the number of shares of Class&nbsp;B common stock held by the Continuing LLC Owner. Shares of Class&nbsp;B common stock are transferable only together
with an equal number of LLC Interests. Shares of Class&nbsp;B common stock will be canceled on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis if the Company, at the election of a Continuing LLC
Owner, redeem or exchange LLC Interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s amended and restated certificate of incorporation and the Bioventus LLC Agreement
requires that the Company and BV LLC at all times maintain a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Class&nbsp;A common stock issued by the Company and the
number of LLC Interests owned by the Company, as well as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Class&nbsp;B common stock owned by the Continuing LLC Owner
and the number of LLC Interests owned by the Continuing LLC Owner. The Company acquired, by merger, ten entities that were members of BV LLC (Former LLC Owners), for which the Company issued 31,838,589 shares of Class&nbsp;A common stock as merger
consideration (Merger). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class&nbsp;B common stock. Upon consummation of the Merger, the Company canceled the 31,838,589 shares of
Class&nbsp;B common stock and recognized the 31,838,589 LLC Interests at carrying value, as the Merger is considered to be a recapitalization transaction. Following the Merger and IPO, as of August&nbsp;10, 2021, the Company holds 41,062,652 LLC
Interests, representing a 72.2% ownership interest in BV LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements for periods prior to the IPO and Transactions have been adjusted
to combine the previously separate entities for presentation purposes. Prior to the Transactions, Bioventus Inc. had no operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interim periods
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reports quarterly interim periods on a <FONT STYLE="white-space:nowrap">13-week</FONT> basis within a standard calendar year. Each annual
reporting period begins on January&nbsp;1 and ends on December 31. Each quarter ends on the Saturday closest to calendar <FONT STYLE="white-space:nowrap">quarter-end,</FONT> with the exception of the fourth quarter, which ends on December 31. The <FONT
STYLE="white-space:nowrap">13-week</FONT> quarterly periods for fiscal year 2021 end on April&nbsp;3, July&nbsp;3 and October 2. Comparable periods for 2020 ended on March&nbsp;28, June&nbsp;27 and September 26. The fourth and first quarters may
vary in length depending on the calendar year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim financial information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in
the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Rule <FONT STYLE="white-space:nowrap">10-01</FONT> of Regulation <FONT
STYLE="white-space:nowrap">S-X.</FONT> Pursuant to these rules and regulations they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal
recurring adjustments) considered necessary for a fair statement of the Company&#146;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that
may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#146;s 2020 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> The balance sheet at December&nbsp;31,
2020 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic spread around the world and in the United States. New variants of the virus have
emerged, some of which have shown to be more contagious. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business
practices. Federal and state governments implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public
gatherings, mandatory closure or reduced capacity of businesses, work from home, supply chain logistical changes and other measures, which caused global business disruptions and significant volatility in U.S. and international debt and equity
markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted by fluctuations in patient visits and elective procedures and any future temporary cessations of elective procedures and could
be further impacted by delays in payments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from customers, supply chain interruptions, extended <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;</FONT></FONT> orders or advisories, facility
closures or other reasons related to the pandemic. Furthermore, the long-term impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our business will depend on many factors, including, but not limited to, the duration and severity of the
pandemic, new and ongoing measures taken in response to the pandemic, the availability, adoption and effectiveness of vaccines, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our
partners, patients and communities in which we operate, all of which continue to be uncertain. As of the date of issuance of these consolidated financial statements, the extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> could
materially impact the Company&#146;s financial conditions, liquidity or results of operations is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent
<FONT STYLE="white-space:nowrap">COVID-19</FONT> disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully
commercialize newly developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual
relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at
providing emergency assistance and health care for individuals, families, and businesses affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes
provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $1,247 Provider Relief
Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> The payment was recorded as other income on the consolidated statement of operations and comprehensive (loss) income for the three and six months ended June&nbsp;27, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent accounting pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected
to comply with <FONT STYLE="white-space:nowrap">non-accelerated</FONT> public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are generally
earlier than when emerging growth companies are required to adopt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting Pronouncements Recently Adopted </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income
Taxes </I>(ASU <FONT STYLE="white-space:nowrap">2019-12),</FONT> which amended the accounting for income taxes. ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> eliminates certain exceptions to the guidance for income taxes related to the
approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise
taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a <FONT STYLE="white-space:nowrap">step-up</FONT> in the tax basis of goodwill. The Company adopted ASU
<FONT STYLE="white-space:nowrap">2019-12</FONT> on January&nbsp;1, 2021 and it did not have a material impact on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Balance sheet information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of
cash and cash equivalents and restricted cash is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,065</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,839</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,068</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,839</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash consists of deposits into escrow with a financial institution for the purpose of paying specific indebtedness
of a company acquired as part of a business combination (refer to<I> Note 3. Business combinations and investments</I>). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounts receivable, net
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses.
Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the
effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable, net of allowances, consisted of the following as of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,048</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,273</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Allowance for credit losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,029</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,283</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to
make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic
conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific
identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#146;s customers or its collection
experience deteriorates. The Company has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#146;s reserves have been adequate to cover credit losses. The
Company&#146;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions,
disruption associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and determined that the estimate of credit losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all
other historical, current and future information that is reasonably available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in credit losses were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recovery (provision)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write-offs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recoveries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inventory </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory
consisted of the following as of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,202</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,665</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,538</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,323</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,740</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,988</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Excess and obsolete reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,020</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,120</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accrued liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued liabilities consisted of the following as of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT>
deductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,980</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,656</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonus and commission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,493</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,188</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,932</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,875</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income and other taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,385</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,434</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,456</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,034</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,246</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,187</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company completed a restructuring plan during the fourth quarter of 2020 and the remaining $247 accrued liabilities were
paid during the six months ended July&nbsp;3, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Business combinations and investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisitions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2021, in order to broaden
its portfolio and increase its global footprint, the Company acquired 100% of the capital stock of Bioness, Inc. (Bioness). Bioness is a global leader in neuromodulation and advanced rehabilitation medical devices through its innovative peripheral
nerve stimulation therapy and premium advanced rehabilitation solutions. The Company had previously made a $1,500 convertible debt investment in Bioness on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
January&nbsp;4, 2021 as part of an exclusive negotiation to purchase Bioness, which was subsequently repaid in conjunction with the acquisition. The consideration paid for Bioness is comprised of
the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash consideration at closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,933</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Bioness consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,933</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contingent consideration is comprised of future <FONT STYLE="white-space:nowrap">earn-out</FONT> payments contingent upon the
achievement of certain research and development projects as well as sales milestones related to Bioness products. Contingent <FONT STYLE="white-space:nowrap">earn-out</FONT> payments could total up to $65,000 for the achievement of the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15,000 for obtaining FDA approval for U.S. commercial distribution of a certain product for certain indications
on or before June&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$20,000 for meeting net sales targets for certain implantable products over a three year period ending on
June&nbsp;30, 2025 at the latest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Up to $10,000 for meeting net sales milestones for certain implantable products over a three year period ending
on June&nbsp;30, 2025 at the latest; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$20,000 for maintaining Centers for Medicare&nbsp;&amp; Medicaid Services coverage and reimbursement for certain
products at specified levels as of December&nbsp;31, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price is preliminary and subject to change.
The primary areas of the purchase price that are not yet finalized are related to contingent consideration, working capital, intangible assets and the residual goodwill. Accordingly, adjustments may be made to the values of assets and liabilities
assumed as additional information is obtained about the facts and circumstances that existed at the acquisition date. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date
and the resulting goodwill, which is expected to be deductible for tax purposes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,933</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets acquired and liabilities assumed:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted
cash<SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,143</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,124</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,318</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,947</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,598</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Resulting goodwill<SUP STYLE="font-size:85%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,335</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of cash and cash equivalents of $2,143 and restricted cash deposited by the former majority owner of
Bioness of $1,000, into escrow with financial institutions for the purpose of paying specific Bioness indebtedness. The Company previously deposited $4,207 into escrow for the same purpose. Prior to the acquisition, Bioness had entered into two
loans in connection with the Paycheck Protection Program (the PPP) under the Coronavirus Aid, Relief and Economic Security Act (CARES Act) administered by the U.S. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Small business Administration. Bioness received proceeds of $3,204 from an unsecured PPP loan that was scheduled to mature on April&nbsp;10, 2022. Bioness applied and was granted forgiveness of
this loan during 2021. Bioness received proceeds of $2,003 from a second unsecured PPP loan bearing an interest rate of 1% scheduled to mature on February&nbsp;5, 2026. Bioness applied for forgiveness of this loan during 2021. As part of the Bioness
acquisition, the balance of $2,003 was placed in restricted cash to cover the repayment of the outstanding unsecured PPP loan in the event it is not forgiven. The $1,000 outstanding unsecured PPP loan balance covered by the former majority owner is
included in other current liabilities within the condensed consolidated balance sheets. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(b)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The U.S. segment was allocated the resulting goodwill from the Bioness acquisition. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the preliminary fair values of identifiable intangible assets and their useful lives: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful&nbsp;Life</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:10pt">10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,500</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,250</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate amortization expense related to acquired intangible assets for the following five periods is as follows:
$2,238&#151;remainder of 2021, $4,475&#151;2022, $4,381&#151;2023, $4,350&#151;2024 and $4,350&#151;2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company incurred $1,833 and $5,029 in
acquisition and integration costs during the three and six months ended July&nbsp;3, 2021, respectively, which are included in selling general and administrative expense within the consolidated condensed statement of operations and other
comprehensive (loss) income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioness&#146; advanced rehabilitation revenue is comprised of Exoskeletal Systems, Vector Units and Bioness Integrated
Therapy Systems (BITS), which is included within the Company&#146;s Restorative Therapies vertical. The Company&#146;s Pain Treatment and Joint Preservation vertical will encompass Bioness&#146; peripheral nerve stimulation therapy products, which
includes the StimRouter, an implantable neuromodulation device used to treat chronic peripheral nerve pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from Bioness&#146; products is
primarily recognized at a point in time upon transfer of control of its products to customers such as medical facilities and individual patients. Revenue is recognized net of discounts, which can be offered through a variety of factors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consolidated Pro Forma Results </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
consolidated condensed statements of operations reflect net sales and net loss attributable to Bioness of $11,870 and $3,529, respectively, for the three and six months ended July&nbsp;3, 2021. Consolidated unaudited pro forma results of operations
for the Company are presented below assuming the 2021 Bioness Acquisition had occurred January&nbsp;1, 2020. Pro forma operating results for the three and six months ended June&nbsp;27, 2020 include operating expenses of $3,939 and $7,135,
respectively, for acquisition integration costs and inventory related adjustments. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,816</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,955</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,541</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,570</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share of Class&nbsp;A common stock(1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>VIE </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a fully diluted 8.8% ownership of
Harbor Medtech Inc.&#146;s (Harbor) Series C Preferred Stock. The Company and Harbor entered into an exclusive Collaboration Agreement in 2019 for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied
by Harbor. The Company&#146;s partial ownership and exclusive Collaboration Agreement created a variable interest in Harbor. As a result, Harbor had been consolidated in the Company&#146;s consolidated financial statements since the third quarter of
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harbor assets that could only be used to settle Harbor obligations and Harbor liabilities for which creditors did not have recourse to the general
credit of the Company were as follows at December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,635</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,863</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,004</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,029</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company terminated the Collaboration Agreement on June&nbsp;8, 2021 and determined that the termination was a triggering
event requiring an impairment assessment of Harbor&#146;s long lived assets. The assessment resulted in an impairment of $5,674, representing Harbor&#146;s long-lived asset balance, which was recorded within impairment of variable entity assets in
the consolidated condensed statements of operations and comprehensive (loss) income, of which $5,176 is attributable to the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest. The Company stopped consolidating Harbor upon the
termination of the Collaboration Agreement, as the Company ceased being the primary beneficiary because it no longer had the power to direct Harbor&#146;s significant activities. The Company also assessed its Harbor investment post deconsolidation,
which resulted in a $1,369 impairment, representing the remaining investment balance in Harbor and was recorded within other expense in the consolidated condensed statements of operations and comprehensive (loss) income. The Company continues to
have license rights to certain technology obtained from Harbor and is continuing product development initiated under the Collaboration Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Method </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an equity investment in
CartiHeal Ltd. (CartiHeal), a privately held entity that does not have a readily determinable fair value, which the Company began recording as an equity investment during the third quarter of 2020. The CartiHeal investment carrying value totaled
$17,737 as of July&nbsp;3, 2021, yielding a 10.03% fully diluted equity ownership. Net losses from CartiHeal for the three and six months ended July&nbsp;3, 2021 totaled $432 and $901, respectively, which are included in other expense within the
consolidated condensed statement of operations and other comprehensive (loss) income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will, if needed to support the completion of a certain
study, purchase an additional 338,089 of CartiHeal Series G Preferred Shares for $5,000. The Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within 45 days following notice
of the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Food and Drug Administration (FDA) approval for a CartiHeal product currently in development. In addition, upon the same FDA approval, CartiHeal may exercise an option within 45 days that
requires the Company to complete the acquisition of the remaining equity in CartiHeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020, the Company entered into an Option and
Equity Purchase Agreement with CartiHeal. The agreement provides the Company with an exclusive option to acquire 100% of CartiHeal&#146;s shares under certain conditions, or the Call Option, and provides CartiHeal with a put option that would
require us to purchase 100% of CartiHeal&#146;s shares under certain conditions, or the Put Option. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA
approval of the <FONT STYLE="white-space:nowrap">Agili-C</FONT> device with a label consistent in all respects with pivotal clinical trial success. The pivotal clinical trial&#146;s objective is to demonstrate the superiority of the <FONT
STYLE="white-space:nowrap">Agili-C</FONT> implant over the surgical standard of care, including microfracture and debridement, for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative
changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;2, 2021, CartiHeal provided a statistical report containing the results of the pivotal clinical trial. The Company is currently
reviewing the report to assess if it is consistent with the terms of the agreement and assessing the findings to determine if all required endpoint have been achieved. CartiHeal continues to work toward submitting the final, clinical module of a
Modular PMA in the fourth quarter of 2021 seeking FDA approval. The Company has the right to terminate the Call Option and Put Option at any time ending 30 days after receipt of the statistical report from CartiHeal upon payment of a break fee of
$30,000. If the Company determines that the results satisfy the requirements of the contract, and elect not to exercise its right to terminate the Call Option and Put Option, the Company will be required to put $50,000 into escrow as a deposit
towards the purchase price. Consideration for the acquisition of all of the shares of CartiHeal, excluding those the Company owns, pursuant to the Call Option or Put Option would be $314,895, inclusive of the deposit, all of which would be payable
at closing, with an additional $150,000 payable upon achievement of certain sales milestones related to <FONT STYLE="white-space:nowrap">Agili-C.</FONT> Such closing would be subject to customary closing conditions. CartiHeal has announced that it
expects to submit its PMA application to the FDA later this year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2021, the Company purchased 406,504 shares of Vaporox, Inc&#146;s (Vaporox) Series A Preferred Stock or 6.0% of fully diluted shares for
$1,000. Vaporox, a privately held entity, is a medical device company dedicated to healing diabetic foot ulcers and does not have a readily determinable fair value. Under the measurement alternative, the investment is recorded at cost, less any
impairment, plus or minus any changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Financial instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term debt consists of the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan due December 2024 (2.60% at July&nbsp;3, 2021)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,084</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,378</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2019 Credit Agreement requires the Company to comply with financial and other covenants. The Company
complied with all covenants as of July&nbsp;3, 2021. The 2019 Credit Agreement contains a $50,000 revolving credit facility, from which there were no outstanding borrowings as of July&nbsp;3, 2021 and December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of the Term Loan as of July&nbsp;3, 2021 was $184,505. The fair value of these obligations was determined by using a discounted cash
flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar obligations and are classified as Level&nbsp;2 instruments within the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. The Company has
one <FONT STYLE="white-space:nowrap">non-designated</FONT> interest rate swap agreement and has no other active derivatives. The swap is carried at fair value on the balance sheet (Refer to<I> Note 5. Fair value measurements</I>) with changes in
fair value recorded as interest income or expense within the consolidated statements of operations and comprehensive (loss) income. Net interest expense of $255 and $933 was recorded related to the change in fair value of the interest rate swap for
the three months ended July&nbsp;3, 2021 and June&nbsp;27, 2020, respectively. Net interest income of $1,310 and expense of $2,001 was recorded related to the change in fair value of the interest rate swap for the six months ended July&nbsp;3, 2021
and June&nbsp;27, 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notional amount of the swap totaled $100,000, or 54.8% of the Term Loan outstanding principal at July&nbsp;3,
2021. The swap locked in the variable portion of the interest rate on the $100,000 notional at 0.64%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Fair value measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our process for determining fair value has not changed from that described in the Company&#146;s 2020 Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no assets measured at fair value on a recurring basis and there were no liabilities valued at
fair value using Level&nbsp;1 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level&nbsp;2 and Level&nbsp;3 inputs: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest rate swap</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,220</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,220</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term contingent consideration, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,421</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,421</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management incentive plan and liability-classified awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,303</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,303</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Participation Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,101</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,101</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,933</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,641</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,006</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,404</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate swap </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not
certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#146;s consolidated balance sheets within accrued liabilities. Changes in
fair value are recognized as interest expense (income) within the consolidated statements of operations and comprehensive (loss) income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios
discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue and the probability of achieving the specific targets as
discussed in <I>Note 3. Business combinations and investments</I>. After the initial valuation, the Company will use its best estimate to measure contingent consideration related to the Bioness Acquisition at each subsequent reporting period using
the following unobservable Level&nbsp;3 inputs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Valuation Technique</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Unobservable inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Range</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bioness contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">Discounted cash flow</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Payment discount rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.0% - 6.8%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Payment period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2021 - 2025</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contingent consideration reported in the above table resulted from the March&nbsp;30, 2021 Bioness acquisition, which is
adjusted on a monthly basis based upon the passage of time or success or failure of achieving certain milestones. Refer to <I>Note 3. Business combinations and investments</I> for further details. Changes in contingent consideration related to the
Bioness acquisition totaled $641 for the three and six months ended July&nbsp;3, 2021, which were recorded as the change in fair value of contingent consideration within the consolidated statements of operations and comprehensive (loss) income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management incentive plan (MIP) and liability-classified awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BV LLC had operated two equity-based compensation plans, the management incentive plan (MIP) and the BV LLC Phantom Profits Interest Plan (Phantom Plan and,
together with the MIP, the Plans), which were terminated on February&nbsp;11, 2021 in connection with the Company&#146;s IPO. Awards granted under the MIP Plan and the 2015 Phantom Units were liability-classified and the 2012 Phantom Units were
equity-classified. Prior to the IPO and during the six months ended July&nbsp;3, 2021, the Company settled the remaining 183,078 units with the sole MIP awardee for $10,802. No awards under the Plans were granted
<FONT STYLE="white-space:nowrap">post-IPO</FONT> and the Phantom Plan awards will be settled 12 months following the termination. Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled for $10,875, which
is included in accrued equity-based compensation on the consolidated condensed balance sheets. Awardees that were active BV LLC employees at the IPO will receive an aggregate of 798,422 shares of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant
unobservable inputs or Level&nbsp;3: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,303</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial estimate (vesting)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">829</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phantom plan conversion to Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at July&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Participation Right (EPR) Unit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, the Continuing LLC owner owned the only EPR Unit and its only entitlement was 0.55% of available distributions arising from a distribution
event such as the IPO. The EPR Unit was redeemed in exchange for $3,327 in connection with the IPO in February 2021, at which time the EPR ceased to exist and all entitlements ended. The revaluation for the EPR liability is recognized in interest
(income) expense on the consolidated statements of operations and comprehensive (loss) income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair
value using significant unobservable inputs Level&nbsp;3: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,101</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at July&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Equity-based compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terminated plans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, BV LLC operated
two equity-based compensation plans, the MIP and the Phantom Plan, which were terminated on February&nbsp;11, 2021 in conjunction with the IPO. Prior to the Plans termination, during the six months ended July&nbsp;3, 2021, (i) the Company granted
90,000 Phantom Plan units; (ii)&nbsp;there were no MIP awards granted; (iii) 900 Phantom Plan units were forfeited and (iv)&nbsp;other Phantom Units were redeemed for $479. Compensation expense related to the Phantom Plan of $829 for the six months
ended July&nbsp;3, 2021. This amount excludes the $25,185 decrease in fair market value of accrued equity-based compensation due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering
price, of which $1,777 was recorded in research and development expense within the consolidated statement of operations and comprehensive (loss) income for the six months ended July&nbsp;3, 2021. Compensation expense of $663 and $1,078 was recorded
for the three and six months ended June&nbsp;27, 2020, excluding $408 and $7,849 in fair market value decreases, respectively, within accrued equity-based compensation due to the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the
market and economy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
operates an equity-based compensation plan (2021 Plan). The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for which the Company competes. The
2021 Plan allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and cash awards. (collectively, Awards). Generally, <FONT
STYLE="white-space:nowrap">non-cash</FONT> Awards granted under the 2021 Plan are equity-classified. As of July&nbsp;3, 2021, 7,592,476 shares of Class&nbsp;A common stock were authorized to be awarded and 2,024,123 shares were available for award.
The number of shares available for issuance will be increased annually on January&nbsp;1 of each calendar year beginning in 2022 through 2031, equal to the lesser of (i) 4.5% of the shares of our Class&nbsp;A common stock outstanding on the final
day of the immediately preceding calendar year and (ii)&nbsp;a smaller number of shares as determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity-based
compensation expense of $5,778 and $7,722 was recognized for the three and six months ended July&nbsp;3, 2021, respectively, for Awards granted under the 2021 Plan. The expense is primarily included in selling, general and administrative expense
with a nominal amount in research and development expense on the consolidated statement of operations and comprehensive (loss) income based upon the classification of the employee. There was no income tax benefit related to this expense for the
three and six months ended July&nbsp;3, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three and six months ended July&nbsp;3, 2021, the Company granted employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
time-based RSUs which vest at various dates through May&nbsp;10, 2025. The compensation expense, which represents the fair value of the stock measured at the market price on the date of grant, is recognized over the vesting period, which is
typically between 1 and 4 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No RSUs were vested or settled during the three and six months ended July&nbsp;3, 2021. Unamortized
compensation expense related to the RSUs amounted to $9,976 at July&nbsp;3, 2021, and is expected to be recognized over a weighted average period of approximately 0.69 years. A summary of the RSU award activity for the six months ended July&nbsp;3,
2021 is as follows (number of units in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average&nbsp;grant-<BR>date fair value<BR>per unit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">945</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at April&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">945</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.90</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.53</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at July&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the
three and six months ended July&nbsp;3, 2021, the Company granted employees time-based stock options which vest over 2 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using
the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 2 to 4 years, net of actual forfeitures. A summary of the Company&#146;s assumptions used in determining the fair value of the stock
options granted during the six months ended July&nbsp;3, 2021 is shown in the following table. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.59%&nbsp;-&nbsp;1.19%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">33.1%&nbsp;-&nbsp;33.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.75&nbsp;-&nbsp;6.25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average fair value of stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$4.21&nbsp;-&nbsp;5.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the
historical volatility of the Company&#146;s peers common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No options vested, expired, forfeited or were exercisable during the six months ended July&nbsp;3, 2021. Unamortized compensation expense related to the
options amounted to $15,797 at July&nbsp;3, 2021, and is expected to be recognized over a weighted average period of approximately 1.19 years. A summary of stock option activity is as follows for the six months ended July&nbsp;3, 2021 (number of
options in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average&nbsp;exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>remaining<BR>contractual&nbsp;term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,621</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.03</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at April&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,621</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.03</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.90</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at July&nbsp;3, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,625</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.03</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding as of July&nbsp;3, 2021 was $16,095 and is calculated
as the difference between the exercise price of the underlying options and the market price of the Company&#146;s common stock for options that had exercise prices lower than $16.51, the closing price of the Company&#146;s stock on
July&nbsp;2,&nbsp;2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2021, in connection with the IPO, the Company began operating the 2021 Employee Stock Purchase Plan (ESPP). The ESPP provides for the issuance of
shares of the Company&#146;s common stock to eligible employees of the Company and its subsidiaries that elect to participate in the plan and purchase shares of common stock through payroll deductions (including executive officers). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During each enrollment period, eligible employees may designate between 1% and 15% of their compensation to be deducted for the purchase of common stock under
the plan (or such other percentage in order to comply with regulations applicable to employees domiciled in or resident of a member state of the European Union). The purchase price of the shares under the ESPP is equal to 85% of the fair market
value on the first day of the offering period or, if lower, on the last day of the offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;3, 2021, the aggregate number of
shares reserved for issuance under the ESPP was 518,257. During the three and six months ended July&nbsp;3, 2021, 24,063 shares were issued and $75 of expense was recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Earnings per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the
computation of basic and diluted loss per share of Class&nbsp;A common stock for the period following the Transactions (amounts in thousands, except share and per share data): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months<BR>Ended July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>February&nbsp;16,<BR>2021 through<BR>July&nbsp;3, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,654</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,062</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Bioventus Inc. Class&nbsp;A common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of Class&nbsp;A common stock outstanding - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,805,347</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,802,840</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share of Class&nbsp;A common stock, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Class&nbsp;B common stock do not share in the losses of the Company and are therefore not participating securities.
As such, separate presentation of basic and diluted losses per share of Class&nbsp;B common stock under the <FONT STYLE="white-space:nowrap">two-class</FONT> method has not been presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following number of weighted-average potentially dilutive shares as of July&nbsp;3, 2021 were excluded
from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three<BR>Months<BR>Ended July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months<BR>Ended July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LLC Interests held by Continuing
LLC&nbsp;Owner<SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,786,737</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,622,287</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,602,747</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,221,555</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">941,031</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares of Class&nbsp;A common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,458</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,698</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,663,037</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,365,213</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Class&nbsp;A Shares reserved for future issuance upon redemption or exchange of LLC Interests by Continuing LLC
Owner. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Income taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a
result of the Transactions, Bioventus Inc. became the sole managing member of BV LLC, which is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, BV LLC is not subject to U.S. federal
and certain state and local income taxes. Any taxable income or loss generated by BV LLC is passed through to and included in the taxable income or loss of its members, including the Company following the Transactions, on a pro rata basis. Bioventus
Inc. is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to its allocable share of any taxable income of BV LLC<B> </B>following the Transactions. The Company is also subject to taxes in foreign
jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax provision for interim periods is determined using an estimate of the Company&#146;s annual effective tax rate, adjusted for
discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period.
The quarterly tax provision, and estimate of the Company&#146;s annual effective tax rate, are subject to variation due to several factors, including variability in <FONT STYLE="white-space:nowrap">pre-tax</FONT> income (or loss), the mix of
jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended
July&nbsp;3, 2021 and June&nbsp;27, 2020 the Company&#146;s estimated effective tax rate was 18.9% and 1.8%, respectively. For the six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020 the Company&#146;s estimated effective tax rate was 10.7%
and 1.6%, respectively. The increase was primarily driven by the change in structure resulting from the IPO and associated Up C structure as well as the impact of <FONT STYLE="white-space:nowrap">non-deductible</FONT> stock option expense during
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded deferred taxes with the offset to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital in connection with the
Transaction. The deferred tax asset of $481 was due to tax credits and the deferred tax liability of $48,410 was for the difference between the book value and the tax basis of the Company&#146;s investment in BV LLC. The Company maintains a
valuation allowance on certain deferred tax assets that has determined are not <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be realizable. The Company assesses the need for an adjustment to this valuation allowance on a quarterly
basis. The assessment is based on estimates of future sources of taxable income for the jurisdictions in which the Company operates and the periods over which deferred tax assets will be realizable. In the event the Company determines that it will
be able to realize all or part of its net deferred tax assets in the future, all or part of the valuation allowance will be reversed in the period in which the Company makes such determination. The release of all or part of the valuation allowance
against deferred tax assets may cause greater volatility in the effective tax rate in the periods in which it is reversed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Receivable Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing
LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or
increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16,
2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes
as a result of (i)&nbsp;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&nbsp;certain other tax benefits related to our making payments
under the TRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will maintain a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of
redemptions of LLC Interests or exchanges described above until it is determined that the benefits are <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be realized. As of July&nbsp;3, 2021, Continuing LLC Owner had not exchanged LLC
Interests for shares of Class&nbsp;A common stock and therefore the Company had not recorded any liabilities under the TRA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Commitments and
contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases
its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 7.25 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease cost were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,614</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost<SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,124</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,943</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,496</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Includes variable lease cost and sublease income, which are immaterial. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental cash flow information and <FONT STYLE="white-space:nowrap">non-cash</FONT> activity related to operating leases were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,696</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental balance sheet and other information related to operating leases were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities- current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities- noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Recall </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2020, the Company voluntarily recalled our ultrasound gel, an accessory to one of the Restorative Therapies product. The Company has incurred, and expects to incur in the future, costs associated with this recall. Based on the information
that has been received, the estimated probable loss related to this recall globally was approximately $2,055 as of July&nbsp;3, 2021. Reserves of $434 and $1,684 were recorded within accrued liabilities on the consolidated balance sheets at
July&nbsp;3, 2021 and December&nbsp;31, 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations
that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and
in other jurisdictions in which the Company operates. As a result, interaction with governmental agencies is ongoing. The Company&#146;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of
legal actions are not within the Company&#146;s complete control and may not be known for extended periods of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing of our
acquisition of Bioness, Bioness had been named as a defendant in a lawsuit, for which we are indemnified for under the indemnification provisions contained in the Merger Agreement pursuant to which we acquired Bioness (the Bioness Merger Agreement).
The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting our acquisition of Bioness. While the complaint
to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover $1,200 in attorney fees and other expenses
incurred by the director and shareholder in connection with the dismissed case and filed a motion on May&nbsp;21, 2021 for summary judgment of their claims. The Company is vigorously defending the matter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2019, the
Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2019, the Company and the Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development
agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF (the Development Agreement). The first phase has been completed. Additional fees for the subsequent phases will be
determined as the development work progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;9, 2016, the Company entered into an amended and restated license agreement for the
exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (OA) product with the supplier of the Company&#146;s single injection OA product for the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> market. The
agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $3,548 and $1,767 during the three months ended July&nbsp;3, 2021 and June&nbsp;27, 2020,
respectively, and $5,925 and $3,969 during the six months ended July&nbsp;3, 2021 and June&nbsp;27, 2020, respectively. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of a supply agreement entered on February&nbsp;9, 2016 for the Company&#146;s three injection OA product, the Company is subject to annual minimum
purchase requirements for ten years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of a supply agreement for the Company&#146;s five injection OA product, that was amended and restated on December&nbsp;22, 2020, the Company is
subject to annual minimum purchase requirements for 8 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an exclusive license agreement for bioactive bone graft putty. The Company
is required to pay a royalty on all commercial sales revenue from the licensed products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties
are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company causes letters
of credit (LOCs) to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers,
competitively determined in the marketplace. As of July&nbsp;3, 2021 and December&nbsp;31, 2020, the Company had one LOC outstanding for a nominal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of
property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured
for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#147;claims made&#148; basis for expenses in excess of $200 per member per year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Revenue recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our policies for recognizing
sales have not changed from those described in the Company&#146;s 2020 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the
legal entity from which the sale originated. The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Primary geographic markets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,682</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,166</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,220</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,136</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,134</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,851</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,374</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,526</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,816</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,594</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,662</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vertical:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pain Treatments and Joint Preservation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,704</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,868</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,234</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,151</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restorative Therapies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,511</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,968</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,332</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,433</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bone Graft Substitutes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,601</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,181</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,028</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,078</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,816</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,594</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,662</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Segments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s two reportable segments are U.S. and International. The Company&#146;s products are primarily sold to orthopedists, musculoskeletal and
sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to
allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company&#146;s Chief Operating Decision Maker for purposes of decisions about allocation of
resources to, and assessing performance of, each reportable segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents segment adjusted EBITDA reconciled to income before
income taxes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;3,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;27,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,149</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,439</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,147</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,151</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,810</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,479</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,195</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,559</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,771</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> benefits, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,101</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,101</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Succession and transition charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency impact</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition and integration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory <FONT STYLE="white-space:nowrap">step-up</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity loss in unconsolidated investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(432</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairments related to variable interest entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,659</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,066</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,389</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,435</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Acquisition of Misonix, Inc. </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;29, 2021, the
Company entered into an Agreement and Plan of Merger (the Misonix Merger Agreement) to acquire Misonix, Inc. (Misonix), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes,
in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-and-stock</FONT></FONT> transaction (the Transaction). The closing of the Transaction is subject to regulatory approvals, the Company&#146;s stockholders&#146; approval,
Misonix stockholder approval and customary closing conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix stockholders will receive aggregate consideration that values Misonix at approximately $518,000 on a fully diluted basis, based on the Company&#146;s <FONT
STYLE="white-space:nowrap">7-day</FONT> weighted average stock price of $16.6284 per share as of July&nbsp;27, 2021. The Transaction involves both cash and stock consideration based on the election of the Misonix stockholder. Each share of Misonix
Common Stock issued and outstanding immediately prior to the Transaction, will be converted into the right to receive, either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Class&nbsp;A common stock of the Company, $0.001 par value per share, based on the election of the holder. The maximum cash amount payable by the Company will be an amount equal to
$10.50 multiplied by the number of outstanding shares of Misonix Common Stock shortly prior to the completion of the Transaction. The Company expects to fund the cash portion of the acquisition with cash on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hand and through committed financing provided by Wells Fargo Bank, National Association (Wells Fargo Bank). The number of shares held by Misonix stockholders electing to receive cash will be
reduced on a pro rata basis if the cash elected to be received exceeds the maximum cash amount payable and will be paid with stock consideration of 1.6839 of shares of the Company&#146;s Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debt Commitment Letter </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
transaction, the Company entered into a debt commitment letter with Wells Fargo Bank, effective July&nbsp;29, 2021. Wells Fargo Bank has committed to provide a senior secured term loan facility (Term Loan Facility) in the aggregate principal amount
of up to $262,000 plus, at the Company&#146;s election, an amount sufficient to fund any original issue discount or upfront fees, subject to customary closing conditions. The Term Loan Facility stipulates a prepayment of $80,000 on the existing Term
Loan under the 2019 Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds of the Term Loan Facility would be available through a single draw on the closing date of the
Transaction and shall be used (i)&nbsp;to finance the Transaction; (ii)&nbsp;pay related fees, premiums and expenses and (iii)&nbsp;for working capital needs and general corporate purposes of the Company, including without limitation for permitted
acquisitions. The Term Loan Facility would have a three year term that would bear interest at either the base rate as prescribed in the Term Loan under the 2019 Credit Agreement or the Eurodollar rate, and, in each case, plus an applicable margin.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting and Support Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;29,
2021, following the execution of the Misonix Merger Agreement, Misonix entered into Voting and Support Agreements with each EW Healthcare Partners Acquisition Fund, L.P. White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.),
Smith&nbsp;&amp; Nephew, Inc., Smith&nbsp;&amp; Nephew USD Ltd. and <FONT STYLE="white-space:nowrap">AMP-CF</FONT> Holdings, LLC (together, the &#147;Bioventus supporting stockholders&#148;). The Bioventus Supporting Stockholders have agreed to vote
their shares in (i)&nbsp;favor of the issuance of shares of the Company&#146;s common stock in connection with the Transaction and against approval of any proposal made in opposition to, in competition with or inconsistent with the Misonix Merger
Agreement. As of the record date for the Bioventus special meeting, the Bioventus supporting stockholders are the beneficial owners of approximately 67.4% of the currently outstanding Class&nbsp;A and Class&nbsp;B common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Other Matters </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unsecured PPP loan of $2,003
associated with Bioness was forgiven in July 2021. The loan amount was recorded in other current liabilities and restricted cash within the consolidated condensed balance sheet at July&nbsp;3, 2021. Refer to <I>Note 3. Business combinations and
investments</I> for further details. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc180330_40"></A>Annex A </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and among: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS INC., </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware
corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OYSTER MERGER SUB I, INC., </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OYSTER
MERGER SUB II, LLC, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware limited liability company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISONIX, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of
July&nbsp;29, 2021 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TABLE OF CONTENTS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE I. THE MERGERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Mergers; Effect of Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing; Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Incorporation and Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of Capital Stock in the Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Dissenting Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Proration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Adjustments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of Equity Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Fractional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing of Transfer Books</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange of Certificates and Cancellation of Book-Entry Positions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Election Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE II. REPRESENTATIONS AND WARRANTIES OF THE COMPANY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Due Organization and Good Standing; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports; Financial Statements; Internal Controls</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Certain Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property and Related Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title to Assets; Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Legal Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legal Proceedings; Investigations; Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Business Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Product Defects and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ownership of Parent Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Opinion of Financial Advisor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.26</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Related Party Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.27</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE III. REPRESENTATIONS AND WARRANTIES OF PARENT AND ACQUISITION SUBS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Due Organization and Good Standing; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports; Financial Statements; Internal Controls</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Certain Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Legal Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legal Proceedings; Investigations; Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Business Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financing; Solvency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ownership of Company Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Opinion of Financial Advisor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Privacy and Security</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent Top Customers, Distributors and Suppliers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Product Defects and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.26</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acquisition Subs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV. COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interim Operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company No Solicitation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent No Solicitation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration Statement; Joint Proxy Statement/Prospectus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Meeting of the Company&#146;s Stockholders; Company Change in Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Meeting of Parent&#146;s Stockholders; Parent Change in Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Filings; Other Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Access</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acquisition Sub Consents; Parent Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Publicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financing and Financing Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stockholder Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stock Exchange Listing and Delisting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;16 Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director Resignations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payoff Documentation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE V. CONDITIONS TO EACH PARTY&#146;S OBLIGATION TO EFFECT THE MERGERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions Precedent to Each Party&#146;s Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Conditions Precedent to Parent&#146;s Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Conditions Precedent to the Company&#146;s Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI. TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VII. MISCELLANEOUS PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Survival of Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; <FONT STYLE="white-space:nowrap">Non-Reliance;</FONT> Third-Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Applicable Law; Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignability; Parties in Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclosure Schedules</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Recourse</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibits </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibit&nbsp;A</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certain Definitions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U><FONT STYLE="white-space:nowrap">Exhibit&nbsp;B-1</FONT></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Support Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Parent Support Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibit C</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of First Certificate of Merger</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibit D</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Second Certificate of Merger</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AGREEMENT AND PLAN OF MERGER</B> (this &#147;<U>Agreement</U>&#148;) is made and entered into as of July&nbsp;29, 2021, by and among:
Bioventus Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;); Oyster Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#147;<U>Acquisition Sub I</U>&#148;), Oyster Merger Sub II, LLC, a Delaware limited
liability company and a wholly owned subsidiary of Parent (&#147;<U>Acquisition Sub II</U>,&#148; and together with Acquisition Sub I, the &#147;Acquisition Subs&#148;); and Misonix, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;).
Certain capitalized terms used in this Agreement are defined in <U>Exhibit A</U>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. </B>The parties to this Agreement desire to, on the terms and subject to the conditions set forth herein, enter into an integrated
transaction pursuant to which, first, Acquisition Sub I, in accordance with the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;) will merge with and into the Company, with the Company as the surviving corporation (the
&#147;<U>First Merger</U>&#148;), and, second, the Company, as the surviving corporation in the First Merger, and in accordance with the DGCL and the Delaware Limited Liability Company Act (the &#147;<U>DLLCA</U>&#148;), will merge with and into
Acquisition Sub II, with Acquisition Sub II as the surviving limited liability company (the &#147;<U>Second Merger,</U>&#148; and together with the First Merger, the &#147;<U>Mergers</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. </B>The Company Board has unanimously: (i)&nbsp;determined that the Mergers are fair to, and in the best interests of, the Company and
its stockholders; (ii)&nbsp;approved and declared advisable this Agreement and the consummation of the transactions contemplated by this Agreement, including the Mergers, upon the terms and subject to the conditions contained in this Agreement; and
(iii)&nbsp;resolved, subject to <U>Section</U><U></U><U>&nbsp;4.5</U>, to recommend that the Company&#146;s stockholders adopt this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. </B>The Parent Board has unanimously: (i)&nbsp;determined that the terms of this Agreement and the Mergers are fair to, and in the best
interests of, Parent and its stockholders; (ii)&nbsp;approved and declared advisable this Agreement and the consummation of the transactions contemplated by this Agreement, including the Mergers and the issuance of shares of Parent Class&nbsp;A
Common Stock in connection therewith, each upon the terms and subject to the conditions contained in this Agreement; and (iii)&nbsp;resolved, subject to <U>Section</U><U></U><U>&nbsp;4.6</U>, to recommend that Parent&#146;s stockholders approve the
issuance of shares of Parent Class&nbsp;A Common Stock in connection with the First Merger on the terms and subject to the conditions set forth in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D. </B>The board of directors of Acquisition Sub I has: (i)&nbsp;determined that it is advisable and in the best interests of Acquisition
Sub I and its sole stockholder for Acquisition Sub I to enter into this Agreement; (ii)&nbsp;approved and declared advisable this Agreement and the consummation of the transactions contemplated hereby, including the Mergers, upon the terms and
subject to the conditions contained in this Agreement; and (iii)&nbsp;recommended that its sole stockholder adopt this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E.
</B>Parent, as the sole member of Acquisition Sub II, has (i)&nbsp;determined that it is advisable and in the best interests of Acquisition Sub II and its sole member to enter into this Agreement and (ii)&nbsp;approved and declared advisable this
Agreement and the consummation of the transactions contemplated hereby, including the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F.</B> It is intended that, for U.S.
federal income Tax purposes, (a)&nbsp;the First Merger will be treated as part of a binding plan that includes the Second Merger, (b)&nbsp;the First Merger will be integrated with the Second Merger and treated as a single transaction, (c)&nbsp;the
Mergers, taken together, will qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, and (d)&nbsp;this Agreement will be a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations Sections
<FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>G. </B>Concurrently with the
execution and delivery of this Agreement, (i)&nbsp;certain stockholders of the Company are entering into Company Support Agreements with Parent substantially in the form attached hereto as
<U>Exhibit</U>&nbsp;<U><FONT STYLE="white-space:nowrap">B-1</FONT></U> (the &#147;<U>Company Support Agreements</U>&#148;) and (ii)&nbsp;certain stockholders of Parent are entering into Parent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Support Agreements with the Company substantially in the form attached hereto as <U>Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT></U> (the &#147;<U>Parent Support Agreements</U>&#148;).
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
parties to this Agreement, in consideration of the representations, warranties, covenants and agreements set forth herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be
legally bound, agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE I. THE MERGERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <B>The Mergers; Effect of Mergers.</B> At the First Effective Time, Acquisition Sub I shall be merged with and into the
Company in accordance with the DGCL and upon the terms and subject to the conditions set forth in this Agreement, whereupon the separate existence of Acquisition Sub I shall cease, and the Company shall be the surviving corporation (the
&#147;<U>Initial Surviving Corporation</U>&#148;) in the First Merger. At the Second Effective Time, the Company shall be merged with and into Acquisition Sub II in accordance with the DGCL and the DLLCA, whereupon the separate existence of the
Company shall cease, with Acquisition Sub II continuing its existence as the surviving limited liability company (the &#147;<U>Surviving Company</U>&#148;). From and after the Second Effective Time, all the property, rights, powers, privileges and
franchises of the Company and the Acquisition Subs shall be vested in the Surviving Company and all of the debts, obligations, liabilities, restrictions and duties of the Company and Acquisition Subs shall become the debts, obligations, liabilities
and duties of the Surviving Company, all as provided under the DGCL and DLLCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <B>Closing; Effective Time.</B> The
consummation of the Mergers (the &#147;<U>Closing</U>&#148;) shall be held remotely by exchange of documents and signatures (or their electronic counterparts) unless a place for the Closing to be held in person is agreed to in writing by the parties
to this Agreement, on a date to be designated jointly by Parent and the Company, which shall be no later than the second Business Day after the satisfaction or, to the extent permitted hereunder and by applicable Legal Requirements, waiver of the
last to be satisfied or waived of all conditions to the parties&#146; respective obligations to effect the Mergers set forth in <U>Sections</U><U></U><U>&nbsp;5.1</U>, <U>5.2</U> and <U>5.3</U>, other than those conditions that by their nature are
to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions at the Closing, unless another time or date is agreed to in writing by Parent and the Company. The date on which the Closing actually takes place is
referred to as the &#147;<U>Closing Date</U>.&#148; Subject to the provisions of this Agreement, at the Closing, the parties shall cause a certificate of merger with respect to the First Merger in the form set forth in <U>Exhibit C</U> hereto (the
&#147;<U>First Certificate of Merger</U>&#148;) and immediately thereafter a certificate of merger with respect to the Second Merger in the form set forth in <U>Exhibit D</U> hereto (the &#147;<U>Second Certificate of Merger</U>,&#148; together with
the First Certificate of Merger, the &#147;<U>Certificates of Merger</U>&#148;) to be duly executed and filed with the Secretary of State of the State of Delaware (the&nbsp;&#147;<U>Delaware Secretary of State</U>&#148;) and make all other filings
or recordings required by the Company, the Acquisition Subs or Parent under the DGCL and DLLCA in connection with effecting the Mergers. The Mergers shall become effective on the date and at such time as the Certificates of Merger are filed with the
Delaware Secretary of State or at such later time as may be mutually agreed to in writing by Parent and the Company and specified in the Certificates of Merger (the time at which the First Merger becomes effective being referred to in this Agreement
as the &#147;<U>First Effective Time</U>&#148; and the time at which the Second Merger becomes effective being referred to in this Agreement as the &#147;<U>Second Effective Time</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3 <B>Certificate of Incorporation and Bylaws</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the First Effective Time, the certificate of incorporation of the Company, as in effect immediately prior to the First
Effective Time, shall continue to be the certificate of incorporation of the Initial Surviving Corporation until, subject to the requirements of <U>Section</U><U></U><U>&nbsp;4.13</U>, thereafter changed or amended as provided therein or by
applicable Legal Requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the First Effective Time, the bylaws of the Company in effect
immediately prior to the First Effective Time shall continue to be the bylaws of the Initial Surviving Corporation until, subject to the requirements of <U>Section</U><U></U><U>&nbsp;4.13</U>, thereafter changed or amended as provided therein or by
applicable Legal Requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At the Second Effective Time, the certificate of formation of Acquisition Sub II in
effect immediately prior to the Second Effective Time shall continue to be the certificate of formation of the Surviving Company until, subject to the requirements of <U>Section</U><U></U><U>&nbsp;4.13</U>, thereafter amended as provided therein or
by applicable Legal Requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The limited liability company agreement of Acquisition Sub II in effect immediately
prior to the Second Effective Time will continue to be the limited liability company agreement of the Surviving Company until, subject to the requirements of <U>Section</U><U></U><U>&nbsp;4.13</U>, thereafter changed or amended as provided therein
or by applicable Legal Requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4 <B>Directors and Officers</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From and after the First Effective Time, the directors and officers of the Acquisition Sub I immediately prior to the First
Effective Time shall be the directors and officers of the Initial Surviving Corporation until their successor has been duly elected, designated or qualified, or until their earlier death, resignation or removal in accordance with the certificate of
incorporation and bylaws of the Initial Surviving Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the Second Effective Time, the officers
of Acquisition Sub II immediately prior to the Second Effective Time shall be the officers of the Surviving Company, each to hold office in accordance with the limited liability company agreement of the Surviving Company until their respective
successors have been duly elected, designated or qualified, or until their earlier death, resignation or removal in accordance with the limited liability company agreement of the Surviving Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Prior to the First Effective Time, Parent shall offer at least two members of the Company Board mutually agreed by Parent
and the Company the opportunity to join the Parent Board effective as of the First Effective Time, and shall take all necessary action so that upon the First Effective Time, such offered members of the Company Board shall become members of the
Parent Board, each to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal as a member of the Parent Board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5 <B>Treatment of Capital Stock in the Mergers</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Treatment of Capital Stock in the First Merger. </B>Subject to the terms and conditions of this Agreement, at the First
Effective Time, automatically, by virtue of the First Merger and without any further action on the part of Parent, Acquisition Sub I, the Company or any stockholder of the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all shares of Company Common Stock that are held in the Company&#146;s treasury or are held directly by a Company
Subsidiary, Parent or Acquisition Sub I immediately prior to the First Effective Time (collectively, with the Dissenting Shares, &#147;<U>Excluded Shares</U>&#148;) shall be cancelled and shall cease to exist, and no consideration shall be paid or
payable in respect thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) except as provided in <U>Section</U><U></U><U>&nbsp;1.5(a)(i)</U> and
Section<U></U><U>&nbsp;1.6</U> with respect to Excluded Shares, each share of Company Common Stock that is issued and outstanding immediately prior to the First Effective Time shall be converted into the right to receive, without interest, at the
election of the holder thereof in accordance with the procedures set forth in <U>Section</U><U></U><U>&nbsp;1.12</U> and <U>Section</U><U></U><U>&nbsp;1.15</U> (such consideration, the &#147;<U>Merger Consideration</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) for each share of Company Common Stock with respect to which an election to receive cash has been made and not revoked or
lost pursuant to <U>Section</U><U></U><U>&nbsp;1.15</U> (such share of Company Common Stock, together with any share of Company Common Stock for which an election to receive cash is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
deemed to have been made under clause (C)&nbsp;below, the &#147;<U>Cash Election Shares</U>&#148;) an amount of cash equal to $28.00, without interest (the &#147;<U>Cash Election
Consideration</U>&#148;), as the same may be adjusted pursuant to <U>Section</U><U></U><U>&nbsp;1.7(a)(ii)</U> and <U>Section</U><U></U><U>&nbsp;1.7(b)(ii)</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) for each share of Company Common Stock with respect to which an election to receive stock has been made and not revoked or
lost pursuant to <U>Section</U><U></U><U>&nbsp;1.15</U> (such share of Company Common Stock, together with any share of Company Common Stock for which an election to receive stock is deemed to have been made under clause (C)&nbsp;below, the
&#147;<U>Stock Election Shares</U>&#148;), 1.6839 validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Parent Class&nbsp;A Common Stock (the &#147;<U>Stock Election Consideration</U>&#148;), as the same may
be adjusted pursuant to <U>Section</U><U></U><U>&nbsp;1.7(a)(ii)</U>; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) for each share of Company Common Stock with
respect to which no election to receive cash or stock has been made, the Cash Election Consideration or the Stock Election Consideration, as provided in <U>Section</U><U></U><U>&nbsp;1.7</U> (such share of Company Common Stock described in this
clause (C), the &#147;<U>No Election Shares</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) each share of common stock, par value $0.0001 per share, of
Acquisition Sub I that is issued and outstanding immediately prior to the First Effective Time shall be converted into one validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of common stock, par value $0.0001
per share, of the Initial Surviving Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Treatment of Capital Stock in Second Merger</B>. Subject to the
terms and conditions of this Agreement, at the Second Effective Time, automatically, by virtue of the Second Merger and without any action on the part of Parent, the Initial Surviving Corporation or Acquisition Sub II, each share of common stock,
par value $0.0001 per share, of the Initial Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be cancelled and shall cease to exist. Each limited liability company interest of Acquisition Sub II issued
and outstanding immediately prior to the Second Effective Time shall remain outstanding as a limited liability company interest of the Surviving Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6 <B>Dissenting Shares</B>. Notwithstanding <U>Section</U><U></U><U>&nbsp;1.5(a)(ii)</U>, shares of Company Common Stock issued
and outstanding immediately prior to the First Effective Time and held by a holder who is entitled to, and has properly exercised and perfected his, her or its demand for, appraisal rights under Section&nbsp;262 of the DGCL (the &#147;<U>Dissenting
Shares</U>&#148;) shall not be converted into the right to receive the Merger Consideration, but each holder of such Dissenting Shares shall be entitled to receive such consideration as shall be determined pursuant to Section&nbsp;262 of the DGCL
(it being understood and acknowledged that at the First Effective Time, such Dissenting Shares shall no longer be outstanding, shall automatically be cancelled and shall cease to exist and such holder shall cease to have any rights with respect
thereto other than the right to receive the fair market value of such Dissenting shares to the extent afforded by Section&nbsp;262 of the DGCL); <I>provided</I>, <I>however</I>, that if any such holder shall have failed to perfect or shall have
effectively withdrawn or lost his or her right to appraisal and payment under Section&nbsp;262 of the DGCL (whether occurring before, at or after the First Effective Time), such holder&#146;s shares of Company Common Stock shall thereupon be deemed
to have been converted as of the First Effective Time solely into the right to receive the Merger Consideration as if such shares were No Election Shares, without any interest thereon, and such shares shall not be deemed to be Dissenting Shares. The
Company shall give Parent prompt written notice of any demands for appraisal of Company Common Stock received by the Company, written withdrawals or attempted withdrawals of such demands and any other instruments, notices or demands served on the
Company pursuant to Section&nbsp;262 of the DGCL. The Company shall not, without the prior written consent of Parent, voluntarily make any payment with respect to, or settle or offer to settle, any such demands, waive any failure to timely deliver a
written demand for appraisal under the DGCL, or approve any withdrawal of any such demands or agree to do or commit to do any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.7 <B>Proration</B>. Notwithstanding any provision of this Agreement to the
contrary: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the product of the aggregate number of Cash Election Shares <I>multiplied by</I> the Cash Election
Consideration (such product being the &#147;<U>Elected Cash Consideration</U>&#148;) exceeds the Maximum Cash Amount, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all Stock Election Shares and all No Election Shares will be exchanged for the Stock Election Consideration; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) a portion of the Cash Election Shares of each holder of shares of Company Common Stock will be exchanged for the Cash
Election Consideration, with such portion being equal to the product obtained by multiplying (A)&nbsp;the number of such holder&#146;s Cash Election Shares by (B)&nbsp;a fraction, the numerator of which will be the Maximum Cash Amount and the
denominator of which will be the Elected Cash Consideration, with the remaining portion of such holder&#146;s Cash Election Shares being deemed to be Stock Election Shares and exchanged for the Stock Election Consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Elected Cash Consideration is less than the Maximum Cash Amount (such difference being the &#147;<U>Shortfall
Amount</U>&#148;), then: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all Cash Election Shares will be exchanged for the Cash Election Consideration; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) all Stock Election Shares and No Election Shares will be treated in the following manner: (A)&nbsp;if the Shortfall Amount
is less than or equal to the product of the aggregate number of No Election Shares <I>multiplied by</I> $28.00 (the &#147;<U>No Election Value</U>&#148;), then (1)&nbsp;all Stock Election Shares will be exchanged for the Stock Election Consideration
and (2)&nbsp;the No Election Shares of each holder of shares of Common Stock will be exchanged for the Cash Election Consideration in respect of that number of No Election Shares equal to the product obtained by multiplying (x)&nbsp;the number of No
Election Shares of such holder by (y)&nbsp;a fraction, the numerator of which is the Shortfall Amount and the denominator of which is the No Election Value, with the remaining portion of such holder&#146;s No Election Shares (if any) being deemed to
be Stock Election Shares and exchanged for the Stock Election Consideration or (B)&nbsp;if the Shortfall Amount exceeds the No Election Value, then (1)&nbsp;all No Election Shares will be exchanged for the Cash Election Consideration and (2)&nbsp;a
portion of the Stock Election Shares of each holder of shares of Company Common Stock will be exchanged for the Cash Election Consideration, with such portion being equal to the product obtained by multiplying (x)&nbsp;the number of Stock Election
Shares of such holder by (y)&nbsp;a fraction, the numerator of which is the amount by which the Shortfall Amount exceeds the No Election Value, and the denominator of which is the product obtained by multiplying the aggregate number of Stock
Election Shares by $28.00, with the remaining portion of such holder&#146;s Stock Election Shares being deemed to be Stock Election Shares and exchanged for the Stock Election Consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the Elected Cash Consideration equals the Maximum Cash Amount, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all Cash Election Shares will be converted into the right to receive the Cash Election Consideration; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) all Stock Election Shares and all No Election Shares will be converted into the right to receive the Stock Election
Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8 <B>Certain Adjustments</B>. Notwithstanding anything in this Agreement to the contrary, if, during the
period from the date of this Agreement through the First Effective Time, the outstanding shares of Parent Class&nbsp;A Common Stock or Company Common Stock are changed or converted into a different number or class or series of shares of capital
stock by reason of any stock split, division, combination, change, exchange or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reorganization, reclassification, recapitalization or other similar transaction, or a
record date with respect to any such event shall occur during such period, then the Merger Consideration shall be adjusted to the extent appropriate to proportionately reflect such change and to otherwise provide the same economic effect to the
Company&#146;s stockholders as contemplated by this Agreement prior to such action. Nothing in this <U>Section</U><U></U><U>&nbsp;1.8</U> shall be construed to permit the parties to take any action except to the extent consistent with, or not
otherwise prohibited by, the terms of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9 <B>Treatment of Equity Awards</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Effective as of the First Effective Time, each Company Option held by an individual who, as of immediately after the First
Effective Time, constitutes an &#147;employee&#148; of Parent within the meaning of Form <FONT STYLE="white-space:nowrap">S-8,</FONT> that is outstanding and unexercised, whether vested or unvested, immediately prior to the First Effective Time
(each, an &#147;<U>Assumed Company Option</U>&#148;) shall cease to represent a right to acquire shares of Company Common Stock and shall be assumed by Parent and converted automatically into a Parent Option on the same terms and conditions
(including applicable vesting, exercise and expiration provisions) as applied to such Assumed Company Option immediately prior to the First Effective Time, except that: (i)&nbsp;the number of shares of Parent Class&nbsp;A Common Stock subject to
each Assumed Company Option shall be determined by multiplying: (A)&nbsp;the number of shares of Company Common Stock subject to such Assumed Company Option immediately prior to the First Effective Time; by (B)&nbsp;the Option Exchange Ratio, and
rounding such product down to the nearest whole share; (ii)&nbsp;the per share exercise price of each Assumed Company Option shall be determined by dividing: (A)&nbsp;the per share exercise price of the Assumed Company Option immediately prior to
the First Effective Time; by (B)&nbsp;the Option Exchange Ratio, and rounding such quotient up to the nearest whole cent, and (iii)&nbsp;the Assumed Company Option shall become fully vested immediately upon the First Effective Time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prior to the First Effective Time, the Company shall take all corporate action necessary to provide that each Company
Option and all Company Restricted Stock shall accelerate in full (to the extent not otherwise previously vested in accordance with their terms) as of immediately prior to the First Effective Time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Effective as of the First Effective Time, each Company Option that is not an Assumed Company Option and that is outstanding
and unexercised shall be settled in cash immediately prior to the First Effective Time in an amount equal to the product of (x)&nbsp;the number of shares of Company Common Stock subject to the Company Option, and (y)&nbsp;the excess, if any, of
(i)&nbsp;the Average Company Stock Price, over (ii)&nbsp;the per share exercise price of such Company Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The
Company shall ensure that (a)&nbsp;no new offering periods under the Company ESPP will commence during the period from the date of this Agreement through the Closing Date, (b)&nbsp;there will be no increase in the amount of payroll deductions
permitted to be made by the participants under the Company ESPP during the current offering periods, except those made in accordance with payroll deduction elections that are in effect as of the date of this Agreement and (c)&nbsp;no individuals
shall commence participation in the Company ESPP during the period from the date of this Agreement through the Closing Date. To the extent applicable, no later than five days prior to the Closing Date, in the case of any outstanding purchase rights
under the Company ESPP, any then-current offering period under the Company ESPP shall end and each participant&#146;s accumulated payroll deductions shall be used to purchase shares of Company Common Stock in accordance with the terms of the Company
ESPP. Shares of Company Common Stock held in participants&#146; Company ESPP account balances immediately prior to the Closing Date shall be treated the same as all other shares of Company Common Stock in accordance with
<U>Section</U><U></U><U>&nbsp;1.5(a)</U>. The Company shall ensure that the Company ESPP shall terminate immediately prior to the First Effective Time contingent upon the occurrence of the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Parent shall take all corporate action necessary to reserve for issuance a sufficient number of shares of Parent
Class&nbsp;A Common Stock for delivery with respect to all Assumed Company Options. Parent shall file and cause to be effective as of no later than the First Effective Time, a registration statement under the Securities Act on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> or other appropriate form under the Securities Act, relating to shares of Parent Class&nbsp;A Common Stock issuable with respect to all Assumed Company Options, and Parent shall use its best efforts to cause
such registration statement to remain in effect for so long as such Assumed Company Options remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.10 <B>No
Fractional Shares</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No fractional shares of Parent Class&nbsp;A Common Stock shall be issued in connection with the
First Merger, and no certificates or scrip for any such fractional shares shall be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Any holder of Company Common Stock who would otherwise be entitled to
receive a fraction of a share of Parent Class&nbsp;A Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)(ii)</U> (after aggregating all fractional shares of Parent Class&nbsp;A Common Stock otherwise issuable to such holder pursuant to
<U>Section</U><U></U><U>&nbsp;1.5(a)(ii)</U>) shall, in lieu of such fraction of a share and upon surrender of such holder&#146;s certificates representing shares of Company Common Stock outstanding as of immediately prior to the First Effective
Time (&#147;<U>Company Stock Certificates</U>&#148;) or book-entry positions representing <FONT STYLE="white-space:nowrap">non-certificated</FONT> shares of Company Common Stock outstanding as of immediately prior to the First Effective Time
(&#147;<U>Company Book-Entry Shares</U>&#148;) in accordance with <U>Section</U><U></U><U>&nbsp;1.12</U>, be paid in cash the dollar amount (rounded to the nearest whole cent), without interest and subject to any required Tax withholding, determined
by multiplying such fraction by the Average Parent Stock Price. No such holder shall be entitled to dividends, voting rights or any other rights in respect of any fractional share of Parent Class&nbsp;A Common Stock that would otherwise have been
issuable as part of the Merger Consideration. The payment of cash in lieu of fractional share interests pursuant to this <U>Section</U><U></U><U>&nbsp;1.10(b)</U> is not a separately <FONT STYLE="white-space:nowrap">bargained-for</FONT>
consideration but merely represents a mechanical <FONT STYLE="white-space:nowrap">rounding-off</FONT> of the fractions in the exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.11 <B>Closing of Transfer Books</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the First Effective Time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) all shares of Company Common Stock outstanding immediately prior to the First Effective Time shall automatically be
cancelled and shall cease to exist, and all holders of Company Stock Certificates and of Company Book-Entry Shares shall cease to have any rights as stockholders of the Company, except (unless such holder holds Excluded Shares, which are subject to
<U>Section</U><U></U><U>&nbsp;1.5(a)(i)</U> or <U>Section</U><U></U><U>&nbsp;1.6</U>) the right to receive the Merger Consideration pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)(ii)</U>, cash in lieu of any fractional share of Parent Class&nbsp;A
Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;1.10(b)</U> and any dividends or other distributions pursuant to <U>Section</U><U></U><U>&nbsp;1.12(f)</U>; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the stock transfer books of the Company shall be closed with respect to all shares of Company Common Stock outstanding
immediately prior to the First Effective Time and no further transfer of any such shares of Company Common Stock shall be made on such stock transfer books after the First Effective Time. If, after the First Effective Time, a valid Company Stock
Certificate or a Company Book-Entry Share is presented to the Exchange Agent or to the Initial Surviving Corporation, the Surviving Company or Parent, such Company Stock Certificate or Company Book-Entry Share shall be cancelled and shall be
exchanged as provided in <U>Section</U><U></U><U>&nbsp;1.12</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.12 <B>Exchange of Certificates and Cancellation of
Book-Entry Positions</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Mailing Date, Parent shall select Parent&#146;s transfer agent or another
reputable bank or trust company, in either case, reasonably satisfactory to both Parent and the Company, to act as exchange agent with respect to the Mergers (the &#147;<U>Exchange Agent</U>&#148;). Promptly following the First Effective Time, (but
in any event within one Business Day following the Closing Date), Parent shall cause to be deposited with the Exchange Agent: (i)&nbsp;certificates or evidence of book-entry shares representing the shares of Parent Class&nbsp;A Common Stock issuable
pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U>; and (ii)&nbsp;cash sufficient to pay the Cash Election Consideration pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U> and to make payments in lieu of fractional shares in accordance with
<U>Section</U><U></U><U>&nbsp;1.10(b)</U>. The shares of Parent Class&nbsp;A Common Stock and cash amounts so deposited with the Exchange Agent pursuant to this <U>Section</U><U></U><U>&nbsp;1.12(a)</U>, together with any dividends or distributions
received by the Exchange Agent with respect to such shares of Parent Class&nbsp;A Common Stock, and any interest or other income with respect to such cash amount, are referred to collectively as the &#147;<U>Exchange Fund</U>.&#148; The Exchange
Agent shall invest the cash available in the Exchange Fund as reasonably directed by Parent; <I>provided</I>, that any investment of such cash shall in all events be limited to (w)&nbsp;direct obligations of, or guaranteed by, the U.S. government,
(x)&nbsp;in commercial paper rated <FONT STYLE="white-space:nowrap">A-1</FONT> or <FONT STYLE="white-space:nowrap">P-1</FONT> or better by Moody&#146;s Investors Service, Inc. or Standard&nbsp;&amp; Poor&#146;s Corporation, respectively, (y)&nbsp;in
certificates of deposit, bank repurchase agreements or banker&#146;s acceptances of commercial banks with capital exceeding $1&nbsp;billion (based on the most recent financial statements of such bank that are then publicly available) or (z)&nbsp;a
money </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
market fund having assets of at least $1&nbsp;billion; <I>provided</I>, <I>further</I>, that no losses on such investments shall affect the cash payable to former holders of shares of Company
Common Stock pursuant to this <U>ARTICLE</U><U></U><U>&nbsp;I</U> (and Parent shall promptly deliver to the Exchange Agent cash in an amount sufficient to replenish any deficiency in the Exchange Fund). The Payment Fund shall not be used for any
purpose that is not expressly provided for in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) With respect to Company Stock Certificates, as promptly
as reasonably practicable, after the First Effective Time, and in any event within three Business Days, Parent shall cause the Exchange Agent to mail to each holder of record of each such Company Stock Certificate (i)&nbsp;a notice advising such
holder of the effectiveness of the Mergers, (ii)&nbsp;a letter of transmittal in customary form and reasonably acceptable to each of Parent and the Company specifying that delivery shall be effected, and risk of loss and title to a Company Stock
Certificate shall pass, only upon delivery of the Company Stock Certificate (or affidavit of loss in lieu of a Company Certificate as provided in <U>Section</U><U></U><U>&nbsp;1.12(e)</U>) to the Exchange Agent (the &#147;<U>Letter of
Transmittal</U>&#148;) and (iii)&nbsp;instructions for surrendering a Company Stock Certificate (or affidavit of loss in lieu of a Company Stock Certificate as provided in <U>Section</U><U></U><U>&nbsp;1.12(e)</U>) to the Exchange Agent. Upon
surrender to the Exchange Agent of a Company Stock Certificate (or affidavit of loss in lieu of a Company Stock Certificate as provided in <U>Section</U><U></U><U>&nbsp;1.12(e)</U>) together with a duly executed and completed Letter of Transmittal
and such other documents as may reasonably be required pursuant to such instructions, Parent shall cause the Exchange Agent to mail to each holder of record of any such Company Stock Certificate in exchange therefor, as promptly as reasonably
practicable thereafter, (i)&nbsp;a statement reflecting the number of whole shares of Parent Class&nbsp;A Common Stock, if any, that such holder is entitled to receive pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U> in <FONT
STYLE="white-space:nowrap">non-certificated</FONT> book-entry form in the name of such record holder (subject to <U>Section</U><U></U><U>&nbsp;1.12(i)</U>) and (ii)&nbsp;a check, or wire transfer of immediate funds (provided such holder has provided
wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required Tax withholdings as provided in <U>Section</U><U></U><U>&nbsp;1.14</U>) of (A)&nbsp;the applicable Cash Election
Consideration such holder is entitled to receive pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U>, <I>plus</I> (B)&nbsp;any cash in lieu of fractional shares of Parent Class&nbsp;A Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;1.10</U>
<I>plus</I> (C)&nbsp;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to <U>Section</U><U></U><U>&nbsp;1.12(f)</U>. Any Company Stock Certificate that has been so surrendered
shall be cancelled by the Exchange Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) With respect to Company Book-Entry Shares not held through DTC (each, a
&#147;<U><FONT STYLE="white-space:nowrap">Non-DTC</FONT> Book-Entry Share</U>&#148;), Parent shall cause the Exchange Agent to pay and deliver to each holder of record of any <FONT STYLE="white-space:nowrap">Non-DTC</FONT> Book-Entry Share, as
promptly as reasonably practicable after the First Effective Time, but in any event within two Business Days thereafter, (i)&nbsp;a statement reflecting the number of whole shares of Parent Class&nbsp;A Common Stock, if any, that such holder is
entitled to receive pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U> in <FONT STYLE="white-space:nowrap">non-certificated</FONT> book-entry form in the name of such record holder (subject to <U>Section</U><U></U><U>&nbsp;1.12(i)</U>) and
(ii)&nbsp;a check or wire transfer of immediately available funds (provided such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000) in the amount (after giving effect to any required Tax withholdings as
provided in <U>Section</U><U></U><U>&nbsp;1.14</U>) of (A)&nbsp;the applicable Cash Election Consideration such holder is entitled to receive pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U>, <I>plus</I> (B)&nbsp;any cash in lieu of fractional
shares of Parent Class&nbsp;A Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;1.10</U> <I>plus</I> (C)&nbsp;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to
<U>Section</U><U></U><U>&nbsp;1.12(f)</U>, and each <FONT STYLE="white-space:nowrap">Non-DTC</FONT> Book-Entry Share shall be promptly cancelled by the Exchange Agent. Subject to <U>Section</U><U></U><U>&nbsp;1.12(i)</U>, payment of the Merger
Consideration with respect to <FONT STYLE="white-space:nowrap">Non-DTC</FONT> Book-Entry Shares shall only be made to the Person in whose name such <FONT STYLE="white-space:nowrap">Non-DTC</FONT> Book-Entry Shares are registered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) With respect to Company Book-Entry Shares held through DTC, prior to the First Effective Time, Parent and the Company shall
cooperate to establish procedures with the Exchange Agent and DTC to provide that the Exchange Agent will transmit to DTC or its nominees as promptly as reasonably practicable after the First Effective Time, but in any event within three Business
Days thereafter, upon surrender of shares held of record by DTC or its nominees in accordance with DTC&#146;s customary surrender procedures, the Merger Consideration, cash in lieu of fractional shares of Parent Common Stock pursuant to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;1.10</U>, if any, and any unpaid cash dividends and any other dividends or other distributions, in each case, that such holder has the right to receive pursuant to
<U>Section</U><U></U><U>&nbsp;1.12(f)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In the event that any Company Stock Certificate shall have been lost,
stolen or destroyed, then, upon the making of an affidavit of that fact (in form reasonably acceptable to Parent and the Exchange Agent) by the Person claiming such Company Stock Certificate to be lost, stolen or destroyed and the posting by such
Person of a bond in a reasonable and customary amount and upon such terms as may reasonably be required as indemnity against any claim that may be made against it with respect to such Company Stock Certificate, the Exchange Agent will issue in
exchange for such lost, stolen or destroyed Company Stock Certificate, the Merger Consideration, cash in lieu of fractional shares of Parent Class&nbsp;A Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;1.10</U>, if any, and any unpaid cash
dividends and any other dividends or other distributions, in each case, payable or issuable pursuant to <U>Section</U><U></U><U>&nbsp;1.12(f)</U>, as if such lost, stolen or destroyed Company Stock Certificate had been surrendered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No dividends or other distributions declared or made with respect to Parent Class&nbsp;A Common Stock with a record date
after the First Effective Time shall be paid or otherwise delivered to the holder of any unsurrendered Company Stock Certificate or Company Book-Entry Shares, as applicable, with respect to the shares of Parent Class&nbsp;A Common Stock that such
holder has the right to receive in the Mergers until the later to occur of: (A)&nbsp;the date on which the holder surrenders such Company Stock Certificate or Company Book-Entry Shares in accordance with this <U>Section</U><U></U><U>&nbsp;1.12</U>;
and (B)&nbsp;the payment date for such dividend or distribution with respect to Parent Class&nbsp;A Common Stock (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar laws, to
receive all such dividends and distributions, without interest). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Any portion of the Exchange Fund that remains
undistributed to holders of Company Stock Certificates or Company Book-Entry Shares as of the date that is one year after the Closing Date shall be delivered to Parent upon demand. Any holders of Company Stock Certificates or Company Book-Entry
Shares who have not theretofore surrendered their Company Stock Certificates or Company Book-Entry Shares in accordance with this <U>Section</U><U></U><U>&nbsp;1.12</U> shall thereafter be entitled to look to Parent for, and be entitled to receive
from Parent, the Merger Consideration pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;1.5(a)</U>, cash in lieu of any fractional shares of Parent Class&nbsp;A Common Stock in accordance with <U>Section</U><U></U><U>&nbsp;1.10(b)</U> and
any dividends or distributions with respect to shares of Parent Class&nbsp;A Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;1.12(f)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) None of Parent, the Initial Surviving Corporation, nor the Surviving Company shall be liable to any holder or former holder
of shares of Company Common Stock or to any other Person with respect to any portion of the Merger Consideration delivered to any public official pursuant to any applicable abandoned property law, escheat law or other similar Legal Requirement. If
any Company Stock Certificate or Company Book-Entry Share has not been surrendered prior to the date on which any portion of the Merger Consideration and any dividends or distributions, in each case, that a holder of such Company Stock Certificates
or Company Book-Entry Share has the right to receive pursuant to this <U>Section</U><U></U><U>&nbsp;I</U> in respect of such Company Stock Certificate or Company Book-Entry Share would otherwise escheat to or become property of any Governmental
Entity, any such shares, cash, dividends or distributions in respect of such Company Stock Certificate or Company Book-Entry Share shall, to the extent permitted by applicable Legal Requirement, become the property of Parent, free and clear of all
claims or interests of any Person previously entitled thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In the event of a transfer of ownership of any shares
of Company Common Stock that is not registered in the transfer records of the Company, the Exchange Agent may deliver the Merger Consideration (and, to the extent applicable, cash in lieu of fractional shares pursuant to
<U>Section</U><U></U><U>&nbsp;1.10(b)</U> or any dividends or distributions pursuant to <U>Section</U><U></U><U>&nbsp;1.12(f)</U>) to such transferee if (A)&nbsp;in the case of Company Book-Entry Shares, written instructions authorizing the transfer
of the Company Book-Entry Shares are presented to the Exchange Agent, (B)&nbsp;in the case of Company Stock Certificates, the Company Stock Certificates formerly representing such shares of Company Common Stock are surrendered to the Exchange
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Agent, and (C)&nbsp;the written instructions, in the case of clause (A), and Company Stock Certificates, in the case of clause (B), are accompanied by all documents required to evidence and
effect such transfer and to evidence that any applicable stock transfer Taxes have been paid or are not applicable, in each case, in form and substance, reasonably satisfactory to Parent and the Exchange Agent. If any Merger Consideration is to be
delivered to a Person other than the holder in whose name any shares of Company Common Stock are registered, it shall be a condition of such exchange that the Person requesting such delivery shall pay any transfer or other similar Taxes required by
reason of the transfer of shares of Parent Class&nbsp;A Common Stock to a Person other than the registered holder of any shares of Company Common Stock, or shall establish to the satisfaction of Parent and the Exchange Agent that such Tax has been
paid or is not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.13 <B>Further Action</B>. If, at any time after the First Effective Time, any further action is
determined by Parent, the Initial Surviving Corporation or the Surviving Company to be necessary to carry out the purposes of this Agreement, the officers and directors of Parent shall (in the name of Acquisition Subs, in the name of the Company or
otherwise) be fully authorized to take such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.14 <B>Tax Withholding</B>. Each of Parent, the Exchange Agent,
Acquisition Sub I, Acquisition Sub II, the Company and the Initial Surviving Corporation and the Surviving Company, as applicable, shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement any amounts as
are required to be deducted and withheld with respect to the making of such payment pursuant to the Code or any other applicable Legal Requirement relating to Taxes. To the extent that amounts are so deducted or withheld and, if required, paid over
to the appropriate Governmental Entity, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding were made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.15 <B>Election Procedures</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Not less than 30 days prior to the anticipated First Effective Time (the &#147;<U>Mailing Date</U>&#148;), Parent will
cause to be mailed to each record holder of shares of Company Common Stock (other than Excluded Shares) as of five business days prior to the Mailing Date (or another date selected by Parent which is reasonably acceptable to the Company) an election
form in a form mutually satisfactory to Parent and the Company (the &#147;<U>Election Form</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Election
Form will permit the holder (or the beneficial owner through customary documentation and instructions) of shares of Company Common Stock to specify (i)&nbsp;the number of shares of Company Common Stock with respect to which such holder elects to
receive the Stock Election Consideration, (ii)&nbsp;the number of Shares with respect to which such holder elects to receive the Cash Election Consideration or (iii)&nbsp;that such holder makes no election with respect to such holder&#146;s shares
of Company Common Stock. Any shares of Company Common Stock with respect to which the Exchange Agent does not receive a properly completed Election Form during the period (the &#147;<U>Election Period</U>&#148;) from the Mailing Date to 5:00 p.m.,
New York Time, on the Business Day that is three Trading Days prior to the Closing Date or such other date as Parent and the Company will, prior to the Closing, mutually agree (the &#147;<U>Election Deadline</U>&#148;) will be deemed to be No
Election Shares. Parent and the Company will publicly announce the anticipated Election Deadline at least five Business Days prior to the anticipated Closing Date. If the Closing Date is delayed to a subsequent date, the Election Deadline shall be
similarly delayed to a subsequent date, and Parent and the Company shall promptly announce any such delay and, when determined, the rescheduled Election Deadline. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Any election made pursuant to this <U>Section</U><U></U><U>&nbsp;1.15</U> will have been properly made only if the Exchange
Agent has actually received a properly completed Election Form during the Election Period. Any Election Form may be revoked or changed by the Person submitting it, by written notice received by the Exchange Agent during the Election Period. In the
event an Election Form is revoked during the Election Period, the Shares represented by such Election Form will be deemed to be No Election Shares, except to the extent a subsequent election is properly made during the Election Period. Subject to
the terms of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Agreement and of the Election Form, the Exchange Agent will have reasonable discretion to determine whether any election, revocation or change has been properly or timely made and to disregard
immaterial defects in the Election Forms, and any good faith decisions of the Exchange Agent regarding such matters will be binding and conclusive. None of Parent, the Company or the Exchange Agent will be under any obligation to notify any Person
of any defect in an Election Form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE II.REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants to Parent and Acquisition Sub that, except as set forth or incorporated by reference in the Company SEC Documents
filed and publicly available prior to the date of this Agreement (excluding any disclosures contained in such documents under the heading &#147;Risk Factors&#148; or in any other section&nbsp;to the extent they are forward-looking statements or
cautionary, predictive or forward-looking in nature) or, subject to <U>Section</U><U></U><U>&nbsp;7.12</U>, in the disclosure schedule delivered to Parent concurrent with the execution of this Agreement (the &#147;<U>Company Disclosure
Schedule</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <B>Due Organization and Good Standing; Subsidiaries</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of
Delaware. The Company has the requisite corporate power and authority to own, lease and operate its assets and to carry on its business as it is being conducted as of the date of this Agreement, except as, individually or in the aggregate, has not
had and would not reasonably be expected to have a Company Material Adverse Effect. The Company is duly qualified and has all necessary Governmental Authorizations to do business, and (where such concept is recognized under the Laws of the
applicable jurisdictions) is in good standing, in each other jurisdiction where the nature of its business makes such qualification necessary, except where the failure to be so qualified or in good standing, individually or in the aggregate, has not
had and would not reasonably be expected to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Exhibit 21.1 of the Most Recent
Company <FONT STYLE="white-space:nowrap">10-K</FONT> is a correct and complete list of each Entity that is a Company Subsidiary as of the date of this Agreement. Neither the Company nor any Company Subsidiary owns any equity interest or joint
venture, partnership or similar interest in any other Entity, other than the Entities identified in Exhibit 21.1 of the Most Recent Company <FONT STYLE="white-space:nowrap">10-K.</FONT> Each Company Subsidiary is duly organized, validly existing and
in good standing under the laws of the jurisdiction of its organization and has the requisite corporate or other organizational power and authority and Governmental Authorizations to own, lease and operate its assets and to carry on its business as
it is being conducted as of the date of this Agreement, except where the failure to be so organized, existing and in good standing or to have such power and authority, individually or in the aggregate, has not had and would not reasonably be
expected to have a Company Material Adverse Effect. Each Company Subsidiary is duly qualified and has all necessary Governmental Authorizations to do business, and (where such concept is recognized under the laws of the applicable jurisdictions) is
in good standing, in each other jurisdiction where the nature of its business makes such qualification necessary, except where the failure to be so qualified or in good standing, individually or in the aggregate, has not had and would not reasonably
be expected to have a Company Material Adverse Effect. All of the outstanding shares of capital stock of each Company Subsidiary are duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned
directly or indirectly by the Company free and clear of all Liens, except for restrictions on transfer under applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <B>Organizational Documents</B>. Prior to the date of this Agreement, the Company has made available to Parent copies of the
Organizational Documents of the Company and each Company Subsidiary, including all amendments thereto in effect prior to the date of this Agreement. The Organizational Documents of the Company and each Company Subsidiary are in full force and effect
and neither (a)&nbsp;the Company nor (b)&nbsp;except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, any Company Subsidiary is in violation of any of the provisions of
such Organizational Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <B>Capitalization</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of the Company consists of: (i) 45,000,000 shares of Company Common Stock and (ii) 2,000,000
shares of preferred stock, par value $0.0001 per share (the &#147;<U>Company Preferred Stock</U>&#148;). All of the outstanding shares of Company Common Stock have been, and all shares of Company Common Stock reserved for issuance pursuant to the
Company Equity Agreements will be when issued, duly authorized and validly issued, and are, or will be when issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in the Company&#146;s Organizational Documents or the Company Equity Agreements: (i)&nbsp;none of the
outstanding shares of Company Common Stock is entitled or subject to any preemptive right, right of repurchase, right of participation or any similar right granted by the Company or a Company Subsidiary; (ii)&nbsp;none of the outstanding shares of
Company Common Stock is subject to any right of first refusal in favor of the Company or any Company Subsidiary; (iii)&nbsp;there are no bonds, debentures, notes or other indebtedness issued by the Company or any Company Subsidiary and outstanding
having the right to vote (or convertible or exercisable or exchangeable for securities having the right to vote) on any matters on which stockholders of the Company may vote; and (iv)&nbsp;there is no Contract to which the Company or any Company
Subsidiary is a party relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any shares of Company Common
Stock. Except as set forth in the Company Equity Agreements, neither the Company nor any Company Subsidiary is under any obligation, nor is it bound by any Contract pursuant to which it will become obligated, to repurchase, redeem or otherwise
acquire any outstanding shares of Company Common Stock, capital or other equity interests of any Company Subsidiary or any other securities of any other Entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of July&nbsp;27,&nbsp;2021 (the &#147;<U>Company Capitalization Date</U>&#148;): (i) 17,410,045 shares of Company Common
Stock were issued and outstanding, which total includes 159,800 shares of Company Restricted Stock; (ii)&nbsp;no shares of Company Preferred Stock were issued and outstanding, (iii) 2,202,301 shares of Company Common Stock were subject to issuance
pursuant to outstanding Company Options, (iv) 400,000 shares of Company Common Stock were reserved for issuance pursuant to the Company ESPP; (v) 524,736 shares of Company Common Stock were reserved for issuance pursuant to the Company Equity
Incentive Plans (excluding securities reflected in clauses (iii)&nbsp;and (iv)); and (vi)&nbsp;no other shares of capital stock or other voting securities of the Company were issued, reserved for issuance or outstanding. From the Company
Capitalization Date through the date of this Agreement, neither the Company nor any of the Company Subsidiaries has issued any shares of Company Common Stock or other equity interests of the Company or any Company Subsidiary, other than pursuant to
Company Options, in each case, that were outstanding as of the Company Capitalization Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth in
<U>Section</U><U></U><U>&nbsp;2.3(c)</U>, there is no: (i)&nbsp;subscription, option, call, warrant or other right (whether or not currently exercisable) to acquire any shares of the capital stock or other equity interests, or any restricted stock
unit, stock-based performance unit, shares of phantom stock, stock appreciation right, profit participation right or any other right that is linked to, or the value of which is based on or derived from, the value of any shares of capital stock or
other equity interest of the Company or any Company Subsidiary, in each case, to which the Company or any Company Subsidiary is a party; (ii)&nbsp;outstanding security, instrument, bond, debenture or note that is or may become convertible into or
exchangeable for any shares of the capital stock or other securities of the Company or any Company Subsidiary; or (iii)&nbsp;stockholder rights plan (or similar plan commonly referred to as a &#147;poison pill&#148;) or Contract under which the
Company or any Company Subsidiary is or may become obligated to sell or otherwise issue any shares of its capital stock or other equity interest or any other securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Prior to the date of this Agreement, the Company has made available to Parent accurate and complete copies of: (A)&nbsp;the
Company Equity Plans; and (B)&nbsp;the forms of all stock option agreements evidencing Company Options outstanding as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <B>Authority; Binding Nature of Agreement</B>. The Company has the requisite corporate power and authority to enter into and
to perform its obligations under this Agreement and, subject to receipt of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Required Company Stockholder Vote, to consummate the First Merger. Assuming the accuracy of Parent&#146;s and Acquisition Subs&#146; representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3.17</U> hereof, on or prior to the date hereof, the Company Board has unanimously: (a)&nbsp;duly and validly authorized and approved the execution, the delivery and, subject to the receipt of the Required Company
Stockholder Vote, the performance of this Agreement and the consummation of the First Merger by the Company; (b)&nbsp;determined that the First Merger is fair to and in the best interests of the Company and its stockholders; (c)&nbsp;approved and
declared advisable this Agreement and the consummation of the transactions contemplated by this Agreement, including the First Merger; and (d)&nbsp;resolved that (i)&nbsp;this Agreement be submitted to a vote of the Company&#146;s stockholders and,
(ii)&nbsp;subject to the terms and conditions contained in this Agreement, including <U>Section</U><U></U><U>&nbsp;4.5</U>, to recommend that the Company&#146;s stockholders adopt this Agreement (the &#147;<U>Company Board Recommendation</U>&#148;),
and to include the Company Board Recommendation in the Joint Proxy Statement/Prospectus. Assuming the accuracy of Parent&#146;s and Acquisition Subs&#146; representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.17</U> hereof, the
execution and delivery of this Agreement by the Company and the consummation by the Company of the First Merger and other transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of the
Company, and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement, in each case other than, with respect to the consummation of the Mergers, the receipt of the Required Company Stockholder Vote and the
filing of the Certificates of Merger as required by the DGCL. This Agreement has been duly executed and delivered on behalf of the Company and, assuming the due authorization, execution and delivery of this Agreement on behalf of Parent and the
Acquisition Subs and the accuracy of Parent&#146;s and Acquisition Subs&#146; representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.17</U> hereof, constitutes the valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, subject to: (i)&nbsp;laws of general application relating to bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, affecting creditors&#146; rights generally;
and (ii)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies (the &#147;<U>General Enforceability Exception</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5 <B>Vote Required</B>. Assuming the accuracy of Parent&#146;s and Acquisition Subs&#146; representations and warranties set
forth in <U>Section</U><U></U><U>&nbsp;3.17</U> hereof, the adoption of this Agreement by the affirmative vote of the holders of at least a majority of the shares of Company Common Stock issued and outstanding on the record date for the Company
Stockholder Meeting and entitled to vote on the proposal to adopt this Agreement (the &#147;<U>Required Company Stockholder Vote</U>&#148;) is the only vote of the holders of any class or series of the Company&#146;s capital stock necessary under
applicable Legal Requirements and the Company Organizational Documents to adopt this Agreement or for the Company to consummate the transactions contemplated hereby, including the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6 <B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement by the Company and, assuming receipt of the Required Company Stockholder Vote
and the accuracy of Parent&#146;s and Acquisition Subs&#146; representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.17</U> hereof, the consummation by the Company of the Mergers will not: (i)&nbsp;cause a violation of any of the
provisions of the Organizational Documents of the Company or any Company Subsidiary; (ii)&nbsp;assuming the consents and filings referred to in <U>Section</U><U></U><U>&nbsp;2.6(b)</U> are made and obtained, conflict with or violate any applicable
Legal Requirements; or (iii)&nbsp;subject to <U>Section</U><U></U><U>&nbsp;4.7</U>, result in any loss, limitation or impairment of any right of the Company or any Company Subsidiary to own or use any assets, result in any violation of or default
(with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation, first offer, first refusal, modification or acceleration of any obligation or to the loss of a benefit under any Material Contract, or
result in the creation of any Liens of any kind (other than Company Permitted Encumbrances) upon any of the properties, rights or assets of the Company or any Company Subsidiary, except, in the cases of clauses &#147;(ii)&#148; and
&#147;(iii),&#148; as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as (i)&nbsp;may be required by the applicable requirements of the Securities Act, the Exchange Act, the DGCL, the
DLLCA, the HSR Act or other applicable Antitrust Laws, applicable state securities takeover and &#147;blue sky&#148; laws, the rules and regulations of Nasdaq, (ii)&nbsp;in connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
filing of the Form <FONT STYLE="white-space:nowrap">S-4</FONT> with the SEC or (iii)&nbsp;the filing of all material applications and notices, consents, approvals, clearances, authorizations,
registrations, and exemptions, as required by the FDA and any other federal, state, local or foreign Governmental Entity that is concerned with or regulates the development, marketing, labeling, sale, use, handling and control, safety, efficacy,
reliability or manufacturing of, or payment for biological products, human cells, tissues, and cellular or tissue-based products (&#147;<U>HCT/Ps</U>&#148;), medical devices or durable medical equipment or is concerned with or regulates public
health care programs (each, a &#147;<U>Healthcare Regulatory Authority</U>&#148;), the Company and the Company Subsidiaries are not required to make any filing, registration, or declaration with, give any notice to, or obtain any consent, Order,
license, permit, clearance, waiver or approval from, any Governmental Entity for the execution and delivery of this Agreement by the Company, the performance by the Company of its covenants and obligations hereunder or the consummation by the
Company of the Mergers, in each case, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.7 <B>Reports; Financial Statements; Internal Controls</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated by
reference therein) required to be filed or furnished by the Company with the SEC under the Exchange Act or Securities Act since January&nbsp;1, 2019 (the &#147;<U>Company SEC Documents</U>&#148;) have been filed or furnished by or on behalf of the
Company with the SEC on a timely basis. As of the time it was filed with the SEC (or if amended or superseded, then on the date of such amended or superseding filing): (i) each of the Company SEC Documents complied in all material respects with the
applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act (as the case may be) and the applicable regulations promulgated thereunder and the listing requirements and corporate governance rules and regulations of
Nasdaq, each as in effect on the date such Company SEC Document was filed; and (ii)&nbsp;none of the Company SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. No Company Subsidiary has been required to file any forms, reports or other documents with the SEC at any time since
January&nbsp;1, 2019. Since January&nbsp;1, 2019 no executive officer of the Company has failed in any respect to make the certifications required of him or her under Section&nbsp;302 or 906 of the Sarbanes-Oxley Act. Neither the Company nor any of
its executive officers has received notice from any Governmental Entity challenging or questioning the accuracy, completeness, form or manner of filing of such certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including any related notes) contained or incorporated by reference in the Company SEC Documents:
(i)&nbsp;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may
be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by the rules and regulations of the SEC applicable thereto, and except that unaudited financial statements may not contain footnotes and are
subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments); (iii) fairly present, in all material respects, the financial position of the Company and the Company&#146;s consolidated Subsidiaries as of the
respective dates thereof and the results of operations and consolidated cash flows of the Company and the Company&#146;s consolidated Subsidiaries for the periods covered thereby subject, with respect to unaudited interim statements, to normal and
recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments; and (iv)&nbsp;have been prepared from, and are in accordance with, the books and records of the Company and the Company&#146;s consolidated Subsidiaries in all material
respects. No financial statements of any Person other than the Company and the Company&#146;s consolidated Subsidiaries are required by GAAP to be included in the consolidated financial statements of the Company. The books and records of the Company
and the Company Subsidiaries have been, and are being, maintained in all material respects in accordance with GAAP and any other applicable legal and accounting requirements. As of the date of this Agreement, Deloitte&nbsp;&amp; Touche LLP has not
resigned (or informed the Company that it intends to resign) or been dismissed as independent public accountants of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company maintains, and at all times since January&nbsp;1, 2019 has maintained, a system of internal control over
financial reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Act) which is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP,
and includes those policies and procedures that: (i)&nbsp;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company and the Company Subsidiaries;
(ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of
management and directors of the Company; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Company and the Company Subsidiaries that could have a
material effect on the financial statements. The Company&#146;s management has completed an assessment of the effectiveness of the Company&#146;s system of internal control over financial reporting in compliance with the requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act for the most recent fiscal quarter ended March&nbsp;31, 2021 and such assessment concluded that such controls were effective. Management of the Company has disclosed to the Company&#146;s auditors and the
audit committee of the Company Board (x)&nbsp;any significant deficiencies or material weaknesses in the design and operation of internal controls over financial reporting since January&nbsp;1, 2019 and (y)&nbsp;any fraud, whether or not material,
that involves management or any other employees who have a significant role in the Company&#146;s internal control over financial reporting, and each such deficiency, weakness and fraud so disclosed to auditors, if any, has been made available to
Parent prior to the date hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Since January&nbsp;1, 2019, (i) none of the Company or any Company Subsidiary nor, to
the knowledge of the Company, any director or officer of the Company or any Company Subsidiary has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding
accounting, internal accounting controls or auditing practices, procedures, methodologies or methods of the Company or any Company Subsidiary or any material complaint, allegation, assertion or claim from employees of the Company or any Company
Subsidiary regarding questionable accounting or auditing matters with respect to the Company or any Company Subsidiary, and (ii)&nbsp;to the knowledge of the Company, no attorney representing the Company or any Company Subsidiary, whether or not
employed by the Company or any Company Subsidiary, has reported evidence of a violation of securities laws, breach of fiduciary duty or similar violation by the Company, any Company Subsidiary or any of their respective officers, directors,
employees or agents to the Company Board or any committee thereof, or to the Chief Financial Officer or Chief Executive Officer of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company maintains disclosure controls as required by <FONT STYLE="white-space:nowrap">Rule&nbsp;13a-15</FONT> or <FONT
STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act. As of the date of this Agreement, the Company is in compliance in all material respects with all current listing requirements of the Nasdaq Global Select Market
(&#147;<U>Nasdaq</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any Company Subsidiary is a party to, or has a commitment to
effect, enter into or create, any joint venture, or <FONT STYLE="white-space:nowrap">&#147;off-balance</FONT> sheet arrangement&#148; (as defined in Item 303(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC
with respect to the Company SEC Documents, and none of the Company SEC Documents is, to the knowledge of the Company, the subject of ongoing SEC review or investigation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company nor any Company Subsidiary has any liabilities of any nature or type (whether accrued, absolute,
determined, contingent or otherwise and whether due or to become due), that would be required by GAAP to be reflected on a condensed consolidated balance sheet of the Company and its consolidated Company Subsidiaries, except for:
(i)&nbsp;liabilities disclosed in the financial statements (including any related notes) contained in the Most Recent Company Balance Sheet; (ii)&nbsp;liabilities incurred in the ordinary course of business in a manner consistent with past practice
since the date of the Most Recent Company Balance Sheet; (iii)&nbsp;liabilities that, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse Effect; and (iv)&nbsp;liabilities and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
obligations incurred in connection with this Agreement, the preparation and negotiation of this Agreement or the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.8 <B>Absence of Certain Changes</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since the date of the Most Recent Company Balance Sheet, there has not been any fact, event, change, effect, circumstance,
occurrence or development that, individually or in the aggregate, has had or would reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From the date of the Most Recent Company Balance Sheet to the date of this Agreement, the businesses of the Company and the
Company Subsidiaries have been conducted in all material respects in the ordinary course of business (other than in connection with <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures) in a manner consistent with past practice, and neither the
Company nor any Company Subsidiary has undertaken any action that if proposed to be taken after the date of this Agreement would require Parent&#146;s consent pursuant to subsections (ii), (iii), (iv), (vi), (vii), (xi), (xii), (xvi), (xvii), (xix)
and (xx)&nbsp;of <U>Section</U><U></U><U>&nbsp;4.1(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.9 <B>Intellectual Property and Related Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;2.9(a)</U> of the Company Disclosure Schedule&nbsp;sets forth an accurate and complete list
as of the date of this Agreement, of all material Company IP that is Registered IP (excluding domain name registrations) (collectively, the &#147;<U>Company Registered IP</U>&#148;), including for each item: (i)&nbsp;the jurisdiction of application
or registration; and (ii)&nbsp;the application or registration number. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the knowledge of the Company, all Company
Registered IP is currently in compliance with all formal legal requirements (including, as applicable, payment of filing, examination and maintenance fees, inventor declarations, proofs of working or use, timely post-registration filing of
affidavits of use and incontestability, and renewal applications) to maintain such Registered Company Intellectual Property in full force and effect, except as, individually or in the aggregate, has not had and would not reasonably be expected to
have a Company Material Adverse Effect. To the knowledge of the Company, all material Company Registered IP is valid, subsisting and enforceable (or solely in the case of applications, applied for and pending), since January&nbsp;1, 2019, none of
the material Company Registered IP has ever been found invalid, unpatentable or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding, except for claims rejected or refused in connection with the prosecution
of any Registered Company Intellectual Property. Since January&nbsp;1, 2019, neither the Company nor any Company Subsidiary has received any written notice or claim challenging the validity or enforceability of any Company Registered IP or
indicating an intention on the part of any Person to bring a claim that any of the Company Registered IP is invalid or unenforceable, and there is currently no Legal Proceeding pending or threatened in writing, in which the validity, enforceability
or ownership of any Company Registered IP is being contested or challenged. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the knowledge of the Company, the
Company or a Company Subsidiary, as applicable, solely owns or has a valid and enforceable exclusive license (as applicable) to all Company IP, free and clear of all Liens other than Company Permitted Encumbrances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither the Company nor any Company Subsidiary is subject to any outstanding or potential Order that restricts in any
material manner the use, transfer or licensing of any material Company IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the knowledge of the Company, the
operations of the businesses of the Company and the Company Subsidiaries as currently conducted, including the Company&#146;s and the Company Subsidiaries&#146; design, manufacture, provision, use and sale of any Company Products, do not infringe,
misappropriate or otherwise violate, and, to the knowledge of the Company, since January&nbsp;1, 2019 have not infringed, misappropriated or otherwise violated, any Intellectual Property owned by any other Person except as, individually or in the
aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. No Legal Proceeding is pending or, to the Company&#146;s Knowledge, threatened in writing against the Company or any Company Subsidiary alleging
that the operation of the business of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company or any Company Subsidiary, the Company Products, Company Intellectual Property or Company Technology (or the exploitation of any of the foregoing) infringes, misappropriates, or violates
(or in the past infringed, misappropriated or violated) any Intellectual Property of any Person, or that any of the Company Intellectual Property or Company Technology is invalid or unenforceable. Neither the Company nor any Company Subsidiary has
received any written complaints, claims or notices since January&nbsp;1, 2019 alleging any infringement, misappropriation or violation of any Intellectual Property of any other Person by the Company or any Company Subsidiary. To the knowledge of the
Company, there is no unauthorized use, unauthorized disclosure, infringement, misappropriation or other violation of any material Company IP by any third Person. Since January&nbsp;1, 2019, neither Company nor any Company Subsidiary has brought any
Legal Proceeding against any other Person, or provided any other Person with written notice or other assertion, alleging any Person is infringing, misappropriating or otherwise violating any material Company IP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the knowledge of the Company, no material Company IP was developed using any material support, funding, resources or
assistance from any government entities, or from any university, college, other academic institutions, or <FONT STYLE="white-space:nowrap">non-profit</FONT> research centers (other than in connection with customer agreements in the ordinary course
of business in a manner consistent with past practice). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) As of the date of this Agreement, (i)&nbsp;neither the Company
nor any Company Subsidiary is obligated to grant licenses to any material Company IP to any industry standards organization, body, working group, patent pool, trade association, or similar organization and (ii)&nbsp;neither the Company nor any
Company Subsidiary, nor any material Company IP is subject to any licensing, assignment, contribution, disclosure, or other requirements or restrictions of any industry standards organization, body, working group, patent pool, trade association, or
similar organization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Company and each Company Subsidiary have taken commercially reasonable steps to protect all
Trade Secrets owned, used or held for use by the Company or a Company Subsidiaries and that are material to the Company or the Company Subsidiaries taken as a whole.&nbsp;&nbsp;&nbsp;&nbsp;Each Person who is or was involved in the creation or
development of any Company Product has entered into a valid and enforceable agreement with the Company or a Company Subsidiary, containing an assignment to the Company or the Company Subsidiaries, as applicable, of Intellectual Property in such
Person&#146;s contribution to the Company IP except to the extent not legally assignable and except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. To the knowledge of
the Company, no Person has materially violated such agreement or otherwise misappropriated any Trade Secret that constitutes material Company IP. Since January&nbsp;1, 2019, no Person has notified the Company or any Company Subsidiary in writing
that it is claiming any ownership of or right to use any material Company IP (other than the right to use Company IP expressly granted to such Person under a Contract with the Company or a Company Subsidiary). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Section</U><U></U><U>&nbsp;2.9(i)</U> of the Company Disclosure Schedule sets forth an accurate and complete list as of
the date of this Agreement of, (i)&nbsp;all Contracts pursuant to which a third Person has licensed (including covenants not to sue) to the Company or a Company Subsidiary any material Intellectual Property and which Contract is material to the
Company and the Company Subsidiaries, taken as a whole (&#147;<U><FONT STYLE="white-space:nowrap">In-Bound</FONT> Licenses</U>&#148;); and (ii)&nbsp;each Contract pursuant to which the Company has granted to any third Person any right or license
(including covenants not to sue) to any material Company IP and which Contract is material to the Company and the Company Subsidiaries, taken as a whole (other than, in all cases, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses
granted in the ordinary course of business in a manner consistent with past practice) (&#147;<U><FONT STYLE="white-space:nowrap">Out-Bound</FONT> Licenses</U>&#148; and, together with the <FONT STYLE="white-space:nowrap">In-Bound</FONT> Licenses,
the &#147;<U>Company IP Licenses</U>&#148;). Neither the Company nor any Company Subsidiary is bound by, and no Company IP is subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the
Company or a Company Subsidiary to use, exploit, assert, or enforce any of its Intellectual Property in any material respect anywhere in the world. Without limiting the foregoing, neither the Company nor any Company Subsidiary has granted any
exclusive licenses to any material Company IP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Except as, individually or in the aggregate, has not been and would not
reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole, the Company and each Company Subsidiary is in compliance, and has since January&nbsp;1, 2019 complied, with all applicable Data Protection Laws. To
the knowledge of the Company, since January&nbsp;1, 2019, there have not been any material <FONT STYLE="white-space:nowrap">non-permitted</FONT> disclosures, material security incidents or material breaches involving the Company, the Company
Subsidiaries, or any of its agents, employees or contractors relating to any Personal Data in its possession or control except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) To the knowledge of the Company, since January&nbsp;1, 2019, there has been no material failure or any
material unauthorized intrusions or material breaches of security with respect to the information technology systems owned or controlled by the Company or any Company Subsidiary that has resulted in a material disruption or material interruption in
the operation of the business of the Company or any Company Subsidiary, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.10 <B>Title to Assets; Real Property</B>. Except as, individually or in the aggregate, has not had and would not reasonably be
expected to have a Company Material Adverse Effect, (a)&nbsp;the Company or a Company Subsidiary owns, and has good and marketable title to, or in the case of assets purported to be leased by the Company or a Company Subsidiary, leases and has valid
leasehold interest in, each of the material tangible assets owned or leased by the Company or a Company Subsidiary, free and clear of all Liens (other than Company Permitted Encumbrances), (b) either the Company or a Company Subsidiary has a good
and valid binding leasehold interest in each material property under which the Company or any Company Subsidiary uses or occupies or has the right to use or occupy any real property (such real property, collectively, the &#147;<U>Company Leased Real
Property</U>&#148;), in each case pursuant to a written lease, sublease, license, or other use or occupancy agreement, in each case that is a valid and binding obligation of the Company or a Company Subsidiary and, to the knowledge of the Company,
each other party thereto, (c)&nbsp;(i) none of the Company or any Company Subsidiary is in default of any provision of any such lease and (ii)&nbsp;the Company has made available to Parent a true and correct copy of each such material lease in
effect as of the date of this Agreement, and (d)&nbsp;all buildings, structures, improvements, fixtures, building systems and improvements situated on the Company Leased Real Property comprise all of the material real property used or intended to be
used in the conduct of the business of the Company or the Company Subsidiaries. Neither the Company nor the Company Subsidiaries owns any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.11 <B>Contracts</B>. <U>Section</U><U></U><U>&nbsp;2.11</U> of the Company Disclosure Schedule&nbsp;contains a list as of the
date of this Agreement of each of the following Contracts to which the Company or a Company Subsidiary is a party, other than Company Plans (each such Contract (x)&nbsp;required to be listed in <U>Section</U><U></U><U>&nbsp;2.11</U> of the Company
Disclosure Schedule, (y)&nbsp;that is a Company IP License or (z)&nbsp;that is required to be filed as a &#147;material contract&#148; (as such term is defined in Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the
Exchange Act) as an exhibit to the Most Recent Company <FONT STYLE="white-space:nowrap">10-K</FONT> under the Exchange Act prior to the date of this Agreement (other than any Company Plan), being referred to as a &#147;<U>Material
Contract</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) each Contract that restricts in any material respect the ability of the Company, any Company
Subsidiary or any Affiliate of any of them to (i)&nbsp;engage or compete in any geographic area or line of business, market or field, or to develop, sell, supply, manufacture, market, distribute, or support any material product or service, or
(ii)&nbsp;transact with any Person (or that would so restrict Parent, any Parent Subsidiary or any Affiliate of any of them following the Closing); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) each joint venture agreement, partnership agreement or similar agreement with a third party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) each material acquisition or divestiture Contract that contains any material indemnification obligations of the Company or
a Company Subsidiary or any &#147;earnout&#148; or other material contingent payment obligations that are outstanding obligations of the Company or any Company Subsidiary as of the date of this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) each Contract evidencing indebtedness for money borrowed by the Company
or any Company Subsidiary from a third party lender, and each Contract pursuant to which any such indebtedness for borrowed money is guaranteed by the Company or any Company Subsidiary, in each case in excess of $250,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) each Contract expressly limiting or restricting the ability of the Company or any Company Subsidiary (i)&nbsp;to make
distributions or declare or pay dividends in respect of their capital stock, membership interests or other equity interests, as the case may be, (ii)&nbsp;to pledge their capital stock or other equity interests, (iii)&nbsp;to issue any guaranty, or
(iv)&nbsp;to make loans to the Company or any Company Subsidiary; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) each Contract that obligates the Company or any
Company Subsidiary to make any loans, or capital contributions to, or investments in, any Person in excess of $250,000 individually; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) each Contract that grants a third party any material right of first refusal, first notice, first negotiation or right of
first offer or similar right with respect to any material assets, rights or properties of the Company or any Company Subsidiary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) each Contract or series of related Contracts (excluding (i)&nbsp;purchase orders given or received in the ordinary course
of business in a manner consistent with past practice and (ii)&nbsp;Contracts between the Company and any wholly owned Company Subsidiary or among any wholly owned Company Subsidiaries) under which the Company or any Company Subsidiary (A)&nbsp;paid
in excess of $750,000 in fiscal year 2020, or is expected to pay in excess of $750,000 in fiscal year 2021 or (B)&nbsp;received in excess of $750,000 in fiscal year 2020, or is expected to receive in excess of $750,000 in fiscal year 2021; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) each &#147;single source&#148; supply Contract pursuant to which goods or materials are supplied to the Company or a
Company Subsidiary from a sole source which is expected to involve payments by the Company and Company Subsidiaries in excess of $250,000 in fiscal year 2021; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) each Contract containing any &#147;take or pay&#148;, minimum commitments or similar provisions which, in each case, is
expected to involve payments (including penalty or deficiency payments) by the Company and Company Subsidiaries in excess of $250,000 in fiscal year 2021; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) each lease involving real property pursuant to which the Company or any Company Subsidiary is required to pay a monthly
base rental in excess of $50,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) each lease or rental Contract involving personal property (and not relating
primarily to real property) pursuant to which the Company or any Company Subsidiary is required to make rental payments in excess of $25,000 per month (excluding leases or rental Contracts for office equipment entered into in the ordinary course of
business in a manner consistent with past practice); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) each Contract relating to the acquisition, sale or disposition of
any business unit or product line of the Company or any Company Subsidiary and with any outstanding obligations that are material to the Company and the Company Subsidiaries, taken as a whole, as of the date of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) any Government Contract with any outstanding obligations under which the Company or the Company Subsidiaries received in
excess of $750,000 in fiscal year 2020, or is expected to receive in excess of $750,000 in fiscal year 2021; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) each
Contract with any material &#147;most favored nation&#148; provision or that otherwise requires the Company or any Company Subsidiary (or, following the Closing, would require Parent or any Parent Subsidiary) to conduct business with any Person on a
preferential or exclusive basis, or that includes a price protection provision in favor of the counterparty to such Contract; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) each settlement agreement entered into since January&nbsp;1, 2019 (i) with a Governmental Entity that imposes material
ongoing obligations or restrictions on the Company or any Company Subsidiary; (ii)&nbsp;that requires the Company or any Company Subsidiary to pay more than $250,000 in excess of insurance coverage after the date of this Agreement; or
(iii)&nbsp;that imposes any material restrictions on the business of the Company or any Company Subsidiary after the date of this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) each Contract (excluding purchase orders given or received in the
ordinary course of business in a manner consistent with past practice) with any Top Customer, Top Distributor or Top Supplier of the Company and the Company Subsidiaries; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) each Contract relating to the creation of a Lien (other than Company Permitted Encumbrances) with respect to any material
asset of the Company or any Company Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a
Company Material Adverse Effect, there are no existing breaches or defaults on the part of the Company or any Company Subsidiary under any Material Contract, and, to the knowledge of the Company, there are no existing breaches or defaults on the
part of any other Person under any Material Contract. Each Material Contract is valid, has not been terminated prior to the date of this Agreement, is enforceable against the Company or the applicable Company Subsidiary that is a party to such
Material Contract, and, to the knowledge of the Company, is enforceable against the other parties thereto, in each case subject to the General Enforceability Exception, and, in each case, except as, individually or in the aggregate, has not had and
would not reasonably be expected to have a Company Material Adverse Effect. Prior to the date of this Agreement, the Company has made available to Parent accurate and complete copies of each Material Contract in effect as of the date of this
Agreement, together with all amendments and supplements thereto in effect as of the date of this Agreement (excluding purchase orders given or received in the ordinary course of business in a manner consistent with past practice). As of the date of
this Agreement, no Top Customer, no Top Distributor and no Top Supplier has canceled, terminated or substantially curtailed its relationship with the Company or any Company Subsidiary, given written notice to the Company or any Company Subsidiary of
any intention to cancel, terminate or substantially curtail its relationship with the Company or any Company Subsidiary, or, to the knowledge of the Company, threatened in writing to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.12 <B>Compliance with Legal Requirements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company and the Company Subsidiaries are, and since January&nbsp;1, 2019 have been, in compliance with all Legal
Requirements applicable to them and their businesses, except where the failure to comply with such Legal Requirements, individually or in the aggregate, has not been or would not reasonably be expected to be material to the Company and the Company
Subsidiaries, taken as a whole. Neither the Company nor any Company Subsidiary has, since January&nbsp;1, 2019: (i) to the knowledge of the Company, received any written notice from any Governmental Entity regarding any potential or actual material
violation by the Company or any Company Subsidiaries of any Legal Requirement; or (ii)&nbsp;provided any notice to any Governmental Entity regarding any potential or actual material violation by the Company or any Company Subsidiary of any Legal
Requirement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company and the Company Subsidiaries hold, and have at all times since January&nbsp;1, 2019 held, all
Governmental Authorizations necessary for the lawful operation of the businesses of the Company and the Company Subsidiaries as they are now being conducted (the &#147;<U>Company Permits</U>&#148;) and have paid all fees and assessments due and
payable in connection therewith, except where the failure to have, file or pay, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. Except as, individually or in the
aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, (i)&nbsp;all Company Permits are valid and in full force and effect, are not subject to any administrative or judicial proceeding that could
result in any modification, termination or revocation thereof and, to the knowledge of the Company, no suspension or cancellation of any such Company Permit is threatened; (ii)&nbsp;the Company and each Company Subsidiary is in compliance with the
terms and requirements of all Company Permits; and (iii)&nbsp;no consent from or notice to any Government Entity is required in order for each Company Permit to continue in full force and effect upon consummation of the Mergers and the other
transactions contemplated by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except where the failure to comply with such Legal Requirements,
individually or in the aggregate, has not been or would not reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole, the Company and each Company Subsidiary have at all times
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
since January&nbsp;1, 2019 complied with applicable Sanctions Laws and Export Control Laws. Neither the Company or any Company Subsidiary has been the subject of or otherwise involved in
investigations or enforcement actions by any Governmental Entity or other Legal Proceedings with respect to any actual or alleged violations of Export Control Laws or Sanctions Laws, and neither the Company or any Company Subsidiary has been
notified of any such pending or threatened actions. Neither the Company, any Company Subsidiary, nor any director or officer of the Company or any Company Subsidiary, or, to the knowledge of the Company, any other employee, independent contractor,
consultant, agent, or other person acting on behalf of the Company or any Company Subsidiary, is a Prohibited Person or is subject to debarment or any list-based designations under the Export Control Laws. Since January&nbsp;1, 2019, the Company and
the Company Subsidiaries have secured and maintained all necessary permits, registrations, agreements or other authorizations, including amendments thereof pursuant to the Export Control Laws or Sanctions Laws, including for (i)&nbsp;the export,
import and <FONT STYLE="white-space:nowrap">re-export</FONT> of its products, services, Software and technologies, and (ii)&nbsp;releases of technologies and Software to foreign nationals located in the United States and abroad
(the&nbsp;&#147;<U>Export Approvals</U>&#148;), and each of the Company and the Company Subsidiaries is and, since January&nbsp;1, 2019, has been in compliance in all material respects with the terms of all Export Approvals. None of the officers,
directors, or employees of the Company or any of the Company Subsidiaries is a foreign or domestic Government Official. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.13
<B>Legal Proceedings; Investigations; Orders</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) There is no Legal Proceeding pending or, to the knowledge of the
Company, threatened in writing against the Company or any Company Subsidiary or affecting any of their respective properties or assets that: (i)&nbsp;would adversely affect the Company&#146;s ability to perform any of its obligations under, or
consummate any of the transactions contemplated by, this Agreement; or (ii)&nbsp;individually or in the aggregate, had or would reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There is no Order under which the Company or any Company Subsidiary is subject to ongoing obligations that, individually or
in the aggregate, has had or would reasonably be expected to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.14 <B>Certain
Business Practices</B>. Except as, individually or in the aggregate, has not been or would not reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole, since January&nbsp;1,&nbsp;2019, neither the Company
nor any Company Subsidiary nor, any director, officer, employee, or, to the Company&#146;s knowledge, other agent or Person acting on behalf of the Company or any Company Subsidiary has, directly or indirectly (a)&nbsp;violated or taken any action
that could potentially result in a violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act of 2010 or its predecessor laws, or any other Legal Requirements concerning corrupt payments (collectively,
the &#147;<U>Anti-Corruption Laws</U>&#148;) applicable to the Company or any Company Subsidiary or (b)&nbsp;(i) used, offered to use or authorized the use of any funds of the Company or a Company Subsidiary for unlawful contributions, unlawful
gifts or unlawful entertainment, or for other unlawful payments, related to political activity or otherwise; (ii)&nbsp;made, offered to make or authorized any unlawful payment from funds of the Company or any Company Subsidiary to foreign or
domestic Government Officials or to foreign or domestic political parties or campaigns; (iii)&nbsp;established or maintained any unlawful fund of monies or other unlawful pool of assets of the Company or any Company Subsidiary; (iv)&nbsp;made any
fraudulent entry on the books or records of the Company or any Company Subsidiary; (v)&nbsp;made, offered to make or authorized any bribe, unlawful rebate, unlawful payoff, unlawful influence payment, unlawful kickback or other unlawful payment to
any Person, private or public, in any form; or (vi)&nbsp;engaged in or facilitated any transaction or dealing in property or interests in property of a Prohibited Person, received funds, goods or services from or made any contribution of funds,
goods or services to or for the benefit of a Prohibited Person, or otherwise engaged in or facilitated any transactions with, any Prohibited Person. Neither the Company nor any Company Subsidiary is or within the past five years has (i)&nbsp;been to
the knowledge of the Company, under investigation by any Governmental Entity for any potential or actual violation of any <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws or (ii)&nbsp;received any written notice from any Governmental
Entity regarding any potential or actual violation of, or potential or actual failure to comply with, any <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Laws. Since January&nbsp;1, 2019, neither the Company nor any Company Subsidiary has made any disclosure (voluntary or otherwise) to any Governmental Entity with respect to any potential
violation or liability arising under or relating to any Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.15 <B>Tax Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company and the Company Subsidiaries have timely filed (taking into account any extension of time within which to
file) all Tax Returns that are required to be filed by or with respect to any of them and all such Tax Returns are accurate and complete; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Company and the Company Subsidiaries have timely paid in full to the appropriate Governmental Entity all Taxes
required to be paid by any of them or, in respect of any Taxes accrued but not yet payable by the Company or any Company Subsidiary, adequate reserves have been recorded in the financial statements of the Company and the Company Subsidiaries in
accordance with GAAP; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Each of the Company and the Company Subsidiaries has (i)&nbsp;timely paid, deducted, withheld
and collected all amounts required to be paid, deducted, withheld or collected by any of them with respect to any payment made or owing to, or received from, their employees, creditors, independent contractors, shareholders, customers and other
third parties (and have timely paid over any amounts so withheld, deducted or collected to the appropriate Governmental Entity) and (ii)&nbsp;otherwise complied with all applicable Legal Requirements relating to such withholding, collection and
remittance of Taxes (including information reporting requirements); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Within the last three years, no claim has been
made in writing by any Tax authority in a jurisdiction where the Company or any Company Subsidiary has not filed Tax Returns of a particular type that the Company or any Company Subsidiary is or may be subject to such type of Tax by, or required to
file Tax Returns with respect to Taxes in, such jurisdiction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Neither the Company nor any Company Subsidiary will be
required to include an item of income (or exclude an item of deduction) in any taxable period (or portion thereof) beginning after the Closing Date as a result of (i)&nbsp;a change in or incorrect method of accounting occurring prior to the Closing
Date, (ii)&nbsp;a prepaid amount received (or deferred revenue recognized) or paid, prior to the Closing Date, (iii)&nbsp;any agreement entered into on or prior to the Closing Date with a Governmental Entity relating to Taxes, or (iv)&nbsp;any open
transaction or installment sale entered into on or prior to the Closing Date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) There are no:
(i)&nbsp;examinations, investigations, audits, or other proceedings pending or, to the knowledge of the Company, threatened in writing with respect to any Taxes of the Company or any Company Subsidiary or any Tax Returns; (ii)&nbsp;extensions or
waivers of the limitation period applicable to any Tax Return or the period for the assessment of any Taxes of the Company or the Company Subsidiaries which period has not yet expired; (iii)&nbsp;deficiencies for Taxes that have been claimed,
proposed or assessed by any Governmental Entity in writing against the Company or any Company Subsidiary that have not been fully satisfied by payment; or (iv)&nbsp;Liens in respect of or on account of material Taxes (other than Company Permitted
Encumbrances) upon any of the property or assets of the Company or any Company Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any
of the Company Subsidiaries (i)&nbsp;is or has been, within the last six years, a member of any affiliated, combined, consolidated, unitary or similar group for purposes of filing Tax Returns or paying Taxes, except for any such group of which the
Company is the common parent or (ii)&nbsp;has any liability for Taxes of any Person (other than the Company or any Company Subsidiary) under Treasury Regulations <FONT STYLE="white-space:nowrap">1.1502-6</FONT> (or any similar state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirement) or as transferee or successor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither the Company nor
any Company Subsidiary is a party to or bound by, or has any obligation under, any Tax indemnity, sharing, allocation, or reimbursement agreement or arrangement, other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
than: (i)&nbsp;customary tax provisions in ordinary course commercial agreements, the principal purpose of which is not related to Taxes; and (ii)&nbsp;any agreement or arrangement solely between
or among the Company and/or the Company Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither the Company nor any Company Subsidiary is bound with
respect to the current or any future taxable period by any closing agreement (within the meaning of Section&nbsp;7121(a) of the Code or any similar or analogous state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirement) or
other ruling or written agreement with a Tax authority, in each case, with respect to Taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Within the last two
years, neither the Company nor any Company Subsidiary has distributed stock of another Person or has had its stock distributed by another Person in a transaction that was purported or intended to be governed in whole or in part by
Section&nbsp;355(a) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any Company Subsidiary has participated in any &#147;listed
transaction&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2)</FONT> (or any similar state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any Company Subsidiary has taken or agreed to take any action or has knowledge of any facts that
would prevent the Mergers from qualifying for the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.16 <B>Employee Benefit Plans</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;2.16(a)</U> of the Company Disclosure Schedule&nbsp;sets forth a list of all material Company
Plans as of the date of this Agreement. There are no Company Plans that are governed by the laws of any jurisdiction other than the United States or provide compensation or benefits to any employee or former employee of the Company or any Company
Subsidiary (or any dependent thereof) who resides outside of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company has made available to
Parent copies of, to the extent applicable: (i)&nbsp;the plan document for each material Company Plan; (ii)&nbsp;the most recent annual report (Form Series 5500 and all schedules and financial statements attached thereto) with respect to each
material Company Plan; (iii)&nbsp;the most recent summary plan description with respect to each material Company Plan; (iv)&nbsp;the most recent IRS determination or opinion letter issued with respect to each Company Plan intended to be qualified
under Section&nbsp;401(a) of the Code; and (v)&nbsp;all material correspondence from any Governmental Entity regarding any active or, to the Company&#146;s knowledge, threatened Legal Proceeding regarding any Company Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No Company Plan is, and neither the Company nor any Company Subsidiary nor any Company Commonly Controlled Entity
contributes to, has at any time in the previous six years contributed to or has or had any liability or obligation, whether fixed or contingent, with respect to (i)&nbsp;a multiemployer plan, as defined in Section&nbsp;3(37) of ERISA, (ii)&nbsp;a
single employer plan or other pension plan that is subject to Title IV of ERISA or Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code, (iii)&nbsp;a multiple employer plan (within the meaning of Section&nbsp;413(c) of the Code), (iv) a
multiple employer welfare arrangement (within the meaning of Section&nbsp;3(40) of ERISA), (v) a voluntary employee benefit association under Section&nbsp;501(a)(9) of the Code, or (vi)&nbsp;a plan providing for post-employment or post-retirement
health, medical, or life insurance benefits for current, former or retired employees of Company or any of the Company Subsidiaries, except as required under Section&nbsp;4980B of the Code or otherwise except as may be required pursuant to any other
applicable Legal Requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each Company Plan that is intended to be qualified under Section&nbsp;401(a) of the
Code has received a favorable determination letter (or opinion letter, if applicable) from the IRS stating that such Company Plan is so qualified and, to the knowledge of the Company, nothing has occurred since the date of such letter that would
reasonably be expected to adversely affect the qualified status of such Company Plan. Each Company Plan has been operated in compliance in all material respects with its terms and with all applicable Legal Requirements. Without limiting the
foregoing, no liability under Title IV of ERISA has been incurred by the Company or any Company Commonly Controlled Entity that has not been satisfied in full and, to the knowledge of the Company, no condition exists that presents a risk to the
Company or any Company Commonly Controlled Entity of incurring a liability under such Title. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither the execution and delivery of this Agreement nor the
consummation of the transactions contemplated hereby could (either alone or together with any other event): (i) entitle any current or former employee, officer, director or independent contractor of the Company or any Company Subsidiary to any
payment or benefit under any Company Plan or otherwise; (ii)&nbsp;increase the amount of any compensation or other benefits otherwise payable by the Company or any Company Subsidiary under any Company Plan or otherwise; or (iii)&nbsp;result in the
acceleration of the time of payment, funding or vesting of any compensation or other benefits under any Company Plan. No Company Plan provides for, and no current or former employee, officer, director or independent contractor of the Company or any
Company Subsidiary is entitled to, any <FONT STYLE="white-space:nowrap">gross-up,</FONT> make-whole or other similar payment or benefit in respect of any Taxes under Section&nbsp;4999 of the Code or Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each Company Plan has been maintained and operated in documentary and operational compliance in all material respects with
Section&nbsp;409A of the Code or an available exemption therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The per share exercise price of each Company Option
was at least equal to the fair market value of one share of Company Common Stock on the date of grant of such Company Option. Prior to the date of this Agreement, the Company has made available to Parent a list of all Company Options outstanding as
of the date of this Agreement, including the holder of such Company Option, the number of shares of Company Common Stock subject to such Company Option, the grant date of such Company Option, the per share exercise price of such Company Option, the
vesting schedule for such Company Option, and the date on which such Company Option expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.17 <B>Labor Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither the Company nor any Company Subsidiary is a party to, nor does the Company or any Company Subsidiary have a duty to
bargain for, any collective bargaining agreement with a labor organization or works council representing any of its employees and, as of the date of this Agreement, there are no labor organizations or works councils representing, purporting to
represent or, to the knowledge of the Company, seeking to represent any employees of the Company or any Company Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement (i)&nbsp;and since January&nbsp;1, 2019, there has not been any strike, slowdown, work
stoppage, lockout, job action, picketing, labor dispute, union organizing activity, or any similar activity or dispute, affecting the Company, any Company Subsidiary or any of their employees and (ii)&nbsp;to the knowledge of the Company, no Person
is currently threatening in writing to commence, any such strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute or union organizing activity or any similar activity or dispute. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of the date of this Agreement there is no material claim or grievance pending or, to the knowledge of the Company,
threatened by or on behalf of any employees of the Company or Company Subsidiary relating to any employment Contract, wages and hours, mass layoffs or reductions in force, plant closing notification, employment statute or regulation, labor dispute,
workers&#146; compensation policy or long-term disability policy, safety, retaliation, privacy right, immigration or discrimination matters involving any employee of the Company or any Company Subsidiary, including material charges of unfair labor
practices or material harassment complaints, material claims or material judicial or administrative proceedings, in each case, which are pending. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material
Adverse Effect, (i)&nbsp;the Company and the Company Subsidiaries are in compliance in all material respects with all applicable Legal Requirements respecting employment and employment practices, terms and conditions of employment of employees,
former employees and prospective employees, wages and hours, pay equity, discrimination in employment, wrongful discharge, collective bargaining, mass layoffs or reductions in force, plant closing notification, fair labor standards, occupational
health and safety, personal rights or any other labor and employment-related matters, and (ii)&nbsp;the Company and the Company Subsidiaries have properly classified all of their service providers as either employees or independent contractors and
as exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT> for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Within the last two years, no employee of the Company or any Company
Subsidiary has transferred into employment with the Company or any Company Subsidiary by means of a relevant transfer pursuant to the Acquired Rights Directive pursuant to EC Directive no. 2001/23 dated March&nbsp;12, 2001, as amended from time to
time, or domestic legislation implementing such directive into the national applicable law of any country in the EEA, as amended from time to time, or any legislation that has substantially the same effect in any country outside the EEA. For
purposes of this Section, &#147;<U>EEA</U>&#148; means European Economic Area, as constituted from time to time, and shall be deemed to include Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.18 <B>Environmental Matters</B>. Except as, individually or in the aggregate, has not had and would not reasonably be expected
to have a Company Material Adverse Effect, the Company and the Company Subsidiaries are, and since January&nbsp;1, 2019 have been, in compliance with all applicable Environmental Laws (which compliance includes the possession, and the compliance
with the terms and conditions, by the Company and each Company Subsidiary of all Company Permits required under applicable Environmental Laws to conduct their respective business and operations), and there are no investigations, actions, suits or
proceedings pursuant to any Environmental Laws pending or, to the knowledge of the Company, threatened against the Company or any Company Subsidiary. During the three-year period prior to the date of this Agreement, neither the Company nor any
Company Subsidiary has received any written notice from a Governmental Entity that alleges that the Company or any Company Subsidiary is violating, or has or may have, violated any Environmental Law, or may have any liability or obligation arising
under, retained or assumed by Contract or by operation of law, except for such violations, liabilities and obligations that, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse
Effect. Since January&nbsp;1, 2019, there has been no release of any hazardous materials by the Company or any Company Subsidiary at or from any facilities owned or leased by the Company or any Company Subsidiary or at any other locations where any
hazardous materials were generated, manufactured, refined, transferred, stored, produced, imported, used, processed or disposed of by the Company or any Company Subsidiary and, in each case, for which the Company or any Company Subsidiary would
reasonably be expected to be subject to any liability, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.19 <B>Insurance</B>. Since January&nbsp;1, 2019, neither the Company nor any Company Subsidiary has received any written
communication notifying the Company or any Company Subsidiary of any: (a)&nbsp;premature cancellation or invalidation of any material insurance policy held by the Company or any Company Subsidiary; or (b)&nbsp;refusal of any coverage or rejection of
any material claim under any insurance policy held by the Company or any Company Subsidiary. As of the date of this Agreement, there is no pending material claim by the Company or any Company Subsidiary against any insurance carrier under any
insurance policy held by the Company or any Company Subsidiary. The Company and the Company Subsidiaries maintain insurance with reputable insurers in such amounts and against such risks as the management of the Company has in good faith determined
to be prudent and appropriate in all material respects. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, all insurance policies maintained by or on behalf of the
Company or any of the Company Subsidiaries are in full force and effect, all premiums and other payments due on such policies have been paid by the Company or a Company Subsidiary and all claims thereunder have been filed in due and timely fashion,
and neither the Company nor any of Company Subsidiary is in breach or default under, has received any written notice of, or has taken any action that would reasonably be likely to permit cancellation, termination or modification of, any such
insurance policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.20 <B>Product Defects and Warranties.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since January&nbsp;1, 2019, all Company Products sold or supported by the Company or any of the Company Subsidiaries have
been provided in conformity with the Company&#146;s and the Company Subsidiaries&#146; applicable contractual commitments, warranties and specifications, except as, individually or in the aggregate, has not had and would not reasonably be expected
to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company&#146;s warranty reserve reflected on the Most Recent Company
Balance Sheet was calculated utilizing historical warranty experience rates consistent with past practice and, to the knowledge </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of the Company, was sufficient as of the date of the Most Recent Company Balance Sheet to cover the unexpired warranty liabilities of the Company and the Company Subsidiaries for any products
(including Company Products) sold by the Company or the Company Subsidiaries to their respective customers prior to the date of the Most Recent Company Balance Sheet. Since the date of the Most Recent Company Balance Sheet, the Company has not
materially modified its practices in calculating warranty reserves. To the knowledge of the Company, the Company&#146;s current warranty reserve is sufficient as of the date of this Agreement to cover the unexpired warranty liabilities of the
Company and the Company Subsidiaries for any products (including Company Products) sold by the Company or the Company Subsidiaries to their respective customers prior to the date of this Agreement, except as, individually or in the aggregate, has
not had and would not reasonably be expected to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.21 <B>Regulatory Matters.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material
Adverse Effect, the Company and each of the Company Subsidiaries is, and has since January&nbsp;1, 2019 been, in compliance with (i)&nbsp;all applicable Healthcare Laws and (ii)&nbsp;all Healthcare Regulatory Authorizations. &#147;<U>Healthcare
Laws</U>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167; 201 et seq.) and the Medical Devices Regulation and the Medical Devices Directive; (ii)&nbsp;all
applicable federal, state, local and foreign health care related fraud and abuse, false claims, anti-kickback, self-referral and transparency Legal Requirements, including the Anti-Kickback Statute (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), the Exclusion Laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the Civil Monetary Penalties Law (42 U.S.C.
&#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the criminal False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the Physician Payments Sunshine Act (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the federal Stark Law (42 U.S.C. &#167; 1395nn), and all criminal Legal Requirements relating to health care fraud and abuse, including 18 U.S.C. &#167;&#167; 286 and 287, and the health care fraud
criminal provisions under HIPAA; (iii)&nbsp;Legal Requirements relating to price reporting requirements and the requirements relating to the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations
relating to the Medicaid Drug Rebate Program (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1396r-8),</FONT> any state supplemental rebate program, and Medicare average sales price reporting (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1395w-3a);</FONT> (iv) the Medicare statute (Title XVIII of the Social Security Act), the Medicaid statute (Title XIX of the Social Security), the federal TRICARE statute (10 U.S.C. &#167; 1071 et seq.), and other
Legal Requirements relating to Government Programs; (v)&nbsp;any other applicable Legal Requirements relating to the research, development, design, testing, manufacturing, labeling, marketing, promotion, sale and distribution of biological products,
HCT/Ps, or medical devices, or durable medical equipment; (vi)&nbsp;Legal Requirements relating to consulting agreements, royalty agreements, and other arrangements with healthcare professionals, physician ownership/investment interests, and
continuing education and trade shows for healthcare professionals; and (vii)&nbsp;in each case, as amended and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2019, neither the Company nor any of the Company Subsidiaries has received written notice of any
pending or threatened claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other action by any Healthcare Regulatory Authority alleging that any Company Product, operation, or activity of the Company or any Company
Subsidiary is in material violation of any applicable Healthcare Laws, or otherwise (i)&nbsp;proposing to modify, suspend, revoke or withdraw a material Healthcare Regulatory Authorization or (ii)&nbsp;contesting the clearance, approval or marketing
of any Company Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company and each of the Company Subsidiaries, as applicable, possess all Healthcare
Regulatory Authorizations required for the conduct of its respective business, including all Healthcare Regulatory Authorizations required for any Company Product, and all such Healthcare Regulatory Authorizations are in full force and effect,
except where the failure to possess such Healthcare Regulatory Authorizations or for such Healthcare Regulatory Authorizations to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect. Since January&nbsp;1, 2019, neither the Company nor any of the Company Subsidiaries has received written notice of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any termination, revocation, withdrawal, suspension, rejection or denial of, any Healthcare Regulatory Authorization, and to the Company&#146;s knowledge, no event has occurred which allows, or
after notice or lapse of time would allow, or would reasonably be expect to lead to, the revocation, withdrawal, termination, suspension, rejection or denial of any Healthcare Regulatory Authorization (or any filing or application therefor) or
result in any other impairment of the rights of the holder of any Healthcare Regulatory Authorization (or any filing or application therefor), except for such terminations, revocations, withdrawals, suspensions, rejections, denials or impairments
as, individually or in the aggregate, have not had or would not reasonably be expected to have a Company Material Adverse Effect.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect:
all reports, documents, registrations, authorizations, claims and notices required to be filed, maintained, or furnished to any Healthcare Regulatory Authority pursuant to any applicable Health Care Laws by the Company or any of the Company
Subsidiaries have been so filed, maintained or furnished and were complete and correct on the date filed (or were corrected in or supplemented by a subsequent filing). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Since January&nbsp;1, 2019, neither the Company nor any of the Company Subsidiaries has voluntarily or involuntarily
initiated, conducted or issued, or caused to be initiated, conducted or issued (or received any written notices from any Healthcare Regulatory Authority issuing, requiring or causing the Company or any of the Company Subsidiaries to issue) any
recalls, seizures, detentions, field notifications, field corrections, market withdrawals or replacements, warnings, &#147;dear doctor&#148; letters, investigator notices, safety alerts or other written notice of action relating to an alleged lack
of safety, efficacy, or regulatory compliance of, or enjoining manufacture or distribution of, any Company Product, except in each case as are immaterial in nature or amount, and to the knowledge of the Company, none of any Healthcare Regulatory
Authority or the Company or any Company Subsidiary is considering such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All preclinical studies, tests and
clinical trials conducted by or on behalf of the Company or any of the Company Subsidiaries, or in which the Company or any of the Company Subsidiaries has participated with respect to its products or product candidates (collectively,
&#147;<U>Studies</U>&#148;) were and, if still pending, have been and are being conducted in compliance with all applicable Healthcare Laws, except as would not, individually or in the aggregate, reasonably be expected to have a Company Material
Adverse Effect. Neither the Company nor any of the Company Subsidiaries has received any written notice from any Healthcare Regulatory Authority requiring or threatening, the termination or suspension of any ongoing or planned Studies, and to the
knowledge of the Company, there are no reasonable grounds for the same, except for such terminations or suspensions as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2019, neither the Company nor any of the Company Subsidiaries has received, (i)&nbsp;from FDA, any
FDA Form 483, warning letter or untitled letter or (ii)&nbsp;from any other Healthcare Regulatory Authority, any similar written notice alleging or asserting material noncompliance with any Healthcare Laws or Healthcare Regulatory Authorizations
held by Company or any of the Company Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company nor any of the Company Subsidiaries is a party
to, has any ongoing obligations pursuant to, or is bound by, any order, individual integrity agreement, corporate integrity agreement, deferred prosecution agreement, settlement agreement, consent agreement, consent decree or other similar form
agreement with any Governmental Entity resulting from a failure, or alleged failure, to comply with any applicable Healthcare Laws of the FDA, Centers for Medicare and Medicaid Services and other Healthcare Regulatory Authorities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Since January&nbsp;1, 2019, neither the Company, any of the Company Subsidiaries nor any Company Products are the subject
of any pending or, to the Company&#146;s knowledge, threatened investigation by the FDA pursuant to its &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; Final Policy set forth in 56 Fed. Reg. 46191 (September
10, 1991) and any amendments thereto. Neither the Company nor any of the Company Subsidiaries, nor any of their respective officers, directors, employees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
nor to the knowledge of the Company, any of their respective contractors, suppliers, agents, or any other company or individual performing research or product-related work on behalf of the
Company or any of the Company Subsidiaries, nor any other Person described in 42 C.F.R. &#167; 1001.1001(a)(1)(ii), (i) has committed any act, made any untrue statement of material fact or failed to make any statement that, at the time such act,
statement or disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; Final Policy; (ii)&nbsp;has been charged with any
conduct for which debarment is mandated by 21 U.S.C. &#167; 335a or any criminal offense relating to the delivery of an item or service under any federal health care program; (iii)&nbsp;has been charged with or been convicted of any crime for which
exclusion is mandated or permitted from the federal health care programs under Section&nbsp;1128 of the Social Security Act of 1935, or any similar Law; (iv)&nbsp;is or has been debarred, excluded suspended or is otherwise ineligible from
participation in any federal health care program, as such term is defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(f),</FONT> or any other government program; (v)&nbsp;has had a civil monetary penalty assessed against it under
Section&nbsp;1128A of the Social Security Act; (vi)&nbsp;is or has been listed on the General Services Administration published list of parties excluded from federal procurement programs and <FONT STYLE="white-space:nowrap">non-procurement</FONT>
programs; or (vii)&nbsp;has been debarred by any federal or international agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.22 <B>Takeover Statutes</B>. Assuming
the accuracy of Parent&#146;s and Acquisition Subs&#146; representation in <U>Section</U><U></U><U>&nbsp;3.17</U>, the Company Board has taken all action necessary to render Section&nbsp;203 of the DGCL, all other potentially applicable state
anti-takeover statutes and any similar provisions of the Company Organizational Documents inapplicable to the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.23
<B>Ownership of Parent Class</B><B></B><B>&nbsp;A Common Stock</B>. During the three years prior to the date of this Agreement, none of the Company, any Company Subsidiary or any &#147;affiliate&#148; or &#147;associate&#148; (as such terms are
defined in Section&nbsp;203(c) of the DGCL) of any of the foregoing &#147;owns&#148; or &#147;owned&#148; (as such terms are defined in Section&nbsp;203(c) of the DGCL), directly or indirectly, any shares of Parent Class&nbsp;A Common Stock or other
securities convertible into, exchangeable into or exercisable for shares of Parent Class&nbsp;A Common Stock. There are no voting trusts or other agreements or understandings to which the Company or any Company Subsidiary is a party with respect to
the disposition or voting of the capital stock or other equity interest of Parent or any Parent Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.24 <B>Opinion
of Financial Advisor</B>. The Company Board has received the opinion of J.P. Morgan Securities LLC (the &#147;<U>Company Financial Advisor</U>&#148;), financial advisor to the Company, dated as of the date of this Agreement, to the effect that, as
of such date and subject to the assumptions, qualifications and limitations set forth in such opinion, the Merger Consideration pursuant to this Agreement is fair, from a financial point of view, to the holders of shares of Company Common Stock (the
&#147;<U>Company Fairness Opinion</U>&#148;). The Company will make available to Parent a copy of such opinion as soon as practicable following the execution of this Agreement for information purposes only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.25 <B>Brokers</B>. No broker, finder or investment banker (other than the Company Financial Advisor) is entitled to any
brokerage, finder&#146;s or other similar fee or commission in connection with the Mergers based upon arrangements made by or on behalf of the Company. The Company has made available to Parent accurate and complete copies of all engagement, fee and
similar Contracts between the Company (or any Subsidiary of the Company) and the Company Financial Advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.26 <B>Related
Party Transactions</B>. Except as disclosed in the Company SEC Documents, neither the Company nor any Company Subsidiary is party to any transaction or arrangement under which any (a)&nbsp;present or former executive officer or director of the
Company or any Company Subsidiary, (b)&nbsp;beneficial owner (within the meaning of Section&nbsp;13(d) of the Exchange Act) of 5% or more of any class of equity of the Company or (c)&nbsp;Affiliate, &#147;associate&#148; or member of the
&#147;immediate family&#148; (as such terms are respectively defined in Rules <FONT STYLE="white-space:nowrap">12b-2</FONT> and <FONT STYLE="white-space:nowrap">16a-1</FONT> of the Exchange Act) of any of the foregoing is a party to any actual or
proposed loan, lease or other Contract with or binding upon the Company or any Company Subsidiary or owns or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has any interest in any of their respective properties or assets, in each case as would be required to be disclosed by the Company pursuant to Item 404 of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.27 <B>Information Supplied</B>. The information
supplied or to be supplied by the Company for inclusion in the Form <FONT STYLE="white-space:nowrap">S-4</FONT> (including the Joint Proxy Statement/Prospectus) will not, at the time the Form <FONT STYLE="white-space:nowrap">S-4</FONT> (and any
amendment or supplement thereto) is declared effective, on the date that the Joint Proxy Statement/Prospectus is first mailed to the stockholders of the Company and the stockholders of Parent, or on the date of the Company Stockholder Meeting or the
Parent Stockholder Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are
made, not misleading, except that, no representation or warranty is made by the Company with respect to statements made therein based on information supplied by Parent for inclusion therein. Notwithstanding the foregoing, the Company makes no
representation or warranty with respect to any information supplied by Parent, the Acquisition Subs or any of their Representatives for inclusion in the Joint Proxy Statement/Prospectus. For purposes of the Joint Proxy Statement/Prospectus, any
information concerning or related to the Company, its Affiliates, or the Company Stockholder Meeting will be deemed to have been provided by the Company, and any information concerning or related to Parent, its Affiliates, or the Parent Stockholder
Meeting will be deemed to have been provided by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE III. REPRESENTATIONS AND WARRANTIES OF PARENT AND ACQUISITION SUBS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent and each Acquisition Sub hereby jointly and severally represent and warrant to the Company that, except as set forth or incorporated by
reference in the Parent SEC Documents filed and publicly available prior to the date of this Agreement (excluding any disclosures contained in such documents under the heading &#147;Risk Factors&#148; or in any other section to the extent they are
forward-looking statements or cautionary, predictive or forward-looking in nature) or, subject to <U>Section</U><U></U><U>&nbsp;7.12</U>, in the disclosure schedule delivered to the Company concurrent with the execution of this Agreement (the
&#147;<U>Parent Disclosure Schedule</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1 <B>Due Organization and Good Standing; Subsidiaries.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent and each Acquisition Sub are corporations duly organized, validly existing and in good standing under the laws of
their respective states of incorporation. Parent and each Acquisition Sub have the requisite corporate power and authority to own, lease and operate their respective assets and to carry on their respective businesses as it is being conducted as of
the date of this Agreement, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Parent and each Acquisition Sub are duly qualified and have all necessary
Governmental Authorizations to do business, and (where such concept is recognized under the Laws of the applicable jurisdictions) are in good standing, in each other jurisdiction where the nature of their business makes such qualification necessary,
except where the failure to be so qualified or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither Parent nor either Acquisition Sub nor any Parent Subsidiary owns any equity interest or joint venture, partnership
or similar interest in any other Entity, other than the Entities identified in Exhibit 21.1 of Parent&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021 (filed with the SEC on
March&nbsp;26, 2021) and any other wholly owned Parent Subsidiary. Each Parent Subsidiary is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite corporate or other
organizational power and authority and Governmental Authorizations to own, lease and operate its assets and to carry on its business as it is being conducted as of the date of this Agreement, except where the failure to be so organized, existing and
in good standing or to have such power and authority, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Each Parent Subsidiary is duly qualified and has all necessary
Governmental Authorizations to do business, and (where such concept is recognized under the laws of the applicable jurisdictions) is in good standing, in each other jurisdiction where the nature of its business makes such qualification necessary,
except where the failure to be so qualified or in good standing, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. All of the outstanding shares of capital stock of each Parent
Subsidiary are duly authorized, validly issued, fully paid and nonassessable and are owned directly or indirectly by Parent free and clear of all Liens, except for restrictions on transfer under applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2 <B>Organizational Documents</B>. Prior to the date of this Agreement, Parent has made available to the Company copies of the
Organizational Documents of Parent and each Acquisition Sub, including all amendments thereto in effect prior to the date of this Agreement. The Organizational Documents of Parent, each Acquisition Sub and each Parent Subsidiary are in full force
and effect and neither (a)&nbsp;Parent, either Acquisition Sub nor (b)&nbsp;except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, any Parent Subsidiary, is in
violation of any of the provisions of such Organizational Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <B>Capitalization</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Parent consists of: (i) 250,000,000 shares of Parent Class&nbsp;A Common Stock, (ii)
50,000,000 shares of Class&nbsp;B common stock, par value $0.001 per share (the &#147;<U>Parent Class</U><U></U><U>&nbsp;B Common Stock</U>&#148; and together with the Parent Class&nbsp;A Common Stock, the &#147;<U>Parent Common Stock</U>&#148;) and
(iii) 10,000,000 shares of preferred stock, par value $0.001 per share. All of the outstanding shares of Parent Common Stock have been, and all shares of Parent Common Stock reserved for issuance pursuant to the Parent Equity Plan will be when
issued, duly authorized and validly issued, and are, or will be when issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in Parent&#146;s restated articles of organization (as amended), Parent&#146;s bylaws or the Parent
Equity Agreements: (i)&nbsp;none of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of repurchase, right of participation or any similar right granted by Parent or a Parent Subsidiary;
(ii)&nbsp;none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent; (iii)&nbsp;there are no bonds, debentures, notes or other indebtedness issued by Parent or any Parent Subsidiary and
outstanding having the right to vote (or convertible or exercisable or exchangeable for securities having the right to vote) on any matters on which stockholders of Parent may vote; and (iv)&nbsp;there is no Contract to which Parent is a party
relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any shares of Parent Common Stock. Except as set forth
in the Parent Equity Agreements, Parent is not under any obligation, nor is it bound by any Contract pursuant to which it will become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other
securities of any other Entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of June&nbsp;25, 2021 (the &#147;<U>Parent Capitalization Date</U>&#148;): (i)
41,062,601 shares of Parent Class&nbsp;A Common Stock were issued and outstanding; (ii) 15,786,737 shares of Parent Class&nbsp;B Common Stock were issued and outstanding; (iii)&nbsp;zero shares of preferred stock, par value $0.001 per share, were
issued and outstanding; (iv) 4,627,100 shares of Parent Class&nbsp;A Common Stock were subject to issuance pursuant to outstanding Parent Options; (v) 936,203 shares of Parent Class&nbsp;A Common Stock were subject to issuance pursuant to
outstanding Parent RSUs; (vi) 542,320 shares of Parent Class&nbsp;A Common Stock were reserved for issuance pursuant to the Parent ESPP; (vii) 7,592,476 shares of Parent Class&nbsp;A Common Stock were reserved for issuance pursuant to the Parent
Equity Plan and (viii)&nbsp;no other shares of capital stock or other voting securities of Parent were issued, reserved for issuance or outstanding. From the Parent Capitalization Date through the date of this Agreement, neither Parent nor any of
the Parent Subsidiaries has issued any shares of Parent Common Stock or other equity interests of Parent or any Parent Subsidiary, other than pursuant to Parent Options, Parent RSUs or the Parent ESPP, in each case, that were outstanding as of the
Parent Capitalization Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth in <U>Section</U><U></U><U>&nbsp;3.3(c)</U>, there is no:
(i)&nbsp;outstanding subscription, option, call, warrant or other right (whether or not currently exercisable) to acquire any shares of the capital stock or other equity interests, or any restricted stock unit, stock-based performance unit, shares
of phantom stock, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
stock appreciation right, profit participation right or any other right that is linked to, or the value of which is based on or derived from, the value of any shares of capital stock or other
equity interest of Parent; (ii)&nbsp;outstanding security, instrument, bond, debenture or note that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent; or (iii)&nbsp;stockholder rights
plan (or similar plan commonly referred to as a &#147;poison pill&#148;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or other equity interest or any other securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4 <B>Authority; Binding Nature of Agreement</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement
and, subject to receipt of the Required Parent Stockholder Vote, to consummate the Mergers. Assuming the accuracy of the Company&#146;s representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;2.23</U>, on or prior to the date
hereof, the Parent Board has unanimously: (i)&nbsp;duly and validly authorized and approved the execution, the delivery and, subject to the receipt of the Required Parent Stockholder Vote, the performance of this Agreement and the consummation of
the Mergers, by Parent; (ii)&nbsp;determined that the Mergers are fair to and in the best interests of Parent and its stockholders; (iii)&nbsp;approved and declared advisable this Agreement and the transactions contemplated by this Agreement,
including the Mergers; (iv)&nbsp;subject to the terms and conditions hereof, approved the issuance of shares of Parent Class&nbsp;A Common Stock in the First Merger as contemplated by this Agreement (the &#147;<U>Parent Share Issuance</U>&#148;);
and (v)&nbsp;directed that the Parent Share Issuance be submitted to a vote of Parent&#146;s stockholders, recommended the approval of the Parent Share Issuance for purposes of the rules and regulations of Nasdaq by the holders of shares of Parent
Common Stock (the &#147;<U>Parent Board Recommendation</U>&#148;), and resolved to include the Parent Board Recommendation in the Joint Proxy Statement/Prospectus, subject to <U>Section</U><U></U><U>&nbsp;4.3</U>. Assuming the accuracy of the
Company&#146;s representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;2.23</U>, the execution and delivery of this Agreement by Parent and the consummation by Parent of the Mergers and other transactions contemplated by this
Agreement have been duly authorized by all necessary corporate action on the part of Parent, and no other corporate proceedings on the part of Parent are necessary to authorize this Agreement, in each case other than the adoption of this Agreement
by Parent as the sole stockholder of Acquisition Sub I and the sole member of Acquisition Sub II (which shall occur immediately following the execution of this Agreement) and, with respect to the Parent Share Issuance, the receipt of the Required
Parent Stockholder Vote. This Agreement has been duly executed and delivered on behalf of Parent and, assuming the due authorization, execution and delivery of this Agreement on behalf of the Company, constitutes the valid and binding obligation of
Parent, enforceable against Parent in accordance with its terms, subject to the General Enforceability Exception. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each
Acquisition Sub is a newly formed, wholly owned Subsidiary of Parent and has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement. The board of directors of Acquisition Sub I has:
(i)&nbsp;determined that the transactions contemplated by this Agreement are fair to, and in the best interests of, Acquisition Sub and its stockholder; (ii)&nbsp;declared that this Agreement is advisable and recommended that its sole stockholder
adopt this Agreement; and (iii)&nbsp;authorized and approved the execution, delivery and performance of this Agreement by Acquisition Sub. The sole member of Acquisition Sub II has (i)&nbsp;determined that the transactions contemplated by this
Agreement are fair to, and in the best interests of, Acquisition Sub; (ii)&nbsp;declared that this Agreement is advisable; and (iii)&nbsp;authorized and approved the execution, delivery and performance of this Agreement by Acquisition Sub II. The
execution and delivery of this Agreement by each Acquisition Sub and the consummation by each Acquisition Sub of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of each
Acquisition Sub, and no other corporate proceedings on the part of either Acquisition Sub are necessary to authorize this Agreement other than, with respect to the Mergers: (A)&nbsp;the adoption of this Agreement by Parent as the sole stockholder of
Acquisition Sub I and the sole member of Acquisition Sub II (which, in each case, shall occur immediately following the execution of this Agreement); and (B)&nbsp;the filing of the Certificates of Merger as required by the DGCL and DLLCA. Parent, as
the sole stockholder of Acquisition Sub I and sole member of Acquisition Sub II, will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
vote to adopt this Agreement immediately after the execution and delivery of this Agreement. This Agreement has been duly executed and delivered by each Acquisition Sub and, assuming the due
authorization, execution and delivery of this Agreement on behalf of the Company, constitutes the valid and binding obligation of each Acquisition Sub, enforceable against each Acquisition Sub in accordance with its terms, subject to the General
Enforceability Exception. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5 <B>Vote Required</B>. Assuming the accuracy of the Company&#146;s representations and
warranties set forth in <U>Section</U><U></U><U>&nbsp;2.23</U>, the approval of the Parent Share Issuance by a majority of the outstanding shares of Parent Common Stock present in person or by proxy at the Parent Stockholder Meeting and entitled to
vote on the proposal to approve the Parent Share Issuance (the &#147;<U>Required Parent Stockholder Vote</U>&#148;) is the only vote of the holders of any class or series of Parent&#146;s capital stock necessary under applicable Legal Requirements
and Parent&#146;s Organizational Documents for Parent to consummate the transactions contemplated hereby, including the Mergers. The approval of the adoption of this Agreement by Parent as the sole stockholder of Acquisition Sub I and sole member of
Acquisition Sub II, which consent will be delivered immediately following the execution hereof in accordance with <U>Section</U><U></U><U>&nbsp;4.9(c)</U>, is the only vote of the holders of any class or series of Acquisition Sub I&#146;s capital
stock and Acquisition Sub II&#146;s membership interests necessary under applicable Legal Requirements and each Acquisition Sub&#146;s Organizational Documents for each Acquisition Sub to consummate the transactions contemplated hereby, including
the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.6 <B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The execution and delivery of this Agreement by Parent and, assuming receipt of the Required Parent Stockholder Vote and
the accuracy of the Company&#146;s representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;2.23</U>, the consummation by Parent of the Mergers will not: (i)&nbsp;cause a violation of any of the provisions of the Organizational
Documents of Parent or any Parent Subsidiary; (ii)&nbsp;assuming the consents and filings referred to in <U>Section</U><U></U><U>&nbsp;3.6(b)</U> are made and obtained, conflict with or violate any applicable Legal Requirements; or
(iii)&nbsp;subject to <U>Section</U><U></U><U>&nbsp;4.7</U>, result in any loss, limitation or impairment of any right of Parent or any Parent Subsidiary to own or use any assets, result in any violation of or default (with or without notice or
lapse of time, or both) under, or give rise to a right of termination, cancellation, first offer, first refusal, modification or acceleration of any obligation or to the loss of a benefit under any Parent Material Contract, or result in the creation
of any Liens of any kind (other than Parent Permitted Encumbrances) upon any of the properties, rights or assets of Parent or any Parent Subsidiary, except, in the cases of clauses &#147;(ii)&#148; and &#147;(iii),&#148; as, individually or in the
aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as
(i)&nbsp;may be required by the applicable requirements of the Securities Act, the Exchange Act, the DGCL, the DLLCA, the HSR Act or other applicable Antitrust Laws, applicable state securities takeover and &#147;blue sky&#148; laws or the rules and
regulations of Nasdaq, (ii)&nbsp;in connection with the filing of the Form <FONT STYLE="white-space:nowrap">S-4</FONT> with the SEC or (iii)&nbsp;the filing of all material applications and notices, consents, approvals, clearances, authorizations,
registrations, and exemptions, as required by the FDA and any Healthcare Regulatory Authority, neither Parent nor either Acquisition Sub, nor any Parent Subsidiary, is required to make any filing, registration, or declaration with, give any notice
to, or obtain any consent, Order, license, permit, clearance, waiver or approval from, any Governmental Entity for the execution and delivery of this Agreement by Parent or the consummation by Parent of the Mergers, the performance by Parent of its
covenants and obligations hereunder or the consummation by Parent of the Mergers, in each case, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.7 <B>Reports; Financial Statements; Internal Controls</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated by
reference therein) required to be filed or furnished by Parent with the SEC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
under the Exchange Act or Securities Act since February&nbsp;11, 2021 (the &#147;<U>Parent SEC Documents</U>&#148;) have been filed or furnished by or on behalf of Parent with the SEC on a timely
basis. As of the time it was filed with the SEC (or, if amended or superseded, then on the date of such amended or superseding filing): (i) each of the Parent SEC Documents complied in all material respects with the applicable requirements of the
Securities Act, the Exchange Act and the Sarbanes-Oxley Act (as the case may be) and the applicable regulations promulgated thereunder and the listing requirements and corporate governance rules and regulations of Nasdaq, each as in effect on the
date such Parent SEC Document was filed; and (ii)&nbsp;none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. Since February&nbsp;11, 2021, no executive officer of Parent has failed in any respect to make the certifications required of him or her under Section&nbsp;302 or 906
of the Sarbanes-Oxley Act. Neither the Parent nor any of its executive officers has received notice from any Governmental Entity challenging or questioning the accuracy, completeness, form or manner of filing of such certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents:
(i)&nbsp;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may
be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by the rules and regulations of the SEC applicable thereto, and except that unaudited financial statements may not contain footnotes and are
subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments); (iii) fairly present, in all material respects, the financial position of Parent and Parent&#146;s consolidated Subsidiaries as of the respective dates
thereof and the results of operations and consolidated cash flows of Parent and Parent&#146;s consolidated Subsidiaries for the periods covered thereby subject, with respect to unaudited interim statements, to normal and recurring <FONT
STYLE="white-space:nowrap">year-end</FONT> adjustments; and (iv)&nbsp;have been prepared from, and are in accordance with, the books and records of Parent and Parent&#146;s consolidated Subsidiaries in all material respects. No financial statements
of any Person other than Parent and Parent&#146;s consolidated Subsidiaries are required by GAAP to be included in the consolidated financial statements of Parent. The books and records of Parent and the Parent Subsidiaries have been, and are being,
maintained in all material respects in accordance with GAAP and any other applicable legal and accounting requirements. As of the date of this Agreement, Grant Thornton LLP has not resigned (or informed Parent that it intends to resign) or been
dismissed as independent public accountants of Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent maintains, and at all times since February&nbsp;11, 2021
has maintained, a system of internal control over financial reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange Act) which is designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that: (i)&nbsp;pertain to the maintenance of
records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of Parent and the Parent Subsidiaries; (ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of management and directors of Parent; and (iii)&nbsp;provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Parent and the Parent Subsidiaries that could have a material effect on the financial statements. Parent&#146;s management has completed an assessment of
the effectiveness of Parent&#146;s system of internal control over financial reporting in compliance with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act for its most recent fiscal year, and such assessment concluded that such
controls were effective and Parent&#146;s independent registered accountant has issued an attestation report concluding that Parent maintained effective internal control over financial reporting. Management of Parent has disclosed to Parent&#146;s
auditors and the audit committee of the Parent Board (x)&nbsp;any significant deficiencies or material weaknesses in the design and operation of internal controls over financial reporting since January&nbsp;1, 2019 and (y)&nbsp;any fraud, whether or
not material, that involves management or any other employees who have a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
significant role in Parent&#146;s internal control over financial reporting, and each such deficiency, weakness and fraud so disclosed to auditors, if any, has been made available to the Company
prior to the date hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Since January&nbsp;1, 2019, (i) none of Parent or any Parent Subsidiary nor, to the
knowledge of Parent, any director or officer of Parent or any Parent Subsidiary has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding accounting, internal
accounting controls or auditing practices, procedures, methodologies or methods of Parent or any Parent Subsidiary or any material complaint, allegation, assertion or claim from employees of Parent or any Parent Subsidiary regarding questionable
accounting or auditing matters with respect to Parent or any Parent Subsidiary, and (ii)&nbsp;to the knowledge of Parent, no attorney representing Parent or any Parent Subsidiary, whether or not employed by Parent or any Parent Subsidiary, has
reported evidence of a violation of securities laws, breach of fiduciary duty or similar violation by Parent, any Parent Subsidiary or any of their respective officers, directors, employees or agents to the Parent Board or any committee thereof, or
to the General Counsel or Chief Executive Officer of Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Parent maintains disclosure controls as required by Rule <FONT
STYLE="white-space:nowrap">13a-15</FONT> or <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act. As of the date of this Agreement, Parent is in compliance in all material respects with all current listing requirements of Nasdaq.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Parent nor any Parent Subsidiary is a party to, or has a commitment to effect, enter into or create, any joint
venture, or <FONT STYLE="white-space:nowrap">&#147;off-balance</FONT> sheet arrangement&#148; (as defined in Item 303(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC
with respect to the Parent SEC Documents, and none of the Parent SEC Documents is, to the knowledge of Parent, the subject of ongoing SEC review or investigation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither Parent nor any Parent Subsidiary has any liabilities of any nature or type (whether accrued, absolute, determined,
contingent or otherwise and whether due or to become due), that would be required by GAAP to be reflected on a condensed consolidated balance sheet of Parent and its consolidated Parent Subsidiaries, except for: (i)&nbsp;liabilities disclosed in the
financial statements (including any related notes) contained in the Most Recent Parent Balance Sheet; (ii)&nbsp;liabilities incurred in the ordinary course of business in a manner consistent with past practice since the date of the Most Recent
Parent Balance Sheet; (iii)&nbsp;liabilities that, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect; and (iv)&nbsp;liabilities and obligations incurred in connection with
this Agreement, the preparation and negotiation of this Agreement or the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.8
<B>Absence of Certain Changes</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since the date of the Most Recent Parent Balance Sheet, there has not been any
fact, event, change, effect, circumstance, occurrence, or development that, individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From the date of the Most Recent Parent Balance Sheet to the date of this Agreement, the businesses of Parent and the
Parent Subsidiaries have been conducted in all material respects in the ordinary course of business (other than in connection with <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures) in a manner consistent with past practice, and neither
Parent nor any Parent Subsidiary has undertaken any action that if proposed to be taken after the date of this Agreement would require the Company&#146;s consent pursuant to <U>Section</U><U></U><U>&nbsp;4.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.9 <B>Compliance with Legal Requirements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent is, and since January&nbsp;1, 2019 has been, in compliance with all Legal Requirements applicable to it and its
businesses, except where the failure to comply with such Legal Requirements would not, individually or in the aggregate, has not been or would not reasonably be expected to be material to Parent and the Parent Subsidiaries, taken as a whole. Neither
Parent nor any Parent Subsidiary has, since </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
January&nbsp;1, 2019: (i) to the knowledge of Parent, received any written notice from any Governmental Entity regarding any material violation by Parent of any Legal Requirement; or
(ii)&nbsp;provided any notice to any Governmental Entity regarding any material violation by Parent or any Parent Subsidiary of any Legal Requirement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent and the Parent Subsidiaries hold, and have at all times since January&nbsp;1, 2019 held, all Governmental
Authorizations necessary for the lawful operation of the businesses of Parent and the Parent Subsidiaries as they are now being conducted (the &#147;<U>Parent Permits</U>&#148;) and have paid all fees and assessments due and payable in connection
therewith, except where the failure to have, file or pay, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Except as, individually or in the aggregate, has not had and would
not reasonably be expected to have a Parent Material Adverse Effect, (i)&nbsp;all Parent Permits are valid and in full force and effect, are not subject to any administrative or judicial proceeding that could result in any modification, termination
or revocation thereof and, to the knowledge of Parent, no suspension or cancellation of any such Parent Permit is threatened, (ii)&nbsp;Parent and each Parent Subsidiary is in compliance with the terms and requirements of all Parent Permits and
(iii)&nbsp;no consent from or notice to any Government Entity is required in order for each Parent Permit to continue in full force and effect upon consummation of the Mergers and the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except where the failure to comply with such Legal Requirements, individually or in the aggregate, has not been or would
not reasonably be expected to be material to Parent and the Parent Subsidiaries, taken as a whole, Parent and each Parent Subsidiary have at all times since January&nbsp;1, 2019 complied with applicable Sanctions Laws and Export Control Laws.
Neither Parent nor any Parent Subsidiary has been the subject of or otherwise involved in investigations or enforcement actions by any Governmental Entity or other Legal Proceedings with respect to any actual or alleged violations of Export Control
Laws or Sanctions Laws, and neither Parent nor any Parent Subsidiary has been notified of any such pending or threatened actions. Neither Parent, any Parent Subsidiary, nor any director or officer of Parent or any Parent Subsidiary, or, to the
knowledge of Parent, any other employee, independent contractor, consultant, agent, or other Person acting on behalf of Parent or any Parent Subsidiary, is a Prohibited Person or is subject to debarment or any list-based designations under the
Export Control Laws. Since January&nbsp;1, 2019, Parent and the Parent Subsidiaries have secured and maintained all necessary Export Approvals, and each of Parent and the Parent Subsidiaries is and, since January&nbsp;1, 2019, has been in compliance
in all material respects with the terms of all Export Approvals. None of the officers, directors, or employees of Parent or any of the Parent Subsidiaries is a foreign or domestic Government Official. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.10 <B>Legal Proceedings; Investigations; Orders</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) There is no Legal Proceeding pending or, to the knowledge of Parent, threatened against Parent, the Acquisition Subs or any
Parent Subsidiary or affecting any of their respective properties or assets that: (i)&nbsp;would adversely affect Parent&#146;s or each Acquisition Sub&#146;s ability to perform any of its obligations under, or consummate any of the transactions
contemplated by, this Agreement; or (ii)&nbsp;individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There is no Order under which Parent, each Acquisition Sub or any Parent Subsidiary is subject to ongoing obligations that,
individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.11
<B>Certain Business Practices</B>. Except as, individually or in the aggregate, has not been or would not reasonably be expected to be material to Parent or any Parent Subsidiary, taken as a whole, since January&nbsp;1, 2019, neither Parent nor any
of the Parent Subsidiaries, nor, any director, officer, employee, or, to the knowledge of Parent, other agent or Person acting on behalf of Parent or any of the Parent Subsidiaries has, directly or indirectly, (a)&nbsp;violated or taken any action
that could potentially result in a violation of any provision of Anti-Corruption Laws applicable to Parent or any Parent Subsidiary or (b): (i) used, offered to use or authorized the use of any funds of Parent or the Parent Subsidiaries for unlawful
contributions, unlawful gifts or unlawful </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entertainment, or for other unlawful payments, related to political activity or otherwise; (ii)&nbsp;made, offered to make or authorized any unlawful payment from funds of Parent or any Parent
Subsidiaries to foreign or domestic Government Officials or employees or to foreign or domestic political parties or campaigns; (iii)&nbsp;established or maintained any unlawful fund of monies or other unlawful pool of assets of Parent or any Parent
Subsidiaries; (iv)&nbsp;made any fraudulent entry on the books or records of Parent or any of the Parent Subsidiaries; (v)&nbsp;made, offered to make or authorized any bribe, unlawful rebate, unlawful payoff, unlawful influence payment, unlawful
kickback or other unlawful payment to any Person, private or public, in any form; or (vi)&nbsp;engaged in or facilitated any transaction or dealing in property or interests in property of a Prohibited Person, received funds, goods or services from
or made any contribution of funds, goods or services to or for the benefit of a Prohibited Person or otherwise engaged in or facilitated any transactions with, any Prohibited Person. Neither Parent nor any Parent Subsidiary is or within the past
five years has (i)&nbsp;been to the knowledge of Parent, under investigation by any Governmental Entity for any potential or actual violation of any Anti-Corruption Laws or (ii)&nbsp;received any written notice from any Governmental Entity regarding
any potential or actual violation of, or potential or actual failure to comply with, any Anti-Corruption Laws. Since January&nbsp;1, 2019 neither Parent nor any of Parent Subsidiaries have made any disclosure (voluntary or otherwise) to any
Governmental Entity with respect to any potential violation or liability arising under or relating to any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.12 <B>Regulatory Matters.</B><B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect,
Parent and each of the Parent Subsidiaries is and has been since January&nbsp;1, 2019, in compliance in all material respects with (i)&nbsp;all applicable Healthcare Laws and (ii)&nbsp;all Healthcare Regulatory Authorizations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2019, neither Parent nor any of the Parent Subsidiaries has received written notice of any pending or
threatened claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other action by any Healthcare Regulatory Authority alleging that any Parent Product, operation or activity of Parent or the Parent Subsidiaries is in
material violation of any applicable Healthcare Laws or otherwise (i)&nbsp;proposing to modify, suspend, revoke or withdraw a material Healthcare Regulatory Authorization or (ii)&nbsp;contesting the clearance, approval or marketing of any Parent
Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent and each of the Parent Subsidiaries, as applicable, possess all Healthcare Regulatory Authorizations
required for the conduct of its respective business, including without limitation, all Healthcare Regulatory Authorizations required for any Parent Product, and all such Healthcare Regulatory Authorizations are in full force and effect, except where
the failure to possess such Healthcare Regulatory Authorizations or for such Healthcare Regulatory Authorizations to be in full force, would not, whether individually or in the aggregate, reasonably be expected to have a Parent Material Adverse
Effect. Since January&nbsp;1, 2019, neither Parent nor any of the Parent Subsidiaries has received written notice of any termination, revocation, withdrawal, suspension, rejection or denial of, any Healthcare Regulatory Authorization, and to
Parent&#146;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, or would reasonably be expect to lead to, the revocation, withdrawal, termination, suspension, rejection or denial of any Healthcare
Regulatory Authorization (or any filing or application therefor) or result in any other impairment of the rights of the holder of any material Healthcare Regulatory Authorization (or any filing or application therefor) except for such terminations,
revocations, withdrawals, suspensions, rejections, denials or impairments, that would not, whether individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect: all
reports, documents, registrations, authorizations, claims and notices required to be filed, maintained, or furnished to any Healthcare Regulatory Authority pursuant to any applicable Healthcare Laws by Parent or any of the Parent Subsidiaries have
been so filed, maintained or furnished and were complete and correct on the date filed (or were corrected in or supplemented by a subsequent filing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Since January&nbsp;1, 2019, neither Parent nor any of the Parent
Subsidiaries has voluntarily or involuntarily initiated, conducted or issued, or caused to be initiated, conducted or issued (or received any written notices from any Healthcare Regulatory Authority issuing, requiring or causing Parent or a Parent
Subsidiary to issue) any recalls, seizures, detentions, field notifications, field corrections, market withdrawals or replacements, warnings, &#147;dear doctor&#148; letters, investigator notices, safety alerts or other written notice of action
relating to an alleged lack of safety, efficacy, or regulatory compliance of, or enjoining manufacture or distribution of, any Parent Product, except in each case as are immaterial in nature or amount, and to Parent&#146;s knowledge none of any
Healthcare Regulatory Authority, or Parent or any of the Parent Subsidiaries is considering such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All
preclinical studies, tests and clinical trials conducted by or on behalf of Parent or any of the Parent Subsidiaries, or in which Parent or any of the Parent Subsidiaries has participated in with respect to Parent Products (collectively,
&#147;<U>Parent Studies</U>&#148;) were and, if still pending, have been and are being conducted in compliance with all applicable Healthcare Laws, except as would not, individually or in the aggregate, reasonably be expected to have a Parent
Material Adverse Effect. Neither Parent nor any of the Parent Subsidiaries has received any written notice from any Healthcare Regulatory Authority requiring or threatening, in writing, the termination or suspension of any ongoing or planned Parent
Studies, and to the knowledge of Parent, there are no reasonable grounds for the same, except for such terminations or suspensions as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2019, neither Parent nor any Parent Subsidiary has received, (i)&nbsp;from FDA, any FDA Form 483,
warning letter or untitled letter or (ii)&nbsp;from any other Healthcare Regulatory Authority, any similar written notice alleging or asserting material noncompliance with any Healthcare Laws or Healthcare Regulatory Authorizations held by Parent or
any Parent Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither Parent nor any Parent Subsidiary is a party to, has any ongoing obligations pursuant
to, or is bound by, any order, individual integrity agreement, corporate integrity agreement, deferred prosecution agreement, settlement agreement, consent agreement, consent decree or other similar form agreement with any Governmental Entity
resulting from a failure, or alleged failure, to comply with any applicable Healthcare Laws of the FDA, Centers for Medicare and Medicaid Services and other Healthcare Regulatory Authorities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Since January&nbsp;1, 2019, neither Parent nor any Parent Subsidiary or their Parent Products are the subject of any
pending or, to Parent&#146;s knowledge, threatened investigation by the FDA pursuant to its &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and
any amendments thereto, or otherwise. Neither Parent nor any of the Parent Subsidiaries, any of their respective officers, directors, employees, nor, to Parent&#146;s knowledge, any of their respective contractors, suppliers, agents, or other
company or individual performing research or Parent Product-related work on behalf of Parent or any of the Parent Subsidiaries, nor any other Person described in 42 C.F.R. &#167; 1001.1001(a)(1)(ii), (i) has committed any act, made any untrue
statement of material fact or failed to make any statement that, at the time such act, statement or disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its &#147;Fraud, Untrue Statements of Material Facts,
Bribery, and Illegal Gratuities&#148; Final Policy; (ii)&nbsp;has been charged with any conduct for which debarment is mandated by 21 U.S.C. &#167; 335a or any criminal offense relating to the delivery of an item or service under any federal health
care program; (iii)&nbsp;has been charged with or been convicted of any crime for which exclusion is mandated or permitted from the federal health care programs under Section&nbsp;1128 of the Social Security Act of 1935, or any similar Law;
(iv)&nbsp;is or has been debarred, excluded, suspended or is otherwise ineligible from participation in any federal health care program, as such term is defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(f),</FONT> or any other
government program; (v)&nbsp;has had a civil monetary penalty assessed against it under Section&nbsp;1128A of the Social Security Act; (vi)&nbsp;is or has been listed on the General Services Administration published list of parties excluded from
federal procurement programs and <FONT STYLE="white-space:nowrap">non-procurement</FONT> programs; or (vii)&nbsp;has been debarred by any federal or international agency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.13 <B>Employee Benefit Plans</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Parent Plan is, and neither Parent nor any Parent Subsidiary nor any Parent Commonly Controlled Entity contributes to,
has at any time in the previous six years contributed to or has or had any liability or obligation, whether fixed or contingent, with respect to (i)&nbsp;a multiemployer plan, as defined in Section&nbsp;3(37) of ERISA, (ii)&nbsp;a single employer
plan or other pension plan that is subject to Title IV of ERISA or Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code, (iii)&nbsp;a multiple employer plan (within the meaning of Section&nbsp;413(c) of the Code), (iv) a multiple employer
welfare arrangement (within the meaning of Section&nbsp;3(40) of ERISA), (v) a voluntary employee benefit association under Section&nbsp;501(a)(9) of the Code, or (vi)&nbsp;a plan providing for postemployment or post-retirement health, medical, or
life insurance benefits for former or retired employees of Parent or any of the Parent Subsidiaries, except as required under Section&nbsp;4980B of the Code or otherwise except as may be required pursuant to any other applicable Legal Requirements.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Parent Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable
determination letter (or opinion letter, if applicable) from the IRS stating that such Parent Plan is so qualified and, to the knowledge of Parent, nothing has occurred since the date of such letter that would reasonably be expected to adversely
affect the qualified status of such Parent Plan. Each Parent Plan has been operated in compliance in all material respects with its terms and with all applicable Legal Requirements. Without limiting the foregoing, no liability under Title IV of
ERISA has been incurred by Parent or any Parent Commonly Controlled Entity that has not been satisfied in full and, to the knowledge of Parent, no condition exists that presents a risk to Parent or any Parent Commonly Controlled Entity of incurring
a liability under such Title. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Parent Plan has been maintained and operated in documentary and operational
compliance in all material respects with Section&nbsp;409A of the Code or an available exemption therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.14 <B>Labor
Matters</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither Parent nor any Parent Subsidiary is a party to, nor does Parent or any Parent Subsidiary have a
duty to bargain for, any collective bargaining agreement with a labor organization or works council representing any of its employees and, as of the date of this Agreement, there are no labor organizations or works councils representing, purporting
to represent or, to the knowledge of Parent, seeking to represent any employees of Parent or any Parent Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As
of the date of this Agreement (i)&nbsp;and since January&nbsp;1, 2019, there has not been any strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute, union organizing activity, or any similar activity or dispute, affecting
Parent, any Parent Subsidiary or any of their employees and, (ii)&nbsp;to the knowledge of Parent, no Person is currently threatening in writing to commence, any such strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute or
union organizing activity or any similar activity or dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of the date of this Agreement there is no material
claim or grievance pending or, to the knowledge of Parent, threatened by or on behalf of any employees of Parent or any Parent Subsidiary relating to any employment Contract, wages and hours, mass layoffs or reductions in force, plant closing
notification, employment statute or regulation, labor dispute, workers&#146; compensation policy or long-term disability policy, safety, retaliation, immigration or discrimination matters involving any employee of Parent or any Parent Subsidiary,
including material charges of unfair labor practices or material harassment complaints, claims or judicial or administrative proceedings, in each case, which are pending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.15 <B>Financing; Solvency</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent has delivered to the Company an accurate and complete copy of the fully executed debt commitment letter, together
with any related fee letters (in the case of the fee letters, redacted in a customary manner for confidential provisions related to fees, flex terms related to fees and pricing and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
economic terms, none of which adversely affect the conditionality, enforceability, availability, termination or aggregate principal amount of the Debt Financing contemplated thereby in any
respect), dated as of the date hereof, by and among the Debt Financing Sources, the Acquisition Subs and other parties thereto, providing for debt financing as described therein (together, including all exhibits, schedules and annexes and the fee
letters associated therewith, the &#147;<U>Debt Commitment Letter</U>&#148;), pursuant to which, upon the terms and subject only to the conditions set forth therein, the Debt Financing Sources party thereto have agreed to lend the amounts set forth
therein (the &#147;<U>Debt Financing</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Debt Commitment Letter is in full force and effect and
constitutes the valid, binding and enforceable obligation of the Acquisition Subs and, to the knowledge of Parent, the other parties thereto, enforceable in accordance with its terms (subject to the applicable bankruptcy, reorganization, fraudulent
conveyance, insolvency, moratorium or other similar Laws affecting creditor&#146;s rights generally and the availability of equitable relief and any implied covenant of good faith and fair dealing). As of the date hereof, there are no conditions
precedent or subsequent related to the funding of the Debt Financing contemplated by the Debt Commitment Letter, other than the conditions precedent set forth in the Debt Commitment Letter (such conditions precedent, the &#147;<U>Financing
Conditions</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of the date hereof, the Debt Commitment Letter has not been amended, waived, supplemented or
modified in any manner, and the respective commitments contained therein have not been terminated, reduced, withdrawn or rescinded in any respect by the Acquisition Subs or, to the knowledge of Parent, any other party thereto, and no such
termination, reduction, withdrawal or rescission is contemplated by the Acquisition Subs or, to the knowledge of Parent, any other party thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As of the date hereof, Parent has no reason to believe that (i)&nbsp;any of the Financing Conditions will not be satisfied
on or prior to the Closing Date or (ii)&nbsp;the Financing contemplated by the Debt Commitment Letter will not be available to the Acquisition Subs on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As of the date hereof, the Acquisition Subs are not in default or breach under the terms and conditions of the Debt
Commitment Letter or any related fee letters and, to the knowledge of Parent, no event has occurred that, with or without notice, lapse of time or both, would or would reasonably be expected to constitute a default or breach or a failure to satisfy
a condition under the terms and conditions of the Debt Commitment Letter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No Debt Financing Source has notified Parent
or the Acquisition Subs of its intention to terminate its commitment under the Debt Commitment Letter or to not provide the Debt Financing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Acquisition Subs have paid in full all commitment or other fees required by the Debt Commitment Letter or any related
fee letter that are due as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.16 <B>Takeover Statutes</B>. Assuming the accuracy of the Company&#146;s
representation in <U>Section</U><U></U><U>&nbsp;2.23</U>, the Parent Board has taken all action necessary to render Section&nbsp;203 of the DGCL, all other potentially applicable state anti-takeover statutes and any similar provisions of the
Parent&#146;s Organizational Documents inapplicable to the Mergers and the Parent Share Issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.17 <B>Ownership of
Company Common Stock</B>. During the three years prior to the date of this Agreement, neither Parent nor any Parent Subsidiary beneficially owns or owned, directly or indirectly, any shares of Company Common Stock or other securities convertible
into, exchangeable into or exercisable for shares of Company Common Stock (other than pursuant to any Parent Plan). There are no voting trusts or other agreements or understandings to which Parent or any Parent Subsidiary is a party with respect to
the voting of the capital stock or other equity interest of the Company or any Company Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.18 <B>Intellectual
Property.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the knowledge of Parent, all material Intellectual Property owned or purported to be owned by Parent
or any Parent Subsidiary (&#147;<U>Parent IP</U>&#148;) that is Registered IP (collectively, the &#147;<U>Parent Registered</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<U>IP</U>&#148;) is valid, subsisting and enforceable (or solely in the case of applications, applied for and pending). Since January&nbsp;1, 2019 , neither Parent nor any Parent Subsidiary has
received any written notice or claim challenging the validity or enforceability of any Parent Registered IP or indicating an intention on the part of any Person to bring a claim that any of the Parent Registered IP is invalid or unenforceable, and
there is currently no Legal Proceeding pending or threatened in writing, in which the validity, enforceability or ownership of any Parent Registered IP is being contested or challenged. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the knowledge of Parent, neither Parent nor any Parent Subsidiary is subject to any outstanding or potential Order that
restricts in any material manner the use, transfer or licensing of any material Parent IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the knowledge of Parent,
the operations of the businesses of Parent and the Parent Subsidiaries as currently conducted do not infringe, misappropriate or otherwise violate and since January&nbsp;1, 2019 have not, to the knowledge of Parent, infringed, misappropriated or
otherwise violated, any Intellectual Property owned by any other Person in a manner that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. Neither Parent nor any Parent Subsidiary has received
any written complaints, claims or notices since January&nbsp;1, 2019 alleging any infringement, misappropriation or violation of any Intellectual Property of any other Person by Parent or any Parent Subsidiary. To the knowledge of Parent, there is
no unauthorized use, unauthorized disclosure, infringement, misappropriation or other violation of any Parent IP by any third Person that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Parent and each Parent Subsidiary have taken commercially reasonable steps to protect all Trade Secrets owned by Parent or
a Parent Subsidiaries and that are material to Parent or the Parent Subsidiaries, taken as a whole. Parent and each Parent Subsidiary has, and uses commercially reasonable measures to enforce, a policy requiring all employees and consultants of
Parent or any Parent Subsidiary, in each case, who have been engaged in the development of any Parent Product, to enter into proprietary information and intellectual property assignment agreements with Parent or a Parent Subsidiary, for the benefit
of Parent or a Parent Subsidiary, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.19 <B>Tax Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Parent and the Parent Subsidiaries have timely filed (taking into account any extension of time within which to file)
all Tax Returns that are required to be filed by or with respect to any of them and all such Tax Returns are accurate and complete. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Parent and the Parent Subsidiaries have timely paid in full to the appropriate Governmental Entity all Taxes required to
be paid by any of them or, in respect of any Taxes accrued but not yet payable by Parent or any Parent Subsidiary, adequate reserves have been recorded in the financial statements of Parent and the Parent Subsidiaries in accordance with GAAP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Each of Parent and the Parent Subsidiaries has (i)&nbsp;timely paid, deducted, withheld and collected all amounts
required to be paid, deducted, withheld or collected by any of them with respect to any payment made or owing to, or received from, their employees, creditors, independent contractors, shareholders, customers and other third parties (and have timely
paid over any amounts so withheld, deducted or collected to the appropriate Governmental Entity) and (ii)&nbsp;otherwise complied with all applicable Legal Requirements relating to such withholding, collection and remittance of Taxes (including
information reporting requirements). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Within the last three years, no claim has been made in writing by any Tax
authority in a jurisdiction where Parent or any Parent Subsidiary has not filed Tax Returns of a particular type that Parent or any Parent Subsidiary is or may be subject to such type of Tax by, or required to file Tax Returns with respect to Taxes
in, such jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Neither Parent nor any Parent Subsidiary will be required to include an
item of income (or exclude an item of deduction) in any taxable period (or portion thereof) beginning after the Closing Date as a result of (i)&nbsp;a change in or incorrect method of accounting occurring prior to the Closing Date, (ii)&nbsp;a
prepaid amount received (or deferred revenue recognized) or paid, prior to the Closing Date, (iii)&nbsp;any agreement entered into on or prior to the Closing Date with a Governmental Entity relating to Taxes, or (iv)&nbsp;any open transaction or
installment sale entered into on or prior to the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) There are no: (i)&nbsp;examinations, investigations,
audits, or other proceedings pending or, to the knowledge of Parent, threatened in writing with respect to any Taxes of Parent or any Parent Subsidiary or any Tax Returns; (ii)&nbsp;extensions or waivers of the limitation period applicable to any
Tax Return or the period for the assessment of any Taxes of Parent or the Parent Subsidiaries which period has not yet expired; (iii)&nbsp;deficiencies for Taxes that have been claimed, proposed or assessed by any Governmental Entity in writing
against Parent or any Parent Subsidiary that have not been fully satisfied by payment; or (iv)&nbsp;Liens in respect of or on account of material Taxes (other than Parent Permitted Encumbrances) upon any of the property or assets of Parent or any
Parent Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither Parent nor any of the Parent Subsidiaries (i)&nbsp;is or has been, within the last six
years, a member of any affiliated, combined, consolidated, unitary or similar group for purposes of filing Tax Returns or paying Taxes, except for any such group of which Parent is the common parent or (ii)&nbsp;has any liability for Taxes of any
Person (other than Parent or any Parent Subsidiary) under Treasury Regulations <FONT STYLE="white-space:nowrap">1.1502-6</FONT> (or any similar state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirement) or as transferee or
successor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Parent nor any Parent Subsidiary is a party to or bound by, or has any obligation under, any Tax
indemnity, sharing, allocation, or reimbursement agreement or arrangement, other than: (i)&nbsp;customary tax provisions in ordinary course commercial agreements, the principal purpose of which is not related to Taxes; and (ii)&nbsp;any agreement or
arrangement between or among Parent and any Parent Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Parent nor any Parent Subsidiary is bound with
respect to the current or any future taxable period by any closing agreement (within the meaning of Section&nbsp;7121(a) of the Code or any similar or analogous state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirement) or
other ruling or written agreement with a Tax authority, in each case, with respect to Taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Within the last two
years, neither Parent nor any Parent Subsidiary has distributed stock of another Person or has had its stock distributed by another Person in a transaction that was purported or intended to be governed in whole or in part by Section&nbsp;355(a) of
the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Parent nor any Parent Subsidiary has participated in any &#147;listed transaction&#148; within the
meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2)</FONT> (or any similar state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither Parent nor any Parent Subsidiary has taken or agreed to take any action or has knowledge of any facts that would
prevent the Mergers from qualifying for the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.20 <B>Opinion of Financial Advisor</B>. The Parent
Board has received the opinion of Perella Weinberg Partners LP (the &#147;<U>Parent Financial Advisor</U>&#148;), financial advisor to Parent, dated as of the date of this Agreement, to the effect that, on such date and subject to the various
assumptions and limitations set forth in such opinion, the aggregate Merger Consideration to be paid by Parent pursuant to this Agreement is fair, from a financial point of view, to Parent (the &#147;<U>Parent Fairness Opinion</U>&#148;). Parent
will make available to the Company a copy of such opinion as soon as practicable following the execution of this Agreement for information purposes only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.21 <B>Brokers</B>. No broker, finder or investment banker (other than the Parent Financial Advisor) is entitled to any
brokerage, finder&#146;s or other similar fee or commission in connection with the Mergers based upon arrangements made by or on behalf of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.22 <B>Information Supplied</B>. The information supplied or to be supplied by
Parent for inclusion in the Form <FONT STYLE="white-space:nowrap">S-4</FONT> (including the Joint Proxy Statement/Prospectus) will not, at the time the Form <FONT STYLE="white-space:nowrap">S-4</FONT> (and any amendment or supplement thereto) is
declared effective, on the date that the Joint Proxy Statement/Prospectus is first mailed to the stockholders of the Company and the stockholders of Parent, or on the date of the Company Stockholder Meeting or the Parent Stockholder Meeting, contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading, except that, no
representation or warranty is made by Parent with respect to statements made therein based on information supplied by the Company for inclusion therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.23 <B>Data Privacy and Security</B>. Except as, individually or in the aggregate, has not been and would not reasonably be
expected to be material to Parent and the Parent Subsidiaries, taken as a whole, Parent and each Parent Subsidiary is in compliance, and has since January&nbsp;1, 2019 complied, with all applicable Data Protection Laws. To the knowledge of Parent,
since January&nbsp;1, 2019, there have not been any material <FONT STYLE="white-space:nowrap">non-permitted</FONT> disclosures, material security incidents or material breaches involving Parent, Parent Subsidiaries, or any of its agents, employees
or contractors relating to any Personal Data in its possession or control that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the knowledge of Parent, since January&nbsp;1, 2019, there
has been no material failure or any material unauthorized intrusions or material breaches of security with respect to the information technology systems owned or controlled by Parent and each of the Parent Subsidiaries that has resulted in a
material disruption or material interruption in the operation of the business of Parent and each of the Parent Subsidiaries that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.24 <B>Parent Top Customers, Distributors and Suppliers</B>. As of the date of this Agreement, no Parent Top Customer, no Parent
Top Distributor and no Parent Top Supplier has canceled, terminated or substantially curtailed its relationship with Parent or any Parent Subsidiary, given written notice to Parent or any Parent Subsidiary of any intention to cancel, terminate or
substantially curtail its relationship with Parent or any Parent Subsidiary, or, to the knowledge of Parent, threatened in writing to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.25 <B>Product Defects and Warranties</B><B>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since January&nbsp;1, 2019, all Parent Products sold or supported by Parent or any of the Parent Subsidiaries have been
provided in conformity with Parent&#146;s and the Parent Subsidiaries&#146; applicable contractual commitments, warranties and specifications, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a
Parent Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the knowledge of Parent, Parent&#146;s warranty reserve reflected on the Most
Recent Parent Balance Sheet was sufficient as of the date of the Most Recent Parent Balance Sheet to cover the unexpired warranty liabilities of Parent and the Parent Subsidiaries for any products (including Parent Products) sold by Parent or the
Parent Subsidiaries to their respective customers prior to the date of the Most Recent Parent Balance Sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.26
<B>Acquisition Subs</B>. Parent is the sole stockholder of Acquisition Sub I and the sole member of Acquisition Sub II. Since their respective dates of incorporation, Acquisition Sub I and Acquisition Sub II have not carried on any business or
conducted any operation other than the execution of this Agreement, the performance of its obligations hereunder and matters ancillary thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE IV.COVENANTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1
<B>Interim Operations.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees that, during the period from the date of this Agreement through the
earlier of the Closing or the termination of this Agreement, except (1)&nbsp;to the extent Parent shall otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
give its prior consent in writing (such consent not to be unreasonably withheld, conditioned or delayed), (2) as set forth in <U>Section</U><U></U><U>&nbsp;4.1(a)</U> of the Company Disclosure
Schedule, (3)&nbsp;as may be required by applicable Legal Requirements (including <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures) or (4)&nbsp;as expressly required by this Agreement, the Company shall, and shall cause the Company
Subsidiaries to, use commercially reasonable efforts to conduct its business in the ordinary course of business; provided that any action expressly permitted by the remaining provisions of this <U>Section</U><U></U><U>&nbsp;4.1(a)</U> (including
<U>Section</U><U></U><U>&nbsp;4.1(a)</U> of the Company Disclosure Schedule will not constitute a violation of the foregoing. During the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement,
except (1)&nbsp;to the extent Parent shall otherwise give its prior consent in writing (in the case of subsections (iv), (vi), (viii), (ix), (x), (xii), (xiii), (xvii), (xxviii), and (xxix)(B) of this <U>Section</U><U></U><U>&nbsp;4.01(a)</U>, such
consent not to be unreasonably withheld, conditioned or delayed), (2) as set forth in <U>Section</U><U></U><U>&nbsp;4.1(a)</U> of the Company Disclosure Schedule, (3)&nbsp;as may be required by applicable Legal Requirements (including <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Measures) or (4)&nbsp;as expressly or required by this Agreement, the Company shall not (and shall not permit any Company Subsidiary to), in each case by merger, consolidation, division, operation of law,
or otherwise: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) amend the Company&#146;s Organizational Documents or the Organizational Documents of any Company
Subsidiary; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of the
Company&#146;s capital stock or other equity interests of the Company or any Company Subsidiary; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) declare, set aside,
make or pay any dividend or other distribution (whether payable in cash, stock or property) with respect to any shares of the Company&#146;s capital stock or the capital stock or other equity interest of any Company Subsidiary, other than dividends
or distributions only to the extent paid by any wholly owned Company Subsidiary to the Company or another wholly owned Company Subsidiary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or assets, formation of
a joint venture or otherwise)&nbsp;(A) any other Person, (B)&nbsp;any equity interest in any other Person (other than investments in equity securities that constitute short term investments that are accounted for as cash equivalents), (C) any
business or division of another Person, or (D)&nbsp;any material assets except, (1)&nbsp;acquisitions by the Company from any wholly owned Company Subsidiary or among any wholly owned Company Subsidiaries; (2)&nbsp;the purchase of equipment,
supplies and inventory in the ordinary course of business or (3)&nbsp;inbound licenses or other grants or assignments of Intellectual Property in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) except in connection with any transaction between the Company and any wholly owned Company Subsidiary of or among any
wholly owned Company Subsidiaries, issue, sell, grant or otherwise permit to become outstanding any additional shares of, or securities convertible or exchangeable for, or options, warrants or rights to acquire, any shares of its capital stock or
other equity interests, other than shares of Company Common Stock issuable upon exercise of outstanding Company Options; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) except in connection with any transaction between the Company and any wholly owned Company Subsidiary or among any wholly
owned Company Subsidiaries of the Company, sell, assign, transfer, lease or license to any third party, or incur any Lien on any of its material tangible property or tangible assets, except for Company Permitted Encumbrances, or otherwise dispose of
(by merger, consolidation, operation of law, division or otherwise), any material Company IP or material tangible assets of the Company, other than: (A)&nbsp;sales of inventory, goods or services in the ordinary course of business in a manner
consistent with past practice or of obsolete equipment or assets in the ordinary course of business consistent with past practice; (B)&nbsp;pursuant to written Contracts or commitments existing as of the date of this Agreement; or (C)&nbsp;as
security for any borrowings permitted by <U>Section</U><U></U><U>&nbsp;4.1(a)(viii)</U>; or (D)&nbsp;licenses granted to customers or other third parties in the ordinary course of business in a manner consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) directly or indirectly repurchase, redeem or otherwise acquire any shares of the Company&#146;s or any Company
Subsidiary&#146;s capital stock or equity interests, or any other securities or obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
convertible (currently or after the passage of time or the occurrence of certain events) into or exchangeable for any shares of the Company&#146;s or any Company Subsidiary&#146;s capital stock
or equity interests, except: (A)&nbsp;shares of Company Common Stock repurchased from employees or consultants or former employees or consultants of the Company pursuant to the exercise of repurchase rights existing prior to the date of this
Agreement; or (B)&nbsp;shares of Company Common Stock accepted as payment for the exercise price of Company Options or for withholding Taxes incurred in connection with the exercise, vesting or settlement of Company Options, as applicable, in
accordance with the terms of the applicable award; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) incur (other than draws on existing revolving loans), redeem,
repurchase, prepay (other than prepayments of revolving loans), defease, or cancel any indebtedness for borrowed money, guarantee any such indebtedness, issue or sell any debt securities or rights to acquire any debt securities (directly,
contingently or otherwise) or make any loans or capital contributions to any other Person, except for any indebtedness among the Company and its wholly owned Company Subsidiaries or among any wholly owned Company Subsidiaries (and guarantees by the
Company or the Company Subsidiaries in respect thereof); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;(A) adopt, terminate or amend any Company Plan except
to the extent permitted by clauses (B), (C), (D) or (E)&nbsp;of this <U>Section</U><U></U><U>&nbsp;4.1(a)(ix)</U>, (B) increase, or accelerate the vesting or payment of, the compensation or benefits of any member of the Company Board, current
employee, or former employee of the Company or any Company Subsidiary, (C)&nbsp;grant any rights to severance, retention, change in control or termination pay to any member of the Company Board, current employee or former employee of the Company or
any Company Subsidiary, (D)&nbsp;hire or promote any employee at or to the level of Vice President or above, or (E)&nbsp;terminate the employment of any employee of the Company or any Company Subsidiary whose annual base salary exceeds $100,000
(other than for cause); except, in each case, for: (1)&nbsp;amendments to Company Plans determined by the Company in good faith to be required to comply with applicable Legal Requirements; (2)&nbsp;hiring any Person for employment (including by
means of internal promotion) to fill any currently existing Vice President or higher position that becomes vacant after the date of this Agreement, and, notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;4.1(a)(ix)</U>,
provide such Person with compensation and benefits for such position consistent with past practice; (3)&nbsp;hiring any Person for employment in accordance with the Company&#146;s present hiring plan made available to Parent or otherwise hiring an
individual below the level of Vice President in the ordinary course of business in a manner consistent with past practice; (4)&nbsp;increases in compensation or benefits required pursuant to any Company Plan in effect on the date hereof;
(5)&nbsp;increases to total target cash opportunities (i.e.,&nbsp;annual base salary or wage rates and target annual cash bonus opportunities) in amounts that are in the ordinary course of business in a manner consistent with past practice;&nbsp;and
(6)&nbsp;any other actions set forth in <U>Section</U><U></U><U>&nbsp;4.1(a)(ix)</U> of the Company Disclosure Schedule; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) except in the ordinary course of business, (i)(A)&nbsp;amend or terminate (except for terminations pursuant to the
expiration of the existing term of any Material Contract) any Material Contract or (B)&nbsp;waive, release or assign any material rights under any Material Contracts, or (ii)&nbsp;enter into any Contract or agreement that, if in effect on the date
of this Agreement, would constitute a Material Contract; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) change any of its methods of financial accounting or
accounting practices in any material respect other than as required by changes in GAAP; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) make (except for elections
made in the ordinary course of business), change or revoke any material Tax election, change any Tax accounting period or material method of Tax accounting, amend any material Tax Return if such amendment would reasonably be expected to result in a
material Tax liability, settle or compromise any material liability for Taxes or any Tax audit, claim, or other proceeding relating to a material amount of Taxes, enter into any agreement with a Governmental Entity relating to Taxes if such
agreement would reasonably be expected to result in a material Tax liability, request any Tax ruling from any Governmental Entity, surrender any right to claim a material refund of Taxes, or, other than in the ordinary course of business, agree to
an extension or waiver of the statute of limitations with respect to a material amount of Taxes; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) other than consignment of Company Products in the ordinary course of
business, make any capital expenditure that is not contemplated by the capital expenditure budget (the &#147;<U>CapEx Budget</U>&#148;) set forth in <U>Section</U><U></U><U>&nbsp;4.1(a)(xiii)</U> of the Company Disclosure Schedule&nbsp;(a &#147;<U><FONT
STYLE="white-space:nowrap">Non-Budgeted</FONT> Capital Expenditure</U>&#148;), except that the Company or any Company Subsidiary may make any <FONT STYLE="white-space:nowrap">Non-Budgeted</FONT> Capital Expenditure that, when added to all other <FONT
STYLE="white-space:nowrap">Non-Budgeted</FONT> Capital Expenditures made by the Company and the Company Subsidiaries since the date of this Agreement would not, in the aggregate, exceed the aggregate CapEx Budget by more than $200,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) except as expressly required by applicable Legal Requirements or the Company&#146;s Organizational Documents, convene
(A)&nbsp;any special meeting of the Company&#146;s stockholders other than the Company Stockholder Meeting or (B)&nbsp;any other meeting of the Company&#146;s stockholders to consider a proposal that would reasonably be expected to impair, prevent
or delay the consummation of the transactions contemplated hereby; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) enter into any agreement, understanding or
arrangement with respect to the voting of any capital stock or other equity interests of the Company (including any voting trust), other than with respect to awards under the Company Equity Plans otherwise permitted under this Agreement or in
connection with the granting of revocable proxies in connection with any meeting of the Company&#146;s stockholders; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi)
adopt a plan of (A)&nbsp;complete or partial liquidation of the Company or any Company Subsidiary or (B)&nbsp;dissolution, merger, consolidation, division, restructuring, recapitalization or other reorganization, other than, in the case of clause
(B), transactions between or among direct or indirect wholly owned Company Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) settle or compromise any
litigation, claim, suit, action or proceeding, except for settlements or compromises other than (A)&nbsp;the payment, discharge or satisfaction, in the ordinary course of business in a manner consistent with past practice, of liabilities reflected
or reserved against in the Most Recent Company Balance Sheet, or (B)&nbsp;those that do not (x)&nbsp;impose any injunctive relief on the Company or any Company Subsidiary (other than confidentiality obligations), (y) involve the payment of money
greater than $250,000 in excess of existing insurance coverage, and (z)&nbsp;do not include an admission of liability or fault on the part of the Company or any Company Subsidiary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) materially reduce the amount of insurance coverage or fail to renew or maintain any material existing insurance
policies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;(A) amend any Company Permits in a manner that adversely impacts the Company&#146;s ability to
conduct its business in any material respect or (B)&nbsp;terminate or allow to lapse any material Company Permits; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;(A) fail to pay any issuance, renewal, maintenance and other payments that become due with respect to any material
Company Registered IP or otherwise abandon, cancel, or permit to lapse any material Company Registered IP, other than in its reasonable business judgment or in the ordinary course of business in a manner consistent with past practice, or
(B)&nbsp;authorize the disclosure to any third party of any material Trade Secret included in the Company IP in a way that results in loss of trade secret protection, other than in the ordinary course of business in a manner consistent with past
practice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxi) take or cause to be taken any action, or knowingly fail to take or cause to be taken any action, which
action or failure to act would reasonably be expected to prevent the Merger from qualifying as a reorganization within the meaning of Section&nbsp;368(a) of the Code; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxii) authorize, approve or enter into any agreement or make any commitment to take any of the actions described in clauses
&#147;<U>(i)</U>&#148; through &#147;<U>(xxi)</U>&#148; of this sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent agrees that, during the period from
the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except (i)&nbsp;to the extent the Company shall otherwise give its prior consent in writing (such consent not to be withheld, conditioned or
delayed), (ii) as set forth in <U>Section</U><U></U><U>&nbsp;4.1(b)</U> of the Parent Disclosure Schedule, (iii)&nbsp;as may be required by applicable Legal Requirements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(including <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures) or (iv)&nbsp;as expressly required by this Agreement, Parent shall, and shall cause the Parent Subsidiaries to, use
commercially reasonable efforts to conduct its business in the ordinary course of business. Parent agrees that, during the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except
(1)&nbsp;to the extent the Company shall otherwise give its prior consent in writing, (2)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;4.1(b)</U> of the Parent Disclosure Schedule, (3)&nbsp;as may be required by applicable Legal Requirements
(including <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures) or (4)&nbsp;as expressly permitted or required by this Agreement, Parent shall not (and shall not permit any Parent Subsidiary to), in each case by merger, consolidation,
division, operation of law, or otherwise: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) amend Parent&#146;s or either of the Acquisition Subs&#146; Organizational
Documents or amend the Organizational Documents of any Parent Subsidiary in any manner that would be adverse in any material respect to the holders of Company Common Stock (after giving effect to the Mergers); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of Parent&#146;s capital stock or
other equity interests of the Company, except for any such transaction involving only wholly owned Parent Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) declare, set aside, make or pay any dividend or other distribution (whether payable in cash, stock or property) with
respect to any shares of Parent&#146;s capital stock or the capital stock of any Parent Subsidiary, except for dividends or distributions only to the extent paid by any wholly owned Parent Subsidiary to Parent or another wholly owned Parent
Subsidiary; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or
assets, formation of a joint venture or otherwise)&nbsp;(A) any other Person, (B)&nbsp;any equity interest in any other Person (other than investments in equity securities that constitute short term investments that are accounted for as cash
equivalents), (C) any business or division of another Person, or (D)&nbsp;any assets material to the Company and the Company Subsidiaries, taken as a whole, except in each case, (1)&nbsp;acquisitions by Parent from any wholly owned Parent Subsidiary
or among any wholly owned Parent Subsidiaries; (2)&nbsp;the purchase of equipment, supplies and inventory in the ordinary course of business; (3)&nbsp;inbound licenses or other grants or assignments of Intellectual Property in the ordinary course of
business or (4)&nbsp;acquisitions that in each case would not reasonably be expected to (x)&nbsp;result in the holders of Company Common Stock having different rights and privileges than holders of Parent Class&nbsp;A Common Stock following the
consummation of the Mergers, (y)&nbsp;materially delay, materially impede or prevent the consummation of the transactions contemplated by this Agreement or (z)&nbsp;result in the failure of any of the conditions set forth in <U>ARTICLE V</U> to be
satisfied prior to the End Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) liquidate (completely or partially), dissolve or adopt any plan or resolution
providing for any of the foregoing, in each case, with respect to Parent, Acquisition Sub I or Acquisition Sub II; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)
take or cause to be taken any action, or knowingly fail to take or cause to be taken any action, which action or failure to act would reasonably be expected to prevent the Merger from qualifying as a reorganization within the meaning of
Section&nbsp;368(a) of the Code; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) authorize, approve or enter into any agreement or make any commitment to take
any of the actions described in clauses &#147;<U>(i)</U>&#148; through &#147;(vi)&#148; of this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <B>Company No
Solicitation</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company will not, and the Company will cause each of the Company Subsidiaries not to, and will
instruct its and their respective Representatives not to, except as expressly permitted by this <U>Section</U><U></U><U>&nbsp;4.2</U> or <U>Section</U><U></U><U>&nbsp;4.5</U>, directly or indirectly: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding,
or the submission or announcement by any Person (other than Parent or its Affiliates or their respective Representatives) of, any proposal or offer that constitutes, or would reasonably be expected to lead to, any Company Acquisition Proposal
(<I>provided, however</I>, that the Company and its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Representatives may refer the Person making such proposal or offer to the provisions of this <U>Section</U><U></U><U>&nbsp;4.2</U> and make inquiries of a Person making a Company Acquisition
Proposal (and its Representatives) to solely clarify the terms of such Company Acquisition Proposal for the purpose of the Company Board informing itself about such Company Acquisition Proposal); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) furnish any information regarding the Company or any Company Subsidiary (other than to Parent and the Parent
Subsidiaries), or afford access to the Company&#146;s or the Company Subsidiaries&#146; Representatives, books, records or property, in each case, in connection with, or for the purpose of soliciting, initiating, encouraging or facilitating, or in
response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to a Company Acquisition Proposal; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person (other than
Parent or its Representatives) with respect to any Company Acquisition Proposal or any inquiry, proposal or offer that would reasonably be expected to lead to any Company Acquisition Proposal (<I>provided</I>, <I>however</I>, that the Company and
its Representatives may refer the Person making any such inquiry, proposal or offer to the provisions of this Section&nbsp;4.2 and make inquiries of a Person making a Company Acquisition Proposal (and its Representatives) to solely clarify the terms
of, such Company Acquisition Proposal for the purpose of the Company Board informing itself about such Company Acquisition Proposal); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) approve, adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or enter
into, any letter of intent, memorandum of understanding or similar document, agreement, commitment, or agreement in principle with respect to any Company Acquisition Proposal; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) resolve or agree to do any of the foregoing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that, notwithstanding anything to the contrary contained in this Agreement, prior to obtaining the Required Company
Stockholder Vote, the Company and its Representatives may engage or otherwise participate in discussions or negotiations with, and provide information to, any Person (or its Representatives and financing sources and their Representatives) that has
made a <I>bona fide</I> written Company Acquisition Proposal after the date hereof that did not result from any breach of this <U>Section</U><U></U><U>&nbsp;4.2(a)</U> or <U>Section</U><U></U><U>&nbsp;4.2(c)</U> by the Company, any of the Company
Subsidiaries or any of its or their respective Representatives if: (A)&nbsp;prior to taking any such action, the Company Board determines in good faith, after consultation with the Company&#146;s outside legal counsel and its financial advisor, that
such Company Acquisition Proposal either constitutes a Company Superior Proposal or would reasonably be expected to lead to a Company Superior Proposal; and (B)&nbsp;prior to providing any information regarding the Company or any Subsidiary of the
Company to such third party in response to such Company Acquisition Proposal, the Company receives from such third party (or there is then in effect with such party) an executed confidentiality agreement that contains nondisclosure provisions that
are at least as restrictive of such third party as the <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement and that does not prohibit compliance by the Company with this <U>Section</U><U></U><U>&nbsp;4.2</U>. Prior to or substantially
concurrently with providing any <FONT STYLE="white-space:nowrap">non-public</FONT> information to such third party, the Company shall make such <FONT STYLE="white-space:nowrap">non-public</FONT> information available to Parent (to the extent such <FONT
STYLE="white-space:nowrap">non-public</FONT> information has not been previously made available by the Company to Parent). The Company shall promptly (and in any event within 48 hours) inform Parent if the Company furnishes <FONT
STYLE="white-space:nowrap">non-public</FONT> information and/or enters into discussions or negotiations as provided for in this <U>Section</U><U></U><U>&nbsp;4.2(a)</U> and will keep Parent reasonably informed, on a current basis (and, in any event,
within 48 hours), of the status and material terms of any Company Acquisition Proposal (including any material changes to the material terms thereof) and the status of any material discussions and negotiations with respect thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Company receives a Company Acquisition Proposal (or notice from any Person that it intends to make a Company
Acquisition Proposal) or any inquiry or request for information with respect to a Company Acquisition Proposal or that is reasonably likely to lead to a Company Acquisition Proposal, then the Company shall promptly (and in no event later than 48
hours after its receipt of such Company Acquisition Proposal or request) notify Parent in writing of such Company Acquisition Proposal or request (which notification shall include the identity of the Person making or submitting such request or
Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Acquisition Proposal and an unredacted copy of any such written request or proposal (or, if not in writing, the material terms and conditions thereof)), together with copies of any proposed
transaction agreements, and the Company shall thereafter keep Parent reasonably informed, on a current basis (and, in any event, within 48 hours), of the status of such Company Acquisition Proposal, including informing Parent of any material change
to the terms of such Company Acquisition Proposal, and the status of any negotiations, including any change in its intentions as previously notified. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly following the execution and delivery of this Agreement (and in any event within 24 hours after the execution and
delivery of this Agreement), the Company shall, and shall cause each of the Company Subsidiaries and shall instruct their respective Representatives to, promptly cease and cause to be terminated any existing solicitation of, or discussions or
negotiations with, any Person (other than Parent and its Representatives) relating to any Company Acquisition Proposal made prior to the date hereof and any access any such Persons may have to any physical or electronic data room relating to any
potential Company Acquisition Proposal. The Company shall not, and shall cause its Affiliates not to, release any third party from, or waive, amend or modify any provision of, or grant permission under, or fail to enforce, any standstill provision
in any agreement to which the Company or any of its Affiliates is a party, unless the failure to take such action would reasonably be expected to be inconsistent with the Company&#146;s Board&#146;s fiduciary duties to the Company and its
stockholders under applicable Legal Requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any violation of the restrictions contained in this
<U>Section</U><U></U><U>&nbsp;4.2</U> by any of the Company Subsidiaries or any Representatives of the Company or any of the Company Subsidiaries shall be deemed to be a breach of this <U>Section</U><U></U><U>&nbsp;4.2</U> by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <B>Parent No Solicitation</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent will not, and Parent will cause each of the Parent Subsidiaries not to and instruct their respective Representatives
not to, except as expressly permitted by this <U>Section</U><U></U><U>&nbsp;4.3</U> or <U>Section</U><U></U><U>&nbsp;4.6</U>, directly or indirectly: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding,
or the submission or announcement by any Person of, any proposal or offer that constitutes, or would reasonably be expected to lead to, any Parent Acquisition Proposal (provided, however, that Parent and its Representatives may refer the Person
making such proposal or offer to the provisions of this Section&nbsp;4.3 and make inquiries of a Person making a Parent Acquisition Proposal (and its Representatives) to solely clarify the terms of, such Parent Acquisition Proposal for the purpose
of the Parent Board informing itself about such Parent Acquisition Proposal); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) furnish any information regarding
Parent or any Parent Subsidiary (other than to the Company and the Company Subsidiaries (and their Representatives)), or afford access to Parent&#146;s or the Parent Subsidiary&#146;s Representatives, books, records or property, in each case, in
connection with, for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to a Parent Acquisition Proposal; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person with respect
to any Parent Acquisition Proposal or any inquiry, proposal or offer that would reasonably be expected to lead to any Parent Acquisition Proposal (<I>provided</I>, <I>however</I>, that Parent and its Representatives may refer the Person making any
such inquiry, proposal or offer to the provisions of this <U>Section</U><U></U><U>&nbsp;4.3</U> and make inquiries of a Person making a Parent Acquisition Proposal (and its Representatives) solely to clarify the terms of, such Parent Acquisition
Proposal for the purpose of the Parent Board informing itself about such Parent Acquisition Proposal); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) approve,
adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment, or agreement in principle with respect
to any Parent Acquisition Proposal; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) resolve or agree to do any of the foregoing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that, notwithstanding anything to the contrary contained in this Agreement,
prior to obtaining the Required Parent Stockholder Vote, Parent and its Representatives may engage or otherwise participate in discussions or negotiations with, and provide information to, any Person (or its Representatives or its financing sources
or their Representatives) that has made a <I>bona fide</I> written Parent Acquisition Proposal after the date hereof that did not result from any breach of this <U>Section</U><U></U><U>&nbsp;4.3(a)</U> or <U>Section</U><U></U><U>&nbsp;4.3(c)</U> by
Parent, any of the Parent Subsidiaries or any of its or their respective Representatives if: (A)&nbsp;prior to taking any such action, the Parent Board determines in good faith, after consultation with Parent&#146;s outside legal counsel and its
financial advisor, that such Parent Acquisition Proposal either constitutes a Parent Superior Proposal or would reasonably be expected to lead to a Parent Superior Proposal; and (B)&nbsp;prior to providing any information regarding Parent or any
Parent Subsidiary to such third party in response to such Parent Acquisition Proposal, Parent receives from such third party (or there is then in effect with such party) an executed confidentiality agreement that contains nondisclosure provisions
that are at least as restrictive of such third party as the <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement and that does not prohibit compliance by Parent with this <U>Section</U><U></U><U>&nbsp;4.3</U>. Prior to or substantially
concurrently with providing any <FONT STYLE="white-space:nowrap">non-public</FONT> information to such third party, Parent shall make such <FONT STYLE="white-space:nowrap">non-public</FONT> information available to the Company (to the extent such <FONT
STYLE="white-space:nowrap">non-public</FONT> information has not been previously made available by Parent to the Company). Parent shall promptly (and in any event within 48 hours) inform the Company if Parent furnishes
<FONT STYLE="white-space:nowrap">non-public</FONT> information and/or enters into discussions or negotiations as provided for in this <U>Section</U><U></U><U>&nbsp;4.3(a)</U> and will keep the Company reasonably informed, on a current basis (and, in
any event, within 48 hours), of the status and material terms of any Parent Acquisition Proposal (including any material changes to the material terms thereof) and the status of any material discussions and negotiations with respect thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If Parent receives a Parent Acquisition Proposal or any inquiry or request for information with respect to a Parent
Acquisition Proposal or that is reasonably likely to lead to a Parent Acquisition Proposal, then Parent shall promptly (and in no event later than 48 hours after its receipt of such Parent Acquisition Proposal) notify the Company in writing of such
Parent Acquisition Proposal or request (which notification shall include the identity of the Person making or submitting such request or Parent Acquisition Proposal and an unredacted copy of any such written request or proposal (or, if not in
writing, the material terms and conditions thereof)), together with copies of any proposed transaction agreements, and Parent shall thereafter keep the Company reasonably informed, on a current basis (and, in any event, within 48 hours), of the
status of such Parent Acquisition Proposal or request, including informing the Company of any material change to the terms of such Parent Acquisition Proposal, and the status of any negotiations, including any change in its intentions as previously
notified. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly following the execution and delivery of this Agreement (and in any event within 24 hours after the
execution and delivery of this Agreement), Parent shall, and shall cause each of the Parent Subsidiaries and shall instruct its and their respective Representatives to, promptly cease and cause to be terminated any existing solicitation of, or
discussions or negotiations with, any Person (other than the Company and its Representatives) relating to any Parent Acquisition Proposal made prior to the date hereof and any access any such Persons may have to any physical or electronic data room
relating to any potential Parent Acquisition Proposal. Parent shall not, and shall cause its Affiliates not to, release any third party from, or waive, amend or modify any provision of, or grant permission under, or fail to enforce, any standstill
provision in any agreement to which Parent or any of its Affiliates is a party unless the failure to take such action would reasonably be expected to be inconsistent with the Parent Board&#146;s fiduciary duties to Parent and its stockholders under
applicable Legal Requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any violation of the restrictions contained in this
<U>Section</U><U></U><U>&nbsp;4.3</U> by any of the Parent Subsidiaries or any Representatives of Parent or any of the Parent Subsidiaries shall be deemed to be a breach of this <U>Section</U><U></U><U>&nbsp;4.3</U> by Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4 <B>Registration Statement; Joint Proxy Statement/Prospectus</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As promptly as reasonably practicable after the date of this Agreement, Parent and the Company shall jointly prepare and
cause to be filed with the SEC the Joint Proxy Statement/Prospectus, in preliminary form, and Parent shall prepare and cause to be filed with the SEC the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Statement, in which the Joint Proxy Statement/Prospectus, in preliminary form, will be included as a prospectus. Each of the parties shall: (i)&nbsp;use reasonable best efforts to cause the Form <FONT
STYLE="white-space:nowrap">S-4</FONT> Registration Statement and the Joint Proxy Statement/ Prospectus to comply in all material respects with all applicable rules, regulations and requirements of the Exchange Act or Securities Act;
(ii)&nbsp;promptly notify the other upon receipt of, and cooperate with each other and use reasonable best efforts to respond to, any comments or requests of the SEC or its staff, including for any amendment or supplement to the Form <FONT
STYLE="white-space:nowrap">S-4</FONT> Registration Statement of Joint Proxy Statement/Prospectus; (iii)&nbsp;promptly provide the other party with copies of all written correspondence and a summary of all oral communications between it or its
Representatives, on the one hand, and the SEC or its staff, on the other hand, relating to the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement or the Joint Proxy Statement/Prospectus; (iv)&nbsp;use reasonable best efforts to
have the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC; (v)&nbsp;use reasonable best efforts to keep the Form <FONT
STYLE="white-space:nowrap">S-4</FONT> Registration Statement effective through the Closing in order to permit the consummation of the Mergers; and (vi)&nbsp;cooperate with, and provide the other party with a reasonable opportunity to review and
comment in advance on the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement and the Joint Proxy Statement/Prospectus (including any amendments or supplements to the <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT>
Registration Statement or the Joint Proxy Statement/Prospectus) and any substantive correspondence (including all responses to SEC comments), prior to filing with the SEC or mailing, and shall provide to the other a copy of all such filings or
communications made with the SEC, except to the extent such disclosure or communication relates to a Company Acquisition Proposal or Parent Acquisition Proposal. The Company will, prior to filing the preliminary Joint Proxy Statement/Prospectus,
obtain all necessary consents of the Company Financial Advisor to permit the Company to include in the Joint Proxy Statement/Prospectus the Company Fairness Opinion. Parent will, prior to filing the preliminary Joint Proxy Statement/Prospectus,
obtain all necessary consents of the Parent Financial Advisor to permit Parent to include in the Joint Proxy Statement/Prospectus the Parent Fairness Opinion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent shall advise the Company, promptly after receipt of notice thereof, of the time when the Form <FONT
STYLE="white-space:nowrap">S-4</FONT> Registration Statement becomes effective or any supplement or amendment has been filed, the issuance of any stop order relating thereto, or the suspension of the shares of Parent Class&nbsp;A Common Stock for
offering or sale in any jurisdiction, or any request by the SEC or its staff for any amendment of or supplement to the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement or the Joint Proxy Statement/Prospectus or comments
thereon and responses thereto or requests by the SEC for additional information, and Parent shall use its reasonable best efforts to as promptly as practicable have any stop order relating to the Form <FONT STYLE="white-space:nowrap">S-4</FONT>
Registration Statement or any such suspension of the shares of Parent Class&nbsp;A Common Stock lifted, reversed or otherwise terminated. Parent shall cause the Joint Proxy Statement/Prospectus to be mailed to Parent&#146;s stockholders, and the
Company shall cause the Joint Proxy Statement/Prospectus to be mailed to the Company&#146;s stockholders, in each case as promptly as practicable after the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement is declared effective
under the Securities Act. Each of the parties shall promptly furnish the other parties all information concerning such party, its Subsidiaries, directors, officers and (to the extent reasonably available to such party) stockholders that may be
required by applicable Legal Requirements or reasonably requested by the other party or its Representatives in connection with any action contemplated by this <U>Section</U><U></U><U>&nbsp;4.4</U>. If, at any time prior to obtaining the Required
Company Stockholder Vote or Required Parent Stockholder Vote, any party becomes aware of any information that should be disclosed in an amendment or supplement to the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement or the
Joint Proxy Statement/Prospectus in order to make any statement therein, in the light of the circumstances under which it is made, not false or misleading with respect to a material fact, or in order to avoid the omission of a material fact
necessary to make the statements in the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement or the Joint Proxy Statement/Prospectus not misleading, then such party: (A)&nbsp;shall promptly inform the other party thereof;
(B)&nbsp;shall provide the other party (and its counsel) with a reasonable opportunity to review and comment on any amendment or supplement to the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement or the Joint Proxy
Statement/Prospectus prior to it being filed with the SEC, other than such disclosures that relate to a Company Acquisition Proposal or a Parent Acquisition Proposal; (C)&nbsp;shall provide the other party with a copy of such amendment or supplement
promptly after it is filed with the SEC; and (D)&nbsp;if mailing is required by law or otherwise appropriate, shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
cooperate in mailing such amendment or supplement to the stockholders of Parent or the stockholders of the Company. For purposes of the Joint Proxy Statement/Prospectus, any information
concerning or related to the Company, its Affiliates, or the Company Stockholder Meeting will be deemed to have been provided by the Company, and any information concerning or related to Parent, its Affiliates, or the Parent Stockholder Meeting will
be deemed to have been provided by Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Prior to the First Effective Time, Parent shall use its reasonable best
efforts to take all other actions required to be taken under the Securities Act and the rules and regulations of the SEC promulgated thereunder, the Exchange Act and the rules and regulations of the SEC promulgated thereunder, or any applicable
state securities or &#147;blue sky&#148; laws and the rules and regulations thereunder, in connection with the issuance of Parent Class&nbsp;A Common Stock to be issued in the First Merger, including the Parent Class&nbsp;A Common Stock to be issued
upon the exercise of converted Company Options; <I>provided</I>, <I>however</I>, that Parent shall not be required to qualify to do business in any jurisdiction in which it is not now so qualified or file a general consent to service of process in
any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5 <B>Meeting of the Company</B><B>&#146;</B><B>s Stockholders; Company Change in Recommendation</B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company: (i)&nbsp;shall take all action necessary under all applicable Legal Requirements and the Company&#146;s
Organizational Documents to, in consultation with Parent and as promptly as reasonably practicable after the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement is declared effective, duly call, give notice of and initially
schedule a meeting of the holders of shares of Company Common Stock (the &#147;<U>Company Stockholder Meeting</U>&#148;), which to the extent permitted by applicable Legal Requirements, shall be within 45 days thereafter, which meeting will be held
to vote on (A)&nbsp;a proposal to adopt this Agreement; (B)&nbsp;a proposal for a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote of the Company&#146;s stockholders to approve certain compensation that may become payable to the
Company&#146;s named executive officers in connection with the completion of the Mergers and (C)&nbsp;an adjournment proposal; and (ii)&nbsp;shall submit such proposals to, and, except in the case where the Company Board has made a Company Change in
Recommendation, use its reasonable best efforts to solicit proxies in favor of the proposal to adopt this Agreement from, such holders at the Company Stockholder Meeting, and the Company shall not submit any other proposals to its stockholders in
connection with the Company Stockholder Meeting without the prior written consent of Parent. The Company, in consultation with Parent, shall set a record date for determining the Persons entitled to notice of, and to vote at, the Company Stockholder
Meeting. The Company shall ensure that all proxies solicited in connection with the Company Stockholder Meeting are solicited in compliance with all applicable Legal Requirements. Notwithstanding anything to the contrary contained in this Agreement,
(A)&nbsp;the Company shall not postpone or adjourn the Company Stockholder Meeting without the prior written consent of Parent, other than: (1)&nbsp;to the extent reasonably necessary to ensure that any supplement or amendment to the Joint Proxy
Statement/Prospectus that the Company Board has determined in good faith after consultation with outside counsel is required by applicable Legal Requirements is disclosed to the Company&#146;s stockholders and for such supplement or amendment to be
promptly disseminated to the Company&#146;s stockholders within a reasonable amount of time (as determined by the Company Board in good faith after consultation with outside counsel) prior to the Company Stockholder Meeting; (2)&nbsp;if required by
applicable Legal Requirement or a request from the SEC or its staff; or (3)&nbsp;if as of the time for which the Company Stockholder Meeting is scheduled there are insufficient shares of Company Common Stock represented (either in person or by
proxy) to constitute a quorum necessary to conduct the business to be conducted at the Company Stockholder Meeting; and (B)&nbsp;the Company may, and if Parent so requests at any time shall, postpone or adjourn the Company Stockholder Meeting in
order to solicit additional proxies in favor of the adoption of this Agreement if, on the date for which the Company Stockholder Meeting is scheduled, there would be insufficient votes to obtain the Required Company Stockholder Vote, whether or not
a quorum is present, in which case, except in the case where the Company Board has made a Company Change in Recommendation, the Company shall use its reasonable best efforts during any such postponement or adjournment to solicit and obtain such
proxies in favor of the adoption of this Agreement as soon as reasonably practicable; <I>provided</I> that (x)&nbsp;without the prior written consent of Parent (not to be unreasonably withheld, conditioned, or delayed in the cases of clauses (A)(1)
and (A)(2)), no single such adjournment or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
postponement pursuant to clauses (A)&nbsp;or (B) shall be for more than ten Business Days, except as may be required by applicable Legal Requirements or a request from the SEC or its staff,
(y)&nbsp;the Company shall not be required to effect, and Parent shall not be required to consent to, any such adjournments or postponements that together cause the date of the Company Stockholder Meeting to be more than 20 Business Days after the
date for which the Company Stockholder Meeting was originally scheduled or, in the case of the foregoing clauses (A)(3) and (B), less than five Business Days prior to the End Date and (z)&nbsp;except as required by Legal Requirements in connection
with adjournments or postponements of the Company Stockholder Meeting effected in accordance with the foregoing, in no event shall the Company change the record date for determining the stockholders entitled to notice of and to vote at the Company
Stockholder Meeting without Parent&#146;s consent. Subject to the foregoing and applicable Legal Requirements, (I)&nbsp;the Company shall cooperate with Parent and use its reasonable best efforts to cause the Company Stockholder Meeting to initially
be called for the same date as the Parent Stockholder Meeting; and (II)&nbsp;if, notwithstanding such efforts, the Parent Stockholder Meeting is initially called for a date prior to the Company Stockholder Meeting, the Company shall use its
reasonable best efforts to call its meeting on a date that is as promptly as reasonably practicable following the date of the Parent Stockholder Meeting. Upon written request by Parent (which shall not exceed one request per day), the Company shall,
during the ten Business Days prior to the date of the Company Stockholder Meeting, advise Parent as to the aggregate number of shares of Company Common Stock entitled to vote at the Company Stockholder Meeting for which proxies have been received by
the Company with respect to the Required Company Stockholder Vote and the number of such proxies authorizing the holder thereof to vote in favor of the Required Company Stockholder Vote. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to <U>Section</U><U></U><U>&nbsp;4.5(c)</U>, the Joint Proxy Statement/Prospectus shall include the Company Board
Recommendation. Neither the Company Board nor any committee thereof shall, except as otherwise expressly permitted by this Agreement: (i)&nbsp;withhold, withdraw, modify, amend or qualify (or publicly propose to withdraw, modify, amend or qualify),
in a manner adverse to Parent or Acquisition Subs, the Company Board Recommendation, or fail to include the Company Board Recommendation in the Joint Proxy Statement/Prospectus; (ii)&nbsp;approve, recommend or declare advisable (or publicly propose
to do so) any Company Acquisition Proposal; (iii)&nbsp;fail to publicly announce, within ten Business Days after a tender offer or exchange offer relating to the equity securities of the Company shall have been commenced by any third party other
than Parent and its Affiliates (and in no event later than one Business Day prior to the date of the Company Stockholder Meeting, as it may be postponed or adjourned pursuant to <U>Section</U><U></U><U>&nbsp;4.5(a)</U>), a statement disclosing that
the Company Board recommends rejection of such tender or exchange offer (for the avoidance of doubt, the taking of no position or a neutral position by the Company Board in respect of the acceptance of any such tender offer or exchange offer as of
the end of such period shall constitute a failure to publicly announce that the Company Board recommends rejection of such tender or exchange offer); or (iv)&nbsp;if requested by Parent, fail to issue, within ten Business Days after a Company
Acquisition Proposal is publicly announced (and in no event later than one Business Day prior to the date of the Company Stockholder Meeting, as it may be postponed or adjourned pursuant to <U>Section</U><U></U><U>&nbsp;4.5(a)</U>), a press release
reaffirming the Company Board Recommendation, <I>provided</I>, <I>however</I>, that the Company must receive the request from Parent at least 48 hours prior to such reaffirmation being required; <I>provided</I>, <I>further</I>, that in no event
shall the Company or the Company Board be obligated to publicly reaffirm the Company Board Recommendation on more than one occasion with respect to each such publicly announced Company Acquisition Proposal or on more than one occasion with respect
to each publicly announced material modification thereof (any action described in clauses (i)&nbsp;through (iv) being referred to as a &#147;<U>Company Change in Recommendation</U>&#148;); (v) cause or permit the Company to enter into any Contract,
letter of intent, memorandum of understanding, agreement in principle or other arrangement or understanding (other than a confidentiality agreement entered into in compliance with <U>Section</U><U></U><U>&nbsp;4.2(a)</U>) contemplating or relating
to a Company Acquisition Transaction; (vi)&nbsp;take any action to make the provisions of any anti-takeover or similar statute or regulation inapplicable to any Company Acquisition Proposal or counterparty thereto; or (vii)&nbsp;publicly propose to
do any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary contained in this Agreement, at
any time prior to obtaining the Required Company Stockholder Vote, the Company Board may make a Company Change in Recommendation related to a Company Acquisition Proposal and/or terminate this Agreement in accordance with
<U>Section</U><U></U><U>&nbsp;6.1(f)</U> if (x)&nbsp;the Company receives from a third party a <I>bona fide</I> written Company Acquisition Proposal after the date of this Agreement that did not result from a breach of
<U>Section</U><U></U><U>&nbsp;4.2</U>, and has not been withdrawn, and (z)&nbsp;prior to making such Company Change in Recommendation or terminating this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;6.1(f)</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Company Board determines in good faith, after consultation with the Company&#146;s outside legal counsel and its
financial advisor, that such Company Acquisition Proposal constitutes a Company Superior Proposal and that failure to take such action would reasonably be expected to be inconsistent with the Company Board&#146;s fiduciary duties to its stockholders
under applicable Legal Requirements; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the Company delivers to Parent a written notice (the &#147;<U>Company Superior
Proposal Notice</U>&#148;) no less than four Business Days in advance stating that the Company Board intends to make a Company Change in Recommendation or terminate this Agreement, which such Company Superior Proposal Notice shall include the
identity of the Person making such Company Acquisition Proposal and a copy of such proposal and a draft of the definitive agreement to be entered into in connection therewith (or, if not in writing, the material terms and conditions thereof); and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;(A) during the four Business Day period commencing on the date of Parent&#146;s receipt of such Company
Superior Proposal Notice, if requested by Parent, the Company engages in good faith negotiations with Parent regarding a possible amendment of this Agreement so that the Company Acquisition Proposal that is the subject of the Company Superior
Proposal Notice ceases to be a Company Superior Proposal; and (B)&nbsp;after the expiration of the negotiation period described in clause (A)&nbsp;above, the Company Board determines in good faith, after consultation with its outside legal counsel
and its financial advisor, and after taking into account any amendments to this Agreement that Parent and each Acquisition Sub have committed in writing to make as a result of the negotiations contemplated by clause (A)&nbsp;above and in a manner
that would be binding upon Parent and each Acquisition Sub if accepted by the Company, that such Company Acquisition Proposal continues to constitute a Company Superior Proposal; <I>provided</I>, that if there is any change to any of the financial
terms or any other material terms of such Company Acquisition Proposal, the Company shall, in each case, be required to deliver to Parent an additional notice consistent with that described in clause (ii)&nbsp;above and a new negotiation period
under clause &#147;(A)&#148; above shall commence (except that the original four Business Day notice period referred to in clause (A)&nbsp;above shall instead be equal to the longer of (1) 11:59 p.m. New York Time on the second Business Day
immediately following Parent&#146;s receipt of such notice, and (2)&nbsp;the period remaining under the original four Business Day notice period of clause (A)&nbsp;above), during which time the Company shall be required to comply with the
requirements of <U>Section</U><U></U><U>&nbsp;4.5(c)(iii)</U> anew with respect to such additional notice (but substituting the time periods therein with the foregoing two Business Day period). The actions of the Company Board making a determination
that a Company Acquisition Proposal constitutes a Company Superior Proposal and the Company&#146;s authorizing and providing the notices to Parent required by this <U>Section</U><U></U><U>&nbsp;4.5(c) </U>shall not in and of itself, constitute a
Company Change in Recommendation, a violation of this <U>Section</U><U></U><U>&nbsp;4.5</U>, or a termination of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary contained in this Agreement, at any time prior to obtaining the Required Company
Stockholder Vote, the Company Board may make a Company Change in Recommendation that is not related to a Company Acquisition Proposal if any state of fact, event, change, effect, circumstance, occurrence or development, or combination thereof,
arises following the date of this Agreement (I)&nbsp;that (x) was neither known to nor reasonably foreseeable by the Company Board as of the date of this Agreement (or, if known to or reasonably foreseeable by the Company Board, the consequences of
which were neither known to nor reasonably foreseeable by the Company Board as of the date of this Agreement) and (y)&nbsp;is material to the Company and the Company Subsidiaries, taken as a whole, and (II)&nbsp;that is not related to (A)&nbsp;a
Company Acquisition Proposal or a Company Superior Proposal or any inquiry or communications relating thereto, any matter relating thereto or consequences thereof, (B)&nbsp;in each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
case in and of itself, any changes in the market price or trading volume of Company Common Stock or the fact that the Company meets, fails to meet or exceeds any internal or published
projections, forecasts or estimates of its revenue, earnings or other financial performance or results of operations for any period (it&nbsp;being understood, however, that any underlying cause of any of the foregoing may be taken into account
unless excluded pursuant to clause (A)&nbsp;or (C)), or (C)&nbsp;any event, condition or circumstance related to Parent or any of the Parent Subsidiaries (any such state of fact, event, change, effect, circumstance, occurrence, development,
condition, circumstance, or combination thereof, being referred to as a &#147;<U>Company Intervening Event</U>&#148;); and, prior to making such Company Change in Recommendation, (1)&nbsp;the Company Board determines in good faith, after
consultation with its outside legal counsel and its financial advisor, that, in light of such Company Intervening Event, a failure to effect a Company Change in Recommendation would reasonably be expected to be inconsistent with the Company
Board&#146;s fiduciary duties to its stockholders under applicable Legal Requirements; (2)&nbsp;less than four Business Days prior to the making of such Company Change in Recommendation, Parent receives a written notice from the Company confirming
that the Company Board intends to effect such Company Change in Recommendation, specifying the reasons therefor in reasonable detail; (3)&nbsp;during such four Business Day period, if requested by Parent, the Company engages in good faith
negotiations with Parent to amend this Agreement in such a manner that obviates the need for the Company Board to effect a Company Change in Recommendation; and (4)&nbsp;following the end of such four Business Day period, the Company Board
determines in good faith, after consultation with its outside legal counsel and financial advisor and after taking into account any amendments to this Agreement that Parent and each Acquisition Sub have committed in writing to make as a result of
the negotiations contemplated by clause (3)&nbsp;above and in a manner that would be binding upon Parent and each Acquisition Sub if accepted by the Company, that, in light of such Company Intervening Event, a failure to effect a Company Change in
Recommendation would reasonably be expected to be inconsistent with the Company Board&#146;s fiduciary duties to its stockholders under applicable Legal Requirements, even if such changes committed to in writing were to be given effect. The actions
of the Company Board making a determination that a Company Intervening Event has occurred and the Company&#146;s authorizing and providing the notices to Parent required by this <U>Section</U><U></U><U>&nbsp;4.5(d)</U> shall not in and of itself,
constitute a Company Change in Recommendation or a violation of this <U>Section</U><U></U><U>&nbsp;4.5</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
Notwithstanding any Company Change in Recommendation, unless this Agreement has been earlier terminated in accordance with <U>Section</U><U></U><U>&nbsp;6.1</U>, this Agreement shall be submitted to the holders of shares of Company Common Stock at
the Company Stockholder Meeting for the purpose of voting on the adoption of this Agreement and nothing contained in this Agreement shall be deemed to relieve the Company of such obligation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Nothing contained in this Agreement shall prohibit the Company, the Company Board or their Representatives from
(i)&nbsp;taking and disclosing to the stockholders of the Company a position contemplated by Rule <FONT STYLE="white-space:nowrap">14e-2,</FONT> Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or Item 1012 of Regulation <FONT
STYLE="white-space:nowrap">M-A</FONT> promulgated under the Exchange Act or issuing a &#147;stop, look and listen&#148; statement to the stockholders of the Company pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated under
the Exchange Act pending disclosure of its position thereunder or (ii)&nbsp;directing any Person (or the Representative of that Person) who makes a Company Acquisition Proposal to the provisions of this <U>Section</U><U></U><U>&nbsp;4.5</U>;
<I>provided</I>, <I>however</I>, that in the case of either clause (i)&nbsp;or clause (ii), no such communication or statement that would constitute a Company Change in Recommendation shall be permitted, made or taken except in accordance with
<U>Section</U><U></U><U>&nbsp;4.5(c)</U> or <U>Section</U><U></U><U>&nbsp;4.5(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Any violation of the
restrictions contained in this <U>Section</U><U></U><U>&nbsp;4.5</U> by any of the Company&#146;s Subsidiaries, or any Representatives of the Company or any of the Company Subsidiaries, shall be deemed to be a breach of this
<U>Section</U><U></U><U>&nbsp;4.5</U> by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6 <B>Meeting of Parent</B><B>&#146;</B><B>s Stockholders; Parent
Change in Recommendation</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent: (i)&nbsp;shall take all action necessary under all applicable Legal Requirements
and Parent&#146;s Organizational Documents to, in consultation with the Company as promptly as reasonably practicable after the <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> Registration Statement is declared effective, duly call, give
notice of and initially schedule a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
meeting of the holders of shares of Parent Common Stock (the &#147;<U>Parent Stockholder Meeting</U>&#148;), which to the extent permitted by applicable Legal Requirements, shall be within 45
days thereafter, which meeting will be held to vote on a proposal to approve the Parent Share Issuance; and (ii)&nbsp;shall submit such proposal to, and, except in the case where the Parent Board has made a Parent Change in Recommendation, use its
reasonable best efforts to solicit proxies in favor of such proposal from, such holders at the Parent Stockholder Meeting, and Parent shall not submit any other proposal to its stockholders in connection with the Parent Stockholder Meeting without
the prior written consent of the Company. Parent, in consultation with the Company, shall set a record date for determining the Persons entitled to notice of, and to vote at, the Parent Stockholder Meeting. Parent shall ensure that all proxies
solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Legal Requirements. Notwithstanding anything to the contrary contained in this Agreement, (A)&nbsp;Parent shall not postpone or adjourn the
Parent Stockholder Meeting without the prior written consent of the Company, other than: (1)&nbsp;to the extent reasonably necessary to ensure that any supplement or amendment to the Joint Proxy Statement/Prospectus that the Parent Board has
determined in good faith after consultation with outside counsel is required by applicable Legal Requirements is disclosed to Parent&#146;s stockholders and for such supplement or amendment to be promptly disseminated to Parent&#146;s stockholders
within a reasonable amount of time (as determined by the Parent Board in good faith after consultation with outside counsel) prior to the Parent Stockholder Meeting; (2)&nbsp;if required by applicable Legal Requirement or a request from the SEC or
its staff; or (3)&nbsp;if as of the time for which the Parent Stockholder Meeting is scheduled there are insufficient shares of Parent Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business
to be conducted at the Parent Stockholder Meeting; and (B)&nbsp;Parent may, and if the Company so requests at any time shall, postpone or adjourn the Parent Stockholder Meeting in order to solicit additional proxies in favor of the approval of the
Parent Share Issuance, if, on the date for which the Parent Stockholder Meeting is scheduled, there would be insufficient votes to obtain the Required Parent Stockholder Vote, whether or not a quorum is present, in which case, except in the case
where the Parent Board has made a Parent Change in Recommendation, Parent shall use its reasonable best efforts during any such postponement or adjournment to solicit and obtain such proxies in favor of the approval of the Parent Share Issuance as
soon as reasonably practicable; <I>provided</I> that (x)&nbsp;without the prior written consent of the Company (not to be unreasonably withheld, conditioned, or delayed in the cases of clauses (A)(1) and (A)(2)), no single such adjournment or
postponement pursuant to clauses (A)&nbsp;or (B) shall be for more than ten Business Days, except as may be required by applicable Legal Requirements or a request from the SEC or its staff, (y)&nbsp;Parent shall not be required to effect, and the
Company shall not be required to consent to, any such adjournments or postponements that together cause the date of the Parent Stockholder Meeting to be more than twenty Business Days after the date for which the Parent Stockholder Meeting was
originally scheduled or, in the case of the foregoing clauses (A)(3) and (B), less than four Business Days prior to the End Date and (z)&nbsp;except as required by Legal Requirements in connection with adjournments or postponements of the Parent
Stockholder Meeting effected in accordance with the foregoing, in no event shall Parent change the record date for determining the stockholders entitled to notice of and to vote at the Parent Stockholder Meeting without the Company&#146;s consent.
Subject to the foregoing and applicable Legal Requirements, (I)&nbsp;Parent shall cooperate with the Company and use its reasonable best efforts to cause the Parent Stockholder Meeting to initially be called for the same date as the Company
Stockholder Meeting; and (II)&nbsp;if, notwithstanding such efforts, the Company Stockholder Meeting is initially called for a date prior to the Parent Stockholder Meeting, Parent shall use its reasonable best efforts to call its meeting on a date
that is as promptly as reasonably practicable following the date of the Company Stockholder Meeting. Upon request of the Company (which shall not exceed one request per day), Parent shall, during the ten Business Days prior to the date of the
Company Stockholder Meeting, advise the Company as to the aggregate number of shares of Parent Common Stock entitled to vote at the Parent Stockholder Meeting for which proxies have been received by Parent with respect to the Required Parent
Stockholder Vote and the number of such proxies authorizing the holder thereof to vote in favor of the Required Parent Stockholder Vote. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to <U>Section</U><U></U><U>&nbsp;4.6(c)</U>, the Joint Proxy Statement/Prospectus shall include the Parent Board
Recommendation. Neither the Parent Board nor any committee thereof shall, except as otherwise expressly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
permitted by this Agreement: (i)&nbsp;withhold, withdraw, modify, amend or qualify (or publicly propose to withdraw, modify, amend or qualify), in a manner adverse to the Company, the Parent
Board Recommendation, or fail to include the Parent Board Recommendation in the Joint Proxy Statement/Prospectus; (ii)&nbsp;approve, recommend or declare advisable (or publicly propose to do so) any Parent Acquisition Proposal; (iii)&nbsp;fail to
publicly announce, within ten Business Days after a tender offer or exchange offer relating to the equity securities of Parent shall have been commenced by any third party (and in no event later than one Business Day prior to the date of the Parent
Stockholder Meeting, as it may be postponed or adjourned pursuant to <U>Section</U><U></U><U>&nbsp;4.6(a)</U>), a statement disclosing that the Parent Board recommends rejection of such tender or exchange offer (for the avoidance of doubt, the
taking of no position or a neutral position by the Parent Board in respect of the acceptance of any such tender offer or exchange offer as of the end of such period shall constitute a failure to publicly announce that the Parent Board recommends
rejection of such tender or exchange offer); or (iv)&nbsp;if requested by the Company, fail to issue, within ten Business Days after a Parent Acquisition Proposal is publicly announced (and in no event later than one Business Day prior to the date
of the Parent Stockholder Meeting, as it may be postponed or adjourned pursuant to <U>Section</U><U></U><U>&nbsp;4.6(a)</U>), a press release reaffirming the Parent Board Recommendation <I>provided</I>, <I>however</I>, that Parent must receive the
request from the Company at least 48 hours prior to such reaffirmation being required; <I>provided</I>, <I>further</I>, that in no event shall Parent or the Parent Board be obligated to publicly reaffirm the Parent Board Recommendation on more than
one occasion with respect to each such publicly announced Company Acquisition Proposal or on more than one occasion with respect to each publicly announced material modification thereof (any action described in clauses (i)&nbsp;through (iv) being
referred to as a &#147;<U>Parent Change in Recommendation</U>&#148;); (v) cause or permit Parent to enter into any Contract, letter of intent, memorandum of understanding, agreement in principle or other arrangement or understanding (other than a
confidentiality agreement entered into in compliance with <U>Section</U><U></U><U>&nbsp;4.3(a)</U>) contemplating or relating to a Parent Acquisition Transaction; (vi)&nbsp;take any action to make the provisions of any anti-takeover or similar
statute or regulation inapplicable to any Parent Acquisition Proposal or counterparty thereto; or (vii)&nbsp;publicly propose to do any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary contained in this Agreement, at any time prior to obtaining the Required Parent
Stockholder Vote, the Parent Board may make a Parent Change in Recommendation related to a Parent Acquisition Proposal if and only if (x)&nbsp;Parent receives from a third party a <I>bona fide</I> written Parent Acquisition Proposal after the date
of this Agreement that did not result from a breach of <U>Section</U><U></U><U>&nbsp;4.3</U>, and has not been withdrawn, and (z)&nbsp;prior to making such Parent Change in Recommendation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Parent Board determines in good faith, after consultation with Parent&#146;s outside legal counsel and its financial
advisor, that such Parent Acquisition Proposal constitutes a Parent Superior Proposal and that failure to take such action would reasonably be expected to be inconsistent with the Parent Board&#146;s fiduciary duties to Parent and its stockholders
under applicable Legal Requirements; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Parent delivers to the Company a written notice (the &#147;<U>Parent Superior
Proposal Notice</U>&#148;) no less than four Business Days in advance stating that the Parent Board intends to make a Parent Change in Recommendation, which Parent Superior Proposal Notice shall include the identity of the Person making such Parent
Acquisition Proposal and a copy of such proposal and a draft of the definitive agreement to be entered into in connection therewith (or, if not in writing, the material terms and conditions thereof); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;(A) during the four Business Day period commencing on the date of the Company&#146;s receipt of such Parent Superior
Proposal Notice, if requested by the Company, Parent engages in good faith negotiations with the Company regarding a possible amendment of this Agreement so that the Parent Acquisition Proposal that is the subject of the Parent Superior Proposal
Notice ceases to be a Parent Superior Proposal; and (B)&nbsp;after the expiration of the negotiation period described in clause (A)&nbsp;above and in a manner that would be binding upon Parent and each Acquisition Sub if accepted by the Company, the
Parent Board determines in good faith, after consultation with its outside legal counsel and its financial advisor, and after taking into account any amendments to this Agreement that the Company has committed in writing to make as a result of the
negotiations contemplated by clause (A)&nbsp;above, that such Parent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Acquisition Proposal continues to constitute a Parent Superior Proposal <I>provided</I>, that if there is any change to any of the financial terms or any other material terms of such Parent
Acquisition Proposal, Parent shall, in each case, be required to deliver to the Company an additional notice consistent with that described in clause (ii)&nbsp;above and a new negotiation period under clause &#147;(A)&#148; above shall commence
(except that the original four Business Day notice period referred to in clause &#147;(A)&#148; above shall instead be equal to the longer of (1) 11:59 p.m. New York Time on the second Business Day immediately following the Company&#146;s receipt of
such notice, and (2)&nbsp;the period remaining under the original four Business Day notice period of clause &#147;(A)&#148; above), during which time Parent shall be required to comply with the requirements of this
<U>Section</U><U></U><U>&nbsp;4.6(c)(iii)</U> anew with respect to such additional notice (but substituting the time periods therein with the foregoing two Business Day period). The actions of the Parent Board making a determination that a Parent
Acquisition Proposal constitutes a Parent Superior Proposal and Parent&#146;s authorizing and providing the notices to the Company required by this <U>Section</U><U></U><U>&nbsp;4.6(c)</U> shall not in and of itself, constitute a Parent Change in
Recommendation or a violation of this <U>Section</U><U></U><U>&nbsp;4.6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary
contained in this Agreement, at any time prior to obtaining the Required Parent Stockholder Vote, the Parent Board may make a Parent Change in Recommendation that is not related to a Parent Acquisition Proposal if any state of fact, event, change,
effect, circumstance, occurrence or development, or combination thereof, arises following the date of this Agreement (I)&nbsp;that (x) was neither known to nor reasonably foreseeable by the Parent Board as of the date of this Agreement (or, if known
to or reasonably foreseeable by the Parent Board, the consequences of which were neither known to nor reasonably foreseeable by the Parent Board as of the date of this Agreement) and (y)&nbsp;is material to Parent and the Parent Subsidiaries, taken
as a whole, and (II)&nbsp;that is not related to (A)&nbsp;a Parent Acquisition Proposal or a Parent Superior Proposal or any inquiry or communications relating thereto, any matter relating thereto or consequences thereof, (B)&nbsp;in each case in
and of itself, any changes in the market price or trading volume of Parent Class&nbsp;A Common Stock or the fact that Parent meets, fails to meet or exceeds any internal or published projections, forecasts or estimates of its revenue, earnings or
other financial performance or results of operations for any period (it being understood, however, that any underlying cause of any of the foregoing may be taken into account unless excluded pursuant to clauses (A)&nbsp;or (C)), or (C)&nbsp;any
event, condition or circumstance related to the Company or any of the Company Subsidiaries (any such state of fact, event, change, effect, circumstance, occurrence, development, condition, circumstance, or combination thereof, being referred to as a
&#147;<U>Parent Intervening Event</U>&#148;); and, prior to making such Parent Change in Recommendation, (1)&nbsp;the Parent Board determines in good faith, after consultation with its outside legal counsel and its financial advisor, that, in light
of such Parent Intervening Event, a failure to effect a Parent Change in Recommendation would reasonably be expected to be inconsistent with the Parent Board&#146;s fiduciary duties to Parent and its stockholders under applicable Legal Requirements;
(2)&nbsp;less than four Business Days prior to the making of such Parent Change in Recommendation, the Company receives a written notice from Parent confirming that the Parent Board intends to effect such Parent Change in Recommendation, specifying
the reasons therefor in reasonable detail; (3)&nbsp;during such four Business Day period, if requested by the Company, Parent engages in good faith negotiations with the Company to amend this Agreement in such a manner that obviates the need for the
Parent Board to effect a Parent Change in Recommendation; and (4)&nbsp;following the end of such four Business Day period, the Parent Board determines in good faith, after consultation with its outside legal counsel and financial advisor and after
taking into account any amendments to this Agreement that the Company has committed in writing to make as a result of the negotiations contemplated by clause (3)&nbsp;above and in a manner that would be binding upon the Company if accepted by
Parent, that, in light of such Parent Intervening Event, a failure to effect a Parent Change in Recommendation would reasonably be expected to be inconsistent with the Parent Board&#146;s fiduciary duties to its stockholders under applicable Legal
Requirements, even if such changes committed to in writing were to be given effect. The actions of the Parent Board making a determination that a Parent Intervening Event has occurred and Parent&#146;s authorizing and providing the notices to the
Company required by this <U>Section</U><U></U><U>&nbsp;4.6(d)</U> shall not in and of itself constitute a Parent Change in Recommendation or a violation of this <U>Section</U><U></U><U>&nbsp;4.6</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding any Parent Change in Recommendation, unless this
Agreement has been earlier terminated in accordance with <U>Section</U><U></U><U>&nbsp;6.1</U>, the Parent Share Issuance shall be submitted to the holders of shares of Parent Common Stock at the Parent Stockholder Meeting for the purpose of the
approval of the Parent Share Issuance and nothing contained in this Agreement shall be deemed to relieve the Parent of such obligation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Nothing contained in this Agreement shall prohibit Parent, the Parent Board or their Representatives from (i)&nbsp;taking
and disclosing to the stockholders of Parent a position contemplated by Rule <FONT STYLE="white-space:nowrap">14e-2,</FONT> Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or Item 1012 of Regulation <FONT STYLE="white-space:nowrap">M-A</FONT>
promulgated under the Exchange Act or issuing a &#147;stop, look and listen&#148; statement to the stockholders of Parent pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated under the Exchange Act pending disclosure of its
position thereunder or (ii)&nbsp;directing any Person (or the Representative of that Person) who makes a Parent Acquisition Proposal to the provisions of this <U>Section</U><U></U><U>&nbsp;4.6</U>; <I>provided</I>, <I>however</I>, that in the case
of either clause (i)&nbsp;or clause (ii), no such communication or statement that would constitute a Parent Change in Recommendation shall be permitted, made or taken except in accordance with <U>Section</U><U></U><U>&nbsp;4.6(c)</U> or
<U>Section</U><U></U><U>&nbsp;4.6(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Any violation of the restrictions contained in this
<U>Section</U><U></U><U>&nbsp;4.6</U> by any of Parents&#146; Subsidiaries, or any Representatives of Parent or the Parent Subsidiaries shall be deemed to be a breach of this <U>Section</U><U></U><U>&nbsp;4.6</U> by Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7 <B>Filings; Other Action</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement, each of the parties hereto shall cooperate with the other and use
(and shall cause their respective Subsidiaries to use) their respective reasonable best efforts to: (i)&nbsp;take, or cause to be taken, all actions, and do, or cause to be done, all things, necessary to cause the conditions to Closing to be
satisfied as promptly as reasonably practicable (and in any event no later than the End Date) and to consummate and make effective, as promptly as practicable, the transactions contemplated by this Agreement, including preparing and filing promptly
and fully all documentation to effect all necessary filings, notifications, notices, petitions, statements, registrations, submissions of information, applications and other documents (including any required or recommended filings under applicable
Antitrust Laws) that are or may become necessary in connection with the consummation of the transactions contemplated by this Agreement; (ii)&nbsp;obtain as promptly as reasonably practicable (and in any event no later than the End Date) all
approvals, consents, clearances, expirations or terminations of waiting periods, registrations, permits, authorizations and other confirmations from any Governmental Entity or third party that are or may become necessary to consummate the
transactions contemplated by this Agreement; (iii)&nbsp;obtain all necessary consents, approvals or waivers from third parties. For purposes of this Agreement, &#147;<U>Antitrust Laws</U>&#148; shall mean the Sherman Act, as amended, the Clayton
Act, as amended, the HSR Act, the Federal Trade Commission Act, as amended, and all other applicable Legal Requirements issued by a Governmental Entity that are designed or intended to prohibit, restrict or regulate actions having the purpose or
effect of monopolization or restraint of trade or lessening of competition through merger or acquisition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each party
shall use their respective reasonable best efforts to file, as soon as practicable and advisable after the date of this Agreement, all notices, reports and other documents required to be filed by such party with any Governmental Entity with respect
to the Mergers and the other transactions contemplated by this Agreement, and to submit as promptly as reasonably practicable any additional information requested by any such Governmental Entity. Without limiting the generality of the foregoing,
each of Parent and the Company shall, in consultation and cooperation with the other, within 10 Business Days after the date of this Agreement (or such other date as may be mutually agreed to by Parent and the Company), prepare and file the
notifications required under the HSR Act. Parent and the Company shall use their respective reasonable best efforts to respond as promptly as reasonably practicable to any inquiries or requests for additional information or documentary material
received from any state attorney general, antitrust authority or other Governmental Entity in connection with antitrust or related matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to the provisions of the
<FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement, Parent and the Company each shall promptly supply the other with any information that may be required in order to effectuate any filings (including applications) pursuant to (and to
otherwise comply with its obligations set forth in) <U>Section</U><U></U><U>&nbsp;4.7(a)</U> and <U>Section</U><U></U><U>&nbsp;4.7(b)</U>. Each of Parent and the Company, as it deems advisable and necessary, may reasonably designate competitively
sensitive material provided to the other as &#147;outside counsel only&#148; or with similar restrictions. Each of Parent and the Company may also reasonably redact material as necessary to (i)&nbsp;comply with other contractual arrangements or
applicable Legal Requirements or (ii)&nbsp;prevent the loss of protection under the attorney-client privilege or the attorney work product doctrine but shall use commercially reasonable efforts to allow for such disclosure (or as much of it as
possible) in a manner that does not result in a violation of contractual arrangements, or Legal Requirements, or a loss of attorney-client privilege. Such materials and the information contained therein shall be given only to the outside legal
counsel of the recipient, or otherwise as the restriction indicates, and be subject to any additional confidentiality or joint defense agreement between the parties. Except where prohibited by applicable Legal Requirements or any Governmental
Entity, and subject to the provisions of the <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement, each of Parent and the Company shall: (i)&nbsp;consult with the other in good faith prior to taking a position with respect to any filing
required or advisable pursuant to <U>Section</U><U></U><U>&nbsp;4.7(a)</U> and <U>Section</U><U></U><U>&nbsp;4.7(b)</U>; (ii) permit the other to review and discuss in advance, and consider in good faith the views of the other in connection with,
any analyses, appearances, presentations, memoranda, letters, responses to requests, briefs, white papers, arguments, opinions and proposals before making or submitting any of the foregoing to any Governmental Entity by or on behalf of any party in
connection with any such filing or any Legal Proceeding in connection with this Agreement or the transactions contemplated hereby; (iii)&nbsp;coordinate with the other in preparing and exchanging such information; (iv)&nbsp;promptly provide the
other party&#146;s counsel with copies of all filings, notices, analyses, presentations, memoranda, letters, responses to requests, briefs, white papers, opinions, proposals and other submissions (and a summary of any oral presentations) made or
submitted by such party with or to any Governmental Entity in connection with any filing required by <U>Section</U><U></U><U>&nbsp;4.7(a)</U> and <U>Section</U><U></U><U>&nbsp;4.7(b)</U> in connection with this Agreement or the transactions
contemplated hereby; and (v)&nbsp;consult with the other party in advance of any meeting, video conference or teleconference with any Governmental Entity or, in connection with any proceeding by a private party, with any other Person, and, to the
extent not prohibited by the Governmental Entity or other Person, give the other party the opportunity to attend and participate in such meetings, video conferences and teleconferences. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Without limiting the generality of <U>Section</U><U></U><U>&nbsp;4.7(a)</U>, Parent shall use reasonable best efforts to
take, or cause to be taken, all actions necessary to avoid or eliminate each and every impediment under any Antitrust Laws to enable the parties to close the transactions contemplated by this Agreement as promptly as practicable, and in any event
prior to the End Date, including proposing, negotiating, committing to and effecting, whether by consent decree, hold separate orders, or otherwise, to sell, divest, hold separate, lease, license, transfer, dispose of, commit to behavioral or
conduct remedies, or otherwise encumber, limit or impair or take any other action with respect to Parent&#146;s or any of its Subsidiaries&#146; ability to own or operate any assets, properties, businesses or product lines of Parent or any of its
Subsidiaries or any assets, properties, businesses or product lines of the Company or any of its Subsidiaries; <I>provided</I>, that, notwithstanding anything to the contrary set forth in this Agreement, (I)&nbsp;the Company and the Company
Subsidiaries shall not enter into or make any consents, offers, agreements or commitments with respect to the actions contemplated by clauses (i)&nbsp;and (ii) except as and to the extent requested in writing by Parent as to actions that are
conditioned upon the consummation of the Mergers, (II)&nbsp;no party shall be required pursuant to the foregoing to commit to or effect any action that is not conditioned upon the consummation of the Mergers, and (III)&nbsp;Parent shall not be
required to (x)&nbsp;sell, divest, exclusively license, hold separate, or otherwise dispose of, or (y)&nbsp;grant any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, accept any operational restrictions or take or commit to any actions
which restrictions or actions would limit Parent&#146;s or any of its Affiliates&#146; freedom of action with respect to assets, licenses, product lines, operations or businesses of Parent, the Company or any of their respective Subsidiaries that,
individually or in the aggregate, would reasonably be expected to have an (A)&nbsp;Effect that results in a material adverse effect on the results of operations of the Company and the Company Subsidiaries, taken as a whole, or (B)&nbsp;Effect that
results in a material adverse effect on the results </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of operations of the Parent and the Parent Subsidiaries, taken as a whole; <I>provided</I> that for purposes of determining whether an Effect is or would be materially adverse to the results of
operations of Parent and the Parent Subsidiaries, taken as a whole, Parent and the Parent Subsidiaries, taken as a whole, shall be deemed to be the same size (in operations and from a financial point of view) as the Company and the Company
Subsidiaries, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything to the contrary contained in this Agreement, without the
prior written consent of Parent, neither the Company nor any of the Company Subsidiaries will grant or offer to grant any accommodation or concession (financial or otherwise) to any third party in connection with seeking or obtaining its consent to
the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) In furtherance and not in limitation of the covenants of the parties
contained in this <U>Section</U><U></U><U>&nbsp;4.7</U>, if any administrative or judicial action or proceeding, including any proceeding by a private party, is instituted (or threatened to be instituted) challenging any transaction contemplated by
this Agreement as violative of any Antitrust Law, each of Parent and the Company shall use reasonable best efforts to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment,
injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8 <B>Access</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon reasonable prior notice, the Company shall afford Parent and its Representatives reasonable access, during normal
business hours throughout the period prior to the First Effective Time, to the Company&#146;s and the Company Subsidiaries&#146; personnel, properties, Contracts, filings with Governmental Entities and books and records and, during such period, the
Company shall furnish promptly to Parent all available information concerning its business as Parent may reasonably request; <I>provided</I>, <I>however</I>, that the Company shall not be required to permit any inspection or provide other access, or
to disclose any information, that in the reasonable judgment of the Company would: (i)&nbsp;violate any obligation of the Company with respect to confidentiality or privacy; (ii)&nbsp;jeopardize protections afforded the Company under the <FONT
STYLE="white-space:nowrap">attorney-client</FONT> privilege, the attorney work product doctrine or similar legal privilege or protection; (iii)&nbsp;violate any Legal Requirement; or (iv)&nbsp;result in the disclosure of any trade secrets of any
third parties, competitively sensitive information, information concerning the valuation of the Company or any of the Company Subsidiaries or personal information that would expose the Company to the risk of liability; <I>provided</I> that in each
case the Company shall inform Parent of the nature of the information being withheld, and shall use its commercially reasonable best efforts to make alternative arrangements that would allow Parent (or its applicable Representative) access to such
information. All information obtained by or provided to Parent and its Representatives pursuant to this Agreement shall be treated as &#147;Confidential Information&#148; of the Company for purposes of the
<FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon reasonable prior notice, Parent shall afford
the Company and its Representatives reasonable access, during normal business hours throughout the period prior to the First Effective Time, to Parent&#146;s and the Parent Subsidiaries&#146; personnel, properties, Contracts, filings with
Governmental Entities and books and records and, during such period, Parent shall furnish promptly to the Company all available information concerning its business as the Company may reasonably request; <I>provided</I>, <I>however</I>, that Parent
shall not be required to permit any inspection or provide other access, or to disclose any information, that in the reasonable judgment of Parent would: (i)&nbsp;violate any obligation of Parent with respect to confidentiality or privacy;
(ii)&nbsp;jeopardize protections afforded Parent under the attorney-client privilege, the attorney work product doctrine or similar legal privilege or protection; (iii)&nbsp;violate any Legal Requirement; or (iv)&nbsp;result in the disclosure of any
trade secrets of any third parties, competitively sensitive information, information concerning the valuation of Parent or any of the Parent Subsidiaries or personal information that would expose Parent to the risk of liability; <I>provided</I> that
in each case Parent shall inform the Company of the nature of the information being withheld, and shall use its commercially reasonable best efforts to make alternative arrangements that would allow the Company (or its Representatives) access to
such information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
All information obtained by or provided to the Company and its Representatives pursuant to this Agreement shall be treated as &#147;Confidential Information&#148; of Parent for purposes of the <FONT
STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any of the information or material
furnished pursuant to this Agreement may include material subject to the attorney-client privilege, work product doctrine or any other applicable privilege, the parties understand and agree that they have a commonality of interest with respect to
such matters and it is their desire, intention and mutual understanding that the sharing of such material is not intended to, and shall not, waive or diminish in any way the confidentiality of such material or its continued protection under the
attorney-client privilege, work product doctrine or any other applicable privilege. All such information that is entitled to protection under the attorney-client privilege, work product doctrine or any other applicable privilege shall remain
entitled to such protection under these privileges, this Agreement, and under the joint defense doctrine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No exchange
of information or investigation by Parent or its Representatives shall affect or be deemed to affect, modify or waive the representations and warranties of the Company set forth in this Agreement. No exchange of information or investigation by the
Company or its Representatives shall affect or be deemed to affect, modify or waive the representations and warranties of Parent set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9 <B>Acquisition Sub Consents; Parent Vote</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the period from the date of this Agreement through the earlier of the First Effective Time or the date of
termination of this Agreement, the Acquisition Subs shall not engage in any activities of any nature except as provided in or contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent shall ensure that each Acquisition Sub duly performs, satisfies and discharges on a timely basis each of the
covenants, obligations and liabilities of such Acquisition Sub under this Agreement, and Parent shall be jointly and severally liable with each Acquisition Sub for the due and timely performance and satisfaction of each such covenant, obligation and
liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Immediately following the execution of this Agreement, Parent shall execute and deliver, in accordance with
the DGCL and DLLCA, as applicable, and in its capacity as the sole stockholder of Acquisition Sub I and sole member of Acquisitions Sub II, a written consent adopting this Agreement on behalf of Acquisition Sub I and Acquisition Sub II respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10 <B>Publicity</B>. Parent and the Company shall consult with one another prior to issuing, and shall provide each other
with the opportunity to review and comment upon, any public announcement, statement or other disclosure with respect to this Agreement or the Mergers and shall not issue any such public announcement or statement prior to such consultation, except as
may be required by applicable Legal Requirement or by the rules and regulations of Nasdaq (in which event Parent or the Company, as applicable, shall endeavor, on a basis reasonable under the circumstances, to provide a meaningful opportunity to the
other party to review and comment upon such public announcement or statement in advance, and shall give due consideration to all reasonable additions, deletions or changes suggested thereto by Parent or the Company, as applicable); <I>provided</I>
that (i)&nbsp;each of the Company and Parent may make public announcements, statements or other disclosures concerning this Agreement or the Mergers that consist solely of information previously disclosed in previous public announcements, statements
or other disclosures made by the Company and/or Parent in compliance with this <U>Section</U><U></U><U>&nbsp;4.10</U>, (ii) each of the Company and Parent may make any public statements in response to questions by the press, analysts, investors or
those participating in investor calls or industry conferences, so long as such statements consist solely of information previously disclosed in previous press releases, public disclosures or public statements made by the Company and/or Parent in
compliance with this <U>Section</U><U></U><U>&nbsp;4.10</U>, (iii) the Company need not consult with Parent in connection with any public announcement, statement or other disclosure to be issued or made with respect to any Company Acquisition
Proposal or Company Change in Recommendation, in each case, in compliance with <U>Section</U><U></U><U>&nbsp;4.2</U> and <U>Section</U><U></U><U>&nbsp;4.5</U>; and (iv)&nbsp;Parent need not consult with the Company in connection with any public
announcement, statement or other disclosure to be issued or made with respect to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parent Change in Recommendation, in each case, in compliance with <U>Section</U><U></U><U>&nbsp;4.3</U> and <U>Section</U><U></U><U>&nbsp;4.6</U>. The Company and Parent agree to issue the
previously agreed upon form of joint press release announcing the execution and delivery of this Agreement promptly following the execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11 <B>Employee Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the period commencing on the Closing Date and ending on the first anniversary of the Closing Date, Parent shall, or
shall cause one of the Parent Subsidiaries (including the Surviving Company and its Subsidiaries) to provide: (i)&nbsp;each employee of the Company or any Subsidiary of the Company who continues employment with Parent or any of the Parent
Subsidiaries (including the Surviving Company or any of its Subsidiaries) after the Second Effective Time (a &#147;<U>Continuing Employee</U>&#148;) with (A)&nbsp;an annual base salary or base wage rate that is, and (B)&nbsp;a target annual cash
bonus opportunity that, taken together with the annual base salary or base wage rate provided to such Continuing Employee after the First Effective Time is, in each case, no less favorable than provided to such Continuing Employee by the Company
immediately prior to the First Effective Time; and (ii)&nbsp;each Continuing Employee with employee welfare and retirement benefits (excluding any benefits provided under any defined benefit pension plan or post-retirement medical plan) that are
substantially comparable or more favorable in the aggregate to those provided to such Continuing Employee by the Company and the Company Subsidiaries immediately prior to the First Effective Time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All service of the Continuing Employees to the Company and the Company Subsidiaries and their respective predecessors shall
be recognized for purposes of determining eligibility to participate, vesting and accrual and level of benefits with respect to each Parent Plan in which any Continuing Employee will participate after the Second Effective Time (excluding any defined
benefit pension or post-retirement medical plan) to at least the same extent as such similarly situated Parent Employees are entitled to credit for service under such Parent Plans, except to the extent such recognition would result in the
duplication of benefits. In addition, Parent or the Subsidiaries of Parent (including the Surviving Company and its Subsidiaries), as applicable, shall use commercially reasonable efforts to cause each Parent Plan that is a welfare benefit plan,
within the meaning of Section&nbsp;3(1) of ERISA to: (i)&nbsp;waive all limitations as to preexisting conditions, exclusions and waiting periods with respect to participation and coverage requirements other than preexisting condition limitations,
exclusions or waiting periods that are already in effect with respect to such Continuing Employees and that have not been satisfied or waived as of the First Effective Time under the analogous welfare benefit plan maintained for the Continuing
Employees immediately prior to the First Effective Time; and (ii)&nbsp;recognize for each Continuing Employee and his or her spouse, domestic partner and dependents for purposes of applying annual deductible,
<FONT STYLE="white-space:nowrap">co-payment</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> maximums under such Parent Plan any deductible, <FONT STYLE="white-space:nowrap">co-payment</FONT>
and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses paid by the Continuing Employee and his or her spouse, domestic partner and dependents under an analogous Company Plan during the plan year of
such plan in which occurs the date on which the Continuing Employee begins participation in such Parent Plan, except to the extent such recognition would result in the duplication of benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If requested by Parent not less than ten Business Days before the Closing Date, the Company Board (or the appropriate
committee thereof) shall adopt resolutions and take such corporate action as is reasonably necessary to terminate the Company&#146;s 401(k) plan (the &#147;<U>Company 401(k) Plan</U>&#148;), effective as of the day prior to the Closing Date. In the
event that Parent requests that the Company 401(k) Plan be terminated, (i)&nbsp;the Company shall provide Parent with evidence that such plan has been terminated (the form and substance of which shall be subject to reasonable prior review and
comment by Parent) not later than the day preceding the Closing Date and (ii)&nbsp;following the Second Effective Time and as soon as reasonably practicable following receipt of a favorable determination letter from the IRS on the termination of the
Company 401(k) Plan, to the extent that Parent requests that the Company seek such determination letter, the assets thereof shall be distributed to the participants, and Parent shall permit the Continuing Employees who are then actively employed to
make rollover contributions of &#147;eligible rollover distributions&#148; (within the meaning of Section&nbsp;401(a)(31) of the Code, inclusive of loans) to Parent&#146;s 401(k) Plan, in the form of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
cash, in an amount equal to the full account balance (including any promissory notes) distributed to such Continuing Employees from the Company 401(k) Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Nothing in this <U>Section</U><U></U><U>&nbsp;4.11</U> or elsewhere in this Agreement, expressed or implied, shall be
construed to create a right in any employee of the Company or any of the Company Subsidiaries to employment with Parent, the Surviving Company or any of their Subsidiaries or shall interfere with or restrict in any way the rights of Parent or any of
its Affiliates, which rights are hereby expressly reserved, to discharge or terminate the services of any Continuing Employee at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a
written agreement between Parent, the Company or any of their respective Affiliates and the Continuing Employee. Nothing in this Agreement shall be deemed to amend or modify any compensation or benefit arrangement of Parent, the Company, or their
respective Affiliates. Nothing herein shall be construed to limit the right of Parent, the Surviving Company or any of their Subsidiaries to amend or terminate any Parent Plan, any Company Plan, or any other employee benefit plan. Notwithstanding
any provision in this Agreement to the contrary, nothing in this <U>Section</U><U></U><U>&nbsp;4.11</U> shall create any third party rights, benefits or remedies of any nature whatsoever in any employee of the Company or any of the Company
Subsidiaries (or any beneficiaries or dependents thereof) or any other Person that is not a party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12
<B>Certain Tax Matters</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For U.S. federal income Tax purposes, (i)&nbsp;the parties hereto intend that the Mergers
will qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code (the &#147;<U>Intended Tax Treatment</U>&#148;) and (ii)&nbsp;this Agreement is intended to be, and is hereby adopted as, a &#147;plan of
reorganization&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a),</FONT> to which the Parent, each Acquisition Sub and the Company are
parties under Section&nbsp;368(b) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties hereto (i)&nbsp;shall use their respective reasonable best
efforts to cause the Mergers to qualify, and will not take any action or cause any action to be taken which action would reasonably be expected to prevent the Mergers from qualifying, for the Intended Tax Treatment and (ii)&nbsp;shall not take any
Tax reporting position inconsistent with the treatment of the Mergers as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code for U.S. federal, state and other relevant Tax purposes, unless otherwise required pursuant
to a &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of the parties shall use
its commercially reasonable efforts in order for any Tax opinions and disclosures required to be filed with the SEC in connection with the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement to be obtained from Tax Opinion
Counsel, including the appropriate officers of Parent, the Acquisition Subs and Company executing and delivering to Tax Opinion Counsel certificates substantially in the forms set forth in <U>Section</U><U></U><U>&nbsp;4.12</U> of the Parent
Disclosure Letter (the &#147;<U>Parent Representation Letter</U>&#148;) and <U>Section</U><U></U><U>&nbsp;4.12</U> of the Company Disclosure Letter (the &#147;<U>Company Representation Letter</U>&#148; and collectively with the Parent Representation
Letter, the &#147;<U>Representation Letters</U>&#148;), respectively. Each Representation Letter shall be dated on or before the date of such Tax opinion and shall not have been withdrawn or modified in any material respect except as otherwise
agreed to in writing by the parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall use commercially reasonable efforts to cooperate with Parent
and its Affiliates to cause any Company Subsidiary that is treated as a corporation for U.S. federal income tax purposes to merge into the Surviving Company, which merger shall be effective after the Second Effective Time and occur, at Parent&#146;s
sole discretion, on the Closing Date after the Closing or after the Closing Date, provided that no officer or employee of the Company or Company Subsidiaries shall be obligated to execute documents prior to the Closing for purposes of effecting any
such merger and the Company and Company Subsidiaries shall not be obligated to make or have be effective any Tax elections or Tax filings in connection therewith prior to the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13 <B>Indemnification; Directors</B><B>&#146;</B><B> and
Officers</B><B>&#146;</B><B> Insurance</B><B>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of no less than six years after the First Effective
Time, the Surviving Company shall (and Parent shall cause the Surviving Company to) indemnify and hold harmless, and provide advancement of expenses to, all current or former directors and officers of the Company or any of the Company Subsidiaries,
any Person who becomes a director or officer of the Company or any of the Company Subsidiaries prior to the First Effective Time and any current or former director of officer of the Company or any of the Company Subsidiaries who is, was or at any
time prior to the First Effective Time serves or served as a director, officer, member, trustee or fiduciary of another corporation, partnership joint venture, trust, pension plan or employee benefit plan at the request of or for the benefit of the
Company or any of the Company Subsidiaries (together with their respective heirs and representatives, the &#147;<U>Indemnified Parties</U>&#148;) to the fullest extent permitted by applicable Legal Requirements in respect of acts or omissions
occurring or alleged to have occurred at or prior to the First Effective Time, whether asserted or claimed prior to, at or after the First Effective Time, by reason of the fact of such Persons serving as an officer or director of the Company or any
of the Company Subsidiaries or, while a director or officer of the Company or any of the Company Subsidiaries, was serving at the request of the Company or any of the Company Subsidiaries as a director, officer, member, trustee or fiduciary of
another corporation, partnership joint venture, trust, pension plan or employee benefit plan, and the Surviving Company shall (and Parent shall cause the Surviving Company to) also advance expenses to the Indemnified Parties as incurred to the
fullest extent permitted by applicable Legal Requirements; <I>provided</I> that the Indemnified Party to whom expenses are advanced provides an undertaking to repay such advances if it is ultimately determined by a final and nonappealable judicial
determination that such Indemnified Party is not entitled to indemnification under this <U>Section</U><U></U><U>&nbsp;4.13(a)</U> or otherwise. The parties hereto agree that for six years after the First Effective Time all rights to elimination or
limitation of liability, indemnification, exculpation or advancement of expenses for acts or omissions occurring or alleged to have occurred at or prior to the First Effective Time, whether asserted or claimed prior to, at or after the First
Effective Time, now existing in favor of the Indemnified Parties as provided in the Organizational Documents of the Company or any of the Company Subsidiaries or in any written agreement between the Company or any of the Company Subsidiaries and
such Person shall survive the Mergers and shall continue in full force and effect. For six years after the First Effective Time, the Surviving Company shall cause to be maintained in effect the provisions in: (i)&nbsp;the Organizational Documents of
the Company and each of the Company Subsidiaries; and (ii)&nbsp;any other agreements of the Company or any of the Company Subsidiaries with any Indemnified Party, in each case, regarding exculpation, elimination or limitation of liability,
indemnification of officers and directors or other fiduciaries and advancement of expenses that are in existence on the date of this Agreement, and no such provision shall be amended, modified or repealed in any manner that would materially and
adversely affect the rights or protections thereunder of any such Indemnified Party in respect of acts or omissions occurring or alleged to have occurred at or prior to the First Effective Time without the consent of such Indemnified Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For a period of no less than six years following the First Effective Time, Parent and the Surviving Company shall cause to
be maintained in effect the existing policy of the Company&#146;s directors&#146; and officers&#146; liability insurance (or a comparable replacement policy) (the &#147;<U>D&amp;O Policy</U>&#148;) covering claims arising from facts or events that
occurred at or prior to the First Effective Time (including for acts or omissions occurring in connection with this Agreement and the consummation of the transactions contemplated by this Agreement) and covering each of the Company&#146;s current
directors and officers, in any case on terms with respect to coverage and amounts that are no less favorable than those terms in effect on the date of this Agreement; <I>provided</I>, <I>however</I>, that in no event shall Parent or the Surviving
Company be required to expend in any one year an amount in excess of 300% of the current annual premium paid by the Company (which annual premium is set forth in <U>Section</U><U></U><U>&nbsp;4.13(b)</U> of the Company Disclosure Schedule) for such
insurance (such 300% amount, the &#147;<U>Maximum Annual Premium</U>&#148;); and <I>provided further</I>, <I>however</I>, that if the annual premium of such insurance coverage exceeds the Maximum Annual Premium, Parent and the Surviving Company
shall be obligated to obtain a policy with the greatest comparable coverage available for a cost not exceeding the Maximum Annual Premium. Notwithstanding anything to the contrary in this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Agreement, in lieu of Parent&#146;s obligations under the first sentence of this <U>Section</U><U></U><U>&nbsp;4.13(b)</U>, the Company may, or if the Company is unable to, Parent may on its
behalf, prior to the First Effective Time, purchase a <FONT STYLE="white-space:nowrap">six-year</FONT> &#147;tail&#148; prepaid policy on the D&amp;O Policy with an annual cost not in excess of the Maximum Annual Premium, and in the event that
Parent or the Company shall purchase such a &#147;tail&#148; policy, Parent and the Surviving Company shall maintain such &#147;tail&#148; policy in full force and effect and continue to honor their respective obligations thereunder, in lieu of all
other applicable obligations of Parent and the Surviving Company under the first sentence of this <U>Section</U><U></U><U>&nbsp;4.13(b)</U> for so long as such &#147;tail&#148; policy shall be maintained in full force and effect. Notwithstanding
anything in this <U>Section</U><U></U><U>&nbsp;4.13</U> to the contrary, if any Indemnified Party notifies Parent on or prior to the sixth anniversary of the First Effective Time of a matter in respect of which such Person may seek indemnification
pursuant to this <U>Section</U><U></U><U>&nbsp;4.13</U>, the provisions of this <U>Section</U><U></U><U>&nbsp;4.13</U> that require Parent and the Surviving Company to indemnify and advance expenses shall continue in effect with respect to such
matter until the final disposition of all claims, actions, investigations, suits and proceedings relating thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The
obligations under this <U>Section</U><U></U><U>&nbsp;4.13</U> shall not be terminated, amended or otherwise modified in such a manner as to adversely affect any Indemnified Party (or any other Person who is a beneficiary under the D&amp;O Policy or
the &#147;tail&#148; policy referred to in Section&nbsp;4.13(b) and any of such Person&#146;s heirs, executors, beneficiaries or representatives) without the prior written consent of such affected Indemnified Party or other Person who is a
beneficiary under the D&amp;O Policy or the &#147;tail&#148; policy referred to in Section&nbsp;4.13(b) (and, after the death of any of the foregoing Persons, such Person&#146;s heirs, executors, beneficiaries or representatives). Each of the
Indemnified Parties or other Persons who are beneficiaries under the D&amp;O Policy or the &#147;tail&#148; policy referred to in <U>Section</U><U></U><U>&nbsp;4.13(b)</U> (and, after the death of any of the foregoing Persons, such Person&#146;s
heirs and representatives) are intended to be third party beneficiaries of this <U>Section</U><U></U><U>&nbsp;4.13</U>, with full rights of enforcement as if a party thereto. The rights of the Indemnified Parties (and other Persons who are
beneficiaries under the D&amp;O Policy or the &#147;tail&#148; policy referred to in <U>Section</U><U></U><U>&nbsp;4.13(b)</U> (and their heirs and representatives)) under this <U>Section</U><U></U><U>&nbsp;4.13</U> shall be in addition to, and not
in substitution for, any other rights that such Persons may have under the Organizational Documents of the Company or any of the Company Subsidiaries, any and all indemnification agreements of or entered into by the Company or any of the Company
Subsidiaries, or applicable Legal Requirements (whether at law or in equity). In the event of any breach by the Surviving Company or Parent of this <U>Section</U><U></U><U>&nbsp;4.13</U>, Parent or the Surviving Company shall pay all reasonable
expenses, including attorneys&#146; fees, that may be incurred by the Indemnified Parties in enforcing the indemnity and other obligations provided in this <U>Section</U><U></U><U>&nbsp;4.13</U> as such fees are incurred upon the written request of
such Indemnified Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event that Parent, the Surviving Company or any of their respective Subsidiaries (or
any of their respective successors or assigns) shall (i)&nbsp;consolidate or merge with any other Person and shall not be the continuing or surviving corporation or entity in such consolidation or merger, or (ii)&nbsp;sell or transfer a substantial
portion of their respective assets to any other Person, then in each case, to the extent necessary to protect the rights of the Indemnified Parties and other Persons who are beneficiaries under the D&amp;O Policy or the &#147;tail&#148; policy
referred to in <U>Section</U><U></U><U>&nbsp;4.13(b)</U> (and their respective heirs and representatives), proper provision shall be made so that the continuing or surviving corporation or entity or the purchaser or transferee entity, as applicable
(or its successors or assigns, if applicable) shall assume the obligations set forth in this <U>Section</U><U></U><U>&nbsp;4.13</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14 <B>Financing and Financing Cooperation</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From the date of this Agreement, the Company shall, and shall cause the Company Subsidiaries and their respective
Representatives to, provide such cooperation as is reasonably requested by Parent, is reasonably and customarily necessary in connection with the Debt Financing and is customarily provided for issuers in financings of the type contemplated by the
Debt Commitment Letter, but limited to, using commercially reasonable efforts to (i)&nbsp;furnish to Parent (x)&nbsp;the Required Information and (y)&nbsp;such other customary financial information with respect to the Company and the Company
Subsidiaries as may be reasonably requested by the Parent as is necessary for Parent to prepare the materials referred to in clause </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(vii)&nbsp;below (including the pro forma financial information and pro forma financial statements contemplated by Paragraph 5 of Exhibit C of the Debt Commitment Letter (provided that, for the
avoidance of doubt, the Company and the Company Subsidiaries shall not be required to provide, and Parent shall be solely responsible for, the preparation of pro forma financial statements)), (ii)&nbsp;provide Parent all documentation and other
information with respect to the Company and the Company Subsidiaries within three Business Days prior to the Closing Date as shall have been reasonably requested in writing (including by email) by Parent at least ten Business Days prior to the
Closing Date that is required in connection with the Debt Financing by U.S. regulatory authorities under applicable &#147;know-your-customer&#148; and anti-money laundering rules and regulations, including the Patriot Act and 31 C.F.R. &#167;
1010.230, and that are required by Paragraph 7 of Exhibit C of the Debt Commitment Letter as in effect on the date hereof, (iii)&nbsp;deliver, or cause the applicable Company Subsidiary to deliver, necessary prepayment and/or termination notices in
accordance with the terms of each of the Company Credit Facilities (<I>provided</I> that such prepayment and termination notices may be conditioned on the occurrence of the Closing), (iv) reasonably facilitate the pledging of collateral and the
provision of guarantees, in each case, only to the extent such pledge or guaranty is a condition in the Debt Commitment Letter to the funding of the Debt Financing on the Closing Date, (v) executing and delivering or helping to procure credit
agreements, hedging arrangements, notes, mortgages, pledge and security documents, landlord waivers, estoppels, consents, and approvals and other definitive financing documents or other requested certificates or documents, in each case, only to the
extent that delivery of such documents is a condition in the Debt Commitment Letter to the funding of the Debt Financing on the Closing Date (in each case, subject to and only effective upon the occurrence of the Closing), (vi) cause members of its
senior management, representatives and advisors to participate in a reasonable number of meetings, conference calls, presentations and roadshows with prospective lenders and investors, due diligence sessions (including accounting due diligence
sessions), drafting sessions and sessions with the ratings agencies, in all such cases upon reasonable advanced notice and at reasonable times and locations mutually agreed upon, and (vii)&nbsp;assist Parent, each Acquisition Sub and the Debt
Financing Sources with the preparation of customary bank information memoranda, lender presentations, investor presentations, offering documents, rating agency presentations and similar customary documents required in connection with the Debt
Financing, in each case, to the extent such materials relate to information concerning the Company and the Company Subsidiaries and (viii)&nbsp;to the extent required by the Debt Financing Sources, executing and delivering customary authorization
letters to the Debt Financing Sources authorizing the distribution of information to prospective lenders, subject to customary confidentiality restrictions and customary exculpatory provisions; provided that such cooperation shall not be required to
the extent it would: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) require the Company, a Company Subsidiary, or any of their Affiliates or any of its or their
Representatives to execute, deliver or enter into, or perform any document (including any agreement, instrument, guaranty, warranty, indemnity or certificate) with respect to the Debt Financing that is not contingent upon the Closing or that would
be effective prior to Closing (other than the authorization and representation letters referred to above), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) cause any
director or officer to incur any personal liability (including that no member of the Company Board, or the board of directors of any Company Subsidiary or any of its or their Affiliates shall be required to enter into any resolutions or take any
similar action approving the Financing until the Closing has occurred), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) require the delivery of any financial
statements in a form or subject to a standard different than those provided to Parent on or prior to the date hereof, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)
prior to the Closing, (x)&nbsp;pay any commitment or other fee for which the Company, any Company Subsidiary, or any of their Affiliates has not received prior reimbursement or (y)&nbsp;provide any indemnity or security or incur any liability or
obligation in connection with the Debt Financing or any other financing, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) take or permit the taking of any action that
would reasonably be expected to conflict with, result in any violation or breach of, or default (with or without lapse of time, or both) under, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Organizational Documents of the Company, any Company Subsidiary, or any of their Affiliates, or any applicable Legal Requirements or Contracts of the Company, any Company Subsidiary, or any of
their Affiliates, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) require any cooperation to the extent that it would materially or unreasonably interfere with the
business or operations of the Company, any Company Subsidiary, or any of their Affiliates, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) require the Company,
any Company Subsidiary, or any of their Affiliates to make any representation, warranty or certification that, in the good faith determination of the Company, any Company Subsidiary, or any of their Affiliates, is not true. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent agrees that in no event shall Company, any Company Subsidiary, or any of their Affiliates be required to execute or
deliver any documents in connection with the Debt Financing which is not conditioned upon, and shall become effective from and after, the Closing. Parent shall indemnify and hold harmless the Company, each Company Subsidiary, and each of their
Affiliates and its and their respective Representatives from and against any and all liabilities, losses, damages, claims and reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses
(including reasonable attorney&#146;s fees) interest, awards, judgments, losses and penalties suffered or incurred in connection with any and all of the matters contemplated by this <U>Section</U><U></U><U>&nbsp;4.14</U> (other than the use of any
information provided by the Company, any Company Subsidiary, or any of their Affiliates or any of its or their Representatives, in each case, in writing for use in connection with the Debt Financing) or in connection with the arrangement of the Debt
Financing or any information utilized in connection therewith, except to the extent arising from fraud, gross negligence or willful misconduct by any of Company, any Company Subsidiary, or any of their Affiliates or any of its or their
Representatives, whether or not the transactions are consummated or this Agreement is terminated. As a condition to the Company and the Company Subsidiaries obligations pursuant to this <U>Section</U><U></U><U>&nbsp;4.14</U>, Parent shall promptly,
upon request by the Company or a Company Subsidiary, reimburse the Company, the Company Subsidiaries and their Affiliates for all reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
costs and expenses (including reasonable and documented attorney&#146;s fees and expenses and disbursements) incurred by the Company, any Company Subsidiary, or any of their Affiliates or its and their Representatives in connection with the
cooperation contemplated by this <U>Section</U><U></U><U>&nbsp;4.14</U>. All <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Company and its Affiliates provided to Parent, its Affiliates or its Representatives pursuant to
this Section&nbsp;4.14 shall be kept confidential by them, except for disclosure to potential lenders, investors, rating agencies or their respective Representatives in connection with the Debt Financing subject to customary confidentiality
provisions including exercising commercially reasonable best efforts to make Company an express third-party beneficiary to the confidentiality agreement. The obligations in this clause (b)&nbsp;shall survive the termination of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent shall use its reasonable best efforts to (i)&nbsp;maintain in effect the Debt Commitment Letter in accordance with
its terms, (ii)&nbsp;negotiate definitive financing agreements with respect to the Debt Financing on the terms and conditions set forth in the Debt Commitment Letter (taking into account any &#147;market flex&#148; provisions), so that such
agreements are in effect as promptly as practicable but in any event no later than the Closing Date, (iii)&nbsp;satisfy on a timely basis all Financing Conditions on the Closing Date applicable to Parent or the Parent Subsidiaries and under the
control of Parent or the Parent Subsidiaries and (iv)&nbsp;consummate on the Closing Date the Debt Financing required to consummate the transactions contemplated hereby in accordance with the terms of the Debt Commitment Letter (which, for the
avoidance of doubt, shall include agreeing to consummate the Debt Financing even if any flex rights are exercised to their maximum extent). Prior to the Closing, Parent shall not permit the Acquisition Subs (without the prior written consent of the
Company) to agree to, or permit, any amendment or modification of, or waiver under, the Debt Commitment Letter that (i)&nbsp;reduces the aggregate amount of the Debt Financing to an amount such that the Closing could not be consummated,
(ii)&nbsp;imposes any additional (or adversely modifies any existing) condition precedent to the availability of the Debt Financing that could reasonably be expected to adversely affect (including with respect to timing) the ability or likelihood of
Parent or the Company to timely consummate the transactions contemplated by this Agreement, (iii)&nbsp;would otherwise reasonably be expected to prevent, impede or delay the funding on the Closing Date of the Debt Financing required to consummate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the transactions contemplated by this Agreement, or (iv)&nbsp;would adversely impact the ability of the Acquisition Subs or their respective Affiliates to enforce their rights against the other
parties to the Debt Commitment Letter or the definitive agreements with respect thereto and shall, in each case, be deemed to be material for purposes of this Agreement; <I>provided</I>, that the Acquisition Subs may, without the Company&#146;s
prior written consent, amend, replace, supplement or otherwise modify the Debt Commitment Letter solely to add lenders, lead arrangers, bookrunners, syndication agents or similar entities that had not executed the Debt Commitment Letter as of the
date hereof. Upon any such amendment, replacement, supplement or modification, the term &#147;Debt Commitment Letter&#148; shall refer to the Debt Commitment Letter as so amended, replaced, supplemented or otherwise modified. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Parent shall keep Company informed on a reasonably current basis and in reasonable detail of the status of Parent&#146;s
efforts to arrange the Debt Financing and promptly provide to Company copies of all definitive documents related to the Debt Financing contemplated by the Debt Commitment Letters. In the event that, in the reasonable opinion of Parent, all
conditions applicable to each of the Debt Commitment Letters have been satisfied, Parent shall use commercially reasonable efforts to cause the lenders and the other Persons providing such Debt Financing contemplated by the Debt Commitment Letters
to fund the Debt Financing contemplated by the Debt Commitment Letters required to consummate the transactions contemplated by this Agreement on or prior to the Closing Date. The Parent shall promptly notify the Company (A)&nbsp;of any breach (or
threatened breach) or default by any party to the Debt Commitment Letter or definitive agreements related to the Debt Financing of which Parent or any of its Affiliates becomes aware, (B)&nbsp;of the receipt by Parent, any of the Parent Subsidiaries
(including the Acquisition Subs) of any written notice or communication from any Debt Financing Source with respect to any breach (or threatened breach) or default, or any termination or repudiation, in each case by any party to the Debt Commitment
Letter or any definitive document related to the Debt Financing and (C)&nbsp;if for any reason Parent at any time believes it will not be able to obtain all or any portion of the Debt Financing necessary to consummate the transactions contemplated
by this Agreement and pay all related fees and expenses payable by Parent hereunder on the terms, in the manner or from the sources contemplated by the Debt Commitment Letters. Parent shall promptly, but in any event within three days of the date of
a written request from the Company, provide any information reasonably requested by Company relating to any circumstance referred to in clause (A), (B) or (C)&nbsp;of the immediately preceding sentence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If the Debt Financing required to consummate the transactions contemplated by this Agreement becomes unavailable under the
Debt Commitment Letter or any definitive agreements with respect thereto, as applicable, Parent shall, and shall cause the Parent Subsidiaries to, as promptly as practicable following the occurrence of such event, use its or their reasonable best
efforts to obtain substitute financing sufficient, together with other financial resources available to Parent, to consummate the Merger (any such financing, a &#147;<U>Substitute Financing</U>&#148;). In the event any Substitute Financing is
obtained, references in this Agreement to the Debt Financing shall also be deemed to refer to such Substitute Financing, and references in this Agreement to the Debt Commitment Letter and the definitive financing agreements with respect thereto
shall also be deemed to refer to the Substitute Financing and the definitive financing agreements with respect thereto, and all obligations of Parent pursuant to this Section<U></U><U>&nbsp;4.14</U> shall be applicable thereto as to the same extent
as Parent&#146;s obligations with respect to the Debt Financing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Parent and each Acquisition Sub expressly
acknowledges and agrees that, notwithstanding anything in this Agreement to the contrary, their obligations hereunder, including their obligation to consummate the Closing, are not subject to, or conditioned on, receipt of the Debt Financing or any
Substitute Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15 <B>Stockholder Litigation</B>. The Company shall provide Parent with prompt written notice of,
and copies of all pleadings and material correspondence relating to, any Legal Proceeding against the Company or any of its directors or officers by any holder of shares of Company Common Stock arising out of or relating to this Agreement or the
transactions contemplated by this Agreement. The Company shall give Parent the opportunity to participate, at Parent&#146;s sole cost and expense, in the defense, settlement, or compromise of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Legal Proceeding (<I>provided</I> that the Company shall, subject to the Company&#146;s consultation with Parent and good faith consideration of its views, control the defense, strategy and
settlement thereof), and no such settlement or compromise shall be agreed to without the prior written consent of Parent (not to be unreasonably withheld, conditioned or delayed). Parent shall provide the Company with prompt written notice of, and
copies of all pleadings and material correspondence relating to, any Legal Proceeding against Parent or any of its directors or officers by any holder of shares of Parent Class&nbsp;A Common Stock arising out of or relating to this Agreement or the
transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16 <B>Stock Exchange Listing and Delisting</B>. Parent shall use its
reasonable best efforts to cause the shares of Parent Class&nbsp;A Common Stock to be issued in the First Merger, including the shares of Parent Class&nbsp;A Common Stock to be issued upon the exercise of converted Company Options, to be approved
for listing (subject to notice of issuance) on Nasdaq at or prior to the First Effective Time. Prior to the Closing, the Company and Parent shall cooperate to cause the shares of Company Common Stock to be delisted from Nasdaq and deregistered under
the Exchange Act as soon as practicable following the First Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17 <B>Section</B><B></B><B>&nbsp;16
Matters</B>. Prior to the First Effective Time, the Parent Board and the Company Board, respectively, shall take all actions that may be required or appropriate to cause any dispositions of shares of Company Common Stock (including derivative
securities with respect to shares of Company Common Stock) or acquisitions of Parent Class&nbsp;A Common Stock (including derivative securities with respect to Parent Class&nbsp;A Common Stock) in connection with the transactions contemplated by
<U>ARTICLE</U><U></U><U>&nbsp;I</U> by each individual who is, or as a result of the transactions contemplated by this Agreement will be, subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act with respect to the Company or
is, or will as a result of the transactions contemplated by this Agreement become, subject to such reporting requirements with respect to Parent, to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18 <B>Director Resignations</B>. Prior to the Closing, the Company shall use commercially reasonable efforts to
deliver to Parent resignations, in form and substance reasonably satisfactory to Parent, executed by each director of the Company in office as of immediately prior to the First Effective Time, in each case, conditioned and effective upon the First
Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19 <B>Payoff Documentation</B>. Prior to the Closing, the Company shall use commercially reasonable
efforts to deliver to Parent a payoff letter in form and substance reasonably acceptable to Parent and the Debt Financing Sources with respect to each of the Company Credit Facilities (such payoff letters, the &#147;<U>Payoff Letters</U>&#148;) duly
executed by the applicable agent(s) to each of the Company Credit Facilities pursuant to which such agent(s) shall agree that upon payment of the payoff amount specified in such Payoff Letter: (i)&nbsp;all obligations of the Company and the Company
Subsidiaries arising under or related to the applicable Company Credit Facility shall be paid in full; (ii)&nbsp;all Liens in connection therewith shall be released; and (iii)&nbsp;all pledged collateral securing the outstanding obligations under
the applicable Company Credit Facility shall be returned in accordance with the terms of the Payoff Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20 <B>Takeover
Statutes</B>. If any antitakeover or similar statute or regulation is or may become applicable to the transactions contemplated by this Agreement, each of the parties hereto and its respective Board of Directors shall (a)&nbsp;grant any approvals
and take all any actions necessary so that the transactions contemplated by this Agreement may be consummated as promptly as practicable on the terms contemplated hereby and (b)&nbsp;otherwise act to eliminate or minimize the effects of any such
statute or regulation on the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE V. CONDITIONS TO EACH PARTY&#146;S OBLIGATION TO EFFECT THE MERGERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <B>Conditions Precedent to Each Party</B><B>&#146;</B><B>s Obligations</B>. The obligations of each party to effect the
Mergers and otherwise cause the transactions contemplated by this Agreement to be consummated are subject to the satisfaction or waiver, as of the Closing, of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Effectiveness of Registration Statement</U>. The Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement
shall have become effective in accordance with the provisions of the Securities Act, no stop order shall have been issued by the SEC and shall remain in effect with respect to the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration
Statement, and no proceedings for that purpose shall have been commenced or be threatened in writing by the SEC that has not been withdrawn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stockholder Approvals</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Required Company Stockholder Vote shall have been obtained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Required Parent Stockholder Vote shall have been obtained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Governmental Approvals</U>. Any waiting period (or any agreed upon extension of any waiting period or commitment not to
consummate the Mergers for any period of time) applicable to the consummation of the Mergers under the HSR Act shall have expired or been terminated by the relevant Governmental Entity, and there shall be no pending agreement between Parent and any
such Governmental Entity not to close. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Listing</U>. The shares of Parent Class&nbsp;A Common Stock to be issued
pursuant to the First Merger, including the shares of Parent Class&nbsp;A Common Stock to be issued upon the exercise of converted Company Options, shall have been approved for listing (subject to notice of issuance) on Nasdaq. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>No Restraints</U>. No Legal Requirement or Order preventing, enjoining or making illegal the consummation of the Mergers
shall have been entered, issued or adopted by any court of competent jurisdiction or other Governmental Entity of competent jurisdiction and remain in effect (any such Legal Requirement or Order issued by a court of competent jurisdiction or other
Governmental Entity of competent jurisdiction, a &#147;<U>Relevant Legal Restraint</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <B>Additional Conditions
Precedent to Parent</B><B>&#146;</B><B>s Obligations</B>. The obligation of Parent to cause the Mergers to be effected and otherwise cause the transactions contemplated by this Agreement to be consummated are subject to the satisfaction or waiver by
Parent, as of the Closing, of each of the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Accuracy of Representations</U>. (i)&nbsp;The
representations and warranties of the Company contained in <U>Section</U><U></U><U>&nbsp;2.3(c)</U> shall have been true and accurate, other than <I>de minimis</I> inaccuracies, at and as of the date of this Agreement and shall be true and accurate,
other than <I>de minimis</I> inaccuracies, at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such
representation and warranty shall only be required to be true and accurate, other than <I>de</I><I></I><I>&nbsp;minimis</I> inaccuracies, as of such particular date or period of time); (ii) the representations and warranties of the Company contained
in the first sentence of <U>Section</U><U></U><U>&nbsp;2.1(a)</U>, <U>Section</U><U></U><U>&nbsp;2.3</U> (other than <U>Section</U><U></U><U>&nbsp;2.3(c)</U>), <U>Section</U><U></U><U>&nbsp;2.4</U>, <U>Section</U><U></U><U>&nbsp;2.5</U>,
<U>Section</U><U></U><U>&nbsp;2.6(a)(i)</U>, and <U>Section</U><U></U><U>&nbsp;2.25</U> shall have been true and accurate in all material respects at and as of the date of this Agreement and shall be true and accurate in all material respects at and
as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty shall only be
required to be true and accurate in all material respects as of such particular date or period of time); <I>provided</I>, <I>however</I>, that, in the case of this clause (ii), for purposes of determining the accuracy of such representations and
warranties, all materiality, &#147;Company Material Adverse Effect&#148; and similar qualifications set forth in such representations and warranties shall be disregarded; and (iii)&nbsp;the representations and warranties of the Company set forth in
this Agreement (other than those representations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and warranties referred to in the foregoing clauses (i)&nbsp;and (ii)) shall have been true and accurate in all respects at and as of the date of this Agreement and shall be true and accurate in
all respects at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty
shall only be required to be so true and accurate as of such particular date or period of time), except as, individually or in the aggregate has not constituted or resulted in or would not reasonably be expected to constitute or result in, a Company
Material Adverse Effect; <I>provided</I>, <I>however</I>, that, in the case of this clause (iii), for purposes of determining the accuracy of such representations and warranties, all materiality, &#147;Company Material Adverse Effect&#148; and
similar qualifications set forth in such representations and warranties shall be disregarded; <I>provided</I> that the reference to Company Material Adverse Effect in <U>Section</U><U></U><U>&nbsp;2.8(a)</U> shall be given effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Covenants</U>. The covenants in this Agreement that the Company is required to comply with or to perform
at or prior to the Closing shall have been complied with and performed in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Company
Material Adverse Effect</U>. Since the date of this Agreement, there shall not have occurred any Effects that, individually or in the aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a Company
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Certificate</U>. Parent shall have received a certificate, dated as of the Closing Date
and executed by the Chief Executive Officer or Chief Financial Officer of the Company, confirming that the conditions set forth in <U>Section</U><U></U><U>&nbsp;5.2(a)</U>, <U>Section</U><U></U><U>&nbsp;5.2(b)</U> and
<U>Section</U><U></U><U>&nbsp;5.2(c)</U> have been duly satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <B>Additional Conditions Precedent to the
Company</B><B>&#146;</B><B>s Obligations</B>. The obligation of the Company to effect the Mergers and otherwise consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver by the Company, as of the Closing, of
each of the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Accuracy of Representations</U>. (i)&nbsp;The representations and warranties of
Parent contained in <U>Section</U><U></U><U>&nbsp;3.3(c)</U> shall have been true and accurate, other than <I>de minimis</I> inaccuracies, at and as of the date of this Agreement and shall be true and accurate, other than <I>de minimis</I>
inaccuracies, at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty
shall only be required to be true and accurate, other than <I>de minimis</I> inaccuracies, as of such particular date or period of time); (ii) the representations and warranties of Parent and each Acquisition Sub contained in the first sentence of
<U>Section</U><U></U><U>&nbsp;3.1(a)</U>, <U>Section</U><U></U><U>&nbsp;3.3</U> (other than <U>Section</U><U></U><U>&nbsp;3.3(c)</U>), <U>Section</U><U></U><U>&nbsp;3.4</U>, <U>Section</U><U></U><U>&nbsp;3.5</U>,
<U>Section</U><U></U><U>&nbsp;3.6(a)(i</U>), and <U>Section</U><U></U><U>&nbsp;3.21</U> shall have been true and accurate in all material respects at and as of the date of this Agreement and shall only be required to be true and accurate in all
material respects at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and
warranty shall only be required to be true and accurate in all material respects as of such particular date or period of time); <I>provided</I>, <I>however</I>, that, in the case of this clause (ii), for purposes of determining the accuracy of such
representations and warranties, all materiality, &#147;Parent Material Adverse Effect&#148; and similar qualifications set forth in such representations and warranties shall be disregarded; and (iii)&nbsp;the representations and warranties of Parent
and each Acquisition Sub set forth in this Agreement (other than those representations and warranties referred to in the foregoing clauses (i)&nbsp;and (ii)) shall have been true and accurate in all respects at and as of the date of this Agreement
and shall only be required to be true and accurate in all respects at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of
time, in which case such representation and warranty shall be so true and accurate as of such particular date or period of time), except as, individually or in the aggregate, has not constituted or resulted in or would not reasonably be expected to
constitute or result in, a Parent Material Adverse Effect; <I>provided</I>, <I>however</I>, that, in the case of this clause (iii), for purposes of determining the accuracy of such representations and warranties, all materiality, &#147;Parent
Material Adverse Effect&#148; and similar qualifications set forth in such representations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
warranties shall be disregarded, provided that the reference to Parent Material Adverse Effect in <U>Section</U><U></U><U>&nbsp;3.8(a)</U> shall be given effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Covenants</U>. The covenants in this Agreement that Parent is required to comply with or to perform at or
prior to the Closing shall have been complied with and performed in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Parent Material
Adverse Effect</U>. Since the date of this Agreement, there shall not have occurred any Effects that, individually or in the aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a Parent Material
Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Tax Opinion</U>. Company shall have received an opinion from Tax Opinion Counsel, dated as of the
Closing Date, to the effect that the Mergers qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code at a level of comfort at least equivalent to the corresponding Tax opinion provided by Tax Opinion Counsel in
the Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement. In rendering such opinion, Tax Opinion Counsel shall be entitled to rely upon the Representation Letters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Certificate</U>. The Company shall have received a certificate, dated as of the Closing Date and executed by the Chief
Executive Officer or Chief Financial Officer of Parent, confirming that the conditions set forth in <U>Section</U><U></U><U>&nbsp;5.3(a)</U>, <U>Section</U><U></U><U>&nbsp;5.3(b)</U> and <U>Section</U><U></U><U>&nbsp;5.3(c)</U> have been duly
satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE VI. TERMINATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <B>Termination</B>. This Agreement may be terminated and the Mergers may be abandoned: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Parent and the Company at any time prior to the First Effective Time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by Parent or the Company if the Mergers shall not have been consummated by 11:59 p.m. New York Time on January&nbsp;31,
2022 (the &#147;<U>End Date</U>&#148;); <I>provided</I>, that if any of the conditions to the Closing set forth in <U>Section</U><U></U><U>&nbsp;5.1(c)</U> or <U>Section</U><U></U><U>&nbsp;5.1(e)</U> (solely if the applicable Relevant Legal
Restraint relates to any Antitrust Law) has not been satisfied or waived on or prior to 11:59 p.m. New York Time on the End Date but all other conditions to Closing set forth in <U>Sections</U><U></U><U>&nbsp;5.1</U>, <U>5.2</U> and <U>5.3</U> have
been satisfied (other than those conditions that by their nature are to be satisfied at the Closing, so long as such conditions are reasonably capable of being satisfied if the Closing were to occur on the End Date) or waived, the End Date will be
automatically extended, without any action on the part of any party hereto, to 11:59 p.m. New York Time on March&nbsp;31, 2022 and, if so extended, such date shall be the &#147;<U>End Date</U>&#148;; <I>provided</I>, <I>further</I>, that a party
shall not be permitted to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;6.1(b)</U> if the material breach by such party (or any Affiliate of such party) of any of such party&#146;s obligation under this Agreement shall have
materially contributed to the failure of the First Effective Time to have occurred on or before the End Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by
Parent or the Company at any time prior to the First Effective Time if a Relevant Legal Restraint permanently preventing, enjoining or making illegal the consummation of the Mergers shall have become final and
<FONT STYLE="white-space:nowrap">non-appealable;</FONT> <I>provided</I>, that the party seeking to terminate the Agreement shall have used reasonable best efforts to prevent the entry of and to remove such Relevant Legal Restraint in accordance with
<U>Section</U><U></U><U>&nbsp;4.7</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by Parent at any time prior to obtaining the Required Company Stockholder Vote
if (i)&nbsp;the Company Board shall have made a Company Change in Recommendation or (ii)&nbsp;the Company shall have Willfully Breached in any material respect <U>Section</U><U></U><U>&nbsp;4.2</U> or <U>Section</U><U></U><U>&nbsp;4.5</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by the Company (i)&nbsp;at any time prior to obtaining the Required Parent Stockholder Vote if the Parent Board shall have
made a Parent Change in Recommendation, (ii)&nbsp;if Parent has Willfully Breached in any material respect <U>Section</U><U></U><U>&nbsp;4.3</U> or <U>Section</U><U></U><U>&nbsp;4.6</U> or (iii)&nbsp;if Parent has materially breached its
representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.15</U> (Financing; Solvency) or its covenants set forth in <U>Section</U><U></U><U>&nbsp;4.14</U> (Financing and Financing Cooperation) (any failure to satisfy any condition
set forth in the Debt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Commitment Letter with respect to Bioventus, LLC, a Delaware limited liability company (&#147;<U>BV Opco</U>&#148;), or its Subsidiaries, including those any condition related to the solvency of
BV Opco or any of its Subsidiaries shall be deemed a material breach for purposes of this <U>Section</U><U></U><U>&nbsp;6.1(e)(iii)</U>), to the extent not waived by the Debt Financing Sources (collectively, the &#147;<U>Financing
Requirements</U>&#148;) and (1)&nbsp;any such breach of the Financing Requirements is not cured by the earlier of the End Date or prior to the 20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Business Day after the Company gives written
notice of such breach to Parent; (2)&nbsp;all of the conditions set forth in <U>Section</U><U></U><U>&nbsp;5.1</U>, <U>Section</U><U></U><U>&nbsp;5.2(a)</U>, <U>Section</U><U></U><U>&nbsp;5.2(b)</U> and <U>Section</U><U></U><U>&nbsp;5.2(c)</U> have
been satisfied and continue to be satisfied (other than those conditions that by their nature cannot be satisfied other than at the Closing) and the Company has irrevocably committed in a written notice delivered to Parent following the expiration
of the cure period specified in clause (1)&nbsp;above that the Company is ready, willing and able to consummate the transactions contemplated by this Agreement; <I>provided, however</I>, that, with respect to the conditions set forth in
<U>Section</U><U></U><U>&nbsp;5.1</U>, <U>Section</U><U></U><U>&nbsp;5.2(a)</U>, <U>Section</U><U></U><U>&nbsp;5.2(b)</U> and <U>Section</U><U></U><U>&nbsp;5.2(c)</U> and the Company&#146;s readiness, willingness and ability to consummate the
transactions contemplated by this Agreement, any condition forth in <U>Section</U><U></U><U>&nbsp;5.1</U>, <U>Section</U><U></U><U>&nbsp;5.2(a)</U>, <U>Section</U><U></U><U>&nbsp;5.2(b)</U> and <U>Section</U><U></U><U>&nbsp;5.2(c)</U> shall be
deemed satisfied if the failure of such condition resulted primarily from (A)&nbsp;any action or inaction by Parent or an Acquisition Sub, or (B)&nbsp;Parent&#146;s breach of the Financing Requirements, and (3)&nbsp;Parent or an Acquisition Sub
fails to consummate the transactions contemplated by this Agreement by the earlier of the End Date or within two Business Days following the written notice delivered by the Company to Parent following the expiration of the cure period specified in
clause (1)&nbsp;above; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by the Company, at any time prior to obtaining the Required Company Stockholder Vote, in the
event that (i)&nbsp;the Company Board has authorized the Company to enter into a definitive agreement relating to a Company Superior Proposal in material compliance with <U>Section</U><U></U><U>&nbsp;4.5(c)</U>; and (ii)&nbsp;substantially
concurrently with the termination of this Agreement, the Company enters into the definitive agreement relating to a Company Superior Proposal and pays Parent the Termination Fee payable to Parent pursuant to <U>Section</U><U></U><U>&nbsp;6.3(a)</U>;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by either Parent or the Company if: (i)&nbsp;the Company Stockholder Meeting (including any adjournments and
postponements thereof) shall have been held and completed; and (ii)&nbsp;the Required Company Stockholder Vote shall not have been obtained, in each case after a vote on such approval was taken; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) by either Parent or the Company if: (i)&nbsp;the Parent Stockholder Meeting (including any adjournments and postponements
thereof) shall have been held and completed; and (ii)&nbsp;the Required Parent Stockholder Vote shall not have been obtained, in each case after a vote on such approval was taken; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) by Parent if: (i)&nbsp;any of the Company&#146;s representations and warranties contained in this Agreement shall be
inaccurate such that the condition set forth in <U>Section</U><U></U><U>&nbsp;5.2(a)</U> would not be satisfied; or (ii)&nbsp;any of the Company&#146;s covenants contained in this Agreement shall have been breached such that the condition set forth
in <U>Section</U><U></U><U>&nbsp;5.2(b)</U> would not be satisfied; <I>provided</I>, <I>however</I>, that for purposes of clauses (i)&nbsp;and (ii) above, if an inaccuracy in any of the Company&#146;s representations and warranties or a breach of a
covenant of the Company is curable by the Company by the End Date and the Company is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Parent may not terminate this Agreement under this
<U>Section</U><U></U><U>&nbsp;6.1(i)</U> on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of 30 Business Days commencing on the date that the Company receives written notice of such
inaccuracy or breach from Parent; <I>provided</I>, <I>further</I>, that Parent shall not have the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;6.1(i)</U> if Parent is then in breach of any of its representations,
warranties or agreements contained in this Agreement, which breach would give rise to the failure of a condition set forth in <U>Section</U><U></U><U>&nbsp;5.3(a)</U> or <U>Section</U><U></U><U>&nbsp;5.3(b)</U>; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) by the Company if: (i)&nbsp;any of Parent&#146;s or Acquisition Subs&#146; representations and warranties contained in this
Agreement shall be inaccurate such that the condition set forth in <U>Section</U><U></U><U>&nbsp;5.3(a)</U> would not be satisfied; or (ii)&nbsp;any of Parent&#146;s covenants contained in this Agreement shall have been breached such that the
condition set forth in <U>Section</U><U></U><U>&nbsp;5.3(b)</U> would not be satisfied; <I>provided</I>, <I>however</I>, that for purposes of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
clauses (i)&nbsp;and (ii) above, if an inaccuracy in any of Parent&#146;s or Acquisition Subs&#146; representations and warranties or a breach of a covenant of Parent is curable by Parent by the
End Date and Parent is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then the Company may not terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;6.1(j)</U> on account of such inaccuracy or
breach unless such inaccuracy or breach shall remain uncured for a period of 30 Business Days commencing on the date that Parent receives written notice of such inaccuracy or breach from the Company; <I>provided, further</I>, that the Company shall
not have the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;6.1(j)</U> if the Company is then in breach of any of its representations, warranties or agreements contained in this Agreement, which breach would give
rise to the failure of a condition set forth in <U>Section</U><U></U><U>&nbsp;5.2(a)</U> or <U>Section</U><U></U><U>&nbsp;5.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for a
termination pursuant to <U>Section</U><U></U><U>&nbsp;6.1(a)</U>, the party seeking to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;6.1</U> shall give written notice of such termination to the other parties in accordance
with <U>Section</U><U></U><U>&nbsp;7.8</U>, specifying the provision of this Agreement pursuant to which such termination is effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <B>Effect of Termination</B>. In the event of the termination of this Agreement as provided in
<U>Section</U><U></U><U>&nbsp;6.1</U>, this Agreement shall be of no further force or effect with no liability to any Person on the part of any party to this Agreement (or any of its Representatives or Affiliates); <I>provided</I>, <I>however</I>,
that: (a)&nbsp;the last sentence of <U>Section</U><U></U><U>&nbsp;4.8(a)</U>, the last sentence of <U>Section</U><U></U><U>&nbsp;4.8(b)</U>, <U>Section</U><U></U><U>&nbsp;4.10</U>, <U>Section</U><U></U><U>&nbsp;4.14(b)</U>, this
<U>Section</U><U></U><U>&nbsp;6.2</U>, <U>Section</U><U></U><U>&nbsp;6.3</U> and <U>Section</U><U></U><U>&nbsp;VII</U> shall survive the termination of this Agreement and shall remain in full force and effect; and (b)&nbsp;subject to
<U>Section</U><U></U><U>&nbsp;6.3(e)</U> and <U>Section</U><U></U><U>&nbsp;6.3(f)</U>, the termination of this Agreement shall not relieve any party from any liability for any fraud or any Willful Breach of this Agreement that is material. The <FONT
STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement shall not be affected by a termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3
<B>Termination Fees</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If this Agreement is terminated by the Company pursuant to
<U>Section</U><U></U><U>&nbsp;6.1(f)</U>, by Parent pursuant to <U>Section</U><U></U><U>&nbsp;6.1(d)</U>, or by either Parent or the Company pursuant to <U>Section</U><U></U><U>&nbsp;6.1(b)</U> (and at the End Date all of the conditions to the
Company&#146;s obligations to close other than receipt of the Required Company Stockholder Vote have been satisfied, or are capable of satisfaction had the Closing occurred on the End Date) or <U>Section</U><U></U><U>&nbsp;6.1(g)</U>, in each case,
at a time when Parent would have been entitled to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;6.1(d)</U>, then, within two Business Days after (or in the case of termination pursuant to
<U>Section</U><U></U><U>&nbsp;6.1(f)</U>, substantially current with) the termination of this Agreement, the Company shall cause to be paid to Parent the Termination Fee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If this Agreement is terminated by the Company pursuant to <U>Section</U><U></U><U>&nbsp;6.1(e)</U>, or by either Parent or
the Company pursuant to <U>Section</U><U></U><U>&nbsp;6.1(b)</U> or <U>Section</U><U></U><U>&nbsp;6.1(h)</U> at a time when the Company would have been entitled to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;6.1(e)</U>, then,
within two Business Days after the termination of this Agreement, Parent shall cause to be paid to the Company the Termination Fee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If this Agreement is terminated by Parent or the Company pursuant to <U>Section</U><U></U><U>&nbsp;6.1(g)</U> or by Parent
pursuant to <U>Section</U><U></U><U>&nbsp;6.1(i)</U> (or by the Company or Parent pursuant to <U>Section</U><U></U><U>&nbsp;6.1(b)</U> (and at the End Date all of the conditions to the Company&#146;s obligations to close other than receipt of the
Required Company Stockholder Vote have been satisfied, or are capable of satisfaction had the Closing occurred on the End Date) at a time when this Agreement could have been terminated pursuant to <U>Section</U><U></U><U>&nbsp;6.1(g)</U> or
<U>Section</U><U></U><U>&nbsp;6.1(i)</U>) and: (i)&nbsp;at or prior to the Company Stockholder Meeting (in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;6.1(g)</U>), or at or prior to the time of the applicable breach by the
Company (in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;6.1(i)</U>), any Person shall have publicly announced an intention to make a Company Acquisition Proposal, or a Company Acquisition Proposal shall have been publicly
disclosed, publicly announced, commenced, submitted or made and shall not have been publicly withdrawn without qualification at least five Business Days prior to the date of the Company Stockholder Meeting, in the case of a termination pursuant to
<U>Section</U><U></U><U>&nbsp;6.1(g)</U>, or the time of such breach, in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;6.1(i)</U>; and (ii)&nbsp;on or prior to the date that is 12 months following the termination of this
Agreement, either (A)&nbsp;a Company Acquisition Transaction is consummated or (B)&nbsp;a definitive agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
relating to a Company Acquisition Transaction is entered into by the Company and the transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this
clause&nbsp;&#147;(B),&#148; each reference to 20% in the definition of &#147;Company Acquisition Transaction&#148; in <U>Exhibit A</U> shall be deemed to be a reference to 50%, then, within two Business Days after the consummation of such Company
Acquisition Transaction, the Company shall cause to be paid to Parent the Termination Fee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If this Agreement is
terminated by Parent or the Company pursuant to <U>Section</U><U></U><U>&nbsp;6.1(h)</U> or by the Company pursuant to <U>Section</U><U></U><U>&nbsp;6.1(j)</U> (or by the Company or Parent pursuant to <U>Section</U><U></U><U>&nbsp;6.1(b)</U> at a
time when this Agreement could have been terminated pursuant to <U>Section</U><U></U><U>&nbsp;6.1(h)</U> or <U>Section</U><U></U><U>&nbsp;6.1(j)</U>) and: (i)&nbsp;at or prior to the Parent Stockholder Meeting (in the case of a termination pursuant
to <U>Section</U><U></U><U>&nbsp;6.1(h)</U>), or at or prior to the time of the applicable breach by Parent (in the case of a termination pursuant to or <U>Section</U><U></U><U>&nbsp;6.1(j)</U>), any Person shall have publicly announced an intention
to make a Parent Acquisition Proposal, or a Parent Acquisition Proposal shall have been publicly disclosed, publicly announced, commenced, submitted or made and shall not have been publicly withdrawn without qualification at least five Business Days
prior to date of the Parent Stockholder Meeting, in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;6.1(h)</U>, or the time of such breach, in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;6.1(j)</U>; and
(ii)&nbsp;on or prior to the date that is 12 months following the termination of this Agreement, either (A)&nbsp;a Parent Acquisition Transaction is consummated or (B)&nbsp;a definitive agreement relating to a Parent Acquisition Transaction is
entered into by Parent and the transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this clause &#147;(B),&#148; each reference to 20% in the definition of &#147;Parent Acquisition Transaction&#148;
in <U>Exhibit A</U> shall be deemed to be a reference to 50%), then, within two Business Days after the consummation of such Parent Acquisition Transaction, Parent shall cause to be paid to the Company the Termination Fee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any Termination Fee due and payable by the Company under this <U>Section</U><U></U><U>&nbsp;6.3</U> shall be paid by wire
transfer of immediately available funds to an account designated in writing by Parent. For the avoidance of doubt, the Termination Fee shall be payable by the Company only once and not in duplication even though the Termination Fee may be payable by
the Company under one or more provisions hereof. If the Company fails to pay the Termination Fee when due and payable by the Company, then the Company shall pay to Parent interest on such overdue amount (for the period commencing as of the date such
overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to Parent) at a rate per annum equal to the &#147;prime rate&#148; (as published in <I>The Wall Street Journal</I>) in effect on the date
such amount was originally required to be paid, and the Company shall pay the costs and expenses (including reasonable and documented legal fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses) in connection with any action, including the filing of any lawsuit or other legal action, taken by Parent to collect payment. In any circumstance where performance by the Company of its obligations under this Agreement would relieve the
Company of its obligation to pay to Parent the Termination Fee, Parent and Acquisition Subs may, in their sole discretion (i)&nbsp;seek specific performance pursuant to <U>Section</U><U></U><U>&nbsp;7.11</U>, (ii) withdraw any claim for specific
performance and require the Company to pay the Termination Fee if Parent is entitled to payment of the Termination Fee under this <U>Section</U><U></U><U>&nbsp;6.3</U> or (iii)&nbsp;if Parent and Acquisition Subs are unable for any reason to obtain
specific performance, require the Company to pay the Termination Fee if Parent is entitled to payment of the Termination Fee under this <U>Section</U><U></U><U>&nbsp;6.3</U>.&nbsp;&nbsp;&nbsp;&nbsp;The parties agree that if the Termination Fee
becomes payable by, and is paid by, the Company, then such Termination Fee shall be Parent&#146;s sole and exclusive remedy for damages against the Company and its Affiliates and its and their Representatives in connection with this Agreement, and
in no event will Parent or any other Person seek to recover any other money damages or seek any other remedy based on a claim in law or equity for any reason in connection with this Agreement; <I>provided</I>, that nothing contained herein shall
relieve any party from satisfying any claim in law or equity or from any liability, in each case arising from fraud or any Willful Breach of this Agreement that is material. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Any Termination Fee due and payable by Parent under this <U>Section</U><U></U><U>&nbsp;6.3</U> shall be paid by wire
transfer of immediately available funds to an account designated in writing by the Company. For the avoidance of doubt, the Termination Fee shall be payable by Parent only once and not in duplication even
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
though a termination fee may be payable by Parent under one or more provisions hereof. If Parent fails to pay the Termination Fee when due and payable by Parent, then Parent shall pay to the
Company interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the Company) at a rate per annum equal to the
&#147;prime rate&#148; (as published in <I>The Wall Street Journal</I>) in effect on the date such amount was originally required to be paid, and Parent shall pay the costs and expenses (including reasonable and documented legal fees and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) in connection with any action, including the filing of any lawsuit or other legal action, taken by the Company to collect payment. In any circumstance
where performance by Parent and Acquisition Subs of their respective obligations under this Agreement would relieve Parent of its obligation to pay to the Company the Termination Fee, the Company may, in its sole discretion (i)&nbsp;seek specific
performance pursuant to <U>Section</U><U></U><U>&nbsp;7.11</U>, (ii) withdraw any claim for specific performance and require Parent to pay the Company the Termination Fee if the Company is entitled to payment of the Termination Fee under this
<U>Section</U><U></U><U>&nbsp;6.3</U> or (iii)&nbsp;if the Company is unable for any reason to obtain specific performance, require Parent to pay the Termination Fee to the Company if the Company is entitled to payment of the Termination Fee under
this <U>Section</U><U></U><U>&nbsp;6.3</U>; <I>provided</I> that, in the event the Company terminates this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;6.1(e)(iii)</U> and the Company requires Parent to pay the Termination Fee, receipt of the
Termination Fee shall be the Company&#146;s sole and exclusive remedy for damages against Parent, each Acquisition Sub and their respective Affiliates and its and their Representatives for the matters set forth in
<U>Section</U><U></U><U>&nbsp;6.1(e)(iii)</U>. The parties agree that if the Termination Fee becomes payable by, and is paid by, Parent, then such Termination Fee shall be the Company&#146;s sole and exclusive remedy for damages against Parent, each
Acquisition Sub and their respective Affiliates and its and their Representatives in connection with this Agreement, and in no event will the Company or any other Person seek to recover any other money damages or seek any other remedy based on a
claim in law or equity for any reason in connection with this Agreement; <I>provided</I>, that nothing contained herein (other than as provided herein with respect to the matters set forth in <U>Section</U><U></U><U>&nbsp;6.1(e)(iii))</U> shall
relieve any party from satisfying any claim in law or equity or from any liability, in each case arising from fraud or any Willful Breach of this Agreement that is material. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Each of the parties hereto acknowledges that the Termination Fee is not intended to be a penalty, but rather is liquidated
damages in a reasonable amount that will compensate the recipient in the circumstances in which the Termination Fee is due and payable and which do not involve fraud or Willful Breach of this Agreement by the other party, for the efforts and
resources expended and opportunities foregone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the Mergers, which amount would otherwise be impossible to calculate with
precision.&nbsp;Each of the parties acknowledges that the agreements contained in this <U>Section</U><U></U><U>&nbsp;6.3</U> are an integral part of the transactions contemplated by this Agreement, and that without these agreements the parties would
not enter into this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLE VII. MISCELLANEOUS PROVISIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1 <B>Amendment</B>. This Agreement may be amended at any time prior to the First Effective Time (whether before or after receipt
of the Required Company Stockholder Vote or the Required Parent Stockholder Vote) by an instrument in writing signed on behalf of each of the parties hereto; <I>provided</I>, <I>however</I>, that: (a)&nbsp;after the Required Parent Stockholder Vote
has been received, no amendment shall be made which by applicable Legal Requirement or rule or regulation of Nasdaq requires further approval of the stockholders of Parent without the further approval of such stockholders; and (b)&nbsp;after the
Required Company Stockholder Vote has been received, no amendment shall be made which by applicable Legal Requirement or regulation of Nasdaq requires further approval of the stockholders of the Company without the further approval of such
stockholders, <I>provided</I>, <I>further</I>, that any amendment, modification, waiver, supplement or change of <U>Section</U><U></U><U>&nbsp;4.14(a)</U>, <U>Section</U><U></U><U>&nbsp;6.3(e)</U>, <U>Section</U><U></U><U>&nbsp;6.3(f)</U>, this
proviso of <U>Section</U><U></U><U>&nbsp;7.1</U>, <U>Section</U><U></U><U>&nbsp;7.4(d)</U>, <U>Section</U><U></U><U>&nbsp;7.5(b)</U>, <U>Section</U><U></U><U>&nbsp;7.5(c)</U> and <U>Section</U><U></U><U>&nbsp;7.13</U> (in each case, solely to the
extent that such provision relates to the Debt Financing Sources Related Parties), and including, in each case, the definitions of defined terms used therein, that is, in each case, adverse to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the interests of the Debt Financing Sources Related Parties, will not be effective against the Debt Financing Sources Related Parties without the prior written consent of the Debt Financing
Sources (which consent shall not be unreasonably withheld, conditioned or delayed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 <B>Waiver</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise provided in this Agreement, any failure of any of the parties to comply with any obligation, covenant,
agreement or condition herein may be waived by the party or parties entitled to the benefits thereof only by a written instrument signed by the party granting such waiver. Any such waiver shall not be applicable or have any effect except in the
specific instance in which it is given. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No failure on the part of any party to exercise any power, right, privilege or
remedy under this Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy. No single or partial exercise of any
such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3 <B>No Survival of Representations and Warranties</B>. None of the representations, warranties, covenants and agreements
contained in this Agreement, or contained in any certificate, schedule or document delivered pursuant to this Agreement or in connection with any of the transactions contemplated by this Agreement, shall survive the First Effective Time, except that
this <U>Section</U><U></U><U>&nbsp;7.3</U> shall not limit any covenant or agreement contained in this Agreement that by its terms is to be performed in whole or in part after the First Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4 <B>Entire Agreement; <FONT STYLE="white-space:nowrap">Non-Reliance;</FONT> Third-Party Beneficiaries</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement, the Company Disclosure Schedule, the Parent Disclosure Schedule, and the
<FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement, constitute the entire agreement and supersede all prior and contemporaneous agreements and understandings, both written and oral, among or between any of the parties with respect to
the subject matter hereof and thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of <U>Section</U><U></U><U>&nbsp;7.4(a)</U>,
except for the representations and warranties expressly contained in <U>ARTICLE</U><U></U><U>&nbsp;II</U>: (i)&nbsp;Parent and each Acquisition Sub acknowledge and agree that the Company has not made and is not making any representations or
warranties, express or implied, whatsoever regarding the subject matter of this Agreement, that none of Parent, either Acquisition Sub or any Parent Subsidiary or any of their respective Representatives is relying on, and none of the foregoing has
relied on, in connection with each of Parent and each Acquisition Sub&#146;s entry into this Agreement and agreement to consummate the transactions contemplated hereby or otherwise, any representations or warranties, express or implied, whatsoever
regarding the Company, any of its Affiliates, any of their respective Representatives, any other subject matter of this Agreement or any other matter, express or implied, except for the representations and warranties expressly set forth in
<U>ARTICLE II</U>, and that no Representative of the Company or any other Person has made or is making any representations or warranties, express or implied, whatsoever regarding the Company, any of its Affiliates, any of their respective
Representatives, any other subject matter of this Agreement or any other matter; and (ii)&nbsp;without limiting the foregoing, Parent and each Acquisition Sub acknowledge and agree that (x)&nbsp;the Company has not made and is not making any
representations or warranties whatsoever regarding, (y)&nbsp;neither the Company nor any other Person will have or be subject to any liability or other obligation to Parent, Acquisition Subs or their respective Representatives or Affiliates or any
other Person resulting from Parent&#146;s, each Acquisition Sub&#146;s or their Representatives&#146; or Affiliates&#146; use of, and (z)&nbsp;none of Parent, the Parent Subsidiaries or any of their respective Representatives has relied on,
(A)&nbsp;any forecasts, projections, estimates or budgets discussed with, delivered to or made available to Parent or either Acquisition Sub or to any of their Representatives, or otherwise (including in certain &#147;data rooms,&#148; &#147;virtual
rooms,&#148; management presentations or in any form in expectation of, or in connection with, the transactions contemplated hereby) regarding the future revenues, future results of operations (or any component thereof), future cash flows or future
financial condition (or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any component thereof) of the Company or any Subsidiary of the Company or the future business and operations of the Company or any Subsidiary of the Company or (B)&nbsp;oral or written
information made available to Parent or Parent&#146;s Affiliates or Representatives in the course of their due diligence investigation of the Company, the negotiation of this Agreement or in the course of the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Without limiting the generality of <U>Section</U><U></U><U>&nbsp;7.4(a),</U> except for the representations and warranties
expressly contained in <U>ARTICLE III</U>: (i)&nbsp;the Company acknowledges and agrees that Parent has not made and is not making any representations or warranties, express or implied, whatsoever regarding the subject matter of this Agreement, that
none of the Company, the Company Subsidiaries or any of their respective Representatives is relying on, and none of the foregoing has relied on, in connection with the Company&#146;s entry into this Agreement and agreement to consummate the
transactions contemplated hereby or otherwise, any representations or warranties, express or implied, whatsoever regarding Parent, any of its Affiliates, any of their respective Representatives, any other subject matter of this Agreement or any
other matter, express or implied, except for the representations and warranties expressly set forth in <U>ARTICLE III</U>, and that no Representative of Parent or any other Person has made or is making any representations or warranties, express or
implied, whatsoever regarding Parent, any of its Affiliates, any of their respective Representatives, any other subject matter of this Agreement or any other matter; and (ii)&nbsp;without limiting the foregoing, the Company acknowledges and agrees
that (x)&nbsp;Parent has not made and is not making any representations or warranties whatsoever regarding, (y)&nbsp;none of Parent, either Acquisition Sub nor any other Person will have or be subject to any liability or other obligation to the
Company or their Representatives or Affiliates or any other Person resulting from the Company&#146;s or their Representatives&#146; or Affiliates&#146; use of and (z)&nbsp;none of the Company, the Company Subsidiaries or any of their respective
Representatives has relied on, (A)&nbsp;any forecasts, projections, estimates or budgets discussed with, delivered to or made available to the Company or to any of its Representatives, or otherwise (including in certain &#147;data rooms,&#148;
&#147;virtual rooms,&#148; management presentations or in any form in expectation of, or in connection with, the transactions contemplated hereby) regarding the future revenues, future results of operations (or any component thereof), future cash
flows or future financial condition (or any component thereof) of Parent or any Subsidiary of Parent or the future business and operations of Parent or any Subsidiary of Parent or (B)&nbsp;any oral or written information made available to the
Company or the Company&#146;s Affiliates or Representatives in the course of their due diligence investigation of Parent, the negotiation of this Agreement or in the course of the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Parent, the Company and each Acquisition Sub agree that their respective representations and warranties set forth in this
Agreement are solely for the benefit of the other parties hereto, in accordance with and subject to the terms of this Agreement, and this Agreement is not intended to, and does not, confer upon any Person other than Parent, the Company, and each
Acquisition Sub and their respective successors, legal representatives and permitted assigns any rights or remedies, express or implied, hereunder, including the right to rely upon the representations and warranties set forth in this Agreement,
except as set forth in <U>Section</U><U></U><U>&nbsp;7.7</U>; <I>provided</I> that <U>Section</U><U></U><U>&nbsp;4.14(a)</U>, <U>Section</U><U></U><U>&nbsp;6.3(e)</U>, <U>Section</U><U></U><U>&nbsp;6.3(f)</U>, the second proviso to the first
sentence of <U>Section</U><U></U><U>&nbsp;7.1</U>, this <U>Section</U><U></U><U>&nbsp;7.4(d)</U>, <U>Section</U><U></U><U>&nbsp;7.5(b)</U>, <U>Section</U><U></U><U>&nbsp;7.5(c)</U> and <U>Section</U><U></U><U>&nbsp;7.13</U> shall (solely to the
extent that any such provision relates to the Debt Financing Sources Related Parties) be for the benefit of, and enforceable by, the Debt Financing Sources Related Parties. The representations and warranties in this Agreement are the product of
negotiations among the parties. Any inaccuracies in such representations and warranties are subject to waiver by the parties in accordance with this Agreement without notice or liability to any other Person. In some instances, the representations
and warranties in this Agreement may represent an allocation among the parties of risks associated with particular matters regardless of the knowledge of any of the parties. Consequently, Persons other than the parties may not rely upon the
representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, nothing in this <U>Section</U><U></U><U>&nbsp;7.4</U> shall restrain, limit, restrict or
prohibit any claim based on fraud. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5 <B>Applicable Law; Jurisdiction</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement is made under, and shall be construed and enforced in accordance with, the laws of the State of Delaware
applicable to agreements made and to be performed solely therein, without giving effect to principles of conflicts of law. Each of the parties hereto: (i)&nbsp;consents to and submits to the exclusive personal jurisdiction of the Court of Chancery
of the State of Delaware or, if that court does not have jurisdiction, a federal court sitting in Delaware in any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement;
(ii)&nbsp;agrees that all claims in respect of such action or proceeding shall be heard and determined in any such court; (iii)&nbsp;shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such
court; and (iv)&nbsp;shall not bring any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient
forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other Person with respect thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LEGAL REQUIREMENTS ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT (INCLUDING ANY DISPUTE ARISING OUT OF OR RELATING TO THE DEBT
FINANCING OR THE DEBT COMMITMENT LETTER OR THE PERFORMANCE OF SERVICES THEREUNDER OR RELATED THERETO). Each of the parties hereto acknowledges that it and the other parties have been induced to enter into this Agreement and the transactions
contemplated by this Agreement, as applicable, by, among other things, the mutual waivers and certifications in this <U>Section</U><U></U><U>&nbsp;7.5</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges and irrevocably agrees, all
disputes against the Debt Financing Sources Related Party in any way relating to this Agreement or any of the transactions contemplated hereby, including but not limited to any dispute arising out of or relating in any way to the Debt Financing or
the performance thereof or the Transactions, whether in contract, tort or otherwise, will be governed by, and construed in accordance with, the Laws of the State of New York applicable to contracts executed in and to be performed entirely within the
State, without regard to conflict of law principles that would result in the application of any Law other than the Law of the State of New York. Each of the parties agrees that it will not bring or support any suit, action or Legal Proceeding of any
kind or description, whether in law or in equity, whether in contract or in tort or otherwise, against the Debt Financing Sources Related Parties in any way relating to this Agreement or any of the transactions contemplated by this Agreement,
including but not limited to any dispute arising out of or relating in any way to the Debt Commitment Letter or the performance thereof, in any forum other than the Supreme Court of the State of New York, County of New York, or, if under applicable
law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the Southern District of New York (and appellate courts thereof), and makes the agreements, waivers and consents set forth in
<U>Section</U><U></U><U>&nbsp;7.5(a)</U> <I>mutatis mutandis</I> but with respect to the courts specified in this <U>Section</U><U></U><U>&nbsp;7.5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6 <B>Payment of Expenses</B>. Whether or not the Mergers are consummated, each party hereto shall pay its own expenses incident
to preparing for, entering into and carrying out this Agreement and the transactions contemplated hereby <I>provided, however</I>, that Parent shall pay all filing fees and printing and mailing costs for the Joint Proxy Statement/Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.7 <B>Assignability; Parties in Interest</B>. This Agreement shall be binding upon, and shall be enforceable by and inure to the
benefit of, the parties hereto and their respective successors and permitted assigns. This Agreement shall not be assignable by any party, in whole or in part, by operation of law or otherwise, without the express prior written consent of the other
parties hereto. Except for the provisions of <U>Section</U><U></U><U>&nbsp;I</U> (which, from and after the First Effective Time, shall be for the benefit of Persons who are holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Company Common Stock immediately prior to the First Effective Time and holders of Company Options) and <U>Section</U><U></U><U>&nbsp;4.13</U> (which, from and after the First Effective
Time shall be for the benefit of the Indemnified Parties and the other Persons identified therein), nothing in this Agreement (including <U>Section</U><U></U><U>&nbsp;4.11</U>), express or implied, is intended to or shall confer upon any Person,
other than the parties hereto, any right, benefit or remedy of any nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.8 <B>Notices</B>. All notices and other
communications hereunder shall be in writing in one of the following formats and shall be deemed given (a)&nbsp;upon actual delivery if personally delivered to the party to be notified if received prior to 6:00 p.m. in the place of receipt on a
Business Day, otherwise such notice or communication shall be deemed not to have been received until the next succeeding Business Day; (b)&nbsp;when sent if sent by email to the party to be notified if received prior to 6:00 p.m. in the place of
receipt on a Business Day, otherwise such notice or communication shall be deemed not to have been received until the next succeeding Business Day; <I>provided</I>, <I>however</I>, that notice given by email shall not be effective unless
(i)&nbsp;such notice specifically states that it is being delivered pursuant to this Section&nbsp;7.8 and (ii)&nbsp;either (A) a duplicate copy of such email notice is promptly given by one of the other methods described in this
<U>Section</U><U></U><U>&nbsp;7.8</U> or (B)&nbsp;the receiving party delivers a written confirmation of receipt for such notice either by email (excluding &#147;out of office&#148; or similar automated replies) or any other method described in this
<U>Section</U><U></U><U>&nbsp;7.8</U>; or (c)&nbsp;when delivered if sent by a courier (with confirmation of delivery) if received prior to 5 p.m. in the place of receipt on a Business Day, otherwise such notice or communication shall be deemed not
to have been received until the next succeeding Business Day; in each case to the Party to be notified at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>if to
Parent or Acquisition Subs: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Bioventus Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4721 Emperor Boulevard, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Durham, North Carolina 27703 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Kenneth Reali, Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">E-mail: <U>kenneth.reali@bioventusglobal.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>with a copy (which shall not constitute notice) to: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Bioventus Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4721 Emperor
Boulevard, Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Durham, North Carolina 27703 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Anthony D&#146;Adamio </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;<U>tony.dadamio@bioventus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>with a copy (which shall not constitute notice) to: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1271 Avenue of the Americas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New
York, NY 10020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Charles Ruck; Mark Bekheit </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;<U>charles.ruck@lw.com;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;mark.bekheit@lw.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>if to the Company: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Misonix, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1938 New Highway
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Farmingdale, New York </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;<U>jdwyer@misonix.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>with a copy (which shall not constitute notice) to: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">250 Vesey Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10281-1047 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jonn R. Beeson; Randi Lesnick </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;<U>jbeeson@jonesday.com; rclesnick@jonesday.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.9 <B>Severability</B>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any
jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment
of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific
words or phrases or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable
term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10 <B>Counterparts</B>. This Agreement may be executed and delivered (including by facsimile or other form of electronic
transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. The
exchange of a fully executed Agreement (in counterparts or otherwise) by facsimile or other electronic delivery shall be sufficient to bind the parties to the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11 <B>Specific Performance</B>. Each of the parties hereto agrees that irreparable damage would occur in the event that any of
the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. It is accordingly agreed that, in
addition to any other remedy that a party hereto may have under law or in equity, in the event of any breach or threatened breach by Parent, either Acquisition Sub or the Company of any covenant or obligation of such party contained in this
Agreement, the other parties shall be entitled to obtain: (i)&nbsp;an Order of specific performance to enforce the observance and performance of such covenant; and (ii)&nbsp;an injunction restraining such breach or threatened breach. In the event
that any action is brought in equity to enforce the provisions of this Agreement, no party hereto shall allege, and each party hereto hereby waives the defense or counterclaim, that there is an adequate remedy at law. Each party hereto further
agrees that no other party hereto or any other Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this
<U>Section</U><U></U><U>&nbsp;7.11</U>, and each party hereto irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument. In no event will the Company, any of the Company&#146;s
Subsidiaries or any of their respective Representatives be entitled to specific performance or any other enforcement of Parent&#146;s or any Acquisition Sub&#146;s obligations under this Agreement to cause the Debt Financing to be funded (or to
themselves directly cause the Debt Financing to be funded under the Debt Commitment Letter or otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12 <B>Disclosure
Schedules</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company Disclosure Schedule&nbsp;has been arranged, for purposes of convenience only, in separate
sections&nbsp;and subsections&nbsp;corresponding to the Sections&nbsp;and subsections&nbsp;of <U>ARTICLE II</U> and, as applicable, <U>ARTICLE </U><U></U><U>IV</U>. Any information set forth in any subsection&nbsp;of the Company Disclosure
Schedule&nbsp;shall be deemed to be disclosed and incorporated by reference in each of the other subsections&nbsp;of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company Disclosure Schedule&nbsp;as though fully set forth in such other subsections&nbsp;(whether or not specific cross-references are made) to the extent it is reasonably apparent on its
face that such disclosure also qualifies or applies to such other subsections. No reference to or disclosure of any item or other matter in the Company Disclosure Schedule&nbsp;shall be construed, in and of itself, as an admission or indication that
such item or other matter is material or that such item or other matter is required to be referred to or disclosed in the Company Disclosure Schedule. The information set forth in the Company Disclosure Schedule&nbsp;is disclosed solely for purposes
of this Agreement, and no information set forth therein shall be deemed, in and of itself, to be an admission by any party hereto to any third party of any matter whatsoever, including any violation of Legal Requirement or breach of any Contract.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Parent Disclosure Schedule&nbsp;has been arranged, for purposes of convenience only, in separate sections&nbsp;and
subsections&nbsp;corresponding to the Sections&nbsp;and subsections&nbsp;of <U>ARTICLE</U><U></U><U>&nbsp;III</U> and, as applicable, <U>ARTICLE</U><U></U><U>&nbsp;IV</U>. Any information set forth in any subsection&nbsp;of the Parent Disclosure
Schedule&nbsp;shall be deemed to be disclosed and incorporated by reference in each of the other subsections&nbsp;of the Parent Disclosure Schedule&nbsp;as though fully set forth in such other subsections&nbsp;(whether or not specific
cross-references are made) to the extent it is reasonably apparent on its face that such disclosure also qualifies or applies to such other subsections. No reference to or disclosure of any item or other matter in the Parent Disclosure
Schedule&nbsp;shall be construed, in and of itself, as an admission or indication that such item or other matter is material or that such item or other matter is required to be referred to or disclosed in the Parent Disclosure Schedule. The
information set forth in the Parent Disclosure Schedule&nbsp;is disclosed solely for purposes of this Agreement, and no information set forth therein shall be deemed, in and of itself, to be an admission by any party hereto to any third party of any
matter whatsoever, including any violation of Legal Requirement or breach of any Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13 <B><FONT
STYLE="white-space:nowrap">Non-Recourse</FONT></B>. In no event will the Company, any of the Company&#146;s Subsidiaries or any of their respective Representatives (i)&nbsp;seek to enforce this Agreement against, make any claims for breach of this
Agreement against, or seek to recover monetary damages from, any of the Debt Financing Sources Related Parties or (ii)&nbsp;seek to enforce the commitments contained in the Debt Commitment Letter against, make any claims for breach of the
commitments contained in the Debt Commitment Letter against, or seek to recover monetary damages from, or otherwise sue, the Debt Financing Sources Related Parties for any reason, including in connection with the Debt Financing or the obligations of
the Debt Financing Sources Related Parties thereunder. The Company, on behalf of itself and the Company Subsidiaries and its and their respective Representatives, hereby waives any and all claims and causes of action (whether in contract or in tort,
in law or in equity) against the Debt Financing Sources Related Parties that may be based upon, arise out of or relate to this Agreement, the Debt Commitment Letter or the Debt Financing. Nothing in this <U>Section</U><U></U><U>&nbsp;7.13</U> will
in any way limit or qualify the obligations and liabilities of the parties hereto to each other or in connection with, or otherwise restrict the Parent or any of its Affiliates from enforcing its rights under, the Debt Commitment Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14 <B>Construction</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice
versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. If a term is defined as one part of
speech, it shall have a corresponding meaning when used as another part of speech. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties hereto agree that any
rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As used in this Agreement, the words &#147;include&#148; and &#147;including,&#148; and variations thereof, shall not be
deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation,&#148; and the words &#147;hereof,&#148; &#147;hereby,&#148; &#147;herein,&#148; &#147;hereunder&#148; and similar terms in this
Agreement shall refer to this Agreement as a whole and not any particular section&nbsp;or article in which such words appear. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this Agreement, any reference to a Legal Requirement
shall include any rules and regulations promulgated thereunder, and any reference to a Legal Requirement in this Agreement shall only be a reference to such Legal Requirement as of the date of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as otherwise indicated, all references in this Agreement to &#147;<U>Sections</U>,&#148;
&#147;<U>Exhibits</U>,&#148; &#147;<U>Annexes</U>&#148; and &#147;<U>Schedules</U>&#148; are intended to refer to Sections&nbsp;of this Agreement and Exhibits, Annexes and Schedules to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All references in this Agreement to &#147;$&#148; are intended to refer to United States dollars. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The table of contents and headings to this Agreement are for convenience of reference only, do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the provisions of this Agreement. The Exhibits, Schedules and Annexes attached to this Agreement constitute a part of this Agreement and are incorporated herein for all purposes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent, Acquisition Sub I and Acquisition Sub II have caused this Agreement to be executed
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOVENTUS INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ken Reali</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ken Reali</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>OYSTER MERGER SUB, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anthony D&#146;Adamio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anthony D&#146;Adamio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>OYSTER MERGER SUB LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anthony D&#146;Adamio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anthony D&#146;Adamio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Person</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE TO AGREEMENT AND PLAN OF MERGER </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has caused this Agreement to be executed as of the date first written above.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MISONIX, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Joseph P. Dwyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joseph P. Dwyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE TO AGREEMENT AND PLAN OF MERGER </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
purposes of the Agreement (including this <U>Exhibit A</U>): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition Subs</U>&#148; shall have the meaning set forth in the
Preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Person shall be deemed to be an &#147;<U>Affiliate</U>&#148; of another Person if such Person directly or indirectly
controls, is directly or indirectly controlled by or is directly or indirectly under common control with such other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; shall mean the Agreement and Plan of Merger to which this <U>Exhibit A</U> is attached, together with this
<U>Exhibit A</U> and each of the other Schedules and Exhibits&nbsp;hereto, as such Agreement and Plan of Merger (including this <U>Exhibit A</U> and the other Schedules and Exhibits&nbsp;hereto) may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-Corruption Laws</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.14(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Antitrust Laws</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.7(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Assumed Company Option</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.9(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Average Company Stock Price</U>&#148; shall mean the average of the daily volume weighted average trading prices per share of Company
Common Stock on Nasdaq (as reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by the parties) on each of the five consecutive Company Trading Days ending on (and including) the Company Trading
Day that is three Company Trading Days prior to the date of the First Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Average Parent Stock Price</U>&#148; shall
mean the average of the daily volume weighted average trading prices per share of Parent Class&nbsp;A Common Stock on Nasdaq (as reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by the
parties) on each of the five consecutive Trading Days ending on (and including) the Trading Day that is three Trading Days prior to the date of the First Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; shall mean any day other than a Saturday, a Sunday or other day on which the SEC or banking institutions in
the City of New York are authorized or required by Legal Requirements to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>BV Opco</U>&#148; shall have the meaning set
forth in <U>Section</U><U></U><U>&nbsp;6.1(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CapEx Budget</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.1(a)(xiii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cash Election Consideration</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.5(a)(ii)(A)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cash Election Shares</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.5(a)(ii)(A)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; shall mean the United States Internal Revenue Code of 1986, as amended.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; shall have the meaning set forth in the Preamble. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company 401(k) Plan</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.11(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Acquisition Proposal</U>&#148; shall mean any offer, indication of interest
or proposal (other than an offer or proposal made or submitted by or on behalf of Parent or any of its Affiliates) contemplating or otherwise relating to any Company Acquisition Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Acquisition Transaction</U>&#148; shall mean any transaction or series of related transactions (other than the Mergers)
involving: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) any merger, consolidation, amalgamation, business combination, joint venture, reorganization or other
similar transaction involving the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any transaction (i)&nbsp;in which any Person or &#147;group&#148; (as
defined in the Exchange Act and the rules thereunder) of Persons acquires beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding
voting power of the Company; or (ii)&nbsp;in which the Company or any of the Company Subsidiaries issues securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding
voting power of the Company (after giving effect to such transaction); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any sale, exchange, transfer, acquisition or
disposition of 20% or more of the consolidated assets (including equity securities of the Company Subsidiaries) of the Company and the Company Subsidiaries, taken as a whole, or of any business or businesses (or the assets of any business or
businesses, including equity securities of any Company Subsidiary) that constitute or account for 20% or more of the consolidated net revenues or net income of the Company and the Company Subsidiaries, taken as a whole; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any tender offer or exchange offer that if consummated would result in any Person or &#147;group&#148; (as defined in the
Exchange Act and the rules thereunder) of Persons acquiring beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for such securities) representing 20% or more of the outstanding voting power of
the Company; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any combination of the foregoing types of transaction if the sum of the percentage of the voting power
of the Company or of the consolidated net revenues, net income or assets of the Company and the Company Subsidiaries, taken as a whole, involved is 20% or more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Board</U>&#148; shall mean the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Board Recommendation</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Book-Entry Shares</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.10(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Capitalization Date</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.3(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Change in Recommendation</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.5(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Common Stock</U>&#148; shall mean the common stock, par value $0.01 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Commonly Controlled Entity</U>&#148; shall mean any entity, trade or business that is a member of a group described in
Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code or Section&nbsp;4001(b)(1) of ERISA that includes the entity, trade or business that is a member of the same &#147;controlled group&#148; as the Company, pursuant to Section&nbsp;4001(a)(14).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Credit Facilities</U>&#148; means, collectively, (x)&nbsp;that certain Loan and Security Agreement, dated as of
December&nbsp;26, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time), by and among Silicon Valley Bank, the Company and certain of affiliates of the Company and (y)&nbsp;that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain Amended and Restated Credit Agreement, dated as of September&nbsp;27, 2019 (as amended, restated, supplemented or otherwise modified from time to time), by and among SWK Holdings
Corporation, the Company and certain affiliates of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Disclosure Schedule</U>&#148; shall have the meaning set
forth in the introductory paragraph of <U>Section</U><U></U><U>&nbsp;II</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Agreements</U>&#148; shall mean the
Company Equity Plans (together with all grant agreements evidencing the Company Options). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Plans</U>&#148; shall
mean the Company&#146;s 2005 Employee Equity Incentive Plan, 2009 Employee Equity Incentive Plan, 2009 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Stock Option Plan, 2012 Employee Equity Incentive Plan, 2012 <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Stock Option Plan, 2014 Employee Equity Incentive Plan, and 2017 Equity Incentive Plan, each as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company ESPP</U>&#148; shall mean the Company&#146;s Employee Stock Purchase Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Fairness Opinion</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.24</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Financial Advisor</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.24</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Intervening Event</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.5(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company IP</U>&#148; shall mean all Intellectual Property owned by the Company or any Company Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company IP Licenses</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.9(h)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Material Adverse Effect</U>&#148; shall mean any state of facts, circumstance, condition, event, change, development,
occurrence, result, effect, action or omission (each, an &#147;<U>Effect</U>&#148;) that, individually or in the aggregate with any one or more other Effects, (i)&nbsp;results in a material adverse effect on the business, condition (financial or
otherwise) or results of operations of the Company and the Company Subsidiaries, taken as a whole or (ii)&nbsp;prevents, materially impairs, materially impedes or materially delays the consummation of the Mergers and the other transactions
contemplated hereby on a timely basis and in any event on or before the End Date; <I>provided</I>, <I>however</I>, that with respect to clause (i)&nbsp;only, no Effect to the extent resulting or arising from any of the following, shall, to such
extent, be deemed to constitute, or be taken into account in determining the occurrence of, a Company Material Adverse Effect: (A)&nbsp;general economic, political, business, financial or market conditions affecting the industry in which the Company
and the Company Subsidiaries operate; (B)&nbsp;geopolitical conditions, including trade and national security policies and export controls and executive orders relating thereto, any outbreak, continuation or escalation of any military conflict,
declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); (C) any pandemic (including the continuation or worsening of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic),
epidemic, plague, or other outbreak of illness or public health event, hurricane, flood, tornado, earthquake or other natural disaster or act of God or changes resulting from weather conditions; (D)&nbsp;any failure by the Company or any of the
Company Subsidiaries to meet any internal or external projections or forecasts or any decline in the price of Company Common Stock (but excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves
constitute or be taken into account in determining whether there has been, or would be, a Company Material Adverse Effect); (E) the public announcement or pendency of the Mergers and the other transactions contemplated hereby, including, in any such
case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, business partners or employees<I> </I>(<I>provided</I> that this clause (E)&nbsp;shall not apply to (x)&nbsp;any representation or warranty
in <U>Section</U><U></U><U>&nbsp;2.6</U> to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Mergers or (y)&nbsp;any
action or omission by the Company, any Company Subsidiary or their respective Representatives in order to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with the Company&#146;s obligations under <U>Section</U><U></U><U>&nbsp;4.1(a)</U>); (F) changes in applicable Legal Requirements (including
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures) or the interpretation thereof; (G)&nbsp;changes in GAAP or any other applicable accounting standards or the interpretation thereof; (H)&nbsp;any action expressly required to be taken by the
Company pursuant to the terms of this Agreement or at the express written direction or consent of Parent or the Acquisition Subs; (I)&nbsp;any claims, suits, actions or Legal Proceedings arising from allegations of breach of fiduciary duty or
violation of Law or otherwise relating to this Agreement or the transactions contemplated by this Agreement; or (J)&nbsp;any breach, violation or <FONT STYLE="white-space:nowrap">non-performance</FONT> of any provision of this Agreement by Parent or
any of its Affiliates; <I>provided</I>, <I>further</I>, that any Effect relating to or arising out of or resulting from any change or event referred to in clause (A), (B), (C), (F) or (G)&nbsp;above may constitute, and be taken into account in
determining the occurrence of, a Company Material Adverse Effect if and only to the extent that such change or event has a disproportionate impact on the Company and the Company Subsidiaries as compared to other participants that operate in the
industry in which the Company and the Company Subsidiaries operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Options</U>&#148; shall mean options to purchase
shares of Company Common Stock from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Permits</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.12(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Permitted Encumbrances</U>&#148; shall mean: (a)&nbsp;Liens for Taxes or
governmental assessments, charges or claims of payment not yet due and payable or which are being contested in good faith by appropriate proceedings; (b)&nbsp;vendors&#146;, mechanics&#146;, materialmen&#146;s, carriers&#146;, workers&#146;,
construction and other similar Liens arising or incurred in the ordinary course of business or with respect to liabilities that are not yet due and payable or, if due, are not delinquent or are being contested in good faith by appropriate
proceedings; (c)&nbsp;encumbrances or imperfections of title relating to liabilities for which appropriate reserves have been established and are reflected in the Most Recent Company Balance Sheet or imposed or promulgated by applicable Legal
Requirements, including zoning, entitlement, building codes, or other Legal Requirements with respect to land use; (d)&nbsp;Liens, pledges or encumbrances arising from or otherwise relating to transfer restrictions under the securities laws of any
jurisdiction; <FONT STYLE="white-space:nowrap">(e)&nbsp;non-exclusive</FONT> licenses of Intellectual Property granted in the ordinary course of business; (f)&nbsp;Liens, encumbrances or imperfections of title which do not and would not reasonably
be expected to, individually or in the aggregate, materially impair the use of the subject property as used by the Company and the Company Subsidiaries and (g)&nbsp;Liens arising under any Company indentures or the Company&#146;s existing credit
facility (or any replacement or refinancing thereof in accordance with this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Plan</U>&#148; shall mean each
&#147;employee benefit plan&#148; (within the meaning of Section&nbsp;3(3) of ERISA, whether or not subject to ERISA) and each other employment, bonus, deferred compensation, equity-based, pension, severance, change in control, employee loan, fringe
benefit, or other employee benefit plan, policy, agreement, program or arrangement, which the Company or any Company Subsidiary maintains for the benefit of its current or former employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Preferred Stock</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Products</U>&#148; shall mean any and all products and services that are or have been since January&nbsp;1, 2019 marketed,
offered, sold, licensed, provided, manufactured, packaged, distributed or supported by the Company or any Company Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Registered IP</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.9(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Representation Letter</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.12(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Restricted Stock</U>&#148; shall mean shares of Company Common Stock subject to vesting conditions based on continuing
service, based on performance, or based on both continuing service and performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company SEC Documents</U>&#148; shall have
the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.7(a)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Stock Certificates</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.10(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Stockholder Meeting</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.5(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Subsidiary</U>&#148; shall mean any direct or indirect <FONT
STYLE="white-space:nowrap">-Subsidiary</FONT> of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Superior Proposal</U>&#148; shall mean any <I>bona
fide</I>, unsolicited written Company Acquisition Proposal made after the date of this Agreement that: (a)&nbsp;if consummated, would result in any Person or &#147;group&#148; (as defined in the Exchange Act and the rules thereunder) of Persons
(other than Parent) directly or indirectly becoming the beneficial owner of (i)&nbsp;any business or businesses that constitute or account for 50% or more of the net revenues, net income or assets of the Company, or (ii) 50% or more of the
outstanding total voting power of the equity securities of the Company; and (b)&nbsp;the Company Board determines in good faith, after consultation with the Company&#146;s outside legal counsel and its financial advisor, is reasonably capable of
being consummated on the terms proposed and which, taking into account such factors as the Company Board reasonably considers in good faith to be appropriate and relevant, including the financial, legal, timing, likelihood of consummation,
confidentiality, regulatory, financing and other aspects of such Company Acquisition Proposal, would be more favorable to the holders of shares of Company Common Stock from a financial point of view than the transactions contemplated by this
Agreement (after giving effect to any revisions to the terms of the Agreement that if accepted by the Company would be legally binding on Parent in response to such Company Acquisition Proposal pursuant to <U>Section</U><U></U><U>&nbsp;4.5</U>).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Superior Proposal Notice</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Trading Day</U>&#148; shall mean a day on which shares of Company Common Stock are traded on Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Continuing Employee</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.11(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; shall mean any contract, subcontract, note, bond, mortgage, indenture, lease, license, sublicense, guaranty,
security agreement, franchise or other legally binding instrument, commitment or obligation, whether oral or in writing, excluding any permits, in each case, that is legally binding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT></U>&#148; means
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> <FONT STYLE="white-space:nowrap">COVID-19,</FONT> any evolutions or mutations of the virus and illness, and any related or associated epidemics, pandemics or
disease outbreaks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</U>&#148; means any quarantine, isolation,
&#147;shelter in place,&#148; &#147;stay at home,&#148; workforce reduction, social distancing, shut down, closure, sequester or any other Legal Requirement, decree, judgment, injunction or other order, directive, guidelines or recommendations by
any Governmental Entity or industry group in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including, the&nbsp;Coronavirus Aid,&nbsp;Relief, and&nbsp;Economic Security (CARES) Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>D&amp;O Policy</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.13(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Data Protection Laws</U>&#148; means all Legal Requirements (including any applicable Legal Requirements of jurisdictions where
personal information is collected) governing the privacy or security of personal information, including, to the extent applicable: <U>HIPAA</U>, the Federal Trade Commission Act, the <FONT STYLE="white-space:nowrap">CAN-SPAM</FONT> Act, the
Telephone Consumer Protection Act, the Telemarketing and Consumer Fraud and Abuse Prevention Act, the Computer Fraud and Abuse Act, state social security number protection applicable laws, state data security laws, state data breach notification
applicable laws, state consumer protection laws, any applicable Legal Requirements concerning requirements for website and internet-connected device privacy policies and practices, data or web scraping, call or electronic monitoring or recording of
any outbound communications, the Data Protection Act 2018, the Data Protection Act 1998 and all other applicable national Laws and secondary legislation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implementing European Directive 95/46/EC, the General Data Protection Regulation (EU) 2016/679 (&#147;<U>GDPR</U>&#148;) and all applicable national Legal Requirements implementing or
supplementing the GDPR and all related national Laws and secondary legislation, the Privacy and Electronic Communications (EC Directive) Regulations 2003 (SI 2003/2426), all other applicable Laws and secondary legislation implementing European
Directive 2002/58/EC, and any other laws applicable to the collection, storage or processing of personal information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Debt
Commitment Letter</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.15(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Debt
Financing</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.15(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>D&amp;O Policy</U>&#148;
shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.13(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Debt Financing Sources</U>&#148; means the
agents, arrangers, lenders and other entities that have committed to provide or arrange or otherwise have entered into agreements pursuant to the Debt Commitment Letter or in connection with all or any part of the Debt Financing described therein,
or replacement debt financings, in connection with the transactions contemplated hereby, including the parties to any commitment letters, joinder agreements, indentures or credit agreements entered pursuant thereto or relating thereto, and their
respective successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Debt Financing Sources Related Party</U>&#148; means the Debt Financing Sources together with
their respective Affiliates, and the respective directors, officers, employees, agents, advisors, other Representatives and successors of each of the foregoing and their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Delaware Secretary of State</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; shall have the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DTC</U>&#148; shall mean The Depository Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Elected Cash Consideration</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.7(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Election Deadline</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.15(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Election Form</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.15(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Election Period</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.15(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>End Date</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Entity</U>&#148; shall mean any corporation (including any <FONT STYLE="white-space:nowrap">non-profit</FONT> corporation), general
partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association,
organization or entity (including any Governmental Entity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Law</U>&#148; shall mean any Legal Requirement
relating to pollution or protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface land, subsurface land, plant and animal life or any other natural resource), including any
such Legal Requirement regulating emissions, discharges or releases of pollutants, contaminants, wastes, toxic substances, exposure to or release of, or the management of any hazardous materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; shall mean the Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; shall mean the Securities Exchange Act of 1934, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Agent</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.12(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Fund</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.12(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Shares</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.5(a)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Export Approvals</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.12(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Export Control Laws</U>&#148; shall mean (a)&nbsp;all applicable trade, export
control, import, and antiboycott laws and regulations imposed, administered, or enforced by the U.S. government, including the Arms Export Control Act (22 U.S.C. &#167; 2778), the International Emergency Economic Powers Act (50 U.S.C. &#167;&#167;
1701&#150;1706), Section&nbsp;999 of the Internal Revenue Code, Title 19 of the U.S. Code, the International Traffic in Arms Regulations (22 C.F.R. Parts <FONT STYLE="white-space:nowrap">120-130),</FONT> the Export Administration Regulations (15
C.F.R. Parts <FONT STYLE="white-space:nowrap">730-774),</FONT> the Export Control Reform Act of 2018 (50 U.S.C. &#167;&#167; 4801-4852), the U.S. customs regulations at 19 C.F.R. Chapter 1, and the Foreign Trade Regulations (15 C.F.R. Part 30); and
(b)&nbsp;all applicable trade, export control, import, and antiboycott laws and regulations imposed, administered or enforced by any other country, except to the extent inconsistent with U.S. law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration, or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Financing Conditions</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.13(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Certificate of Merger</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Effective Time</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement</U>&#148; shall mean the registration statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> to be filed with the SEC by Parent in connection with the Parent Share Issuance, as such registration statement may be amended prior to the time it is declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; shall mean United States generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>General Enforceability Exception</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Generally Available Software</U>&#148; means generally, commercially available <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software and (i)&nbsp;is used in the general operation of the business but is not material to the Company or any of the Company Subsidiaries, and (ii)&nbsp;has not been modified or customized
for the Company or any of the Company Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Government Contract</U>&#148; means any prime contract, subcontract, basic
ordering agreement, letter contract, purchase order, delivery order, change order, arrangement or other commitment of any kind between the Company or any Company Subsidiary, on the one hand, and any Governmental Entity or prime contractor or
subcontractor to a Governmental Entity, on the other hand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Government Official</U>&#148; means (a)&nbsp;any elected or appointed
government official, officer, employee or Person acting in an official or public capacity on behalf of a Governmental Entity, (b)&nbsp;any official or employee of a quasi-public or <FONT STYLE="white-space:nowrap">non-governmental</FONT>
international organization, (c)&nbsp;any employee or other Person acting for or on behalf of any entity that is wholly or partially government owned or controlled by a Governmental Entity, (d)&nbsp;any Person exercising legislative, administrative,
judicial, executive, or regulatory functions for or pertaining to a Governmental Entity (including any independent regulator), (e) any political party official, officer, employee, or other Person acting for or on behalf of a political party and
(f)&nbsp;any candidate for public office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Government Programs</U>&#148; means any foreign, federal, or state healthcare program,
including the U.S. federal health program as defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(f),</FONT> including Title XVIII (&#147;<U>Medicare</U>&#148;) and Title XIX </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#147;<U>Medicaid</U>&#148;) of the Social Security Act, CHAMPUS, TRICARE and any other federal health care program, as defined in 42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(f),</FONT> any health insurance program for the benefit of federal employees, including those under chapter 89 of title 5 or State health care program, as defined in 42 U.S.C. &#167; 1320a-7(h), or successor
programs to any of the above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authorization</U>&#148; shall mean any franchise, grants, easement, variance,
exception, consent, certificate, approval, clearance, permission, permit, license, registration, qualification or authorization granted by any Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Entity</U>&#148; shall mean any federal, state, local or foreign governmental authority, any transnational governmental
organization or any court of competent jurisdiction, arbitral, administrative agency or commission or other governmental authority or instrumentality, domestic or foreign, or Notified Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Harmful Code</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.9(h)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HCT/Ps</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Healthcare Regulatory Authority</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Healthcare Regulatory Authorizations</U>&#148; means any Governmental Authorizations required by the Company or any of the Company
Subsidiaries to conduct its respective business under applicable Healthcare Laws, including without limitation, any such Governmental Authorizations required for the testing, manufacturing, marketing, promotion, sale, distribution, packaging,
storage, export or import, of any Company Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HIPAA</U>&#148; means the Health Insurance Portability and Accountability Act
of 1996 and all regulations promulgated thereunder, including the Privacy Standards (45 C.F.R. Parts 160 and 164), the Electronic Transactions Standards (45 C.F.R. Parts 160 and 162), and the Security Standards (45 C.F.R. Parts 160, 162 and 164), as
amended by the HITECH Act, the final HIPAA/HITECH Omnibus Rules published by the U.S. Department of Health and Human Services on January&nbsp;25, 2013, and as otherwise may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HITECH Act</U>&#148; means the Health Information Technology for Economic and Clinical Health Act provisions of the American Recovery
and Reinvestment Act of 2009, Pub. Law <FONT STYLE="white-space:nowrap">No.&nbsp;111-5</FONT> and its implementing regulations, including 42 C.F.R. &#167;&#167; 412, 413, 422 and 495, as amended by the HIPAA Omnibus Rule, issued on January&nbsp;25,
2013, effective as of March&nbsp;26, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; shall mean the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">In-Bound</FONT> Licenses</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.9(h)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indemnified Parties</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.13(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Initial Surviving Corporation</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; shall mean any and all past, present and future common
law or statutory rights anywhere in the world arising under or associated with: (i)&nbsp;patents, patent applications, statutory invention registrations, registered designs, industrial designs and design patents, and similar or equivalent rights in
inventions and designs, and all intellectual property rights therein provided by international treaties and conventions, including all divisions, continuations,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> provisionals and extensions thereof (&#147;<U>Patents</U>&#148;);
(ii) trademarks, service marks, trade dress, trade names, company names, logos and other designations of origin, together with any registrations, applications for registration, renewals, and extensions thereof, and the goodwill associated with any
of the foregoing (&#147;<U>Marks</U>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii) URL and domain name registrations, uniform resource locators, and Internet Protocol addresses, social media handles and other names, identifiers and locators associated with Internet
addresses, sites and services; (iv)&nbsp;copyrights and any other equivalent rights in works of authorship (including intellectual property rights in Software as a work of authorship), whether registered or unregistered, moral rights, and any other
rights of authors, and any registrations and applications for registration thereof (&#147;<U>Copyrights</U>&#148;); (v) mask work rights (as defined in the Semiconductor Chip Protection Act, 17 U.S.C.
<FONT STYLE="white-space:nowrap">&#167;&nbsp;&#167;&nbsp;901-914)</FONT> and any other intellectual property right in semiconductor topology or mask works, and any registration therefore (&#147;<U>Mask Work Rights</U>&#148;) (vi) trade secrets and
industrial secret rights, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and confidential and proprietary data and business or technical information, including any ideas, formulas, compositions, inventions (whether patentable or not
and however documented), processes, techniques, specifications, business plans, proposals, designs, technical data, invention disclosures, customer data, financial information, pricing and cost information, bills of material or other similar
information, in each case, excluding any of the foregoing that comprise or are protected by issued Patents or published Patent applications (&#147;<U>Trade Secrets</U>&#148;); (vii) all claims and causes of actions arising out of or related to any
past, current or future infringement or misappropriation of any of the foregoing; and (viii)&nbsp;other similar or equivalent intellectual property rights anywhere in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intended Tax Treatment</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.12(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>IRS</U>&#148; shall mean the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Joint Proxy Statement/Prospectus</U>&#148; shall mean the joint proxy statement/prospectus to be sent to the Company&#146;s
stockholders in connection with the Company Stockholder Meeting and to Parent&#146;s stockholders in connection with the Parent Stockholder Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>knowledge of the Company</U>&#148; or &#147;<U>the Company&#146;s knowledge</U>&#148; shall mean the current actual knowledge, after
inquiry of direct reports reasonably likely to have knowledge of the applicable subject matter, of the individuals listed in Part &#147;Definitions&#148; of the Company Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>knowledge of Parent</U>&#148; shall mean the current actual knowledge, after inquiry of director reports reasonably likely to have
knowledge of the applicable subject matter, of the individuals listed in Part &#147;Definitions&#148; of the Parent Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Legal Proceeding</U>&#148; shall mean any legal or administrative proceeding (including before the United States Patent and Trademark
Office or the Patent Trial and Appeal Board), lawsuit, arbitration, mediation, court action, or other proceeding before any court or public or private body or tribunal or other Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Legal Requirement</U>&#148; shall mean any law (including common law), statute, ordinance, rule regulation, judgment, order,
injunction, decision, decree, guidance, ruling, administrative or judicial doctrine, or requirement of any Governmental Entity, including but not limited to the Anti-Corruption Laws as defined herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Letter of Transmittal</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.12(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; shall mean, with respect to any property or asset, any mortgage, lien, pledge, charge, security interest, encumbrance
or limitation on transfer in respect of such property or asset, but excluding, with respect to Intellectual Property, licenses. A Person shall be deemed to own subject to a Lien any property or asset that it has acquired or holds subject to the
interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such property or asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement in the Agreement to the effect that any information, document or other material has been &#147;<U>made available</U>&#148; by
the Company shall mean that such information, document or material was: (a)&nbsp;uploaded to the virtual data room maintained by the Company in connection with the transactions contemplated by the Agreement, (b)&nbsp;publicly filed with the SEC or
(c)&nbsp;otherwise delivered to Parent or its Representatives (with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receipt thereof confirmed by Parent or its Representatives). Any statement in the Agreement to the effect that any information, document or other material has been &#147;<U>made
available</U>&#148; by Parent shall mean that such information, document or material was: (i)&nbsp;uploaded to the virtual data room maintained by Parent in connection with the transactions contemplated by the Agreement (ii)&nbsp;publicly filed with
the SEC or (iii)&nbsp;otherwise delivered to the Company or its Representatives (with receipt thereof confirmed by the Company or its Representatives). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Mailing Date</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.15(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Contract</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Maximum Annual Premium</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.13(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Maximum Cash Amount</U>&#148; shall mean an amount equal to the product of $10.50 multiplied by the aggregate number of shares of
Company Common Stock issued and outstanding as of 5:00 p.m., New York Time on the Election Deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Medical Devices
Directive</U>&#148; shall mean Directive 93/42/EEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Medical Devices Regulation</U>&#148; shall mean Regulation (EU) 2017/45.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Mergers</U>&#148; shall have the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Consideration</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.5(a)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Most Recent Company <FONT STYLE="white-space:nowrap">10-K</FONT></U>&#148; shall mean the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended June&nbsp;30, 2020 (filed with the SEC on September&nbsp;3, 2020). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Most Recent Company Balance Sheet</U>&#148; shall mean the balance sheet of the Company as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Most Recent Parent Balance Sheet</U>&#148; shall mean the balance sheet of Parent as of April&nbsp;3, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Nasdaq</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.7(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>No Election Shares</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.5(a)(ii)(C)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>No Election Value</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.7(b)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Budgeted</FONT> Capital Expenditure</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.1(a)(xiii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement</U>&#148; shall
mean that certain <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, dated as of June&nbsp;2, 2021, by and between the Company and Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-DTC</FONT> Book-Entry Share</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;1.12(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Notified Body</U>&#148; means an independent conformity assessment body designated in
accordance with the Medical Devices Regulation or the Medical Devices Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>OFAC</U>&#148; shall mean the U.S. Department
of Treasury, Office of Foreign Assets Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Option Exchange Ratio</U>&#148; means the quotient (rounded to the 4th decimal
place) obtained by dividing (i)&nbsp;the Average Company Stock Price by (ii)&nbsp;the Average Parent Stock Price (as adjusted as appropriate to reflect any stock splits, stock dividends, combinations, reorganizations, reclassifications or similar
events). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; shall mean any order, decision, judgment, writ, injunction,
stipulation, award, or decree, issued by any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Organizational Documents</U>&#148; shall mean, with respect to
any Entity: (a)&nbsp;if such Entity is a corporation, such Entity&#146;s certificate or articles of incorporation, <FONT STYLE="white-space:nowrap">by-laws</FONT> and similar organizational documents, as amended; (b)&nbsp;if such Entity is a limited
liability company, such Entity&#146;s certificate or articles of formation and operating agreement, as amended; and (c)&nbsp;if such Entity is a limited partnership, such Entity&#146;s certificate or articles of formation and limited partnership
agreement, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Out-Bound</FONT> Licenses</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.9(h)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent</U>&#148; shall have the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Acquisition Proposal</U>&#148; shall mean any offer, indication of interest or proposal (other than an offer or proposal made
or submitted by or on behalf of the Company or any of its Affiliates) contemplating or otherwise relating to any Parent Acquisition Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Acquisition Transaction</U>&#148; shall mean any transaction or series of related transactions (other than the Mergers)
involving: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any merger, consolidation, amalgamation, business combination, joint venture, reorganization or other
similar transaction involving Parent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any transaction (i)&nbsp;in which any Person or &#147;group&#148; (as defined in
the Exchange Act and the rules thereunder) of Persons acquires beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting
power of Parent; or (ii)&nbsp;in which Parent or any Parent Subsidiaries issues securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of Parent
(after giving effect to such transaction); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any sale, exchange, transfer, acquisition or disposition of 20% or more of
the consolidated assets (including equity securities of the Parent Subsidiaries) of Parent and the Parent Subsidiaries, taken as a whole, or of any business or businesses (or the assets of any business or businesses, including equity securities of
any Subsidiaries of Parent) that constitute or account for 20% or more of the consolidated net revenues or net income of Parent and the Parent Subsidiaries, taken as a whole; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any tender offer or exchange offer that if consummated would result in any Person or &#147;group&#148; (as defined in the
Exchange Act and the rules thereunder) of Persons acquiring beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for such securities) representing 20% or more of the outstanding voting power of
Parent; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any combination of the foregoing types of transaction if the sum of the percentage of the voting power of
Parent or of the consolidated net revenues, net income or assets of Parent and the Parent Subsidiaries, taken as a whole, involved is 20% or more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Board</U>&#148; shall mean the board of directors of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Board Recommendation</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Capitalization Date</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.3(a)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Change in Recommendation</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.6(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Class</U><U></U><U>&nbsp;A Common Stock</U>&#148; shall mean the Class&nbsp;A
common stock, par value $0.01 per share, of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Class</U><U></U><U>&nbsp;B Common Stock</U>&#148; shall have the meaning set
forth in <U>Section</U><U></U><U>&nbsp;3.3(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Common Stock</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.3(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Commonly Controlled Entity</U>&#148; shall mean any entity, trade or business
that is a member of a group described in Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code or Section&nbsp;4001(b)(1) of ERISA that includes the entity, trade or business that is a member of the same &#147;controlled group&#148; as Parent,
pursuant to Section&nbsp;4001(a)(14). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Disclosure Schedule</U>&#148; shall have the meaning set forth in the introductory
paragraph of <U>Section</U><U></U><U>&nbsp;III</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Equity Agreements</U>&#148; shall mean the agreements pursuant to
which outstanding awards are granted under the Parent Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Equity Plan</U>&#148; shall mean the 2004 Equity
Incentive Plan of Parent, as amended and restated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent ESPP</U>&#148; shall mean Parent&#146;s 2021
Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Fairness Opinion</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.17</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Financial Advisor</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.20</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Intervening Event</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.6(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent IP</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.18(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Material Adverse Effect</U>&#148; shall mean any Effect that, individually or
in the aggregate with any one or more other Effects, (i)&nbsp;results in a material adverse effect on the business, condition (financial or otherwise) or results of operations of Parent and the Parent Subsidiaries, taken as a whole or
(ii)&nbsp;prevents, materially impairs, materially impedes or materially delays the consummation of the Mergers and the other transactions contemplated hereby on a timely basis and in any event on or before the End Date; <I>provided</I>,
<I>however</I>, that with respect to clause (i)&nbsp;only, no Effect to the extent resulting or arising from any of the following, shall, to such extent, be deemed to constitute, or be taken into account in determining the occurrence of, a Parent
Material Adverse Effect: (A)&nbsp;general economic, political, business, financial or market conditions affecting the industry in which Parent and the Parent Subsidiaries operate; (B)&nbsp;geopolitical conditions, including trade and national
security policies and export controls and executive orders relating thereto, any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including
cyber-terrorism); (C) any pandemic (including the continuation or worsening of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic), epidemic, plague, or other outbreak of illness or public health event, hurricane, flood, tornado,
earthquake or other natural disaster or act of God or changes resulting from weather conditions; (D)&nbsp;any failure by Parent or any of the Parent Subsidiaries to meet any internal or external projections or forecasts or any decline in the price
of Parent Class&nbsp;A Common Stock (but excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves constitute or be taken into account in determining whether there has been, or would be, a Parent
Material Adverse Effect); (E) the public announcement or pendency of the Mergers and the other transactions contemplated hereby, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers,
distributors, business partners or employees, (<I>provided</I> that this clause (E)&nbsp;shall not apply to (x)&nbsp;any representation or warranty in <U>Section</U><U></U><U>&nbsp;3.6</U> to the extent that the purpose of such representation or
warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Mergers or (y)&nbsp;any action or omission by Parent, any Parent Subsidiary or their respective Representatives in order
to comply with Parent&#146;s obligations under <U>Section</U><U></U><U>&nbsp;4.1(b)</U>); (F) changes in applicable Legal Requirements (including <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures) or the interpretation thereof;
(G)&nbsp;changes in GAAP or any other applicable accounting standards or the interpretation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof; or (H)&nbsp;any action expressly required to be taken by Parent pursuant to the terms of this Agreement or at the express written direction or consent of the Company; (I)&nbsp;any
claims, suits, actions or Legal Proceedings arising from allegations of breach of fiduciary duty or violation of Law or otherwise relating to this Agreement or the transactions contemplated by this Agreement; or (J)&nbsp;any breach, violation or <FONT
STYLE="white-space:nowrap">non-performance</FONT> of any provision of this Agreement the Company or any of its Affiliates; <I>provided</I>, <I>further</I>, that any Effect relating to or arising out of or resulting from any change or event referred
to in clause (A), (B), (C), (F) or (G)&nbsp;above may constitute, and be taken into account in determining the occurrence of, a Parent Material Adverse Effect if and only to the extent that such change or event has a disproportionate impact on
Parent and the Parent Subsidiaries as compared to other participants that operate in the industry in which Parent and the Parent Subsidiaries operate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Options</U>&#148; shall mean options to purchase shares of Parent Class&nbsp;A Common Stock from Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Permits</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.9(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Permitted Encumbrances</U>&#148; shall mean: (a)&nbsp;Liens for Taxes or governmental assessments, charges or claims of
payment not yet due and payable or which are being contested in good faith by appropriate proceedings; (b)&nbsp;vendors&#146;, mechanics&#146;, materialmen&#146;s, carriers&#146;, workers&#146;, construction and other similar Liens arising or
incurred in the ordinary course of business or with respect to liabilities that are not yet due and payable or, if due, are not delinquent or are being contested in good faith by appropriate proceedings; (c)&nbsp;Liens, encumbrances or imperfections
of title relating to liabilities for which appropriate reserves have been established and are reflected in the Most Recent Parent Balance Sheet or imposed or promulgated by applicable Legal Requirements, including zoning, entitlement, building
codes, or other Legal Requirements with respect to land use; (d)&nbsp;Liens, pledges or encumbrances arising from or otherwise relating to transfer restrictions under the securities laws of any jurisdiction;
<FONT STYLE="white-space:nowrap">(e)&nbsp;non-exclusive</FONT> licenses of Intellectual Property granted in the ordinary course of business; (f)&nbsp;Liens, encumbrances or imperfections of title which do not and would not reasonably be expected to,
individually or in the aggregate, materially impair the use of the subject property as used by Parent and the Parent Subsidiaries; and (g)&nbsp;Liens arising under any Parent indentures or existing credit facility of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Plan</U>&#148; shall mean each &#147;employee benefit plan&#148; (within the meaning of Section&nbsp;3(3) of ERISA) and each
other employment, bonus, deferred compensation, equity-based, pension, severance, change in control, employee loan, fringe benefit, or other employee benefit plan, policy, agreement, program or arrangement, which Parent or any Parent Subsidiary
maintains for the benefit of its employees or former employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Products</U>&#148; shall mean any and all products and
services that are or have been since January&nbsp;1, 2019 tested, marketed, offered, sold, licensed, provided, manufactured, packaged, distributed or supported by the Parent or any Parent Subsidiary, including any and all products and services
currently under development by the Parent or any Parent Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Registered IP</U>&#148; shall have the meaning set
forth in <U>Section</U><U></U><U>&nbsp;3.18(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Representation Letter</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.12(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent RSUs</U>&#148; shall mean restricted stock units representing the right to
vest in and be issued shares of Parent Class&nbsp;A Common Stock by Parent that are subject to vesting restrictions based on continuing service or based on performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent SEC Documents</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.7(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Share Issuance</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Stockholder Meeting</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.6(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Subsidiary</U>&#148; shall mean any direct or indirect Subsidiary of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Superior Proposal</U>&#148; shall mean any <I>bona fide</I>, unsolicited
written Parent Acquisition Proposal made after the date of this Agreement that: (a)&nbsp;if consummated, would result in any Person or &#147;group&#148; (as defined in the Exchange Act and the rules thereunder) of Persons (other than the Company)
directly or indirectly becoming the beneficial owner of (i)&nbsp;any business or businesses that constitute or account for 50% or more of the net revenues, net income or assets of Parent, or (ii) 50% or more of the outstanding total voting power of
the equity securities of the Parent; and (b)&nbsp;the Parent Board determines in good faith, after consultation with Parent&#146;s outside legal counsel and its financial advisor, is reasonably capable of being consummated on the terms proposed and
which, taking into account such factors as the Parent Board reasonably considers in good faith to be appropriate and relevant, including the financial, legal, timing, likelihood of consummation, confidentiality, regulatory, financing and other
aspects of such Parent Acquisition Proposal would be more favorable to the holders of shares of Parent Common Stock from a financial point of view than the transactions contemplated by this Agreement (after giving effect to any revisions to the
terms of the Agreement that if accepted by the Company would be legally binding on the Company in response to such Parent Acquisition Proposal pursuant <U>Section</U><U></U><U>&nbsp;4.6</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Superior Proposal Notice</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.6(c)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Top Customer</U>&#148; shall mean a top ten customer of the Parent and the Parent Subsidiaries, taken as a whole, based on
revenues during the 12 months ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Top Distributor</U>&#148; shall mean a top five distributor of
the Parent and the Parent Subsidiaries, taken as a whole, based on revenues during the 12 months ended March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Top Supplier</U>&#148; shall mean a top five supplier of inventory or manufacturing services to the Parent and the Parent
Subsidiaries, taken as a whole, based on expenditures during the 12 months ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Payoff Letters</U>&#148;
shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.19</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; shall mean any individual or
Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Personal Data</U>&#148; means any information that relates to, identifies, could reasonably be used to identify, or is
otherwise identifiable with an individual, including any information relating to an identified or identifiable natural Person (an identifiable natural Person is one who can be identified directly or indirectly, in particular by reference to an
identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person, and any
information that is defined as &#147;personal data,&#148; &#147;personally identifiable information,&#148; &#147;individually identifiable health information,&#148; &#147;Protected Health Information&#148; or &#147;personal information&#148; under
any applicable Data Protection Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prohibited Person</U>&#148; shall mean any Person that is the target of Sanctions Laws,
including (a)&nbsp;a Person that has been determined by a competent authority to be the subject of a prohibition on such conduct of any law, regulation, rule or executive order administered by OFAC; (b)&nbsp;the government, including any political
subdivision, agency or instrumentality thereof, of any country against which the United States maintains comprehensive economic sanctions or embargoes (currently Iran, Syria, Cuba, North Korea, and the Crimea region of Ukraine); (c) any Person that
acts on behalf of or is owned or controlled by a government of a country against which the United States maintains comprehensive economic sanctions or embargoes; (d)&nbsp;any Person organized or resident in a country or territory subject to
comprehensive sanctions; (e)&nbsp;any Person that has been identified on the OFAC Specially Designated Nationals and Blocked Persons List (Appendix A to 31 C.F.R. Ch. V), as amended from time to time, or 50% or more of which is owned, directly or
indirectly, by any such Person or Persons, or, where relevant under applicable Sanctions Laws, controlled by any such Person or Persons or acting for or on behalf of such Person or Persons; or (f)&nbsp;any Person that has been designated on any
similar list or Order published by a Governmental Entity in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Protected Health Information</U>&#148; means individually identifiable health
information transmitted or maintained by a covered entity or its business associates in any form or medium as defined at 45 C.F.R. &#167; 160.103. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registered IP</U>&#148; shall mean all U.S., international or foreign (a)&nbsp;issued Patents and Patent applications,
(b)&nbsp;registered Marks and applications to register Marks, (c)&nbsp;registered Copyrights and applications for Copyright registration, (d)&nbsp;registered Mask Work Rights and applications to register Mask Work Rights, (e)&nbsp;domain name
registrations and (f)&nbsp;all other Intellectual Property, in each case of (a)&nbsp;through (f) that are registered with, issued by or applied for by or with any Governmental Entity (or, in the case of domain name registrations, other public or
quasi-public legal authorities such as domain name registrars). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Relevant Legal Restraint</U>&#148; shall have the meaning set
forth in <U>Section</U><U></U><U>&nbsp;5.1(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representation Letters</U>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.12(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representatives</U>&#148; shall mean, with respect to a Person, all of the officers,
directors, employees, consultants, legal representatives, agents, advisors, auditors, investment bankers, Affiliates and other representatives of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Company Stockholder Vote</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Information</U>&#148; means the financial statements regarding the Company and the Company Subsidiaries that are necessary
to satisfy the condition set forth in Paragraph 5 of Exhibit C (Conditions Annex) to the Debt Commitment Letter as in effect on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Parent Stockholder Vote</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctions Laws</U>&#148; shall mean applicable economic or financial sanctions or trade embargoes imposed, administered, or enforced
by relevant Governmental Entities, including those administered by OFAC or the U.S. Department of State, the European Union or its Member States, or Her Majesty&#146;s Treasury of the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; shall mean the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; shall mean the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shortfall Amount</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.7(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Software</U>&#148; shall mean any computer software, programs and databases in any applicable form, including object code, source
code, firmware and embedded versions thereof tools, assemblers, applets, compilers, application programming interfaces, developers kits, utilities, graphical user interfaces, menus, images, icons, and forms, and all versions, updates, corrections,
enhancements and modifications thereof, and all related documentation, developer notes, comments and annotations related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stock Election Consideration</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.5(a)(ii)(B)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stock Election Shares</U>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;1.5(a)(ii)(B)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Entity shall be deemed to be a &#147;<U>Subsidiary</U>&#148; of another Person if such Person directly or indirectly owns, beneficially or
of record: (a)&nbsp;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity&#146;s board of directors or comparable governing body; or
(b)&nbsp;at least 50% of the outstanding voting equity interests issued by such Entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Opinion Counsel</U>&#148;<B> </B>means Jones Day (or other nationally
recognized tax counsel reasonably acceptable to the Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Returns</U>&#148; shall mean any and all returns, reports,
elections, claims for refund, estimated Tax filings, declarations, certificates or other documents filed or required to be filed with any Governmental Entity with respect to Taxes, including any schedules or attachments thereto, and any amendments
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; shall mean any and all U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
taxes, assessments, levies, duties, tariffs, imposts and other similar charges and fees imposed by any Governmental Entity, including, without limitation, any income, franchise, windfall or other profits, gross receipts, premiums, property, sales,
use, net worth, capital stock, payroll, employment, social security, workers&#146; compensation, unemployment compensation, excise, withholding, ad valorem, stamp, transfer, value-added, and license, registration and documentation fees, severance,
occupation, environmental, disability, real property, personal property, registration, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum, or estimated tax, and including any interest, penalty, additions to tax and any additional
amounts imposed with respect thereto, whether disputed or not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Termination Fee</U>&#148; shall mean an amount in cash equal to
$20,661,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Top Customer</U>&#148; shall mean a top ten customer of the Company and the Company Subsidiaries, taken as a whole,
based on revenues during the 12 months ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Top Distributor</U>&#148; shall mean a top five distributor of
the Company and the Company Subsidiaries, taken as a whole, based on revenues during the 12 months ended March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Top Supplier</U>&#148; shall mean a top five supplier of inventory or manufacturing services to the Company and the Company
Subsidiaries, taken as a whole, based on expenditures during the 12 months ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148;
shall mean a day on which shares of Parent Class&nbsp;A Common Stock are traded on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; shall
mean the regulations prescribed under the Code (including any temporary regulations, amended or successor provisions with respect to such regulations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Willful Breach</U>&#148; means a breach that is the result of a willful or intentional act or failure to act where the breaching
party knows, or would reasonably be expected to have known, that such act or failure to act is, or would reasonably be expected to result in, a breach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc180330_41"></A>Annex B </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g180330g20u43.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">767 Fifth Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">New York, NY 10153</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">T&nbsp;&nbsp;&nbsp;&nbsp;212.287.3200</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">F&nbsp;&nbsp;&nbsp;&nbsp;212.287.3201</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">pwpartners.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;29, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of
Directors of Bioventus Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4721 Emperor Boulevard, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, North Carolina 27703 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Board: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We understand that Bioventus Inc. (&#147;<U>Parent</U>&#148;), Oyster Merger Sub I, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent
(&#147;<U>Acquisition Sub I</U>&#148;), Oyster Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Parent (&#147;<U>Acquisition Sub II</U>&#148;), and Misonix, Inc. (the &#147;<U>Company</U>&#148;), a Delaware
corporation, propose to enter into an Agreement and Plan of Merger (the &#147;<U>Merger Agreement</U>&#148;) pursuant to which, among other things, Acquisition Sub I will merge with and into the Company, with the Company as the surviving corporation
(the &#147;<U>First Merger</U>&#148;), and the Company, as the surviving corporation in the First Merger, will merge with and into Acquisition Sub II, with Acquisition Sub II as the surviving limited liability company (the &#147;<U>Second
Merger</U>,&#148; and together with the First Merger, the &#147;<U>Mergers</U>&#148;), and each share of common stock, par value $0.01 per share (the &#147;<U>Company Common Stock</U>&#148;), of the Company issued and outstanding immediately prior
to the effective time of the First Merger, other than Excluded Shares (as defined in the Merger Agreement), will be converted into the right to receive, at the option of the holder thereof and subject to certain limitations and proration procedures
set forth in the Merger Agreement (as to which we express no opinion), (i) $28.00 in cash (the &#147;<U>Cash Election Consideration</U>,&#148;) or (ii) 1.6839 shares of Class&nbsp;A Common Stock of Parent (the &#147;<U>Parent
Class</U><U></U><U>&nbsp;A Common Stock</U>&#148;) (such number of shares, the &#147;<U>Stock Election Consideration</U>,&#148; and the aggregate consideration described in clauses (i)&nbsp;and (ii), the &#147;<U>Merger Consideration</U>&#148;). The
terms and conditions of the Mergers are more fully set forth in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have requested our opinion as to the fairness, from a financial
point of view, to Parent of the Merger Consideration to be paid by Parent pursuant to the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the opinion set forth herein,
we have, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed certain publicly available financial statements and other publicly available business and financial
information with respect to the Company and Parent, including equity research analyst reports; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed certain publicly available financial forecasts relating to the business and financial prospects of the
Company, derived from a consensus of selected equity research analysts that were identified by the Company&#146;s management and discussed with us by the Company for use in our analysis, as adjusted by Parent management, and which forecasts were
extrapolated by the management of Parent for certain fiscal years (the &#147;<U>Adjusted and Extrapolated Company Street Forecasts</U>&#148;) and approved for our use by Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed certain publicly available financial forecasts relating to the business and financial prospects of
Parent, derived from a consensus of selected equity research analysts that were identified by Parent&#146;s management, as adjusted by the management of Parent (the &#147;<U>Adjusted Parent Street Forecasts</U>&#148;), and approved for our use by
Parent; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed certain internal financial statements, analyses and/or other financial and operating data relating to
the business of the Company and Parent, prepared by the management of the Company and the management of Parent, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">discussed the past and current business, operations, financial condition and prospects of the Company with
representatives of the Company and Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">discussed the past and current business, operations, financial condition and prospects of Parent with
representatives of Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">discussed with members of the senior managements of the Company and Parent their assessment of the strategic
rationale for, and the potential benefits of, the Mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed certain estimates as to the amount and timing of certain cost savings anticipated by the management of
Parent to result from the consummation of the Mergers (the &#147;<U>Cost Savings</U>&#148;), as prepared by the management of Parent and approved for our use by Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">compared the financial performance of the Company and Parent with that of certain publicly-traded companies
which we believe to be generally relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">compared the financial terms of the Mergers with the publicly available financial terms of certain other
transactions which we believe to be generally relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed the historical trading prices for the Company Common Stock and the Parent Class&nbsp;A Common Stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">participated in discussions among representatives of the Company and Parent and their respective advisors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reviewed a draft of the Merger Agreement dated July&nbsp;28, 2021 (the &#147;<U>Draft Merger
Agreement</U>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conducted such other financial studies, analyses and investigations, and considered such other factors, as we
have deemed appropriate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of our opinion, we have assumed and relied upon, without independent verification, the accuracy
and completeness of the financial and other information supplied or otherwise made available to us (including information that is available from generally recognized public sources) for purposes of this opinion and have further relied upon the
assurances of the management of Parent that such information does not contain any material omissions or misstatements of material fact. At your direction, we have relied on the Adjusted and Extrapolated Company Street Forecasts, the Cost Savings and
the Adjusted Parent Street Forecasts. With respect to the Adjusted and Extrapolated Company Street Forecasts and the Cost Savings, we have assumed, with your consent, that they have been reasonably prepared on bases reflecting the best currently
available estimates and good faith judgments of the management of Parent as to the matters covered thereby and we express no view as to the assumptions on which they are based. In that regard, we have been advised by you, and have assumed, with your
consent, that the Adjusted and Extrapolated Company Street Forecasts and Cost Savings are a reasonable basis upon which to evaluate the future financial performance of the Company and we have used the Adjusted and Extrapolated Company Street
Forecasts and Cost Savings in our analysis. We have further assumed, with your consent, that the Adjusted Parent Street Forecasts represent the best currently available estimates as to the matters covered thereby. In arriving at our opinion, we have
not made or been provided with any independent valuation or appraisal of the assets or liabilities (including any contingent, derivative or <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> assets and liabilities) of the Company or Parent,
nor any of their respective subsidiaries. We have not assumed any obligation to conduct, nor have we conducted, any physical inspection of the properties or facilities of the Company or Parent. In addition, we have not evaluated the solvency of any
party to the Merger Agreement, or the impact of the Mergers thereon, including under any applicable laws relating to bankruptcy, insolvency or similar matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed that the final executed Merger Agreement will not differ from the Draft Merger Agreement reviewed by us in any respect material to our
analysis, and that the Mergers will be consummated in accordance with the terms set forth in the Merger Agreement, without modification, waiver or delay in any respect material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to our analysis. In addition, we have assumed that in connection with the receipt of all the necessary approvals for the Mergers, no delays, limitations, conditions or restrictions will be
imposed that could have an adverse effect on the Company, Parent or the contemplated benefits of the Mergers, in each case, in any way material to our analysis. We have relied as to all legal matters relevant to rendering our opinion upon the advice
of counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion addresses only the fairness from a financial point of view, as of the date hereof, of the Merger Consideration to be paid by
Parent pursuant to the Merger Agreement. We have not been asked to, nor do we, offer any opinion as to any other term of the Merger Agreement or any other related document, the form, structure or financing of the Mergers or the likely timeframe in
which the Mergers will be consummated. Nor do we express any opinion with respect to the allocation of the Cash Election Consideration and Stock Election Consideration among the holders of Company Common Stock. In addition, we express no opinion as
to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any party to the Mergers, or any class of such persons, relative to the Merger Consideration or otherwise. We express no opinion as
to the fairness of the Mergers to the holders of any other class of securities, creditors or other constituencies of Parent or the Company or as to the underlying decision by any person to engage in the Mergers or as to the relative merits of the
Mergers compared to any alternative transactions or business strategies. Nor do we express any opinion as to any tax or other consequences that may result from the transactions contemplated by the Merger Agreement or any related document, nor does
our opinion address any legal, tax, regulatory or accounting matters, as to which we understand Parent has received such advice as it deems necessary from qualified professionals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as financial advisor to Parent with respect to the Mergers and will receive a fee for our services, a portion of which is payable upon the
rendering of this opinion (or would have become payable if we had determined that we were not able to render this opinion) and a significant portion of which is contingent upon the consummation of the Mergers.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>In addition, Parent has agreed to reimburse us for certain expenses and indemnify us for certain liabilities that may arise out of our engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except in connection with our engagement as financial advisory to Parent in connection with the Mergers, during the two year period prior to the date hereof,
no material relationship existed between Perella Weinberg Partners LP and its affiliates, on the one hand, and Parent, the Company or any of their respective affiliates, on the other hand, pursuant to which we or our affiliates have received or
anticipate receiving compensation. However, Perella Weinberg Partners LP and its affiliates in the future may provide investment banking and other financial services to Parent and/or the Company and their respective affiliates and in the future may
receive compensation for the rendering of these services. In the ordinary course of our business activities, Perella Weinberg Partners LP or its affiliates may at any time hold long or short positions, and may trade or otherwise effect transactions,
for our own account or the accounts of clients, in debt, equity or other securities (or related derivative securities) or financial instruments (including bank loans or other obligations) of Parent, the Company or their respective affiliates. The
issuance of this opinion was approved by a fairness opinion committee of Perella Weinberg Partners LP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is for the information and assistance
of the Board of Directors of Parent in connection with, and for the purposes of its evaluation of, the Mergers. This opinion is not intended to be and does not constitute a recommendation to any holder of Parent Class&nbsp;A Common Stock or any
other person as to how such person should vote or otherwise act with respect to the proposed Mergers or any other matter. We express no opinion as to what the value of the Parent Class&nbsp;A Common Stock actually will be when issued or the prices
at which the Company Common Stock or Parent Class&nbsp;A Common Stock will trade at any time. Our opinion is necessarily based on financial, economic, market and other conditions as in effect on, and the information made available to us as of, the
date hereof. Subsequent developments may affect this opinion and the assumptions used in preparing it, and we do not have any obligation to update, revise, or reaffirm this opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein,
we are of the opinion that, on the date hereof, the Merger Consideration to be paid by Parent pursuant to the Merger Agreement is fair, from a financial point of view, to Parent. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/ PERELLA WEINBERG PARTNERS LP</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc180330_42"></A>Annex C </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g11i11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;29, 2021 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1938 New Highway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Farmingdale, NY 11735 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Board of Directors: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have requested our opinion as to the fairness, from a financial point of view, to the holders of common stock, par value $0.01 per share (the &#147;Company
Common Stock&#148;), of Misonix, Inc. (the &#147;Company&#148;) of the consideration to be paid to such holders in the proposed merger (the &#147;Transaction&#148;) of the Company with a wholly-owned subsidiary of Bioventus Inc. (the
&#147;Acquiror&#148;). Pursuant to the Agreement and Plan of Merger, dated as of July&nbsp;29, 2021 (the &#147;Agreement&#148;), among the Company, the Acquiror and the Acquiror&#146;s subsidiaries, Acquisition Sub I (as defined in the Agreement)
and Acquisition Sub II (as defined in the Agreement), the Company will become a wholly-owned subsidiary of the Acquiror, and each outstanding share of Company Common Stock (other than shares of Company Common Stock held in treasury or held directly
by any Company subsidiary, the Acquiror or Acquisition Sub I, and the Dissenting Shares (as defined in the Agreement)) will be converted into the right to receive, at the election of the holder of such shares of Company Common Stock, consideration
per share equal to (i) $28.00 in cash (the &#147;Cash Consideration&#148;) or (ii) 1.6839 shares of the Acquiror&#146;s Class&nbsp;A common stock, par value $0.01 per share (the &#147;Acquiror Common Stock&#148;), per share Company Common Stock (the
&#147;Stock Consideration&#148;, and, together with the Cash Consideration, the &#147;Consideration&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with preparing our opinion, we
have (i)&nbsp;reviewed the Agreement; (iii)&nbsp;reviewed certain publicly available business and financial information concerning the Company and the Acquiror and the industries in which they operate; (iv)&nbsp;compared the proposed financial terms
of the Transaction with the publicly available financial terms of certain transactions involving companies we deemed relevant and the consideration paid for such companies; (v)&nbsp;compared the financial and operating performance of the Company and
the Acquiror with publicly available information concerning certain other companies we deemed relevant and reviewed the current and historical market prices of the Company Common Stock and the Acquiror Common Stock and certain publicly traded
securities of such other companies; (vi)&nbsp;reviewed certain internal financial analyses and forecasts prepared by or at the direction of the managements of the Company and the Acquiror relating to their respective businesses, as well as the
estimated amount and timing of the cost savings and related expenses and synergies expected to result from the Transaction (the &#147;Synergies&#148;); and (vii)&nbsp;performed such other financial studies and analyses and considered such other
information as we deemed appropriate for the purposes of this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have held discussions with certain members of the management of
the Company and the Acquiror with respect to certain aspects of the Transaction, and the past and current business operations of the Company and the Acquiror, the financial condition and future prospects and operations of the Company and the
Acquiror, the effects of the Transaction on the financial condition and future prospects of the Company and the Acquiror, and certain other matters we believed necessary or appropriate to our inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving our opinion, we have relied upon and assumed the accuracy and completeness of all information that was publicly available or was furnished to or
discussed with us by the Company and the Acquiror or otherwise reviewed by or for us. We have not independently verified any such information or its accuracy or completeness and, pursuant to our engagement letter with the Company, we did not assume
any obligation to undertake any such independent verification. We have not conducted or been provided with any valuation or appraisal of any assets or liabilities, nor have we evaluated the solvency of the Company or the Acquiror under any state or
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
federal laws relating to bankruptcy, insolvency or similar matters. In relying on financial analyses and forecasts provided to us or derived therefrom, including the Synergies, we have assumed
that they have been reasonably prepared based on assumptions reflecting the best currently available estimates and judgments by management as to the expected future results of operations and financial condition of the Company and the Acquiror to
which such analyses or forecasts relate. We express no view as to such analyses or forecasts (including the Synergies) or the assumptions on which they were based. We have also assumed that the Transaction and the other transactions contemplated by
the Agreement will be consummated as described in the Agreement. We have also assumed that the representations and warranties made by the Company, the Acquiror and the Acquisition Subs (as defined in the Agreement) in the Agreement and the related
agreements are and will be true and correct in all respects material to our analysis. We are not legal, regulatory or tax experts and have relied on the assessments made by advisors to the Company with respect to such issues. We have further assumed
that all material governmental, regulatory or other consents and approvals necessary for the consummation of the Transaction will be obtained without any adverse effect on the Company or the Acquiror or on the contemplated benefits of the
Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is necessarily based on economic, market and other conditions as in effect on, and the information made available to us as of,
the date hereof. It should be understood that subsequent developments may affect this opinion and that we do not have any obligation to update, revise, or reaffirm this opinion. Our opinion is limited to the fairness, from a financial point of view,
of the Consideration to be paid to the holders of the Company Common Stock in the proposed Transaction and we express no opinion as to the fairness of any consideration paid in connection with the Transaction to the holders of any other class of
securities, creditors or other constituencies of the Company or as to the underlying decision by the Company to engage in the Transaction. Furthermore, we express no opinion with respect to the amount or nature of any compensation to any officers,
directors, or employees of any party to the Transaction, or any class of such persons relative to the Consideration to be paid to the holders of the Company Common Stock in the Transaction or with respect to the fairness of any such compensation<B>.
</B>We are expressing no opinion herein as to the price at which the Company Common Stock or the Acquiror Common Stock will trade at any future time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have acted as financial advisor to the Company with respect to the proposed Transaction and will receive a fee from the Company for our services, a substantial portion of which will become payable only if the proposed Transaction is consummated. In
addition, the Company has agreed to indemnify us for certain liabilities arising out of our engagement. During the two years preceding the date of this letter, we and our affiliates have had commercial or investment banking relationships with the
Company, the Acquiror and Bioventus LLC, an affiliate of the Acquiror, for which we and such affiliates have received customary compensation. Such services during such period have included acting as financial advisor to the Company in connection
with its acquisition of Solsys Medical in September 2019, joint lead arranger and joint bookrunner on Bioventus LLC&#146;s term loan and revolving line of credit in December 2019 and active bookrunner and stabilization agent on the Acquiror&#146;s
IPO in February 2021<I>. </I>In addition, we and our affiliates hold, on a proprietary basis, less than 1% of the outstanding common stock of each of the Company and the Acquiror. In the ordinary course of our businesses, we and our affiliates may
actively trade the debt and equity securities or financial instruments (including derivatives, bank loans or other obligations) of the Company or the Acquiror for our own account or for the accounts of customers and, accordingly, we may at any time
hold long or short positions in such securities or other financial instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of and subject to the foregoing, it is our opinion as of the
date hereof that the Consideration to be paid to the holders of the Company Common Stock in the proposed Transaction is fair, from a financial point of view, to such holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of this opinion has been approved by a fairness opinion committee of J.P. Morgan Securities LLC. This letter is provided to the Board of
Directors of the Company (in its capacity as such) in connection with and for the purposes of its evaluation of the Transaction. This opinion does not constitute a recommendation to any shareholder of the Company as to how such shareholder should
vote with respect to the Transaction or any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
matter. This opinion may not be disclosed, referred to, or communicated (in whole or in part) to any third party for any purpose whatsoever except with our prior written approval. This opinion
may be reproduced in full in any proxy or information statement mailed to shareholders of the Company but may not otherwise be disclosed publicly in any manner without our prior written approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>J.P. Morgan Securities LLC </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc180330_43"></A>Annex D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 262 OF THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#167; 262 Appraisal rights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand
pursuant to subsection (d)&nbsp;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger or consolidation, who has otherwise complied with subsection (d)&nbsp;of this section and who
has neither voted in favor of the merger or consolidation nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#146;s shares of stock
under the circumstances described in subsections (b)&nbsp;and (c)&nbsp;of this section. As used in this section, the word &#147;stockholder&#148; means a holder of record of stock in a corporation; the words &#147;stock&#148; and &#147;share&#148;
mean and include what is ordinarily meant by those words; and the words &#147;depository receipt&#148; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a
corporation, which stock is deposited with the depository. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appraisal rights shall be available for the shares of any class or series of stock of a constituent corporation
in a merger or consolidation to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263 or &#167; 264 of this
title: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provided, however, that no appraisal rights under this section shall be available for the shares of any class
or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders to act upon the agreement of merger or consolidation (or, in
the case of a merger pursuant to &#167; 251(h), as of immediately prior to the execution of the agreement of merger), were either: (i)&nbsp;listed on a national securities exchange or (ii)&nbsp;held of record by more than 2,000 holders; and further
provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in
&#167; 251(f) of this title. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall be available for
the shares of any class or series of stock of a constituent corporation if the holders thereof are required by the terms of an agreement of merger or consolidation pursuant to &#167;&#167; 251, 252, 254, 255, 256, 257, 258, 263 and 264 of this title
to accept for such stock anything except: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares of stock of the corporation surviving or resulting from such merger or consolidation, or depository
receipts in respect thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or
depository receipts in respect thereof) or depository receipts at the effective date of the merger or consolidation will be either listed on a national securities exchange or held of record by more than 2,000 holders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs
(b)(2)a. and b. of this section; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional
depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253
or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Repealed.] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall
be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation or the sale of all or substantially
all of the assets of the corporation. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d),(e) and (g)&nbsp;of this section, shall apply as nearly as is
practicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appraisal rights shall be perfected as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a proposed merger or consolidation for which appraisal rights are provided under this section is to be
submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice
in accordance with &#167; 255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&nbsp;or (c)&nbsp;of this section that appraisal rights are available for any or all of the shares of the
constituent corporations, and shall include in such notice a copy of this section and, if one of the constituent corporations is a nonstock corporation, a copy of &#167; 114 of this title. Each stockholder electing to demand the appraisal of such
stockholder&#146;s shares shall deliver to the corporation, before the taking of the vote on the merger or consolidation, a written demand for appraisal of such stockholder&#146;s shares; provided that a demand may be delivered to the corporation by
electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and
that the stockholder intends thereby to demand the appraisal of such stockholder&#146;s shares. A proxy or vote against the merger or consolidation shall not constitute such a demand. A stockholder electing to take such action must do so by a
separate written demand as herein provided. Within 10 days after the effective date of such merger or consolidation, the surviving or resulting corporation shall notify each stockholder of each constituent corporation who has complied with this
subsection and has not voted in favor of or consented to the merger or consolidation of the date that the merger or consolidation has become effective; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the merger or consolidation was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253 or &#167; 267 of
this title, then either a constituent corporation before the effective date of the merger or consolidation or the surviving or resulting corporation within 10 days thereafter shall notify each of the holders of any class or series of stock of such
constituent corporation who are entitled to appraisal rights of the approval of the merger or consolidation and that appraisal rights are available for any or all shares of such class or series of stock of such constituent corporation, and shall
include in such notice a copy of this section and, if one of the constituent corporations is a nonstock corporation, a copy of &#167; 114 of this title. Such notice may, and, if given on or after the effective date of the merger or consolidation,
shall, also notify such stockholders of the effective date of the merger or consolidation. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167;
251(h) of this title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice, demand in writing from the surviving or resulting corporation the appraisal of such
holder&#146;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient
if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#146;s shares. If such notice did not notify stockholders of the effective date of the merger
or consolidation, either (i)&nbsp;each such constituent corporation shall send a second notice before the effective date of the merger or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
consolidation notifying each of the holders of any class or series of stock of such constituent corporation that are entitled to appraisal rights of the effective date of the merger or
consolidation or (ii)&nbsp;the surviving or resulting corporation shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following
the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days following the sending of the
first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#146;s shares in accordance with this subsection. An affidavit of the secretary or assistant
secretary or of the transfer agent of the corporation that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the
stockholders entitled to receive either notice, each constituent corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the
effective date of the merger or consolidation, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the
day on which the notice is given. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 120 days after the effective date of the merger or consolidation, the surviving or resulting corporation
or any stockholder who has complied with subsections (a)&nbsp;and (d)&nbsp;of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a
determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger or consolidation, any stockholder who has not commenced an appraisal proceeding or
joined that proceeding as a named party shall have the right to withdraw such stockholder&#146;s demand for appraisal and to accept the terms offered upon the merger or consolidation. Within 120 days after the effective date of the merger or
consolidation, any stockholder who has complied with the requirements of subsections (a)&nbsp;and (d)&nbsp;of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any)
expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the corporation surviving the merger or resulting from the consolidation a statement setting forth the aggregate number of shares not voted in favor
of the merger or consolidation (or, in the case of a merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of,
and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of holders of such shares.
Such statement shall be given to the stockholder within 10 days after such stockholder&#146;s request for such a statement is received by the surviving or resulting corporation or within 10 days after expiration of the period for delivery of demands
for appraisal under subsection (d)&nbsp;of this section hereof, whichever is later. Notwithstanding subsection (a)&nbsp;of this section, a person who is the beneficial owner of shares of such stock held either in a voting trust or by a nominee on
behalf of such person may, in such person&#146;s own name, file a petition or request from the corporation the statement described in this subsection. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the filing of any such petition by a stockholder, service of a copy thereof shall be made upon the
surviving or resulting corporation, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all stockholders who have
demanded payment for their shares and with whom agreements as to the value of their shares have not been reached by the surviving or resulting corporation. If the petition shall be filed by the surviving or resulting corporation, the petition shall
be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving or resulting
corporation and to the stockholders shown on the list at the addresses therein stated. Such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
notice shall also be given by one or more publications at least one week before the day of the hearing, in a newspaper of general circulation published in the City of Wilmington, Delaware or such
publication as the Court deems advisable. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving or resulting corporation. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the hearing on such petition, the Court shall determine the stockholders who have complied with this section
and who have become entitled to appraisal rights. The Court may require the stockholders who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery
for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with such direction, the Court may dismiss the proceedings as to such stockholder. If immediately before the merger or consolidation the shares
of the class or series of stock of the constituent corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise
entitled to appraisal rights unless (1)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&nbsp;the value of the consideration provided in the merger or
consolidation for such total number of shares exceeds $1&nbsp;million or (3)&nbsp;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the Court determines the stockholders entitled to an appraisal, the appraisal proceeding shall be
conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value
arising from the accomplishment or expectation of the merger or consolidation, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant
factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger through the date of payment of the judgment shall be compounded
quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger and the date of payment of the judgment. At any time before
the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&nbsp;the difference,
if any, between the amount so paid and the fair value of the shares as determined by the Court and (2)&nbsp;interest theretofore accrued, unless paid at that time. Upon application by the surviving or resulting corporation or by any stockholder
entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any stockholder whose name appears on the list
filed by the surviving or resulting corporation pursuant to subsection (f)&nbsp;of this section and who has submitted such stockholder&#146;s certificates of stock to the Register in Chancery, if such is required, may participate fully in all
proceedings until it is finally determined that such stockholder is not entitled to appraisal rights under this section. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the
surviving or resulting corporation to the stockholders entitled thereto. Payment shall be so made to each such stockholder, in the case of holders of uncertificated stock forthwith, and the case of holders of shares represented by certificates upon
the surrender to the corporation of the certificates representing such stock. The Court&#146;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving or resulting corporation be a corporation of this
State or of any state. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems
equitable in the circumstances. Upon application of a stockholder, the Court may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable
attorney&#146;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the effective date of the merger or consolidation, no stockholder who has demanded appraisal
rights as provided in subsection (d)&nbsp;of this section shall be entitled to vote such stock for any purpose or to receive payment of dividends or other distributions on the stock (except dividends or other distributions payable to stockholders of
record at a date which is prior to the effective date of the merger or consolidation); provided, however, that if no petition for an appraisal shall be filed within the time provided in subsection (e)&nbsp;of this section, or if such stockholder
shall deliver to the surviving or resulting corporation a written withdrawal of such stockholder&#146;s demand for an appraisal and an acceptance of the merger or consolidation, either within 60 days after the effective date of the merger or
consolidation as provided in subsection (e)&nbsp;of this section or thereafter with the written approval of the corporation, then the right of such stockholder to an appraisal shall cease. Notwithstanding the foregoing, no appraisal proceeding in
the Court of Chancery shall be dismissed as to any stockholder without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just; provided, however that this provision shall not affect the right of any
stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder&#146;s demand for appraisal and to accept the terms offered upon the merger or consolidation within 60 days after the
effective date of the merger or consolidation, as set forth in subsection (e)&nbsp;of this section. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of the surviving or resulting corporation to which the shares of such objecting stockholders would
have been converted had they assented to the merger or consolidation shall have the status of authorized and unissued shares of the surviving or resulting corporation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330snap3.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">BIOVENTUS INC. 4721 EMPEROR BOULEVARD, SUITE 400 DURHAM, NORTH CAROLINA 27703 (919) 474-6700 VOTE BY INTERNET Before The Meeting - Go to
www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information. Transmit your voting instructions by 11:59 p.m. Eastern Time on October 25, 2021. Have your proxy card in hand when you access the
web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/BVS2021SM You may attend the meeting via the Internet and vote during the
meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions. Transmit your voting instructions
by 11:59 p.m. Eastern Time on October 25, 2021. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to
Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Proxies submitted by mail must be received by the close of business on October 25, 2021. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: D59612-TBD KEEP THIS PORTION
FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY BIOVENTUS INC. The Board of Directors recommends you vote FOR the following proposals: 1. To approve the issuance of shares of Bioventus class
A common stock to the stockholders of Misonix, Inc., which is referred to as &#147;Misonix,&#148; in connection with the mergers contemplated by the Agreement and Plan of Merger, dated July 29, 2021, as it may be amended from time to time, which is
referred to as the &#147;merger agreement,&#148; by and among Bioventus, Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus and Misonix, which issuance is referred to
as the &#147;share issuance&#148; and which proposal is referred to as the &#147;Bioventus share issuance proposal&#148;; and For Against Abstain 2. To approve the adjournment of the Bioventus special meeting, if necessary or appropriate, to solicit
additional proxies if there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is
timely provided to Bioventus stockholders, which proposal is referred to as the &#147;Bioventus adjournment proposal.&#148; NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Please sign exactly as your
name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full
corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g25n67.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">4721 Emperor Boulevard, Suite 400 Durham, North Carolina 27703 (919) 474-6700 You are cordially invited to attend our Special Meeting of
the Stockholders to be held at 11:00 a.m., Eastern Time on October 26, 2021. In light of ongoing developments related to the COVID-19 pandemic, the Bioventus special meeting will be held solely in a virtual meeting format via live webcast. You will
be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM. Whether or not you plan to virtually attend the Bioventus special meeting, please vote over the internet or by telephone
or sign and return your proxy card as soon as possible in the envelope provided. Stockholders of record at the close of business on September 22, 2021 and holders of proxies for those stockholders may attend and vote at our Special Meeting.
Important Notice Regarding the Availability of Proxy Materials for the Special Meeting: The Notice and Proxy Statement are available at www.proxyvote.com. D59613-TBD BIOVENTUS INC. Special Meeting of Stockholders October 26, 2021 11:00 a.m. Eastern
Time This proxy is solicited by the Board of Directors The undersigned hereby appoint(s) Kenneth M. Reali and Gregory O. Anglum, or either of them, as proxies, each with the power to appoint (his/her) substitute, and hereby authorize(s) them to
represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of BIOVENTUS INC. that the undersigned is entitled to vote at the Special Meeting of Stockholders to be held at 11:00 a.m., Eastern Time on
October 26, 2021, virtually at www.virtualshareholdermeeting.com/BVS2021SM, and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will
be voted in accordance with the Board of Directors&#146; recommendations. Continued and to be signed on reverse side </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g180330g03a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g03a11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1904&AO=&]S:&]P(#,N,  X0DE-! 0
M    %C2^5H0X0DE-!"4      !                      .$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              R@
M Y4          0                         !              .5
MR@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MR@    !29VAT;&]N9P   Y4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ,H     4F=H=&QO;F<
M  .5     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MSJX_NUL^G8[^36N3ZW];,/.LJQL/.&+B.(%V18RZO0_2=]"ISF-;^9O8Q_\
MA?T:J=&Z9=];>LYW5\][AB47OQZ6CD-8?9CUS/I,:S99>_\ PMMJET_I^'G=
M7S.G9C&TXU/KM996=KFFI^UI-CR]KOT.[=ZC5'DF 8Q)E'C- Q_[YMX\4(V9
M>J4!Q2'Z,;_J_I)^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&B0E)S(T-FB!A[3_Q  = 0$  @(# 0$             !08$!P$" P@)_\0
M3Q$  @$# P(#!0()" <$"P   0(#  01!1(A!C$305$'%")A<3*!%2,U-D)R
MD:'P4F)T=;&RL\$D,S=3<X2T"!9#T24T5(.4E:.UU.'Q_]H # ,!  (1 Q$
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M^ZAM&/NI6,=<^T='DZJD2-6=VM+,*B*69B4. J@$DGR !-=]>!;4G"@DF.,
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M9Z>K9CLXG+!N<A[B4A3.X[@;5C0X*1ALL=$7NHSWAVG$4(.5B0G'U<]W/IG
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M*J!CQCE@N?\ ]\]^:MHHM HVKZJ'HNMZ?6:%2Z_&^4!U2GA!M=KXJ-ZLK4U
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(*4=*4=*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g180330g03b22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g03b22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %%:^4@8X0DE-! 0      &$< 5H  QLE1QP"   "A< < E  "')R,CDS
M-S0Y' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@3WES=&5R("T@4RTT
M(%],5R Y+C S+C(Q7S$R-3<Q.#4Q-BXY7RYD #A"24T$)0      $,?L3Y^\
MG06E$,H[VX?F DLX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              "-   #@0         !
M      $              X$   "-                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     "=4    !    H
M !D   '@   NX   ";D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( !D H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6W8\[%>(]!HC&!_Z#3VA=@3X]MC^Z1/^=.C]''UV?VDZ6_D]0WYM/'LMNO\
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M>8?L1\@\,:JT-(;&$) ]?G/RG3E^>>O31XTU4*S^OL9S[?9^F85C]_ZCS_\
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MTJSOVYS]N<_90<8^W/\ :\Q$W?MB>IB4X_\ <)^7XEZ=3^-A>W D "X;M
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MD*5_51_,.E6TW8"BQPQ6=Y*VF0I!2\JT;<DK:C!( 46ZO7REIY8 *DOL4A#
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M@&GNN^*.>('I#0I]?['NG04'B:DN3YM4GK>-T_J>1VG%)::9Z2;8MA4K@5J
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E:N5R#@(!MQA"W&Y>QRQ11!M@L<N]]'R.TTZ/MC'XL8QXTU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g180330g09d44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g09d44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &-J^8V(X0DE-!"4      !                      .$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0']            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              EP
M L0          0                         !              +$
MEP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MEP    !29VAT;&]N9P   L0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   )<     4F=H=&QO;F<
M  +$     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M'--==FZG?0W&93:_T?3LL?;99ZS[/]++ZIN9?UMSK3^F:+["
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @<    $!0,& 0('" D5 !(3%!$6%PJW(24Q.#EV>/_$ !T!  $% 0$! 0
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MKNI6>:*94:-!'*I0Q):=.W7EM::9$: ;IZDIW,J?5XVR<J.2<D\ Y*G -_\
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MT%__ $W/_M,]+_\ [>ZM_P!O.1?HW\3/]7TO_P!CJ?\ 46^I6M_Y];_DJ_\
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M!7+K?5N30=,Y5:Z/^3=F*G-I_-=?%)HH=_LB;=K7S[,S=V$T9:!%H0J'9EC
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F=T"E"X3!SMB9MR0KP,1Q9;8 .-S'Z])=MYSC'O\ 7/'V_;GK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g180330g09f66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g09f66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+2^8R0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              6
M 3@          0                         !              $X
M6                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M6     !29VAT;&]N9P   3@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   %@     4F=H=&QO;F<
M  $X     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MO^,3KXRQT_J]3'8;_3L-S*T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < &0# 1$
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M&6, ?Z2DDES1C"Z[SSZ:;17<4%F[WAE*=;F\]C,300(&(V\LW!1\Z5=D%C\
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M=JXV"M0PT%F"ABTFD*(MJ*2.:26RR-)+-(\GD>0H.14 CD7=B^N82Q.D2)'
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M==<5W["CY7V2!ZV?GIZ\)\$9X1YL[SY*3]KL]FXCT==TRO\ '4UF0Q'O_/\
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+L_7==UGZ[KNO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g180330g10c33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g10c33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &02^9 0X0DE-! 0      &$< 5H  QLE1QP"   "A< < E  "')R,CDS
M-S0Y' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@3WES=&5R("T@4RTT
M(%],5R Y+C S+C(Q7S$R-3<Q.#4Q-BXY7RYD #A"24T$)0      $,?L3Y^\
MG06E$,H[VX?F DLX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5\            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M     !P  /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &               K    H          !
M  $              *     K                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<    K     %)G:'1L;VYG    H     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    *P    !29VAT;&]N9P   *     #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     #PX    !    H    "L
M  '@  !0H   #O( &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( "L H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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ML8Q,8P^T,\6TUOJQ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@ + "B 0$1 /_$ !T
M  (" @,!              D*!P@%!@,$"P+_Q  L$  !! ,  @(" @$%  ,
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M8;*NO9<84DM:6WW'5N8_H<O"W"'DRF- 0GCIA.>]O<TT3H3;I%XZ\WI:X?\
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L$_'WCU_R5[RZ4I0E*$)2A"<82E*<82E*<?UC"4XQC&,8Q_6,8QZQ^?7Y_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g180330g11g62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g11g62.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &I"^:  X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             $YP
M!RT          0                         !              <M   $
MYP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
MYP    !29VAT;&]N9P  !RT    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !.<     4F=H=&QO;F<
M  <M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M\XUO[B<_\JM_\+N_ZMJPOJ5K9G'_ (K_ -'+>+'_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)5978<'4,C-E<:$:)"92<Y&5F+/3*$)(5%64TO_$ !P! 0 " @,!
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M+QZ\<K&.LX=.G"JB[A=4YE%55#J',8QLYR'(> @\SXGSES!,B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M!$!$!$!$C[RT\E7DS]7W<WW<V00W(^!\I*\QXCSE4Z#\1>EO1-KGV/A@7D/
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MEA5OX?I#URR_Q?1/JDY1:5@(@(@(@(D%>7?COZ-[O?\ ZS[)_9_^"CE_W_\
MA_:(/-?'U&2.3>'K$G4)D0$0$0$0$0$0$2T/(/Q";O\ 1#LKV,FA*\QXCSB:
M7HSS7@(EH]%^+&#^E+G[<600O+[3YF2>?V#R$NX)D38RZ'3R?=D>F:2]AJ*,
M3\QX>LS*G(^/J$RW"DO 1 1(+]&CY#/'GS7FO;2S"!R'@))YGQ/G)T"9$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$Q]](%PHN?-FM::K=8Y *:0:
M:EVY"[C=1[K5<'MRKWVQU)(RU(:VZJ3]CKL;*1-6FSFL+>(E#RL'(RB3%:4B
M'1XYD=%[^_X>_*?1VD$'=E2#D;0 &W KM)))VE6#+MVD$-N!7#'H+HX>DBX;
MZ^TQ;:17=4<A]HI<4^3/$6XZ[E+["ZRC-51.V-VR6WM<WJ'M*D1(L-AP\1./
MI:6NL8J6*LBC6PI0<,1V6(3<%G SS[.9SQ..0P,\3P&>'>0)D9*]Q5+5VK6Q
MWOUF+' +!45:BR%N"*'&T,-S6*A]'8%X7:#><6N)?'/CK)3#6PRVFM/T6@3<
MXQ*L2/EIZ @6;2=?QI'*:3DD8YERO58TCA)-P1B9N59,BN#%Q$P@8 '<,2^M
MSJ$'?ZI8*59DY-6OVB*=PTPG#6"P525.P>IY2<%C[)5)2%LD(ZR3.<)2,)+1
MTBV-U*-G:*F,&P(SPD\IC0Y,]'WQCKW&_D%/QD5N<LE!Z0VO,1YGW+'EE+,L
M/HRAS[UIEW%RN[GL9)-<+H)Y782+-TP>)=FW=MEVZBB1J%0 >'(''$_/\\N&
M)(X\R,\![)4>ENCSXOR^G-32SZ*W69[*:SHDB\,VY;<MV#<SI[5HIRXR@Q8[
MQ;,6:.553Y2:LVZ#5N3L46Z*2)"$*"J0.'8.T^V"S GCVGL'LF1V"A6%;A(>
MO1171(N!BX^&C2/I&1F'I6$6T19,RO)>8=OY>4=8;H)X<2,H^>R+U;LW+UVX
M<JJK'O*3M0B B B B:1=]\.KKYW67UT]&Q->4F$2T6LO"?>OI=;_ '1:G%5Y
MO](?D66;DGT3^=I=T6E9F<Z&CQB;N_K^!=5]>2/5_P 11^0\?49D3D?'W]_F
MFP(,4R3RR[EX7VKSDG/6CH?3M?R=?T$_*)Z)3\E5]6GY1*;%YDE/P7_6V#S@
M=?J4>.+Z+^-TIV__ %;4_P"7TG^\U=-\;4_UA_)94 Y2;4VC_<SOA-R]^@M,
M^L-D#S3]9'R'1'UNN_)I9UGI_P"-I_HOYCW^Z;9(\JG78"("("("("(")!KF
M3XP> 7UWX+]F[DL*M_#](>N67^+Z)]4G*+2L!$!$!$!$@IR[\=_1O?7/LG[%
M'+\0>:^/J,D<F\/6).L3(@(@(@(@(@(@(EH>0?B$W?Z(=E>QDT)7F/$><32]
M&>:\!$M'HOQ8P?TI<_;BR"J\N'>WF9)Y_8OD)=P6D38RZ'3R?=D>F:2]AJ*,
M3\QX>LS*G(^/J$RW"DO 1 1(+]&CY#/'GS7FO;2S"%Y#P'E);F?$^<G0)D0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$2/O+3R5>3/U?=S
M?=S9!#<CX'RDKS'B/.53H/Q%Z6]$VN?8^&!>0\!Y0W,^)\Y=D3(@(@(@(@(F
MD7??#JZ^=UE]=/1L37EOYI:9;QCI:OQ\?*S!"IY9,)647A6#@V5DRJX<2C:*
MFUVN"-\JJD,G%N\J*D(CDJ95#+)P<XX#)[B<?C@^4D8SQ.!W@9_#(\Y9NAQ>
MVH.RV]Y-U2BI15XNJ5H?.([8$T^?0K<E0J=5,V;,7&O(]&55QFKX>X,H_C"Y
MP^[GSV/<W;EZ@,"<A<$Y/I$D>B!_1'=G\/GEB4(&"V0,#(&/C$\?2/?C\?FE
M^!>4F9WH:/&'NWS,JWKR0%'Y#Q]1F2OM^SUS8#&*9)Y9=R\+[5YR3GK1T/IV
MOY.OZ"_E$]$J^2J^K3\HE)NC.B(',S10<.<=CVM)PX.U1/UG+@_9KIMG9R=B
M3)C%ZFZG9&P4F>PP;)RUO:Y:G;3UUVW #97=<U%;$L =UJTWLF%)(Q4^2 OH
M@EEERX4FM5=\C"LQ0?/E@K8P,D<.)P/GE/Q"$^T<O,NV,45N_DEGRJB$LZ66
M;E4002P0B)X9 BYL90QG.3+H8ZCYZO\ HX[+B>CZ^E:+M0+])H5IU6LMU3O5
MTA?;94+*JDV+6W1U2V$&H<394"&)X%<-JT+J4=]]506RUG8BXL5! X!>J7)X
M=XYRJ!S<W9M'^YG?";E[]!:9]8;('FGZR/D.B/K==^32SK/Z0?'T_P!%_,3;
M)'E4Z[ 1 1 1 1 1 1(-<R?&#P"^N_!?LW<EA5OX?I#URR_Q?1/JDY1:5@(@
M(@(@(D%>7?CNZ-[ZYUD_8HY?_P">^(/-?'U&2.3>'K$G4)D0$0$0$0$0$0$2
MT/(/Q";O]$.RO8R:$KS'B/.)I>C/->4[975J:,45*C"0D[(F=$(NUGK$\K31
M)EE)8QW"3UE7;*JLX*N5NF5J9BBF=-557+HAD2I+0<]@!\3CR!DC;GTLX^8
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M(M*P$0$0$0$2"G+OQW]&]]<^R?L4<OQ!YKX^HR1R;P]8DZQ,B B B B B B
MB6AY!^(3=_HAV5[&30E>8\1YQ-+T9YKP$0$0$38RZ'3R?=D>F:2]AJ*,3\QX
M>LS*G(^/J$RW"DO 1 1*1H="J&L*C"4.@P3.LU"N-U6D)!,,KF9QS==TX>JI
M(9<K+KY*=VZ<+F[8L?/9JFZLXQU8PY1SE7!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$C[RT\E7DS]7W<WW<V00W(^!\I*\QXCSE4Z#\
M1>EO1-KGV/A@7D/ >4-S/B?.79$R("("("(")I%WWPZNOG=9?73T;$UY281
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M04Y=^._HW?KGV3]B?E^(/-?'U&2.3>'K$G6)D0$0$0$0$0$0$2T/(/Q";O\
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M":.7QSG27?.>EOLZT]_AZ/:__A#]&_\ [77_ .8UO_N9V_\ D?0?\$_^(_\
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M:?K(^1Z(^MUOY-+.L]/_ !M/]%_,3;)'E4Z[ 1 1 1 1,"O3/>$7'[Z%V/\
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M>WP'JQ'?^4@\Q?\ 8]QK_N_L_P#Q2':__EYT/_VOI/\ \72_^TG)_P @:?\
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MK=*1N1&89QI 2,@9 (.,\1V5LZ"TZ([==<2JLW\&#@9 ^+WS<7'D,ZO 1 1
M1 1+0\@_$)N_T0[*]C)H2O,>(\XFEZ,\UX"("(")L9=#IY/NR/3-)>PU%&)^
M8\/69E3D?'U"2XY\^0_R\^K;NC[OI\<GT#_/?1']I:+_ #%<V])^]:?ZZO\
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M B B B;&70Z>3[LCTS27L-11B?F/#UF94Y'Q]0DN.?/D/\O/JV[H^[Z?')]
M_P ]]$?VEHO\Q7-O2?O6G^NK_.)YKH^BIZ! 1 1 1-UOW.3Y$>ROK,W/[M=2
M#QS]8G\\Z7^S*O\ -:R=.Z;_ 'T_03/]T>_,^,S^CH4XB B B B B B B B
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MO9#;"S,-X:8FVCN3<21JN1QV;O*IHQ'&<IDDA=Q"DE<G:6&TD#."5!8 D8R
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M67UT]&Q->4F$0$0$3,[T-'C#W;YF57UY(?V_Y[W](H_(>/J,R)R/O_I[^$V
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MEHO\Q7-O2?O6G^NK_.)YKH^BIZ! 1 1 1-UOW.3Y$>ROK,W/[M=2#QS]8?\
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M* B B7)TUXX-4^DFC>U$6-?5_NFJ_J]W^&TQW?)6_5O^*D3U#Q\SSSN B B
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MZD'CGZP_YYTG]F5?YK63I_3?[Z?JT_*/?L]9S^CH4X> B B B B B B B B
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MCO'WB;$U!?=*IBFW1QC[$Q3=6K[MU]CG&>K_ -*V'R]6<CUO]7''1=)XX_\
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M D'ISHC!'\Y:+M_[Q7-O2?O6G^NK_.)YL ^C,'N,] R.\0&#W&1D=X^^!$F
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M)]L;V[_P'LG&ST9/1YYSG.>%W&W.<]_.<ZFJ'7G/]>?]&!L7N_$^V-[=_P"
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MNK.,X[V<9[V<!L7N_$^V-[=_X#V3C_%D]'G\RWC;]DM0_# V+W?B?;&]N_\
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MR;C/]D%-_"@W-_3?^^WMCK;/Z9^^/BP.CJ^9-QG^R"F_]W_\5_5W@W-_3?\
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MJ DD*NYGVJ.2KN9FP,#<S-S))NF$K 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MFY2GFK;0"6>.5LKAGE)0V%&"9BN((()!Y@@X(.>P@Y!!&>P\B)4%ZVKL1RC
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M=SN=V=VL=G<^E8[.[,SN68YP3@ #*F(F. B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M6-2G;K:UH]OE_(-X2NQCB7D#-6"9R*.GF6;90S5H4Q%'*F2)DSUGQD2!D@9
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M3T6QE6D=-L7$/--TGS-)\5I)0[XB+Z/DVB2V$Y".<HD=,'!%6[E--1(Y<5F
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MB6/=T[89>=I],J%UB9^6-N77J\@L:YZODK7%1UCTFBUK-*0G5BG;5NA78DJ
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M:JQTF4]@9D05ERN5Z=WI=Y[>!Y=W,@#EGAC)Y@:P9@*U%Q499Q@V 5.WH,2
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M1=:XZ12A7+G#=AQR<Y1<86L3]N,MK$GTAM9]MCDEB6)088Y&07):W()!%H[
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M22"1<GR5)%,J29<G.90^<$)@I<9.H8QSYQCK,<QC9Z\YSG*)] B B B B B
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MN+G9H\\7*I.H"K6J7ETEHB71,S[;%2!&US6X7?@8XY 92ZX(!+("709( 9E
M)(P3F;9T.I&G&IV(U>YU9$OT[ZFH5D!WU&C2UM7IZLD!;KZ*ZG8@([$@20(I
M-2 B6XK&W-=7.POJM6+*A+3L<>W)NV:+&513*:AW!>@7#"+YTP0CW>("Z-7E
M:?&:.EREE63UNEE3+)UE*Y1PN\J=H*KN[,LI=1]J@F;3:+5)IVU;4L-,MM%#
M7>B4%NIH;545G!)W64(]@&."J0V#PE4VJSP-)K%CN=ID4H>L5&!F+/8Y9=-=
M5&+@8"/<2LO(K)-4EW*J3*/:.'*B;=!9<Y$LE1244R4F:>_=YS64%F"C&6(
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M.6Z"('3?1))  Z2T1)/  #45Y)/8!-C2<-3IR> ZZO\ ,)YOWP.MW^JUC_\
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MG@HPVGTE]%\['XGT&;T6^*=B\)6 B B B B B B B B B B B B B B B B
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M@, HR_E"H-JE2AJJ]4Z.UNF>O3ZE6%;):H-52TKH[['>^S05U5U*RT5UVHE
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MNS*J;LVWQ^VZI?;E>=<2<GK'&L5=0L-DM-@JP]RDY*5NL^MIQWL6INZ!'V:
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M[GVN;?')G=2E^DJSB&IEAU]LK6^Y6]8C6>QG"F*Y,6"P5O8U-X_.J:[E<33
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M4WS?6*NLY&&O5H:61G?28/6W4D^D[+%5$M/0>9N#>Q*/%7$ E7&*L\,[6?\
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MS(*FS\=?ZIMHK!*XP.D;)/P6MKI#3D''2U@)36:41*NH T5VUEBUM:'8A*!
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MS<*LWB&5$C')A9J[07:N4NOLT'"*J"I2JIG+A$Y 1 1 1 1 1 1 1 1 1 1
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M3]N!GP$C<Q4(6)52S!<G:&8*&8#D"P1 Q R0J@YVC'=!(@(@(@(@(@(G15B
M@JM782N5B%B:Y7H6,9QT- P,<SB(:)CVR!$VS&,BX]%NQ8,VZ>,$0:M4$D$B
M8P5,A2XZ@))XDY/>9+,SL69BS,<EF)+$]Y)R2?G,[T)$!$!$!$!$!$!$!$!$
F!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g180330g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g11i11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %>2^5@0X0DE-! 0      #T< 5H  QLE1QP"   "-G@< E  "')R,3DU
M-C<V' (% !Q-:6-R;W-O9G0@5V]R9" M(%))1$52($0N9&]C #A"24T$)0
M    $.E2_H6AMCK]7EO<82Y9@^XX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              !8   !D          !
M                  $              9    !8
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   !8     %)G:'1L;VYG   !
MD     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    6     !29VAT;&]N9P   9     #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     "X@
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ /55YW]8/M.#]=^D=+Q\W-;A93:S?4<N\[B^RYCO<;M[
M?:UOT%Z(O/?K;_\ E)Z#_5H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 ! P0" P$     !0(#! 8' 0@) !$2"A,4%18A%R,Q(O_$ !H!  (# 0$
M               " P0% 0;_Q  U$0 #  (! P($! 4$ 04    ! @,$$1(
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M-'O2/QA ]O;L%_R;4+CAV<7(%8*#=;]FA:F6G2V:A$*34CZS9!W7UP?[J5_
M&V1)U(AS\5-H7,:Z^NQELV7V=<@/6-J8\:*TJUB9O;TP3I&'MR.@P;C]O(WU
M5PU3"[VV*4CD0GDVFZVC&ZTG'U"!NB-K84;*%.7[>-(;X-/46IWS.-N\@>E;
M%9K%Z4\;Z:=I=I,W0J1-V:RT\B:*)"&)I<SUTR4Y#+0C R/.*3)TF0(2%>;D
M_P 1V.RS6^'<RU)Y.#EL[96#5D9J,S.TRQ )9OJ.F# $D_25\Z( M?%&#"5L
M7N.$B)A]Q@E$6:A42BHO)0J_0NU*DJH Y<O&]DY-_4%>C-U$2LOSS!M8OV3
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M"(?$L+;D0G7(A5S]N+*@]GPX\]#G6)#J6NJ6VWQ(S)3M%)^+#/0(1KEH\25
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B6>2222222223LDGR22?))/DD^_7L?7>N='T='1]'1U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g180330g13h77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g13h77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &O:^:0(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              E@
M =4          0                         !              '5
ME@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
ME@    !29VAT;&]N9P   =4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   )8     4F=H=&QO;F<
M  '5     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MOHY!X;#V.L_-?].IKV?14V0D&,0>&-"OK^DN/9Y[%^H Z7]8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( #  E@,!$0 "$0$#$0'_Q  =   " @,! 0$
M           ("0 '! 8*!0$#_\0 .A   00#  $#!  #! <)    ! (#!08!
M!P@) !(4$1,5%@H7(A@:E]89(2,F.55X)$115UB8MK?7_\0 ' $  @(# 0$
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MYYSP:_CF_P"']Q!_TE\\_P#U/4_0/F7_ &1:[_ROJ/\ E<O%2]_;EK_")O\
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M(MQQY$-#(=4EO"W3C7"I,LLIU=U35)M3GWOE($)$$ .513^DWR:1NV]\?15
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MB0&E7ZG8]FV3$3:B[0)<C'6(DH4:AUAR':K641X%JE)20%5$QST<"0KU](E
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;:1A^BOS6)23L3/U9LL2>+Y]5."O$]3B<?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g180330g13i88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g13i88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &.B^8W8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RO_O@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  "$   !TP         !                          $
M =,   "$                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   "$     %)G:'1L;VYG   !TP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    A     !29VAT
M;&]N9P   =,    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #KL    !    H    "T   '@  !48   #I\
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MT\AEO^B3AC) /$!>UJI[])<8WJ'UM^L_2L#J7U<RZ.G:6UY]-L._2M<UC0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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ME9U,RRJ\KII]BJ;;54L-/7!Z>2G!6.>!!ZD.#A@JL,G'JRI&?4""QUN3Q?\
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MI!N-;*O;A]&5C4XRVXG@DDD@>=JC/)U)%/\ '_+UILAEQL6B=;3%J/,9D"[
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<SG!^O///OI=Z3K&CT:-'HT:/1HT>C1H]&C7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g180330g16j01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16j01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %VR^698X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              @@
M FP          0                         !              )L
M@@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M@@    !29VAT;&]N9P   FP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ((     4F=H=&QO;F<
M  )L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MK&;_ .NK/5>N8O3+*:'57965D;C5BXS/4L+6_P Y9MEC
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( !\ E0,!$0 "$0$#$0'_Q  >   !! (# 0
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M!YDG8 62=JQ"WUG\UG4WJ>2G^8*L+1\R"9&==9=C9;-2"<Z;QD2T"NMP81E
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M"XD*^-10-G8;]KKN>V"R!5['&7GROPCI/9Z!Z#NE&_,]=Y<&"!1K9_9+8O\
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JQ@=!,%*E#K*A  YCB:MF+$+)S44 ?* 69B0<2&_6=C-QGZ,&,_1@Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g180330g16k02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16k02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %3Z^5#@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              B@
M FT          0                         !              )M
MB@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MB@    !29VAT;&]N9P   FT    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   (H     4F=H=&QO;F<
M  )M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M##Z>GY[7O=[EHV=;8RH?H7#(/-1(AO\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%#I_.XG0.M8Y;3HL+CXXJL0NP\M-ET9RY8I'[,E-;,.K#-\LD>EG<G4SGFJ
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:?&&#XPP?&&#XPP?&&#XPP?&&#XPP?&&/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g180330g16l03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16l03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %@2^5C8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              B
M FP          0                         !              )L
MB                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MB     !29VAT;&]N9P   FP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   (@     4F=H=&QO;F<
M  )L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M W>UJL9O6>G8&17CY=OI.LKLN#G [ RJ#:Y]GT&?3_.4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M! (# 0             $  4'" 8) 0(#"O_$ #,0  (" P ! P0 ! (+
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MAL%2W5O89IJBJ:*%-IZ)VDXL?6K3HK,OM%@0O"%RS$CB]D#F0!U/+&N.8/\
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M;RX%?.P4!&,YA2HY,SG22D8THJUU;BM*K,13% #^Y]Y3R8DOR_,/M]V?[?\
M:[TO=K]HKT-TWS=HM]NQU8E#F&CLC6'?9V::9EJ[?MWT=+5:.6::&#B?B>0S
M2,6^J.SNY=GMF[&;-<DL5*%1Z$)F<X#6+PCX;H"(#+8L^LI,KJB/)[.%7@4
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@>?\ ^/M#K;:W^Y^X?]17_P!MOU+_ -=9UJ6E]&C7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g180330g16m04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16m04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<04&AO=&]S:&]P(#,N,  X0DE-! 0
M    %O2^6'8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              C@
M FP          0                         !              )L
MC@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MC@    !29VAT;&]N9P   FP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   (X     4F=H=&QO;F<
M  )L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MN53AY.%4W)MZ?D-R?LCSM%H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (" P$!               " 0,$!08'"/_$ #D1  ("  0$ P8$!00# 0
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MASR3*<-TS25>*,0_3,B5S?#&*(;2)S'.9%D$(C*D$Z" #OU&HCE8.VXY@X+
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M!ZX"010 'YXMZ^LK"X_-,^5[U[ZW]$^[/0/(;U8[N77^?=TO'*>9</KV[/\
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MVTF^NNV^<[8QGZ,&,FQYGS=NX:6%MS^D-+ [5Y1NGC&J(37#=+G2&+*=HS)
ME-/5YC''CRO+GE$SI!#IF']L6F-;ES.81%C2>98T;6B+*ZHC\]:J&"JU[Z@
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#,?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g180330g17n05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g17n05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %B"^5F0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              F@
M FT          0                         !              )M
MF@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MF@    !29VAT;&]N9P   FT    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   )H     4F=H=&QO;F<
M  )M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M'3<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MR)[!6>B.6)A[F,"LCW&\1ZS:4B@_L)"Y?6J(DEUP,H&GRH7XGE./B7I13(5
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MO4N8+?1JI%.K[\74Z!<="5%F'(C@@\2:2'6B5LZ@ 6?=T)'OZ$8.U=?CW^.
M<W=>O^35\<7VI2\>;83%?DZ[J?QV.SY5?3P%LPVN>EQW7ZE9#_UY=CH<7#$F
M<G1D8>8Q/B/_ )JM%?\ UY;K_P KK^1\<)^OWV^_UO$B%J\&>L^1?@6!XX^6
M'75MT[:%,+:*_P!.6*=I(*I:DT)$%8&9D9P!/=<"+#FE>L5C( 5LW2YR=/B+
M=L/$Y+E,3/%H=K;J#Z'L#Z[6"??W[KB/"D#^NKXWT@'QYI7-*1T2M5H#2L4/
MI$QE L)2- ''@53"C<N[O68]5JJ#72%5!T6HEE!!10 Y'P ,*-%$/Q*#0%!
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(?!@PO@P8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g180330g17o06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g17o06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %$2^48@X0DE-!"4      !                      .$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              5P
M =$          0                         !              '1
M5P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M5P    !29VAT;&]N9P   =$    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   %<     4F=H=&QO;F<
M  '1     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ ' "5 P$1  (1 0,1 ?_$ !T
M  $%  ,!              @ ! 4&!P$#"0K_Q  N$  !!0$  0,$ @$"!P
M   $ 0(#!08'"  1% D2$Q46(1<*(R0E,C0Y>+;_Q  < 0 " @,! 0
M         P$"! 8'!0C_Q  ^$0 " 0(% 04%!08$!P     ! @,$$0 %$B$Q
M4083(D%A%#)QP? C0H&1H0<S4K'1X19R@O$D)31$8H.S_]H # ,!  (1 Q$
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M4]#Y!]1KK:WSWC?03X6SW--2TU@^N.T^ZU%?KC>;X_'0SJ$QVF-ULX4A-A
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M8Y[#GY#\?6S$2B33=#?<WU9!FY:PBOT'[L9'FSTHF7O;&R:.#"%.<XU*7C5
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M+$Q<KEK149#&U%L2_)FM((._I/\ N9IIY9))O^MRR.]W*BJGH;:A'K;_ .F
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M8IT>J_8_VP?9W#&T#:E76UHSJ52%.HV6X6SH;G;Q+_$+YO?16![V.Q<Q@ZU
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17HP87HP87HP87HP87HP8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g180330g18p07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g18p07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S84&AO=&]S:&]P(#,N,  X0DE-! 0
M    '+R^<U8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              P0
M F0          0                         !              )D
MP0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MP0    !29VAT;&]N9P   F0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ,$     4F=H=&QO;F<
M  )D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MQWMIJW-_XQ_^#J?^D7*_XJ+F5_MF]YAC*L9[CY#[4Y<MA=3P,SH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2QP#CQ232[ZQZYVQ5T<<DTB0Q(\DLKK''&BEG>1V"HB* 2S,Q"JH!)) '?@
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M^K1B37IP%&R$&>-?@-(%*X[^$9F*_;"]NW9_'PF^.N5^8_"_#KI6JZIEZCZ
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MQ4T22-U.59'74PRL#X((/ 5= C4AEU.)64@@@*"".X((ER"#P!_P9],MG/\
MY7@HJ'RV\\DXEZ,BZS53>=-)7EB55&NX26#I%$3%69BA1:.IJBZK2U&JL1JP
M%G(M-80R?[VA^"3_ #[5AL\HDV+<%R]IAIS+901Q/-)OCJV'$2R2%!,DK2/$
MKLF]5/\ 8N'NLQI)IB;YXY[%8H>HK(&<?H<[0Q/N!#$ G+ ''VD/0//-*]3?
M4D7'BO1U^&]!L'=C[!;DV^=L#O4W/>*:]$FKYWV9UWRLL$U6@2--8]XY-US
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M(IQBX^-G_N./:7_W?V=_^G:?J[N9_P#1GH?^YT7_ (5N)5J/_0&G_P"U7_\
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MV=2Y]YIHPK!'J1GC10J>KAALNH'C\Z1#,V!V&^1P!V'@<"XM7U"% B66VCL
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M'Z6SW%(/AQH%5%5K;EL=RH%Q# 757(?G<#[9=\12Z3PPZFTG485FE])9EK0
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M2C9U6VXF,<$2,9K&J%DVHJPK!&")&)<<F;VA%!"CIXRW?V-(^20 ,EI#C [
M#Y\PBM> >A5,"C4E;V#GY_.:_P!K\Y]^L4S_ (^P9]1;W?ABOERADK3W?'1Q
MURE':8>8B95'GUIU8*FG:%TZ,YL@C$_BN)>8:TS3SO2L+9DH:EIT0CN*E5(+
M[VW1WK^F+/)";1WJLL<4SHLY5)-V[LV%8LQ1@QCDC&& 4!RV"5QDD;N_?!P#
MQ.NT^-.@]0Z)WMHGZASZO\W],T?F'/.F)VW)#;!TA$BYWK88I6'.[]!T!,M4
MV!D-9#OZ,Q[4'L%*?Q+K:I@)/!F"8(4=:K5*VGH]2Q+9TN>U9JNEQ8ZLDEGI
MD)9K&N[/$IB3J".:)IX]\+D*P9-+.JI$"KEHBY!#X0ESD97!\']6""P[$X Q
M7-X^.BRWVI.N6N.KTR'F*O;TPRYQL+RHO_475UZ;!O(%CBZG;)[Y*MO-?1P]
M&LL\Z]77:L9=FX=.?60_5I5MY73J#F6*O-'<2G,;C?A:6<VU]-T]+:!HC4A%
M?=7ED-:(!FDF6!#/'$NR;";6R$8.%;?F//N&W$>,;!MRIR 1W..X'8\2'M?Q
M^,>B=7>=DIW3(*G9";G/8T:'.>LU:O!+6W$^;\=<B'M.(=DX[=B6^D?-$S-4
M>+9@U>$A36HLT1T1HSI8E1YB2M42E-4ZT0A$<DG]'+*S)>LW8RBWJ5V!4)M2
M(ZM$S=0).LBE3&^DG"IL*;@?+>PMV;< "Z. .YR,?J(;XP;P0>2$M;JOB>G+
MWP\R?QU8AGP<9J4@S%LW#X!U/B@T86I[P^>L["F](TM &\QEAW '31HX=]MI
MHF@K"36'EEUR9HR'UJ(QL5D"]$'4:EXEML:B7<M7I-A8PQ<R$=BAX:4L9B1W
ME_?Q[U;O@#/C![#OWQ\<!^L^*Z54_12Z=@W/JQ<G')KZIGD[2DW(SQ2V3V.N
MBT]%2>\53FT098VBP0*._P!"OLM/=CL[0BEFG:PK%9EN;-\4@-/;,OK17<>A
M?'KH1%*T\D^GS6BP)<MZ>Q7$T96%\!"[K&V2/T8(# $;.^\88L6C+D^>X8$C
M )[9XD3;XZ;^Z64"C%=DYY#S?CR/KM<YOL)QD^/IABWJ\FDLI%_NDG295SML
ML_#!EV<FK*+-[<:RVEY&,TEC@@37F2LC6)Q2LFU=DIRVLW5]*K5 1BM!Z7=&
MC9_+5Y9!73$,>4&3H65 <['W2;=WYGM&T$=EVC]L9)QC \YXG%1^/K%7KEV3
M[=$7&,[?T3RG>,/(:;N":")YG[:LZ_A)B;2Q3$[_ .41BL$(9L1$&*[*V):8
M$:8S*#,WFYBZLD#BLRK#6U>#89@RL=4HO3WXZ8'Y1*R,I!ZH0)E.S#DV,D';
MX$PQGM^:FSO_ +.,G[^.WG@$?C/OC+KGJ%)SL4M# C^.S@O3/-K '7G8]<?E
ML;A=.6IDN\5_%O%DUZL(,+Q-Y,_MY%!X/*S<E"/L\YD)LIXU4D'-%=:>E262
M)#)S)J%34U8V3+&JPU[<C_TYKQ>D)-^,1PBQJ 1%,?J<1*9E[*[8=QSFPZ2?
MJRHPK$X4J-O=P ,N0 1NQYOOM?CMRO@J%">]%&AQW[V,4NJHW/U-CJJ/GW*[
M_P RZPZ]'4@;_*;IT-Y!#VGF2N_ G*J\T24NO]*:UBYU2L5LA61/D?1UJ-C/
M9CK'_)VBAIC8>*:2S;KVJ<>F3GI5ZR$T;;UG5Y%DGDJI+!++*& X228>=N=D
M)SN.2SJ1TV. /\VVW&>Y4;23P2RCQ78P>@VBQ[='KBBC'=\YWVJJ\TJ5-L:Y
M @GIK[H+NP3:QO>AV4=9:;_'<U(]H*I@E3II;RKEWK2D166ZV'? N37(FK11
M>FE>PNG6:$UN:>)Y)1-'62,9CK1,T-<P.8A.TTXCF%<SF*"(#GKC9MVDL8FB
M+%NY!V8\*.R[3@')[@;L <#S1?BCCJH%60M>L1V)#S8;E%9HF7&O9;2>?1N>
M^D>)]Z=+;BKZ'W>[4,-A;5_$4=4-@YI2N?UG+EFTMY" @35/4$Q&QS:9FED2
MH8Y++6YK&PTHE6>QIMZA&T#UM/@L%86O23*;,]B78JPB0'?,_;6MQ)"8+%F8
M>Q0&9'3*[(U8 ;VP&+=L+]SP7M+\BBTOI-/Z$OLJN+>O=M]-]B;@@U71?-8I
M?1&#M-%99T+7;/\ *K$4JV,EJ0.7EYJI%Q@1;B.'$(>?6&GK35WC<B2CI=)&
M:8L(AINWW*I3],N&(0%>GO;N^3E%I2P(.<=*.,=_'3*D''\ @#XW']\F;^@G
$"/'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g180330g20u43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g20u43.jpg
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M,'8AYM)C3JK_ 'T7-'1$=$1T1'1%K,/I<'(SU7L@]R.5&<(<U.5&,?(]4;1
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M/90![Y1Z&J$K_N9//S&D0Q)]Y8DJJN5Q=B8Z<XMZN59"2)7JJJY>A+DG- &
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MKJ>5")1[#-X?21EZ'6YX4N![)H7Y2#+W^=&-AD8X"709EKG+-/ I%859P''
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MT4Q4BI@?> <I_558#25=;35@[!*VI #K*\6-/$8P( \8HD#$_P!R&"*.-O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g180330g25n67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g25n67.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MGQ%KM]/J>MZ_\*/AYK>LZE<D-<ZAJNJ^$-'OM1OIV55!GGNYYI7( &Z0X H
M^(/V&_C%\2O'OCO]LNS\;>)]:\7V'PZ^(JZ=X,TJ\:%_[(TY-;^)$1TK2UB@
M4JLL&CZ;" ^\_P"BQ>^0#Y$^"VN?MF_M4Z-XS^-7PX_:BL/#_C[P]XMGCLO@
M"&6TT6ST>(6MQ:"ZL+F:2UMK"07$EI:OJ&DWRW9LI?M&HQSB78 ?L##\-/%^
MM2>$?$7B3Q[JFD^*++3O"C>,-.\%W>J:?X0UG6=%O+75-46QTO4;ZX:STJ]N
MH!:.I_>RV:F.1OW\H(![E0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&EZUI"1_VM:[X+F.*TUG4=2O;BVDDCM;;23YCEI2B'Z!^A[1^U5:K8?MF?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M;W7+'6[![Z8W%S'#XCM]475'LVG+R?8Y;N2V5Y'=80SL2;!L>@_![]F?X&_
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M*L2N !:BQ%L  !" *-@V/KY$6-0B#:J@  <8 X  [ #M0 Z@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * (IIH;:&6XN)8H+>"-YIYYI%BAAAB
M4O)++(Y"QQHBLS,Q  !).!43J4Z,)U*LXTJ=-.4I2:C&,4KN4I.RBDE=MM)(
MJ$)3E&G3BY3DU&,8IN3DW9**6K;>B2U;T1YI=_&[X+Z?X?TOQ7??%WX7V/A;
M7+F[LM$\2W?C[PI;>']8O-/=H[ZTTO69M66TU"YMG1UFB@FD>,HP<*0:NI^Y
MJ4J-7]U5K4O;4X2]V<Z-XKVL(NSE2O**]I%.-Y15]4*,92564(N4</.-*JTK
MJE5E%SC3J-?!.4$YQA*TG%.25E<>/C5\&_["L_% ^+7PR_X1G4+V33=/\1#Q
MYX6_L*^U&"2.*;3[/5_[5^RW-['+-$C01RM(K2HI4%@"W&49T*3BXU,3'GHP
M:M*K#FG#FIQWG'GISC>*:YH3C>\6E,6I1KR@U*.%?+6:U5&7+":C4:TIODG"
M=I6?+.$MI)OK]8\4^&/#NA3>*-?\1Z#H7AFWMXKN?Q%K&KZ?IFA06LY007,V
MKWMQ':Q6\ADC"2-*%;S%P3N&54:HSC2JOV524U2C"?NR=5NT::B[-S;T4$N9
MO1*Y5).O'FH)UHJ+G>'OKDBKN=XW7+%:N6R6K=C1?4=/AT]]6EO[.+2H[-M1
M?4WNH$T]-/2 W+7SWK.(5LUM@93,7"!!OW;>:5>4<(JKQ+6&6'YO:NJ_9JER
M74O:.=N3EL^;FMRV=["H?[3['ZM^_P#;\OLO9>_[3GMR>SY+\_/=<O+?FNK7
MN<-X1^,/PC\?ZE+HW@/XI_#GQKJ\%I)?SZ5X1\;^&?$>I0V$4L,$M[+8Z-J=
MQ-':)-<6\;3,@16GC4L"Z@ZQI594YU8TY2I4G&,YJ+<(2GS<BE)*T7+DERIM
M.7+*U[.TRE&$H0E)1E-M0BVDY-)R:BGJVHIMI;)-[(]&K,H* "@ H * "@#S
MC5?C%\(M!\2GP9K?Q3^'&C>,%DMH6\*:KXX\,Z=XE66\ACN+.(Z%=ZI'>B2>
MWEBEC7R,NDJ,H*L"2A_M,G##?OYQE*#C3]]J4-)1:C=J4?M1W75(JK&6'A"K
M7BZ%.<>>,ZB<(RAS."G&4K)QYXRCS)VYHN-[IH]&!! ((((R".00>A!':BUM
M-K="$TTFG=/9K\!:!G&CX@>$3X^/PO&K?\5TOA1?&YT/[!J8QX7;53HJZG_:
M?V+^S_\ D)J8?LWVO[1QO\KR_GIT8NO#&5*2YH9?4H4J[V]G4Q-.I5H1L[.7
M/"C4E>"E&/+:;BW%-U4\/'!RJ^[''RQ$:#WYY854I5UI?EY%7I.\^52YO<YG
M&5NRI""@ H @NKF"RMKB\N7\JVM();FXDVN_EP01M+*^R-69ML:L<*I)Q@ F
MLJ]>EA:%;$UI<E'#PG4J2LWRPA%RD[13D[13=DFWLDV:4J52O5I4*4>:I6E&
M$(W2O*;48J[:2NVE=M)=6D<YX(\:^&?B+X4T/QOX,U/^V/"_B2R74=%U/['J
M&G_;+-I'B6;[%JMI;7=O\\3C9/!$_P N=N",]=>A5PTU2K0Y)N%*HE=/W*U.
M%:F[Q;7O4YQE:]U>TDI)I<U&M2KQE*E+FC"I5HR=FK5*%6="K'5+X:M.<;KW
M96O%N+3:>*?'G@?P+%93^-?&?A3P=!J-P+33IO%/B+2/#T5_=DJJVME)JUY;
MK=7!+H!'$6;YAQR*PC*,JL*$9*5>:O&FFG.276,%[S2L]ET-^2:ISJ\K5*G\
M4[/DCVYI;1^;1T\4L4\4<T$D<T,T:2PRQ.LD4L4BAXY(Y$)5XV0@AE)!!!'!
MJI1E"4H2BXRBVG%IIIIV::>J:>C3U3,XRC.,9PDI0DE*,HM---7336C36J:T
M:,K_ (2/P]_;Y\*?V[HW_"4KI0UX^&O[4LO[?&AFZ-B-9.C>?]K&E?;0;?[7
MY/D^:/+W[^*()U(UI4USQPTJ<*KCJJ4ZL92I1J-74)5(PG*G&5G.,).*:B[7
M-.FJ+FN18AU%2<M%5=)0=54[VYW252#J*-^13AS6YE?9I""@#G(/&'A*Y\2W
MO@NV\4^')_&.FZ?%JVH^$X-;TR7Q+8:5,T20ZG>Z#'=&]M=/=YX56XE@6-C,
M@#$L,D/WE.O5I>_2PLXTJTXZPHU91<XTZDE=4YRA&4HPDU)QBVE9-A/]U*C"
MI^[EB(RG1C+W75A!N,I4T[.<8R3C*4;I---IH;H7C3P=XHFU:W\,>+/#7B*?
M0;HV.N0:%KNEZO-HMZH):SU:+3[J5M.N@ 28K@1N,'BA-.A#%+7#3YN6JOX4
MN3XN6I\#Y;>]9Z6UL.2=.M+#37)B(I-TGI42=N5N#M))W5KK6ZL+X=\9>$/%
MZW[^$O%7AOQ0FDWCZ=JC>'=<TS6UTS4(B1)8W[:9=3"SO$*L&AFV.,'*\4TF
MZ5*O%-T*U_9U$O<GRNSY)KW9<KT?*W9Z,4O<JSH2]VM2MSTWI.%]8\T'[T;K
M572OT.DI % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M(L777ML;G&78/%RJ?!&DXSQ5&JE"+Y9RQ,HPJ5)-1A2]G3A0IP_>RJQBY?\
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MTDZ#59Q5E)>;>"?B)\2_B5J^@6M]XP_LO7?%'[!NE?$"_P#%FC^#_ 2>*?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M]K7Y7;LSLP.&^NXW"8/G]E]:K4J//;FY?:3C#FY;QYN6][<RO:UUN?&/@O\
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MWE96.BHO8TX5:O[JE-\L)S]V,I:JT9.R;T>B=]&<]XF^,_PD\&QZPWB;XE^
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MG&/ZG]3JQ_>X3&XNI@J=3X)JM3H5,2G*D[VISI4I.,E4E).RG".K7TO68PH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /C/XY>%OBE
M;_M#? GXL^!/AEJ7Q)T3P+X7^)>C:_9Z3XG\$^';RUNO%5OI%II;#_A,/$.F
MB>+_ $>XD=K=9RJPD$;F56G+YSPF.S^<J?[O-,KP.#I3<DHJK1S&>+J<Z7-4
M4(TXQ3:A)MS7*I<LDECZ4<3@LFA"HHU,MS/$8RI#E?-*E/ /#14&[0YI3F[)
MSBDH/F:O&_CWBO\ 9J^,OC'PC\=O'^KZ7X:M/BO\5O'?PD\6Z7\/=.\0+<Z=
MI/AKX0ZKI=SI7AJY\57-M:V=QXBO;*VO3)="%+19GB7SA&Q:+7"3_LJ/"ZIW
MQSRG/:^=8UTTJ?M'BJ3H2HX95I1NL/3Y&I5'2=1\ZY;J,IUC+YJLWPU6?U'"
MU\BJ9-@7->TE3<ZDL34KXA4DW;$8BR4(.I["%FG+6*P?BW\$/CQ\53^U#K$G
MPN&CO\5?"7P%TKP;H,GC3P=<ZA<_\(7XK:^\2V6K7<&N1V>FZE:V9FG;9=26
MTD<D*VMW<3[TC,!A\-A_J-'%3C7HKB[#9EB4HR=+^SHX.AAYU$G%3FE&GR5*
M7)&LZGM%3ISI*G5J=*Q<O:8:M3BZ$\-PUG6 BY<LG]>Q;JSP].RYHVG4J6A-
MN5-049UI4I2E3A] 7W[/EM#^T1\-_$>D?#?PU;?"_P '_!+QIX7B%M:>&[;2
M](\7:UK>F/:P6V@B5+@W5SI9U3?>Q6;QXEE$LX>7#\]15*D.-95/>K9K@,#A
M<$VU[ZIUL?5Q%*/2C!.K0E:7LX.]H7M-+DA%4\#PM2C[M;+\QKXG%:OFBGE^
M&H4JLYO^-/VM+E34JDTX1DTDHR/!?"'P3_:0T'X3_!;X=3>&3I>FZ+X6^(FB
M^*#X?O\ X.ZAXST/5];\5W]YH%G>:W\0-)\3:5;_  ]FT,69NX_#MM>ZD95M
MHS$$@*KKFE\:L5"_/S9%E&&I+X*57&87+_8XRCC6DL1-QJ)0PKHSA1YI5IRK
MP4H5%UTI4,+BL;6PR4*4^(<PQ<8J,DXX"KB'4PM;!4[QHTZK<ZDZRQ,>:-+2
M%-U)2A+5^%/[.'Q)T_4?@1+X^\"VEQ;^ _V7O'7P\UG^U=5\*:TFD>-=4UZ#
M^Q]*BBBU6Y^T>9H7VF-+NU26UBB<PO-&3Y=&;VQ=/C6=!<^(SC),DPF%EM.K
MB<-AJZQM-RD_<E'$.DY5*LHQJRM.%2HDY'/@+8=</0JNT<OXFSG'UNJA@L15
MD\)62C&*DI1LXTH052GHI4:=DE!\-/@5X\^$VG_L?>);WP!!I)^#'@+XSR?%
MXZ5?^&9+^TO-;\/M<:99S'2M2FF\2S7VHPOM_LX:DJ2%6DV<&NO'9C2P>*XA
MQ].,J^'EPSE^#P]."DG7QV%K8"I+#Q@H2E&=Z5>U64.1R<G&4I32EA@L%+%9
M?A<OJ.-/&U.*?K2G-Q?LL#5EFE)U_:.2C&"H5L'&5+VD9^S4(."C2DH?:-EJ
MOBCXH_ 6;5K[P?+X2\5>._AOJD\?@JXU1;VZTF^U[0[M=.TF[U*]L-+5;S;<
M6PE\ZVM5ADD='XC+GR^)\NJ+ YKEF%G'%XB6&E27(XJ#KRI+VE.$W/DE&%5R
MIQJN48U%%5+14N5=N0XVFL?E^.K1=##4,;&:<E)R^KT<4U"M*"CS1=6C"-;V
M:4G#FY%*;5W^?>M_LI_&G3_#O[+4_A#PY;B]L(O@?I?[0/A9M;\.0FPF^%&J
MV&J:/XK@O)=:CLM4O=.M)-;TR?\ L^:]EG@DM%A2580T?O\ UFA'C!XOGYLE
M>(GF-.IRR7L,<\KJY962IN/M7#&T:M%SY8657!1G)KGO+S94IRX<S##VY<TE
M1S'!4X:-5\#C,?+,*4)3OR1EA\12C4I<TDU'&XB+:LTNU\:_LZ?%F]TOX_\
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M3B)RQ>"RS+\CI*3UYL3A%-8YQIS:?M)*G0O.24962A-I2MY;X)^ ?Q'ET?\
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M46ND7^OMOM9OB=XOL]>\:6>HW-]:VSDZ9IPLE-F'D<K)<'+<^2MTJE3&8O\
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MM&A]7J8;V<J%*C:-JLJT:4Y58T:+M!WG--QG]Y5B4% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >*?M&_$F\^$/P.^)?Q%
MTR.-]5\,^&+N?1EE0O"-9O'BTW2))D .^&/4;RVD=3P51@2 <UPX]UI4\/A,
M--TL1F6*PN!IU%O2>+KTZ$JJOIS4H3E4C?3FBEKL>AE="G6Q:]K#VE'#TL1B
M9T[\OM(82A4Q,J?,M8JHJ7(VM4I76J/C+QC\5/B#\)]1^'GPIU;XT2_#VPM/
MV?+OXB#XF>,[?3/%FK?%;XJ17T8N?!D=_P"-OMJ2P>;<>=_9&EF+47AO;>VT
M^2WCCA ]#-*\*.)XLJX.G&3X>^J4<NRQIN>-PZIUX3Q%:<6L36E^XA2J5*<U
M45>53%8F=2*FGPY72EBL!PWB,2W?B'%UY9ABHRC&GERJ0I8BG2HP=Z&'@O;5
M%3=6D\.J-&%*G&-1MJY\5_VA_CW=?LR_!_XX> ;KPEX,L_$EI\/[SQS>O8'5
MM>DU7Q%XFT3P_/HGAK1]:T^YTZQT:;[9J%R]_=/=W"QQ10P(CO\ :AWSPM*A
MQCDF6S<GE68X_+Z-.CHZE6GC*%7%U(8BJN65-4*,*=)>Q4:E6K5<^>E&DZ=3
MSHXFI+A?/<;"W]I99A<TDZK7)3IO 5GAJ=6E2O)3JU:J<W&K>C2IP:Y:KJ1=
M.S^T1^T=X\\!_$;XJ:';_$?1/A99_#;X4Z-X\^'>@:OH6@:B_P </$-TNISZ
MKHPFUN-[RZTZU:SAL3:>'9+&_CDD>ZDG,$3)7AT,5[.EF6+G%8JM@,UP>#67
MW<']0JPHSK8QRA:M=\]7DKJ3PV'C1_?TY2;M[:PT*DLBP_.Z%'-,%BZU7&J+
M;HXNE6]CA\+#F3H<TTX5/8.$L17=6,*#BY1/2OAC\3M?N/VA-&TNZU/5[CPE
M\>O@%X<^,FB>']5U&^OX?!?BG2FT[3M=TS0HKZ5SIFCWVF:G8W#VD(BA%U92
MRK&LEQ*7]KZI#"XCB_)93]M5X<S"E6P]:27M)8+&SKX>I2J3WDJ.*PRG14K^
MRA7G2A:G&$8^-'$RQ67\*9Q:-%YM2Q&!Q-&%_9_6<+1IXREB::NXKFI5:U"I
M**3K*G1JSE.2N<Q^VM\??B3\/--_L'X,:Q;Z+X@\+V.A^-_B)X@ETK2=:&B^
M%=8\4Z=X0T#08;76;*[M(]5UW5+^\F1G@9X[3P]=NFTR(XX<KB\7GV5TJNN4
MQS/+LNQ$=4\3BLPJ<T<-&:7-&-#"0J8C$2ISA4C*M@XJ251I^K5I*&6XKETQ
M]?!YEBL,W>U&AE>$J8FOBG':3G76'P=&,U*$G5Q$N5NAIJ_M4:E\:?!EMH6K
M?#/X[>)=#\3_ !'\9>#? GP_^',7@?X6ZMH2ZMJS6T>KWMQJ.M>"KW67L+;3
M+75M5N)'O&$14(I2+:H>"@Y9YEV6SE[>EB<37KXARM'V&682$J^*FN1P;]G3
M4*--N3G*I5AJVS"-:DLDK9E5I*#P.!IV4)M2QF/KR5/"TESMPC4K5:D8N%.*
M7LJ,Y1AS*3>#^T?\>?BCX9^(7P^\'_##7[;3](\*^._A/H?QGUY]&T?47U>\
M^)/B"STS2O!5D-2L+F'3;F31(M3U:\DM5AN(([O3%BEC\XYO*G3QN?8;VD.7
M*,5B\5E]"C=WJXFA@,3F&(G[1-5/9X&%/"T+QDE4K8FI&?,Z#2C%0J8+(,5S
M2]IG%#+)YC*MLJ-"E5IX*E-TN7D<\=BJE6=*,H\L*6"J/EM4B>\_M(_':S^#
MWPL\3^)O#^I>'+SQ79WVA^'M,L[Z[%[;:5JWB+7;#P_#J>MZ;IT_VV2PTY[Y
MKN:WB"R2"U\E2K2 CC;G6Q.58*A4=/\ M3&TL)[:%.5=TH.%6M5E3I03=6M[
M&A5C0I)/GK."<9*\7U4XTZ-+'XK$0<H9?@ZV*]ESQI.M*$8JC3YYN,:<*E:I
M252HVE"E*4T[I'#_  O\0Z]\4?#7C?PWHG[2_CC_ (3?PSK6BMX@U'6/@QX5
M\ ^+_!45U937PTYO!7C7P-#&?#^JV[)-:7=]IMS<+%;%1>22>8R]6)A&."PV
M.IS]E@Z%?%QJ5N>G4=14*<8SPV+LG&C7PLG[6HZ4:#ES1BX\D9<_+2E..)J4
M*T(RK8G#4)T:4(U%27-5=\3A)MN5>E54?8I3G54;\^CJ4[?/WA?X\_&ZW^&\
M6JR?$B7Q7_PM_P#:;TKX+?!GQSX@\(>#;.[TSP0E]<Z7K'C8Z5X7T+3--U*X
MN9M(UE[!+NWGB!2V>021EHSIA:$\8^%<#5B\!C,UPF99OC)07[ZC@*&&GBL)
MAHPK*=.&)J4H4)SFZ;48XJ7NRY(.-XKEP53BS%*7UG#</TL'A*5*:M3J9K.M
M3HXIN5*4:LL-3J8CE_B0=\)**Y92ES[TG[1?Q6M]4N/@6?%5C)\0U_:4T[X+
MP_%!O#>E+>KX(O\ PM_PF?\ PDLGA]+0:&_C)+".6P %DNGF8K.;+8#&<<!R
MYO\ V*X?[!]8H\1SQBH^\G4X?DZ:CA_;^U=.&*=;"SG[1U)02KQ@[N#A&-G#
M*7FW-?&^PI\/O"QJ^XHU<^G[.U=T73=2GA?8XF<.3V<IWHPF])2E],_LV?$O
MQ/X[TWXF^'?&M];:QXF^$GQ7\5?#6\\0VNGPZ6/$=AI L[S1]:NM/M%2UM-3
MFT^_BCN8[2.&#SK=VBBC1U4:0E3Q64Y-FM.FJ$LPHUE6I1<G3IXC"XJMA:OL
MG.4I^RFJ4*L%.<Y1]HXN3Y;)XBE/!9IC<NE5=:G2I8'%4*DE%5/J^/PL*\*=
M7D48.I2J>UIN4(QC*"A+E4G(^DJR&% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M75253,\!EN)I2O%2IU,(\PH8A^[.%:E4HJ,XU)UHX>CXD^-^N:=J]_X=\->
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M_:'\+Q^-?".C^%[F'X+>.+BS;0?%MQXMT^Z2Z\8?#D7%M+=WGA?09K74;26
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M58W8%KHWAR+6-1^(ENFFZ%H\4KQ6<:Z=I6E1W%P7>>]GM7N)G :.&WSPT?\
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M,\-AZ&%G"C5IQ]C2I\BC4ITZD<W%.$.;WL3!5E]:E[V)G[>=2M4]K.5XUO\
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M:K5=6=:4U4=3D]M6JNO-4?9)58QY%"$JL*GI5( H * "@ H * "@ H * "@
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MI2Z1JMA>>'U>2/3&M+>6SN;P2P.8+8V_-];I8:6*CB(/ZG' 8W%+D@I3P]3
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M\&7?[0MSX4O]?7Q7.NM0:KXRU7P[H5A<:5X:3PO)#J>CP:YJ^G6LT]SJ^FW
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M*?L[Q<IJHZDJG,G.I",.6E3]IZOJG[1$>BV5C8:OI7@[0?&D_C+Q%X-O=/\
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M+V4L+2J2H15&I7PN-PUG*6)D_2+3XSZ_<6NA^)W\#Z=#\//%7B-/#'AG7_\
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M5U82A-3C.E7R_-I0;LDZ<XRC4ISIR5TX<\7*G.$Y?8-<1UA0 4 % !0 4 %
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MN+HJ5">(K*E5]C[9*:<JDITZ4J=6[^ 'AVYU3Q?<0^*_&^G>'_'VHZ7?>,O
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M$>H^)_#RQ1RZ;)(L5Q?ZG/'>!I6,D*1K UNX,C1AJLL(Z3II/V.+QV,CS?\
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MM2,E&,93<*=2<I5I5ZE;V2L"PH * "@ H * "@ H * "@ H * "@ H * "@
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M2>'I_P =O NI^)?A_P"&+)]3FF^)'@P>.-!U06]HNC6^FSV$VJZ;8:K=&_\
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MZSXDM+U;(ZI=WU_<PZ%IVHF'[1+=7,:&X#2S@VJ^#RZE;V=7$9CC,#"K-/\
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MI4FTG;$MXV*=)Z)X?%+G_<OFQK7P_P!8YXRB\/F']G-<LDYUG#$UJ=2%TO\
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M[&AFM&$I0JX?#T>64'%PE[+B:.6SQ%.HFYIUE0JPARN-.>#E2DXQJ5:T3N_
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M/INH-@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#B-4\&_VCX_\
M"7CG^T?(_P"$6\-^,_#W]E_8_,^W?\)==^$KK[7]M^U+]E^R?\(MM\K[/+YO
MV[.^+R<2J*Y:>94_^AA0H4;_ //OV-2M/FM]KF]K;EO&W+>[O9:RJ\V$IX7E
MMR8VCC.:_P#SYPN.POL^6VG-]=Y^>^GLN7E?/S0\QF_9^TS4/!_@OP3K6NR7
M^C^&/!_C7P;J?DZ8MG-KEAXTT*30KJ:%FU"<:3+!#*\B@B]#-@$KC)RG2YIJ
MHI<LX95A\NIOEA/DJ8:OE.(I8KEJ*=.=JF51?U><)0?M;2G*,&JFD<5.EC%C
M*249QSVMG2C*[C^]_M9/"RLXMQ2S2SJIQ<E1=J<?:WIX4/[-6FW7A;7O"NNQ
M?"A8=0M= 33=5\&_!?3/"&J"]\-:]9^(=.N?%8E\4:K9>*[-]0TG1GN=.2ST
MNVG,%UE%2YCCM.FK4G/V=6"A2Q-+$T\3&/*YX*\:=2G.F\+.3J.$XU\13C+Z
MU[:C1JVI58UX_6'RX:*PO[N$IRH/"8K!N4I1>+]EB:7L7..(4%"-:%/WN;ZN
MX3KQA4=/DC[)[(^!MT?!6J>'8;OX8>&=;G\3^"O%6FZO\/\ X1-X.T5+[P-K
M^C>)M+C\0>'$\=WT_B&)]5TN97,>L:<RVUZ8HBDB-/-:KSHU,!5P\G&>"K8B
MIRU9.I1E'$X>K@ZD8TX^R=.H\+6E'VO/.]:-.HX.G!4&Z=H+&QG&,HXW!5<&
MY)*%6/M*=2//[3WE*,9SC.-+D27+./->IS1U],^#MU:>*['Q;?>*+>[O8/B3
MJ/Q'O+:T\/R6%K<76I_"F#X9SZ7;";7KN2S@66%]329WN6"N+1E8J;IJH5H8
M:$*5*G+V=+ YI@8*4TY<N8\04\\C4E)0BFZ"IK".*C%56_;ITK>P.:M0G7E.
MI4J14ZF)RW$RY8-1OE^65,N<5%SDTJSJ>V3<FZ5O9_O+^T..\2>"'^'-Y8^,
MM)\1ZM#XF/B?XF75I>67P@\<?%/31HOQ&U2R\3:OH&K>%OA_?KJ:-!<Z!I36
MNK?;;.,S6?E-$QO%MWXL/*IA*-' TYMTY865*LG3=JKI8W%8O#U85+J%"M0E
MCZU)0J2J0K4:E>7)S1A4P_I57]:>(J32C"6)R^O"*J4XRA/#952RAI\Z<JE&
MM3IRJS]G&#HU'0<ING2J>V[;]GWPYXB\-_#GR?%9NFUK6O&/Q$\63F_L4TR_
M-KXM\<^(/$.FO?:4CO\ V3=R:=J-K(]BSN]J93;R,9(6)[<1&FL-EF$45_LF
M78+#58\\:J]K##P5:$JD/W=64:CE"I4I+V-6<93I?NI0.6=:6)QF/QEY.&(K
M4_9N5-T?<P^$PV#BX4I.52E1E]6<L-"M)XB.'=+ZQ^_]HEYM<_LLEO"'BGP[
M8?$2_P!,UC4_','B3P?XHA\/6CWG@'PO:/>VEEX'TNT.I*MY:6^@:[XLTV.]
M:6!U'B*27R3Y(CDY*5*G&ADN&K1]O1P'/#'1<IQ69T*F#AEE2C5M)NC[3+<-
M@*$I1<[XC!QQG+[6;C'=UIK%YGC*7[FIC84I45K+V&*HX^6<PKSYF_;P>=5*
MV*G0:IQ>$J+ 1G%05=]_JWP/L[W6IM2T_6TTFP\[X(FRTF/1Q/'86GP7\4:G
MXAMK..<:G$'34H=02S#")/L@MA+MN=_EIW4L74AB%BJO[^J\RS7,9N_+SSS3
M(89+*&SM[)Q>+Y]?:<WL.2%O;/S)X&G]5CA*3]E2IY=@\NAIS<L<'F?]HQJ;
MQOS)*AR:<O\ %YG_  SL/"_P_P#^$:\"ZKX*_M;[8-3OO'EY_:0L/LWD?\)O
MXCU_Q!Y7V/[9+YGV+^W/L^[SU\[[+YF(O,V1^9F&'^O953RSF]E[/*<)E?M+
M<W^ZY?2P'M^2\;<_LO:^RYO=YN3VDK<[]+!5/J68U<PY?:>TS&MC_9WY;>UQ
M+Q/LN;6_+?D]IRJ]N;D7PGEFG?L^:EJ'AK0_!GQ(\=6OC/PSX7^'NK?#_0X=
M+\(?\(KJLT.N^&QX1U+6_$&HR^)=7AU+5%T'SK>V6RLM*AB:]N9)H[EFB^S]
M^/K?7L5F>/E'V./S'F2G'EE2HP>-P^8Z4*D9QJ5)8O!82I4E4E*C)47"%"G"
MI.)S99#^RJ>34<.HRHY-B*&*I1FI<WM</A<1A*=-24URX:-'&8J"IM3K<LJ*
MEB)2I3G7[3X7?"EOAY<7<TUO\+6=M-MM,M;_ ,#?"6V^'>NS10S.\S^(-3MO
M%6J1:P9DCL6:.VL],A$\$TPCVRQPVI*OS4ZL7'V<ZU2-24:4I0PZY8M6C1E[
M2:Y9SJ.G*=:HX4I*G[TN>K.(4(TG0C!N<,/"5.,JW+4KVO!1;K15.-^2%JO+
M2BJL[3M!)0(]<^#_ /;.F_&;3O\ A(OLW_"V]4TS4O._LGSO^$?_ +.\*>%_
M#'D^7_::?VMYG_"-?:=^ZSV_;?*VMY/F2YT9^QCDRMS?V1FE',NWM?99I1S+
MV/7V?-[+V/M/?MS>T]F[>S?1F#^O8?$4/X7M\DQ.3<WQ<OUA9JOK-O=OR?VG
M_!NN;V'\6/M/W>%;? 33]-\>ZCXLL+;X8W>G:QXL7QA?Q>)_A-9:_P"-[/5)
MA'+J*>'_ !_%XFL#IL,E]!!=V[7>D:G+:227(25XW@2RSPD5A*$,/'W:=!8M
M4Y4;TJO^TU,177M9WFJGLZV(G'W84G/#1A0DU-.O)8J^(<ZC;=2M##0J1J_O
M:/)AJ.'PJ5.E:#@IX7#J,DZDX>WE[=1Y>>C.;2?@UXC\)1^'KGP5XZTK3-<T
MOP]J?A76+S7O!4^OZ9K6CW>O:AXBTZ2#2[/Q?I,^EZMIVH:C="*X.HW<$D5U
M<+-:.SQ/;9TJ3I8=853:HRP&4X*K**M5Y\IP;P4,10D^:G2=:E4K.I3J4JZC
M+ZO:35&HL14VIU)U6FYQQ^;XVC&_[N*S?%QQ=:C5BDIU53='#PA4IU*$FJ=1
MV7M5&GUW@_P!K7@CX5Z9X TSQ/8:IKFDZ7<6,7BCQ'X:>_T^_NKF\N+N:\U?
MPQ8:]8&ZBE%S*DMO!JEJ&+$JZ [1K74:M+"4*=.G3HX;#8'"2IN+J0E1P>&H
M86<8J4DXNK3HODYW55)R7.JZ@U.:5X5L97E)NIBL5F&,3A^[]G5QF*Q&+A;X
MKQH5*T4[<KJQ@^5TG).'GV@? ?6O"<UAKOAGQCX=TCQ;IVJ>*I;2*W\ W<?P
MWT[P[XPC\-KJ_A?1? %MXXANM'L6N_"FDZJLD'B/C4Y;^Y\OR+YK1-%5J4J5
M*A1E^Z6%6&K*K^]E5=/$XC%86I&:]FZ:P3Q-;"X6D_:0A@)_5I<\X4:])NT_
M;>U7*IXJCBXJE:G:K2PU7"SE4YE5YYXF%:=3$SA[)U*\*-5VY*D:S-0_9NT[
M7;,VOB+Q//J3ZIX=^+>E>++B'1K:U;6-6^+.I>&=2O=6TZ"XO+J#2+/23X:@
MM[/3[B+4PT'D+<7$KP2/=PE2HTO886FJ=.A' /#JK:MR5L!F%7-/;5TXPAB'
MB<;6J5J])0HTWSSA3C"FXPAM&NW3KPQ$(U)8O&4<17]FZE"$Z-+*,5DGU:')
M-UJ5\%B(15>-=UHRHN:;J5.>$ME\ GCT#4-%N9_A;H\]SK?P^U:+5?AY\'8O
M EW+'X'\9:3XNGM-;6/QKJ0U8W[Z/! CQ&QCM&FEF$$^5B7>E75&MA*_+)2P
MN)EB)4X3:HS7U6I0C"--J<XRA*M6FJDJE5^SE"ERJ49U:F%)>R6*C_$C7R['
MX",ZBBZ\?KN'JX;VLJD5"$E",J<YTH4J4:M2FWS4XRA&E%\*O Y7XO?%OXD+
M!KUIX>O[RWTGP9IGB#0;[P\UA>W]KI=Y\2M5T?3]6LK6^.EZSKVDZ&_VF>%5
MN)]*NI[=I+>=)9<, _J^3NC;EEB\54G36TX9?2J8C$82E5INSHU5C\RSBIR3
M4:JPT\'&I&*ITXQ6-7M<RHRC\.$PL57<95)0JYA+EPDIIMNE-4,KP&64:=3#
MN5&]3$*,O;2Q/-U7C;X.?\)CXCUKQ!_PD?\ 9W]KV'PDL?LG]D?:_L__  JS
MXE7_ ,0_-\_^U(/._M/[=_9^WRT^R^5]HS<;O(73"5?JE2G/EY^3'?7;7Y?^
M8"6"]E>SM\7M>?RY.3[9URQ/-A88;DMRX//,)S7_ .ASA,+A?:6M_P PWU;G
MY;_ON?EYJ7+S2[K2/"']E>-?&7C#^T//_P"$NT_PG8_V=]D\K^SO^$7BUF+S
M?M?VE_M?VG^U\[?)A\K[/C,GF?)G1?L<+6POQ>UQ^(QW-M;V^"RS!^RY=;\O
M]G>TY[KF]MR<B]GS3X)T^?&QQ=^7EP.'P7);_H'QF98OVO-?[7]H>SY.7W?8
M\_._:<L/%;?]G39\0M/\<W6O^&+N;2OB'J7CZVU)_AY ?B+>QZA;:U;0^%=;
M^(=SXEGDO/#FG0Z[/!8P6>E:=Y%MI^GP-YJP2M=&":P:P]HKFH4,30DJ=Z4*
M[Q%&I2EB<1%.4JV*=Z4YU)3=.<H5+48<V'^J].-G];6)BHQ@L2LO5IWJ>P^H
M5L%64<-K%4:=9X2;G&TI*IB:M13?-4C5[OXO?"*#XKV_A>!M>G\/'0M<\_5)
M+>PBOSXB\(:E;/8^+/!-TLES#]FL-9L3!')<*93"]I#((I"@%+#6PV987,+<
MRPZM*GM[1TL1AL=A)<ZOR_5\PP.$KM<LO:T85L,^2.(E..=:]3 XK!ING.LF
MZ-6,IQEAZLJ.(P<ZT5"4.:?U+&8RC3O)*E5K0Q*O.A"+;JGPD&H^+;OQ0NOB
MW%SXR\!>+5T\:3Y@B'@?2K[2QIPN1J2;A>"\\SS_ "5\CRMOE2[MRYX6#PU6
ME5YO:.ECLSQMMK_VCD=/)O9WN[>Q]G]9Y]?:<WL>6%O:N,1"-:G4IQ2I1E@L
MLP:25U%9=GE3.5-)6TJJ?U50T]GR^VYIW]DJ7B[X/W_B;6?']W#XJMM,TCX@
M>%O#VCWMB?#LE[JNF:[X3N-2N=!UW3M7.OP6S6237T37&F7&E3F<V@"W<*R,
MH=)3HT^2#BYT,VH9SAG*,N6&*H+*ER5XQG%U\/)9517)3GAJL?:U7[9^YRNK
M3HU:CJ24XK$9=6RG%*,HKGP559EK0;@_88F+S3$/VU18BDU&DOJZ<92GRVL?
M CQ9XFG\:ZIXH^(>@ZEK/C'2_ASI,MI:_#V[LO!BV'P]\0^(M=_LK6/#-QX]
MN[S7] UI?$,]MJ%A+K<'F(D@$HAF\B/5.G"C1HQI1J0AF.(Q\XXA*K3J>WR^
MCERI>S2II/#QH0Q6&J2<W3QL*=:4*D::I&DJE6<*,?;3HRP^&K8>G4H2]E4B
MZM;#8B553:FXRG.A.A74.15,%5]A3]A6C+%59O!_[/$/A2[T^\BUS0;;[)\7
MA\6)=*\+^!K;PGX=BE_X5=+\-7\/Z-HUKKER-*LSO&I_:9)KR0OOAD61I#<#
MHIXETXX.%IU%@\)F.%4ISYIR_M#&RQKFWRI1C1E-TJ=-1UIJ%Y<RE*0Y)T\?
M34(4_KV'R_#^Y%0C367YA1QL)65Y3E5A1C2J.4]*DI58<M)4\-3]9U+P5]O\
M>:9XV_M/R?[.\$>*/!O]F?8O,\[_ (235O#6J?VE]M^UKY?V;_A'?*^S^0WF
M?;-WFQ^5MDX*E+VF"SO!\W+_ &Q2P5+GM_!^IPS2%^6Z]I[3^TKVYH<GL;7E
M[3]VF_\ :,JK_P#0LJ8JIR_\_/K*P:M?[')]4WM+F]IM'D][S!/V>M,N/"_@
M+PCK6OR:EH_A#X+>*O@SJ:0Z6MC-K]AXKTKP?I-UK,,C:A<#1Y8H?"KLML5O
M@6U$9F'V?]_W9AB/KV*SG%*/L)YI+#3IKW*GU>IA<5/%4IVJ0<*UJDH^Y.FH
M/D]Y2C)Q77AL;/".G*E%<]/-_P"U4Y7Y?@S*#P\DK-Q:S#6HI)VI-*"]I>&
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MG])URB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MIU*.VWPL\>W6AZ3HFI_$;0;QO!EYH6J?#_6HOA]=VNM:?JOAYI[6UN/&+_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MM4J]*=TN6TTKW32<XNFJ'.N58A594_[RHRIQJ/3;EE5@O>M>_NWY96VJD04
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M1YI*/NQNTC,TOQA_:/CWQ;X(_L[R/^$5\/\ @[7?[3^U^9]O_P"$LN?%-O\
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MRW YA?EM[O)]=]C:\N;V?M/=Y^2/9TC4* "@ H * "@ H * "@ H * "@ H
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M)/,X1RA?5I*,<1A(X>&(5#D4Z%&A44G#V=6%2/L?PQ^%MM9?%.Y\2>)]-O\
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MQ$>)ZE:JZ?NJ4<13IMXN-2%JD(\N+IR2Y*I9UWX>)HFK>)-&@\!WG_"EM/\
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M\=FM.AG/M$J=ZU.HI\TES3^R*R * "@ H * "@ H * "@ H * "@ H * "@
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MDX4Z<%:%*G&=6K45.G&,/:5:D^7GJ3;Z6@84 % !0 4 % !0 4 % !0 4 %
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MW"%6,?JLHJIIBIT$K05=NLYJO%:7JSFG.$_:QJTZCA5CXAI'CCPGKG_")?\
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M4DHQ5&,\#@:V&Q%2*3Q%:="KB/:3CSI4XTYXK.J-2K]6PF3X_*,;5ERSJ26
MKY-E\\TCS.4IQHT9YI5S:44ITZ5/ NG2I0@H^SY?6[OX@>'=3G\'^+?B7I/A
MSQ7I_@GPA_PA/B3QM\<?%WPZLK_Q5JUM)<^(=>L_"]IX?O=-^)PA\;7 LGTC
M4KZZCM[.#3;".TM(K\27G9A_8O'5:>%7M8X3-:.%H4Y/ZQB,1EF'PV7TZ"J8
M67*I3QZ>,53&Q7MZV,J5Y*O&MA:;IYN:=##XG&49X?"8O"5\;BH4W[&GA,5B
M,;F->OAJ6/DIRI++\(L(J%&I%4:-"$:LJ%6G.I"/4RZK'I_C7QC:>+?$M]X/
M^'U_\=-:3QGXBTOQ'J?@RW&L6WP=^&DOA?2M3\7:7?6-WX?T:]U$WK^8M_9"
MXN;*PL7D=;UK>YQI.B\+E4*LO9X:.!X@J893J.ES8E<7XV$8MQG!5*L,'/%3
MA0?/&<56K<CEAHRCG;$0K9E))5,4JN0T\5*G3510PCX=YL15BI1DZ4/K=/!T
MY5U%2I0JVYJ:FYK!?QAII\0?#ZP\5?%+Q7H_P?N_%?Q<LO"_BL_$/Q%H$'B[
MPMI>D^#+CP[+KWQ M=7MKZ]TFV\176O6FG:Y<:HLM_%9V2F]NEU)S?Q3M*K3
M^OMT,8\DQE:I1G_LB56GG\,/A:SHP]E&.)GE'L:OLU&+E&M4K.FI)J/1/VD*
M>,^J04Z$,YRJE"=.*Q-J57AW'5\;2527MG[%9E&2JNZ5"K3]DE36&A*$-WXQ
M\1K:>!;;7?%;P_"^ZD^+G_"/>+_%WQE\8?""#Q%;:7XRM++X=R:G\2_#^C7N
MH:S*_@V:^N-.2\OK<:S;PG4I9+^6 2!OVEY/'J&"S*.79=4C3;5!JM-X_P"N
MUG@G"-"6(A0I996Q6'J04<%4Q%>"PL8N?U=R4(N2RZ^*RYXSDG52>(<&L'@9
MTZ$,1*HZL<+/,:F:48UX1J>U>%PE#ZY&-2,,=[5\0=8\3Z+^RAX@UNX\:/=^
M)++X<?;5\>>"=1EOIKIA%$]KX@T#5+2RMFU*YDLFAF2XALX5N9&+)"$E"5KB
MU&&9912Q$9812S;(J.,A[-T+.>8X&ECX^Q<INE1J2E77L).?+1E[*?-9IX46
MY8+.*F'5*LHX+/*N$BZ\I0C&&$QU3!0EBG*G-RH1C1C+%>TA/VE-UE54K3/*
M?$_B"W_LCXE6WPC^*/BS7?"Y\!^&9-6\36GQ!UWQC<^%/'=]XQTW3[9='\1:
MMJ6H2:#KEUX>N+R:]T."XAAMUMK&5K"#[<QNLX0E.IA*-6/)@IY_PWA\).$G
M^_H8C,)T\UH1Q,9.IBL/&FL!'VLZE;7$U8*M*\H05:K.EAYUHI2Q,,DXGQ&*
M51<E2G6PV7T:N75*N$CR1PE15WF+@J=+#RYJ$H17^RP5+I?%<OACPIKOC?PY
MXT^)OCKP='X=\,:/)\(H;CXJ>-[35-?ENK:]O=1U6QDNO$1N?BCXH/BYHK Z
M1J1UQ(88-+LX[&.WU/RKOEG6Q4L'CZN"I1JYU0Q-2CA<-&$:K="CE^!^HQ^J
M2<H5:5:L\5[;&5*;JUJJKNMB'/#^TCWT:-*.+RVEB9?\)5>E"KBJ]27LH?6J
MN.QRQD98N+IO#1I8..%JTL-2G0HT(5'.A244O9U++Q'\2F\:>&/A5XAU'Q%I
M_B#XEGX;_%>]NK;4+Z/_ (1K0_#V@VLOQ7\+:9=1S;M-TK_A+/#&@V,EI%(B
MA?B=,L8*;P/7G#"_7\RHX64:F#X:Q6:5TW[1_6<#BN99*JE5Z5JBS'%XIPA)
MM/+\GC1E#V?*GY-*>(CE.7XNNO9XO/,#A<"HN,G.GF-*2>95W1;]G@W+)90E
M1J4I>YF<9UN7V\O:5*&B>*+&\M/A\?BW\2/$?A3PI<^"/$]YHVL-\0_$7@>/
MQ!XUA\8ZM:7EKJ7B73-8L)]8U/3_  Y#8R6&CW-[-'+'->3+9SFQ#VOCT&W@
M5-RD\;_8?#%7#12]I4J2Q&5RJ8VO3PTN>.-KU,6L(L0YT:\E*K2A*WUVI&KZ
M%52C7KQA&^&6=<3TL2VK4Z5/#YG"GEU&5=<LL)15%XZ-)4ZE"+C0LI6P\%'Q
MWP;XHUR+PAX5TS4/'=CX1T<?"W3+WX=>)/&OQD\2_!6*\\17WB7QF-9U^;3=
M)\*W&G^.]=M9[?P])=Z'JTKP6\<L4;:>(]3E:3MHQK2I86%*-&CFL*&24:&'
MBWBH1PW]A9+["-+ N7)7HU<;5Q>&]M"I.K4<*=&%6A)4YUE>E3Q6)E.FZ^4O
M,\_J5:BE[.56M'/,S56E5QL)^VH>SP,:%>C[E&+=;$U^;$N@XX/L/C;K.FOX
M.^/%G\2/B/K6C_$>R@M+#P;X2TWQGKNC:5K'AR3PCX?DCN="^'T5_!8>+M$U
M36+CQ2M[J=SI>H26WDW:FXMCI$9M-\#[&68\.RP<92K2XCPGUJC/]].A3AQ/
M&&$A4A+GCA81RN&!Q$:M-4_:5:CE[6I*<H')4^M1R_,8XSV:P\<@Q+PV(I>Y
M#%5)9).6+K>TBXRJ5UF4J^'CAIM*&&IX6V'C'$NIB/T#TO7=%U2YU73--U2Q
MOM0\.7%II^O65K<1S7&CWUUIUIJEM::A$C%K6XDTZ]M+E4< F*YC<##@GG:Y
MH^VBN:C*I5IQFOA<Z,^2K%/;FIR]V:Z/1FE%.G2PU.:<9RP]&LHO1NE4YX0J
M)=82E2J1C+9N$DMF;52:A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <SX7\*Z=X2M]7MM-FO
M9X]9\2Z_XINC>R02/'J'B/49M3OH;<P6\(2S2>9EB1P[J@ >1V^8JFE2PV%P
ML?X>$A.$&_B:J5ZV(?,U9-J=>:5E'W5%--IR=5).IB*^)EI/$?5U)+X5]6P>
M&P5/E3NU>EA:<IW;O4<VN6+C"/34R0H * "@ H * "@#@?&/@>^\7DP)X_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >"_&.S
MUU=2\,:S/;>/-7^'.EV>NIXNT7X9^(O$7AWQ;;ZC<OI3:+XFV^$M8TO6/$>C
M:?9V^MPSZ1IUU-<,^I03QV%\]NJV^471IUJSQ;E3HU*5.-&OSU%1PLXNM]8>
M)A3=W&O"5!4L0X5(X25&<I*G&L\11W2J3H0IX54WB(UXRG3G&FIUZ7+:$*-:
MJU2I2IU;5*E.;A]9IOD5:/LWAL7@CXFZOI?CS0;?1Y]#U3X+6_P4U3QY_;L_
MBO5M5UV\TO2+G0UCU\O?^&;R[U6]CLIGB$=SKQ-TMW+=7,PN8UB?6O6GAEQ3
MB,RI<L\K>6SA"A"GI+$QSJ4H4Z=-4J-L3/!TXVC^[P\:-)X?VD<155/DI474
MQ/#F7X&4W4S%YC1G#$>T4O:8;$9/14:M2JYUX5,,L943A."J5*M2K2KJD\-"
M530G^.>I^&+#3=?^)?@NT\(^&-?\,Z_XET*^TGQ3+XHU9%\/>'KSQ?<Z-XDT
M=O#&EQ:3K4OABQO+B--/U#6K<SV%U;&Y&V"6\UJT*M&OC,!R>WS/"1YE1H-2
MI5W]=PF7>SH5ZOL6ZCQN.PM**JT:4)4ZGM>=*$XQTPKAC7EM3"RMA<TQ-'#4
M9UDZ4XO$8?$8FE5JTX^TC3HNEA:O/+VKG"3I1=-N<E3XOXM_$'7] \,>!O&W
MQ0\-:'X*\.:7\4/A_J=L-&\5:IXRUPI=-K$?V+5]+C\%:9!I^HKYNFQ".PO]
M8B>>ZFC$PBMTGN<7%8?.<CH7^L8V>(S3"PI44G2JU:V0YG0HQI5JSH.]7$S]
MG%UJ5"G&')5J5*:E.-/.4UBLGS*M13AA/8Y;BI5*UH5*="EGN48B<ZE*FZRM
M##PJ59J%2<UR\D(5)21M^,M>\=S^-O@1J5KX%TZ'Q+J%Q\2%B\.:KXP6UL]+
MTZ3PY#-!=>(-?TSP_J(M+T6<42S6NF6.L1I=W"P17-Q &O J4)4LVQ5.G*G5
MG'(<5[5\TXTU-9QD'-&C)T^>JN:T82G2H<RO*48))-UITZF PM3WXT_[:PKH
M+EBZE1/)\^47./.HT5K*<OWDY1I1TC*M)43?TGXT:[XGC\.Z5X2\%:7>^--2
MA\<S:YI&M^,+O1?#7A[_ (5WXL_X0?Q !XGLO!VJ7>J";Q+F+3S'H4/VBWBE
MGG%H4$3[.FY?O</[^$C@\MQLIU+4ZJCF]"M7P5%4HNK%UG'#XA5OWRI4O8MQ
MJU.>FIW)K#3^K8O]SC'B*U"G2A^]4Z>&C0JUL2JG[M1HQHXO!2BI159U,91I
M.E'DQ$Z'G=[\7--'C;2OB7>Z1?6P\+?!GXX6NN>'H9H+F^A\0>#OB1X"T#5]
M$L[M_)AN]^M:9-!;73"%)8Y89F6(.52\/%JCF?U5>V>;O@U8.,[4G*>9SS^E
MAJ=:SJ1HRA6KQI8CE=6-*4*G)*K&*<L<7'V.(RNGCY1P2RUY[5Q53WJM.GAJ
M."RG&O%0Y(J=2E/ N&+I1]G&M*G.,)TJ=;FIQK^)OB5XC\%_%6U\7_$SPAH_
MAN+P[\"_&U_:QZ#XU7Q#IVIRZGXX^&=E#ID^L:UX<\.)I%_%J;6L,TD\#6<<
M=]#.+ME698,Z$X4:.>TXSBZ]?%\+X2/M'[.A[3$5N(J-*I[:TIJ@I5&ZLI4(
MU81IS:HS?(I.M&56KD<^2<:-.EQ!BI)1YZ\:6&PN6XBK%T8MP=;V-.\*=.M.
M,ZEZ?M$DIRWT_:4O[E)-*T;PKX,\7>+3K_@71;6U\%?%6#Q%X,D3QW/K5G:S
MW/C6/P=!)9WFFW6@WDE_8G1I)4M9;:XMS<-<+#25.=2>"IT%KBL1CL/*57FI
M4X?4LKK9JJL)1C5E5I5J=%T$^2$Z==58RIN,*<JUSG"A2K5ZWNTH4J%2$:;A
M4KR=3,<#ETZ52ESQ5&I"6.HU*<I3EAZRO"->+A7E0]&\)_$_7M?\>:KX'U3P
M]X2\/76A0@ZC9S^.=4E\5W@73[*>36O#?AB[\!6,>O\ @MM2NVLXM:75+<M]
MG8S6EO/FU1T53KTL17IRDZ5*I6A&/+'VU/V>*G0H?7:2FUA)8JE2J8JBHSQ$
M94G0]G.I[2I*A-252C/#4JE.,:E6-*4I<S]C/FP_MJJP=5P3Q7U:I.EAZRE#
M#SA45=RA&-*E]9ZSQ[XTN/",'AZSTK28M=\3>+_$$?ACPOI%UJ3Z+I]SJ9TO
M5==N9M5UF+3=0DTS3+71M$U2ZEFBL+V7%NL<4$LDJJ<X1J5:\,/1@I-4ZM>K
M*4N6-'#T.15*CM&4I2=2K0H4J<8^]6KTU.5*DJE:GOR*.'Q.)E=4\*J*:BHN
M4IU\12PU*,5*4%\=53J/FO&C"K.,9RC&G+YT^+'C'Q5XMT.S\&7W@?PLNJZ7
M\9/ACX=\;>&]3\9W]UX8UC2]9U/1M;T06>HKX"DDUS0-31_LUY%?Z38/!)87
M49MKN+89ZPD:6)S+))JU7#^USBE6A4@N:CC<%D.88KE<'S0G[&G/#YC@ZT9W
ME4^JQE'#5?:2PW/CJD\)@,RA[65"M*GE%2E.B[N6#QV?8;+YJ3O3E3G6E2Q&
M"Q%*TH_5ZE:<:E6/)3K_ %1K>I)X7\+:MJ\5A"T?AW0+_48],MI!;6[)I.G2
MW*6$$JVY%O"5MQ$KB A%P1'QMKES3&O!83'Y@U+$RPU.M7:E+EG5<(RF^:3Y
M[2G;5OGLW?WCKRW"+$8C 8%<N&5>I1H+D7-"ESRC3]R-J?-&%_=5H722M'I\
MY3?M':M86GA>'7O#7PX\(^(O$_A8>.X=(\8?&BU\/V-EX5NH[5-(ADUBZ\#D
MWGC"ZO9;N)]+LK.XLK>/3Y)9=7S+#'+VXR,,%B\RPCG[>IDW+'%1HKFJRJ5*
MV+C"&"IR</K%J&$E4J2K3PJC7JTJ$/:PD\0N/!U7B\'@,:J;HT<T4GA92OR<
MM*CA*E:>)DDW0BIXRG&@H1KU:U).K.E1G&="';>&OB_K?Q"FL'^''@[3M1TM
M=#\(:WXBU'QAXJN_"4FD_P#"7V$&M6VCZ=8Z7X3\02:QK5GHDR7-PDS:;;!K
MJTBBNI#+,]II*A[+$8J%6I%87"8RI@W5@I.I4G2I8>M4J4Z,E3C[)4\3247.
MM"<JJJ4W"*I\[N4W&G3AR_[;.C4K>SYH2H14,1B\'%/$TY5(SY\7@J\%.C3J
MP]C#VZE+GI4ZD$?QGU<QVWB>3P;8Q?#"[\;IX$M_$_\ PE4[^*/M\_B__A ;
M/69?!H\+BTC\.S^*2D2S#Q"]TMM-%=-9@%XXLL)"5=Y="HO8SS;#K$X51:G'
MV=7 RS'"JO)^S=*IB<+&\8TXUU"M5H4JDH\U65&ZNG]H?5?]J_LEU5BO^7=G
M@Y2AF7L>:_M?[/<*OM>;V7M5AL4\/[7EP_UK$T?XY>-M<2Q^P?#+18I_$WCW
MQ;X%\$07_P 0[BW.I_\ "":IXNM/$WB+Q&]MX$N!X;T9;'PJ)K-;4:U=7,^H
MI;RV]K'%]JE5&$ZM' -<L:^+RRCG%2FY/DH8&M2RYQ_>*+=3$O$9E0I0HQIJ
MFZ,HUYUZ<_:8>DJU2CAZN,INHY0PN-J9;3DHN^(QL76G&G3C>T:4</AL56Q%
M6I.#I2PU2E1AB7*C*KK? 6\UB_OOC?<Z_H\.@ZP?C+>17^EVVI?VS:6\UM\/
M?AY;B2QU0V5D]]8SI$EQ!++9VDIBGC\VWADWQIK#D_L;(?9N3BXYL_?BH33?
M$>=-QE&,ZD4XN\7RSE%VNFTS"7,LXSA227+'*TG%MQ:_LC N+3<8O9KF7+[L
MKQ3DES.Q\2/C;#\./%&E:/?K\/YM/OKSPQ:26=W\3;?2OB1(GB378/#_ -OT
M/X=2^&I1K>GVEW>V;O(=:M'DC6[\N,O;QI=88.V*Q:PE[2G6C0@Z5ZSC.I2<
MZ+Q$$HNA"I43I\UZG+#]])*"ER]5>/L,+4Q-^54<-B<5+VO[J$H81.I5IT9^
M_P"UJ^QA)QBXPBZTJ-!S7M'4IW?A=XM\?>(?&?QGTKQ39:!!H?A'QY;:%X<D
MTS6KB^O+6TD\#>"-<2QFM7\)::)89&UJYOGNI;V>6.>]DLU1[>UBN)=:,$\I
MR[$U5RXK$/&<RB^>$O89CC<,]7R<OL50ITJ=J;]O!.O4]E4;I%8R/L<=3HT4
MOJ[P6'K7;:FYU*N(BIN-I).I&G:<%4Y*7LX<CJ.I.4)?&'BKQ]IGQ=^&7A;0
MK#P_/X3\0Z/XPO-=>_URYL=1D?17T &2"TB\(7XW65OJ+2P1IJ-LMY)</%.U
MLENDDW+0?M,3F-*L^6C0RZ=:GRKF:G]9PM)5&FX:WJ2H\G,X*G.5:[J0A2:Q
M$53P&'K4M:\LQH8>7-I'DG@<SK^SO[]HREAH5)5%!3A*C"G&,H5JDH>3?!CX
ME:WX8\'_  VTSQ/X4T_2_"?B;4_'6B:%XB@\3S7^MM?Z WC'Q09]6\+KX;BM
MM.TJ[TGPYK4D-Q#KE[,#':+-;1-<N+8HU(4LGP=;$/V;R_A;*LQ:@N>+P^&R
M[*:-6,I/V;A72Q5*I"G&%2G**JQ=:,H050="K4Q^:K"P=>$N(,SP]24FJ;A4
MQ><XZG2E"+<O:4EB'3P\Y-TYJ<^>-*5",JIVGPP_:&TSXC:]H6DPVWA%;?Q9
MH-]XB\/'PS\0]-\9:Y86ED+*X6S\=Z#8Z3:CPEJL^GW\4L<5O>ZQ");6[MI+
MA)(HOM/;]6J0EBZ%6RQ6!@IU?97JX;E]K"A.-/%)1C.I3JU*:Y?9QC5@Y5:$
MZM.G4E'GE6H\M"K1GSX;$U_847.,J->=Z-:O"M]6FN:%"<,/5UJ2C6I.>'A6
MH4ZE:4*7I_CGQI>>%Y/#6D:'HD/B'Q3XQU>?1_#^EWFJMH6E!['2;_6]2O\
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M]FIU/:_&_BRX\'>$Y?$4O_"'6,UNVGK=MXV\:KX*\+6/VF:**Y-YXKDT+43
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M&DJ3<N:E3J+$8>IB(*<Z7_+W#0Q&'HUI4H<E2K3JMX>SJTN(T_XF)IL?P_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F_Q ^'
M*_$2TETC4O&'BS2/#-_8/IFO^%]$3PBNE^(K*6=)9XM0O=8\)ZAJ]@\D"R6Q
MFTC4],E2.9GB=+A(IXG0?L,51Q3_ 'SPU;#8BE3G\%.OA*CK4JB]GR5)-5E2
MJ2C.I*#="G'D]G*O"LY2?LI4H/V4I0K4Y5(I2DX5X*G*+C44Z348<\8_N_\
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M&JCQ,IPC)XBO@\2GK^ZK8'+X972G32=GS82,XU(U54@YU9U(QA*-+V7G.H?
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M<)1H\O)[M2?M%.7(X>B5P'<% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M8G#>QE&\KN/U?G<^9:SY.3W>:4GQI^+'_"H-"\*ZU_8'_"0_\)+\1O _P_\
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MC4* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M"TE7<:E&OQ!B<14<E*I]8JX;+Y495IS4HT9XVM2E"-:I%0]ISU;2Y)GS]?\
MP\^*?_"&?M-Z'H?P\\1VWAGQM\!_"NI:!X<\(_!3QU\-] U/QNOB^[75+;2_
M!6N>(O$=]-XN2R9A=2-)87MY#'#<2V'EK%<W&KCRX>GAYS=18#BGAVKAG*4&
MHX'GIU,56HP@FL/A8NE2G7I*I4AAJBDZCHSG*FL\)-1S3+L0XQPZK9-Q!2Q6
MMVL4J5.&%I8C$-I8FJ_:UH8:MR0]O%RC1E5C'W?H+6O!7BG2/VG/ _B[P_X*
M\3?$:[U2?X?Z3XBMO'GP^\01>'?A3X=TSP_$NI>*?AA\6#?6^D:(Z7!A:_\
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MIM+50C*<(N6R<XIN\E=V:A*=K0@XJ4OLQ<Y*$$WLG*<HPC?XI-15VTBY2$%
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M;$VLVHTYMT\1R6G4P57%8=22KR/)OASXX\/>(-,T'4_&'BK7?AY\)O$WBO\
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M1-8[>5CI"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%A?$'POYOVO[1+Y/V#[=M^PS_:/(W0?:#8$O.UOZZ'$?\+7\>?\ 1LOQO_\
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MIID=YI/C&]\,B^U);:%[5W\1);(M_!]MN+1EG6V!;?(\Z_X6OX\_Z-E^-_\
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M*7AO4&OHXX(IV>&QEMC'>PA+AY5FC@-@2\[6]?T.6_X6OX\_Z-E^-_\ X/\
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M/[/--):R?:]+M<RVLIB\V Q33&P6\[??_D8G_"U_'G_1LOQO_P#!_P#LW?\
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M4X)? 7C'Q)IZV,DD\L"I-?17(DLIB]ND30R3FPMOD>=?\+7\>?\ 1LOQO_\
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M:^CC@BG9X;&6V,=["$N'E6:. V!+SM;U_0Y;_A:_CS_HV7XW_P#@_P#V;O\
MZ(.@++NOQ_R/1=0\0ZO9>$X_$5MX%\5:MK#6.F7;> M/N_!$7BR&XOWM$NM,
MDO-5\8V7ADWVFK<3/=.GB)[9UL)_L5Q=LT"W(+]#SK_A:_CS_HV7XW_^#_\
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M;_PKWX@^*/*^R?9XO.^W_8=WVZ#[/Y^V?[.;?(+6ZG$?\+7\>?\ 1LOQO_\
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M'0%EW7X_Y!_PM?QY_P!&R_&__P '_P"S=_\ 1!T!9=U^/^1[?0(* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M ,PU <DNP?\ #QW]C'_HLG_F//BK_P#,-0')+L'_  \=_8Q_Z+)_YCSXJ_\
MS#4!R2[!_P /'?V,?^BR?^8\^*O_ ,PU <DNP?\ #QW]C'_HLG_F//BK_P#,
M-0')+L'_  \=_8Q_Z+)_YCSXJ_\ S#4!R2[!_P /'?V,?^BR?^8\^*O_ ,PU
M <DNP?\ #QW]C'_HLG_F//BK_P#,-0')+L'_  \=_8Q_Z+)_YCSXJ_\ S#4!
MR2[!_P /'?V,?^BR?^8\^*O_ ,PU <DNP?\ #QW]C'_HLG_F//BK_P#,-0')
M+L'_  \=_8Q_Z+)_YCSXJ_\ S#4!R2[!_P /'?V,?^BR?^8\^*O_ ,PU <DN
MP?\ #QW]C'_HLG_F//BK_P#,-0')+L'_  \=_8Q_Z+)_YCSXJ_\ S#4!R2[!
M_P /'?V,?^BR?^8\^*O_ ,PU <DNP?\ #QW]C'_HLG_F//BK_P#,-0')+L'_
M  \=_8Q_Z+)_YCSXJ_\ S#4!R2[!_P /'?V,?^BR?^8\^*O_ ,PU <DNP?\
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M ,PU <DNP?\ #QW]C'_HLG_F//BK_P#,-0')+L'_  \=_8Q_Z+)_YCSXJ_\
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M  \=_8Q_Z+)_YCSXJ_\ S#4!R2[!_P /'?V,?^BR?^8\^*O_ ,PU <DNP?\
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M"[[L/^&9/V;?^C?/@A_X:?P'_P#*"@+ONP_X9D_9M_Z-\^"'_AI_ ?\ \H*
MN^[#_AF3]FW_ *-\^"'_ (:?P'_\H* N^[#_ (9D_9M_Z-\^"'_AI_ ?_P H
M* N^[#_AF3]FW_HWSX(?^&G\!_\ R@H"[[L/^&9/V;?^C?/@A_X:?P'_ /*"
M@+ONP_X9D_9M_P"C?/@A_P"&G\!__*"@+ONP_P"&9/V;?^C?/@A_X:?P'_\
M*"@+ONP_X9D_9M_Z-\^"'_AI_ ?_ ,H* N^[#_AF3]FW_HWSX(?^&G\!_P#R
M@H"[[L/^&9/V;?\ HWSX(?\ AI_ ?_R@H"[[L/\ AF3]FW_HWSX(?^&G\!__
M "@H"[[L/^&9/V;?^C?/@A_X:?P'_P#*"@+ONP_X9D_9M_Z-\^"'_AI_ ?\
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M3]FW_HWSX(?^&G\!_P#R@H"[[L/^&9/V;?\ HWSX(?\ AI_ ?_R@H"[[L/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /@[_ (*6?\F=_$O_ +"?@'_U
M/?#E!4/B1]7_  C_ .24?#'_ +)[X+_]1O3:"3X3_P""<7_-U/\ V<?XM_K0
MBI?9]#]+J"0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#X._X*
M6?\ )G?Q+_["?@'_ -3WPY05#XD?5_PC_P"24?#'_LGO@O\ ]1O3:"3X3_X)
MQ?\ -U/_ &<?XM_K0BI?9]#]+J"0H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#X._X*6?\F=_$O_L)^ ?_ %/?#E!4/B1]7_"/_DE'PQ_[)[X+
M_P#4;TV@D^$_^"<7_-U/_9Q_BW^M"*E]GT/TNH)"@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /@[_@I9_R9W\2_P#L)^ ?_4]\.4%0^)'U?\(_
M^24?#'_LGO@O_P!1O3:"3X3_ ."<7_-U/_9Q_BW^M"*E]GT/TNH)"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /@[_ (*6?\F=_$O_ +"?@'_U
M/?#E!4/B1]7_  C_ .24?#'_ +)[X+_]1O3:"3X3_P""<7_-U/\ V<?XM_K0
MBI?9]#]+J"0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#X._X*
M6?\ )G?Q+_["?@'_ -3WPY05#XD?5_PC_P"24?#'_LGO@O\ ]1O3:"3X3_X)
MQ?\ -U/_ &<?XM_K0BI?9]#]+J"0H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#X._X*6?\F=_$O_L)^ ?_ %/?#E!4/B1]7_"/_DE'PQ_[)[X+
M_P#4;TV@D^$_^"<7_-U/_9Q_BW^M"*E]GT/TNH)"@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /@[_@I9_R9W\2_P#L)^ ?_4]\.4%0^)'U?\(_
M^24?#'_LGO@O_P!1O3:"3X3_ ."<7_-U/_9Q_BW^M"*E]GT/TNH)"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /@[_ (*6?\F=_$O_ +"?@'_U
M/?#E!4/B1]7_  C_ .24?#'_ +)[X+_]1O3:"3X3_P""<7_-U/\ V<?XM_K0
MBI?9]#]+J"0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#X._X*
M6?\ )G?Q+_["?@'_ -3WPY05#XD?5_PC_P"24?#'_LGO@O\ ]1O3:"3X3_X)
MQ?\ -U/_ &<?XM_K0BI?9]#]+J"0H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@#X._X*6?\F=_$O_L)^ ?_ %/?#E!4/B1]7_"/_DE'PQ_[)[X+
M_P#4;TV@D^$_^"<7_-U/_9Q_BW^M"*E]GT/TNH)"@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /@[_@I9_R9W\2_P#L)^ ?_4]\.4%0^)'U?\(_
M^24?#'_LGO@O_P!1O3:"3X3_ ."<7_-U/_9Q_BW^M"*E]GT/TNH)"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MGPG_ ,$XO^;J?^SC_%O]:$5+[/H?I=02% !0 4 % !0 4 % !0 4 % !0 4
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MN,-0C%8C"*%_WBQ;3G.M.7/2E.2IQY%"$??JR- H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^#O^"EG_ "9W\2_^PGX!_P#4]\.4%0^)'U?\(_\ DE'PQ_[)
M[X+_ /4;TV@D^$_^"<7_ #=3_P!G'^+?ZT(J7V?0_2Z@D* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /&?
MCK\9]'^!?@B/Q;J6CZGXDO\ 5/$&B^$?"_AC1Y+6#4?$7BCQ#<FVTK2H+F]D
M2"S5RDTDD\I(2.!R%=MJ-BYU98O 9?A:/M\;F-5TJ-/F5./N0E4G.I4=U"$8
MQLY--<TH)V3<EO3I1^KX_%UJGL,)E>'EB<14Y93<*49PIKEA'WI2E4J0BDN[
M?2PG@/XC>-;KPUXB\1?&[X=Z9\"8/#PCN99]4^)7AKQ5H;Z3]G:>YU6Z\0V5
MO86VDP6I BF%XD05MS*S1!9).FK]7HT:4WB8JI*JZ,H27(E)NC&BX3D[5%7J
M573I1M&HYPLX)SBGS4_;5*\Z5.A*5*-*-6$UK)_Q75A.G&[A*C3IQJ5)*4Z?
M)434WR3Y>XTKX@^ M=UJY\-:'XW\(:QXCL[2&_N] TKQ+HVH:U:V-P@DM[RY
MTJSO9+J"TEC9629XE1E(*D@T*G-JLU"36&J2I56D[4JL'RRIU']BI&6DH2M)
M/1I,.>"6'?/%+%056@[JU:G*/-&I2_Y^0E'WE.%XN.J=A?\ A8'@,>*/^$'_
M .$V\(CQJ(!<_P#"'_\ "2:,/% MB,BX_P"$?^V_;_((YW^1M]ZBE^_55T/W
MT:#M4</?5-J^DW&_(U9Z2MLRJB]@J3J_N56_AN?N<^WP<UN;=?#?==QNO?$+
MP#X5U32="\3^./!_AO6M=E2#0]'U[Q+HNCZIK,TDGE1PZ3I^H7L,^HRM+\BI
M;QR$MP!GBBE^^K?5J/[W$)7]E#WJEK7OR1O*UM;VV"HO8T7B*O[K#Q=G5E[M
M-/LYNT4_F<9X.^*R:Q<?%1_%<7A'PEHOPW\:W7AB+68_B)X5UZ"[TZWL[.X3
M5/$D>G78/@746EN_+;1]7:*Z0*DC+MF2HI5*;RS!X^M.-"6)JXJFX<RE2C]7
MK.E#DQ"?LJLIQCS3A!N5"5Z51*:9I5I3IX^I@J4955#"X/$*7*X5+XFE*I.+
MH/\ >1ITG&U.NU[/$1O4I-Q3*OC;XR>'X/@Q\2_BC\+_ !-X+\='P7X,\4Z]
MIUUI&LV7B?P[)JVA:->:C;V>H3^'M4&^$S6Z"6**[@D*%@KH2&'/F=6O@<''
M$QI6YJE",'4C+DE&K7I4I.+3CS6C4NFG9/E;NM'U93AZ&.S3#8"K4<5.HH5%
M"454A?FZ-2Y7>+7O1Z/30Z?X2>+]2\>?"CX<^.]8@L;?5O%W@3POXHU.VTR.
M>#3H;_6M#L]3NX;&*ZN;F:*T6>X=8UEGG=4"AI'(+'V.(:%+)L=G&'H<U6CE
ME3$1@IR7/*-!RMS2C%14I*.K4$KZJ/0\?+JT\9AZ56HHQE.=2+Y4[)0JSIK1
MMO:*;UWOLM#YT_95_:_C_:4U3QCHU]\/9/AUJ'ANRL]9T>.7Q2GB9/$_A^;6
MM<\.W>K6SKX?THV26FLZ'+;21LLWS3+\P ^;&G14LHIYG*?LYQE15>BU_ AB
M<'2QN%J.I=*4:]*=5JT5RJBW)WERQ[<R@\NSW$Y,VJL:,L5"E67NNK+!XB-"
MNG2][DM[2A-6J3;]I)-)04IGP(_:_3XX_&7Q]\+K/X>2Z!HGA33==UGP]XWD
M\4IJ:>,M*T3QG+X*_M"WT)?#UK_9EM<7]I?NK'4+HC[(5PP8.,\OIRQN2SS>
MHOJTH2P%L._>?L\PP^(Q5"<IODY7["E3FX<CO[;XK0O.,S:R[-Z.5+]^YQQ*
MG5MR>SK818>->DH/FYE&K7E353FC=4^;E]_EA]1Z3\0/ >O:[J?A?0O&WA'6
M?$NAG&L^'=)\2:-J.NZ.1VU/2+.]DNM//_7>*.HIKVU%XBC^]H1?*ZD/>II]
MN>-XIZK2]PJ+V-2-*K^ZJS7-&$_=E):ZQB[-K1ZI6T?8+CX@> [/Q/!X)NO&
MWA&U\9W40GM?"-QXDT:#Q/<0'&V:#0)+U;Z:([EPZ0$<CGFBE^_=54/WSH?Q
M%#WW37]]1OR;/XK;!47L(TYU?W,*SY:<I^XIOM!RLI/RC=GE-A^U!\&M1^,N
MH_ ZT\8Z"WB_3-,@N&F;Q%X972[W7)=3FTM_!.ENNM-=7OC2UEMIY+K2EM%F
MMT"E@2Q59PLGC<-C\3A4JBP4H1A&ZOB(/#5<54Q&'MS*>%P].ERXC$74*4W9
MZ1DTL8_[/K8.CBHRHO%TY5.:2<84'[:A0H4:\I<OLZ^+E7C+"TM95J:<H[P4
MM;X<?&;3O$W@O2O%'CFY\#> [K6_%^M^#](L;?XF^$/%FF:KJ6G:IJ%CI]CI
MGB/1[[[#J&NWEKI\MPVD0.]W;,DT$L?F6\F+BHRH9;44OWV.P$<=*DE?DC&G
M*KB'2FO=Q%##TUSSQ5*]%PO/F44V76@Z.+S:BDWA\KQ?U;VTDX-J3HPI2K4I
M>]A:E6K5C2CAZW+5YW!)-U()^B^&O'/@KQE!?W7@_P 8>%O%5MI5U)9:I<>&
MO$&DZY!IMY%N\VTOY=+NYTL[I-C[HI2CKM.0,&DURT88E^[AZB<H57I3E&.L
MG&?PR44U=IM+J3M6EA]J\+<U+_EY&_P\T/B5^EUKT,?3_BU\*M6E@@TKXF?#
M[4YKG7E\*VT.G^,_#E[+<>*'BGF3PW!';:D[2Z\T-K=2#3T!N"MM*PCQ&Q%4
MX2J^Q]E%U/;TZM6ER)R]I2P\5*O4IVOSTZ,6I59QO&G%IS<4Q591H>T5:2H^
MPE2A44VH>SG7DH4(3YK<LJTVH4HNSJ2:C!-M([FZN[6PMI[V^N;>RL[2)Y[J
M[NIH[:VMH(E+R33SS,J0Q(@)9W8  $DX%9SG"E%SJ25.$=Y2:BET5V[):Z%Q
MA*<E"$7*4MHQ3;?HEJ_D<CHOQ+^''B31]6\1>'?B!X)U[P_H$=S+KFN:+XKT
M+5-'T6*QBDFO)-6U.QOY;;38[>&&:25KB2,1K$[.0%)#J-4*$<35?L<-+6-6
M?N4VKI7C.5HO5I:/=KN%.$JV(6$HQ=7%.48*C!.57FD[1BJ<;SYI/2*Y;MZ)
M'S;^SC^TI?\ Q\\=_%""SUSX3+X*\)>(/$'A[PMX=T+79=6^)NJ66@:E8V4/
MC[41#JTEC)X+U5+EQ:S6MBJ[_+"W4P:ML)1J3R7"YAB(26)Q:IU?9TTU#!0J
M3Q,(X7&\R<HXV:H*K"/[M>RYFH25I++&5:5'-98##3O2PT5&52K9/%U%2I3J
M5,%RNTL-1E45.4O?;;7,Z4ER/J?BG^T-KOA/XFZ1\&/AA\++[XM_$J^\*2^.
MM2TH^+M&\"Z)H'A./4O[)CU"_P#$&L6MV);J:^#QQ6D%K(Q.PLR*^1SX=UL5
M/'NE1;PF5RH0Q-9RBN6MB(2J4J%*#LZE5TXJ;3E3@HR3Y_=GR]-:G3PV'PE6
MM54:N/J5*>&I)-N7L4G4J5&G^ZI+WE&?++FE3J12YE%3G\:?M2_#WX5CX7Z7
M\6;C3_ ?C3XC7.DVU[X1O/%GA&XN/ 2:C!=R7&L>+=1DUFUAM_"]I<6-U9MK
M%NDUM+<QB.(L"67;_9YYE++\-BH5H0HXBM+$-.G1A[##QKJC/G]^G7Q'-&GA
M:,XJ=63O:*1SSCB*. >.JX6<8_6:>&A3IIU)U?:8GV#K4K)*5&C!QQ&)G=>P
MHR7.N9J+]AUWXF_#?PO;Z+=^)OB#X(\.VGB,6[>';K7?%>@Z1;Z\MTB26IT6
M;4+^)-4$T<D;1FV:7>KJ5R",IPG#$RP4HN.,@Y*5!IJM%P;C).D_?3BTU)..
MC33LT%.4:N&6,I253!N*FJ\6I4>1I2C)5%>'*XM-2YK---.S1N:SXE\.>'-&
MF\1>(-?T30O#UK"ES<:[K.JV&EZ-;V[@,D\VJ7L\5M#"RD$.TH4@C!YK.K*-
M!J-:2HOFY$IM0?/K[MI6][1^[OH]-#2E&5>WL(NLFN9<B<_=T]Y<M]-5KMJC
MYV\4?'^2+XR?LW^#/ >H>"O%?@'XT0_$Z;4_$^G79UUBG@CP]#J>GOX9UK1M
M9&G>6]^TT-R98+X%8RB&)U+5U8*A*KC,[PV*A*A'+,HHYC2NG"3G5QU+#?O.
M=-.BZ-1SCRJ+<K2YW'W68CV=/*8XZC-3K+-,+@)1NG",*T*LJEU&TE5BX1M>
M5DF[P=U:O\9OVB[?PA;?".^^&FM> O&.G^,_V@/"7P?\67T>HIXAM-%M-5.H
M#7H;>YT#7(8M.\2V1M8ALO&G6'<WG6K9&,\OC'%9IEV&JOER_'Y?FN.A7BTE
M.. PDJ]*=*J[TY495(N-224DXIJ,X239=:FJ66Y_B%=8_)H4+4'O&K5Q%*DZ
M=>GI4B^2HW&-X2O9ZK1_0OAKQMX,\91W\W@_Q;X8\50Z5=O8:G+X:U[2M<CT
MV^B+"2ROWTN[G6SNT*L&AE*.-IRO%19JC3KV:H54W"I;]W-1^)QG\,E&ZNTW
M;J9/W:LZ#]VM3MS4WI./-K'FA\4>9;72OT*FA?$7X?>*-6U+0/#'COP;XBUW
M16*ZQHFA>)]$U?5M)93M*ZEINGWTMQ8,"0")XTYHIIU:/UBDO:8=/E]I#WJ=
M^W.KQOY7N%3]S55"K^ZK6NJ<_=G;>_([2M9;V/'OA%\;-0\8:O\ M"1>-9/"
MWA[0?@_\5-3\%Z;JR//I-N/#]AI&F:@-0\1WVK:M-;B\$MY*'GB%E $5!Y2D
M%FRPU6G/(<MS7$3C1J8NOF%*=Y*%**PF,EAZ7+S.ZE**7/><N:?PJ*]TUQ5&
M=+.*N6X>$JL(8#*\5'1RJ.IC<-.M67NI)P@X^XE'FC&_-*>Y2L_C^/$'[0_@
MCX:>#=3\$^*OASXJ^$GB7Q[_ ,)3H-Z-<N9M7T3Q'::-%;:;K>E:S)IDFF^3
M/)YL?V6:7S%&)D *G;!4ZE:KG]/$4Y45E>&RVO0]UP<_KM:M3FY\R?-!1IIT
MW!0UNVYJR6>*=.CA,GKT9J<\=F..P5=735..%P-/$Q45&SA5YYVGSN2Y+)0B
M_>?N5A\0/ >J>([_ ,'Z9XV\(ZCXMTM=^I^%K#Q)HUWXCTY!GY[_ $2WO7O;
M-?E;F6%!P?2II?OJ<ZU'][1IOEE.'O0C+16E*-XQ>JT;3U0JB]A.G3J_N9U5
M>G&?N2FN\%*SDO-70RV^(?P_O+Z/2[/QSX.NM2FO];TJ'3K;Q-HL]]+JGAA#
M)XDTV.TBO6E>_P!)16:^MU0R6@4F=8P*46IT_:P:E2^K_6^>.L/JOMOJ_P!9
MYEI]7]O^X]M?V?MOW?-S^Z$U[.;I5/<J1K0P[A+22KU*,<33H<KLU6J8>4:\
M*=N>5&4:L8N#4@\+_$3X?^-Y]3M?!7CGP=XNN=%E%OK%OX7\3:+K\^DSEF00
MZG%I-[.UA+O1UV3A#E",9!JXQE*E&O&+E0D[1J)-TV[-I*:]UNR;LGLGV"?[
MNK["?N5DN;V<M)\JLG+D=I63E%7M;5=T=C4@% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\'?\ !2S_
M ),[^)?_ &$_ /\ ZGOAR@J'Q(^K_A'_ ,DH^&/_ &3WP7_ZC>FT$GPG_P $
MXO\ FZG_ +./\6_UH14OL^A^EU!(4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MAB<&\MQF&4,+^XP:H5,*OJT:M*HYNG/"5H4:E&C4FZWM8SY7.4W4.?%TZU/
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M?^SC_%O]:$5+[/H?I=02% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % %'4]4TS1-.OM8UG4;'2-(TNTN+_4
M]4U.[M[#3M.L+2)I[J]OKZZDCAL[2&!'DDFE=$149F8 $U$ZE.E'GJ3C3@G%
M<TFHJ\FHQ5W97E)J,5U;26K+ITJE:<:5&G*K4D[1A"+E)OM&,4VWY)'$>-_"
MGA7XV?##7_",^LRW7@[XC>%YM/.O>%-1TZ>2YT36[0&+4M!U1[:^L9EEMI4E
M@N/)N865U8*ZD9G'X!U+X3%0J4*F'KT:DH-<E2%7"UZ=>,)QG%N/[RDHSBTI
M<O,DXNS3PF+]E)U\/*%12IUJ5[\T;5:=2A.SBU[T5.5M;*:U3LT^L\.:':>&
M/#VA>&K"2XEL?#VC:9H=E+>/$]W)::3906%O)=/##%&]PT-NA=HXHU+$E448
M [L9BJF-QF*QM51C5Q=:I6FH)J"G5G*<E%-R:BG)J*<I-*UVWJ<.!PE/ 8+"
M8&BY2HX*C2H0<VG-PI0C3BY.*C%R:BN9J,5>]DEH;-<QU!0 4 % !0 4 % !
M0 4 (5!QD [3E<@'!' (]#R:-O*P?U]VJ^YJXM %+4K%=2TZ_P!->XO;-+^S
MNK)KO3KJ2QU"U6Z@>!KBQO82)+.\C#EXIHR&C=59>5%9UJ7MJ4Z7/.ESJW-3
MDX3CYQDOA:Z,THU/8U:550A-TI1DHU(J<)<K3Y9P>DHNUI1>C5TSY\\-?LS>
M&-'\:Z#X^\3>//BQ\4M=\(27TW@N/XE^+K;6M*\(W&HVS65U>:/I>E:-I<$V
MH-9NT(O=16^N0I!$N]59>BA4^K2KU:5."Q6(HRP\\0XKVJH3DIU*5.UJ=&%1
MQBJGLH0<XKDDW!N+PKP]O3I4)2E'"T:M.LJ$9/V<JU%-4JM5R<JE65-MR@JE
M2483;G&*DVW](5F6% !0 4 (0""" 01@@\@@\$$>E +3;2VPH    P!P .
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M@D* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MM,9D6*^'^Q*6)I<F_MOK%>G7YN;3V?)[/EM:?-?FO&UGQ'PH_9Y\8_"+P/\
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M?2SK3?LX>;XC_:@\0?\ "9;?^&D?"VB>&OL?_".Y_P"$,_L;P9J?A'[;Y_\
M;@_X2+SO[1^U^3Y>F;/)\KS&W^:OE5J'M>'JF0\W+SYCC,?[>U[?6Y8:7LO9
M77\/ZO;VGM/>Y_@CR^][=''^QSK(LX]ES?V)AZ-#V/-;VWLL6\5S>TY7[/FO
MR<O).WQ7?PE.R_9D%G:_LLVK>-1,O[--K+:L3X;V#QL)/!Z^$RQ7^WF_X1P
M+]JVYU3KY6?^6E>GB\3#&9]F.<U**]GF&7XW 2PSE=1CC'1;FZO*N905*W)[
M./-S?'&VODTZ;IY15RI3UGF6%S%5K6Y7AL3B<2J7)?7F^L<GM.=<O)S<DN;E
MCS?AG]DW5O 6H_V9X%^*%AI'PP_X2.[\0)X)UGX3^#/%&O:=#J.KG6-2\/:+
MX\U*59[/09II;J)%NM-OKJWBNF$%TC(CISX.I/#QP-/%2>+AEU.E1HO^%5G3
MH+EHQQ-2%W5=.*C'G@J-22@E*;6AT8Z;Q=;'8JE_L^*S&4ZE:5W4@J]2'+.O
M1IR:5.<I)5'"4JE%35U25Y7^S0 H  "A1@ <  <  #H!4&:2BDDN51T26B26
MR2Z6%H&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 ?!W_!2S_DSOXE_]A/P#_ZGOAR@J'Q(^K_A'_R2CX8_]D]\%_\
MJ-Z;02?"?_!.+_FZG_LX_P 6_P!:$5+[/H?I=02% !0 4 % !0 4 % !0 4
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MC[XR6OPT\:7&GZM!XEET&WET;5-1FBM9O#VNI'I>NK-8HNV^2X4+O!@SAE>
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MTL92HS]UN2Q&&HKVM-VJ.E:L_A<'S<OO6NG]5R21PQO+*Z111(SR22,$CC1
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M?Q9PLXNTE\Q:5=?"?XC?M#?LUW?[,'AFR@L?!6D^+]/^,6I^'O!]YX;T31?
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M'A803=*4:?LYW7[G#S2E4E'V2HK]=*S("@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#X._X*6?\ )G?Q+_["?@'_ -3WPY05
M#XD?5_PC_P"24?#'_LGO@O\ ]1O3:"3X3_X)Q?\ -U/_ &<?XM_K0BI?9]#]
M+J"0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:-&*24(<]24Y/6=23YJLYR29[!610@ 7A0%&2<  <L26.!W)))]S1MY6 6@
MH * "@ H * "@ H * "@ H * "@ H * "@!" 1@@$ @X(! *D,IP>X(!'N*-
MO*P"T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % 'P=_P4L_Y,[^)?_83\ _^I[X<H*A\2/J_X1_\DH^&/_9/?!?_
M *C>FT$GPG_P3B_YNI_[./\ %O\ 6A%2^SZ'Z74$A0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % 'P=_P4L_Y,[^)?\ V$_ /_J>^'*"H?$CZO\
MA'_R2CX8_P#9/?!?_J-Z;02?"?\ P3B_YNI_[./\6_UH14OL^A^EU!(4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MC\/OB3KU_JUNG@(7%_KGA_5OA]::-!!)XY\+ZTL\T=IKNLNME90K+.2,J_E
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MK=UX=U[0=>72_P"U='U:UMK.^%O<R:'JNI:?<)-INHZ==Q2V=_<QM%>QY99
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M:E)PE*#E2JPG"3A*4&XMPE*+3>_6104 % !0 4 % 'P=_P %+/\ DSOXE_\
M83\ _P#J>^'*"H?$CZO^$?\ R2CX8_\ 9/?!?_J-Z;02?"?_  3B_P";J?\
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M7UWGYN=V]ER\KY^:'*>'_A%XP\%Z3\-H-%\3>']4UKX?>'M4^'5GJUQX:O\
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MQ='#M4HTYU,%0?NX=5JE.G6K1FZ\Y5)XB4:L)5*$\+WOA7X.?\(SXKTCQ/\
M\)']M_LJ_P#C5??8?[(^S>?_ ,+@\;:/XQ\K[3_:DOE?V3_97V/=Y3_:_/\
M.Q:[/*>*%7V&'5#EYK8' X+FO;_<JE:I[6UG_$]K;DO[G+?GG>R[L9B?K?MO
M<]G[7&9?B]^:WU#)9Y1[/97]KS_6.;3DM['EG?VJX[Q5^SE_PE'CBZ\6W6O>
M%V$WCKP/XXM+W4?AY#J_C_2?^$*U3P[J<?A31_'=UXF5=+\)7,F@S8L[71X9
M(9-8O)#/+YLBRK+:G]GU</5Y5*>&EF#YH?NI8A8ZCC:*6,FN>5>6%AC94Z#3
MIQ5'#X2BX6I3E5Y<3?$4\52YFH8K"K#*$[5(8?\ =1A*>$@XQC1=6=.G6K\R
MJSG4EB90J4Y5*$L+VD'P?\C0;30_^$BW"U^,M_\ %O[3_9.W?]M\?ZCXX_X1
M_P G^TSMV?;_ +%]N\P[O*\_[,-WDK--J$\F<H\T<IP>(PCCM[98C*L?ECG?
M7V?*L=[;E]^_LO9\RY_:0,Q_V[^T?^7/U]Y._P"?V?\ 94\GG_=YO;_V3;[/
MLOK%_P!Y[*U3G;?X)^*K6;P1H\7Q%T]/ 'P^\;P^+] \.Q^"'3Q!<6=K_:36
M7AK6O%)\6M;7EA9MJDX@GMM#L9MMI9"=KAHIGNIPW[FKEU>LO;U,LP=3!T[7
MA&499;6RN%>HFYMXB-"=-SDI1I5)?6&J-/VU+ZL8K]_3S*G3_=_VIBJ>+K2G
M^\E&JLUP^;5HTK>S4:56O1G&,9JI.E&<%[6:IRC5]!\3>!M8NO$L'C;P5XDL
MO"WBK^R(?#NJ-K/AZ3Q1X>U[0K:^FU"RMM5T>TUW1+S[=I]S>:F]E=6NK6WE
M'5;H3Q7,<@C6:?/1E74))T,2Z<JM*2;2J4E*,:U%J452JRIR]E5DXU(5:<*2
MG!RHT9T])RC4I4*=12Y\)*O*A*,K<OUB-)5H3@U*-2G.6'P\[)0JQE17LZL(
M5*T:G&Z/\&=6@U'3==U_Q?IVIZY;_&"Z^+.IR:/X4N=#TF\ED^'=[\.K;0K#
M3KWQ7JUQIL<>GS6=V]W+?WQDFMY@L,27"BVZ:%6.&A@J<(-QPF#S#"OFDKSG
MF./JYA5JZ12C&G5K3A3I6D_9\BE5E).4L[NV=<UKYLLNBK*RHPRVMEU2FFFW
M[252&7J$Y7II2JN:C:"IRHZ)^S_I?A[QG>Z_I]I\,;K1=0\6:QXPG76_A/::
ME\0[74M?N[[5]3BTKXCQ>*+7[+ NNWAN;9[C0[R>VA\RV69E,$EIRT81A@_J
M55.5*GAJV$@Z%L/-T*D)4Z<*SBIJHZ=&<Z$W"-&5>DJ7M6ZBK5,1IBJD\37E
MB;_O9O"2DJB52FI86G1HITX6@X.<,/3G[TJG)B'4K*\91I0\GTOP;XAU3Q/\
M(/A]I>I>(-3^'/PI\0ZP\UEK7P>\;> 7T_PM8^!/&G@C2K+5/'GBFZ73?'=[
M'-K%I9VI\.V%J)H-U_,9(O+EFV@_[2685\SDZSQV3XK!U*NF'E5KXR>#@Y_5
M97K0Q-6C"K5K32CAJ4X5X>RI2KX>C3UKXB>#>+CA6Z>(QF8T,2E!0K0@Z68T
MLUJWK1M1A@X5:?+2II3Q,ZDL)3YY0P^.J2]BTGX,:]#%X,T?Q%XYLM=\+?#6
MVN(O ]A;>$IM(UQ+D>&-4\&Z7?>+M<;Q5>VWB*>Q\/ZQ>QJMCI6AI+/()Y%.
MU46,=*MF,,VJ8JHO[0S;!8K!U*T(*-&+QLZ<\1B(X=N4O;3=&"LJ\:48U,1&
M-->TI^PQP;IY=]6P^!I_5\MP^(P]5X?FYY.AA*L,1AL%&M)7CAZ->G2J1;A.
MO)8?#0G6FHXAXK@/B/\ "-M1\-_ /X1V%QK]Y>^%IO#^A^(/$=AX9OX-#U#X
M::=X=?0_'NF:[J[Q7&G:1!KUA9VMO'IO]HR7K7$UH\2216\LT?;/&+&<4U,Y
M]DJ-*+Q.*KTY2=O]XIYAEU*E4<8>WJ4\XP>7U*D*:NL)#$^UC"G5M/BIX9X+
MAZIE\:O/B'[*CA*D'4A4I5Y7P>)Q/+2F_9.EE..S+V4Z[5)UI05*;Q,:7+]$
M^.O!4/C/1[*QBU&?0M4T/6=+\1^&M;LX(;B71=<T:4R6=Q]DGQ'>64L#W-G=
M6K-'Y]I>W,(DC,@D3@?M(8C#XNE*,<1AI57%U(N<)1KT*N&KTZL%*$I0J4:U
M2+Y9PG"?)5A.-2G"2ZX*DL/6PDX-X:O3A3E&$O9RC[&K2Q%"=.2349T,10HU
MH*49TVZ:A5IU*4IPEREC\/O&=SKT?B_Q?XVT'6?$^B>']9T7P6-"\$7_ (=\
M+^'[K78;,:CKM_H.H>.-;O-<U1Y;"VC4_P!L64<=H9K>-$>XEN)&U[.GC'A?
MW6,Q=.-'VU5*K&E0A5]LJ5.G%4I*%2I&C4Q/-5DZT\-AW!T8P<)":E/"0KKG
MP6%KK$.E"T*E6JJ4Z"G*NU4Y73H5L33I*%*,%]9J2JPK.-+V>KX_^'DWQ'\%
MV7@KQ!KOEV%W>^'I?&DNF65UIY\3Z;I-U;7^J:-9FWUA;CP]:ZK=VD4<DB75
MY)%:R3P*S/()X[FJ3Q^&Q5.$H8?!XB>)I474ESJI"%7ZC)UZ?LGSX/$NABU*
M,(^UJX:":A&3(I.M#!5\/4G">)Q.&^K5*JI1]GRU7"GC+8>HZL;8C"O$8>,9
M3DZ/MU54JDJ24O-_&G[-FCZ_<75]X=\5^)M U'5/ 7COX<:Y<^(=>\9?$9-1
M\,^--&DM8K>*'Q7XRD.G2Z9KT6FZI$UO(HD%O<VS*OVP3VZHMT:F(>DJ.)6#
ME4I\L$WB,!C:6*PM=U>5U'[*D\=AE3OR<N.E4^*DHSZ\)7CA<5E&*5+FJ9/C
MJ>+I>]RKV7)*&)PJ5FH0Q/+AJDII7C4P>';C.,7!]!\0/A58ZXMUK>HZSJL%
MOIGPVN/"R0Z'H,^K:Q#>V6O:!XJTWQ%IMG:M<RZC>6>H>&[5H]*CL;EKEF"!
MF/[N15J[I5L?CHKEJXC&Y/C:2Y*E6-&IE6(S&M"-2G2Y:E>E6>8\E:--T9QI
M4I\LE*HITO/PV"_=Y7A'4YJ>#P&;9=4]Z%%UJ6:X;+\+5<:E1NGAYPI8&7LY
M3]I#GKQ<K1I-5/)-)\%^-_BSXI\<:EXB\07RZ-=^ ?"?A.PUFY^$?BOX7V::
MI8>,9?%&H1Z;X-\=:W-KMZ?)M+1;C4)KN.T8WUM%:*SV=UNJA1CA^?%22C4>
M;Y)C81]I&<ZE/(Z^)KRI\L%;#T:LJZI495'4K2J+$XAQEAWA8.L5^_IT<+"5
MXK+<_P '.3ISBZ;SK"X##4JDIRY85ZD(T*M2I2HQIP@H4Z4W"K.;CZ1KGP3\
M1:G?ZA:6/CZPTSP7J7Q1\+?%:XT-_!DE[K_]L^'O$/ASQ'=Z2GB<^*X;8:%?
M7WAX.$.B&ZMWO&Q=2PQB!GETE@99<Y1]K'*WF?L(Q_=\T<R68N7MF_:<\J-3
M-,3*G*G[%2C"A"<6X5)UMJSY_P"TW3;ISS;#4\/7D[2Y'2P5' QG07+'D4J.
M$PJJPJ>V<DL3[.=*5>E+"[]A\(/L-KH5K_PD/F_V)\8_%?Q:W_V3L^T_\)/J
MGC#4O^$?V_VFWD_9O^$K\O[=F3S?L&[[-'Y^V&:;]G/*)[_V5@JN#MM[7VF$
MK87VG]SE]KS\GOWY>7F5^9;8NM]:>:^[R?VG'*H[W]E_9CRAWV7/[;^RO[OL
M_;_\O/9?O+6G>'/&7@[6[2S\-#2]6T/Q=\2/%?B[QQJFI6QMI/#^@ZAHT\UG
MI>D6\6M))>:O-K\&DPK=F&:%;?[8TEM&WE-4X.*I4L-@JU_J^!PF82A4C92K
M8O$YO/&4*/+>7LX0I8_$NI)J2G]3BE.E.O&,>>OK/&8JFN;$8W$9=%0;M"A1
MPV78?!XBM-M7J\RR^$:=.#A*%7&TY-5*6&JN=KQ'X"\22^+KCQMX%\5Z1X8U
MO5O#FG^%?$$?B'PG=>+M-U#3=%O=7U'0[JSM;'Q7H$NG:M976O:N!,]Q=02Q
M7A22V+1QR1RHS5/%85U6L)BZD:THQ256E65.-"I5H5)*<(NMAX4H3C5HUHJ>
M'P]2"BHUJ=?:=13AA%*-YX'ZS[*[]R4<3]7E*%:*2J2C"IAJ<H>SJTFE.O%M
MNI"=*M\/_A'9?#[6AJ=AK-S?VR_#SPEX%%M>VD:WDT_AG6O%VN7?B"[OX9EC
MENM2N_%D[26\5G D3V[,C,LHCAZO:PA1KX>E15"A*M0E1IQ<G&A0PV"HX&AA
MTY.4IJG1H02J2ES.WO)N\G$YRJ4\*JCO6HXC-L55FDHJM7S>O@\17E&"TI1A
M5PTW&*<TU64;Q]G>?,^+_@/8Z_XYU/QM8P?#.YG\0VVBP:]:?$7X3V?Q#F$N
MAJ+2"Z\.ZH/$VBSZ))-I1-O+%<#4X/,MK6>.&,I<)>\^#C'"3G:*]E4Q?UR3
MI_NL1SRI8>C4A&O[\5!QPU.=*]&4J56=:?-.,XPIF(E*M"G:<HUZ&&>&I\SY
MZ"@JN)Q%.4J'NR<XU\54=1QK056BHTK1E&-57+OX-7\4VF:CH7BJPT[5]%^+
MFN?%+39-1\+S:II2)X@\.:QX6O?#UUIEGXETV:94TO6[MH;V*^M]DT<+M;/&
MC127@ISP2P<&_;4Z.'S#"XB]U.M0S#-JF;2]E-N2H5J=5TJ:J3AB(RC"I)TD
MZJ5*:EI4\VITXQI?VC_9LJ5E[N'GEF&R[#4[Q7+[6G46 <I4TZ3BJRC&?[KF
MJ7H/@_Y&@VFA_P#"1;OLOQDOOBW]I_LC;O\ MOC[4?''_"/^3_:9V;/M_P!B
M^W>8V?*\_P"S#=Y*E-QA/)FX\T<IPF(PCC>WMEB,JQ^6.=_^7?*L=[;EM/F]
ME[/FCS^T@9C?'K,?^7+Q[R=_S>S_ +)GD\]O=YO;_P!DV^S[+ZQ_R\]E^\YC
MP;^SWI_@K4Y?[-B^&+Z)$?$?]DWG_"H[*V^)=@NN)=>1%<?$2U\4)%?+9M?W
M</F_V##<7%J((9IS*DUQ=<M2@ZF4U\KY_8\^7++H5**=-<D*,,/"K7I\TO;2
M=&"=:,)T85:[=9*G']T;^WMF,,?9U6\<\?6A6?M.:I.M4Q-2%&5HNC%8B4)4
M7-5W1IQ=/W[PG2] A^%U@_P=L?@_J>IW-U8VW@+3O \^MV4"6%XXT[1K?2H]
M8M+:62Z2SNEEMTNHXG>Y5'558R*"6]+,\5/'9E6S.DOJE=X^GF%#:JJ.(H8N
M&,P]TU!58TZU.',FHJ<4T^6^G!E^&IX+!T\#6C'&8?ZO4PM>$N:G&O0KTIT*
M]-\DN>"JT:DX-PFIQYKQDI),Y:^^$7B;Q,=9N_'7CC2=8U>;X>^+OAWX<NM
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M5KONJ/GQ&.KVY?KF,QN+Y?Y/KF+K8KV=_M>S]M[/GM'GY>;EC?E795(@H *
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MNG2FJ=24*TFJ4^6<Z<7&$Y2O6P]E_M%#VG?:3X@T[6-'37;==2L=.9+J1O\
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MISA'CK'XQ?#_ %'4QI-EJFJS3S2ZK;Z;='PAXRBT7Q!=Z+;W-UJ5CX4\13:
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M+-*%)6MRT,/F6*H8>&J4GR4:=.%Y7G+EO-RFY-^IU!H% !0 4 % !0!\'?\
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M;]G05JD9T[SJP?/&*?7Z#\(M6M-9\"^(9-&T/P_?:)\0]?\ &'BF(?$3QO\
M$J\UB*[^'&L^ M)O8_$WC30[2_NM56*ZTJ-[::*W@M[6R*Q3S,BK)T4*JH2G
M9N5.65XW"1IJG""IXC%9KEF.;O%WG2E3P5252I*U3VU505*4+U%EB8U<13IP
MD[2H8S!5(N52<E]5PV'Q]Z:BURTW'%8Z<J=.-X2BI5I3A4E[*/-ZA\'/B#JG
M_":6EC:^#O GA_Q#9 _\(OH_C?Q7XGT'5_$?_"8Z3KB^*3INI>#-+MO =VNF
M:?J0N+718+R/4;K7F>[??I\=S=<^%2HTLM56[>!S+(\73I)\\<)0R[$0KXRA
MAZ\N6I4A5C&G1PN&E"CAZ"PL)TU0^LUH4]<9'VZS"-'W98O YSA957[CKSQV
M#K8;"SQ%&"E!5(U*GML1BE.K7:E.D_K"C3DN!^*%YJ6CQ^-/A'X8\0?##7+[
MQG\3-#UZ#0W\6W<OQ3L&\2^*?#^N:SI1^'5IHD_VNU@5+F\379=7LH;33IO/
MFM2FF[[R,L@JE;AW#I.I1R7,H5ZE2BU->QPV:SS2I.NVH1PGU95G"JFZTL1*
MG2ITU&MF%.-&\P3C0SZN[4ZN:937H4Z=7]RO:SR)Y3AXT)+G>*EBGAH^S@H4
MG&K.K%RE##S;]KMOA+XA@\-6>C->:)]J@^/VI?%661+B^\AO#]Y\3M4\9Q6B
MN=-#G6AI5[#"T100"X1D%R8P)6UI<L)Y!S74,KP.+PM91W<\1DN9Y=&5+:\5
M7QM.<G+DDJ<:DE%S4836;?[;_:WL?=^O2R%T^?2W]EU,AE7Y^7FMSK*\0J/+
MS<SG1Y_9\T_9\5X?_9ZU&T@_X1/Q#8VFJ>&].B\80:!XP;XP?%._U;3E\0:9
MK6DZ?>V_PIU:QE\,Z9JT.E^(=1L)9[76/+"AY[>&/[8;:UY94'4RJ6!Y_J^(
MCE=++HU$EB%-TJ6'H.4G5Y)TJ5:.'C7E1C[3DDHX93G37MEUPQ<\/F3QU)>V
MI5\R>85:+_V>*OC9YDJ5J7/&NJ.*5%0E.-/VB3KU(JK34:O7>'_!'Q7F\9_"
MW5?%<'P[L="^&OA_Q-HDLOAW6O$&IZOXBN=5TO3M(L-4AL=1\*:=!X=MO)TW
MS9M,%]J>Q[P*MY*+16N?0E6C5S'-,SJP=*IF&#J4(T8R]I&C4K8_ XZIS5G&
MFZT/]FG3A/V5*4.2,G"7UB:P_EQP_P!7R_+<LH2]K3R_&8>M[::]G*I2P^79
ME@8+V,74C"HWC*<Y?O91:4[.')%5;GCKX9:WKOC'Q3XCA\/^#_%NF:]X-^'_
M (:M]$\1>*=?\(W%K?\ A7Q/XUURZUJVUS0O"NL7.DWUJGB+3)=/N;)5N/M%
MM-^]M-D<S\L>:%"K22:J3QWUJ%6%6=*I1BLO^JITYTUSJI.:=*HHRA'ZM5J-
MRGK0J>G4K0GAL!1W>$_M#VD)TX5*598RKE$J<90FW&4::P-:H^>$DJL<.HKW
MI5*.B_PU\4>(?@=K'PR\8>)?-\1:[X?U_2)-<@O=4U?^REU*YOI=$LVUFX&G
M:EXC72;*;3[&35+@6%YJ(L'NI1!/<L$UQDE.K@:V']ZM@*F68AR<?JJQ&*R^
MIAL14J.&&DUA8XO$8>4G##R?U>-5^R^"*./#0A'ZW2KQDL)BUC*#IQFJ\Z.%
MQ=*K0<(5<13DJLZ=*K)TY5Z4X\W+"HJL8MSX&3X+^*=7T;4(]2T30-'\22:O
M\+YH=8G^,GQ3^*(O]&\'_$31/&>MV3_\)WX>AD\/HT6D2&TMK3[8LT]WMN)H
M43S7UP]2EA\3A,2DX*&+C6KTU"$I.%+"8FEA[8CW)U9TJN,KQ490I0C"]9/G
MJNE3JDW".)IU'[;FRO-L%1J+F@E6S'"2PW-]7YIPI4ZCIX:I6DJE6I%0]G%5
M%24JO5>./A7XFU^Y^*U]I-UH0G\76GPLF\.6^H7FH6L)U'X=ZU=ZW/:ZW<6V
MDW3:=97DK6T"7-K#J$D:R2R&W8QK'+R4>:A2PR24JF&X@CFUKN,98=87)<.Z
M?-RMQK7R[$-+D<+2H^_[TU3EP4\7BZLI<M'%</U<HNES3A6JRSV]7D;C&5*,
M<TH-+VD92E3JQM%*$IX^L_"CQWJVF_$:^'_")6WB'Q5\3OA+\2](TG^W=8ET
M:.;X=V?PSDU#0M1U[_A%4N;>.ZU#P3J,$-]#I%R1#=6T[VJN9+:/JHUE@WE3
MH+V_]G8K,ZDN?]UST<QIXS#WCR^VM5I4L6ZG(_=E.FJ7M(QE[6/75KQKPJ0G
M%T_:9'4RQN-I\M9XG-*].I9\EZ3CC,.I[3BU62C)0@ZF/JWP0\:WNN7WC*.7
M1VUF;XAZIXIC\.Z?\1OB!X*LI]%\1_#_ ,$^%=4L9/&_A#2+?5+/4;+5O"SW
M,'_$KN[:[MU6.:.VDNB]CC&,*"P4*7-66'PN:X.3E)T?=QF?U\XP]90BZL9N
M-)TJ-:A-J*J5)SA6DL/3=;C?/5EBY5.6C[>MEF*@HQ5;]Y@,HGEM2BY35)TX
M3E7JSA7IWFHP@I4FJE2G'H-%^&OC7P/?Z3XD\#>'/!$.I7WAS5M$\6>%]=^(
MGC;4;"TU"_\ $NI>+%\0:5X[U'P=J.J^([N;5M6U(WT6HZ3I[W1O4E6XA-H(
MKF9IVQN'A->PQ>'RZE";IPB\-+!4\52Y%AX-1KT>7&3]G>O1DOJ\;K_:IO#Z
M2;K/#UJS;KX2KC6ESRG[>EB89?1I\U:?O8>=*CE>%C&$:5>G!5)TX\RHPG5]
M)^#_ (1UKP%\-?"?A+Q'<Z5=ZYHUC/#JEUH:W":1-=SW]W>2/I\=W#%-%;?Z
M2-L;H"F-N6"AFUDZ:IX*E24HPPF!R_"^^U*7-@\%A\+)\R2YDY46XR<8N46I
M.$&W%9I3=;'UIV3Q>/S'%I1;?+#&8_$XJG%MI/FC"M&,]TI)I2DK2?I59EA0
M 4 % !0 4 ?!W_!2S_DSOXE_]A/P#_ZGOAR@J'Q(^K_A'_R2CX8_]D]\%_\
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M_P <OA3X?\'/X\?QUX5U3PNNL:?H"ZIH?B7P]J%I-JVH7UM8I8PWJZJEJ]S
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M:FM-8^\M-3AK?XP:!JGCC1M/T'Q+X-UCP%=^ /'/BO4O%>FZS9:A9V=_X/\
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M/?ASX.\/^%+F.XT>UN-5U+0K#Q0C6?G3W<36 M;N_L#')>-;QAG5HW/E,4O
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M%#"QE"*E#V\L'3QF(A.:GRTG0C4EAXPE+VU?%4,33C1A3PU>M#H/B+X_\?\
MP_\ #6H^,&\!^%M5\/\ A?PE+XH\8NOQ%OM/U*U?3H9;S7--\*V4WP_D@\0M
M;6-M<26\^I7GAX74C01%(/-D>W;E1CBE3E*:PE3%4,-2J1I\]=QKU(4859X:
M,FHVJ5()TJ5>M4:51TU.4:<*UX3#U\9]7H4E3CCZ_,O9RFXX>,TDXIXGDYE&
M3NG4EAXQ@ES3:C=Q@\1_%C6[*[U[_A$O!,/B;2_!GAO3/$_C"YOO$DGAW4[:
MVU2TN-5ATCPWI(\/:BFN>(8]$M);N2VOKS1(%-U8PBZ9KB1K6:DJ>&^MU<95
MC0P. Q=3!5ZT+U90J4*5"M7K>R2BI8:A#%4)3J1J.K)>V]E1J3I*%3'"KZ['
M+Z6$3EC<RP]'%4*-5.E#V.(J5:&'52M[_+5K5L/7IQA&$XP]FY5JE*,J;F>-
M?BEXD\):;#XSM?!^A:U\,\>%YIM>A\:W=IXLFL?$MU8V8O-(\'GP9-9ZCY$N
MIV96"7Q#9S7"^:(H_,6*.YU]E.CF%++<9'V%6OCZ>74W#]Y:O5J1P]*59/V?
MLZ7UB2A4E!U72I*59Q<8N)C&O2K9;+,L*W5ITLOKYE*,HN'[G#T9XN<*;C[5
MSJ/"TIS@G"$'5=.BY)2E5AL^(OB7<Z#\2O 7P^C\):M=V?C*74H+GQ?+,EAH
MFDW-KX?\0Z_9Z?:+)!))KVI30^&[T3Q0&%+..:WDFE+W$,,LX2#Q-;'TOX,<
M#@YXJ+E9RK2IXK+L/.$()J4:<%F-*<L1*T)5$Z-*-64<1+#WBIK"T,'57[UX
MO%T\,XK14HSHXFI&I.5FN:4L.XTZ*O)Q4ZE25**I*O'HWCWQ1XF\7^(=(T#P
MOX;?PQX1\2CPQXAU?5_&M_IWBB&\BTNVU.YN=/\ !UGX)OX)[(QZA8"U>]UW
M3FND>:=4CA2%KN*#Y\+3QE1>SH5_KGLE%.<[X/$8C"-58R5.--SKX>3M&=1P
MP\Z59ISG[%76:IUIX:G>5>A'#2FIKDI\N)IT:ZE2FG.511H59)R=.$7BJ4\-
M>T9UH9OP=^,MM\4_"WB#Q#J&A/X,NO#'B#6])U72[W4XM22+3=/=[C2?$,>H
M+9VJOIVI:(UO>C,*^0YN+9V=[1V.;K489/E^<3J*%#%X&GC*T-.;"SE0A7J8
M>;3?-*%*I2K0E:+JT*U"K[.'M%%6Z<_[4QN64XNI/#XFI0H35O\ :80Q%7!^
MUC!-N%\9AL5AG"3;53#SLY0<9.[\%/BH_P 8?"-YXL/AJZ\*PQ>)M=T:QT^]
MOA?7=WI6G7"'1];N +*V.GRZEI=Q9WIL'21[7[1Y,DCO&QKJE1J4L-@:M9>R
MQ&(I5'7H73>%Q%#%XG!8C"N<7RU94*^%J0E4BE"4D^2\4I2P]K2EB\PP]":K
MT,'6ITZ6(BTX8FE5PF%Q=+$4[72I5:>)BZ34I<]/EJ77/RQ[GQ/XS\'>"+.#
M4/&?BSPUX1T^YG-K;7WB?7=+T"SN+E89;EK>"YU6Z@CEG%O!-*8U8L$A=L;4
M)&'/!5(4N9*I--QA=<TE&RDXQW:CS13:6G,K[HWC3G*,I1A*4(N,6TFTG-\L
M$VE9.3TBGK)Z*[,W6/B9\-_#K6::_P#$'P1H37]M87E@NL>*]!TQKVSU3[4-
M,NK-;V_C-S;7?V&]\B6/<LWV.?RRWE/MTY)^V^K<DOK"J.E[*S]I[5.G%T^3
MXO:)U:2<+<R=6FK7G&\)IX>.*6N%FIRC67\*4:<5.;C4^!J$)1G-IVC&2D[)
MIF9\0_BAX0\ Z5J/]I>+O!^D>)6\/:MJ_AS0_$&OZ987FM36-K(UL+/3+C4+
M>ZU*W>]\B$_9>2TJHK!V6O/S#$U<-@\QJ86*K8O!4*E54K.;4H4ZE2*G3@U-
M1:I3>\6XPFTTHMKKP-"GB,3@(UY.G@\7B*-%UDU&-JE2G!\E22<.9*I&V^LH
MW3NK[VD>*+0^!](\8^)+[2]$LYO#&F^(-:O[NYCTW1],CN-,@OKV>:ZO[C99
MV$)D<[YYB$1?G<X)/L9G2HX#'8[#>TY:.%Q-6A"5244VHUG2I\TK1BYR?*M$
MN:3M%:I'E955KYA@,OQ'L^:OB\-1K2A2C)KFG1C4FH1O*7+&[:NVU%:MV;**
M?%#X:2:%'XGC^(G@5_#4E[=:;%XA3Q;H#:$^H6-M<WE[81ZLNH&U:]M[2RO)
MY8!*7CCM)G=0L3%>:<94O9JI%T_:QYX*2Y>>/M(T5*-[<T?:RC2NKKVDHPOS
M-(ZZ:=55O9+VBPZC*KR^][)3Y'!U+7Y%)5*;BY64O:0M?FC?6TGQEX0U\:6=
M"\5>&]:77+/4-0T0Z3KFEZB-8L-)N+:SU6^TLV=U)_:%G97=Y:07$T'F)#)=
M0I(RM(H:G3G'FO"453A2JRT:Y:==-T*DM/=A649.E-VC446X-V9*:Y7)-<D:
MKH-]%7C&4I4;[*K&,)R=/XU&$FU:+M=3Q!H,FCS>((];TA] M8;RXN-;34K)
MM'M[?3GFBU">;4EF-O##:R6UPDSM(%B:"0.5*-C&=2G2I0K5)QIT9TZ=6-23
M482I5H1J4:D9.T73JPG"=.:?+.$XRBVI)NZ<)5:CHTHNI6C4G1=."<IJM3G*
ME4I.,;R52G4C*G.%N:,XRA)*2:,*R^)/PZU'P[J'B_3O'W@N_P#">D,Z:KXH
MLO%.AW7AW3&B2*21=0UJ"^:SLF2.>%F$TR8$R$\.,Z5$Z*I.JG2C7ER4W/W5
M4G[1TN6#=N:7M8RI\L;OVD7"W,FB:?[Z<J='][4IQ4I1A[THQ</:*4HQNXQ=
M/]XFTER>]\.IP?AWXOVGB;Q/XFL="U7P/KGAK3=?\$Z+H^M67B>VBAOO^$CT
MF\O-26TU&"2_M=>UB&[M#';Z=;+:,X656EW1DF<.JE2"=6#IRGC\=AH*S4IT
M,-D^!S*E4ITFKUG*>(J^UG&<84\)%XA1E[":JYUJD:=64*4HRA3P.!Q$FVE&
M-;$YQCLMJ4YU%=4E&GAZ3HPE%SJ8J2P[E'ZQ"5+T33_'O@;5=>OO"NE^-/">
MI>)]+\\ZEX<T_P 1:/>:]IPMO*%Q]NT>WO'N[/RC-#O\V%-GFINQN&2,HSHU
M,3!J6'HJ\ZL7>G!<TXWE->[%<U.<;MI<T)K>+MI->RG3I5?W=2I\$)>[*7NJ
M?NQ=G+W)1EHG[LE+9IE^'Q1X:N+;1[RW\1:%/:>(8)+K0+J'5M/DMM<MH+)]
M1FN-'G2X*:E!'I\4ETTELTBK#&TI(12P=3]PZRJ_N7AZ,L154_<]E0A*E"=>
MHI6Y*,)5J,95)6A&56E%R3J03;C*-14G%QJRQ#PB@U:3Q2]K?#*.[Q"^KU[T
M4O:+V-7W?W<^7D1\:/@[]B?41\6/AI_9\<DD+WX\=^%OL2311Z7-+$]U_:OE
M+(D.N:([*6!5=8L6( NX3)4XRI).I%TU)R2<DXING*M":5[7<)X>O&27PRH5
MHNSIS42$933=.+DH^RNXJZ7MXRE0NUM[:,)RI?\ /R,).%U%VU]7^)/PZ\/6
M6G:EKWC[P7H>G:O9KJ.DW^K^*=#TRRU/3V\G;?Z==7E]'%>V9%Q;XFA9T_?Q
M_-\ZY)0E"O+"RBXXF,X4W1::JJ=3VOLX.F_?4Y^QK<D6KR]E5Y4_9RM$)1J4
MXU:<E.E*,I1G%IP<:<J4)R4E=.,)UZ,9-.T95J479U()W=(\;>#/$&HZGH^@
M^+O#&MZOHB1R:SI6D:_I6I:CI$<I98GU.QLKN2:P1V5@IG2,$J0.E3;]U*O;
M]Q3E*$JG_+N,X\RE"4_AC*+A-2BVFN65U[KL[I2IT[I3JQ4X1^U.#4)*<%O*
M+C4IR4E=6J0=[2C?/LOB9\-]1L=3U/3OB#X(O]-T6[M=/UC4++Q7H-U8Z3?W
MUTMC96.IW<%^T5A=W%ZZ6\4,[(\DKK&BER!2;4:5.NWRT*JDX5-H34*7MI.,
M_ADHT?WLK-VI?O':.I:A-UIX=0DZ]*,YSI)/VD(4W-3G*'Q1C!TZBG)I*+A.
M[7*[<[K_ ,<_A1X?\'R>.W\=>%=5\,1ZSIWA\:IH?B7P]J-I)J^HWEI:1V$5
MXNJI:M=0QW:W4T7GB2.VAEF*E4Y<KTZN"HS3IRQ]6-*DY+ECK5]C.JV[?N:,
M[JO.*E[/EDFN9<HHIRAC90][ZAAZN(JQCK)1I4)8B,++:K7C%1P\9<OM:DZ<
M4TI7/1'UW0X]&_X2-]9TI/#PL!JO]O/J%HNC#2VA%PNI?VH9A;?8#;D2BX\W
MR]A#;MO-%=K"\ZQ/^S^R?+-5/W?)*_+:7-;E=VE9V=]-PHIUW&-!>V<FU%4_
M?;:NFDHWNU9WMM9]CGK?XE_#B[T";Q7:_$#P3<^%K>\CTZ?Q);^*]"FT"#4)
M9HK>*QFUB._-I%>///#&L+3!V>9%"EF )47L%3=7]RJJJ.#G[BFJ4:DZKCS6
MYE3A2JSJ-7Y(TJDI64)-3!JHYQIOG=/V?,HZN/M7"-+F2OR^T=2FJ=[<[G!1
MNY1OKCQ7X6/A^V\6#Q)H!\*WEM8WMGXE&L:<?#]U9ZF\,>FW=MK(N?L<]M=2
M7-NL$J3,DIGC$98NN77C+"U'2Q,7AZL9JFX55[.2FW:,.65FIMZ*-KM[(=/]
M\I.C^]C!5)2</>48T5)U9-QO94E";J-Z04).5E%VS]*^(/@'7=(U/Q!H?C?P
MAK&@Z*9!K&MZ5XET74-(TDPP+<RC4]2L[V2WL"ELZ2MY\B;48.<*0:FHU1HP
MQ%5JE0G?EJ3]VG+EER/EF[1?+/W'9Z2]UZZ#A&4Z\L+3BY8FFTI4HJ]2+:;2
ME37O1;2;5TKI/L4D^*?PP?0&\5Q_$?P&WA9+]=+;Q(GB_P /-H":FY"IIS:P
MNH_9%OV9E MS-YA) "\TZG[GV2J_NO;*;IJ?N\ZIJ3J.%[<R@H3<^6_*HRO;
ME=E#]ZZBI?O'14934?>Y%/EY'-*_*I\\.5NRES1M?F5\2#XW_"NY\62^#H/'
M'A>34XO"5IXV%PGB/P^VG3:#>17=W'<07"ZH7EVZ39OJCLL7E+82Q71E\J0-
M19Q_M'VD71_LJ=.&(]HN3V<INK&7-?X?8SI>SK\_)[.I4I0=Y2LJY7_PG\B]
MK_:;K1PZA[SG*C+#044E\3K3Q*CAU#F=65&O%6=.TNJT'Q]X%\43ZE:^&/&G
MA+Q%<Z*H?6+?0?$>CZO/I*,TL:MJ46GWDK6"EX)U!G"#,+CJAPY)PI2KR7+0
MIR<)5'I3C*,5.493?NQE&+4FFTU%IM6(33J4Z*:=6I"-2$%\<H2MRSC'>4)7
M7+))IW5GJ5]*^)7PZUVQU?4]#\?>"M8TWP\N_7M0TKQ5H6H6.AH%9]^KW=I?
MR1::NQ';-P\8PC'H#19^SI5;?NJ\X4Z<_LU*E1PC3IPEM*=1U*:A&+<I.I!1
M3<HW)-4YU*<VH3H0J5*D9.TJ=.ES^UJ33LXPI^SJ>TD[1A[.?,URRM8T?Q_X
M$\0V6KZCH'C7PEKFG>'F==>O]'\2:-J=EH;1P&YD75[JRO)(M-9;8&4BX:/"
M N?E&:F<HT\/'%3DH86=W&M)I4I)<K?+4=H.RE&]GIS1[HM0DZ[PL8MXF.CH
MI/VJ]^=-?NU[Z]^G.&WQPG'>+2K0?$OX<7.@MXJMO'_@F?PNES)9MXC@\5:%
M+H*7<4+7$MJVL1WYM%N4MT>1HC-N5$9B H)IU/W#I*K^Y=?F]DI^Y[3DY^;D
M4K<W+[.IS<M^7DG>W+*TTU[5U(TOWCH\G.H^\X>U<(TN9*_+[256G&%[<[J0
M4;N<;LTWXG?#76+[2M,TCXA>!M4U+789;C0]/TWQ9H%]?:S! UTDTVE6EKJ#
MRZC#&]A?*SVZ2*ILYP2#$^VHPG*4X1A*4Z5.-6<4FW"E.,)0JR2UC3E&I3E&
M;M&49P:;4E>7.$8QG*2C"525*,FTHNK!\LJ:;T=2,FHR@O>3T:3-"U\<^";W
M6]2\,V7C'PM=^(]&CEFU?P_:^(-)GUO2H;=87GEU+28KMKJQCC2XMV=IHD"B
M>,D@.N<U.'L*V*4X_5L.FZM6Z]E22<XMU*GP02=.HGS-6<)K>+MHX2C5HT'%
MQK5[>RIM-3J72:]G#XIW337*G=--;F5:?%7X8ZA#K,VF?$3P-JB>'M.&KZ[_
M &;XM\/WQT?2R&*:AJ8MM1?[!9OM(6>X\N-B,!JG$3^J8:OBJL)*CA9.G-J.
MU9.4505[+V\IPE3C2;4Y5$X)<R:%27MJE"E3DG/$0]I35_BI<D*CJQM>]*-*
MK3JRJ*\53G"=^646T\%?$[P7X\\!:;\2-"UO3_\ A%;_ $>'6IKZZU#3%31;
M=[&+4+FVUV>VOI[73+ZRMYE^U127!\AE8.V!FNG'TGETJBQ$H\M.]IQ=Z=1*
M;IWI3=E44JD73BXZ2FG%:Z"I?OJU6A1_>U*%:I0E&'O/GIR<;I*[Y9Q2JT[I
M.5*<)V2D>8V_[1W@75?^%:>(=)\4^$K3P%XR'BI-9UO7-:TFU;1+O1=,M+S3
M["ZOX=;-AI=_+-=Q>9;W+RNR7$(4(S@G"+Y,3&EB+4*-;*'F-%R]R4JCQ>5T
M(TKR]V7)3QM>-:$+N->C93Y:<U,K*4(RC27M:V'S5X"LH^_%4J>%SBK/$1Y=
M?9SJ9;3E1JRM"6'G*3@I2BZ?K6H_$;X>Z1I.CZ]JWCSP9I>A>(0C:!K6H^*-
M#LM)UQ9(#<QG1]1N;Y+?4@ULIE4VTDF4!<?*,UI*$Z>(6$G!PQ4K6HM-57[T
M8JU-VF_>G"*M'XIQ6\E=0:G1GB*;4L/3^*I'6G&W,O>FO=C9QDM6OAEV9:N/
M'/@FSUZP\*W7C#PM:^)]4BCGTOPY<>(-)@U[489;:]O(IK#1Y+M;N\B>TTS4
M9U>*%P8]/N7!VP2%5%.7MU%.7U13=9)7]BJ2HNHZMOX:IK$4'-SMR*O1<K*I
M#F&TH4YW2A5]GR2O[L_:SE3I<KVE[2<)PIVOSSA*,;N+2KZ9\1/A]K5EK.IZ
M/XZ\':MIOASS/^$AU#3/$^B7]EH/E"1I?[9N[6^>+2]BPREOM+1;1$Y.-IQ$
MI1IT(XJ<E##3MRU9-*E*ZA)<M1V@[QJ0:L]5.#6DE>U";KO"QBWB8WO12?M5
M:4H/]VO?5I0G%Z:2C*.\6EYY\0OCGX+\._#34_'?A;QQ\/M6A&I:;X<T?5G\
M2Z3J/AL:_JNI6>G+'=W&G:Q"MY]ABNY+^XLH+R"9K>RF^>( R(JJJ0KY=A]*
M$L?B:%%2J1=HT98B%+$5U&\.=4(.=VI*,:BBIRBKCH\DJ>/JI.LL!A,3B90A
M)*4I4L)5Q-"BY<M3V;Q4H0ITY.$F_:1<(3;2?L.BW$MWI&EW4VI:9K$MQ86D
M[ZMHL#6ND:F9H$D^WZ7;MJ6H&&PG#>9$AOKS".O[^3[[=%:'LZM2'LIT.23B
MZ=1WJ0:T<9ODI^\FFG[D;;6,*4N>G&:J0JJ5W&4/A<;OEM[T[VC9-J5FTVE%
M/E6G61H% !0 4 % !0 4 % &/JWA[0->;36UW0]'UEM&U&#5](;5M,LM1;2M
M6M=PMM4TTWD$AL=1A#OY=S#LE3<=K#)HA^[JQKT_<K0C.$:D=)QA57+4A&:M
M)1J12C.*=II6DF@DE.G.C-<U&;BY4WK"3@[P<HOW6XO6+:]UZJQL4 % !0 4
M % !0 4 ?!W_  4L_P"3._B7_P!A/P#_ .I[X<H*A\2/J_X1_P#)*/AC_P!D
M]\%_^HWIM!)\)_\ !.+_ )NI_P"SC_%O]:$5+[/H?I=02% !0 4 % #7W!&\
ML+O"G8&R%W ':&(Y"YQG%9U?:*E4]BHNLH2]FI74>>SY5)K51YK7MK;8<>7F
MCS74;J]M[=;7ZVV/C+P_X+^-/B#Q;H.L^-=.\16LMCX!^)WA[6?[7N_A-;^$
M]/USQ5%H$=C:> ;7P1'+K]UX3DN-(GD6;Q-=M>JB6;3VXG>7[-AC,.JN5Y]A
ML.Y2EC\G>$H*O:.(EB%4I34<0J,E@Z2A&=2G2=-55%1JQ]K!-3QG='$4Z&/P
M4H.7U;"9]2QJ5-?N_J5*AF=*%1NJ_K$L0U6P[K1M&,JM6<HQE",5A_;?!GA:
MYU_X(Z3\/_''AF_T"2;P!;>!?$&BZI=:#?RLD/A^+0;Z>"Y\/:QJ=G+9S[99
M(&^T++L*&6*%\HOI\0S_ +2Q.9XK!5I8>ICJU;%8>>L*V%K2KSK8:4FKQC7H
M5%3JWI3J04DN6I)IV\CAV-;)*&58>:C5J9/##47*+;HXCZO3IQG*FI*-3V-6
MTH<M:E2J./,I4DFK_+:_!_XYW\_@3QMJ&CP6OQ!UA?$GP>^)TT/B/2%?3?A)
MJ>@:7H-OXPL[N&Z9+^ZBUGPG#XEM-.@:2ZAE\97$+QHZW!B:EAJ^+K1KT8T<
MLS_#_7,SPZO.%/'4L?'&X?!.W+*?_"94Q&05*]*])RG'$W=&*;UY:F#P\88*
MJJV(X9Q-&GDE>K37M,1A(X>OAY5*ZNH)O&8FGF5:G44'.C@(T(1=5PA4[SXB
M? +5_%?B7Q9X%L-'MK3X.^/?!T>JZO?07MC;G2OB#X<\+7_@7P_:1:691=/Y
MFGS>$=5@O(86BMY_ *!W62:(-Q5:N-G0S.O&JUF> Q%7,LGJRDV_[0Q=3"UI
M<J^&E3PU;"8VK551QC6GG<W!/V=:W5A_JV$>30C#VV#]E1RO,,-.*</[)P=2
MMB:7*WRRE5Q%3$+"S2<N7#8:,;04U(SE^'_QI;X8Z#\1Y_"]E)^TAINNZ'X@
ME\-GQ'I/V(+:^&#\-K_1#XA^TFP:PDT"]U7Q T0F>,7MXZH7E52W7CE2GBX4
M\NJ/"8/-/[0I8VJH7EAJ6<.-7VG(W>I+**N&R>G+V+OB:>4_N4U62?'@J2I4
M*E#'J.+660P5+"34%[3$0R>O*O%P;<72JYLJV:T:-2JX/#T<VC#$JG&E5C&W
MX7^#WC'X<^-8['2_#ESXC^&7A'3(_BAH@M-<T6WU7Q#\7AX+C\!7OAV"PU;4
M;6.W>\C@U#Q"^H:A-!:-J6O"1KA9%E:-PKPB\;-4(T(8.IB,%E5"$(\M++LS
MQ5#&59QE?]V\ME'&82,+*=3!8WV5*,E3<77LZM;ZG[;$0CB,T^K5LYK\LE&I
MB\%+$3E4JTX4Y7CC*E3*ZM-86"5.63R56,%4I>U['QE\./&&N?%;0+JPTE5^
M'/C0^$-?^*/GZGI\4FD:Y\++N[UKPS:+81W)FU2XUN_NM!L[J6V\^!+;P?LE
M8+-%YF>!4<)B\7&<HO#8&M5S' SC!OV^.Q.$_LNK3DI6E3IT*5/#9GAIRA!Q
MQ5&6OM)V58B3K8&A.G"5'&XC#O+<3%S]ZG@9XBGC;.W/1E'DGFV75U2DJM19
MK3DI3I4'*G6^&7PO\3:%XY\(:_K_ (>A@AT+1?V@;3[?)>:1=RZ?=>//C+IG
MB?0%@6VO)95;4/#5O-.SQ*1$JF"X:*9O*;3"SA1P-2DWRUI9/P?@K6=W4RO+
ML?2S"CS)6Y:.(GADW?V=:2A.BZD:;E'GQ$*D\7&45S8>.;Y_C;75N3%U,.L%
M6Y6[\TZ7UA)6YZ:E)5(PYDGEV'@OQ_I&E: O_"#:O?77PZ_:$\>?$2*UL]7\
M&*?&GACQOJGQ0-O<>%YKWQ3;QVUW8V/CRPGN+?7CHK,UE<10&;,;O%&NZ4<E
MJNE*]#*%E%>G>/M*,Z.#PU&.*7O>RJ8>K6PJ4%"K[>-*HZE2C&</8S]3$U8U
M:G$=.F_<S*.65:%25U!RPU?*<16H-)2J1JQ6!K4XN4%1E4=+]\J<I5*;+72?
MC58PZQJ-GX5\5>&X/%7Q9\2^*=3L?"6H?"#5O'UAH-SX7\/VGA[R9O'6IW/A
M:WBGNM/O+;5%BEO+J)MJ6+20.;VL*<)4\/E.#G.,HX?"9K&HZ>E)8K%<08W&
MT(5I3I^VEA?J>*=6]"DZCKJBJL8J%2B^%1_VG.L3&*B\3B\L=)5;\TL-A\BP
M6!Q-2C&E-PCB(XS#0C!8B2@\-]8DHNI*BG@^%OA'XNT[P[:6?C7P5X@\0PV_
MP^N]&N-.\.^(_!MOXC_MY?C%>^+=$ETK4)=:T/3(+[3[%M-U:.56L+139B".
M)7 LZ4%[)+V:E2JT\'P=2I5*#_@XG*,LQ^'QLTJSDY4\/7K4X2515?K%.H^6
M&(C[05)5/;<]27-3J8KC2I55?5U<+G.,P=3#49^QORU,;A:=>G^[E&-">DZN
M']R:[WPAX1^).I>//AEXK\>:1=7$/A'1?C!IEIJ?B&;P:_BK3[;Q!?\ @"+P
MJ_B2#PE=R:2WB6[TW2O$233Z LEHL$:"8PS7+1-TT?9PAC:E14XXO&9?AJ%3
MV*G[*4HX_$UITH*I[T?]GC@9XJ+_ '#QD:JPTIT(4F;2ES8.KA5S.G2SG"8G
M#QJ-.I]7I91F&'K5')>ZXQQV*E##*4GB7A9T)5TZRKN/%7'@SXU:?X+TKP7I
M^D>)K32Y-"^(MC+%X/N_A!+<+J6N>+M>;1--\5WGQ#-\EGX*;PY?:;,B^&[2
MZO8S%+'*B?9XK:?R<70K8G*Y8+E4JL>'\DP=.,WRT'B\/E,</CX5YT_W\JU/
M$TZ=/#SIRC0DI8BI[5\].K#; 5%A<<\9.32EG^<XR<ES3Q"PE?-98O 5<,I-
M4%&I1G5E7A7_ 'L9?5(*G&U=1GMO@KXVNO WQ+TN73K?2_$_B;X=?!SP_::A
M+>Z)<3:M<>"?#5JFN:!=WCPZG$EG)J*7]BS7UG<VLG]HRR^5<PLX?V<QK*>-
MS#$X:4_8OB^IG-.-)0C.M@H+))4YTXU>6FJLOJ>(5&G7=/EJ4X^U]E3FIOR,
MIP]7#X/+,-BE%5:/"E/*)2G*4H4<;4_MJ%6[I2]IR4_K>#JU:E"[G%1]G*=2
MERQFO/A?XC\5VT^K:EX:^)$^N7GC;X%/J]G\3+[X)B&X\,?#[Q[#XIN;G3[/
MX6W0TZ1=,@OM5\QK[_3+CRHX;:.6..(-6#J0P^+RZKS0C2I8S-,74E:HZL*]
M7A_%X##UW\44ZM=X.E'V3E4A.DJM7DA!5#?%JI5P.-PL(VG]3I8:DH*FJ=2E
M5S/"5<3A^=QA6E"&'P]:I&%90HQAB*D:4?;UZ]-=%XD^'WC./QOK_C+3O#LF
MM:9IWQ;\'>/[;PS:ZCH=M<>,K#3/A4_@N^:Q74M3M;*#6=/UNXL[^W75[BPC
MEE\/0$31@0S)QX"<L(J;JTG4Y:^;TZ=G%SPE+'T<$J6*HJ34;.I3QF'K4XRC
M4CA\;C*L85*DU2K^ABY0KTJM&+C>IEF64>:=U'V^"S_&9A4HRM"<M<*Z#ISC
M'D=7V%.52,(UG3RKSX<>._$GB>V\6+X;N?"-OK/QAM_$]QHUSJGAV75O#^D6
M/P4\5^ 7\5:N='UB\L)=8O=<OM,3[-I=[J,@MH;&61@RW"VN3P\O[/Q6"^LI
M3Q>!SR,))3Y,)4S*.#C0PD'92:52A6QE:<(*E'%8O$QA*:4:U;:CBJ<*F+JR
MI.2AA\DP\:<^6^*EE_$-+,:]7W>91A]3E[&G[:2J2IX2,>6+E3HKFA\.?B+K
M5I\$/""_#6?P8WPQ\-^+_"^J>/SKG@N>PM9=1^%GB#P79ZCX1@TG7[C6+G2+
M[6Y-/OY/MVFZ;=(?L326I9;@VG3FDEFE;B?%THK K.,FQN$H4*GQPK5\RRG%
M4L+4=)5*,:%&CAL1"$XRE%0C)<E-RA"?GX.,LNCDE"K6GFSRS.L#C:^(=T\3
M2P]#,(UL7456:G]:Q%3$PE7IOG_>U*MJM:,56E0?X.>,/$/@F70M;\+?$2;7
M="^'UGX$TZQ\2ZC\"$\!7FF7'B/PE-KNE: G@*/3]1O=/-OX6ANK9O$-G8[;
M4[/)CN[B:!>BMB(U\PIXZ%XPKYWD6,KK$+_:5A\!F;QCJ2C1E/#<V%IU*ZG&
MG*4YNKR8>,XMI<T:-7#Y95RY2C*K2RS-J5&KA[J#Q=?*:^"I1C5KJ.+@L75Q
M$6[VA[2A&KBZEZ-"I+U[QU\-M;UOQ1\8M3L?#]K=VOB;]GG3_A[X:G:;28S=
M:VE]\2+B]T*..XN4>RMRNL>'F:2X6&U;S(\2$V\@B\K%TI5LGSK#1CS8K'XV
MA546U>K3HX:$(RE)OEO3JRK<JG)23E*25I7?T& KX;#8OA.;DJ='*<5CYUK1
M=J-*O/)?9\L8QO)2A@ZZY::DTJ=I)<T%+D/'_P '?&6MV<%CX9L5TB"Q^%/P
M[T14LKKP];K=:CX)^(&B^)[GPE%!J$-[9XN=&T^^LX9+VPN=-!OBDX>%Y4;T
M,17:SK.<R2G7HU<SRO%T5#V?M*L:"SV%:M25=<D:^&>,P.)I*LZ,IU:5%4ZU
M*=/VU#P\NI>QRS)L#5IPC*CE&>X&LIN7LZ-?,,%E&'P_M'2YI2ISJ8?$JK*@
MJLHTXU)*+E.DJF9J_P ,O'6LQ6WC:QM?C%9^)]-\>>%/$&M:3XEOOV>4\3^(
M]*\.^%O$^C63^%[;P]%>>"EU&QN_%4,RR>(#!+-)X>C5)X!;V-RL4W'"5,,Z
M:C*E.IF,JCI+]]1K8S#X/"+%2=>*C[.5' QHSAAIPK1PV)Q,W[2I.IA:W1[M
M2ECZ=2%ZM7!X"A1=1_N%#"9I_:3HI4TZBJ*4J[A.</9NM.C!R5%5)PZ-/ GB
M?2X_AWXITSPK\0=8O],^-.N^//%NA>*-4^%$/BXPZS\/_%?@675;*/POK6G^
M$X[1KK4-+U![6VODN&BFNIWC>]D> [X2=/#5<)A[0AA999C<$IP4[8:IC<TP
M^:2EB>?]Y.,:E.O"7U6%90=2E"E"5*+G&9N^%SQOVDL3B:F6U(1;A:NL!+!4
ME&C9J,&L+AXQBZ[I\TJ+YI+F@Y6/ 'PQ\5:3XN^&FKZWH$4-MX7'[2DMU<R7
MFD7+Z9<?$'XG:1K?A22%(+V61I-0\.QZA(6MU?R$+PW1ADD$;9T'3IX90E95
M?]7N'<N>E_WV"PM&&-H7M9QA6I0N[^RJN$94Y323*DU+#YA"WO5^)JV8TT^N
M%E0SJ$*U]D^;&4%R-JJO:7Y$HS<<GP=X1\:_#:XT+7[WP%>>*UM_"/C?PJ^B
M:3K7@F#4?"EO<_$77/$VG7BOXC\1Z;I__".ZGH5SID%R+.^EGMSI.GQ-9N@<
MV? W&CEM:A5Y4JV2\-4*TZCM0IULKRFMA<;1Q4ES3Y(UZ\IPJ4:->%50Q4[M
MJ@JTQA4J8A5;OGI9SQ-B::5Y5JU'-<SHU\%5PZTASPHT-85:E&</K5.&C]K&
M%?X<:!XC\6_LNZ5\/M+\/)H \2_"?57TO68]0T\>%+>\UC4-1%AX9C2VN%U7
M^SYM-N(7%[%I@MS97 */YQ$-=N)A.G_9GMJ<\14RBEPQ.K0Q*Y*F.^IX?!U<
M;AJL9>T5&=\(\-BH8FW[S$I)58PK\CI2:Q6:\E:IA'CLPXFC'$T.6=3+Y5L?
MBH87%T[3@JM2+Q+Q.%=";7-@Y.=2C[2A*IVNMCQKK\_P[U^'X/\ B;28_ACX
MF&I7'@R]UGX9[]<MK_PCXC\,QW7@R;3?'5QIQN=%NK^UFC37)M!#VUPYAQ<)
MY2.-3V>,J8YRG76+PN,P=I66(H3Q%?+<5'&54Y.DU*&'Q&"K*CB*M9*MB'&-
M2BXO$8*E+ZE' 1:PWU6IA,0_9W>%Q4,-]8I/ IVA645*5#,,/*KAXTG7PN#C
M4]E-U)X;G])^&OBV_P#'?AKQOJ?A7^R-.NOC;KWQ&F\-W]]X?NKSP9ILOP5O
M/ 5I>WW]G:K=V,VM:AXCA%Y-'H]S?K$VL"1I6*SRKI@94\)"E2E*/-1RC-\.
MIP4N6-?,.(,!F%/#4VX0G98..)=6;A&G[9XBE&<H2HNK>82EBDE2H^RC'%Y4
MJNL5+%T\!A\P4L962?+>%2M@\+0@Y2JO#8+"5)1A)2HT,J/X;^/?#'A3PA=>
M'O!$5[XB\,_'OXU?$B71K35/#=A)>Z7XCC^,Y\,W#7UQJD%KNU+_ (2/PI;M
M&T_FPI>H+E(EM9O(P<JE/#Y=1PLHT:E#AJGEB<D_94,9.A@(S4XQC)RITL53
MJUZCI1G&;IN5/GG*GS>MS8.OBL_^L5.2AF.)RFI":C)RE'#8K)I8FI%*+<:D
M</AL6DYJ+FDX)OVB4J6N?!K5]'A^#UG<^$/&_P 0-.\/> ?B?IWCM_A]XWT_
MP+K>H^,O'=_X+UK5+V>]F^(7A"2ZLM6U:T\3S/%%?RQ*[PF6,8B=:Q,<)/$9
MCAJ-*H\N^I8#+\"JDVX+#8&<J-*.(CS-SG'#1HRE.5&HW+VKBN>3C/DPM>O_
M &:ZM:5.AFF)SBEFE>G%2FJ<IX7-G5C0G)5.6&'KXNAAZ,754O81A%-TX2MO
M:I\/?B=X>^$/PVN?!^B:9??%'X6W5P/#/AI-2TO3+$>&=8AU3PS'X4O]8=8+
M.9=)\*ZII,]Q.@5;N\\*1R1^8\B;YQCK8K&T9RQ*]KF.!CEF:8Z-._)+$8?#
M2Q694*5J4N2EFV$HXVG0A"G-X55*%.C3<U3CSX.-"G0Q=.M1E]7HXZ688.C*
M3E64*&,JU:6&E452498K$Y97Q>7>UK5:E.-?%JKB*\^26).L\0>!-.T3X>>#
MOAI+\*_$WQ2T[1=&B6'5]!U;P;HVIZ+XCTN"%(_$":OXD\:^']2TC7[V\NKZ
M[CU319)KB&0W!=XS(@F6.G]8Q=6K@:7]G/#QC'+ZD9<D,+347AZ6'C*FJE6-
M+#X>%&%2'L:E.K03@X56O92>#]K2PW/C:E/%5L74G6Q])THRAB*]6H\77JNA
M*,,-*-3%2J2A!RA[.JZ;BH13J4^.UK2/B[JUE\.? GCGP1XF\:>%-$\-^']9
M^(^L^&-:^'A_X3_QCI[QO;^%+Q/$OC'0+H>'+2\M(K_4KC[#$NJR"VME1+1[
MV&7?VE/^U*^-4%&&!G2>!2IJ%*>*Y%*>8^R4ZCHPPU2[P&&;E.EB']8E)/!X
M:5>912P=3"T4XPQ\L7"JJDY5*N&RZ=6<:.!YY7]MB*^&DJ&,Q+G-+#QJPA*I
M7Q;K87J_$FD^/]&UCXFR^%_ M[XBA^*WA_1SI]W'K7A;3[?PCXGM_#[^%KF+
MQ?%JFNP3G1H[--(NA/H,.MRM]FOXQ;;EMVO/-JX*.*P.89+4K^QIXS&8F?UO
ME<Z4<+C,+@\/5<8*U>5>G+#5ZE.$J<(5?;4(3JT4JLJ?7A\2J&,RK-73E)8#
M#8:A+!Q48U^;"XW&XZ#C4YOJ[C4^NNA/]ZG1E1YX*O&I:&!?>'?&@\2^"_!^
MI?#7Q;KWPI^%.E>$7T&XT;5?AP;;QQXQT:PMH[#6M:L]=\?:=?6>A>')+>&>
MVLI+-I+G4U%VP$>FVIN_7>*>,S;,,XK7PN*KXK$QPL9:T\+2Q7-'$8V<J7/*
M=>K3K5<-1A&'^SX;V]1QJ8C$THX/RJ.$> R;+<HH5(UZ5/!T(8QP34ZOU?EC
M2P,/:J$8TI2HPQ&)J<UJ_-1PW/"A'%QQ'KWC?P[K.K^-/@[J^G6?GZ?X5\7^
M(-4UZ?[1:1?V?8WWP\\7:%:S^5-.DEUOU75+&#9;),Z^?O91&CNG-A)*CB\;
M4F^6G5RG%86#WO7J9GDN(A"RU7-1PF(GS-*"]GRN2E.$9;8J,JN$PU.$??IY
MCA,1*.BY:5/"YA3G*][/EG7I1Y4W)\UXIQC)K@O%V@:_KOQ#T36/#'PUU[PK
MXGT;Q+H=K?\ Q7EUCP9:Z#KW@"PO(+O7=%U"PT;QA/KOB2TO=+N=3LK&QUC0
M8TLM0E-[&]MY$5Q/G@K4ZLZDE[##5Z>,CBL/)W=>7U;$4,'.,8*=)5HXE8/$
M1Q#G2JT\)"=&4WS5,'5VQGO89T4_;U:7L7A*D'R?5JDZE*==RG4BIJC&"JPK
MX>$9PQ4G!1Y')8O#>6O\&OB3;^'O!F@Z5I,-I;>.=-E^'WQL5M6TU)M)\&6O
MB_5/$MKK-H8KUDU"[GT#4?$_A_R[(RSJWC"SG?$>F/Y9ERC264X7%*V!PF"R
M3%U8Z-1S3)\JPN&GA'3Y)*I3Q^)H8*EBZE_8_5<K<(2?UB$W5><XK-,7A9.&
M8_VCG<<'.+]G)X/.,RQ-6GC%54?:1JY9":Q^!HRG!QJXC$Q<8U9M+V/PA>M\
M-]6D\+ZQHFHK>_$SXN^-I?"L&DC3+JWM="BT5M;&O:H4U%/[-T:.TTDVY 62
MX6>]LXC;@3;D6"YZN&P6!J2Y<7A,+FV-Q#F](TWG^*J0O)7YZE99I@W!1YM:
MLE4=-TZG+C4IT\-5Q^*@E#"U*^487#0BGS5)QR3 8:5.G&WNJA_9^-G-U'37
ML<+4G3<W*C&IJ?%9?B2^H^%8_!EKXE?0636_^$CNO W_  K(^+K>^":=_84"
MGXKDZ1'X9GC_ +72_>TAN-1$JZ>($6%KATQG2=9XFE/2$\,X4E+E6'E4J2<*
MBQ<E&>(4(P=.I26'IRYG&JZK;A2I5NM.G'#73_VB.)I2:M)R5"-.NYN@N:-+
MV[J^QA>M*,51G546IR4X>/\ PM^$'C+0-/NHO$_ARU%Z?V:_"'PT21[_ $*_
M#Z]8:O\ $2XUG08Y+5HD%G]GU;P^S2_9K6SE$D:H%^SO'!6;Q>)R//<+ADY8
MS'T\+R1UC*K.ADM'#)RG4J3M*GBW7C&52O.2E*53VDXR]K+KP^)I0S')\34G
M)0PF=<0XRI*27-3P^/S/+<1AJC5.*3E5HX>I)PI1O#DY90IMPBZ%QX#^(NA^
M"_&WAZ3X7W/Q!U+XB_!KPAX6\X:_X*BL]%US1/ C>%[[PQXMGU_Q!:3OHRZM
M//J,5WI$>M*[W^HDI$XB:[VX@2QW^LN&P<W&.-SG'9AA:UN2#I8BEA(T*E.+
M:J0Q="6"?LH5*=*FN;"7K0_VB5#RN&5++5PGB,:N2>5Y9EV!Q5*+YZT:N&Q.
M*KUVVKT9T:L,7&E-QJRF_83_ '52/LN?W?6K#Q[I'P<TO2_".GB7QIIGA[PA
MI\E@CZ%/>Q1V;:1;>(UT9M=N4T2X\0P:7'J;:?\ VE<+I[WL5K]ID^S%R>K-
MJL,5FV(K4JE3ZG7Q]6I*I1C!5E0G5J3A4IQQ"4(OG=)SYX2G"C[25.G.M&%.
M6.1T?JN5X3#8J,8XC#Y;[)0FY.E]:A@^2G3K.@W*5%UDHU/92]Z%TI*+YEX3
MX>^%OQ%O/&.F^(/$>BZ_>V'_  O?PYX\DN/&M_\ #.3Q''HNB_!77?!_]LZO
M9?#^.UT2._B\3G3(HH=.CNI_+-K.SD1R?98P3IX=TW/DA.E'.N1P]JU3>/A@
M%2C&51RDI3BL7"KR1ITXS=9>_&HL1B.ZM457#X^ES5)>TRW)\+!5%37-5P?$
MDL?7C%0T4(87EKQE4=Y?!'EFHT(5/B?X9\<^"-"\2^._#=A!;>,;'XZWMSX"
MLYK^SCM];TCXL:3X?^'<T3BU:=H83X@U@:V]HZPS27'AY)&5?-$C<.'P_M:>
M0Y4I>PEF5#.<HQTXQYJF%PF,SG,\WABJ23495,+0H8/%74I*GAO;TY<LHSC"
M82C'$<08W$4_;X?"5,KS;"QE4<(U9Y3DN6X3$4$[M1GBZ<<SRNC&K!QGB<31
MG&+4J51_1-]X8UWP1\'H_"/PWMHK_6O#7A73=#T&&Z%@\MX;"&UM+F=!J\\5
MC/J\UJEU-"-1GCM9+MX_M<BPO(PZ<RKSQ6*]O2INA1GBZ#E3H*DIT,&J]-3A
MA55_<QJ4,,G'#J:Y(.$/==E%Y8"G.G2<<76C7Q<J.(G.M6]I[.MCZM.K4]KB
M?8KVOL:^-FIXGV253V<ZGLTI6M\^V?PZ^*4NI^)?%VJZ%XN\1BW\7?";Q98:
M!XVU3X26_BOQ=#X*M/$-CJ]I+'X#^P^%+'5K>:]TW4; 75Q%%-+IM@)K^WVE
M=/,.XX5X.IRQ4J>:YO7E&ASN4:&89!@LLH5[UI4XN=/$1K*M"$DXT(U9TX5J
MLJ;KY583Q-7&P;Y:=?*<JPT'6LJ<:^"S_%YK7I1C2]K44*F&E3I1G*,KU:SC
M-^RA*467VA>)8_&VI>*M:\$3> +;QS\>?A%<Z+;W6H^&K_6-2&C^$;_2+[5=
M6C\,ZOJ5K:ZB)[8($%U/F""W?S"WF)%Q4*$DLNP*K^SKU\9Q37@H<W+AZ>+X
M3K4Z<H2:C[SKTJU2JDE;$.KR\].5*M5VQT^>GC<3[.4J5#+^&\-)SY5SU</Q
MA"M.%HRE+DC1Q.'4)/>FXKW91E3I]3X3\#>.8M*^#/@'4/!-UH[_  GUR'4=
M8^(\^K>%KC2/$":;H&N:3=W_ (<M].UZYUZ34_$MQK DO4U;2M-6-+S4S)--
M(D'VOLQ'+C:D\5"*RNFLMQ&$6"C[T;XC!K!T\%!T[T_J&"J1IXNC.3C-_4\
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M$5+[/H?I=02% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MXM7C)6<7JFF.[49QO:-2$Z4UTE3J0E3J4Y+:4*E.4H3@[QE"4HR3BVB[0(*
M*UY9VFH6EUI]_:VU]87MO-:7ME>017-I=VES&T-Q:W5M,K1SV\L+NCQR*RLK
M%6!!(J9PA4BX5(*<);QDDXOU3NF73J3HSA5I3E2J4Y*4)Q;C*,HN\91DK.,H
MM)IIIIJZ)888K:**WMXHX(((TA@@A18HH8HE"1Q11H L<:(JJJJ    !@5I*
M4IRE.<G*<FY2E)MR<F[MMO5MO5MZMF4(0I0A3IP5.G32C&,4HQC&*M&,8JRB
MHI)))))*R)*DH* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /@[_@I9_R9W\2_^PGX!_\ 4]\.4%0^)'U?\(_^24?#
M'_LGO@O_ -1O3:"3X3_X)Q?\W4_]G'^+?ZT(J7V?0_2Z@D* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M>!]I['ZW5A2Y^7GY.=I<W+S1YK=N97[H?\/?%G_">> O!?C?[!_97_"7>%=
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MFL/7RFBO?6:8/%XM2^'V:PN)HX90Y=>?VGM>?FO#EY>7EE?F7L5(L* "@ H
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M8>>*Q.'PM-J-3$5(4HN5U%2J24(N32;23:O9-VV3V/F ?M3V'B"P^ %Q\._
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MI?!CX,>*_ _@[]C?Q/I_@/QUH?CV+XN>*].^)=W-H_B>'6-*\ ZK+XY=M/\
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M#/VE?!TFC^+X/VD=7U'0;[4/B/+#>);_ !+\'BWT==,TKPAXM6'1[+^T-/\
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MI<\I146UU9!*-",/:R5&V78R'O\ NVG++J].,&G;WI3:@H[RDU%)MI'Q7?\
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M-1AB<+DN02H595(U%6S+"8URE7O&,*-;&TXR=>O&*JQIXASQ$6[0FO-Q,I/
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M]DTJ-'#*+A/#8A4Z\*KC@>2%:CC.:<:N&Q2YN1.E2E*A["4)\;\:/A7XXO\
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MHRKQC2;C-_6W[+/A+6? EY\?/"LN@ZWX;\%Z9\;-:?X:Z5J5CJ-CH]OX2N]
M\/W _P"$06_C6-_#?]JMJ'EBQ+6J2B=8\,'%3AZM2KD&2?6IN6.H2S*C4]I_
M'5"EF6(6#55/WVEAG#V,IZRH\G*W!1MKC(4X9UC)8>*CAJV"RNJW3_A2Q<\,
M_KDDU[OMG44?K"7O*?QI29\Q^*_A;KVKZ)^TI;Z[IWQ/T&RU/]J>/QAH5OHG
MPO\ %'C[2/'>DV/@W15@M?$?@O2!:WGC+X<7UW;2VUPUC<K!]HAAWR[8G \[
M#\U#)>&;4(XC%X*MQ#/ZGB*;E1E+$9EB/8.LN:/U:K*%2-;!XFK:E!.56TER
ML]"O-3S7.%&I[*ABLGR*@\32J*%:E*C23K?5YVDJE2E**AB*%.]5P;I^ZVT_
MNC]GG_A)A\&O :^,/ 6E_#'Q"NE2+?\ @C1EDATS0]M]=_9TM+*6XN)-+CN+
M7R;K^SY+B=[0W1MVD9H2:]O,73^L1=.O*O\ N,-S.4U4=.I]7I*I1]JE%5E0
MFG155)*HH<RO?F?B82/)&O"--0I0Q&(5&7LW0=:E[:;A7=!RDZ+JI\[IN3:O
M>T+\D?9ZX#K"@ H * "@ H ^#O\ @I9_R9W\2_\ L)^ ?_4]\.4%0^)'U?\
M"/\ Y)1\,?\ LGO@O_U&]-H)/A/_ ()Q?\W4_P#9Q_BW^M"*E]GT/TNH)"@
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MM3O&,7*,)>TDE34I+N:D04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M*LJ>>Y(ZF,=-*G.I5GCO9JJIQM*G4@IOEG#EG:,*;DZ2<'O^&/BCJOB+XE>
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M._B?0OB!KUYXEO9X?%VBV^H:5_PF]W>SZS9QV.MO(@CMKVWDMCI,5DK);1O
MWHYBZM/%^(F*A)P5# 9/5PLHI*-6*KYG/"8N<DO]JYJ<>=RJNI#%>U=6NJS:
M;X<&W3RC@RE4IJ-?^U<73Q-&<$E1J+)\%[7#QI-<N&LK1<*<8NDI2]G[.3YE
MYQ;_ !B^.7B+X<_LYZGXE\<C2/!6L^"O'HU_QYKOQ#\7?"?3-6\>>'O&]QH7
MAZW\4_$#P+X/UN\M[]="M(IK;3[H65GJTS7?VAYGA6"><7&^85VI4\)6KY+D
M6*P,+M0EB<;@XU<?5H87D=#%U8U94G]5J-QI4ZG-1H24I2H]KI0P=/'86E[3
M%0P'$.;X+$2E%5*D,!AG/ZI&K6YHU*%)_OHSQ=.*J*5&C&I5BY.4OT'\.7?C
M&]_94NKGQ]K^C>*O%C_"KQ2-6\2^'QJ*Z5KQCTC5HK/5;<:KH.BW.^YL4MI)
M2^F6BM*TC1J8V1V\WC-4EE.;.E1EAU++XSG3E%0Y:T\)"5?E@IS<(.JYRITY
M-3IP<:<XPG&45IPPY?VOEUZBJ4XYKRT6I.;5"..<:,)S<8^TG2IJ-*557C6<
M/;*4E.Y^:O[..O7VHW_[,#^!/$TWQW\3^#_@W\18O^$4N]-TVSTO]G[7)_"B
M'2'.M>&M(L(9GU6_MHM$:V\1RZI>E+CS+>>-@?,]K,JF*A+BW%8%.M5>18:%
M',+7E4KTYX:2RV%/2A6DW^\2HTXUT\,E6G.E4F<&!CAGALIPF-JO"4I<1>TJ
MX"-VJV'E7QBGF$Y:U:2P].;Q$'5F\/4E6E&C3C4IP</:_A=\3/&\FL_ "Z\/
M^/?B?XZ^*>NZAJ9_:>^'6O7&K7^G>$M(MM$U&YU>2?PA=V"67PXOK#6H;.WT
MB'3HM-_M)756%YYAE&4I83#U\<\&IX[ARADN)Q+Q*_>U_K]/#X:>$C2K3?.\
M9B*TJE.M@;NG24G+V%'E4VJZQ,Z+590P>=2SG#X:C0O[*C]0GC,33K2E3CS0
MEA:6$C&LL<U.;E&/[^;?LS'^'GQM\8:O\8/A_<:'KGBBP\,?$?1OB]:^(O#O
MB;XK>+_'>OZ=JGAKPI<ZUI5OXA\+:IX/TO0OA1XNL;FU1_[+\.:G=,(KEUN8
ML+',_G583HY+Q-2=>-3ZMPU/,,+6H3=51Q-/$82A*I1Q\O9UZM2$:\Z>(IPI
MNA2KJ\72G&*EZ$I0GF&658T94I1XAPF!K4JD/8WPU?ZZ_9U,%'VE*-"JZ<*F
M%JUJD<15ITXV]O#VRI8GA35_B+IGP7_9?\<^-_C9\89O OQ8UBT3XV^-)_%^
MJ6P\(:)HVE^(%\)6%CKNG1"_\(:;J>I-;P:MKOVU;J\EM+8W%VF\(?9Q4</0
MSW"9?7M2PCRR>.HS;]F\1FU?!9;.CAISAR1]E"+J3PF!2]G6JNHYQK5:E24_
M+P\ZM?*,UQU"\L9A\Q^I1I0C[14LMIYIC*6,Q"A/G;JP5.#EB;<^&HU%3IN%
M*E24/I7]AN:QN+C]IR;2]:UKQ'IC_M":V=-USQ#Y[:QJ=@/"_AI;.ZNYKJ"&
M:[#6XC$=U+&'N(A%.Q8REFY\.JD>&.'E5I1HU>?-7*"BH>\\RK-N<(Z4JLF^
M:M22C[*K*=/DAR\BZ<:Z7]OXSV-1U*:R[)E%\[J)6H5DXPJ2NYTX-.%*?-/G
MIQC)5*B?/+PKQ/\ $SXH6Y^(%Y_PG/Q$LOVHM,^-QT+X<?!>TO=43PEJ_P -
MQXIT6UTWRO R69TK7O"=WX4GNKN[\5SQ2SV\K.1?6Q40G'(TJJX1_P"8F>-F
MEQ$JNJP:]IC5B5+F2^H0P]*%*6%G2]F\0U%\V(YFEMF*A"KQ%'$-X/ X7#.6
M2U:"O/$36$I2P\XVDOKN)K8QSIXG"5'*-&&BI4K*;]K_ &?_  /9:=^UU^UC
MJ@UCQE+=:5/\+95M+[QQXIU/3+B3Q/X-N[^_CU+3KW5'MM7BLYR8]-%W#(--
M@ @L1;P_NZTRM1H<-35-N</[9S7")U/>?L\/#+)PJ^]?EQ4]J^)7[^O'W*M2
M<=#'-.>KF613K1]E5EDE+%3C3;48U9X_,J,Z,>6R6%BKRAAE^XC5_?Q@JOOF
M-XE^*7P^^%/[=GC;5?B%XFT_PW8ZE^S=X2L--%XMQ<7.JWZ>,]8NCIVEV%G!
M/<ZE?M;Q2,EM;PR2/MPJDG%<N5U::RWC'#N+K5JN<9;.-"$74J584\GG&IRT
MTFY*+JP4NBYUS-*[#,J-66/X3KQM"C1R[,X3JRDH4Z<ZN8T/9J<Y-1BY>SGR
MW>O*[;'DWP>7Q[X,\5? YHT\6?#[P9\7_P!J7X\^+M"\!7$FH^'6/P]U/P5?
MW_AVQ\0>'EEB_P!%>_LY-3AL+Z#$#31R)&I*M75@H3H0RC*L4U+%97P;FCKT
M^=5(T<3',L/5P\;IR@Z^%H8CV:JI^TI\\Z;<9*<1YE5HXB'$6:8.G[*CB,\X
M>I4ZR4HRQ+5*=#&XF',HSA2QM2FE*GI":I*34HN+,33M8^.D'[/L'Q3T?XH?
M$GQ#=:[\;-?\%>,!K'C#78M$\$?"O2OB-XEM[B^M+_1_#VMZUH3?:K6SM;SQ
M);VU]>V&FWIBMUAMK&(V_)1Y:6%X-ABIQ>&S3*,'B\9B*U6="^*AE=;ZI2EB
M*:YL/2KSFI5YN4'C<;1H/$XB'MI2CV8J%\SXS^KQ<:^4XO$4,!AJ-*%1<E;$
M9?+$5(X:;4,16P]#VOU:E;DP]"5:=&A.JI1K=/)X]^+ME\,=#GOOBM;ZC\(M
M0^/&AZ1XI^(OPL\:^-?'VN>!OA+<^'EN-1T^Z^*&O^"=&U2ZL!K_ -F\[Q/
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MTZDHRER.<;*5*=.2YCTBW@AM((+6VB2"WMH8X+>"-0D<,,*+'%%&HX5$154
M= !6LYSJSG4J2<JE23E*3W<I.[;?=MW9A2I4Z%.G1I14*5&,80BMHQ@E&,5Y
M)))$U06% !0 4 % !0 4 % "8 ). "< G&"<=,GVR:-O+^K?HON#]!: "@ H
M * "@ H * "@ H * "@ H * "@ H 0@$$$ @C!!Y!!X((]* V\K"]/;'X8Q0
M&WE8* $ "\ !1DG &.222<#N22:-O*P"T % !0 4 % !0 4 % !0 4 % !0
M4 (0#P0" 0<$9P5((./4$ _A1MY6 6@ H * "@ H * "@ H * "@ H * "@
MH 3 !)P 3@$XP3CID^V31MY?U;]%]P?H+0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 ?!W_!2S_DSOXE_P#83\ _^I[X<H*A\2/J_P"$?_)*
M/AC_ -D]\%_^HWIM!)\)_P#!.+_FZG_LX_Q;_6A%2^SZ'Z74$A0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'P=_P %+/\ DSOXE_\ 83\ _P#J
M>^'*"H?$CZO^$?\ R2CX8_\ 9/?!?_J-Z;02?"?_  3B_P";J?\ LX_Q;_6A
M%2^SZ'Z74$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'P=_P4
ML_Y,[^)?_83\ _\ J>^'*"H?$CZO^$?_ "2CX8_]D]\%_P#J-Z;02?"?_!.+
M_FZG_LX_Q;_6A%2^SZ'Z74$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % 'P=_P4L_Y,[^)?_83\ _^I[X<H*A\2/J_X1_\DH^&/_9/?!?_ *C>
MFT$GPG_P3B_YNI_[./\ %O\ 6A%2^SZ'Z74$A0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % 'P=_P4L_Y,[^)?\ V$_ /_J>^'*"H?$CZO\ A'_R
M2CX8_P#9/?!?_J-Z;02?"?\ P3B_YNI_[./\6_UH14OL^A^EU!(4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\'?\ !2S_ ),[^)?_ &$_ /\
MZGOAR@J'Q(^K_A'_ ,DH^&/_ &3WP7_ZC>FT$GPG_P $XO\ FZG_ +./\6_U
MH14OL^A^EU!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\'?\
M%+/^3._B7_V$_ /_ *GOAR@J'Q(^K_A'_P DH^&/_9/?!?\ ZC>FT$GPG_P3
MB_YNI_[./\6_UH14OL^A^EU!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!\'?\%+/^3._B7_V$_ /_J>^'*"H?$CZO^$?_)*/AC_V3WP7_P"H
MWIM!)\)_\$XO^;J?^SC_ !;_ %H14OL^A^EU!(4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!\'?\%+/^3._B7_ -A/P#_ZGOAR@J'Q(^K_ (1_
M\DH^&/\ V3WP7_ZC>FT$GPG_ ,$XO^;J?^SC_%O]:$5+[/H?I=02% !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?!W_  4L_P"3._B7_P!A/P#_
M .I[X<H*A\2/J_X1_P#)*/AC_P!D]\%_^HWIM!)\)_\ !.+_ )NI_P"SC_%O
M]:$5+[/H?I=02% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?!W
M_!2S_DSOXE_]A/P#_P"I[X<H*A\2/J_X1_\ )*/AC_V3WP7_ .HWIM!)\)_\
M$XO^;J?^SC_%O]:$5+[/H?I=02% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 ?!W_!2S_DSOXE_]A/P#_ZGOAR@J'Q(^K_A'_R2CX8_]D]\%_\
MJ-Z;02?"?_!.+_FZG_LX_P 6_P!:$5+[/H?I=02% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?!W_!2S_DSOXE_P#83\ _^I[X<H*A\2/J_P"$
M?_)*/AC_ -D]\%_^HWIM!)\)_P#!.+_FZG_LX_Q;_6A%2^SZ'Z74$A0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'P=_P %+/\ DSOXE_\ 83\
M_P#J>^'*"H?$CZO^$?\ R2CX8_\ 9/?!?_J-Z;02?"?_  3B_P";J?\ LX_Q
M;_6A%2^SZ'Z74$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'P
M=_P4L_Y,[^)?_83\ _\ J>^'*"H?$CZO^$?_ "2CX8_]D]\%_P#J-Z;02?"?
M_!.+_FZG_LX_Q;_6A%2^SZ'Z74$A0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % 'P=_P4L_Y,[^)?_83\ _^I[X<H*A\2/J_X1_\DH^&/_9/?!?_
M *C>FT$GPG_P3B_YNI_[./\ %O\ 6A%2^SZ'Z74$A0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % 'P=_P4L_Y,[^)?\ V$_ /_J>^'*"H?$CZO\
MA'_R2CX8_P#9/?!?_J-Z;02?"?\ P3B_YNI_[./\6_UH14OL^A^EU!(4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!\*^!K?Q/^T7\1?CI=^)/B5\1O!WA;X7?$NZ^&7A'P3\._%%UX%,+>']
M/TZ\O?%7B+4=%":CK=SJ-W?$P6US<FR6"':UM)N.)P%.^39?FTZDJF+S2MC9
MP]Y.EA*.&Q-7"4L.J+3I2K6INKB'7C5?-.GR<D4D;8]O#YH\LIJ"PV%P&7UY
MOE_>5ZN/HO$3DZM^>%.FDJ5)473NHR<FYW;Z;Q#^U%/X9'Q-NO#OP\U;QO\
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MM&MA<*+>6^*OY:RZ+QL>&_:_[*^)_:T\+'^)RXBG/$QC&I;EY:%3ZK4C&O\
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M_P"24?#'_LGO@O\ ]1O3:"3X3_X)Q?\ -U/_ &<?XM_K0BI?9]#]+J"0H *
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M3A[*G3I\TI*G&,>:;<IOE25Y2>LI.UY-ZMW9/4%A0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MO_Z*G^SK_P""?6/_ )WM >YYA]J_X*7_ /14_P!G7_P3ZQ_\[V@/<\P^U?\
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MW/,/M7_!2_\ Z*G^SK_X)]8_^=[0'N>8?:O^"E__ $5/]G7_ ,$^L?\ SO:
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MZQ_\[V@/<\P^U?\ !2__ **G^SK_ ."?6/\ YWM >YYA]J_X*7_]%3_9U_\
M!/K'_P [V@/<\P^U?\%+_P#HJ?[.O_@GUC_YWM >YYA]J_X*7_\ 14_V=?\
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MG7_P3ZQ_\[V@/<\P^U?\%+_^BI_LZ_\ @GUC_P"=[0'N>8?:O^"E_P#T5/\
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M%3_9U_\ !/K'_P [V@/<\P^U?\%+_P#HJ?[.O_@GUC_YWM >YYA]J_X*7_\
M14_V=?\ P3ZQ_P#.]H#W/,/M7_!2_P#Z*G^SK_X)]8_^=[0'N>8?:O\ @I?_
M -%3_9U_\$^L?_.]H#W/,/M7_!2__HJ?[.O_ ()]8_\ G>T![GF'VK_@I?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g180330g33q08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g33q08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1,04&AO=&]S:&]P(#,N,  X0DE-! 0
M    $O2^2%(X0DE-! 0      &$< 5H  QLE1QP"   "_VD< E  "')R,CDS
M-S0Y' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@3WES=&5R("T@4RTT
M(%],5R Y+C S+C(Q7S$R-3<Q.#4Q-BXY7RYD #A"24T$)0      $'^'V2B@
MX\AO0B]@$2\VDB<X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5\            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &               A    HP         !
M      $              *,    A                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     "'0    !    H
M "    '@   \    "%@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
M'VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@
M6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V
M.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W
M=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I
M;F1O=W,I/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S
M:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(Q+3 Y+3 T5#$S.C(X.C4P*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#DM,#14,3$Z
M,C0Z-3DK,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUE
M=&%D871A1&%T93XR,#(Q+3 Y+3 T5#$S.C(X.C4P*S U.C,P/"]X;7 Z365T
M861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @
M(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@
M5V]R9" M(%!R;VIE8W0@3WES=&5R("T@4RTT(%],5R Y+C S+C(Q7S$R-3<Q
M.#4Q-BXY7RYD;V,\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(R
M.3,W-#D\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S
M9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#HT13DU,#$U-S4U,$1%0S$Q.$$U.#DQ.4$T0C,U0T%&1#PO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HT
M0SDU,#$U-S4U,$1%0S$Q.$$U.#DQ.4$T0C,U0T%&1#PO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.C1#.34P,34W-34P1$5#,3$X034X.3$Y031",S5#049$/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HT0SDU,#$U-S4U,$1%
M0S$Q.$$U.#DQ.4$T0C,U0T%&1#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP.2TP-%0Q,SHR.#HT-2LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C1$.34P,34W-34P1$5#,3$X034X.3$Y031",S5#
M049$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(Q+3 Y+3 T5#$S.C(X.C4P*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HT13DU,#$U-S4U,$1%
M0S$Q.$$U.#DQ.4$T0C,U0T%&1#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP.2TP-%0Q,SHR.#HU,"LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HT1#DU,#$U-S4U,$1%0S$Q.$$U.#DQ.4$T0C,U0T%&1#PO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#HT0SDU,#$U-S4U,$1%0S$Q.$$U.#DQ.4$T0C,U0T%&1#PO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.C1#.34P,34W-34P1$5#,3$X034X.3$Y031"
M,S5#049$/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S
M:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P
M:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( "$
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MVR+D5IL:*'*?]J+,]O[ %^.T.)UQ=(R##K\VGQ^AR(3W)ZN\NTD1SBD@@ G
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M,ZE<##NC2.QP@K35MQKN^>*L&P@X*=)PP:C')3B Y;"0( 5SU+;$5)B&^^<
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M;.:7<;JNM;4OI\.HO#Y=3TFXJ DZR"2=+3+F"203J,& .:O+HUG$,+=&P+)
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J !.B*OHB.B(Z(CHB.B(Z(CHB.B(Z(CHB.B(Z(CHB.B(Z(CHB.B(Z(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g180330g60w51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g60w51.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( "\
MGP,!$0 "$0$#$0'_Q  =   " P$!  ,            )"@8'" 4# 00+_\0
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MX'E'3JF3_33T-J[S5Y>E%]S[1L?E3G?:,4_6>'^K$G9=COFRRHL*DKKHLLQ
M#$4E3DO.ZMUM0\?9.<MTGAAV'%D2Y,:7N ',\!WZJ:>=75A;M_BZB>J#L3%P
M8O;X&0&'T2#$71<8$6"S:3Q/#5J2>H-G3S7;0!HNHJLW1S^99375/7377'P1
MPRN(O!6 ^DO<*O8UT1MQ;PQ1LS[_ .MT7C\:=B-:GQ<4JBOGPM75L;TG=NDF
MA<6RVC#A9'22KLAB\9!._P H212^/GTE!R9:&&,SCE;N;GD+G?ILN!<W6?N?
MSO"6MS2WA+CZZX0D2!MY#4//EU6T4O("U.E&8E#9=Y((7B+E/U'S]JW)O(D*
ME28Y'=8PY9Z V) @U(!ADQF<.):(]''O6J63]I.B+N[>]DZZY0J:9RVOW$;4
MI#E1</!)N7_CC;+FQ9F;M1VZ(A51"!C$*DL[>1 T8<LF;=1G7NSS=LU:Z;9^
M"[8;0UA<0#<B0+"8ZGGK"9&MKN:W^D)1OYU^,;825<U<&"US>7=9K78U1'+T
M9$#D0*$?@9?9-VSM2X]1C'* M(;_ $QS)TAE5LF5R@?.P<N0:&PY]C4-%SK/
M!O\ I?7OLS4/R[7G\6N*+MY3TY?$XL.&0XO.;PL XXFEUV)+B#^12AR].NLR
M->'QP=' \SDXV+QUHJS_ 'F+14Z[-'7Q.2O2 '%<!1H L!0 ?)W/]!<RH/3/
MV7ONE:]OFI/'N RR 6C&&<OAA!;M>M8J3)QXCE3887WC<U&1LPU:%6VFA$;J
MXTT4>#7+1ZC]Z#E+?8A8P$@XD$&/P)]B>^J^'GS $.A/J5'/.2U*TC,>"K/(
M+6DQO83/'#T+';_E\#!&5X8F#= 4$E(J.L0SI62\C=&VZ[0I]Q%^R0'M'2V"
M##)87SO3@*$SYTBP3&"JJ2"2BRRB:***>ZJJJN^J:222>N=U%%%-\XTT3TTQ
MG;??;.-==<9VVSC&,Y^"YH&53>E?</5O+D@Z3XXX4BEP,R?4U@U54(D]?$<K
MX=,>?*_4/"UKZ,')FG'463TW+&3&)C87'D)&JD]8R5\[):-&3/#DK+0" YT>
M$$TF"1,0#ZT6).TO=CT$\]0D)*=8><]&01[8;Y\RB,?%=J1B72DQH+0_,4+)
M1:)0Z0%VX ;MNU:O#CK5(6D_?L!^'>SQTFCDJ;AM>2&O-*U;]JZ[E]K>D^7_
M #>BW=737'\,K&<W+:$-AM"<Z+VA(<RLU$3H@S)2,TL$@\A+=W$-UHV!?D@P
M1,$\=MD5P>T@V'.SB(QJ6!@<\M#J"9,;=:UIHJ$OWYBN[J6@O FC3C.*2F_.
MW*\4ME*D4+6.-W<2A4]GND-YUU'F_P#$[K'#%LLF98YNFY#"T!>-AS)#]W.S
MAQJ6C"!S^*C#$QM>D\-_LB<'ZK]J)%8$?BLS\JZDK2'E-BN"]GN>T:XFP:.X
M9!2)$?\ M1F-MT9:]P7)M&0)#9@,7U:N"B+QYA)BV=*Z%)#(H\D[92-=Y.E?
MM&H^"A*P>V\%<=]W=9/*[%=VZK?@/@'HWM*R4&#A;1@3Z/F]=2J+\Q0POLAM
MJJW+1YD(/6.R3Q]B#X,1=M'6SA!PHTV+KAG+#MW!HX@$%WQ[):CP&]&ZR\Y;
M"[ GUG-RAS64<WM-:W@(--;<W:5O@K(BHZ$5Z'W2;NM6CLNC,#9!Z25;KZ"8
M^(.$TVK]PT1'/"[8K2X-C>O 1?D%KWUZH:V*?X0QUWVXY1->AGH[>T.1D,<<
MZ;:B^;N:X("-6 *HF##W"KG<.X#G1]7?[3.BJBR3I)H"7=O2 X]():[[NHPR
M"\-;^+03Q)H"32]>$;Q1,%?+^!J_XP\48=>MNG!=?1*5O;BZ6LJ2&=LMV@L%
M@^ZB(8FOG33==ZN1@M?Q188R:).'Q%=\Q&#F[IZN@@J48DNQ"!)L .G]R4%S
MU6)"NX^!.A_2^\9C&&$N.%:JAG!/,JLVC[V247S:2N2':&K'D\3'%W*J=TWV
MQ22D<K6PV=+Q:!IB([J378*Y9""MGA<UHM7,="[*:3J&^\F%,D_0Z3\8_*]<
MD,JM.N@%V]#E[RH>&GQKC=L8AD=9WU=CFPYF*<I[)K-"@^*-&4<#$&:R) (;
MF@8\PWT7%8VT)ES8SIL()D7H*>O]RC(?+@<&Q3E+@6!785"-5+QZZ""K>F,G
M<-]%"C.N3.BC^I(:/>;ZX62":1)TRFCU#&NF[B22PEATH[;CA.6Q<\5V9QV%
M!TN>O](S_3%ZQ?F+GJZ>A9GMI_FZ:K286&0;;+80W*;1H*[(L 313.,_4A("
M*+0&,3QC.ZY @U1TUSNIKC)0!) W('FOR+"L;Z3L>&W7Z#+/#28MS?VL'L6Q
MQ;Y^-*/;0Z'C]GS0^FW69;86U'/A(DZQDZJCM))+$QCXI3#G4[G34O;X9#.
M(%(@$1W&A3[/RI]\ +)\WBM0-V8<;*N=[FF4?-(CF+)D^- ;#W3L*,2LVHT2
M24(/G;PK)XH@_??E>[,(4U:[+;-VC?70O-C"'SN 1PT]QR0QOF8;!L7LWOSD
M7S)H,2O.97%1Z<E+1 <9'!,%;2M[5)<6*+%"VW\L+F)5='&\EU.$L:L!(B>$
MGKO"J"*FNI7A#*USS06'?$P.B.56W8O?W-L"D9GJOSIJSDSC?F/G6829S,XY
MU1 [9))#ZGA&C2O*NBL8C>K4I@K)'302!%NG@O8?HFCNTPI_2=CD%BY$-/XN
M+G$BF6+S)N>]-E9/2WR5LN/><G/GJ4Z3-$.A[*?F;K[=03W?Y6;YZ8G1&RZ[
MFS8>HKNI'UZ_4EX2O9@V2V47R[+!W^VC- &35^'SO]^R[8;QF+/VV;TIM'B%
M=*\PC)5G[&2+J3POEFX4U_5[P.OH-Y[X!Z/-4I'+;KOE5.OH%9([;7/YM'LO
MKQ:2S_5^FW30Q.8;,A[!#]82GOG#K%X4%F7$_P 0"Z> T\Z=11%=OGIGF/PD
M\ZJFC$F=-S2U7UL$JVFZT%.6XZ5W?8P0(AL9?MT=M%\BQQ60.7<PL27+-%A\
M=2,K*X;OS1,"!+ZH =B.XFI.R$'Y5^<-V^AM^Z>POJ>SWD)&4.V$CY=H ZP7
M0C N-,%]WT(E;R)D=W&HBM8VFMAW5D.>X6<RM\JM9<L5)Y)M7\J=][*WN#1D
M8:?N=J3P/OY+.OO8;+>B/K]Q+Y=P@BY6C\#?1Q.R<C5<Y6#'[>4&S6QBRZ*6
M-]'"D#H&,!)0P46QE1ML6-M]-$=5EMUBK#\#'//3I3U-^6ZQ] )!?'='NS9O
M3/'G,\>Z@@/$!T>+J:K"5HQFGZ_%5W2HY6GJ5+#9?)DGC)HCO+F&+=C@!H@J
M^>O47F^OZK)H\V0+3#<, D@O$S$FL$TH;4/-.W\4VMW#:X:PR7:W*D,Y1*"#
MH@=7<9BMRQJZ',K$;L'+HY(21J*+K"Q39!XHP&C1R^C8FJJW)N7+;1KLQ45+
M@X-'XNS;F([WZK9ADP+CP@J?./VHH*#&OC!@H]5U09#18QJJ](/W:^^<:(M6
M;1!9PX5WSC5-)/??;.,8S\%*!;Y40(ATSS-VWV;,!ZZ$H]/[6N:21W0LCE$F
M,YVBPHW1?/D1(Z+8_)LB%BPHR19+;_8FY'R)!PDBFDKKG<K?X2&_Q G8DU/O
M!Y(-/R]WAO)*]G2/<'>%?.X$=K\\NUY[I*R&&@DRSEPE?9%>X9H *X358; 7
MB>Z%9BB*.KI4NDM.OUFR0V'$2)=,7$GPM--3\#ANK!^9]YF[>[*N;F6$\V\T
MV_<584Y5TPEI66P:,N2D=WF]HR5D/? TW6FZ>A$J'CM<1Y_NDTU<Y:MY&GKI
MMA1=QI@F"6MS$D F!79;HK[DVV^KI?S/P3:506!6WFUYX4W1Z%JI3R*'(@-[
MIZ,AD3&B D6'(%VC#,NHBOI&$*2B5NV^KH'-I,DW4<-R0<U#SS(HS 2Z[G$Q
M_B#K3]Q]%X>U7E%S=KYT73KQAP#5>W12AJI48-F@* C^;1T:[6U"LRO<)M#(
M]_?U:_Y'4WJ<50S^'0-L_P O-M6N5ML%N&\YQF<8K,DD6,>J#1(O(CM3I?PP
MY;A(BF9Y$NDN.KRZ,*?\$L<(]KZ8S:MK5DJ<B,/HLREJ8A%\99NT@I(&U75;
M-CX]*1LQ+QR=2'B216,1HQ7'1P G2P]-$9[SX]9)-5_*E*<\=(>?/HU%;_H>
MLH93[^-07C^RIB+G;6N@#"( )#&W^C45H/<&PXAB],-9"@#$CBJKW4>5?"-6
M[W)0]DN)#F$$DSF:+G6OM]*CO;JTO0CK?SWB]053P7T9%BO1ENN"DCKT+%2M
MDSZ)T!4BHDT"WNE6OVIB*P&;6?8ZP Z$K]F>D#H;%(<[U*E'1,@_&A"8>5KY
M+AX?(DR*3!IROPO*><?)0VG\NC.>295 "X+H>YH#,^D"<4,!'0J7,+\;D6DV
MJ>,D1+QND8"GT 4%KJO3X]RCH1:[[FV"[73\Z['X(7SBYM 8%=+7V-3U0W/E
MJJB[IXBZOM0#?7(?4E<4?>]-$\E9'(J.LH>&&6#4^SJ8PM8HHI'OHV</XX[L
M2,A62Z:3TO))"$##L+$'S=FY*\5S' $$$@]8/W'*JA/%RO:E8^KM_>G74WE_
MZ!V*4G>+1?U'%H)0I9R5A!2</6$:CNI%S*W '1%A#:71)5VPT9Y?.UTWZ>^^
M-=&^V5B.REC6->T09,D\=0"#4HT_9U@]-^GU-<>\VM.*>H>>ZRZ7ZV$YZH0M
M6#F1K^#\P4.>"2DQI8CIH/1%PEW:\F:XW@K$B165)MX2DXSG=I*!.%"YB&DG
M,"0VD?R-*3%KS'JF#[%K&"VO6DSI^>1P>>KFP(:<@$JBZZ.J8XC$Y"(< R8G
M":.-/UDE!KE5!#=M^)1IG":K;9)1)/;4N8,&1<5"02XK\MNC?.CTAN6V+/YK
MZ3O.A>,5YA8]%(5E5TPEK?J2Q]TMHISFWC7\ ,^"['PXZR'4WDD@SA4961.,
MR-B_<[.$MQ9(O0YX>P $!SJ&:0)$UF@) WD:+QC42[;ZJ]!E>VO5?S9]!KOA
M4-RDYJ'FZJN?"SNN /\ /(Y>Q>&G&,Z*QK3%?QK&_P#8+"$FS]]9<F6R\FCK
M<8H6%'2$M:S(Q[9/Y.),GE /*]!O,IM+G3TML&\; *P@QYI]_<_QF,U[+YX2
MGET4UI&HZJUB#!)9K#XFT$/S+F53J2.5VP^,Q -]Q,C]KM9JDHDP6UR7$M@3
MF:> ))]O=*J\N4-Z,B[6]5/3RS>.NEQ'4$PK>913EV .:BGFTP2M'J^4OHKB
M601CD)A^[$<[U>/(MGSW&FC :%?"QSM7#H@Q05+LYS8PV!P(!&;:!$WWK"OC
MQ+FG0OE)1-R [ \EO2"R;HM^Q!Y\Y(H'0BZ<>T@L3CZ(Z#1G#DJ]0/K/!I@O
M.B[O?0'EOK_H444,*[-U%=W??JLQ(>X'.T "-9]OE.T0DV6DT,B4C/QI[##L
M@C($V9AY)RD\(Q0J5%-7Y&-OW:":*+IZ"=KK"W;A%%))9=JHHFGIIMC7!<$)
M'W5NZ3UUPJ8I&L'&<WCW%84'XPJ$>BKOJZ=%;N*8"2];\:'U=IL]8 G)16Q!
M'&NK J:#;;J8W7125*V#Q2;-!<>E8ZF!U6NK$D==^;/GU(C8M)NG >/.9?T8
MPR=8T;9.;5A!$0L0$*_9OKC<K,#C 2+SOE7"CLN8QNJOE5;=7)8 7.C5Q]S=
M)0^.W$_+-G<'^B?H]Z-0X38,)0S+1$(,R\B1$$VTE!1\E*9Y*HD^8/QRZLPG
M$VFT/B,2<L]]G2TL&OP[%)P[>[H?!=\1S@YK&$R!IKSW@";1\<?Q&]%B/EGQ
MKTCT3?2TWFU0V;9==5IR]0K<_P#HKS^RXNB?*7A+X5J:U>,HS%H1%C\+;3B3
MCQRPPQ(7T9C#K;<VV::-W???PF(W.\ 7 .8[?Q!C6\3HG@^XNUZ^X7Y'GW74
M\#D9/&(4/B*[**!7S)B<E1.;20#&@@80Y?:[M=76[@\F^<*;IJ:(#63]YOKA
M%NIMJ7G:"XAHN4,(S[R8K)WQ4:Z"X?N*H:I[R4 [T=8:%E5C.R*HR1*PW5F7
MD=?A';.3AFS=E8$1,NVR^O\ 16#E<J!V9<DV6%X*\DYH<"6R3>PFQBMOM?8N
MKV[M:@+RIOG6RO,N^@]K=&2-<!0\21O'G8H8L#3_ $+2.,";IH'EY%.",7SU
M^TVV=3US'1[-+4FNX?\ Z@,RZ8D# 03G: (FAI-K@5X"5W;W]S ?'A:@@/;/
M)=G<RG;YM200QJ%-6755@O817$9Q7:!.\I2XKHN>#?XC)2>NAS,<-+.Y \S"
M9:X28_C:LM7I!AETY2' #21/"H%8KY51>N@+YA/.W/MM='2YSJ^@U2UA*K1)
M9&NFVRAP7&P#HXV&A76V^S5P_D6R#<8#SC?9)V_(,TT\[X5U^I0!) &ICS0>
MQ/M[))]TP^Y'I'@*[[HO*,4A7UUV-$(Y:%01G>N6LWAD%F)**2(M8!B*Q[^]
M",V-%HQ(TFYG??:6.'H<<W=[L%5,E>2F8N :20#!),&\ 4%%->CO9 QRG%^7
M&ET<3V]&K^ZUMF45;67-B%C5@:GB>0)2)QX9(BQX"1*1%-I*9)- (P.S:%'2
MGXGFKQ=QILFY:MR-9FS0X0T DUCU .ATT7S"_;6M _6=K<==;49->1+'J2IC
MMT2.32B=5_9E<H0>.Q)G/'SMW)Z_(.U&;IU$'F"@EHB.?K/72"H%35K(%QPQ
M^69*!P((+LL6,\CW8\K,A/H]T):C&EK7J[SENF3\M7I-X3'8;;9"T:S 63F$
M3PBBQ!76_H?;<B3$U6Z:+:2)(J?FP4SK%5FDA( QP]XBIDL@6+H(G2DC21\"
M-B46[X*4K]\UKT_I47 $4Y_$$LM93U+:@<6[:)K?A<*5M4JX^?RIXEMIMA;Z
M)3/2L!RNFN-4UFI9TFJI]O\ \5G??HNN")?.P)^ O#PW[!YQYT+P7QM>!3D:
MZ3A=:(6M/IP9=B\Q^R+XG45CMM6A60_&BW]?,SJD')582OA^V31=#ZE-)HJ_
M>/;8>D>TG_DIE)(&D 4;0[QW*.QTOUA'><)5S1!',5+3B9=.W@RIZ* PI$:-
M4 "&D5D<XL"TSZY+;&FL*K.*1IR8E.S755]JB[9ZMTMLJ;9U+F!,G0"3Y@ =
M2?=8O!>MH?H>RYO5_GGS;9/;V*P);!K$NH+*8=3O,4>-:Z_78"-N6=KN59J<
MUS]JN&<'ALA;.QRS8T*?$@J_]#0J+"(S$-FL&9\@*=2.%EKCDSI*Y+X?7!&[
MNY'LCE:7T]* 49<Z2F70ZPH'8.3X+61)$ZPGL45:ZRD<,&.16YQRK'QC8<[,
MLP_[*YUA(A0(I( B#,B;$1P*V1\%B7$F!_3N[Y@FMJU8*?UZ5\H*7D%F2O.N
M?SA'O3=Q-!0P..551SE%4C&@Y.+%Q>N^<K"9%7<O9[JIJ9<M%"Z_CASJ\Q_Y
M'W?>0J"^;)ZJS6W'%6<I1TAMK*>GK(1,24>U4RHNM5]/K#9 Z:N&Z.?S)Y+6
M.3KU4;NI]$WFD?,MT4UMT%LMW??5,%LNDV:)ZF@^3T4PBGC#POS%Y]U5)?0"
MQ^D)G6=$UC'[.LVC)%?,W84*(M\^T0-2X7!ZDA*T9W?2([8L@?QJ+#&Y%U(9
M07*,@^JKIP4_5W+"]Q<2V 23! $QI4B;<N*!OZTQ-=_P1O9=F<8WOSC9Y#H&
MN8Y4\5/TJC Z!Y:Y9B0:VF,!Y\K@VD1TU4EDP>R#%GVX:UCHA:>6$_=ZJI8%
MPR/9V;<.^^071GYP'9H!),F22!)J-+ 5(\T1OW&L>:]E1WR2\T*650+SCIT'
M7'0\T&;NUFR*<90@>HB%/2RS/.SK8#LT7MN3%-<8URE_BV+U'55PBBHW*<.&
MYWF0&R!O)TUK85I6JM/R%TA7M#:([N+K!!@.G7GQ-Q56<[\?P,9O'Z+I41H!
MCQ^&V<]9&'QV82F:/#X-^S;9*F!P@>1K4.M@0Y0&"F(HL?.&,K;.$DZD;<(]
M05W>6MM?0[YCOJ+I)7.#=/>;5>8HBM76<_M#T;(7S(X"KC7Z_<R<(N9,0Z*D
M@M\A]^VN1T==(94W22=ID,MPFC^9+CR$?14JZOX&#^T[+TMMIOALK+:JEX+E
MC@V2NU]6[1A(^4&9\Y;KI![KMABI%+FNVQ9Q5Q<MONZ03&PH(?T366CPW&2-
M=D+:T-7#@ZVM8 #@-).Z&3PUZ,D^HN+JO\O>FD9&,/\ -UQ,Y'U&:D8]ZEKM
MY^\=AS]^2T'+G3G1/<?(A,HJV)\^E!#K#59S'2H+]E9R\<F]DLOUWVY=_"I[
M<KB]HD$4_P"QI8#C(&JO_P 2.=>_>DQ_6OI]3_1M3\]3#LF]9TWW:69SHYO)
M\4C$=DKX^NO%9!M:,&;QJ,(2Z2%8;L(3!%_S[5T.V_,V;L6S7XU8\M;E803E
M;6# DU)_$R=;Q6RS3Z3=573(/6>XNK*PC$/O>+>*E,0 <3:3= HVA!^UC$L
MU_))*X#Q-Z.=-I+'+:MLK)-Q[(B+;Z,:*6^KI) <DBL5- R!I,?J.TT KZQ%
M2;\T1FD?+.M_3GS]NKKUY>Q:0=N>GE3Q,])+CDHYDUB-5/*ZG\(,&*,@D) J
M*/1E6@IC502K) 8<DI!*5(T $+:92VU<@2A07EK@(&5A(#=S423O4F8Z*.^$
M70'H5S[V'<WD7V.H)F4%Y4I762A9;L_9E_\ D@(;M7V]?AP]@(),L':RED-G
M#%U%@DL0UDT9:-QXUIH &@BT;8EN(&$![9\1J.-R>>\4.B;Q_P#?_/@N*_/[
M]>;PAO7GN?&X-,7.ICFCSSA3J26PT36TW$EA5(1XIT+>HKZJ?DPB:FA9B(H'
M1+\>5'4F8!![9!5PNCLN7H8,N&3J\P.M!\GALIOZ1^:UU<Y\@<C>N]5;D8]V
MM6YQAT)V,4&(K9*+S.\;'(74UFKYAG.VKO>H9S._^425JJDY1*5XH)2*9U 1
M!WE<L8\.)PW5::-Z6XU !K8CBJ!]8O4N0]P4/#.JJJ'FX7%6-2Q+D!SIG1\T
M3B5X=""#EG=DCXH6WPFJYT8UY5%55$B_W^W^_75J2[;;&F2&R#9WWNM8R'97
M :NK%A1I',DSR'$)WWSUY=@?&_&O/] P!@/;LHE74<=R8LP32QM,)^?&-3,[
MFCYPGC[GCJ1R5X0?(J***X:#=AXIKOH/'LT4BX.<7$DZ^G#HMDI+HK?DPBLD
MKE%79!;"2FBGXEM,:YW14^W.?QJZXVUSLGM]-]<;:YSC&,X^I8O7X(L.\=^?
MM%\2R'H29U:0L*43SJ&Q_P#J5R3NSY&.DTHDDGPL:>::ZO!@".MFHI$I)I*6
M08:LM]4'Y\CE)71KLV:MBHN+H!L!  L/O<ZK/G7?C=RYV[U55?6U[3&\R<RI
MW6O6T.@ 66PMA4VHFO9@YG"(0I&WM=%#CT?*S;U]B8J:2EN3),'7Z3 @*3:,
M,M"T/+6EHB#,WFH(WX^G-;+O/E.O.BI_0<UL\U-2@7GB?;VK%:I:E [:K)39
M+(>NRATSL,&K'W)N3%*X=.5CL#;)208'%2';0J]&%%T4,)%()$QJ(XQK'/50
M3O?@ZFO1>B->>+U,V$#@N)M'9YEY69H" DFYB,-RK<>WV?R*+RYA@:IJ8<[.
MT=!6CE3=-#*3Q#75314M:XL,B)XVJL_TKY!<TTGU=6O8[";WI/+;J&AX;SO7
M;:QI9"BT1C,%A%5A:@&/1XD%7,:(HR5]&!I9Z8(:&M6#T_,Y>0T%-T"+-D-=
M_:%Y(+:03FH(KWHNWQQY0\]<*6YTM<- SF[A9;J9T3(3N*GI+!BL'CQ-U*)#
M*@A&#!6U<#7@YS"W$I/"HKJ?*R5J@%(KM3#8RXS^Y\%KGEP (%.%>1KUYJ3\
M&>9=#>=5>6_ :&E=NEGEVS)W.IG8UF2.*2JQO[RP%$(SW8EQ\&CX91L'6P1D
M U(U'S*G]\Z9<D%G[)TD/;ECG%T3%! '=?5:.Y5YGKOCVA(!SK5;F3$(57K<
MYJP+S0FS-3$\2D\G-3&22"4F6 P,U*GCDDD!8H2?(BV6J[AUMMA#7Z?!83)E
M8"L[Q%XVLJR.SK7;DK@KB:=U0H= ;H(UK)H:'T'Q[:2Q"63A.!(FJ]D7\%U;
MQB%"E;2<$]S^#^CLSD<F$7*+KX*@]P#12&F1.]?::;*3\F>3,#XU?50RJCK_
M +P?U=3JIU6,<_RR[(<K1S_!].0+.D)'#HG5$1>%FJ,@D;R7IM/[C9LZDJ+=
MV62),]GC!V6.<7$D@2=:R+6KPCDN+2_BUR=2E1=MU$PE%W3U#O\ :%D+_GUD
M2F$&;%<.RK27:?UXL6"UQ' HPH.-S>02X:J5CIUNE)W*;QPV=,D=1_P6EY):
M:#+8"T#2]E5M)^'<2Y<S7>.7^].[J?;5M'I[#8^,VDO/4Z M8A9LH%36;!VD
M8F'/!"+HN3,L#L3NYEV%(DD7K9KE%71-DS31(7S)+6DF)OI:Q&E/]F:%MCRM
MC'0-N'^1H-(YV&YVS,8?=WIET',)NI(ND^SK248I&:AH(C*--!SH7!HO&ED)
MG)% X,!7,=1.1(/68!K)Q4D4#N_Z6Y]8$@0T1 :-3SVK-R302Q8"!BHR##QL
M R1%@X^)'@PHYO\ ?E <*$LT6 YDA^3913*+1FW102_)OOO]B>OW[;9^N<ES
M0$HU\N)Q*"G=O6.4MGJZ;RF^B[(M;SN9SNJ7^DWTQ<46O.1!R6HRDQ"J0:<S
MJ&@=I@DS6;OWX5!R(8$1B! ALY*SB.( I M B*$><'Y1UIW!HG9L(F%;SP&Q
MDT(GT8.PR7QPDG^4>=C,E%N@QP0]3QG7.S8@,>.6JV-=M=\:*YSIMKMC7;!0
M#!D7%0A21_PSX.#<(/?/4C'IY+::=V*7MY"72*2B-;=%6D3TRR:SL5+(_%P(
M=L=!Q_",1&Y4BZX]U%&^ I]@;0<D-GA7^H[-GF#Z1M&WS6ZDE;>7\U@]?1^E
M3OI#WE-:+B0QE'X_7*DFI.(%U(L-039,(M(;AAU*B+L+ FXU),9ADPL$%KL.
MTT'_ ':C]?U,EA=,G*T$R9KKP)(]%<WG?YVU'YOU/,:OJN8V=8KFQ;(-6K/9
M[;<A9GY=)I::9#1:CIQN+%A1:":0X2ST442'Y($7NSL@4?O%ET]6Y'.+B"0!
,    @ !;]^"E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g180330snap3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330snap3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MU+[=:#X<7%IK6G?$#XF>#KC2KKQ6L9ET?P#X5\=^(=-\7V,__"-DW>GZS?>
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MK9<T82<X1EU49RA3<DNDG"#?\J+506% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\D^&_P!GWX :O/\
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MM%NW9-]&/H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H X[QA\0/!7@&P?4/&'BSPWX8MUBDDA;Q!KFF:*+D
MQ@GR[8ZE=0B>1B-H5"220!R: /@_PKX_^*W[4OC;6[#PKXINO 'PU\.,DUQK
M.CZM?07&H">1UL[71+CPKJ^EWE]<%89Q->3:Q/:*J)+]A@DF6U(!SEI\9OBO
M^R_^U#X9^"/Q:\>7WQ+^#OQ4M[$^ O%_B2VLD\6>$=6U6]DTG3=+UG5K&*(Z
MM9?VW;?8II;P32+%JMC=^?&(KB%S8-C]0SP#CL.!TZ=* /GK]FG]HOPS^TYX
M$U7Q]X4T+7?#VG:1XNU/P?-9>(?[/%[)?:5I^CZC-=1_V;>7,7V5HM9@5<R!
M]T4F5 VE@#Z&H ^4O%7[5WASPK^TQX*_9FN/!OBZ[U[QGHAUBU\4VMK"VA68
M>WU6Z@0PF3[3>6:Q:->+<WL*^5:R&-6#A9VM@#ZMH * "@ H * "@ H * $)
MP/I0!X%\ /VB/"/[1.D^,]8\(:/XDT>V\#>.-4\ ZI'XEMM*MI[G5M)M;*[N
M+K3UTK5]05].9+^((\SPR$J^8E !8 ]^H * "@ H * "@ H * "@ H * "@
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M#J=/%YC4PM)Q5.&+Q5' QAD]-1<DXX6KA<6Z$W/ZDO[0C[Z=*4X^#>"OB/\
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MEF/UAQNXNG!*CBY0P?)3?[:BL@6B7D% !0 4 % !0 4 % !0 4 % !0 4 %
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M1F@!] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=FENKHP6QM)+F4M)<MI[7+L[7!=C] _0^SJ "@ H * "@ H * "@ H * "@
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M2_2:XT'04MS&T0^U">*6N"L^;(L5C/:.-=87#5HRIO2,L5AL55JT7R.HJ5;
M5*,,/*4JZJ5JOMK8?#SP]6G'B=1K&T*$:;C3E[?F4])6H?4E3JP4E3E4I8I5
MZE>#C2<(8>6%DZLU7A.?D^A_$[XH'P+;&'5?#[PMHECX9TN]N]'UO4_%2:RO
M[/5K\4&\2ZIJ\_B<0:M</K"W%M]E^P0LRRQS/<LZNDO?F\526:U5*-#V=/,\
M33Y(J$*5/!9O2P"IM-M>]1=6;J)PC3G[/]W*,9*7J8:A2EF6%I)<U/ZS15:-
M36,EB,QQ>%Y*?+RN%.FEA96;DY1C7I)T^>G4IVW^//CHR>(;+1I/ 6JG1/#L
MCV-[.^G9U"[3P;HVNV7B[^SK?XE?VQJ/ANXUF_GL6LK+2& 15G&L9CEC6U2C
M6Q:I+]Q&OF%+#127.\/"IG^#RI4YP@VW*M@\1+,:%:K+"PA"IA*3IUXXBE7K
M?/0Q$Z&74<1.$J\Z6 GB*G-)4O;2I91C\PER3E%)NGB,+# 5HTH5Y.M1Q\[4
MO83I4>B\3_%GXC^$%\37MXO@S6+#3-7USPWIT%EH6JZ3<V]WHWA#1M>D\1:M
M?:AXTFM#I$=U<:K)/9G["(K2*)GU)3#+(_%"I&=/"NSIO%K$55-N+C0HT.)Z
M.0VFI.FJLEAZZQ,JCJX>'M:;I\L83YZ?=[\*U:GR>V>&JTJ/LX<RGB)SX<Q&
M>*-)QA5E3E4K488.G%4L1*T_:*-2=J3VOA_\0?%?B7QCX;CUO7?"D.EZMX9\
M;M::5I(TFX'B"]\/^*K&Q@U33+W1_'FOVL4\.ER@7-A%=Z@]N\5UYKH75;?I
MHT_=S+VD)*K2H935C3UO1]M4S:E6J7<(\]*L\/AZETN6G[?"T?:RG2J2Q.5:
M<HUL#"$E[*53&PG4LDJML-E&(H4W'GDZ=2#Q.*C3;DG7I4:U=4>2I3]AR.H?
M&+Q=X:?Q+97?BOP$UYI>K_$V[M5US2-3CFOY/#NK6">&?AS86]EXH1XO$>I:
M=?\ G6TVVZN)(1"UOI-Y^\D'-@I.MA\,W%UZL?8P=.E95<94JYEC<-B'AW)R
M4/J4</0I5(.-6,)X_!^WJT(Q7UGNJTX+,ZF&]HL)A:LL/?$5+.C@*;RG XA5
M<1>5)2A6J5L17NZN'@XY=F%I14U]4[3XJ^._%_A/6=&N=$U?P]I<=Y\-/'^J
M6?A[Q'IMS<IJ/BS2KGP<VEQR3VNNV$TWV6WU&^D>UMT\QH+>^.X;DEL^BC34
ML97P?M(U.?&Y'AJ4HIN4*.,S*I@\7B(Q4O?C&G.EORQC5EA^::3<:O(ZO+DS
MS*="5*>'I8C$5(2ER^]3RS%XJEAG-P_=RE6H<CDXRE+[,%*+OR6L_'+Q79^-
M?$'@72+WPA?:IIFDNL,]YH(M5LM:M?$'PZ\.7%W>:-9?%"\UFXT66Y\7:G+"
MM[I^@;UM(!:W=]"INKG/#KZW2=6E[E/Z_@L/%R]]QH5\?B\+6YE!<OM8PP[5
M)RJ4I>TISG/#>SJ1C2WKP^J4I3JR4JE'"XJK*$?<4ZE/*<5FE+DE-\W)"-"A
M'$*G3Q$$L5&+Q-&O3E1E!K7QR\:Z!<>(-/O+WX?RZCI6A?$0Z7:V>FW<UYJ/
MB'P9'XUN;2XUC1CX\75/#GAVZLM L)$FBM-7AFELM4MY-0L99;(2&$C]=C!4
M?W=6M/#TXW_>4Z7-CL)@*]2<HN+E-5*\JL<-..'Y*-7"\N)Q,Y3@:JC&EB\/
M0KR;H+$8:%:<;4ZDZ>+P>%Q=..'IS;4I4_;3I3J0G7G)Q=:6$HX>C6JQNZO\
M1OB5I=Y-IVNW?@O4;1?'>G>"U;0M!\6>&KPW(TWPEXE_M<W<?C^[>.V\O5[F
MR;3E)$OE))+<-#)+9O5*,:L\'&-XRQ*Q%>#>L:<<)Q%A\E4)P5E6]I&H\1*[
MA"Z5&5.I%N3X)57'#8BKRKW*%2,H]>:?#>99M)PG:\.6KAJ=.$XVJPC*4Z<Z
M=:-.HM^W^)NO>&?@]?\ C_6-5T;Q1)X1\5ZPGC>>PTZXB?3O"NE>-+O3_$.R
MPM]8NI(-7TCP]NO1')(Y,5FJ&!F<,V$JG)AN'ZJI3J+'X# <Z@G.I6QF+RU1
MP\:5DHJ57-YX?#XEVE&-\2TJ+2C2ZJ%"KB,3G&&I2C"OA\9CUAX5+I1H8;&3
MJ*G+E7-*57+Z<_J;2C>=7"2J.I#GJ5>+E^.WQ$LM/NIM0L_!4'BBVTZ^EE^'
M$.F:_<>*;00_#*;QS#XEDDCUTO<^'8M86+1I$CTZ.*5U;R]42[=;,=:I4:5:
MG2K8F%2E3K5:6,Q%-QIT<&L+F-+ UJM9SE/DIXBBI8V@ZCIRI4,=@7*%>C3J
M8BO.&<,9/FHQG1H5JF#E@HUE&-;&X?'U8^RC37,HPQ&'H5G]95-XB/MLKS&T
M84Y)X7T;P]\5=1\9^-DT?PIJO@Z_\+6_B77;"YU>TM[O6FO],T3P=X"UF6VT
MW4+'7XK2+4O[;\67L+W1CN8HXK)(OLQF5Y&BG3DG1E5BXTZF$Q];E7NR=7#Y
MN\NH.+::5+V49U*J<7*I-1]G*G"6F4ZD?JN'J4I)UYU\!2J)ZQIK$X/,<947
M*K/GY,)05.\OW:JS<U-I17.>*_C-XPT/QGXD\'0V7AK3XO#5WI-[JOBC6;+5
M9-'T;PAXNU'POI?A7Q!J$4&KV^]([NY\=+=LUU:0G_A#'9I+.*<S1981>WC3
ME5JQH1AB*N#K3E!J#Q?+C<=AZ5&4YQC+VN7T,!AI>]*2S'-L,Z:J*G]4K:XM
M/"QBZ=.5>>(I1Q5"$+NV%I<F#QSKR4?=JX;'5(XZ,80E"654JT9RIUE[:&!!
M\5?%>H:M;RWVO^&+C3+J?PA8Z/9:1;ZWI%OXF,?QM/A"]\7^'KR'Q4MS<:3<
MZ,+&X:T#:C9LMU!'+/>V,[?;U"3@J\W3:K1PD,5&G.S="+RG-Z]ZD+6E2KUL
M-3G3E4C"4:=2BDH8FDJII7C&$Z-.G4C*G%9K"52-K59TL+E6(A1NI24:V$EB
M:^%J.$E/VV%Q<^6E*2I81UG\:_'MOIGAP^)M:^&/AU_$'A?P9XNN/%M_H&NV
MOA;P];>*?#WCG51HU]97?CF-[JZ%[X2MK>"^;5K%)!?2*+4RI&DMYA'ZDLQC
M&HG5R[^T(Q4E_O=;!T<JE3HT8J7-"I4>/Q%=PC]8F\/@Y1C"[G5IU4IJ-=>R
MISJ8:MC)X:*NN?#TJ>)K0>*Q$[>SE"=..&PJ5J,:>,Q,)NK.#C1?4>(/B=XH
MB^&?PT\;Z?%H8\1^)O!\WB!EF77T\.Q:M<^ KC6H]VE6>NVTEYI0OV7%O>3W
M#K$ 8Y$N%2=.O%894.(:^54FX4N>&&4JB52<(U>(LARV4G%.%-U(4<;5DIP4
M)JI%0C4C0J8BE6\V6(Y,K^O2<:[H5,3/]TY4H55ALFSS&0Y6U*<85)X*FG"I
MSPY9.<J;K4Z%2EGW/Q7\;VGB>X\&ZAK/@."^6X\0Z#:W.F:+//JU]K5MHUUK
M.E7Q\*W?Q"CU'2-&%J(X_M%O'X@CFGT^^\^338@CUX^)JRGE>.Q%#FIU8X#'
MUZ48M3]G+ 8K,<)5=2HHM4Y58X2%;#QJT:=*+DZ/UC$5ZE"C4]/#QC#%T*=9
M*5.GC\%AZK=X1E#%X?)L1!TXMKVBA/'UJ&(Y*KJ4H2PN(]DZ*Q,Z;?"/Q>\1
M+I6B:QXA\2>!KOPE%-X T35O$26-U8!+G7?!G]LZIK%]KDGBF?3K./\ MJ:Q
MTY(F@ 6:217D+RI''ZN8.E0Q^/I\L:5%8_,:6'Y6U#ZOA<NCC*37-S.;KU'*
M5.TK?5E3A%U:DO:GFX-8B>7X2?O5,5_9>7XFI!QO4^L8G.IY=7IRC%1Y7AL-
M2J2JKE3^L1G4DJ5*FZ)@R_&OQ3XF\%>)=7TSQA\/_"-]9^$]+UW2=.N=(O;W
M6]9TV^\.V>OW'B_2&N/&5B(O#JFYO;-&%E?+&_A^_>2Z)W16F$*<X3RWV[49
M2QV64\72MR_5(5<;EM&O'%-M\L)1Q$IO^%:AB</!5554IRZ\7RTUF$,,W54<
M/G3PLXRC-UZF$GG%'"PP[BI0G64<#0K.RJ.<YM_5XT94W4U/^%S:]8ZEJ%E:
MZCX.6"VU":XTFVOUU_4-0^)DMYX[U+0)M*\!W$_BEULKBUL;.RF,=LFM0QMX
METX+:VEK&INGA8^UEA*<X2C*IC(X6>'U^L8>C4Q6)ISQM63BY2HX:,9UJG-3
MBE3R_&P=:A3=-X:<8U0HXNO3J1J.GAG6C45E1G4H9+E&,I4(0C.T9XZMBIT*
M-I1<IRIU(PQN(>(<X-8^-'Q T"Q_M'5+_P"&]K97K^)=1M9)M.N=.N=/T3PU
MXMU70I;."#7?B)IUIXK\03:;%877E1ZCH846NHO#%=,(;9L,/-3IX)U6U*>%
MR+$UO9Q<Y3><Y?B\3R4</'GK<N%KX>*E*FL77JTI\M/"NK9NTG+$8BE2@[1K
MYQ1I1E-17_"5F>7X).K7E&-*#Q5+%5N252-*C3Q/U>%2M&E*I47;_$OXPS>"
MM<^'>E:?/ICMXKU#PU!=6NJ:=:6LMY9^(O%7A[P]&^E3ZEXWTF\AOXH=2OYS
M:6.B^))8_)B:\2SBV-=]%*FYYGB, U94(3<DI)RC)8?,*L??@I^TCS82[DJ5
M.ER4ZB]O&56$J649)Y3''\Z4I4:U>$G%QC*.'H4ZTU*$Y15'VLJM&A34\0ZW
MM*\?94,4Z56!QR_&3QY9V^@_V_J_PXT*W\36NAZHOBF_T+6[3P]X/T_53XW=
M8M>AN_&\8U*29_#FC:=#=?VEI$?VO6/]5)F*"3DC.^':J5(TL12P5#$REKR5
MZE? *NL/AX7<X3IU(XBOS.5:53"4915*%2+J/KJ453K8GDC*I3IXS,L+3IJW
MM.7+\VP& 52<[-3]K1QO,XPHQ]G5@FW*E*3IWM/UOQ9K7PI^ >K6WB/[1<Z[
M?^&KWQ#=6K>(6G\30CP[J^MFVL[^VU^QOH+6ZNK"(A;I[OS$:)+B.6,2Q3[X
MYRP.+H2AAZDUA,%7JK#3:]K4K4<IJ580K.,94ZD^>+YTZ,XRKN-5*\$GFH0K
MTL^I_6*<;YC*C3Q,-*-*C4XDHX3GHQC4DZ=)4:B4/9U_<PRE2A4]Z-6$'AGX
MQ^-_$NM>#=&T_4OAYJ">(;_PU)K>HZ9HNOS1>%EU/PMX^\0:SX(O(&\4G=XP
ML9?"6G1&XGGLWB3497NM&A(@6?KAAZ:KXFG[98C#8*-:4<32Y52Q\*?U&$*F
M%:G5C3@Y8M5Y2YL5!T:N'A"K*?M)F/-?">V<)8;%5:<FL)4LZN"J+&X6@EC/
M@G-3IU\31@E2P]\5E]?EG*$IT\/:^)GQ5\5:7XL\2>"M+CT>QLK;PO=3+)/J
M&DZ=XGN1=^$?$^JMKWA^6Z\:V-_)%8WFFVL:Q:?X>U1F-EJ#_:H#;D0^3S3K
M8;-)/F@L*\13BX-J5+V6%PF(I5Y\OM)RA6JUIX91Y*$8/DK>WFHU*2]+#4XT
M\=DZY%4C7J8&<E-7I556S1X*MAO>4*<)4:,8XF3=2M*K[:EA_J]-U:56KS%C
M\>O&;:K<:5,/!FAZ5:ZK<Z%=ZSXBN--EN?!T>F:YI6C6>O>*M-@^(L>KZE8:
M[:W+7%O/-I7ARVM7U72O,N[J*\CEG]&:C.;E*<*$:N(DDTKTH>YFM7ZH^23I
MT\1S8*CA8^TK4VZZQ4(8>=6G"@_'H_NL#AW&4L56IX' U7"[]K56(PV6SK8O
MFDN9T<#+%5:F)C"%9U*,8U)XC"QC6J0ZB/XA^.H?&)T2P\6>!/$::MXH\-0V
ML%OH%^<>%I?A3K7B^\U+0+>T\;3/+%JVLZ'Y%G=2RW$$/GW&6O#&J+S\TJ=#
M-:GU>I4EE?\ :5:5%?QG["&6K#8-OD?LZDGBY2<G2E*?+-PI1YTH=W)2G4HQ
M5>-%5\!@Y4YZ.DJU7.<3@Z]:I[R<HT</&\XPE'WOJT7*FE.=3+T7XQ_$#Q+?
M^%]'T+5OAK=W/B&;0)=0U:U\/>([^Q\)S:EX3^('B#5/!>J:?'XQ@>Y\56%Q
MX2TV-Y)+W3I4CU"5KG2K9O(\[7$06'AF4Z=6.*HY90Q5:&(@E[',(T(X)4ZF
M&<:E14Z<I8I5I24\5#V%:A"G5E-3F9T7"5&E5K4ZE"M7C[V#DX^WP<ECL+0M
MBFTI2YZ5?$T:?[BBOK>7UVG.$ITL//X/^,6MZYJ^EPWFI>#_  9;>))-*U)[
MSQ&VMZG:ZC>W7@'X5:N/"7AM+[Q786VG:M-+XKU&6);=MC1V'FKIES<2WMT>
MN>&IT\15P\9.4<-*LJ='W?K&(A_:V:8:52$]9..%AA*$*W[NLHU<?AXQEAZ,
M*.'J9XA5,/3I*=G-4JT:N(4>3#T:F'=>*=2G>Z5=QG7IJ5925'"8F$ZL_<J4
MK'Q7^*.O:#XMM="L=;\/V"Z;XF\%-:^#O*U%/'7CFTNK;4-6O'T.\M]>AB_L
MEY[$V,D#:1>HXT[4%DF5I(TC\:.(J0G4K1I_6)819U:A&Z26&X=KXJA6Q.DN
M:D\152A[M.,:T</4A5E5IRIOHK48NG0H^T>'CBGD[>)E\*EB.(\/@JU"D_<Y
M:E/#4_:UK3FY4,2X3ITZ4O:2Y"Q^+GC'Q-!H.J7-UH3*TIMX3X:UF*/1[QK^
MZ^&#^7JEGX0^(^LS1WFG3ZW?!%NM2LWG@N8S)9QPW,L<W=5HSI8F%*C)2J2;
MI4Y33=&K;,L#2I8J,(-TU&4:LZ4Z2KXF/[NHY5)4JRIKG]I? 5JM2C*ARPEB
M)4K\E>BUDO$U6I@ISG"-5\E3!4)NO]7PLE6M[.G2Q&$4XQ7'[1OQ$\F$PZ!X
M5L)+677/#M_/K)M-)TR_\?>!+#3/^$N\.Z=J7BGQ]X?M;2SO=9U66WL+IKB]
MGMXO#&JS-9ZA'E[2\(J.+JX&=-2AA<RE1Q&'IN498GZC7Q&%PO+.,$Y/%X7$
M1Q]*O&E1J1G.>7QC"FZC]KK6I+#_ %R%3$1C]2J0P]2K*E.$:<YK-*\,5*FY
M-/#U,#0RK&TX>WBG2QTX_6N>,8KLI?B]\1['5O#MG=:;X7O8/'_C[QEX%\))
M8Z/K43Z/>^$_'[Z6R^(+UO$-Q'J4C?#W2?%FN/)!!IT?G^'G@7*S)N6$I*M5
MPN&J3?M*V"PN92J1@U26$5"IB,?&S<G3J<U7+,'@Y3G+FKXJ=2=*4(>S4XM>
MQP^(Q=*+C2H*CAW2E:I66-QN$P[P4VX.--X.GCY5Z>,:?M%AGAY4I.ISI_4]
M9""@ H * "@ H * "@ H * "@ H * "@ QV_R* .<U'P=X3U:Y:]U3PUH6H7
MK")7O+S2K&XNV2W;?#&US+ 96C1B2J%BHR>.: /C_P"+'[*^JOK5UXU^"VIV
MGA_6;NZEU#4O#E[<7%AILUZ[O/)>Z%?VL,KZ7>23LS&VD46Y:3,<ELJ[7-@V
M/)KWX%?M;?%Q[#PI\3_%=MX<\#VTXEO;IM1TK5M2DA$;V[I90:*ADOKMX)9(
M]VHW44:I-(6+G]U(?H'Z'Z(^"/!NB?#_ ,(Z!X*\.PR0:+X<TV#3+%9I/,N'
MCA7]Y<7,H"^9=3RM)-*X50TDKL%4' -OD&WR/'-2_9#_ &9M6\+'P7>_!;P,
MWAP:I>:U%96^F-83VNJW]O:VM]?6.J6$T-_I\\]O96:2&VN8MXMH]P.P8-O(
M-O([;X6? KX0_!*QNM.^%G@'0/!D%\8VU";38)9=2U'R01"-1U>_FN+_ %!(
M\ML6XN9%0LQ4 L<FP;&_?_#/P#J?CO1OB=J'A/1[OX@>'M*FT/0_%LUL&UK2
M](N5U%)]/M+O=F*V==7U,,@'/VV7^]1MY!MY$7Q$^%GP[^+.A'PU\2?!VA>,
MM$\T3QV6MV:7'V6Y52JW5C< K/I]V$+*)[:6*3:S+NPQ!/T#]#@_A;^R_P#
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MF]A7Q%3V*LJD)83V="=>6T9TO8XR5:A^\FJE%5:E&#J*"E] UB 4 % !0 4
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M>:?6<3&;7NU'B(O+L17IP=E2G5IX5T/:0A3G*C!.G+V<U*6KK3IXFM2NHXK
M5Z"JVC'GA6I5J6;4:52:7OQHXBM#$.A*4J=*M*I3G3C-5::U-7T/X7WLVI#4
M6U%?L'BSPOH&L6MKK7C2PL+CQ-<6OA)?#-AJFGZ;?PVFLP_99_# 'VB*YM$$
MT@F*E[O*]G]8G1ER^TECZF,KTU+X95</"O+%55"7N4ZE*.7U9TYVA*,Z$9X=
MJHZ3EE*,:&'5!KDH4L'1PR2^)8.=7$4*5'G5ZCA.IC:\*D7)N:J+VUX4Z;AT
ML?PV\%0VEO81Z+MM;2P\+Z7!%_:.K'98^#&NV\-0;VOB[?8VOKH[V8O-YO\
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M5E'&1FW>7.ZT)1G=\T)1<5RV:/1JR&% !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MIQA)J:J0^M4*E2-2,/9TI.K-J$*CCSY_:4\$!=-1-'\6-?:AH\FK_P!C_9=
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MR:A\0/"MLFO7<WVRZ\'Z:^JC3A\/+S4;7299_$WP?T&T>W3Q-]@62:VT>?\
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MI-*/*Y2O*4IN\I2E*<G:,813E)M\L(1A3IQORTZ4(4J:C3A"*UJ0PH * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M4J:;[0I4Z=*"^S3A"$;1BDK= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7'$RIX6E@I35.;A2P]/'4HRO:G"IBJBC@J^-K3C0]O7KS@I5*='VCZ*7+[3
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MI\[ISA@E"4N2%6EB*3I1Q]::IMTY4,3#!05"C%^Z\PK5I4Z-3VE.'TY61H%
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M(RI+,.:$E4R]XI>RL_:XA8/,8Y95GA*;LZU/ZQ*+C+W5[-IRY9M4SU^+XO\
MPFFG\/VL/Q0^'<MSXKL)=4\+6\7C;PT\_B73+<W GU'P_"FIE]8L(C:78>XM
M!-&OV67+#RVQG-.E+$0J+V<L'16(KQE[KH4'#VBKUD[.E1=/]XJD^6#A[W-R
MZBC[\*=2'O4ZM9X:G*.L9XA3A3="#6DJRJ5(0=)7FISA'EYI)/F=6_:)^"FF
MZ+JVL6/Q-\"^)I=+\-Z]XIBT'PIXS\)ZUXBUK3/#FDS:WJ0T'2X=;4ZE.MA
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MURG2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MXJ^"S')L54Q7(YOE>(P>0Y;@/9*25)TI8GGJN;HK]7ZXSL"@ H * "@ H *
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MDHR4DVFF/9SCM*G.=.2ZQJ4YNG4A)?9G3G&4)Q=G&<7&23318H * "@ H *
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M?VE*NXN44W/#9M]252"C!R4,35P2I1YJZ4(T)5Y1=.K"ESKVZPN+23CB:E/
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MGV+6)J% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_#R?6J_PVYN?W^;EARMI2=-O5T?:<GE[7V?/Z\WLJ>][<NEKROI4AA0 4 %
M!0 4 % !0 4 % !0 4 % &->:!I-]JVD:Y>6SSZCH/VPZ1(]W>?9[&6_MGL[
MJZCT];@6C7S6<L]NMT\#31Q7,\4<BI/*KN#=*=6</=G6I>PF]_W7M:=9P5[\
MJE5I4ISY;.;I4^?F4(V4TIPITY*\*-55HK;]XJ<Z2DVK.7+"I-1C)N,7)R24
MM39I#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M7AJN%]K'GYTI*%2G-PM[&=7"X9U:52,:D*GK=2 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MQ>$GBHRJ0]O*5.<\90H5%AG!SK<?&TK<ZPOB7QZ@\KXD:U;^'+CP7X,\J-M
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M-12IJKR4YW0IU*\?W<;UOK4L%&CST^>6*A+$0E2C)3=&RGAJD'6=58?F=/\
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M=*5.4)7DIPDW9-17!1E5:M7C[.M&-*4J?*UR>TI0G92;<:JO*252'NW3IO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M<:6'HUE7PD\$U5GC.6G7<\/S1C[5^S5\&;[X4>%OB'8ZGI%S8ZKK'C?Q59:
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M]?UYIZ 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\.ZZNHRK_P + DU36;=I]5W/-<^&]+MY)+V#RKZY:"5;GU\X:5?B>=+EP]+
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MC!4<%3DTXRE*I4DTX12@_,]=^./BK3=4^)%EINJ?#S5;OPJ_Q$M]/\)Q:=K
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M.9TI2IYUB, L/222Y,11HPIUFJ4G3IO&X10P^%PU/WOLJLS4* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MTXJ#QE#FE9QC"?/*45"JJ>_X3^(GA/QO<7]KX<O-1N)]-L=(U2X34/#GB30
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M74II.%J2UA5J4*R2DX5L/!0;=Y3C[;#X64)OF;YINC"A5BY73Y^:2:DDN/\
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M#;ZSD@C$)C:W2+P]>B1FE1E:6 *CAG,<T9*G''1?_,3]2Y+=/JSQW/S;6O\
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M<9I/>#G2J04E[KG3G%.\))6Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 5[JVCO+6XLYC.L-S#)!(UK=7-C<+'*A1C!>64T5Q:3!2=LL,L
M<B'#(RL 1%2G"K"5*:;A)6:3:NNJO%IV>S5[-73NFT5"3IRC*-KQ=U=*2T[Q
MDFGZ-,K:/I&FZ!I6G:'H]I'8:5I%E;:=IUE"7,=K96<*06T"-(S.P2)%&YV9
MCC+$DDG>K5G6J3JU'><W=M)17HHQ2C%+91BE&*22222(2Y;ZRDY2E.4I2E.<
MISDYSG.<VY3G.<I3G.3<I2;E)MMLT:S&% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % ;>5BK96-EIMM'9:=9VMA9PF0Q6EE;PVMM$997GE,<$"*B%YI))&
MPHW-(S')8DBTC3@M(4H0IPCTA3I0C3ITXK:,*=.,80BK1A",8Q2BD@LDYRM:
M52<ZDWUE4J3E4J5)/[4ZE24ISD[RE.4I2;DVRU0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MXAUNT\,Z!K?B*^2>2QT#2-1UF\BM5C>Z>UTNSFO;A+9)I8HVG:*!P@>6-2Q
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M^ _^@!\;_P#Q&7]I'_YU% 6]/O7^9V_@WX@Z#X[_ +2_L.P\<6']E?8_M/\
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M35MY;BYMDCGUGP%X(UC3[6^$EI*6LIKF.Y2-H97B6*YA>4V!+\/-'+?\-!^
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MM5I!>1?8_$GA#X>ZGI.I;8;B-9/LE[/Y,JRP2[)X)8XS8+?+YHQ/^&@_ ?\
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M7*@ZE&C%KXI5<1&I.A3C3=JDIU%2J<L8P;O'E:4I13Y27]J?X#0^)-,\*?\
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M>88;*U3:Q^+A1J4:3LN>%?V?LFIMJFN;VM)M.:E!5(.:BI)O@K+]KK]GV_\
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MAS8:&'48T\/6IQQ+]I3FZ![O7*=(4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M'\0__(M <DNP?\//?V1_^AM\4?\ A#^(?_D6@.278/\ AY[^R/\ ]#;XH_\
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MV^*/_"'\0_\ R+0')+L'_#SW]D?_ *&WQ1_X0_B'_P"1: Y)=@_X>>_LC_\
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M#;XH_P#"'\0__(M <DNP?\//?V1_^AM\4?\ A#^(?_D6@.278/\ AY[^R/\
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MX>>_LC_]#;XH_P#"'\0__(M <DNP?\//?V1_^AM\4?\ A#^(?_D6@.278/\
MAY[^R/\ ]#;XH_\ "'\0_P#R+0')+L'_  \]_9'_ .AM\4?^$/XA_P#D6@.2
M78/^'GO[(_\ T-OBC_PA_$/_ ,BT!R2[!_P\]_9'_P"AM\4?^$/XA_\ D6@.
M278/^'GO[(__ $-OBC_PA_$/_P BT!R2[!_P\]_9'_Z&WQ1_X0_B'_Y%H#DE
MV#_AY[^R/_T-OBC_ ,(?Q#_\BT!R2[!_P\]_9'_Z&WQ1_P"$/XA_^1: Y)=@
M_P"'GO[(_P#T-OBC_P (?Q#_ /(M <DNP?\ #SW]D?\ Z&WQ1_X0_B'_ .1:
M Y)=@_X>>_LC_P#0V^*/_"'\0_\ R+0')+L'_#SW]D?_ *&WQ1_X0_B'_P"1
M: Y)=@_X>>_LC_\ 0V^*/_"'\0__ "+0')+L'_#SW]D?_H;?%'_A#^(?_D6@
M.278/^'GO[(__0V^*/\ PA_$/_R+0')+L'_#SW]D?_H;?%'_ (0_B'_Y%H#D
MEV#_ (>>_LC_ /0V^*/_  A_$/\ \BT!R2[!_P //?V1_P#H;?%'_A#^(?\
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M_0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5
M!_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7
M_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)T
MW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8N
MC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-
M4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P
MM?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\
M0)TW_P  +7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']
MBZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P M?\
MXU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW
M_P  +7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_
M - G3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P M?\ XU0
M?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW_P
M+7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G
M3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H
M_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_X
MU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\
MP M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T
M"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?
MV+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?
M_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H__0)TW_P M?\ XU0 ?V+H_P#T"=-_
M\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5 !_8NC_\ 0)TW_P  +7_XU0 ?V+H_
M_0)TW_P M?\ XU0 ?V+H_P#T"=-_\ +7_P"-4 ']BZ/_ - G3?\ P M?_C5
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MX*U30?"?A^S\6?$#P[#X8^%O_"E[J_T+4/#"ZCXL^&SV]C;W7A[Q*^K>$K^
M&X^P1NU]H]OI%[$T\_V:X@64J+QM;Z_C\UQV*IPG#.:V&KXS"V:PU:IA*M>K
MAGI+V\52>)KPY85XJI3J.%95$HVC".6!I8&&&DZ=?*ZV)KX/$:.MAZF+4/;N
M%U[*2DZ5&252E-1G1ISC:46WU:_ CPZ?'?@OQM=>(_%=[;_#:WDA\ >#)_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'YS?\%%_P#D!_LS?]G2?#C_ -(]
M=H*CU]&?HS02?F]\9/\ E))^R#_V3WXJ?^H=\1*"E\,OD?I#02% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?BI_ZAWQ$H*7PR^1^D-!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?EC_P5U_Y-M\$_
M]EO\-_\ J!_$J@N&_P C]3J" H _.;_@HO\ \@/]F;_LZ3X<?^D>NT%1Z^C/
MT9H)/S>^,G_*23]D'_LGOQ4_]0[XB4%+X9?(_2&@D* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * /RQ_X*Z_\ )MO@G_LM_AO_ -0/XE4%PW^1^IU! 4 ?G-_P47_Y ?[,
MW_9TGPX_](]=H*CU]&?HS02?F]\9/^4DG[(/_9/?BI_ZAWQ$H*7PR^1^D-!(
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 ?EC_P %=?\ DVWP3_V6_P -_P#J!_$J@N&_
MR/U.H("@#\YO^"B__(#_ &9O^SI/AQ_Z1Z[05'KZ,_1F@D_-[XR?\I)/V0?^
MR>_%3_U#OB)04OAE\C](:"0H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _+'_ (*Z_P#)
MMO@G_LM_AO\ ]0/XE4%PW^1^IU! 4 ?G-_P47_Y ?[,W_9TGPX_](]=H*CU]
M&?HS02?F]\9/^4DG[(/_ &3WXJ?^H=\1*"E\,OD?I#02% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % '@7[1G[.?@C]ISP1I?@+Q[JGBK2-'TCQ58^+K:Y\(7VD6&I/J5A
MI&N:-#!/-K.AZK UB;77[QF1+=)#)%"1*JJZ2'Z#3Y=CWV@04 ?G-_P47_Y
M?[,W_9TGPX_](]=H*CU]&?HS02?F]\9/^4DG[(/_ &3WXJ?^H=\1*"E\,OD?
MI#02% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'YS?\%%_^0'^S-_V=)\./_2/
M7:"H]?1GZ,T$GYO?&3_E))^R#_V3WXJ?^H=\1*"E\,OD?I#02% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'YS?\%%_P#D!_LS?]G2?#C_ -(]=H*CU]&?HS02
M?F]\9/\ E))^R#_V3WXJ?^H=\1*"E\,OD?I#02% !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'YS?\ !1?_ ) ?[,W_ &=)\./_ $CUV@J/7T9^C-!)^;WQD_Y2
M2?L@_P#9/?BI_P"H=\1*"E\,OD?I#02% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5PLJF74\17:BY>VK.E'$TY4,'6PZJNG*G%QC5J>>>(/VOOB+:>&M"\76EAX
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M5Y4J>"PU7$SP\:*>%E"I6Q,)4:,_8UHPYYU9TJ=*2>N,A"CC\[?.XX/+<P6
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M_=M?E;3ZBD 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M4E5G.4JLY*4IR;<Y256A64I2>KDJV%PU5-NZJX>A4^*E3<7WOP;^$.I?V?\
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MO$^I0:)8Z^NDZ';-XK6[^V2Z?>2>7)?VUA;-)IUU$;@.L8FZI4:E.M]6<?\
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M1A-2B[QM9ORCQ)^T#X#\)>*K/P?KL>O6.J7GB36/#*3'3H'T^*ZT?P-!X_\
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M]ZC&SYJE&,:3J5N6W[N-*=:%&4*_LJ\JO-[.E.E"=59_ASXWR:O9:')+X/\
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MZ=1J>?QI\&_$5K'=:Y_:UCJ^JVG@^_N$T>#X@K=1ZOIZZ7+I&D>&]?\ #5E
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MI&IS1E"?-.5.4)*T(2BY2^GJQ*"@"GJ%T;+3[Z\5 YM+.YNEC)VAS;PO*$)
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MHZW+!J$UE-+F'PMI<< T_P 4R>++6"RT[PYX9TW3[&W6^D%OY<%F@^SQJ/\
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M=/!8=0Y5&G2HX.KB:[GS\[E4J5:E>,5'DIQI0IR?-4E42I98ESKPRV@HJ-+
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MZ<\9&>/I)SI2G6CA\13A"HZE*M65/V$ZE.DHS4FB?L\3V4D]_=:=X6@U*%M
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M6F^2$8U<7C,)3Q563BY0QF)<83KU).K5Q/A%X>2XG^,'A2PT3PMX7U27X5>
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M%"563I0E.['\ ?%BZIKNJ7TOA_Q!<7^KR:A,FJZW#%IWC#3)/&GAWQ-#X?\
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MQ$W5KY/_ &;4K22YG5J8"CCL+*E&I)J7LY4L;[6%::YE.BJ+H<L_;4]OX:^
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MT77M(8W<3SQ3Z<)OM5N74?K4*:4</6Q>-JT(<K<J-.MBN%8T:E1*</:58X;
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M%AL3"$4^:T/[+C7<H4_<FJE>-2,J]:4911E*I' SQKC+$T*.%]K*G!0A.O\
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M.5**;G",N>G.<7-59-$?PS\-?&2S\8:7J7CK4?$1M8-'TR*\#W]GJ.@W4?\
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MA[L*=2%6')>?[OV^(I2P<'%UN:K&*A?$<M6ABHK#UU4RVC/$26)K'Q*^+O\
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M?FLTY2IRJX+DE*-D^3)\LI34'RQ4HTZU.I1YDG[U.47*;BY/V*H-@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M-)@_AG#[-2$Z<X])4ZD73J0DMI0G"4H3B[QE&3C)--HL4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!^<W_  47_P"0'^S-_P!G2?#C_P!(
M]=H*CU]&?HS02?F]\9/^4DG[(/\ V3WXJ?\ J'?$2@I?#+Y'Z0T$A0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M"-..)I9U5Q#_ ':3E*%/+X.A!IN=6,:4FU5;3J)-4;/V$:>'S'$590CS2G'
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M]Y<JYJLJ;]PKGXX>*K=I[R^^'VB0:#;2SW$M]!X\O;G5!HD'Q!D\"?;%T@^
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MX_\ 2/7:"H]?1GZ,T$GYO?&3_E))^R#_ -D]^*G_ *AWQ$H*7PR^1^D-!(4
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MF=+!KER]R<VY2JX;)Z7#U>4ZDW*+J7KR]DH/V-3VF!KRI2JU&I]OIG@3X0>
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M5G4Y7&JXU(8*C.$:=:DZ<*F+I.=1UJ5;#] /@Y"MM]G77$4B P^:NCJK#?\
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MX_\ 2/7:"H]?1GZ,T$GYO?&3_E))^R#_ -D]^*G_ *AWQ$H*7PR^1^D-!(4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-_P47_Y ?[,W_9TGPX_](]=H*CU]
M&?HS02?F]\9/^4DG[(/_ &3WXJ?^H=\1*"E\,OD?I#02% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M)I%N@97DN[2"XMK26ZMX;J\\[[';2311W%U]F027'V:%F#S^5&RL^P-M!!;
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M<)#+ZJJ<]E1PV(C.5>"=-2<,1.5'&K$14L7_ (5I\5K+3C?:1K7CA?$\6C>
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MZ0T$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^<W_!1?_D!_LS?]G2?#C_TC
MUV@J/7T9^C-!)^;WQD_Y22?L@_\ 9/?BI_ZAWQ$H*7PR^1^D-!(4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?G-_P47_Y ?[,W_9TGPX_](]=H*CU]&?HS02?
MF]\9/^4DG[(/_9/?BI_ZAWQ$H*7PR^1^D-!(4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 ?G-_P47_ .0'^S-_V=)\./\ TCUV@J/7T9^C-!)^;WQD_P"4DG[(
M/_9/?BI_ZAWQ$H*7PR^1^D-!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-
M_P %%_\ D!_LS?\ 9TGPX_\ 2/7:"H]?1GZ,T$GYO?&3_E))^R#_ -D]^*G_
M *AWQ$H*7PR^1^D-!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-_P47_Y
M?[,W_9TGPX_](]=H*CU]&?HS02?F]\9/^4DG[(/_ &3WXJ?^H=\1*"E\,OD?
MI#02% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'YS?\%%_^0'^S-_V=)\./_2/
M7:"H]?1GZ,T$GYO?&3_E))^R#_V3WXJ?^H=\1*"E\,OD?I#02% !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'YS?\%%_P#D!_LS?]G2?#C_ -(]=H*CU]&?HS02
M?F]\9/\ E))^R#_V3WXJ?^H=\1*"E\,OD?I#02% !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'YS?\ !1?_ ) ?[,W_ &=)\./_ $CUV@J/7T9^C-!)^;WQD_Y2
M2?L@_P#9/?BI_P"H=\1*"E\,OD?I#02% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'YS?\%%_^0'^S-_V=)\./_2/7:"H]?1GZ,T$GYO?&3_E))^R#_P!D]^*G
M_J'?$2@I?#+Y'Z0T$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^<W_!1?_D!
M_LS?]G2?#C_TCUV@J/7T9^C-!)^;WQD_Y22?L@_]D]^*G_J'?$2@I?#+Y'Z0
MT$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^<W_!1?\ Y ?[,W_9TGPX_P#2
M/7:"H]?1GZ,T$GYO?&3_ )22?L@_]D]^*G_J'?$2@I?#+Y'Z0T$A0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!^<W_  47_P"0'^S-_P!G2?#C_P!(]=H*CU]&
M?HS02?F]\9/^4DG[(/\ V3WXJ?\ J'?$2@I?#+Y'Z0T$A0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!^<W_!1?_D!_LS?]G2?#C_TCUV@J/7T9^C-!)^;WQD_Y
M22?L@_\ 9/?BI_ZAWQ$H*7PR^1^D-!(4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?G-_P47_Y ?[,W_9TGPX_](]=H*CU]&?HS02?F]\9/^4DG[(/_9/?BI_Z
MAWQ$H*7PR^1^D-!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-_P47_ .0'
M^S-_V=)\./\ TCUV@J/7T9^C-!)^;WQD_P"4DG[(/_9/?BI_ZAWQ$H*7PR^1
M^D-!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-_P %%_\ D!_LS?\ 9TGP
MX_\ 2/7:"H]?1GZ,T$GYO?&3_E))^R#_ -D]^*G_ *AWQ$H*7PR^1^D-!(4
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MXX\1ZWI:>(H/"UMI6O?\)HEIIFD6EVVIZ+/X3N=!MECN_$">([_3]>262_U
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MDHSJXCZQ%U)PQ+I^VY8U93G2Q*F=H_QOUR#7X_"S_#VXO-;L-2-IXGBT"_\
M$?B&STVS?5M(L+>^TF\TWP(_]H9LM3EO95U6+0(HAI\T?VA]RN>>A*GB'"4'
M*.':BG.<5%PJ3QF:8%<R<O9*C"OE<YU:DJT9QP]:%6%&I.%2E%UI2H0K*44Z
M])591A%W514,ORW,*D(V3JNM..9T*&'A&C*%2O&<:E6C%TY5*=[K?B1_ 2_$
M/PUH>G>&?%GQ \6?#_2[RZ?Q9=:U/#X:OO&.F^'[%[>[UGPC?6ME<?8=5NRN
MFQ:6UI:R:I=7"//.7\^\)%RGDN&DW3H8Q2Q^)IK5QK5<L>,J4U-^]67)AJ%"
M53FHR<**HT71AR58;3C%5\YE*"E5RV..P5"3O%3C@*V)I0J2C%I4G[5U:ZBO
M;<\G!5G-.48UH_BWXKOIM'M-)TVU33;;XB:%X7\0ZYJWB*P.NNNH:[JRR6>G
M:!;>#H;2^L7T^SLX!<K=6-Q&+B<A9GL))[GEI5TX9=B9P_<5L%6JNFG>5:M2
MX2_MI*K+3V5JM:$Y3I*TZM'3"T<+B%3ASXCFH4<=3C)O$4,127,^7EA1GQ5+
M)/<LO><H8>O%0J03ITJE-K$5L3%S.@L?C5>ZU=>$M*T+PMIUQK7B_P +^"?$
MME!J7BM].TRU7Q7H_C/7+FSN]0MO#E].6LK+P=,(6AL96NWO1F*VB@DE'HU,
M+*&)QN'A)26 JXR%2;35Z>$65QYH)*2=2=7-L.O92E&,*,:E;VLI*%&>];DP
MZI^UE).IB*N&C&,4Y*=*I5CS33E'EA*&'Q#YM;5H0P^KJ.<,Z#XWW%EJ.G:1
M/H_]IO=^(O%FDZC/_:&K3W6C2Z;XE\;:7IL3W&F?#N#0DL9O^$82.UCO]5L=
M0:V,CF*^FM'GOO/KUXT<-4KPBZD*67+$P?P>UK4\H>;5*%1R?(JKP\5*K]5]
MNZ4J]"<\-0P]:FUJJ+]K3I3E&%:=7!0G3C[ZIT\9B<OP4*L/^7CI^WQ=7EE7
MC1A6>&K1HU)3C4I8>]X0^->IZ]XD\+^#=8\'66B^)_$FBZ3XO-A8>*9-;M[#
MP/JGAR]U%O$)NYO#6G-=R6OB:UM] FM4A51+?P7 N"C+&_HSPJIXK-,+[1MY
M14Q-&M+EM%U*$\!"BH>\VHXM8RK*A*HJ<I++\:E"3HNWGT\3SX/+\;[*<:.:
M4\/+#72UJ57BJE:C5:?+&6%PF&A7K.FZR53&8.CI&M[>.O\ $3Q]<^%_$5I#
M%X0T77;;P[X7U#QSJ&K:AXD_LG5M(L;>_M]!O4\.Z6/#M^=4U&2PU"\.U[S3
MHF*QV\DRFZ1EY<'^^QE6C_!7M<IP'M(^].4LYQ=>E2A*/N*-"%? 4:E6]1RE
M:,J=*I.A9ZXN<</AZ,[>TE*GF>,4)<L8Q64X:A4G)3;;56<,<Z4)<D84X.JZ
ME6,)\LN!\+_&6>QO=1L9_"S7-I;ZIKMWXR\9K:ZO8V=C<(_B62SU#5GT;P;<
MZ8FG6FB>']"L[B_O=5M;A5FB\NVN/L_[S'#U95,OP<XP:<<#A/9QM/EK8ZOE
M67YK7BHQA+D6-Q68UE2AA88BM/&U/90PB5:G(UY/]LKT]9U*F-KKEBHN:PD<
MZQ>2X507,G4J8:C@N:K[?V%)86C[5XJI456,:J_'2)KR3Q=XA^'LVDP>$=+\
M7Z=)KDNH>-+<F5="TOQA?^'M)TC6/A]I4RZO>:?IVB.L7B:V\.NT@,6G-=D3
M!MFI4XR=-7JXVG)4*5XN6(GALPQV!E33@ZE-*G5P_M9*E.KB50G6JRPWLL+.
M<JPZ>+E1PBG%0^OX2$Y>][.A4KX;!K#UYRY%/V<X9KB:%*2B\/.K3HPG4A5Q
M>'4.W\.^/;K2_ FMZPGP_N- U*/QK:Z;:Z)J%_XFL-)UK7/B!K>BSIJUOKGB
MKPCIVH1:*^O>+W2ZN(M$E2WDL;V*TBN%@C5]IT6GEV'I3C)U74HJ,FH.C3PT
M\3S.27/-REAL.ZU"$U"=652E2DX<WM%G3J?698G$RNE]3CB^9+F<H8? J,*<
ME&U*%2$<*J,N2I4IJDJ>)G4O4FH\G=?M"W.@RWVI^*_#D6G:7H]SJ^C^(O[)
M\4V^N:3H\^E:WXYT2PU"RD;PA87VI7&J:OX:TO3O)DD@$,NN6\:VYDMY7N>2
M$W5C&.'ISKXG%T*3P=%I1=;'26+E'!0DFXPA6AA,1.&)GSQFZ=",*</;,Z:E
M#V5:E2J5:="G3K<M6I)N,5AJT,@E'$5.963PW]M4Y5(7I4Z=&GBZU3$55&A&
M'8?#CXDW?C7Q1J"W/PYNO#TC:?JNFW7B-4UN[B-_X)UM='O_  ]J6KW'A#3]
M-DCCUK4]<?3?L>JZB\T-I?3RV]E([PCKE1BJ&*E2JJ5-3A4HQE>FL13K/$0I
MU^5OGC-T,/AIU>6%10C7IT_:S]DN;D<JB6"]K#EFZ=&4X<W-+#SQ>"PN-Y$H
MIIQBI.C6G4=%QK4J:C3G&LIQYGPC\2M8\,Z!X@CU_2-,9M,N/B9JVE6&F:M9
MP:=9:1X3^(9\'6&@V8@\)::ZJ3('-S<)>3R29=W8W0BM8H1C4IY91NXSE'A>
MA.32LGGU2O1AR1BXQC3P5/#Q5*C&,%*GRT>9.DZ]8Q\UA<1C:D8\U/ZMFV-2
MO9REEF!P6.K2FVIR]KCJN-G.M-SFJ4^:48S4N5=#X%\;>+-6M/'\]U=6^J76
MA:;)=:-;7<=MIUJ+J/6O'-K''<7.GZ>TBPM!HVFQ,YBG*B LJ%W<OY]>O4H\
M-O,HI2Q4*%"HY2VUX:X?S&H^16B_]JQN+K**Y4W45)2ITHTU3VPD%7S^6 G)
MQPSK5::C&UTEQ!GN C:3UTPV#PU*[<OX?M&I5)5'/B9_BU\0GTNRE@M-(M[N
MYT&YO=:N&U5;B+3+M?@^OC6UE\-VO_"(Q&XB&HL)9(M2FERZ&-7$$@6'OS""
MPV+S_#TI.-++:>9.E)VG457"8O)L/&+TC"5*/U^<4W%3GS2K2:Y(8=YY7/ZS
M_JK*M&,I9Q/*?;07-"G*CC)9XZCNI2J4ZTHY=3?NR=.*4:$8\[J8N?HWP\^*
MU_XTURZTA_"FJ6ND6D.OP0^*WM]<%E=:EX3U>S\/ZM!?23^%[32+*2ZU"6^F
ML8[#6=3>6#3;AYH[5T,2Z584XT\7B)-8:G2E&=.$Y6OAZL\4X2O/EG>G1HT:
ME6T)0C]8BO:R<&Y84'5C0P"G)5ZM6AA9591LFJF(P&'QL6H04HJ%JLZ=24W2
M<*L:<84YPK1E'F;;X^WMW/?&U\(VDFCZ;J.C_;?$S:GXQMM!M?#6NC7(M+\2
MRO>?#.&^DL)KK1"/MMO87&BK;W:7IUO[,ID,8:E4K/!QJP>'GB*\\)*+7O1Q
M<*.55XX:,9^SE&M5AF4XT:>+6#G.MAEAW&.(Q-&D:XJ:PU3'4HKGE@J2K/I^
MZ]KF-*=2;7/'DHO P5;ZO+%3@Z\GR.CAJM8['QA\4+WP?XECT:\\-P#2KN+1
MAI.LW>K:A:'6KW4-3BL-1L-.C@\,W6G+<Z=;SQ7;6]WJ]K=SPQW,D%JT%I+.
M,L/^^J3HM>SJ1KT*48[RE1KU<'0CBK/D3I1K8F=&2INI.G6IT8UHTHXRA-W6
MM1I.JGS0CA<77;VC[3"87&XOZMIS252=/"1DISC"E[.K*5*=:IAZU%53\3M8
MU;4-7T;PWH.EM-HZ^*GU34-1\226:VEEX>\077AU+O2K6#PY??VOJ+36-Y/)
M93&SA@,4$,MT3<ADX<57J1RK,L;3?L/JN"G7C))5)*K4>90PW+"24)0;R]U)
M3G**M42ITZRA4Y>RE1A#,\%@:B]J\1B*4%%^Y&5/ZIE.+K\\DW.#3S:A1IJ$
M9\\85:LITFJ=.IH_";QKXB\5:-!;^+=(L=+\06?AOP;K%W+INL'6;34(?$VC
MF[CNGD.A:2+*_P#M5I>B:TBMI8(_W9AGD5R(_>Q]"E2Q.8*BO9PPF8XO RIZ
MRC">'IX6O:G4D^>K2]EC*48U*D:=1RA/FII<LI>'@,1.KA\![1NI/$9?A,:J
MC482G'$5,507/3A>%.HY82524(2G"*J1C&;Y68FO>//$%IXQ\1>#=-TZSUR>
M[@B.F6NH^(Y/!EGIUA;>&'U'6)%\0:7HNH7ZZA+<3V@A6.$O&K33K- MM\_B
M^V@\+F,JRE[/!U,=5JSA/DJ1PF&PV2>Y2494[U%6S&I-3G4HQ5^6=>+]C%^L
MU[+%8'D?+[>E@(4X."J1>+Q&+SYRG4C+F?LUA<K47"$*W-4A3BJ-JM:K'S/P
M;\4H=$MM2O\ PCX.O]2T/5HKCQ[X@U+Q;\0+^\\16VGKIGP]@AM[-[S0M4N-
M9NDTW7E$-K>ZNL<0TDPI>B&>);;UE0G"=/ U)1BL/C:>!C.,?>GB,QXBSW+*
M4ZD>6FN2%3+8RG4:5:&&G2I>RKU,/*I6\RIB53^LUVI3J4\+7K\GM54I4Z&6
M9+E68U*5"HI35JE3,9N"AS4:N(EB<7STXXA4X^KZ=\1O$5KX U;Q1KNBZ1-J
M\/C[6_!ND:;I^M3PZ==.WQ*N/ /ATZEJMWH\;Z;"MR]I]KGCL[QA%#)<10R2
MR"T7F4'..3TX?Q\PPV%JU+MQA"57"?6ZSA))RE:E&;I0Y8RE5<*">OMGZ4J:
M5?,8W<:&"I5*T7:\Y4Z.#6)DG'2,92LU=S]G!/FG-0@Y'A5_\>?#WPEUKQ!)
MK'@748]:.O\ @_0/$.K3?$K6?&%O%X<;Q3J&B>(-?L-3\50&XA\->$QJVE7U
MW:6]O:*)O%21R1V[*\S1@JE"K3P-"-5T*.(KUHU95(WE1<*=3 X2K5J<TI5E
MCLWP-?+,-%U'*,(K'249UZN'CGBHUX/'5I*%2I@\/7JT:<9RBJDZ=#"9MC*-
M&E[-4J-193BZ.+YH1OB9X2I@5^ZPF$K3]:A^-NL1W,MUJ?@>VL/#$%S;6[ZC
M#XHFN]= OO".J>-;"7_A'6\,P0[6TBSL4E0ZH'CGU!XU65;8O+E6K/"X?%5<
M52E3K86&)3HQM-_6,'@,-C<31E*\5%1G4Q.&IU(J?//#0FX0A7O2UA0E6KTJ
M.'G"I"K]6G&JY6A*AC,ZKY-A:M-Q4^95'3HXN49<BC1K.*E.I3M/,T_XX^.=
M5DM[73OA#.]_/X>\0>)8[>]U[Q%HL=Y8Z-9>#I;6'1VUKX<VEQK-W->^+6MI
M_L]J88?[(F:WFO7FAA;KJ4G1^M>T=E@*U"A7Y8SG*,JN(JTW6ITHQ]O/#4Z%
M*==R=*&(G.%3#T\+.45.6%*=.O0A7I-M8B-&>'B^6+G"K1QM50J5'/ZM2Q*E
MA*=-TU7JT$L9AZL\5"DJDH=QJ/Q/O+/PKX6\5VFAZ?>Z7K%\]MK^HG5/$5OI
M/A&WC:ZMY+G4V/@B35X##J,"VETNH:+I<>GR+<G49K-;5BPJ7^W83!MVABZ=
M&5.JG"<:E2O]5=&E0<)RI57B:=>I4P=25:E3Q7LZ5*$E7Q5&D\W4MA,5B;7G
MA)U8SIZKDA1]NJM2KS1C4BJ,J,85X4Z56I3=1S4)T:-6K'A] ^,/C&%=.T?6
MO#&DW^L^(=;URQ\)7W_"5?8K34;2Q\<:MH*OXC$/A)5\.O#I=O:R0QV<>M/<
MMMB=DF<LV&'<J]#+8126+J9?E&(KIMJFWC<EQ>8SJQDHN3J2>78EU*,:,:=*
M=:"A4="$ZE-U9QH5,=*3D\/2QF:TJ3M%32PF<8++*-)QY[>S57,L/!5G4E5=
M"A4K2IRKRC0GT6C?&@:O#/%+X?BL;VU\0>'_  K>PQ:\EW"FJZMXF\1^%-2D
ML+I=,B:]L;2^\-WLUO,8H'NX&5GBLW5T7/$>_@HU:%248XN&,]C-JTX1H\,4
M.(J=1Q4I14Y1Q$<-*,)SA"4?;PJUH.,&3JO#UL33E",I8.."G)*2<9?6\\J9
M.H[/EY/9K$24TIJ<GA:E.G4A*9Y7\,/%FHRM\%;6P\/Z);Z?=ZQ>:/K_ (JO
M-8AO_%VL:YXB^%%W\3O%!&FWV@R36=CJ?B.6ROKB[M];6>672X!);?9I5V>O
M*E%8S'0450PU+ XY82E"[M1RS.L+E,%5?N2BXSCB)03]O":G&K5J+$S45IBJ
MG+/'P3E5G2S##1JNI+E4*M6G.5%T4W-5?8Y?.EA(+]W.C"=>E1IJAAI3GZ(W
MQSNC?^)88O!=ZNE:1?ZYI&D:W<P^.&L]7UGP[XLT_P (7FE3?V/\.=11=0O;
M^YO9-,M=%E\07%U'I<QGALRK^5YE-RGAJ-914:V(=!T:+<E*I2KK%574C[G/
M^XPV&CB<0_9^PHTJDIU,1&G1G4-<136&JSA.:]G0IQE4FG'W)U<)0Q.'C;FM
MRU*E981N4H5GB94:6'P^)GB*4'DWOQE\7>(/ ?B3Q#X0\,Z983Z)X2M=4NY]
M2\1W$%]9Z_?V%S=VVGZ9I5[X,D&H:<)XK6!K[41IC@7$Y-CYMF\#732J5<!*
MFU*ABLRR?#4U)QO6AC:F45JM.M*DZL:$987,E3=2C4Q%124ITX\CHU9\V(FJ
M-/,J;<HU\'@LWKRE&*?L_J53-<)2JTXS<'4J*OE=:M["M"C3Y?8TYU)>TK*C
MWUQ\1?$=MX4UW63X+ANM<\,^)3H&M:-I>MZKJVGV]M$;"YN]:M;_ $_PA+JV
MI6L&DZA%<&VM?#LMTTJ/"D)1?M%1.I3A2P&(C+EPV+>*4ZM6U..'^JU\=A'*
MJXNHHTIXK!*FJLI1ITJ5>&(Q$J-.G5Y-*2E.KC</R-U\)]64:<&I.L\1A\%B
MN6',Z:YJ='%N4H_'4E0G3H1JU:E*$^&N/CAJUM_PDDVC:!I7B.ST%;;6=1N[
M[QM%IEFNC7X\.Q6@\*2V7@:0ZU$PU"_G1;XV[L8[=3<G[?''9;4J;=;"8>HI
M4E/'TL!.<XKV\:F+S_-,II2G14E3_<_48N48SIOV;5-/$5J5;$5>>I7C"AB\
M1%J;I83$8RG"+_=.G@<ARO-:T8U'%5(^UECZ<(.=.I>7MJK]A35'"Q[/P)XV
MN?$WB6[.I^"]'T"[O]+ULZ3K5AK0UK4]3T/PEXQU'PZMMK)D\.Z<^F@W%RM_
M;VD5SJ,2?VG=*721"9XPW[S!JLG[.I+#9/C*M-:PMF^#KXG#I3]UU*E"&'J4
MJKE2@E>'LY3C*2CK5J\N)AAM94Z>(SC#TI2LG&678G!X7$R4$Y*$<3.=*4>6
M;<HT(^T2<8)>QTBPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S
MF_X*+_\ (#_9F_[.D^''_I'KM!4>OHS]&:"3\WOC)_RDD_9!_P"R>_%3_P!0
M[XB4%+X9?(_2&@D* /$O&^O> [+QOI\?B'X:2^)M6\.:?X=U[_A.#X>\(:C;
M^#;;6/$-]HFCW U'6-5AU>VGBU"#4;@C2K.Y:&)9I1\S%3G2E3A5K5-,+[U/
M"RKR5E4EB:56$*'-34JDE4C+ZO/FBJ<?K4(U91I5)SC6)@XX.E.JO;T4L;B(
MT=_9QRZ.#Q.)K<L^6G%P4L/6ARR=6I+#?NXRJ4J:?G?A3XH?! WD3^ _A?#+
MJ>K:UI/D#PCX;^'8U"^AO_#OCN\TSQ1<'2]?62UM_P"P/#OBZ 6]^UOJZ)?_
M &?^SQ_:.R31QG' 3O1E'!T\/BI5:*2E&G2IT<NJ5Z3I0<H5'55?!4/9T/:J
M=6C&$[1H1DMYT*D,9BE4J1CBJ53DE4G-1E5K1S*&&J1C.?+-NCBJT,3.K4Y*
M+IU'B:=6;53EZ&+XD_#2]T6VU>/X9W5WIMIX=;4M6%MI/P\U,>$?"NCO+H3R
M:P-/\3W$:16,3:W:MI&G/?7]NFE:G UBC!(KCH4:DL=&"K)UJ]?"S^LJ3E">
M)Q^)@L)55>-_;/$5LMP>(CBZ7M*,(T<#7K5Z?LJ;I\#C3E02]@Y7CB*-/#.D
MU5E3PF&;Q%)49I.E[.GFD\-]5K*E7G/'5Z5*A.%3$,@U3QU\*=;L]8O_ !1\
M+(#;6\VH7,%QXRTWX66EMXC2#Q2O@34M3L=0\0>*TLX=VH168VZO<:;<W5O<
M6HMXIY"(%XH3A2P^'Q4(^S?LLOQ,::Y55I1S"ACLSP+23Y95*C^O34*$ZE2E
MB*U:=2,%6J5'O&2GB*M.$^;7,:<JRC4Y)K+*F!P^,N^7VBITW3P45.I"-.4,
M+1:ER8>GRX-M\4/!<FNIKG_"$>'F\*^+K/26N]5@\,Z6WB*;2?%.@_#F"VN/
M$=U]O^SW&EP0^*DCU!@URBV&FQB,2I;?O=W24<1BLNQ<J<81K8VC>7-&A*HZ
MF J)5(U(J5\;B*ZA:5.,ZN+EA?:Q@U.2=5O"T:.*HWI5,)##UJBYX<]'ZG#B
M>%;V,Z<W3YL%1REJA*G5E%4YXN-"=3V]**]7\,Z=\))?!EOXRTCP/X4T+PQ!
M;>)=>LYF\+^'M/BBTZ]CFMM9UZ!+&%XH;36M)L(;AY@RO=6;V_VE008H\,=5
MCA<#*MBHR=&. A.=&<7SPH5J:QLL'4I27NSC5JR5;#V<%BO:6YY/GE>%HU98
MNI@L/!TL1','0<5:'-C,%6E@:=9--7=-TN3#U7:<**AR\B]U?.^D>,K.]^'^
MH:+J'PT\">&;R[F\6:3?^'-*T.YT*W3X?^-?A+KOQ/T..,:5?VUU9WE[#HFD
M:3K,EO<I%<WGAW46B2$I;_9.S%1JX>C5=6HJF+RNC7>+@I.I0CFV3YE@[TUS
M**K824<PCCZ5*I&5Z>-4*DJBG6]K>6.A7S*'U.JX8/%U,NQ. K4W[/$3P&,K
M_P!F4<543A&>'Q2^KXJ-#W8U*%*GA]FG%>R>*?$V@GQ)X=T?Q;\.K+Q3H-KX
M<\)Z[:ZLNA>'M4@\(ZOX@\1#PY!/*FNZM'/;VAE-B8O[*LKRXC6UN'D.U(P9
M=EFN/CS.C6PE?#T:.)EI)RQ$\7-4W4@G4YYUL%0LXQC2C5E3G5E%6G3\VA*^
M29745-2HXK"8ZOB,-%?NU1P&#P,YRA";4'"GA\;BHSA.<ZLZ;5.C&5ZBG4UG
MXM>%K72HM/3PA-IOAWQ!>3WK-X@T32)/#WBSPI>>*(M,\:ZQ8:?I6K7$IEDD
MUJ&\>/6;.SENAK<<QM[@M<K%RJ4*M+#3K0;PT<.ZDZ+C>M"@LDS/,LN5.'O4
MO>>6QINBI.=",?95(8><J4EWR5>E6J1PTF\93QF'P<*L7*,%BEFF7Y97ISF^
M2<9TEB*L*,]*=26&E.C.M0IWGQ-S\4/AGX;FNK'Q/\(+/PUI6BVUM=^$M"OM
M!^&EAJ<=MXBT/4_$/BS5;5Y/%IT:"RN(K6U@D@MKN&^N;II(7MIV*E=XU.2I
M+VU;V>,PF+Q&'E).3^K8;+EDM6G*3BI3J2HXO,(UZ<<'[=JG&E4I4U5H5FN:
M$8XA+#X>,:N Q^&P-6$>7EAB\1C9YQAZ<'&:C3IP>#R^<5+&K#J"]K3J5$JU
M&G+N?^$U^&?B'Q3H<-U\+VO+N]\5ZM8^&_%VLZ)\/8M/N=<TJXT,WVIZ/J6J
M^(DOFOF>VL;B*&"W_M2Y3PU-/!:2)IH97AJ<U/D@OJE:E#%KD?NU(TZ.+QU.
MLHPI\TI0J8BGBZLW34H4_K,:V+=#ZW&50G5A*A5J7=:A4^H2GI[E1X[+\/4H
M.HY\L$XX2OAL(_:N+FY1PV']M&G45/4UOXF^'M$U.[\%0?"[Q7K5EX?UVTT:
MS.D:=X"3P^^N:5X7L_B3#'I5OK'B^PDMWT[21#>)<S6=K$EU9A+>1IUB#XQJ
MJG1>+E>A2PF'QF(4WO2PF!J0RZO5BJ;G-4^>LL-"G!>UE3<E[)4;LZW0G[2A
M34XSJYE.FFDW>57&U<4FJK:2<ZDL/6K5VW*\:D9S;<Y)8NJ>,?@W:0:;XY;X
M<6VIWNGZI)::+JEMX0\*G6K"X@T=?%QU"TU'4+JW.C626WB&[N)+R6YM4MWN
M;^>Y:"'SISK.#P594O=H3C1Q=.4E*-.%+#X#,J7#=>$ZC<8QHQDH1C&_(\!3
M5-)35/#2XJ-:&.HQY8RK4ZE6C4C3E%SE4Q&+RR?$=.4*:YG.O4C3^RG5GF,H
M**G?VR9HDWPWU+3?B7>R?!'18-"T.#0_$-Q%8>&_A]KL_C5E\-IXGL9;>U\/
M:C?6VK:K;_VI<+:R23-$3>;X;G$\A6)+ZKAXJ<?8?4<;4PU.B_W2P\O8X7#R
MJWJ^SIX9>RJ1I5ZDY4XTL-32JRC3A)0Z8/VV-HQI55+Z_A88B6(YG)34L?C$
MKNGSU:L75PGUBFHPG5E7YG[-5/9.I23Q/\,;S7=&U"P^%.F>(]9N-(TS5_"=
MKH?AGX9:CKL UJ?XDWFH:C8^,D\9/H[VT]OHFM3LEM>0%7U:7,]W/JLT%B\0
MO84L;.I!U?94<3]8:5O]AI8/*U4A.%11G6A)8_"85*'/&K&<(*C]6H/$3FG)
M.C@O>]A"6)5"C3F]L5AYP=.,8PYHT*F&CAZM:\W%TEA)).G7ITJ56OH>M_#7
MXC^(8_M/@OQDNE^*O#.A_#S37U>T\+Z=X7L=.U/P5I_Q5?PA8P^']9_MBW\_
M0I;0WIFBFL3-I7V.&<1@+/V/#UZ&*Q[E5YL7'%QQTJTIRE*O4R+,7AL/5@]I
M0HX[%5JM-5XQJUE4K.LITXTZ:RJ4H+#X&/L/94Z.$Q.'5&"C!X6CF<IX+$1J
MI->SJ267T:"6'FW0C+#U*:@YU:L;7QL-GH_C'PUKT7@K1/&6N1^$M2AT1=9T
M71=9_L&_M?'OPYL;#5=/CU?5-+\@QS>)))I5@U"WEDDL;'9)"(GDKCPBE#%8
MJ=)NG6Q&(R/#RK+XJ=*I6S6%2S3C-.<9.,;<R51PE.$H1DGT5:<)X!RJ?PLN
MI9I5A1VIU&\N==\\>647R?V?"*:2:H5,5"*G.I32ZSQ5>?"KPSXJ\':7XB\$
M>%I_$7B@+H^G:B-,\ )?6XU:]ETNXMQINH:RFO7&FSW_ (FO(K@Z79:E!&-<
MN3=2*ES*[NC"%?$5\OP\$H>QY7'24)8?#X3$U84IJ$;QA3PN6NG25:E2I25.
ME2HW]G*-+*5:IAL+0Q=64HN->,M/<<<56Q>%<JD6YN'M9XO$0Q$G3JU*O/3E
M5DW4]BZN5*/A1X6U34_[%^"5C(V@ZY:^'XM9\.>#?A]9177BWQ''90?V'I37
M.IV-[]NG@\2(ES?2V]OIZI=7:SWH"3A9IIUZ=&FH7ACUBL-2A)QM7P^&GB98
MU-<SBL/2EA<?4J4JW)*J\-6=*E5G6PRQ!)T\-[3WE'ZI+#UJO*FO8UJL,/'"
M-V2O7JK^S:5*5/G</;8/GE3ITJLL/SEYX\^']OX=UWP-X=^%7BK2+&0:!8ZW
MHGA?PE\+;>&TUKQ-XUO/AS9Z#<:5KVK/H>HZBVH^'+A9YVMK[3ETZWAG%X4:
M"KY*F-6#2J.=.5>U"3E%QYZ%">;XE)5$Y4OJRC5EB'R4ZBQ+G[!SK/G-736"
M5>I)4Z4W'$*I%/W^58?"*C4E[)^]]9HX["?5(.4I3O['$4H>SJT4SPIJ?PI\
M,>&1X8M?AYK>J:9IKS:CXSDU7PSX!;_A%I6^)&O0K+XDL].NK/3YHK7QII7B
M"]M[?PO9:A;VBZ0UW!%$KVSW-IN;R^46H4XO+:&%K)SM]:G1C+!TTWS5HXF$
M\32IRFXPI8:OC(J-2E051T<J\9X>./KU[N<HYC4K4_W=WA5A,++%SY8<M-T*
M^6/"R<9OZQCJ%.U>-?&1JQ?06OQ/^'&E:EH7B.#X>OH7B/XD37%M87K1_"_3
M/%NO1R:CI^DVEU=6\?C%=9U/3[Z^31T6:.&Z6%?LCW_V1(P4Y(U90PLJ>&@X
M\^"CF+PZ:BE?!X_,XPKQAS1IUHTJ6*FY37LW5KSA2JU*KQ$8574:=6I4Q#7^
MR8VIEKK23?OTL9A<OFZ4I)2E2]K."48_O?98?F=%+ZNJN/IOC#P9XPTOPK-K
M_P (;77=9U?3O#WB/0?!D?A7P3J-_IVJ^+K+6/&>LW]MK>L^(TTH+++H;ZC)
M<2/IDIF6!G-S>7 CM^VK2^J8K$^Q<IULHK8BDJT$J<\/A\NPV4SCRJ[G>C6S
M/#4*7U><G[2K&%.A&AAJF,JQ5G>I6PF(ERT*ZIP=.K><:]2KB,UP24E'GB[X
M3+L1*<*D.6%"E5_?5'7AAH=CX-^)W@?6M9CTOP_X*UG2;+7;VST5?$4FA^'M
M,T?4]7N_!I^(ZZ/<V\&K'5OM$6BZI?R2O=:6ENMVUY#YQDDS+"PWM*$Z'[N6
M%5&M5IPNI4:^&PU3"96ZE**3A[.5-8:C2C45.4L+AX0Y(PI4X%U(SPU1590<
M<4I6K\KBZN&J/&X^$X5JD9.,IQQ]/$.;H5*T76Q4<1&4HUZE5<]JGBSX4:)9
MR6/_  I^2YT/3];U72_#AL?!_@8:3KOB?P]=+X3U#3_#EE<ZO!)9ZA"\^HV,
M=QJ5KI<$L&G7H@N)+<Q&XRC.5:=#23Q&+IT73A+XYX3&XC"8!UI2NX1P[57+
MW6A4J1JO#5,.U1FJ-2%&JJ>#<I.2C'"Q=64X-VIU,/@L5GM.$>7WG55.&,K4
MI4XRA2Q?M8SJ4JU3W^GUKQ+X*^'WB1KR'X7WL.KZAX9D\2>*?$WA[0O!<$NB
M:%%>Z5IMV?$VI'6[6]U!H3';2-;Z<NJL\.C,T2R?9XE;2C^^KXC 4ZBC3>(P
M-*4GS*A6Q&9XC&T\(N6WM)2J5XXESJ5*48TGB7.K.'MJC7-5Y*%##8F=*TUA
M\9*G344ZM+#Y=A\+4Q$4U^[BHTZF&I4Z5.HY5'",*<'&FFN"M/$?P+E\57'A
M/1O@[H.I^(/^$STW2YXM T#X2:E'_:Z6_C6:V\07]YIWB22/3FL;7P'KNY-0
M:UU6W+6T0LA+*T<:P<9SH8:OA8NE2H1KU*;BU&-!4X9=*HZ<X/V;=2=3!T?]
MFG4O5P\'4Y:5*C5?5BJ3B\8\3RSE.G&=7GUGB7.M&BZ<J<[592C_ &JZS=>$
M*<J.+Q%2G4J7Q"5R#Q[X(U^ZBU/Q7\&+AM6U2TN-+US6KG1/ &LQZ=X>OO&U
MWX!L;;6M0DU][Z\L+NYM29;.T@OE6*&8O'L5-^-)T?9TIWC0ABL+E.,K3::I
MNOF&$6,H0O&+E.49X2DH5902A_L4JDJ4E)4,ZLIP=65G5^HU\YHTN5WDJ&2S
ME#%5H\[BH)4L95?LXRYY2GBX4HU(S4JV7X>^)/P,\07'A_0O"_PJM=6%I?O>
M^'K71?#/PXO(-'L=:MO$'B.7Q9:VEEKSOHD%\_A._FDM3#;ZS)<BT\W3O,F0
MUI)2>'K8BI2ERT,!BG4BUSSCAL/#+XU,$E#G53VCS6A0C0I.I2<O;QJ.$(.3
MTK0EA<0L+4DHU:^8*A'WN55,?2^M4YU'*7*HO#4L+.3Q5;D@Z-2DJ%6JY2C'
M5TGXK>%[W7=%O[3X:RKH":+X;N+/6[2Q\ WFH^$=1N==U'P#;0ZI/I7B^Y^Q
M16L6I76G"STV.YO;)1K$%Q%"C>5)JG56(QD9UK3KRH25=2E.GB)YA[=MRJQY
MOK'UMY7@90KTW*A./U.5:LE"+H\TE3IX;#2I47&%&GCU4HR@J<Z.'RBC@L5'
MEI3Y'16%CC\6Y8>JH5XU&U0H7E/VDV@^*/AMXPD70M3^%,5_I^K^(M+;5_$5
M]X)\%0>$;_QOXB\+?VS#<W6ES>(]2U-]6ET>X@M);V2TNPKWL<#W;([,N6&2
MJ0P+@O8.-.;P:DK-RI8>EC*_U904O8KV;JU5S.$;X:M352I5A3]KU8QU,+5Q
M:G)U%&7LZKC*[A0IYQB<JPL:LI\GME#&8:*AR1;2G3Q'L,/&4X4>Z\;Z[X3\
M&7MK9/\ #B\\377B#1?%&J7Z^'=%\)2>3H7AV'1)-:FUE]=U?3/M$$GG:-&E
MO#]KDF>VA7ROW*$0J\:4ZG/)T*.$5'%U:[O[.BZ>,J5:59\G-5=6CB<3B<;!
MTZ<ZL92Q5>FG5G/GF.#]K3@Z=*%25>M'+Z=%**G5EB\).#HKFY:4:53"Y=3P
MU3VE2%-PIX:C.].,>3SRR^+GPQBN[[P;K'AW0C'XS\4ZA!J-M8:;X9M-(U&T
M\2^+KKPAH.I^)=*UG5H+OQ%?:S>6K1W+V-AJ;CR7EO([> HS:4:,JD:6$=-1
MG@WB$X>[[*E6PE7'5W"E%-^SE"&#C5<VHTU7K4VJB<WR34J-<^/IRE*C4HX:
M5.HVU5E0_LK*L56YYRY8J%"&9>Y3<E-X>G*G2IU:D&IUM/\ B%\#O$%Y8>$T
M^&FB3VJR:WX3B$EA\(]0\,:?9Z@=%UO7=)BU'3_%=WITZ:A+LO;C0M/DNM0N
M6\,WEQ+IS"RCD>85U[!X[VKI4L-1I8AS?-S1CEM)8S"NDH*4JZP5-TJ]"OA5
M6PV#=:B_;T)S5JJTI4I5<"E[1RKJ,J4-(SJ8NKC<ME.I&?)&E.M.GB,+.&)]
MCB*JK^Q5*?/5A'J=%^,'PU\3>'/$OC/3?#<][#X<.@:[>0Q6G@^]U2Z@UBQ-
MCH>OB:RUZXM=-"Z9]KAE?6;S3+C3K6SN?MT=I;IN9XBE]7HQGB(1A&6*JX2L
MI2I\E'$2I8>.*]M5<OJ\H+#XFBJ]:C5K4JM-NE"=6<?9$491JUYX7#R]I*CA
M(UJ:@I/VN&H5\76PU.A32]JW+$X2K5PF'=.$_;SI5(PC.HI'+OXM^%OAZRUJ
MSTSX0VFL68T#4->F\-^#_"'PW4Q>%8/#'A#7->N+N]?Q?'HOB&VE6X\+0[;&
MX)N&AL(XH;J&P%VKGS1CB*6(O&C@,12IUI3C*-.A.G.E/#J=*:=53I5*V)KQ
MG&F^3V.(:A3FH/$;TJ<\36PWL)QE/,*=.--^T4G7EB:^;T$_:)\JI5H86M%Q
MJ:1^L7JU;XJI1H=IH&L_#CQ??Z7X-;X7K::3HEQKO_")3ZUX:\&OX:2Z\*7.
MEPZF?#=G9ZE>7&DR0W&IP>7)+I]@'-M,8V)C7?<%-U'B.;V>*PL9QIN3:K>Q
MP^,E@I2IS5^6G&OA:+C!SA-TY8:I&G:,O9<7/"5!14.;"XN6&=16C[/VV89=
M/,J<:L&USU*F$KXCVLU&<.>5>G*HW47M,FQ\:^!-=O(O"^J_#I]5L9+VVTB\
MUN7PEX2B\)VL_B#Q?X@BTK3;C3KOQ)>Z@[S:]X82XF>WL[F$W,UG>R^0TC+:
M986G#%4,&XQC!5Z&#C24TDJL\)D&'SB$*<(J?L887+\=/ZO3J2Y,/>MA*%>L
M_P!Y6=6M'#5<7=MSH5<8JG(FG"GC,[K9//GD[*H\7B\-_M,X6>(C".(KT:-U
M2@ME/X3'Q)?1-4^&/ANRMO"^L:%X-^'NJQ^$O"KWFGW5MX+UGQH9['5(M;EG
MTC28-.M[V"UMK?2[-X7N@=S"ZF6TF%7GP^9XZM?V])8V53^>>#P]'!8>K"I+
MWE5G66-44I5(0>&?LIQNI7WQ%+DEAL-&T\*L-0Q<HM7BL1B<RK4H.$7RJ/+5
MPE.I*7)*3KTI55-*%%U,CX>ZYX1\4?$73[[2_A]X)TN"#P]?WWAK75\)Z99>
M,=+TFU\$_!R\TNQ_M.VEF6R5=.^(.J6,L-JPC%O9V<$9"12&Y[ITY8.AF=>M
M5Y*T9-8F<)/EJ_\ "AFM"K*HVE.HG'*L-4O/5U(N;3M3C3K%0NZ$97JRA4C!
M<_O<LN?,')T[_#^]A.<7H[UJLG[U1VO7/B/X:ZHAUAO@=>:Y+XVTK4/$HG/A
M3X;W%[XL\*Z(VD7D_B>\:^\1I)-8K*?"LD-IJ9AU*22ZTXQV):SG^P\-2,,+
MAZ\,3!83#X3EK8N$XWCA.?VK4ZU.DJG-4_?Y@Y1H1KU5[+'WC>K36(T5*N\3
M-4G[7$0K?4*4XS2E6JM58.A2G-Q:IKZE&#JU'3PK7U:U5Q<6J0\6?"W[78VF
M@? J]UZ/2_.\*^&[S1?"/PUMK,Z+8>$H_%ES%H9UCQ)I\NG>'8-,UM;7R)8;
M,-<ZC)!#!('D<;59U,+4JU\3.6&J4Z>+Q->I)MSIT\CS2EECJU'2<YS='&TX
M2PD*?M*T84%6C"GR4[\-.5#%4J-*DE7H5ZN'HP@X-4W6SG /,G!JI&,(^VP=
MZF+G*U.4G[*4ZE1\A=U[XJ_"^^\.W]]J7PYU3Q-X-U2;4=0MKR3PQX4O](\7
M^(])\/#7)K"TTS5-7CN9=>.EV5Y#'=ZI96=LTFC30"]!$'GGU6?MZ6#=)*O0
MQ,J&'IODTE5S=917JTI-^SI0>/QTG5<I4ZM6E7K8F%.K3E4F[6(A"C7Q?/*G
M3^KT<5BI\E3FI4XY?#,:"Q$8Q<YRAA*&$]FX1JPIU983#\\*T/9TN!^*NI?#
MG6+R_P!"E\&W7_"0>"-&/C!O".G1? VX>[;3[KP'<W=KJ-T;O5M;\*7D,=[H
M$$DD%QH;W$%B[6=Q.(;*8O"\SQV$Q=*3KNAFN78933ERTZN+S/%05>%2/LY2
ME]:K3Q4Z%:K'VM:K36(HJG6S)"Q5.-+*\72J4UAL/7R_&SE!I+GC2RRLJ5*=
M-J?NO!X&MAZ.(H4:D</2A*"J1K0P<%[5X,^)/P_\0>,[_P (:#H\>G:[HUMX
MFB681^%4W)HNO6%GXOL88-'UBYU'3Q!XEOX!-]NL[*&\G22XM7NXT\XJA!U,
M+5KT&OJ]..#I^[=*5"'UNC@'%)<JI4J5*K]7ISY9T*->"5*G[645I7@Z%6C&
MM2Y:LW*=WRWIUL;1H8^HF[WE4Q4'&K6J4?:4YU</-5JOM(4U+V>H * "@ H
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M>()O%,,5LMWJ<@L+5->N)[I;:U$,(,K1B/RCY=9J$8TJ-%13IX>&%A!-7]S
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M"'LN6&(53G6)A'V,4H8CVD;3KJUL3B/:ZNK5<ZM3VDHSK55B)2@W!K$+V_\
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M>;C><:C<G.,(PNY2]Z,*=*E%SU_>3C3HTXJI4YII)^]><W+K:@H* "@ H *
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M\"=8U#QC;>)-3\?R7^G6$FFOI^BW6E:Y<&U33O%OP]\41VT0N_&\VCV-NJ>
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\YO\ @HO_ ,@/
M]F;_ +.D^''_ *1Z[05'KZ,_1F@D_-[XR?\ *23]D'_LGOQ4_P#4.^(E!2^&
M7R/TAH)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#\YO^"B__ " _V9O^SI/A
MQ_Z1Z[05'KZ,_1F@D_-[XR?\I)/V0?\ LGOQ4_\ 4.^(E!2^&7R/TAH)"@#Q
M"^^,NI_\)3XS\+^%_@Q\5/'G_"!ZYI_AO7==\-W_ ,'=/T4:UJ'A#POXW2RL
MT\;_ !;\/ZG<>3H?B_13),=-2+S998XY)/*9J-AVM;6WW_Y!_P +7\>?]&R_
M&_\ \'_[-W_T0= 67=?C_D'_  M?QY_T;+\;_P#P?_LW?_1!T!9=U^/^0?\
M"U_'G_1LOQO_ /!_^S=_]$'0%EW7X_Y!_P +7\>?]&R_&_\ \'_[-W_T0= 6
M7=?C_D'_  M?QY_T;+\;_P#P?_LW?_1!T!9=U^/^0?\ "U_'G_1LOQO_ /!_
M^S=_]$'0%EW7X_Y!_P +7\>?]&R_&_\ \'_[-W_T0= 67=?C_D'_  M?QY_T
M;+\;_P#P?_LW?_1!T!9=U^/^0?\ "U_'G_1LOQO_ /!_^S=_]$'0%EW7X_Y!
M_P +7\>?]&R_&_\ \'_[-W_T0= 67=?C_D'_  M?QY_T;+\;_P#P?_LW?_1!
MT!9=U^/^0?\ "U_'G_1LOQO_ /!_^S=_]$'0%EW7X_Y!_P +7\>?]&R_&_\
M\'_[-W_T0= 67=?C_D'_  M?QY_T;+\;_P#P?_LW?_1!T!9=U^/^0?\ "U_'
MG_1LOQO_ /!_^S=_]$'0%EW7X_Y!_P +7\>?]&R_&_\ \'_[-W_T0= 67=?C
M_D'_  M?QY_T;+\;_P#P?_LW?_1!T!9=U^/^0?\ "U_'G_1LOQO_ /!_^S=_
M]$'0%EW7X_Y!_P +7\>?]&R_&_\ \'_[-W_T0= 67=?C_D'_  M?QY_T;+\;
M_P#P?_LW?_1!T!9=U^/^0?\ "U_'G_1LOQO_ /!_^S=_]$'0%EW7X_Y!_P +
M7\>?]&R_&_\ \'_[-W_T0= 67=?C_D'_  M?QY_T;+\;_P#P?_LW?_1!T!9=
MU^/^1A^'OCWXB\4V%QJ>@_LX_&^_L;77/$_AN>?^UOV>+79K7@WQ)JWA#Q)9
M>5>_'R&1OL?B+0]4M/.5#%-]E\V"26"2.60"UNJ_'_(W/^%K^//^C9?C?_X/
M_P!F[_Z(.@++NOQ_R#_A:_CS_HV7XW_^#_\ 9N_^B#H"R[K\?\@_X6OX\_Z-
ME^-__@__ &;O_H@Z LNZ_'_(/^%K^//^C9?C?_X/_P!F[_Z(.@++NOQ_R#_A
M:_CS_HV7XW_^#_\ 9N_^B#H"R[K\?\CT7P+XNTWX@>"/!WCW1H+ZUT?QOX5\
M/>+M)MM3BMX-2M]-\2Z19ZS8P:A#:7-S!#?1VM[$DJ0W$\:R*X2610'8%:VG
M8ZJ@ H * "@ H * "@ H * "@ H * "@ H Y7QUXNTWX?>"/&/CW68+ZYT?P
M1X5\0^+M5MM,BMYM2N--\-:1=ZS?0:?#=7-M!+?/:V4J0I-<01M(R!Y8U)=0
M$NFQYU_PM?QY_P!&R_&__P '_P"S=_\ 1!T#LNZ_'_(/^%K^//\ HV7XW_\
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M_CS_ *-E^-__ (/_ -F[_P"B#H"R[K\?\@_X6OX\_P"C9?C?_P"#_P#9N_\
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M\/\ XE^)I[:^ANO'.@,J7=O;1R1R3%)6:$H38+6Z['L- @H * "@ H * "@
MH * "@ H * "@ H _.;_ (*+_P#(#_9F_P"SI/AQ_P"D>NT%1Z^C/T9H)/S>
M^,G_ "DD_9!_[)[\5/\ U#OB)04OAE\C](:"0H \0^$__(^?M-?]EOT#_P!9
MN_9\H&]EZ?JSV^@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 >(?L^?\B'K_\ V6_]IK_UI'XKT#?Z+\D>WT""@ H * "@#Q#]F3_D
MVW]GS_LB'PG_ /4#T"@;W?J>WT""@ H * "@ H * "@ H * "@ H * "@#Q#
M]IK_ )-M_:#_ .R(?%?_ -0/7Z!K=>J/;Z!!0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!XA^T'_P B'H'_ &6_]F7_ -:1^%% U^C_
M "9[?0(* "@ H * /$-?_P"3D?A1_P!D0_:#_P#4\_9EH'T?JOU/;Z!!0 4
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M % 'B'[37_)MO[0?_9$/BO\ ^H'K] UNO5'M] @H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H \0_:#_ .1#T#_LM_[,O_K2/PHH&OT?
MY,]OH$% !0 4 % 'B&O_ /)R/PH_[(A^T'_ZGG[,M ^C]5^I[?0(* "@ H *
M "@ H * "@ H * "@ H * /SF_X*+_\ (#_9F_[.D^''_I'KM!4>OHS]&:"3
M\WOC)_RDD_9!_P"R>_%3_P!0[XB4%+X9?(_2&@D* /$/A/\ \CY^TU_V6_0/
M_6;OV?*!O9>GZL]OH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'B'[/G_ "(>O_\ 9;_VFO\ UI'XKT#?Z+\D>WT""@ H * "@#Q#
M]F3_ )-M_9\_[(A\)_\ U ] H&]WZGM] @H * "@ H * "@ H * "@ H * "
M@ H \0_::_Y-M_:#_P"R(?%?_P!0/7Z!K=>J/;Z!!0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!XA^T'_R(>@?]EO\ V9?_ %I'X44#
M7Z/\F>WT""@ H * "@#Q#7_^3D?A1_V1#]H/_P!3S]F6@?1^J_4]OH$% !0
M4 % !0 4 % !0 4 % !0 4 % 'YS?\%%_P#D!_LS?]G2?#C_ -(]=H*CU]&?
MHS02?F]\9/\ E))^R#_V3WXJ?^H=\1*"E\,OD?I#02% 'S#\1_AC\,-8^)FF
MZGXS^$?P8U*R\1P:?;W_ (T\8_!_1/&FN>(?$2.NF6.@7GBB::$^'9H]'L=.
MM;"?58;Z*[DN(+*W:*6UBM[W+VG*L;S_ !4,/.M1@H^]55*AB*E:4).2C5E0
MY*=6>%7LJLL/3K5*=24%6JX*JON4</.G)KFJRA7D]8T8N>&CA[Q34K5W/$4_
M;+FIT:D*7M5>K3C5\DBTS]E2U\/V&N7G[*G@/4M-DT>>YN?$6E_!'X06>EW&
MK:=\.)OB5?:7;:1=ZQ<:E;7;Z+;3QQ(1=6JW1%L=0D"M/794H26(K4:=-IQG
M6C0@YQDZZH9I1R>7LYVA&ZQM9P7MHX=RA0K55!0]E[32%.4\4\)"HN>.)I8>
MJVVH8:5=N5)UI22O!4G0J3J4HS2CB:/NQJ.K2H[M]X9_9*TB.V&M_LP_"W0K
MV3Q)#X6N](U;X<_ >TU73]1N+;P[?PL+0ZN?[=A.F^)M.NRN@-J\\<:S+)"D
MRK%)G&'-7PF'IRC.6,]HJ;C=^]3QL\OY902]I%2Q45!5G#ZO%5*<ZM:G%MQY
MW4<<+7QDE*%'#TE7O+3GI/"5\8Y0;?)S1AAJ]-T9RA7E5IR5.E.FG4)='\$?
MLQ7&F:Q?:Y^RO\+-&GTA_'5PUJ/A5\*;TW&E>"_&<OA!IX9+2&1!=SS>2_DR
M-&%9+@;RBQ/.4H>UC@^5\M3%+(HRB]/9U<_G5IX:+:NG"E.C.564;M4I4Y1C
M*HYTJ;Q=3ZG4Q$9.4J="AC\3&<?MTLMPF$Q>(LFTU*<<7!4%)1YFG[1T[7>=
M+I/[']G=:7::A^S+\,M*DU75M0TVU.I?"[X)VC?9+#Q8G@M-=6WDOOM-UI=U
MK)G,$-I!<7YM[.:>6QB0(9(PUL3/"4Z;49XO#9?B8Q>LJ:S2C4KX&E.,.=^T
MK1I\LG352C0G.FL15I*3:*T_80Q=1MRIX2KF%)R2<8S_ +*:CF$X2J<B4<,W
M&T:CIU,1?_9*>(M+E3QM\*O@QH.M:K8:;\ /V>8+.VU[PIHEK(?V=-,\9:G"
M-7\/Z[K6H7+:-X96WO-9<R:?9PPV]G!$T2^?)(TP8"'FC5J.#Y8\U3ZYCL/"
M*C)IPPN48?'4T[/W9SQ%9QE5DU35)1AR*;]H;R2A*>KY:>!P&):=2,+U,9GM
M3+)+FE[L84\/3<XQ:<I5I)\W(O9RSH/AM\)&\ C7-3_9H_9]T#Q,GC7PCX5O
M]/'P%T/Q,NF#6K;PO)JJ-H&CVL>H:CJ%O<:Q>QHD$Z[/*C+H_E2>9W5(4U7R
MNG1G>ECJN<QE)+VEHY=//504)4[)\RRO#JK5LZ;YZU2"IPE!4^3VLX+./>]J
MLNJ9="C-QEAO;0QG]D)UITJSE.DY1S"K5I8:356G^ZP]1SJQFZEK7? /P#T3
MQ[X*\,K^SI^SY>:!);>&X/B'K5Q\%O#6C7FE:K\0Y=2TKX>#3=/N]*D.FK=^
M(-$NK:[L=0\ZX@75].S(C!O.5&$JV*QE*,+4E[?#8/EG"I[3,,)A)9IBJ-6I
M#W52HY;&,U.,/WM?$T(P;2G%Z5I^QP=*M[3FK?[Q5A:2E# _6\/@(U'1UJ0]
MIB,5*K&O-JC&AE>8IP;:GA\N7X:_".SCT.PU+X#?LYZ=XFO_ !HN@:[H<7[+
M]OK5[X8L)?"WC'Q#:&#3](O9;CQ;;W$OA^UA@U^P$%C*EOJ#&WCECD@T^</%
M5HX>S<E+#U:E2?(XVQ%&674ZF&J0;G]4E3EBJE24JM2I"=*>%E2G.E4IXC$[
MS2A4S-)OV>&<'AKSC%U*%3&^PI8CFVJJK0:?L*<85:%95(UO>ISI1](\8_ K
MX'^']3\(^5\ OV?-,\,W[2P^(_$FH? 7PQK$%IJ#W&E0Z3IKV]C]@D\,P:@M
MQJ>-6OA>VMK+:P07"J]Q&92FHO&2HS]V$N2.'IIKFK593FI4UB-:4:D8QIPH
MTW2;QE6NHT)*I2C0Q&$I2C@95U*\Z47.I)J25*DJ4FZSP[_>2I0GRSQ%JL98
M:C"4JD72=;$X3@;3X;?!75+?6=2_X49^S3X7T3PBDY\1:E>?L\:5XODN'D\0
M:_9P/!I^B26,NBZ;8Z+H<<UUJ%PU[%)+J$C8M(M/<7,X2U>CEE>6JQKRVDZ,
M5R.5?$Y7E695U&O+FIT85'F2PV%52$G3G&,JDZSG"G,J2G[3&X2DG]9H3QTH
M3?OP5"CF6999A5["+56O6=3 .MB(TY4TX+EI1_>RGA8_"7@CX'ZMXHMO"FM_
MLT_L[6%]=_$_QGH&G26GPE\)&+5OA_HL7Q%ATC6+0W&E?NM>AU?P0MGJ* SQ
M()8YECA74K=8=<)3]OAZ<Y^[7IY?'$XBFFO<JU9X"IA9P6LOJM?"XR<8N:C)
MXS"XNE"4X89SJ:XEQI5:RI2<L/*GA)X:<GK-RC@X8ZG-)+WZ%;$*I#E7*L-B
ML'S.57VR5/6O"7P-T+Q?9>'+O]F[]G$6ND?$'5=)\>7S_"/PE#_9G@B^7PU;
M>"M1TX'3W6/5KC4_B#X.2YFN/,MWCTW6S%%"PB$.%"I!T%B<0N6C3P>.E6<)
M+FHXW#U,SGA8M./\'%X3)L9-4[^UC5Q6!2J2CS\[Q$*D/:4\-"<L1.I@*F$I
M2=Y5\ Z-!9MBURV]W XNI5IMOEY:=)N4:EN=FB_##X<>(;'1[V#X ?LO:&VI
M>(?"&GO:7_[/V@:E-!IOC+P[9^)+,.8M8L?*U&SM[Q()<JZ2.K,JQ ;3LJ-2
MAC*&#Q7+[6-;%87$*GLL1@,H>-Q+I2=[TYXN%2G24HMPH<KE*I.\GC6JTXTJ
M]?#5/;T%2P^)P]1-J-;#8SB*OE6&G:R:O@8T<0WIS5I2]V$&H136_"_P&T[0
M+JXM/V:O@6^M6.M?&+3IVO/V?;"U\/R6_P .['X@7&CO::O/H45C=W,\GA;2
M_M,=OJ,Q=9KP1)"5S;UA(0Q-? P5X4L3@LOQ,T_=FJF+Q^282HH*2BY4XPS'
M$.G)0DN:%";G*%U5VE!TL30PTY<WM<3AZ#E#5<M7 5<7)MQ<XTY*=-)*;]U-
MTY)U+,N>$/!/P0U?Q-:>%==_9I_9VL+^\^)WC+0;![3X2^$C%JO@#1H?B+%I
M.L6AN-*/E:]#K'@@66HH#<1()8YECA74K=85A::KT(3E[M:EEZQ.(@FO<JU9
MX"IA9P6LOJU?"XR<8N:C)XS"XNE"4X89SJ9U9>SE/E;]E.C@JE"3>LIRA@X8
M^E-:>]0KXA5(<ONK#8K!\TI5?;)9NM^$?@IHWC'Q3H,?[.?[.MY;Z?<:YINB
MV5Q\!]%T79>VEOX(32;J\\97EI+I6MP-J/BF87=CIMDEU;V\8G8JMM+YW/A>
M;$T,.KQA6Q=14U4TY:+EQ#7R:+^JRG&KBH^P@L1*I2JTZ4<126$G.%3'8;V:
MQ$_J\\5*SE2P?ORAS6E5IT^'IYW52K).GAZOM*?U>G2J0G4E2J?6(PG##UFY
M_''P_P#A)\*DUJZ\4?L\_LS^*;'PK9>%/$.K_P#"-? _PCX?U75="\37FM>&
MWTW0M+U;4M12/Q!:>(--L[V(S7<L=]9W-Q9Q0Q75L)YW[6FW&$:;C*5>>%3G
M4C&G&I6I>WP6(J5'"T,/25+$4LR37^RX=+-755&G4PCV5&JX4I>T4?;4ZU6/
MN5)?[C/"_7*24.:4ZM:EC*/]GJ"YJV+C]2G37MZ>(AZ5X)^!7P8U+7;K1_$O
MP _9JEV>!O!GBF-O#?P?\(B""^\1W_BNWOK2/4KNVN4U;3XH=%L1!<QV]H9"
M9I2NV9(X.JI1C1^M4[RE4PF)^KN;A[)3Y,/1<Y.C)SE2<J_M9J#J3=.G*G1D
MYSI3K5>:%7VN'RW%4_=I9BL=.,')3<*=&>#GAESQ:A*7L,9&%:45R3JTW4I\
MD)JG'U'_ (9D_9M_Z-\^"'_AI_ ?_P H*YS2[[L/^&9/V;?^C?/@A_X:?P'_
M /*"@+ONP_X9D_9M_P"C?/@A_P"&G\!__*"@+ONP_P"&9/V;?^C?/@A_X:?P
M'_\ *"@+ONP_X9D_9M_Z-\^"'_AI_ ?_ ,H* N^[/$+WX/?!RP\2:_,_P!_9
MJD\(Z%\1O"7@)]*'P/\ "L?B.=/%VD^"/LVJ1Z^TK69DMM:\7%GM?[&'F6MO
MM65)5+R7AH>T^H*H[_7XYERN/N^RE@'F$X-I\_M8SIY?*$TG2Y)5O;<W)1=*
MK6)O3IWHMQG1H4*]3VDKQG&>(J4JL8-<GLI*FHSI<WM?:58>PLOK$9T,Q]'_
M &4)M:MM*TW]F+X/7<%IXFNM#\3ZE#X!^!NHV6AV-KX=\9ZV^JF;0;Z_60I+
MX,U.*6P<QWT"VTWG6J2FWBN<(5(?4ZN85;T<'1PF)Q+G;F?-AJ>65G37(Y1J
M*=+,Z/)5HRJTI5%RQFZ=ZD;5.I+$UL#2O4QE.6%C&FGR\_UG&UL%!VFX2IVE
M0E+EJQIS49T_=YE5C3[[X=?#']D[XF6&H7VA?L[_  ;MAI=S:6UU;7OPQ^$M
MW,GV[3+/5;27S?#L6J6JJ]K>(IB>X2>*2&6.:&-DPW3.C.E!2E96J5:,DG?D
MJT7'GASJ].I[LZ=2,Z,ZM)PJ1M4YU.$.6->,YJ-.3E&5&GB*<M8JI0JSJPIU
M.27+5I\TZ%5>SKTZ5:/+>5-1E%R]$_X9D_9M_P"C?/@A_P"&G\!__*"LC6[[
ML/\ AF3]FW_HWSX(?^&G\!__ "@H"[[L/^&9/V;?^C?/@A_X:?P'_P#*"@+O
MNSV'3-,TW1--T_1M&T^QTC1](L;33-)TG3+2WL--TS3;"WCM+'3]/L;2.."R
ML;:UBBAA@A1(XXXD1%55 !MY6$7J "@ H * "@ H * "@ H * "@ H * "@#
M/U;3-/UG2M3T?5M-L-8TK5=/O=,U+1]5MH+W2]5T^^MI+6\TW4K.ZBDAN["Y
MMI9()H9HY(Y(Y75U96(.=5U(4JKHP52K&$G3@WRJ4TGRQ<OLJ3LF^E[E14>:
M*DW&-U=I7:5]6E=7:72Z]3X;L/ 7P T?2;"Y\:_L^_ J3Q"VI7.FZOX0T+]G
MCP;I>K:9J@T5[ZS\.QSZWK,MO>2W%_Y<5GKL3-IVH*Z&,6T3/<V^R]E*I3I8
M>4L4ITI<E115'GK+'Y5@;3I3<I86<99A&I4PM:;<:%6GB%B72IT_KTU92I5)
M^TG'#TZ=1N5W.JEAHX/-L<Z\:D(P=:DZ&724:M.CS^WP]?#RPL:]2=/ Z3>&
MOV6X+NXLKO\ 9!\'V4VF2ZT-?\[X0_!%X_#MIH6H:!87.I:C)::K,+JTE7Q%
M8W4*:9_:%P\$5PQ@62,1N8>*Q/L'3DHPKSPE&,I<R2KXW,,QRO#T&E%S4Y8O
M+,1"4U%T(0E2J2JJ,VXY5\0L-[=5.;GPU/$UI16K]CA,NP.9UZB:?(U##YAA
MXJ/,JDJWM(1@U#F;+CPS^RS-JNH:%H'[+OP@UO5-%\7>%_#6KQ6?@+X%WL-M
M;>(_$6L^'AJ0FTS4+D6\D-SH-_NT^^^QW\9D@$UI&3((9PR^L?V?47NX?&SQ
M<'/?V;PN5U<RWAS4ZB:A[.3HSJ<JIUFKOZNL1MC'/!4\0YWE4HQH2A"_*ZCJ
MXS X6<.67+4IRC''T*D'5A3I5?:4U"HXJM.CM2^!OV4E_P"$=2R_9>^&^J7/
MB:'0;C3;.R^$'PG2=(=?N-9AADNGU#[+!"MK'H-_/<8F?;&J>5YSL47.-2#G
M3A)^SA*G3JRJ2^"C2J8'$8]3J./-)*-'#3C)0C.3JRIP@IJ3DJKJ>&IXB;O+
MZM6QF'<8/WIU<%F&!RR:A?EC:IB,PH.DYR@O91J3J>S<8QEFZ!X>_8[\3Z!X
MUU_1/V>/@[/;^"O#8\5SQ/\ ##X37$FIZ'/;ZU/IM]:+H\-^]C]K&@WP6TU-
M+"^B C,]I$)%SI.EB?JE.M1I)UZ]:&%I4INW^U588:5*G4G'F@H\V+I0G.$Y
MJ$HU4_@UVC1<<QAEU:?L7[6I2E4WBG0KNAB+0NJDO8M1GS<BIU85*;HSJ7GR
M6(?A=\!M*U"30M<_9>^"NO\ B$GPY8V6D^#/A!\.(9KS5+SPO=^(=><3^)C:
M65MIMJMA=&)[F^@8J(HAYT\JJS<J;ECE14ZD,)B<:E*T4U@\)A\JDJTX<W,Z
MD\1F=.C[.E[27[VE[GLZ=>NN*-5OZG*HUAHXS"82M&$I2J2CB,7B\U@L.IP@
ME)4<+ESJRJ.%.,O8UYKE=2CAU@)I'[)ZF[N(?V7_ (>:WIRV6I^(&GTSX&_"
MS3SX=\-:'X6\ ^(-7NM<&LW\,][/"/'-H=EE:+<DQW%LEC(;(7-]M3H.;H0C
M*,HUIT::KJ7[F<L7F.)P.$<4DZBC4^KRGS6DO91]M)TG/V%/IE3K0A)\KC7I
MS="6&YHRK?6*?U[VM)2C+V'N3P-2@Y*JZ7M94N6M.G54H=,WPO\ @"_@OQCX
MD3]E?X*:=?:#XEU?POI%IJWPT^&GV/4KFVUU/#VF:C<7&F:=<M:Z<]Y/#).'
M$4L:)+M0@*S<JYZE'*W&4:-;,J]'#M2BY_5W5Q[P3G*$9059TXIS]E3K1]K.
M+I0J14HS(E*-.KF2]ZK0RW"/&<T9>S]M"&4T\TE"+E&3IN:ER0G.FU&$Z<YP
M<U4I0YG4_ O[/GPZ\1WWA;XD?L]? ?7)F\,#Q/HFL^"?@/X*TN*^EM]/\1W=
MUX5DT'5;[5;HZ_=+X5U*;36BNFBO SVS""6S\V\4\11C1QTXT:OM,O7M9Q7+
M-5J-2OA,/05)^Y;$*KBXTZM*3Y?9P6)52,:CHT=(T:R>7RE5A&ACZM2@YRYX
MQPLL/256OB,3.THPP:A.DE6TE&K-4I4VY0G*U%I/[(E[IEAK&@_LL^ O$>F7
MVD2:ZMWI/P=^$,<=OI=MX1T3QG>W$W]KSV)=K72O$.E1210">3[5,T$:N8G*
M].(HRP>*K8;$.-.&'>)YJ]^:A[+"XRA@:E>+@I5)4GB*LXPY:;JRCA<1/V:C
M&DZN5#VN(AAO9TYQQ&(J8?#K#3M"O2Q>(CCIK!UXS:A0Q%*& G*M&K.,8*OA
MFIR527)"]G^QQ)K4^@:5^S1\,=?U-=4&CV%MH_PL^"TD^JW<'B72/">J&"SO
M+RVN],M].UC6K59I=8M],62.&>:S-U'%EIHTIU7!1CR\TYQ;>JC"&'S'%.JW
M#G3BZ&65YQA'FKOVF'2HWJVC%6JJ%".)G)JE*GA9IVE=RQJP<L)246DY3K1Q
MM-\R3HTO9UE7JTI02EOZ'\._V:O$=]X7FT_]F;X,V&C:UXCUOP;>V^K?"KX5
MG7K#Q!8Z%=>(K)[FUT8WYT>-;31]4M[G3=4@M-1CFN[-I(8$1UF*,/:1A-M*
M%?!RQ5%Q=_>I5J-*I1E**E2F[5:EYTJKC1JX.M1ESRJ1]GI5YZ7UJ%G[3 5Z
M4,1>22C2JU*F'C."OSR<L1+!2I2Y?95L+BEB*<Y1BSV+_AF3]FW_ *-\^"'_
M (:?P'_\H*@5WW8?\,R?LV_]&^?!#_PT_@/_ .4% 7?=A_PS)^S;_P!&^?!#
M_P -/X#_ /E!0%WW8?\ #,G[-O\ T;Y\$/\ PT_@/_Y04!=]V'_#,G[-O_1O
MGP0_\-/X#_\ E!0%WW8?\,R?LV_]&^?!#_PT_@/_ .4% 7?=A_PS)^S;_P!&
M^?!#_P -/X#_ /E!0%WW8?\ #,G[-O\ T;Y\$/\ PT_@/_Y04!=]V'_#,G[-
MO_1OGP0_\-/X#_\ E!0%WW8?\,R?LV_]&^?!#_PT_@/_ .4% 7?=A_PS)^S;
M_P!&^?!#_P -/X#_ /E!0%WW9R'C[X ?L_>&O!GB37=(_9[^ 9U/2]+N+FP_
MM'X0>"KJP%T@"Q-=VUMIEK+/ K,"T<=S S 8$B$Y"2<J^ H1:C];Q^7X63:O
MRPQ>.P^%J2237O1A5E*%W922NI*Z:J3]EAL=7=Y?5,%C<3&*=N:6%PE;$0BW
M9VC*5)1E97Y6[-.S7G6I?#S]G7P!:>+!\0/V?OV>M4G\,W^F!+_PY\+/A-X1
MMK_3]=TZ_P!2TV 6'CO6HXH]8A.F75JUM#K%S+=$VUQ!;QI.\5K'MZ*HTYM.
MFXXG$82IK[3W\-A,+C:E:G3IQ=>5/ZOBX-TJ5.O5A*E5^.-I&L*52>*>'A)/
MFPN$Q,>9."C]:QN(R^-*51MTU^_PSJ*K4="GRU8T5S58)UL:^M?V2-!CU*X\
M2?LQ?";2[:#5]:ATMS\-O@O$VH>'- T;P_JVI>)-NHW%K^[A3Q#8#^SXC)J,
MOVN(6]E,Z3K!TTJ,YSP>':5/%5ZE>E4A>ZHSIYOB,IIIN',Y*I4H2DW3C-0]
MCB)/]U&E4K849RQ$*];#QE5H4_J,:37NRK5,;E<,SITK3Y8TY\CE#FJSA1O*
MBI58SG*%/Z+7]F?]FQU5D_9]^![*RAE(^%'@/!5AE2/^)!W!%9M.#<6K.+LU
MYK1CA452$*E.7-"<5*+76+5T_FF._P"&9/V;?^C?/@A_X:?P'_\ *"D5=]V'
M_#,G[-O_ $;Y\$/_  T_@/\ ^4% 7?=G4^$/@]\)/A]J4^L^ OA;\.?!&L7-
MC+IESJOA#P1X9\-:E<:;-<6UU-I\]]HVF6T\MB]U96<S0,YC:2TA<J6B0J;>
M07??8]&H$% !0 4 % !0 4 % !0 4 % !0 4 % 'YS?\%%_^0'^S-_V=)\./
M_2/7:"H]?1GZ,T$GYC_MI7.K?!S]H']FO]JR?1-4UWX?_#\^)/!GCMM&MS=7
MF@6?BC3]4TR#598=FT6[VFO:KL>1XXS<:?!;&2.6]A+FWR*CLX[=OD?2>F_M
ML_LI:I86FHV_QS\"P07D"3Q0ZEJ$VDW\2N,A+O3=3MH+JRG'1HIX8W4]5H%R
MM=-B]_PV3^RQ_P!%X^''_A06_P#A0'*^QR^L?M,_L=Z_J.GZGJWQT\%7<NF3
M65Q:67_"P-8@T/[5IMS)>V%W=>&[;4X])U"[M[QUGCGNK*:1);:UD#![2 PQ
MR13J.UW5A4IN[;M"K1J4*BA=OV3G1JU*<I4^63C.6NI4N=TU2MRP3O[JY9/W
MJ<G&<HVE.%Z4/<FY0Y7./+RU:JGY+-\1_P!C6X\1:?=/\?OAE!X-TNRO;*W\
M'V'B7Q5;_:DO? P^'[MJEW/X[N--N)UT&6[B^W6VA66HLHM%-_\ N)VO^FAB
M*E*MB,3.7M*]93Y'HH493S+#9G*<(24^1O$X6G4E3I2IT*E6=>K4HSE4M$K<
MTY49P3I5(5J=>I.RO5J4UB(Q;Y5!.RK1BG55:4:=*-*$HTE3A2[O6?CA^PYK
MVI3ZMJ/QC\#_ -H75[#J%Y-8?$?Q%HZ7\]NGAU(H]0M]'UJUAU"R"^$] S9W
M$<MLQL26B)N)S-E2DZ,Z4Z>CH5*=6":4H>THXC$XJE.4)7A.5'$8S$U:3G&3
MIRJODY5&"C$X>TH?5YQO3^KU<*M+3CAZ\/9UZ4:BM4A&M!*-7EFG448<[?)&
MU?4?C-^POJGF_;/C)X-*SW^KZC-';_$_Q3812S:]K%IK^KVTD-CK\*-I5SK5
MC;WCZ:5^Q"7S66W7[1-YJHMT)X:=)VEA'A'2O[Z3P%2=7!.<9\T:KPDZD_JS
MJJ;HQDX4^6'NCKQ>)C6A6BI*O2J4)VBH/V5;#K"5X1E!1E35>A"$*[IN+KNG
M2G5<ZE*G..N/VA/V+([O2[VV^-O@S3[K1VNC:2Z3\1_$&D>;'>:S_P )!<6V
MIII>L6Z:W8MJQEF%KJ*W4"K<W$21K#<S1R%+]QR>SM%4\/A<,HM<T?8X*C+#
MX6,H2O&4J-&4H0J23J:N3FY/F"47*,X..DZV*KMVM-5<;-U,5*$U:=/VU2TY
M1IRC!2A2E&,71I<CU_:5_9,?Q/J/B*]^/OPUNTN;S0]4L+,ZW]GETS5]%TW4
M-(6\%W#?!+R&6QU"51;RVVU&+,6<E!$J*5",TM9O$U\1&6W+]8P>&P56'+JI
M)T\.FI:-<\K*ZC)%52JR6CC"6%H86I'I..%S"MF-":>C@XUZMY)-\ZIP5U'V
MD:E2^^/7[%&H7.IW5S\<?"JRZOJ]GKUZEG\5/%FG6PUG3WTY[34[.RT_7X+?
M3+Q#I-B#)916Y<1NK[EGE$I32HQH1IWBL)+$3I:MNF\5];^L*,G>2C5^OXOF
MA?D_?:17)3Y"</:.LYP3]O[#VFB2F\,L.J#DDDFZ7U3#<KWO2BVV[MT[WXS?
ML&ZD=4DU/XF?"K5+[6)M.N+[6=3\47&H^(C<:39Z=8:;/:>);V\EU739K:#2
MK%HWL[R!EFC>Y!^T3S2RU%\DJ4J:5&5"NL3&5**IOVZK*NIR=-1<_?C&/+4Y
MH>PC##<OU>$:252#JTZE*KS3IU,-4PDHRE)I8>K&M&=.-W^[O]8K-2ARSC.H
MZD9*=I*1OCA^Q$TL=S)\</#4NH0W]GJ46KS?%OQG-KL5Q8:;J^D6<<>O2^)&
MU&.PBL=?UI%L5N1:[]5N9O)\Z9I"0DZ48QIMQC%5%9?:]K]751U/^?KDL)AE
M>IS-*C!)JVNDI3DZK:3]LE&2Y8\L4JWUA>SA;EH_O;-NDH-QC&FVZ4(P6_KO
M[2_['?B46$>L_'7P;=6^GA52QB^(FN6.FWBI<6ERJ:WI>GZK!:>(8_-L8,IJ
MD-XI0S1D&.YF65QDX5UB8I*K&<*D;QBXPJ4I3E3J4Z;3ITZE.<_:4YPC&4*D
M*-2+4Z%&5/)T[X>>%:;HSA.G-._-.G4A[.I"=3^)*$Z;<)QE)J<924D^:5^>
MU'XV?L-:G%-!/\8_!-O#=:?J&DW\>E?$KQ+H::KIFIW][J=S8ZVNBZY:_P!M
MVJWNIZF\,=_]I%L-3O([;RH[N9)%1;P[PWLGRK!_4_8P?O4X/ 4Z%+"S]G*\
M)5*=+#8>G*I*+J5H4:4:\JBA%*WS6GO&4ZN(K.<?=J*IBJE2KB'"I&U2$9U:
MLZG)"4:<*CC.$8RA!QTE_:!_8B35?#>MCXM?#$:MX1U3Q5K'AV_/BJ<W&F:A
MXU>^D\4R([71\^"_DU&Z=[:<2P(QB:*.,V\)B=.<J4I3IOEE+!T\!)]\)2G0
MJ4Z33T?)+#47&H_WJM-*=JM95)G#VE.-*:;IPK4L1&.J2JT*,\/2GI9^[1G*
M#C\,KJ4E*48R6?XA^-O["?BF;QK/K_Q3^&-_-\0_#NE^$_&,I\77ML^L:#HL
MFH2Z99YM+Z+^SY()-3NV%U9?9KEB8=\S?98/)B"C2@J<(Q4(XZCF7*XQDGC,
M.L.J-6:DGSJ"PM%*C/FH-1GS4W[:M[37GJJI1JW:J8?#5\)3EUAA\2YNO373
M]XYR;D_?5_=DK*W1#]IG]C19S<K\9?AJDQU32M9RGBF1$&HZ)I\6EZ7.L2W
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ME:@X4X=]_P -D_LL?]%X^''_ (4%O_A4"Y7V#_ALG]EC_HO'PX_\*"W_ ,*
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M))"1QZ:J1KD\*JA0.  !B@=WW8W_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\
MAD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_
M (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP
M_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[
ML/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N
M^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@
M+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_RO
MH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\
MKZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-_
M_*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#
M?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('
MPW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"
M!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\
MP@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_
M ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB
M_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\
M(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B
M_"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H
M@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_
MZ(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9
M/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]
MF3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/
M_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&
M3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\
MAD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_
M (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP
M_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[
ML/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N
M^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@
M+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_RO
MH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\
MKZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-_
M_*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#
M?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('
MPW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"
M!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\
MP@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_
M ,('PW_\KZ N^[#_ (9/_9D_Z(#\(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB
M_P#"!\-__*^@+ONP_P"&3_V9/^B _"+_ ,('PW_\KZ N^[#_ (9/_9D_Z(#\
M(O\ P@?#?_ROH"[[L/\ AD_]F3_H@/PB_P#"!\-__*^@+ONP_P"&3_V9/^B
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/>V !G  !MY"_0[&@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
